Toxicological Profile for Mercury

October 2024

U.S. Department of Health and Human Services
Agency for Toxic Substances and Disease Registry

ATSDR

CS274127-A

DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR.

Each profile includes the following:

(A)   The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance due to associated acute-, intermediate-, and chronic-duration exposures;

(B)   A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, intermediate, and chronic health effects; and

(C)   Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

Christopher M. Reh, Ph.D.
Associate Director
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention

*Legislative Background

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to "…effectuate and implement the health related authorities" of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the NPL, in an effort to "…establish and maintain inventory of literature, research, and studies on the health effects of toxic substances" under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

VERSION HISTORY

Date	Description
October 2024	Final toxicological profile released
April 2022	Draft for public comment toxicological profile released
March 2013	Addendum to the toxicological profile released
March 1999	Final toxicological profile released
May 1994	Final toxicological profile released
December 1989	Final toxicological profile released

CONTRIBUTORS & REVIEWERS

CHEMICAL MANAGER TEAM

Rae T. Benedict, Ph.D. (Lead)
Breanna Alman, M.P.H
Fahim Atif, Ph.D.
Franco Scinicariello, M.D., M.P.H.

Julie M. Klotzbach, Ph.D.
Mario Citra, Ph.D.
Gary L. Diamond, Ph.D.
Deborah Herber, Ph.D.
Lisa Ingerman, Ph.D., D.A.B.T.
Connor McGuire, Ph.D.
Sara Nieman, M.S.
Sabah Tariq, M.S,
Kimberly Zaccaria, Ph.D., D.A.B.T.

ATSDR, Office of Innovation and Analytics,
Toxicology Section, Atlanta, GA

SRC, Inc., North Syracuse, NY

REVIEWERS

Interagency Minimal Risk Level Workgroup:
Includes ATSDR; National Center for Environmental Health (NCEH); National Institute for
Occupational Safety and Health (NIOSH); U.S. Environmental Protection Agency (EPA), Center for
Public Health and environmental Assessment; EPA, Office of Water; National Toxicology Program
(NTP).

Additional reviews for science and/or policy:
ATSDR, Office of Community Health Hazard Assessment; ATSDR, Office of Capacity Development
and Applied Prevention Science; ATSDR, Office of Science; NCEH, Division of Laboratory Sciences;
NCEH, Division of Environmental Health Science and Practice; EPA, Office of Research and
Development; EPA, Office of Water.

PEER REVIEWERS

1. Harvey Clewell, Ph.D.; Principal Consultant; Ramboll US Consulting, Inc.; Monroe, Louisiana

2. William Pan, Ph.D.; The Elizabeth Brooks Reid and Whitelaw; Reid Associate Professor of
   Population Studies; Durham, North Carolina

3. Kristine Vejrup, Ph.D.; Associate Professor; Norwegian Institute of Public Health; Division of
   Occupational and Environmental Medicine; Lund University; Lund, Sweden

These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers
were selected in conformity with Section 104(I)(13) of the Comprehensive Environmental Response,
Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers' comments and determine whether changes will be made to the
profile based on comments. The peer reviewers' comments and responses to these comments are part of
the administrative record for this compound.

The listing of peer reviewers should not be understood to imply their approval of the profile's final
content. The responsibility for the content of this profile lies with ATSDR.

CONTENTS

LIST OF FIGURES

LIST OF TABLES

CHAPTER 1. RELEVANCE TO PUBLIC HEALTH

1.1   OVERVIEW AND U.S. EXPOSURES

Mercury occurs naturally as a mineral and is distributed throughout the environment by both natural and anthropogenic processes. The environmental fate of mercury has been well-characterized. The natural global bio-geochemical cycling of mercury involves degassing of the element from soils and surface waters, followed by atmospheric transport, deposition of mercury back to land and surface water, and sorption of the compound to soil or sediment particulates. Mercury deposited on land and open water is, in part, revolatilized back into the atmosphere. This emission, deposition, and revolatilization creates difficulties in tracing the movement of mercury to its sources. Anthropogenic emissions of mercury have typically been to the atmosphere; although these emissions have been declining for the past several decades in North America, global emissions continue to rise due to activities such as artisanal gold mining and fossil fuel burning.

Mercury exists in different valence states and as several types of compounds (Section 4.1). For this profile, mercury compounds are classified into three general categories: (1) elemental mercury; (2) inorganic mercury compounds (e.g., mercuric chloride); and (3) organic mercury compounds (e.g., methylmercury). Each mercury class has distinct chemical properties that contribute to different toxicokinetics and toxicodynamics (Section 2.1). A complete list of the mercury compounds evaluated in this profile can be found in Table 4-1.

Atmospheric mercury is primarily in the form of Hg^0 (gaseous elemental mercury), which is subject to long-range transport. Therefore, mercury is ubiquitous in the environment and is found in locations far removed from its release site. When deposited into water bodies, mercury can be methylated by anaerobic bacteria producing a highly bioaccumulative form of organic mercury (methylmercury) that biomagnifies up the aquatic food web. For this reason, mercury can often be detected at high levels in fish and other aquatic organisms, rice, and other vegetation.

Mercury has many uses due to its unique properties. However, several of these uses have been eliminated or reduced drastically, such as use in alkaline batteries; electronic switches and lighting applications; fungicides and pesticides; paints and pigments; and thermometers and other scientific and medical devices. Historically, mercury compounds were also used in a variety of industrial processes and products (e.g., felting, explosives) and as pharmaceutical agents (e.g., antibiotics, mercurial diuretics)

(Clarkson and Magos 2006). The most important domestic end users of mercury in 2019 were in the production of chlorine-caustic soda (chloralkali), dental products, electronics, and fluorescent-lighting manufacturing industries. In 2020, the use of mercury in the production of chloralkali was reduced when one of the two operating facilities in the United States converted to a non-mercury process.

The general population is exposed to all forms of mercury. However, exposure of the general population is primarily to organic mercury from dietary exposure to methylmercury (e.g., fish, seafood, rice) and elemental mercury from dental amalgams. Relative to organic and elemental mercury, exposure of the general population to inorganic mercury compounds is minimal. Occupational exposures are primarily to elemental mercury (e.g., dentistry, chloralkali process). Predominant sources of exposure to the general population and occupational exposures are described in greater detail in Sections 5.6 and 5.7.

Mercury levels in blood and urine are measured as part of the National Health and Nutrition Examination Survey (NHANES) (CDC 2024). Based on survey data for the period 2017–2018 (the most recent data available in CDC 2024), the geometric mean total blood mercury (BHg) level in the adult U.S. population was estimated to be 0.730 µg/L (95% confidence interval [CI] 0.620, 0.840). The geometric mean methylmercury blood level was 0.500 µg/L (95% CI 0.420, 0.610). Total and methylmercury blood levels in young children were lower than in adults. For the 2011–2012 period, the detection limits for total mercury were lower, reporting a geometric mean total BHg level of 0.262 µg/L (95% CI 0.237, 0.291) in children 1–5 years of age. The 50th percentiles for methylmercury blood levels in children 1–5 years of age were less than the detection limit (0.12 µg/L) during both time periods.

1.2   SUMMARY OF HEALTH EFFECTS

The toxicity of mercury compounds has been recognized since ancient times (Clarkson 2006; Genchi et al. 2017). Despite the long-established recognition of mercury-induced toxicity, toxicity associated with environmental exposure to mercury compounds has only been recognized since the 1950s (Ekino et al. 2007). Since that time, the relationship between mercury exposure and health outcomes has been extensively studied in epidemiological and animal studies. The focus of this profile is to summarize toxicological effects relevant to occupational and environmental (e.g., diet, water, soil, air) exposures. Therefore, other than mentioning past or current uses of mercury in consumer products (e.g., cosmetics, herbal remedies, tattooing pigments, paints) or for medicinal, preservative, ritual, or spiritual purposes (Section 5.5.4), the profile does not include in-depth discussion of these topics.

1. RELEVANCE TO PUBLIC HEALTH

The mechanisms of toxicity for mercury compounds are diverse and include targets that are common to all cells. The targets include intracellular calcium homeostasis, cytoskeleton, mitochondrial function, oxidative stress, neurotransmitter release, and deoxyribonucleic acid (DNA) methylation. A contributor to the diversity of mercury effects on biological systems is the high affinity of Hg^{2+} and CH_3Hg^{2+} for the thiolate anion and formation of Hg^{2+} and CH_3Hg^{2+} S-conjugates. This enables mercury to bind to and disrupt the structure and activity of enzymes, transporters, and other proteins that depend on functional thiol groups for activity. Given these diverse mechanisms, mercury compounds have the potential to adversely affect numerous targets.

As noted in Section 1.1, this profile classifies mercury compounds into three categories: (1) elemental mercury; (2) inorganic mercury compounds (primarily inorganic mercury salts); and (3) organic mercury compounds. Each mercury class exhibits different chemical properties that contribute to different toxicokinetics and toxicodynamics. The relevant routes of exposure for environmental exposure to the three mercury classes are: elemental mercury—inhalation; inorganic mercury salts—oral; and organic mercury compounds—oral. The following provides an overview of available studies in the epidemiological and animal databases.

Epidemiological Studies. All populations are exposed to a combination of elemental, inorganic, and organic mercury compounds; thus, no population is exposed to only one mercury category. In this profile, epidemiological study populations are classified as follows: (1) predominant exposure to elemental mercury; (2) predominant exposure to methylmercury; and (3) general population in which exposures are not defined by mercury class. Information on exposure of humans to inorganic mercury salts is limited to reports of acute-duration accidental or intentional exposure to near-fatal or fatal levels. With few exceptions, exposure duration for epidemiological populations is considered to be chronic-duration exposure.

For elemental mercury, populations are exposed predominantly to elemental mercury vapor in occupational settings and exposures to amalgams in dental restorations. Studies of associations between health outcomes and exposure to methylmercury have focused on populations in which methylmercury was the dominant contributor to total mercury exposure. These studies fall into two general categories: studies of outbreaks of mercury poisoning related to exposure to methylmercury (Minamata, Japan; and Iraq) and studies of populations that consume large amounts of fish and/or marine mammals (Faroe Islands, Seychelles Islands, and others).

Numerous epidemiological studies have examined associations between mercury biomarkers and health effects in general populations in children and adults, although many studies do not identify the predominant form of mercury. In general, populations without mercury amalgam dental restorations are assumed to primarily be exposed through the diet. In people who have amalgams, mercury vapor released from the amalgams will contribute to inhalation exposure. The use of mercury amalgam in dental restorations is being phased out in the United States. This will decrease exposure of the general population to elemental mercury. Exposure to atmospheric mercury also occurs, particularly in populations near mining or fuel combustion facilities.

To quantify mercury exposure in epidemiological populations, mercury levels are generally measured in blood (BHg), urine (UHg), hair (HHg), or nails (NHg). Measurements of total mercury in blood and urine are biomarkers of total mercury exposure. In populations predominantly exposed to elemental mercury vapor, total mercury in urine serves as a reliable biomarker of exposure. For populations predominantly exposed to methylmercury from consumption of high fish diets, total BHg or HHg serves as a reliable biomarker of exposure. In studies of general population, BHg and HHg are the biomarkers most commonly used to assess exposure, although as noted above, this does not allow for confidence in distinction between methylmercury or elemental mercury. Mercury in hair or nails can provide a measure of cumulative, long-term exposure because mercury is retained in hair and nails. Mercury levels in blood and urine are much more dynamic (Section 3.1) and more greatly affected by recent exposure history.

Animal Studies. Animal studies generally focus on similar exposure routes as epidemiological studies. For elemental mercury vapor, the animal database consists of acute- and intermediate-duration inhalation studies. No studies were identified for chronic-duration inhalation of elemental mercury vapor or for oral or dermal exposure to elemental mercury. The animal database for inorganic mercury salts includes acute-, intermediate-, and chronic-duration oral studies on mercuric chloride, with a few acute-duration oral studies conducted on mercuric sulfide and mercuric acetate. In addition, a few intermediate-duration inhalation studies were conducted on mercuric oxide. For organic mercury compounds, acute-, intermediate-, and chronic-duration oral studies were conducted in animals.

Health Effects of Mercury. The health effects of mercury identified from studies in humans and animals are summarized below for the three chemical classes of mercury. For all forms of mercury, neurological and renal effects have been consistently observed in epidemiological and/or animal studies. More detailed information, including reference citations, is provided in Chapter 2.

1. RELEVANCE TO PUBLIC HEALTH

Elemental Mercury. Neurological and renal effects have been observed in humans and animals exposed to elemental mercury vapor. Case reports of exposure to elemental mercury at fatal or near-fatal levels have observed severe adverse respiratory effects, including lung inflammation, pneumonitis, and respiratory failure due to pulmonary edema. Other targets of elemental mercury have not been well-studied in epidemiological or animal studies.

> *Neurological effects.* Neurological effects of occupational exposure to mercury have been recognized since the mid-19th century, referred to as "mad hatter's syndrome" due to severe neurological and psychological symptoms in hatters exposed to metallic mercury vapor during the felt-making process. Additionally, epidemiological studies provide consistent evidence of neurological effects in adults, including tremor, vision, nerve conduction, motor speed and fine motor coordination, cognitive performance (memory, and integrative function), and subjective physiological symptoms (mood swings, irritability, nervousness, timidity, loss of confidence). Animal studies provide additional evidence of neurodevelopmental effects (altered learning and behavior, altered motor activity, impaired habituation) and impaired motor function and damage to the central nervous system in adult animals.

> *Renal Effects.* Epidemiological studies provide some evidence of renal toxicity, such as decrements in glomerular function and tubular injury. Results of animal studies show dose- and duration-dependent increases in severity of nephrotoxicity characterized by damage to proximal tubules, distal tubules, and glomerular membrane, loss of brush border membranes, and renal necrosis.

Inorganic Mercury Salts. Information on health effects is primarily from oral studies in laboratory animals, with supporting data from acute poisoning case reports in humans. No epidemiological studies specific for exposure to inorganic mercury salts were identified. In addition to neurological and renal effects, studies provide some evidence of cardiovascular, hematological, immunological, and reproductive effects.

> *Neurological and neurodevelopmental effects.* Animal studies provide consistent evidence that the neurological system is an important target of inorganic mercury salts. Neurodevelopmental findings include hyperactivity, impaired motor coordination, impaired memory, and decreased sociability. In adult animals, neurological effects (hyperactivity, impaired coordination, impaired learning and memory), and overt signs of neurotoxicity in adults (hindlimb crossing, ataxia,

tremor, partial paralysis) and neuropathological changes to sensorimotor regions in the central nervous system (dorsal spinal route, cerebellum) have been observed.

Renal effects. Nephrotoxicity of inorganic mercury salts has long been established. Impaired renal function and damage in humans has been reported following acute inorganic mercury poisoning (Cappelletti et al. 2019; Park and Zheng 2012). Animal studies provide consistent evidence of dose- and duration-dependent increases in severity of renal toxicity, including damage to proximal tubules, distal tubules, and glomerular membrane, loss of brush border membranes, and necrosis.

Cardiovascular effects. Results of animal studies provide evidence of cardiovascular effects, including blood pressure, altered cardiac function, positive inotropic effects, and altered baroreceptor reflex sensitivity.

Hematological effects. Animal studies provide some evidence of hematological effects of inorganic mercury salts. Findings include impaired clotting, mild decreases in red blood cell (RBC) parameters (count, hemoglobin, hematocrit), and increases in white blood cell (WBC) counts. However, findings are of uncertain biological relevance due to limited evidence, small magnitude of effect, and/or inconsistency of observations.

Immunological Effects. Studies in genetically susceptible strains of mice indicate that inorganic mercury salts stimulate the immune system and induce immune complex disease.

Reproductive Effects. Dose-dependent impairment of fertility and decreased sperm motility and number have been observed in animal studies.

Organic Mercury. Neurological and neurodevelopmental effects are established as the most sensitive effects of oral exposure to organic mercury compounds. In addition, oral studies in humans and/or animals provide some evidence of renal, cardiovascular, immune, reproductive and developmental effects.

Neurological and neurodevelopmental effects. Epidemiological studies provide evidence of cognitive, neuromotor, and neurosensory effects associated with prenatal exposure to methylmercury. In adults, studies show decreased performance on tests of fine motor

coordination and speed, muscle strength, tactile sensation, color vision and visual contrast sensitivity, and memory and learning. Neurological effects in animals include sensorimotor dysfunction, vision and hearing deficits, impaired learning and memory, and overt signs of neurotoxicity (clumsiness, gross and fine motor incoordination, lethargy, hindlimb crossing, tremor, ataxia, partial paralysis). The developing nervous system is more vulnerable to methylmercury exposure than the mature nervous system because maternal-fetal and maternal-child transfer of methylmercury can occur at critical stages of development of the brain and cognition and prior to maturation of the blood-brain barrier to an adult functioning blood-brain barrier.

Renal effects. Studies in animals show consistent evidence of dose- and duration-dependent increases in severity of nephrotoxicity (damage to proximal tubules, distal tubules, and glomerular membrane, loss of brush border membranes, necrosis).

Cardiovascular effects. Some epidemiological studies show associations between mercury biomarkers and small increases in blood pressure, clinical hypertension, and altered cardiac function. In animals exposed to methylmercury, increased blood pressure, positive inotropism (strengthening of heart contraction), and decreased baroreflex sensitivity (maintenance of constant blood pressure) have been observed.

Immunological effects. Epidemiological studies have shown associations between biomarkers indicating increased mercury exposure and markers indicating changes in immune system function (serum cytokine levels, immunoglobulins, and immune cell counts); however, it is unknown if immune system function is altered. Studies in animals observed immune stimulation and immune complex disease in genetically susceptible strains of mice and some evidence of immune suppression in non-susceptible animals.

Reproductive effects. A*nimal studies provide consistent evidence of impairment in fertility.

Developmental effects. Developmental effects, including polydactyly (extra fingers or toes), syndactyly (fused or webbed fingers or toes), craniofacial malformations, microcornea (cornea less than 10 mm in diameter), undescended testicles, enlarged colon, and protrusion of the coccyx, were observed in the Minamata poisoning population, poisoned by organic mercury consumed in fish. Animal studies show consistent evidence of dose- and duration-dependent

decreases in offspring survival, increased fetal malformations and variations (cleft palate, skeletal malformations [ribs, sternebrae], and hydronephrosis [swelling of kidney]), and decreased fetal weight.

Cancer. Carcinogenicity has been assessed in rats and mice following chronic-duration oral exposure to mercuric chloride, methylmercury, and phenylmercuric acetate. Mercuric chloride induced forestomach and thyroid tumors in male rats and methylmercury induced renal tumors in male mice. There is limited evidence of renal tumors in male rats exposed to phenylmercuric acetate.

The Department of Health and Human Services has not classified the potential for elemental mercury, inorganic mercury compounds, or methylmercury compounds to cause cancer in humans (NTP 2016). The International Agency for Research on Cancer (IARC 1993) concluded that elemental mercury and inorganic mercury compounds are not classifiable as to their carcinogenicity to humans (Group 3) and methylmercury compounds are possibly carcinogenic to humans (Group 2B) based on inadequate evidence in humans for mercury and mercury compounds, inadequate evidence in experimental animals for elemental mercury, limited evidence for carcinogenicity of mercuric chloride in experimental animals (forestomach tumors in rats), and sufficient evidence for carcinogenicity of methylmercuric chloride in experimental animals (kidney tumors in male mice). The U.S. Environmental Protection Agency (EPA) Integrated Risk Information System (IRIS 1995a) concluded that elemental mercury is not classifiable as to human carcinogenicity (Group D) based on inadequate human and animal data. IRIS (1995b) concluded that mercuric chloride is a possible human carcinogen (Group C) based on no human data and limited evidence of carcinogenicity in animals (forestomach and thyroid tumors in male rats). IRIS (2001) also concluded that methylmercury is a possible human carcinogen (Group C) based on inadequate data in humans and limited evidence of carcinogenicity in animals (kidney tumors in male mice).

Health effects of mercury compounds observed in animals at various inhalation exposure levels or oral doses are summarized in the following figures: Figure 1-1, inhaled elemental mercury; Figure 1-2, oral inorganic mercury salts; and Figure 1-3, organic mercury. Note that for all studies, exposure is expressed in terms of mercury (i.e., mg Hg/kg/day), and not in terms of specific mercury compounds, to allow comparison of doses across studies. Epidemiological studies do not typically report exposure levels (mg Hg/m^3) or doses (mg/kg/day) and are summarized in separate tables throughout the profile. The MRLs shown in Figures 1-1 and 1-3 are based on human data with exposure levels predicted from reported biomarkers (Appendix A).

1. RELEVANCE TO PUBLIC HEALTH

Figure 1-1. Health Effects Found in Animals Following Inhalation Exposure to Elemental Mercury

Dose (mg Hg/m³)   **Effects in Animals**

27   **Acute:** Death, asphyxiation, lung damage

8   **Acute:** Developmental effects (decreased pup weight, decreased litter size)

4   **Acute:** Renal effects (urinalysis, increased kidney weight), decreased body weight

3   **Intermediate:** Renal effects (histology)

0.5   **Acute:** Neurological effects (behavior, histology)

                       Intermediate: Neurological effects (behavior, histology), decreased body weight

0.188   **Intermediate:** Developmental effects (neurological)

0.05   **Acute:** Developmental effects (neurological)

0.0003 mg Hg/m³   **Chronic MRL (based on human data and exposure levels predicted from biomarkers)**

Figure 1-2. Health Effects Found in Animals Following Oral Exposure to Inorganic Mercuric Salts*

*Inorganic mercury studies primarily evaluated mercuric chloride, with a few acute-duration oral studies conducted on mercuric sulfide and mercuric acetate.

Figure 1-3. Health Effects Found in Animals Following Oral Exposure to Organic Mercury

Dose (mg Hg/kg/day)   **Effects in Animals**

>1

Acute: Death, decreased body weight, and renal effects (increased kidney weight) and decreased heart rate

0.6-1

Intermediate: Death

Chronic: Death, decreased body weight

0.1-0.5

Acute: Male reproductive effects (decreased seminal vesicle weight, sperm and hormone effects)

Intermediate: Decreased body weight, developmental effects (decreased fetal weight and survival)

Chronic: Renal effects (histology)

0.01-0.08

Acute: Developmental effects (defects, variations)

Intermediate: Developmental effects (neurological)

Chronic: Renal effects (histology) Developmental effects (neurological), neurological effects (behavior, histology), female reproductive effects (reduced viable pregnancies)

0.005-0.008

Acute: Developmental effects (neurological)

Intermediate: Elevated blood pressure, renal effects (clinical chemistry), neurological effects (behavioral), male reproductive effects (resulting in no viable pregnancies)

0.0004

Intermediate: Altered immune function

0.0003

Intermediate: Developmental effects (immune)

0.0001 mg Hg/kg/day   **Chronic MRL (based on human data and exposure levels predicted from biomarkers)**

1.3   MINIMAL RISK LEVELS (MRLs)

MRLs have been developed for each class of mercury compounds (Tables 1-1, 1-2, and 1-3 for elemental mercury, inorganic mercury salts, and methylmercury, respectively). Figures 1-4, 1-5, and 1-6 show the most sensitive targets for inhaled elemental mercury, oral inorganic mercury salts in animals, and oral methylmercury, respectively. For elemental mercury, a chronic-duration inhalation MRL was derived based on neurological effects observed in epidemiological studies (Figure 1-4). For inorganic mercury salts, acute- and intermediate-duration oral MRLs were developed from studies in animals showing renal toxicity (Figure 1-5). For methylmercury, a chronic-duration oral MRL based on neurodevelopmental effects was derived using epidemiological data (Figure 1-6). Details of MRL derivations are provided in Appendix A.

Figure 1-4. Summary of Sensitive Targets of Elemental Mercury – Inhalation

Available data indicate that the developing nervous system and the adult neurological and renal systems are the most sensitive targets of elemental mercury inhalation exposure.

Numbers in circles are the lowest LOAELs for all health effects in animals and the number in the triangle is the point-of-departure (POD) for the chronic-duration inhalation MRL based on human data*.

*This value (0.00284 mg/m^3 or 2.84 µg/m^3) is the lower 95% confidence limit on the weighted mean for neurological effects (tremor) from seven occupational studies.

1. RELEVANCE TO PUBLIC HEALTH

Figure 1-5. Summary of Sensitive Targets of Inorganic Mercuric Salts – Oral

Available data indicate that the renal, cardiac, immune, and reproductive systems are the most sensitive targets of inorganic mercuric salts oral exposure.

Numbers in circles are the lowest reliable LOAELs for all health effects in animals.

Acute (mg Hg/kg/day)

Renal ——————————————————————// (1.8)———

Reproductive —————————————————————————— (3)

Intermediate (mg Hg/kg/day)

Renal (0.015)——————————————————————————

Cardiovascular ——(0.07)——————————————————————

Immunological ————(0.118)———————————————————

Chronic (mg Hg/kg/day)

Cardiovascular ——————————————————(0.66)——————

Renal ———————————————————//—(1.8)——

Cancer ———————————————————//————(4)

Figure 1-6. Summary of Sensitive Targets of Organic Mercury – Oral

Available data indicate that the developing nervous and immune systems and the adult neurological, immune, male reproductive, renal, and cardiac systems are the most sensitive targets of organic mercury oral exposure in animals; the developing nervous system is the most sensitive target of methylmercury oral exposure in humans.

Numbers in circles are the lowest LOAELs for all health effects in animals and the number in the triangle is the point-of-departure (POD) for the chronic-duration oral MRL based on human data*.

Acute (mg Hg/kg/day)

Developmental (neuro)   0.008

Neurological   0.2

Reproductive   0.5

Renal   2.8

Intermediate (mg Hg/kg/day)

Developmental (immune)   0.0003

Immunological   0.0004

Cardiovascular   0.005

Renal   0.006

Chronic (mg Hg/kg/day)

Developmental (neuro)   0.00041

*This value (0.00041 mg Hg/kg/day or 0.41 µg Hg/kg/day) is the no-adverse-effect level for neurodevelopmental effects (decreased IQ) from a meta-analysis (Axelrad et al. 2007a, 2007b) of three epidemiological studies.

Table 1-1. Minimal Risk Levels (MRLs) for Elemental Mercury[a]

Exposure route	Exposure duration	MRL	Critical effect	POD type	POD value	Uncertainty/ modifying factor	Reference
Inhalation	Acute	None	–	–	–	–	–
	Intermediate	None	–	–	–	–	–
	Chronic	**0.3 µg Hg/m³**	Tremors	95% lower confidence limit of weighted median of seven principal studies	2.84 µg Hg/m³	UF: 10	Bast-Pettersen et al. 2005; Boogaard et al. 1996; Chapman et al. 1990; Ellingsen et al. 2001; Fawer et al. 1983; Langworth et al. 1992a; Wastensson et al. 2006, 2008
Oral	**No oral MRLs were derived for any duration**						

[a]See Appendix A for additional information.

POD = point of departure; UF = uncertainty factor

Table 1-2. Minimal Risk Levels (MRLs) for Inorganic Mercury Salts[a]

Exposure route	Exposure duration	MRL	Critical effect	POD type	POD value	Uncertainty/ modifying factor	Reference
Inhalation	**No inhalation MRLs were derived for any duration**						
Oral	Acute	**0.002 mg Hg/kg/day**	Elevated relative kidney weight	BMDL$_{ADJ}$	0.21 mg Hg/kg/day	UF: 100	Dieter et al. 1992; NTP 1993
	Intermediate	**1x10^{-5} mg Hg/kg/day**	Decreased renal function and histopathological changes	LOAEL	0.015 mg Hg/kg/day	UF: 1,000	Apaydin et al. 2016
	Chronic	None	–	–	–	–	–

[a]See Appendix A for additional information.

ADJ = adjusted; BMDL = 95% lower confidence limit on the BMD; LOAEL = lowest observed adverse effect level; POD = point of departure; UF = uncertainty factor

1. RELEVANCE TO PUBLIC HEALTH

Table 1-3. Minimal Risk Levels (MRLs) for Methylmercury[a]

Exposure route	Exposure duration	MRL	Critical effect	POD type	POD value	Uncertainty/ modifying factor	Reference
Inhalation	**No inhalation MRLs were derived for any duration**						
Oral	Acute	None	–	–	–	–	–
	Intermediate	None	–	–	–	–	–
	Chronic	**0.1 µg Hg/kg/day**	Neurodevelopmental effects (decreased IQ)	NAEL	0.41 µg Hg/kg/day	UF: 3	Axelrad et al. 2007a, 2007b

[a]See Appendix A for additional information.

IQ = intelligence quotient; NAEL = no-adverse-effect level; POD = point of departure; UF = uncertainty factor

CHAPTER 2. HEALTH EFFECTS

2.1   INTRODUCTION

The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and other interested individuals and groups with an overall perspective on the toxicology of mercury. It contains descriptions and evaluations of toxicological studies and epidemiological investigations and provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health.

A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile.

To help public health professionals and others address the needs of persons living or working near hazardous waste sites, the information in this section is organized by health effect. These data are discussed in terms of route of exposure (inhalation, oral, and dermal) and three exposure periods: acute ($\leq$14 days), intermediate (15–364 days), and chronic ($\geq$365 days).

As discussed in Appendix B, a literature search was conducted to identify relevant studies examining health effect endpoints. The following figures provide overviews of the human and animal databases included in this chapter of elemental mercury (Figure 2-1), inorganic mercury (Figure 2-2), organic mercury (Figure 2-3), and for exposures where the predominant form mercury is unknown (general populations) (Figure 2-4). These studies evaluate the potential health effects associated with inhalation and oral exposure to mercury but are not inclusive of the entire body of literature.

Results of epidemiological studies are provided in each section of Chapter 2. Animal studies are presented as follows: inhaled elemental mercury, Table 2-1 and Figure 2-5; inhaled mercuric oxide, Table 2-2 and Figure 2-6; oral inorganic mercuric salts, Table 2-3 and Figure 2-7; and oral organic mercury, Table 2-4 and Figure 2-8. No quantitative dermal data were identified for mercury compounds.

Levels of significant exposure (LSEs) for each route and duration are presented in tables and illustrated in figures. Note that for all studies, exposure is expressed in terms of mercury (i.e., mg Hg/kg/day), and not in terms of specific mercury compounds, to allow comparison of doses across studies. The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest-observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies. Effects have been classified into "less serious LOAELs" or "serious LOAELs (SLOAELs)." "Serious" effects are those that evoke

failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress or death). "Less serious" effects are those that are not expected to cause significant dysfunction or death, or those whose significance to the organism is not entirely clear. ATSDR acknowledges that a considerable amount of judgment may be required in establishing whether an endpoint should be classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be insufficient data to decide whether the effect is indicative of significant dysfunction. However, the Agency has established guidelines and policies that are used to classify these endpoints. ATSDR believes that there is sufficient merit in this approach to warrant an attempt at distinguishing between "less serious" and "serious" effects. The distinction between "less serious" effects and "serious" effects is considered to be important because it helps the users of the profiles to identify levels of exposure at which major health effects start to appear. LOAELs or NOAELs should also help in determining whether or not the effects vary with dose and/or duration, and place into perspective the possible significance of these effects to human health. Levels of exposure associated with cancer (Cancer Effect Levels, CELs) of oral inorganic mercury are indicated in Table 2-3 and Figure 2-7; CELs for oral organic mercury are indicated in Table 2-4 and Figure 2-8.

A User's Guide has been provided at the end of this profile (Appendix C). This guide should aid in the interpretation of the tables and figures for LSEs and MRLs.

Mercury and mercury compounds have been used for industrial and medicinal purposes since ancient times and the toxicity of mercury compounds has long-been recognized (Clarkson 2006; Genchi et al. 2017). Environmental mercury exposures that could result in adverse health effects were only recognized in the early 1950s when residents of Minamata, Japan consumed methylmercury-contaminated fish and seafood (Ekino et al. 2007). Since the Minamata poisoning, an extensive database of epidemiological and animal studies has examined relationships between exposures to mercury and effects on health outcomes.

In this profile, mercury compounds are classified into three categories: (1) elemental mercury; (2) inorganic mercury compounds (primarily inorganic mercury salts); and (3) organic mercury compounds, with each mercury category exhibiting different properties. These properties play a significant role in defining the toxicokinetics and toxicity profiles for each mercury class. Mercury has no known physiological role in humans (Carocci et al. 2014). The focus of this profile is to summarize toxicological effects of the three mercury classes using epidemiological and animal studies that are relevant to the major sources of environmental exposure. Various consumer (e.g., skin lightening creams and soaps, herbal remedies, laxatives, tattooing dyes, fingerpaints, artists paints, and make-up paints) and

medicinal products (e.g., thimerosal, an ethylmercury-containing compound that was used as a preservative in vaccines) that contain mercury or mercury compounds can contribute to exposure to consumers (DeVito and Brooks 2013; McKelvey et al. 2011; Rastogi 1992; Wendroff 1990). Toxicities of consumer and medicinal products, other than mercury dental amalgams, are not specifically considered or evaluated in this profile, as these exposures are not classified as environmental exposures. However, any mercury released into air, water, or soil via consumer use or disposal of mercury-containing products would contribute to exposures detected in environmental media and/or biomarkers of exposure in epidemiological studies. The toxicology of mercuric cyanide is not discussed in this profile because the exposure-response relationship for mercuric cyanide will reflect contributions of inorganic mercuric mercury and cyanide. The toxicology of inorganic mercuric mercury is described in this the profile. The toxicology of cyanide is described in the ATSDR Toxicological Profile for Cyanide.

Since the development of the previous Toxicological Profile on Mercury in 1999, the database for epidemiological studies has grown considerably, with more extensive investigations of populations with high dietary exposure to mercury-contaminated fish and of general populations with lower levels of mercury exposures. Studies have also expanded investigations to focus on effects and endpoints other than neurological. In addition, more epidemiological studies have included biomarkers of exposure (e.g., mercury in blood, hair, or urine). The literature database for studies in laboratory animals has expanded with evaluations of effects in other organ systems, and more recent studies have evaluated lower exposure levels than those used in earlier studies.

Literature Search Strategy and Inclusion Criteria. The literature database on health effects of mercury is enormous, with a large number of epidemiological studies, including studies in children, and studies in laboratory animals. Due to the extent of the literature database, it is not practical or realistic to cite all, or even most, of the studies on health effects of mercury. Thus, this profile does not attempt to provide a comprehensive review of all literature; instead, the profile summarizes the major lines of evidence regarding health effects. Due to the extensive number of available epidemiological studies, case reports are generally not included in the profile. However, exceptions include discussion of acute-duration accidental or intentional exposure to near-fatal or fatal levels of mercury, and to describe portal-of-entry effects following acute-duration exposures.

ATSDR's approach for assessing study quality and weight-of-evidence evaluation is described in ATSDR's Guidance for the Preparation of Toxicological Profiles document (https://www.atsdr.cdc.gov/toxprofiles/guidance/profile_development_guidance.pdf). For

epidemiological studies, well-conducted and reported studies were considered for inclusion in the profile. Quality criteria were considered in selecting studies to include in the mercury profile and, in particular, for consideration as support for MRLs. In general, epidemiological studies that attempted dose-response assessments (e.g., regression models) were included in the profile if the following criteria were met: (1) reported estimates of variance in the dose-response metrics (e.g., standard error [SE], confidence level [CL]); (2) included adjustments for confounding; and (3) reported biomarker data. For studies used to derive MRLs, reporting of quality assurance of analytical methods was also required. For most studies included in the profile, these inclusion criteria were followed, although there are a few exceptions. For example, biomarkers were not available for some mercury poisoning outbreaks from the 1950s–1970s because mercury exposure was not recognized as the cause of symptoms at the time of exposure (e.g., Minamata disease). However, these studies are included because they identified severe neurological and neurodevelopmental effects in populations exposed to environmental methylmercury, providing the rationale for subsequent environmental and biomarker-based epidemiological investigations of these endpoints.

For animal studies, all well-conducted and reported studies were considered for inclusion, with the focus on relevant routes of exposure. A large amount of parenteral (injection) studies in animals exist, with most focusing on induction of renal toxicity using high doses of inorganic mercury salts. These studies are not included for dose-response assessments because they do not provide information about effects at low doses of mercury, and parenteral administration is not a relevant route for human exposure.

Mechanism of Toxicity. Mercury produces toxicity by a variety of mechanisms, which are discussed in depth in Section 2.21 and in discussions of specific categories of health effects. In general, these mechanisms include alteration or disruption of regulation of intracellular calcium homeostasis, cytoskeleton, mitochondrial function, oxidative stress, neurotransmitter release, and DNA methylation. Mercury binding to thiolate anions may underlie many of these alterations or disruptions since: (1) thiolates are present in almost every biological system, and (2) Hg^{2+} and CH_3Hg^{2+} have high affinity for the thiolate anion and formation of Hg^{2+} and CH_3Hg^{2+} S-conjugates.

Mercury binds to and disrupts the activity of enzymes, transporters, and other proteins that depend on functional thiol groups. Mercury can also displace other physiological metals (e.g., iron, zinc) that regulate enzyme activity through interactions with protein thiols. While binding to thiol groups is reversible, the binding kinetics are sufficiently fast enough that Hg^{2+} and CH_3Hg^{2+} migrate from one accessible thiolate anion to another.

Low molecular weight thiols also serve as important ligands for mercury transport in and out of cells. Conjugates of Hg^{2+} and CH_3Hg^{2+} with extracellular thiols (e.g., cysteine, glycinyl-cysteine, glutathione) are recognized by physiological transport systems for amino acids (e.g., molecular mimicry) and, once in cells, mercury can distribute to other critical intracellular thiol groups. Transport of mercury S-conjugates has been shown to be important in a variety of tissues, including brain, intestines, kidneys, liver, placenta, and RBCs. The high lipid solubility of elemental mercury (Hg^0) contributes to partitioning of inhaled mercury vapor into blood and delivery of Hg^0 to the brain where it can be oxidized to Hg^{2+} and form Hg^{2+}-thiol conjugates.

Toxicokinetics of Mercury Compounds. Humans are exposed to many forms of mercury, and these exhibit route-dependent and chemical-species-dependent toxicokinetics. The major categories discussed in this section are elemental mercury (Hg^0, e.g., mercury vapor) and inorganic mercuric (Hg^{2+}, e.g., mercuric chloride), inorganic mercurous (Hg^+, calomel), and organic mercuric (Hg^{2+}, e.g., methylmercury, dimethylmercury, phenylmercury) compounds.

Elemental mercury. Absorption of inhaled mercury vapor was estimated to range from 69 to 85% in human adults. Absorption of elemental mercury ingested as mercury amalgam was estimated to be 0.04% in human adults. Systemic absorption of mercury has been shown to occur in human adults following skin exposure to mercury vapor (approximately 2% of absorption from inhalation during a full-body immersion in mercury vapor) (Hursh et al. 1989).

Following inhalation exposure to mercury vapor, mercury distributes throughout the body, with the highest concentrations occurring in the kidneys. Vascular proximity of the heart and brain coupled with a limiting oxidation rate of Hg^0 in blood contributes to a first-pass effect on uptake of Hg^0 in these tissues following inhalation of mercury vapor. Inhaled mercury vapor can be transferred from the mother to the fetus and also from the mother to infants via maternal milk.

Absorbed Hg^0 is eliminated in exhaled air and by oxidation to mercuric mercury (Hg^{2+}). The major oxidative pathway for Hg^0 is catalyzed by the enzyme catalase. Following oxidation of Hg^0 in blood and tissues, Hg^{2+} is excreted in urine and feces.

Following inhalation of mercury vapor, mercury elimination kinetics exhibit multiple phases. The terminal half-time, thought to largely reflect urinary and fecal excretion of Hg^{2+}, has been estimated in

humans to range from 30 to 90 days. Several pharmacokinetics models of inorganic mercury have been published. Of these, two models were developed to predict the absorption and distribution of inhaled mercury vapor (Jonsson et al. 1999; Leggett et al. 2001).

Inorganic mercuric mercury. Following accidental inhalation exposures to mercuric oxide (^{203}HgO), mercury was detected in various body regions, including head, kidneys, pelvis, and in the legs, indicating systemic absorption. Absorption of mercury following ingestion of inorganic mercury compounds was estimated to range from 1 to 16% in human adults. Studies conducted in rodents have found that gastrointestinal absorption is higher in younger rats. Inorganic mercuric mercury was shown to be absorbed across isolated human and pig skin. Following ingestion of mercuric chloride, mercury distributes throughout the body, with the highest concentrations occurring in the kidneys and liver.

Inorganic mercury is found in human cord blood, placenta, and breast milk, indicating transfer to the fetus and infant, respectively. Exhaled Hg^0 was observed in mice following parenteral doses of mercuric chloride, suggesting that Hg^{2+} had been reduced to Hg^0. Salivary and gastrointestinal bacteria have been shown to methylate Hg^{2+}; however, the quantitative significance of methylation in the disposition of absorbed Hg^{2+} remains uncertain. The major routes of excretion of absorbed mercuric mercury are feces and urine.

Kinetics of elimination of absorbed inorganic mercuric mercury exhibits multiple phases. The terminal half-time has been estimated in humans to range from 49 to 120 days (Farris et al. 2008). Several pharmacokinetics models of inorganic mercury have been published. These models are based on studies of pharmacokinetics of absorbed inorganic mercuric mercury.

Inorganic mercurous mercury. No studies were located that provide quantitative information on the absorption, distribution, metabolism, or excretion of mercury following exposure to inorganic mercurous compounds. Pharmacological and cosmetic uses of calomel (mercurous chloride) ointments (skin lightening creams, acne) have resulted in elevated urinary mercury levels and mercury poisoning, indicating that absorption of mercury can occur following oral and/or dermal exposure to inorganic mercurous compounds. Toxicity may have been from absorbed inorganic mercuric mercury, as the low pH and high chloride concentration of the gastric environment favor oxidation of ingested Hg^1 to Hg^{2+}.

Organic Mercuric Mercury. No studies were found that have estimated absorption of inhaled organic mercuric mercury. Studies conducted in humans, monkeys, and rodents have shown that gastrointestinal

absorption of mercury is close to 100% following ingestion of methylmercury chloride or when incorporated into fish or other ingested protein. Dimethylmercury is rapidly absorbed through human skin.

Following ingestion of methylmercury, mercury distributes throughout the body, with the highest concentrations occurring in the liver, kidneys, and brain. Methylmercury is also found in human cord blood, placenta, and breast milk, indicating transfer to the fetus and infant, respectively. Studies conducted in humans and in a variety of other mammalian species have observed both methylmercury and inorganic mercury in tissues and excreta following exposure to methylmercury. Demethylation occurs in liver, phagocytes, brain, and other tissues. The major routes of excretion of absorbed methylmercury are feces, urine, and hair. Following exposure to phenylmercury, absorbed mercury is eliminated in bile, feces, urine, and hair.

Kinetics of elimination of absorbed methylmercury exhibits multiple phases. The terminal half-times have been estimated in humans to range from 50 to 130 days. Pharmacokinetics models of methylmercury have been developed for humans and a variety of other animal species.

Routes of Exposure and Mercury Sources. Relevant routes of exposure for humans vary based on the category of mercury compound.
- *Elemental mercury*. The most relevant route of exposure to elemental mercury is through inhalation of mercury vapor. Exposure of workers to elemental mercury vapor has occurred in several occupational settings, including chloralkali processing (i.e., production of chlorine and sodium hydroxide), fluorescent lamp production, gold mining and processing, lithium-6 purification (column exchange [COLEX] process), mercury amalgam dentistry, mercury battery production, natural gas production, recycling, and thermometer production. Humans can also be exposed to elemental mercury from inhalation and ingestion of mercury released from mercury amalgam dental restorations.
- *Inorganic mercury salts*. Oral exposure is the primary route of exposure to inorganic mercury salts. Exposure may occur through diet or contaminated environmental media (e.g., soil). Exposure to inorganic mercury salts is currently not a predominant exposure for the general U.S. population.
- *Organic mercury compounds*. Methylmercury is by far the predominant form for organic mercury exposure in populations. Exposure to methylmercury occurs worldwide through the diet, with fish as the main dietary source of methylmercury.

Epidemiological Studies. Numerous epidemiological studies have examined effects of environmental exposures to mercury compounds. The following provides a brief overview of the epidemiological database and important considerations for epidemiological studies.

Metrics of exposure (biomarkers). Humans are exposed to a mixture of methylmercury and inorganic mercury (primarily mercuric and elemental) in their local environments, with either being more or less pronounced under certain circumstances (e.g., occupational exposure to Hg^0 vapor, consumption of methylmercury in fish). Exposure to mercury that leads to absorption of mercury in any form can be detected from measurement of total mercury (inorganic plus organic) in blood or urine. A change in exposure will be reflected in a change in blood (BHg) or urine total mercury (UHg). Measurements of total mercury in blood and urine can be considered biomarkers of total mercury exposure. These measurements do not provide information to confidently estimate the magnitude of exposures specifically to methylmercury, inorganic mercury compounds, or elemental mercury.

Biomarkers that are more strongly correlated to methylmercury exposure are blood methylmercury concentration or total mercury concentrations in hair (HHg) or RBCs. Blood and hair are more significant depots for accumulation of methylmercury than inorganic mercury. Biomarkers that are more strongly correlated to exposure to inorganic forms of mercury (primarily mercuric and elemental) are inorganic mercury in blood (or plasma) and inorganic mercury or total mercury in urine. However, demethylation after absorption contributes inorganic mercury to blood and urine; this complicates distinguishing exposures to inorganic mercury from exposures to methylmercury based solely on measurements of total mercury in blood or urine.

In workers exposed to high levels of mercury vapor, elemental mercury is likely to be the dominant form, and total mercury in urine can serve as a reliable biomarker of exposure. Epidemiological studies of methylmercury have focused on populations that consume large amounts of fish or marine animals. In these populations, methylmercury is likely to be the dominant contributor to exposure, and total mercury in blood or hair can serve as a reliable exposure biomarker.

Duration of exposure. With few exceptions, the duration of exposure to mercury in epidemiological studies is considered to be chronic. Exceptions include intermediate-duration exposures in an occupational study in elemental mercury workers and studies on the Iraq methylmercury poisoning

outbreak. No epidemiological studies examining populations exposed to mercury for acute durations were identified.

Study populations and sources of exposure. All populations are exposed to a combination of elemental, inorganic, and organic mercury compounds; thus, no population is exposed to only one mercury category. In this profile, epidemiological study populations are classified as follows: (1) predominant exposure to elemental mercury; (2) predominant exposure to methylmercury; and (3) general populations in which the predominant form of mercury is unknown and cannot be discerned from the reported biomarker measurements. Details of these population are described below. Information on exposure of humans to inorganic mercury compounds is limited to reports of acute-duration accidental or intentional exposure to near-fatal or fatal levels. Clinical findings associated with these high-dose, acute-duration exposures are reviewed in Section 2.2.

Elemental Mercury. Populations exposed predominantly to elemental mercury consist of occupational exposures and exposures to mercury amalgam in dental patients. Studies of exposures to mercury vapor have been conducted in workers of various industries including chloralkali, fluorescent lamp production, gold mining and processing, lithium-6 purification (COLEX process), dentistry applications of mercury amalgam, mercury battery production, natural gas production, recycling, and thermometer production. In some occupational studies, work area or breathing zone mercury levels in a subset of the study group were reported. The most common biomarker reported is mercury concentration in urine (UHg; expressed in terms of µg/L or µg/g creatinine). The timing of measurement varied across studies. In some cross-sectional studies, these were based on measurements made at a single time, typically at the time of outcome assessment. For some retrospective studies, UHg estimates were derived from historical industrial hygiene monitoring data. In some studies, the individual subject data were aggregated into metrics of cumulative exposure (e.g., sum of quarterly average values for all exposure years) or exposure intensity (sum/exposure years). Most occupational studies have assessed health outcomes by comparison of exposed and reference (unexposed) groups. Inhalation is the primary route of exposure. Exposures of workers may be relatively constant during the workday (e.g., chloralkali workers) or highly intermittent (e.g., dental workers). For exposure of populations with amalgam fillings, biomarker levels are typically lower than those observed in occupational populations.

Methylmercury. Studies of associations between health outcomes and exposure to methylmercury have focused on populations in which methylmercury was the dominant contributor to total mercury exposure. These studies fall into two general categories: studies of outbreaks of mercury poisoning related to

exposure to methylmercury and studies of populations that consume large amounts of fish and/or marine mammals. Two major outbreaks of methylmercury poisoning have been extensively studied.

- *Minamata poisoning outbreak.* In the Minamata outbreak, discharges of wastewater from an acetaldehyde production facility into the Shiranui Sea located in the Kumamato Prefecture of Japan resulted in elevated levels of methylmercury in fish and shellfish (Harada 1995). Methylmercury entered the waste stream as a side product of the acetaldehyde production process, which used mercury sulfate as a reactant. In the mid-1950s, an outbreak of a neurological disorder (Minamata disease and congenital Minamata disease) occurred in the area. The timing of the outbreak appears to have been related to the expansion of acetaldehyde production at the facility (Harada 1995). Exposure to methylmercury resulted from ingestion of locally harvested fish and shellfish. Studies of health outcomes in this population focused on neurological and neurodevelopmental effects. Measurements of mercury in blood and hair were not made until several years following the period of most intense exposure and, therefore, do not provide reliable estimates of exposures that may have contributed to Minamata disease.

- *Iraq poisoning outbreak.* An outbreak of methylmercury poisoning occurred in Iraq in 1972–1973 as a result of widespread consumption of bread made from wheat that had been treated with a methylmercuric fungicide (Al-Mufti et al. 1976; Bakir et al. 1973; Clarkson et al. 1976). Studies of health outcomes in this population focused on neurological and neurodevelopmental effects. Based on measurements of methylmercury in flour used to bake contaminated bread and estimates of bread consumption, methylmercury intake was estimated to have ranged from 80 to 1,000 mg over a 3-month period (Al-Mufti et al. 1976). BHg levels in poisoning cases measured approximately 65 days after exposure ranged from 10 to 3,000 µg/L (Clarkson et al. 1976). Prenatal exposures were reconstructed from segmental analysis of single maternal hair strands and used to derive prenatal dose-response relationships for neurodevelopmental outcomes (Cox et al. 1989; Crump et al. 1995; Marsh et al. 1987).

- *Studies of populations with high fish diets.* Biomagnification of mercury levels in aquatic systems contributes to relatively high levels of methylmercury in predatory fish and marine mammals. As a result, methylmercury can be the dominant form of mercury exposure in populations that consume large amounts of these organisms. In these populations, BHg or HHg levels are typical biomarkers of methylmercury exposure. Several populations of high fish consumers have been extensively studied for associations between exposure to methylmercury and health outcomes. Examples include studies conducted on populations in the Republic of Seychelles, Faroe Islands, North Island New Zealand, Nunavik region of arctic Canada, and

Amazon River basin. In each of these populations, BHg or HHg levels positively correlated with consumption of fish.

Predominant Mercury Form Unknown (General Populations). Numerous epidemiological studies have examined association between mercury biomarkers and health effects in adults and children. Many of these studies do not identify the predominant form of mercury. In general populations that do not have mercury amalgam dental restorations, dietary exposure is assumed as the primary exposure. In people who have amalgams, mercury released from the amalgams will contribute to exposure. In people who have 7–13 amalgam restorations, amalgam mercury can contribute approximately half of the mercury absorbed from all sources (Mackert and Berglund 1997; Snapp et al. 1989). Biomarkers used to quantify exposures in studies of general populations vary and include BHg, HHg, and UHg. The study population sizes have varied greatly from <100 to almost 50,000 and included prospective studies and cross-sectional studies in large populations, such as participants in the U.S. National Health and Nutrition Examination Survey (NHANES) and the Korea National Health and Nutrition Examination Survey (KNHANES).

Potentials sources of bias. Bias can occur in epidemiological studies when the background risk of the outcome being measured is not the same in the exposed and reference groups. Confounders are factors that account for all or part of the difference in the measured outcome between groups and are not a direct effect of exposure. Not adjusting for confounders may attenuate or strengthen the apparent associations between mercury exposure and the outcome, depending on whether it is a negative or positive confounding variable. Confounders can be addressed in epidemiological studies using a variety of strategies including stratification and matching of subjects, or, in regression models, including these factors as co-variables in the models.

Because of the importance of dietary fish consumption as a source of exposure to methylmercury, fish consumption is a particularly important potential confounder between exposure to methylmercury and health outcomes. For example, fish contain nutrients that have been shown to be important modifiers of development (e.g., 3-omega long-chain polyunsaturated fatty acids, LCPUFA) (Cheatham 2008; Muldoon et al. 2014). In populations consuming marine mammals, dietary intake of polychlorinated biphenyls (PCBs) and selenium that accumulate in marine mammal tissue, can also be a source of confounding bias (Boersma and Lanting 2000; Park et al. 2010; Skröder et al. 2017).

The list of factors than can introduce bias into assessment outcome association with mercury exposure can be quite large. For example, assessing potential associations between mercury exposure and human

developmental outcomes involves accounting for many confounders. These factors may include (but are not limited to) child sex, birth weight, birth order, gestational age, and breastfeeding; maternal age, alcohol and tobacco use, and medical history; parental education, caregiver general intelligence, family income, family language; home learning, language, and social stimulation; exposure to other neurotoxins (e.g., lead, PCBs); nutritional factors (e.g., fish consumption); history of neurological disease or head injuries; and genetic factors that may influence mercury toxicity.

Effect modification. Effect modifiers occur when the relationship between an exposure and an outcome vary by a third variable (the effect measure modifier). For example, renal disease from any cause can affect blood pressure and could thereby interact with mercury to change blood pressure. A variable may act as both an effect modifier and a confounder, depending on a variety of factors. Effect modifiers may be investigated, often to identify susceptible populations or co-exposures that may interact with mercury and change the association of mercury exposure with a health outcome to produce a synergistic or antagonistic effect.

Studies in Laboratory Animals. Animal studies focus on the relevant exposure routes as discussed above for epidemiological studies. For elemental mercury vapor, the animal database consists of acute- and intermediate-duration inhalation studies. No adequate studies were identified for chronic-duration inhalation of elemental mercury vapor or for oral or dermal exposure to elemental mercury. The animal database for inorganic mercury salts includes acute-, intermediate-, and chronic-duration oral studies on mercuric chloride, with a few acute- and intermediate-duration oral studies conducted on mercuric sulfide and one acute-duration study conducted on mercuric acetate. In addition, two intermediate-duration inhalation studies were conducted on mercuric oxide. For organic mercury compounds, acute-, intermediate-, and chronic-duration oral studies were conducted in animals.

Most studies evaluated effects of methylmercury (chemical form not specified) or methylmercury chloride; other compounds tested include methylmercury hydroxide, methylmercuric sulfide, bis(methylmercury)sulfide, tris(methylmercury)sulphonium ion, and phenylmercuric acetate. For all animal studies, doses are expressed in terms of mercury, not the mercury compound that was administered. Additionally, exposure to methylmercury (chemical form not specified) or methylmercury chloride in oral animal studies is referred to as "methylmercury exposure" when discussing toxicity effects since methylmercury chloride rapidly dissociates upon ingestion. Specific mercury compounds tested in each study are included in the LSE tables.

Overview of Health Effects of Mercury Compounds. The health effects of mercury identified from studies in humans and animals are summarized below for the three chemical categories of mercury. For all forms of mercury, neurological and renal effects have been consistently observed in epidemiological and/or animal studies.

Elemental mercury. Neurological and renal effects have been observed in humans and animals exposed to elemental mercury vapor. Case reports of exposure to elemental mercury at fatal or near-fatal levels have reported severe adverse respiratory effects, including lung inflammation, pneumonitis, and respiratory failure due to pulmonary edema. No evidence for other targets of elemental mercury were identified in epidemiological or animal studies.

- **Neurological Effects:**
  - o **Epidemiological studies.** Epidemiological studies provide consistent evidence of neurological effects in adults, including tremor, vision, nerve conduction, motor speed and coordination, cognitive performance (memory, integrative function), and subjective physiological symptoms (mood swings, irritability, nervousness, timidity, loss of confidence).
  - o **Animal studies.** Some evidence of neurodevelopmental effects (altered learning and behavior, altered motor activity, impaired habituation) and impaired motor function and damage to the central nervous system in adult animals.
- **Renal Effects:**
  - o **Epidemiological studies.** Some evidence of decrements in glomerular function and tubular injury.
  - o **Animal studies.** Evidence of dose- and duration-dependent increases in severity of nephrotoxicity (damage to proximal tubules, distal tubules, and glomerular membrane, loss of brush border membranes, necrosis).

Inorganic mercury salts. Neurological and renal toxicity have been consistently observed in animals orally exposed to inorganic mercury salts. Other findings in animal studies provide some evidence of cardiovascular, immunological, and reproductive effects. In addition, there is some evidence of carcinogenicity in male rats. No epidemiological studies specific for exposure to inorganic mercury salts were identified.

- **Neurological Effects:** Consistent evidence of neurodevelopmental effects, including hyperactivity, impaired motor coordination, impaired memory, and decreased sociability. In adult animals, neurobehavioral effects have included hyperactivity, impaired coordination, and impaired learning and memory. Adult animals have also shown overt neurotoxic signs such as hindlimb crossing, ataxia, tremor, and partial paralysis as well as neuropathological changes to sensorimotor regions in the central nervous system (dorsal spinal route, cerebellum).

- **Renal Effects:** Consistent evidence of dose- and duration-dependent increases in severity of nephrotoxicity (damage to proximal tubules, distal tubules, and glomerular membrane, loss of brush border membranes, necrosis).

- **Cardiovascular Effects:** Evidence of increased blood pressure, altered cardiac function, positive inotropic effects, and altered baroreceptor reflex sensitivity.

- **Immunological Effects:** Evidence of immune stimulation and immune complex disease in genetically susceptible strains of mice.

- **Reproductive Effects:** Evidence of dose-dependent impairment of fertility and decreased sperm motility and number.

- **Cancer:** Some evidence of carcinogenicity in male rats (forestomach and thyroid tumors).

Organic mercury. Neurological and neurodevelopmental effects of organic mercury compounds are established as the most sensitive effect of exposure to organic mercury compounds.

- **Neurological Effects:**
  - **Epidemiological studies (children).** Evidence of cognitive, neuromotor and neurosensory effects associated with prenatal exposure to methylmercury.
  - **Epidemiological studies (adults).** Evidence of decreased performance on tests of fine motor coordination and speed, muscle strength, tactile sensation, color vision and visual contrast sensitivity, and memory and learning.
  - **Animals.** Consistent evidence of dose-dependent neurological effects (sensorimotor dysfunction, vision and hearing deficits, impaired learning and memory) and overt signs of neurotoxicity were observed (clumsiness, gross and fine motor incoordination, lethargy, hindlimb crossing, tremor, ataxia, partial paralysis). Developing animals are more sensitive to methylmercury-induced neurotoxic effects than adult animals.

Other systems have not been as extensively studied, although there is some evidence of effects in humans and/or animals, including renal (animal), cardiovascular (humans and animals), immune (humans and

animals), reproductive (animal), and developmental (other than neurodevelopmental; humans and animals) effects. However, it does not appear that these effects are sensitive targets for environmental exposures to methylmercury. In general, these effects occur at much higher levels than those found in the environment.

- **Renal Effects:**
    - **Animal studies.** Consistent evidence of dose- and duration-dependent increases in severity of nephrotoxicity (damage to proximal tubules, distal tubules, and glomerular membrane, loss of brush border membranes, necrosis).
- **Cardiovascular Effects:**
    - **Epidemiological studies.** Inconsistent evidence of small increases in blood pressure, clinical hypertension, and altered cardiac function.
    - **Animal studies.** Evidence of increased blood pressure, positive inotropism, and decreased baroreflex sensitivity.
- **Immunological Effects:**
    - **Epidemiological studies.** Some evidence of alterations in some immune markers (serum cytokine levels, immunoglobulins, and immune cell counts), but unclear if immune system function is affected.
    - **Animal studies.** Evidence of immune stimulation and immune complex disease in genetically susceptible strains of mice and some evidence of immune suppression in non-susceptible animals.
- **Reproductive Effects:**
    - **Animal studies.** Consistent evidence of dose-related impairment in fertility.
- **Developmental Effects (other than Neurodevelopmental):**
    - **Epidemiological studies.** Evidence of congenital effects (polydactyly, syndactyly, craniofacial malformations, microcornea, undescended testicles, enlarged colon, and protrusion of the coccyx) in the Minamata poisoning outbreak.
    - **Animal studies.** Consistent evidence of dose- and duration-dependent decreases in offspring survival, increased fetal malformations and variations (cleft palate, skeletal malformations [ribs, sternebrae], and hydronephrosis), and decreased fetal weight.

Figure 2-1. Overview of the Number of Studies Examining Elemental Mercury Health Effects in Chapter 2*

Most studies examined the potential neurological, developmental, and renal effects of elemental mercury
Fewer studies evaluated health effects in animals than humans (counts represent studies examining endpoint)

*Includes studies discussed in Chapter 2. A total of 155 studies (including those finding no effect) have examined toxicity; most studies examined multiple endpoints.

2. HEALTH EFFECTS

Figure 2-2. Overview of the Number of Studies Examining Inorganic Mercuric Salts Health Effects in Chapter 2*

Most studies examined the potential body weight, renal, and reproductive effects of inorganic mercury
Fewer studies evaluated health effects in humans than animals (counts represent studies examining endpoint)

*Includes studies discussed in Chapter 2. A total of 101 studies (including those finding no effect) have examined toxicity; most studies examined multiple endpoints.

Figure 2-3. Overview of the Number of Studies Examining Organic Mercury Health Effects in Chapter 2*

Most studies examined the potential developmental, neurological, and body weight effects of organic mercury
Fewer studies evaluated health effects in humans than animals (counts represent studies examining endpoint)

*Includes studies discussed in Chapter 2. A total of 312 studies (including those finding no effect) have examined toxicity; most studies examined multiple endpoints.

2. HEALTH EFFECTS

Figure 2-4. Overview of the Number of Studies Examining Mercury Health Effects—Unspecified General Population Exposure in Chapter 2*

Most studies examined the potential developmental, cardiovascular, and reproductive effects of mercury (unspecified mercury form and route of exposure)
General population studies in humans (counts represent studies examining endpoint)

*Includes studies discussed in Chapter 2. A total of 78 studies (including those finding no effect) have examined toxicity; most studies examined multiple endpoints.

Table 2-1. Levels of Significant Exposure to Elemental Mercury – Inhalation (mg Hg/m³)

Figure keya	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
ACUTE EXPOSURE									
Danielsson et al. 1993									**Elemental mercury**
1	Rat (Sprague-Dawley) 12 F	8 days GDs 11–14 and GDs 17–20 1 or 3 hours/day (WB)	0, 1.8	CS, BW, DX	Bd wt	1.8			
					Developb		1.8		Decreased spontaneous locomotion, rearing, and total activity at 3 months; reduced novel environment habituation at 7 months
[Behavior assessed in adult offspring: activity (3 and 14 months), habituation (7 months), and spatial learning (4, 7, and 15 months)]									
Davis et al. 2001									**Elemental mercury**
2	Rat (Sprague-Dawley) 8–18 F	11 days 2 hours/day (N)	0, 1, 2, 4	BW, BC, OW, RX	Bd wt	2	4		17% decrease in final body weight
					Repro	1	2		Prolonged estrous cycle at ≥2 mg Hg/m3; decreased serum estradiol and increased serum progesterone at 4 mg Hg/m³
Davis et al. 2001									**Elemental mercury**
3	Rat (Sprague-Dawley) 5–6 F	8 days (premating) 2 hours/day (N)	0, 2	BC, GN, RX	Repro	2			
Davis et al. 2001									**Elemental mercury**
4	Rat (Sprague-Dawley) 6 F	8 days (post-mating) 2 hours/day (N)	0, 1, 2	BC, GN, RX	Repro	2			
Davis et al. 2001									**Elemental mercury**
5	Rat (Sprague-Dawley) 6 F	1–8 days 2 hours/day (N)	0, 2	BC, OW, HP, RX	Repro		2		Prolonged estrous cycle after 6–8 days of exposure; immature corpora lutea during estrus and metestrus phases

Table 2-1. Levels of Significant Exposure to Elemental Mercury – Inhalation (mg Hg/m³)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Fredriksson et al. 1992									**Elemental mercury**
6	Rat (Sprague-Dawley) 8–10 M	7 days PNDs 11–17 4 hours/day (WB)	0, 0.05	DX	Develop[b]		0.05		Increased spontaneous locomotion and decreased rearing at 2 months of age; decreased spontaneous locomotion and rearing at 4 months of age; and impaired spatial learning at 6 months of age
[Behavior assessed in adulthood: motor activity (2 and 4 months) and spatial learning (5 and 6 months)]									
Fredriksson et al. 1992									**Elemental mercury**
7	Rat (Sprague-Dawley) 8–10 M	7 days PNDs 11–17 1 hours/day (WB)	0, 0.05	DX	Develop[b]		0.05		Increased spontaneous locomotion and decreased rearing at 4 months of age; impaired spatial learning at 6 months of age
[Behavior assessed in adulthood: motor activity (2 and 4 months) and spatial learning (5 and 6 months)]									
Fredriksson et al. 1996									**Elemental mercury**
8	Rat (Sprague-Dawley) 12 F	6 days GDs 14–19 1.5 hours/day (WB)	0, 1.8	CS, BW, DX	Bd wt	1.8			
					Develop[b]		1.8		Increased spontaneous locomotion, rearing, and total activity at 4 months of age; impaired spatial learning at 4.5 months of age
[Behavior assessed in adult male offspring at 4–5 months of age]									
Herr et al. 2004									**Elemental mercury**
9	Rat (Long-Evans) 10–12 F	10 days GDs 6–15 2 hours/day (N)	0, 4	DX	Develop[b]	4			
[Sensory evoked potentials measured in adult offspring]									
Livardjani et al. 1991									**Elemental mercury**
10	Rat (Wistar) 32 M	2 hours (WB)	0, 27.0	LE, CS, BW, HP	Death			27	20/32 died prior to scheduled sacrifice (none survived longer than 5 days post-exposure)
					Bd wt			27	15–25% body weight loss

2. HEALTH EFFECTS

Table 2-1. Levels of Significant Exposure to Elemental Mercury – Inhalation (mg Hg/m³)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
					Resp			27	Dyspnea and asphyxiation; lung edema, necrosis of alveolar epithelium, hyaline membranes, occasional fibrosis
[Animals sacrificed 1, 2, 3, 4, 5, 6, 7, or 15 days post-exposure (4/group)]									
Livardjani et al. 1991									**Elemental mercury**
11	Rat (Wistar) 32 M	1 hour (WB)	0, 26.6	LE, CS, BW, GN	Bd wt	26.6			
					Resp	26.6			
[Animals sacrificed 1, 2, 3, 4, 5, 6, 7, or 15 days post-exposure (4/group)]									
Morgan et al. 2002									**Elemental mercury**
12	Rat (Long-Evans) 5 F	2 hours GD 6 (N)	0, 1, 2, 4, 8	CS, BW, UR, OW, HP, DX	Bd wt	8			
					Resp	8			
					Hepatic	8			
					Renal	8			
					Develop	8			
Morgan et al. 2002									**Elemental mercury**
13	Rat (Long-Evans) 5 F	5 days GDs 6–10 2 hours/day (N)	0, 1, 2, 4, 8	CS, BW, UR, OW, HP, DX	Bd wt	4	8		10% decrease in maternal body weight
					Resp	8			
					Hepatic	8			
					Renal	8			
					Develop	8			
Morgan et al. 2002									**Elemental mercury**
14	Rat (Long-Evans) 10 F	10 days GDs 6–15 2 hours/day (N)	0, 1, 2, 4, 8	CS, BW, UR, OW, HP, DX	Bd wt	2	4	8	LOAEL: >10% decrease in maternal body weight SLOAEL: 17% maternal body weight loss
					Resp	8			
					Hepatic	8			

Table 2-1. Levels of Significant Exposure to Elemental Mercury – Inhalation
(mg Hg/m³)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
					Renal	2	4		Elevated maternal relative kidney weight (32% on GD 15); increased urinary protein and ALP
					Neuro	4	8		Mild tremor, lethargy, unsteady gait
					Develop	4	8		Increased resorptions, decreased litter size and pup weight

[50% of dams sacrificed on GD 15, 50% sacrificed on PND 1]

Stankovic 2006 **Elemental mercury**

| 15 | Mouse (129S/v) 6 F | 4 hours (WB) | 0, 0.5 | HP, NX | Neuro | | 0.5 | | Reduced grip strength 4–7 months post-exposure, decreased motor axon diameter 7 months post-exposure |

INTERMEDIATE EXPOSURE

Newland et al. 1996 **Elemental mercury**

| 16 | Monkey (Squirrel) 5–6 F | 15–17 weeks Last 2/3 gestation 5 days/week 4 or 7 hours/day (WB) | 0, 0.5, 1.0 | DX | Develop[b] | | 0.5 | | Impaired operant training in offspring |

[Offspring behavioral testing at 0.8–4 years old]

Altunkaynak et al. 2015 **Elemental mercury**

| 17 | Rat (Sprague-Dawley) 6 M | 6 weeks 7 days/week 9 hours/day (WB) | 0, 1 | HP | Repro | | | 1 | Seminiferous tubule atrophy; damage to spermatogenic cells; decreased testicular and seminiferous tubule volume, decreased seminiferous tubule diameter; decreased Sertoli cells, spermatogonia, spermatocytes, and spermatids |

Table 2-1. Levels of Significant Exposure to Elemental Mercury – Inhalation (mg Hg/m³)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Altunkaynak et al. 2019									**Elemental mercury**
18	Rat (Wistar albino) 6 F	45 days 9 hours/day (WB)	0, 0.1	HP	Neuro		0.1		Histopathological changes in the cerebellum (gliosis, vacuolization, decreased Purkinje cells), decreased cerebellar volume
Kishi et al. 1978									**Elemental mercury**
19	Rat (Wistar) 12–14 M	12-42 weeks 5 day/week 3 hours/day (WB)	0, 3	CS, BW, HP, NX	Bd wt			3	Body weight loss (magnitude not reported)
					Resp	3			
					Hepatic	3			
					Renal		3		Dense black deposits in tubular cells, lysosomal inclusions, slight degeneration of tubular cells
					Neuro		3		Tremors; altered neurobehavior (decline in conditioned avoidance, increased escape response latency)
Raffee et al. 2021									**Elemental mercury**
20	Rat (SD) 7 M, 7 F	65 days 2 hours/day (WB)	0, 0.5	LE, CS, BW, BC, GN, HP	Death			0.5	Death of 2/7 males and 4/7 females
					Bd wt			0.5	22% body weight loss (from initial)
					Resp			0.5	Severe pulmonary lesions (emphysema; thickening, destruction, and obstruction of intra-alveolar septae; alveolar dilation; intra-alveolar edema and inflammatory cell infiltrate)

Table 2-1. Levels of Significant Exposure to Elemental Mercury – Inhalation (mg Hg/m³)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Raffee et al. 2021									**Elemental mercury**
21	Rat (SD) 7 M, 7 F	21 days 2 hours/day (WB)	0, 0.5	LE, CS, BW, BC, GN, HP	Bd wt			0.5	15% body weight loss (from initial)
					Resp			0.5	Severe pulmonary lesions (emphysema; thickening, destruction, and obstruction of intra-alveolar septae; alveolar dilation; intra-alveolar edema and inflammatory cell infiltrate)
Sørensen et al. 2000									**Elemental mercury**
22	Rat (Wistar) 12 M	8 weeks 4–5 days/week 5 hours/day (WB)	0, 0.5	CS, BW, HP	Bd wt		0.5		17% decrease in body weight gain
					Neuro		0.5		Irritability, aggressiveness; loss of Purkinje and granular cells in cerebellum
Yahyazedeh et al. 2017									**Elemental mercury**
23	Rat (Wistar) 6 F	45 days 24 hours/day (WB)	0, 1	HP	Hepatic			1	Extensive hepatocyte degeneration; enlarged blood vessels, dilated sinusoids, increased perivascular connective tissue; increased liver volume; increased number and density of binucleated hepatocytes
Warfvinge et al. 1995									**Elemental mercury**
24	Mouse (SJL/N) 10–14 F	10 weeks 5 days/week 0.5–19 hours/day (WB)	TWA: 0, 0.01, 0.03, 0.06, 0.08, 0.1, 0.4	BC, BI, IX	Immuno	0.01	0.03		Serum antinucleolar antibodies at ≥0.03 mg Hg/m³; increased serum immunoglobins and renal immune complex deposits at ≥0.06 mg Hg/m³

[Autoimmune susceptible mouse strain; TWA doses were calculated due to varying daily exposure duration]

Table 2-1. Levels of Significant Exposure to Elemental Mercury – Inhalation (mg Hg/m^3)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Yoshida et al. 2011									**Elemental mercury**
25	Mouse (C57BL/6) NS F	19 days GDs 0–18 6 hours/day (WB)	0, 0.03	DX	Develop[b]	0.03			
[Motor activity, learning, and memory assessed at PND 56]									
Yoshida et al. 2013									**Elemental mercury**
26	Mouse (C57BL/6) 6 F	20 days PNDs 1–20 24 hours/day (WB)	0, 0.057	DX	Develop[b]	0.057			
[Motor activity, learning, and memory assessed at 3 and 15 months]									
Yoshida et al. 2018									**Elemental mercury**
27	Mouse (C57BL/6J) 7–8 F	27 days PNDs 2–28 24 hours/day (WB)	0, 0.188	DX	Develop[b]		0.188		Decreased motor activity at PND 77
[Motor activity, learning, and memory assessed at PNDs 77–84]									
Fukuda 1971									**Elemental mercury**
28	Rabbit (NS) 6 M	13 weeks 4 days/week 6 hours/day (WB)	4.0	NX	Neuro		4		Clonus and tremors after 11 weeks, exaggerated reflexes

Table 2-1. Levels of Significant Exposure to Elemental Mercury – Inhalation (mg Hg/m^3)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
CHRONIC EXPOSURE									
Bast-Pettersen et al. 2005; Boogaard et al. 1996; Chapman et al. 1990; Ellingsen et al. 2001; Fawer et al. 1983; Langworth et al. 1992a; Wastensson et al. 2006, 2008									**Elemental mercury**
29	Human 18– 85 per study	Occupational	0.00457– 0.00874	NX	Neuro				Tremor; weighted median of 0.00492 mg Hg/m^3 (95% LCL of 0.00284 mg Hg/m^3)[c]

[a]The number corresponds to entries in Figure 2-5; differences in levels of health effects between male and females are not indicated in Figure 2-5. Where such differences exist, only the levels of effect for the most sensitive sex are presented.
[b]The neurodevelopmental effects are discussed in Section 2.16 (Neurological).
[c]Used to derive a chronic-duration inhalation MRL of 0.0003 mg Hg/m^3 (0.3 µg Hg/m^3) for elemental mercury; based on a 95% lower confidence limit of the weighted median of 0.00284 mg Hg/m^3 from seven occupational exposure studies and divided by an uncertainty factor of 10 for human variability; see Appendix A for more detailed information regarding the MRL.

Principal studies for the MRLs

ALP = alkaline phosphatase; BC = serum (blood) chemistry; Bd wt or BW = body weight; BI = biochemical changes; CS = clinical signs; Develop = developmental; DX = developmental toxicity; F = female(s); GD = gestation day; GN = gross necropsy; HP = histopathology; Immuno = immunological; IX = immune function; LCL = lower confidence limit; LE = lethality; LOAEL = lowest-observed-adverse-effect level; M = male(s); MRL = Minimal Risk Level; N = nose-only; Neuro = neurological; NOAEL = no-observed-adverse-effect level; NS = not specified; NX = neurological function; OW = organ weight; PND = postnatal day; Repro = reproductive; Resp = respiratory; RX = reproductive function; SLOAEL = serious lowest-observed-adverse-effect level; TWA = time-weighted average; UR = urinalysis; WB = whole body

Figure 2-5. Levels of Significant Exposure to Elemental Mercury – Inhalation
Acute (≤14 days)

Figure 2-5. Levels of Significant Exposure to Elemental Mercury – Inhalation
Acute (≤14 days)

2. HEALTH EFFECTS

Figure 2-5. Levels of Significant Exposure to Elemental Mercury – Inhalation
Intermediate (15–364 days)

Figure 2-5. Levels of Significant Exposure to Elemental Mercury – Inhalation
Intermediate (15–364 days)

2. HEALTH EFFECTS

Figure 2-5. Levels of Significant Exposure to Elemental Mercury – Inhalation
Chronic (≥365 days)

Table 2-2. Levels of Significant Exposure to Mercuric Oxide – Inhalation (mg Hg/m³)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
INTERMEDIATE EXPOSURE									
Altunkaynak et al. 2016									**Mercuric oxide**
1	Rat (Wistar) 6 F	45 days 24 hours/day (WB)	0, 0.9	HP	Repro		0.9		38% reduction in ovary volume, 33–50% decrease in ovarian follicles, histopathological changes in ovaries
Altunkaynak et al. 2019									**Mercuric oxide**
2	Rat (Wistar) 6 F	45 days 9 hours/day (WB)	0, 1	HP	Neuro		1		Decreased cerebellar volume and cerebellar damage (gliosis, vacuolization, loss of Purkinje cells)

[a]The number corresponds to entries in Figure 2-6.

F = female(s); HP = histopathology; LOAEL = lowest-observed-adverse-effect level; Neuro = neurological; NOAEL = no-observed-adverse-effect level; Repro = reproductive; WB = whole body

Figure 2-6. Levels of Significant Exposure to Mercuric Oxide – Inhalation
Intermediate (15–364 days)

Table 2-3. Levels of Significant Exposure to Inorganic Mercury Salts – Oral (mg/kg/day)									
Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
ACUTE EXPOSURE									
Albasher et al. 2020									**Mercuric chloride**
1	Rat (Wistar albino) 7 M	7 days (W)	0, 0.3	BC, HP	Repro		0.3		24% decreased serum testosterone; histopathological changes in seminiferous tubules (vacuolation, degeneration of spermatogenic cells, detachment of spermatogenic cells from the basement membrane)
Boujbiha et al. 2009									**Mercuric chloride**
2	Rat (Wistar) 6 M	3 or 7 days (W)	0, 3, 6	BW, FI, WI, BC, BI, OW, HP, RX	Repro		3		Decreased sperm number and motility; non-monotonic changes in serum testosterone
Chang and Hartmann 1972									**Mercuric chloride**
3	Rat (Holtzman) 4 M	1–2 weeks (G)	0, 0.7	CS, BW, HP	Bd wt	0.7			
					Neuro		0.7		Ultrastructural changes in dorsal root ganglia and cerebellum
Chuu et al. 2007									**Mercuric sulfide**
4	Rat (Sprague-Dawley) 6 M	5 days (GW)	0, 860	NX	Neuro		860		Impairment of compound muscle action potential recovery after tetany
Chuu et al. 2007									**Mercuric sulfide**
5	Rat (Sprague-Dawley) 6 M	14 days (GW)	0, 860	BW, NX	Bd wt	860			
					Neuro		860		Transient suppression of compound muscle action potentials followed by incomplete recovery after tetany

2. HEALTH EFFECTS

Table 2-3. Levels of Significant Exposure to Inorganic Mercury Salts – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Dieter et al. 1992; NTP 1993									**Mercuric chloride**
6	Rat (Fischer-344) 5 M, 5 F	16 days 5 day/week (GW)	0, 0.923, 1.8, 4, 7.4, 15	LE, BW, GN, OW, HP	Death			15 M	2/5 died
					Bd wt	4	7.4	15	LOAEL: 17–18% decrease in body weight gain SLOAEL: 30–41% decrease in body weight gain in both sexes, 11% decrease in body weight in females
					Gastro	15			
					Renal	1.8 F	4 F	15 F	LOAEL: ≥17% increase in relative kidney weight SLOAEL: Acute renal necrosis
						0.923 M[b]	1.8 M	7.4 M	LOAEL: ≥17% increase in relative kidney weight SLOAEL: Acute renal necrosis $BMDL_{1SD}$=0.29 mg Hg/kg/day
Goldman and Blackburn 1979									**Mercuric chloride**
7	Rat (Long-Evans) 8–12 F	6 days (GW)	0, 7.4	OF	Endocr		7.4		Increased thyroid function (accelerated release and turnover of radiolabeled iodine)
Kostial et al. 1978									**Mercuric chloride**
8	Rat (albino) 6 B	Once (G)	Six unspecified dose levels	LE	Death			25.9	LD_{50} in 2-week-old rats
Kostial et al. 1978									**Mercuric chloride**
9	Rat (albino) 6 F	Once (G)	Six unspecified dose levels	LE	Death			77.7	LD_{50} in 3-week-old rats
Kostial et al. 1978									**Mercuric chloride**
10	Rat (albino) 6 F	Once (G)	Six unspecified dose levels	LE	Death			68.1	LD_{50} in 6-week-old rats

2. HEALTH EFFECTS

Table 2-3. Levels of Significant Exposure to Inorganic Mercury Salts – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Kostial et al. 1978									**Mercuric chloride**
11	Rat (albino) 6 F	Once (G)	Six unspecified dose levels	LE	Death			37	LD$_{50}$ in 18-week-old rats
Kostial et al. 1978									**Mercuric chloride**
12	Rat (albino) 6 F	Once (G)	Six unspecified dose levels	LE	Death			37	LD50 in 54-week-old rats
Lecavalier et al. 1994									**Mercuric chloride**
13	Rat (Sprague-Dawley) 10 F	Once (GO)	0, 7.4, 9.24	LE, CS, BW, FI, BC, HE, OW, GN, HP	Bd wt	9.24			
					Resp	9.24			
					Cardio	9.24			
					Gastro	9.24			
					Hemato		7.4		9–10% decrease in erythrocyte count, hemoglobin, and hematocrit
					Musc/skel	9.24			
					Hepatic	9.24			
					Renal		7.4		Mild histopathological changes (protein casts, cellular casts, interstitial sclerosis)
					Dermal	9.24			
					Ocular	9.24			
					Endocr	9.24			
					Immuno	9.24			
					Neuro	9.24			
					Repro	9.24			
Mahour and Saxena 2009									**Mercuric chloride**
14	Rat (albino) 5–20 NS	Once NS	0, 0.684	HE	Hemato		0.684		Increased bleeding and clotting time; 10% increase in WBC count

Table 2-3. Levels of Significant Exposure to Inorganic Mercury Salts – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Mahour and Saxena 2009									**Mercuric chloride**
15	Rat (albino) 5–20 NS	7 or 14 days NS	0, 0.033	HE	Hemato		0.033		Increased bleeding and clotting time; 7–9% decrease in hemoglobin; 10–21% increase in ESR; 13% increase in WBC count (14 days only)
Papp et al. 2005									**Mercuric chloride**
16	Rat (Wistar) 8 F	11 days GDs 5–15 (GW)	0, 0.4, 0.8, 1.6	DX	Develop	1.6[c]			
[Neurophysiological recordings in male offspring at PND 84]									
Sun et al. 2018									**Mercuric chloride**
17	Rat (Sprague-Dawley) 10–15 M	2 weeks (G)	0, 3.10, 6.3, 12.6	LE, CS, BW, HP, NX	Death			12.6	Death of 4/15 animals
					Neuro			3.1	Limb paralysis in 2/10 animals; hypersensitivity to thermal and mechanical pain
Sun et al. 2018									**Mercuric chloride**
18	Rat (Sprague-Dawley) 10–15 M	1 week (G)	0, 3.10, 6.3, 12.6	LE, CS, BW, HP, NX	Immuno	3.1	6.3		Increased density of Langerhans cells (inflammatory cells) in hind paw skin samples
					Neuro	3.1	6.3		Decreased density of intraepidermal nerve fibers in hind paw skin samples
Chen et al. 2012									**Mercuric chloride**
19	Mouse (ICR) 16 M	2 weeks (GW)	0, 3.7	BC, BI, HP	Endocr		3.7		~17% increase in baseline plasma insulin and ~60% decrease in fasting plasma insulin; ~15% decrease in blood glucose and impaired glucose tolerance; apoptosis in pancreatic islet cells

Table 2-3. Levels of Significant Exposure to Inorganic Mercury Salts – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Chuu et al. 2001a									**Mercuric sulfide**
20	Mouse (NS) 8–10 M	7 days (G)	0, 86, 860	NX	Neuro	86	860		Reversible hearing loss
[Vehicle was saline]									
Hultman and Johansson 1991									**Mercuric chloride**
21	Mouse (DBA/2) 5 F	2 weeks (W)	0, 0.7	IX	Immuno	0.7			
[Autoimmune resistant mice]									
Hultman and Johansson 1991									**Mercuric chloride**
22	Mouse (SJL/N) 5 F	2 weeks (W)	0, 0.7	IX	Immuno		0.7		Increase in lymphoproliferation in response to T- and B-cell mitogens
[Autoimmune susceptible mouse strain]									
Jalili et al. 2020b									**Mercuric chloride**
23	Mouse (BALB/c) 6 M	14 days (IN)	0, 0.061	BW, BC, OW, HP	Bd wt			0.061	29% decrease
					Renal		0.061		Increased BUN and creatinine; renal lesions (renal tubular casts, intracellular vacuolization, renal vascular congestion, tubular detachment and dilation)
Kim et al. 2003									**Mercuric chloride**
24	Mouse (BALB/c) 4 M	14 days (W)	0, 0.06, 0.31, 1.39, 4.81	BW, BC, FI, WI, HE, OW	Hemato		0.06		11–19% decrease in RBC count at 0.06 mg Hg/kg/day; 91% increase in WBC count at 4.81 mg Hg/kg/day
					Hepatic	4.81			
					Renal	0.31	1.39		11% increase in relative kidney weight

Table 2-3. Levels of Significant Exposure to Inorganic Mercury Salts – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
					Immuno	0.06	0.31		Decreased T-lymphocytes, T-helper, and T-suppressor in spleen; decreased T-suppressor cells in thymus at ≥1.39 mg Hg/kg/day
Nielsen et al. 1991									**Mercuric chloride**
25	Mouse (NMRI) 10–20 F	Once (GW)	0, 5, 10, 20, 40	BI, HP	Renal	5	10	20	LOAEL: Regeneration of proximal tubule SLOAEL: Proximal tubule necrosis
NTP 1993									**Mercuric chloride**
26	Mouse (B6C3F1) 5 M, 5 F	16 days 5 day/week (GW)	0, 4, 7.4, 15, 30, 59	LE, BW, GN, OW, HP	Death			59	5/5 males and 4/5 females died within 2–4 days
					Bd wt	30			
					Gastro	30	59		Inflammation of forestomach; necrosis of forestomach and glandular stomach
					Renal		4		≥19% increase in relative kidney weight
								59 F	Acute renal necrosis
								30 M	Acute renal necrosis
					Immuno	30			
Sin et al. 1990									**Mercuric sulfide**
27	Mouse (Swiss albino) 6 F	10 days (GW)	0, 6	BC	Endocr		6		59% decrease in serum T3
Sin et al. 1990									**Mercuric chloride**
28	Mouse Swiss albino 6 F	10 days 1 times/day (GW)	0, 6	BC	Endocr		6		70% decrease in serum T3; 42% decrease in serum T4

Table 2-3. Levels of Significant Exposure to Inorganic Mercury Salts – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Zhao et al. 2021									**Mercuric chloride**
29	Mouse (Kunming) 6 F	3 days (W)	0, 24	BW, HP	Bd wt		24		17% decrease in body weight
					Gastro		24		Histopathological changes in cecum (atrophy of glands, mild-to-moderate necrosis; decreased goblet cells)
Gale 1974									**Mercuric acetate**
30	Hamster Golden 3–10 F	Once GD 8 (GW)	0, 2.5, 5, 15.8, 22.1, 31.5, 47.3, 63	DX	Develop	2.5	5	15.8	LOAEL: Decreased crown-rump length SLOAEL: Increased abnormal embryos and resorption
Chuu et al. 2001b									**Mercuric sulfide**
31	Guinea pig (Hartley) 14–90 F	7 days (G)	0, 8.6, 86, 860	HP, NX	Neuro	8.6	86		Abnormal vestibular ocular reflex, impaired equilibrium at ≥86 mg Hg/kg/day; Purkinje cell loss in cerebellum at 860 mg Hg/kg/day
[Vehicle was saline]									
Chuu et al. 2001b									**Mercuric sulfide**
32	Guinea pig (Hartley) 8–12 F	14 days (G)	0, 86	NX	Neuro		86		Abnormal vestibular ocular reflex
[Vehicle was saline]									
INTERMEDIATE EXPOSURE									
Agrawal and Chansouria 1989									**Mercuric chloride**
33	Rat (albino) 5 M	60 days (W)	0, 2.9, 5.8, 11.8	CS, BC, BI, OW	Endocr		2.9		31% increase in relative adrenal weight, 146% increase in adrenal corticosterone; nonmonotonic changes in plasma corticosterone
Agrawal and Chansouria 1989									**Mercuric chloride**
34	Rat (albino) 5 M	120 days (W)	0, 2.9, 5.8, 11.8	CS, BC, BI, OW	Endocr		2.9		19% increase in relative adrenal weight, 87 and 218% increase in plasma and adrenal corticosterone, respectively

Table 2-3. Levels of Significant Exposure to Inorganic Mercury Salts – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Agrawal and Chansouria 1989									**Mercuric chloride**
35	Rat (albino) 5 M	180 days (W)	0, 2.9, 5.8, 11.8	CS, BC, BI, OW	Endocr		2.9		14% increase in relative adrenal gland weight
Agrawal et al. 2014									**Mercuric chloride**
36	Rat (Wistar) 5 M	6 months 7 days/week (NS)	0, 0.4	BW, BC, BI, HE	Bd wt	0.4			
					Hemato		0.4		140% increase in WBC
					Hepatic		0.4		21–56% increase in AST, ALP, and LDH
Apaydin et al. 2016									**Mercuric chloride**
37	Rat (Wistar) 6 NS	28 days (GW)	0, 0.015	BC, BI, HP	Renal		0.015[d]		Altered serum chemistry (increased urea, uric acid, creatinine); tubular dilation and glomerular lobulation
Atkinson et al. 2001									**Mercuric chloride**
38	Rat (Sprague-Dawley) 15–25 M, 15–25 F	79–81 days/ generation 2 generations (GW)	M: 0, 0.37, 0.74, 1.31 F: 0, 0.55, 1.11, 1.98	CS, BW, FI, GN, OW, RX, DX	Death			1.98 F	50% mortality in F0 females
					Bd wt	0.55 F		1.11 F	Female: transient F0 body weight decreases up to ~21% during gestation at ≥1.11 mg Hg/kg/day
						0.37 M			Male: 16% decreased in adult F1 body weight at 0.37 mg Hg/kg/day; decreased F0 body weight at 1.31 mg Hg/kg/day
					Hepatic		0.55 F		>20% decrease in relative liver weight in F0 females
						1.31 M			
					Renal	0.55 F	1.11 F		>10% increase in relative kidney weights in F1 females
						0.37 M			>10% increase in relative kidney weights in F0 males
					Endocr	1.98 F			
						1.31 M			

Table 2-3. Levels of Significant Exposure to Inorganic Mercury Salts – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
					Repro		0.55 F	1.11 F	LOAEL: Decreased F0 fertility and implant efficiency, decreased F1 live birth index SLOAEL: ≥50% reduction in F0 fertility with reduced F1 implant efficiency, F2 live birth index
							0.37 M	0.74 M	LOAEL: Decreased F0 fertility SLOAEL: ≥50% reduction in F0 fertility, F0 relative seminal vesicle weight
					Develop			0.55	~20% reduction in F1 pup body weight at 0.55 mg Hg/kg/day; reduced PND 4 survival for F1 and F2 pups at 1.98 and 1.11 mg Hg/kg/day, respectively
Behzadfar et al. 2020									**Mercuric chloride**
39	Rat (Albino-Wistar) 7 M	21 days (GW)	0, 0.4, 0.8, 1.6	NX	Neuro		0.4		Impaired spatial learning
Bittencourt et al. 2021									**Mercuric chloride**
40	Rat (Wistar) 10–27 M	45 days (GW)	0, 0.277	LE, BW, HP, NX	Bd wt	0.277			
					Neuro		0.277		Decreased motor coordination, decreased cerebellar Purkinje cell density, neuronal apoptosis in cerebellum
Boscolo et al. 1989									**Mercuric chloride**
41	Rat (Wistar) 8 M	350 days (W)	0, 6, 24	CS, HP, OF	Cardio		6		Increased aortic blood pressure; positive cardiac inotropism; decreased baroreceptor reflex sensitivity
					Renal		6		Tubular degeneration and membranous glomerulonephritis

Table 2-3. Levels of Significant Exposure to Inorganic Mercury Salts – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Boscolo et al. 1989; Carmignani et al. 1989									**Mercuric chloride**
42	Rat (Sprague-Dawley) 8 M	350 days (W)	0, 6	CS, HP, OF	Cardio		6		Increased aortic blood pressure; positive cardiac inotropism; decreased baroreceptor reflex sensitivity
					Renal		6		Tubular degeneration and desquamation
Boujbiha et al. 2009, 2011									**Mercuric chloride**
43	Rat (Wistar) 6 M	15–90 days premating (W)	0, 3, 6	BW, FI, WI, BC, BI, OW, HP, RX	Repro		3	6	LOAEL: >10% increase in relative testes weight, sperm impairments, increased testicular testosterone, decreased serum and testicular estradiol, histopathological changes in testes, 36% decrease in viable embryos SLOAEL: 50% decrease in mating index and 76% decrease in viable embryos
[Mated to untreated females]									
Boujbiha et al. 2012									**Mercuric chloride**
44	Rat (Wistar) 6 M	90 days (W)	0, 5.5, 11	HE	Hemato	5.5	11		10% decrease in RBC count and hemoglobin, 7% decrease in hematocrit
Carmignani and Boscolo 1984									**Mercuric chloride**
45	Rat (Sprague-Dawley) 10 M	320 days (W)	0, 6	OF	Cardio		6		Positive cardiac inotropism, reduced baroreflex sensitivity
Carmignani and Boscolo 1984									**Mercuric chloride**
46	Rat (Sprague-Dawley) 10 M	350 days (W)	0, 6	OF	Cardio		6		Increased systolic and diastolic blood pressure, positive cardiac inotropism, reduced baroreflex sensitivity

Table 2-3. Levels of Significant Exposure to Inorganic Mercury Salts – Oral (mg/kg/day)

| Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Carmignani et al. 1992									**Mercuric chloride**
47	Rat (Wistar) 8 M	180 days (W)	0, 24	CS, BW, HP, OF	Cardio		24		Increased systolic and diastolic blood pressure
					Renal		24		Mesangial proliferative glomerulonephritis
Chang and Hartmann 1972									**Mercuric chloride**
48	Rat (Holtzman) 4 M	11 weeks (G)	0, 0.7	CS, BW, HP	Bd wt			0.7	Body weight loss
					Neuro			0.7	Hind-limb crossing, ataxia, tremor; cellular degeneration and ultrastructural changes in dorsal root ganglia and cerebellum
Chehimi et al. 2012									**Mercuric chloride**
49	Rat (Wistar) 10 F	21 days GDs 1–21 (W)	0, 6.1, 9.6	WI, RX, DX	Repro		6.1		Reduced maternal care
					Develop[c]		6.1	9.6	LOAEL: 14% decrease in body weight, impaired/delayed sensorimotor development, decreased anxiety at PND 63 SLOAEL: 16% pup mortality and >20% decrease in body weight
Corrêa et al. 2020									**Mercuric chloride**
50	Rat (Wistar) 25 M	45 days (GW)	0, 0.277	BW, HP	Neuro			0.277	Loss of motor neurons and axonal damage in the spinal cord
Dieter et al. 1992; NTP 1993									**Mercuric chloride**
51	Rat (Fischer-344) 10 M, 10 F	26 weeks 5 days/week (GW)	0, 0.230, 0.462, 0.923, 1.8, 4	BW, BC, GN, OW, HP	Bd wt	4			
					Resp	4			
					Cardio	4			
					Gastro	4			
					Musc/skel	4			
					Hepatic	4			

2. HEALTH EFFECTS

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
					Renal		0.23		8–10% increase in relative kidney weight at 0.23 mg Hg/kg/day; increased severity of nephropathy in males at ≥0.923 mg Hg/kg/day; minimal nephropathy in females at 4 mg Hg/kg/day
					Endocr	4			
					Immuno	4			
					Neuro	4			
					Repro	4			
dos Santos Chemelo et al. 2021									**Mercuric chloride**
52	Rat (Wistar) 10 M	45 days (GW)	0, 0.277	BW, HE	Bd wt	0.277			
					Hemato		0.277		Increased leukocytes and decreased platelets
Galiciolli et al. 2022									**Mercuric chloride**
53	Rat (Wistar) 7–9 F	42 days GD 0–PND 21 (W)	0, 0.019, 0.094	BW, FI, WI, BC, BI, OW, DX	Bd wt	0.094			
					Renal		0.019		Increased absolute and relative kidney weight
					Develop	0.094			
Goldman and Blackburn 1979									**Mercuric chloride**
54	Rat (Long-Evans) 8–12 F	40 days (G)	0, 9.4	BW, OW, OF	Bd wt	9.4			
					Endocr		9.4		28% increase in absolute thyroid weight, increased thyroid activity (increased uptake of radiolabeled iodine), decreased thyroid T3 synthesis

Table 2-3. Levels of Significant Exposure to Inorganic Mercury Salts – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Goldman and Blackburn 1979									**Mercuric chloride**
55	Rat (Sprague-Dawley) 8–12 F	3 months (F)	0, 2.2	CS, BW, OF	Bd wt			2.2	37% decrease in final body weight
					Resp		2.2		Labored breathing
					Endocr		2.2		Impaired thyroid function (decreased uptake, release, and turnover of radiolabeled iodine)
					Neuro			2.2	Inactivity; abnormal gait; hind-limb spread
Heath et al. 2009									**Mercuric chloride**
56	Rat (Sprague-Dawley) 20 F	60 days (premating) (G)	0, 0.7, 1.5	CS, BW, BC, GN, OW, RX	Bd wt	1.5			
					Repro	0.7	1.5		15% decrease in implantation, increased dead/resorbed fetuses, 18% decrease in serum progesterone, 19% increase in pituitary LH
[Vehicle was 0.15% nitric acid]									
Heath et al. 2012									**Mercuric chloride**
57	Rat (Sprague-Dawley) 10–11 M	60 days Premating (G)	0, 0.7, 1.5	CS, BW, BC, RX	Bd wt	0.7	1.5		12% decrease in body weight
					Repro		0.7		30% decrease in testicular testosterone at 0.7 mg Hg/kg/day; 10% decrease in epididymis sperm counts; increased latency to impregnation and decreased fertility index at 1.5 mg Hg/kg/day
[Vehicle was 0.15% nitric acid]									
Ismail and El-Meligy 2021									**Mercuric chloride**
58	Rat (Albino) 10 F	21 days GDs 1–21 (GW)	0, 3	RX, DX	Repro			3	58% reduction in the number of fetuses/litter
					Develop			3	17% decrease in fetal body weight; severe microscopic and ultrastructural changes in fetal lungs (e.g., collapsed alveoli, cellular degeneration)

2. HEALTH EFFECTS

Table 2-3. Levels of Significant Exposure to Inorganic Mercury Salts – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Janse van Rensburg et al. 2020									**Mercuric chloride**
59	Rat (SD) 6 M	28 days (GW)	0, 0.13	HE	Hemato		0.13		Morphological alterations in erythrocytes, platelets, and fibrin networks
Jindal et al. 2011									**Mercuric chloride**
60	Rat (Wistar) 10 B	1 month (W)	0, 0.12	OF	Cardio		0.12		Altered left ventricular function; impaired baroreflex
Jonker et al. 1993									**Mercuric chloride**
61	Rat (Wistar) 5–10 M, 5–10 F	4 weeks (F)	M: 0, 5.8, 11.4, 20.9; F: 0, 6.1, 11.9, 23.6	BW, FI, WI, BC, HE, UR, OW, HP	Bd wt	6.1 F	11.9 F	23.6 F	LOAEL: 15% decrease in final body weight SLOAEL: 34% decrease in terminal body weight
						11.4 M		20.9 M	34% decrease in final body weight
					Hepatic	6.1 F	11.9 F		Increased serum ALP; increased AST at 23.6 mg Hg/kg/day
						11.4 M	20.9 M		Increased serum ALT and AST
					Renal		6.1 F		Nephrosis and proteinaceous casts, 16% increase in relative kidney weight
							5.8 M		Nephrosis and proteinaceous casts, 13% increase in relative kidney weight; ketones in urine
					Endocr	23.6 F			
						20.9 M			
Jonker et al. 1993									**Mercuric chloride**
62	Rat (Wistar) 5–10 M, 5–10 F	4 weeks (F)	M: 0, 0.61, 5.1; F: 0, 0.76, 5.5	BW, FI, WI, BC, UR, HE, OW, HP	Bd wt	5.5 F			
						5.1 M			
					Hemato	5.5 F			
						5.1 M			
					Renal		0.76 F		13% increase in relative kidney weight

Table 2-3. Levels of Significant Exposure to Inorganic Mercury Salts – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
						0.61 M	5.1 M		17% increase in relative kidney weight; ketones in urine and basophilic tubules in outer cortex
					Endocr	5.5 F 5.1 M			
Koopsamy Naidoo et al. 2019									**Mercuric chloride**
63	Rat (SD) 6 M	28 days (GW)	0, 0.848	HP	Resp		0.848		Histopathological and ultrastructural changes in lung tissue
Mahour and Saxena 2009									**Mercuric chloride**
64	Rat (albino) 5–20 NS	21 days NS	0, 0.033	HE	Hemato		0.033		13% decrease in RBC count, 5% decrease in hemoglobin, 17% increase in WBC count; 41% increase in ESR
Nunes et al. 2022									**Mercuric chloride**
65	Rat (Wistar) 10 M	45 days (GW)	0, 0.277	BW, HP	Bd wt	0.277			
					Musc/skel		0.277		Altered alveolar bone structure, increased trabecular volume with decreased trabecular space
Oliveira et al. 2012									**Mercuric chloride**
66	Rat (Wistar) 3–7 F	21 days GDs 0–20 (W)	0, 0.0002, 0.0004, 0.0085, 0.0301	BW, BC, OW, DX	Renal Develop	0.0301 0.0301			
Oliveira et al. 2016									**Mercuric chloride**
67	Rat (Wistar) 7–8 F	42 days GD 1–PND 21 (W)	0, 0.75, 3.8	DX	Develop[c]	3.8			
[Offspring motor coordination assessed PNDs 17–20]									

Table 2-3. Levels of Significant Exposure to Inorganic Mercury Salts – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Papp et al. 2005									**Mercuric chloride**
68	Rat (Wistar) 8 M	94 days GDs 5–15 and PNDs 2–28 (via dam) PNDs 29–84 (direct; 5 days/week) (GW)	0, 0.4, 0.8, 1.6	DX	Develop[c]		0.4		Decreased peripheral sensory nerve conduction velocity at PND 84 at ≥0.4 mg Hg/kg/day; decreased spontaneous sensory cortex potentials at ≥0.8 mg Hg/kg/day
Papp et al. 2005									**Mercuric chloride**
69	Rat (Wistar) 8 F	38 days GDs 5–15 and PNDs 2–28 (GW)	0, 0.4, 0.8, 1.6	DX	Develop[c]	1.6			
[Neurophysiological recordings in male offspring at PND 84]									
Perry and Erlanger 1974									**Mercuric chloride**
70	Rat (Long-Evans) 16 F	6 months (W)	0, 0.33, 0.66, 1.3, 3.3	OF	Cardio	3.3			
Raeeszadeh et al. 2021									**Mercuric chloride**
71	Rat (Wistar) 6 M	30 days (GW)	0, 1.5	BW, BC, HP	Bd wt		1.5		15% decrease in body weight accounting for differences in group start weights
					Hepatic			1.5	SLOAEL: Hepatic necrosis, hemorrhage, inflammatory cell inflammation; increased serum ALT (2.5-fold) and AST (2.3-fold)
					Renal			1.5	SLOAEL: Acute tubular necrosis, interstitial nephritis, glomerular damage and hyaline casts; increased serum urea, creatinine, and uric acid

Table 2-3. Levels of Significant Exposure to Inorganic Mercury Salts – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Ramalingam et al. 2003									**Mercuric chloride**
72	Rat (Wistar) 15 M	30 days (GW)	0, 0.7, 1.5	BC	Repro		0.7		Decreased serum testosterone and LH at ≥0.7 mg Hg/kg/day; decreased FSH and prolactin at 1.5 mg Hg/kg/day
Sabir et al. 2022									**Mercuric chloride**
73	Rat (NS) 5 B	30 days (IN)	0, 0.3	BC, UR, OW, OF, HP	Hepatic		0.3		Increased serum ALP (80%), ALT (102%), and bilirubin (332%)
					Renal			0.3	Relative kidney weight increased by ~50%; severe renal tubular degeneration and renal cell apoptosis; 45% reduction in glomerular filtration rate; elevated serum urea, uric acid, and creatinine; proteinuria and glucosuria
Sun et al. 2018									**Mercuric chloride**
74	Rat (Sprague-Dawley) 10–15 M	3 weeks (G)	0, 3.1, 6.3	LE, CS, BW, HP, NX	Immuno		3.1		Decreased density of skin LCs
					Neuro	6.3			
Szász et al. 2002									**Mercuric chloride**
75	Rat (Wistar) 5 F	7–8 weeks premating– PND 21 (W)	0, 0.6	CS, BW, FI, WI, RX, DX	Bd wt	0.6			
					Repro	0.6			
					Develop[c]		0.6		Increased susceptibility to seizure activity at PND 90
Takahashi et al. 2000a									**Mercuric chloride**
76	Rat (Wistar) 10 M	21 weeks (F)	0, 0.06, 0.17, 0.51, 1.7	BW, BC, UR, OW, OF	Bd wt	1.7			
					Cardio	0.51	1.7		23% increase in relative heart weight; elevated plasma angiotensin-II
					Hepatic		1.7		16% decrease in plasma HDL

Table 2-3. Levels of Significant Exposure to Inorganic Mercury Salts – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
					Renal		0.06		11% increase in relative kidney weight at 0.06 mg Hg/kg/day; elevated urinary protein at 1.7 mg Hg/kg/day
Takahashi et al. 2000b									**Mercuric chloride**
77	Rat (SHR Wistar) 18 M	12 weeks (F)	0, 0.07, 0.21, 0.72, 2.2	BW, BC, UR, OW, OF	Bd wt	2.2			
					Cardio		0.07		6–9% increase in systolic blood pressure (SBP) at 5 weeks; higher SBP but not significant at 12 weeks
					Hepatic		0.07		At 12 weeks: 18% decrease in plasma HDL; 45% decrease in plasma triglycerides
					Renal	0.72	2.2		At 12 weeks: Elevated relative kidney weight; elevated urinary amino acids and alkaline phosphatase
					Endocr	0.72	2.2		At 12 weeks: increased relative adrenal weight
[Spontaneously hypertensive rat strain]									
Teixeira et al. 2014									**Mercuric chloride**
78	Rat (Wistar) 10 M	45 days (GW)	0, 0.277	NX	Neuro		0.277		Reduced motor activity, impaired motor coordination
Teixeira et al. 2018									**Mercuric chloride**
79	Rat (Wistar) 20 M	45 days (GW)	0, 0.277	BW, BI, NX	Bd wt	0.277			
					Neuro		0.277		Impaired motor coordination and balance; apoptosis and loss of neurons and astrocytes in motor cortex
Teixeira et al. 2019									**Mercuric chloride**
80	Rat (Wistar) 10 M	45 days (GW)	0, 0.277	BW, BI, NX	Bd wt	0.277			
					Neuro		0.277		Decreased motor activity; impaired learning and memory

Table 2-3. Levels of Significant Exposure to Inorganic Mercury Salts – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Venter et al. 2020									**Mercuric chloride**
81	Rat (Sprague-Dawley) 6 M	28 days (GW)	0, 0.847	BW, HP	Bd wt	0.847			
					Immuno			0.847	Severe necrosis and decreased cellularity in spleen
Wildemann et al. 2015a									**Mercuric chloride**
82	Rat (Wistar) 5–6 M	4 weeks (W)	0, 0.005, 0.010, 0.021, 0.037, 0.244, 1.18, 2.07, 5.91	LE, BW, OW, OF	Death			5.91	100% mortality
					Bd wt	2.07		5.91	Weight loss
					Cardio	5.91			
					Renal	0.037	0.244		15% increase in relative kidney weight
Wildemann et al. 2015b									**Mercuric chloride**
83	Rat (Wistar) 5–6 M	4 weeks (W)	0, 0.038, 0.244	BW, OW, OF	Bd wt	0.244			
					Cardio	0.244			
Wildemann et al. 2016									**Mercuric chloride**
84	Rat (Wistar) 5–6 M	4 weeks (W)	0, 0.264, 2.955	BC, BI, UR, OF	Cardio	2.955			
					Hepatic	2.955			
					Renal	2.955			
Amirhosseini et al. 2021									**Mercuric chloride**
85	Mouse (Swiss-Webster) 8 F	5 weeks (W)	0, 0.148	IX	Immuno		0.148		Induced serum (IgG) antinucleolar antibodies; increased serum IgG; renal and spleen immune complex deposits
Chen et al. 2012									**Mercuric chloride**
86	Mouse (ICR) 16 M	4 or 6 weeks (GW)	0, 3.7	BC	Endocr		3.7		~70–95% decrease in plasma insulin; ~35% increase in blood glucose

Table 2-3. Levels of Significant Exposure to Inorganic Mercury Salts – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Dieter et al. 1983									**Mercuric chloride**
87	Mouse (B6C3F1) 10 M	7 weeks (W)	0, 0.4, 2, 11	BW, BC, BI, HE, OW, HP, IX	Bd wt	2	11		14% decrease in body weight
					Hemato		0.4		Nonmonotonic alterations in WBCs and lymphocytes (35% increase at 0.4 mg Hg/kg/day, 36% decrease at 11 mg Hg/kg/day)
					Hepatic	0.4	2		14% decrease in absolute liver weight; >50% increase in serum cholinesterase
					Renal	0.4	2		19% increase in absolute kidney weight at 2 mg Hg/kg/day; minimal renal nephropathy at 11 mg Hg/kg/day
					Endocr	11			
					Immuno	0.4	2		≥25% decrease in lymphoproliferation in response to T-cell mitogens at 2 mg Hg/kg/day; >60% decrease in antibody response to T-dependent antigen at 11 mg Hg/kg/day
					Neuro	11			
He et al. 2021									**Mercuric chloride**
88	Mouse (B10.S) 4–12 B	4 weeks (W)	0, 0.51, 2.7	HE, HP	Hemato	0.51	2.7		Increased RBCs, platelets, and hemoglobin; increased number and proliferation of erythropoietic progenitor cells in bone marrow
[Autoimmune-susceptible mice]									
He et al. 2021									**Mercuric chloride**
89	Mouse (DBA/2) 9 B	4 weeks (W)	0, 2.7	HE, HP	Hemato	2.7			

Table 2-3. Levels of Significant Exposure to Inorganic Mercury Salts – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Huang et al. 2011									**Mercuric chloride**
90	Mouse (ICR) 12–15 M	7 weeks PNDs 21–70 (GW)	0, 0.4	DX	Develop[c]		0.4		Hyperactivity, impaired motor coordination, and hearing impairment at PND 70
Huang et al. 2011									**Mercuric chloride**
91	Mouse (ICR) 12–15 F	10–17 weeks Premating through PND 21 (via dam) Select pups: PNDs 21–70 (direct) (GW)	0, 0.4	RX, DX	Repro		0.4		14% decrease in litter size
					Develop[c]		0.4 M		Effects at PND 70: 12–15% decrease in pup weight, increased motor activity and impaired hearing (both groups), impaired motor coordination (direct group only)
Hultman and Enestrom 1992									**Mercuric chloride**
92	Mouse (SJL/N) 7 F	10 weeks (W)	0, 0.07, 0.14, 0.28, 0.56	HP, IX	Immuno	0.07	0.14		Positive ANoA; evidence of immune-complex disease
[Autoimmune susceptible mice]									
Hultman and Nielsen 2001; Nielsen and Hultman 2002									**Mercuric chloride**
93	Mouse (A.SW) 8 M, 8 F	10 weeks (W)	M: 0, 0.121, 0.241, 0.464, 0.942; F: 0, 0.049, 0.105, 0.199, 0.401	BW, BC, BI, IX	Immuno	0.105 F	0.199 F		Positive ANoA; positive for ANA, splenic vessel immune deposits, polyclonal B-cell activation, and elevated IgE at ≥0.401 mg Hg/kg/day
						0.121 M	0.241 M		Positive ANoA; positive for ANA, splenic vessel immune deposits, polyclonal B-cell activation, and elevated IgE at ≥0.401 mg Hg/kg/day
[Autoimmune susceptible mice]									

2. HEALTH EFFECTS

Table 2-3. Levels of Significant Exposure to Inorganic Mercury Salts – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Hultman and Nielsen 2001; Nielsen and Hultman 2002									**Mercuric chloride**
94	Mouse (B10.S) 8 M, 8 F	10 weeks (W)	M: 0, 0.134, 0.232, 0.479, 0.962, 1.872; F: 0, 0.118, 0.218, 0.444, 0.954, 1.774	BW, BC, BI, IX	Immuno		0.118		Polyclonal B-cell activation at ≥0.118 mg Hg/kg/day; positive ANoA and ANA, splenic and renal immune deposits, and elevated IgE at ≥0.444 mg Hg/kg/day
[Autoimmune susceptible mice]									
Khan et al. 2004									**Mercuric chloride**
95	Mouse (C57BL/6) 25 M, 25 F	61–79 days (premating through lactation) (GW)	0, 0.18, 0.37, 0.74	CS, BW, FI, BC, HE, GN, OW, HP, RX	Bd wt	0.74			
					Hepatic	0.74			
					Renal	0.18 F	0.37 F		Increased relative kidney weight
							0.18 M		Increased relative kidney weight
					Endocr	0.74			
					Neuro	0.74			
					Repro			0.18	28% decrease in fertility index at 0.18 mg Hg/kg/day; 81% decrease in viability index at 0.74 mg Hg/kg/day
Li et al. 2019a									**Mercuric chloride**
96	Mouse (Kunming) 7 M	16 weeks (W)	0, 4.0, 8.10, 16.1	BC, HP	Renal			4	Renal tubular degeneration, necrosis, and hemorrhage; 40% increased serum BUN and 5% increased creatinine
Malqui et al. 2018									**Mercuric chloride**
97	Mouse (Swiss albino) 10 M	16–17 weeks GD 0–PND 21 (via dam) PND 21– PNDs 63–70 (direct) (W)	0, 3.3	WI, DX	Develop[c]	3.3			Increased anxiety and impaired memory and sociability in PND 63–70 offspring

Table 2-3. Levels of Significant Exposure to Inorganic Mercury Salts – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Mohammad Abu-Taweel and Al-Fifi 2021									**Mercuric chloride**
98	Mouse (Swiss-Webster) 10 F	35 days, GD 1–PND 15 (W)	0, 2.4	DX	Develop		2.4		At PND 40: Decreased motor activity and increased depression- and anxiety-like behaviors; elevated serum cortisol and corticosterone
NTP 1993									**Mercuric chloride**
99	Mouse (B6C3F1) 10 M, 10 F	6 months 5 days/week (GW)	0, 0.923, 1.8, 4, 7.4, 15	LE, BW, BC, GN, OW, HP	Bd wt	15 F			
						7.4 M	15 M		12% decrease in body weight
					Resp	15			
					Cardio	15			
					Gastro	15			
					Musc/skel	15			
					Hepatic	15			
					Renal	15 F			
						1.8 M	4 M		Cytoplasmic vacuolation of tubule epithelium, ≥19% increase in kidney weight
					Endocr	15			
					Immuno	15			
					Neuro	15			
					Repro	15			
Pilones et al. 2009									**Mercuric chloride**
100	Mouse (BALB/c) 6–7 F	3 weeks GDs 0–21 (W)	0, 1.5	DX	Develop[e]		1.5		Alteration in immune endpoints in offspring at PND 70 (increased splenocyte proliferation and IFNγ and IL-4 production in mitogen assay)

[DBF1 offspring; progeny of DBA/1 males × BALB/c females]

Table 2-3. Levels of Significant Exposure to Inorganic Mercury Salts – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Sin and Teh 1992									**Mercuric sulfide**
101	Mouse (Swiss albino) 20 F	4 weeks (GW)	0, 6	BW, BC	Bd wt	6			
					Endocr		6		28–41% decreased plasma T4
Son et al. 2010									**Mercuric sulfide**
102	Mouse (ICR) 5 M	4 weeks (GW)	0, 17, 170, 1,700	BW, FI, WI, BC, OW, HP	Bd wt	1,700			
					Hepatic	1,700			
					Immuno		17		Altered T-cell populations in spleen at ≥17 mg Hg/kg/day; hyperplasia and/or increased lymphoid density in spleen and thymus at 1,700 mg Hg/kg/day
Zhang et al. 2011									**Mercuric chloride**
103	Mouse (A.SW) 3–5 F	5 weeks GD 8–PND 21 (W)	0, 2.7	DX, IX	Immuno		2.7		Induction of serum IgG antibodies to brain antigens
					Develop[c,e]		2.7		Altered immune endpoints in offspring at PNDs 21 and 70 (induction of serum IgG antibodies to brain antigens; IgG deposits in brain, brain inflammation); hyperactivity in female offspring
[Autoimmune-susceptible mouse strain]									
Zhang et al. 2011									**Mercuric chloride**
104	Mouse (A/WySnJ) 3–5 F	5 weeks GD 8–PND 21 (W)	0, 2.7	DX, IX	Immuno	2.7			
					Develop[c,e]	2.7			
[Offspring immune and behavioral endpoints evaluated at PNDs 21 and 70]									

Table 2-3. Levels of Significant Exposure to Inorganic Mercury Salts – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Zhang et al. 2013									**Mercuric chloride**
105	Mouse (SJL/J) 7 F	5 weeks GD 8 to PND 21 (W)	0, 2.7	DX, IX	Immuno		2.7		Elevated serum IgG
					Develop[c,e]		2.7		Altered immune endpoints in offspring at PNDs 21 and 70 (elevated serum IgG, IgG deposits in brain, brain inflammation); decreased sociability
[Offspring were SFvF1; autoimmune susceptible SJL/J females × wild-type FVB males]									
Zhang et al. 2013									**Mercuric chloride**
106	Mouse (FVB) 6–7 F	5 weeks GD 8 to PND 21 (W)	0, 2.7	DX, IX	Immuno		2.7		Induction of serum IgG antibodies to brain antigens
					Develop[c,e]		2.7		Altered immune endpoints in offspring at PNDs 21 and 70 (elevated serum IgG, induction of serum IgG antibodies to brain antigens, IgG deposits in brain); decreased social interaction
[Offspring were FvSF1; autoimmune susceptible SJL/J males × wild-type FVB females]									
Zhao et al. 2020									**Mercuric chloride**
107	Mouse (Kunming) 6 F	90 days (W)	0, 15	BW, BC, HP	Bd wt			15	21% decrease in body weight
					Gastro		15		Histopathological changes in cecum and rectum (atrophy of glands, mild-to-moderate necrosis, apoptosis)
					Endocr		15		Decreased blood glucose
Chuu et al. 2001b									**Mercuric sulfide**
108	Guinea pig (Hartley) 8–12 F	21 days (G)	0, 86	NX	Neuro		86		Abnormal vestibular ocular reflex
[Vehicle was saline]									

2. HEALTH EFFECTS

Table 2-3. Levels of Significant Exposure to Inorganic Mercury Salts – Oral (mg/kg/day)									
Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
CHRONIC EXPOSURE									
Dieter et al. 1992; NTP 1993									**Mercuric chloride**
109	Rat (Fischer-344) 60 M, 60 F	2 years 5 days/week (GW)	0, 1.8, 4	LE, BW, BC, UR, GN, OW, HP	Death			1.8 M	Decreased survival (21%) compared to control (52%)
					Bd wt	1.8 F	4 F		16% decrease in body weight
						1.8 M		4 M	LOAEL: 16% decrease in body weight SLOAEL: 22% decrease in body weight
					Resp	1.8	4		Nasal mucosa inflammatory lesions
					Cardio	4 F			
								1.8 M	Heart mineralization (secondary to marked renal impairment)
					Gastro	1.8 F	4 F		Epithelial hyperplasia and forestomach ancanthosis
							1.8 M		Epithelial hyperplasia ≥1.8 and forestomach ancanthosis at 4 mg Hg/kg/day
					Musc/skel	4 F			
								1.8 M	Fibrous osteodystrophy (secondary to marked renal impairment)
					Hepatic	4			
					Renal	4 F			
								1.8 M	Marked thickening of glomerular and tubular basement membranes; degeneration and atrophy of tubule epithelium
					Endocr	4 F			
								1.8 M	Parathyroid hyperplasia (secondary to marked renal impairment)

Table 2-3. Levels of Significant Exposure to Inorganic Mercury Salts – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
					Immuno	4			
					Neuro	4			
					Repro	4			
					Cancer			4 M	CEL: Forestomach squamous cell papilloma and thyroid follicular cell carcinoma in males; no exposure-related neoplastic lesions in females
Perry and Erlanger 1974									**Mercuric chloride**
110	Rat (Long-Evans) 16 F	1 year (W)	0, 0.33, 0.66, 1.3, 3.3	CS, BW, OF	Bd wt	1.3	3.3		13% decrease in final body weight
					Cardio	0.33	0.66		Increased systolic blood pressure
NTP 1993									**Mercuric chloride**
111	Mouse (B6C3F1) 60 M, 60 F	2 years 5 days/week (GW)	0, 4, 7.4	LE, BW, BC, UR, GN, OW, HP	Bd wt	7.4			
					Resp		4 F		Increased metaplasia in the olfactory epithelium; increased inflammatory lesions at 7.4 mg Hg/kg/day
							4 M	7.4 M	Increased metaplasia in the olfactory epithelium; increased inflammatory lesions
					Cardio	7.4			
					Gastro	7.4			
					Musc/skel	7.4			
					Hepatic	7.4			
					Renal		4		Increased incidence (females only) and/or severity of renal nephropathy; ≥20% increase in kidney weight
					Endocr	7.4			
					Immuno	7.4			

Table 2-3. Levels of Significant Exposure to Inorganic Mercury Salts – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
					Neuro	7.4			
					Repro	7.4			

[a]The number corresponds to entries in Figure 2-7; differences in levels of health effects and cancer effects between male and females are not indicated in Figure 2-7. Where such differences exist, only the levels of effect for the most sensitive sex are presented.
[b]Used to derive an acute-duration oral MRL. Using BMD modeling, BMD_{1SD} and $BMDL_{1SD}$ values of 0.64 and 0.29 mg Hg/kg/day, respectively, were calculated for elevated relative kidney weight in male rats. The $BMDL_{1SD}$ was adjusted for continuous exposure (5 days/7 days) to a $BMDL_{ADJ}$ of 0.21 mg Hg/kg/day and divided by an uncertainty factor of 100 (10 for animal to human, and 10 for human variability), resulting in an MRL of 0.002 mg Hg/kg/day.
[c]The neurodevelopmental effects are discussed in Section 2.16 (Neurological).
[d]Used to derive an intermediate-duration oral MRL. The LOAEL of 0.015 mg Hg/kg/day was divided by an uncertainty factor of 1,000 (10 for use of a LOAEL, 10 for animal to human, and 10 for human variability), resulting in an MRL of 0.00001 mg Hg/kg/day (1×10^{-5} mg Hg/kg/day; 0.01 µg Hg/kg/day).
[e]Immunodevelopmental effects are discussed with adult immune system effects in Section 2.15 (Immunological).

Principal studies for the MRLs

ADJ = adjusted; ALP = alkaline phosphatase; ALT = alanine aminotransferase; ANA = antinuclear antibodies; ANoA = antinucleolar antibodies; AST = aspartate aminotransferase; B = both males and females; BC = serum (blood) chemistry; Bd wt or BW = body weight; BI = biochemical changes; BMD = benchmark dose; BMDL = 95% lower confidence limit on the BMD (subscripts denote benchmark response: i.e., $_{1SD}$ = exposure dose associated with a 1 SD change from the control); BUN = blood urea nitrogen; Cardio = cardiovascular; CEL = cancer effect level; CS = clinical signs; DX = developmental toxicity; Endocr = endocrine; ESR = erythrocyte sedimentation rate; (F) = feed (dietary); F = female(s); FI = food intake; FSH = follicle-stimulating hormone; (G) = gavage; (GO) = gavage in oil; (GW) = gavage in water; Gastro = gastrointestinal; GD = gestation day; GN = gross necropsy; HDL = high-density lipoprotein; HE = hematology; Hemato = hematological; HP = histopathology; IFNγ = interferon gamma; IgE = immunoglobulin E; IgG = immunoglobulin G; IL-4 = interleukin 4; Immuno = immunological; (IN) = ingestion; IX = immune function; LC = Langerhans cell; LD_{50} = lethal dose, 50% kill; LDH = lactate dehydrogenase; LE = lethality; LH = luteinizing hormone; LOAEL = lowest-observed-adverse-effect level; M = male(s); MRL = Minimal Risk Level; Musc/skel = musculoskeletal; Neuro = neurological; NOAEL = no-observed-adverse-effect level; NS = not specified; NX = neurological function; OF = organ function; OW = organ weight; PND = postnatal day; RBC = red blood cell; Repro = reproductive; Resp = respiratory; RX = reproductive function; SD = standard deviation; SLOAEL = serious lowest-observed-adverse-effect level; T3 = triiodothyronine; T4 = thyroxine; UR = urinalysis; (W) = drinking water; WBC = white blood cell; WI = water intake

Figure 2-7. Levels of Significant Exposure to Inorganic Mercury Salts – Oral
Acute (≤14 days)

2. HEALTH EFFECTS

Figure 2-7. Levels of Significant Exposure to Inorganic Mercury Salts – Oral
Acute (≤14 days)

Figure 2-7. Levels of Significant Exposure to Inorganic Mercury Salts – Oral
Acute (≤14 days)

Figure 2-7. Levels of Significant Exposure to Inorganic Mercury Salts – Oral
Acute (≤14 days)

Figure 2-7. Levels of Significant Exposure to Inorganic Mercury Salts – Oral
Acute (≤14 days)

Figure 2-7. Levels of Significant Exposure to Inorganic Mercury Salts – Oral
Intermediate (15–364 days)

Figure 2-7. Levels of Significant Exposure to Inorganic Mercury Salts – Oral
Intermediate (15–364 days)

Figure 2-7. Levels of Significant Exposure to Inorganic Mercury Salts – Oral
Intermediate (15–364 days)

Figure 2-7. Levels of Significant Exposure to Inorganic Mercury Salts – Oral
Intermediate (15–364 days)

Figure 2-7. Levels of Significant Exposure to Inorganic Mercury Salts – Oral
Intermediate (15–364 days)

Figure 2-7. Levels of Significant Exposure to Inorganic Mercury Salts – Oral
Intermediate (15–364 days)

2. HEALTH EFFECTS

Figure 2-7. Levels of Significant Exposure to Inorganic Mercury Salts – Oral
Intermediate (15–364 days)

2. HEALTH EFFECTS

Figure 2-7. Levels of Significant Exposure to Inorganic Mercury Salts – Oral
Intermediate (15–364 days)

Figure 2-7. Levels of Significant Exposure to Inorganic Mercury Salts – Oral
Intermediate (15–364 days)

Figure 2-7. Levels of Significant Exposure to Inorganic Mercury Salts – Oral
Intermediate (15–364 days)

2. HEALTH EFFECTS

Figure 2-7. Levels of Significant Exposure to Inorganic Mercury Salts – Oral
Intermediate (15–364 days)

Figure 2-7. Levels of Significant Exposure to Inorganic Mercury Salts – Oral
Chronic (≥365 days)

2. HEALTH EFFECTS

Figure 2-7. Levels of Significant Exposure to Inorganic Mercury Salts – Oral
Chronic (≥365 days)

Figure 2-7. Levels of Significant Exposure to Inorganic Mercury Salts – Oral
Chronic (≥365 days)

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
ACUTE EXPOSURE									
Arito and Takahashi 1991									**Methylmercuric chloride**
1	Rat (Sprague-Dawley) 4–16 M	2 days (GW)	0, 1.32, 4, 12	BI, NX	Neuro	1.32	4		Decreased paradoxical sleep and increased slow-wave sleep
Arito and Takahashi 1991									**Methylmercuric chloride**
2	Rat (Sprague-Dawley) 6 M	2 days (GW)	12	CS	Cardio		12		10–18% decrease in heart rate for up to 16 days post-exposure (compared to pre-exposure values)
					Other noncancer		12		Hypothermia for >1 month post-exposure
Bornhausen et al. 1980									**Methylmercuric chloride**
3	Rat (Wistar) 10 M, 10 F	4 days GDs 6–9 (GW)	0, 0.004, 0.008, 0.035	DX	Develop[b]	0.004	0.008		Impaired operant conditioning at 4 months
Cagiano et al. 1990									**Methylmercuric chloride**
4	Rat (Sprague-Dawley) NS F	Once GD 15 (G)	0, 6.4	DX	Develop[b]		6.4		Decreased avoidance latency in offspring on PND 60
Carratu et al. 2006									**Methylmercury**
5	Rat (Sprague-Dawley) 9–10 F	Once GD 8 or 15 (G)	0, 7	BW, DX	Bd wt	7			
					Develop[b]			7	Decreased postnatal survival; 18% decrease in pup weight at PND 21 (GD 8 exposure only); decreased exploratory behavior and impaired habituation at PND 40
Carratu et al. 2008									**Methylmercury**
6	Rat (Sprague-Dawley) 10 F	Once GD 15 (G)	0, 7	DX	Develop[b]		7		Impaired associative learning and elevated corticosterone levels at PND 90

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure keya	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Chang and Hartmann 1972									**Methylmercuric chloride**
7	Rat (Holtzman) 4 M	1–2 weeks (G)	0, 0.8	CS, BW, HP	Bd wt	0.8			
					Neuro		0.8		Ultrastructural changes in dorsal root ganglia and cerebellum
Chen et al. 2019a									**Methylmercuric chloride**
8	Rat (Sprague-Dawley) 6 M	5 days (G)	0, 9	BI, HP, RX	Repro		9		Decreased sperm count and motility; disruption of germinal epithelium in seminiferous tubules with reduced spermatozoa; increased germ cell apoptosis
[Vehicle was sodium carbonate]									
Chuu et al. 2007									**Methylmercury**
9	Rat (Sprague-Dawley) 6 M	5 days (GW)	0, 1.9	NX	Neuro		1.9		Impaired balance, suppression of compound muscle action potentials followed by incomplete recovery after tetany
Chuu et al. 2007									**Methylmercury**
10	Rat (Sprague-Dawley) 6 M	14 days (GW)	0, 1.9	BW, NX	Bd wt		1.9		~10% decrease in body weight
					Neuro		1.9		Impaired balance, suppression of compound muscle action potentials followed by incomplete recovery after tetany; transient decrease in motor nerve conduction velocity and nociception
Coluccia et al. 2007									**Methylmercuric chloride**
11	Rat (Sprague-Dawley) 8 M	10 days PNDs 14–23 (IN)	0, 0.6	DX	Developb		0.6		Impaired associative learning (PND 90) and decreased rearing in open field (PNDs 31–45)
[Administered via micropipette as 1:1 ratio of MeHg:L-cysteine in 10% condensed milk]									

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Fehling et al. 1975									**Methylmercuric chloride**
12	Rat (Wistar) 10 M	2 days (G)	0, 10, 20	HP, NX	Neuro		10	20	SLOAEL: Decreased nerve conduction velocity and degeneration of peripheral nerves and dorsal nerve roots and ganglia LOAEL: Impaired balance and coordination
Fossato da Silva et al. 2011									**Methylmercury**
13	Rat (Wistar) 15 M	14 days (GW)	0, 0.5, 0.93, 2.8	BW, BC, OW, HP	Bd wt	2.8			
					Renal	0.93	2.8		18% increase in relative kidney weight
					Repro		0.5		Nonmonotonic sperm effects (decreased count and motility, increased abnormal) at ≥0.5 mg Hg/kg/day; 65% decrease in serum testosterone and 28% decrease in relative seminal vesicle weight at 2.8 mg Hg/kg/day
Fossato da Silva et al. 2012									**Methylmercury**
14	Rat (Wistar) 10 M	14 days (GW)	0, 0.5, 0.93, 2.8	BW, OW, HP	Bd wt	2.8			
					Repro		0.5		Inflammatory foci and thickening of epithelium in prostate at ≥0.5 mg Hg/kg/day; progressing to epithelial atrophy and dilation of glandular acini at 2.8 mg Hg/kg/day
Fredriksson et al. 1996									**Methylmercury**
15	Rat (Sprague-Dawley) 12 F	4 days GDs 6–9 (G)	0, 1.9	CS, BW, DX	Bd wt	1.9			
					Develop[b]	1.9			

[Behavior assessed in adult male offspring at 4–5 months of age]

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Fuyuta et al. 1978									**Methylmercuric chloride**
16	Rat (Wistar) 20 F	8 days GDs 7–14 (GW)	0, 2, 4, 6	CS, BW, FI, WI, DX	Neuro	4		6	Spasms, gait disturbance, and hind limb crossing in dams
					Develop	2		4	Decreased fetal weight; increased incidence of fetal malformations
Kendricks et al. 2022									**Methylmercuric chloride**
17	Rat (Long-Evans) 12 M	9 days PNDs 1–10 (GW)	0, 0.064, 0.280	DX	Develop	0.064	0.280		Slower acquisition (Impaired learning) at PND 91
Khera 1973									**Methylmercuric chloride**
18	Rat (Wistar) 15–20 M	7 days (G)	0, 1, 2.5, 5	CS, BW, RX	Bd wt	5			
					Repro	2.5		5	Decreased fertility and decreased viable fetuses
[Males mated to untreated females after exposure]									
Lee and Han 1995									**Methylmercuric chloride**
19	Rat (Fischer-344) 30 F	Once GD 7 (G)	0, 8, 16, 24	LE, BW, DX	Death			16	17% maternal death
					Bd wt		8	16	LOAEL: 14% decrease in maternal body weight SLOAEL: >20% decrease in maternal body weight
					Develop			8	Decreased fetal survival; decrease in fetal weight and length, delayed ossification, spinal curvature
Miyakawa et al. 1974									**Methylmercuric sulfide**
20	Rat (Wistar) 5 M	10 days (IN)	0, 7	CS, BW, HP	Bd wt	7			
					Neuro			7	Ataxia and instability post-exposure; peripheral nerve degeneration
[Rats sacrificed 600 days post-exposure]									

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Nolen et al. 1972									**Methylmercuric chloride**
21	Rat (NS) 20 F	9 days GDs 6–14 (W)	0, 0.024, 0.23, 4.6	BW	Bd wt	0.23		4.6	55% decreased maternal weight gain
					Develop		0.024		Increased incidence of fetal urinary bladder defects and missing 5th sternebra
Post et al. 1973									**Methylmercuric chloride**
22	Rat (Sprague-Dawley) 15 M	Once (G)	0, 20	CS, HP, NX	Neuro		20		Transient lethargy and ataxia; impaired spatial learning; decreased motor activity
[Behavioral tests administered over a 60-day period post-exposure]									
Post et al. 1973									**Methylmercuric chloride**
23	Rat (Sprague-Dawley) 15 M	Once PND 15 or 21 (G)	0, 16	DX	Develop[b]		16		Transient lethargy and ataxia
[Behavioral tests administered over a 60-day period post-weaning]									
Sakamoto et al. 2020									**Methylmercuric chloride**
24	Rat (Wistar) 8 M	10 days PNDs 14–23 (IN)	0, 8	DX	Develop			8	>20% decrease in body weight; hind-limb paralysis and dystonia; impaired motor coordination; impaired memory; severe cerebral degeneration
Shinoda et al. 2019									**Methylmercuric chloride**
25	Rat (Wistar) 3 M	2 weeks 5 days/week (GW)	0, 5.4	HP	Neuro			5.4	Decreased number and area of axons and neuronal loss in dorsal root ganglion of lumbar spinal cord; Schwann cell proliferation of sensory nerve fibers
Shinoda et al. 2019									**Methylmercuric chloride**
26	Rat (Wistar) 3 M	5 days (GW)	0, 5.4	HP	Neuro	5.4			

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Stoltenburg-Didinger and Markwort 1990									**Methylmercuric chloride**
27	Rat (Wistar) NS F	4 days GDs 6–9 (G)	0, 0.02, 0.04, 0.4, 4	CS, HP	Develop[b]	0.04	0.4	4	SLOAEL: Altered behavior and dendritic spine abnormalities LOAEL: Increased startle response in adult offspring
Su et al. 1998									**Methylmercuric chloride**
28	Rat (Wistar) 4 NS	10 days (G)	0, 8	LE, CS, BW, HP	Death			8	14/34 rats died prior to scheduled sacrifice
					Bd wt			8	Body weight loss
					Musc/skel			8	Neurogenic atrophy of gluteal muscle
					Neuro			8	Ataxia, hind-limb crossing, weakness, degeneration of cortical and cerebellar neurons, large motor neurons in spinal cord, and myelinated fibers of spinal anterior roots
[Vehicle was L-cysteine; rats sacrificed at intervals 1–8 days post-exposure]									
Usuki et al. 1998									**Methylmercuric chloride**
29	Rat (Wistar) NS M	12 days (GW)	0, 4	CS, BW, HP	Death			4	50% death by 3 weeks post-exposure
					Bd wt			4	37% decrease in body weight
					Musc/skel			4	Muscle weakness and wasting
					Neuro		4		Weakness, hind-limb crossing
Zanoli et al. 1994									**Methylmercuric chloride**
30	Rat (Sprague-Dawley) NS F	Once GD 15 (G)	0, 6.4	DX	Develop[b]		6.4		Decreased passive avoidance latency in PND 42 offspring

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Belles et al. 2002									**Methylmercuric chloride**
31	Mouse (CD-1) 10–12 F	Once GD 10 (GW)	0, 9.99	BW, OW, DX	Bd wt	9.99			
					Develop			9.99	17% decrease in fetal weight; increased incidence of cleft palate; delayed ossification
Bellum et al. 2007									**Methylmercuric chloride**
32	Mouse (C57BL/6J) 22–29 B	5 days PNDs 29–33 (F)	0, 0.2, 0.8	DX	Develop[b]		0.2		Impaired balance and motor coordination on PND 38
Bellum et al. 2013									**Methylmercuric chloride**
33	Mouse (C57BL/6) 20–25 B [Aged mice]	5 days (F)	0, 0.9	BI, NX	Neuro		0.9		Hypoactivity, motor incoordination
Chen et al. 2012									**Methylmercuric chloride**
34	Mouse (ICR) 16 M	2 weeks (GW)	0, 1.6	BC, BI, HP	Endocr		1.6		~60–70% decrease in baseline and fasting plasma insulin; impaired glucose tolerance; apoptosis in pancreatic islet cells
Chuu et al. 2001a									**Methylmercury**
35	Mouse (NS) 8–10 M	7 days (G)	0, 0.2, 1.9, 9.3	LE, NX	Death			9.3	100% mortality
					Neuro		0.2	1.9	LOAEL: Reversible hearing loss SLOAEL: Persistent hearing loss
Das et al. 1997									**Methylmercuric chloride**
36	Mouse (Swiss-Webster) NS M	4 days (G)	0, 12	BW, BI, OW, HP	Bd wt			12	10% body weight loss
					Resp	12			22–23% increase in absolute and relative lung weight; reduced alveolar diameter and increased alveolar wall thickness; increased minimal surface tension

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Dietrich et al. 2005									**Methylmercuric chloride**
37	Mouse (Swiss) 13–14 M	7–14 days (W)	0, 4.7, 8.7	CS, WI, NX	Neuro		4.7		Impaired motor coordination, hypoactivity
Dore et al. 2001									**Methylmercuric chloride**
38	Mouse (C57BL/6) 10–21 F	3 days GDs 7–9 (G)	0, 3, 5	DX	Develop[b]		3	5	LOAEL: Impaired spatial memory at PND 49 SLOAEL: 28% decrease in postnatal survival
[Vehicle was phosphate-buffered saline]									
Dore et al. 2001									**Methylmercuric chloride**
39	Mouse (C57BL/6) 10–21 F	3 days GDs 12–14 (G)	0, 3, 5	DX	Develop[b]		3	5	LOAEL: Hypoactivity at PND 42 SLOAEL: 26% decrease in postnatal survival and impaired spatial learning at PNDs 49–98
[Vehicle was phosphate-buffered saline]									
Fischer et al. 2008									**Methylmercuric chloride**
40	Mouse (NMRI) NS M	Once PND 10 (GW)	0, 0.37, 3.7	DX	Develop[b]		0.37		Decreased motor activity and impaired learning and memory at 2–6 months of age at ≥0.37 mg Hg/kg/day; impaired exploratory habituation at 3.7 mg Hg/kg/day
Fuyuta et al. 1978									**Methylmercuric chloride**
41	Mouse (C57BL/6N) 9–10 F	8 days GDs 6–13 (GW)	0, 2, 4, 4.8, 6	CS, BW, FI, WI, DX	Develop			2	Increased incidence of fetal malformations
Fuyuta et al. 1979									**Methylmercuric chloride**
42	Mouse (ICR) 20 F	Once GD 10 (GW)	0, 8, 12, 16, 20	DX	Develop		8	12	SLOAEL: Cleft palate and decreased fetal weight LOAEL: Incomplete fusion of sternebrae

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Hughes and Annau 1976									**Methylmercury hydroxide**
43	Mouse (CFW) NS F	Once GD 8 (G)	0, 1, 2, 3, 5, 10	DX	Develop[b]	2	3	10	LOAEL: 35% decrease in litter size, 13% decrease in pup weight on PND 21, decreased conditioned avoidance SLOAEL: 73% decrease in litter size
Inouye et al. 1985									**Methylmercuric chloride**
44	Mouse (C3H/HeN) 10 F	Once on GD 13, 14, 15, 16, or 17 (GW)	0, 16	DX	Develop[b]			16	Decreased survival of offspring; neurological effects in offspring (impaired righting response, altered gait, hindlimb crossing, decreased brain weight, dilated lateral ventricles; smaller caudate putamen)
Ishihara et al. 2019									**Methylmercuric chloride**
45	Mouse (ICR) 10 M	2 weeks (IN)	0, 3.2	HP, NX	Neuro		3.2		Increased reactive astrocytes in inferior colliculus
Khera 1973									**Methylmercuric chloride**
46	Mouse (Swiss-Webster) 10–12 M	7 days (G)	0, 1, 2.5, 5	CS, BW, RX	Bd wt Repro	5 5			
[Males mated to untreated females after exposure]									
Khera and Tabacova 1973									**Methylmercuric chloride**
47	Mouse (Swiss-Webster) 6–17 F	12 days GDs 6–17 (GO)	0, 0.001, 0.01, 0.1, 1, 10	LE, CS, BW, DX	Death Develop	 1		10	100% maternal mortality

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Khera and Tabacova 1973									**Methylmercuric chloride**
48	Mouse (Swiss-Webster) 5–14 F	12 days GDs 6–17 (GO)	0, 0.001, 0.01, 1, 5	CS, BW, BI, DX	Develop[b]	0.01	1	5	LOAEL: Delayed cerebellar development SLOAEL: 100% stillbirth
Kim et al. 2000									**Methylmercury**
49	Mouse (BALB/c) 6 F	3 days GDs 12–14 (G)	0, 3	CS, DX	Develop[b]		3 M		Effects in male offspring: 15% reduction in body weight; decreased motor activity and decreased anxiety-like behaviors at PND 42; altered nocturnal rhythm at PNDs 84–98
Kim et al. 2000									**Methylmercury**
50	Mouse (C57BL/ 6Cr) 5–6 F	3 days GDs 12–14 (G)	0, 3	CS, DX	Develop[b]		3 M		Effects in male offspring: Decreased motor activity and rearing at PND 42; impaired spatial learning and memory at PND 56
Kim et al. 2000									**Methylmercury**
51	Mouse (C57BL/6J) 4 F	3 day GDs 12–14 (G)	0, 3	CS, DX	Develop[b]		3 M		Effects in male offspring: Impaired spatial learning on PND 56; increased grooming/preening behaviors on PND 42
Kirkpatrick et al. 2015									**Methylmercury**
52	Mouse (C57BL/6N) NS M	7–14 days (IN)	0, 4.6	BW, NX	Bd wt	4.6			
					Neuro	4.6			
[Mice given MeHg-dosed cookies]									
Montgomery et al. 2008									**Methylmercuric chloride**
53	Mouse (C57BL/6) 6 F	11 days GDs 8–18 (F)	0, 0.009	DX	Develop[b]		0.009		Impaired learning and memory and decreased motor activity and coordination in adult offspring

2. HEALTH EFFECTS

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Moreira et al. 2012									**Methylmercury**
54	Mouse (C57BL/6) 8 M	14 days (W)	0, 5.6	BC, BI, NX	Hepatic			5.6	Elevated plasma total cholesterol
					Neuro	5.6			
Moreira et al. 2012									**Methylmercury**
55	Mouse (C57BL/6) 8 M	7 days (W)	0, 5.6	BC, BI, NX	Hepatic	5.6			
					Neuro	5.6			
Yasuda et al. 1985									**Methylmercuric chloride**
56	Mouse (JCL:ICR) 10 F	Once GD 10 or 12 (GW)	0, 10, 12, 16, 20	DX	Develop	12		16	Cleft palate; dilatation of renal pelvis; decreased fetal weight
Yasutake et al. 1991									**Methylmercuric chloride**
57	Mouse (C57BL/6N) 4–6 M, 4–6 F	Once (G)	0, 4, 8, 16, 24, 32, 40	LE, BC, HP, OF	Death			40 F	
								16 M	4/6 died
					Renal	24 F		32 F	Impaired renal function
						8 M		16 M	Impaired renal function; increased serum creatinine at ≥32 mg Hg/kg
Reuhl et al. 1981a									**Methylmercuric chloride**
58	Hamster (Golden Syrian) 10 F	Once GD 10; or 6 days GDs 10–15 (GW)	0, 1.6	DX	Develop[b]			1.6	Degeneration of cerebellar neurons in neonates
Reuhl et al. 1981b									**Methylmercuric chloride**
59	Hamster (Golden Syrian) 10 F	Once GD 10; or 6 days GDs 10–15 (GW)	0, 1.6	DX	Develop[b]			1.6	Degeneration of cerebellar neurons in adult offspring

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Inouye and Kajiwara 1988									**Methylmercuric chloride**
60	Guinea pig (Hartley) 5–9 F	Once GD 21, 28, 35, 42, or 49 (GW)	0, 11.5	CS, FI, DX	Develop			11.5	>30% total litter loss, 12–30% decrease in fetal body weight, abnormal fetal brain development
INTERMEDIATE EXPOSURE									
Charleston et al. 1994									**Methylmercury hydroxide**
61	Monkey (Macaca fascicularis) 4–5 F	6 months (IN)	0, 0.05	CS, OW, HP	Neuro		0.05		72% increase in reactive glia in the brain
Charleston et al. 1995									**Methylmercury**
62	Monkey (Macaca fascicularis) NS F	6 months (IN)	0, 0.05	HP	Neuro		0.05		72% increased number of reactive glia
Charleston et al. 1996; Vahter et al. 1994									**Methylmercury hydroxide**
63	Monkey (Macaca fascicularis) 4 F	6 months (IN)	0, 0.05	BC, BW, CS, GN, HE, HP	Bd wt	0.05			
					Hemato	0.05			
					Neuro		0.05		Decreased astrocytes in thalamus
Eto et al. 2001									**Methylmercury**
64	Monkey (Marmoset) 4 M	Up to 242 days (W)	0, 0.5	CS, BW, HP	Bd wt			0.5	Body weight loss
					Neuro		0.5		Mild ataxia; cerebral edema and gliosis, microcystic change in occipital white matter

2. HEALTH EFFECTS

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Mohamed et al. 1987									**Methylmercury**
65	Monkey (Macaca fascicularis) 3 M	20 weeks (IN)	0, 0.046, 0.065	CS, BW, BC, HP, RX	Bd wt	0.065			
					Repro		0.046		Increased sperm tail-defects; decreased spermatozoa motility; decreased sperm speed and forward progression
Petruccioli and Turillazzi 1991									**Methylmercuric chloride**
66	Monkey (Macaca fascicularis) 4–6 F	150 days (IN)	0, 0.0003, 0.0032, 0.04	CS, BW	Bd wt	0.04			
					Neuro	0.04			
Willes et al. 1978									**Methylmercuric chloride**
67	Monkey (Macaca fascicularis) 2 M, 2 F	28–29 days PNDs 0–28 or 29 (IN)	0, 0.5	DX	Develop[b]			0.5	Severe signs of neurotoxicity (loss of dexterity, decreased locomotor activity, ataxia, blindness, comatose); neuronal degeneration; body weight loss
Abd El-Aziz et al. 2012									**Methylmercuric chloride**
68	Rat (Sprague-Dawley) 8 F	3 weeks GDs 0–20 (GW)	0, 0.9, 1.8	DX	Develop	0.9			Incomplete skeletal ossification at ≥0.9 mg Hg/kg/day; 13–14% decrease in fetal weight, length, and head size and decrease in long bone width/length at 1.8 mg Hg/kg/day
Albores-Garcia et al. 2016									**Methylmercuric chloride**
69	Rat (Sprague-Dawley) 15 F	38 days GD 5–PND 21 (GW)	0, 0.2, 0.4	CS, DX	Develop[b]		0.2		Effects in PND 40 offspring: Impaired learning and memory at ≥0.2 mg Hg/kg/day; altered open field activity (decreased rearing) at 0.4 mg Hg/kg/day; no effect on PND 90

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure keya	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Beyrouty et al. 2006									**Methylmercuric chloride**
70	Rat (Sprague-Dawley) 8 F	7–8 weeks (4 weeks premating–GD 20) (GW)	0, 0.5, 0.9	CS, BW, FI, DX	Bd wt	0.9			
					Develop	0.5	0.9		6–9% decrease in pup body weight gain from PND 4 to 41
[Offspring neurobehavior assessed PNDs 17–38]									
Bittencourt et al. 2019									**Methylmercuric chloride**
71	Rat (Wistar) 30 M	60 days (GO)	0, 0.04	BI, NX	Neuro		0.04		Impaired social and spatial memory; decreased number of mature neurons and astrocytes in hippocampus
Bittencourt et al. 2019									**Methylmercuric chloride**
72	Rat (Wistar) 30 M	60 days (GO)	0, 0.04	HP, NX	Neuro		0.04		Impaired social factual memory and spatial memory; decreased number of hippocampal neurons and astrocytes
Bittencourt et al. 2022									**Methylmercuric chloride**
73	Rat (Wistar) 27 M	60 days (GO)	0, 0.04	HP, NX	Neuro		0.04		Decreased motor activity, impaired motor coordination, reduced cerebellar density of Purkinje cells, mature neurons, astrocytes, microglia, oligodendrocytes and synaptic vesicles
Chang and Hartmann 1972									**Methylmercuric chloride**
74	Rat (Holtzman) 4 M	6 weeks (G)	0, 0.8	CS, BW, HP	Bd wt		0.8		Body weight loss
					Neuro			0.8	Hind-limb crossing, severe ataxia, tremor, partial paralysis; cellular degeneration and ultrastructural changes in dorsal root ganglia and cerebellum

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Chemelo et al. 2022									**Methylmercuric chloride**
75	Rat (Wistar) 4 F	42 days GD 0–PND 21 (F)	0, 0.03	DX	Develop		0.03		Alveolar bone loss, decreased osteocyte density and collagen in mandibles on PND 41
[Rats were given methylmercury-dosed cookies; controls were treated with vehicle-dosed cookies (ethanol)]									
Cheng et al. 2015									**Methylmercury**
76	Rat (Wistar) 3 F	6 weeks GD 1 to PND 21 (W)	0, 0.05, 0.23	RX, DX	Repro	0.23			
					Develop[b]	0.05	0.23		Delayed acquisition of neurodevelopmental reflexes; impaired motor coordination PNDs 34–35; increased motor activity in females on PND 36
da Silva et al. 2022									**Methylmercuric chloride**
77	Rat (Wistar) 3 F	42 days GD 0–PND 21 (F)	0, 0.03	DX	Develop			0.03	Loss of motor neurons and decreased myelination in the spinal cord at PND42
[Rats were given methylmercury-dosed cookies; controls were treated with vehicle-dosed cookies (ethanol)]									
de Oliveira Lopes et al. 2021									**Methylmercuric chloride**
78	Rat (Wistar) 15 M	60 days (GO)	0, 0.03	BW, HP	Bd wt	0.03			
					Musc/skel		0.03		Loss of alveolar bone volume and microstructure in mandible
Elsner 1991									**Methylmercuric chloride**
79	Rat (Wistar) 16 F	~60 days premating through lactation (W)	0, 0.19, 0.74	BW, RX, DX	Bd wt	0.74			
					Repro	0.74			
					Develop[b]		0.19		Impaired operant training and decreased ultrasonic vocalization in offspring

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Fagundes et al. 2022									**Methylmercuric chloride**
80	Rat (Wistar) 5 F	42 days GD 0–PND 21 (IN)	0, 0.03	DX	Develop		0.03		Decreased motor activity, impaired motor coordination, and impaired short-term memory in offspring on PND 41
[Rats were given methylmercury-dosed cookies]									
Freire et al. 2020									**Methylmercuric chloride**
81	Rat (Wistar) 9 M	60 days (GO)	0, 0.03	BW, HP, NX	Bd wt	0.03			
					Neuro		0.03		Decreased motor activity, moderate bristling of back hair; impaired motor coordination (balance); reduced number and altered morphology of astrocytes in visual cortex; decreased contrast index
Friedmann et al. 1998									**Methylmercuric chloride**
82	Rat (Brown Norway) 5–14 M	19 weeks 2 days/week (G)	0, 0.0008, 0.008, 0.08	CS, BW, BC, OW, RX	Bd wt	0.08			
					Repro	0.0008		0.008	No viable litters produced at 0.008 mg Hg/kg/day; 100% infertility, 8% decrease in absolute testes weight, 17% reduction in caudal sperm count, and 44% reduction in testicular testosterone at 0.08 mg Hg/kg/day
[Mated to untreated females during week 11]									
Fujimura et al. 2012									**Methylmercury**
83	Rat (Wistar) 3 F	6 weeks GD 1–PND 21 (W)	0, 0.05, 0.23, 0.5	RX, DX	Repro	0.23		0.5	No viable litters
					Develop[b]	0.05	0.23		Impaired motor coordination in PND 34–35 offspring

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Gandhi et al. 2013									**Methylmercury**
84	Rat (Wistar) 7–8 F	~17 days GD 5 until parturition (~GD 21) (G)	0, 0.5, 0.9, 1.9	CS, BW, DX	Bd wt	0.9		1.9	>50% decrease in maternal body weight gain
					Neuro	0.9		1.9	Incoordination, altered gait, hindlimb ataxia
					Develop		0.5	1.9	LOAEL: 12% decrease in mean litter weight on PND 1 SLOAEL: 100% full-litter resorption
Giménez-Llort et al. 2001									**Methylmercury hydroxide**
85	Rat (Sprague-Dawley) 7 F	22 days GD 7–PND 7 (W)	0, 0.5	BW, FI, WI, DX	Bd wt	0.5			
					Develop[c]		0.5		Increased motor activity at PND 14
Grotto et al. 2009a									**Methylmercuric chloride**
86	Rat (Wistar) 7 M	100 days (G)	0, 0.08	BW, BC, OF	Bd wt	0.08			
					Cardio		0.08		Increased systolic blood pressure
Ilback et al. 1991									**Methylmercury**
87	Rat (Sprague-Dawley) 8 F	~15 weeks 11 weeks premating through GD 21 (F)	0, 0.37	BW, DX	Bd wt	0.37			
					Develop[c]		0.37		45% increase in WBCs in offspring on PND 15
Ilback et al. 1991									**Methylmercury**
88	Rat (Sprague-Dawley) 8 F	15 days PNDs 1–15 (via dam) (F)	0, 0.37	BW, DX	Bd wt	0.37			
					Develop[c]		0.37		7% decrease in pup weight; 13% decrease in relative spleen weight; altered immune function in offspring (decreased splenic lymphoproliferative response to mitogen)

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Ilback et al. 1991									**Methylmercury**
89	Rat (Sprague-Dawley) 8 F	~17 weeks 11 weeks premating through PND 15 (F)	0, 0.37	BW, DX	Bd wt	0.37			
					Develop[c]		0.37		9% decrease in pup weight; altered immune function in offspring (increased thymic lymphoproliferative response to mitogen, decreased cell-mediated cytotoxicity)
Jindal et al. 2011									**Methylmercuric chloride**
90	Rat (Wistar) 10 B	1 month (G)	0, 0.5	OF	Cardio		0.5		Altered left ventricular function; impaired baroreflex
Kakita et al. 2000									**Methylmercuric chloride**
91	Rat (Wistar) 6 F	25 days premating–GD 19 (GW)	0, 0.8	DX	Develop[b]			0.8	Evidence of neuronal damage on PNDs 1 and 3 (not PNDs 7–180); decreased cell numbers in amygdala and hippocampus on PND 70; impaired associative learning at PND 180
Kendricks et al. 2020a									**Methylmercuric chloride**
92	Rat (Long-Evans) 8–11 M	39 days PND 21–60 (W)	0, 0.032, 0.320	DX	Develop	0.032			
[Attention and memory assessed at 7.5 months]									
Kendricks et al. 2020b									**Methylmercuric chloride**
93	Rat (Long-Evans) 12 M	39 days PND 21–60 (W)	0, 0.032, 0.320	DX	Develop	0.032			
[Operant learning assessed at 6 months]									

2. HEALTH EFFECTS

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Khera 1973									**Methylmercuric chloride**
94	Rat (Wistar) 14–19 M	95–125 days (G)	0, 0.1, 0.5, 1	CS, BW, RX	Bd wt	0.5		1	Body weight loss
					Repro	0.1		0.5	Decreased viable fetuses at ≥0.5 mg Hg/kg/day; decreased fertility at 1 mg Hg/kg/day
[Males mated to untreated females concurrent with exposure]									
Khera and Tabacova 1973									**Methylmercuric chloride**
95	Rat (Wistar) 35 F	Up to 122 days 2 generations (F)	0, 0.002, 0.01, 0.05, 0.25	CS, BW, HP, DX	Bd wt	0.25			
					Renal	0.25			
					Repro	0.25			
					Develop	0.05	0.25		Increased incidence of ocular lesions (delayed eyelid separation, suborbital edema, corneal opacity)
Larsen and Brændgaard 1995; Schiønning et al. 1998a									**Methylmercuric chloride**
96	Rat (Wistar) 10–18 M	19 days (GW)	0, 1.6	CS, BW, OW, HP	Bd wt			1.6	Body weight loss
					Neuro			1.6	Axonal destruction in dorsal root of spinal cord, loss of large motor neurons in dorsal root ganglia; clinical signs of neurotoxicity (apathy, hindlimb crossing, clumsiness, ataxia)
Moussa et al. 2010									**Methylmercury**
97	Rat (Wistar) 10 M	8 weeks (W)	0, 3.2	BW, BC, OW, HP	Bd wt			3.2	29% decrease in final body weight
					Repro		3.2		98% decrease in serum testosterone; 54–73% decrease in testicular testosterone

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Newland and Reile 1999; Newland and Rasmussen 2000; Newland et al. 2004									**Methylmercuric chloride**
98	Rat (Long-Evans) 10 F	~10–13 weeks 4–7 weeks premating–PND 16 (W)	0, 0.045, 0.6	RX, DX	Repro	0.6			
					Develop[b]		0.045		Acceleration of age-related cognitive decline in operant training in offspring from 6 months to 2.5 years
Oliveira et al. 2018									**Methylmercury**
99	Rat (Wistar) 5 F	35 days PNDs 31–65 (GW)	0, 0.037	DX	Develop		0.037		Decreased locomotor activity, bradykinesia, impaired motor coordination
Ortega et al. 1997a									**Methylmercuric chloride**
100	Rat (Sprague-Dawley) 6 M	8 weeks (W)	0, 0.0004, 0.04	BC, BW, IX	Bd wt	0.004			
					Immuno		0.0004		Biphasic lymphocyte response to mitogen PHA (544% increase at 0.0004 mg Hg/kg/day; 56% decrease at 0.04 mg Hg/kg/day)
Ortega et al. 1997a									**Methylmercuric sulfide**
101	Rat (Sprague-Dawley) 6 M	8 weeks (W)	0, 0.0004, 0.04	BC, BW, IX	Bd wt	0.04			
					Immuno		0.0004		278% increase in lymphocyte response to mitogen PHA at 0.0004 mg Hg/kg/day; no change at 0.04 mg Hg/kg/day
Ortega et al. 1997a									**Bis(methylmercury)sulfide**
102	Rat (Sprague-Dawley) 6 M	8 weeks (W)	0, 0.0004, 0.04	BC, BW, IX	Bd wt	0.04			
					Immuno		0.0004		300% increase in lymphocyte response to mitogen PHA at 0.0004 mg Hg/kg/day; no change at 0.04 mg Hg/kg/day

2. HEALTH EFFECTS

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)									
Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Ortega et al. 1997a									**Tris(methylmercuric)sulphonium ion**
103	Rat (Sprague-Dawley) 6 M	8 weeks (W)	0, 0.0004, 0.04	BC, BW, IX	Bd wt	0.04			
					Immuno		0.0004		56% decrease in lymphocyte response to mitogen PHA
Ortega et al. 1997b									**Methylmercuric chloride**
104	Rat (Sprague-Dawley) 6 M	8 weeks (W)	0, 0.0004, 0.04	BC, IX	Endocr		0.0004		>100% increase in ACTH
					Immuno		0.0004		Biphasic lymphocyte response to mitogen Con-A (313% increase at 0.0004 mg Hg/kg/day; 67% decrease at 0.04 mg Hg/kg/day); >275% increase in IL-6 at both doses
Ortega et al. 1997b									**Bis(methylmercury)sulfide**
105	Rat (Sprague-Dawley) 6 M	8 weeks (W)	0, 0.0004, 0.04	BC, IX	Endocr		0.0004		>100% increase in ACTH
					Immuno		0.0004		>133% increase in lymphocyte response to Con-A; 300% increase in IL-6 at 0.04 mg Hg/kg/day
Ortega et al. 1997b									**Bis(methylmercury)sulfide**
106	Rat (Sprague-Dawley) 6 M	16 weeks (W)	0, 0.0004, 0.04	BC, IX	Endocr	0.04			
					Immuno		0.0004		Biphasic lymphocyte response to mitogen Con-A (69% decrease at 0.0004 mg Hg/kg/day; 200% increase at 0.04 mg Hg/kg/day); >140% increase in IL-6 at both dose levels

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Ortega et al. 1997b									**Methylmercuric chloride**
107	Rat (Sprague-Dawley) 6 M	16 weeks (W)	0, 0.0004, 0.04	BC, IX	Endocr		0.0004		149% increase in ACTH
					Immuno		0.0004		>75% decrease in lymphocyte response to mitogen Con-A at ≥0.0004 mg Hg/kg/day; 14-fold increase in IL-6 at 0.04 mg Hg/kg/day
Rosa-Silva et al. 2020a, 2020b									**Methylmercuric chloride**
108	Rat (Wistar) 10 M	45 days (GO)	0, 0.4	BW, FI, BC, NX	Bd wt		0.4		21% decrease in body weight with 8% decrease in food consumption
					Hepatic		0.4		174% increase in serum AST and 106% increase in serum ALT
					Neuro		0.4		Increased motor activity and increased anxiety-like behavior (at age PND 145 days)
Rosa-Silva et al. 2020a, 2020b									**Methylmercuric chloride**
109	Rat (Wistar) 10 F	87 days GD 1–PND 22 + PNDs 100– 145 (GO)	0, 0.4	BW, FI, BC, NX, DX	Develop		0.4		25% decrease in body weight with 8% decrease in food consumption Hepatic: 220% increase in serum AST and 123% increase in serum ALT; increased motor activity and increased anxiety-like behavior at PND 145
Rossi et al. 1997									**Methylmercury hydroxide**
110	Rat (Sprague-Dawley) 8 F	22 days GD 7–PND 7 (W)	0, 0.474	BW, FI, WI, DX	Bd wt	0.474			
					Develop[b]	0.474 F			
							0.474 M		Decreased motor activity in male offspring at 6 months

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Sakamoto et al. 2002									**Methylmercury**
111	Rat (Wistar) 4–10 F	One generation 8 weeks premating through PND 30 (via dam) PNDs 31–55 (direct) (F)	0, 0.5	DX	Develop[b]		0.5		Impaired motor coordination and memory at PNDs 35–42; focal dysplastic lesions in cerebellum
Sakamoto et al. 2004									**Methylmercuric chloride**
112	Rat (Wistar) 12 M	30 days PNDs 1–30 (IN)	0, 0.8, 2, 4	DX	Develop[b]		0.8	4	LOAEL: Impaired associative learning at 6 weeks of age SLOAEL: Body weight loss, impaired motor coordination and hindlimb crossing/paralysis, widespread CNS degeneration and neuronal loss
[Via micropipette in water and condensed milk]									
Sakamoto et al. 2017									**Methylmercuric chloride**
113	Rat (Wistar) 5 M	5 weeks (W)	0, 0.3, 1.4	BW, HP	Bd wt	0.3		1.4	Body weight loss
					Neuro			1.4	Severe damage and degeneration of sensory regions of the spinal cord (dorsal root ganglia, posterior roots, posterior column)
Sakamoto et al. 2017									**Methylmercuric chloride**
114	Rat (Wistar) 10 M	5 weeks (W)	0, 1.9, 9.72	BW, HP	Bd wt	1.9		9.72	Body weight loss
					Neuro			9.72	Severe damage and degeneration of sensory regions of the spinal cord (dorsal root ganglia, posterior roots, posterior column)

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Santana et al. 2019									**Methylmercury**
115	Rat (Wistar) 20 M	60 days (GO)	0, 0.037	BW, HP, NX	Bd wt	0.037			
					Neuro		0.037		Decreased motor activity and impaired coordination; decreased density of neurons and astrocytes in motor cortex
Sitarek and Gralewicz 2009									**Methylmercuric chloride**
116	Rat (Wistar) 11–12 F	5 weeks GD 7–PND 21 (W)	0, 0.5, 1.9	CS, BW, FI, WI, DX	Bd wt	0.5			
					Neuro	0.5		1.9	Ataxia
					Develop	0.5	1.9		~8–10% decrease in PND 21 pup weight; delayed development of righting reflex
Szász et al. 2002									**Methylmercuric chloride**
117	Rat (Wistar) 5 F	7–8 weeks premating– PND 21 (W)	0, 0.3	CS, BW, FI, WI, RX, DX	Bd wt	0.3			
					Repro	0.3			
					Develop[b]		0.3		11% decrease in birth weight; increased susceptibility to seizure activity at PNDs 28 and 90
Tamashiro et al. 1986									**Methylmercuric chloride**
118	Rat (SHR/NCrj) 10 M, 10 F	26 days (NS)	0, 1.6	LE, CS, BW, NX, OF	Death			1.6 M	100% mortality
					Bd wt			1.6	Body weight loss; severe in males
					Cardio		1.6 F		Increased systolic blood pressure
					Neuro		1.6		Hind limb crossing, disturbed righting reflex, abnormal gait

[Spontaneous hypertensive rat strain]

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Tonk et al. 2010									**Methylmercuric chloride**
119	Rat (Wistar) 11–14 F	26 days GD 6–PND 10 (GO)	0, 0.08, 0.3, 0.6, 0.8, 1.2, 1.6	LE, CS, BW, DX	Death			1.6	5/11 dams sacrificed moribund
					Bd wt	0.8	1.2	1.6	LOAEL: Decreased maternal weight SLOAEL: Weight loss
					Neuro	1.2		1.6	Unsteady gait, partial hind limb paralysis
					Develop[c]		0.08	0.8	LOAEL: Altered functional immune endpoints in PND 21–70 offspring SLOAEL: Decreased body weight and prenatal/neonatal death
Vezér et al. 2005									**Methylmercuric chloride**
120	Rat (Wistar) 24 M	5 weeks 5 days/week (GW)	0, 0.5, 2.0	NX	Neuro		0.5		Decreased motor activity; altered acoustic startle response; altered electrophysiological responses in sensory cortices and hippocampus
Vilagi et al. 2000									**Methylmercuric chloride**
121	Rat (Wistar) 8 F	6 weeks GD 0–PND 21 (W)	0, 0.347	DX	Develop[b]			0.347	>20% decrease in F1 body weight at PND 28; decreased spontaneous and evoked cortical potentials in F1 pups at PND 28
Wakita 1987									**Methylmercuric chloride**
122	Rat (Wistar) 9 M	23–28 days (G)	0, 0.4	CS, BW, OF	Bd wt	0.4			
					Cardio		0.4		Persistent increases in systolic blood pressure post-exposure
Wang et al. 2022a									**Methylmercuric chloride**
123	Rat (Sprague-Dawley) 6 F	17 days GD5-PND1 (GW)	0, 0.48, 0.96, 1.9	DX	Develop[c]		0.48		PND 60: Impaired spatial memory, decreased neuronal density in hippocampus

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Wild et al. 1997									**Methylmercuric chloride**
124	Rat (Sprague-Dawley) NS M, F	14–16 weeks premating– PND 21 (W)	0, 0.0006, 0.06	BW, DX	Bd wt	0.06 F			
					Develop[c]		0.0006		Altered functional immune endpoints in PND 42 and 84 offspring (enhanced lymphoproliferation in response to mitogens; decreased NK cell activity)
Wild et al. 1997									**Bis(methylmercury)sulfide**
125	Rat (Sprague-Dawley) NS M, F	14–16 weeks premating– PND 21 (W)	0, 0.0003	BW, DX	Bd wt	0.0003 F			
					Develop		0.0003		Altered functional immune endpoints in PND 84 offspring (enhanced lymphoproliferation in response to mitogens)
Wildemann et al. 2015a									**Methylmercuric chloride**
126	Rat (Wistar) 5–9 M	4 weeks (W)	0, 0.002, 0.005, 0.009, 0.018, 0.036, 0.216, 0.879	BW, OW, OF	Bd wt	0.216		0.879	66% decrease in body weight gain
					Cardio	0.002	0.005		Elevated systolic blood pressure and pulse pressure at ≥0.005 mg Hg/kg/day; elevated diastolic blood pressure at ≥0.009 mg/kg/day
Wildemann et al. 2015b									**Methylmercuric chloride**
127	Rat (Wistar) 5–6 M	4 weeks (W)	0, 0.018, 0.216	BW, OW, OF	Bd wt	0.216			
					Cardio	0.018	0.216		Elevated systolic blood pressure and pulse pressure
Wildemann et al. 2016									**Methylmercuric chloride**
128	Rat (Wistar) 5–6 M	4 weeks (W)	0, 0.006, 0.285	BC, BI, UR, OF	Cardio		0.006		Elevated systolic blood pressure at ≥0.006 mg Hg/kg/day; elevated diastolic at 0.285 mg/kg/day
					Renal	0.006	0.285		Elevated urinary creatinine

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Wu et al. 2023									**Methylmercuric chloride**
129	Rat (Sprague-Dawley) 8 M	3 months (G)	0, 0.09	BW, BI, OW, HP, NX	Bd wt	0.09			
					Neuro		0.09		Impaired spatial memory; reduced hippocampal neurons in pyramidal layer
Yip and Chang 1981									**Methylmercuric chloride**
130	Rat (Charles River) 6 M	8 weeks (G)	0, 1.6	HP	Neuro			1.6	Extensive degeneration of dorsal root fibers
Algahtani et al. 2023									**Methylmercuric chloride**
131	Mouse (C57BL/6) 8 M	3 weeks PNDs 21–42 Oral	0, 0.08	DX	Develop	0.08			
Algahtani et al. 2023									**Methylmercuric chloride**
132	Mouse (BTBR) 8 M	3 weeks PNDs 21–42 Oral	0, 0.08	DX	Develop	0.08			
Al-Mazroua et al. 2022									**Methylmercuric chloride**
133	Mouse (C57BL/6) 6 M	28 days (IN)	0, 0.16	BC, BI, NX	Immuno		0.16		Increased serum IFN-γ
					Neuro	0.16			
[locomotor behavior]									
Berthoud et al. 1976									**Methylmercuric chloride**
134	Mouse (CD-1) 12 M	60 days (G)	0, 0.25, 1, 4	CS, BW, FI, HP	Neuro		0.25	1	LOAEL: Hindleg weakness SLOAEL: Motor incoordination and neuronal degeneration and microgliocytosis in subcortical regions of the brain

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Blakley et al. 1980									**Methylmercuric chloride**
135	Mouse (ICR) 9–10 M	3 weeks (W)	0, 0.08, 0.35, 1.7	BW, WI, GN, IX	Bd wt	1.7			
					Immuno		0.08		Suppressed immune response to antigens
Boomhower and Newland 2019									**Methylmercuric chloride**
136	Mouse (C57BL/6N) 12 M	39 days PNDs 21–59 (W)	0, 0.032, 0.32	DX	Develop		0.032		Impaired operant learning (faster minimum response times and higher saturation rates) on PND 200
Boomhower and Newland 2019									**Methylmercuric chloride**
137	Mouse (C57BL/6N) 12 M	39 days PNDs 24–62 (W)	0, 0.32	DX	Develop	0.32			
[Operant learning tested on PND 200]									
Bourdineaud et al. 2011									**Methylmercury**
138	Mouse (C57Bl/6) 12 M	2 months (F)	0, 0.00046, 0.0073	BW, NX	Bd wt	0.0073			
					Neuro	0.00046	0.0073		Impaired memory
Chen et al. 2012									**Methylmercuric chloride**
139	Mouse (ICR) 16 M	4 or 6 weeks (GW)	0, 1.6	BC	Endocr		1.6		~80–95% decrease in plasma insulin; ~25–40% increase in serum glucose
Dietrich et al. 2005									**Methylmercuric chloride**
140	Mouse (Swiss) 13–14 M	21 days (W)	0, 4.7, 8.7	LE, CS, BW, WI, NX	Death			8.7	100% mortality
					Bd wt			4.7	>10% body weight loss
					Neuro	4.7			Impaired motor coordination, hypoactivity, altered gait

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Franco et al. 2006									**Methylmercuric chloride**
141	Mouse (albino) 7 F	21 days PNDs 1–21 (via dam) (W)	0, 4.7	BW, WI, DX	Bd wt	4.7			
					Develop		4.7		Impaired motor coordination in PND 21 offspring
Ghizoni et al. 2018									**Methylmercuric chloride**
142	Mouse (Swiss) 21–22 F	42 days GD 1–PND 21 (W)	0, 1	BW, FI, WI, DX	Bd wt	1			
					Develop[b]		1		Impaired motor coordination (balance) in offspring on PND 22
Goulet et al. 2003									**Methylmercuric chloride**
143	Mouse (C57BL/6) 14–34 F	6 weeks GD 2–PND 21 (W)	0, 0.9, 1.3, 1.7	DX	Repro	1.3	1.7		18% decrease in number of pups/litter
					Develop[b]	1.7 F			
							0.9 M	1.7 M	LOAEL: Reduced locomotor activity SLOAEL: Impaired working memory at ≥1.3 mg Hg/kg/day; 14% reduction in postnatal survival at 1.7 mg/kg/day
[Neurobehavior assessed at PNDs 35–70]									
Havarinasab et al. 2007									**Methylmercuric chloride**
144	Mouse (A.SW) 5–7 F	30 days (W)	0, 0.420	BC, BI, IX	Immuno		0.42		Positive ANoA and ACA; elevated serum IgG1, IgG2a; polyclonal B-cell activation
[Autoimmune susceptible mice]									
Hirano et al. 1986									**Methylmercuric chloride**
145	Mouse (ICR) 6 M, 6 F	26 weeks (F)	M: 0, 0.0300, 0.150, 0.724 F: 0, 0.0254, 0.115, 0.627	CS, BW, GN, HP	Bd wt	0.724			
					Resp	0.724			
					Cardio	0.724			
					Gastro	0.724			
					Musc/skel	0.724			

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
					Hepatic	0.724			
					Renal	0.115	0.627		Epithelial degeneration and regeneration of the renal proximal tubules
					Dermal	0.724			
					Ocular	0.724			
					Endocr	0.724			
					Immuno	0.724			
					Neuro	0.724			
					Repro	0.724			
[Interim sacrifice group]									
Huang et al. 2011									**Methylmercury**
146	Mouse (ICR) 12–15 M	7 weeks PNDs 21–70 (GW)	0, 0.02	DX	Develop[b]		0.02		Hyperactivity, impaired motor coordination, and hearing impairment at PND 70
Huang et al. 2011									**Methylmercury**
147	Mouse (ICR) 12–15 F	10–17 weeks Premating through PND 21 (via dam) Select pups: PNDs 21–70 (direct) (GW)	0, 0.02	RX, DX	Repro		0.02		16% decrease in litter size
					Develop[b]			0.02 M	Effects at PND 70: 19–32% decrease in pup weight, decreased motor activity and impaired hearing (both groups), impaired motor coordination (direct group only)
Ilback 1991									**Methylmercury**
148	Mouse (BALB/c CUM) 8 F	12 weeks (F)	0, 0.77	BW, BC, OW, IX	Bd wt	0.77			
					Immuno		0.77		Reduced natural killer T-cell activity, enhanced T-cell lymphoproliferative response, 22% decrease in absolute thymus weight, and ~50% decrease in thymic cell number

2. HEALTH EFFECTS

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Ishihara et al. 2019									**Methylmercuric chloride**
149	Mouse (ICR) 10 M	4–8 weeks (IN)	0, 3.2	HP, NX	Neuro		3.2		Impaired motor coordination at 5–8 weeks; impaired auditory function, ventricular enlargement and reactive astrocytes in inferior colliculus
Kendricks and Newland 2021									**Methylmercuric chloride**
150	Mouse (C57BL/6) 8–10 M	37 days PNDs 22–59 (W)	0, 0.032, 0.400	DX	Develop	0.032	0.4		Impaired attention at 11–14 months
Kirkpatrick et al. 2015									**Methylmercury**
151	Mouse (C57BL/6N) NS M	21–28 days (IN)	0, 4.6	BI, NX	Bd wt	4.6			
					Neuro		4.6		Impaired motor coordination at 4 weeks
[Mice given MeHg-dosed cookies]									
Loan et al. 2023									**Methylmercuric chloride**
152	Mouse (C57BL/6) NS F (dams); 9–16 B (pups)	3 weeks GDs 0–21 (W)	0, 0.05	DX	Develop		0.05		Decreased frequency and length of ultrasonic pup vocalizations at PND 9; decreased socialization, increased stereotypical behaviors, and impaired reversal learning at PND 60
MacDonald and Harbison 1977									**Methylmercuric chloride**
153	Mouse (Swiss) 35–40 M	28 weeks (W)	0, 0.89, 9.5	CS, BW, WI, HP	Death			9.5	100% mortality by 4–5 weeks
					Bd wt	0.89		9.5	Body weight loss
					Gastro	9.5			
					Hepatic	9.5			
					Renal	0.89	9.5		Slight degenerative changes in proximal tubular epithelial cells
					Neuro			0.89	Severe neurotoxicity (clinical signs, behavioral signs, histopathologic cerebellar changes)

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Maqbool et al. 2019									**Methylmercuric chloride**
154	Mouse (NMRI) 6 M	4 weeks (GW)	0, 2.0, 4.0, 8.0	BC	Other noncancer		2		47% increased plasma insulin
Mitsumori et al. 1981									**Methylmercuric chloride**
155	Mouse (ICR) 60 M, 60 F	26 weeks (F)	0, 2.3, 4.5	LE, CS, HP	Death			4.5	51/60 males and 59/60 females died or were sacrificed moribund by study week 26
					Neuro			4.5	Clinical signs of neurotoxicity prior to death or sacrifice
Moreira et al. 2012									**Methylmercury**
156	Mouse (Swiss Albino) NS M	28 days (W)	0, 5.6	BC	Hepatic		5.6		Elevated plasma total cholesterol, HDL cholesterol, non-HDL cholesterol, and triglycerides
Moreira et al. 2012									**Methylmercury**
157	Mouse (C57BL/6) 6 M	21 days (W)	0, 5.6	BC, HP	Hepatic		5.6		Elevated plasma total cholesterol
					Renal		5.6		Glomerular shrinkage and tubular vacuolization
Moreira et al. 2012									**Methylmercury**
158	Mouse (C57BL/6) 8 M	21 days (W)	0, 5.6	BC, BI, NX	Hepatic		5.6		Elevated plasma total cholesterol
					Neuro		5.6		Decreased motor activity
Nascimento et al. 2022									**Methylmercuric chloride**
159	Mouse C57BL/6 60 M	30 days (W)	0, 0.21	BW, BC, BI, NX	Bd wt	0.21			
					Hepatic		0.21		Increased serum total cholesterol and triacylglycerol levels
					Immuno		0.21		Increase plasma TNF and LPS levels

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure keya	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
					Neuro		0.21		Decreased motor activity and exploration, increased stereotypy, impaired spatial learning and memory
Rand et al. 2020									**Methylmercuric chloride**
160	Mouse (C57BL/6) 3–18 F	56 days 2 weeks prior to mating– PND 21 (W)	0, 0.13, 1.3	HP, DX	Musc/skel	1.3			
					Develop	0.13		1.3	PND 0: Decreased weight in males (~5%) and females (~8%) PND 60: decreased forelimb strength in both sexes; males with decreased rearing distance, and increased resting time in open field
Silva et al. 2021									**Methylmercuric chloride**
161	Mouse (C57BL/6) 8–15 F	15 days (W)	0, 2.7	BW, FI, WI, BC, HP, OF	Bd wt	2.7			
					Cardio		2.7		Elevated blood pressure, atherosclerotic lesions
					Hepatic		2.7		Elevated total cholesterol and non-HDL cholesterol
Thuvander et al. 1996									**Methylmercuric chloride**
162	Mouse (BALB/c) 27–72 F	15–16 weeks 10 weeks premating through PND 15 (F)	0, 0.098, 0.98	CS, BW, RX, DX	Bd wt	0.98			
					Repro	0.98			
					Developc		0.098		Alterations in functional immune endpoints and thymocyte cell populations in offspring at ≥0.098 mg Hg/kg/day; 8% decrease in pup body weight at 0.98 mg Hg/kg/day

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Weiss et al. 2005									**Methylmercuric chloride**
163	Mouse (B6C3F1/H SD) 15–18 F	9–10 weeks Premating – PND 13 (W)	0, 0.2, 0.6	BW, RX, DX	Bd wt	0.6			
					Repro	0.6			
					Develop[b]		0.2		Impaired spatial learning and increased hindlimb splay at 5 and/or 15 months
Yoshida et al. 2011									**Methylmercury**
164	Mouse (C57BL/6) NS F	19 days GDs 0–18 (F)	0, 0.9	DX	Develop[b]		0.9		Male offspring: Increased activity, decreased anxiety, and impaired spatial learning at PND 56 Female offspring: Decreased activity at PND 56
Yoshida et al. 2018									**Methylmercuric chloride**
165	Mouse (C57BL/6J) 7–8 F	27 days PNDs 2–28 (F)	0, 0.9	DX	Develop[b]		0.9		Decreased motor activity at PND 77
Zhang et al. 2011									**Methylmercury**
166	Mouse (A.SW) 2–7 F	5 weeks GD 8–PND 21 (W)	0, 0.03, 0.06, 0.13	DX	Develop	0.06		0.13	Complete litter loss in 6/7 dams
[Autoimmune susceptible mouse strain]									
Zhang et al. 2011									**Methylmercury**
167	Mouse (A.SW) 3–5 F	5 weeks GD 8–PND 21 (W)	0, 0.06	DX, IX	Immuno	0.06			
					Develop[b,c]		0.06 F		Hyperactivity, cerebellar inflammation
						0.06 M			
[Autoimmune susceptible mouse strain; offspring immune and behavioral endpoints evaluated at PNDs 21 and 70]									
Zhang et al. 2011									**Methylmercury**
168	Mouse (A/WySnJ) 3–5 F	5 weeks GD 8–PND 21 (W)	0, 0.06	DX, IX	Immuno	0.06			
					Develop[b,c]	0.06			
[Offspring immune and behavioral endpoints evaluated at PNDs 21 and 70]									

2. HEALTH EFFECTS

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Koller et al. 1977									**Methylmercuric chloride**
169	Rabbit (New Zealand) 10 M, 10 F	14 weeks (F)	M: 0, 0.05, 0.53, 1.1 F: 0, 0.05, 0.49, 1.0	LE, CS, BW, BC, HE, HP, IX	Death			1	100% mortality
					Bd wt	0.05			
							0.49 F		Decreased body weight gain (13%)
								0.53 M	Decreased body weight gain (43%)
					Hemato	0.53			
					Renal	0.49	1		Mild-to-moderate proximal tubule necrosis
					Immuno	0.05	0.49		Decreased immune response to influenza infection
					Neuro	0.05		0.49	Ataxia and intermittent convulsions at ≥0.49 mg Hg/kg/day; cerebellar degeneration at ≥1.0 mg Hg/kg/day
Chang et al. 1974									**Methylmercury**
170	Cat 15–16 B	11 months (F)	0, 0.012	CS, BW, HP	Neuro			0.012	Serious clinical signs of neurotoxicity, degenerative brain lesions
Charbonneau et al. 1976									**Methylmercury**
171	Cat 4–5 M, 4–5 F	Up to 1 year (F)	0.003, 0.0084, 0.020, 0.046, 0.074, 0.176	LE, CS, BW, FI, WI, BC, UR, GN, HP	Death	0.074		0.176	100% sacrifice moribund by ~16 weeks
					Bd wt	0.176			
					Resp	0.176			
					Cardio	0.176			
					Gastro	0.176			
					Hemato	0.176			
					Hepatic	0.176			
					Renal	0.176			
					Endocr	0.176			
					Immuno	0.176			

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
					Neuro	0.046	0.074	0.176	LOAEL: Clinical signs of neurotoxicity first observed at ~40 weeks SLOAEL: Clinical signs of neurotoxicity first observed at ~14 weeks; serious clinical signs and degeneration in cerebral cortex, cerebellum, and dorsal root ganglia observed at ~16 weeks
Khera et al. 1974									**Methylmercuric chloride**
172	Cat 3 or 5 M, 2 or 6 F	44–243 days (G)	0, 0.25, 0.37, 0.5, 0.75, 1.0	CS, HP	Neuro			0.25	Degeneration in granule cells, Purkinje cells, and cerebral neurons; distorted myelination in cortical hemispheres
CHRONIC EXPOSURE									
Axelrad et al. 2007a, 2007b									**Methylmercury**
173	Human 238–917 per study	Chronic dietary intake; high fish consumers (F)	0.34–0.62	DX	Develop[b]	0.00041[d]			NOAEL is based on estimated mercury dose associated with a 1-point decrease in IQ (calculated from -0.18 IQ points per µg Hg/g hair)
[meta-analysis of three prospective birth cohorts]									
Burbacher and Mottet 1988; Burbacher et al. 2005									**Methylmercury hydroxide**
174	Monkey (*Macaca fascicularis*) 7–16 F	Up to ~4 years (two breeding cycles) (IN)	0, 0.04, 0.06, 0.08	BW, BC, NX, RX, DX	Bd wt	0.08			
					Neuro	0.06		0.08	Slight tremors, decreased sucking response, gross motor incoordination, apparent blindness
					Repro	0.04		0.06	54% decrease in number of viable pregnancies

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Burbacher et al. 1984									**Methylmercury hydroxide**
175	Monkey (*Macaca fascicularis*) 7–8 F	Up to 395 days (four menstrual cycles, mating, gestation) (IN)	0, 0.04, 0.08	CS, BW, NX RX, DX	Bd wt	0.08			
					Neuro	0.04		0.08	Gross motor incoordination, decreased sucking responses, intention tremors, blindness
					Repro	0.04		0.08	Decreased number of viable pregnancies
					Develop	0.04			
Charleston et al. 1994									**Methylmercury hydroxide**
176	Monkey (*Macaca fascicularis*) 4–5 F	12 or 18 months (IN)	0, 0.05	CS, OW, HP	Neuro		0.05		Up to 152% increase in number of reactive glia in the brain
Charleston et al. 1995									**Methylmercury**
177	Monkey (*Macaca fascicularis*) NS F	12 or 18 months (IN)	0, 0.05	HP	Neuro		0.05		89–152% increased number of reactive glia
Charleston et al. 1996; Vahter et al. 1994									**Methylmercury hydroxide**
178	Monkey (*Macaca fascicularis*) 4–5 F	12 or 18 months (IN)	0, 0.05	BC, BW, CS, GN, HE, HP, OW	Bd wt	0.05			
					Hemato	0.05			
					Neuro		0.05		Increased microglia and decreased astrocytes in thalamus
Rice 1989c									**Methylmercuric chloride**
179	Monkey (*Macaca fascicularis*) 4 M, 1 F	6.5–7 years (starting at birth) (IN)	0, 0.05	CS, NX	Neuro		0.05		Clumsiness, impaired fine motor skills, and diminished touch and pinprick sensitivity at 13–14 years

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Rice 1998a; Rice and Hayward 1999									**Methylmercuric chloride**
180	Monkey (*Macaca fascicularis*) 1–2 B	Gestation– 4 years of age 5 days/week (IN)	0, 0.010, 0.025, 0.050	DX	Develop[b]		0.01		Impaired auditory function and visual spatial discrimination in offspring at 10–19 years
Rice 1998b; Rice and Hayward 1999									**Methylmercuric chloride**
181	Monkey (*Macaca fascicularis*) 2–4 M, 1–2 F	7 years 5 days/week (C)	0, 0.050	NX	Neuro	0.05			
[Visual function and operant training assessed at 10–20 years]									
Rice and Gilbert 1982, 1990									**Methylmercuric chloride**
182	Monkey (*Macaca fascicularis*) 5 treated, 2 controls, NS	3–4 years (starting at birth) (IN)	0, 0.05	DX	Develop[b]		0.05		Spatial visual impairment at 3– 4 years; 3/5 high luminance impairment, 3/5 high and middle frequency impairment; 5/5 low luminance impairment
Rice and Gilbert 1990									**Methylmercuric chloride**
183	Monkey 1–5 NS	Gestation–4– 4.5 years old; 3 days/week during gestation; 5 days/week postnatally (IN)	0, 0.01, 0.025, 0.05	DX	Develop[b]	0.025		0.05	Overt neurotoxicity in 2/5 offspring
Rice and Gilbert 1992									**Methylmercuric chloride**
184	Monkey (*Macaca fascicularis*) 3–5 NS	7 years (starting at birth) (C)	0, 0.05	CS, NX	Neuro		0.05		Clumsiness and impaired high-frequency hearing at 13–14 years

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Solecki et al. 1991									**Phenyl mercuric acetate**
185	Rat (Wistar) 20 M	103 weeks (W)	0, 0.37, 3.7	LE, BW, HE, HP	Death			3.7	14/20 treated died, compared to 7/20 control
					Bd wt		0.37		Approximately 10% decrease in body weight gain
					Gastro	0.37	3.7		Ulcerative cecitis
					Hemato	0.37	3.7		Increased leukocytes; decreased erythrocytes, hemoglobin, and hematocrit
					Renal		0.37		Increased severity of chronic renal nephrosis
					Endocr	3.7			
					Cancer			3.7	CEL: Renal cell adenoma
Verschuuren et al. 1976									**Methylmercuric chloride**
186	Rat (NS) 25 M, 25 F	2 years (F)	M: 0, 0.006, 0.03, 0.16; F: 0, 0.007, 0.04, 0.18	LE, CS, BW, FI, BC, BI, UR, HE, OW, HP, NX	Bd wt	0.18 F 0.16 M			
					Resp	0.18 F 0.16 M			
					Cardio	0.18 F 0.16 M			
					Gastro	0.18 F 0.16 M			
					Hemato	0.18 F 0.16 M			
					Musc/skel	0.18 F 0.16 M			
					Hepatic	0.18 F 0.16 M			
					Renal	0.04 F	0.18 F		36% increase in relative kidney weight, decreased kidney enzyme activity

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
						0.03 M	0.16 M		30% increase in relative kidney weight, decreased kidney enzyme activity
					Dermal	0.18 F			
						0.16 M			
					Ocular	0.18 F			
						0.16 M			
					Endocr	0.18 F			
						0.16 M			
					Immuno	0.18 F			
						0.16 M			
					Neuro	0.18 F			
						0.16 M			
					Repro	0.18 F			
						0.16 M			
Hirano et al. 1986									**Methylmercuric chloride**
187	Mouse (ICR) 54 M, 54 F	104 weeks (F)	M: 0, 0.0300, 0.150, 0.724; F: 0, 0.0254, 0.115, 0.627	LE, CS, BW, GN, HP	Bd wt	0.724			
					Resp	0.724			
					Cardio	0.724			
					Gastro	0.724			
					Musc/skel	0.724			
					Hepatic	0.724			
					Renal	0.115 F	0.627 F		Epithelial degeneration and regeneration of the renal proximal tubules at 0.627 mg Hg/kg/day

2. HEALTH EFFECTS

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
						0.03 M	0.15 M		Epithelial degeneration and regeneration of the renal proximal tubules, urinary casts, and pelvic dilation at ≥0.15 mg Hg/kg/day; cystic kidney and epithelial regeneration and focal hyperplasia at 0.724 mg Hg/kg/day
					Dermal	0.724			
					Ocular	0.724			
					Endocr	0.724			
					Immuno	0.724			
					Neuro	0.115 F		0.627 F	Degeneration or fibrosis of sciatic nerve
						0.724 M			
					Repro	0.627 F			
						0.15 M	0.724 M		Decreased sperm in testes
					Cancer			0.724 M	CEL: Renal epithelial adenocarcinoma in males
Mitsumori et al. 1981									**Methylmercuric chloride**
188	Mouse (ICR) 60 M, 60 F	78 weeks (F)	0, 2.1, 4.1	CS, HP	Neuro		2.1 M		Clinical signs of neurotoxicity
					Cancer			2.1 M	CEL: kidney tumors (11 adenocarcinomas, 5 adenomas)

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
Mitsumori et al. 1990									**Methylmercuric chloride**
189	Mouse (B6C3F1) 60 M, 60 F	104 weeks (F)	M: 0, 0.0305, 0.139, 0.686 F: 0, 0.0265, 0.133, 0.601	LE, CS, BW, GN, HP	Death			0.686 M	50/60 males died versus 31/60 controls
					Bd wt	0.133 F	0.601 F		~10% decrease in body weight gain
					Resp	0.686			
					Cardio	0.686			
					Gastro	0.601 F			
						0.139 M	0.686 M		Stomach ulceration
					Musc/skel	0.686			
					Hepatic	0.686			
					Renal	0.133 F	0.601 F		Increased chronic nephropathy with epithelial cell degeneration; regeneration of the proximal tubules; interstitial fibrosis
						0.0305 M	0.139 M		Increased chronic nephropathy with epithelial cell degeneration; regeneration of the proximal tubules; interstitial fibrosis
					Dermal	0.686			
					Ocular	0.686			
					Endocr	0.686			
					Immuno	0.686			
					Neuro	0.601 F			
						0.139 M		0.686 M	Sensory neuropathy; cerebral and cerebellar necrosis; posterior paresis/paralysis

2. HEALTH EFFECTS

							Less	Serious	
Figure key[a]	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	serious LOAEL	LOAEL	Effects
					Repro	0.601 F			
						0.139 M		0.686 M	Tubule atrophy of testes
					Cancer			0.686 M	CEL: renal epithelial cell adenomas and carcinomas
Weiss et al. 2005									**Methylmercuric chloride**
190	Mouse (B6C3F1/H SD × CBA/J HSD) F0: 15–18 F, F1: 16–28 M	Lifetime GD 0–PND 21 (via dam) PNDs 22–26 months (direct) (W)	0, 0.2, 0.6	NX	Neuro			0.2	Impaired spatial learning at ≥0.2 mg Hg/kg/day; impaired operant training and increased hindlimb splay at 0.6 mg Hg/kg/day
[Behavioral testing at 5, 15, and 26 months]									
Charbonneau et al. 1976									**Methylmercuric chloride**
191	Cat 4–5 M, 4–5 F	2 years (F)	0.003, 0.0084, 0.020, 0.046, 0.074	CS, BW, FI, WI, BC, UR, GN, HP	Death			0.074	100% sacrifice moribund by ~55 weeks
					Bd wt	0.074			
					Resp	0.074			
					Cardio	0.074			
					Gastro	0.074			
					Hemato	0.074			
					Hepatic	0.074			
					Renal	0.074			
					Endocr	0.074			
					Immuno	0.074			

Table 2-4. Levels of Significant Exposure to Organic Mercury – Oral (mg/kg/day)

Figure keya	Species (strain) No./group	Exposure parameters	Doses	Parameters monitored	Endpoint	NOAEL	Less serious LOAEL	Serious LOAEL	Effects
					Neuro	0.02	0.046	0.074	LOAEL: Decreased nociception and mild clinical signs SLOAEL: Ataxia, incoordination, impaired reflexes, and degeneration in cerebral cortex, cerebellum, and dorsal root ganglia

aThe number corresponds to entries in Figure 2-8; differences in levels of health effects and cancer effects between male and females are not indicated in Figure 2-8. Where such differences exist, only the levels of effect for the most sensitive sex are presented.
bThe neurodevelopmental effects are discussed in Section 2.16 (Neurological).
cThe immunodevelopmental effects are discussed in Section 2.15 (Immunological).
dUsed to derive a chronic-duration oral MRL of 0.1 µg Hg/kg/day for methylmercury; based on a NAEL of 0.00041 mg Hg/kg/day divided by a total uncertainty factor of 3 (for human variability). The NAEL represents an estimated mercury dose associated with a 1-point decrease in IQ, based on a meta-analysis of three prospective birth cohorts in populations with high fish consumption: Faroe Islands (Grandjean et al. 1997, 1999), Seychelles Islands (Myers et al. 2003), and New Zealand (Kjellstrom et al. 1989). See Appendix A for more detailed information regarding the MRL.

Principal studies for the MRLs

ACA = antichromatin antibodies; ACTH = adrenocorticotrophic hormone; ALT = alanine aminotransferase; ANoA = antinucleolar antibodies; AST = aspartate aminotransferase; B = both sexes; BC = serum (blood) chemistry; Bd wt or BW = body weight; BI = biochemical changes; (C) = capsule; Cardio = cardiovascular; CEL = cancer effect level; CNS = central nervous system; Con-A = concanavalin-A; CS = clinical signs; Develop = developmental; DX = developmental toxicity; Endocr = endocrine; (F) = feed (dietary); F = female(s); FI = food intake; (G) = gavage; (GO) = gavage in oil; (GW) = gavage in water; Gastro = gastrointestinal; GD = gestation day; GN = gross necropsy; HDL = high-density lipoprotein; HE = hematology; Hemato = hematological; HP = histopathology; IFN-γ = interferon gamma; IgG = immunoglobulin G; IL-6 = interleukin-6; Immuno = immunological; IQ = intelligence quotient; (IN) = ingestion; IX = immune function; LE = lethality; LOAEL = lowest-observed-adverse-effect level; LPS = lipopolysaccharide; M = male(s); MeHg = methylmercury; MRL = Minimal Risk Level; Musc/skel = musculoskeletal; Neuro = neurological; NAEL = no-adverse-effect level (estimated no-effect level); NK = natural killer; NOAEL = no-observed-adverse-effect level; NS = not specified; NX = neurological function; OF = organ function; OW = organ weight; PHA = phytohemagglutinin; PND = postnatal day; Repro = reproductive; Resp = respiratory; RX = reproductive function; SLOAEL = serious lowest-observed-adverse-effect level; TNF = tumor necrosis factor; UR = urinalysis; (W) = drinking water; WBC = white blood cell; WI = water intake

Figure 2-8. Levels of Significant Exposure to Organic Mercury – Oral
Acute (≤14 days)

2. HEALTH EFFECTS

Figure 2-8. Levels of Significant Exposure to Organic Mercury – Oral
Acute (≤14 days)

Figure 2-8. Levels of Significant Exposure to Organic Mercury – Oral
Acute (≤14 days)

Figure 2-8. Levels of Significant Exposure to Organic Mercury – Oral
Acute (≤14 days)

Figure 2-8. Levels of Significant Exposure to Organic Mercury – Oral
Acute (≤14 days)

2. HEALTH EFFECTS

Figure 2-8. Levels of Significant Exposure to Organic Mercury – Oral
Intermediate (15–364 days)

Figure 2-8. Levels of Significant Exposure to Organic Mercury – Oral
Intermediate (15–364 days)

Figure 2-8. Levels of Significant Exposure to Organic Mercury – Oral
Intermediate (15–364 days)

2. HEALTH EFFECTS

Figure 2-8. Levels of Significant Exposure to Organic Mercury – Oral
Intermediate (15–364 days)

Figure 2-8. Levels of Significant Exposure to Organic Mercury – Oral
Intermediate (15–364 days)

2. HEALTH EFFECTS

Figure 2-8. Levels of Significant Exposure to Organic Mercury – Oral
Intermediate (15–364 days)

Figure 2-8. Levels of Significant Exposure to Organic Mercury – Oral
Intermediate (15–364 days)

2. HEALTH EFFECTS

Figure 2-8. Levels of Significant Exposure to Organic Mercury – Oral
Intermediate (15–364 days)

Figure 2-8. Levels of Significant Exposure to Organic Mercury – Oral
Intermediate (15–364 days)

2. HEALTH EFFECTS

Figure 2-8. Levels of Significant Exposure to Organic Mercury – Oral
Intermediate (15–364 days)

Figure 2-8. Levels of Significant Exposure to Organic Mercury – Oral
Intermediate (15–364 days)

Figure 2-8. Levels of Significant Exposure to Organic Mercury – Oral
Intermediate (15–364 days)

Figure 2-8. Levels of Significant Exposure to Organic Mercury – Oral
Chronic (≥365 days)

Figure 2-8. Levels of Significant Exposure to Organic Mercury – Oral
Chronic (≥365 days)

Figure 2-8. Levels of Significant Exposure to Organic Mercury – Oral
Chronic (≥365 days)

Figure 2-8. Levels of Significant Exposure to Organic Mercury – Oral
Chronic (≥365 days)

Figure 2-8. Levels of Significant Exposure to Organic Mercury – Oral
Chronic (≥365 days)

Figure 2-8. Levels of Significant Exposure to Organic Mercury – Oral
Chronic (≥365 days)

Figure 2-8. Levels of Significant Exposure to Organic Mercury – Oral
Chronic (≥365 days)

2.2   ACUTE POISONING IN HUMANS

Case reports of accidental or intentional poisonings provide information on acute-duration exposure effects in humans. These reports include acute-duration exposure poisonings from elemental mercury vapor, ingestion of mercuric chloride, and dermal exposure to dimethylmercury. In these cases, exposures are at near-lethal or lethal levels. Yawei et al. (2021) summarized collective symptoms in 288 cases of poisoning from exposures to inorganic mercury (mercury vapor, mercuric or mercurous mercury). The most prominent symptoms were neurological, renal, respiratory, gastrointestinal, and dermatological.

Elemental Mercury. Numerous cases of poisoning from acute-duration exposures to elemental mercury vapor have been reported. Symptoms of toxicity in lethal cases included chills, fever, dyspnea, headache, gastrointestinal disturbances (cramps, diarrhea), erythema, disturbances of hearing and vision, hypertension, and pulmonary edema (Jung and Aaronson 1980; Kanluen and Gottlieb 1991; Pastor-Idoate et al. 2021; Rowens et al. 1991; Teng and Brennan 1959; Ursitti et al. 2022). Deaths were typically attributed to respiratory failure related to pulmonary edema.

Inorganic Mercuric Mercury. Numerous cases of poisoning from acute-duration ingestion of mercuric chloride have been described. A review of 45 published cases of acute mercuric chloride poisoning indicated that the primary systems with symptoms were the gastrointestinal tract, kidney, and brain (Cappelletti et al. 2019). Gastrointestinal tract effects observed following acute poisoning have included abdominal pain, nausea, diarrhea, ulceration, and hemorrhages of the upper and lower tract. Kidney effects have included oliguria, proteinuria, hematuria, casts, nephritis, and acute renal failure; and, at autopsy, renal proximal tubular atrophy and glomerular pathology. Symptoms of neurological effects have included disturbances of vision and behavior and seizures; at autopsy, brain abscesses in the cerebrum have also been observed. In most cases of poisoning, the dose ingested was not known; however, for some cases, the dose was estimated to have been ≥1 g of mercury (Cappelletti et al. 2019).

Organic Mercury. A lethal dose of dimethylmercury occurred following accidental contact to the dorsal surface of a latex gloved hand. The 48-year-old female chemistry professor reported the dose as "a few drops" of liquid dimethylmercury (Nierenberg et al. 1998; Siegler et al. 1999). Approximately 5 months after the exposure, the patient developed severe neurological symptoms that included deterioration of balance, gait and speech, paresthesia, and disturbances of vision and hearing (Nierenberg et al. 1998). The patient died 298 days following the exposure; autopsy revealed thinning of the cerebral cortex and

atrophy of the cerebellum (Siegler et al. 1999). The applied dose was reconstructed based on measurements of BHg made approximately 5 months following the accident and the estimated half-time of 75 days for HHg in the subject (Nierenberg et al. 1998). The applied dose was estimated to have been approximately 1,344 mg mercury contained in approximately 0.44 mL of liquid dimethylmercury (Nierenberg et al. 1998).

2.3   DEATH

Overview. Epidemiological studies evaluating associations between mercury exposure and specific causes of death are evaluated in subsequent sections of Chapter 2 when data are available (e.g., cardiovascular). This section reviews information on all-cause death or mortality (death not attributed to a specific underlying cause). Few epidemiological studies have assessed associations between mercury exposure and all-cause death. Most of the available studies did not provide biomarker data and did not adjust results for confounding factors. Available studies have evaluated all-cause death in workers exposed to elemental mercury, the Minamata population exposed to fish and shellfish with a high methylmercury content, the population in Iraq exposed to high levels of methylmercury in contaminated wheat, and general populations in Finland and Sweden. Studies show increases in all-cause death from exposure to methylmercury, but not for occupational exposures or in general populations.

Increased mortality in animals has been observed at high inhalation or oral exposure levels. Death following inhalation of high mercury vapor concentrations is associated with asphyxiation; no oral LC_{50} value is available. Oral LD_{50} values for mercuric chloride range from 25.9 to 77.7 mg Hg/kg/day, and death following chronic-duration oral exposure is associated with renal nephropathy. Mortality following oral exposure to methylmercury at high doses is associated with overt neurotoxicity and/or renal nephropathy. Oral LD_{50} values for methylmercury are not available.

The following summarizes results of epidemiological and animal studies on mortality.
- ***Elemental mercury***
  - Few studies have evaluated all-cause mortality in workers exposed to elemental mercury. No increases in deaths in workers were observed. Biomarker data were not available.
  - *Animal studies*
    - Death due to asphyxiation has been reported following acute-duration exposure to very high concentrations. No LC_{50} values were identified.

- ***Inorganic mercury salts***
  - *Epidemiology studies*
    - No epidemiological studies evaluating associations between exposure to inorganic mercury salts and death were identified.
  - *Animal studies*
    - Oral LD_{50} values for mercuric chloride in rats range from 25.9 to 77.7 mg Hg/kg/day.
    - Male rats are the most sensitive to lethal effects of mercuric chloride; with chronic-duration exposure, increased mortality is associated with increased severity of nephropathy.
    - Mercuric sulfide is not lethal to rats, mice, or guinea pigs at extremely high oral doses.
- ***Organic mercury***
  - Two long-term follow-up studies in populations with Minamata disease reported increases in all-cause mortality. Biomarker data are not available in this population.
  - All-cause death was elevated in the Iraq population exposed through methylmercury-contaminated wheat.
  - A study of a high fish-eating population found that HHg was associated with an increase in early death.
  - *Animal studies*
    - No LD_{50} values were identified.
    - Methylmercury is associated with increased mortality at high acute- and intermediate-duration doses associated with overt signs of neurotoxicity.
    - Following chronic-duration exposure, male mice are the most sensitive to lethal effects of methylmercury. Increased mortality is associated with increased severity of nephropathy.
- ***Predominant mercury form unknown (general populations)***
  - Studies conducted in populations in the United States, Finland, and Sweden found no associations between mercury biomarkers and all-cause death.

Confounding Factors. Numerous factors can influence results of epidemiological studies evaluating associations between mercury exposure and mortality, including age, sex, body mass index (BMI), ethnicity, poverty level, education, alcohol consumption, smoking status, hypertension, diabetes, family history of diseases, activity level, total cholesterol, postmenopausal status, nutritional status, and co-exposure with other metals (i.e., arsenic or cadmium). Failure to account for these factors when they are associated with both mortality and exposure to mercury may reduce or strengthen the apparent associations between mercury exposure and the outcome.

Elemental Mercury—Epidemiological Studies. Few epidemiological studies have evaluated mortality due to all causes in workers exposed to elemental mercury, with the available studies showing no increases in all-cause death (Barregard et al. 1990; Cragle et al. 1984; Ellingsen et al. 1993). Cumulative exposure was reported in studies reporting an exposure metric. Extrapolation of these study results to other populations is highly uncertain due to reporting inadequacies and lack of adjustments for confounding factors.

Elemental Mercury—Animal Studies. Rats, guinea pigs, and mice died from severe pulmonary edema following a 24–48-hour exposure to an unspecified concentration of metallic mercury vapor resulting from spillage of mercury droplets on the floor of a static exposure chamber (Christensen et al. 1937). Death due to asphyxiation was reported in 20/32 rats exposed to 27.0 mg Hg/m^3 for 2 hours; all remaining animals died within 5 days of exposure (Livardjani et al. 1991). No deaths occurred in rats similarly exposed for 1 hour (Livardjani et al. 1991). An intermediate-duration inhalation study in rats reported death of 6/14 animals exposed to 0.5 mg Hg/m^3 for 2 hours/day over 65 days (Raffee et al. 2021).

Inorganic Mercury Salts—Animal Studies. Oral LD_{50} values for mercuric chloride reported in female rats at 3, 6, 18, and 54 weeks of age are 77.7, 68.1, 37, and 37 mg Hg/kg/day, respectively. At 2 weeks of age, the oral LD_{50} in rats of unspecified sex was 25.9 mg Hg/kg/day (Kostial et al. 1978). However, in repeat-exposure studies, male rats appeared to be slightly more sensitive to the lethal effects of mercuric chloride, with 2/5 males and 0/5 females dying following gavage exposure to 15 mg Hg/kg/day for 4–5 days (NTP 1993). Mice showed slightly less toxicity, with no deaths at 14.8 mg Hg/kg, death in 1/5 males at 29 mg Hg/kg, and deaths in 5/5 males and 4/5 females at 59 mg Hg/kg when administered by gavage for up to 4 days (NTP 1993).

In intermediate-duration studies in rats and mice, no mortality was observed following exposure to gavage doses up to 4 or 15 mg Hg/kg/day, respectively (NTP 1993). Mortality was 100% in male rats exposed to mercuric chloride at drinking water doses of 5.91 mg Hg/kg/day for 4 weeks (Wildemann et al. 2015a). In a multigenerational study, 50% mortality was observed in F0 rat dams exposed to gavage doses of 1.98 mg Hg/kg/day for up to 81 days (Atkinson et al. 2001). Prior to death, rats showed signs of toxicity (e.g., significant decrease in body weight gain/weight loss, reduced food and water intake).

In a chronic-duration gavage study, decreased survival until scheduled sacrifice was observed in male F344 rats exposed to 1.8 or 4 mg Hg/kg/day (21 or 10%, respectively), compared to controls (52%);

increased mortality was associated with increased severity of nephropathy (Dieter et al. 1992; NTP 1993).
Mortality was comparable to controls in similarly treated female rats. No effects on survival were
observed in mice exposed to mercuric chloride at chronic-duration doses up to 7.4 mg Hg/kg/day,
respectively (NTP 1993).

No exposure-related deaths followed repeated oral exposure to mercuric sulfide at doses up to 860 mg
Hg/kg/day in rats (Chuu et al. 2007), 1,700 mg Hg/kg/day in mice (Chuu et al. 2001a; Son et al. 2010), or
86 mg Hg/kg/day in guinea pigs (Chuu et al. 2001b).

Organic Mercury—Epidemiological Studies. Associations between methylmercury exposure and all-
cause death in populations with high fish diets have been evaluated in long-term (≥20 years), follow-up
studies in the Minamata population (Futatsuka et al. 2005; Tamashiro et al. 1985, 1986). Unfortunately,
no biomarkers or adjustments for contributing factors were reported, limiting the interpretation of study
results. Increased standardized mortality ratios (SMRs) for all-cause death were reported by Futatsuka et
al. (2005) and Tamashiro et al. (1985). The Futatsuka et al. (2005) study, which evaluated 1,500 patients
diagnosed with Minamata disease, reported SMRs ranging from 1.14 (95% CI 1.03, 1.26) to 1.27 (95%
CI 1.15, 1.41), based on two different control groups. Tamashiro et al. (1985) evaluated 1,483 patients
with Minamata disease; SMRs were 1.27 (95% CI 1.12, 1.44) in males and 1.30 (95% CI 1.10, 1.53) in
females. In contrast, when not limiting deaths to patients with Minamata disease, this study did not find
increased SMRs in a large population living in the Minamata area (n=36,782).

Information on mortality is available on the Iraq population exposed to methylmercury for approximately
3 months through widespread consumption of wheat that had been treated with a methylmercuric
fungicide (Al-Mufti et al. 1976; Bakir et al. 1973; Clarkson et al. 1976). Based on measurements of
methylmercury in flour used to bake contaminated bread and estimates of bread consumption,
methylmercury intake was estimated to have ranged from 80 to 1,000 mg over a 3-month period (Al-
Mufti et al. 1976). Approximately 6,500 cases of mercury poisoning occurred, with approximately
459 related deaths (Clarkson et al. 1976). Greenwood (1985) evaluated mortality by comparing death
registries in the 2 years prior to exposure to death registries during exposure through 2 years after.
Individuals were considered exposed if BHg >5 µg/g or HHg >5 µg/g. The number of deaths was
significantly increased following exposure. The biggest increase in mortality (4-fold increase) was in age
ranges 1–10 and 11–20 years. When limiting to 3 months after exposure cessation, there were no
increases in deaths.

A recent retrospective longitudinal study of a population of a First Nation community in Canada evaluated associations between HHg and premature death (Philibert et al. 2020). The study population consisted of 657 adults with HHg measurements over the period of 1970–1997. Over the course of the study duration, median HHg significantly declined in cases from 22.2 to 5.0 µg/g; the median HHg in controls declined from 7.1 to 2.6 µg/g, but this change was not significant. Analysis of longevity found that for each 6.25-µg/g increase in HHg, the age of death decreased by 1 year.

Organic Mercury—Animal Studies. No oral LD_{50} values were identified for organic mercury compounds; however, oral exposure has been associated with increased mortality at high doses.

In rats, a single exposure to 16 mg Hg/kg/day during gestation resulted in 17% maternal death (Lee and Han 1995). In repeat-dose studies, mortality was 41% in nonpregnant rats exposed to 8 mg Hg/kg/day for 10 days (Su et al. 1998), 50% in male rats exposed to 4 mg Hg/kg/day for 12 days (Usuki et al. 1998) and 27% in male rats exposed to 12.6 mg Hg/kg/day for 14 days (Sun et al. 2018). Furthermore, 100% mortality was observed in SHR/NCrj rats (spontaneously hypertensive strain) exposed to 1.6 mg Hg/kg/day for 26 days (Tamashiro et al. 1986), and 45% in pregnant rats exposed to 1.6 mg Hg/k/day during pregnancy and lactation (Tonk et al. 2010). Mortality in acute- and intermediate-duration studies was preceded by severe body weight effects and/or clinical signs of neurotoxicity. Mortality was comparable to controls in rats following chronic-duration exposure to methylmercury at doses up to 0.18 mg Hg/kg/day (Verschuuren et al. 1976). A chronic-duration study with phenylmercuric acetate reported a 50% increase in mortality associated with renal nephrosis in male rats at 3.7 mg Hg/kg/day (females not evaluated); no changes in survival were observed at doses up to 0.37 mg Hg/kg/day (Solecki et al. 1991).

In mice, a single oral dose exposure to methylmercury at 16 mg Hg/kg resulted in the death of 4/6 males but no deaths in females (Yasutake et al. 1991). No increase in mortality was observed in female mice until 40 mg Hg/kg was administered, at which dosage 4/6 females died (and 6/6 males died). Increased death in males was associated with impaired renal function. In other mouse studies, 100% mortality was observed in mice following acute-duration exposure to ≥9.3 mg Hg/kg/day (Chuu et al. 2001a; Khera and Tabacova 1973) and or intermediate-duration exposure to ≥8.7 mg Hg/kg/day (Dietrich et al. 2005; MacDonald and Harbison 1977). Intermediate-duration doses of 4.5 mg Hg/kg/day were associated with 85 and 98% mortality in male and female mice, respectively (Mitsumori et al. 1981). Moderate-to-severe signs of clinical neurotoxicity were observed prior to death in the intermediate-duration studies. One chronic-duration study reported a 31% increase in male B6C3F1 mouse mortality at dietary doses of

0.686 mg Hg/kg/day (Mitsumori et al. 1990), but another chronic-duration study reported survival comparable to controls in male ICR mice at dietary doses up to 0.724 mg Hg/kg/day (Hirano et al. 1986); both studies reported increased renal nephropathy and tumors in male mice. Female mouse survival in chronic-duration dietary studies was comparable to controls in both studies at doses up to 0.627 mg Hg/kg/day (Hirano et al. 1986; Mitsumori et al. 1990).

In a study designed to evaluate immune function, 80% of rabbits exposed to 1 mg Hg/kg/day died within 4 weeks of exposure (prior to influenza inoculation); the remaining 20% of rabbits died between 4 and 12 weeks of exposure (post-inoculation) (Koller et al. 1977). As observed in rodents, body weight effects and severe neurotoxicity preceded death; however, deaths post-inoculation may be attributed (in part) to decreased immune response to influenza infection.

In a chronic-duration study in cats, all animals exposed to 0.074 or 0.176 mg Hg/kg/day were sacrificed early due to overt signs of neurotoxicity after approximately 16 and 55 weeks of exposure, respectively (Charbonneau et al. 1976). One animal was similarly sacrificed at 0.046 mg Hg/kg/day after 38 weeks of exposure; the remaining animals in this group survived to terminal sacrifice.

Predominant Mercury Form Unknown (General Populations). Associations between mercury levels and all-cause mortality in general populations exposed to mercury have not been well-studied. However, available studies have been conducted in large study populations (n=1,397–26,056). Study results are summarized in Table 2-5. Prospective studies evaluated associations between mercury biomarkers and all-cause death in general populations of in the United States (using NHANES data), Finland, and Sweden (Ahlqwist et al. 1999; Bergdahl et al. 2013; Sun et al. 2021; Virtanen et al. 2005). None of these studies found positive associations between mercury levels all-cause mortality. A meta-analysis of data from the Bergdahl et al. (2013) and Virtanen et al. (2005) studies also did not find an association between mercury biomarkers and all-cause mortality (Hu et al. 2021). In Swedish women, an inverse relationship (decreasing death with increasing serum mercury [SHg]) was observed between SHg and all-cause death (Ahlqwist et al. 1999). In addition to prospective studies, a cohort study of a large population (n=26,056) using NHANES data did not find associations between BHg and all-cause mortality (Duan et al. 2020).

Table 2-5. Results of Epidemiological Studies Evaluating Exposure to Mercury (Predominant Mercury Form Unknown) and Death in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Ahlqwist et al. 1999 Prospective; 1,397 women (ages 38–60 years at baseline in 1968–1969), followed for approximately 24 years 1974–1975, 1980–1981, and 1992–1993) (Sweden)	SHg mean: 17.0 µg/L	All-cause death	↓ (SHg)
Bergdahl et al. 2013 Prospective; 1,462 women (ages 38–60 years); followed for approximately 32 years (Sweden)	SHg median: 1.38 µg/L	All-cause death	↔ (SHg)
Duan et al. 2020 Cohort; 26,056 adults; mean age 45.9 years; followed for an average of 7.4 years (NHANES 1999–2014)	BHg median: 0.90 µg/L	All-cause death	↔ (BHg)
Sun et al. 2021 Prospective cohort; 17,294 adults; mean age 45.9 years (NHANES 2003–2012)	BHg mean: 1.62 µg/L	All-cause death	↔ (BHg)
Virtanen et al. 2005 Prospective; 1,871 men (42–60 years of age at baseline), followed for approximately 14 years (Finland)	HHg <2.03 µg/g ≥2.03 µg/g	All-cause death	↔ (HHg, <2.03 µg/g) ↔ (HHg, ≥2.03 µg/g)

↓ = inverse association; ↔ = no association; BHg = blood mercury; HHg = hair mercury; NHANES = National Health and Nutrition Examination Survey; SHg = serum mercury

Mechanisms of Action. Mortality is likely the result of effects on multiple organ systems.

2.4   BODY WEIGHT

Overview. Few epidemiological studies have evaluated effects of mercury on body weight. In humans, data are limited to a single study in a population with high fish diets and studies of general populations, with no epidemiological studies identified for elemental mercury. Studies in general populations were

conducted in children, adolescents, and adults. Positive associations were observed between mercury exposure and body weight outcomes in adults; findings were inconsistent in children and adolescents.

Body weight is a well-studied endpoint in animals following inhalation and oral exposure. Body weight effects have been noted following inhalation exposure to elemental mercury and oral exposure to inorganic salts and organic mercury compounds. However, available data do not indicate that body weight is a sensitive effect of mercury toxicity since adverse effects are observed at exposure levels an order of magnitude higher than those associated with the most sensitive effects associated with exposure via the same route and duration. Following oral exposure to inorganic mercury salts or organic mercury, rats are more sensitive than mice. Limited data indicate that monkeys and rabbits may be more sensitive than rodents following oral exposure to organic mercury. It is not known whether there are more sensitive animals than rats following inhalation exposure, as rats are the only species that evaluated body weight via the inhalation route.

The following summarizes results of epidemiological and animal studies on body weight outcomes.

- **Elemental mercury**
  - *Epidemiology studies*
    - No epidemiological studies evaluating associations between exposure to elemental mercury and body weight were identified.
  - *Animal studies*
    - Body weight effects were reported in rats following acute- or intermediate-duration exposures ≥4 or 0.48 mg Hg/m^3, respectively.
    - Body weight data are not available in other species.
- **Inorganic mercury salts**
  - *Epidemiology studies*
    - No epidemiological studies evaluating associations between exposure to inorganic mercury salts and body weight were identified.
  - *Animal studies*
    - Body weight effects were consistently reported in rats at intermediate- or chronic-duration exposures ≥1.5 mg Hg/kg/day via gavage or drinking water, with inconsistent evidence for body weight effects at lower doses. In general, higher dietary doses were required to cause body weight effects.
    - Body weight effects in mice were only observed at high oral doses in males (>10 mg Hg/kg/day).

- ***Organic mercury***
  - *Epidemiology studies*
    - Two epidemiological studies did not find associations between BHg and BMI or waist circumference in a population of adults with high fish diets.
  - *Animal studies*
    - Decreases in body weight gain were observed in monkeys and rabbits after intermediate-duration exposure to ≥0.49 mg Hg/kg/day.
    - In rodents, body weight effects were noted in rats at acute-, intermediate-, and chronic-duration exposures ≥1.9, 0.8, and 0.37 mg Hg/kg/day, respectively. Mice are less sensitive, with body weight effects at acute-, intermediate-, and chronic-duration exposures ≥12, 4.7, and 0.6 mg Hg/kg/day, respectively.
- ***Predominant mercury form unknown (general populations)***
  - Epidemiological studies in adults reported positive associations between mercury exposure of general populations and body weight outcomes, including BMI, percent body fat, visceral adipose tissue, waist circumference, and overweight.
  - Results of studies in children and adolescents in general populations are inconsistent, with some studies finding positive associations between mercury biomarkers and BMI, waist to height ratio, and obesity, and other studies finding no associations.

Confounding Factors. Numerous factors contribute to body weight (or BMI), including age, sex, race, nutrition, diet, daily activity level, intercurrent illness, genetic pre-disposition for body type, income level, education, and alcohol and tobacco use. Failure to account for these factors when they are associated with both body weight and exposure may reduce or strengthen the apparent associations between mercury exposure and the outcome.

Elemental Mercury—Epidemiological Studies. No epidemiological studies evaluating associations between exposure to elemental mercury and body weight were identified.

Elemental Mercury—Animal Studies. Body weight effects have been reported in rats following acute-duration exposure to high concentrations. Male rats exposed to a lethal concentration of 27.0 mg Hg/m^3 for 2 hours showed body weight loss; no body weight effects were noted in rats similarly exposed for 1 hour (Livardjani et al. 1991). Maternal body weight loss was observed in rat dams exposed to 8 mg Hg/m^3 on gestation days (GDs) 6–10 or 6–15 (Morgan et al. 2002). At lower exposure levels, maternal body weight was decreased approximately 10–20% from GD 13 to postnatal day (PND) 3 in dams

exposed to 4 mg Hg/m^3 on GDs 6–15, but not GDs 6–10 (Morgan et al. 2002). No changes in maternal body weight were observed in rat dams following gestational exposure to concentrations ≤8 mg Hg/m^3 for 1 day or ≤4 mg Hg/m^3 for 3–10 days (Danielsson et al. 1993; Fredriksson et al. 1996; Morgan et al. 2002). In nonpregnant female rats, a 17% decrease in body weight was observed following intermittent exposure to 4 mg Hg/m^3 for 11 days (Davis et al. 2001).

In intermediate-duration studies, a 17% decrease in body weight gain was observed in male rats intermittently exposed to 0.05 mg Hg/m^3 for 8 weeks (Sørensen et al. 2000) and body weight loss was observed in male rats intermittently exposed to 3 mg Hg/kg/day for 12–42 weeks (Kishi et al. 1978).

Inorganic Mercury Salts—Animal Studies. Body weight effects were not observed in rats exposed to mercuric chloride at gavage doses up to 9.24 mg Hg/kg/day for 1 day (Lecavalier et al. 1994) or 0.7 mg Hg/kg/day for 7–14 days (Chang and Hartmann 1972). In intermediate- and chronic-duration studies, body weight and/or body weight gain decreases ≥10% were reported in rats exposed to mercuric chloride at doses ≥1.5 mg Hg/kg/day via gavage or drinking water (Raeeszadeh et al. 2021), with serious decreases (≥20%) at intermediate- and chronic-duration doses ≥5.91 and 4 mg Hg/kg/day, respectively (Heath et al. 2012; NTP 1993; Perry and Erlanger 1974; Wildemann et al. 2015a). There is inconsistent evidence for body weight effects in rats at lower gavage and drinking water doses, including decreased body weight in female F344 rats exposed to ≥0.462 mg Hg/kg/day for 6 months (NTP 1993), F0 and F1 male Sprague-Dawley rats exposed to 1.31 or ≥0.37 mg Hg/kg/day, respectively, in a 2-generation study (Atkinson et al. 2001), and male Holtzman rats exposed to 0.7 mg Hg/kg/day for 11 weeks (Chang and Hartmann 1972). Other studies reported no body weight effects in female Long-Evans rats exposed to 9.4 mg Hg/kg/day via gavage for 40 days (Goldman and Blackburn 1979), female Sprague-Dawley rats exposed to 1.5 mg Hg/kg/day for 60 days (Heath et al. 2009), or male Wistar rats exposed to intermediate-duration gavage or drinking water doses up to 0.4 mg Hg/kg/day (Agrawal et al. 2014; Teixeira et al. 2018, 2019; Wildemann et al. 2015b).

Body weight effects data in rats following intermediate-duration dietary exposure to mercuric chloride suggest differences between strains and sexes. In Sprague-Dawley rats, final body weight decreases of 37% were observed in females at 2.2 mg Hg/kg/day (Goldman and Blackburn 1979). In Wistar rats, body weight decreases >20% were observed in males at ≥11.4 mg Hg/kg/day and in females at 23.6 mg Hg/kg/day; no body weight effects were observed in Wistar rats at dietary doses up to 5.8 mg Hg/kg/day (Galiciolli et al. 2022; Goldman and Blackburn 1979; Jonker et al. 1993; Takahashi et al. 2000a, 2000b).

In pregnant Wistar rats, no maternal body weight effects were noted following drinking water exposure to 0.6 mg Hg/kg/day for 1 week prior to mating through PND 21 (Szász et al. 2002). In a 2-generation study in Sprague-Dawley rats, transient body weight decreases up to approximately 21% during gestation were observed in F0 females at gavage doses ≥1.11 mg Hg/kg/day (Atkinson et al. 2001).

Body weight effects in mice orally exposed to mercuric chloride were limited to males exposed to high doses. Body weight decreases of 12–14% were reported in male mice following intermediate-duration exposure to gavage doses of 15 mg Hg/kg/day (NTP 1993) or drinking water doses of 11 mg Hg/kg/day (Dieter et al. 1983). No body weight effects were observed in mice exposed to gavage doses up to 30 mg Hg/kg/day for 16 days, 6 mg Hg/kg/day for 4 weeks, or 1.7 mg Hg/kg/day for up to 2 years (NTP 1993; Sin and Teh 1992). In a 1-generation study, no body weight effects were noted in F0 male or female rats at gavage doses up to 0.74 mg Hg/kg/day (Khan et al. 2004).

Gavage exposure to mercuric sulfide was not associated with body weight effects in rats exposed to 860 mg Hg/kg/day for 14 days (Chuu et al. 2007) or mice exposed to doses up to 1,700 mg Hg/kg/day for 28 days (Son et al. 2010).

Organic Mercury—Epidemiological Studies. A prospective study of 3,083 Greenland Inuit adults (1,338 males, mean age 44 years; 1,745 females, mean age 43 years) did not find associations between BHg and BMI or waist circumference (Larsen et al. 2018).

Organic Mercury—Animal Studies. In primates, body weight loss was observed in marmoset monkeys exposed to methylmercury at 0.5 mg Hg/kg/day for up to 242 days (Eto et al. 2001). In macaque monkeys, no body weight effects were observed after intermediate- or chronic-duration exposure to methylmercury at doses up to 0.08 mg Hg/kg/day (Burbacher and Mottet 1988; Burbacher et al. 1984, 2005; Mohamed et al. 1987; Petruccioli and Turillazzi 1991).

In acute-duration oral studies in rats, body weight effects were not noted in any strain exposed to methylmercury at doses up to 1 mg Hg/kg/day (Chang and Hartmann 1972; Fossato da Silva et al. 2011, 2012; Khera 1973). Findings following methylmercury exposure at higher doses were inconsistent and differed between rat strains. In Sprague-Dawley rats, body weight decreases of approximately 10% were noted after a 14-day exposure to 1.9 mg Hg/kg/day (Chuu et al. 2007) and body weight loss was observed after a 10-day exposure to 8 mg Hg/kg/day (Su et al. 1998). In Wistar rats, a 37% decrease in body weight was observed after a 12-day exposure to 4 mg Hg/kg/day (Usuki et al. 1998); however, no body

weight effects were observed after exposure to doses up to 5 mg Hg/kg/day for 7 days (Khera 1973) or
2.8 mg Hg/kg/day for 14 days (Fossato da Silva et al. 2011, 2012). No body weight effects were
observed in Wistar rats exposed to methylmercuric sulfide at doses up to 7 mg Hg/kg/day for 10 days
(Miyakawa et al. 1974).

Fifteen intermediate-duration studies reported no exposure-related body weight effects in rats exposed to
methylmercury compounds at doses up to 0.5 mg Hg/kg/day (LSE Table 2-4 for references). In contrast,
Rosa-Silva et al. (2020a, 2020b) reported a 21% decrease in body weight in rats exposed to 0.4 mg
Hg/kg/day for 45 days. Serious decreases in body weight or body weight gain (>20%) were consistently
reported in all rat strains tested at intermediate-duration oral methylmercury doses ≥0.8 mg Hg/kg/day
(Chang and Hartmann 1972; Khera 1973; Larsen and Brændgaard 1995; Moussa et al. 2010; Sakamoto et
al. 2017; Schiønning et al. 1998a; Tamashiro et al. 1986; Wildemann et al. 2015a), with the exception of
one study reporting no body weight effects following exposure to 1.9 mg Hg/kg/day for 5 weeks
(Sakamoto et al. 2017). In chronic-duration studies, exposure to phenylmercuric acetate at doses of
0.37 mg Hg/kg/day resulted in an approximate 10% decrease in final body weight in male rats (Solecki et
al. 1991); no body weight effects were noted in male or female rats chronically exposed to methyl
mercuric chloride at doses up to 0.16 or 0.18 mg Hg/kg/day, respectively (Verschuuren et al. 1976).

In maternal rats, single methylmercury exposures during gestation were associated with body weight
effects at doses ≥8 mg Hg/kg/day (Lee and Han 1995), but not 7 mg Hg/kg/day (Carratu et al. 2006).
Following a 9-day exposure during gestation, a 55% decrease in maternal body weight gain was observed
in rats exposed to 4.6 mg Hg/kg/day; no changes were observed in similarly exposed dams at 0.23 mg
Hg/kg/day (Nolen et al. 1972). No maternal body weight effects were observed following exposure to
doses up to 1.9 mg Hg/kg/day for 4 days during gestation (Fredriksson et al. 1996). Following
intermediate-duration exposure during premating, gestation, and/or lactation periods, maternal body
weight and/or body weight gain decreases ≥10% were observed at 1.2 mg Hg/kg/day with serious
decreases (≥20%) at ≥1.6 mg Hg/kg/day (Gandhi et al. 2013; Tonk et al. 2010). Sitarek and Gralewicz
(2009) also report a 30–40% decrease in maternal body weight after gestational and lactational exposure
to 1.9 mg Hg/kg/day; however, findings were associated with a 10–20% decrease in food consumption.
Body weight effects were observed at maternal doses up to 0.9 mg Hg/kg/day (see LSE Table 2-4 for
references).

No body weight effects were observed in mice orally exposed to methylmercury at acute-duration doses
up to 5 mg Hg/kg/day (Khera 1973; Kirkpatrick et al. 2015) or intermediate-duration doses up to 4.6 mg

Hg/kg/day (Blakley et al. 1980; Bourdineaud et al. 2011; Hirano et al. 1986; Ilback 1991; Kirkpatrick et al. 2015; MacDonald and Harbison 1977; Nascimento et al. 2022). Acute-duration exposure to 12 mg Hg/kg/day or intermediate-duration exposures ≥4.7 mg Hg/kg/day resulted in body weight loss in mice (Das et al. 1997; Dietrich et al. 2005; MacDonald and Harbison 1977). In chronic-duration studies, female B6C3F1 mice showed an approximate 10% decrease in final body weight following dietary exposure to 0.601 mg Hg/kg/day for 2 years; male B6C3F1 mice also showed a decrease in body weight at 0.686 mg Hg/kg/day, but findings were associated with decreased food consumption (Mitsumori et al. 1990). In ICR mice, no body weight effects were noted at chronic-duration doses up to 0.724 mg Hg/kg/day (Hirano et al. 1986). No body weight effects were noted in maternal mice following a single gestation exposure to 9.99 mg Hg/kg/day (Belles et al. 2002) or intermediate-duration exposure during premating, gestation, and/or lactation periods to doses up to 4.7 mg Hg/kg/day (Franco et al. 2006; Thuvander et al. 1996; Weiss et al. 2005).

Data in other species are limited. In an intermediate-duration oral study in rabbits, body weight gain was decreased by 13% in females at 0.48 mg Hg/kg/day and by 43% in males at 0.53 mg H/kg/day; no effects were observed in either sex at 0.05 mg Hg/kg/day (Koller et al. 1977). No body weight effects were noted in cats exposed to doses up to 0.176 mg Hg/kg/day approximately 16 weeks, 0.074 mg Hg/kg/day for approximately 55 weeks, or 0.046 mg Hg/kg/day for 2 years (Charbonneau et al. 1976).

Predominant Mercury Form Unknown (General Populations). Associations between mercury biomarkers and body weight have been evaluated in several cross-sectional studies; results are summarized in Table 2-6. Studies include large populations (n=1,567–11,159) of participants from NHANES (Fan et al. 2017; Wang et al. 2018) or KNHANES (Bae et al. 2016; Lee et al. 2016; Moon et al. 2022; Park and Lee 2013; Shin et al. 2018). Studies also evaluated body weight effects in children and adolescents (Cho 2021; Fan et al. 2017; Shin et al. 2018), with the remaining studies conducted in adults. Studies used BHg, SHg, UHg, and NHg as exposure biomarkers.

Table 2-6. Results of Epidemiological Studies Evaluating Body Weight Effects of Mercury Exposure (Predominant Mercury Form Unknown) in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated	Result

Bae et al. 2016
 	
Cross-sectional;
11,159 adults, 5,543 males and 5,616 females (KNHANES 2008–2012)
	BHg mean
	  Males: 5.07 µg/L
	  Females: 3.59 µg/L
		BMI	↑ (BHg, males)
			↑ (BHg, females)

		Waist circumference	↑ (BHg, males) ↑ (BHg, females)

Cho 2021
 	
Cross-sectional;
1,327 children and adolescents (672 males and 655 females), ages 10–18 years (KNHANES 2010–2013)
	BHg mean
	  Normal weight:
	  2.09 µg/L
	  Overweight: 2.43 µg/L
		BMI	↑ (BHg)

		Waist to height ratio	↑ (BHg)
Fan et al. 2017 Cross-sectional; 5,404 children (2,734 males and 2,659 females), ages 6–19 years (NHANES 2011–2014)	SHg mean: 0.65 µg/L	BMI	↔ (SHg)

Hernández-Mendoza et al. 2022
 	
Cross-sectional; 86 adults, 27 males and 59 females, mean age 27 years (Mexico)
	SHg mean
	  Males: 0.95 µg/L
	  Females: 0.9 µg/L
		BMI	↔ (SHg, males and females)

Jeon et al. 2021
 	
Cross-sectional; 495 adults, ages 40–69 years, 46% male (Korea)
	NHg tertiles
	  T1: 0.09–0.27 µg/g
	  T2: 0.28–0.41 µg/g
	  T3: 0.42–2.15 µg/g
		Obesity	↑ (BHg,T3)

		Abdominal obesity	↑ (BHg,T3)

Lee et al. 2016
 	
Cross-sectional; 9,228 adults, 4,283 males and 4,945 females (KNHANES 2007–2013)
	BHg quartiles, males
	  Q1: <3.04 µg/L
	  Q2: 3.04–4.52 µg/L
	  Q3: 4.52–6.84 µg/L
	  Q4: ≥6.84 µg/L
	BHg quartiles, females
	  Q1: <2.24 µg/L
	  Q2: 2.24–3.17 µg/L
	  Q3: 3.17–4.55 µg/L
	  Q4: ≥4.55 µg/L
		Overweight	↑ (BHg, males, Q1–Q4)
			↑ (BHg, females, Q1–Q4)

Table 2-6. Results of Epidemiological Studies Evaluating Body Weight Effects of Mercury Exposure (Predominant Mercury Form Unknown) in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Moon et al. 2022 Cross-sectional; 3,787 adults, ≥19 years of age, 1,648 males and 2,139 females (KNHANES 2015–2017)	BHg quartiles Q1: <1.86 µg/L Q2: 1.86–<2.18 µg/L Q3: 2.18–4.44 µg/L Q4: ≥4.44 µg/L UHg quartiles Q1: <0.20 µg/L Q2: 0.23–<0.35 µg/L Q3: 0.35–0.64 µg/L Q4: ≥0.64 µg/L	Obesity	↑ (BHg, males, Q3–Q4) ↑ (BHg, females, Q4) ↑ (UHg, males, Q4) ↑ (UHg, females, Q2–Q4)
Park and Lee 2013 Cross-sectional; 4,522 adults, 2,217 males and 2,395 females (KNHANES 2008–2010)	BHg Gmean Males: 4.337 µg/L Females: 3.733 µg/L	Body fat (%)	↓ (BHg, males) ↔ (BHg, females)
Park et al. 2017 Cross-sectional; 200 adults, 96 males and 104 females (Korea)	BHg tertiles T1: 1.06–2.66 µg/L T2: 2.69–4.43 µg/L T3: 4.46–7.16 µg/L	Visceral adipose tissue	↑ (BHg)
Shin et al. 2018 Cross-sectional; 1,567 children and adolescents, 793 males and 774 females; ages 10–19 years (KNHANES 2010–2013)	BHg Gmean: 1.93 µg/L BHg quartiles boys Q1:<1.47 µg/L Q2: 1.47–1.93 µg/L Q3: 1.94–2.67 µg/L Q4: >2.67 µg/L BHg quartiles girls Q1: <1.39 µg/L Q2: 1.39–1.79 µg/L Q3: 1.80–2.41 µg/L Q4: >2.41 µg/L	Overweight/obesity	↑ (BHg, males and females, Q4)
		Abdominal obesity	↑ (BHg, males, Q4) ↔ (BHg, females, Q4)

↑ = positive association; ↓ = inverse association; ↔ = no association; BHg = blood mercury; BMI = body mass index; Gmean = geometric mean; KNHANES = Korean National Health and Nutrition Examination Survey; NHANES = National Health and Nutrition Examination Survey; NHg = toenail mercury; SHg = serum mercury; Q = quartile; T = tertile; UHg = urine mercury

Cross-sectional studies in children and adolescents were conducted in NHANES (Fan et al. 2017) and KNHANES (Cho 2021; Shin et al. 2018) participants. No association was observed between SHg and BMI in NHANES participants who had a mean SHg of 0.65 µg/L (Fan et al. 2017). In contrast, in the KNHANES population with higher mercury levels (4th BHg quartile: 4.08–4.77 µg/L), positive associations were observed for overweight/obesity in males and females and abdominal obesity in males,

but not females; no associations were observed at lower quartiles (Q1–Q3: 1.82–3.73 µg/L) (Shin et al. 2018). Similarly, Cho (2021) reported positive associations between BHg and BMI and waist to height ratio. It is difficult to directly compare the NHANES and KNHANES studies because different biomarkers were used. In adults, most studies showed positive associations between mercury biomarkers and several body weight outcomes, including BMI, percent body fat, visceral adipose tissue, waist circumference, and overweight, as summarized in Table 2-6.

Mechanisms of Action. A recent review by Moon (2017) noted that "mercury has no known physiological role in human metabolism." However, proposed mechanisms for mercury-induced effects on body weight include the following: (1) mitochondrial dysfunction; (2) oxidative stress; (3) insulin resistance; and (4) pancreatic β-cell dysfunction and apoptosis (Moon et al. 2017). In addition, based on a study in adipocyte cell lines, mercuric chloride may influence signaling events and subsequent metabolic activity in adipose tissue (Barnes et al. 2003).

2.5   RESPIRATORY

Overview. Few epidemiological and animal studies have evaluated respiratory effects of mercury. However, based on the available data, the respiratory tract does not appear to be a sensitive target of environmental exposures to mercury. Most epidemiological studies were conducted in general populations of children and examined associations between biomarkers and asthma, with only one study reporting positive associations between biomarkers and asthma. Case studies of acute-duration exposures to high levels of elemental mercury vapor in confined occupational or residential spaces indicate that damage to the respiratory tract can occur.

Studies evaluating respiratory effects in animals are available for inhalation exposure to mercury vapor and oral exposure to mercuric chloride or methylmercury. Consistent with human data, respiratory distress and lung damage have been reported following exposure to acute-duration lethal air concentrations of mercury vapor. Oral data do not indicate that the lung is a sensitive target of mercury toxicity in animal studies, although limited data indicate alveolar effects at high acute-duration methylmercury doses. Nasal lesions have been reported in both mice and rats following chronic-duration gavage exposure to mercuric chloride.

The following summarizes results of epidemiological and animal studies on respiratory outcomes.

- ***Elemental mercury***
  - *Epidemiology studies*
    - No epidemiological studies on respiratory effects of exposure to elemental mercury were identified.
    - Case studies show that acute-duration exposure to high levels of mercury vapor in confined occupational or residential spaces produces adverse respiratory effects, which can be severe.
  - *Animal studies*
    - Respiratory distress and lung damage were reported at acute-duration lethal air concentrations in one study.
    - Data are insufficient to determine if exposure to elemental mercury at nonlethal concentrations is associated with adverse respiratory effects.

- ***Inorganic mercury salts***
  - *Epidemiology studies*
    - No epidemiological studies evaluating associations between exposure to inorganic mercury salts and respiratory effects were identified.
  - *Animal studies*
    - One study reported labored breathing in rats following intermediate-duration dietary exposure to mercuric chloride.
    - Chronic-duration gavage exposure to mercuric chloride is associated with nasal lesions in both rats and mice.
    - There is no evidence of lung lesions following acute-, intermediate-, or chronic-duration gavage exposure to mercuric chloride in rats or mice.

- ***Organic mercury***
  - *Epidemiology studies*
    - Data are insufficient to determine if exposure to organic mercury is associated with adverse respiratory effects. The only identified study did not show an association between cord BHg and asthma in children.
  - *Animal studies*
    - One acute-duration study reported elevated lung weight and alveolar changes following oral exposure to high doses of methylmercury.
    - There is no evidence of lung lesions in cats, rats, or mice orally exposed to methylmercury for up to 2 years.

- ***Predominant mercury form unknown (general populations)***
    - Results of studies conducting pulmonary function tests are inconsistent, with some studies showing inverse associations between biomarkers and pulmonary function and other studies showing no associations.
    - Several studies evaluated outcomes related to asthma in children. Of the available studies, only one study found an association between biomarkers and asthma.
    - No associations were observed between respiratory symptoms (wheeze and cough) and gestational exposure to mercury.

Confounding Factors. The etiology for most respiratory diseases is multifactorial; therefore, several factors may contribute to clinical findings. These include poor housing conditions, exposure to allergens (e.g., pet dander, seasonal allergies), exposure to tobacco smoke and other respiratory irritants, and asthma compounded by obesity (Ali and Ulrik 2013). In addition, Aligne et al. (2000) reported that children living in urban settings have an increased risk of asthma. Failure to account for these factors when they are associated with both respiratory outcomes and exposure may attenuate or strengthen the apparent associations between mercury exposure and the outcome, depending on the direction of the effect of the variable on the outcome.

Elemental Mercury—Epidemiological Studies. Epidemiological studies evaluating effects of elemental mercury in respiratory effects meeting inclusion criteria were not identified (see inclusion criteria, Section 2.1). Several case studies of individuals reported adverse respiratory effects following acute-duration exposure (a few hours) to near-fatal or fatal elemental mercury vapor generated from heating elemental mercury to high temperatures in confined spaces in occupational or residential settings. Findings include the following: cough, wheeze, and shortness of breath (Haddad and Stenberg 1963; Kanluen and Gottlieb 1991; Milne et al. 1970); decreased pulmonary function, including decreased vital capacity (VC), forced expiratory volume (FEV), and FEV in 1 second (FEV_1) (Gore and Harding 1987; Lilis et al. 1985); restrictive lung disease (Hallee 1969; Lilis et al. 1985); lung inflammation classified as bronchiolitis, bronchitis, or pneumonitis (Gore and Harding 1987; King 1954; Milne et al. 1970; Rowens et al. 1991; Teng and Brennan 1959; Tennant et al. 1961); interstitial and alveolar fibrosis (Hallee 1969; Kanluen and Gottlieb 1991); and respiratory failure (Kanluen and Gottlieb 1991; Rowens et al. 1991; Teng and Brennan 1959). No information regarding respiratory effects at lower exposure levels (i.e., not near-fatal or fatal levels) of elemental mercury were identified.

Elemental Mercury—Animal Studies. Data on respiratory effects in animals following inhalation exposure to mercury vapor are limited. In rats, exposure to a lethal air concentration (27.0 mg Hg/m^3) for 2 hours resulted in dyspnea and asphyxiation. At necropsy, lung edema, necrosis of the alveolar epithelium and hyaline membranes, and occasional lung fibrosis were observed (Livardjani et al. 1991). In other studies, no evidence of respiratory distress or lung damage was observed in rats following nonlethal exposure to 26.6 mg Hg/m^3 for 1 hour (Livardjani et al. 1991), 8 mg Hg/m^3 for 2 hours/day for up to 10 days (Morgan et al. 2002), or 3 mg Hg/m^3 for 12–42 weeks (5 days/week; 3 hours/day) (Kishi et al. 1978). Emphysema, obstruction of intra-alveolar septae, alveolar dilation, and intra-alveolar edema and inflammatory cell infiltrate were observed in rats exposed to 0.5 mg Hg/m^3 for 2 hours/day for both 21 and 65 days of exposure (Raffee et al. 2021).

Inorganic Mercury Salts—Animal Studies. The only study located regarding respiratory function in animals after oral exposure to inorganic mercury salts described forceful and labored breathing, bleeding from the nose, and other unspecified respiratory difficulties in rats after dietary exposure to 2.2 mg Hg/kg/day as mercuric chloride for 3 months (Goldman and Blackburn 1979).

Nasal lesions were observed in both rats and mice following chronic-duration gavage exposure to mercuric chloride. Increased incidence of nasal mucosa inflammatory lesions was observed in rats at 4 mg Hg/kg/day and mice at 7.4 mg Hg/kg/day (NTP 1993). In mice, increased metaplasia in the olfactory epithelium was also observed in females at ≥4 mg/kg/day and in males at 7.4 mg/kg/day. No nasal lesions were observed in rats or mice following a 6-month exposure to gavage doses up to 4 or 15 mg/kg/day, respectively (NTP 1993).

For intermediate-duration exposure, histopathological changes, including increased type 1 collagen deposition, infiltration of inflammatory cells in the bronchus, decreased type III collagen and irregular elastic fibers, were observed in rats administered at 0.8480 mg Hg/kg/day via gavage for 28 days (Koopsamy Naidoo et al. 2019). Other studies found no changes in lung histology in rats exposed to mercuric chloride via gavage at acute-duration doses up to 9.24 mg Hg/kg/day, intermediate-duration doses up to 15 mg Hg/kg/day, or chronic-duration doses up to 4 mg Hg/kg/day (Lecavalier et al. 1994; NTP 1993). In mice, no changes in lung histology were observed following gavage exposure to intermediate-duration doses up to 59 mg Hg/kg/day or chronic-duration doses up to 7.4 mg Hg/kg/day (NTP 1993).

Organic Mercury—Epidemiological Studies. Data are not sufficient to determine if exposure to mercury in populations with high fish diets produces adverse respiratory effects, with only one study meeting inclusion criteria (see inclusion criteria, Section 2.1). A prospective study of 656 singleton births in the Faroe Islands did not find an association between cord BHg (mean 11.3 µg/L) and asthma at ages 5 and 7 years (Grandjean et al. 2010). Adjustments included parental smoking in the home and PCB exposure.

Organic Mercury—Animal Studies. One acute-duration study in mice reported a 22–23% increase in absolute and relative lung weight, reduced alveolar diameter, increased alveolar wall thickness, and increased minimal surface tension following gavage exposure to 12 mg Hg/kg/day as methylmercuric chloride for 4 days (Das et al. 1997).

No exposure-related changes in lung histology were observed following oral exposure to methylmercuric chloride in cats at doses up to 0.176 mg Hg/kg/day approximately 16 weeks, 0.074 mg Hg/kg/day for approximately 55 weeks, or 0.046 mg Hg/kg/day for 2 years (Charbonneau et al. 1976); rats at doses up to 0.18 mg Hg/kg/day for 2 years (Verschuuren et al. 1976), or mice at doses up to 0.724 mg Hg/kg/day for 2 years (Hirano et al. 1986; Mitsumori et al. 1990).

Predominant Mercury Form Unknown (General Populations). Respiratory effects of mercury in general populations have not been well studied. Available studies evaluated asthma and signs of respiratory effects in large populations (n ≥582) of children using prospective, longitudinal, and cross-sectional designs. Most studies did not find associations between mercury exposure and asthma, signs of respiratory effects, or pulmonary function, although there are a few exceptions. Studies are summarized in Table 2-7. Evidence for effects of mercury on respiratory function is inconclusive as there are few studies and these provide inconsistent results.

Only one prospective study evaluated pulmonary function (Miao et al. 2023). This study of Chinese college students showed an inverse association between pulmonary function tests and BHg (mean BHg: 1.4 µg/L), but no associations at lower exposures. A large longitudinal study that examined additional endpoints found positive associations between BHg and asthma and wheeze, but not asthma medication use or airway hyperresponsiveness (Kim et al. 2015a). A cross-sectional study (n=382) found inverse associations between UHg and pulmonary function parameters (e.g., FEV_1, FVC) (Zheng et al. 2023).

Other cross-sectional studies did not find associations between BHg and asthma, wheeze, or bronchial hyperresponsiveness (Heinrich et al. 2017; Wu et al. 2019); however, these studies did not conduct

pulmonary functions tests. Prospective and longitudinal studies evaluating effects of gestational
exposure, based on cord BHg or maternal mercury biomarkers, and respiratory symptoms (wheeze and
cough) did not find any associations (Carrasco et al. 2021; Emeny et al. 2019; Miyake et al. 2011;
Shaheen et al. 2004).

Table 2-7. Results of Epidemiological Studies Evaluating Exposure to Mercury (Predominant Mercury Form Unknown) and Respiratory Effects in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Studies based on current mercury measurements			
Chen et al. 2023a Cross-sectional; 9,556 adults (NHANES 2007–2012)	SHg Q1: <0.044 µg/L Q2: 0.44–0.79 µg/L Q3: 0.79–1.50 µg/L Q4: ≥1.50 µg/L	PRISm	↔ (SHg, Q4)
Chen et al. 2023b Cross-sectional; 1,227 children and adolescents, 6–17 years of age (NHANES 2007–2012)	UHg median: 0.292 µg/g creatinine	FEV_1	↔ (UHg)
		FVC	↔ (UHg)
		$FEF_{25–75\%}$	↔ (UHg)
		PEF	↔ (UHg)
Heinrich et al. 2017 Cross-sectional; 1,056 children 5–14 years of age (Germany)	BHg Gmean: 0.36 µg/L[a]	Asthma	↔ (BHg)
		Wheeze	↔ (BHg)
		Bronchial hyper-responsiveness	↔ (BHg)
Kim et al. 2015a Longitudinal; 4,350 children enrolled at 7–8 years of age, examined every 2 years through age 11–12 years (Korea 2005–2010)	BHg Gmean Ages 7–8: 2.02 µg/L Ages 9–10: 1.79 µg/L Ages 11–12: 1.96 µg/L	Asthma (age 9–10 years)	↑ (BHg at age 7–8 years) ↑ (BHg at age 9–10 years)
		Asthma (age 11–12 years)	↑ (BHg at age 7–8 years) ↔ (BHg at age 9–10 years) ↔ (BHg at age 11–12 years)
		Wheeze	↑ (BHg)[a]
		Asthma medication use (age 11–12 years)	↔ (BHg)[a]
		Airway hyper-responsiveness (age 11–12 years)	↑ (BHg)[a]
Miao et al. 2023 Prospective cohort; 1,800 college students; mean age 18.1 years (China)	BHg mean All: 0.8 µg/L Low: 0.4 µg/L Medium: 0.7 µg/L High: 1.4 µg/L	FEV_1	↓ (BHg, all, high) ↔ (BHg, low, medium)
		FVC	↓ (BHg, all, high) ↔ (BHg, low, medium)
		PEF	↓ (BHg, all, high) ↔ (BHg, low, medium)

Table 2-7. Results of Epidemiological Studies Evaluating Exposure to Mercury (Predominant Mercury Form Unknown) and Respiratory Effects in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated	Result

Nguyen 2023
 	
Cross-sectional;
1,162 premenopausal women and 659 postmenopausal women (KNHANES 2009–2017)
	SHg Gmean (µg/L)
	  Premenopausal: 3.19
	  Postmenopausal: 3.08
		FEV_1/FVC	↔ (SHg, premenopausal)
			↔ (SHg, postmenopausal)

Pan et al. 2020 Cross sectional; 221 children (mean age: 12.5 years) (China)	BHg Gmean: 1.41 µg/L	FEV_1	↔ (BHg)
		FVC	↔ (BHg)
Wu et al. 2019 Cross-sectional; 5,866 children, 2–15 years of age (NHANES 2007–2012)	BHg mean: 0.54 µg/L	Asthma	↔ (BHg)
		Wheeze	↔ (BHg)

Zheng et al. 2023
 	
Cross-sectional; 382 adults, mean age 56.69 years (China)
	UHg mean (µg/g Cr)
	  All: 0.21
	  Without PVD: 0.13
	  With PVD: 0.27
		PVD	↑ (UHg)

		FEV_1	↓ (UHg)
		FVC	↓ (UHg)
		FEV_1/FVC	↓ (UHg)
Studies based on prenatal exposure measurements			
Carrasco et al. 2021 Longitudinal; children 4 years of age with prenatal BHg (n=1,868) and HHg at age 4 years (n=1,347) (Spain)	Cord BHg Gmean: 8.23 µg/L HHg Gmean: 0.97 µg/g	Wheezing	↔ (cord BHg) ↔ (HHg)
		Severe wheezing	↔ (cord BHg) ↔ (HHg)
		Persistent cough	↔ (cord BHg) ↔ (HHg)
Emeny et al. 2019 Prospective; 639–706 infants, assessed 0–4 months, 5–8 months, 9–12 months, >12 months (New Hampshire)	Maternal NHg Gmean: 0.02 µg/g	Wheeze	↔ (NHg)

Miyake et al. 2011
 	
Prospective; mothers enrolled October 2002–March 2003; 582 mother-child; maternal and child exposure and child outcomes assessed at age 29–39 months (Japan)
	HHg median
	  Mother: 1.52 µg/g
	  Child: 1.38 µg/g
		Wheeze	↔ (HHg, mother and child)

Table 2-7. Results of Epidemiological Studies Evaluating Exposure to Mercury (Predominant Mercury Form Unknown) and Respiratory Effects in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Shaheen et al. 2004 Prospective; mothers enrolled April 1991–December 1992; 1,755 newborns, assessed for wheeze at 18–30 months and 30–42 months of age (United Kingdom)	Cord BHg Gmean: 0.0127 µg/L	Wheeze	↔ (BHg, cord, 18–30 months) ↔ (BHg, cord, 30–42 months)

[a]Child age at time of BHg sampling not specified.

↑ = positive association; ↓ = inverse association; ↔ = no association; BHg = blood mercury; Cr = creatinine; FEV_1 = forced expiratory volume in 1 second; $FEF_{25–75\%}$ = the average flow from the point at which 25% of the FVC has been exhaled to the point at which 75% of the FVC has been exhaled; FVC = forced vital capacity; Gmean = geometric mean; HHg = hair mercury; KNHANES = Korea National Health and Nutrition Examination Survey; NHg = toenail mercury; NNHANES = National Health and Nutrition Examination Survey; PEF = peak expiratory flow; PRISm = preserved ratio impaired spirometry (FEV_1/FVC ≥0.7 and FEV_1 <80% predicted); PVD = pulmonary ventilation dysfunction (FVC <80%, FEV_1% <80%, and FEV_1/FVC <70%); Q = quartile; SHg = serum mercury; UHg = urine mercury

Mechanisms of Action. Epidemiological and animal studies do not provide strong evidence that exposure to mercury at environmental levels adversely affects the respiratory system, although exposure to near-fatal or fatal concentrations of mercury vapor produces respiratory damage. General mechanisms of toxicity of mercury (reviewed in Section 2.21) are likely involved in the development of toxicity to the respiratory system. In addition, immunomodulatory effects and subsequent cellular release of histamine and cytokines have been proposed as possible mechanisms of toxicity (Miyake et al. 2011).

2.6   CARDIOVASCULAR

Overview. Data on cardiovascular effects of mercury are available from studies in humans and animals. Numerous epidemiological studies have evaluated associations between biomarkers of mercury exposure and cardiovascular outcomes. Studies in humans are available for occupational exposures to elemental mercury, populations exposed primarily to methylmercury through high fish diets, and general populations with unspecified mercury exposures likely to be a combination of methylmercury in food and inorganic mercury from dental amalgams (elemental mercury) and other sources. Cardiovascular outcomes evaluated include blood pressure, cardiac function, or diagnosis of clinical hypertension or cardiovascular disease, and results are inconsistent for these outcomes. For blood pressure, the most

studied outcome, evidence for effects is conflicting, and studies that do show positive associations indicate that the magnitude of changes is small. Taken together, results of current epidemiological studies do not provide conclusive evidence that the cardiovascular system is a highly sensitive target for mercury. Limitations for epidemiological studies that provided results for cardiovascular and neurological endpoints are discussed in Section 2.16.1.

Studies evaluating functional cardiovascular endpoints in animals (blood pressure, baroreflex sensitivity, cardiac inotropism) are available for oral exposure to mercuric chloride or methylmercury. Overall, studies indicate that systolic and diastolic blood pressure are increased in a duration-dependent manner for mercuric chloride, and a dose- and duration-dependent manner for methylmercury. A limited number of studies indicate that both compounds also have positive inotropic effects and decreased baroreceptor reflex sensitivity. These data provide evidence that cardiovascular function in rats is altered following exposure to mercuric chloride and methylmercury.

The following summarizes results of epidemiological and animal studies on cardiovascular outcomes.

- ***Elemental mercury***
    - *Epidemiology studies*
        - Findings regarding effects on blood pressure are inconsistent, with no associations at the highest exposures and some positive associations at lower exposures.
        - Few studies investigated effects on cardiac function; data are insufficient to draw conclusions.
    - *Animal studies*
        - No adequate studies have evaluated cardiovascular effects of elemental mercury.
- ***Inorganic mercury salts***
    - *Epidemiology studies*
        - No studies on cardiovascular effects of exposure to inorganic mercury salts were identified.
    - *Animal studies*
        - Findings consistently show duration-dependent increases in systolic and diastolic blood pressure in rats.
        - A few studies have reported positive inotropism and decreased baroreflex sensitivity in rats.
        - No histopathological lesions have been identified in cardiovascular tissue following intermediate- or chronic-duration exposure in rats or mice.

- ***Organic mercury***
  - *Epidemiology studies*
    - Small increases in systolic and diastolic blood pressure have been reported in some studies; however, results are not consistent, and data do not provide clear evidence of a dose-response relationship between methylmercury exposure and increased blood pressure in populations with high fish diets. Associations between methylmercury exposure and prevalence of clinical hypertension are also inconsistent.
    - Data on effects of methylmercury on cardiac function are inconclusive, although some studies reported inverse associations for heart rate variability, which may lead to more serious cardiac effects.
    - No consistent evidence of associations between exposure and cardiovascular diseases has been reported.
  - *Animal studies*
    - Findings show dose- and duration-dependent increases in systolic and diastolic blood pressure in rats.
    - A few studies report positive inotropism and decreased baroreflex sensitivity in rats.
    - No histopathological lesions were identified in cardiovascular tissue following chronic-duration exposure in rats or mice.
- ***Predominant mercury form unknown (general populations)***
  - Evidence for effects of mercury exposure on blood pressure in general populations is inconclusive.
  - Most studies evaluating clinical hypertension reported no associations with mercury biomarkers, although a few studies reported increased risk of hypertension.
  - Evidence for associations between mercury exposure and cardiovascular disease is very limited, with most studies reporting no associations.
  - A study in children reported decreased heart rate variability, indicative of decreased parasympathetic modulation of the autonomic function of the heart.

Confounding Factors. For epidemiological studies, numerous factors affect cardiovascular function, including age, body mass, race, smoking, alcohol consumption, ongoing family history of cardiovascular disease, low density lipoprotein (LDL) cholesterol levels, diet (including n-3 polyunsaturated fatty acids and selenium), other diseases (e.g., renal disease), and co-exposure to substances (lead, PCBs) that may affect the cardiovascular system either directly or indirectly through effects on other systems (e.g., renal, neurological). Failure to account for these factors when they are associated with both cardiovascular

outcomes and exposure may attenuate or strengthen the apparent associations between mercury exposure and the outcome, depending on the direction of the effect of the variable on the outcome (e.g., Møller and Kristensen 1992). Although it is impractical to assess all possible confounders, epidemiological studies reviewed in this section include some of the adjustments listed above. No specific confounder or covariate was mandatory for the inclusion of the study into the profile; however, studies of cardiovascular outcomes that did not consider, at a minimum, age, body mass, race, smoking, alcohol consumption, and ongoing family history of cardiovascular disease are potentially more confounded than studies that did consider these variables.

In addition to potential confounding factors listed above, interpretation of study results is further complicated by the risks and benefits of fish consumption, particularly in populations with high fish diets. Fish contain high levels of n-3 polyunsaturated fatty acids and selenium, which are considered beneficial to cardiovascular health (Choi et al. 2008a, 2009; Hu et al. 2017). Therefore, cardiovascular effects of methylmercury may be offset by the beneficial effects of fatty acids and selenium (e.g., negative confounding) in high fish diets (Chan and Egeland 2004; Choi et al. 2008a; Guallar et al. 2002; Hu et al. 2017; Mozaffarian 2009; Smith et al. 2009; Virtanen et al. 2005). Several study authors noted that the balance between beneficial nutrients and methylmercury in high fish diets may contribute to the equivocal findings in some studies examining cardiovascular effects (Choi et al. 2008a; Guallar et al. 2002; Hu et al. 2017; Stern 2005; Virtanen et al. 2005).

Elemental Mercury—Epidemiological Studies. Studies evaluating effects of elemental mercury on cardiovascular function are summarized in Table 2-8. The database consists of several cross-sectional studies of dental professionals, miners, chloralkali workers, and adults with amalgam fillings. Population sizes in these studies are small (n=28–386), limiting the power to detect associations between elemental mercury and cardiovascular outcomes. All studies quantified exposure using UHg, with some studies also measuring BHg and/or HHg. Choice of biomarkers used in the studies may have impacted the strength and direction of the associations found. UHg has been shown to correlate with elemental mercury exposure in populations in which the main source of exposure was to elemental mercury (e.g., workers in mercury production and processing) (Section 3.3.1, Biomarkers of Exposure). UHg ranged from 0.94 µg/L in a study of U.S. dental professionals (Goodrich et al. 2013) to 51.4 µg/L in mercury-exposed Turkish adults, including dentists and "industrial" exposures (Yilmaz et al. 2016). Evidence for effects of elemental mercury on cardiovascular function is inconclusive.

Table 2-8. Results of Epidemiological Studies Evaluating Exposure to Elemental Mercury (Hg⁰) and Effects on Cardiovascular Outcomes

Reference, study type, and population	Biomarker	Outcome evaluated	Result[a]
Goodrich et al. 2013 Cross-sectional; 262 dental professionals (Michigan)	HHg mean: 0.45 µg/g UHg mean: 0.94 µg/L	SBP	↔ (HHg) ↓ (UHg)
		DBP	↑ (HHg) ↔ (UHg)

Kobal et al. 2004
 	
Cross-sectional; 54 male mercury miners, 58 male controls (Slovenia)
	UHg mean
	  Workers: 2.1 µg/L
	  Controls: 1.4 µg/L
		SBP	↑ (workers versus controls)

		DBP	↑ (workers versus controls)

Piikivi 1989
 	
Retrospective, cross-sectional; 41 chloralkali male workers, 41 male referents (Finland)
	Means for workers
	  BMeHg: 3.8 µg/L
	  BIHg: 7.8 µg/L
	  UHg: 19.3 µg/L
	
	Means for referents
	  BMeHg: 2.9 µg/L
	  BIHg: 0.9 µg/L
	  UHg: 1.8 µg/L
		SBP	↔ (workers versus referents)

		DBP	↔ (workers versus referents)
Poreba et al. 2012 Cross-sectional; 115 adult chloralkali workers (Poland)	UHg mean: 4.11 µg/g Cr	LVF	↓ (UHg)
Rajaee et al. 2015 Cross-sectional; 70 adult current and former mercury miners (Ghana)	HHg mean: 1.11 µg/g UHg mean: 37.6 µg/L	SBP	↔ (BHg, UHg)
		DBP	↔ (BHg, UHg)

Siblerud 1990
 	
Cross-sectional; 101 adults with amalgam fillings, 51 adults with no amalgam fillings (Colorado)
	HHg mean
	  Amalgam: 1.43 µg/g
	  No amalgam: 1.13 µg/g
	UHg mean
	  Amalgam: 3.70 µg/L
	  No amalgam: 1.23 µg/L
		SBP	↑ (amalgam versus no amalgam)

		DBP	↑ (amalgam versus no amalgam)
		HR	↔ (amalgam versus no amalgam)

Xu et al. 2023a
 	
Cross-sectional; 386 dental professionals (United States)
	Gmean
	  BHg: 3.64 µg/L
	  UHg: 1.44 µg/L
	  HHg: 0.60 µg/g
		SBP	↔ (BHg)
			↔ (UHg)
			↑ (HHg)

		DBP	↔ (BHg) ↔ (UHg) ↔ (HHg)

Table 2-8. Results of Epidemiological Studies Evaluating Exposure to Elemental Mercury (Hg^0) and Effects on Cardiovascular Outcomes

Reference, study type, and population	Biomarker	Outcome evaluated	Result[a]

Yilmaz et al. 2016
 	
Cross-sectional; 28 adults with exposure to Hg^0 (15 dentists, 10 workers with unspecified "industrial" exposure, and 3 individuals with chronic-duration exposure in office or home after fluorescent lightbulb break) and 28 control adults (Turkey)
	BHg mean
	  Exposed: 14.8 µg/L
	  Controls: 0.9 µg/L
	HHg mean
	  Exposed: 2.1 µg/g
	  Controls: 0.2 µg/g
	UHg mean
	  Exposed: 51.4 µg/L
	  Controls: 1.3 µg/L
		SBP
		DBP
		HRR
			↔ (exposed versus controls)
			↔ (exposed versus controls)
			↓ (exposed versus controls)

[a]Biomarkers are not considered in outcome analyses for studies that assess outcomes by comparisons between exposure groups.

↑ = positive association; ↓ = inverse association; ↔ = no association; BHg = blood mercury; BIHg = blood inorganic mercury; BMeHg = blood methylmercury; Cr = creatinine; DBP = diastolic blood pressure; HHg = hair mercury; HR = heart rate; HRR = heart rate recovery (post-exercise); LVF = left ventricular function; SBP = systolic blood pressure; UHg = urine mercury

Blood pressure. Results of studies evaluating associations between occupational exposure to elemental mercury and blood pressure are inconsistent, with no apparent relationship between level of exposure (as reflected by biomarkers) and outcomes (Table 2-8). At the highest mean UHg evaluated, no differences were observed for systolic or diastolic blood pressure in mercury-exposed subjects, including dentists, workers with "industrial" exposures, and individuals with chronic-duration exposure in office or home after fluorescent lightbulb break (UHg: 51.4 µg/L), compared to controls (UHg: 1.3 µg/L) (Yilmaz et al. 2016). Similarly, no associations were observed between elemental mercury exposure and systolic or diastolic blood pressure in miners with mean UHg of 37.6 µg/L (Rajaee et al. 2015). However, increased blood pressure was observed at substantially lower UHg in a study of male miners with mean UHg of 2.1 µg/L, compared with controls with mean UHg of 1.4 µg/L (Kobal et al. 2004). This study found increases in both systolic (miners: 134.4 mmHg; controls: 125.9 mmHg) and diastolic (miners: 87.9 mmHg; controls: 81.2 mmHg;) blood pressure. In adults with amalgam fillings (mean UHg: 3.70 µg/L), average systolic and diastolic blood pressure were increased by 5.73 and 4.37 mmHg, respectively, compared to adults with no amalgam fillings (mean UHg: 1.23 µg/L) (Siblerud 1990). At the lowest UHg evaluated (0.94 µg/L) in U.S. dental professionals, an inverse association was reported for systolic blood pressure (decrease in blood pressure with increasing UHg), with no association for diastolic blood pressure (Goodrich et al. 2013). However, using HHg as the biomarker, associations between mercury and blood pressure showed different effects; no association was observed between HHg

and systolic blood pressure and a positive association was observed for HHg and diastolic blood pressure (Goodrich et al. 2013). The difference between the associations observed with UHg and HHg may reflect a contribution of exposure to methylmercury, which may have contributed to HHg.

Cardiac function. Few studies have investigated effects of elemental mercury on cardiac function; however, studies have not evaluated the same endpoints and findings in single studies have not been corroborated (Table 2-8). For heart rate, no differences were observed in adults with amalgam fillings compared to adults with no amalgam fillings (Siblerud 1990). Heart rate recovery during the first 3 minutes post-exercise was decreased in mercury workers compared to controls (Yilmaz et al. 2016). An inverse association was observed between elemental mercury exposure and left ventricular diastolic function in chloralkali workers; the study authors noted that workers did not clinically present with cardiac dysfunction (Poreba et al. 2012).

Cardiovascular disease. No studies evaluating the relationships between cardiovascular diseases and exposure to elemental mercury that included biomarker data and assessed appropriate confounders were identified.

Elemental Mercury—Animal Studies. No adequate studies evaluating cardiovascular effects in animals following exposure to elemental mercury were identified.

Inorganic Mercury Salts—Animal Studies. Studies in laboratory animals have evaluated effects of inorganic mercuric mercury (e.g., mercuric chloride) on cardiovascular function following intermediate-duration oral exposure. Results indicate that exposure to mercuric chloride alters some cardiovascular functions, including systolic and diastolic blood pressure, ventricular pressure, baroreflex sensitivity, and cardiac inotropism.

Effects of mercuric chloride on blood pressure may exhibit duration-dependence following exposure via drinking water; however, there is no clear evidence for increased magnitude of effect with increasing dose (Table 2-9). In rats, blood pressure was generally unaffected at oral doses up to 5.91 mg Hg/kg/day for 28 days, with the exception of a spurious 15% increase in diastolic blood pressure at doses of 0.264 mg Hg/kg/day, up to 1.3 mg Hg/kg/day for 182 days (Jindal et al. 2011; Perry and Erlanger 1974; Wildemann et al. 2015a, 2015b, 2016), or 6 mg Hg/kg/day for 320 days (Carmignani and Boscolo 1984). However, systolic and diastolic blood pressures were increased in rats exposed to 24 mg Hg/kg/day for 180 days or 6 mg Hg/kg/day for 350 days, and systolic blood pressure was increased in rats exposed to 0.66 or 1.3 mg

Hg/kg/day for 365 days; systolic blood pressure was not altered at 3.3 mg Hg/kg/day for 365 days, but this may have been due to poor general health at this dose (Carmignani and Boscolo 1984; Carmignani et al. 1992; Perry and Erlanger 1974). Aortic blood pressure was also increased in rats exposed to ≥6 mg Hg/kg/day for 350 days (Boscolo et al. 1989; Carmignani et al. 1989). No alterations in pulse pressure and/or heart rate were observed in these studies.

Table 2-9. Effects on Blood Pressure in Rats Exposed to Mercuric Chloride via Drinking Water Exposure

Duration; dose (mg Hg/kg/day)	ABP	SBP	DBP	Reference
28 days; dose: 0.005–0.244	–	↔ (M)	↔ (M)	Jindal et al. 2011; Wildemann et al. 2015a, 2015b
28 days; dose: 0.264	–	↔	↑ (M) (15[a])	Wildemann et al. 2016
28 days; dose: 1.18–2.07	–	↔ (M)	↔ (M)	Wildemann et al. 2015a
28 days; dose: 2.955	–	↔ (M)	↔ (M)	Wildemann et al. 2016
28 days; dose: 5.91	–	↔ (M)	↔ (M)	Wildemann et al. 2015a
180 days; dose: 24	–	↑ (M) (15[b])	↑ (M) (28[b])	Carmignani et al. 1992
182 days; dose: 0.33–1.3	–	↔ (F)	–	Perry and Erlanger 1974
320 days; dose: 6	–	↔ (M)	↔ (M)	Carmignani and Boscolo 1984
350 days; dose: 6	↑ (M) (32[b])	–	–	Boscolo et al. 1989; Carmignani et al. 1989
350 days; dose: 6	↑ (M) (43[b])	–	–	Boscolo et al. 1989
350 days; dose: 6	–	↑ (M) (35[b])	↑ (M) (32[b])	Carmignani and Boscolo 1984
350 days; dose: 24	↑ (M) (45[b])	–	–	Boscolo et al. 1989
365 days; dose: 0.33	–	↔ (F)	–	Perry and Erlanger 1974
365 days; dose: 0.66	–	↑ (F) (15[b])	–	Perry and Erlanger 1974
365 days; dose: 1.3	–	↑ (F) (13[b])	–	Perry and Erlanger 1974

Table 2-9. Effects on Blood Pressure in Rats Exposed to Mercuric Chloride via Drinking Water Exposure

Duration; dose (mg Hg/kg/day)	ABP	SBP	DBP	Reference
365 days; dose: 3.3	–	↔[c] (F)	–	Perry and Erlanger 1974

[a]Percent change compared to control, estimated from graphically presented data.
[b]Percent change compared to control, calculated from quantitative data.
[c]Lack of exposure-related effect may have been due to poor general health at this dose.

↑ = increased; ↔ = no change; – = not assessed; ABP = aortic blood pressure; DBP = diastolic blood pressure; F = female; M = male; SBP = systolic blood pressure

In dietary studies, no alterations in systolic blood pressure were observed in normotensive Wistar rats exposed to doses up to 2.2 mg Hg/kg/day as mercuric chloride for 21 weeks (Takahashi et al. 2000a). In similarly exposed spontaneously hypertensive Wistar rats, systolic blood pressure was significantly increased by 6–9% following exposure to ≥0.07 mg Hg/kg/day for 4 or 5 weeks; however, no significant effects were noted following exposure to doses up to 2.2 mg Hg/kg/day for 12 weeks (Takahashi et al. 2000b). Findings in spontaneously hypertensive rats are difficult to interpret due to the transient nature of observed effects in a rat strain prone to hypertension.

Alterations in cardiac function in rats exposed to mercuric chloride include increased left ventricular end diastolic pressure (LvEDP), positive inotropic effects, and/or altered baroreceptor reflex sensitivity at daily doses of 0.012–24 mg Hg/kg/day for exposure durations of 1 month to 350 days. LvEDP was significantly increased by 3-fold and the maximum differential of LvEDP to the left ventricular end systolic pressure (LvESP) was decreased by 56–62% in rats administered 0.12 mg Hg/kg/day by gavage for 1 month (Jindal et al. 2011). Sprague-Dawley and Wistar rats showed a significant 25–32% increase in the maximum rate of rise in the left ventricular pressure after exposure to 6 mg Hg/kg/day for 350 days, indicating increased contractility (positive inotropic response); however, these effects were not observed in Wistar rats similarly exposed to 24 mg Hg/kg/day for 180 or 350 days (Boscolo et al. 1989; Carmignani et al. 1989, 1992). It is unknown if the lack of effects in Wistar rats indicates a difference in strain susceptibility or a non-monotonic dose-response. Increased cardiac inotropic responses to cardiac drugs (e.g., isoprenaline) were also observed after exposure for 350 days to 6 mg Hg/kg/day in Sprague-Dawley rats (47–90% increase) and 24 mg Hg/kg/day in Wistar rats (87% increase); findings were not significant at 6 mg Hg/kg/day in Wistar rats (Boscolo et al. 1989; Carmignani et al. 1989). Decreased baroreceptor reflex sensitivity was also observed in Wistar and Sprague-Dawley rats after drinking water exposure to mercuric chloride, with ≥27% decrease in the change in aortic blood pressure at ≥6 mg

Hg/kg/day following exposure to various vasoactive drugs (e.g., norepinephrine, phenylephrine) (Boscolo et al. 1989; Carmignani and Boscolo 1984; Carmignani et al. 1989). No exposure-related changes in electrocardiogram parameters, stroke volume, cardiac output, left ventricular wall thickness, or carotid artery diameter or thickness were observed in rats following drinking water exposure to mercuric chloride at doses up to 5.91 mg Hg/kg/day for 4 weeks (Wildemann et al. 2015a, 2015b).

Oral exposure to inorganic mercury salts has not been associated with histopathological lesions in the rodent heart. In an acute-duration study, no treatment-related histopathological changes were observed in the hearts of rats exposed once to mercuric chloride at gavage doses up to 9.24 mg Hg/kg/day (Lecavalier et al. 1994). In intermediate-duration studies, no treatment-related histopathological changes were observed in the hearts of rats or mice exposed to mercuric chloride at gavage doses up to 4 or 15 mg Hg/kg/day, respectively (Dieter et al. 1992; NTP 1993). No treatment-related histopathological changes were observed in the hearts of mice exposed to mercuric chloride at gavage doses up to 7.4 mg Hg/kg/day for up to 2 years (NTP 1993). One chronic-duration study in rats reported heart mineralization in males following exposure to mercuric chloride at gavage doses ≥1.8 mg Hg/kg/day for up to 2 years; however, this lesion was considered secondary to severely impaired renal function (Dieter et al. 1992; NTP 1993). Similarly exposed female rats, which did not show renal impairment, did not have heart mineralization at gavage doses up to 4 mg Hg/kg/day.

No exposure-related changes in heart histology were observed following oral exposure to methylmercuric chloride in cats at doses up to 0.176 mg Hg/kg/day for approximately 16 weeks, 0.074 mg Hg/kg/day for approximately 55 weeks, or 0.046 mg Hg/kg/day for 2 years (Charbonneau et al. 1976).

Organic Mercury—Epidemiological Studies. Studies evaluating effects of methylmercury exposure on cardiovascular function (blood pressure, heart rate, and heart rate variability) in populations with high fish diets are summarized in Table 2-10. Studies of high fish consumers are categorized as two types based on the timing of biomarker measurement: (1) cross-sectional studies of adults assessing outcomes based on current exposure measurements (biomarkers measured at the time outcome measures were assessed) and (2) prospective birth cohort studies assessing outcomes in children or adolescents based on prenatal exposure measurements. Cross-sectional studies based on current biomarker measurements include small populations (n=42–732) of adults and adolescents, except for one larger population of 1,861 (Nielsen et al. 2012). The most common biomarker used to assess mercury exposure was BHg, although HHg and toenail mercury (NHg) have also been used in some studies (Basta et al. 2021; Choi et al. 2009; Fillion et al. 2006). Prospective birth studies include cohorts of children from the Faroe Islands and Seychelle

Islands; population sizes ranged from 95 to 897. The main biomarkers to assess prenatal exposure were

cord BHg and maternal HHg at parturition.

Table 2-10. Epidemiological Studies Evaluating Associations between Mercury and Blood Pressure and Cardiac Function in Populations with High Fish Diets

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Studies based on current mercury measurements			
Basta et al. 2021 Cross-sectional; 200 participants ≥12 years of age (Brazilian Amazon community)	HHg range: 1.4–23.8 µg/g	Hypertension	↑ (HHg)
Choi et al. 2009 Cross-sectional; 42 whaling men (Faroe Islands)	BHg Gmean: 29.5 µg/L HHg Gmean: 7.31 µg/g NHg Gmean: 2.04 µg/g	SBP	↑ (BHg) ↔ (HHg, NHg)
		DBP	↑ (BHg, NHg) ↔ (HHg)
		HR	↔ (BHg, HHg, NHg)
		HRV	↔ (BHg, HHg, NHg)[a]
Fillion et al. 2006 Cross-sectional; 251 adults (Brazilian Amazon community)	HHg: ≥10–77.2 µg/g	SBP	↑ (HHg)
		DBP	↔ (HHg)
Hu et al. 2017 Cross-sectional study; 2,169 Inuit adults (Canada)	BHg Gmean: 7.0 µg/L 1st–99th percentile: 0.3–70 µg/L Low BHg: <20 µg/L High BHg: ≥20 µg/L Low BSe: <280 µg/L High BSe: ≥20 µg/L	Hypertension	↔ (low BHg + low BSe) ↔ (low BHg + high BSe) ↑ (high BHg + low BSe) ↑ (high BHg + high BSe)
Inoue et al. 2012 Cross sectional study; approximately 40,000 residents of Minamata, with approximately 1,000 with Minamata disease	Median HHg: 30 µg/g[b]	Hypertension	↔ (HHg) in 1953–1957 ↔ (HHg) in 1958–1962 ↑ (HHg) in 1963–1967 ↔ (HHg) in 1998–1970
Miller et al. 2018 Cross-sectional; 94 adults, avid seafood consumers (Long Island, New York)	BHg mean: 8.4 µg/L	HRV	↔ (BHg)
		QTc	↔ (BHg)

Table 2-10. Epidemiological Studies Evaluating Associations between Mercury and Blood Pressure and Cardiac Function in Populations with High Fish Diets

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Nielsen et al. 2012 Cross-sectional; Inuit adults; 812 men and 1,049 women (Greenland)	BHg quintile ranges Men Qi4: 27–49 µg/L Men Qi5: 50–280 µg/L Women Qi5: 36–170 µg/L	SBP	↔ (Men, BHg Qi5) ↔ (Women BHg Qi5)
		DBP	↓ (Men, BHg Qi4) ↔ (Women, BHg Qi5)
		PP	↔ (Men, BHg Qi5) ↔ (Women, BHg Qi5)
		Hypertension	↔ (Men, BHg Qi5) ↔ (Women, BHg Qi5)
Valera et al. 2008 Cross-sectional; 205 Nunavik Inuit adults (Quebec)	BHg mean: 27 µg/L	SBP	↑ (BHg)
		DBP	↔ (BHg)
		PP	↑ (BHg)
		HRV	↓ (BHg)
Valera et al. 2009 Cross-sectional; 732 Nunavik Inuit adults (Quebec)	BHg mean: 10 µg/L	SBP	↑ (BHg)
		DBP	↔ (BHg)
		PP	↑ (BHg)
Valera et al. 2011a Cross-sectional; 180 adults (French Polynesia)	BHg mean: 14.5 µg/L	SBP	↔ (BHg)
		DBP	↔ (BHg)
		PP	↔ (BHg)
		HR	↔ (BHg)
		HRV	↔ (BHg)
Valera et al. 2011a Cross-sectional; 101 adolescents (French Polynesia)	BHg mean: 8.1 µg/L	SBP	↔ (BHg)
		DBP	↔ (BHg)
		PP	↔ (BHg)
		HRV	↓ (BHg)
Valera et al. 2011b [adjustments included Pb, PCBs, and 3-n polyunsaturated fatty acids] Cross-sectional; 724 Cree Inuit adults (Quebec)	BHg mean: 3.1 µg/L HHg mean: 0.47 µg/g	SBP	↔ (BHg, HHg)
		DBP	↔ (BHg, HHg)
		PP	↔ (BHg, HHg)
		HRV	↓ (BHg, HHg)
Valera et al. 2013 Cross-sectional; 313 Inuit adults (Quebec) [adjustments included Pb, PCBs, and 3-n polyunsaturated fatty acids]	BHg mean: 15.4 µg/L BHg Q4: 28.4–112 µg/L	SBP	↔ (BHg)
		DBP	↔ (BHg)
		PP	↔ (BHg)
		HR	↑ (BHg, Q4)
Yorifuji et al. 2010 Cross-sectional; 120 adults (Minamata, Japan)	HHg Q4: >28.3 µg/g Hair samples were analyzed in 1960[c]	Hypertension	↔ (HHg, Q4)

Table 2-10. Epidemiological Studies Evaluating Associations between Mercury and Blood Pressure and Cardiac Function in Populations with High Fish Diets

Reference, study type, and population	Biomarker	Outcome evaluated	Result

Zuk et al. 2021
 	
Cross-sectional; 759 adult indigenous Canadians (312 males and 447 females)
	BHg Gmean
	  Males: 4.29 µg/L
	  Females: 3.17 µg/L
		SBP	↔ (BHg)

		Hypertension	↑ (BHg)
Studies based on prenatal exposure measurements			
Grandjean et al. 2004a (follow-up to Sørensen et al. 1999) Prospective birth cohort; 878 adolescents; blood pressure assessed at age 14 years (Faroe Islands)	BHg median (cord): 24.27 µg/L HHg median: Maternal at parturition[b]: 5.65 µg/g Child, age 14[c]: 0.96 µg/g	SBP	↔ (BHg, HHg)
		DBP	↔ (BHg, HHg)
		HR	↔ (BHg, HHg)
		HRV	↓ (BHg) ↔ (HHg)

Periard et al. 2015
 	
Prospective birth cohort; 95 adults (age 19 years, 47 males, 48 females) (Seychelles Islands)
	HHg mean
	  Maternal during pregnancy: 6.7 µg/g
	  Males, age 19: 11.2 µg/g
	  Females, age 19: 7.9 µg/g
		HRV	↔ (HHg)

Sørensen et al. 1999 Prospective birth cohort; 894–897 children; blood pressure assessed at age 7 years (Faroe Islands)	BHg mean (cord): 31.8 µg/L HHg mean (maternal at parturition): 5.65 µg/g[b]	SBP	↑ (BHg, HHg)
		DBP	↑ (BHg) ↔ (HHg)

Thurston et al. 2007
 	
Prospective birth cohort; 644–559 children; blood pressure assessed at ages 12 and 15 years (Seychelles Islands)
	HHg mean (maternal) for:
	  Boys age 12: 6.6 µg/g
	  Boys age 15: 6.5 µg/g
	  Girls age 12: 7.0 µg/g
	  Girls age 15: 7.0 µg/g
		SBP	↔ (HHg)

		DPB	↔ (HHg, age 12 years) ↑ (HHg, boys, age 15 years) ↔ (HHg, girls, age 15 years)
Valera et al. 2012 Prospective birth cohort; 226 Nunavik Inuit children (Quebec) assessed at age 11 years (adjustments included Pb and PCBs)	BHg mean (cord): 21.5 µg/L BHg mean (age 11 years): 4.5 µg/L HHg mean (age 11 years): 1.3 µg/g	SBP	↔ (BHg, HHg)
		DBP	↔ (BHg, HHg)
		HRV	↔ (BHg, cord) ↓ (BHg, age 11 years) ↔ (HHg, age 11 years)

[a]The study authors considered results for HRV to be equivocal, possibly due to the small study population size.
[b]Reported by Grandjean et al. (1992).
[c]Biomarkers were not measured in this population; for reference, the median HHg in a healthy Minamata fishermen measured in 1960 was 30 µg/g, compared to a median HHg of 2.1 µg/g in the control population in 1960.

↑ = positive association; ↓ = inverse association; ↔ = no association; BHg = blood mercury; BSe = blood selenium; DBP = diastolic blood pressure; Gmean = geometric mean; HHg = hair mercury; HR = heart rate; HRV = heart rate variability; NHg = toenail mercury; Pb = lead; PCB = polychlorinated biphenyl; PP = pulse pressure; Q = quartile; Qi = quintile; QTc = QT interval duration; SBP = systolic blood pressure

Blood pressure. Results of cross-sectional studies in adult populations using current biomarker measurements provide conflicting evidence regarding associations between methylmercury exposure from fish consumption and blood pressure. For studies reporting positive associations, the mean or median BHg range was 10–29.5 µg/L, whereas the range for studies reporting no associations was 3.1–15.4 µg/L. However, results are not consistent and data do not provide clear evidence of a dose-response relationship between methylmercury exposure from fish and increased blood pressure. Furthermore, observed changes in blood pressure were small. The lowest mean BHg (10 µg/L) associated with increased blood pressure was reported in a study of Nunavik Inuit adults in Quebec, with positive associations between BHg and systolic blood pressure (Valera et al. 2009). Based on log transformed (base not reported) BHg, a 1% increase in BHg was associated with a 0.02 mmHg increase in systolic blood pressure. No association was observed for diastolic blood pressure. Similar results were observed in a smaller population of Nunavik Inuit adults (Valera et al. 2008).

For the highest mean BHg of 29.5 µg/L in a population of 42 whaling men from the Faroe Islands, BHg was positively associated with systolic and diastolic blood pressure (Choi et al. 2009). The magnitude of the association was reported in standardized beta coefficients (percent of standard deviation [SD] of outcome variable per 1 SD change in $\log_{10}$ BHg). The reported effect on systolic blood pressure was a 37.5% increase per 1 SD increase in $\log_{10}$ BHg. This would correspond to an increase of approximately 7 mmHg (0.375x18) in blood pressure per 1 SD increase in $\log_{10}$ BHg (approximately 90 µg/L). The reported effect on diastolic blood pressure was a 33.2% increase per 1 SD increase in $\log_{10}$ BHg. This would have corresponded to an increase in diastolic blood pressure of approximately 2.6 mmHg (0.332x8) per 1 SD increase in $\log_{10}$ BHg (approximately 90 µg/L increase in BHg; see legend of Table 2-10 for the basis for this estimate). No association between BHg and systolic or diastolic blood pressure was observed at mean BHg of 3.1–15.4 µg/L (Valera et al. 2011a, 2011b, 2013). Two of these studies adjusted for co-exposure to other chemicals that may also affect blood pressure (lead and PCBs) (Valera et al. 2011b, 2013). Using BHg data stratified by quintiles in a study of Inuit men and women, no association was observed for systolic blood pressure for the highest quintile in men and women; an inverse association was observed for diastolic blood pressure in men in the 4th and 5th quintiles, although no association was observed in women (Nielsen et al. 2012).

Prospective, prenatal exposure studies show inconsistent results regarding associations between methylmercury exposure from fish consumption and blood pressure in children and adolescents. Studies of the Faroe Island population evaluated blood pressure in children at 7 and 14 years of age (Grandjean et

al. 2004a; Sørensen et al. 1999). The study in 7-year-olds found a positive association between cord BHg and maternal HHg for systolic blood pressure and between cord BHg and diastolic blood pressure, with increases in systolic blood pressure of 13.9 mmHg and diastolic blood pressure of 14.6 mmHg for an increase in cord BHg from 1 to 10 μg/L (Sørensen et al. 1999). However, in the follow-up study assessing blood pressure at age 14 years, no association was observed between BHg, maternal HHg (at parturition), or child HHg (Grandjean et al. 2004a). In a population of children in the Seychelles Islands, no association was observed between prenatal exposure and systolic or diastolic blood pressure in girls at ages 12 and 15 years, or in boys at 12 years (Thurston et al. 2007). However, a positive association was observed between maternal HHg and diastolic blood pressure in boys at age 15; the study authors stated that biological significance of this finding is uncertain. No association between cord BHg and blood pressure was observed in a study of Nunavik Inuit children evaluated at age 11 years (Valera et al. 2012). This study also adjusted for exposure to lead and PCBs.

Hypertension. Associations between methylmercury exposure from fish consumption and clinical hypertension are inconsistent (Table 2-10). In a cross-sectional study of an Arctic Inuit population, the prevalence of hypertension was increased at BHg ≥20 μg/L, but not <20 μg/L (Hu et al. 2017); the increase appeared to be attenuated at higher blood selenium levels (≥280 μg/L) compared to lower blood selenium levels (<280 μg/L). Some evidence that severe exposure to methylmercury is associated with hypertension mortality was reported in a large study of the Minamata population (Inoue et al. 2012). In a population of approximately 46,000 residents of Minamata, including approximately 1,000 Minamata disease patients, the age-standardized mortality ratio (AMSR) for hypertension (ASMR 1.38; 95% CI 1.06, 1.64) was increased compared to a control group during the period of 1963–1967; however, AMSRs were not elevated for the periods 1953–1957, 1959–1962, or 1969–1970. A small study of Minamata residents with HHg measured in 1960 did not find an association between HHg and prevalence of hypertension as assessed in 1971 (Yorifuji et al. 2010). A positive association was observed between BHg and hypertension in a population of indigenous Canadians at mean BHg levels of 4.29 and 3.17 μg/L in males and females, respectively (Zuk et al. 2021). In contrast, a cross-sectional study of an Inuit population did not show associations between exposure and hypertension at higher BHg levels in males and females (Nielsen et al. 2012). In this study, associations were observed for the 4th and 5th quintiles in males (quintile 4: 27–49 μg/L; quintile 5: 50–280 μg/L) and the 5th quintile in females (36–170 μg/L).

Cardiac function. Associations between methylmercury exposure from fish consumption and cardiac function have been evaluated in cross-sectional and prospective birth cohort studies. Outcome variables include heart rate and heart rate variability. Cross-sectional studies reported conflicting results on heart

rate. A positive association between BHg and resting heart rate was reported in a population of Inuit adults from Quebec, with resting heart rate increased by 6.9 beats per minute in the highest BHg quartile relative to lower BHg quartiles (Valera et al. 2013); potential confounders considered in this study included co-exposure to other contaminants (lead and PCBs) and n-3 polyunsaturated fatty acids levels. No associations between methylmercury exposure and heart rate were observed for mean BHg in French Polynesian adults and Faroe Island whalers, respectively (Choi et al. 2009; Valera et al. 2011a). In addition, a prospective birth cohort study of the Faroe Island population did not find an association between cord BHg or maternal HHg and heart rate assessed at age 14 years (Grandjean et al. 2004a).

Several studies have evaluated the effects of methylmercury exposure and heart rate variability. Heart rate variability, which is mediated through the autonomic nervous system, reflects a balance between sympathetic and parasympathetic control (Gribble et al. 2015; Karita et al. 2018). Decreased heart rate variability may lead to cardiac arrhythmias and increased risk of ventricular fibrillation and sudden cardiac death (Karita et al. 2018; Valera et al. 2011a, 2012). Taken together, results of cross-sectional and prospective birth cohort studies do not provide compelling evidence that methylmercury exposure is associated with heart rate variability. Results of cross-sectional studies report conflicting results, with some studies showing inverse associations between exposure biomarkers and heart rate variability (Valera et al. 2008, 2011a, 2011b) and other studies reporting no associations (Choi et al. 2009; Miller et al. 2017, 2018; Valera et al. 2011a). The range of mean BHg for studies showing decreased heart rate variability (3.1–27 µg/L) is similar to the range for studies showing no change (8.4–29.5 µg/L); thus, results indicate that there is no apparent relationship between exposure level and outcome. In Faroe Island whalers with the highest reported mean BHg of 29.5 µg/L, study authors considered results on heart rate variability to be unclear; however, study power is limited by the small population size (n=42) (Choi et al. 2009). One study of Faroe Island adolescents and adults showed no association between BHg (mean 14.5 µg/L) and heart rate variability in adults, but an inverse association in adolescents at lower BHg (mean: 8.1 µg/L) (Valera et al. 2011a). Retrospective birth cohort studies also report inconsistent results on effects of methylmercury exposure and heart rate variability. Heart rate variability was inversely associated with current BHg, but not cord BHg or current HHg in 11-year-old Nunavik children (Valera et al. 2012). In a Faroe Island birth cohort with outcomes assessed at age 14 years, an inverse association was observed between cord BHg and heart rate variability, but not for maternal HHg at parturition or age 14 years child HHg (Grandjean et al. 2004a). Similarly, follow-up of the Seychelles Islands prospective cohort at age 19 years showed no association between maternal HHg during pregnancy or current HHg in males or females; cord BHg was not reported (Periard et al. 2015).

Cardiovascular disease. Few studies reporting biomarker data and confounding factors have evaluated associations between methylmercury exposure in populations with high fish diets and cardiovascular disease morbidity and mortality. However, results do not provide evidence that exposure to methylmercury is associated with cardiovascular disease. Studies of various Inuit populations have not found associations for myocardial infarction (Hu et al. 2017), stroke (Hu et al. 2017), or non-specific cardiovascular disease (Larsen et al. 2018).

Organic Mercury—Animal Studies. Alterations in cardiovascular function have been reported in rats following acute- and intermediate-duration oral exposure to methylmercuric chloride, with blood pressure as the most studied cardiovascular endpoint. Generally, results show that exposure to methylmercuric chloride increases systolic and diastolic blood pressure in a dose- and duration-dependent manner; pulse pressure is also increased in some studies, but with no apparent dose-related effect (Table 2-11). A 15-day drinking water exposure study in mice reported increased systolic (by ~18%) and diastolic (by ~22%) blood pressure and artherosclerotic lesions at 2.7 mg Hg/kg/day (Silva et al. 2021). In rats, systolic blood pressure was increased by 10–30% after exposure to doses of 0.005–1.6 mg Hg/kg/day for 26–28 days, and 40% after exposure to 0.08 mg Hg/kg/day for 100 days (Grotto et al. 2009a; Tamashiro et al. 1986; Wakita 1987; Wildemann et al. 2015a, 2015b, 2016). Diastolic blood pressure was slightly less sensitive, with significant increases of 22–31% with exposures to doses ≥0.009–0.879 mg Hg/kg/day for 28 days (not tested at other durations) (Wildemann et al. 2015a, 2015b, 2016). Pulse pressure increases of 10–20% were observed in a non-dose-related fashion in rats exposed to 0.005–0.216 mg Hg/kg/day, but not 0.879 mg Hg/kg/day (Wildemann et al. 2015a, 2015b). One study, however, did not observe changes in systolic or diastolic blood pressure or pulse pressure in rats exposed to 0.5 mg Hg/kg/day for 28 days (Jindal et al. 2011). No alterations in heart rate were observed in any of these studies.

Table 2-11. Effects on Blood Pressure in Laboratory Animals Exposed to Methylmercuric Chloride via Oral Exposure

Strain (sex)	Duration (days)	Route	Dose (mg Hg/kg/day)	SBP	DBP	PP	Reference
Rats							
SHR/NCrj[a] (F)	26	Oral NS	1.6	↑ (10%[b,c])	–	–	Tamashiro et al. 1986
Wistar (M)	28	DW	0.002	↔	↔	↔	Wildemann et al. 2015a
Wistar (M)	28	DW	0.005	↑ (14%[b])	↔	↑ (17%[b])	Wildemann et al. 2015a

Table 2-11. Effects on Blood Pressure in Laboratory Animals Exposed to Methylmercuric Chloride via Oral Exposure

Strain (sex)	Duration (days)	Route	Dose (mg Hg/kg/day)	SBP	DBP	PP	Reference
Wistar (M)	28	DW	0.006	↑ (17%[b])	↔	–	Wildemann et al. 2016
Wistar (M)	28	DW	0.009	↑ (20%[b])	↑ (22%[b])	↑ (20%[b])	Wildemann et al. 2015a
Wistar (M)	28	DW	0.018	↑ (19%[b])	↑ (21%[b])	↑ (18%[b])	Wildemann et al. 2015a
Wistar (M)	28	DW	0.018	↔	↔	↔	Wildemann et al. 2015b
Wistar (M)	28	DW	0.036	↔	↔	↑ (16%[b])	Wildemann et al. 2015a
Wistar (M)	28	G	0.08	↑ (10%[b])	–	–	Grotto et al. 2009a
Wistar (M)	28	DW	0.216	↑ (21%[b])	↑ (24%[a])	↑ (17%[a])	Wildemann et al. 2015a
Wistar (M)	28	DW	0.216	↑ (10%[b])	↔	↑ (10%[a])	Wildemann et al. 2015b
Wistar (M)	28	DW	0.285	↑ (30%[b])	↑ (30%[b])	–	Wildemann et al. 2016
Wistar (M)	28	G	0.4	↑ (20%[b,d])	–	–	Wakita 1987
Wistar (B)	28	G	0.5	↔	↔	↔	Jindal et al. 2011
Wistar (M)	28	DW	0.879	↑ (23%[b])	↑ (31%[b])	0	Wildemann et al. 2015a
Wistar (M)	100	G	0.08	↑ (40%[b])	–	–	Grotto et al. 2009a
Mice							
C57BL/6 (F)	15	DW	2.7	↑ (18%[b])	↑ (22%[b])	–	Silva et al. 2021

[a]Spontaneously hypertensive rat strain; blood pressure could not be adequately assessed in similarly exposed males due to 100% mortality.
[b]Percent change compared to control, estimated from graphically presented data.
[c]Blood pressure elevated after 21 days of exposure and 9 days post-exposure.
[d]Blood pressure elevations observed 42 days to ~1 year post-exposure.

↑ = increased; ↔ = no change; – = not assessed; B = both males and females; DBP = diastolic blood pressure; DW = drinking water; F = female(s); G = gavage; M = male(s); NS = not specified; PP = pulse pressure; SBP = systolic blood pressure

The effects of methylmercuric chloride on other cardiovascular functions have not been well-studied. LvEDP was significantly increased 3.7-fold with the maximum differential of LvEDP to LvESP decreased by 46–53% in rats administered gavage doses of 0.5 mg Hg/kg/day for 1 month (Jindal et al. 2011). Additionally, these rats showed a 46–53% attenuation of baroreceptor reflex sensitivity at 0.5 mg Hg/kg/day. Heart rate was decreased by 10–18% for up to 16 days in male rats following exposure to two

gavage doses of 12 mg Hg/kg (Arito and Takahashi 1991). Exposure to gavage doses of 0.5 mg Hg/kg/day for 1 month did not alter heart rate in male rats (Jindal et al. 2011), and no exposure-related changes in heart rate, stroke volume, cardiac output, electrocardiogram parameters, left ventricular wall thickness, or carotid artery diameter or thickness were observed.

Oral exposure to methylmercuric chloride has not been associated with histopathological lesions in the rodent heart. No treatment-related histopathological changes were observed in the hearts of rats or mice exposed chronically to dietary doses up to 0.1 or 0.724 mg Hg/kg/day, respectively (Hirano et al. 1986; Mitsumori et al. 1990; Verschuuren et al. 1976).

Predominant Mercury Form Unknown (General Populations). Numerous studies have evaluated the relationship between mercury exposure and cardiovascular effects in general populations. Outcomes evaluated were blood pressure parameters, clinical hypertension, and cardiovascular disease. Study designs include meta- and pooled analyses, prospective studies, and cross-sectional studies. Many studies evaluated large populations (n=2,114–>33,000). The most common biomarkers were BHg and HHg, with some studies measuring mercury in urine, toenails, serum, or erythrocytes. Mean BHg in these studies was <6 µg/L, which is lower than most studies evaluating exposures to methylmercury in populations with high fish diets (Table 2-10).

Blood pressure. Associations between mercury biomarkers and changes in blood pressure have been well-studied; however, evidence for effects of mercury exposure on blood pressure in general populations is inconclusive. A few studies showed associations between biomarkers and small increases in systolic and/or diastolic blood pressure, although most studies did not show associations (Table 2-12). The largest study, a pooled analysis of 33,298 adults from 23 studies of various population types (general populations, populations with high fish diets, and workers), showed positive associations between HHg and systolic and diastolic blood pressure (Hu et al. 2018). Pooled weighted mean differences (PWMD) in systolic or diastolic blood pressure were calculated as the inverse-variance weighted mean of individual differences between the mean pressure in the lowest and highest mercury category in each study. PWMDs were calculated separately for groups of studies in which the mean HHg was <2 or ≥2 µg/g. For studies with HHg ≥2 µg/g, the PWMD for systolic blood pressure was an increase of 2.20 (95% CI 0.90, 3.49) mm Hg. A dose-response model suggested that systolic blood pressure increased with HHg concentrations above 2–3 µg/g. For diastolic blood pressure, the PWMD was increased by 0.96 mmHg (95% CI 0.08, 1.85) for combined study categories (HHg: 2 and ≥2 µg/g). Similar small increases in blood pressure were observed in a prospective longitudinal study in women (Wang et al. 2021b), a large

cross-sectional study of Korean adults (Park and Choi 2016), and in a small cross-sectional study of
pregnant women showing a positive association between blood methylmercury levels, but not blood
inorganic mercury levels, and systolic blood pressure (Wells et al. 2017). A cross-sectional study in
adults using NHANES data found positive associations between BHg and blood methylmercury and
diastolic blood pressure, but not systolic blood pressure (Tang et al. 2022a). In a small cross-sectional
study of adolescents with hypertension, UHg was associated with increased risk of higher diastolic and
systolic blood pressures (Yalçin et al. 2022). However, other studies did not find associations or found
inverse associations between mercury biomarkers and blood pressure outcomes, including large
prospective birth cohort studies in children (Desai et al. 2021; Gregory et al. 2016; Kalish et al. 2014; Yao
et al. 2020), a cross-sectional study in male adolescents (Castiello et al. 2020), and cross-sectional studies
in adults (Mordukhovich et al. 2012; Park et al. 2013; Vupputuri et al. 2005). Most prospective birth
cohorts do not show associations between gestational mercury exposure and blood pressure (Farzan et al.
2021; Gregory et al. 2016; Kalish et al. 2014). However, two studies found positive associations between
maternal erythrocyte mercury and BHg and systolic blood pressure (Ma et al. 2023; Zhang et al. 2021b).

Table 2-12. Overview of Epidemiological Studies Evaluating Associations between Mercury (Predominant Mercury Form Unknown) and Blood Pressure in General Populations

Reference, study type, and population	Biomarker	Blood pressure outcome (biomarker)			
		SBP	DBP	PP	Hypertension
Studies based on current mercury measurements					
Al-Saleh et al. 2006 Case-control; 185 women (Saudi Arabia)	BHg mean Hypertensive: 3.5 µg/L Control: 3.7 µg/L	–	–	–	↔ (BHg)
Bautista et al. 2009 Cross-sectional; 101 adults (Wisconsin)	BHg Gmean: 1.16 µg/L HHg Gmean: 0.27 µg/g	–	–	–	↔ (BHg) ↑ (HHg)
Castiello et al. 2020 Cross-sectional; 133 male adolescents (ages 15–17 years) (Spain)	UHg Gmean: 0.03 µg/g creatinine	↔ (UHg)	↔ (UHg)	↔ (UHg)	–
Choi et al. 2015 Cross-sectional; 6,213 adults (KNHANES 2008–2010)	SHg mean Men: 5.7 µg/L Women: 4.0 µg/L	–	–	–	↑ (SHg, M, F)

Table 2-12. Overview of Epidemiological Studies Evaluating Associations between Mercury (Predominant Mercury Form Unknown) and Blood Pressure in General Populations

Reference, study type, and population	Biomarker	Blood pressure outcome (biomarker)			
		SBP	DBP	PP	Hypertension
Desai et al. 2021 Cross-sectional survey; 1,642 children, ages 8–17 years (NHANES 2009–2016)	BHg median: 0.37 µg/L	↔ (BHg)	↔ (BHg)	↔ (BHg)	–
Eom et al. 2014 Cross-sectional; 2,114 adults (South Korea)	BHg Gmean: 3.90 µg/L	–	–	–	↔ (BHg)
Hu et al. 2018 Pooled analysis; 9 studies, 21,757 adults[a]	HHg stratified <2 µg/g ≥2 µg/g	–	–	–	↔ (HHg)
Hu et al. 2018 Pooled analysis; 23 studies, 33,298 adults[b]	HHg stratified <2 µg/g ≥2 µg/g	↑ (HHg)	↑ (HHg)	–	–
Joo et al. 2022 Cross-sectional; 1,360 adolescents ages 12–17 years (KNHANES)	BHg median: 1.805 µg/L	–	–	–	↔ (BHg)
Kim et al. 2014 Cross-sectional; 3,800 adults (KNHANES 2008–2009)	BHg, mean: 5.44 µg/L	–	–	–	↔ (BHg)
Mordukhovich et al. 2012 Cross-sectional; 639 men; samples and assessments conducted 1999–2009 (NAS)	NHg median: 0.22 µg/g	↔ (NHg)	↔ (NHg)	↔ (NHg)	–

Mozaffarian et al. 2012
 	
Prospective cohort; 1,624 male adults (HPFS cohort) and 4,421 female adults (NHS cohort) (United States)
	NHg median
	  Males: 0.30 µg/g
	  Females: 0.21 µg/g
		–	–	–	↔ (NHg, M, F)

Table 2-12. Overview of Epidemiological Studies Evaluating Associations between Mercury (Predominant Mercury Form Unknown) and Blood Pressure in General Populations

Reference, study type, and population	Biomarker	Blood pressure outcome (biomarker)			
		SBP	DBP	PP	Hypertension
Park and Choi 2016 Cross-sectional; 8,371 adults (KNHANES 2008–2012)	BHg Gmean Males: 4.70 µg/L Females: 3.26 µg/L	↑ (BHg, M, F)	↑ (BHg, M, F)	–	–
Park et al. 2013 Cross-sectional; 6,607 adults (NHANES 2003–2006)	BHg Gmean: 1.03 µg/L BHg Q4: 1.84–32.8 UHg Gmean: 0.51 µg/L UHg Q4: 1.03–50.2	↓ (BHg) ↓ (UHg)	↔ (BHg) ↔ (UHg)	–	↔ (BHg, Q4) ↔ (UHg, Q4)
Sanders et al. 2019 Cross-sectional; 2,709 adolescents (ages 12–19 years of age) (NHANES)	BHg mean: 0.41 µg/L	↔ (BHg)	–	–	–
Tang et al. 2022a Cross-sectional; 1,422 adult non-Hispanic Asians (with BHg levels) and 633 adult non-Hispanic Asians (with UHg levels) (NHANES 2011–2018	BHg Gmean: 1.95 µg/L BMeHg Gmean: 1.64 µg/L UHg Gmean: 0.433 µg/g creatinine	↔ (BHg) ↔ (BMeHg) ↔ (UHg)	↑ (BHg) ↑ (BMeHg) ↔ (UHg)	–	↑ (BHg) ↑ (BMeHg) ↔ (UHg)
Virtanen et al. 2012b Cross-sectional; 1,757 adults (Finland)	HHg mean: 1.42 µg/g	↔ (HHg)	↔ (HHg)	↔ (HHg)	–
Vupputuri et al. 2005 Cross-sectional; 1,240 women (NHANES 1999–2000)[d]	BHg median: 0.9 µg/L	↔ (BHg)	↔ (BHg)	–	–

Table 2-12. Overview of Epidemiological Studies Evaluating Associations between Mercury (Predominant Mercury Form Unknown) and Blood Pressure in General Populations

Reference, study type, and population	Biomarker	Blood pressure outcome (biomarker)			
		SBP	DBP	PP	Hypertension
Wang et al. 2021b Prospective longitudinal; 1,317 women (aged 45–56 years at enrollment), followed for 19–21 years (United States)	UHg median: 1.2 µg/L	↑ (UHg)	↑ (UHg)	–	–
Wells et al. 2017 Cross-sectional; 263 pregnant women (Baltimore, Maryland)	BMeHg Gmean: 0.95 µg/L BIHg Gmean: 0.13 µg/L	↑ (BMeHg) ↔ (BIHg)	↔ (BMeHg) ↔ (BIHg)	↑ (BMeHg) ↔ (BIHg)	–
Xu et al. 2021 Cross-sectional; 957 adults (≥21 years); GuLF study participants (United States)	BHg median: 0.9 µg/L	↔ (BHg)	↔ (BHg)	–	↔ (BHg)
Yalçin et al. 2022 Cross-sectional; 48 adolescents with hypertension and 38 controls; mean age 13.3 years for each group (Turkey)	UHg median (all participants): 0.19 µg/g creatinine	↑ (UHg)	↑ (UHg)	–	–
Yao et al. 2020 Cross-sectional; 7,061 children ages 8–17 years (NHANES 2007–2016)	BHg Gmean: 0.44 µg/L BMeHg Gmean: 0.24 µg/L UHg Gmean: 0.24 µg/L	↔ (BHg) ↔ (UHg) ↔ (BMeHg)	↓ (BHg) ↓ (BMeHg) ↓ (UHg)	–	↔ (BHg) – (BMeHg) ↔ (UHg)
Yen et al. 2022 Cross-sectional; 10 adult acute ischemic stroke patients (n=4 men; n=6 women); mean age: 57.7 years (Taiwan)	UHg mean (men): 0.7 µg/L UHg mean (women): 0.9 µg/L SHg mean (men): 6.1 µg/L SHg mean (women): 7.3 µg/L	↔ (SHg) ↔ (UHg)	↔ (SHg) ↔ (UHg)	–	↔ (SHg) ↔ (UHg)

Table 2-12. Overview of Epidemiological Studies Evaluating Associations between Mercury (Predominant Mercury Form Unknown) and Blood Pressure in General Populations

Reference, study type, and population	Biomarker	Blood pressure outcome (biomarker)			
		SBP	DBP	PP	Hypertension
Studies based on prenatal exposure measurements					
Farzan et al. 2021 Prospective birth cohort; 395 mother-child pairs; assessments at ages 5–6 years (New Hampshire)	Maternal NHg mean (GW 24): 0.129 µg/g Maternal NHg mean (PNW 6): 0.128 µg/g Child NHg mean (age 3 years): 0.055 µg/g Child UHg mean (ages 5–6 years): 0.071 µg/L	↔ (NHg, maternal) ↔ (NHg, child) ↔ (UHg, child)	↔ (NHg, maternal) ↔ (NHg, child) ↑ (UHg, child)	–	–
Gregory et al. 2016 Prospective birth cohort; children assessed at ages 7 years (n=1,754) and 17 years (n=1,102); mother enrollment with delivery expected between April 1991 and December 1992 (ALSPAC)	BHg median, maternal: 2.86 µg/L	↔ (maternal BHg)	↔ (maternal BHg)	–	–
Kalish et al. 2014 Prospective birth cohort; children assessed at early childhood (median age: 3.2 years; n=1,031) and mid-childhood (median age: 7.7 years; n=865); pregnant women enrolled between April 1999 and July 2002) (Massachusetts; Project Viva)[c]	ErHg mean, maternal (2nd trimester): 4.0 ng/g	↔ (maternal ErHg)[d]	–	–	–
Ma et al. 2023 Birth cohort; 2,534–2,680 mother-child pairs; children assessed at 5–6 years of age (China)	Maternal BHg median, 3rd trimester: 1.00 µg/L	↔(BHg, maternal)	↑ (BHg, maternal)	–	–

Table 2-12. Overview of Epidemiological Studies Evaluating Associations between Mercury (Predominant Mercury Form Unknown) and Blood Pressure in General Populations

Reference, study type, and population	Biomarker	Blood pressure outcome (biomarker)			
		SBP	DBP	PP	Hypertension
Zhang et al. 2021b Prospective birth cohort; 1,194 mother-infant pairs (assessment at most recent well-child visit (ages 3–15 years of age (Boston)	Maternal ErHg median: 2.15 µg/L Maternal ErHg quartiles Q1: <LOD– 1.06 µg/L Q2: 1.07– 2.14 µg/L Q3: 2.16– 3.70 µg/L Q4: 3.72– 27.80 µg/L	↑ (ErHg, maternal, Q4)	–	–	–

aIncludes nine studies (five studies of general populations and four studies of populations with high fish diets); BHg and NHg biomarkers were converted to HHg equivalents.
bIncludes 23 studies (13 studies of general populations, 6 studies of populations with high fish diets, and 3 studies of populations with occupation exposure to elemental Hg); BHg, NHg, and UHg were converted to HHg equivalents.
cChild blood pressure assessed at ages 3.2 and 7.7 years; no association observed for either age.
dFish consumers (n=759) and non-fish consumers (n=481).

↑ = positive association; ↓ = inverse association; ↔ = no association; – = not reported; ALSPAC = Avon Longitudinal Study of Parents and Children (United Kingdom); BHg = blood mercury; BIHg = blood inorganic mercury; BMeHg = blood methylmercury; DBP = diastolic blood pressure; ErHg = erythrocyte mercury; F = female(s); Gmean = geometric mean; GuLF = Gulf Long-term Follow-up Study (Deepwater Horizon oil spill); GW = gestation week; HHg = hair mercury; HPFS = Health Professionals Follow-up Study; KNHANES = Korea National Health and Nutrition Examination Survey; LOD = limit of detection; M = male(s); NAS = Normative Aging Study; NHANES = United States National Health and Nutrition Examination Survey; NHg = toenail mercury; NHS = Nurses' Health Study; PNW = postnatal week; PP = pulse pressure; Q = quartile; SBP = systolic blood pressure; SHg = serum mercury; UHg = urine mercury

Hypertension. Of the several studies that have investigated associations between mercury exposure and clinical hypertension in general populations, three cross-sectional studies reported positive associations (Table 2-12). Using NHANES data, Tang et al. (2022a) observed positive associations between BHg and blood methylmercury, but not UHg, and hypertension. A large study of the KNHANES population showed an association between SHg levels and hypertension (Choi et al. 2015). A small cross-sectional study in adults reported an increased risk of hypertension (adjusted odds ratio [OR] 4.19; 95% CI 1.28, 13.76) associated with HHg, but not with BHg (Bautista et al. 2009). Other studies, including a pooled analysis of 21,757 adults from nine studies (Hu et al. 2018) and a large prospective cohort study in 3,427 adults from the United States (Mozaffarian et al. 2012), did not find associations between mercury biomarkers and hypertension. In a cross-sectional study of 1,360 adolescents, no association was observed between BHg and hypertension.

Cardiac function. Few studies have evaluated cardiac function in the general population. No arrhythmias were observed in a cross-sectional study of 60 adult traffic workers (mean age: 36.6 years; 88% male) with a mean BHg level of 3.2 µg/L (Regencia et al. 2022). Cardiac function was assessed by QT interval, JT interval, QRS duration, and electrocardiogram markers of ventricular repolarization and depolarization. A birth cohort study of 604 children (7–8 years old) from Hong Kong examined associations between BHg and heart rate variability (Chan et al. 2021). Heart rate variability was inversely associated with cord BHg ≥5.8 µg/L compared to cord BHg <5.8 µg/L. In contrast, BHg obtained at age 7–8 years was not associated with heart rate variability. Results suggest that decreased heart rate variability is related to prenatal exposure to mercury and to modulation of parasympathetic modulation of cardiac function. A cross-sectional study of 532 children aged 12 years found no association between BHg (mean: 1.26 µg/L) and resting heart rate in the full cohort (Liu et al. 2021a). When stratified by sex, an inverse association was observed between BHg (1.33 µg/L) and resting heart rate in boys, but not in girls (BHg 1.17 µg/L).

Cardiovascular disease. Results of numerous studies indicate that exposure of the general population to mercury is not associated with cardiovascular disease (myocardial infarction, stroke, angina, and other cardiovascular diseases) or mortality due to cardiovascular disease; studies are summarized in Table 2-13. No associations between mercury biomarkers and myocardial infarction were found in most studies, including prospective studies, cohort studies, and cross-sectional studies. In contrast, two studies of Finnish men found an association between HHg and myocardial infarction (Salonen et al. 1995; Virtanen et al. 2005) and one case-control study found an association for NHg (Guallar et al. 2002). No studies reported associations between mercury biomarkers and stroke. No convincing evidence was obtained for associations with other cardiovascular diseases (coronary artery disease, coronary heart disease, or cardiovascular disease), with most studies reporting no associations. For example, two large meta-analyses (n=5,830; 17,294) did not find associations between mercury biomarkers and cardiovascular disease, coronary heart disease, or mortality due to cardiovascular disease (Chowdhury et al. 2018; Mozaffarian and Rimm 2006; Sun et al. 2021). However, a small cross-sectional study reported an association between SHg and coronary artery disease, and a prospective study in Finnish men found an association between HHg and atherosclerosis (Asgary et al. 2017; Salonen et al. 2000). Virtanen et al. (2005) found a positive association between HHg and increased risk of cardiovascular disease in a Finish population. In contrast, a cross-sectional study of 891 Korean adults found an inverse association between HHg and decreased arterial stiffness (Park et al. 2022). The study authors proposed that nutrients in fish consumption may have contributed to this effect.

Table 2-13. Epidemiological Studies Evaluating Associations between Mercury (Predominant Mercury Form Unknown) and Cardiovascular Disease and Mortality due to Cardiovascular Disease in General Populations

Reference, study type, and population	Biomarker	Cardiovascular disease[a] (biomarker)			
		MI	Stroke	Angina	Other results and endpoints[b]
Ahlqwist et al. 1999 Prospective; 1,397 women (Sweden)	SHg mean: 17.0 µg/L	↔ (SHg)[c]	↔ (SHg)	–	–
Asgary et al. 2017 Cross-sectional; 65 male cases, 65 controls (Iran)	SHg mean: 10.14 µg/L	–	–	–	↑ (SHg) CAD
Bergdahl et al. 2013 Cohort; 1,391 women (Sweden)	SHg median: 1.4 µg/L	↔ (SHg)[c]	↔ (SHg)[c]	–	–

Chen et al. 2018
 	
Case-cohort;
662 cases;
2,494 controls
(Southern United States)
	SHg median
	  Cases: 0.03 µg/L
	  Controls: 0.03 µg/L
		↔ (SHg)	–	–	–

Chowdhury et al. 2018 Meta-analysis; 11,410 adults from four studies	Ranges of study means BHg: 0.0039–3.54 µg/L HHg: 1.9 µg/g NHg: 0.25–0.63 µg/g	–	–	–	↔ (BHg, HHg, NHg)[d] CVD
Chowdhury et al. 2018 Meta-analysis; 9,169 adults from five studies		–	–	–	↔ (BHg, HHg, NHg)[d] CHD
Daneshmand et al. 2016 Prospective; 1,828 men (Finland)	HHg mean: 1.90 µg/g	–	↔ (HHg)	–	–

Table 2-13. Epidemiological Studies Evaluating Associations between Mercury (Predominant Mercury Form Unknown) and Cardiovascular Disease and Mortality due to Cardiovascular Disease in General Populations

Reference, study type, and population	Biomarker	Cardiovascular disease[a] (biomarker)			
		MI	Stroke	Angina	Other results and endpoints[b]

Downer et al. 2017
 	
Nested case-control; 147 cases, 267 controls (Spain)
	NHg mean
	  Cases: 0.63 µg/g
	  Controls: 0.67 µg/g
		–	–	–	↔ (NHg) CVD

Guallar et al. 2002 Case-control; 684 male cases, 724 male controls (9 countries)	NHg mean: 0.26 µg/g[e]	↑ (NHg)	–	–	–
Guo et al. 2022 Cross-sectional; 9,404 adults (NHANES 2003–2016)	UHg median: 0.33 µg/L	–	–	–	↔ (UHg) CVD

Hallgren et al. 2001
 	
Prospective case-control; 78 cases, 156 controls (Sweden)
	ErHg mean
	  Cases: 4.44 µg/g
	  Controls: 5.42 µg/g
		↔ (ErHg)	–	–	–

Hu et al. 2021 Meta-analysis; >34,000 participants from 14 studies (17 countries)	HHg: >2 µg/g	–	↑ (HHg)[c]	–	↑ (HHg)[c] CVD
Kim et al. 2014 Cross-sectional; 3,800 adults (KNHANES 2008–2009)	BHg mean: 5.44 µg/L	↔ (BHg)	↔ (BHg)	↔ (BHg)	–

Table 2-13. Epidemiological Studies Evaluating Associations between Mercury (Predominant Mercury Form Unknown) and Cardiovascular Disease and Mortality due to Cardiovascular Disease in General Populations

Reference, study type, and population	Biomarker	Cardiovascular disease[a] (biomarker)			
		MI	Stroke	Angina	Other results and endpoints[b]
Mozaffarian and Rimm 2006 Meta-analysis; 5,830 adults from five studies	SHg mean: 17.0 µg/L (one study) ErHg mean: 4.44 µg/g (one study) HHg: >2.03 µg/g (one study) NHg mean: 0.26–0.91 µg/g (range of means from two studies)	–	–	–	↔ (SHg, ErHg, HHg, NHg)[d] CHD
Mozaffarian et al. 2011 Nested case-control from two cohorts: adult male cases (n=1,211) and controls (n=1,211) from HPFS cohort; female cases (n=2,216) and controls (n=2,166) from NHS cohort (United States)	NHg median Cases: 0.23 µg/g Controls: 0.25 µg/g	–	↔ (NHg)	–	↔ (NHg) CHD ↔ (NHg) all CVD
Park et al. 2022 Cross-sectional: 891 adults (Korea)	HHg quintiles Qi1: ≤0.6 µg/g Qi2: 0.6–0.8 µg/g Qi3: 0.8–1.1 µg/g Qi4: 1.1–1.5 µg/g Qi5: >1.5 µg/g	–	–	–	↓ (HHg, Qi1) AS
Raymond et al. 2016 Cross-sectional; 154 men (United States)	BHg median: 2.5 µg/L HHg median: 0.5 µg/g	↑ (BHg) ↔ (HHg)	–	↔ (BHg, HHg)	↔ (BHg, HHg) CHD
Salonen et al. 1995 Cohort; 1,833 men (Finland)	HHg mean: 1.92 µg/g	↑ (HHg)[c]	–	–	↔ (HHg) CHD ↔ (HHg) CVD
Salonen et al. 2000 Prospective; 1,014 men (Finland)	HHg mean: 1.8 µg/g	–	–	–	↑ (HHg) ATH

Table 2-13. Epidemiological Studies Evaluating Associations between Mercury (Predominant Mercury Form Unknown) and Cardiovascular Disease and Mortality due to Cardiovascular Disease in General Populations

Reference, study type, and population	Biomarker	Cardiovascular disease[a] (biomarker)			
		MI	Stroke	Angina	Other results and endpoints[b]
Sun et al. 2021 Prospective cohort; 17,294 adults (NHANES 2003–2012)	BHg mean: 1.62 µg/L	–	–	–	↔ (BHg) CVD[f]
Virtanen et al. 2005 Prospective; 1,871 men (Finland)	HHg T3: ≥2.03 µg/g	↑ (HHg)[f]	–	–	↑ (HHg)[e] CVD ↔ (HHg)[e] CHD
Virtanen et al. 2012a Prospective; 1,857 men (Finland)	HHg mean: 1.91 µg/g	↔ (HHg)	–	–	–
Wang et al. 2023a Cross-sectional; 3,268 non-Hispanic, white adults (NHANES 1999–2018)	BHg quartiles Q1: ≤0.49 µg/L Q2: 0.49–≤0.91 µg/L Q3: 0.91–≤1.80 µg/L Q4: >1.80 µg/L	–	–	–	↔ (BHg, Q4) ASCVD
Wennberg et al. 2011 Prospective, nested, case-control; 431 cases, 499 controls (Sweden)	ErHg median: 3.54 µg/L	↔ (ErHg)	–	–	–
Wennberg et al. 2012 Prospective, nested case-control; 572 cases, 1,041 controls (Sweden and Finland)	HHg median Sweden: 0.57 µg/g Finland: 1.32 µg/g	↑ (HHg)	–	–	–

Table 2-13. Epidemiological Studies Evaluating Associations between Mercury (Predominant Mercury Form Unknown) and Cardiovascular Disease and Mortality due to Cardiovascular Disease in General Populations

Reference, study type, and population	Biomarker	Cardiovascular disease[a] (biomarker)			
		MI	Stroke	Angina	Other results and endpoints[b]
Yoshizawa et al. 2002 Nested case-control; 470 cases; 464 controls (United States)	NHg mean Dentists: 0.91 µg/g Controls: 0.45 µg/g	–	–	–	↔ (NHg) CHD

[a]Unless otherwise noted, associations are for nonfatal effects.
[b]Description as reported by the study authors.
[c]Fatal and nonfatal effects.
[d]Biomarkers in individual studies (BHg, HHg, or NHg) were not transformed to a single biomarker type. For example, BHg and NHg concentrations were not converted to an equivalent HHg concentration.
[e]Group mean HHg was not reported for separately for cases and controls.
[f]Fatal effects.

↑ = positive association; ↔ = no association; – = not reported; AS = arterial stiffness; ASCVD = atherosclerotic cardiovascular disease; ATH = carotid atherosclerosis; BHg = blood mercury; CAD = coronary artery disease; CHD = coronary heart disease; CVD = cardiovascular disease; ErHg = erythrocyte mercury; HHg = hair mercury; HPFS = Health Professionals Follow-up Study; KNHANES = Korea National Health and Nutrition Examination Survey; MI = myocardial infarction; NHANES = National Health and Nutrition Examination Survey; NHg = toenail mercury; NHS = Nurses' Health Study; Q = quartile; Qi = quintile; T = tertile; SHg = serum mercury; UHg = urine mercury

Mechanisms of Action. Possible mechanisms that may be involved in mercury-induced effects on cardiovascular function have been proposed (da Cunha Martins et al. 2018; Genchi et al. 2017; Grandjean et al. 2004a; Houston 2011; Kim and Park 2023; Omanwar and Fahim 2015; Roman et al. 2011; Virtanen et al. 2007). These include: (1) increased oxidative stress and lipid peroxidation due to an imbalance between production of reactive oxygen species (ROS) and anti-oxidative mechanisms; (2) endothelial cell damage and dysfunction resulting from impaired nitric oxide signaling, decreased enzymatic degradation of catecholamines, and increased intracellular levels of calcium, leading to altered coronary vascular reactivity; (3) altered function of the renin-angiotensin system by stimulation of angiotensin converting enzyme (ACE); (4) altered sodium channel function in cardiac muscle, vascular endothelium, or at other sites important for cardiovascular function; (5) inhibition of Na^+-K^+ ATPase on platelet membranes, leading to increased platelet aggregation and clotting disorders; (6) neurological damage, resulting in altered balance of sympathetic and parasympathetic control of heart rate; (7) increased formation of inflammatory mediators (e.g., prostaglandins and leukotrienes); (8) increased C-reactive protein; and (9) decreased expression of genes involved in anti-inflammatory responses. Control of cardiovascular

function is multi-factorial; therefore, numerous mechanisms are likely involved. For additional information on general mechanisms of toxicity, see Section 2.21 (General Mechanisms of Action).

2.7   GASTROINTESTINAL

Overview. Gastrointestinal effects of mercury have not been well-studied in humans or animals. No epidemiological studies meeting inclusion criteria were identified for any form of mercury (see inclusion criteria, Section 2.1). Case studies and information from reviews indicate that adverse gastrointestinal effects occur following exposure to mercury vapor or from ingestion of high doses of mercury compounds at levels that were near fatal or fatal. However, the gastrointestinal tract does not appear to be a target of lower, environmental exposures to mercury.

Studies evaluating gastrointestinal effects in animals are available for oral exposure to mercuric chloride and methylmercury. Damage to the gastrointestinal tract (ulceration, hyperplasia) has been reported in rodents following exposure to inorganic salts or organic mercury at high oral doses associated with mortality. There is no evidence of gastrointestinal effects at nonlethal oral doses.

The following summarizes results of epidemiological and animal studies on the gastrointestinal system.
- ***Elemental mercury***
  - *Epidemiology studies*
    - No epidemiological studies on gastrointestinal effects from exposure to elemental mercury were identified.
    - Case studies of individuals acutely exposed to fatal or near-fatal levels of mercury vapor reported nausea and vomiting.
  - *Animal studies*
    - No adequate studies have evaluated gastrointestinal effects of elemental mercury.
- ***Inorganic mercury salts***
  - *Epidemiology studies*
    - No epidemiological studies on gastrointestinal effects from exposure to inorganic mercury salts were identified.
    - Case studies of individuals acutely exposed to fatal or near-fatal levels of inorganic mercuric compounds reported abdominal pain, nausea, diarrhea, ulceration, and hemorrhages of the upper and lower gastrointestinal tract.

- ▪ *Animal studies*
  - ▪ Gavage doses associated with increased mortality are associated with damage to the forestomach and glandular stomach in mice and with forestomach hyperplasia in rats.
  - ▪ No evidence of gastrointestinal effects at nonlethal oral doses was reported.
- • ***Organic mercury***
  - ▪ *Epidemiology studies*
    - ▪ One epidemiological study found no associations between hair methylmercury and severe chronic gastritis or gastric atrophy.
  - ▪ *Animal studies*
    - ▪ Irritative effects (ulceration) in rats and mice have been reported at chronic-duration oral methylmercury doses associated with increased mortality.
    - ▪ No evidence of gastrointestinal effects at nonlethal oral doses was reported.
- • ***Predominant mercury form unknown (general populations)***
  - ▪ No epidemiological studies on gastrointestinal effects from mercury exposure of general populations were identified.

Confounding Factors. The only studies that were identified regarding gastrointestinal effects of mercury are case reports. Confounding factors are not considered in case reports.

Elemental Mercury—Epidemiological Studies. Epidemiological studies evaluating gastrointestinal effects of elemental mercury and meeting inclusion criteria were not identified (see inclusion criteria, Section 2.1). Abdominal pain (classified by the study authors as a gastrointestinal effect) was observed in a population of gold miners in the Philippines (Cortes-Maramba et al. 2006); however, due to inadequate reporting, it is not possible to provide additional information on gastrointestinal findings. Several case reports of individuals exposed acutely to high levels of elemental mercury vapor generated from heating elemental mercury to high temperatures in confined spaces stated that exposed individuals had nausea, vomiting, and diarrhea (Bluhm et al. 1992; Gore and Harding 1987; Haddad and Stenberg 1963; Hallee 1969; King 1954; Teng and Brennan 1959). No information regarding gastrointestinal effects at low exposure levels of elemental mercury were identified.

Elemental Mercury—Animal Studies. No adequate studies evaluating gastrointestinal effects in animals following exposure to elemental mercury were identified.

Inorganic Mercury Salts—Human Studies. Studies evaluating gastrointestinal effects in populations exposed to inorganic mercury salts were not identified. However, as reviewed by Berlin et al. (2015), cases of accidental or intentional ingestion of near-fatal or fatal doses of mercuric salts indicate that the gastrointestinal tract is a target organ. Acute-duration exposure to mercuric salts at near-fatal or fatal doses has corrosive effects on the gastrointestinal tract, causing gastric and abdominal pain, bloody diarrhea, and necrosis of the intestinal mucosa.

Inorganic Mercury Salts—Animal Studies. In rats, increased incidence of forestomach hyperplasia was observed in male rats exposed to mercuric chloride at chronic-duration gavage doses associated with increased mortality ($\geq$1.8 mg Hg/kg/day); findings were not observed in female rats at doses up to 4 mg Hg/kg/day (NTP 1993). No gross or microscopic changes in the gastrointestinal tract were observed in rats following acute- or intermediate-duration exposure to mercuric chloride at gavage doses up 15 mg Hg/kg/day (Lecavalier et al. 1994; NTP 1993).

In mice, inflammation of the forestomach and necrosis of the forestomach and glandular stomach were observed in mice exposed to mercuric chloride via gavage at a dose of 59 mg Hg/kg/day for 4–5 days; this dose was associated with increased mortality (NTP 1993). Drinking water studies in mice reported lesions, colorectal gland atrophy, and mild-to-moderate necrosis in the cecum at 24 mg Hg/kg/day for 3 days and 15 mg Hg/kg/day for 90 days respectively (Zhao et al. 2020, 2021). In contrast, no gross or microscopic changes in the gastrointestinal tract were observed in mice at gavage doses up to 30 mg Hg/kg/day for 16 days, 15 mg Hg/kg/day for 6 months, or 7.4 mg Hg/kg/day for 2 years (NTP 1993).

Organic Mercury—Epidemiological Studies. Little information on gastrointestinal effect of exposures to methylmercury from high fish diets is available. A cross-sectional study of 80 indigenous Arctic adults (mean age: 53.2 years) in Canada found no associations between hair methylmercury (mean: 0.565 µg/g; range: 0.063–2.07 µg/g) and severe chronic gastritis or gastric atrophy (Walker et al. 2021). Nausea and diarrhea were observed in a gold mining community in the Philippines exposed to mercury through ingestion of methylmercury in fish (Cortes-Maramba et al. 2006); interpretation of study results is not possible due to inadequate reporting.

Organic Mercury—Animal Studies. Two chronic-duration studies reported gastrointestinal effects consistent with local irritation at doses associated with increased mortality. The first study reported necrosis and ulceration of the cecum in rats following exposure to 3.7 mg Hg/kg/day via drinking water as phenylmercuric acetate (Solecki et al. 1991). The second study reported ulceration of the glandular

stomach in male mice following dietary exposure to methylmercuric chloride at 0.686 mg Hg/kg/day; this was not observed in female mice at dietary doses up to 0.601 mg Hg/kg/day (Mitsumori et al. 1990).

In other studies, no exposure-related histopathological changes in the gastrointestinal tract were observed following oral exposure to methylmercuric chloride in cats at intermediate-duration doses up to 0.176 mg or chronic-duration doses up to 0.074 mg Hg/kg/day (Verschuuren et al. 1976), or mice at intermediate- or chronic-duration doses up to 9.5 or 0.724 mg Hg/kg/day, respectively (Hirano et al. 1986; MacDonald and Harbison 1977).

Predominant Mercury Form Unknown (General Populations). Studies evaluating gastrointestinal effects of mercury exposure in general populations were not identified.

Mechanisms of Action. Mercury has a direct caustic effect to the intestinal mucosa and causes extensive precipitation of proteins. Mercury ingestion can destroy and/or modify the composition of intestinal flora (Rice et al. 2014; Seki et al. 2021; Zhao et al. 2020). Mercury exposure biomarkers have been associated with changes in intestinal microflora profiles (Laue et al. 2020; Rothenberg et al. 2016a, 2019). Mercury biomarkers have also been associated with changes in microbiome profiles observed in certain disease states including autism, gestational diabetes, and autoimmune disease (Khan and Wang 2020; Shen et al. 2022; Zhai et al. 2019; Zhang et al. 2021c). General mechanisms of toxicity of mercury (reviewed in Section 2.21) are likely involved in the development of toxicity to the gastrointestinal system.

2.8   HEMATOLOGICAL

Overview. Epidemiological and animal studies have evaluated hematological effects of mercury, although hematological effects have not been well-studied in humans. Furthermore, few epidemiological studies on hematological effects meet the inclusion criteria for this toxicological profile (see inclusion criteria, Section 2.1). Although there are plausible mechanisms for mercury to adversely affect erythrocytes, data from epidemiological studies are insufficient to determine if exposure to mercury produces adverse hematological effects in humans.

Effects of mercury on the hematological system in animals have been evaluated following acute- and intermediate-duration oral exposure to mercuric chloride and intermediate- and chronic-duration oral exposure to inorganic mercury salts. Available data suggesting impaired clotting, small decreases in RBC counts, and increased WBC counts in rodents exposed to mercuric chloride are of uncertain biological

relevance. Available data are inadequate to determine if exposure to organic mercury is associated with adverse hematological effects.

The following summarizes results of epidemiological and animal studies on hematological outcomes.

- **_Elemental mercury_**
  - _Epidemiology studies_
    - Inadequate data are available to determine if exposure to elemental mercury is associated with adverse effects to the hematological system. One study showed increased lipid peroxidation in erythrocytes, but erythrocyte function was not assessed.
  - _Animal studies_
    - No studies evaluating hematological effects following exposure to elemental mercury were identified.
- **_Inorganic mercury salts_**
  - _Epidemiology studies_
    - No epidemiological studies evaluating associations between exposure to inorganic mercury salts and hematological effects were identified.
  - _Animal studies_
    - A few studies reported impaired clotting in rats following oral exposure to mercuric chloride.
    - Some evidence of small decreases in RBC parameters (count, hemoglobin, hematocrit), but findings are of uncertain biological significance.
    - Inconsistent evidence for increased WBC counts in rodents following oral exposure to mercuric chloride.
- **_Organic mercury_**
  - _Epidemiology studies_
    - Data are insufficient to determine if exposure to organic mercury is associated with adverse hematological effects. The only identified study showed an inverse association between HHg and blood hemoglobin; however, the study did not account for iron status, a major confounding factor.
  - _Animal studies_
    - Data are insufficient to determine if exposure to organic mercury is associated with adverse hematological effects. One study reported anemia in rats following chronic-duration exposure to phenylmercuric acetate but this finding is attributed to ulceration in the gastrointestinal tract.

- *Predominant mercury form unknown (general populations)*
  - Inadequate data are available to determine if exposure of the general population to mercury is associated with adverse effects to the hematological system. One study showed a positive association between BHg and hemoglobin.

Confounding Factors. Numerous factors can complicate interpretation of studies on hematological function. These include nutritional status, negative iron balance, infectious or chronic diseases (e.g., malaria, obesity), micronutrient balance (e.g., vitamin D, vitamin A, vitamin B12, zinc, folate), and other environmental exposures (e.g., lead, cadmium, PCBs) (Weinhouse et al. 2017), which may also vary by mercury exposure status. Few of these factors were considered in the epidemiological studies reviewed in this section and no studies assessed iron balance as a confounding factor for changes in blood hemoglobin.

Elemental Mercury—Epidemiological Studies. Little information is available regarding effects of elemental mercury on the hematological system in humans, with only two studies meeting inclusion criteria for this toxicological profile (see inclusion criteria, Section 2.1); study results are summarized in Table 2-14. A prospective study of women with amalgam fillings found a positive association between SHg and blood hemoglobin at the baseline assessment but no association at the 22-year follow-up assessment (Ahlqwist et al. 1999). The toxicological significance of this increased blood hemoglobin is unclear. No associations were observed between SHg and leukocyte or platelet counts at the enrollment or follow-up assessments. Due to high participant attrition between the enrollment (n=1,462) and follow-up assessments (n=135), effects on blood hemoglobin reported in this study are difficult to interpret. A cross-sectional study of chloralkali workers found increased erythrocyte activities of glutathione peroxidase (GPX), superoxide dismutase (SOD), and glucose-6-phosphate dehydrogenase (G6PDH), and increased erythrocyte levels of malondialdehyde, compared to controls (Bulat et al. 1998). The study authors stated that results are consistent with increased lipid peroxidation.

Table 2-14. Results of Epidemiological Studies Evaluating Exposure to Elemental Mercury (Hg^0) and Hematological Effects

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Ahlqwist et al. 1999 Prospective; 1,462 women with amalgam fillings, enrolled in 1968–1969, and followed through 1980–1981(n=135 at follow-up) (Sweden)	SHg mean: 3.4 µg/L	Blood hemoglobin	↑ (SHg, baseline) ↔ (SHg, follow-up)
		Leukocyte count	↔ (SHg, baseline) ↔ (SHg, follow-up)
		Platelet count	↔ (SHg, baseline) ↔ (SHg, follow-up)
Bulat et al. 1998 Cross-sectional; 42 chloralkali workers and 75 controls (former Yugoslavia)	BHg mean Workers: 35.9 µg/L Controls: 4.6 µg/L UHg mean Workers: 41.1 µg/g Cr Controls: 4.8 µg/g Cr	Erythrocyte GPX	↓ (BHg, UHg, workers versus controls)
		Erythrocyte SOD	↓ (BHg, UHg, workers versus controls)
		Erythrocyte MDA	↑ (BHg, UHg, workers versus controls)
		Erythrocyte G6PDH	↓ (BHg, UHg, workers versus controls)

↑ = positive association; ↓ = inverse association; ↔ = no association; BHg = blood mercury; Cr = creatinine; G6PDH = glucose-6-phosphate dehydrogenase; GPX = glutathione peroxidase; MDA = malondialdehyde; SHg = serum mercury; SOD = superoxide dismutase; UHg = urine mercury

Elemental Mercury—Animal Studies. No studies were located regarding hematological effects in animals after exposure to elemental mercury.

Inorganic Mercury Salts—Animal Studies. Hematological findings following oral exposure to mercuric chloride are shown in Table 2-15. Limited rat data suggest a potential for impaired clotting following acute- or intermediate-duration oral exposure to mercuric chloride, but the effects lessened in severity with increased duration of exposure. Data suggest small decreases in RBC parameters in rodents following acute- or intermediate-duration oral exposure to mercuric chloride; however, the biological relevance of these small changes is unclear. There is inconsistent evidence for increased WBC counts in rodents following oral exposure to mercuric chloride.

Table 2-15. Hematological Effects in Rodents Orally Exposed to Mercuric Chloride

Strain (sex); duration; dose (mg Hg/kg/day)	Clotting measures[a]	RBC count[a]	Hemo-globin[a]	Hct[a]	WBC count[a]	Total lympho-cytes[a]	Reference
Rat (NS); 1 day; dose: 0.684	BT: ↑ (88) CT: ↑ (66)	↓ (3)	↔	–	↑ (10)	–	Mahour and Saxena 2009
Rat (F); 1 day; dose: 7.4	–	↓ (10)	↓ (9)	↓ (10)	–	–	Lecavalier et al. 1994
Rat (F); 1 day; dose: 9.24	–	↓ (9)	↔	↓ (8)	–	–	Lecavalier et al. 1994
Rat (NS); 7 days; dose: 0.033	BT: ↑ (21) CT: ↑ (26)	↓ (1)	↓ (7)	–	↑ (2)	–	Mahour and Saxena 2009
Rat (NS); 14 days; dose: 0.033	BT: ↑ (4) CT: ↑ (13)	↓ (2)	↓ (9)	–	↑ (13)	–	Mahour and Saxena 2009
Rat (NS); 21 days; dose: 0.033	BT: ↓ (2) CT: ↓ (18)	↓ (13)	↓ (5)	–	↑ (17)	–	Mahour and Saxena 2009
Rat (B); 28 days); dose: 0.61–0.76	–	↔	↔	–	↔	–	Jonker et al. 1993
Rat (B); 28 days; dose: 5.1–5.5	–	↔	↔	–	↔	–	Jonker et al. 1993
Rat (M); 45 days; dose: 0.277	↓ PLT (13)	↔	↔	–	↑ (45)	–	dos Santos Chemelo et al. 2021
Rat (M); 90 days; dose: 5.5	–	↓ (5)	↓ (5)	↓ (4)	–	–	Boujbiha et al. 2012
Rat (M); 90 days; dose: 11	–	↓ (10)	↓ (10)	↓ (7)	–	–	Boujbiha et al. 2012
Rat (M); 182 days; dose: 0.04	0 PLT	↔	↔	↔	↑ (140)	–	Agrawal et al. 2014
Mouse (M); 14 days; dose: 0.06	–	↓ (13)	–	–	↔	–	Kim et al. 2003
Mouse (M); 14 days; dose: 0.31	–	↓ (13)	–	–	↔	–	Kim et al. 2003

Table 2-15. Hematological Effects in Rodents Orally Exposed to Mercuric Chloride

Strain (sex); duration; dose (mg Hg/kg/day)	Clotting measures[a]	RBC count[a]	Hemo-globin[a]	Hct[a]	WBC count[a]	Total lympho-cytes[a]	Reference
Mouse (M); 14 days; dose: 1.39	–	↓ (11)	–	–	↔	–	Kim et al. 2003
Mouse (M); 14 days; dose: 4.81	–	↓ (19)	–	–	↑ (91)	–	Kim et al. 2003
Mouse (B10.S) (B); 28 days; dose: 2.7	↑ PLT (~29)	↑ (~38)	↑ (~37)	–	–	–	He et al. 2021
Mouse (DBA/2) (B); 28 days; dose: 2.7	↔ PLT	↔	↔	–	–	–	He et al. 2021
Mouse (M); 49 days: dose: 0.4	–	↔	–	–	↑ (35)	↑ (51)	Dieter et al. 1983
Mouse (M); 49 days; dose: 2	–	↔	–	–	↔	↔	Dieter et al. 1983
Mouse (M); 49 days; dose: 11	–	↓ (8)	–	–	↓ (36)	↓ (35)	Dieter et al. 1983

[a]Numbers in ( ) are percent change compared to control, calculated from quantitative data.

↑ = increased; ↓ = decreased; ↔ = no change; – = not assessed; B = both males and females; BT = bleeding time; CT = clotting time; F = female(s); Hct = hematocrit; M = male(s); NS = not specified; PLT = platelet; RBC = red blood cell; WBC = white blood cell

Increased bleeding and clotting times were observed in rats following a single oral exposure to 0.684 mg Hg/kg or repeated exposure to 0.033 mg Hg/kg/day for 1–3 weeks (Mahour and Saxena 2009). However, biological relevance is unclear as findings became less pronounced with increased duration of exposure. Scanning electron microscopy data from another 4-week study also suggest impaired clotting, showing platelet activation (spreading of platelets, formation of pseudopods) and a poorly developed fibrin network in rats exposed to 0.848 mg Hg/kg/day; fibrin fiber thickness did not differ between groups (Arbi et al. 2017). Due to the qualitative nature of scanning electron microscopy data, Arbi et al. (2017) was not included in the LSE table. No other studies identified measured clotting, but Agrawal et al. (2014) indicated no exposure-related changes to the number of platelets in mice exposed to 0.04 mg Hg/kg/day for 6 months (Agrawal et al. 2014). Morphological changes in rat platelets were observed at 0.13 mg Hg/kg/day for 28 days (Janse van Rensburg et al. 2020).

Several studies have reported changes in RBC parameters following oral exposure to mercuric chloride; however, the reported changes are small in magnitude and the toxicological relevance is unclear. In single exposure studies in rats, RBC counts were minimally (<5%) decreased at 0.684 mg Hg/kg and mildly (<20%) decreased at ≥7.4 mg Hg/kg (Lecavalier et al. 1994; Mahour and Saxena 2009). Hemoglobin and hematocrit were mildly decreased at ≥7.4 mg Hg/kg (Lecavalier et al. 1994). Following repeated exposure to 0.033 mg Hg/kg/day, RBC counts were minimally decreased after 1 or 2 weeks and mildly decreased after 3 weeks; hemoglobin levels were mildly decreased at all time points (no duration-dependency) (Mahour and Saxena 2009). Other intermediate-duration studies in rats report no changes in RBC count, hemoglobin levels, or hematocrit following exposure to 0.04 mg Hg/kg/day for 6 months (Agrawal et al. 2014) or doses up to 5.5 mg Hg/kg/day for 28 days (Jonker et al. 1993), and mild decreases in RBC parameters at doses ≤5.5 mg Hg/kg/day for 90 days (Boujbiha et al. 2012). In mice, mild decreases in RBC counts were reported following exposure to ≥0.06 mg Hg/kg/day for 2 weeks (Kim et al. 2003). In contrast, no changes in RBC counts were observed in mice exposed to doses up to 2 mg Hg/kg/day for 7 weeks; similar exposure to 11 mg Hg/kg/day resulted in a mildly decreased RBC count (Dieter et al. 1983). Moderate increases in RBC counts, hemoglobin, and platelets were observed at 2.7 mg Hg/kg/day for 4 weeks in BS.10 mice but not in DBA/2 mice (He et al. 2021).

The evidence for elevated WBC counts in rodents following oral exposure to mercuric chloride is inconsistent. In rats, WBC counts were mildly increased following a single exposure to 0.684 mg Hg/kg or repeated exposure to 0.033 mg Hg/kg/day for 2 or 3 weeks; exposure to 0.033 mg Hg/kg/day for 1 week resulted in minimal increases in WBC count (Mahour and Saxena 2009). Larger elevations in WBC count (>2-fold) were observed in rats exposed to 0.04 mg Hg/kg/day for 6 months or by 45% in rats exposed to 0.277 mg Hg/kg/day for 45 days (dos Santos Chemelo et al. 2021). However, other intermediate-duration studies in rats reported no changes in WBC counts at doses up to 5.5 mg Hg/kg/day for 28 days (Jonker et al. 1993). In mice, an increase in WBC count (~2-fold) was observed following exposure to 4.81 mg Hg/kg/day for 14 days; no changes were observed at ≤1.39 mg Hg/kg/day (Kim et al. 2003). A 7-week study in mice observed a non-monotonic response for WBC counts, with increases at 0.4 mg Hg/kg/day, no change at 2 mg Hg/kg/day and decreases at 11 mg Hg/kg/day (Dieter et al. 1983).

The erythrocyte sedimentation rate (ESR) was increased by 21, 10, and 41% in rats exposed to 0.033 mg Hg/kg/day for 7, 14, or 21 days, respectively (Mahour and Saxena 2009). This finding may be related to immune function, as elevated ESR is a marker for inflammation.

Organic Mercury—Epidemiological Studies. Data are not sufficient to determine if exposure to mercury in populations that consume high fish diets produces adverse hematological effects, with only one study meeting inclusion criteria for this toxicological profile (see inclusion criteria, Section 2.1). In a cross-sectional study, Weinhouse et al. (2017) evaluated the association between total HHg (median: 1.18 µg/g) and blood hemoglobin levels in a population of 83 children <12 years of age. This population, from the Peruvian Amazon, was primarily exposed through fish consumption. HHg was inversely associated with blood hemoglobin (β -0.18; 95% CI -0.31, -0.046). Several covariates, including age, sex, and micronutrients, were considered; however, iron status, a major confounding factor, was not assessed in this population.

Organic Mercury—Animal Studies. Hematological data following exposure to organic mercury compounds are very limited. Rats that received phenylmercuric acetate in their drinking water for 2 years showed decreases in hemoglobin, hematocrit, and RBC counts at a dose of 3.7 mg Hg/kg/day (Solecki et al. 1991). The anemia observed in this study may have been secondary to blood loss associated with the ulcerative lesions in the large intestine seen at this dose (Section 2.7, Gastrointestinal). In other studies, no hematological effects were noted following dietary exposure to methylmercury in rats at doses up to 0.18 mg Hg/kg/day for 2 years (Verschuuren et al. 1976), rabbits at doses up to 0.53 mg Hg/kg/day for 14 weeks (Koller et al. 1977), or cats at doses up to 0.176 mg Hg/kg/day for approximately 16 weeks, 0.074 mg Hg/kg/day for approximately 55 weeks, or 0.046 mg Hg/kg/day for 2 years (Charbonneau et al. 1976).

Predominant Mercury Form Unknown (General Populations). Studies evaluating hematological effects of mercury in general populations meeting inclusion criteria are summarized in Table 2-16. In a cross-sectional study of 4,522 adults from the 2008–2010 KNHANES population, positive associations were observed between BHg and hemoglobin in men and women (Park and Lee 2013). Mean BHg was 4.34 µg/L in men and 3.73 µg/L in women. A cross-sectional study of 2,026 adults from the 2011–2018 NHANES did not find an association between BHg and peripheral eosinophil counts (Wen et al. 2023). A subset of pregnancies from a prospective study found an association between increasing NHg in late pregnancy and frequency of regulatory T-cells and natural killer cells in cord blood (Movassagh et al. 2021). A cross-section study off children found an association between increasing BHg and increased peripheral lymphocyte counts (Kim et al. 2015d)

Table 2-16. Results of Epidemiological Studies Evaluating Exposure to Mercury (Predominant Mercury Form Unknown) and Hematological Effects in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated	Result

Kim et al. 2015d
 	
Cross-sectional; 311 children (South Korea)
	BHg median: 2.19 µg/L	Cell counts
		  Total leukocytes
		  Segmented leukocytes
		  Lymphocytes
		  Monocytes
		  Basophils
		  Eosinophils
			
			↔ (BHg)
			↔ (BHg)
			↑ (BHg)
			↔ (BHg)
			↔ (BHg)
			↔ (BHg)

Movassagh et al. 2021 Prospective; subset of New Hampshire Birth Cohort Study (n=63 pregnant women) (United States)	NHg Gmean 0.072 µg/g	Cord blood T-cell frequency:	
		T-helper	↔ (NHg)
		T-regulatory	↑ (NHg)
		Natural killer	↑ (NHg)

Park and Lee 2013
 	
Cross-sectional;
5,533 adults, age ≥20 years, from 2008–2010 KNHANES (Korea)
	BHg Gmean
	  Women: 3.733 µg/L
	  Men: 4.377 µg/L
		Blood hemoglobin	↑ (BHg)

Wen et al. 2023
 	
Cross-sectional;
2,026 adults, age ≥18 years, from 2011–2018 NHANES
	BHg mean for eosinophil count quartiles
	  Q1: 1.53 µg/L
	  Q2: 1.40 µg/L
	  Q3: 1.24 µg/L
	  Q4: 1.13 µg/L
		Eosinophil count	↔ (BHg)

Zhang et al. 2020a
 	
Cross-sectional; 73 children exposed to e-waste and 74 referents, age 3–7 years (China)
	BHg median
	  1.46 µg/L
		Peripheral cell counts:
		  Lymphocyte
		  Neutrophil
		  Monocyte
			
			↔ (BHg)
			↑ (BHg)
			↔ (BHg)

↑ = positive association; ↔ = no association; BHg = blood mercury; KNHANES = Korea National Health and Nutrition Examination Survey; NHANES = National Health and Nutrition Examination Survey; NHg = toenail mercury; Q = quartile

Mechanisms of Action. Epidemiological and animal studies do not provide strong evidence that mercury adversely affects the hematological system. However, mercury is transported into erythrocytes and has a high affinity for hemoglobin and other protein and non-protein sulfhydryls (Section 3.1, Toxicokinetics); therefore, there is the potential for mercury to adversely affect erythrocytes. Weinhouse et al. (2017) reviewed several possible mechanisms for mercury-induced adverse effects on erythrocytes, including:

(1) oxidative damage and inflammatory effects; (2) erythrocyte apoptosis; (3) decreased erythrocyte production; (4) decreased heme biosynthesis; (5) dysregulation of iron homeostasis; and (6) exacerbation of vitamin B12 or folate deficiency.

2.9 MUSCULOSKELETAL

Overview. Few epidemiological and animal studies have evaluated musculoskeletal effects of mercury. However, based on the available data, the musculoskeletal system does not appear to be a sensitive target of mercury exposure. No epidemiological studies were identified for elemental and organic mercury. A few studies in general populations evaluated associations between mercury biomarkers and indicators of bone mineral status, and risks of sarcopenia, and periodontitis. Results indicate mercury exposure does not adversely affect bone mineral. Data are inadequate to determine if mercury is associated with sarcopenia or periodontitis.

No primary musculoskeletal effects were observed in rodents following oral exposure to inorganic salts. Studies in rodents observed bone loss and altered bone microstructure in the mandible from methylmercuric chloride exposure. Effects secondary to renal impairment (mercuric chloride) and neurological impairment (methylmercury) included fibrous osteodystrophy and muscle weakness/atrophy, respectively. No inhalation studies were available.

The following summarizes results of epidemiological and animal studies on musculoskeletal outcomes.
- *Elemental mercury*
  - *Epidemiology studies*
    - No epidemiological studies on musculoskeletal effects from exposure to elemental mercury were identified.
  - *Animal studies*
    - No studies evaluating musculoskeletal effects following exposure to elemental mercury were identified.
- *Inorganic mercury salts*
  - *Epidemiology studies*
    - No epidemiological studies evaluating associations between exposure to inorganic mercury salts and musculoskeletal effects were identified.

- ▪ *Animal studies*
  - ▪ No primary musculoskeletal effects were observed in rats or mice following acute-, intermediate-, or chronic-duration oral exposure to mercuric chloride.
  - ▪ Fibrous osteodystrophy was reported in male rats following chronic-duration exposure to mercuric chloride. This was considered secondary to marked renal impairment.
- • **Organic mercury**
  - ▪ *Epidemiology studies*
    - ▪ No epidemiological studies on musculoskeletal effects from exposure to organic mercury were identified.
  - ▪ *Animal studies*
    - ▪ Bone loss and altered microstructure were observed in the mandible of adult rats following intermediate-duration oral exposure to methylmercury. Similar effects were observed in offspring of rats after gestational and lactational exposure.
    - ▪ Muscle weakness and atrophy were reported in rats following acute-duration exposure to methylmercury. This was considered secondary to neurological impairment.
- • **Predominant mercury form unknown (general populations)**
  - ▪ Based on the limited data in adults, exposure of the general population to mercury is not associated with adverse effects on bone.
  - ▪ A study in children and adolescents found an inverse association between BHg and bone density in males, but not in females.
  - ▪ Results of single studies found positive associations between mercury biomarkers and sarcopenia and periodontitis.

Confounding Factors. Factors associated with bone mineral status that may also be associated with mercury exposure status include nutrition, age, pregnancy, menopausal status, activity level, and exposure to other chemicals that act on bone mineral (e.g., cadmium).

Elemental Mercury—Epidemiological Studies. No studies on musculoskeletal effects from exposure to elemental mercury were identified.

Elemental Mercury—Animal Studies. No studies were located regarding musculoskeletal effects in animals after exposure to elemental mercury.

Inorganic Mercury Salts—Animal Studies. Fibrous osteodystrophy was reported in male rats following chronic-duration exposure to mercuric chloride at gavage doses ≥1.8 mg Hg/kg/day; this finding is considered secondary to marked renal impairment observed at these doses (NTP 1993). Fibrous osteodystrophy was not observed in female rats at chronic-duration doses up to 4 mg Hg/kg/day; renal impairment was also not observed in females. In acute-duration exposure studies, no histopathological lesions in muscle or bone were observed in rats at doses up to 9.24 mg Hg/kg/day (Lecavalier et al. 194). Intermediate-duration exposure studies show conflicting results. A gavage study observed alterations in alveolar bone structure and decreased trabecular space were observed in rats exposed to 0.277 mg Hg/kg/day for 45 days (Nunes et al. 2022). However, no lesions in muscle or bone were found in rats at gavage doses up to 4 mg Hg/kg/day for 15 months (NTP 1993). In mice, no histopathological lesions in muscle or bone were observed at intermediate- or chronic-duration doses up to 15 or 7.4 mg Hg/kg/day, respectively (NTP 1993).

Organic Mercury—Animal Studies. Studies in rats have found adverse effects of methylmercury on bone. A study in adult rats exposed to 0.03 mg/kg/day as methylmercuric chloride by gavage (oil) for 60 days observed bone loss and microstructural changes in mandibular bone (de Oliveira Lopes et al. 2021). Microstructural changes were decreased trabecular number, trabecular thickness, and bone volume fraction. The root area of the bone was exposed and bone height was decreased. Similar effects on mandibular bone were observed in offspring of rats following gestational and lactational exposure (Chemelo et al. 2022). In this study, dams were administered cookies laced with methylmercuric chloride at a dose of 0.05 mg/kg/day for 41 days during gestation and lactation. Following exposure, mandibles in offspring showed increased spacing between trabeculae, decreased amount of trabecular bone, decreased osteocyte density, and reduced bone collagen.

In contrast, at higher doses, no exposure-related changes in muscle or bone histology were observed following oral exposure to methylmercuric chloride in cats at doses up to 0.176 mg Hg/kg/day for approximately 16 weeks, 0.074 mg Hg/kg/day for approximately 55 weeks, or 0.046 mg Hg/kg/day for 2 years (Charbonneau et al. 1976). No effects on muscle or bone histology were observed in rats at doses up to 0.18 mg Hg/kg/day for 2 years (Verschuuren et al. 1976). Similarly, studies in mice reported no effects on muscle or bone histology at doses up to 1.3 mg Hg/kg/day for 56 days (Rand et al. 2020) or 0.724 mg Hg/kg/day for 2 years (Hirano et al. 1986; Mitsumori et al. 1990).

Skeletal muscle weakness and wasting/atrophy were observed in rats exposed to methylmercuric chloride at gavage doses of ≥4 mg Hg/kg/day for 10–12 days (Su et al. 1998; Usuki et al. 1998). These findings are considered neurogenic in nature, as opposed to a direct toxic action of methylmercury on skeletal muscle. Effects occurred at doses associated with overt signs of neurotoxicity and mortality.

Predominant Mercury Form Unknown (General Populations). Few studies on musculoskeletal effects of mercury in general populations were identified. Cross-sectional studies evaluated associations between mercury biomarkers and bone outcomes (bone mineral density, bone resorption, and risks of osteopenia, osteoporosis, arthritis, and fracture), sarcopenia, and periodontitis; studies are summarized in Table 2-17. Several studies evaluated outcomes in KNHANES participants (Cho et al. 2012; Kim et al. 2016a; Lim et al. 2016; Yoo et al. 2016) and NHANES participants (Guan et al. 2023; Tang et al. 2022b; Xu et al. 2023b; Wei et al. 2021). BHg was used as the biomarker in all studies, except for one study that used HHg (Han et al. 2009).

Table 2-17. Results of Epidemiological Studies Evaluating Exposure to Mercury (Predominant Mercury Form Unknown) and Musculoskeletal Effects in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Callan et al. 2015 Cross-sectional; 77 women ≥50 years of age (Australia)	BHg median: 2.04 µg/L	Bone resorption	↓ (BHg, Q2−Q4)
Cho et al. 2012 Cross-sectional; 481 post-menopausal women (KNHANES)	BHg, quartiles Q1: <2.67 µg/L Q2: ≥2.67−<3.74 µg/L Q3: ≥3.74−<5.23 µg/L Q4: ≥5.23 µg/L	Risk of osteoporosis	↓ (BHg, Q2−Q4)
Guan et al. 2023 Cross-sectional; 2,174 adults (NHANES 2013−2016)	BHg median: 1.52 µg/L	Risk of arthritis	↔ (BHg)
Han et al. 2009 Cross-sectional; 598 men and 730 women (Korea)	HHg, median With periodontitis: 1.11 µg/g No periodontitis: 0.97 µg/g	Risk of periodontitis	↑ (HHg, men) ↔ (HHg, women)
Jalili et al. 2020a Meta-analysis of 4 studies[a] with combined 4,348 adults	BHg[b]	Risk of osteopenia and osteoporosis	↔ (BHg)

Table 2-17. Results of Epidemiological Studies Evaluating Exposure to Mercury (Predominant Mercury Form Unknown) and Musculoskeletal Effects in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated	Result

Kim et al. 2016a
 	
Cross-sectional; 1,190 men ≥50 years of age (KNHANES)
	BHg, quartiles
	Q1: <3.347 µg/L
	Q2: 3.347−5.337 µg/L
	Q3: 5.337−8.914 µg/L
	Q4: >8.014 µg/L
		Bone mineral density
		    Total hip
		    Femur neck
		    Lumbar spine
			
			↔ (BHg)
			↑ (BHg)
			↔ (BHg)

		Risk of osteopenia and osteoporosis
		    Total hip
		    Femur neck
		    Lumbar spine
			
			↓ (BHg, Q4)
			↓ (BHg, Q4)
			↔ (BHg, Q4)

		Risk of facture	↔ (BHg, Q4)
Lim et al. 2016 Cross-sectional; 2,429 adults (KNHANES)	BHg, quartiles Q1: <2.549 µg/L Q2: 2.549−3.798 µg/L Q3: 3.798−5.710 µg/L Q4: >5.710 µg/L	Risk of osteopenia and osteoporosis	↔ (BHg, Q4)

Pollack et al. 2013
 	
Cross-sectional;
248 premenopausal women (Buffalo, New York)
	BHg, mean: 1.51 µg/L	Bone mineral density
		    Whole body
		    Total hip
		    Lumbar spine
		    Wrist
			
			↔ (BHg)
			↔ (BHg)
			↔ (BHg)
			↔ (BHg)

		Risk of low bone mineral density
		    Whole body
		    Total hip
		    Lumbar spine
		    Wrist
			
			↔ (BHg)
			↔ (BHg)
			↓ (BHg)
			↔ (BHg)

Tang et al. 2022b
 	
Cross-sectional; 8,665 adults, mean age 44.39 (NHANES 2005−2010)
	BHg: 1.68 µg/L	Bone mineral density
		    Femur total
		    Femur neck
		    Trochanter
		    Intertrochanter
		    Spine total
		    Spine L1
		    Spine L2
		    Spine L3
		    Spine L4
			
			↑ (BHg)
			↑ (BHg)
			↑ (BHg)
			↑ (BHg)
			↑ (BHg)
			↑ (BHg)
			↑ (BHg)
			↔ (BHg)
			↔ (BHg)

Wei et al. 2021 Cross-sectional; 2,545 adults, mean age 39.4 years (NHANES 2011−2016)	BHg, Gmean: 0.77 µg/L	Bone mineral density (lumbar spine)	↔ (BHg)

Table 2-17. Results of Epidemiological Studies Evaluating Exposure to Mercury (Predominant Mercury Form Unknown) and Musculoskeletal Effects in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated	Result

Xu et al. 2023b
 	
Cross-sectional: 2,818 children and adolescents, ages 12−19 years; 1,458 boys and 1,360 girls (NHANES 2011−2018)
	BHg
	  Low: <1.09 µg/L (boys)
	  Low: <2.37 µg/L (girls)
	  High: >1.09 µg/L (boys)
	  High: >2.37 µg/L (girls)
		Total bone mineral density	↓ BHg (high, boys)
			↔ BHg (high, girls)

Yoo et al. 2016
 	
Cross-sectional; 344 men and 360 women >65 years of age (KNHANES)
	Men, BHg, quartile means
	  Q1: 1.79 µg/L
	  Q2: 2.95 µg/L
	  Q3: 4.48 µg/L
	  Q4: 9.69 µg/L
	Women, BHg, quartile means
	  Q1: 1.79 µg/L
	  Q2: 2.95 µg/L
	  Q3: 4.41 µg/L
	  Q4: 10.30 µg/L
		Risk of sarcopenia	↑ (BHg, Q4, men and women)

[a]Studies included in the meta-analysis are Cho et al. (2012), Kim et al. (2016a), Lim et al. 2016, and Pollack et al. (2013).
[b]Mean BHg mean or range was not reported for the combined population. BHg levels are reported in the individual studies noted in footnote "a" above.

↑ = positive association; ↓ = inverse association; ↔ = no association; BHg = blood mercury; Gmean = geometric mean; HHg = hair mercury; KNHANES = Korean National Health and Nutrition Examination Survey; NHANES = National Health and Nutrition Examination Survey; Q = quartile

Associations between mercury and bone outcomes were evaluated in postmenopausal women (≥50 years of age), pre-menopausal women, men ≥50 years of age, adults ≥18 years of age, and children and adolescents (12–19 years of age). Results indicate that mercury exposure of general populations is not associated with adverse effects on bone; instead, mercury could possibly have a protective effect. In older women, inverse associations were observed between BHg and bone resorption and the risk of osteoporosis (Callan et al. 2015; Cho et al. 2012). In pre-menopausal women, no associations were observed between BHg and bone mineral density, and the risk of having a low bone mineral density of the lumbar spine was decreased (Pollack et al. 2013). In older men, an inverse association was observed between BHg and risk of osteopenia and osteoporosis of the hip and femur, and increasing BHg was associated with increasing bone mineral density of the femur (Kim et al. 2016a). The Tang et al. (2022b) study in a large NHANES population also showed that BHg was associated with increased bone mineral density in the femur and spine. However, no association was observed between BHg and the risk of

fracture. A meta-analysis of four studies did not find associations between BHg and the risk of
osteopenia and osteoporosis in adults (Jalili et al. 2020a). Similarly, in adults ≥18 years of age, no
associations were observed between BHg and the risk of osteopenia and osteoporosis (Lim et al. 2016),
lumbar bone mineral density (Wei et al. 2021), or arthritis (Guan et al. 2023). A study in children and
adolescents found an inverse association between BHg (>1.09 µg/L) and bone mineral density in boys,
but no association in girls (BHg: >2.37) (Xu et al. 2023b). Taken together, results of these studies
indicate that mercury exposure of general populations does not adversely affect bone mineral status.

Other studies found positive associations between HHg and the risk of periodontitis in men, but not
women (Han et al. 2009), and between BHg and the risk of sarcopenia in men and women (Yoo et al.
2016). These findings have not been corroborated.

Mechanisms of Action. Mechanisms for possible positive effects of mercury on bone mineral status have
not been well-investigated. It has been proposed that mercury may alter activity of osteoclasts and
osteoblasts (Cho et al. 2012; Kim et al. 2016a).

2.10 HEPATIC

Overview. Hepatic effects of mercury have not been extensively studied in humans or animals. Few
epidemiological studies have evaluated hepatic effects associated with mercury exposures, most likely
because the liver does not appear to be a sensitive target organ for mercury, relative to other systems (e.g.,
nervous system). No epidemiological studies of hepatic effects that reported mercury biomarkers were
identified for exposure to elemental mercury or in populations with high fish diets. A few studies on liver
effects in general populations were identified; these studies evaluated associations between mercury
biomarkers and dyslipidemias. Data are not adequate to determine if general exposure to mercury
adversely affects the liver.

Studies evaluating hepatic effects are available for inhalation exposure to mercury vapor and oral
exposure to mercuric chloride, mercuric sulfide, or methylmercury. There is limited evidence of
moderate-to-severe liver damage following inhalation exposure to mercury vapor at high acute-duration
concentrations or repeated exposure to lower concentrations. Available data do not indicate that the liver
is a sensitive target of toxicity following oral exposure to inorganic mercury salts or organic mercury.
There is no evidence of histopathological damage following oral exposure, and very limited evidence of

mild hepatic effects (altered clinical chemistry and serum lipids; altered lipid profiles; decreased liver weight).

The following summarizes results of epidemiological and animal studies on hepatic outcomes.

- ***Elemental mercury***
    - *Epidemiology studies*
        - A single study in dental workers found a positive association between mercury biomarkers and LDL cholesterol, but not for total cholesterol, high-density lipoprotein (HDL) cholesterol, or triglycerides.
    - *Animal studies*
        - Limited data indicate that acute-duration exposure to high concentrations or continuous exposure to low concentrations may cause moderate-to-severe liver damage.
- ***Inorganic mercury salts***
    - *Epidemiology studies*
        - No epidemiological studies evaluating associations between exposure to inorganic mercury salts and hepatic effects were identified.
    - *Animal studies*
        - Hepatic lesions have not been reported in rodents following exposure to mercuric chloride.
        - Evidence of mild hepatic effects in rodents following exposure to mercuric chloride (altered serum chemistry, decreased liver weight) is limited and inconsistent, especially at low oral doses.
        - One study found no adverse hepatic effects in mice exposed to extremely high levels of mercuric sulfide.
- ***Organic mercury***
    - *Epidemiology studies*
        - No studies reporting mercury biomarkers and hepatic endpoints in populations with high fish diets were identified.
        - No adverse hepatic effects were observed in a long-term follow-up study of the Minamata population; biomarkers were not reported.
    - *Animal studies*
        - Hepatic lesions have not been reported in cats or rodents following exposure to methylmercury.

- ▪ Evidence of mild hepatic effects in rodents is very limited following exposure to methylmercury; one study reported decreased liver weight and one study reported a duration-related increase in serum cholesterol following exposure to moderate-to-high doses of methylmercury.

- • *Predominant mercury form unknown (general populations)*
  - ▪ Studies evaluating associations between mercury biomarkers and serum liver enzyme activities have inconsistent results. For studies showing positive associations between biomarkers and liver enzymes, the magnitude of changes was small and did not represent toxicologically significant increases.
  - ▪ Studies in adults found positive associations between BHg and total cholesterol and hypercholesterolemia, providing consistent evidence of a relationship between mercury and increased cholesterol.
  - ▪ In children and adolescents, positive associations were observed between BHg or SHg and total cholesterol and borderline hypercholesterolemia.

Confounding Factors. Numerous factors that can affect measures of hepatic function may also be associated with mercury exposure status. These include age, obesity, family history of liver disease, alcohol use, smoking, exposure to other chemicals, concurrent disease, and drug use, including prescription drugs and over-the-counter medications.

Elemental Mercury—Epidemiological Studies. A single study evaluated associations between mercury biomarkers and lipid levels in a population of 386 dental workers in the United States (Xu et al. 2023a); geometric mean BHg, UHg, and HHg levels were 3.64 µg/L, 0.25 µg/L, and 0.60 µg/g respectively. A positive association was observed between UHg and LDL cholesterol, but not for BHg or HHg. No associations were observed between mercury biomarkers and total cholesterol, HDL cholesterol, or triglycerides.

Elemental Mercury—Animal Studies. Serious liver effects have been noted in a two animal studies. Extensive hepatocyte degeneration was reported in female rats continuously exposed to 1 mg Hg/m^3 for 45 days (Yahyazedeh et al. 2017). Additional histopathological findings included enlarged blood vessels, dilated sinusoids, and increased perivascular connective tissue. Stereology showed increased liver volume in the sinusoids and decreased volume of the parenchyma. The numerical density and total number of hepatocytes were significantly decreased, but the mean numerical density and total number of binucleated hepatocytes were significantly elevated. The nuclear diameter of hepatocytes was

significantly decreased. A series of studies in rabbits reported hepatic effects ranging from moderate pathological changes to severe liver necrosis following exposure to 28.8 mg Hg/m^3 for 6–30 hours or 6 mg Hg/m^3 for 6–11 weeks (7 hours/day, 5 days/week) (Ashe et al. 1953). Mild pathological changes were observed at shorter exposure durations and following intermittent exposure to 3 mg Hg/m^3 for up to 12 weeks (Ashe et al. 1953). The usefulness of these results is limited because of small animal numbers per timepoint, lack of controls (in acute-duration studies), lack of incidence data, lack of details regarding observed pathological changes, and unclear distinction between primary and secondary effects (i.e., pathological changes secondary to induced shock). Due to lack of controls, acute-duration studies are not presented in the LSE table.

In other studies, no changes in liver histology were reported in rats following exposure to 8 mg Hg/m^3 for 2 hours/day for up to 10 days (Morgan et al. 2002) or 3 mg Hg/m^3 for 12–42 weeks (5 days/week; 3 hours/day) (Kishi et al. 1978).

Inorganic Mercury Salts—Animal Studies. Available data do not indicate that the liver is a sensitive target of toxicity in rodents orally exposed to mercuric chloride or sulfide.

No changes in liver weight or histology were observed in rats exposed to mercuric chloride at acute-duration doses up to 9.24 mg Hg/kg/day (Lecavalier et al. 1994) or intermediate- or chronic-duration doses up to 4 mg Hg/kg/day (NTP 1993), or in mice at intermediate- or chronic-duration doses up to 15 or 7.4 mg Hg/kg/day, respectively (NTP 1993). However, decreased liver weight has been reported following oral exposure to mercuric chloride in one rat and one mouse study. In a 2-generation study in rats, relative liver weights were decreased >20% in F0 females exposed to gavage doses ≥0.55 mg Hg/kg/day; no changes in liver weight were observed in F1 females at doses up to 1.98 mg Hg/kg/day or F0 or F1 males at doses up to 1.31 mg Hg/kg/day (Atkinson et al. 2001). In mice, absolute liver weight was decreased by 14 and 16% following exposure to 2 or 11 mg Hg/kg/day, respectively, as mercuric chloride in drinking water for 7 weeks (Dieter et al. 1983). Relative organ weights were not reported, but body weight effects were only noted at 11 mg Hg/kg/day. In 16-day gavage studies that only evaluated liver weight, no changes were observed in rats or mice at intermediate-duration doses up to 15 mg Hg/kg/day and 30 mg Hg/kg/day, respectively (NTP 1993). Similarly, no exposure-related changes in maternal liver weights were observed in rats exposed to doses up to 0.094 mg Hg/kg/day throughout gestation and lactation (Galiciolli et al. 2022). Due to lack of organ weight findings, these studies were not included as NOAELs in the LSE table (inadequate hepatic endpoint evaluation).

Altered hepatic clinical chemistry values (alkaline phosphatase [ALP], aspartate aminotransferase [AST], lactate dehydrogenase [LDH], cholinesterase) have been reported in rodents in some oral exposure studies, generally at high doses (Table 2-18). No changes in serum alanine aminotransferase (ALT), acid phosphatase, sorbitol dehydrogenase, and/or bilirubin were observed in studies included in Table 2-18. Acute-duration exposure to gavage doses up to 9.24 mg Hg/kg/day was not associated with adverse changes in serum chemistry; however, a significant decrease in serum LDH (non-adverse direction) was observed at ≥7.4 mg Hg/kg/day (Lecavalier et al. 1994). Dietary exposure to doses ≥11.9 mg Hg/kg/day resulted in increased serum ALP and AST levels in rats; no changes were observed at ≤11.4 mg Hg/kg/day (Jonker et al. 1993). Some 30-day gavage studies in rats reported increased ALP at doses ranging from 0.3 to 1.5 mg Hg/kg/day, and increased AST at 1.5 mg Hg/kg/day (Raeeszadeh et al. 2021; Sabir et al. 2022). Another study reported increased ALP, AST, and LDH in Wistar rats exposed to 0.4 mg Hg/kg/day via an unspecified oral route for 6 months (Agrawal et al. 2014). However, no alterations in hepatic serum chemistry were observed at intermediate- or chronic-duration gavage doses up to 4 mg Hg/kg/day (NTP 1993). In mice, alterations in clinical chemistry are limited to increased serum cholinesterase levels in males exposed to drinking water doses ≥2 mg Hg/kg/day (Dieter et al. 1983). In other studies, no changes in hepatic clinical chemistry were observed at intermediate- or chronic-duration doses up to 15 or 7.4 mg Hg/kg/day, respectively (Khan et al. 2004; Kim et al. 2003; NTP 1993).

Table 2-18. Hepatic Clinical Chemistry in Rodents Orally Exposed to Mercuric Chloride

Species; duration	Dose (mg Hg/kg/day)	ALP[a]	AST[a]	LDH[a]	Cholinesterase[a]	Reference
Rat; 1 day	7.4–9.24	↔	↔	↓ (38–54)	–	Lecavalier et al. 1994
Rat; 28 days	5.8	↔	↔	–	–	Jonker et al. 1993
Rat; 28 days	6.1	↔	↔	–	–	Jonker et al. 1993
Rat; 28 days	11.4	↔	↔	–	–	Jonker et al. 1993
Rat; 28 days	11.9	↑ (21)	↔	–	–	Jonker et al. 1993
Rat; 28 days	20.9	↑ (28)	↑ (16)	–	–	Jonker et al. 1993
Rat; 28 days	23.6	↑ (22)	↑ (18)	–	–	Jonker et al. 1993
Rat; 30 days	1.5	↑ (48)	↑ (125)	–	–	Raeeszadeh et al. 2021

Table 2-18. Hepatic Clinical Chemistry in Rodents Orally Exposed to Mercuric Chloride

Species; duration	Dose (mg Hg/kg/day)	ALP[a]	AST[a]	LDH[a]	Cholinesterase[a]	Reference
Rat; 30 days	0.3	↑ (80)	–	–	–	Sabir et al. 2022
Rat; 182 days	0.230	↔	↔	↔	↔	NTP 1993
Rat; 182 days	0.4	↑ (40)	↑ (56)	↑ (21)	–	Agrawal et al. 2014
Rat: 182 days	0.462–4	↔	↔	↔	↔	NTP 1993
Rat: 450 days	1.8–4	↔	–	–	↔	NTP 1993
Mouse; 14 days	0.06–4.81	–	↔	–	–	Kim et al. 2003
Mouse; 49 days	0.4	–	↔	↔	↔	Dieter et al. 1983
Mouse: 49 days	2	–	↔	↔	↑ (59)	Dieter et al. 1983
Mouse: 49 days	11	–	↔	↔	↑ (55)	Dieter et al. 1983
Mouse: 61–79 days	0.18–0.74	↔	↔	↔	–	Khan et al. 2004
Mouse; 182 days	0.923–15	↔	↔	–	–	NTP 1993
Mouse; 450 days	4–7.4	↔	–	–	↔	NTP 1993

[a]Numbers in ( ) are percent change compared to control, calculated from quantitative data.

↑ = increased; ↓ = decreased; ↔ = no change; – = not assessed; ALP = alkaline phosphatase; AST = aspartate aminotransferase; LDH = lactate dehydrogenase

Two intermediate-duration dietary studies evaluated serum lipids in wild-type and spontaneously hypertensive Wistar rats exposed to mercuric chloride (Takahashi et al. 2000a, 2000b). In spontaneously hypertensive rats, serum HDL and triglycerides were decreased in a dose-related manner at all tested doses (≥0.07 mg Hg/kg/day); however, HDL was not decreased in wild-type rats until doses of 1.7 mg Hg/kg/day and triglycerides were unaffected. No exposure-related changes in total cholesterol or LDL were observed in spontaneously hypertensive or wild-type rats at doses up to 2.2 or 1.7 mg Hg/kg/day (Takahashi et al. 2000a, 2000b). In other studies, no changes in total cholesterol were observed in rats at acute-duration gavage doses up to 9.24 mg Hg/kg/day (Lecavalier et al. 1994), or in mice at intermediate-duration water or gavage doses up to 11 or 0.74 mg Hg/kg/day, respectively (Dieter et al. 1983; Khan et al. 2004).

No liver histopathology was reported in rats exposed to 0.3 mg Hg/kg/day mercuric chloride for 30 days (Sabir et al. 2022), but hepatic necrosis, hemorrhage, and inflammatory cell inflammation were observed in rats exposed to 1.5 mg Hg/kg/day of mercuric chloride for 30 days (Raeeszadeh et al. 2021). No changes in hepatic clinical chemistry, weight, or histology were observed in mice exposed to mercuric sulfide at gavage doses up to 1,700 mg Hg/kg/day for 4 weeks (Son et al. 2010).

Organic Mercury—Epidemiological Studies. No studies evaluating hepatic effects in populations with high fish diets and reporting exposures based on mercury biomarkers were identified. A cross-sectional screening survey of the Minamata population (n=1,406) did not find an increase in the prevalence of liver disease or abnormal findings on ultrasonographic examinations; no mercury biomarkers were reported (Futatsuka et al. 1992).

Organic Mercury—Animal Studies. Available data do not indicate that the liver is a sensitive target of toxicity in rodents orally exposed to methylmercury. No changes in liver histology were observed in mice or cats at intermediate-duration doses up to 9.5 or 0.176 mg Hg/kg/day, respectively (Charbonneau et al. 1976; MacDonald and Harbison 1977), or in rats, mice, or cats at chronic-duration doses up to 0.18, 0.724, or 0.074 mg Hg/kg/day, respectively (Charbonneau et al. 1976; Hirano et al. 1986; Mitsumori et al. 1990; Verschuuren et al. 1976). One study in rats reports a 20% decrease in relative liver weight following exposure to 0.879 mg Hg/kg/day for 28 days (Wildemann et al. 2015a). No changes in liver weight were observed in rats or mice at acute-duration doses up to 2.8 and 9.99 mg Hg/kg/day, respectively or intermediate-duration doses up to 0.216 or 0.77 mg Hg/kg/day, respectively (Belles et al. 2002; Fossato da Silva et al. 2011; Ilback 1991; Wildemann et al. 2015a, 2015b). Studies evaluating liver weight in the absence of histology or clinical chemistry were not included in the LSE table due to inadequate endpoint evaluation.

Few studies have evaluated serum lipids in mice following acute- or intermediate-duration exposure; however, no other hepatic endpoints were evaluated (Moreira et al. 2012; Nascimento et al. 2022; Silva et al. 2021). A study in C57BL/6 mice reported increased total cholesterol (by ~30%) and non-HDL cholesterol (by ~40%), but no difference in HDL cholesterol, at 2.7 mg Hg/kg/day for 15 days (Silva et al. 2021). Total cholesterol and triacylglycerol levels were increased by approximately 40 and 150%, respectively, in C57BL/6 mice exposed to 0.21 mg Hg/kg/day for 30 days (Nascimento et al. 2022). In the Moreira et al. (2012) study, total cholesterol was increased approximately 40 and 80% in C57BL/6 mice after exposure to 5.6 mg Hg/kg/day for 14 or 21 days; no changes in total cholesterol were observed after a 7-day exposure, and no changes in HDL, non-HDL, or triglycerides were observed at any time

point. In Swiss mice, total cholesterol, HDL, non-HDL, and triglyceride levels were all increased by
approximately 110, 135, 110, and 90%, respectively, following exposure to 5.6 mg Hg/kg/day for
28 days.

Predominant Mercury Form Unknown (General Populations). Several studies have evaluated
associations between mercury exposure and hepatic effects in general populations. Outcomes evaluated
include serum liver enzymes, serum lipid profiles, and hepatic diseases. In general, results show positive
associations between mercury biomarkers and increased liver enzymes (ALT, AST, and gamma-
glutamyltransferase [GGT]) and cholesterol. Two studies also examined associations between biomarkers
and liver disease (Chung et al. 2020; Yang et al. 2021).

Serum hepatic enzymes. Studies examining potential associations between mercury exposure and serum
hepatic enzymes are summarized in Table 2-19. Most studies examined large populations of adults using
data national surveys (NHANES, KNHANES, Korean National Environmental Health Survey
[KoNEHS]), with 2,953–17,137 participants; a few other studies examined smaller populations (≤550).
Two studies were conducted in adolescents using NHANES data (Chen et al. 2019b; Yang et al. 2023)
and a longitudinal birth cohort study examined associations between maternal BHg and serum hepatic
enzymes (Stratakis et al. 2021). Total BHg concentrations ranged from 0.7 µg/L (mean) in NHANES
studies of adults and adolescents (Li et al. 2023; Yang et al. 2023) to 4.33 µg/L (geometric mean at
baseline) in a Korean population of adults (Choi et al. 2017). Results of associations between BHg and
serum liver enzymes were inconsistent, although more studies found positive associations between BHg
and increased ALT, AST, and GGT, than no associations However, the magnitude of changes in serum
liver enzymes was very small. For example, GGT was increased by 10.3% compared to baseline at the
5-year follow-up period (Choi et al. 2017). Lee et al. (2014) reported that ALT increased by 1.067 U/L
and AST increased 0.676 U/L per doubling of BHg; mean ALT 22.23 U/L and mean AST 22.21 U/L.
These changes represent a small increase per doubling of BHg and do not represent toxicologically
significant increases; the study authors classified changes in ALT and AST as subclinical. Given the
inconsistent results and the small magnitude of changes, the liver does not appear to be a sensitive organ
for mercury in the general population.

Table 2-19. Results of Epidemiological Studies Evaluating Exposure to Mercury (Predominant Mercury Form Unknown) and Hepatic Serum Enzymes in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated		
		ALT	AST	GGT
Chen et al. 2019b Cross-sectional; 6,389 adolescents, ages 12–17 years (NHANES 1999–2014)	BHg mean: 0.73 µg/L	↑ (BHg)	NR	NR
Choi et al. 2017 Longitudinal; 508 adults; biomarker and liver enzymes were assessed at baseline and at a 4-year follow-up (Korea)	BHg Gmean Baseline: 4.33 µg/L Follow-up: 4.08 µg/L	↔ (BHg)	↔ (BHg)	↑ (BHg)
Chung et al. 2023 Cross-sectional; 3,712 adults, 1,617 men and 2,095 women (KoNEHS)	BHg mean Men: 3.28 µg/L Women: 2.30 µg/L	↑ (BHg) men and women combined	↔ (BHg) men and women combined	NR
Kim et al. 2021a Cross-sectional; 2,953 adults (KoNEHS)	BHg quartiles Q1: 0.33–1.86 µg/L Q2: 1.86–2.81 µg/L Q3: 2.81–4.42 µg/L Q4: 4.43–125.49 µg/l UHg Q4: 0.62–8.70 µg/L	↑ (BHg, Q2) ↔ (UHg)	↑ (BHg, Q4) ↔ (UHg)	↑ (BHg, Q3) ↔ (UHg)
Lee et al. 2014 Cross-sectional; 6,689 adults (KNHANES)	BHg Gmean: 3.987 µg/L	↑ (BHg)	↑ (BHg)	NR
Lee et al. 2017a Longitudinal (panel); 550 elderly adults ≥60 years of age (Korea)	BHg Gmean: 2.78 µg/L Q4 men: ≥5.41 µg/L Q4 women: ≥3.53 µg/L	↑ (BHg, Q4) OR for abnormal ALT	↔ (BHg, Q4)	↔ (BHg, Q4)
Li et al. 2023 Cross-sectional: 15,328 adults (NHANES 2011–2018)	BHg median: 0.7 µg/L	↔ (BHg)	↑ (BHg)	↔ (BHg)
Lin et al. 2014a Cross-sectional; 3,769 adults (NHANES)	Median BHg (total): 0.94 µg/L BMeHg: 0.60 µg/L	↔ (BHg)	↔ (BHg)	↔ (BHg)
Moon et al. 2022 Cross-sectional: 3,740–3,745 adults (KoNEHS)	BHg median: 2.71 µg/l UHg median: 0.34 µg/L	↑ (BHg) ↑ (UHg)	↑ (BHg) ↔ (UHg)	↑ (BHg) ↑ (UHg)

Table 2-19. Results of Epidemiological Studies Evaluating Exposure to Mercury (Predominant Mercury Form Unknown) and Hepatic Serum Enzymes in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated		
		ALT	AST	GGT
Yang et al. 2021 Cross-sectional: 5,919 adults; 3,614 classified as non-obese and 2,305 classified as overweight (KoNEHS)	BHg Gmean: All: 1.15 µg/L Non-obese: 1.08 µg/L Overweight: 1.25 µg/L	↑ (BHg, all, non-obese, and overweight)	↑ (BHg, all, non-obese, and overweight)	↑ (BHg, all, non-obese, and overweight)
Yang et al. 2023 Cross-sectional; 1,143 children and adolescents 12–19 years of age, 565 males and 578 females (NHANES 2011–2016)	BHg mean: 0.7 µg/L	↔ (BHg) males ↑ (BHg) females	NR	NR
Zhou et al. 2022 Cross-sectional; 17,137 adults (NHANES 2007–2016)	BHg Gmean: 0.87 µg/L	↑ (BHg)	NR	NR
Studies based on prenatal exposure measurements				
Stratakis et al. 2021 Longitudinal birth cohort; 872 mother-child pairs; children assessed at 8 years of age (Europe)	Maternal BHg median: 2.0 µg/L	↑ (BHg, maternal)	↔ (BHg, maternal)	↑ (BHg, maternal)

↑ = positive association; ↔ = no association; ALT = alanine aminotransferase; AST = aspartate aminotransferase; BHg = blood mercury; BMeHg = blood methylmercury; GGT = gamma-glutamyltransferase; Gmean = geometric mean; KNHANES = Korean National Health and Nutrition Examination Survey; KoNEHS = Korean National Environmental Health Survey; NHANES = National Health and Nutrition Examination Survey; NR = not reported; OR = odds ratio; Q = quartile; UHg = urine mercury

Serum lipid profiles. Several recent cross-sectional studies of large general populations have evaluated associations between mercury biomarkers and dyslipidemia; studies are summarized in Table 2-20. Nearly all studies evaluated data from large national surveys, specifically NHANES, KNHANES, KoNEHS, and China National Human Biomonitoring (CHGBM). Population sizes in these studies range from 1,088 to 12,526 participants. Most studies were conducted in adult populations, although a few studies evaluated children and adolescents (Cho et al. 2020; Fan et al. 2017; Jin et al. 2021; Yang et al. 2023). Two studies evaluated populations with large age ranges. A study on an NHANES population had an age range of 0–80 years (Buhari et al. 2020) and a study on a Canadian population had an age range of 3–79 years. Most studies evaluated total cholesterol, hypercholesterolemia, LDL cholesterol, HDL cholesterol, and triglycerides; a few studies reported dyslipidemia as an outcome, without data on

specific lipid profiles. Biomarkers used to assess associations were BHg, SHg, UHg, and NHg. Total

BHg concentrations ranged from the geometric mean of 0.35 µg/L (Sohn et al. 2020) to a 4th quartile

range of 4.30–60.60 µg/L (Kim et al. 2022a).

Table 2-20. Results of Epidemiological Studies Evaluating Exposure to Mercury (Predominant Mercury Form Unknown) and Dyslipidemia in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Buhari et al. 2020 Cross-sectional; 19,591 participants ages 0–80 years of age (NHANES 2009–2012)	BHg mean: 1.42 µg/L T1 mean: 0.26 µg/L T2 mean: 0.68 µg/L T3 mean: 3.03 µg/L	Total cholesterol	↑ (BHg, T2)
		LDL	↔ (BHg)
		Triglycerides	↔ (BHg)

Bulka et al. 2019
 	
Cross-Sectional; 1,088 adults (NHANES 2011–2014)
	Gmeans, 2011–2012
	  BMeHg: 0.63 µg/L
	UHg: 18.9 ng/hour
	Gmeans, 2013–2014
	  BMeHg: 0.56 µg/L
	  UHg: 16.8 ng/hour
		High triglycerides	↔ (BMeHg)
			↑ (UHg)

		Low HDL	↔ (BMeHg) ↑ (UHg)
Cakmak et al. 2023 Cross-sectional; 27,550 participants, ages 3–79 years (Canada)	BHg median: 0.57 µg/L	Total cholesterol	↑ (BHg)
		LDL	↑ (BHg)
		HDL	↑ (BHg)
		Triglycerides	↑ (BHg)

Cho et al. 2020
 	
Cross-sectional;
1,890 adolescents (963 males and 927 females), ages 10–19 years (KNHANES)
	BHg Gmean: 1.89 µg/L
	  Males: 1.96 µg/L
	  Females: 1.83 µg/L
		Total cholesterol	↑ (BHg, M)
			↔ (BHg, F)

		Hyper-LDL-cholesterolemia	↑ (BHg, M) ↔ (BHg, F)
		Total HDL	↔ (BHg, M, F)
		Hypo-HDL- cholesterolemia	↔ (BHg, M, F)
		Total triglycerides	↔ (BHg, M, F)
		Hypertriglyceridemia	↔ (BHg, M, F)
Fan et al. 2017 Cross-Sectional; 5,404 children and adolescents, ages 6–19 years (NHANES)	SHg mean: 0.65 µg/L	Total cholesterol	↑ (SHg, F, ages 6–12 years) ↑ (SHg, F, ages 13–19 years) ↑ (SHg, M, ages 13–19 years)
		LDL	↔ (SHg, all)
		HDL	↔ (SHg, all)
		Triglycerides	↔ (SHg, all)

Table 2-20. Results of Epidemiological Studies Evaluating Exposure to Mercury (Predominant Mercury Form Unknown) and Dyslipidemia in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Jin et al. 2021 Cross-sectional; 1,559 adolescents (806 males and 753 females), aged ages 10–18 years (KNHANES)	BHg Gmean: 1.88 µg/L	Borderline hypercholesterolemia	↑ (BHg)
		Borderline hyper-LDL-cholesterolemia	↔ (BHg)
Kang et al. 2021 Cross-sectional; 5,345 adults, 2,424 males and 2,921 females (KNHANES)	BHg stratifies as <2.75 and ≥2.75 µg/L	Dyslipidemia	↑ (BHg, all, M) ↔ (BHg, F)
Kim et al. 2022a Cross-sectional; 2,591 adults (KNHANES)	BHg quartiles Q1: 0.33–1.85 µg/L Q2: 1.86–2.77 µg/L Q3: 2.77–4.30 µg/L Q4: 4.30–60.60 µg/l UHg quartiles Q1: 0.01–0.23 µg/L Q2: 0.24–0.35 µg/L Q3: 0.36–0.64 µg/L Q4: 0.65–8.70 µg/L	Elevated total cholesterol	↑ (BHg, Q4) ↔ (UHg)
		Elevated LDL	↑ (BHg, Q2) ↔ (UHg)
		Elevated non-HDL	↑ (BHg, Q4) ↔ (UHg)
		Elevated triglycerides	↔ (BHg, UHg)
Lee et al. 2020a Cross-sectional; 6,454 adults (KNHANES)	BHg Gmean: 3.12 µg/L	Hyperlipidemia	↑ (BHg)
Liang et al. 2023 Cross-sectional; 12,526 adults (NHANES 2011–2020)	BHg median: 1.455 µg/L	Dyslipidemia[a]	↑ (BHg)
Park and Seo 2017 Cross-sectional; 232 adult males and 269 females; South Korea	NHg mean Males: 0.49 µg/g Females: 0.34 µg/g HSe: Low: ≤0.685 µg/g High: >0.685 µg/g	Hypercholesterolemia	↑ (NHg, low NSe) ↔ (NHg, high NSe)
		LDL-hypercholesterolemia	↑ (NHg, low NSe) ↔ (NHg, high NSe)
		HDH-hypocholesterolemia	↑ (NHg, low NSe) ↔ (NHg, high NSe)
		Hypertriglyceridemia	↔ (NHg, low NSe) ↔ (NHg, high NSe)

Table 2-20. Results of Epidemiological Studies Evaluating Exposure to Mercury (Predominant Mercury Form Unknown) and Dyslipidemia in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Sohn et al. 2020 Cross-sectional; 3,228 adults, 1,400 males and 1,828 females (KNHANES)	BHg Gmean All: 2.17 µg/L Males: 3.32 µg/L Females: 2.29 µg/l UHg Gmean All: 0.35 µg/L Males: 0.40 µg/L Females: 0.32 µg/L	Total cholesterol	↑ (BHg, M, F) ↑ (UHg, M) ↔ (UHg, F)
		LDL	↑ (BHg, M, F) ↑ (UHg, M, F)
		HDL	↑ (BHg, M) ↔ (BHg, F) ↔ (UHg, M, F)
		Triglycerides	↑ (BHg, M, F) ↑ (UHg, M, F)
Wang et al. 2023b Cross-sectional; 2,327 adults with hyperlipidemia and 966 without hyperlipidemia (NHANES 2007–2016)	UHg median: 0.383 µg/g Cr	Hyperlipidemia	↑ (UHg)
Wu et al. 2022 Cross-sectional; 10,780 adult participants in CNHBM (China)	BHg median: 1.18 µg/L	Triglycerides	↑ (BHg)
Yang et al. 2023 Cross-sectional; 1,143 children and adolescents 12–19 years of age, 565 males and 578 females (NHANES 2011–2016)	BHg mean: 0.7 µg/L	Total cholesterol	↑ (BHg)
		LDL	↑ (BHg)
		HDL	↔ (BHg)
		Triglycerides	↔ (BHg)

[a]Dyslipidemia defined as participants receiving any lipid-lowering medication, serum total cholesterol ≥200 mg/dL, and/or triglycerides ≥150 mg/dL, and/or LDL ≥130 mg/dL, and/or HDL <40 mg/dL in males, and/or HDL <50 mg/dL in females.

↑ = positive association; ↔ = no association; BHg = blood mercury; BMeHg = blood methylmercury; CNHBM = China National Human Biomonitoring; Cr = creatinine; F = females; Gmean = geometric mean; HDL = high-density lipoprotein; KNHANES = Korean National Health and Nutrition Examination Survey; LDL = low-density lipoprotein; M = males; NHANES = National Health and Nutrition Examination Survey; NHg = toenail mercury; NSe = toenail selenium; Q = quartile; SHg = serum mercury; T = tertile; UHg = urine mercury

Studies in adults found positive associations between BHg and total cholesterol and hypercholesterolemia (Table 2-20), providing consistent evidence of a relationship between mercury and increased cholesterol. Much less data are available for associations between UHg or NHg and total cholesterol, with inconsistent results. Most studies found positive associations between mercury biomarkers and LDL cholesterol, whereas inconsistent results were observed for HDL cholesterol and triglycerides. Bulka et al. (2019) is the only study evaluating associations between blood methylmercury and dyslipidemias. No associations

were observed between blood methylmercury and high triglycerides or low HDL cholesterol, but positive associations were observed for UHg. Park and Seo (2017) evaluated associations between NHg and dyslipidemias (hypercholesterolemia, LDL-hypercholesterolemia, HDL-hypocholesterolemia, and hypertriglyceridemia) and the potential modifying effect of selenium (measured in toenails) in a population of adults from Korea. Although the study authors stated that the study population had a high fish intake, no measurements were provided for BHg or HHg to compare exposures to biomarker levels reported in other populations with high fish diets that are reviewed in this profile (e.g., Faroe Islands or Seychelle Islands). Hypercholesterolemia and dyslipidemia were positively associated with NHg in participants with low, but not high, selenium. LDL-hypercholesterolemia was positively associated with NHg, and hair selenium did not affect the association. No associations were observed between NHg and HDL-hypocholesterolemia and hypertriglyceridemia in low- and high-selenium groups. In children and adolescents, positive associations were observed between BHg or SHg and total cholesterol and borderline hypercholesterolemia (Cho et al. 2020; Fan et al. 2017; Jin et al. 2021; Yang et al. 2023). Studies by Cho et al. (2020) and Yang et al. (2023) observed a positive association between BHg and LDL-cholesterol.

Liver disease. In addition to studies examining associations between mercury biomarkers and serum liver enzymes and plasma lipids, two cross-sectional studies evaluated associations between BHg levels and liver disease, including non-alcoholic fatty liver disease (NAFLD), hepatic stenosis, and hepatic fibrosis (Chung et al. 2020; Yang et al. 2021). Yang et al. (2021) found a positive association between BHg (mean: 1.15 µg/L) and NAFLD using KoNEHS data from 5,191 participants. The positive association was observed in non-obese participants (n=3,614; BHg geometric mean: 1.08 µg/L), but not for overweight participants (n=2,305; BHg geometric mean: 1.25 µg/L). In a population of 4,420 KNHANES participants (1,860 males and 2.560 females) with a mean BHg of 1.08 µg/L, a positive association was observed between BHg in men and women. No association was observed between BHg and hepatic fibrosis in men or women. Although both studies found positive associations between BHg and liver disease, data are inadequate to determine if there is a consistent relationship between mercury and liver disease.

Mechanisms of Action. General mechanisms of toxicity of mercury (reviewed in Section 2.21) are likely involved in the development of hepatic effects. These general mechanisms include increased ROS production and oxidative stress, degeneration of fatty acids, mitochondrial depolarization and ATP depletion, damage to hepatic cell membranes, and cell necrosis and death.

2.11 RENAL

Overview. The renal toxicity of mercury is well established. All forms of mercury are nephrotoxic, but inorganic forms appear to be more nephrotoxic than organic forms (Zalups 2000). Nephrotoxicity of mercury is characterized primarily by damage to the *pars recta* segment of the proximal tubule, with involvement of proximal convoluted tubules and distal tubule in severe toxicity (Berlin et al. 2015; Zalups and Diamond 2005). Damage to the *pars recta* segment of the proximal tubule is consistent with localized uptake of mercury in the renal cortex and outer stripe of the outer medulla (Section 3.1.2). In the proximal tubule, early changes include loss of the brush boarder membrane, resulting in urinary excretion of brush boarder enzymes, such as ALP and GGT. As damage to the proximal tubule becomes more severe and progresses to necrosis, intracellular enzymes, such as alanine aminopeptidase (AAP) and N-acetyl-β-D-glucosaminidase (NAG), are excreted in the urine. The glomerular basement membrane has also been shown to be a target of inorganic mercuric mercury in rabbits and some strains of rats (Druet et al. 1978; Roman-Franco et al. 1978; Sapin et al. 1977). The mechanism for mercury-induced glomerulonephritis in these animal models involves auto-immunity and deposition of immune complexes in the glomerular basement membrane. Although mercury has not been definitively shown to be a cause of glomerulonephritis in humans, were it to occur, the primary outcomes could include proteinuria and declines in glomerular filtration rate (GFR).

While it is established that mercury is nephrotoxic, results of epidemiological studies evaluating renal effects of mercury at occupational and environmental exposure levels are inconsistent with regard to markers of glomerular and tubular damage. There is some evidence that supports associations between elemental mercury exposure and adverse renal effects and between mercury exposure and renal effects in the general population; however, the kidney does not appear to be a sensitive target organ for mercury under these occupational and environmental exposure conditions. Epidemiological data are from studies evaluating associations between mercury and renal effects in workers exposed to elemental mercury, populations exposed to elemental mercury through dental amalgam fillings, and general populations exposed to unknown forms of mercury. Few studies have been conducted in populations exposed to mercury from high fish diets, presumably because the kidney is not a sensitive target organ for methylmercury at these environmental exposures. Although there are no epidemiological studies on populations exposed to inorganic mercury salts, case reports of accidental or intentional ingestion show severe renal damage from high-dose exposure. In this discussion, the following markers were interpreted to be indicative of changes in glomerular function: GFR; blood urea nitrogen (BUN), or serum urea nitrogen (SUN); serum creatinine and serum 2-microglobuin (β_2M); and urine protein and albumin. In

most studies in which GFR was assessed, GFR was estimated using equations relating GFR to serum creatinine and other factors that contribute to variance in GFR (e.g., body size, age, sex, race) (Levey et al. 2009). GFR estimated from these equations is referred to as eGFR to distinguish it from estimates based on measurements of clearance of GFR markers (e.g., creatinine, iothalamate). Decreases in GFR typically result in increases in BUN, SUN, serum creatinine, and serum β_2M. Increases in urinary excretion of protein or albumin is typically observed in association with impaired glomerular function (i.e., increased glomerular filtration of protein); however, impaired renal tubule processing of filtered protein can also contribute to proteinuria. Renal tubular damage was assessed from measurements of renal tubule cell proteins in urine, which are not typically released from renal tubule cells unless the cells are damaged. These proteins include AAP, ALP, glycosaminoglycans (GAG), NAG, and GGT. Renal tubular damage was assessed in some studies from measurements of urinary excretion of proteins that are typically removed from the glomerular filtrate unless tubular reabsorption of protein is disrupted. These include α_1-microglobulin (α_1M), β_2M, and retinol binding protein (RBP). A few studies have assessed serum uric acid, which can become elevated as a result of disruption of renal tubular transport of organic acids.

Nephrotoxicity of inorganic and organic mercury has been extensively studied in animal models (Berlin et al. 2015; Zalups and Diamond 2005). Inorganic mercuric mercury produces a lesion in the proximal tubule that is initially focused in the *pars recta*, with toxicity developing within 24 hours after a single dose of mercuric chloride. The rapid onset of this focal lesion has prompted use of mercuric chloride as a tool for studying structural and functional correlates to damage to the proximal tubule. As noted above, auto-immune glomerulonephritis has been observed in rabbits and some strains of rats following dosing with mercury chloride (Druet et al. 1978; Roman-Franco et al. 1978; Sapin et al. 1977).

The following summarizes results of epidemiological and animal studies on renal outcomes.

- ***Elemental mercury***
  - *Epidemiology studies*
    - Several studies in workers exposed to elemental mercury vapor provide some evidence of decrements in glomerular function and tubular injury, although conflicting results are reported.
    - Results of studies on populations with amalgam fillings (at lower exposures than mercury workers) also report some evidence of decrements in glomerular function and tubular injury; however, results are not consistent.

- ▪ Elemental mercury appears to be associated with glomerular and tubular damage, but the kidney is not a sensitive target for elemental mercury at exposure levels in these studies.
  - ▪ *Animal studies*
    - ▪ Available studies indicate dose- and duration-dependent increases in the occurrence and severity of renal effects in animals, although some studies are limited based on lack of quantitative data and/or inadequate description of pathological lesions.
    - ▪ One study in maternal rats suggests impaired renal function following inhalation exposure based on urinalysis parameters.

- • ***Inorganic mercuric salts***
  - ▪ *Epidemiology studies*
    - ▪ No epidemiological studies evaluating associations between exposure to inorganic mercury salts and renal effects were identified.
    - ▪ Severe renal damage has been reported in case studies of accidental or intentional ingestion of high doses of inorganic mercury salts.
  - ▪ *Animal studies*
    - ▪ There is consistent evidence of dose- and duration-dependent increases in the occurrence and severity of renal effects in animals.

- • ***Organic mercury***
  - ▪ *Epidemiology studies*
    - ▪ Little information is available on effects of methylmercury exposure in populations with high fish diets.
    - ▪ Minamata disease is associated with renal dysfunction.
    - ▪ Limited information suggests that the kidney is not a highly sensitive target for methylmercury, even in populations with very high methylmercury exposures from fish.
  - ▪ *Animal studies*
    - ▪ Available studies indicate dose-dependent increases in the occurrence and severity of renal effects in animals, although some studies are limited based on lack of quantitative data.
    - ▪ Impaired renal function was reported in one study in mice at lethal/near-lethal acute-duration oral doses.

- • ***Predominant mercury form unknown (general populations)***
    - ▪ Studies indicate that mercury exposure of the general population may be associated with glomerular and tubular damage, but results are inconsistent.

Confounding Factors. Inconsistencies in the reported outcomes for renal effects across studies may derive from several causes, including failure to account for confounding factors. Various factors that can affect kidney function may also be associated with mercury exposure status, including age, underlying diseases (e.g., hypertension), and concomitant exposure to other nephrotoxicants (e.g., lead, cadmium). Kidney function is also important for elimination of mercury since mercuric mercury is excreted in urine (Section 3.1.4). Decreased GFR or impaired renal tubular transport could decrease clearance of mercury and contribute to correlations between renal GFR or indicators of tubular damage and BH. This is an example of reverse causation, in which impaired renal function results in higher BHg levels due to decreased clearance.

In epidemiological studies in which GFR appears to have been severely depressed, reverse causation (lower mercury clearance contributing to higher mercury body burden) could be a substantial complication in interpreting causal relationships from statistical associations between BHg and GFR. Studies that evaluate associations between UHg and urinary renal outcome markers typically adjust the urinary concentrations relative to creatinine (e.g., µg Hg/g creatinine; mg albumin/g creatinine). This adjustment reduces autocorrelation resulting from interindividual variation in urine flow rate (L/day) similarly affecting the concentrations of mercury and the renal outcome marker (Diamond 1988). Autocorrelation would tend to strengthen the observed association between UHg and the urinary renal outcome marker.

Elemental Mercury—Epidemiological Studies. Studies evaluating effects of elemental mercury on renal function include cross-sectional and retrospective studies in workers, and cross-sectional studies, survey studies, and clinical trials in participants with amalgam fillings; studies are summarized in Table 2-21. Several of the studies summarized in Table 2-21 are of workers who participated in artisanal gold mining where exposure to elemental mercury would have occurred. However, these workers also may have been exposed to methylmercury formed from oxidation of elemental mercury released into the local environment. Most studies evaluated effects by comparison of exposed versus control groups. Based on UHg (the main biomarker in most studies), exposure of workers was greater than nonoccupational exposure from amalgam fillings. For example, the highest UHg in workers (23.7 µg/g creatinine) (Boogaard et al. 1996) is approximately 10-fold greater than the highest UHg in nonoccupational amalgam studies (2.94 µg/g creatinine) (Al-Saleh et al. 2013). In general, population sizes in worker studies (range 40–291) were smaller than in nonoccupational amalgam studies (range 46–801).

Table 2-21. Results of Epidemiological Studies Evaluating Exposure to Elemental Mercury (Hg^0) and Renal Effects

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Workers			

Afrifa et al. 2017
 	
Cross-sectional; 61 male gold miners and 49 controls (Ghana)
	BHg mean
	  Workers: 18.37 µg/L
	  Controls: 2.90 µg/L
		eGFR	↓ (BHg)

		Urine protein	↑ (BHg)
		Microalbuminuria	↑ (BHg)
		Serum creatinine	↑ (BHg)

Boogaard et al. 1996
 	
Cross-sectional; male natural gas workers, 18 high exposure, 22 low exposure, and 19 controls (The Netherlands)
	UHg mean
	  High: 23.7 µg/g Cr
	  Low: 4.1 µg/g Cr
	  Controls: 2.4 µg/g Cr
		Urine albumin	↔ (UHg, high versus low and controls)

		Urine total protein	↔ (UHg, high versus low and controls)
		Urine NAG	↑ (UHg, high versus low and controls)
		Urine β$_2$M	↑ (UHg, high versus low)

Cardenas et al. 1993
 	
Cross-sectional; male chloralkali workers, 44 workers and 49 controls (Belgium)
	UHg Gmean
	  Workers: 21.9 µg/g Cr
	  Controls: 1.6 µg/g Cr
		Serum creatinine	↓ (UHg, workers versus controls)

		Urine albumin	↔ (UHg, workers versus Ellingsen controls)
		Urine protein	↔ (UHg, workers versus controls)
		Urine β$_2$M	↓ (UHg, workers versus controls)
		Urine NAG	↔ (UHg, workers versus controls)
		Urine GAG	↓ (UHg, workers versus controls)
		Urine BBA[a]	↑ (UHg, workers versus controls)
		Urine BB50[a]	↑ (UHg, workers versus controls)
		Urine HF5[a]	↑ (UHg, workers versus controls)

Ellingsen et al. 2000a
 	
Cross-sectional; 47 chloralkali workers and 47 controls (Norway)
	UHg mean
	  Workers: 10.5 µg/g Cr
	  Controls: 2.3 µg/g Cr
		Urine albumin	↔ (UHg, workers versus controls)

		Urine β$_2$M	↔ (UHg, workers versus controls)
		Urine NAG	↑ (UHg, workers versus controls)
		Urine AAP	↔ (UHg, workers versus controls)
		Urine ALP	↔ (UHg, workers versus controls)
		Urine GAG	↔ (UHg, workers versus controls)

Table 2-21. Results of Epidemiological Studies Evaluating Exposure to Elemental Mercury (Hg⁰) and Renal Effects

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Franko et al. 2005 Cross-sectional; male mercury miners, 33 active miners, 20 retired miners, and 53 controls (Slovenia)	UHg mean All miners: 2.12 µg/g Cr Active: 2.50 µg/g Cr Retired: 1.42 µg/g Cr Controls: 1.36 µg/g Cr	Urine albumin	↑ (UHg, all miners versus controls)
		Urine NAG	↔ (UHg, all miners versus controls)
		Urine α_1M	↑ (UHg, all miners versus controls)
Frumkin et al. 2001 Retrospective cohort; males and females, 147 chloralkali workers, 132 controls (Georgia)	UHg mean Workers: 2.76 µg/g Cr Controls: 2.31 µg/g Cr	Serum creatinine	↔ (UHg, workers versus controls)
		Urine albumin	↔ (UHg, workers versus controls)
		Urine NAG	↔ (UHg, workers versus controls)
		Urine AAP	↔ (UHg, workers versus controls)
		Urine RBP	↔ (UHg, workers versus controls)
Jarosinska et al. 2008 Cross-sectional; 179 chloralkali workers (Italy, Poland, Sweden)	UHg median in workers Italy: 4.6 Poland (1): 6.0 Poland (2): 45.9 Sweden: 3.8	Urine NAG	↑ (UHg)
		Urine α_1M	↑ (UHg)
Kobal et al. 2004 Cross-sectional; 54 mercury miners and 58 controls (Slovenia)	UHg mean Miners: 2.1 µg/L Controls: 1.4 µg/L	Urine albumin	↑ (UHg, miners versus controls)
		Urine NAG	↔ (UHg, miners versus controls)
		Urine α_1M	↑ (UHg, miners versus controls)
Piikivi and Ruokonen 1989 Cross-sectional; 60 male chloralkali workers and 60 matched controls (Finland)	UHg mean: Workers: 17.9 µg/g Cr Controls: 2.1 µg/g Cr	Urine albumin	↔ (UHg, workers versus controls)
		Urine NAG	↔ (UHg, workers versus controls)
Rodriguez et al. 2017 Cross-sectional; 164 gold miners and 127 controls (Columbia)	UHg median Miners: 3.9 µg/g Cr Controls: 1.5 µg/g Cr BHg median Miners: 7.0 µg/L Controls: 2.5 µg/L	Blood Cr	↔ (UHg, miners versus controls)
		Cr clearance	↔ (UHg, miners versus controls)
		GFR	↑ (UHg, miners versus controls) ↔ (UHg, BHg, multivariable regression)
		Urine albumin	↔ (UHg, miners versus controls)
		Urine β_2M	↔ (UHg, miners versus controls)

Table 2-21. Results of Epidemiological Studies Evaluating Exposure to Elemental Mercury (Hg^0) and Renal Effects

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Amalgam fillings			

Al-Saleh et al. 2012
 	
Survey; 106 children with amalgam fillings and 76 children without amalgam fillings (Saudi Arabia)
	UHg median
	  Amalgam: 2.94 µg/g Cr
	  No amalgam: 2.42 µg/g Cr
		Urine NAG	↑ (UHg)

Barregard et al. 2008
 	
Randomized clinical trial; 534 children, 267 receiving amalgam fillings and 267 receiving resin fillings over 5 years (Boston, Massachusetts)
	HHg mean
	  Amalgam: 0.4 µg/g
	  No amalgam: 0.4 µg/g
		Urine albumin	↔ (HHg, amalgam versus no amalgam)

		Microalbuminuria	↑ (HHg, amalgam versus no amalgam)
		Urine NAG	↔ (HHg, amalgam versus no amalgam)
		Urine α_1M	↔ (HHg, amalgam versus no amalgam)
		Urine GGT	↔ (HHg, amalgam versus no amalgam)

Eti et al. 1995
 	
Cross-sectional; 100 adults, 66 with amalgam fillings and 34 without amalgam fillings (New York, New York)
	UHg median
	  Amalgam: 1 µg/L
	  No amalgam: 0 µg/L
		Urine NAG	↑ (UHg, amalgam versus no amalgam)

Herrstrom et al. 1995
 	
Cross-sectional; 23 men with amalgam fillings and 23 men without amalgam fillings
	UHg median
	  Amalgam: 0.32 µg/g Cr
	  No amalgam: 0.17 µg/g Cr
		Urine albumin	↔ (UHg, amalgam versus no amalgam)

		Urine Cr	↔ (UHg, amalgam versus no amalgam)
		Urine NAG	↔ (UHg, amalgam versus no amalgam)
		Urine α_1M	↔ (UHg, amalgam versus no amalgam)

Mortada et al. 2002
 	
Cross-sectional; 101 adults with amalgam fillings and 52 adults without amalgam fillings (Egypt)
	UHg mean
	  Amalgam: 1.79 µg/g Cr
	  No amalgam: 0.48 µg/g Cr
		Serum Cr	↔ (UHg, amalgam versus no amalgam)

		Serum β_2M	↔ (UHg, amalgam versus no amalgam)
		BUN	↔ (UHg, amalgam versus no amalgam)
		Urine albumin	↑ (UHg, amalgam versus no amalgam)
		Urine NAG	↑ (UHg, amalgam versus no amalgam)
		Urine β_2M	↔ (UHg, amalgam versus no amalgam)

Table 2-21. Results of Epidemiological Studies Evaluating Exposure to Elemental Mercury (Hg⁰) and Renal Effects

Reference, study type, and population	Biomarker	Outcome evaluated	Result
		Urine ALP	↔ (UHg, amalgam versus no amalgam)
		Urine GGT	↑ (UHg, amalgam versus no amalgam)

Woods et al. 2008
 	
Randomized clinical trial 507 children, age 8–12 years (Portugal)
	UHg mean
	  Amalgam: 1.8 µg/g Cr
	  No amalgam: 1.9 µg/g Cr
		Urine albumin	↔ (amalgam versus no amalgam)

		Urine GGT-α	↔ (amalgam versus no amalgam)
		Urine GGT-π	↔ (amalgam versus no amalgam)

Ye et al. 2009
 	
Cross-sectional; 403 children (ages 7–11 years), 198 with amalgam fillings and 205 without amalgam fillings (China)
	UHg Gmean:
	  Amalgam: 1.6 µg/g Cr
	  No amalgam: 1.4 µg/g Cr
		Urine albumin	↔ (UHg, amalgam versus no amalgam)

		Urine NAG	↔ (UHg, amalgam versus no amalgam)

[a]Brush border tubular antigens.

↑ = positive association; ↓ = inverse association; ↔ = no association; $\alpha_1 M$ = α_1-microglobulin; $\beta_2 M$ = β_2-microglobulin; AAP = alanine aminopeptidase; ALP = alkaline phosphatase; BHg = blood mercury; BUN = blood urea nitrogen; Cr = creatinine; eGFR = estimated glomerular filtration rate; GAG = glycosaminoglycans; GFR = glomerular filtration rate; GGT = gamma-glutamyltransferase; Gmean = geometric mean; HHg = hair mercury; NAG = N-acetyl-β-D-glucosaminidase; RBP = retinol binding protein; UHg = urine mercury

Several studies in mercury workers provide some evidence of impaired glomerular function or renal tubular damage, although conflicting results are reported. For assessments of glomerular function, results are inconsistent. Some studies reported signs of impaired glomerular function, including decreased GFR, increased urine protein and albumin, microalbuminuria, decreased urine $\beta_2 M$, and increased serum creatinine (Afrifa et al. 2017; Cardenas et al. 1993; Franko et al. 2005; Kobal et al. 2004), whereas other studies did not observe alterations in markers of glomerular function (Boogaard et al. 1996; Ellingsen et al. 2000a; Frumkin et al. 2001; Piikivi and Ruokonen 1989; Rodriguez et al. 2017). For studies showing altered glomerular function, the magnitude of changes is toxicologically significant. Afrifa et al. (2017) reported marked alterations in GFR markers in gold miners compared to controls; mean estimated GFR in exposed miners (BHg ≥5 µg/L) was 52.6% lower than the control group (BHg <5 µg/L), and mean urine protein and serum creatinine were higher by 68- and 2.3-fold, respectively. Given the very large differences in GFR between exposed and non-exposed subjects, reverse causation is a potential contributor to the relatively high age-adjusted ORs for low GFR reported in this study (263; 95% CL 48,

1,420). Urine albumin was higher by 1.33–1.6-fold in mercury miners than in controls (Franko et al. 2005; Kobal et al. 2004). Results of evaluations of occupational exposure and tubular damage are also inconsistent. Some studies showed altered urinary excretion of at least one marker of tubular damage, including increased urine NAG and $\alpha_1 M$, and decreased $\beta_2 M$ (Boogaard et al. 1996; Ellingsen et al. 2000a; Franko et al. 2005; Jarosinska et al. 2008; Kobal et al. 2004). In other studies, no changes indicative of tubular damage were observed (Franko et al. 2005; Frumkin et al. 2001; Piikivi and Ruokonen 1989; Woods et al. 2008). Although Cardenas et al. (1993) did not find elevated urinary markers of tubular damage, brush border tubular antigens in urine were increased, indicative of an immune response against the proximal tubule. Taken together, results suggest that studies of occupational exposures are inconsistent. Some studies have found associations between exposure to mercury and decreased GFR or tubular damage; however, these outcomes were not consistently observed across studies at similar exposures (based on exposure biomarkers). These inconsistencies may reflect differences in exposure levels as well as differences in study designs or the exposure markers utilized.

Several studies have examined associations between indicators of impaired glomerular function or tubular damage and exposures to elemental mercury from mercury amalgam restorations. Exposures to elemental mercury in these populations (UHg mean or median <3 µg/g creatinine) were lower than exposures observed in workers (UHg mean or median: 2–24 µg/g creatinine). A clinical trial reported microalbuminuria (urinary albumin >30 mg/g creatinine) in children in the amalgam group (Barregard et al. 2008) and a cross-sectional study reported increased urine albumin in adults with amalgam fillings compared to those with no amalgam fillings (Mortada et al. 2002). Other studies did not observe differences in glomerular function markers in children (Herrstrom et al. 1995) or adults (Ye et al. 2009) with amalgam fillings compared to no amalgam fillings. Urine NAG and/or GGT were increased in amalgam groups compared to no amalgam groups in children and adults (Al-Saleh et al. 2012; Eti et al. 1995; Mortada et al. 2002); however, other urinary markers of tubular damage ($\beta_2 M$, ALP) were not increased (Mortada et al. 2002). In addition, other studies did not observe increased urinary excretion of any markers of tubular damage, including NAG, $\alpha_1 M$, GGT, and ALP (Barregard et al. 2006, 2008; Herrstrom et al. 1995; Ye et al. 2009). Together, these results do not provide consistent evidence of associations between low-level exposure to elemental mercury from amalgam fillings and renal effects.

Elemental Mercury—Animal Studies. Data following acute-duration exposure of rats to elemental mercury suggest that that occurrence and severity of renal effects are increased in a dose- and duration-dependent manner. A series of experiments evaluated maternal kidney effects in rats following exposure to elemental mercury vapor at concentrations up to 8 mg Hg/m^3 for 1, 5, or 10 days during pregnancy

(Morgan et al. 2002). After exposure to 1, 2, and 4 mg Hg/m^3 for 10 days (GDs 6–15), total urinary protein was increased 1.7-, 1.9-, and 1.8-fold, respectively, and urinary ALP activity was increased 7-, 2-, and 10-fold, respectively (urinalysis was not conducted at 8 mg Hg/m^3). Maternal relative kidney weights were significantly increased by >30% at ≥4 mg Hg/m^3; findings may be attributable in part to body weight effects (maternal weight gain decreases of 7–17% at ≥4 mg Hg/m^3). Absolute kidney weights were not reported. No histopathological lesions were observed in maternal kidneys at concentrations up to 8 mg Hg/m^3. No exposure-related renal effects were noted in dams similarly exposed for 1 day (GD 6) or 5 days (GDs 6–10). In nonpregnant rats, no exposure-related changes in kidney weight were observed in Sprague-Dawley rats following acute-duration exposure to concentrations up to 4 mg Hg/m^3 for 2 hours/day (Davis et al. 2001); however, renal function and histology were not evaluated in this study and a NOAEL for renal effects was therefore not included in the LSE table (inadequate endpoint evaluation).

Intermediate-duration studies in rats also provide evidence for dose- and duration-dependent increases in occurrence and severity of renal lesions, although no measures of renal function were conducted in intermediate-duration studies. In rats, slight degenerative changes (i.e., dense deposits in tubule cells and lysosomal inclusions) in the renal tubular epithelium were evident following exposure to 3 mg Hg/m^3 for 3 hours/day, 5 day/week for 12–42 weeks (Kishi et al. 1978). Akgul et al. (2016) also reported histopathological and stereological changes in renal glomeruli in male and female rats following exposure to 0.0487 mg Hg/m^3 for 45 days for an unspecified daily duration. Due to lack of exposure details, this study was not included in the LSE table, but findings are discussed below. Mercury-exposed rats showed reductions in the mean numerical density of glomeruli (-5%), total number of glomeruli (-7%), and mean volumes of glomeruli (-19%), cortex (-21%), and proximal tubule (-38%), compared to controls. Additionally, increased mean volume of medulla (29%) and distal tubule (250%) were seen in exposed rats, compared to controls. Histopathological findings, reported qualitatively only, included changes in vacuoles, pyknotic nuclei of glomerular and tubular cells, tubular necrosis, glomerular sclerosis, glomerular degeneration, and dilation of Bowman's space. In addition, kidneys of treated rats had cells with darkly stained cytoplasm, collecting tubules that were indistinguishable from cytoplasm borders, tubules with dead cells, and structures that were possible residue of dead cells. No pathological kidney changes were noted in control animals. Electron microscopy evaluations revealed pathological changes in the vacuole, nucleus, and mitochondria of distal tubule cells of exposed animals as well as cytoplasmic disorganization and damage to the podocytes, mesangial cells, glomerular cells, and basement membrane.

Inorganic Mercury Salts—Exposure of Humans. No epidemiological studies assessing associations between inorganic mercury salts and renal function were identified. As discussed in Section 2.1 (Introduction), exposure of humans to inorganic mercury salts in the environment is minimal relative to exposures to other forms of mercury and, as a result, it would be difficult to discern outcomes associated with exposure to inorganic mercury salts from outcomes contributed by exposures to other forms of mercury. However, the kidney, specifically the proximal tubule, is the primary target organ for inorganic mercury salts (Bhan and Sarkar 2005; Clarkson and Magos 2006; Clarkson et al. 2003). Case reports of acute-duration accidental or intentional ingestion of high doses of inorganic mercury salts show that renal damage can be very severe, including necrosis of the tubular epithelium and anuria, with complete collapse of renal function (Clarkson and Magos 2006; Magos and Clarkson 2006; Syversen and Kaur 2012).

Inorganic Mercury Salts—Animal Studies. The kidney is a clear target of toxicity for inorganic mercury. There is clear and consistent evidence of dose- and duration-dependent increases in occurrence and severity of renal effects in rats and mice following oral exposure to mercuric chloride.

Histopathological lesions have been reported in rats and mice following acute-, intermediate-, and chronic-duration oral exposure to mercuric chloride. In general, occurrence and severity of lesions appear to increase in a dose- and duration-related manner for specific exposure routes (e.g., gavage, diet, drinking water), beginning with mild histopathological damage after lower, shorter exposures (e.g., mild protein casts, cellular casts, interstitial sclerosis, tubular regeneration) and progressing to greater incidence and severity of renal nephropathy and necrosis with higher and/or longer durations (lesion types, incidence, and severity summarized in Tables 2-22 and 2-23). In both rats and mice, males appear more susceptible than females. In rats, renal lesions have been consistently observed following gavage exposure to ≥7.4 mg Hg/kg/day for 1–16 days (Dieter et al. 1992; Lecavalier et al. 1994; NTP 1993) or ≥0.923 mg Hg/kg/day for >180 days (Dieter et al. 1992; NTP 1993). One study qualitatively reported histopathological changes in the kidney in rats after gavage exposure to 0.015 mg Hg/kg/day for 28 days (Apaydin et al. 2016), but other repeat-dose studies did not confirm findings at doses <0.923 mg Hg/kg/day. Gavage studies in mice are less consistent, with renal lesions observed after single exposures ≥10 mg Hg/kg/day (Nielsen et al. 1991) but not until doses ≥30 mg Hg/kg/day following up to 12 doses over 16 days (NTP 1993). An acute-duration oral (not specified) study in mice reported renal lesions at 0.062 mg Hg/kg/day for 14 days (Jalili et al. 2020b). In longer-duration gavage studies, renal lesions were observed in mice at ≥4 mg Hg/kg/day (NTP 1993). In both rats and mice, renal lesions have been consistently observed following intermediate-duration dietary or drinking water exposure to >5 mg

Hg/kg/day. Most studies reported no renal effects at ≤2 mg Hg/kg/day (Boscolo et al. 1989; Carmignani et al. 1989; Dieter et al. 1983; Jonker et al. 1993; Khan et al. 2004), except for two studies that reported lesions at doses of 0.3 and 1.5 mg Hg/kg/day (Raeeszadeh et al. 2021; Sabir et al. 2022)

Table 2-22. Kidney Lesions in Rats[a] Orally Exposed to Mercuric Chloride

Duration; dose (mg Hg/kg/day)	Histology	Lesion details	Reference
Gavage studies			
1 day; dose: 7.4	↑ (F)	Mild protein casts, cellular casts, interstitial sclerosis[b]	Lecavalier et al. 1994
1 day; dose: 9.24	↑ (F)	Mild protein casts, cellular casts, interstitial sclerosis[b]	Lecavalier et al. 1994
16 days; dose: 0.923–4	↔ (M, F)		Dieter et al. 1992; NTP 1993
16 days; dose: 7.4	M: ↑ F: ↔	Acute renal necrosis M: 3/5 minimal, 2/5 mild (control 0/5)	Dieter et al. 1992; NTP 1993
16 days; dose: 15	↑ (M, F)	Acute renal necrosis M: 2/5 mild; 3/5 moderate F: 1/5 minimal; 4/5 mild (M, F control: 0/5)	Dieter et al. 1992; NTP 1993
28 days; dose: 0.015	↑ (NS)	Renal tubular dilation and glomerular lobulation[b]	Apaydin et al. 2016
30 days; dose: 0.3	↑ (NS)	Severe renal tubular degeneration and renal cell apoptosis	Sabir et al. 2022
30 days; dose: 1.5	↑ (M)	Tubular necrosis, interstitial nephritis, glomerular damage, and hyaline casts	Raeeszadeh et al. 2021
182 days; dose: 0.23–0.462	↔ (M, F)		Dieter et al. 1992; NTP 1993
182 days; dose: 0.923	M: ↑ F: ↔	Renal nephropathy M: 6/10 minimal; 4/10 mild (control 8/10 minimal)	Dieter et al. 1992; NTP 1993
182 days; dose: 1.8	M: ↑ F: ↔	Renal nephropathy M: 7/10 minimal; 3/10 mild (control 8/10 minimal)	Dieter et al. 1992; NTP 1993
182 days; dose: 4	↑ (M, F)	Renal nephropathy M: 6/10 minimal; 4/10 mild (control 8/10 minimal) F: 4/10 minimal (control 0/10)	Dieter et al. 1992; NTP 1993
450–730 days; dose: 1.8	M: ↑ F: ↔	M: Increased severity of nephropathy (32% increase in severity score at 15 months and 15% at 2 years)	Dieter et al. 1992; NTP 1993

Table 2-22. Kidney Lesions in Rats[a] Orally Exposed to Mercuric Chloride

Duration; dose (mg Hg/kg/day)	Histology	Lesion details	Reference
450–730 days; dose: 4	M: ↑ F: ↔	M: Increased severity of nephropathy (mild to marked; 68% increase in severity score at 15 months; 22% at 2 years)	Dieter et al. 1992; NTP 1993
Dietary studies			
28 days; dose: 0.61–0.76	↔ (M, F)		Jonker et al. 1993
28 days; dose: 5.1–5.5	M: ↑ F: ↔	Basophilic tubules in outer cortex M: 5/10 single-to-few; 5/10 several (control: 3/10 single-to-few)	Jonker et al. 1993
28 days; dose: 5.8–23.6	↑ (M, F)	Nephrosis and proteinaceous casts[b]	Jonker et al. 1993
Drinking water studies			
180 days; dose: 24	↑ (M)	Focal tubule degeneration, mesangial proliferative glomerulonephritis in 80% of glomeruli[b]	Carmignani et al. 1992
350 days; dose: 6	↑ (M)	Tubular degeneration and desquamation[b]	Boscolo et al. 1989; Carmignani et al. 1989
350 days; dose: 6	↑ (M)	Membranous glomerulonephritis in 30% of glomeruli and tubular degeneration[b]	Boscolo et al. 1989
350 days; dose: 24	↑ (M)	Membranous glomerulonephritis in 100% of glomeruli and tubular degeneration[b]	Boscolo et al. 1989

[a]Sexes evaluated are indicated in the results columns.
[b]Reported qualitatively only (incidence data not provided).

↑ = increase in histopathological lesions; ↔ = no change; F = female; M = male; NS = not specified

Table 2-23. Kidney Lesions in Mice[a] Orally Exposed to Mercuric Chloride

Duration; dose (mg Hg/kg/day)	Histology	Lesion details	Reference
Gavage studies			
1 day; dose: 5	↔ (F)		Nielsen et al. 1991
1 day; dose: 10	↑ (F)	Proximal tubule regeneration F: 10/10; severity grade 2/3 (control 0/10)	Nielsen et al. 1991

Table 2-23. Kidney Lesions in Mice[a] Orally Exposed to Mercuric Chloride

Duration; dose (mg Hg/kg/day)	Histology	Lesion details	Reference
1 day; dose: 20	↑ (F)	Proximal tubule degeneration F; 10/10; severity grade 2.5/3 Proximal tubule regeneration F: 10/10; severity grade 2.5/3 (control 0/10)	Nielsen et al. 1991
1 day; dose: 40	↑ (F)	Proximal tubule degeneration F; 10/10; severity grade 3/3 Proximal tubule regeneration F: 10/10; severity grade 0.25/3 (control 0/10)	Nielsen et al. 1991
2–4 days; Dose: 59	↑ (M, F)	Acute renal necrosis M: 5/5 (control 0/5) F: 5/5 (control 0/5)	NTP 1993
14 days; dose: 4–15	↔ (M, F)		NTP 1993
14 days; dose: 30	M: ↑ F: ↔	Acute renal necrosis M: 2/5 (control 0/5)	NTP 1993
61–79 days; dose: 0.18–0.74	↔ (M, F)		Khan et al. 2004
182 days; dose: 0.923–1.8	↔ (M, F)		NTP 1993
182 days; dose: 4–15	M: ↑ F: ↔	Dose-related increase in incidence and severity of cytoplasmic vacuolation in the renal tubule epithelium[b]	NTP 1993
450–730 days; dose: 4	↑ (M, F)	Renal nephropathy M: Severity grade increased 61% F: Severity grade increased by 117%; incidence increased, 43/50 versus 21/49	NTP 1993
450–730 days; dose: 7.4	↑ (M)	Renal nephropathy M: Severity grade increased 132% F: Severity grade increased by 164%; incidence increased, 42/50 versus 21/49	NTP 1993
Drinking water studies			
49 days; dose: 0.4–2	↔ (M)		Dieter et al. 1983
49 days; dose: 11	↑ (M)	Minimal renal nephropathy[b]	Dieter et al. 1983
112 days; dose: 4.0	↑ (M)	Tubular degeneration, necrosis, and hemorrhage	Li et al. 2019a
14 days; dose: 0.062 mg	↑ (M)	Tubular casts, intracellular vacuolization, vascular congestion, tubular detachment and dilation	Jalili et al. 2020b

[a]Sexes evaluated are indicated in the results columns.
[b]Reported qualitatively only (incidence data not provided).

↑ = increase in histopathological lesions; ↔ = no change; F = female; M = male; NS = not specified

Renal lesions associated with autoimmunity (e.g., IgG deposits in renal vessels) have been observed in mouse strains genetically susceptible to autoimmune disease following oral exposure to mercuric chloride. Due to the autoimmune nature of these lesions, these studies are discussed in Section 2.15. (Immunological) and are included in the LSE table as evidence of immune-complex disease.

Increased kidney weights have been consistently reported in rats following intermediate- and chronic-duration oral exposure to mercuric chloride. In general, findings are dose-dependent; however, duration of exposure does not seem to greatly impact magnitude of effect (Table 2-24). In male rats, significant dose-related increases in kidney weights were observed following repeated exposure to gavage doses ≥1.8 mg Hg/kg/day for 12 days (over 16 days) (Dieter et al. 1992; NTP 1993). Similarly, increased kidney weights were observed in intermediate- and chronic-duration gavage at doses of ≥0.23 and 1.8 mg Hg/kg/day, respectively (Atkinson et al. 2001;). Increased kidney weights were observed following dietary exposures at doses ≥5.1 mg Hg/kg/day for 28 days (Jonker et al. 1993) and at doses ≥0.06 mg Hg/kg/day following exposure for 35–147 days (Takahashi et al. 2000a, 2000b). For drinking water exposures, kidney weights were increased following exposure to doses ≥0.244 mg Hg/kg/day for 28 days (Wildemann et al. 2015a, 2016). No changes in kidney weight were observed in male rats at dietary doses of 0.61 mg Hg/kg/day for 28 days (Jonker et al. 1993).

The duration of exposure did not seem to affect the magnitude of kidney effects in female rats either. No change in kidney weight was observed following single gavage doses up to 0.24 mg Hg/kg/day (Lecavalier et al. 1994). In repeat-dose studies, significant dose-related increases in kidney weights were observed in female rats following gavage doses ≥4 mg Hg/kg/day for 12 days (over 16 days). Similarly, increased kidney weight was observed at all tested intermediate- and chronic-duration gavage doses in non-breeding female animals exposed to ≥0.23 and 1.8 mg Hg/kg/day, respectively. Dietary exposures at ≥0.76 mg Hg/kg/day in intermediate-duration studies also observed increased kidney weights (Dieter et al. 1992; Jonker et al. 1993; NTP 1993). Dose-related increases in kidney weights were observed in rat dams exposed to drinking water doses ≥0.019 mg Hg/kg/day throughout gestation and lactation (Galiciolli et al. 2022). However, in breeding females from a 2-generation study, no changes in kidney weight were observed in the F0 generation, but F1 females showed a significant increase in kidney weight at a gavage dose of 1.98 mg Hg/kg/day (Atkinson et al. 2001). Neither male nor female rats had significant changes in kidney weight at drinking water doses ≤0.037 mg Hg/kg/day (Oliveira et al. 2012; Wildemann et al. 2015a).

Table 2-24. Relative Kidney Weight and Clinical Chemistry in Rats Orally Exposed to Mercuric Chloride

Duration; dose (mg Hg/kg/day)	Relative kidney weight (sex) (percent change)[a]	BUN/ SUN	Serum creatinine	Serum uric acid	Reference
Gavage studies					
1 day; dose: 7.4–9.24	↔ (F)	–	–	↔ (F)	Lecavalier et al. 1994
16 days; dose: 0.923	↔ (F)	–	–	–	Dieter et al. 1992; NTP 1993
16 days; dose: 4	↑ (M) (19) ↑ (F) (38)	–	–	–	Dieter et al. 1992; NTP 1993
16 days; dose: 7.4	↑ (M) (35) ↑ (F) (34)	–	–	–	Dieter et al. 1992; NTP 1993
16 days; dose: 15	↑ (M, F) (43)	–	–	–	Dieter et al. 1992; NTP 1993
28 days; dose: 0.015	–	↑ (NS) (28)	↑ (NS) (17)	↑ (NS) (54)	Apaydin et al. 2016
79 days; dose: 0.55–1.11	↔ (F)	–	–	–	Atkinson et al. 2001
79 days; dose: 1.98	F0: ↔ (F) F1:↑ (F) (14)	–	–	–	Atkinson et al. 2001
81 days; dose: 0.37	F0: ↑ (M)(14) F1: ↔ (M)	–	–	–	Atkinson et al. 2001
81 days; dose: 0.74	F0: ↑ (M) (14) F1: ↔ (M)	–	–	–	Atkinson et al. 2001
81 days; dose: 1.31	F0: ↑ (M) (29) F1: ↔ (M)	–	–	–	Atkinson et al. 2001
182 days; dose: 0.23	↑ (M) (10) ↑ (F) (8)	↔ (M,F)	↔ (M) ↓ (F) (11)	–	Dieter et al. 1992; NTP 1993
182 days; dose: 0.462	↑ (M) (18) ↑ (F) (13)	–	–	–	Dieter et al. 1992; NTP 1993
182 days; dose: 0.923	↑ (M) (18) ↑ (F) (17)	↔ (M, F)	↔ (M) ↓ (F) (5)	–	Dieter et al. 1992; NTP 1993
182 days; dose: 1.8	↑ (M) (19) ↑ (F) (20)	–	–	–	Dieter et al. 1992; NTP 1993
182 days; dose: 4	↑ (M) (14) ↑ (F) (22)	↔ (M) ↓ (F) (11)	M: ↔ ↓ (F) (11[a])	–	Dieter et al. 1992; NTP 1993

Table 2-24. Relative Kidney Weight and Clinical Chemistry in Rats Orally Exposed to Mercuric Chloride

Duration; dose (mg Hg/kg/day)	Relative kidney weight (sex) (percent change)[a]	BUN/ SUN	Serum creatinine	Serum uric acid	Reference
450 days; Dose: 1.8	↑ (M) (20) ↑ (F) (18)	↔ (M, F)	–	–	Dieter et al. 1992; NTP 1993
450 days; Dose: 4	↑ M: (15) ↑ F: (18)	↔ (M, F)	–	–	Dieter et al. 1992; NTP 1993
Dietary studies					
28 days; dose: 0.61	↔ (M)	↔ (M)	↔ (M)	–	Jonker et al. 1993
28 days; dose: 0.76	↑ (F) (13)	↔ (F)	↔ (F)	–	Jonker et al. 1993
28 days; dose: 5.1–5.5	↑ (M) (17) ↑ (F) (20)	↔ (M, F)	↔ (M, F)	–	Jonker et al. 1993
28 days; dose: 5.8–6.1	M: ↑ (13) F: ↑ (16)	↔ (M, F)	↔ M, F)	–	Jonker et al. 1993
28 days; dose: 11.4–11.9	M: ↑ (17) F: ↑ (21)	↔ (M, F)	↔ (M, F)	–	Jonker et al. 1993
28 days; dose: 20.9–23.6	↑ (M) (25) ↑ (F) (22)	↔ (M, F)	↔ (M, F)	–	Jonker et al. 1993
35 days; dose: 0.07	↑ (M) (10)	–	–	–	Takahashi et al. 2000b
35 days; dose: 0.21	↑ (M) (14)	–	–	–	Takahashi et al. 2000b
35 days dose: 0.72	↑ (M) (16)	–	–	–	Takahashi et al. 2000b
35 days; dose: 2.2	↑ (M) (24)	–	–	–	Takahashi et al. 2000b
147 days dose: 0.06	↑ (M) (11)	↔ (M)	↔ (M)	–	Takahashi et al. 2000a
147 days dose: 0.17	↑ (M) (18)	↔ (M)	↔ (M)	–	Takahashi et al. 2000a
147 days dose: 0.51	↑ (M) (15)	↔ (M)	↔ (M)	–	Takahashi et al. 2000a
147 days dose: 1.7	↑ (M) (12)	↓ (M) (NS[b])	↔	–	Takahashi et al. 2000a
Drinking water studies					
21 days; dose: 0.0002–0.0301	↔	↔	–	–	Oliveira et al. 2012
28 days; dose: 0.005–0.01	↔ (M)	–	–	–	Wildemann et al. 2015a
42 days; dose: 0.019	↑ (F) (13)	↔ (F)	(F)	–	Galiciolli et al. 2022

Table 2-24. Relative Kidney Weight and Clinical Chemistry in Rats Orally Exposed to Mercuric Chloride

Duration; dose (mg Hg/kg/day)	Relative kidney weight (sex) (percent change)[a]	BUN/ SUN	Serum creatinine	Serum uric acid	Reference
28 days; dose: 0.021–0.037	↔ (M)	–	–	–	Wildemann et al. 2015a
42 days; dose: 0.094	↑ (F) (31)	↔ (F)	↔ (F)	–	Galiciolli et al. 2022
28 days; dose: 0.244–0.264	↑ (M) (15)	–	↔ (M)	–	Wildemann et al. 2015a
28 days; dose: 1.18	↑ (M) (26)	–	–	–	Wildemann et al. 2015a
28 days; dose: 2.07	↑ (M) (32)	–	–	–	Wildemann et al. 2015a
28 days; dose: 2.955	–	–	↔ (M)	–	Wildemann et al. 2016
28 days; dose: 5.91	↑ (M) (77[c])	–	–	–	Wildemann et al. 2015a

[a]Calculated from quantitative data or estimated from graphically reported data.
[b]Biological relevance of decreased BUN is unclear.
[c]Organ weight effects may be due in part to observed body weight loss; 100% mortality at this dose
↑ = increased; ↓ = decreased; ↔ = no change; – = not assessed; BUN = blood urea nitrogen; F = female;
F0 = F0 generation; F1 = F1 generation; M = male; NS = not specified; SUN = serum urea nitrogen

Increased kidney weights have also been consistently reported in mice following acute-, intermediate-, and chronic-duration oral exposure to mercuric chloride. In general, findings are dose- and duration-dependent in male mice; however, findings in female mice are less consistent than effects in males (Table 2-25). In male BALB/c and B6C3F1 mice, significant dose-related increases in kidney weights were consistently observed following exposure to acute oral doses ≥1.39 mg Hg/kg/day, intermediate-duration oral doses ≥2 mg Hg/kg/day, and at all tested chronic-duration oral doses ≥4 mg Hg/kg/day (Dieter et al. 1983; Kim et al. 2003; NTP 1993). One study reported an unspecified increase in kidney weight in C57Bl/6 male mice at intermediate-duration gavage doses ≥0.18 mg Hg/kg/day (Khan et al. 2004)); however, no exposure-related changes were observed at intermediate-duration oral doses ≤1.8 mg Hg/kg/day in male B6C3F1 mice (Dieter et al. 1993; NTP 1993). In female B6C3F1 mice, elevated kidney weights were reported following 12 gavage exposures (over 16 days) or 15 months at doses ≥4 mg Hg/kg/day; however, kidney weights were not altered at doses up to 15 mg Hg/kg/day for 6 months (NTP 1993). In C57Bl/6 mice, elevated kidney weights were observed in females after exposure to doses ≥0.37 mg Hg/kg/day for 79 days (Khan et al. 2004).

Table 2-25. Kidney Weight and Clinical Chemistry in Mice[a] Orally Exposed to Mercuric Chloride

Duration; dose (mg Hg/kg/day)	Kidney weight[b,c]	BUN[b]	Reference
Gavage studies			
14 days; dose: 0.06–0.31	↔ (M)	–	Kim et al. 2003
14 days; dose: 1.39	↑ (M) (11)	–	Kim et al. 2003
14 days; dose: 4.81	↑ (M) (12)	–	Kim et al. 2003
16 days; dose: 4	↑ (M) (21) ↑ (F) (20)	–	NTP 1993
16 days; dose: 7.4	↑ (M) (25) ↑ (F) (27)	–	NTP 1993
16 days; dose: 15	↑ (M) (38) ↑ (F) (19)	–	NTP 1993
16 days; dose: 15	↑ (M) (31) ↑ (F) (29)	–	NTP 1993
61 days; dose: 0.18–0.74	↑ (NS)	–	Khan et al. 2004
79 days; dose: 0.18	↔ (F)	–	Khan et al. 2004
79 days; dose: 0.37–0.74	↑ (NS)	–	Khan et al. 2004
182 days; dose: 1.8	↔ (M, F)	↔ (M, F)	NTP 1993
182 days; dose: 4	↑ (M) (19[d]) ↔ (F)	↔	NTP 1993
182 days; dose: 7.4	↑ (M) (32) ↔ (F)	↔	NTP 1993
182 days; dose: 15	↑ (M) (46) ↔ (F)	↔	NTP 1993
450 days; dose: 4	↑ (M) (21[d]) ↑ (F) (24)	↔	NTP 1993
450 days; dose: 7.4	↑ (M) (39) ↑ (F) (28)	↓ (M) (20[e]) ↓ (F) (22[e])	NTP 1993
Drinking water studies			
49 days; dose: 0.4	↔ (M)	↔ (M)	Dieter et al. 1983
49 days; dose: 2	↑ (M) (19[f])	↓ (M) (13[e])	Dieter et al. 1983

Table 2-25. Kidney Weight and Clinical Chemistry in Mice[a] Orally Exposed to Mercuric Chloride

Duration; dose (mg Hg/kg/day)	Kidney weight[b,c]	BUN[b]	Reference
49 days; dose: 11	↑ (M) (23[f])	↓ (M) (13[e])	Dieter et al. 1983

[a]Sexes evaluated are indicated in the results columns.
[b]Numbers in ( ) are percent change compared to control, calculated from quantitative data.
[c]Relative-to-body organ weight, unless otherwise noted.
[d]Absolute kidney weight; change in relative kidney weight not significant at this dose.
[e]Biological relevance of decreased BUN is unclear.
[f]Absolute kidney weights; relative organ weights were not reported, body weights decreased at 11 mg Hg/kg/day.

↑ = increased; ↓ = decreased; ↔ = no change; – = not assessed; BUN = blood urea nitrogen; F = female; M = male; NS = not specified

No consistent alterations in renal clinical chemistry parameters were observed in rats or mice (Tables 2-24 and 2-25, respectively). One gavage study reported increased SUN, creatinine, and uric acid levels in rats (sex not specified) following exposure to 0.015 mg Hg/kg/day for 28 days (Apaydin et al. 2016). However, these findings have not been confirmed in other oral studies in rats or mice. No changes in serum uric acid were observed in rats following a single gavage exposure to doses up to 9.24 mg Hg/kg/day (Lecavalier et al. 1994). Increased levels of BUN were not observed in rats following intermediate- or chronic-duration oral doses up to 23.6 and 4 mg Hg/kg/day, respectively (Dieter et al. 1992; Galiciolli et al. 2022; Jonker et al. 1993; NTP 1993; Oliveira et al. 2012; Takahashi et al. 2000a), or in mice following intermediate- or chronic-duration oral doses up to 15 and 7.4 mg Hg/kg/day, respectively (Dieter et al. 1983; NTP 1993). Occasional observations of significantly decreased BUN are of unclear biological significance. Additionally, increases in serum creatinine were not observed in rats at intermediate-duration doses up to 23.6 mg Hg/kg/day (Dieter et al. 1992; Galiciolli et al. 2022; Jonker et al. 1993; NTP 1993; Takahashi et al. 2000a; Wildemann et al. 2016).

In general, most urinalysis findings in rats following oral exposure to mercuric chloride were inconsistent between studies and sexes (Table 2-26). Elevated urinary ALP was observed in male (but not female) rats after 12 gavage exposures (over 16 days) to 4 mg Hg/kg/day (Dieter et al. 1992; NTP 1993). Intermediate-duration studies show similar results for male rats exposed 2.2 mg Hg/kg/day in the diet for 84 days or ≥0.06 mg Hg/kg/day in the diet for 147 days (Takahashi et al. 2000a, 2000b). Urinary ALP was observed in female (but not male) rats at a gavage dose of 0.462 mg Hg/kg/day for 6 months or ≥1.8 mg Hg/kg/day for 15 months (Dieter et al. 1992; NTP 1993). Similarly, elevated urinary AST was observed in male (but not female) rats after 12 gavage exposures (over 16 days) to 4 mg Hg/kg/day, in

male (but not female) rats after exposure to 1.8 mg Hg/kg/day for 6 months, and in male and female rats
after exposure to 4 mg Hg/kg/day for 15 months; no changes were observed in males or females exposed
to 0.462 mg Hg/kg/day for 6 months (Dieter et al. 1992; NTP 1993). Occasional reports of elevated
urinary creatinine, protein, amino acids, GGT, and LDH were reported; however, no exposure-related
trends were observed within or across studies (Table 2-26). In a 28-day dietary study, urinary ketones
were present in male rats exposed to ≥5.1 mg Hg/kg/day; ketones were not present in females at doses up
to 23.6 mg Hg/kg/day (Jonker et al. 1993).

Table 2-26. Urinalysis in Rats[a] Orally Exposed to Mercuric Chloride

Duration; dose (mg Hg/kg/day)	Cr	TP	AA	ALP	AST	LDH	GGT	Reference
Gavage studies								
16 days; dose: 4	–	–	–	↑ (M) (80[b,c]) ↔ (F)	↑ (M) (83[c]) ↔ (F)	↔ (M,F)	(M, F)	Dieter et al. 1992; NTP 1993
182 days; dose: 0.462	–	–	–	↔ (M) ↑ (F) (570[c])	↔ (M, F)	↔ (M) ↑ (F) (70[c])	↔ (M) ↑ (F) (145[c])	Dieter et al. 1992; NTP 1993
450 days; dose: 1.8	↔ (M,F)	–	–	↔ (M) ↑ (F) (172[d])	↑ (M) (7[d]) F: 0	↔	↔	Dieter et al. 1992; NTP 1993
450 days; dose: 4	↔ (M.F)	–	–	↔ (M) ↑ (F) (61[d])	↑ (M) (29[c]) ↑ (F) (50[c])	↔	↓ (M) (52[c]) ↑ (F) (28[c])	Dieter et al. 1992; NTP 1993
Dietary studies								
28 days; dose: 0.61–23.6	–	↔ (M)	–	–	–	–	–	Jonker et al. 1993
35 days; dose: 0.07–2.2	–	↔ (M)	↔ (M)	–	–	–	–	Takahashi et al. 2000b
84 days; dose: 0.07	–	↔ (M)	↔ (M)	↔ (M)	–	–	↔ (M)	Takahashi et al. 2000b
84 days; dose: 0.21	–	↔ (M)	↑ (M) (40)	↔ (M)	–	–	↑ (M) (52[c])	Takahashi et al. 2000b
84 days; dose: 0.72	–	↔ (M)	↔ (M)	↔ (M)	–	–	↔ (M)	Takahashi et al. 2000b
84 days; dose: 2.2	–	↔ (M)	↑ (M) (63)	↑ (M) (100[c])	–	–	↔ (M)	Takahashi et al. 2000b
147 days; dose: 0.06	–	↔ (M)	–	↑ (M) (100)	–	–	–	Takahashi et al. 2000a
147 days; dose: 0.17	–	↔ (M)	–	↑ (M) (110[c])	–	–	–	Takahashi et al. 2000a

Table 2-26. Urinalysis in Rats[a] Orally Exposed to Mercuric Chloride

Duration; dose (mg Hg/kg/day)	Cr	TP	AA	ALP	AST	LDH	GGT	Reference
147 days; dose: 0.51	–	↔ (M)	–	↑ (M) (105[c])	–	–	–	Takahashi et al. 2000a
147 days; dose: 1.7	–	↑ (M) (90c)	–	↔ (M)	–	–	–	Takahashi et al. 2000a
Drinking water studies								
28 days; dose: 0.264	↑ (M) (86[c])	–	–	–	–	–	–	Wildemann et al. 2016
28 days; dose: 2.955	↔ (M)	–	–	–	–	–	–	Wildemann et al. 2016

[a]Sexes evaluated are indicated in the results columns.
[b]Numbers in ( ) are percent change compared to control, calculated from quantitative data.
[c]Percent change compared to control, estimated from graphically reported data.
[d]Percent change compared to control, calculated from quantitative data.

↑ = increased; ↓ = decreased; ↔ = no change; – = not assessed; AA = amino acids; ALP = alkaline phosphatase; AST = aspartate aminotransferase; Cr = creatinine; F = female; GGT = gamma-glutamyl transferase; LDH = lactate dehydrogenase; M = male; TP = total protein

Urinalysis was only conducted in mice exposed to mercuric chloride following gavage exposure for 15 months (NTP 1993); no consistent findings indicative of renal damage or impaired renal function were observed. Urinary ALP was significantly elevated by 63% in male mice at 4 mg Hg/kg/day; however, urinary ALP was not elevated in male mice at 7.4 mg Hg/kg/day or female mice at either dose. No exposure-related changes in urinary urea nitrogen, AST, LDH, or GGT were observed in males or females at either dose (NTP 1993).

Organic Mercury—Epidemiological Studies. Little information on renal effects of organic mercury in populations with high fish diets is available, presumably because most studies of high fish consumers have focused on evaluating outcomes in other more sensitive organ systems (e.g., neurological system and developing fetus). Anuria was reported following acute-duration ingestion of high doses of organic mercury (Magos and Clarkson 2006).

Studies of patients with Minamata disease provide some information regarding renal effects of chronic-duration methylmercury exposure, although studies did not provide data on associations with mercury exposure biomarkers. Reviews indicate that there is little clinical evidence of renal damage in the Minamata population, except some evidence of proteinuria and high urinary β_2M in severely affected patients (George 2011; Igata 1993). Increased urine levels of renal tubular epithelial antigen and β_2M

were observed in 19 Minamata disease patients, compared to 35 healthy controls, indicating that renal tubular function is associated with Minamata disease (Iesato et al. 1977). Follow-up studies of Minamata disease patients have examined long-term renal effects. In two studies following >1,000 patients with Minamata disease for at least 40 years, no effects were observed on creatinine clearance or the prevalence of renal disease (Futatsuka et al. 2000, 2005). In contrast, a study of 1,483 Minamata disease patients followed through 1981 reported increased mortality due to combined nephritis, nephrosis, and nephrotic syndrome, with SMRs (95% CI) of 3.23 (1.05, 7.54) in men and 4.74 (1.54, 11.07) in women (Tamashiro et al. 1985). Although limited data are available to evaluate associations between organic mercury and renal effects, the kidney appears to be less sensitive than other targets such as the nervous system and developing fetus.

Organic Mercury—Animal Studies. Nephrotoxicity has been observed in rats, mice, and rabbits following intermediate- and chronic-duration exposure. Impaired renal function was reported in one study in mice at lethal/near-lethal acute-duration doses.

Renal function was assessed in one acute-duration oral study in mice following gavage exposure to methylmercury. Impaired renal function (96–100% inhibition of phenolsulfonphthalein excretion) was observed in males 24 hours after a single exposure to ≥16 mg Hg/kg (Yasutake et al. 1991). In females, phenolsulfonphthalein excretion was decreased by approximately 60 and 90% at 32 and 40 mg Hg/kg, respectively. Renal impairment mostly occurred at doses associated with 67% mortality (≥16 mg Hg/kg in males and 40 mg Hg/kg in females); therefore, observed effects may be secondary to widespread toxicity rather than renal-specific damage. The study authors noted slight pathological changes in the kidney in rats exposed the methylmercury, but dose- and sex-specific data were not reported.

Damage to the renal proximal tubules and increased incidence and/or severity of chronic nephropathy have been observed in rats, mice, and rabbits following intermediate- and/or chronic-duration oral exposure to organic mercury (Table 2-27). In rats, chronic-duration drinking water exposure to phenylmercuric acetate resulted in increased severity of chronic renal nephrosis at ≥0.37 mg Hg/kg/day (Solecki et al. 1991). No exposure-related kidney lesions were observed in rats following dietary exposure to methylmercury at intermediate-duration doses up to 0.25 mg Hg/kg/day (Khera and Tabacova 1973) or chronic-duration doses up to 0.18 mg Hg/kg/day (Verschuuren et al. 1976). In mice, dietary exposure to methylmercury resulted in damage to the renal proximal tubules at intermediate-duration doses ≥0.627 mg Hg/kg/day and dose-related proximal tubule damage, urinary casts, pelvic dilatation, cystic kidney, and chronic nephropathy at chronic-duration doses ≥0.139 mg Hg/kg/day (Hirano et al.

1986; Mitsumori et al. 1990). Intermediate-duration drinking water exposure to methylmercury also resulted in damage to the proximal tubule at ≥5.6 mg Hg/kg/day (MacDonald and Harbison 1977; Moreira et al. 2012). Damage to the proximal renal tubule was also observed in rabbits following intermediate-duration exposure to methylmercury at dietary doses ≥1 mg Hg/kg/day (Koller et al. 1977). No exposure-related renal lesions were observed in cats following intermediate- or chronic-duration dietary exposure to methylmercury at doses up to 0.176 mg or 0.074 Hg/kg/day, respectively (Charbonneau et al. 1976).

Table 2-27. Kidney Lesions in Animals[a] Orally Exposed to Organic Mercury

Species; duration	Dose (mg Hg/kg/day)	Histology	Lesion details	Reference (compound)
Rat; 122 days	0.002–0.25	↔ (F)		Khera and Tabacova 1973 (MMC)
Rat; 721 days	0.37	↑ (M)	Chronic renal nephrosis >grade 2: 19/20 (control: 7/20)	Solecki et al. 1991 (PMA)
Rat; 721 days	3.7	↑ (M)	Chronic renal nephrosis >grade 2: 14/20 (control: 7/20)	Solecki et al. 1991 (PMA)
Rat; 730 days	0.006–0.18	↔ (M, F)		Verschuuren et al. 1976 (MMC)
Mouse; 21 days	5.6	↑ (M)	Glomerular shrinkage and tubular vacuolization[b]	Moreira et al. 2012 (MM)
Mouse; 182 days	0.0254–0.15	↔ (M, F)		Hirano et al. 1986 (MMC)
Mouse; 182 days	0.627	↑ (F)	Epithelial degeneration and regeneration of the renal proximal tubules[b]	Hirano et al. 1986 (MMC)
Mouse; 182 days	0.724	↑ (M)	Epithelial degeneration and regeneration of the renal proximal tubules; more severe than females[b]	Hirano et al. 1986 (MMC)
Mouse; 196 days	0.89	↔ (M)		MacDonald and Harbison 1977 (MMC)
Mouse; 196 days	9.5	↑ (M)	Slight degenerative changes in proximal tubular epithelial cells[b]	MacDonald and Harbison 1977 (MMC)
Mouse; 728 days	0.0254–0.115	↔ (M, F)		Hirano et al. 1986 (MMC)
Mouse; 728 days	0.0265–0.133	↔ (M, F)		Mitsumori et al. 1990 (MMC)
Mouse; 728 days	0.139	↑ (M)	Chronic nephropathy: 27/60 (control: 8/60)	Mitsumori et al. 1990 (MMC)

Table 2-27. Kidney Lesions in Animals[a] Orally Exposed to Organic Mercury

Species; duration	Dose (mg Hg/kg/day)	Histology	Lesion details	Reference (compound)
Mouse; 728 days	0.150	↑ (M)	Mild epithelial degeneration of the renal proximal tubules: 12/28 Increased incidence of urinary casts and pelvic dilatation[b]	Hirano et al. 1986 (MMC)
Mouse; 728 days	0.601	↑ (F)	Chronic nephropathy: 56/60 (control: 5/60)	Mitsumori et al. 1990 (MMC)
Mouse; 728 days	0.627	↑ (F)	Epithelial degeneration and regeneration of the renal proximal tubules: 19/60	Hirano et al. 1986 (MMC)
Mouse; 728 days	0.686	↑ (M)	Chronic nephropathy: 59/60 (control: 8/60)	Mitsumori et al. 1990 (MMC)
Mouse; 728 days	0.724	↑ (M)	Epithelial degeneration and regeneration of the renal proximal tubules: 40/59 Focal hyperplasia of tubular epithelium: 13/59 Cystic kidney: 8/59	Hirano et al. 1986 (MMC)
Rabbit; 98 days	0.05–0.52	↔ (M, F)		Koller et al. 1977 (MMC)
Rabbit; 98 days	1–1.1	↑ (M, F)	Mild-to-moderate proximal tubule necrosis: 20/20[c]	Koller et al. 1977 (MMC)
Cat; ~112 days	0.176	↔ (M, F)		Charbonneau et al. 1976 (MMC)
Cat; 730 days	0.0084–0.074	↔ (M, F)		Charbonneau et al. 1976 (MMC)

[a]Sexes evaluated are indicated in the results columns.
[b]Reported qualitatively only (incidence data not provided).
[c]Eight rabbits per sex died by 4 weeks; the remaining rabbits died by 12 weeks.

↑ = increase in histopathological lesions; ↔ = no change; F = female; M = male; MM = methylmercury; MMC = methylmercury chloride; PMA = phenylmercuric acetate

Data regarding alterations in kidney weights following oral exposure to organic mercury are limited. Relative kidney weights were significantly elevated by 18% in male rats following gavage exposure to methylmercury at 2.8 mg Hg/kg/day for 14 days; no changes were observed at ≤0.93 mg Hg/kg/day (Fossato da Silva et al. 2011). Following chronic-duration dietary exposure to methylmercury, relative kidney weights were significantly increased by 30% in males exposed to 0.16 mg Hg/kg/day and 36% in females exposed to 0.18 mg Hg/kg/day; no changes were observed at ≤0.04 mg Hg/kg/day (Verschuuren et al. 1976).

Adverse changes in renal clinical chemistry values following oral exposure to methylmercury were only observed in one acute-duration study in mice at doses associated with increased mortality. Serum creatinine was elevated in a dose-related manner in male mice following a single oral gavage exposure to methylmercury at doses ≥16 mg Hg/kg, doses that also resulted in ≥67% mortality (Yasutake et al. 1991). No changes in serum creatinine were observed in similarly exposed females at single doses up to 40 mg Hg/kg. In other studies, no adverse, exposure-related changes in renal clinical chemistry (e.g., creatinine, uric acid, urea, BUN) were observed in rats at chronic-duration dietary doses up to 0.18 mg Hg/kg/day (Verschuuren et al. 1976), mice at intermediate-duration drinking water doses up to 5.6 mg Hg/kg/day (Moreira et al. 2012), rabbits at intermediate-duration dietary doses up to 0.53 mg Hg/kg/day for 98 days (Koller et al. 1977), or cats at an intermediate-duration dose of 0.176 mg Hg/kg/day or chronic-duration dietary doses up to 0.074 mg Hg/kg/day (Charbonneau et al. 1976). No changes in urinalysis parameters were observed in rats at chronic-duration dietary doses up to 0.18 mg Hg/kg/day (Verschuuren et al. 1976) or cats at an intermediate-duration dose of 0.176 mg Hg/kg/day or chronic-duration dietary doses up to 0.074 mg Hg/kg/day (Charbonneau et al. 1976).

Rats given methylmercuric chloride in the diet for 2 years at a dose of 0.1 mg Hg/kg/day had decreased enzymes (ALP, ATPase, NADH- and NADPH-oxidoreductase, and AMPase) in the proximal convoluted tubules (Verschuuren et al. 1976).

Predominant Mercury Form Unknown (General Populations). Renal effects of mercury in general populations have not been extensively studied. Studies (summarized in Table 2-28) include prospective, cross-sectional, and retrospective cohort designs, and examined markers of glomerular function and tubular damage. Several studies were of large populations (n=800–30,000). Mercury exposure was assessed using BHg and UHg.

Table 2-28. Results of Epidemiological Studies Evaluating Associations between Mercury (Predominant Mercury Form Unknown) and Renal Effects in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Al-Saleh et al. 2017 Cross-sectional; 944 lactating mother-infant pairs[a] (Saudi Arabia)	UHg Gmean Mothers: 0.955 µg/g Cr Infants: 0.635 µg/L	Urine albumin	↑ (UHg, mothers) ↔ (UHg, infants)
		Urine NAG	↑ (UHg, mothers) ↔ (UHg, infants)
		Urine α₁M	↑ (UHg, mothers) ↔ (UHg, infants)

Table 2-28. Results of Epidemiological Studies Evaluating Associations between Mercury (Predominant Mercury Form Unknown) and Renal Effects in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated	Result
de Burbure et al. 2006 Cross-sectional; 804 children (age: 8.5–12.3 years) (France, Poland, Czech Republic)	UHg mean Exposed females: France: 1.19 µg/g Cr Poland: 0.06 µg/g Cr Czech Republic: 0.18 µg/g Cr Exposed males: France: 0.92 µg/g Cr Poland: 0.06µg/g Cr Czech Republic: 0.13 µg/g Cr Control males: France: 0.99 µg/g Cr Poland: 0.06 µg/g Cr Czech Republic: 0.26 µg/g Cr	Urine NAG	↑ (UHg)
Joo et al. 2022 Cross-sectional; 1,360 adolescents, age 12–17 years (KNHANES 2010–2017)	BHg median 1.805 µg/L	GFR	↔ (BHg)
Kim and Lee 2012 Cross-sectional; 5,924 adults (KNHANES 2008–2010)	BHg Gmean: 4.3 µg/L	GFR	↔ (BHg)
Kim et al. 2015b Cross-sectional; 1,797 adults (KNHANES 2011)	BHg mean: 4.35 µg/L	CKD	↔ (BHg)

Kort et al. 2022
 	
Cross-sectional; 1,189 pregnant women age 16–45 years (Suriname)
	BHg median by age:
	  16–24 years: 2.39 µg/L
	  25–29 years: 2.46 µg/L
	  30–34 years: 3.48 µg/L
	  ≥35 years: 3.31 µg/L
		SCr
		BUN
		Serum cystatin C
			↑ (BHg)
			↑ (BHg)
			↔ (BHg)

Li et al. 2013
 	
Cross-sectional; 54 participants living near a mercury mine and 47 controls (China)
	BHg mean
	  Near mine: 6.09 µg/L
	  Control: 3.67 µg/L
		SCr
		SUN
			↑ (BHg, exposed versus controls)
			↑ (BHg, exposed versus controls)

Table 2-28. Results of Epidemiological Studies Evaluating Associations between Mercury (Predominant Mercury Form Unknown) and Renal Effects in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Li et al. 2015 Cross-sectional; 4,250 participants living near a mercury mine (China)	UHg Gmean: 8.32 µg/g Cr	SCr	↑ (UHg)
		BUN	↔ (UHg)
Lin et al. 2014b Cross-sectional; 1,046 adults (NHANES 2003–2004)	BHg range: <0.66–>1.64	GFR	↓ (BHg)
		Albuminuria	↔ (BHg)
Lin et al. 2023 Cross-sectional; 1,040 pregnant women (United States)	BHg median: 3.36 µg/kg blood	GFR	↔ (BHg)
Liu et al. 2022 Cross-sectional; 1,502 adult men (China)	UHg median: 0.69 µg/L	Kidney stones	↔ (UHg)
Nan et al. 2024 Cross-sectional; 9971 adults age ≥40 years (NHANES 2015–2016)	BHg median 0.74 µg/L	GFR	↔ (BHg)
		Albuminuria	↔ (BHg)
Ohno et al. 2007 Cross-sectional; 59 women (Japan)	UHg mean: 0.86 µg/g Cr HHg mean: 1.51 µg/g NHg mean: 0.59 µg/g	Urine NAG	↑ (UHg, HHg, NHg)
		Urine α_1M	↑ (UHg, HHg, NHg)
		Urine β_2M	↔ (UHg, HHg, NHg)
Pollack et al. 2015 Prospective cohort; 259 women followed for two menstrual cycles (Buffalo, New York)	BHg median: 1.1 µg/L BHg mean: 1.50 µg/L	GFR	↔ (BHg)
		BUN	↔ (BHg)
		SCr	↔ (BHg)

Sommar et al. 2013
 	
Population-based, prospective nested case-referent; 118 cases and 378 referents (Sweden)
	ErHg Gmean:
	  Cases: 2.44 µg/L
	  Referents: 3.06 µg/L
		ESRD	↔ (ErHg)

Sun et al. 2019 Cross-sectional; 29,121 adults age ≥20 years (NHANES 2007–2016)	BHg median: 0.85 µg/L BMeHg median: 0.62 µg/L UHg median: 0.31 µg/L	Kidney stones	↔ (BHg) ↔ (BMeHg) ↔ UHg

Table 2-28. Results of Epidemiological Studies Evaluating Associations between Mercury (Predominant Mercury Form Unknown) and Renal Effects in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Tan et al. 2023 Cross-sectional; 4,074 adults age ≥20 years (NHANES 2011–2016)	BHg Gmean 0.86 µg/L	Elevated serum uric acid	↔ (BHg)
Wei et al. 2022 Cross-sectional; 2,711 adults (China)	BHg Q2–Q3 range: 0.57–2.13 µg/L UHg Q2–Q3 range: 0.08 0.76 µg/g Cr	CKD	↑ (BHg) ↑ (UHg)
Xu et al. 2022c Cross-sectional; 14,871 adults age ≥18 years (NHANES 2011–2018)	BHg median: 0.78 µg/L	Elevated blood uric acid	↑ (BHg)
		Gout	↑ (BHg)
Zhang et al. 2020b Cross-sectional; 165 pregnant women living near a mercury mine and 65 referents (China)	UHg Gmean: Mining: 1.09 µg/L Reference: 0.29 µg/L	SCr	↑ (UHg)
Zhu et al. 2019 Cross-sectional; 2,926 adults age ≥20 years (NHANES 2009–2012)	BHg Q2–Q3 range: 0.539–1.876 µg/L UHg Q2–Q3 range: 0.205–0.853 µg/L	Elevated urine albumin	↔ (BHg) ↔ (UHg)

[a]415 infants and 41 mothers were excluded from the analysis because samples were not obtained, or sample volume was inadequate.

↑ = positive association; ↓ = inverse association; ↔ = no association; α$_1$M = α$_1$-microglobulin; β$_2$M = β$_2$-microglobulin; BHg = blood mercury; BUN = blood urea nitrogen; CKD = chronic kidney disease; Cr = creatinine; ErHg = erythrocyte mercury; ESRD = end-stage renal disease; GFR = glomerular filtration rate; Gmean = geometric mean; HHg = hair mercury; KNHANES = Korea National Health and Nutrition Examination Survey; Q = quartile; NAG = N-acetyl-β-D-glucosaminidase; NHANES = National Health and Nutrition Examination Survey; NHg = toenail mercury; SCr = serum creatinine; SUN = serum urea nitrogen; UHg = urine mercury

Similar to studies on elemental mercury, results of studies evaluating mercury exposure in general populations are inconsistent. Some evidence of altered glomerular function (increased urine albumin, serum creatinine, and SUN) was observed in cross-sectional studies (Al-Saleh et al. 2017; Kort et al. 2022; Li et al. 2013; Zhang et al. 2020b). However, no changes in metrics of glomerular function were observed in several large cross-sectional studies using the U.S. NHANES (Nan et al. 2024; Zhu et al. 2019) or KNHANES data (Joo et al. 2022; Kim and Lee 2012), or in other cross-sectional or prospective

studies evaluating markers of glomerular function (Lin et al. 2014b; Pollack et al. 2015). One study based on NHANES found an association between BHg and increasing GFR (Sanders et al. 2019; n=2,709).

Several studies focused on cohorts of pregnant women. Kort et al. (2022) found that increasing BHg was associated with increasing serum creatinine and BUN in a cross-sectional study of 1,189 pregnant women. A smaller study of pregnant women who resided in a gold inning area found that increasing UHg was associated with increasing serum creatinine (Zhang et al. 2020b). Lin et al. (2023) found no association between BHg and GFR in a cross-sectional study of 140 pregnant women.

Studies of chronic kidney disease have found mixed results. A cross-sectional study (n=2,711 adults) found an association between increasing BHg or UHg and chronic kidney disease (Wei et al. 2022). Kim et al. (2015b) found no association between BHg and chronic kidney disease in a cross-sectional study of 1,797 adults. Sommar et al. (2013) found no association between erythrocyte mercury and end-stage renal disease in a prospective case-referent study (118 cases, 378 referents). Liu et al. (2022) (n=357 with nephrolithiasis and 1,145 without nephrolithiasis) did not find an association between UHg and OR of nephrolithiasis (kidney stones).

The few cross-sectional studies evaluating markers of tubular damage found positive associations between UHg and urine NAG, and α_1M (Al-Saleh et al. 2017; de Burbure et al. 2006; Ohno et al. 2007). Several studies evaluated associations between mercury exposure biomarkers and serum uric acid and/or gout based on data from NHANES (Gao et al. 2022; Sanders et al. 2019; Tan et al. 2023; Xu et al. 2022c) or KNHANES (Jung et al. 2019; Park and Kim 2021). The largest of these studies (Xu et al. 2022c) (n=14,781) found associations between increasing BHg and ORs of hyperuricemia and gout. Results of several smaller studies have been mixed. Tan et al. (2023) (n= 4,074), Gao et al. (2022) (n=4,794) and Jung et al. (2019) (n=2,682) found no associations between BHg and serum uric acid. Park and Kim (2021) (n=4,784) found a beta coefficient association with the doubling of BHg at the 3rd and 4th quartiles with serum uric acid in females but not in males.

While not all studies in general populations have found associations between mercury exposure biomarkers and biomarkers of renal function, collectively, the epidemiology of renal outcomes indicates that mercury exposure of the general population may be associated with glomerular and tubular damage.

Mechanisms of Action. Numerous mechanisms for renal toxicity have been proposed (Barnett and Cummings 2018; Jan et al. 2011; Zalups 2000); these include decreased function of renal transporters;

blockage of aquaporins (water channels); decreased renal content of glutathione; formation of ROS, leading to lipid peroxidation and oxidative stress leading to cellular injury; decreases in the activity of SOD, catalase, GPX, and glutathione disulfide reductase, leading to enhanced susceptibility of renal epithelial cells to oxidative injury; interference with mitochondrial respiratory function; altered intracellular distribution of calcium; inactivation of the plasma membrane (Na^+K^+)-stimulated ATPase; increased expression of stress proteins; and interactions between mercury and cellular microtubular networks.

An important contributing factor to the nephrotoxicity of mercury is that absorbed mercuric mercury accumulates in the renal proximal tubule with the highest concentrations occurring in the region of the kidney (inner cortex and outer stripe of the outer medulla) where mercury-induced tubule damage is initiated (Berlin et al. 2015; Zalups and Diamond 2005). This region of the kidney receives a relatively high dose of mercury regardless of the form of mercury absorbed. This includes inorganic mercuric mercury following absorption and oxidation of elemental mercury, as well as absorbed methylmercuric mercury, and inorganic mercuric mercury produced from demethylation of absorbed methylmercury (Section 3.1.2). Accumulation of mercuric mercury in the kidneys is facilitated by several membrane transport systems in the proximal tubule that recognize S-conjugates of mercuric mercury as transport substrates. These transport systems, coupled with oxidative metabolism of mercury compounds to mercuric mercury species, and the high affinity of mercuric mercury for the thiolate anion explain why mercury in most of its forms can be nephrotoxic at a sufficiently high absorbed dose (Berlin et al. 2015). The exact mechanisms by which mercury impairs renal cellular function and damages the proximal tubule have not been fully characterized and are likely to involve many different molecular targets, as discussed above. Central to these mechanisms are ligand exchange reactions that enable mercuric mercury to distribute to membrane and intracellular sulfhydryl groups that are important in the structure or catalytic activity of structural proteins and enzymes critical to cell metabolism and function (Carty and Malone 1979).

2.12 DERMAL

Studies of dermal effects associated with an immunological mechanism of action (e.g., dermal hypersensitivity reactions and acrodynia) are discussed in Section 2.15 (Immunological).

Overview. One epidemiological study of elemental mercury investigating associations between biomarkers and non-immunological dermal effects was identified; this study evaluated effects in a

population of dentists. No epidemiological studies were identified for populations with high fish diets or general populations. Data are insufficient to determine if non-immunological dermal effects are associated with mercury exposure.

A few animal studies evaluating dermal effects are available for oral exposure to mercuric chloride or methylmercury. Available data do not indicate that the skin is a sensitive target of mercury toxicity following oral exposure.

The following summarizes results of epidemiological and animal studies on dermal outcomes.
- ***Elemental mercury***
  - *Epidemiology studies*
    - One epidemiological study found an increased risk of self-reported dermal hyperpigmentation in dentists exposed to elemental mercury, compared to controls.
  - *Animal studies*
    - No studies evaluating dermal effects following exposure to elemental mercury were identified.
- ***Inorganic mercury salts***
  - *Epidemiology studies*
    - No epidemiological studies evaluating associations between exposure to inorganic mercury salts and dermal effects were identified.
  - *Animal studies*
    - Available data are inadequate to assess potential dermal effects following exposure to inorganic mercury salts.
- ***Organic mercury***
  - *Epidemiology studies*
    - No epidemiological studies on non-immunological dermal effects of exposure to organic mercury compounds were identified.
    - Case reports have noted rashes in individuals exposed to phenylmercury.
  - *Animal studies*
    - No evidence of dermal effects was found in rodents following intermediate- or chronic-duration oral exposure to methylmercury.
- ***Predominant mercury form unknown (general populations)***
    - No epidemiological studies of general populations evaluating non-immunological dermatological changes in general populations exposed to mercury were identified.

Confounding Factors. One epidemiological study evaluating non-immunological dermal effects from exposure to elemental mercury in dentists was identified (Neghab et al. 2011). Covariates considered in this study as potential cofounders were age, marital status, number of personal amalgam fillings, and dental clinic type.

Elemental Mercury—Epidemiological Studies. One epidemiological study evaluating dermatological effects of elemental mercury was identified (Neghab et al. 2011). This cross-sectional study compared self-reported dermal symptoms (dermatitis, eczema, and hyperpigmentation) in exposed dentists (n=106; median UHg: 3.16 µg/g creatinine) to a control group of physician general practitioners (n=94; median UHg: 2.18 µg/g creatinine) from Iran. The OR for hyperpigmentation in exposed dentists compared to controls was 4.62 (95% CI 1.2, 17.68), although no increased risk was observed for dermatitis or eczema. Results of this study have not been corroborated.

Elemental Mercury—Animal Studies. No studies were located regarding dermal effects in animals after exposure to elemental mercury.

Inorganic Mercury Salts—Animal Studies. No exposure-related changes in skin histology were observed in rats exposed once to mercuric chloride at gavage doses up to 9.24 mg Hg/kg/day (Lecavalier et al. 1994). No additional studies evaluating dermal effects in animals after exposure to inorganic mercury compounds were identified.

Organic Mercury—Epidemiological Studies. Epidemiological studies evaluating dermatological effects of exposures to methylmercury from high fish diets were not identified. A case report of three individuals exposed to phenylmercury through weed killers and pharmaceutical ointments reported pruritic papular rashes (Morris 1960). No biomarkers were evaluated and the underlying mechanism of action for the rashes was not identified.

Organic Mercury—Animal Studies. No exposure-related changes in skin histology were observed in rats following chronic-duration exposure to doses up to 0.18 mg Hg/kg/day (Verschuuren et al. 1976) or mice following intermediate- or chronic-duration exposure up to 0.724 mg Hg/kg/day (Hirano et al. 1986; Mitsumori et al. 1990).

Predominant Mercury Form Unknown (General Populations). No epidemiological studies of general populations evaluating non-immunological dermatological changes in general populations exposed to mercury were identified.

Mechanisms of Action. Mechanisms of potential non-immunological dermatological changes associated with mercury exposure have not been established.

2.13 OCULAR

Studies evaluating neurological ocular effects are reviewed in Section 2.16 (Neurological).

Overview. Two epidemiological studies that investigated associations between biomarkers and non-neurological ocular effects were identified; both studies evaluated effects in a general population. No epidemiological studies were identified for populations exposed to elemental mercury or in populations with high fish diets. Data are insufficient to determine if adverse non-neurological ocular effects are associated with mercury exposure. The clinically distinct brownish discoloration of the lens known as mercurialentis (Byrns and Pennings 2017; El-Sherbeeny et al. 2006) is not discussed below as it is not associated with adverse ocular effects; Section 3.3.1 (Biomarkers of Exposure) for additional details.

A few animal studies evaluating ocular effects are available for oral exposure to mercuric chloride or methylmercury. Available data do not indicate that the eye is a sensitive target of mercury toxicity following oral exposure. Observed visual impairment in primates following oral exposure to methylmercury are considered neurological in nature and are discussed in Section 2.16 (Neurological).

The following summarizes results of epidemiological and animal studies on non-neurological ocular outcomes.
- ***Elemental mercury***
  - *Epidemiology studies*
    - No epidemiological studies on non-neurological ocular effects of exposure to elemental mercury were identified.
  - *Animal studies*
    - No studies evaluating ocular effects following exposure to elemental mercury were identified.

- ***Inorganic mercury salts***
  - *Epidemiology studies*
    - No epidemiological studies on non-neurological ocular effects of exposure to inorganic mercury salts were identified.
  - *Animal studies*
    - Available data are inadequate to assess potential ocular effects following oral exposure to inorganic mercury salts.
- ***Organic mercury***
  - *Epidemiology studies*
    - No epidemiological studies on non-neurological ocular effects of exposure to organic mercury compounds were identified.
  - *Animal studies*
    - No evidence of ocular damage was found in rodents following intermediate- or chronic-duration oral exposure to methylmercury.
- ***Predominant mercury form unknown (general populations)***
    - Two large epidemiological studies of the general population found positive associations between BHg and dry eye symptom disease in higher versus lower BHg groups.
    - Data are inadequate to determine if non-neurological ocular effects are associated with mercury exposure in general populations.

Confounding Factors. One epidemiological study regarding non-neurological ocular effects of mercury was identified (Chung and Myong 2016). Covariates considered in this study as potential confounders were age, gender, education, household income, smoking status, alcohol consumption, sleeping time, perceived stress status, and history of atopy.

Elemental Mercury—Epidemiological Studies. Epidemiological studies evaluating non-neurological ocular effects in populations exposed to elemental mercury were not identified.

Elemental Mercury—Animal Studies. No studies were located regarding ocular effects in animals after exposure to elemental mercury.

Inorganic Mercury Salts—Animal Studies. No histopathological changes in the eye were observed in rats exposed once to mercuric chloride at gavage doses up to 9.24 mg Hg/kg/day (Lecavalier et al. 1994).

No additional studies evaluating ocular effects in animals after exposure to inorganic mercury were identified.

Organic Mercury—Epidemiological Studies. Epidemiological studies evaluating non-neurological ocular effects of exposures to methylmercury from high fish diets were not identified.

Organic Mercury—Animal Studies. No histopathological changes in the eye were observed in rats following chronic-duration exposure to doses up to 0.18 mg Hg/kg/day (Verschuuren et al. 1976) or mice following intermediate- or chronic-duration exposure up to 0.724 mg Hg/kg/day (Hirano et al. 1986; Mitsumori et al. 1990).

Predominant Mercury Form Unknown (General Populations). Two studies evaluating associations between mercury biomarkers and non-neurological ocular effects were located (Chung and Myong 2016; Jung and Lee 2019). In a cross-sectional study of a KNHANES population (n=4,761 adults) with a median BHg of 3.7 µg/L, the odds of self-reported dry eye symptoms (persistent dryness or eye irritation) were increased in the high (BHg ≥3.7 µg/L) relative to the low (BHg <3.7 µg/L) exposure groups (OR 1.324; 95% CI 1.059, 1.655). Jung and Lee (2019) evaluated associations between BHg and dry eye disease in a large cross-sectional study using KNHANES data from 2010–2012. With data stratified by BHg tertiles, a positive association (OR 1.39; 95% CI 1.02–1.89) between BHg and dry eye disease was observed for the highest BHg tertile (≥4.919 µg/L) compared to the lowest BHg tertile (<2.85 µg/L).

Mechanisms of Action. Chung and Myong (2016) speculated that the following mechanisms could be involved in the development of dry eye: (1) altered conjunctival mucus; (2) induction of conjunctival inflammation; (3) recruitment and activation of inflammatory and immune cells on the ocular surface; and (4) depletion of antioxidant proteins (e.g., metallothionein) in the lacrimal glands and conjunctiva.

2.14 ENDOCRINE

Overview. Data on endocrine effects of mercury are available from studies in humans and animals. Compared to other systems, effects of mercury on endocrine functions have not been well investigated in humans. Studies are available in workers exposed to elemental mercury, a population with a high fish diet, and in general populations with exposure to unspecified forms of mercury. Epidemiological studies have focused on associations between mercury biomarkers and thyroid function and glucose homeostasis.

Studies of effects on thyroid function and glucose homeostasis report inconsistent findings and do not provide evidence that the endocrine system is a sensitive target for mercury.

A few animal studies have evaluated endocrine function following oral exposure to inorganic salts or organic mercury compounds. Based on the limited number of studies and endpoints assessed, limited information on dose- or duration-response (e.g., single exposure level study design), and/or inconsistent findings between studies, available data are insufficient to determine if the endocrine system is a sensitive target for mercury.

The following summarizes results of epidemiological and animal studies on endocrine outcomes.

- ***Elemental mercury***
  - *Epidemiology studies*
    - A few studies evaluating effects of elemental mercury exposure on thyroid function provide conflicting results, with most studies showing no differences in thyroxine (T4), triiodothyronine (T3), and thyroid-stimulating hormone (TSH) levels between workers and controls.
  - *Animal studies*
    - No studies evaluating endocrine effects following exposure to elemental mercury were identified.
- ***Inorganic mercury salts***
  - *Epidemiology studies*
    - No epidemiological studies evaluating associations between exposure to inorganic mercury salts and endocrine effects were identified.
  - *Animal studies*
    - Data are insufficient to determine if exposure to inorganic mercury salts is associated with adverse endocrine effects. A limited number of studies suggest that inorganic mercury salts may alter thyroid, pancreatic, or adrenocortical function; however, findings are inconsistent across studies, doses, and/or durations.
- ***Organic mercury***
  - *Epidemiology studies*
    - Data are insufficient to determine if exposure to organic mercury is associated with adverse endocrine effects. The only identified study showed a very small increase in the risk of increased fasting glucose levels and type 2 diabetes in a population with a high fish diet.

▪ *Animal studies*

  ▪ Data are insufficient to determine if exposure to organic mercury is associated with adverse endocrine effects. One study suggested that organic mercury may impair pancreatic function, while another provided limited evidence of adrenocortical dysfunction.

● ***Predominant mercury form unknown (general populations)***

  ▪ Several studies have evaluated the effects of mercury exposure on thyroid function, specifically thyroid hormones in general populations. Evidence for associations between exposure to mercury and thyroid function is conflicting, with inconsistent results across studies.

  ▪ Effects of mercury exposure on glucose homeostasis has been evaluated in several studies. Most results showed no associations between mercury and type 2 diabetes or all diabetes, including a large meta-analysis. For studies showing associations, one studies showed a positive association between biomarkers and type 2 diabetes, while another study showed an inverse relationship. Two studies showed positive associations between mercury biomarkers and insulin resistance.

Confounding Factors. Several factors that may be associated with mercury exposure status can complicate interpretation of studies on thyroid function. These include selenium status (selenium-containing enzymes are involved in thyroid hormone homeostasis), negative iodine balance (iodine deficiency is rare in the United States), underlying thyroid disease, genetic predisposition for thyroid disease, and some pharmaceutical agents. The epidemiological studies reviewed in this section have not considered most of these potential confounders. For glucose homeostasis, there are numerous potential confounding factors. These include body weight/BMI (obesity), age, diet, family history of diabetes, age, exercise, high blood pressure, and low HDL cholesterol. Most epidemiological studies reviewed below include some of these adjustments when appropriate. No specific confounder or covariate was mandatory for the inclusion of the study into the profile; however, studies of thyroid and glucose homeostasis outcomes that did not consider the aforementioned potential confounders are potentially more confounded than studies that did consider these variables.

Elemental Mercury—Epidemiological Studies. Studies evaluating effects of elemental mercury on endocrine function are summarized in Table 2-29. The database consists of a few cross-sectional studies examining associations between exposure to elemental mercury and markers of thyroid function in miners, chloralkali workers, and dentists. Worker populations in these studies were small (n ≤80),

limiting the power to detect associations between exposure to elemental mercury and thyroid effects.

Primary outcome measures to evaluate thyroid function included measurements of plasma or serum levels

of T4, T3, and TSH, with comparisons between exposed workers and controls.

Table 2-29. Results of Epidemiological Studies Evaluating Exposure to Elemental Mercury (Hg^0) and Effects on Thyroid Hormones

Reference, study type, and population	Biomarker	Outcome evaluated	Result

Afrifa et al. 2018
 	
Cross-sectional; 80 gold miners and 57 controls (Ghana)
	BHg median
	  Miners: 8.0 µg/L
	  Controls: 1.0 µg/L
		T4[a]	↓ (BHg, miners versus controls)

		T3[a]	↓ (BHg, miners versus controls)
		TSH	↔ (BHg, miners versus controls)

Barregard et al. 1994a
 	
Cross-sectional; 41 male chloralkali workers and 41 matched controls (Sweden)
	UHg mean
	  Workers: 27 µg/g Cr
	  Controls: 3.4 µg/g Cr
		Free T4	↔ (BHg, workers versus controls)

		Free T3	↔ (BHg, workers versus controls)
		TSH	↔ (BHg, workers versus controls)

Ellingsen et al. 2000b
 	
Cross-sectional; 47 chloralkali workers and 47 controls (Norway)
	UHg median
	  Workers: 10.5 µg/g Cr
	  Controls: 2.3 µg/g Cr
		Free T4	↔ (UHg, workers versus controls)

		Free T3	↔ (UHg, workers versus controls)
		Reverse T3	↑ (UHg, workers versus controls)
		Anti-TPO	↓ (UHg, workers versus controls)

Erfurth et al. 1990
 	
Cross-sectional; 9 male dentists and 11 controls and 11 chloralkali workers and 10 controls (Sweden)
	UHg mean
	  Dentists: 2.3 µg/g Cr
	  Controls: 0.71 µg/g Cr
	UHg mean, Workers
	  Workers: 46 µg/g Cr
	  Controls: 1.1 µg/g Cr
		Free T4	↔ (UHg, workers or dentists versus respective controls)

		Free T3	↔ (UHg, workers or dentists versus respective controls)
		TSH	↔ (UHg, workers or dentists versus respective controls)

[a]Not specified if total or free T4 and T3.

↑ = increased levels; ↓ = decreased levels; ↔ = no difference; Anti-TPO = thyroid peroxidase antibodies; BHg = blood mercury; Cr = creatinine; T3 = triiodothyronine; T4 = thyroxine; TSH = thyroid-stimulating hormone; UHg = urine mercury

Evidence for effects on the thyroid gland in workers exposed to elemental mercury is inconclusive. Three

studies did not find differences in T4, T3, or TSH levels in workers compared to controls (Barregard et al.

1994a; Ellingsen et al. 2000b; Erfurth et al. 1990). Ellingsen et al. (2000b) observed a 15% increase in

reverse T3 (a thyroid hormone metabolite) in chloralkali workers compared to controls (Ellingsen et al.

2000b); however, in the absence of effects on T4 and T3, the clinical significance of this finding is uncertain. In contrast to the studies showing no effects on T4 and T3 levels in exposed chloralkali workers, a study in gold miners (median BHg 8 µg/L) reported decreases in T4 and T3 of 39 and 43%, respectively, compared to controls (median BHg 1 µg/L), although TSH levels were similar between miners and controls (Afrifa et al. 2018).

Elemental Mercury—Animal Studies. No studies were located regarding endocrine effects in animals after exposure to elemental mercury.

Inorganic Mercury Salts—Animal Studies. A limited number of studies in laboratory animals have evaluated effects of inorganic mercury salts on thyroid, pancreas, and adrenocortical function following acute- or intermediate-duration oral exposure. Additional data regarding endocrine gland weight and/or histology are available from acute-, intermediate-, and chronic-duration oral studies. Overall, available data are insufficient to determine if exposure to inorganic mercury salts is associated with adverse endocrine effects due to the limited number of studies, limitations of study design (e.g., single exposure level), and/or inconsistent findings.

Thyroid function has been evaluated in a limited number of studies in rats and mice following acute- and intermediate-duration oral exposure to mercuric chloride or mercuric sulfide (Table 2-30). In a series of experiments, Goldman and Blackburn (1979) evaluated thyroid function in female rats following acute- or intermediate-duration exposure to mercuric chloride. Increased thyroid function, as evidence by increased iodine uptake, release, and/or turnover, was observed following gavage exposure to 7.4 or 9.4 mg Hg/kg/day for 6 or 40 days, respectively. However, decreased iodine uptake, release, and turnover were observed following dietary exposure to 2.2 mg Hg/kg/day for 90 days. It is unclear if the opposing effects were attributable to exposure route (gavage versus dietary) and/or evidence of non-monotonic dose or duration effects (since only one dose was tested at each duration, biphasic responses cannot be evaluated). Evidence for decreased T3 synthesis in the thyroid was also observed following exposure to 9.4 mg Hg/kg/day for 40 days (not evaluated at other durations). In mice, significant decreases in plasma T3 were observed following acute-duration gavage exposure to 6 mg Hg/kg/day as mercuric chloride or mercuric sulfide; plasma T4 was also decreased with mercuric chloride exposure (Sin et al. 1990). However, in an intermediate-duration study with mercuric sulfide, significant decreases were observed in plasma T4, but not T3, 1–4 weeks post-exposure to 6 mg Hg/kg/day (Sin and Teh 1992). In addition to thyroid effects, a 90-day drinking water study with mercuric chloride reported significantly decreased

blood glucose (by 19%) at 15 mg Hg/kg/day (Zhao et al. 2020). Study designs in mice are inadequate to

assess dose- or duration-dependence of observed effects.

Table 2-30. Thyroid Function and Hormone Levels in Female Rats and Mice Orally Exposed to Inorganic Mercury Salts

Species; Duration	Dose (mg Hg/kg/day)	T3[a]	T4[a]	Iodine uptake[a]	Iodine release Half-life[a]	Iodine turnover rate[a]	Reference (compound)
Rat; 6 days	7.4	–	–	–	↓ (69)	↑ (200)	Goldman and Blackburn 1979 (MC)
Rat; 40 days	9.4	↓ Thyroid (19)	↔ Thyroid	↑ (108)	–	–	Goldman and Blackburn 1979 (MC)
Rat; 90 days	2.2	–	–	↓ (27)	↑ (56)	↓ (37)	Goldman and Blackburn 1979 (MC)
Mouse; 10 days	6	↓ Plasma (70)	↓ Plasma (42)	–	–	–	Sin et al. 1990 (MC)
Mouse; 10 days	6	↓ Plasma (59)	↔ Plasma	–	–	–	Sin et al. 1990 (MS)
Mouse; 28 days	6	↔	↓ Plasma (28–41[b])	–	–	–	Sin and Teh 1992 (MS)

[a]Numbers in ( ) are percent change compared to control, calculated from quantitative data.
[b]Measured 1–4 weeks post-exposure.

↑ = increased; ↓ = decreased; ↔ = no change; – = not assessed; MC = mercuric chloride; MS = mercuric sulfide; T3 = triiodothyronine; T4 = thyroxine

One study showed a 28% increase in absolute thyroid weight in female rats following gavage exposure to

mercuric chloride at 9.4 mg Hg/kg/day for 40 days; relative organ weights were not reported but no body

weight effects were noted (Goldman and Blackburn 1979). Based on evidence of increased thyroid

function in this study, elevated thyroid weights are considered treatment related. Thyroid weights were

not assessed in other identified studies.

In a series of experiments, Agrawal and Chansouria (1989) evaluated adrenocortical function in male rats

exposed to mercuric chloride via drinking water for 60, 120, or 180 days (Table 2-31). Corticosterone

levels in the adrenal gland were significantly elevated in a dose- and duration-dependent manner after

exposure to ≥2.9 mg Hg/kg/day for 60–120 days. Plasma corticosterone levels also showed a significant,

dose-related increase following exposure for 120 days, but findings were biphasic at 60 days (levels

increased at 2.9 mg Hg/kg/day but decreased at ≥5.8 mg Hg/kg/day). After 180 days of exposure, adrenal

and plasma corticosterone levels were comparable to controls. The study authors considered recovery at 180 days an indication of acquired resistance to mercury. Agrawal and Chansouria (1989) also reported significantly elevated relative adrenal weights after exposure to 2.9 mg Hg/kg/day for 60, 120, or 180 days, but findings do not show a clear dose- or duration-dependence (Table 2-31). Altered relative adrenal gland weight findings should be interpreted with caution because neither absolute adrenal gland weights nor body weights were reported. Other studies do not show exposure-related changes in adrenal gland weights in male or female rats following exposure to mercuric chloride at intermediate-duration dietary doses up to 20.9 or 23.6 mg Hg/kg/day, respectively (Jonker et al. 1993), or gavage doses up to 1.65 mg Hg/kg/day (Atkinson et al. 2001). In mice, no exposure-related changes in adrenal gland weight were observed following intermediate-duration exposure to mercuric chloride at gavage doses up to 0.74 mg Hg/kg/day (Khan et al. 2004).

Table 2-31. Corticosterone levels and Adrenal Gland Weight in Rodents[a] Orally Exposed to Mercuric Chloride

Species Duration	Dose (mg Hg/kg/day)	Plasma corticosterone[b]	Adrenal corticosterone[b]	Adrenal weight[b]	Reference
Rat (B) 28 days	0.61–23.6	–	–	↔ (M, F)	Jonker et al. 1993
Rat (M) 60 days	2.9	↑ (M) (33)	↑ (M) (146)	↑ (M) (31)	Agrawal and Chansouria 1989
Rat (M) 60 days	5.8	↓ (M) (31)	↑ (M) (157)	↑ (M) (34)	Agrawal and Chansouria 1989
Rat (M) 60 days	11.8	↓ (M) (60)	↑ (M) (203)	↑ (M) (27)	Agrawal and Chansouria 1989
Rat (B) 79–81 days	0.37–1.98	–	–	↔ (M, F)	Atkinson et al. 2001
Rat (M) 120 days	2.9	↑ (M) (87)	↑ (M) (218)	↑ (M) (19)	Agrawal and Chansouria 1989
Rat (M) 120 days	5.8	↑ (M) (42)	↑ (M) (313)	↑ (M) (10)	Agrawal and Chansouria 1989
Rat (M) 120 days	11.8	↑ (M) (20)	↑ (M) (372)	↑ (M) (51)	Agrawal and Chansouria 1989
Rat (M) 180 days	2.9	↔ (M)	↔ (M)	↑ (M) (14)	Agrawal and Chansouria 1989
Rat (M) 180 days	5.8	↔ (M)	↔ (M)	↑ (M) (30)	Agrawal and Chansouria 1989
Rat (M) 180 days	11.8	↔ (M)	↔ (M)	↑ (M) (31)	Agrawal and Chansouria 1989

Table 2-31. Corticosterone levels and Adrenal Gland Weight in Rodents[a] Orally Exposed to Mercuric Chloride

Species Duration	Dose (mg Hg/kg/day)	Plasma corticosterone[b]	Adrenal corticosterone[b]	Adrenal weight[b]	Reference
Mouse (B) 61–79 days	0.18–0.74	–	–	↔ (M, F)	Khan et al. 2004

[a]Sexes evaluated are indicated in the results columns.
[b]Numbers in ( ) are percent change compared to control, calculated from quantitative data.

↑ = increased; ↓ = decreased; ↔ = no change; – = not assessed; B = both males and females; F = female(s); M = male(s)

Pancreatic function was evaluated in one study in mice following exposure to mercuric chloride at a gavage dose of 3.7 mg Hg/kg/day for 14 days (Chen et al. 2012). Fasting insulin levels were significantly decreased by 60%. In a glucose tolerance test (after fasting), blood glucose levels were significantly elevated by 45–70% when measured 30–150 minutes after glucose administration. For reference, baseline insulin levels were increased by 17% and baseline glucose levels were decreased 15% in treated mice, compared to controls. However, exposure to the same dose for 28 or 42 days resulted in duration-dependent increases of 70–95% in baseline insulin levels and a 35% increase in baseline glucose levels; glucose tolerance was not tested in longer-duration studies (Chen et al. 2012). After the 14-day exposure, apoptosis in pancreatic islet cells was significantly increased. In other studies, blood glucose levels were unaltered by exposure to mercuric chloride in rats at acute-duration doses up to 9.24 mg Hg/kg/day (Lecavalier et al. 1994) and in mice at intermediate-duration doses up to 0.74 mg Hg/kg/day (Khan et al. 2004).

Parathyroid hyperplasia was observed in male rats following chronic-duration exposure to mercuric chloride at dietary doses ≥1.8 mg Hg/kg/day; however, this lesion was considered secondary to impaired renal function observed in male rats at ≥1.8 mg Hg/kg/day (Dieter et al. 1992; NTP 1993). Parathyroid hyperplasia was not observed in similarly exposed female rats (with normal renal function) at doses up to 4 mg Hg/kg/day (Dieter et al. 1992; NTP 1993). No exposure-related parathyroid lesions were observed following intermediate-duration gavage doses up to 4 or 15 mg Hg/kg/day in rats or mice, respectively (Dieter et al. 1992; Khan et al. 2004; NTP 1993), or chronic-duration gavage doses up to 7.4 mg Hg/kg/day in mice (NTP 1993).

No exposure-related histopathological changes were observed in the pancreas or the thyroid, adrenal, or pituitary glands following exposure to mercuric chloride at acute-duration dietary doses up to 9.24 mg

Hg/kg/day (Lecavalier et al. 1994); intermediate-duration gavage doses up to 4 or 15 mg Hg/kg/day in rats or mice, respectively (Dieter et al. 1992; Khan et al. 2004; NTP 1993); or chronic-duration gavage doses up to 4 or 7.4 mg Hg/kg/day in rats or mice, respectively (Dieter et al. 1992; NTP 1993).

Organic Mercury—Epidemiological Studies. Data are not sufficient to determine if exposure to mercury in populations with high fish diets produces adverse effects to the endocrine system, with only two studies meeting inclusion criteria for this toxicological profile (inclusion criteria, Section 2.1) (Cordier et al. 2020; Jeppesen et al. 2015). Jeppesen et al. (2015) examined measures of glucose tolerance in 2,640 Inuit adults from Greenland with a median BHg of 16.5 µg/L. Results showed that, for each 5 µg/L in total BHg, the odds of impaired fasting glycemia (fasting plasma glucose ≥6.1 and <6.9 mmol/L and 2-hour challenge plasma glucose <7.8 mmol/L) and type 2 diabetes (fasting plasma glucose ≥7.0 mmol/L or 2-hour challenge plasma glucose ≥11.1 mmol/L) were increased by 3% (adjusted OR 1.03; 95% CI 1.02, 1.05) and 2% (adjusted OR 1.02; 95% CI 1.01, 1.04), respectively. No increased risk was observed for impaired glucose tolerance (fasting plasma glucose <7.0 and <6.9 mmol/L and 2-hour challenge plasma glucose ≥7.8 and <11.1 mmol/L; adjusted OR 0.97; 95% CI 0.94, 1.0). A cross-sectional study of Inuit (n=877) and Cree (n=788) adults did not find associations between BHg and type 2 diabetes (Cordier et al. 2020). Median BHg levels in the Inuit and Cree population were 10.3 and 3.00 µg/L, respectively.

Organic Mercury—Animal Studies. A very limited number of studies in laboratory animals have evaluated effects of organic mercury on pancreatic and adrenocortical function following acute- or intermediate-duration oral exposure. Additional data regarding endocrine gland weight and/or histology are available from intermediate- and chronic-duration oral studies. Available data are insufficient to determine if organic mercury adversely affects the endocrine system in laboratory animals.

Pancreatic function was evaluated in mice following exposure to methylmercury at a gavage dose of 1.6 mg Hg/kg/day for 14 days (Chen et al. 2012). Baseline and fasting insulin levels were significantly decreased by 60–70%. In a glucose tolerance test (after fasting), blood glucose levels were significantly elevated by 30–65% when measured 30–150 minutes after glucose administration (no changes in baseline blood glucose levels). Exposure to the same dose for 28 or 42 days resulted in duration-dependent increases of 80–95 and 25–40% in baseline insulin and glucose levels, respectively; glucose tolerance was not tested in longer-duration studies (Chen et al. 2012). After the 14-day exposure, apoptosis in pancreatic islet cells was significantly increased. Dose-dependent increases in plasma insulin were found in male NMRI mice exposed for 4 weeks, with increases of 47% at 2 mg Hg/kg/day to 191% at 8.0 mg Hg/kg/day (Maqbool et al. 2019). Fasting blood glucose was significantly elevated (by 44%) at 8.0 mg

Hg/kg/day but was not significantly increased at lower doses; however, this finding is inconsistent with increased plasma insulin levels.

One study evaluated adrenocortical function in male rats following exposure to methylmercuric chloride or bis(methylmercury)sulfide at drinking water doses of 0.0004 or 0.04 mg Hg/kg/day for 8 or 16 weeks (Ortega et al. 1997b). Following exposure to methylmercuric chloride, serum levels of adrenocortico-tropic hormone (ACTH) were significantly increased by >100% at ≥0.0004 mg Hg/kg/day after 8 or 16 weeks; however, findings did not have an increasing response with dose. For bis(methylmercury) sulfide, a dose-dependent 105–220% increase in ACTH was observed at ≥0.0004 mg Hg/kg/day after 8 weeks only. No consistent dose-response relationship was found for serum corticosterone for either compound after 8 or 16 weeks of exposure.

No exposure-related changes in endocrine organ weight and/or histology were observed following dietary exposure to methylmercury at intermediate-duration doses up to 0.627 or 0.176 mg Hg/kg/day in mice or cats, respectively (Charbonneau et al. 1976; Hirano et al. 1986), or chronic-duration doses up to 0.18, 0.686, or 0.074 mg Hg/kg/day in rats, mice, or cats, respectively (Charbonneau et al. 1976; Hirano et al. 1986; Mitsumori et al. 1990; Verschuuren et al. 1976). Additionally, no exposure-related changes in adrenal gland weight or histology were observed in rats following chronic-duration exposure to phenylmercuric acetate at drinking water doses up to 3.7 mg Hg/kg/day (Solecki et al. 1991).

Predominant Mercury Form Unknown (General Populations). Endocrine effects of mercury on endocrine effects in general populations have not been well-studied. Available studies have examined associations between mercury exposure and thyroid function and glucose homeostasis. Studies on thyroid function used cross-sectional or cohort designs and measured plasma or serum levels of T4, T3, TSH, and thyroid autoantibodies. Glucose homeostasis was assessed by examining type 2 diabetes and insulin resistance in prospective and cross-sectional studies and in meta-analyses. Nearly all studies evaluated large populations (n ≥1,100); biomarkers were BHg, UHg, HHg, and NHg.

Thyroid function. Studies examining associations between mercury exposure in general populations and thyroid function are summarized in Table 2-32. Due to the small number of studies and conflicting results, evidence for effects of mercury exposure on thyroid function are inconclusive. All studies used cross-sectional and case-control designs. Results of studies on thyroid hormones (T4, T3, TSH) yield conflicting results. A study using NHANES 2007–2008 data examined the relationship between BHg and blood methylmercury in adults and adolescents (Chen et al. 2013). In adolescents, inverse associations

were observed between total BHg and total T4 and free T3 and between blood methylmercury and free T3, although there were no associations between BHg or blood methylmercury and TSH. Nascimento et al. (2018) also examined a population of adolescents and found an inverse relationship between BHg and T4 and a positive association for TSH. In adults, total BHg and blood methylmercury were inversely associated with total T4, total T3, and free T3 in adults. However, no associations were observed between TSH and total BHg or blood methylmercury in adolescents or adults; therefore, the clinical significance of the inverse associations between mercury and T4 and T3 is unclear. In contrast, no effects on T4 and T3 in a large NHANES population in adults (Kim et al. 2022b) or on T4, T3, or TSH in a population of pregnant Spanish women were observed (Llop et al. 2015). Three studies of the NHANES 2007–2008 population evaluated associations between mercury exposure and thyroid auto-antibodies, with conflicting results (Chen et al. 2013; Gallagher and Meliker 2012; Kim et al. 2021b). No associations were observed between BHg or blood methylmercury levels and anti-thyroglobulin (anti-Tg) or anti-thyroid peroxidase (anti-TPO) in adults or adolescents (Chen et al. 2013; Kim et al. 2021b). However, the Gallagher and Meliker (2012) study of women reported an increase in anti-Tg, but not anti-TPO.

Table 2-32. Overview of Epidemiological Studies Evaluating Associations between Mercury (Predominant Mercury Form Unknown) and Thyroid Hormones in General Populations

Reference, study type and population	Biomarker	Outcome evaluated	Result
Castiello et al. 2020 Cross-sectional; 133 male adolescents (ages 15–17 years) (Spain)	UHg Gmean: 0.03 µg/g creatinine	Free T4	↔ (UHg)
		T3	↔ (UHg)
		TSH	↔ (UHg)
		Free T3:TSH ratio	↔ (UHg)
Chen et al. 2013 Cross-sectional: 1,109 adolescents (NHANES 2007–2008)	BHg Gmean: 0.47 µg/L	T4	↓ (BHg) ↔ (BMeHg)
		Free T4	↔ (BHg, BMeHg)
		T3	↔ (BHg, BMeHg)
		Free T3	↓ (BHg) ↓ (BMeHg)
		TSH	↔ (BHg, BMeHg)
		Tg	↔ (BHg, BMeHg)
		Anti-Tg	↔ (BHg, BMeHg)
		Anti-PO	↔ (BHg, BMeHg)

Table 2-32. Overview of Epidemiological Studies Evaluating Associations between Mercury (Predominant Mercury Form Unknown) and Thyroid Hormones in General Populations

Reference, study type and population	Biomarker	Outcome evaluated	Result
Chen et al. 2013 Cross-sectional: 4,409 adults (NHANES 2007–2008)	BHg Gmean: 0.96 µg/L	T4	↓ (BHg, BMeHg)
		Free T4	↔ (BHg, BMeHg)
		T3	↓ (BHg, BMeHg)
		Free T3	↓ (BHg, BMeHg)
		TSH	↔ (BHg, BMeHg)
		Tg	↔ (BHg, BMeHg)
		Anti-Tg	↔ (BHg, BMeHg)
		Anti-TPO	↔ (BHg, BMeHg)

Gallagher and Meliker 2012
 	
Cross-sectional;
2,047 women (NHANES 2007–2008)
	BHg quintiles:
	  Qi1: ≤40 µg/L
	  Qi2: >0.40–≤0.68 µg/L
	  Qi3: >0.68–≤1.06 µg/L
	  Qi4: >1.06–≤1.18 µg/L
	  Qi5: >1.18–≤15.10 µg/L
		Anti-Tg	↑ (BHg, Qi5)

		Anti-TPO	↔ (BHg)
		Thyrotropin	↔ (BHg)

Liu et al. 2021b
 	
Case-control; 197 adults with thyroid tumor or goiter and 197 controls (China)
	UHg median
	  Cases: 0.27 µg/L
	  Controls: 0.38 µg/L
		T4	↔ (UHg)

		Free T4	↔ (UHg)
		TSH	↔ (UHg)
Llop et al. 2015 Cohort; 1,407 pregnant women (Spain)	Cord BHg Gmean: 7.7 µg/L	Free T4 (M)	↔ (cord BHg)
		Free T3 (M)	↔ (BHg)
		TSH (M)	↔ (BHg)

Kim et al. 2021b
 	
Cross-sectional;
1,254 adults, 630 men and 624 women (NHANES 2015–2017)
	BHg Gmean
	  All: 2.85 µg/L
	  Men: 3.44 µg/L
	  Women: 3.26 µg/L
	UHg Gmean
	  All: 0.44 µg/L
	  Men: 0.46 µg/L
	  Women: 0.42 µg/L
		T4	↔ (BHg, males, females)
			↔ (UHg, males)
			↑ (UHg, females)

		Free T4	↑ (BHg, males) ↔ (BHg, females) ↔ (UHg, males, females)
		T3	↔ (BHg, males) ↑ (BHg, females) ↓ (UHg, males, females)
		Free T3	↔ (BHg, males, females) ↔ (UHg, males, females)
		TSH	↔ (BHg, males, females) ↔ (UHg, males, females)
		Tg	↓ (BHg, males) ↔ (BHg, females) ↔ (UHg, males, females)
		Anti-Tg	↔ (BHg, males, females) ↔ (UHg, males, females)
		Anti-TPO	↔ (BHg, males, females) ↔ (UHg, males, females)

Table 2-32. Overview of Epidemiological Studies Evaluating Associations between Mercury (Predominant Mercury Form Unknown) and Thyroid Hormones in General Populations

Reference, study type and population	Biomarker	Outcome evaluated	Result

Kim et al. 2022b
 	
Cross-sectional;
4,378 adults, 2,399 men and 1,988 women
(NHANES 2007–2012)
	NHg Gmean:
	  Men: 0.99 µg/L
	  Women: 0.88 µg/L
		T4	↔ (BHg, males, females)

		T3	↔ (BHg, males, females)
		T3:T4 ratio	↔ (BHg, males, females)

Nascimento et al. 2018
 	
Cross-sectional:
54 children and adolescents ages 5–15 years (Brazil)
	HHg mean
	  Low: 0.2 µg/g
	  High: 0.9 µg/g
		T4	↓ (UHg)

		TSH	↑ (HHg)

↑ = positive association; ↓ = inverse association; ↔ = no association; Anti-Tg = thyroglobulin antibodies; Anti-TPO = thyroid peroxidase antibodies; BHg = blood mercury; Gmean = geometric mean; BMeHg = blood methylmercury; HHg = hair mercury; M = maternal; NHANES = National Health and Nutrition Examination Survey; Qi = quintile; T3 = triiodothyronine; T4 = thyroxine; Tg = thyroxin-binding globulin; TSH = thyroid-stimulating hormone; UHg = urine mercury

Glucose homeostasis. Studies evaluating effects of mercury exposure of general populations on glucose homeostasis (type 2 diabetes, insulin resistance, and β-cell function) report conflicting results, with most studies showing no associations; studies are summarized in Table 2-33. Type 2 diabetes is the most studied outcome for effects of mercury exposure on glucose homeostasis. Results are conflicting, but study results generally indicate that alteration in glucose homeostasis is not a sensitive effect of mercury in general populations. A large meta-analysis did not find associations between biomarkers and all diabetes (Guo et al. 2023). Two prospective studies of U.S. populations, with 18–20-year follow-up periods, provide conflicting results (He et al. 2013; Mozaffarian et al. 2013). He et al. (2013) reported a positive association between NHg and type 2 diabetes, whereas Mozzaffarian et al. (2013), in a larger study population, did not find an association. Mozzaffarian et al. (2013) conducted a meta-analysis of combined data from both studies, with results showing no association. A cross-sectional study of Taiwanese adults reported a positive association between erythrocyte mercury and type 2 diabetes (Tsai et al. 2019), although a cross-sectional study of Korean adults did not find an association between BHg and type 2 diabetes (Moon 2013). Kim et al. (2015c) reported a positive association between NHg and insulin resistance in men, but not in women, whereas Moon (2013) did not find associations between BHg and insulin resistance or β-cell function in adults. A large cross-sectional study (n=30,994) of adults reported inverse relationship between BHg and blood methylmercury and type 2 diabetes (Zhang et al. 2021a).

Table 2-33. Overview of Epidemiological Studies Evaluating Associations between Mercury Exposure (Predominant Mercury Form Unknown) Glucose Homeostasis in General Populations

Reference, study type and population	Biomarker	Outcome evaluated			
		Insulin resistance	β-cell function	Type 2 diabetes	Diabetes mellitus
Chang et al. 2011 Cross-sectional; 1,449 adults (Taiwan)	BHg mean: 10.8 µg/L	↑ (BHg)	–	–	–
Guo et al. 2023 Meta-analysis of eight studies with combined 40,891 subjects	No combined quantitative data reported for biomarkers; biomarkers in individual studies were BHg, ErHg, UHg, and HHg	–	–	↔ (meta-analysis)[a]	–

He et al. 2013
 	
Prospective; 3,875 adults, followed for 18 years; free of diabetes in 1987 with follow-up until 2005; CARDIA cohort, (United States)
	NHg quintile median:
	  Qi1: 0.073 µg/g
	  Qi2: 0.139 µg/g
	  Qi3: 0.213 µg/g
	  Qi4: 0.331 µg/g
	  Qi5: 0.607 µg/g
		–	–	↑ (NHg, Qi5)	–

Kim et al. 2015c
 	
Cross-sectional; 2,643 men and 2,745 women (KNHANES 2008–2010)
	Men BHg quartile median
	  Q1: 2.6 µg/L
	  Q2: 4.3 µg/L
	  Q3: 6.1 µg/L
	  Q4: 11.5 µg/L
	Women BHg quartile median
	  Q1: 2.0 µg/L
	  Q2: 3.0 µg/L
	  Q3: 4.2 µg/L
	  Q4: 7.5 µg/L
		↑ (BHg, men, Q4)
		↔ (BHg, women)
			–	–	–

Lee et al. 2017d
 	
Cross-sectional; 5,184 adults, 2,523 men and 2,661 women (KNHANES)
	BHg mean
	  Men: 5.88 µg/L
	  Women: 4.11 µg/L
	BHg quartiles:
	Men:
	  Q1: 0.68–3.54 µg/L
	  Q2: 3.55–5.13 µg/L
	  Q3: 5.14–7.41 µg/L
	  Q4: 7.42–56.97 µg/L
		↑ (BHg, men, Q4)
		↔ (BHg, women)
			–	–	–

**Table 2-33. Overview of Epidemiological Studies Evaluating Associations
between Mercury Exposure (Predominant Mercury Form Unknown)
Glucose Homeostasis in General Populations**

Reference, study type and population	Biomarker	Outcome evaluated			
		Insulin resistance	β-cell function	Type 2 diabetes	Diabetes mellitus
	Women: Q1: 0.76–2.54 µg/L Q2: 2.55–3.56 µg/L Q3: 3.57–4.94 µg/L Q4: 4.95–33.93 µg/L				
Moon 2013 Cross-sectional; 2,851 adults without diabetes and 333 adults with diabetes (KNHANES 2009–2010)	BHg mean with diabetes: 4.42 µg/L BHg mean, without diabetes: 4.37 µg/L	↔ (BHg)	↔ (BHg)	↔ (BHg)	–
Moon et al. 2022 Cross-sectional; 3,787 adults, ≥19 years of age, 1,648 males and 2,139 females (KNHANES 2015–2017)	BHg quartiles Q1: <1.86 µg/L Q2: 1.86–<2.81 µg/L Q3: 2.81–<4.44 µg/L Q4: ≥4.44 µg/L UHg quartiles: Q1: <0.20 µg/L Q2: 0.20–<0.35 µg/L Q3: 0.35–<0.64 µg/L Q4: ≥0.64 µg/L	–	–	–	↑ (BHg men, Q3) ↑ (BHg, women, Q4) ↑ (UHg, men, Q4) ↑ (UHg, women, Q2)
Mozaffarian et al. 2013 Prospective cohort; 9,267 adults without diabetes at study enrollment (2,541 men and 6,726 women) from the HPFS (men) and NHS (women) cohorts, with follow-up of approximately 20 years (United States)	NHg median Men: 0.30 µg/g Women: 0.21 µg/g	–	–	↔ (NHg)	–

Table 2-33. Overview of Epidemiological Studies Evaluating Associations between Mercury Exposure (Predominant Mercury Form Unknown) Glucose Homeostasis in General Populations

Reference, study type and population	Biomarker	Insulin resistance	β-cell function	Type 2 diabetes	Diabetes mellitus
		Outcome evaluated			
Mozaffarian et al. 2013 Meta-analysis; combined data from He et al. (2013) and Mozaffarian et al. (2013); 13,142 adults (United States)	Combined NHg not reported; see individual study biomarker data	–	–	↔ (NHg)	–
Tsai et al. 2019 Cross-sectional; 646 adults (Taiwan NAHSIT 2005–2008)	ErHg Gmean with diabetes: 18.95 ErHg Gmean without diabetes: 13.21	–	–	↑ (ErHg)	–

Valcke et al. 2019
 	
Cross-sectional; 70 adults, 42 men and 28 women (Canada)
	BHg Gmean
	    Men: 0.82 µg/L
	    Women: 0.58 µg/L
	UHg Gmean
	    Men: 0.33 µg/g Cr
	    Women: 0.65 µg/g Cr
		–	–	↔ (BHg, men and women)
				↔ (UHg, men and women)
					–

Zhang et al. 2021a
 	
Cross-sectional; 30,994 adults with total BHg measurements and 15,327 adults with BMeHg measurements
	BHg mean: 1,57 µg/L
	BMeHg mean:1.38 µg/L
	Total BHg quartiles:
	    Q1: ≤0.44
	    Q2: 0.45–0.84
	    Q3: 0.85–1.69
	    Q4: >1.69
	BMeHg quartiles:
	    Q1: ≤0.22
	    Q2: 0.23–0.57
	    Q3: 0.585–1.43
	    Q4: >1.43
		–	–	↓ (BHg, Q3)
				↓ (BMeHg, trend)
					–

[a]Includes both type 2 diabetes and diabetes mellitus.

↑ = positive association; ↔ = no association; – = not reported; BHg = blood mercury; BMeHg = blood methylmercury; CARDIA = Coronary Artery Risk Development in Young Adults; ErHg = erythrocyte mercury; Cr = creatinine; Gmean = geometric mean; HHg = hair mercury; HPFS = Health Professionals Follow-up Study; KNHANES = Korea National Health and Nutrition Examination Survey; NAHSIT = National Nutrition and Health survey in Taiwan; NHg = toenail mercury; NHS = Nurses' Health Study; Q = quartile; Qi = quintile; UHg = urine mercury

Mechanisms of Action. Numerous mechanisms have been proposed that may be involved in mercury-induced effects on thyroid function (Afrifa et al. 2018; Chen et al. 2013; Gallagher and Meliker 2012;

Llop et al. 2015; Soldin et al. 2008; Tan et al. 2009; Zhu et al. 2000). These include: (1) inhibition of the biosynthesis of thioredoxin reductase; (2) binding of mercury to sulfhydryl (SH)-containing ligands in the thyroid; (3) reduced TSH production; (4) inhibition of deiodinases; (5) inhibition of TPO and lysosomal enzymes; and (6) decreased iodine uptake. In addition, mercury has been shown to significantly accumulate in the pituitary and thyroid glands, providing a toxicokinetic mechanism for mercury-induced effects (Kosta et al. 1975).

Potential mechanisms for effects of mercury on pancreatic β-cell function were recently reviewed by Schumacher and Abbott (2017). Proposed mechanisms for β-cell dysfunction include: (1) disruption of cell protein structure and function due to binding of mercury to sulfhydryl groups; (2) inhibition of mitochondrial enzymes; (3) depolarization of mitochondrial membranes; (4) decreased mitochondrial ATP synthesis; and (5) decreased insulin gene expression. These mechanisms can contribute to increased formation of ROS, causing metabolic and oxidative stress to pancreatic β-cells. Mercury biomarkers have also been associated with changes in microbiome profiles observed in gestational diabetes (Zhang et al. 2021c).

2.15 IMMUNOLOGICAL

Overview. Epidemiological and animal studies have investigated effects of mercury on the immune system. Epidemiological studies are available in workers exposed to elemental mercury and in dental workers or children exposed to amalgams, populations with a high fish diet, and in general populations in which the chemical form of mercury exposures are unknown. Immunological endpoints examined were primarily serum antibodies, immunoglobulins, cytokines, and immune cell counts; and findings are often conflicting. The toxicological and clinical significance of associations between mercury biomarkers and these endpoints has not been established. Studies in general populations also examined associations between mercury exposure biomarkers and immunological diseases. Dermal sensitization has been shown in skin patch tests in general populations. Epidemiological studies evaluating associations between mercury biomarkers and thyroid antibodies are discussed in Section 2.14 (Endocrine).

Studies evaluating immune function in animals are available for inhalation exposure to mercury vapor and oral exposure to mercuric chloride, mercuric sulfide, or methylmercury. Oral exposure to mercuric chloride or methylmercury results in the induction of autoimmunity in mouse strains prone to autoimmune disease. Mercury-induced autoimmunity is characterized by the presence of serum antinucleolar antibodies (ANoAs), antinuclear antibodies (ANAs), and/or antichromatin antibodies

(ACAs); polyclonal B-cell activation; elevated serum immunoglobulins; and (with mercuric chloride only) immune complex deposits in the kidney and spleen. Very limited evidence from inhalation studies suggests that elemental mercury can also stimulate the immune system and result in formation of immune complexes. In non-susceptible animals, the majority of data indicate that oral exposure to methylmercury results in immune suppression following exposure during development or adulthood (e.g., decreased antibody production, lymphoproliferative responses; natural killer cell activity); however, there is limited evidence that very low exposure levels may stimulate T-cell immune responses. Available data in non-susceptible animals following oral exposure to inorganic mercury salts are insufficient to determine potential exposure-related effects on the immune system. No inhalation data were available in non-susceptible animals.

The following summarizes results of epidemiological and animal studies on immunological outcomes.

- ***Elemental mercury***
  - *Epidemiology studies*
    - No associations were observed between occupational exposure to elemental mercury or exposure to amalgam and immune system effects. Available studies did not examine the same immunological endpoints; therefore, data are insufficient to draw conclusions on the immunological effects of elemental mercury.
  - *Animal studies*
    - A single study in a mouse strain genetically susceptible to autoimmune disease reported general stimulation of the immune system and formation of immune complexes following intermediate-duration inhalation exposure. No other studies evaluating potential immune effects from exposure to mercury vapor were available.
- ***Inorganic mercury salts***
  - *Epidemiology studies*
    - No epidemiological studies evaluating associations between exposure to inorganic mercury salts and immunological effects were identified.
  - *Animal studies*
    - Immune stimulation and immune complex disease can occur in mouse strains genetically susceptible to autoimmune disease following oral exposure to mercuric chloride.
    - Data in wild-type mice are limited, but report alterations in T- and B-cell subpopulations in immune organs and altered immune responses (some stimulated, some suppressed) following oral exposure to mercuric chloride.

- One study reported alterations in splenic and thymic histology and cell populations in wild-type mice following oral exposure to mercuric sulfide at high doses. No other studies evaluating potential immune effects from exposure to mercuric sulfide were available.

- ***Organic mercury***
  - *Epidemiology studies*
    - Associations between BHg and some immunological markers (serum cytokine levels, immunoglobulins, and immune cell counts) were observed; however, it is not known if immune system function was altered in these study populations.
    - Data are insufficient to determine if exposure to organic mercury is associated with adverse immunological effects.
  - *Animal studies*
    - Immune stimulation in the absence of immune complexes can occur in mouse strains genetically susceptible to autoimmune disease following developmental or post-pubertal (adult) exposure.
    - One developmental study in wild-type mice reports immune stimulation in offspring following exposure during gestation plus lactation.
    - Developmental exposure in rats and adult exposure in wild-type animals are generally associated with immune suppression (decreased antibody production, lymphoproliferative responses; natural killer cell activity); however, limited data suggest that very low doses may be associated with immune stimulation (increased immune responses to T-cell antigens).

- ***Predominant mercury form unknown (general populations)***
  - Studies examining immune diseases found associations between mercury biomarkers and atopic dermatitis (but not eczema), systemic lupus erythematosus (SLE), and celiac disease seropositivity.
  - A few studies found associations between mercury biomarkers and other immunological endpoints (serum cytokines, antibodies, and immune cell counts). The clinical significance of these findings has not been established.
  - Several studies in general populations indicate that mercury exposure induces dermal sensitization based on positive skin patch tests to elemental and/or inorganic mercuric salts.

Confounding Factors. The immune system is responsive to a multitude of environmental and physiological factors, which can be confounding factors in studies of associations between mercury exposure and immunological outcomes. Potential confounders that have been considered in some studies, but not consistently across studies, include age, sex, smoking, physical activity, allergen exposures, history of inflammatory and immune diseases, socioeconomic status (SES) factors, recreational activities, and co-exposures to other chemicals. No specific confounder or covariate was mandatory for the inclusion of the study into the profile; however, studies of immunological outcomes that did not consider the aforementioned potential confounders are potentially more confounded than studies that did consider these variables.

Elemental Mercury—Epidemiological Studies. Immune effects of elemental mercury have not been well studied and few epidemiological studies meeting inclusion criteria were identified (inclusion criteria summarized in Section 2.1). Studies were conducted in chloralkali workers (Barregard et al. 1997; Langworth et al. 1992b; Vimercati et al. 2001), miners (Sanchez Rodriguez et al. 2015),), and children or adults with amalgam fillings (Chen et al. 2021; Shenker et al. 2008); results are summarized in Table 2-34. Studies evaluated several different endpoints, including immune cell counts and function; and serum antibodies, immunoglobulins, immune complexes, cytokines and inflammatory conditions (e.g., primary Sjogren's syndrome). No studies found associations between mercury biomarkers and immunological endpoints. However, studies did not evaluate the same immunological endpoints; therefore, data are not sufficient to determine if occupational exposure to elemental mercury or exposure to amalgam is associated with adverse effects to the immune system.

Table 2-34. Results of Epidemiological Studies Evaluating Exposure to Elemental Mercury (Hg^0) and Immunological Effects

Reference, study type, and population	Biomarker	Outcome evaluated	Result

Barregard et al. 1997
 	
Cross-sectional; 41 male chloralkali workers and 41 male controls (Sweden)
	BHg mean
	  Workers: 9.2 µg/L
	  Controls: 3.4 µg/L
	UHg mean
	  Workers: 27 µg/g
	  Controls: 3.4 µg/g
		Serum ANA	↔ (workers versus controls)

		Serum CIC	↔ (workers versus controls)
Chen et al. 2021 Case-control; 5,848 cases of primary Sjogren's syndrome and 5848 controls; age ≥18 years (China)	None	PSS diagnosis	↔ (amalgam restorations versus none)

Table 2-34. Results of Epidemiological Studies Evaluating Exposure to Elemental Mercury (Hg⁰) and Immunological Effects

Reference, study type, and population	Biomarker	Outcome evaluated	Result

Langworth et al. 1992b
 	
Cross-sectional; 89 chloralkali workers and 75 controls (Sweden)
	BHg median
	  Workers: 11 µg/L
	Controls: 3 µg/L
	UHg median
	  Workers: 25.4 µg/g Cr
	  Controls: 1.9 µg/g Cr
		Serum IgA	↔ (workers versus controls)

		Serum IgG	↔ (workers versus controls)
		Serum IgM	↔ (workers versus controls)

Sanchez Rodriguez et al. 2015
 	
Cross-sectional; 164 gold miners and 127 controls (Columbia)
	BHg median
	  Miners: 7.03 µg/L
	  Controls: 2.46 µg/L
	UHg median
	  Miners: 3.96 µg/g Cr
	  Controls: 1.48 µg/g Cr
	HHg median
	  Miners; 0.79 µg/g
	  Controls: 0.39 µg/g
		Elevated serum ANA	↔ (miners versus controls)

		Elevated serum RF	↔ (miners versus controls)

Shenker et al. 2008
 	
Randomized clinical trial; 59 children (6–10 years of age at baseline); 29 children randomized to amalgam fillings and 30 randomized to control composite fillings (New England)
	BHg, baseline mean
	  Amalgam: 0.4 µg/L
	  Composite: 0.4 µg/L
	UHg, 5-year mean
	  Amalgam: 0.85 µg/g Cr
	  Composite: 0.68 µg/g Cr
		Lymphocyte function	↔ (amalgam versus composite)

		Monocyte function	↔ (amalgam versus composite)
		Neutrophil function	↔ (amalgam versus composite)

Vimercati et al. 2001
 	
Cross-sectional; 19 mercury workers and 25 controls
	UHg mean
	  Workers: 9.7 µg/L
	  Controls: 2.4 µg/L
		Monocyte-macrophage cell count[a]	↔ (workers versus controls)

		Cytokines IL-8	↔ (workers versus controls)
		GM-CSF	↔ (workers versus controls)
		TNF-α	↔ (workers versus controls)
		NK cell count	↔ (workers versus controls)

[a]Includes the following cell types: leukocytes, lymphocytes, monocytes, CD13, CD14, CD15, CD33D, and CD45.

↔ = no association; ANA = antinuclear antibodies; BHg = blood mercury; CIC = circulating immune complex; Cr = creatinine; GM-CSF = granulocyte-macrophage colony-stimulating factor; HHg = hair mercury; Ig = immunoglobulin; IL = interleukin; PSS = primary Sjogren's syndrome; RF = rheumatoid factor; NK cell = natural killer cell; TNF-α = tumor necrosis factor-alpha; UHg = urine mercury

Elemental Mercury—Animal Studies. A single study evaluating immunological endpoints following

inhalation exposure to elemental mercury reported a general stimulation of the immune system in a mouse

strain genetically susceptible to autoimmune disease (Warfvinge et al. 1995). In this study, susceptible
SJL/N mice were exposed to 0.3, 0.05, or 1 mg Hg/m^3 for 0.5–19 hours/day, 5 days/week, for 10 weeks
(time-weighted average [TWA] concentrations of 0.01–0.4 mg Hg/kg/day). All mice exposed to TWA
concentrations ≥0.03 mg Hg/kg/day (absorbed dose of 0.170 mg Hg/kg/week) showed positive ANoA;
this was not observed at the TWA concentration of 0.01 mg Hg/kg/day (absorbed dose of
0.075 mg/kg/day). Mice exposed to TWA concentrations ≥0.06 mg Hg/kg/day also showed B-cell
stimulation (increased serum immunoglobins) and glomerular disease accompanied by vascular immune
complex deposits.

Inorganic Mercury Salts—Animal Studies. Data from oral studies indicate that exposure to mercuric
chloride can result in immune stimulation and immune complex disease in mouse strains genetically
susceptible to autoimmune disease. Positive antinucleolar antibody (ANoA) and/or antinuclear antibody
(ANA) and immune complex effects (e.g., renal, splenic, and cardiac vessel immune deposits, renal
mesangium deposits) were observed in susceptible strains of mice at ≥0.14 mg Hg/kg/day for up to
10 weeks (Amirhosseini et al. 2021; Hultman and Enestrom 1992; Hultman and Nielsen 2001; Nielsen
and Hultman 2002). Additional effects included polyclonal B-cell activation in mice at ≥0.118 mg
Hg/kg/day, and elevated serum IgE mice at ≥0.942 mg Hg/kg/day. Another series of studies reported
induction of serum IgG antibodies to brain antigens and/or elevated serum IgG in dams and offspring in
susceptible mouse strains following gestational and lactation exposure to 2.7 mg Hg/kg/day (Zhang et al.
2011, 2013). Additional findings in offspring only included IgG deposits in the brain and brain
inflammation. Immune stimulation was not observed in similarly exposed wild-type A/WySnJ dams or
offspring (Zhang et al. 2011). However, immune stimulation (increased splenocyte proliferation and
interferon gamma (IFNγ) and interleukin-4 (IL-4) production in mitogen assay) was observed in wild-
type DBF1 adult offspring (progeny of DBA/1 males × BALB/c females) following exposure to 1.5 mg
Hg/kg/day throughout gestation (Pilones et al. 2009).

Data on immunotoxicity in wild-type adult mice following exposure to mercuric chloride is limited. In an
acute-duration study, changes in immune cell populations of the spleen and thymus were observed in
BALB/c mice following exposure to mercuric chloride for 14 days, including dose-related changes in
T-lymphocytes (CD3+), T-helper (CD4+), and T-suppressor (CD8+) cells in the spleen at ≥0.31 mg
Hg/kg/day and CD4-/CD8+ suppressor cells in the thymus at ≥1.39 mg Hg/kg/day (Kim et al. 2003). In
an intermediate-duration study, dose-related increases in splenocyte proliferation in response to the B-cell
antigen *Escherichia coli* lipopolysaccharide (LPS) were observed in B6C3F1 mice exposed to ≥2 mg
Hg/kg/day, respectively, for 7 weeks (Dieter et al. 1983). Non-dose-dependent decreases in mitogenic

response to T-cell antigens (concanavalin A, phytohemagglutinin) and mixed lymphocyte responses were also observed at ≥2 mg Hg/kg/day. In the plaque-forming assay, exposed mice showed a 60% decrease in the antibody response to a T-dependent antigen (sheep red blood cells) at 11 mg Hg/kg/day; no changes in the antibody response to the B-cell antigen LPS were observed. No exposure-related changes in serum IgG, IgM, or IgA were observed (Dieter et al. 1983).

No histopathological changes in the bone marrow, thymus, or spleen were observed in rats after acute-, or chronic-duration oral exposure to mercuric chloride doses up to 9.23, 4, or 4 mg Hg/kg/day, respectively, or in mice after chronic-duration oral exposure to doses up to 7.4 mg Hg/kg/day, respectively (NTP 1993). Intermediate-duration studies in rats describe severe necrosis and decreased cellularity in the spleen at 0.847 mg Hg/kg/day (Venter et al. 2020), while other studies report no histological effects on the bone marrow, thymus, or spleen at doses up to 4 mg Hg/kg/day (Dieter et al. 1983, 1992). Son et al. (2010) found treatment-related changes in T-lymphocyte populations in the spleen in mice exposed to ≥17 mg Hg/kg/day, including increased CD4+CD8+ and CD8 single-positive lymphocytes. There were no treatment related changes in T-lymphocytes of the thymus. Pathological findings observed at 1,700 mg Hg/kg/day included enlargement of the spleen and marked hyperplasia of the white pulp, increased cellular density in the splenic lymphoid follicles, and increased density of lymphoid cells in the thymus. There was no exposure-related effect on splenocyte or thymocyte proliferation.

One study evaluated immune endpoints in ICR mice following oral exposure to mercuric sulfide for 4 weeks (Son et al. 2010). Treatment-related changes in T-lymphocyte populations in the spleen were observed at ≥17 mg Hg/kg/day, including increased CD4+CD8+ and CD8 single-positive lymphocytes. There were no treatment related changes in T-lymphocytes of the thymus. Pathological findings observed at 1,700 mg Hg/kg/day included enlargement of the spleen and marked hyperplasia of the white pulp, increased cellular density in the splenic lymphoid follicles, and increased density of lymphoid cells in the thymus. There was no exposure-related effect on splenocyte or thymocyte proliferation.

Organic Mercury—Epidemiological Studies. Few studies have evaluated immunological effects in populations with high fish diets; studies meeting inclusion criteria are summarized in Table 2-35 (inclusion criteria, Section 2.1). Studies consist of two prospective studies in children (Hui et al. 2016; Oulhote et al. 2017a), one cross-sectional study in mother-infant pairs (Nyland et al. 2011), two prospective cohort studies in pregnant women (McSorley et al. 2018, 2020), and a cohort of children (Wyatt et al. 2019). Endpoints examined include serum levels of cytokines (Hui et al. 2016; McSorley et al. 2018, 2020; Nyland et al. 2011) and immunoglobulins (Hui et al. 2016; Nyland et al. 2011), immune

cell counts (Oulhote et al. 2017a), anti-nuclear proteins (McSorley et al. 2020), and antibody response to

vaccinations (Wyatt et al. 2019).

Table 2-35. Results of Epidemiological Studies Evaluating Immunological Effects in Populations with High Fish Diets

Reference, study type, and population	Biomarker	Outcome evaluated	Result

Hui et al. 2016
 	
Prospective; 407 children from a high fish-eating population; cytokines measured at ages 6–9 years (China)
	BHg median
	  Cord: 9.2 µg/L
	  Current: 2.6 µg/L
		Cytokines
		  IL-4
		  IL-5
		  IL-6
		  IL-8
		  IL-10
		
		  IL-13
		  TNF-α
			$\leftrightarrow$ (BHg, cord and current)
			$\leftrightarrow$ (BHg, cord and current)
			$\leftrightarrow$ (BHg, cord and current)
			$\leftrightarrow$ (BHg, cord and current)
			$\leftrightarrow$ (BHg, cord), $\downarrow$ (BHg, current)
			$\leftrightarrow$ (BHg, cord and current)
			$\leftrightarrow$ (BHg, cord and current)

McSorley et al. 2018
 	
Prospective cohort; 1,158 pregnant women assessed at 28 weeks of gestation (Seychelles)
	BHg mean: 18.14 µg/L	Th1 cell cytokines
		  IL-1β
		  IL-2
		  IFN-γ
		  TNF-α
		  Total
			
			$\downarrow$ (BHg)
			$\downarrow$ (BHg)
			$\leftrightarrow$ (BHg)
			$\downarrow$ (BHg)
			$\downarrow$ (BHg)

		Th2 cell cytokines
		  IL-4
		  IL-5
		  IL-10
		  Total
			
			$\downarrow$ (BHg)
			$\leftrightarrow$ (BHg)
			$\downarrow$ (BHg)
			$\leftrightarrow$ (BHg)

		Th1:Th2 cytokine ratio	$\downarrow$ (BHg)

		Other cell cytokines
		  CRP
		  IL-6
		  MCP-1
		  TARC
		  sFlt-1
		  VEGF-D
			
			$\downarrow$ (BHg)
			$\leftrightarrow$ (BHg)
			$\leftrightarrow$ (BHg)
			$\uparrow$ (BHg)
			$\leftrightarrow$ (BHg)
			$\uparrow$ (BHg)

McSorley et al. 2020
 	
Prospective cohort; 497 mother-child pairs assessed at age 19 years (Seychelles)
	HHg mean
	  Maternal: 6.84 µg/g
	  Child: 10.23 µg/g
		ANA	$\leftrightarrow$ (BHg maternal)
			$\uparrow$ (BHg child)

		A-RNP	$\leftrightarrow$ (BHg maternal) $\leftrightarrow$ (BHg child)

		Immunoglobulins
		  IgG
		  IgM
		
		  IgA
			
			$\leftrightarrow$ (BHg maternal, child)
			$\leftrightarrow$ (BHg maternal)
			$\downarrow$ (BHg child)
			$\leftrightarrow$ (BHg maternal, child)

Table 2-35. Results of Epidemiological Studies Evaluating Immunological Effects in Populations with High Fish Diets

Reference, study type, and population	Biomarker	Outcome evaluated	Result
		Cytokines	
		IL-1 beta	↔ (BHg maternal, child)
		IL-2	↔ (BHg maternal, child)
		IL-6	↔ (BHg maternal, child)
		IL-10	↔ (BHg maternal)
		TNF-α	↑ (BHg child)
		IFN-γ	↔ (BHg maternal, child)
		NF-α:IL-10 ratio	↔ (BHg maternal)
			↓ (BHg child)
		CRP	↔ (BHg maternal)
			↑ (BHg child)

Nyland et al. 2011
 	
Cross-sectional;
61 mother-infant pairs (Brazilian Amazon); fetal and immune responses were assessed
	BHg Gmean
	  Maternal: 6.90 µg/L
	  Cord: 9.63 µg/L
		IgG	↓ (BHg, maternal and cord)

		IgA, IgE, IgM	↔ (BHg, maternal and cord)
		ANA	↓ (BHg, maternal and cord)
		Cytokines	
		IL-1β	↑ (BHg, maternal and cord)
		IL-6	↑ (BHg, maternal and cord)
		IL-1ra	↔ (BHg, maternal and cord)
		TNF-α	↑ (BHg, maternal and cord)
		IFN-γ	↔ (BHg, maternal and cord)

Oulhote et al. 2017a
 	
Prospective 53 mother-child pairs; endpoints assessed at 5 years of age (Faroe Islands)
	BHg Gmean
	  Maternal: 3.066 µg/L
	  Cord: 4.649 µg/L
	  Child age 5-years:
	  2.328 µg/L
	HHg Gmean
	  Maternal: 0.748 µg/L
	  Child age 5-years:
	  0.611 µg/L
	
	Maternal exposure based on a composite factor of cord and maternal BHg and maternal HHg; child exposures based on a composite of child BHg and HHg at 5 years of age
		WBC counts	

		Neutrophils	↔ (BHg, maternal and cord)
		Basophils	↔ (BHg, maternal and cord)
		Eosinophils	↔ (BHg, maternal and cord)
		Lymphocytes	↓ (BHg, maternal)
			↔ (BHg, cord)
		Monocytes	↔ (BHg, maternal and cord)
		Total WBCs	↓ (BHg, maternal)
			↔ (BHg, cord)
		Lymphocyte counts	
		CD3	↓ (BHg, maternal)
			↔ (BHg, cord)
		CD4	↓ (BHg, maternal)
			↔ (BHg, cord)
		CD8	↔ (BHg, maternal and cord)
		CD4-RTE	↓ (BHg, maternal)
			↔ (BHg, cord)
		NK cells	↔ (BHg, maternal and cord)
		B-lymphocytes	↓ (BHg, maternal)
			↔ (BHg, cord)

Table 2-35. Results of Epidemiological Studies Evaluating Immunological Effects in Populations with High Fish Diets

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Wyatt et al. 2019 Longitudinal study of children, age 4–8 years (n=98), Peru	HHg Mean:1.5 µg/g	Post-vaccination diphtheria-specific antibodies response	↓ (BHg, child with malnutrition)
		Post-vaccination measles-specific antibody response	↓ (BHg, child with malnutrition)
		Post-vaccination pertussis-specific antibody response	↓ (BHg, child with malnutrition)

↑ = positive association; ↓ = inverse association; ↔ = no association; ANA = anti-nuclear antibodies; A-RNP = anti-ribonuclear protein; BHg = blood mercury; CD3 = T-cells; CD4 = t-helper cells; CD8 = t-cytotoxic cells; CD4-RTE = CD4+ recent thymic emigrant cells; CRP = C-reactive protein; Gmean = geometric mean; IFN-γ = interferon-gamma; Ig = immunoglobulin; IL = interleukin; MCP-1 = monocyte chemotactic protein-1; NK cells = natural killer cells; sFlt-1 = soluble fms-like tyrosine kinase-1; TARC = thymus- and activation-regulated chemokine; Th1 = T-helper cell 1 (cell-mediated immunity); Th2 = T-helper cell 2 (humoral immunity); TNF-α = tumor necrosis factor-alpha; VEGF-D = vascular endothelial growth factor-D; WBC = white blood cell

Plasma cytokine levels are the only immunological endpoint evaluated in more than one study; however, results are conflicting. Inverse associations were observed between BHg and several cytokines in a cohort of pregnant women (McSorley et al. 2018); however, the study authors noted that changes were small and of unknown clinical significance. A follow-up of children in this cohort at age 19 years found associations between increasing child HHg level (but not maternal HHg levels) and decreasing serum IgM, increasing interleukin-10, and increasing C-reactive protein (McSorley et al. 2020). No associations were observed in this study for other immunological endpoints including serum levels of other cytokines (interleukins, tumor necrosis factors) or antibodies (IgA, IgG, anti-nuclear proteins). In contrast, a prospective study in children did not find any associations between cord or child BHg and several interleukins and tumor necrosis factor-alpha (Hui et al. 2016), and positive associations were observed between maternal and cord BHg and some cytokines in mothers and infants in a cross-sectional study (Nyland et al. 2011). In addition to plasma cytokine levels, Nyland et al. (2011) also reported an inverse association between mother and cord BHg and plasma IgG levels, but not IgA, IgE, or IgM; the toxicological significance of this association was not established. For cell counts, inverse associations were observed between maternal and child BHg and total leukocyte and total lymphocyte counts, and some lymphocyte subpopulation counts (CD3, CD4, and B cells) (Oulhote et al. 2017a). Cell counts for CD4-RTE also were inversely associated with BHg in mothers, but not in children. Although associations between BHg and some immunological endpoints were observed, it is not known if alterations in immune markers or cell counts are associated with compromised immune system function in

these study populations. A study of children who resided in the Amazonian River Basin, where exposure to dietary methylmercury occurs as a result of wastes from gold mining operations, found decreased antibody response to diphtheria, measles, and pertussis vaccinations in association with a combination of malnutrition and increasing HHg (Wyatt et al. 2019).

Organic Mercury—Animal Studies. Most available data are from oral intermediate-duration studies. Data indicate that exposure to methylmercury can result in immune stimulation in the absence of an immune complex formation in mouse strains genetically susceptible to autoimmune disease. There is limited evidence of immune stimulation in wild-type mice following developmental exposure. Developmental exposure in rats and exposure during adulthood in rats, mice, and rabbits is generally associated with immune suppression; however, there are limited data for immune stimulation at very low doses.

Polyclonal B-cell activation and serum ANoA and ACA were observed in autoimmune susceptible A.SW mice at 0.420 mg Hg/kg/day immediately after a 30-day exposure to methylmercury; ANoA was still detected 8 weeks post-exposure. Serum IgG was elevated immediately and 2 weeks after the 30-day exposure; serum IgE was not significantly elevated. No significant increases in tissue immune complex deposits were observed in the kidneys or spleen at any timepoint (Havarinasab et al. 2007). Another study evaluated immune stimulation in A.SW dams and offspring following gestational and lactation exposure to methylmercury at 0.06 mg Hg/kg/day (Zhang et al. 2011). No evidence of serum IgG antibodies to brain antigens or IgG deposition in the brain was observed in dams or offspring; however, cerebellar inflammation was observed in exposed female offspring and IL-12 was decreased in male offspring at PND 21. Exposure-related changes were not observed in similarly exposed wild-type A/WySnJ dams or offspring (Zhang et al. 2011).

Functional immune assays in rats and wild-type mice following developmental exposure to methylmercury indicate a complicated pattern of immunomodulatory effects, including nonmonotonic findings and differential findings between rats and mice (Table 2-36). In rats, low exposure levels during gestation and lactation periods are associated with increased lymphoproliferative responses to T-cell mitogens, with smaller or no effect at higher exposure levels (Ilback et al. 1991; Tonk et al. 2010; Wild et al. 1997). No clear pattern was observed for cytokine release in response to T-cell mitogens (Tonk et al. 2010). Exposure during the postnatal period only was associated with a decreased response in rat offspring (Ilback et al. 1991). Other findings in rat offspring following gestational plus lactational exposure generally indicate immune suppression, including decreased lymphoproliferation in response to

B-cell mitogens, decreased antibody production and cytokine release in response to the Keyhole Limpet hemocyanin antigen, and decreased natural killer cell activity (Ilback et al. 1991; Tonk et al. 2010; Wild et al. 1997). Data in wild-type mice following developmental exposure are limited to a single study, which reports decreased lymphoproliferative responses to T-mitogens at low doses, with increased responses at higher doses, increased lymphoproliferative responses to B-mitogens, increased antibody production following influenza inoculation, and increased natural killer cell activity (Thuvander et al. 1996).

Table 2-36. Functional Immune Assays in Rodents Orally Exposed to Methylmercury During Development[a]

Species; duration	Dose (mg Hg/ kg/day)	T-cell mitogen	B-cell mitogen	CK production	AB production	NKC activity	Reference (compound)
Rat; 15 days [PNDs 1–15]	0.37	Con A Th: ↔ Sp: ↓ (32)[b] [PND 15]	LPS: ↔	–	–	Sp: ↔	Ilback et al. 1991 (MM)
Rat 26 days [GD 6–PND 10]	0.08	Con A: ↔	LPS: ↔	Con A: ↑ (20)[c] [PND 70] KHL: ↔ [PND 63]	KHL: ↓ (30)[c] [PND 35]	Sp: ↔ [PND 70]	Tonk et al. 2010 (MMC)
Rat 26 days [GD 6–PND 10]	0.3	Con A: ↔	LPS: ↓ (8)[c] [PND 42]	Con A: ↓ (6)[c] [PND 70] KHL: ↓ (28)[c] [PND 63]	KHL: ↓ (55)[c] [PND 35]	Sp: ↓ (>5)[d] [PND 70]	Tonk et al. 2010 (MMC)
Rat 26 days [GD 6–PND 10]	0.6	Con A: ↔	LPS: ↓ (21)[c] [PND 42]	Con A: ↑ (24)[c] [PND 70] KHL: ↓ (34)[c] [PND 63]	KHL: ↓ (70)[c] [PND 35]	Sp: ↓ (>5)[d] [PND 70]	Tonk et al. 2010 (MMC)
Rat 26 days [GD 6–PND 10]	0.8	Con A: ↔	LPS: ↓ (32)[c] [PND 42]	Con A: ↑ (26)[c] [PND 70] KHL: ↓ (36)[c] [PND 63]	KHL: ↓ (75)[c] [PND 35]	Sp: ↓ (>5)[d] [PND 70]	Tonk et al. 2010 (MMC)
Rat 26 days [GD 6–PND 10]	1.2	Con A: ↔	LPS: ↓ (22)[c] [PND 42]	Con A: ↑ (28)[c] [PND 70] KHL: ↓ (3)[c] [PND 63]	KHL: ↓ (55)[c] [PND 35]	Sp: ↓ (>5)[d] [PND 70]	Tonk et al. 2010 (MMC)

Table 2-36. Functional Immune Assays in Rodents Orally Exposed to Methylmercury During Development[a]

Species; duration	Dose (mg Hg/ kg/day)	T-cell mitogen	B-cell mitogen	CK production	AB production	NKC activity	Reference (compound)
Rat 26 days [GD 6–PND 10]	1.6	Con A: ↔	LPS: ↓ (>5)[d] [PND 70]	Con A: ↑ (96)[c] [PND 70] KHL: ↓ (54)[c] [PND 63]	KHL: ↓ (95)[c] [PND 35]	Sp: ↓ (>5)[d] [PND 70]	Tonk et al. 2010 (MMC)
Rat 105 days [8 weeks PM–PND 21]	0.0006	Con A: ↔ PWM ↑ (250)[b] [PND 42] ↑ (110)[b] [PND 84]	–	–	–	Sp: ↓ (56)[b] [PND 84]	Wild et al. 1997 (MMC)
Rat 105 days [8 weeks PM–PND 21]	0.003	Con A: ↑ (9)[b] PWM ↑ (120)[b] [PND 84]	–	–	–	Sp: ↔	Wild et al. 1997 (MM2S)
Rat 105 days [8 weeks PM–PND 21]	0.06	Con A: ↑ (290)[b] [PND 42] PWM ↑ (160)[b] [PND 42] ↑ (88)[b] [PND 84]	–	–	–	Sp: ↓ (56)[b] [PND 84]	Wild et al. 1997 (MMC)
Rat 105 days [11 weeks PM–GD 21]	0.37	Con A: ↔	LPS: ↔	–	–	Sp: ↔	Ilback et al. 1991 (MM)
Rat 119 days [11 weeks PM–PND 15]	0.37	Con A Th: ↑ (47)[b] Sp: 0 [PND 15]	LPS: ↔	–	–	Sp: ↓ (42)[b] [PND 15]	Ilback et al. 1991 (MM)
Mouse 112 days [10 weeks PM–PND 15]	0.098	Con A Th: ↔ Sp:↓ (45)[b] [PND 50]	LPS: ↔	–	Influenza: ↑ (11)[b] [14 dpi] 0 [35 dpi]	Sp: ↔	Thuvander et al. 1996 (MMC)

Table 2-36. Functional Immune Assays in Rodents Orally Exposed to Methylmercury During Development[a]

Species; duration	Dose (mg Hg/ kg/day)	T-cell mitogen	B-cell mitogen	CK production	AB production	NKC activity	Reference (compound)
Mouse 112 days [10 weeks PM– PND 15]	0.98	Con A Th: ↔ Sp: ↑ (50)[b] [PND 50]	LPS: S: ↑ (35)[b] [PND 22] S: ↑ (25)[b] [PND 50]	–	Influenza: ↔ [14 or 35 dpi]	Sp: ↑ (255)[b] [PND 22] Sp: ↔ [PND 50]	Thuvander et al. 1996 (MMC)

[a]Studies with exposure prior to puberty only, including studies that evaluate adult animals after developmental exposure. These findings are listed under "Develop" in the LSE table.
[b]Percent change compared to control, calculated from quantitative data.
[c]Percent change compared to control, estimated from graphically presented data.
[d]Dose-specific data not reported; data based on reported BMD_5 values.

↑ = increased; ↓ = decreased; ↔ = no change; – = not assessed; AB = antibody; BMD = benchmark dose; Con A = concanavalin A (T-cell mitogen); dpi = days post-infection; GD = gestation day; KHL = Keyhole Limpet hemocyanin; LPS = *Escherichia coli* lipopolysaccharide (B-cell mitogen); LSE = Level of Significant Exposure; MM = methylmercury; MM2S = bis(methylmercury)sulfide; MMC = methylmercuric chloride; NKC = natural killer cell; PM = premating; PND = postnatal day; PWM = pokeweed mitogen (T-cell mitogen); Sp = spleen/splenocytes; Th = thymus/thymocytes

Studies evaluating functional immune assays in animals following exposure during adulthood are reviewed in Table 2-37. Intermediate-duration functional immune assays in laboratory animals orally exposed to methylmercury during adulthood generally show dose-related suppression of immune function, including suppressed antibody production in response to antigen exposure, decreased IgM- and IgG producing cells in the spleen during the plaque forming assay, and decreased natural killer cell activity in the blood and the spleen (Blakley et al. 1980; Ilback 1991; Koller et al. 1977).

In an 8-week exposure to methylmercuric chloride, it was observed that male rats had an initial increase in the lymphoproliferative response to T-cell mitogens at 0.0004 mg/kg/day prior to proliferative suppression at the higher dose (0.04 mg/kg/day) (Ortega et al. 1997b). Different response patterns were observed with different forms of methylmercury [methylmercury chloride, methylmercury sulfide, bis(methylmercury)sulfide, tris(methylmercuric)sulphonium ion] (Ortega et al. 1997a, 1997b). One study reported increased lymphoproliferation in mice in response to a B-cell mitogen; no change was observed for T-cell mitogen responses (Ilback 1991).

Table 2-37. Functional Immune Assays in Laboratory Animals Orally Exposed to Methylmercury During Adulthood

Species; duration	Dose (mg Hg/ kg/day)	Mitogen	HG titers	AB production	PFA	NKC activity	Reference (compound)
Rat; 56 days	0.0004	PHA: ↑ (533)[a] Con A: ↑ (313)[a]	–	–	–	–	Ortega et al. 1997a, 1997b (MMC)
Rat; 56 days	0.0004	PHA: ↑ (267)[a]	–	–	–	–	Ortega et al. 1997a (MMS)
Rat; 56 days	0.0004	PHA: ↑ (300)[a] Con A: ↑ (150)[a]	–	–	–	–	Ortega et al. 1997a, 1997b (MM2S)
Rat; 56 days	0.0004	PHA: ↓ (56)[a]	–	–	–	–	Ortega et al. 1997a (MM3S)
Rat; 56 days	0.04	PHA: ↓ (67)[a] Con A: ↓ (67)[a]	–	–	–	–	Ortega et al. 1997a, 1997b (MMC)
Rat; 56 days	0.04	PHA: ↔	–	–	–	–	Ortega et al. 1997a (MMS)
Rat; 56 days	0.04	PHA: ↔ Con A: ↑ (280)[a]	–	–	–	–	Ortega et al. 1997a, 1997b (MM2S)
Rat; 56 days	0.04	PHA: ↓ (56)[a]	–	–	–	–	Ortega et al. 1997a (MM3S)
Rat; 112 days	0.0004	Con A: ↓ (79)[a]	–	–	–	–	Ortega et al. 1997b (MMC)
Rat; 112 days	0.0004	Con A: ↓ (69)[a]	–	–	–	–	Ortega et al. 1997b (MM2S)
Rat; 112 days	0.04	Con A: ↓ (86)[a]	–	–	–	–	Ortega et al. 1997b (MMC)
Rat; 112 days	0.04	Con A: ↑ (173)[a]	–	–	–	–	Ortega et al. 1997b (MM2S)
Mouse; 21 days	0.08	–	SRBC: ↓ (23)[b] LPS: ↓ (31)[b]	LPS: ↓ (39)[b] [28 dpi]	PFA[c]: 1°:↓ (43)[b] 2°:↓ (19)[b]	–	Blakley et al. 1980 (MMC)

Table 2-37. Functional Immune Assays in Laboratory Animals Orally Exposed to Methylmercury During Adulthood

Species; duration	Dose (mg Hg/ kg/day)	Mitogen	HG titers	AB production	PFA	NKC activity	Reference (compound)
Mouse; 21 days	0.35	–	SRBC: ↓ (43)[b] LPS: ↓ (45)[b]	LPS: ↓ (53)[b] [28 dpi]	PFA[c]: 1°:↓ (56)[b] 2°:↓ (27)[b]	–	Blakley et al. 1980 (MMC)
Mouse; 21 days	1.7	–	SRBC: ↓ (36)[b] LPS: ↓ (45)[b]	LPS: ↓ (56)[b] [28 dpi]	PFA[c]: 1°:↓ (58)[b] 2°:↓ (24)[b]	–	Blakley et al. 1980 (MMC)
Mouse; 84 days	0.77	Con A Th: ↔ Sp: ↑ (20)[b] LPS: ↔	–	–	–	Bl: ↓ (75)[b] Sp: ↓ (44)[b]	Ilback 1991 (MM)
Rabbit; 98 days	0.05	–	–	Influenza: ↔	–	–	Koller et al. 1977 (MMC)
Rabbit; 98 days	0.49	–	–	1°:↓ (50)[b] [7 dpi] 2°:↓ (50)[b] [24 dpi]	–	–	Koller et al. 1977 (MMC)
Rabbit; 98 days	0.53	–	–	1°:↓ (75)[b] [7 dpi] 2°:↓ (50)[b] [24 dpi]	–	–	Koller et al. 1977 (MMC)

[a]Percent change compared to control, estimated from graphically presented data.
[b]Percent change compared to control, calculated from quantitative data.
[c]Primary (1°) response is production of IgM-producing cells in the spleen; secondary (2°) response is production of IgG-producing cells in the spleen.

↑ = increased; ↓ = decreased; ↔ = no change; – = not assessed; AB = antibody; Bl = blood; Con A = concanavalin A (T-cell mitogen); dpi = days post-infection; HG = hemagglutination; Ig = immunoglobulin; LPS = *Escherichia coli* lipopolysaccharide (B-cell mitogen); MM = methylmercury; MM2S = bis(methylmercury)sulfide; MM3S = tris(methylmercuric)sulphonium ion; MMC = methylmercuric chloride; MMS = methylmercury sulfide; NKC = natural killer cell; PFA = plaque-forming assay with SRBCs; PHA = phytohemagglutinin (T-cell mitogen); Sp = spleen; Th = thymus; SRBC = sheep red blood cell

Plasma IL-6 was elevated in rats exposed to ≥0.0004 mg Hg/kg/day as methylmercuric chloride or 0.004 mg Hg/kg/day as bis(methylmercury)sulfide for 8 weeks (Ortega et al. 1997b). With exposure for 16 weeks, plasma IL-6 levels were significantly elevated with exposure to ≥0.0004 mg Hg/kg/day as bis(methylmercury)sulfide (although there was not an increasing response at the higher dose) or 0.04 mg Hg/kg/day as methylmercuric chloride. These results are difficult to interpret due to lack of a clear dose- and duration-dependence. Nascimento et al. (2022) reported increased levels of plasma tumor necrosis factor (TNF) and circulating lipopolysaccharide (LPS) in mice exposed to 0.21 mg Hg/kg/day as

methylmercuric chloride for 30 days, compared to controls; no additional immunological endpoints were assessed. Increased serum IFN-γ was observed in mice exposed to 0.16 mg Hg/kg/day methylmercuric chloride for 28 days (Al-Mazroua et al. 2022).

Data for spleen and thymic weight and cellularity following developmental or adult exposure to methylmercury are presented in Table 2-38. There is limited evidence of increased thymus weight and/or cellularity in rodents following intermediate-duration developmental exposure to methylmercury (Thuvander et al. 1996; Tonk et al. 2010; Wild et al. 1997). In contrast, decreased thymus weight and cellularity were reported in a single intermediate-duration adult exposure study (Ilback et al. 1991). Available data are not adequate to assess dose- or duration-dependence of thymic changes for either exposure paradigms. No consistent, exposure-related changes in spleen weight or cellularity have been observed in rodents following developmental or adult exposure (Table 2-38).

Table 2-38. Immune Organ Weight and Cellularity in Rodents Orally Exposed to Methylmercury

Species; duration	Dose (mg Hg/ kg/day)	Spleen weight	Spleen cellularity	Thymus weight	Thymus cellularity	Reference (compound)
Developmental exposure[a]						
Rat; 15 days [PNDs 1–15]	0.37	Relative: ↓ (13)[b] [PND 15]	↔	↔	↔	Ilback et al. 1991 (MM)
Rat; 26 days [GD 6– PND 10]	0.08	Relative: ↔ [PNDs 21– 70]	↔	Relative: 0 [PNDs 21– 70]	–	Tonk et al. 2010 (MMC)
Rat; 26 days [GD 6– PND 10]	0.3	Relative: ↓ (>5)[c] [PND 21]	↔	Relative: 0 [PNDs 21– 70]	–	Tonk et al. 2010 (MMC)
Rat; 26 days [GD 6– PND 10]	0.6–1.6	Relative: ↓ (>5)[c] [PNDs 21– 42]	↑ (>5)[b] [PND 42]	Relative: ↑ (>5)[c] [PND 70]	–	Tonk et al. 2010 (MMC)
Rat; 105 days [8 weeks PM– PND 21] (W)	0.0006	Absolute ↑ (62)[d] [PND 42]	–	Absolute ↑ (105)[d] [PND 42]	–	Wild et al. 1997 (MMC)
Rat; 105 days [8 weeks PM– PND 21]	0.0003	Absolute ↔ [PNDs 42– 84]	–	Absolute ↑ (56)[d] [PND 42]	–	Wild et al. 1997 (MM2S)

Table 2-38. Immune Organ Weight and Cellularity in Rodents Orally Exposed to Methylmercury

Species; duration	Dose (mg Hg/ kg/day)	Spleen weight	Spleen cellularity	Thymus weight	Thymus cellularity	Reference (compound)
Rat; 105 days [8 weeks PM– PND 21]	0.06	Absolute ↑ (122)[d] [PND 42]	–	Absolute ↑ (105)[d] [PND 42]	–	Wild et al. 1997 (MMC)
Rat; 105 days [11 weeks PM– GD 21]	0.37	↔	↔	↔	↔	Ilback et al. 1991 (MM)
Rat; 119 days [11 weeks PM– PND 15]	0.37	↔	↔	↔	↔	Ilback et al. 1991 (MM)
Mouse; 112 days [10 weeks PM– PND 15]	0.098	Absolute: ↑ (28)[b] [PND 10]	↑ (30)[b] [PND 10] ↑ (25)[b] [PND 22]	Absolute: ↔ [PNDs 10– 50]	↑ (33)[b] [PND 22]	Thuvander et al. 1996 (MMC)
Mouse; 112 days [10 weeks PM– PND 15]	0.98	↔	↔	↔	↔	Thuvander et al. 1996 (MMC)
Post-pubertal (adult) exposure						
Rat; 28 days	0.002– 5.91	Relative: ↔	–	–	–	Wildemann et al. 2015a (MMC)[e]
Rat; 730 days	0.006–0.16	Relative: ↔	–	–	–	Verschuuren et al. 1976 (MMC)
Mouse; 84 days	0.77	Absolute: ↔	↔	Absolute: ↓ (22)[b]	↓ (50)[b]	Ilback 1991 (MM)

[a]Studies are listed under "Develop" in the LSE table.
[b]Percent change compared to control, calculated from quantitative data.
[c]Dose-specific data not reported; data based on reported BMD$_5$ values.
[d]Percent change compared to control, estimated from graphically presented data.
[e]NOAEL for immune effects not included in LSE table; the only immune endpoint evaluated was spleen weight (endpoint assessment too limited for evaluation of adversity).

↑ = increased; ↓ = decreased; ↔ = no change; – = not assessed; BMD = benchmark dose; GD = gestation day; LSE = Level of Significant Exposure; MM = methylmercury; MM2S = bis(methylmercury)sulfide; MMC = methylmercuric chloride; NOAEL = no-observed-adverse-effect level; PM = premating; PND = postnatal day

There is limited evidence for changes in subpopulations of immune cells in the thymus following developmental exposure to methylmercury. In a gestation plus lactation exposure study in wild-type mice, exposed offspring showed decreased number and percentages of CD8+ cells, CD4+ cells, and

natural killer cells and increased ratio of CD4+/CD8+ cells in the spleen during the postweaning period (Tonk et al. 2010). Dose-specific data were not reported, but benchmark doses (BMDs) associated with a benchmark response (BMR) of 5% ranged from 0.14 to 0.52 mg Hg/kg/day. Another study reported a decreased percentage of CD4+ cells and CD4+CD8+ cells at PND 10 and an increased percentage of CD8+ cells at PNDs 22 and 50 in wild-type mouse offspring following maternal exposure to ≥0.098 mg Hg/kg/day and 0.98 mg Hg/kg/day, respectively, for 11 weeks premating through PND 15 (Thuvander et al. 1996).

No histopathological changes in the bone marrow, thymus, or spleen were observed in rats at chronic-duration methylmercury doses up to 0.18 mg Hg/kg/day (Verschuuren et al. 1976), or wild-type mice after intermediate- or chronic-duration doses up to 0.724 mg Hg/kg/day (Hirano et al. 1986; Mitsumori et al. 1990). In other species, no histopathological changes in the spleen were observed following exposure to methylmercury for intermediate-durations at dietary doses up to 1.1 mg Hg/kg/day in rabbits (Koller et al. 1977) or 0.176 mg Hg/kg/day in cats (Charbonneau et al. 1976), or chronic-durations at dietary doses up to 0.074 mg Hg/kg/day in cats (Charbonneau et al. 1976).

Predominant Mercury Form Unknown (General Populations). Studies of general populations have examined associations between mercury biomarkers and several immune endpoints including immunological diseases, ANAs, and serum cytokines (Table 2-39). Studies used prospective and cross-sectional designs and evaluated effects in children and adults. A few studies examined the same endpoints (eczema, ANA titers, and cytokines), and the most common biomarker was BHg.

Table 2-39. Results of Epidemiological Studies Evaluating Exposure to Mercury (Predominant Mercury Form Unknown) and Immunological Effects in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Crowe et al. 2015 Cross-sectional; 52 patients with SLE (Northern Ireland)	UHg mean: 1.1 ng/g Cr HHg mean: 1.5 µg/g	SLE activity	↔ (UHg, HHg)
		SLE damage	↔ (UHg) ↓ (HHg)

Gallagher et al. 2013
 	
Cross-sectional; males and females ages 12–85 (NHANES 2003–2004)
	BHg mean, females
	  ANA+: 1.30 µg/L
	  ANA−: 1.47 µg/L
	BHg, males not reported
		Serum ANA	↔ (BHg, males and females)

Table 2-39. Results of Epidemiological Studies Evaluating Exposure to Mercury (Predominant Mercury Form Unknown) and Immunological Effects in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Hui et al. 2016 Prospective; 407 children; cytokines measured at ages 6–9 years (China)	Cord BHg median: 9.2 µg/L	Plasma cytokines IL-4 IL-5 IL-6 IL-8 IL-10 IL-13 TNF-α	 ↔ (cord BHg) ↔ (cord BHg) ↔ (cord BHg) ↔ (cord BHg) ↔ (cord BHg) ↔ (cord BHg) ↔ (cord BHg)
Kamycheva et al. 2017 Cross-sectional; 3,643 children and 11,040 adults (NHANES 2009–2012)	BHg mean, children CD+: 0.47 µg/L CD-: 0.64 µg/L BHg mean, adults CD+: 1.32 µg/L CD-: 1.64 µg/L	CD	↓ (BHg, children) ↔ (BHg, adults)
Miyake et al. 2011 Prospective; 582 mother-child; maternal and child exposure and child outcomes assessed at age 29–39 months (Japan)	HHg median Mother: 1.52 µg/g Child: 1.38 µg/g	Eczema	↔ (HHg, mother and child)
Miyazaki et al. 2023 Prospective; 94,794 mother-infant pair; child outcomes assessed at ages ≤3 years (Japan)	BHg median Maternal: 3.6 µg/kg	Atopic dermatitis	↔ (BHg)
		Food allergies	↔ (BHg)
		Asthma	↔ (BHg)
		Allergic rhinitis	↔ (BHg)
		Any allergic disease	↔ (BHg)
Monastero et al. 2017 Cross-sectional; 287 adults (Long Island, New York)	BHg median: 4.58 µg/L	Serum cytokines IL-1β IL-1ra IL-4 IL-10 IL-17 IFN-γ TNF-α	 ↔ (BHg) ↔ (BHg) ↔ (BHg) ↔ (BHg) ↔ (BHg) ↔ (BHg) ↔ (BHg)
		Serum ANA	↔ (BHg)
Park and Kim 2011 Cross-sectional; 127 adults with lifetime prevalence of atopic dermatitis and 176 with atopic dermatitis diagnosed in the past year (Korea)	BHg tertiles T1: <3.56 µg/L T2: 3.56–6.04 µg/L T3: >6.04 µg/L	Atopic dermatitis (lifetime prevalence)	↑ (BHg, T3)
		Atopic dermatitis (1-year prevalence)	↑ (BHg, T3)

Table 2-39. Results of Epidemiological Studies Evaluating Exposure to Mercury (Predominant Mercury Form Unknown) and Immunological Effects in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Shaheen et al. 2004 Prospective; 1,755 newborns, assessed for eczema at 18–30 months of age (ALSPAC, United Kingdom)	Cord BHg Gmean: 0.0127 µg/L	Eczema	↔ (cord BHg)

Somers et al. 2015
 	
Cross-sectional;
1,352 females, ages 16–49 years (NHANES 1999–2004)
	BHg quartiles (µg/L)
	  Q1: <0.4
	  Q2: 0.4–0.8
	  Q3: 0.9–1.5
	  Q4: 1.6–32.8
	UHg quartiles (µg/L)
	  Q1: <0.0029
	  Q2: 0.0029–0.0063
	  Q3: 0.0063–0.0135
	  Q4: 0.0137–0.8873
	HHg tertiles (µg/g)
	  T1: <0.11
	  T2: 0.11–0.27
	  T3: 0.271–5.96
		Serum ANA	↑ (BHg, Q4)
			↔ (UHg, Q4)
			↑ (HHg, T3)

Stratakis et al. 2021
 	
Cohort; mother-child pairs participating in the HELIX cohort; mean child age: 8.1 years; children were stratified into Group 1 (n=669; low risk for NAFLD) and Group 2 (n=123; high risk for NAFLD) (France, Greece, Lithuania, Norway, Spain, United Kingdom)
	BHg median (maternal during pregnancy)
	  Group 1: 1.8 µg/L
	  Group 2: 2.7 µg/L
		Serum cytokines
		  IL-1β
		  IL-6
		  IL-8
		  TNF-α
			
			↑ (BHg, Group 2)
			↑ (BHg, Group 2)
			↑ (BHg, Group 2)
			↑ (BHg, Group 2)

Wang et al. 2022b Meta-analysis; number of studies included per outcome: atopic dermatitis, 5; eczema, 6; wheeze 7; and asthma, 4	BHg, HHg, UHg NR	Atopic dermatitis	↑
		Eczema	↔
		Wheeze	↑
		Asthma	↔

Table 2-39. Results of Epidemiological Studies Evaluating Exposure to Mercury (Predominant Mercury Form Unknown) and Immunological Effects in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Zhang et al. 2020a Cross-sectional; 73 children exposed to e-waste and 74 referents, age 3–7 years (China)	BHg median 1.46 µg/L	Serum cytokines (all adjustments) IL-1β IL-6 IL-8 TNF-α IL-1RA IL-4 IL-10 IL-13	 ↔ (BHg) ↔ (BHg) ↔ (BHg) ↔ (BHg) ↔ (BHg) ↔ (BHg) ↔ (BHg) ↔ (BHg)

↑ = positive association; ↓ = inverse association; ↔ = no association; ALSPAC = Avon Longitudinal Study of Parents and Children; ANA = antinuclear antibodies; BHg = blood mercury; CD = celiac disease; CD+ = celiac disease seropositive; CD- = celiac disease seronegative; Gmean = geometric mean; HELIX = European Early-Life Exposome; HHg = hair mercury; IFN-γ = interferon-gamma; IL = interleukin; NAFLD = nonalcoholic fatty liver disease; NHANES = National Health and Nutrition Examination Survey; NR = not reported; Q = quartile; SLE = systemic lupus erythematosus; T = tertile; TNF-α = tumor necrosis factor-alpha; UHg = urine mercury

Epidemiological studies evaluating autoimmune diseases in general populations have investigated associations between mercury biomarkers and atopic dermatitis, eczema, SLE, and celiac disease seropositivity. The largest prospective study evaluated 94,794 mother-infant pairs for allergic disease at ages ≤3 years (Miyazaki et al. 2023). This study found no associations between maternal BHg and diagnosis of atopic dermatitis, food allergies, asthma, allergic rhinitis, or any allergic disease. Two prospective studies in newborns that were followed through ages 18–39 months did not find associations between cord BHg or HHg and eczema (Miyake et al. 2011; Shaheen et al. 2004). A cross-sectional study of 303 adult atopic dermatitis patients found that atopic dermatitis was positively associated with BHg in adults with a life-long prevalence of atopic dermatitis and adults with a diagnosis within the past year (Park and Kim 2011). No association was observed between UHg or HHg and SLE activity, although HHg was inversely associated with SLE damage (Crowe et al. 2015). A large cross-sectional study in NHANES children and adults found an inverse association between BHg and celiac disease seropositivity in children and no association in adults (Kamycheva et al. 2017). A meta-analysis of 4–7 studies examining associations between metal exposure biomarkers and allergic diseases found that increased mercury exposure was associated with increased pooled ORs for atopic dermatitis and wheeze, but not asthma or eczema (Wang et al. 2022b).

Three studies evaluated associations between mercury biomarkers and serum levels of ANA. A cross-sectional study of women reported positive associations between the highest BHg quartile and highest HHg tertile and serum ANA, but no association for the highest UHg quartile (Somers et al. 2015). The risks (OR) of a positive ANA were 2.51 (95% CI 1.04, 6.03) and 3.75 (95% CI 1.06, 13.28) for the fourth BHg quartile and the third HHg tertile, respectively. Study authors considered the positive association between mercury biomarkers and ANA titers to be indicative of subclinical autoimmunity, although the incidence of autoimmune disease in this population was not reported. In contrast, no associations were observed between BHg and positive ANA in other cross-sectional studies of men and women (Gallagher et al. 2013; Monastero et al. 2017).

Three studies examined the relationship between BHg and plasma cytokine levels in children (Hui et al. 2016; Monastero et al. 2017; Stratakis et al. 2021). A prospective study evaluated associations between maternal BHg and child plasma cytokine levels at age 8 years (Stratakis et al. 2021). Children were stratified into two groups: those at low risk and those at high risk for nonalcoholic fatty liver disease (NAFLD). This study found positive associations between maternal BHg and cytokine levels (IL-1β, IL-6, IL-8, and tumor necrosis factor-alpha [TNF-α]) in children with high risk of NAFLD. No associations were observed, except for an inverse association between current BHg and plasma IL-10 in a prospective study of children (Hui et al. 2016). A cross-sectional study evaluating immune cell counts in children reported a positive association between BHg and total lymphocyte count, but no associations for counts of total leukocytes, segmented leukocytes, monocytes, basophils, or eosinophils (Kim et al. 2015d). The clinical significance of these findings has not been established.

Several studies show that mercury induces dermal sensitization based on positive skin patch tests to elemental and/or inorganic mercuric salts; study results are summarized in Table 2-40. The specific form or forms of mercury that produced the initial sensitization cannot be determined. However, exposures were most likely to a combination of elemental and methylmercury exposures; therefore, the study populations are classified as general populations. Studies were conducted in populations with known elemental mercury exposure (Kawahara et al. 1993), sensitivity to amalgam (Kawahara et al. 1993; Laine et al. 1997; Nordlind and Liden 1992; Skoglund and Egelrud 1991; Thanyavuthi et al. 2016; Tiwari et al. 2018), and general populations (Handley et al. 1993; Mori et al. 2007; Nonaka et al. 2011).

Table 2-40. Results of Skin Patch Tests to Mercury Compounds in General Populations

Reference and population	Challenge chemical	Result
Handley et al. 1993; 441 patients with suspected contact dermatitis (Northern Ireland)	$HgCl_2$, $HgNH_2Cl$, Hg^0	+ (14/441 patients to one or more compounds)
Kawahara et al. 1993; 12 male dental students (Japan)	$HgNH_2Cl$	+ (3/12 patients)
Koch and Bahmer 1999; 19 patients with oral lichenoid lesions (Germany)	$HgCl_2$ and $HgNH_2Cl$	+ (15/19 patients)
Laine et al. 1997; 118 patients with oral lichenoid lesions (Finland)	$HgNH_2Cl$	+ (80/118 patients)
Mori et al. 2007; 580 students (Japan)	$HgCl_2$	+ (55/580 subjects)
Nonaka et al. 2011; 930 adults (Japan)	$HgCl_2$	+ (94/930 subjects)
Nordlind and Liden 1992; 12 patients with oral lesions	$HgCl_2$, Hg^0	+ (5/12 patients)
Skoglund and Egelrud 1991; 24 patients with oral lesions	$HgNH_2Cl$	+ (8/12 patients)
Thanyavuthi et al. 2016; 53 patients with oral lichenoid lesions (Thailand)	Hg^0	+ (19/53 patients)
Tiwari et al. 2018; 68 patients with oral lichen planus (Australia)	Hg^0	+ (24/68 patients)

+ = positive skin patch test

In addition to studies showing positive skin patch to dermal mercury challenge, acrodynia, a syndrome that may involve a hypersensitivity reaction to mercury, is occasionally observed in infants and young children exposed to different forms of mercury (as reviewed by Jao-Tan and Pope 2006). Acrodynia, also known as "pink disease" due to characteristic pink coloration of toes and fingers, is of more historical interest, as it typically has been associated with mercury exposure through discontinued mercury-containing pharmaceuticals (e.g., teething and diaper powders, antihelminthics, ointments) and preservatives. However, acrodynia has been observed following inhalation exposure to elemental mercury in accidental spills. Symptoms of acrodynia include pink, perspiring, swollen, and peeling hands and feet. Epidemiological studies on associations of acrodynia with environmental exposures to mercury were not identified.

Mechanisms of Action. Effects of mercury on the immune system are complex, as mercury has been shown to both stimulate and inhibit the immune system function (Havarinasab and Hultman 2005). Several mechanisms have been proposed for mercury-induced effects on immune function (Fournie et al. 2002; Havarinasab and Hultman 2005; reviewed by Maqbool et al. 2017; Silbergeld et al. 2005; Vas and Monestier 2008). These include: (1) proliferation and activation of T and B cells, leading to increased serum IgG and IgE; (2) increased ANAs and ANoAs; (3) dysregulation of lymphocyte signal-transduction pathways; (4) altered gene expression of cytokines; (5) induction of protein kinase C (PKC), leading to phosphorylation of numerous proteins; (6) PKC-induced alteration of L-type calcium channels, resulting in increased intracellular calcium; (7) inhibition of nitric oxide production; (8) increased formation of ROS and lipid peroxidation; and (9) alteration of the intestinal microbiome (Khan and Wang 2020).

2.16 NEUROLOGICAL

Overview. Neurological effects of mercury exposure have been recognized for centuries, and occupational toxicity of mercury has a long history (Clarkson and Magos 2006). In the 19th century hatting industry, mercury was used to produce felt hats and workers in this industry commonly exhibited slurred speech, tremors, irritability, shyness, depression, and other neurological symptoms, a syndrome known as "Mad Hatter's Disease" (NIOSH 2010). This section on neurological effects is divided into two sections: Section 2.16.1, Neurodevelopmental Effects; and Section 2.16.2, Neurological Effects in Adults. Data on neurodevelopmental and neurological effects of mercury are available from clinical case studies, epidemiology studies, and studies in animals. Epidemiological studies have been conducted in workers, general populations, and populations known to consume large amounts of fish, seafood, or marine mammals, in which dietary intake of methylmercury is expected to be the dominant source of mercury exposure. Neurotoxicity of mercury has been extensively studied in animal models.

The following summarizes results of epidemiological and animal studies on neurodevelopmental and neurological outcomes.

- ***Elemental mercury***
  - *Epidemiology studies*
    - Intermediate-duration exposures to mercury vapor (50–400 µg Hg/m^3) has produced cases of severe neurological and cognitive effects in children.
    - Studies of cognitive function in children exposed to elemental mercury released from mercury amalgam dental restorations have yielded mixed results. Most studies found no association between exposure (number or restorations or biomarkers) and cognition.

- Studies of neurological function in adults have been conducted in workers in various industries who were exposed to mercury vapor. Collectively, these studies provide evidence for associations between exposure to mercury vapor and several categories of neurological effects, including tremor, vision, nerve conduction, motor speed and coordination, cognitive performance (memory, and integrative function), and subjective physiological symptoms (mood swings, irritability, nervousness, timidity, loss of confidence).

- *Animal studies*
  - Limited neurodevelopmental studies in animals have reported altered learning and behavior (altered motor activity, impaired habituation) in monkeys, rats, and mice following gestational or early postnatal exposure to metallic mercury vapor.
  - Few studies have evaluated effects of exposure to elemental mercury and neurological outcomes in adult animals. Available data suggest impaired motor function and damage to the central nervous system, particularly the cerebellum.

- ***Inorganic mercury***
  - *Epidemiology studies*
    - No epidemiological studies evaluating associations between exposure to inorganic mercury salts and neurological effects were identified.
    - Case studies of individuals acutely exposed to fatal or near-fatal levels of inorganic mercuric compounds reported disturbances of vision and behavior and seizures; at autopsy, brain abscesses in the cerebrum have also been observed.
  - *Animal studies*
    - Neurobehavioral changes are consistently reported in rodents following oral exposure to mercuric chloride during development, including hyperactivity, impaired motor coordination, impaired memory, and decreased sociability. There is limited evidence for altered neurophysiology at comparable doses (increased auditory thresholds, decreased peripheral nerve conduction, induction of seizure activity).
    - Neurobehavioral changes (hyperactivity, impaired coordination, impaired learning and memory) have been reported in rodents following oral exposure to mercuric chloride during adulthood at doses similar to those associated with developmental findings; however, lower doses have not been evaluated in developmental studies.
    - Overt signs of neurotoxicity (hindlimb crossing, ataxia, tremor, partial paralysis) and neuropathological changes to sensorimotor regions in the central nervous system (dorsal

spinal route, cerebellum) have been reported in adult animals following oral exposure to mercuric chloride at doses higher than those associated with neurobehavioral changes.

▪ Oral exposure to mercuric sulfide can result in neurological effects in adult rodents at doses markedly higher than those associated with mercuric chloride toxicity, including impaired coordination, altered neurophysiology (decreased nerve conduction, increased auditory thresholds), and cerebellar damage.

▪ Available data following inhalation exposure to mercuric oxide are too limited to draw conclusions.

- ***Organic mercury***

  ▪ *Epidemiology studies*

    ▪ Severe neurodevelopmental effects occurred in association with maternal ingestion of methylmercury in seafood (congenital Minamata disease) and from ingestion of wheat contaminated with a methylmercury fungicide (Iraq outbreak). In both incidents, levels of exposure were sufficient to produce frank neurological effects in adults.

    ▪ Cognitive and neurosensory effects have been observed in association with prenatal exposures to methylmercury in high fish and marine mammal consumers in the absence of evidence of maternal toxicity. Results of these studies have been inconsistent, with some studies finding associations between mercury exposure biomarkers (BHg or HHg) and declines in tests of cognitive or neurosensory function, some studies finding improved function, and some studies finding no associations with mercury exposure biomarkers. Differences in outcomes may be due to differences in confounders and how they were controlled in regression models, and may also arise where groups (e.g., people of a specific sex or age) are differentially susceptible to mercury. Potential confounders include fish intake and related nutritional factors (e.g., 3-omega polyunsaturated long-chain fatty acids), co-exposure to other contaminants in fish or marine mammals (PCBs, selenium), and social variables affecting child development. Potential effect measure modifiers include genetic susceptibility factors.

    ▪ Studies of associations between exposure to methylmercury and neurological function in adults have also been conducted in populations that consume large amounts of fish or marine mammals. Collectively, these studies provide evidence for associations between exposure to methylmercury and decreasing performance on tests of fine motor coordination and speed, muscle strength, tactile sensation, color vision and visual contrast sensitivity, and memory and learning.

- *Animal studies*
    - Neurobehavioral and neurophysiological effects have been observed in multiple species following acute-, intermediate-, and chronic-duration exposure to methylmercury, including sensorimotor dysfunction (altered motor activity, impaired coordination, impaired reflexes), vision and hearing deficits, and impaired learning and memory. At higher doses, overt signs of neurotoxicity were observed (clumsiness, gross and fine motor incoordination, lethargy, hindlimb crossing, tremor, ataxia, partial paralysis).
    - Neuropathological changes were observed in both the central and peripheral nervous system, at doses above those associated with neurobehavioral changes. Central lesions were observed, primarily, in regions associated with sensorimotor and movement control (e.g., cerebellum, motor cortex, subcortical regions, dorsal ganglion, and nerve roots of the spinal cord).
    - In both primates and rodents, developing animals are more sensitive to methylmercury-induced neurotoxic effects than adult animals.

- ***Predominant mercury form unknown (general populations)***
    - Studies of general populations, in which exposures to mercury derive from a variety of potential sources (e.g., mercury amalgam restoration, diet) have found inconsistent associations between biomarkers of exposure and performance on tests of cognitive function.
    - The different outcomes in cognitive development may reflect differences in how well confounders were adjusted for and whether effect measure modification was investigated. Potential confounders include fish consumption and related nutritional factors, and exposure to other chemicals (e.g., selenium, PCBs).
    - Few studies of neurological effects in general adult populations have been reported precluding conclusive statements.

Confounding Factors. Numerous factors can complicate interpretation of statistical associations between mercury exposure (or biomarkers of exposure) and neurological outcomes (Castoldi et al. 2008). These include a variety of factors that can affect performance on tests of cognitive or neurosensory function that, if not homogenously distributed in the study population, can bias findings. These factors include (but are not limited to) child sex; birth weight; birth order; gestational age and child age; breastfeeding; maternal age, alcohol, and tobacco use, and medical history; parental education; caregiver general intelligence; family income; family language; home learning, and social stimulation; exposure to other neurotoxins

(e.g., lead, PCBs); nutritional factors (e.g., fish consumption); history of neurological disease or head injuries; and genetic factors that may influence toxicity of mercury.

Some factors can introduce confounding bias because they are also associated with mercury exposure. For example, the dominant source of exposure to methylmercury in most populations is through consumption of contaminated fish. However, fish also contain nutrients that have been shown to be important modifiers of development. These include 3-omega LCPUFA, iodine, iron, selenium, and vitamin E (Cheatham 2008; Choi et al. 2008a; Muldoon et al. 2014; Strain et al. 2021). In populations in which consumption of marine mammals contributes to dietary mercury intake (e.g., Faroe Islands, Nunavik), dietary intake of PCBs and selenium, which accumulate in marine mammal tissue, can also be a source of confounding bias (Boersma and Lanting 2000; Park et al. 2010; Skröder et al. 2017). Unless otherwise specified, studies summarized in this section of the profile have considered potential confounders in assessments of associations of outcomes with mercury exposure.

In addition to confounding factors, design and statistical factors must also be considered when interpreting studies that measure multiple outcomes in the same cohorts (Puty et al. 2019). As the number of outcomes tested increases, the probability of finding a statically significant association by chance increases, even if there is no underlying causal association (Thurston et al. 2022). For example, Thurston et al. (2022) examined 85 neurodevelopmental outcomes in a 9–24-year follow-up of the Seychelles Child Development Study (SCDS). While some statically significant associations were found based on regression slope 95% confidence limits, none of the outcomes were significantly associated with mercury exposure after the Bonferroni correction for multiple comparisons was applied to the type 1 error p-value threshold for significance.

2.16.1 Neurodevelopmental Effects

Elemental Mercury—Epidemiological Studies. Cases of severe neurological and cognitive effects in children exposed to elemental mercury vapor have been reported. Available epidemiological studies have focused on associations between exposures to elemental mercury released from mercury amalgam dental restorations and cognitive function in children. These studies have yielded mixed results. Most studies found no associations between exposure (number or restorations or biomarkers) and cognitive function.

Poisoning case studies. A case study of two children, ages 13 and 15 years, who were accidentally exposed to mercury vapor for a period of 3 months observed cognitive deficits that improved 1 year after

exposure and treatment with a mercury complexing agent, 2,3-dimercaptosuccinic acid (DMSA) (Yeates
and Mortensen 1994). Exposure resulted from vaporization of elemental mercury that had been spilled
from a container in the residence. Exposure levels measured in the residence ranged from 50 to 400 µg
Hg/m^3. At diagnosis, the 15-year-old patient had a UHg level of 1,314 µg Hg/L and BHg levels that
ranged from 10 to 30 µg Hg/L. The 13-year-old patient had a UHg level of 624 µg Hg/L and a BHg level
of 69 µg Hg/L. Both patients presented with rash (consistent with acrodynia, further discussed in Section
2.15, Immunological), anorexia, tremor, and paresthesia. Cognitive testing of the 15-year-old at diagnosis
(Wechsler Intelligence Scale for Children, Revised [WISC-R]) indicated a full-scale IQ of 79 compared
to a value of 101 measured at age 9 years, with the largest deficit on the digit span test of attention and
short-term memory. Following DMSA chelation therapy and a period of 1 year following exposure, full-
scale IQ increased to 93 with most of the improvement attributed to performance on the digit span test.
Cognitive testing of the 13-year-old patient indicated a full-scale IQ of 79, which did not improve when
retested 1 year later and after DMSA chelation therapy.

Exposures to mercury amalgam dental restorations. Studies evaluating effects of elemental mercury on
neurological development include several longitudinal studies of associations between metrics of
exposure from child or maternal mercury amalgam dental restorations and cognitive function and
behavior, and one study that evaluated exposures to mercury in a gold mining community (Table 2-41).
In the study populations, exposures included elemental mercury released from amalgams as well as
exposures to other forms of mercury (e.g., dietary methylmercury). As a result of this mixed exposure,
reported biomarkers such as urinary or HHg cannot be interpreted as specific metrics of exposures to
amalgam mercury and most studies included an exposure metric directly related to amalgams such as
number of amalgam surfaces, or compared outcomes between groups of people who had mercury
amalgam restorations and groups with restorations made of other materials. In some studies, biomarkers
more specific to methylmercury exposure, such as HHg, were used to adjust the models for potential
confounding by methylmercury exposure (Bellinger et al. 2006, 2007a, 2008; Watson et al. 2011, 2012).
This adjustment was particularly important in studies of the Seychelle Islands cohort, which had relatively
high exposures to methylmercury (mean prenatal HHg 6–7 µg Hg/g; Watson et al. 2011, 2012). Some
studies adjusted measurements of associations for exposures to lead (Bellinger et al. 2006, 2007a, 2008;
Surkan et al. 2009); however, other potential chemical exposures associated with mercury exposure that
might have contributed to outcomes were not considered. Most studies included analysis of covariates
such as age, sex, race, birth weight, SES, caregiver education and/or IQ, and metrics of home
environment as potential confounders.

Table 2-41. Results of Epidemiological Studies Evaluating Exposure to Elemental Mercury (Hg⁰) in Populations with Mercury Amalgam Dental Restorations and Neurodevelopmental Effects

Reference, study type, and population	Biomarker	Outcome evaluated	Result

Bellinger et al. 2006, 2007b, 2008; Surkan et al. 2009
 	
Randomized clinical trial (NECAT); 534 children, 267 receiving amalgam fillings and 267 receiving resin fillings at age 6–10 years; neurological testing at 5 years following restoration; Boston, Massachusetts, Farmington, Maine
	UHg mean
	  Amalgam: 0.99 µg/g Cr
	  No amalgam: 0.61 µg/g Cr
	
	HHg mean
	  Female: 0.31 µg/g
	  Male: 0.32 µg/g
	
	Amalgam surface-years mean: 31.7
		IQ	↔ (amalgam versus no amalgam)
			↔ (UHg, HHg)
			↔ (surface-years)

		Learning and memory	↔ (amalgam versus no amalgam) ↔ (UHg, HHg) ↔ (surface-years)
		Visuomotor	↔ (amalgam versus no amalgam) ↔ (UHg, HHg) ↔ (surface-years)
		Competence	↔ (amalgam versus no amalgam)
		Internalization	↓ (amalgam versus no amalgam)
		Externalization	↔ (amalgam versus no amalgam)

DeRouen et al. 2006
 	
Randomized clinical trial; 507 children, 253 receiving amalgam fillings and 254 receiving resin fillings at age 8–10 years; annual neurological testing through 7 years following dental mercury amalgam or resin restorations; Portugal
	UHg mean at baseline
	  Amalgam: 1.8 µg/g Cr
	  No amalgam: 1.9 µg/g Cr
	
	UHg mean at 2 years following restoration (peak exposure)
	  Amalgam: 3.2 µg/g Cr
	  No amalgam: 1.5 µg/g Cr
		Learning and memory	↔ (amalgam versus no amalgam)

		Attention	↔ (amalgam versus no amalgam)
		Visuomotor	↔ (amalgam versus no amalgam)
		Non-verbal IQ	↔ (amalgam versus no amalgam)
Orlando et al. 2023 SCDNS follow-up at age 9 years (n=210)	Maternal or child amalgam surface areas	Auditory brainstem response	↔ (amalgam surface area)
		Otoacoustic emissions	↔ (amalgam surface area)

Watson et al. 2011
 	
Prospective cohort of 587 mother-child pairs recruited with follow-up at age 66 months; 249 mothers had amalgam restorations present during pregnancy; Seychelles
	HHg mean
	  Prenatal: 6.8 µg/g (based on Davidson et al. 1998)
	
	Amalgam group
	  Number of maternal amalgam surfaces (mean): 5.12
		General cognitive	↔ (amalgam surfaces)

		Language	↔ (amalgam surfaces)
		Reading and arithmetic	↔ (amalgam surfaces)
		Visuomotor	↔ (amalgam surfaces)
		Adaptive behavior	↔ (amalgam surfaces)

Table 2-41. Results of Epidemiological Studies Evaluating Exposure to Elemental Mercury (Hg⁰) in Populations with Mercury Amalgam Dental Restorations and Neurodevelopmental Effects

Reference, study type, and population	Biomarker	Outcome evaluated	Result

Watson et al. 2012
 	
Prospective cohort of 242 mother-child pairs recruited with follow-up at age 9 and 30 months; 196 mothers had amalgam restorations present during pregnancy; Seychelles
	HHg mean
	  Prenatal: 6.8 µg/g (based on Davidson et al. 1998)
	
	Amalgam group
	  Number of maternal amalgam surfaces (mean): 8.49
		Mental development index	↔ (amalgam surfaces)

		Psychomotor development index	↔ (amalgam surfaces)

Woods et al. 2012, 2014
 	
Randomized clinical trial; 239 children, 121 boys and 118 girls, receiving amalgam fillings or resin fillings at age 8–12 years; neurological testing at 7 years following restoration; Portugal
 	
Note: Subjects included children from a dental amalgam clinical trial (DeRouen et al. 2006) with CPOX4 genotyping; amalgam status was not reported.
	UHg mean at baseline
	  Boys: 1.65 µg/g Cr
	  Girls: 1.98 µg/g Cr
	
	UHg mean at 2 years following restoration (peak exposure)
	  Boys: 2.17 µg/g Cr
	  Girls: 2.86 µg/g Cr
	
	UHg mean at 7 years following restoration
	  Boys: 1.25 µg/g Cr
	  Girls: 1.77 µg/g Cr
		Attention	Boys: ↓ (cumulative UHg)
			Girls: ↔ (cumulative UHg)

		Visual-spatial	Boys: ↓ (cumulative UHg) Girls: ↔ (cumulative UHg)
		Learning and memory	Boys: ↓ (cumulative UHg) Girls: ↔ (cumulative UHg)
		Motor	Boys: ↔ (cumulative UHg) ↑ (cumulative UHg and CPOX4 genotype) Girls: ↔ (cumulative UHg)

Woods et al. 2013, 2014
 	
Randomized clinical trial; 239 children, 120 boys and 119 girls, receiving amalgam fillings or resin fillings at age 8–12 years; neurological testing at 7 years following restoration; Portugal
 	
Note: Subjects included children from a dental amalgam clinical trial (DeRouen et al. 2006) with MT1M and MT2A genotyping; amalgam status not reported
	UHg mean at baseline
	  Boys: 1.68 µg/g Cr
	  Girls: 1.97 µg/g Cr
	
	UHg mean at 2 years following restoration (peak exposure)
	  Boys: 2.18 µg/g Cr
	  Girls: 2.86 µg/g Cr
	
	UHg mean at 7 years following restoration
	  Boys: 1.26 µg/g Cr
	  Girls: 1.76 µg/g Cr
		Visual spatial	Boys: ↔ (cumulative UHg)
			↑ (cumulative UHg and MT2A genotype)
			Girls: ↔ (cumulative UHg)

		Learning and memory	Boys: ↔ (cumulative UHg) ↑ (cumulative UHg and MT1M genotype) ↑ (cumulative UHg and MT2M genotype) Girls: ↔ (cumulative UHg)

Table 2-41. Results of Epidemiological Studies Evaluating Exposure to Elemental Mercury (Hg⁰) in Populations with Mercury Amalgam Dental Restorations and Neurodevelopmental Effects

Reference, study type, and population	Biomarker	Outcome evaluated	Result

Ye et al. 2009
 	
Cross-sectional cohort of 403 children ages 7–11 years; 198 with amalgam fillings and 205 without amalgam fillings; Shanghai
	UHg median
	  Amalgam: 1.6 µg/g Cr
	  No amalgam: 1.4 µg/g Cr
		CBCL	↔ (amalgam versus no amalgam)

		EPQ	↔ (amalgam versus no amalgam)
		Academic math score	↔ (amalgam versus no amalgam)
		Academic language	↔ (amalgam versus no amalgam)

↑ = positive association; ↓ = inverse association; ↔ = no association; CBCL = Child Behavior Checklist; Cr = creatinine; CPOX = coproporphyrinogen; EPQ = Eysenck Personality Questionnaire; HHg = hair mercury; IQ = intelligence quotient; MT = metallothionein; NECAT = New England Children's Amalgam Trial; SCDNS = Seychelles Child Development Nutrition Study; UHg = urine mercury

Outcomes were based on a variety of tests that measured various domains of cognitive function or nerve function, including verbal and non-verbal IQ, learning and memory, visual-spatial and visual-motor function, hearing, and psychosocial behavior. In some studies, as many as 20–30 different tests were administered, introducing the potential for random outcomes of "significant" associations based on p-levels. Therefore, interpretation of these studies requires consideration of the overall outcomes and consistencies or inconsistencies in outcomes across tests of similar domains of cognitive function. Most studies did not find consistent evidence for associations between exposures to mercury from amalgams and cognitive function (Bellinger et al. 2006, 2007b, 2008; DeRouen et al. 2006; Orlando et al. 2023; Surkan et al. 2009; Watson et al. 2011, 2012). The exception were studies reported by Woods et al. (2012, 2013), which found decreased performance on some tests of attention, learning and memory, and visuomotor function in association with increased cumulative urinary mercury, based on analysis of data from a mercury amalgam random clinical trial (DeRouen et al. 2006). Woods et al. (2012, 2013) also found interactions between cumulative urinary mercury and genotypes for coproporphyrinogen (CPOX), an enzyme in the heme metabolism pathway, and metallothionein (MT), an inducible metal binding protein. Cumulative urinary mercury was used as the exposure metric, without adjustment for other potential sources of urinary mercury unrelated to amalgams. The highest mean urinary mercury levels were observed in the amalgam group in the 2-year follow-up, 3.2 µg Hg/g creatinine, compared to the baseline (prior to restorations), 1.8 µg Hg/g creatinine (DeRouen et al. 2006). This suggests that more than half of the urinary mercury may have derived from sources other than amalgam mercury. Adjustments for other potential contributors to cognitive performance outcomes were not reported. An

analysis of data from this same study compared cognitive performance in restoration groups and did not find differences in performance between mercury amalgam and resin restoration groups (DeRouen et al. 2006).

Elemental Mercury—Animal Studies. Neurodevelopmental studies have found altered learning and behavior in monkeys, rats, and mice following gestational or early postnatal exposure to metallic mercury vapor; however, data are limited and/or inconsistent between studies and testing paradigms. One study reported neurodevelopmental effects in squirrel monkeys following gestational exposure to metallic mercury vapor. Long-term impairment in operant training performance in a lever-press paradigm was observed in monkey offspring at 0.8–4 years of age following intermittent exposure to 0.5 or 1 mg Hg/m^3 (5 days/week; 4 or 7 hours/day) during the last two-thirds or more of the gestation period (Newland et al. 1996). No difference in sensitivity to reinforcer ratios was identified in the steady state, but there was much more variability in the steady-state performance of exposed monkeys, with exposed monkeys producing smaller or slower transitions than controls. The magnitude and stability of lever-press durations for controls and exposed monkeys were indistinguishable early in the study, but at the end, the exposed monkeys had longer lever-press durations and the session-to-session variability was much greater. One monkey's exposure began during the third week of gestation (earlier than any of the others) and its behavior was so erratic that some of the analyses could not be accomplished. The median maternal BHg levels were 0.025–0.09 µg Hg/g at 0.5 mg Hg/m^3 and 0.12–0.18 µg Hg/g at 1 mg Hg/m^3. Offspring BHg levels were not reported.

Alterations in neurobehavior have been observed in rats and mice following gestational or early postnatal exposure to metallic mercury vapor, including altered motor activity, impaired spatial learning, and decreased habituation to a novel environment. However, findings have been inconsistent between studies and different testing paradigms.

Increased motor activity (total, horizontal, and vertical) was reported in 4-month-old male rat offspring following intermittent exposure to 1.8 mg Hg/m^3 during GDs 14–19 (Fredriksson et al. 1996). Exposure to the same vapor level during GDs 11–14 plus GDs 17–20 resulted in decreased motor activity in 3-month-old male and female rat offspring (Danielsson et al. 1993). When rats were postnatally exposed to 0.05 mg Hg/m^3 during PNDs 11–17 for 1–4 hours/day, total and vertical (rearing) activity was increased in 4-month-old males exposed for 1 hour/day and 2-month-old males exposed for 4 hours/day, but decreased in 4-month-old males exposed for 4 hours/day; vertical activity was decreased in each group of rats (Fredriksson et al. 1992). No changes were observed in motor activity in 2-month-old males

exposed for 1 hour/day. In mice, total motor activity was decreased in 11-week-old females following continuous exposure to 0.188 mg Hg/m^3 from PND 2 to 28 (Yoshida et al. 2018); no changes were observed in female mice exposed to 0.03 mg Hg/m^3 during GDs 0–18 or 0.057 mg Hg/m^3 during PNDs 1–20 (Yoshida et al. 2011, 2013).

Impaired spatial learning was observed in male and female rats following gestational exposure to 1.8 mg Hg/m^3 (GDs 14–19 or GDs 11–14 plus GDs 17–20) or postnatal exposure to 0.05 mg Hg/m^3 (PNDs 11–17) when evaluated using the radial arm maze at 4–6 months of age, as indicated by increased latency to finish and increased number of errors (Danielsson et al. 1993; Fredriksson et al. 1992, 1996). Impaired spatial learning was also observed in male rat offspring exposed to 1.8 mg Hg/m^3 during GDs 14–19 (1.5 hours/day) when evaluated using a swim maze at 4.5 months of age (increased latency to escape) (Fredriksson et al. 1996). However, no deficits in the swim maze were observed in male or female rat offspring exposed to 1.8 mg Hg/m^3 during GDs 11–14 plus GD 17–20 (1 or 3 hours/day) when evaluated at 7 and 15 months of age (Danielsson et al. 1993) or male rats exposed to 0.05 mg Hg/m^3 on PNDs 11–17 (1 hour/day) when evaluated at 5 months (Fredriksson et al. 1992). In mice, no changes in spatial learning were observed in female mice at 2–15 months of age following gestational or postnatal exposures up to 0.03 or 0.188 mg Hg/m^3, respectively (Yoshida et al. 2011, 2013, 2018).

Decreased habituation, as indicated by sustained activity in a novel environment over time as opposed to expected decreases in exploratory behavior, was observed in male and female rat offspring following exposure to 1.8 mg Hg/m^3 during GDs 11–14 plus GDs 17–20 (3 hours/day) (Danielsson et al. 1993). Similar effects were not noted when exposure was only 1 hour/day.

No changes in passive avoidance learning were observed in female mice at 2–15 months of age following gestational or postnatal exposures up to 0.03 or 0.188 mg Hg/m^3, respectively (Yoshida et al. 2011, 2013, 2018). No changes in sensory evoked potentials (visual, auditory, cortical and cerebellar somatosensory, or peripheral nerve) were observed in adult offspring of rats exposed to metallic mercury vapor at 4 mg Hg/m^3 for 2 hours/day during GDs 6–15 (Herr et al. 2004).

No exposure-related changes in reflex ontogeny (e.g., surface righting, negative geotaxis) were observed in rats following acute-duration gestational inhalation exposure to 1.8 mg Hg/m^3 for 1–5 hours/day (Danielsson et al. 1993; Fredriksson et al. 1996).

2. HEALTH EFFECTS

Inorganic Mercury—Animal Studies. Several studies have evaluated potential neurodevelopmental effects of gestational and/or early postnatal exposure to mercuric chloride in rats and mice. While only a limited number of studies evaluated each endpoint, available data suggest potential associations between developmental exposure to mercuric chloride and hyperactivity, impaired motor coordination, impaired memory, and decreased sociability in rodents. Studies evaluating electrophysiological endpoints are limited and reported mixed findings.

Increased motor activity during open field testing has been reported in male ICR mice following exposure to a gavage dose of 0.4 mg Hg/kg/day throughout gestation and lactation, during GD 1–PND 70, or postnatally only from PNDs 21–70 (Huang et al. 2011). Effects were most prominent with exposure during GD 1–PND 70. Increased stereotypical behavior during open field testing was observed in both groups with post-weaning exposure. Increased locomotor activity was also observed in autoimmune susceptible mouse offspring exposed to 2.7 mg Hg/kg/day during GD 8–PND 21 via maternal drinking water, but not similarly exposed wild-type mice (Zhang et al. 2011). Another drinking water study did not observe overall increases in locomotor activity in male Swiss mice following drinking water exposure to 3.3 mg Hg/kg/day during GD 0–PND 70; however, the time spent in the periphery of the open field was significantly increased, suggesting increased anxiety (Malqui et al. 2018). Offspring were observed to have increased anxiety and depressive behaviors in the light-dark chamber test, forced swim test, tail suspension test, and elevated plus maze when dams (Swiss mice) were exposed to 2.4 mg Hg/kg/day from GD 1 to PND 15 (Mohammad Abu-Taweel and Al-Fifi 2021). The PND 40 male offspring of mercuric-chloride-exposed mouse dams showed decreased activity and exploratory behaviors in an open field. In contrast to findings by Malqui et al. (2018) and Mohammad Abu-Taweel and Al-Fifi (2021), decreased anxiety was observed in the elevated plus maze in PND 63 female rat offspring following maternal exposure to ≥6.1 mg Hg/kg/day during GDs 1–21 (Chehimi et al. 2012).

Impaired motor coordination in the rotarod test was observed in PND 70 male mice following exposure to 0.4 mg Hg/kg/day via gavage during GD 1–PND 70 or PNDs 21–70 (Huang et al. 2011). No effects on motor coordination were observed in similarly exposed mice during GD 1–PND 21 only (Huang et al. 2011). In rats, sensorimotor development and balance and motor coordination (while walking on the rim of a beaker at PNDs 17–20) were normal in offspring following maternal drinking water exposure to doses up to 3.8 mg Hg/kg/day during GD 1–PND 21 (Oliveira et al. 2016). However, dose-related delays in sensorimotor development were observed in female rat offspring following maternal exposure to ≥6.1 mg Hg/kg/day during GDs 1–21, including delayed rooting reflex, vibrissae placing response, righting reflex, grip strength, and negative geotaxis (Chehimi et al. 2012).

Decreased sociability, particularly decreased preference for a novel stranger, was observed in PND 70 mice exposed to ≥2.7 mg Hg/kg/day during both gestational and postnatal periods (Malqui et al. 2018; Zhang et al. 2013). These findings may be secondary to increased anxiety, supported by increased self-grooming (stereotypical behavior) during sociability testing at 3.3 mg Hg/kg/day (Malqui et al. 2018). Alternatively, decreased preference for novelty may be due to impaired memory since performance was also impaired in mice exposed to 3.3 mg Hg/kg/day in the Y-maze spontaneous alternation and object recognition tests (Malqui et al. 2018).

One study reported impaired auditory function (increased auditory thresholds) in male mice following exposure to a gavage dose of 0.4 mg Hg/kg/day throughout gestation and lactation, during GD 1–PND 70, or postnatally only from PNDs 21–70 (Huang et al. 2011). Effects were most prominent with exposure during GD 1–PND 70.

No exposure-related changes in electrophysiological recordings, including spontaneous and evoked sensory potentials (somatosensory, visual, and acoustic) and tail nerve conduction velocity and refractory period, were observed in adult male rat offspring following exposure during gestation or gestational plus lactation at maternal doses up to 1.6 mg Hg/kg/day during GDs 5–15 (Papp et al. 2005). However, when offspring exposed during gestation and lactation were additionally exposed postweaning (PNDs 29–84), dose-related decreases in peripheral sensory nerve conduction velocity were observed at doses ≥0.4 mg Hg/kg/day, and decreased spontaneous sensory cortex potentials were observed at ≥0.8 mg Hg/kg/day (Papp et al. 2005). In another study, induction of epileptiform activity was promoted in PND 90 rat offspring following gestational and lactational exposure to 0.6 mg Hg/kg/day; no changes in epileptiform activity were observed at PND 28 and baseline cortical activity was comparable to control at both time points (Szász et al. 2002).

No changes in reflex ontogeny were observed in rat offspring following drinking water exposure to doses up to 3.8 mg Hg/kg/day during GD 0–PND 21 (Oliveira et al. 2016). No other identified studies specifically evaluated reflex ontogeny following developmental exposure to mercuric chloride.

Organic Mercury—Epidemiological Studies. Human epidemiological studies provide strong support for the developing nervous system being a sensitive target of methylmercury. Severe neurodevelopmental effects occurred in association with maternal ingestion of methylmercury in seafood (congenital Minamata disease) (Harada 1995) and from ingestion of wheat contaminated with a methylmercury

fungicide (Iraq outbreak) (Amin-Zaki et al. 1974). In both incidents, exposure levels were sufficient to produce severe neurological effects in adults.

Studies of lower levels of prenatal exposures have largely focused on populations consuming large amounts of marine fish or mammals. In these populations, the dominant source of the mercury body burden derives from consumption of methylmercury in fish or marine mammals, providing a strong basis for use of blood or HHg as a biomarker of methylmercury exposure. Results of these studies have been inconsistent, with some studies finding associations between mercury exposure biomarkers (BHg or HHg) and declines in tests of cognitive or neurosensory function, and other studies finding improved function or no associations with mercury. Differences in outcomes may be due to differences in confounders and how they were controlled in regression models. These variables include fish intake and related nutritional factors (e.g., 3-omega polyunsaturated long-chain fatty acids), co-exposure to other contaminants in fish or marine mammals (selenium, PCBs), and social variables affecting child development. In addition, genetic susceptibility factors may act as effect measure modifiers, impacting the associations observed between mercury and a health outcome.

Epidemiological studies have evaluated neurodevelopmental effects in the following populations with high dietary methylmercury exposure, relative to most general populations: Minamata, Japan; Iraq; Seychelle Islands; Faroe Islands; North Island, New Zealand; Nunavik region of arctic Canada; Amazon River basin, Madeira, and Portugal. Meta-analyses of the studies of high fish consumers have estimated effect sizes for prenatal methylmercury exposure and IQ (Axelrad et al. 2007a, 2007b; Cohen et al. 2005; Ryan 2008).

Minamata, Japan. Discharges of wastewater from an acetaldehyde production facility into the Shiranui Sea located in the Kumamato Prefecture of Japan, that occurred in the mid-1950s resulted in exposure of pregnant women to methylmercury ingested in locally contaminated fish and shellfish (Harada 1995). Severe neuromotor and cognitive impairments resembling cerebral palsy were observed in infants exposed prenatally (Harada 1995). Patients diagnosed with congenital Minamata disease showed a common set of signs which included severe cognitive impairments, primitive reflex, cerebellar ataxia, disturbances in physical growth and nutrition, dysarthria (speech and vocalization impairment), limb deformities, hyperkinesia (restlessness), hypersalivation, strabismus (abnormal eye alignment), paroxysmal symptoms, and pyramidal symptoms (Harada 1995). Measurements of mercury in blood and hair were not made until several years following the period of most intense exposure and, therefore, do not provide reliable estimates of exposures that may have contributed to congenital Minamata disease.

Methylmercury levels in umbilical cord tissue of congenital Minamata disease patients ranged from 0.15 to 4.65 µg Hg/g dry weight (Harada et al. 1999). Long-term follow-up of congenital Minamata disease patients have observed neuromotor and cognitive impairments as adults, including hand tremor, postural sway, low scores on cognitive processing speed, and more rapid declines in cognitive function with age (Iwata et al. 2016; Yorifuji et al. 2015, 2016, 2018). The follow-up studies have included small numbers of subjects (<20), limiting the power to associate clinical outcomes with measures of exposure. In a study of 22 congenital Minamata disease patients (age range 42–57 years), low performance on the digit symbol-coding test of the Wechsler Adults Intelligent Scale III were observed in subjects from pregnancies in which cord tissue methylmercury levels ranged from 0.1 to 2 µg Hg/g dry weight (Yorifuji et al. 2015). In a study of 18 congenital Minamata disease patients (mean age 50 years), low scores on tests of fine motor control were observed in subjects from pregnancies who had a mean umbilical cord tissue level of 0.7 µg Hg/g dry weight (Yorifuji et al. 2016).

Iraq. An outbreak of methylmercury poisoning occurred in Iraq in 1971–1972 as a result of widespread consumption of wheat that had been treated with a methylmercuric fungicide (Al-Mufti et al. 1976; Bakir et al. 1973; Clarkson et al. 1976). Approximately 6,500 cases of mercury poisoning occurred, with approximately 459 related deaths (Clarkson et al. 1976). Sixty-five days after exposure, BHg levels in poisoning cases ranged from 10 to 3,000 µg Hg/L (Clarkson et al. 1976). Cases of neurological abnormalities in infants exposed prenatally were reported which included impaired motor function, hyperreflexia, and delayed attainment of development milestones (walking, speech) and, at the highest exposure levels, seizures (Amin-Zaki et al. 1974, 1978, 1981; Marsh et al. 1987). BHg levels in infant cases ranged from approximately 10 to 1,600 µg Hg/L (Amin-Zaki et al. 1981). Prenatal exposures were reconstructed from segmental analysis of single maternal hair strands and used to derive prenatal dose-response relationships for neurodevelopmental outcomes (Cox et al. 1989; Crump et al. 1995; Marsh et al. 1987). Cox et al. (1989) constructed prenatal mercury dose response models based on observations of 83 mother-infant pairs (Marsh et al. 1987). The dose metric used in these models was the estimated maximum HHg level during gestation. Outcome metrics were attainment of developmental milestones (age of walking) or scores from a clinical examination for signs of neurological abnormalities (e.g., muscle tone, reflexes). Based on a threshold model ("hockey-stick" model), Cox et al. (1989) concluded that the best estimate of the threshold for delayed walking (not walking by age 18 months) was 7.3 µg Hg/g hair (95% CL: 0, 13.6). However, confidence limits on the threshold estimate were sensitive to the estimated background response (probability of delay in walking when there is no prenatal exposure to mercury). For the upper 95% limit on the estimated background response (0.04), the threshold was estimated to be 9 µg Hg/g (95% CL: 4, 190). The best estimate of the threshold for an abnormal score on

neurological examination (score >3 of 11) was 10 µg Hg/g (95% CL: 9, 287). Based on a logit model applied to the same data, HHg levels of 5 and 50 µg Hg/g were associated with excess risks of 2.5 and 19%, respectively, for delayed walking, and 2.3 and 13%, respectively for abnormal neurological signs (Cox et al. 1989). Data from 81 mother-infant pairs were analyzed using an outcome metric that was a composite score for delayed walking (age >18 months), delayed talking (age >24 months), and neurological signs (score >3 of 11; Marsh et al. 1987). An analysis of covariance showed an increase in composite score with increasing HHg levels (range 1–674 µg Hg/g) with a higher slope for males compared to females. In males, when stratified by maximum prenatal HHg, scores were 2.6-fold higher in children from pregnancies in which HHg ranged from 23 to 72 µg Hg/g (score 1.14), compared to pregnancies in which HHg was 1 µg Hg/g (score 0.43).

Crump et al. (1995) utilized data on 81 mother-infant pairs (Marsh et al. 1987) to estimate BMDs for delayed walking (age >18 months), delayed talking (age >24 months), and neurological signs score (score >3 of 11). The lower confidence limits on the BMDs (BMDLs) were 73 µg Hg/g for delayed walking, 54 µg Hg/g for delayed talking, and 80 µg Hg/g for neurological signs, when the background response probability was 0.05 and the quantal BMR was 0.1. The large differences in the dose-response thresholds estimated by Cox et al. (1989) and Crump et al. (1995) demonstrate the importance of model selection in estimating a statistically based NOAEL from these data.

Seychelle Islands. Two prospective studies of methylmercury and neurodevelopmental outcomes have been conducted in the Republic of Seychelles: the SCDS and the Seychelles Child Development Nutrition Study (SCDNS). A summary of the major outcomes of the Seychelles studies are presented in Table 2-42. Oceanic fish consumption, typically consumed at every meal, is the major contributor to methylmercury exposure in the Seychelle population. Maternal fish intake in the SCDNS cohort was estimated from a food use questionnaire and 4-day diet diary. The median was 77 g Hg/day (range 0–346 g Hg/day) (Davidson et al. 2008b). Marine mammals were not consumed and there were no other local sources of PCB exposure (Shamalaye et al. 2004). PCBs were not detectable in cohort serum samples (Davidson et al. 1998).

Table 2-42. Results of Epidemiological Studies Evaluating Exposure to Methylmercury and Neurodevelopmental Effects—Prospective Birth Cohorts in the Seychelle Islands

Reference, age at follow-up	Biomarker	Outcome evaluated	Result[a]
SCDS (listed in order of follow-up age)			
Myers et al. 1995 SCDS follow-up at age 6.5 months (n=779)	HHg median Maternal: 5.9 µg/g	DDST	↔ (HHg, maternal)
Davidson et al. 1999 SCDS follow-up at age 6.5 months (n=740)	HHg median Maternal: 5.9 µg/g	FTII (2 metrics)	↔ (HHg, maternal) ↔ (HHg, maternal with maternal x caregiver intelligence and x family income)[b]
Axtell et al. 1998; Myers et al. 1997 SCDS follow-up at age 19 months (n=738)	HHg median Maternal: 5.8 µg/g	Age of talking	↔ (HHg, maternal)
		Age of walking	↔ (HHg, maternal) ↑ (HHg, maternal ≤7 µg/g) ↓ (HHg, maternal >7 µg/g)
Davidson et al. 1995, 1999 SCDS follow-up at age 19 months (n=738)	HHg median Maternal: 5.9 µg/g	BSID MDI	↔ (HHg, maternal) ↑ (HHg, maternal with caregiver intelligence and x family income)[b]
		BSID PDI	↔ (HHg, maternal)
Davidson et al. 1995, 1999 SCDS follow-up at age 29 months (n=736)	HHg median Maternal: 5.9 µg/g	BSID MDI	↔ (HHg, maternal)
		BSID PDI	↔ (HHg, maternal)
		BSID IBR	↔ (HHg, maternal) ↔ (HHg, maternal with maternal x caregiver intelligence and x family income)[b]

Axtell et al. 2000;
Davidson et al. 1998
 	
SCDS follow-up at age 66 months (n=711)
	HHg mean
	    Maternal: 6.8 µg/g
	    Child (age 66 months):
	    6.5 µg/g
		BVMGT	↔ (HHg, maternal)
			↔ (HHg, child, females)
			↓ (HHg, child, males)

		CBCL	↔ (HHg, maternal) ↑ (HHg, maternal ≤15 µg/g) ↓ (HHg, maternal >15 µg/g) ↔ (HHg, child)
		MSCA GCI	↔ (HHg, maternal) ↔ (HHg, child) ↑ (HHg, child ≤10 µg/g) ↓ (HHg, child >10 µg/g)
		PLS	↑ (HHg, maternal) ↓ (HHg, maternal ≤10 µg/g) ↑ (HHg, maternal >10 µg/g) ↑ (HHg, child)

Table 2-42. Results of Epidemiological Studies Evaluating Exposure to Methylmercury and Neurodevelopmental Effects—Prospective Birth Cohorts in the Seychelle Islands

Reference, age at follow-up	Biomarker	Outcome evaluated	Result[a]
		WJTA	↔ (HHg, maternal) ↑ (HHg, child)
Myers et al. 2000 SCDS follow-up at age 66 months (n=711)	HHg mean Maternal: 6.8 µg/g Child (age 66 months): 6.5 µg/g	CBCL (10 subscales)	↔ (HHg, maternal) ↔ (HHg, child)
Palumbo et al. 2000 SCDS follow-up at age 66 months (n=711)	HHg mean Maternal: 6.8 µg/g Child (age 66 months): 6.5 µg/g	MSCA verbal	↔ (HHg, maternal)
		MSCA perceptual	↔ (HHg, maternal) ↔ (HHg, child)
		MSCA memory	↔ (HHg, maternal) ↑ (HHg, child)
		MSCA quantitative	↔ (HHg, maternal) ↔ (HHg, child)
		MSCA motor	↔ (HHg, maternal) ↔ (HHg, child)
Young et al. 2020 SCDS follow-up at age 66 months (n=544)	HHg mean Maternal: 6.8 µg/g Child: 6.5 µg/g	Language development PLS consonant distortion error	
		Initial consonant	↔ (HHg, maternal) ↔ (HHg, child)
		Final consonant	↔ (HHg, maternal) ↔ (HHg, child)
Strain et al. 2021 SCDS follow-up at age 7 years (n=1,237)	HHg mean Maternal: 3.91 µg/g	BNT	↔ (HHg, maternal)
		CBCL	↔ (HHg, maternal)
		CELF-5	↔ (HHg, maternal)
		KBIT-2	↔ (HHg, maternal)
		SCQ	↔ (HHg, maternal)
		SRS-2	↔ (HHg, maternal)
		WJTA-III	↔ (HHg, maternal)
Myers et al. 2003; Huang et al. 2005 SCDS follow-up at age 9 years (n=643)	HHg mean Maternal: 6.9 µg/g	BOT	↔ (HHg, maternal)
		BNT	↔ (HHg, maternal)
		CVLT	↔ (HHg, maternal)
		CBCL	↔ (HHg, maternal)
		CTRS (hyperactivity index)	↓ (HHg, maternal) ↑ (HHg, maternal, ≤5 µg/g) ↓ (HHg, maternal, >5 µg/g)
		Finger tapping	↔ (HHg, maternal)
		GPB (dominant hand)	↔ (HHg, maternal) ↓ (HHg, maternal, ≤10 µg/g) ↑ (HHg, maternal, >10 µg/g)

Table 2-42. Results of Epidemiological Studies Evaluating Exposure to Methylmercury and Neurodevelopmental Effects—Prospective Birth Cohorts in the Seychelle Islands

Reference, age at follow-up	Biomarker	Outcome evaluated	Result[a]
		GPB (non-dominant hand)	↑ (HHg, maternal, males) ↓ (HHg, maternal, ≤5 µg/g, males) ↑ (HHg, maternal, >5 µg/g, males) ↔ (HHg, maternal, females)
		HAPDT	↔ (HHg, maternal)
		Trail making	↔ (HHg, maternal)
		VMI	↔ (HHg, maternal)
		WJTA	↔ (HHg, maternal)
		WISC-III FSIQ	↔ (HHg, maternal)
		WRAML	↔ (HHg, maternal)
van Wijngaarden et al. 2009 SCDS follow-up at age 9 years (n=643)	HHg mean Maternal: 6.9 µg/g (as reported by Myers et al. 2003)	OR for total abnormal cases any domain (1st or 99th test score)	↔ (maternal Hg)
		OR for abnormal cognition cases	↔ (maternal Hg)
		OR for abnormal motor function cases	↔ (maternal Hg)
Davidson et al. 2010 SCDS follow-up at age 9 years (n=437–456 for academic achievement scores; 225 for SACMEQ)	HHg mean Maternal: 6.89 µg/g Child (age 9 years): 6.09 µg/g	Mathematics score	↔ (HHg, maternal) ↑ (HHg, child; female) ↔ (HHg, child; male)
		Social studies score	↔ (HHg, maternal) ↓ (HHg, child)
		English language score	↔ (HHg, maternal) ↔ (HHg, child)
		French language score	↓ (HHg, maternal) ↑ (HHg, child; female) ↔ (HHg, child; male)
		Kreol language score	↔ (HHg, maternal) ↔ (HHg, child)
		Science score	↔ (HHg, maternal) ↔ (HHg, child)
		SACMEQ: reading comprehension	↔ (HHg, maternal) ↑ (HHg, child; female) ↓ (HHg, child; male)
		SACMEQ: mathematics	↔ (HHg, maternal) ↔ (HHg, child; female) ↓ (HHg, child; male)

Table 2-42. Results of Epidemiological Studies Evaluating Exposure to Methylmercury and Neurodevelopmental Effects—Prospective Birth Cohorts in the Seychelle Islands

Reference, age at follow-up	Biomarker	Outcome evaluated	Result[a]

Davidson et al. 2006a
 	
SCDS longitudinal analysis, age 19 months to 9 years (n=738, 736, 735, 711, and 643 at 19, 29, 66, and 107 months, respectively)
	HHg mean
	  Maternal: 6.8 µg/g
	  Child (age 66 months): 6.5 µg/g
	  Child (age 107 months): 6.1 µg/g
		Global cognition based on BSID MDI, MSCA GCI, WISC-III FSIQ, WJTA, WRAML	↔ (HHg, maternal)
			↑ (HHg, child, males at 66 months)
			↓ (HHg, child, females at 107 months)

Myers et al. 2009
SCDS follow-up at age 9 years (n=483)
	HHg mean
	  Child (age 66 months): 6.5 µg/g
	  Child (age 107 months): 6.1 µg/g
		WISC IQ for various metrics of HHg:	

		AUC	↔ (HHg, child)
		Brain growth weighted	↔ (HHg, child)
		High versus low	↔ (HHg, child)

Myers et al. 2020
SCDS follow-up at age 9 years (n=643)
	HHg mean
	  Maternal: 6.8 µg/g
	  Child (age 107 months): 6.1 µg/g
		CBCL subscale:	

		Social problems	↓ (HHg, maternal) ↔ (HHg, child)
		Thought problems	↔ (HHg, maternal) ↑ (HHg, child)
		Somatic complaints	↔ (HHg, maternal) ↔ (HHg, child)
		Withdrawn	↔ (HHg, maternal) ↔ (HHg, child)
		Anxious/ depressed	↔ (HHg, maternal) ↔ (HHg, child)
		Attention problems	↔ (HHg, maternal) ↔ (HHg, child)
		Delinquent behaviors	↔ (HHg, maternal) ↔ (HHg, child)
		Aggressive behaviors	↔ (HHg, maternal) ↔ (HHg, child)
		Externalizing	↔ (HHg, maternal) ↔ (HHg, child)
		Internalizing	↔ (HHg, maternal) ↔ (HHg, child)

Table 2-42. Results of Epidemiological Studies Evaluating Exposure to Methylmercury and Neurodevelopmental Effects—Prospective Birth Cohorts in the Seychelle Islands

Reference, age at follow-up	Biomarker	Outcome evaluated	Result[a]
van Wijngaarden et al. 2013 SCDS follow-up at age 10 years (n=537)	HHg mean Maternal: 6.8 µg/g	TSRSS for ASD (5 metrics)	↔ (HHg, maternal)

Davidson et al. 2008a
 	
SCDS follow-up at age 11 years (n=613)
	HHg mean
	  Maternal: 6.83 µg/g
	  Child (age 11 years): 6.97 µg/g
		BVMGT	↔ (HHg, maternal)
			↔ (HHg, child)

Davidson et al. 2010
 	
SCDS follow-up at age 17 years (n=351–384)
	HHg mean
	  Maternal: 6.89 µg/g
	  Child (age 17 years): 8.00 µg/g
		Seychelles academic achievement scores (6 subjects)	↔ (HHg, maternal)
			↔ (HHg, child)

Davidson et al. 2011; Huang et al. 2018
 	
SCDS follow-up at age 17 years (n=462)
	HHg mean
	  Maternal: 6.89 µg/g
	  Child (age 17 years): 7.98 µg/g
		CANTAB (4 tests)	↓ (HHg, maternal; IED)
			↓ (HHg, maternal, ≤12 µg/g; IED)
			↔ (HHg, maternal; all other tests)
			↔ (HHg, child)

		CVLT (2 tests)	↔ (HHg, maternal) ↑ (HHg, maternal, ≤8 µg/g; calculation) ↔ (HHg, child)
		WJTA (6 tests)	↑ (HHg, maternal; calculation) ↑ (HHg, maternal, ≤15 µg/g; calculation) ↔ (HHg, maternal, >15 µg/g; calculation) ↓ (HHg, child; passage comprehension)
		Behavioral endpoints (6 endpoints)	↓ (HHg, maternal; substance use, male) ↓ (HHg, maternal; incidents/year) ↑ (HHg, maternal; referrals/year) ↔ (HHg, child)

Table 2-42. Results of Epidemiological Studies Evaluating Exposure to Methylmercury and Neurodevelopmental Effects—Prospective Birth Cohorts in the Seychelle Islands

Reference, age at follow-up	Biomarker	Outcome evaluated	Result[a]

Orlando et al. 2014
 	
SCDS follow-up at age 19 years (n=517)
	HHg mean
	  Maternal: 6.89 µg/g
	  Child (age 19 years): 10.32 µg/g
		Pure tone hearing	↔ (HHg, maternal)

		Auditory brainstem response	↔ (HHg, maternal)
		Otoacoustic emissions	↔ (HHg, maternal)

van Wijngaarden et al. 2017
 	
SCDS follow-up at age 22 years (n=571)
	HHg mean
	  Maternal: 6.83 µg/g
	  Child (age 22 years) 5.17 µg/g
		CANTAB (7 tests, 23 metrics)	↑ (HHg, maternal, reaction time)
			↑ (HHg, maternal, delayed match to sample)
			↔ (HHg, maternal, all other tests)
			↑ (HHg, child, IED)
			↔ (HHg, child, all other tests)

		BNT	↔ (HHg, maternal) ↔ (HHg, child)
		Profile of mood states (2 metrics)	↔ (HHg, maternal) ↔ (HHg, child)
		Healthy behavior (4 metrics)	↔ (HHg, maternal) ↔ (HHg, child)

van Wijngaarden et al. 2017
 	
SCDS follow-up at age 24 years (n=577)
	HHg mean
	  Maternal: 6.80 µg/g
	  Child (age 24 years): 4.95 µg/g
		Stroop interference	↔ (HHg, maternal)
			↔ (HHg, child)

		Barkley ADHD rating (4 metrics)	↔ (HHg, maternal ↔ (HHg, child)
		Visual attention (5 metrics)	↔ (HHg, maternal) ↔ (HHg, child)
		Auditory attention (5 metrics)	↓ (HHg, maternal, mean response time) ↔ (HHg, child)
		Finger tapping (2 metrics)	↔ (HHg, maternal) ↔ (HHg, child)
		Healthy behavior (3 metrics)	↔ (HHg, maternal) ↔ (HHg, child)

Thurston et al. 2022
SCDS follow-up at ages 9, 10.5, 17, 19, 22, and 24 years (n=312–550)
	HHg TWA
	  Child (6 months to 5.5 years): 5.34 µg/dL
	  Adult (17–24 years): 7.13 µg/dL
		After Bonferroni correction for multiple comparisons (85 tests performed):	

		Executive function	↔ (HHg, TWA child) ↔ (HHg, TWA adult)
		Attention	↔ (HHg, TWA child) ↔ (HHg, TWA adult)
		BNT	↔ (HHg, TWA child) ↔ (HHg, TWA adult)
		BVMGT	↔ (HHg, TWA child) ↔ (HHg, TWA adult)

Table 2-42. Results of Epidemiological Studies Evaluating Exposure to Methylmercury and Neurodevelopmental Effects—Prospective Birth Cohorts in the Seychelle Islands

Reference, age at follow-up	Biomarker	Outcome evaluated	Result[a]
		Before Bonferroni correction for multiple comparisons:	
		CPT risk-taking	↑ (HHg, TWA child, 9 years)
		WCST errors	↑ (HHg, TWA adult, 17 years)
		BVGMT errors	↓ (HHg, TWA child, 10.5 years)
		CANTAB Visual processing false alarms	↑ (HHg, TWA adult, 17 years)
		CANTAB IED total errors	↑ (HHg, TWA adult, 22 years
		CANTAB IED total trials	↑ (HHg, TWA adult, 22 years)
		BNT total score	↓ (HHg, TWA child, 22 years) ↓ (HHg, TWA adult, 22 years)
		BNT no cue score	↓ (HHg, TWA child, 22 years) ↓ (HHg, TWA adult, 22 years)
		TOVA auditory response time variance	↑ (HHg, TWA child, 24 years)
		TOVA visual response time mean	↑ (HHg, TWA child, 24 years)
		TOVA visual response time variance	↑ (HHg, TWA child, 24 years)
		WJTA passage comp	↓ (HHg, TWA adult, 17 years)
SCDNS			
Davidson et al. 2008b SCDNS follow-up at age 5 months (n=215)	HHg mean Maternal: 5.7 µg/g	FTII (2 metrics)	↔ (HHg, maternal)
		VEXP (2 metrics)	↔ (HHg, maternal)
Davidson et al. 2008b SCDNS follow-up at age 9 months (n=226)	HHg mean Maternal: 5.7 µg/g	FTII (2 metrics)	↔ (HHg, maternal)
		VEXP (2 metrics)	↔ (HHg, maternal)
		BSID MDI	↔ (HHg, maternal)
		BSID PDI	↔ (HHg, maternal)

Table 2-42. Results of Epidemiological Studies Evaluating Exposure to Methylmercury and Neurodevelopmental Effects—Prospective Birth Cohorts in the Seychelle Islands

Reference, age at follow-up	Biomarker	Outcome evaluated	Result[a]
Strain et al. 2015 SCDNS follow-up at age 20 months (n=1,265)	HHg mean Maternal: 3.92 µg/g	BSID MDI	↔ (HHg, maternal)
		BSID PDI	↔ (HHg, maternal)
		CDI	↔ (HHg, maternal)
		BSID IBR	↔ (HHg, maternal)
Davidson et al. 2008b SCDNS follow-up at age 25 months (n=218)	HHg mean Maternal: 5.7 µg/g	DSA (4 metrics)	↔ (HHg, maternal)
Davidson et al. 2008b SCDNS follow-up at age 30 months (n=228)	HHg mean Maternal: 5.7 µg/g	BSID MDI	↔ (HHg, maternal)
		BSID PDI	↓ (HHg, maternal)
Strain et al. 2012 SCDNS follow-up at age 5 years (n=225)	HHg mean Maternal: 5.7 µg/g	Finger tapping (2 metrics)	↔ (HHg, maternal)
		PLS (3 metrics)	↔ (HHg, maternal)
		WJTA	↔ (HHg, maternal)
		KBIT (2 metrics)	↔ (HHg, maternal)
		CBCL	↔ (HHg, maternal)
Strain et al. 2021 SCDNS follow-up at age 7 years (n=1,237)	HHg mean Maternal: 3.91 µg/g	BNT	↔ (HHg, maternal)
		CBCL	↔ (HHg, maternal)
		CELF-5	↔ (HHg, maternal)
		KBIT-2	↔ (HHg, maternal)
		SCQ	↔ (HHg, maternal)
		SRS-2	↔ (HHg, maternal)
		WJTA-III	↔ (HHg, maternal)
		SRS	↔ (HHg, maternal)
		SCQ	↔ (HHg, maternal)
		Trail making	↔ (HHg, maternal)
Orlando et al. 2023 SCDNS follow-up at age 9 years (n=210)	HHg mean Maternal: 5.87 µg/g	Pure tone hearing	↔ (HHg, maternal)
		Auditory brainstem response	↔ (HHg, maternal)
		Otoacoustic emissions	↔ (HHg, maternal)

[a]Interpretation of neurobehavioral test scores:
  Age of talking or walking: increased age = delay in development
  Barkley ADHD: higher score = lower performance
  BNT: higher score = higher performance
  BOT: higher score = higher performance
  BSID IBR: higher score = higher performance
  BSID MDI: higher score = higher performance
  BSID PDI: higher score = higher performance

Table 2-42. Results of Epidemiological Studies Evaluating Exposure to Methylmercury and Neurodevelopmental Effects—Prospective Birth Cohorts in the Seychelle Islands

Reference, age at follow-up	Biomarker	Outcome evaluated	Result[a]

BVMGT: higher score = lower performance
CANTAB: higher score = lower performance
CBCL: higher score = lower performance
CDI: higher score = higher performance
CELF-5: higher score = higher performance
CPT: higher score = lower performance
CTRS: higher score = lower performance
CVLT: higher score = higher performance
DDST: milestones evaluated against a standard; below standard = delayed development
DSA: higher score = higher performance
Finger tapping: higher score = higher performance
FTII: higher score = higher performance
GPB: higher score = lower performance
HAPDT: higher score = higher performance
KBIT-2: higher score = higher performance
MSCA: higher score = higher performance
PLS: higher score = higher performance
SCQ: higher score = higher performance
SRS-2: higher score = higher performance
Stroop interference: higher score = higher performance
TOVA: higher score = lower performance
Trail making: higher score = higher performance
TSRSS: higher score = higher performance
VEXP: higher score = higher performance
VMI: higher score = higher performance
WCST: higher score = higher performance
WJTA: higher score = higher performance
WRAML: higher score = higher performance

[b]This study examined potential effect modification from caregiver intelligence, family income, and home environment on the association between maternal hair mercury and neurodevelopmental outcomes.

↑ = positive association; ↓ = inverse association; ↔ = no association; x represents interaction; ADHD = attention deficit/hyperactivity disorder; ASD = autism spectrum disorder; AUC = area under the curve; BNT = Boston naming test; BOT = Bruininks-Oseretsky Test of Motor Proficiency; BSID = Bayley Scales of Infant Development; BVMGT = Bender Visual Motor Gestalt Test; CANTAB = Cambridge Neuropsychological Test Automated Battery; CBCL = Child Behavior Checklist; CPT = Continuous Performance Test; CDI = MacArthur-Bates Communicative Development Inventories; CELF-5 = Clinical Evaluation of Language Fundamentals; GCI = Global Cognition Index; CTRS = Connors' Teacher Rating Scale; CVLT = California Verbal Learning Test; DDST = Denver Developmental Screening Test; DSA = Delayed Spatial Alternation; FSIQ = full scale intelligence quotient; FTII = Fagan Test of Infant Intelligence; GPB = grooved pegboard; HAPDT = Haptic Discrimination Test; HHg = hair mercury; IBR = Infant Behavior Record; IED = Intra-extra dimensional set shift; KBIT = Kauffman Brief Intelligence Test; MDI = BSID Mental Development Index; MSCA = McCarthy Scales of Children's Abilities; OR = odds ratio; PDI = BSID Psychomotor Development Index; PLS = Preschool Language Scale; SACMEQ = Southern and Eastern African Consortium for Monitoring Educational Quality; SCDNS = Seychelles Child Development Nutrition Study; SCDS = Seychelles Child Development Study; SCQ = Social Communication Questionnaire; SRS = Social Responsiveness Scale; TOVA = Tests of Variables of Attention; TSRSS = Total Social Responsiveness Social Scores; TWA = time-weighted average; VEXP = Visual Expectation Paradigm; VMI = Visual Motor Integration; WCST = Wisconsin Card Sorting Test; WISC-III = Wechsler Intelligence Scales for Children, 3rd edition; WJTA = Woodcock-Johnson Test of Achievement; WRAML = Wide Range Assessment of Memory and Learning

The SCDS included a cohort of 779 mother-infant pairs (6 months post-partum), recruited in 1989–1990.

Neurodevelopmental outcomes were initiated at age 6 months and continued through age 24 years (Myers

et al. 1995; van Wijngaarden et al. 2017). The primary methylmercury exposure metric has been average maternal gestational HHg. Methylmercury accounted for >80% of total mercury in hair (Cernichiari et al. 1995). Annual median maternal HHg measured over the period 1986–1989 ranged from 5.9 to 8.2 μg Hg/g; the highest observed value was 36 μg Hg/g (Cernichiari et al. 1995). The main cohort followed from age 6 months and later had a median prenatal maternal level of 5.9 μg Hg/g (range 0.5–26.7 g Hg/day) (Myers et al. 1995). Approximately half of the maternal HHg were ≤6 μg Hg/g, while the highest 15% (approximately 95 women) were >12 μg Hg/g; therefore, power to discern significant associations was higher at HHg <12 μg Hg/g. Neurodevelopmental outcomes were assessed using a variety of tests, which changed as the children aged. These included tests of learning and memory, visual-motor function, auditory function, developmental milestones (e.g., age of waking, age of talking), intellectual achievement, and behavior (e.g., signs of attention deficit/hyperactivity disorder or autism spectrum disorder; referrals for substance use, mental health, antisocial behavior, or self-injury). Outcome associations were adjusted for covariates that included (in most studies): child sex, birth weight, birth order, gestational age, medical history, and breastfeeding; maternal age, alcohol and tobacco use, and medical history; and parental education, caregiver general intelligence (Raven's Progressive Matrices), family income, family language, home learning, and social stimulation (Home Observation Measurement of the Environment; HOME score).

In addition to the SCDS, a second prospective study, the SCDNS, evaluated associations between prenatal mercury exposure (maternal HHg), nutrition, and cognitive outcomes (Davidson et al. 2008b; Strain et al. 2008). This study included 300 pregnant women recruited in 2001, with follow-up of infants and children from age 5 months to age 5 years. As in the SCDS, the highest HHg during pregnancy was used as the exposure metric. Mean prenatal maternal HHg level was 5.7 μg/g (range 0.2–18.5 μg/g). Mean maternal fish consumption was 77 g/day (range 0–346 g/day), estimated based on a food use questionnaire and 4-day diet recall (Davidson et al. 2008b). Prenatal maternal nutritional variables associated with child development were assessed in regression models of mercury exposure and developmental outcomes. These included arachidonic acid (AA), choline, Ω-3 and Ω-6 LCPUFAs, docosahexaenoic acid (DHA), thyroid hormone status, and iron status. Neurodevelopmental outcomes were assessed from tests of learning and memory, visual-motor function, and behavior.

Seychelles Child Development Study (SCDS). In general, the SCDS has not found consistent evidence for associations between exposure to methylmercury and neurodevelopmental outcomes at any age thus far studied. This conclusion is supported by cross-sectional follow-ups of the cohort from ages 6.5 months to 24 years (Davidson et al. 1995, 1998, 1999, 2008a, 2010, 2011; Huang et al. 2005; Myers et al. 1995

1997, 2000, 2003, 2009, 2020; Orlando et al. 2014; Palumbo et al. 2000; Thurston et al. 2022; van Wijngaarden et al. 2009, 2013, 2017; Young et al. 2020), longitudinal analyses of individual outcome metrics (Axtell et al. 1998; Davidson et al. 1998; Myers et al. 1997), and longitudinal analysis of metrics of global cognition based on aggregation of outcome metrics (Davidson et al. 2006a). Accounting for error in measuring HHg (and other covariates) had no appreciable effect on dose-response models assessed at age 66 months (Huang et al. 2003).

Although linear regression models consistently found no association between exposure (maternal or child HHg) and cognitive development, nonlinear models of cognitive test scores suggested that performance improved or declined in association with prenatal maternal HHg or child HHg, depending on the hair level (Axtell et al. 1998, 2000; Davidson et al. 1998, 2006a; Huang et al. 2005, 2007, 2018; Myers et al. 1997, 2003, 2020). For some outcomes, performance declined at lower HHg (e.g., ≤7 µg Hg/g), but improved at higher levels; and, for some outcomes, the opposite pattern was observed. At age 66 months, lower performance was not evident in a subgroup of the cohort that had a mean HHg of 15.3 µg Hg/g (>85th percentile) (Davidson et al. 1998). It is uncertain if these nonlinear patterns reflect actual dose-level effects or differential statistical power across the HHg range; or, possibly, random outcomes from the numerous (>20) tests evaluated (Axtell et al. 2000; Davidson et al. 2006b; Huang et al. 2005, 2007). Age of walking increased with increasing prenatal maternal HHg over the range of 1–7 µg Hg/g, however; the effect size was <1 day and the association was not evident at higher levels of HHg (Axtell et al. 1998). Aggregating scores of cognitive performance into metrics of global cognitive function (Davidson et al. 2006a) or dichotomizing test scores into a binomial metric (benchmark response) also revealed no associations in cognitive development and prenatal maternal HHg <20 µg Hg/g (Crump et al. 2000; van Wijngaarden et al. 2006, 2009).

Further complicating the interpretation of associations with mercury exposure were interactions between social variables (e.g., HOME score, caregiver intelligence, SES) and prenatal mercury exposure (Davidson et al. 2004; Huang et al. 2007, 2018; Love et al. 2017). For example, when assessed at age 9 years, performance on tests of motor skills improved in association with increasing maternal mercury in approximately half of children who had an average HOME score; however, performance declined in response to HHg in children who had below average HOME scores (Huang et al. 2007). Given the large number of potential effect modifiers on the cognitive outcomes assessed, the possibility of non-homogeneous susceptibility to methylmercury exposures has been considered in the SCDS (Engstrom et al. 2016; Huang et al. 2007, 2018; Love et al. 2017). The number of maternal mercury amalgam restorations was not associated with performance on tests of cognitive abilities (Watson et al. 2011).

BMD modeling of data from follow-ups up to age 66 months (Crump et al. 2000) and 9 years (van Wijngaarden et al. 2006) evaluated dose-response models for more than 20 cognitive performance endpoints. Based on endpoints measured in follow-ups through age 66 months, the mean BMDL for 144 endpoints was 25 µg Hg/g (range 19–30 µg Hg/g) maternal HHg, when the background response probability was 0.05 and the quantal benchmark response was 0.1 (Crump et al. 2000). Based on the follow-up at age 9 years, the mean BMDL for 26 endpoints was 20.1 µg Hg/g (range 17.2–22.5 µg Hg/g) HHg (van Wijngaarden et al. 2006).

Seychelles Child Development Nutrition Study (SCDNS). The SCDNS found an association between increasing maternal HHg and decreasing psychomotor development index (PDI of the Bayley Scales of Infant Development) when assessed at age 30 months (Davidson et al. 2008b). However, the mercury association was modified by an interaction with maternal omega-3 fatty acid status (Strain et al. 2008). Increasing maternal serum omega-3 levels (or decreasing omega-6/omega-3 ratio) was associated with increases in PDI at age 9 months and the association persisted when maternal HHg was included in the model. At age 30 months, the association between PDI and maternal omega-3 levels was not evident (Strain et al. 2008). At ages 5 and 7 years, increasing maternal DHA and Ω-3 LCPUFA continued to be associated with improved performance on the preschool language scale, whereas no association was found with HHg (Strain et al. 2012, 2021). Analysis of the data from the follow-ups at ages 9 and 30 months showed that increasing maternal DHA levels were associated with improved PDI and mental development index (MDI) scores; however, the benefit of increasing maternal DHA (increasing scores) was attenuated with increasing maternal HHg. Neurobehavioral endpoints were re-examined at age 7 years in a second cohort from the SCDNS (Strain et al. 2021). The study did not find associations between maternal mercury hair levels (mean 2.91 µg/g; range 0.01, 31.66) and scores of tests that evaluated executive function, cognition, and linguistic skills. The study found improved scores in association with maternal serum omega-3 levels and no interaction between serum omega-3 levels and maternal HHg. Hearing function was evaluated at age 9 years and no associations were found between pre- or postnatal HHg levels and auditory brainstem responses or otoacoustic emissions (Orlando et al. 2014). These observations suggest that nutritional benefits of the relatively high fish consumption of the cohort may have weakened possible associations between measured neurodevelopmental outcomes and prenatal mercury exposure.

Faroe Islands. A prospective study of methylmercury and neurodevelopmental outcomes has been conducted in the Faroe Islands (Faroes study). A summary of the major outcomes of the Faroes study are

presented in Table 2-43. Consumption of marine fish and mammals (e.g., pilot whale) is the major
contributor to methylmercury exposure in the Faroes population (Grandjean et al. 1992). The Faroes
study included a cohort of 1,022 singleton births pairs recruited in 1986–1987. Assessment of
neurodevelopmental outcomes began with pediatric observations at age 2 weeks and cognitive function
testing conducted periodically, with the most recent follow-up at age 22 years (Steuerwald et al. 2000;
Oulhote et al. 2017b). The primary methylmercury prenatal exposure metric has been total mercury in
cord blood, which was predominantly (>80%) methylmercury (Grandjean et al. 1992). Maternal HHg
was also measured and used as an exposure metric in some analyses. The median cord BHg
concentration was 24 µg Hg/L and interquartile range (IQR) was 13–40 µg Hg/L; approximately 25% of
the cord mercury levels were >40 µg Hg/L (Grandjean et al. 1992). Cord BHg levels (µg Hg/L) were
approximately 5 times maternal HHg measured at parturition (median 4.5 µg Hg/g, IQR: 2.5, 7.7)
(Grandjean et al. 1992). Based on a dietary survey, the average daily consumption in the Faroe Island
population was 72 g fish/day and 12 g whale/day (Grandjean et al. 1992). Mercury levels in blood and
hair were correlated with the number of fish meals per week and number of whale meals per week and
were not correlated with number of mercury amalgam dental restorations (Grandjean et al. 1992; Weihe et
al. 1996). Although both fish and whale consumption correlated with BHg levels, the largest fraction of
the variance in blood and HHg was explained by variance in consumption of pilot whale, whereas fish
consumption was a less important explanatory variable.

Table 2-43. Results of Epidemiological Studies Evaluating Exposure to Methylmercury and Neurodevelopmental Effects—Prospective Birth Cohort in the Faroe Islands

Reference (listed in order of age at follow-up)	Biomarker	Outcome evaluated	Result[a]
Steuerwald et al. 2000 Follow-up at age 2 weeks (n=182)	BHg Gmean Cord: 20.4 µg/L	Neurologic optimality score	↓ (BHg, cord)

Grandjean et al. 1995
 	
Follow-up at age 12 months (n=583)
	BHg median
	  Cord: not reported
	
	HHg Gmean:
	  Maternal: 4.47 µg/g
	  Child (age 12 months):
	  0.9–1.3 µg/g
		Age of sitting	↔ (BHg, cord)
			↔ (HHg, maternal)
			↓ (HHg, child)
			↓ (duration of nursing)

		Age of crawling	↔ (BHg, cord) ↔ (HHg, maternal) ↓ (HHg, child) ↓ (duration of nursing)
		Age of standing	↔ (BHg, cord) ↔ (HHg, maternal) ↓ (HHg, child) ↓ (duration of nursing)

Table 2-43. Results of Epidemiological Studies Evaluating Exposure to Methylmercury and Neurodevelopmental Effects—Prospective Birth Cohort in the Faroe Islands

Reference (listed in order of age at follow-up)	Biomarker	Outcome evaluated	Result[a]

Grandjean et al. 1997, 1998, 1999, 2003
 	
Follow-up at age 7 years (n=917)
	BHg Gmean
	  Cord: 22.9 µg/L
	
	HHg Gmean
	  Maternal: 4.27 µg/g
	
	Low-level mercury exposure considered maternal HHg <10 µg/g
		VEPL	↔ (BHg, cord)

		BAEPL	↑ (BHg, cord)
		Postural sway	↔ (BHg, cord)
		HRV	↔ (BHg, cord)
		NES FTT	↓ (BHg, cord) ↔ (BHg, cord; low-level only)
		NES HECT	↔ (BHg, cord) ↔ (BHg, cord; low-level only)
		NES CPT (reaction time)	↑ (BHg, cord) ↑ (BHg, cord; low-level only)
		WISC-R (digit span)	↓ (BHg, cord) ↓ (BHg, cord; low-level only)
		WISC-R (similarities)	↔ (BHg, cord) ↔ (BHg, cord; low-level only)
		WISC-R (block design)	↔ (BHg, cord) ↔ (BHg, cord; low-level only)
		BVMGT (copy)	↔ (BHg, cord) ↔ (BHg, cord; low-level only)
		BVMGT (reproduction)	↔ (BHg, cord) ↓ (BHg, cord; low-level only)
		BNT	↓ (BHg, cord) ↓ (BHg, cord; low-level only)
		CVLT	↓ (BHg, cord) ↓ (BHg, cord; low-level only)
		NVAPMS	↔ (BHg, cord) ↔ (BHg, cord; low-level only
		CBCL	↔ (BHg, cord)

Yorifuji et al. 2013
 	
Follow-up age at 7 years (n=139)
	BHg Gmean
	  Cord: 22.8 µg/L
	
	HHg Gmean
	  Maternal: 4.6 µg/g
		VEPL	↔ (BHg, cord)
			↑ (HHg, maternal)

Grandjean et al. 2014
 	
Follow-up at age 7 years (n=694)
	BHg Gmean
	  Cord: 22.3 µg/L
	Child (age 7 years):
	  8.36 µg/L
		NES FTT	↓ (BHg, cord)
			↔ (BHg, child)

		NES HECT	↑ (BHg, cord) ↔ (BHg, child)

Table 2-43. Results of Epidemiological Studies Evaluating Exposure to Methylmercury and Neurodevelopmental Effects—Prospective Birth Cohort in the Faroe Islands

Reference (listed in order of age at follow-up)	Biomarker	Outcome evaluated	Result[a]
		NES CPT (reaction time)	↑ (BHg, cord) ↔ (BHg, child)
		WISC-R (digit span)	↔ (BHg, cord) ↔ (BHg, child)
		WISC-R (similarities)	↔ (BHg, cord) ↔ (BHg, child)
		WISC-R (block design)	↔ (BHg, cord) ↔ (BHg, child)
		BVMGT (copy)	↔ (BHg, cord) ↔ (BHg, child)
		BVMGT (reproduction)	↔ (BHg, cord) ↓ (BHg, child)
		BNT	↓ (BHg, cord) ↔ (BHg, child)
		CVLT	↔ (BHg, cord) ↔ (BHg, child)

Oulhote et al. 2019
 	
Follow-up at age 7 years (n=503)
	BHg Gmean
	  Cord: 13.0 µg/L
	Child (age 5 years):
	  2.68 µg/L
		BNT (without cues)	↓ (BHg, cord)
			↔ (BHg, child)

		BNT (with cues)	↓ (BHg, cord) ↔ (BHg, child)
		SDQ (total)	↔ (BHg, cord) ↔ (BHg, child)

Debes et al. 2006
 	
Follow-up at age 14 years (n=860)
	BHg Gmean
	  Cord: 22.5 µg/L
	
	HHg Gmean
	  Maternal: 4.21 µg/g
		NES FTT	↓ (BHg, cord)
			↓ (HHg, maternal)

		CATSYS FTT (reaction time)	↔ (BHg, cord) ↑ (HHg, maternal)
		NES CPT (reaction time)	↑ (BHg, cord) ↑ (HHg, maternal)
		Digit span	↔ (BHg, cord) ↔ (HHg, maternal)
		Spatial span	↑ (BHg, cord) ↑ (HHg, maternal)
		ST-BI copying	↔ (BHg, cord) ↔ (HHg, maternal)
		WISC-R (block design)	↔ (BHg, cord) ↔ (HHg, maternal)
		WISC-R (similarities)	↔ (BHg, cord) ↔ (HHg, maternal)
		BNT	↓ (BHg, cord) ↔ (HHg, maternal)
		CVLT	↔ (BHg, cord) ↔ (HHg, maternal)

Table 2-43. Results of Epidemiological Studies Evaluating Exposure to Methylmercury and Neurodevelopmental Effects—Prospective Birth Cohort in the Faroe Islands

Reference (listed in order of age at follow-up)	Biomarker	Outcome evaluated	Result[a]
Julvez et al. 2010; Debes et al. 2006 Follow-up at age 14 years (n=860)	BHg Gmean Cord: 22.5 µg/L Child (age 7 years): 9.00 µg/L Child (age 14 years): 4.08 µg/L HHg Gmean Maternal: 4.21 µg/g Child (age 7 years): 2.99 µg/g Child (age 14 years): 0.92 µg/g	NES CPT (reaction time during 1–2 minutes of testing)	↔ (BHg, cord) ↔ (BHg, child) ↔ (HHg, maternal) ↔ (HHg, child)
		NES CPT (reaction time during 3–6 minutes of testing)	↑ (BHg, cord) ↔ (BHg, child) ↑ (HHg, maternal) ↔ (HHg, child)
		NES CPT (reaction time during 7–10 minutes of testing)	↑ (BHg, cord) ↔ (BHg, child) ↑ (HHg, maternal) ↔ (HHg, child)
		NES CPT (reaction tine during 3–10 minutes of testing)	↑ (BHg, cord) ↔ (BHg, child) ↑ (HHg, maternal) ↔ (HHg, child)
Murata et al. 2004a Follow-up at age 14 years (n=859)	BHg Gmean: Cord: 22.6 µg/L HHg median Maternal: 4.22 µg/g Child (age 14 years): 0.96 µg/g	BAEPL	↑ (BHg, cord) ↑ (HHg, maternal) ↑ (HHg, child)
Debes et al. 2016 Follow-up at age 22 years (n=814)	BHg Gmean Cord: 22.91 µg/L Child (age 22 years): 2.53 µg/L HHg Gmean Maternal: 4.24 µg/g Child (age 22 years): 0.68 µg/g	WJTA (concept formation)	↔ (BHg, cord) ↔ (HHg, maternal)
		WJTA (synonyms, antonyms)	↓ (BHg, cord) ↓ (HHg, maternal)
		WJTA (numbers reversed)	↔ (BHg, cord) ↔ (HHg, maternal)
		WJTA (word memory)	↔ (BHg, cord) ↔ (HHg, maternal)
		WJTA (spatial)	↔ (BHg, cord) ↔ (HHg, maternal)
		WMS (spatial span)	↔ (BHg, cord) ↔ (HHg, maternal)
		WISC-R (block design)	↔ (BHg, cord) ↔ (HHg, maternal)

Table 2-43. Results of Epidemiological Studies Evaluating Exposure to Methylmercury and Neurodevelopmental Effects—Prospective Birth Cohort in the Faroe Islands

Reference (listed in order of age at follow-up)	Biomarker	Outcome evaluated	Result[a]
		CVLT	↔ (BHg, cord) ↔ (HHg, maternal)
		WFRT	↔ (BHg, cord) ↔ (HHg, maternal)
		RSPM	↓ (BHg, cord) ↓ (HHg, maternal)
		BNT	↓ (BHg, cord) ↔ (HHg, maternal)
		NES CPT (reaction time)	↔ (BHg, cord) ↔ (HHg, maternal)
		NES (finger tapping)	↔ (BHg, cord) ↔ (HHg, maternal)

[a]Interpretation of neurobehavioral test scores:
  Age of crawling, sitting or walking: increased age = delay in development
  BAEPL: higher score = lower performance
  BVMGT: higher score = lower performance
  BNT: higher score = higher performance
  CATSYS FTT: higher score = higher performance
  CBCL: higher score = lower performance
  CVLT: higher score = higher performance
  Digit span: higher score = higher performance
  HRV: higher score = lower performance
  NES CPT: longer response time = lower performance
  NES FTT: higher score = higher performance
  NES HECT: higher score = higher performance
  Neurologic optimality score: higher score = higher performance
  NVAPMS: higher score = more negative mood
  Postural sway: higher score = lower performance
  RSPM: higher score = lower performance
  Spatial span: higher score = higher performance
  ST-BI copying: higher score = higher performance
  VEPL: higher score = lower performance
  WFRT: higher score = higher performance
  WISC-R: higher score = higher performance
  WJTA: higher score = higher performance
  WMS: higher score = higher performance

↑ = positive association; ↓ = inverse association; ↔ = no association; BAEPL = Brainstem auditory evoked potential latencies; BHg = blood mercury; BNT = Boston naming test; BVMGT = Bender Visual Motor Gestalt Test; CATSYS FTT = Catsys (equipment name) Finger Tapping Test; CBCL = Child Behavior Checklist; CPT = Continuous Performance Test; CVLT = California Verbal Learning Test; FTT = Finger Tapping Test; Gmean = geometric mean; HECT = Hand Eye Coordination Test; HHg = hair mercury; HRV = heart rate variability; NES = Neurobehavioral Evaluation Systems; NVAPMS = Nonverbal Analogue Profile of Mood States; RSPM = Raven Standard Progressive Matrices; SDQ = Strengths and Difficulties Questionnaire; ST-BI = Stanford-Binet; VEPL = visual evoked potential latencies; WFRT = Warrington's Face Recognition Test; WISC-R = Wechsler Intelligence Scale for Children, Revised; WJTA = Woodcock-Johnson Test of Achievement; WMS = Wechsler Memory Scale

2. HEALTH EFFECTS

Neurodevelopmental outcomes were assessed using a variety of tests that changed as the children aged. These included tests of learning and memory, visual-motor function, auditory function, autonomic nervous function, developmental milestones (e.g., sitting, crawling, standing), intellectual achievement, and behavior. Outcome associations were adjusted for covariates that included (in most studies, depending on the outcome measured): child age, sex, and birth weight; breastfeeding; maternal age, alcohol and tobacco use, and medical history; and caregiver general intelligence (Raven's Progressive Matrices).

The Faroe Islands study found associations between prenatal (cord) BHg and decreasing performance on tests of cognitive function assessed at age 7 years (Grandjean et al. 1997, 1998, 2003, 2014; Oulhote et al. 2019), 14 years (Debes et al. 2006; Julvez et al. 2010), and 22 years (Debes et al. 2016). The associations were not consistently observed in all tests of cognitive function and tended to cluster in domains of fluid reasoning (e.g., identifying rules for visual similarities and differences), comprehension and knowledge (e.g., naming, word synonyms and antonyms), decision and reaction speed, and motor coordination (Debes et al. 2016). For example, tests that consistently showed associations with cord mercury included the Boston Naming Test, Woodcock-Johnson test of synonyms and antonyms, Neurobehavioral Evaluation Systems Continuous Performance Test Hit Reaction Time latencies, and Neurobehavioral Evaluation Systems Finger Tapping test. At ages 7 and 14 years, the size of the effect was estimated to be approximately 5–10% of the test score SD per doubling of cord BHg (Debes et al. 2006; Grandjean et al. 1997, 1999; Oulhote et al. 2019). Latencies of brainstem auditory evoked potentials measured at age 7 or 14 years increased in association with increasing prenatal or child HHg (Grandjean et al. 1997; Murata et al. 2002, 2004a). BMD modeling was applied to auditory evoked potentials observed at age 7 and 14 years (Murata et al. 2002, 2004a). At age 7 years, estimated BMDLs ranged from 7 to 9 µg Hg/g maternal HHg when the background response probability was 0.05 and the quantal BMR was 0.05; and from 12 to 14 µg Hg/g when the BMR was 0.1. At age 14 years, the BMDL was 10 µg Hg/g for BMR 0.1 and 0.05 background response. When the data from the 7-year follow-up of the Faroes study was combined with the data from the Madeira Portugal study (described below), the BMDL (BMR 0.1) ranged from 16 to 17 µg Hg/g hair (Murata et al. 2002).

A variety of factors have been explored to assess potential bias in the associations observed in the Faroe Islands study. Exposure measurement error based on estimation of biomarker imprecision was estimated to exceed laboratory measurement error, which would tend to attenuate dose-slopes and bias estimates of effect sizes downward (Grandjean and Budtz-Jorgensen 2007; Grandjean et al. 2004b). The observed associations with cognitive test outcomes persisted after excluding subjects who had large variability in

HHg during pregnancy (Grandjean et al. 2003). Postnatal HHg correlated with duration of breastfeeding; however, breastfeeding was not a significant explanatory variable for cognitive test outcomes in the cohort (Grandjean et al. 1995; Jensen et al. 2005). Blood selenium levels correlated with BHg levels and whale consumption (Grandjean et al. 1992); however, prenatal selenium level (cord blood) was not a significant explanatory variable for cognitive test outcomes in the cohort (Choi et al. 2008b). Cord blood PCB concentration correlated with BHg levels; however, associations between cord BHg levels and cognitive tests scores persisted after adjustment for cord blood PCB concentrations (Grandjean et al. 1997). Analysis of data from the 7-year follow-up found no evidence of interactions between mercury and exposure to PCBs and long-chain perfluoroalkyls (Oulhote et al. 2019). Adjustment for cord serum Ω-3 LCPUFA strengthened associations between prenatal mercury exposure and cognitive test scores or brainstem evoked potential latencies (Yorifuji et al. 2013). Improved cognitive performance was associated with higher aerobic capacity (maximum oxygen utilization; VO_{2Max}); however, the association was attenuated with increasing prenatal mercury exposure (Oulhote et al. 2017b).

North Island New Zealand. A prospective study of methylmercury exposure and neurodevelopmental outcomes was conducted in North Island, New Zealand (Kjellstrom et al. 1989). The original cohort consisted of 10,930 children and mother pairs recruited in 1978. Consumption of marine fish was the major contributor to methylmercury exposure in this population. The prenatal exposure metric was that average total mercury in maternal hair during pregnancy. A subset of 935 high consumer subjects was selected based on consumption >3 fish meals per week. HHg levels in this group ranged from 0.24 to 86.4 µg Hg/g. A high exposure subset of 73 high consumers was selected based on HHg >6 µg Hg/g, from which 38 were tested at age 4 years, along with a set of 31 matched referents from mothers who consumed no more than one fish meal per week and matched for maternal ethnic group, age, residence time in New Zealand, tobacco smoking, and child birth date and sex. Assessment of neurodevelopmental outcomes occurred at age 4 and 6 years. Mean HHg was 8.8 µg Hg/g (range 6.0–86.4 µg Hg/g) in the high exposure group and 1.9 µg Hg/g (range 0.5–6.1 µg Hg/g) in the reference group. At age 4 years, children were assessed for performance on the Denver Developmental Screening Test (DDST; function, language, and personal-social behavior), Sheridan-Gardiner Letter Matching Test or Miniature Toy Test (vision), and tactile sensory function (touch, temperature), and the parent was surveyed with a questionnaire on child health and neurological signs (Kjellstrom et al. 1986). The OR for abnormal or questionable scores on the DDST at age 4 years (n=31, relative matched referents) was 6.5 (p<0.005). Performance of high-exposure children on vision and sensory function tests were not different from matched referents.

At age 6 years, 61 children in the high-exposure group were re-evaluated along with a set of 3 referent groups (n=58–60), each matched with the high-exposure group for maternal ethnic group, age, residence time in New Zealand, tobacco smoking, and child birth date and sex (Kjellstrom et al. 1989). Geometric mean maternal HHg was 8.3 µg Hg/g (range 6–86 µg Hg/g) in the high-exposure group (follow-up Group 1). HHg levels in the three referent groups were as follows: Group 2 (consumed >3 fish meals per week): 4.5 µg Hg/g (range 3–6 µg Hg/g); Group 3 (consumed >3 fish meals per week): 2.0 µg Hg/g (range 0.1–3 µg Hg/g), and Group 4 (consumed ≤3 fish meals per week): 2.0 (µg Hg/g (range 0.1–3 µg Hg/g). Geometric mean cord blood lead levels in the four groups were as follows: Group 1: 4.9 µg Pb/L (geometric standard deviation [GSD] 1.4); Group 2: 5.5 µg Pb/dL (GSD 1.3); Group 3: 6.5 µg Pb/dL (GSD 1.4); and Group 4: 5.7 µg Pb/dL (GSD 1.2). The study did not evaluate associations between blood lead levels and outcomes. Children were assessed for performance on tests of academic attainment, language development, motor coordination, intelligence, and behavior. Language development was assessed from performance on the Test of Language Development (TOLD; phonology, syntax, semantics) and Peabody picture vocabulary test (word knowledge). Intelligence was assessed using the McCarthy scales and Weschler Intelligence Scale for Children (WISC). Outcome associations were adjusted for significant covariates; variables explored included maternal ethnic group, age, smoking and alcohol consumption, residence time in New Zealand, social class, language spoken at home, siblings, duration of breastfeeding, and child sex, birth weight, maturity at birth, and Apgar score. Maternal HHg was associated with lower scores on the TOLD spoken language quotient (β -5.48, p=0.0064), WISC full-scale IQ (β -4.41, p=0.019), and McCarthy perceptual scale (β -4.23, p=0.0034). When the high-exposure group (Group 1) was split into two maternal HHg categories, 6–<10 or ≥10 µg Hg/g, a larger fraction of variance in the TOLD and WISC tests were explained by the higher HHg category. Performance on TOLD spoken language quotient was inversely associated with HHg in the lower HHg category, whereas performance on both the TOLD spoken language quotient and WISC full scale was inversely associated with HHg ≥10 µg Hg/dL. Children scored as having an abnormal Denver test at age 4 years had lower WISC full scale IQ scores at age 6 years.

Crump et al. (1998) analyzed data on 237 children from the original North Island New Zealand study (age 6–7 years) to estimate BMDLs for cognitive outcomes. The cohort included 61 children born to mothers who consumed fish more than 3 times per week and who had HHg ≥6 µg Hg/g, matched to 176 control children from mothers who had HHg <6 µg Hg/g (matched for ethnicity, place of residence of mother, and maternal smoking). Outcome measures used in the analysis were the scores on a subset of 5 of the 26 tests administered in the original study: TOLD (spoken language quotient), Wechsler Intelligence Scale (performance and full sale IQ), and McCarthy Scales of Children's Abilities (perceptual and motor).

Estimated BMDLs for the five tests ranged from 7.4 to 10 µg Hg/g when the background response probability was 0.05 and the quantal BMR was 0.1.

Nunavik region of arctic Canada. A prospective study of methylmercury exposure and neuro-developmental outcomes was conducted in the Nunavik region of arctic Canada (Nunavik study). A summary of the major outcomes of the Nunavik study are presented in Table 2-44. Consumption of marine fish and mammals was the major contributor to methylmercury exposure in the Nunavik population (Blanchet and Rochette 2008). The Nunavik study included a cohort of pregnant women recruited in 1995–2001, as part of the Nunavik Environmental Contaminants and Child Development Study (NECCDS), Arctic Cord Blood Monitoring Program (Muckle et al. 1998), and Nunavik Preschool Study (Saint-Amour et al. 2006). Assessment of neurodevelopmental outcomes began at age 6.5 months with periodic follow-ups, the most recent at age 11 years (Boucher et al. 2010, 2012a, 2012b, 2014, 2016; Despres et al. 2005; Ethier et al. 2012; Jacobson et al. 2015).

Table 2-44. Results of Epidemiological Studies Evaluating Exposure to Methylmercury and Neurodevelopmental Effects—Prospective Birth Cohort in the Nunavik Region of Arctic Canada

Reference (listed in order of age at follow-up)	Biomarker	Outcome evaluated[a]	Result
Boucher et al. 2010 Follow-up at age 11 years (n=118)	BHg mean Cord: 21.5 µg/L Child (11 years): 4.69 µg/L	Auditory oddball test	↔ (BHg, cord) ↔ (BHg, child)
		Test EEG ERP amplitude	↓ (BHg, cord) ↔ (BHg, child)
		Test EEG ERP latency	↑ (BHg, cord) ↔ (BHg, child)
Boucher et al. 2012a Follow-up at age 11 years (n=196)	BHg mean Cord: 21.2 µg/L Child (11 years): 4.6 µg/L	Go/no go test	↔ (BHg, cord) ↔ (BHg, child)
		Test EEG ERP amplitude	↔ (BHg, cord) ↔ (BHg, child)
		Test EEG ERP latency	↔ (BHg, cord) ↔ (BHg, child)
Boucher et al. 2012b Follow-up at age 11 years (n=279)	BHg mean Cord: 21.6 µg/L Child (11 years): 4.6 µg/L	TRF internalizing	↔ (BHg, cord) ↔ (BHg, child)
		TRF externalizing	↔ (BHg, cord) ↔ (BHg, child)
		TRF attention	↔ (BHg, cord) ↔ (BHg, child)
		ADHD inattentive	↑ (BHg, cord)
		ADHD hyperactive-impulsive	↑ (BHg, cord)
		ODD or CD	↔ (BHg, cord)

Table 2-44. Results of Epidemiological Studies Evaluating Exposure to Methylmercury and Neurodevelopmental Effects—Prospective Birth Cohort in the Nunavik Region of Arctic Canada

Reference (listed in order of age at follow-up)	Biomarker	Outcome evaluated[a]	Result
Boucher et al. 2014 Follow-up at age 6.5 and 11 months (n=94)	BHg mean Cord: 22.5 µg/L	FTII	0 (BHg, cord)
		A not B test	↓ (BHg, cord)
		BSID MDI	↔ (BHg, cord)
		BSID PDI	↔ (BHg, cord)

Boucher et al. 2016
 	
Follow-up at age 11 years (n=265)
	BHg mean
	  Cord: 21.4 µg/L
	  Child (11 years): 4.8 µg/L
		SAFB	↔ (BHg, cord)
			↔ (BHg, child)

		NES FTT	↔ (BHg, cord) ↓ (BHg, child)
		ST-BI copying	↔ (BHg, cord) ↔ (BHg, child)
Despres et al. 2005 Follow-up at age 4–6 years (n=110)	BHg mean Cord: 22.2 µg/L	Reaction time	↔ (BHg, cord)
		Postural sway	↔ (BHg, cord)
		Alternating movements	↔ (BHg, cord)
		Pointing tremor	↑ (BHg, cord)

Ethier et al. 2012
 	
Follow-up at age 11 years (n=149)
	BHg mean
	  Cord: 21 µg/L
	  Child (11 years): 5 µg/L
		VEP amplitude	↑ (BHg, cord)

		VEP latency	↑ (BHg, cord)

Jacobson et al. 2015
 	
Follow-up at age 11 years (n=282)
	BHg mean
	  Cord: 21.8 µg/L
	  Child (11 years): 4.7 µg/L
		WISC-IV (FSIQ)	↓ (BHg, cord)
			↔ (BHg, child)

[a]Interpretation of neurobehavioral test scores:
  A not B test: higher score = higher performance
  BSID MDI: higher score = higher performance
  BSID PDI: higher score = higher performance
  CD: higher score = more behavioral problems
  FTII: higher score = higher performance
  NES FTT: higher score = higher performance
  ODD: higher score = more behavioral problems
  SAFB: higher score = higher performance
  ST-BI copying: higher score = higher performance
  TRF: higher score = more behavioral problems
  WISC-IV: higher score = higher performance

↑ = positive association; ↓ = inverse association; ↔ = no association; ADHD = attention deficit/hyperactivity disorder; BHg = blood mercury; BSID = Bayley Scales of Infant Development; CD = Conduct Disorder; EEG ERP = electroencephalogram event related potential; FSIQ = full scale intelligence quotient; FTII = Fagan Test of Infant Intelligence; MDI = BSID Mental Development Index; NES = Neurobehavioral Evaluation Systems; FTT = Finger Tapping Test; ODD = Oppositional Deviant Disorder; PDI = BSID Psychomotor Development Index; SAFB = Santa Ana Form Board; ST-BI = Stanford-Binet; TRF = Teacher Report Form; VEP = visual evoked potential; WISC-IV = Wechsler Intelligence Scale for Children, 4th edition

The primary methylmercury prenatal exposure metric has been total mercury in cord blood. Based on results from the Arctic Cord Blood Monitoring Program, the geometric mean (GM) cord BHg concentration was 23 µg Hg/L and the IQR was 12–27 µg Hg/L (Muckle et al. 2001). Cord BHg levels (µg Hg/L) were approximately 5 times maternal HHg measured during the third trimester (GM 4.4 µg Hg/g; IQR 2.4, 6.0) (Muckle et al. 2001). Based on a dietary survey of Nunavik population, the average daily consumption was approximately 50 g/day of fish and 22 g/day of marine mammals (Blanchet and Rochette 2008).

Neurodevelopmental outcomes were assessed using a variety of tests that changed as the children aged. These included tests of learning and memory, visual-motor function, auditory function, and behavior problems (e.g., attention deficit/hyperactivity disorder). Outcome associations were adjusted for covariates that included (in most studies, depending on the outcome measured): sex; age at testing; cord and current blood lead, selenium, DHA, and PCBs; SES; maternal marital status; education; caregiver general intelligence (Raven's Progressive Matrices); tobacco smoking and marijuana use during pregnancy; and HOME score.

The Nunavik study found associations between increasing prenatal (cord) BHg and slower reaction times in tests of visual and auditory information processing tasks (Boucher et al. 2010, 2014, 2016; Ethier et al. 2012), pointing tremor (Despres et al. 2005), full scale IQ (Jacobson et al. 2015), and higher symptom scores for attention deficit/hyperactivity disorder (Boucher et al. 2012b). In some studies of information processing, increased latency of electrophysiological (e.g., EEG) event response potentials were evident, suggesting a possible effect of exposure on behavioral reaction time (Boucher et al. 2010, Ethier et al. 2012). At age 11 years, the size of the mercury effect on IQ (WISC) was a decrease of 4.8 points in children whose cord BHg had been ≥7.5 µg Hg/L, compared to children whose cord BHg had been <7.5 µg Hg/L (Jacobson et al. 2015).

A variety of factors have been explored to assess potential bias in the associations observed in the Nunavik study. Cord BHg was correlated with cord PCB, lead, selenium, and DHA levels (Boucher et al. 2010). Cord PCB levels were independently associated with many of the outcomes measured. In some studies, associations with cord mercury were no longer evident when cord or child blood PCB levels were included as covariates (Boucher et al. 2012a, 2016; Despres et al. 2005). Cord PCBs and lead interacted with cord mercury in explaining variance in some cognitive outcomes (Boucher et al. 2012a). Nutrients such as cord blood DHA and selenium tended to strengthen associations between cord mercury levels and response latency and IQ outcomes (Boucher et al. 2010; Jacobson et al. 2015). When stratified by

breastfeeding duration, children who were breastfed for <3 months tended to show stronger associations with cord mercury levels (Boucher et al. 2010). These observations suggest that associations between cognitive performance outcomes and prenatal mercury exposures can be modified by co-exposure to other agents that may independently affect cognitive performance (e.g., PCBs, lead, nutrients).

Amazonian riverine populations. Studies of methylmercury exposure and neurodevelopmental outcomes have been conducted in populations living in Amazon River basins (Amazonian studies). These include several cross-sectional studies of children from birth cohorts who resided in various river basins, with neurodevelopmental assessments in infancy and various later ages, with the oldest cohort being 14 years of age. Exposure to methylmercury in these populations derived primarily from methylation of inorganic mercury released to local aquatic ecosystems from alluvial gold mining (Marques et al. 2007). A summary of the major outcomes of the Amazonian studies are presented in Table 2-45.

Table 2-45. Results of Epidemiological Studies Evaluating Exposure to Methylmercury and Neurodevelopmental Effects—Amazonian River Basin Studies

Reference, study type, and population	Biomarker	Outcome evaluated	Result[a]
Hoshino et al. 2015 Cross-sectional cohort of 58 individuals (age range 1–47 years); Brazil	HHg median 10.91 µg/g	Tympanometry	↔ HHg
		Acoustic reflexes	↔ HHg
		Pure tone audiometry	↔ HHg
		Transient otoacoustic emissions	↔ HHg

Marques et al. 2007
 	
Prospective study of birth cohort, follow-up at age 6 months (n=100); Brazil
	HHg median
	  Maternal: 5.40 µg/g
	  Child (birth): 1.59 µg/g
	  Child (6 months): 1.81 µg/g
		GDS	↔ (HHg, birth)
			↔ (HHg, 6 months)

Marques et al. 2015
 	
Prospective study of birth cohort, follow-up at age 6 months (n=294), Brazil
	HHg median (female, male)
	  Child (birth): 0.79, 0.81 µg/g
	  Child (6 months): 0.98, 0.97 µg/g
		BSID MDI	↔ (HHg, birth)
			↔ (HHg, 6 months)

		BSID PDI	↔ (HHg, birth) ↔ (HHg, 6 months)

Marques et al. 2015
 	
Prospective study of birth cohort, follow-up at age 24 months (n=294); Brazil
	HHg median (female, male)
	  Child (birth): 0.79, 0.81 µg/g
	  Child (6 months): 0.98, 0.97 µg/g
	  Child (24 months): 1.75, 1.72 µg/g
		BSID MDI	↔ (HHg, birth)
			↔ (HHg, 6 months)
			↔ (HHg, 24 months)

		BSID PDI	↔ (HHg, birth) ↔ (HHg, 6 months) ↔ (HHg, 24 months)

Table 2-45. Results of Epidemiological Studies Evaluating Exposure to Methylmercury and Neurodevelopmental Effects—Amazonian River Basin Studies

Reference, study type, and population	Biomarker	Outcome evaluated	Result[a]

Dorea et al. 2012
 	
Cross-sectional cohort study of children, 1–6 months of age (n=281); Brazil
	HHg mean (infant)
	  Itapua: 3.95 µg/g
	  Bom Futuro: 1.85 µg/g
	  Porto Velho: 3.84 µg/g
		GDS	↔ (HHg, current age)

Cordier et al. 2002
 	
Cross-sectional cohort of children age 5–12 years (n=378); French Guiana
	HHg geometric mean (maternal)
	  Upper Maroni: 12.7 µg/g
	  Camopi: 6.7 µg/g
	  Awala: 2.8 µg/g
		ST-BI copying	↓ (HHg, maternal)

		NES FTT	↔ (HHg, maternal)
		Leg coordination	↔ (HHg, maternal)
		Digit span (forward)	↔ (HHg, maternal)

Chevrier et al. 2009
 	
Pooled analysis of children, age 7 to 12 years (n=395); Brazil, French Guiana
	HHg mean
	  Maternal: 10.3 µg/g
	  Child: 9.8 µg/g
		ST-BI copying error	↑ (HHg, maternal)
			↑ (HHg, child)

Dorea et al. 2014
 	
Cross-sectional cohort study of children, 12–24 months of age (n=299); Brazil
	HHg median (infant)
	  Itapua: 3.5 µg/g
	  Bom Futuro: 2.2 µg/g
		GDS	↔ (HHg, infant)

		Age of talking	↔ (HHg, current age)
		Age of walking	↔ (HHg, current age)

dos Santos Freitas et al. 2018
 	
Cross-sectional cohort study of children, 7–14 years of age (n=176); Brazil
	HHg mean (child)
	  Tapajos basin: 4.5 µg/g
	  Tocantins basin: 0.49 µg/g
		Color vision	↔ (HHg, current age)

dos Santos-Lima et al. 2020 Cross-sectional cohort study of children, 6–14 years of age (n=263); Brazil	HHg mean (child) 3.1 µg/g	WISC IQ	↓ (HHg, child)
		WISC digit span	↓ (HHg, child)
		Block tapping	↓ (HHg, child)
		Phonology	↓ (HHg, child)
		Word generation	↓ (HHg, child)

Table 2-45. Results of Epidemiological Studies Evaluating Exposure to Methylmercury and Neurodevelopmental Effects—Amazonian River Basin Studies

Reference, study type, and population	Biomarker	Outcome evaluated	Result[a]
Reuben et al. 2020	HHg mean (child) 2.06 µg/g	Visual-motor integration	↔ (HHg, child)
Longitudinal cohort study of children, 5–12 years of age (n=163); Peru		Cognitive ability	↓ (HHg, child)

[a]Interpretation of neurobehavioral test scores:
  Block tapping: higher score = higher performance
  BSID MDI: higher score = higher performance
  BSID PDI: higher score = higher performance
  Digit span: higher score = higher performance
  GDS: higher score = higher performance
  NES FTT: higher score = higher performance
  Phonology: higher score = higher performance
  ST-BI copying: higher score = higher performance
  ST-BI copying error: higher error score = lower performance
  Word generation: higher score = higher performance

↑ = positive association; ↓ = inverse association; ↔ = no association; BSID = Bayley Scales of Infant Development; HHg = hair mercury; GDS = Gesell Developmental Scales; IQ = intelligence quotient; MDI = BSID Mental Development Index; NES FTT = Neurobehavioral Evaluation System Finger Tapping Test; PDI = BSID Psychomotor Development Index; ST-BI = Stanford-Binet Bead Memory test; WISC = Wechsler Intelligence Scales for Children

The primary methylmercury prenatal exposure metric in these studies has been total mercury in hair. In riverine populations in the Madeira Basin, the median maternal HHg was 12 µg Hg/g (range 1– 131 µg Hg/g) and correlated with newborn HHg (median 3 µg Hg/g; range 0.1–19 µg Hg/g) (Marques et al. 2013a). In the Madeira Basin population, the median number of fish meals per week was 5 (range 0–7) and number of fish meals per week correlated with maternal HHg (Marques et al. 2013b). Neurodevelopmental outcomes were assessed using a variety of tests that changed as the children aged. These included developmental milestones (e.g., age of talking and walking) and tests of learning and memory, vision, and visual-motor function. Outcome associations were adjusted or stratified for covariates that included (in most studies, depending on the outcome measured): sex, age at testing, breastfeeding, SES, maternal marital status, education, general intelligence caregiver general intelligence (Raven's Progressive Matrices), tobacco smoking, and HOME score.

Studies of Amazonian populations have found associations between prenatal (maternal) or child HHg and performance on tests of cognitive ability (Chevrier et al. 2009; Cordier et al. 2002; dos Santos-Lima et al. 2020; Reuben et al. 2020,). A study of families residing in an artisanal and small-scale gold mining

region of Amazonian Peru evaluated associations between child (mean age 8 years; n=163) HHg and visual-motor coordination, general cognitive ability, and physical health (Reuben et al. 2020). The mean HHg was 2.06 µg Hg/g (range 0.08, 14.61). Increasing HHg was associated with decreasing scores of the Spanish language Woodcock-Johnson Tests of Cognitive Abilities (β = -2.59 points per ln[µg Hg/g hair], 95% CI -4.52, -0.66). In a pooled analysis of children, age 7–12 years, from Amazonian Brazil and French Guiana, the size of the association was an increase of 1.2 in error score on the Stanford-Binet copying test for an increase in child HHg concentration of 10 µg Hg/g (Chevrier et al. 2009). In a population from Amazonian Brazil, age 5–12 years, the effect was a decrease of 2.98 in performance score on the on the Stanford-Binet copying test for an increase in child HHg concentration of 10 µg Hg/g (Cordier et al. 2002). In a cross-sectional study of children 6–14 years of age, increasing HHg was associated with decreasing WISC IQ (dos Santos-Lima et al. 2020). Scores on other tests of cognitive development were not associated with mercury exposure, including Bayley Scales of Infant Development at age 6–12 months (Marques et al. 2015), Gesell Development Scales at age 6–20 months (Dorea et al. 2012, 2014; Marques et al. 2015), age of talking or walking (Dorea et al. 2014), various tests of visual-motor coordination at age 5–12 years (Cordier et al. 2002), or color vision at age 7–14 years (dos Santos Freitas et al. 2018). The above studies did not explore the potential impacts of other exposures (e.g., lead, PCBs) or nutritional factors that may have also correlated with fish consumption.

Madeira, Portugal. Cognitive function was studied in a cross-sectional cohort of 149 mothers and children who resided in Madeira, a fishing village in Portugal (Murata et al. 1999a, 2004b). Fish consumption was a major contributor to exposure to methylmercury in this population. Maternal fish consumption ranged from <1 meal per week (25%) to ≥5 meals/week and correlated with maternal HHg (22%; Murata et al. 1999a). Increasing maternal HHg (median 9.6 µg Hg/g) was associated with delays in brainstem auditory and visual evoked potentials measured at age 7 years. Murata et al. (2002) estimated BMDLs (BMR 0.1) of 14 and 19 µg Hg/g hair for the increased latency of auditory evoked potentials. When the data from the Madeira cohort were combined with the data from the 7-year follow-up of the Faroe Islands study, BMDL estimates (BMR 0.1) ranged from 16 to 17 µg Hg/g hair (Murata et al. 2002).

Artisanal gold mining. Studies have been conducted of neurodevelopment outcomes in populations exposed to mercury released from artisanal gold mining operations (Counter 2003; Counter et al. 1998, 2002, 2006, 2012; Nyanza et al. 2021; Ramirez et al. 2000, 2003; Reuben et al. 2020). In artisanal mining, gold is extracted from a substrate (e.g., pulverized ore, sediment, soil) by mixing the substrate with elemental mercury to form mercury-gold amalgam. The amalgam is washed, sedimented, and

roasted to vaporize the elemental mercury out of the amalgam. This process can result in direct exposures of mine workers to mercury vapor. Exposures of the general population to methylmercury can also occur as a result of methylation of inorganic mercury released to local aquatic ecosystems (Ramirez et al. 2000). Although human exposures to wastes from artisanal goldmines can be a mixture of elemental mercury, inorganic mercuric mercury, and methylmercury, studies of neurodevelopmental outcomes in children residing near gold mine operations are included in the discussion of epidemiological studies of methylmercury because methylmercury is likely to have been a major source of exposures in these populations (Counter et al. 1998; Ramirez et al. 2000).

A prospective study examined developmental milestones and cognitive performance in children from a birth cohort of 78 pregnancies in an area in Philippines where mercury amalgam was used to extract gold from ore (Tagum study) (Ramirez et al. 2000, 2003). In a subset of the cohort (n=12), the mean cord BHg level was 53 µg Hg/L (range 20–130 µg Hg/L). The mean level in fetal meconium (n=36) was 49 µg Hg/L (range 20–200 µg Hg/L). The follow-up conducted at age 2 years (n=48) evaluated cognitive performance based on a cognitive adaptive test (CAT), clinical linguistic auditory milestone scale (CLAMS), and full-scale developmental quotient (FSDQ), and compared outcomes to a control group (from Saranggani, a coastal area not impacted by gold mining waste). Mean BHg levels in the children were higher in the control group (3.25 µg Hg/L) compared to the children from the Tagum region (2.6 µg Hg/L); however mean HHg were higher in the Tagum area (1.28 µg Hg/g) compared to the control group (0.66 µg Hg/g). Mean scores on CAT, CLAMS, and FSDQ were lower in the exposed group. ORs (not adjusted for potential covariates) for "abnormal scores" with the control group (n=88) as the reference, were 4.8 (95% CI 2.03, 11.4) for CLAMS, 1.26 (95% CI 0.32, 1.97) for CAT, and 3.10 (95% CI 0.85, 11.2) for FSDQ. Adjusted ORs were not reported, although a comparison of means between the exposed and control groups were reported for various SES and childcare variables.

A study of families living in an artisanal and small-scale gold mining area of Peru evaluated performance in children at mean age 8 years (n=163; Reuben et al. 2020). The study evaluated associations between child HHg and visual-motor integration, cognitive ability, and physical health. The mean HHg was 2.06 µg Hg/g (range 0.08, 14.61). Decreasing general cognitive ability, measured by a Spanish-language Woodcock-Johnson Tests of Cognitive Abilities, was associated with increasing HHg after adjustment for potential confounding variables (β, -2.59 points per ln µg/g; 95% CI -4.52, -0.66).

Several cross-sectional studies of children residing near gold mining operations in Ecuador have been conducted (Counter et al. 1998, 2002, 2006, 2012). These studies were largely ecological in design in

that they compared mean outcomes between children who resided near gold mines and had higher mercury levels than a control group that did not reside near goldmines. In general, associations between outcomes and BHg (or HHg) were not adjusted for potential covariates. In a population from the Nambija gold mining area, the mean BHg level (n=77; mean age 9 years) was 18 µg Hg/L (range 2–89 µg Hg/L) (Counter et al. 2002). Brainstem auditory evoked responses in children who had BHg levels >20 µg Hg/L (median) showed longer latencies than in children who had BHg levels <20 µg Hg/L (Counter 2003). Children from the Nambija and Portovelo mining areas had lower scores on the Raven's Coloured Progressive Matrices (RCPM), a test of visual-spatial processing, than children from other areas (e.g., Peru, Puerto Rico, United States) (Counter et al. 2006). RCPM scores were also lower among children who had BHg levels >5 µg Hg/L or HHg >2 µg Hg/g compared to children who had lower mercury levels (Counter et al. 2006). Increasing brainstem-mediated acoustic stapedius reflex thresholds in children correlated with increasing BHg (Counter et al. 2012).

A prospective birth cohort that resided in an artisanal gold mining areas of Tanzania assessed Bayley Scales of Infant Development (BSID) scores in infants at age 6–12 months (Nyanza et al. 2021). Increasing maternal BHg levels (median 1.2 µg/L) were associated with increasing prevalence ratio of impaired language, social behavior, and global neurodevelopment.

Meta-analyses. Cohen et al. (2005) conducted a meta-analysis of outcomes of the Faroe Islands study, Seychelles Child Development Study, and North Island New Zealand study. Outcomes from various domains of cognitive function were aggregated into a weighted IQ metric and the meta outcome was expressed as the change in IQ points as a fraction of the outcome SD per 1 µg Hg/g increase in maternal HHg. The meta average effect size was a decrease in 0.043 SD per µg Hg/g. For a SD of 15 IQ points, the meta estimate corresponds to approximately 0.7 IQ points per µg Hg/g (range 0–1.5 IQ points per µg Hg/g). A follow-up to the Cohen et al. (2005) meta-analysis included outcomes from the Faroe Islands study at age 7 years, Seychelles Child Development Study at age 9 years, and North Island New Zealand study at age 6 years (Axelrad et al. 2007a, 2007b; Ryan 2008). The meta estimate for the effect size was -0.18 IQ points per increase of 1 µg Hg/g hair (95% CI -0.378, -0.009). Murata et al. (2002) pooled data on auditory evoked potentials observed at age 7 years in the Faroe Islands and Madeira Portugal studies and estimated BMDLs (BMR 0.1) that ranged from 16 to 17 µg Hg/g hair.

Organic Mercury—Animals Studies. Numerous studies have identified the nervous system as a target of methylmercury toxicity in nonhuman primates and rodents following developmental exposures. Collectively, these studies provide conclusive evidence that methylmercury is associated with adverse neurodevelopmental effects. Neurodevelopmental effects are observed at doses at or below those associated with adverse neurological effects of exposure during adulthood.

Neurodevelopmental effects have been reported in macaque monkeys following prenatal and/or postnatal exposure to methylmercury compounds (Table 2-46). The most sensitive effects were impaired spatial visual discrimination and progressive hearing loss at doses ≥0.01 mg Hg/kg/day (Burbacher et al. 2005; Rice 1998a; Rice and Gilbert 1992); no impairments in peripheral vision and no negative changes in temporal visual discrimination were observed at 0.05 mg Hg/kg/day (Rice and Gilbert 1982, 1990). Mild deficits in operant training were observed in adult monkeys exposed to 0.04–0.08 mg Hg/kg/day during gestation; however, a NOAEL/LOAEL determination cannot be made because the study authors combined all exposed monkeys for data presentation and analysis (Gilbert et al. 1996). In other studies, no impairments in operant training were observed following pre- and postnatal exposure to 0.05 mg Hg/kg/day (Rice 1998b; Rice and Hayward 1999). Overt clinical signs of neurotoxicity were observed at developmental exposures ≥0.05 mg Hg/kg/day (Rice and Gilbert 1990; Willes et al. 1978) and diffuse neuronal degeneration in the cerebral cortex (especially the calcarine, insular, pre-, and postcentral gyri, and occipital lobe), cerebellum, basal ganglia, thalamus, amygdala, and lateral geniculate nuclei were observed at developmental exposures of 0.5 mg Hg/kg/day (Willes et al. 1978).

Table 2-46. Neurodevelopmental Effects[a] in Male and Female Primates Following Oral Exposure to Methylmercury Compounds

Species (sex), exposure duration, and time of examination	Overt clinical signs[b]	Learning/ memory[b]	Auditory function[b]	Visual function[b]	Neuro-pathology[b]	Reference (compound)
Macaca fascicularis; up to 29 days from birth; examined 2 weeks post-exposure	+ L: 0.5 (8.0–9.4)	–	–	–	+ L: 0.5 (8.0–9.4)	Willes et al. 1978 (MMC)
M. fascicularis; 165 days during gestation; examined at 8–15 years	–	↓ L: 0.04–0.08[c] (1.04–2.45)	–	↓ L: 0.04–0.08[c] (1.04–2.45)	–	Burbacher et al. 2005; Gilbert et al. 1996 (MMH)

Table 2-46. Neurodevelopmental Effects[a] in Male and Female Primates Following Oral Exposure to Methylmercury Compounds

Species (sex), exposure duration, and time of examination	Overt clinical signs[b]	Learning/ memory[b]	Auditory function[b]	Visual function[b]	Neuro-pathology[b]	Reference (compound)
M. fascicularis; up to 1,460 days from birth (i.e., 4 years old); examined at 3– 5.5 years	–	–	–	↓ L: 0.05 (0.6–0.9)	–	Rice and Gilbert 1982; Rice and Gilbert 1990 (MMC)
M. fascicularis; up to 1,625 days from gestation through age 4 years; examined at 4.3–19 years	+ L: 0.05 (0.8)	↔ N: 0.05 (0.8)	↓ L: 0.01 (0.21)	↓ L: 0.01 (0.21)	–	Rice 1998a; Rice and Gilbert 1990 (MMC)
M. fascicularis; up to 2,555 days from birth (i.e., 7 years old); examined at 10– 20 years	–	↔ N: 0.05 (0.8)	–	↔ N: 0.05 (0.8)	–	Rice 1998b; Rice and Hayward 1999 (MMC)

[a]Studies with exposure prior to puberty only, including studies that evaluate adult animals after developmental exposure. These findings are listed under "Develop" in the LSE table.
[b]NOAEL (N) or LOAEL (L) for dose administered in mg Hg/kg/day (blood level in mg Hg/L).
[c]The study authors combined dose groups for data presentation and analysis; NOAEL/LOAEL determinations could not be made.

↓ = decreased; ↔ = no change; – = not assessed; + = present; Develop = developmental; LOAEL = lowest-observed-adverse-effect level; LSE = Levels of Significant Exposure; MMC = methylmercuric chloride; MMH = methylmercury hydroxide; NOAEL = no-observed-adverse-effect level

Twenty studies have evaluated neurobehavioral effects in rodents following acute-duration developmental exposure to methylmercury compounds during gestation or early postnatal periods (Table 2-47). Reported exposure-related effects included decreased motor activity and coordination, impaired learning and memory, delayed or altered reflexes, and altered nocturnal rhythms; findings for anxiety were inconsistent (some reported an increase, others a decrease). In most acute-duration neurodevelopmental studies in rodents, no overt clinical signs of neurotoxicity were reported. Exceptions were "abnormal" walking posture and transient lethargy and ataxia observed in neonatal mice following a single exposure to 16 mg Hg/kg/day during gestation or early postnatal development (Inouye et al. 1985; Post et al. 1973) and hindlimb paralysis and dystonia in neonatal rats exposed to 8 mg Hg/kg/day on PNDs 14–23 (Sakamoto et al. 2020). In rats, the most sensitive effect was impaired operant conditioning (associative learning which is learning by association) following exposure to 0.008 mg Hg/kg/day during GDs 6–9 (Bornhausen et al. 1980). In mice, the most sensitive effects were noted at a comparable gestational dose

of 0.009 mg Hg/kg/day (during GDs 8–18), and included hypoactivity, impaired motor coordination, impaired spatial learning, and increased anxiety (Montgomery et al. 2008).

Table 2-47. Neurobehavioral Effects in Rodents Following Acute-Duration Oral Exposure to Methylmercury Compounds During Development

Species; duration	Motor activity, coordination[a]	Anxiety[a]	Associative learning[a]	Spatial/ working learning and memory[a]	Other[a]	Reference (compound)
Gestational exposure						
Rat; 1 day, GD 15	↔ (N: 6.4)	–	↓ (L: 6.4)	–	–	Cagiano et al. 1990; Zanoli et al. 1994 (MMC)
Rat; 1 day, GD 8 or 15	↓ (L: 7)	↔ (N: 7)	↓ (L: 7)	↓ (L: 7)	Reflexes, ASR, PPI ↔ (N: 7)	Carratu et al. 2006, 2008 (MM)
Rat; 4 days, GDs 6–9	–	–	↓ (L: 0.008)	–	–	Bornhausen et al. 1980 (MMC)
Rat; 4 days, GDs 6–9	↓ (L: 4)	–	0 (L: 4)	↓ (L: 4)	ASR ↑ (L: 4)	Stoltenburg-Didinger and Markwort 1990 (MMC)
Rat; 4 days, GDs 6–9	↔ (N: 1.9)	–	–	↔ (N: 1.9)	Reflexes ↔ (N: 1.9)	Fredriksson et al. 1996 (MM)
Mouse; 1 day, GD 8	↔ (N: 5)	–	↓ (L: 3)	↔ (N: 5)	–	Hughes and Annau 1976 (MMH)
Mouse; 1 day, GD 13, 14, 15, 16, or 17	↓ (L: 16)	–	–	–	Righting reflex ↓ (L: 16)	Inouye et al. 1985 (MMC)
Mouse; 3 days, GDs 7–9	↔ (N: 5)	↔ (N: 5)	–	↓ (L: 3)	–	Dore et al. 2001 (MMC)
Mouse; 3 days, GDs 12–14	↓ (L: 3)	↔ (N: 5)	–	↓ (L: 5)	–	Dore et al. 2001 (MMC)
Mouse; 3 days, GDs 12–14	↓ (L: 3)	↓ (L: 3)	–	↓ (L: 3)	Altered nocturnal rhythm (L: 3)	Kim et al. 2000 (MM)
Mouse; 11 days, GDs 8–18	↓ (L: 0.009)	↑ (L: 0.009)	–	↓ (L: 0.009)	–	Montgomery et al. 2008 (MMC)
Postnatal exposure						
Rat; 1 day, PND 15 or 21	↔ (N: 16)	–	–	↔ (N: 16)	–	Post et al. 1973 (MMC)

Table 2-47. Neurobehavioral Effects in Rodents Following Acute-Duration Oral Exposure to Methylmercury Compounds During Development

Species; duration	Motor activity, coordination[a]	Anxiety[a]	Associative learning[a]	Spatial/ working learning and memory[a]	Other[a]	Reference (compound)
Rat; 9 days, PND 1–10	–	–	↓ (L: 0.280)	↔ (N: 0.280)	–	Kendricks et al. 2022 (MMC)
Rat; 10 days, PND 14–23	↓ (L: 6.3)	–	–	↓ (L: 6.3)	–	Sakamoto et al. 2020 (MMC)
Rat; 10 days, PNDs 14–23	↓ (L: 0.6)	↔ (N: 0.6)	↓ (L: 0.6)	–	Nociception ↔ (N: 0.6)	Coluccia et al. 2007 (MMC)
Mouse; 1 day PND 10	↓ (L: 0.37)	–	–	↓ (L: 0.37)	–	Fischer et al. 2008 (MMC)
Mouse; 5 days, PNDs 29–33	↓ (L: 0.2)	–	–	–	–	Bellum et al. 2007 (MMC)

[a]NOAEL (N) or LOAEL (L) dose in mg Hg/kg/day for endpoint category. Associative learning is learning by association.

↑ = increased; ↓ = decreased; ↔ = no change; – = not assessed; ASR = acoustic startle reflex; GD = gestation day; LOAEL = lowest-observed-adverse-effect level; MM = methylmercury; MMC = methylmercuric chloride; MMH = methylmercury hydroxide; NOAEL = no-observed-adverse-effect level; PND = postnatal day; PPI = paired-pulse inhibition

Thirty-five studies have evaluated neurobehavioral effects in rodents following intermediate-duration developmental exposure during gestation and/or early postnatal periods (Table 2-48). Reported exposure-related effects included decreased motor coordination, impaired learning and memory, and delayed reflex ontogeny; findings for motor activity were inconsistent (some reported increases, others decreases). In most studies, no overt clinical signs of neurotoxicity were reported in intermediate-duration neurodevelopmental studies in rodents. An exception was hindlimb crossing and paralysis observed in neonatal rats following direct exposure to 4 mg Hg/kg/day from PND 1 to 30 (Sakamoto et al. 2002). The most sensitive neurobehavioral effects following intermediate-duration developmental exposure were observed in mice following exposure to 0.02 mg Hg/kg/day during gestation and/or early postnatal development, including altered motor activity and impaired motor coordination (Huang et al. 2011). Impaired hearing, as indicated by decreased auditory brainstem responses, was also observed at this exposure level. The only other neurophysiological study identified in rodents following developmental exposure reported elevated epileptiform activity following maternal exposure to 0.3 mg Hg/kg/day for 7–8 weeks premating through PND 21; baseline cortical activity was comparable (Szász et al. 2002).

Table 2-48. Neurobehavioral Effects in Rodents Following Intermediate-Duration Oral Exposure to Methylmercury Compounds During Development

Species; duration	Motor activity[a]	Motor coordi-nation[a]	Associative learning (OC, AA, PA)[a]	Spatial/ working learning, and memory[a]	Other[a]	Reference (compound)
Gestational exposure						
Rat; 25 days, PM–GD 19	–	–	↓ (L: 0.8)	↔ (N: 0.8)	–	Kakita et al. 2000 (MMC)
Rat; 49–56 days, PM–GD 20 (gavage)	↔ (N: 1)	–	–	–	FOB, ASR ↔ (N: 1)	Beyrouty et al. 2006 (MMC)
Mouse; 19 days, GDs 0–18 (diet)	M: ↑; F: ↓ (L: 0.9)	–	↔ (N: 0.9)	↓ (L: 0.9)	Anxiety ↓ (L: 0.9)	Yoshida et al. 2011 (MM)
Mouse; 21 days, GDs 0–21	0 (N: 0.05)	–	–	↓ (L:0.05)	Socialization and pup vocalizations ↓ (L: 0.05) Stereotypy ↑ (L: 0.05) Anxiety ↔ (N: 0.05)	Loan et al. 2023
Gestational plus postnatal exposure						
Rat; 17 days, GD 5–PND 1	–	–	–	↓ (L: 0.48)	–	Wang et al. 2022a (MMC)
Rat; 22 days, GD 7–PND 7	↑ (L: 0.5)	–	–	–	–	Giménez-Llort et al. 2001 (MMH)
Rat; 22 days, GD 7–PND 7	↓ (L: 0.474)	–	–	↔ (N: 0.474)	–	Rossi et al. 1997 (MMH)
Rat; 35 days, GD 7–PND 21	–	–	–	–	Reflex ontogeny ↓ (L: 1.9)	Sitarek and Gralewicz 2009 (MMC)
Rat; 38 days, GD 5–PND 21	↓ (L: 0.4)	–	↓ (L: 0.2)	↓ (L: 0.2)	–	Albores-Garcia et al. 2016 (MMC)
Rat; 42 days, GD 1–PND 21	↑ (L: 0.23)	↓ (L: 0.23)	–	↔ (N: 0.23)	Reflex ontogeny ↓ (L: 0.23)	Cheng et al. 2015; Fujimura et al. 2012 (MM)
Rat; 42 days GD 0–PND 21	↓ (L: 0.03)	↓ (L: 0.03)	↓ (L: 0.03)	–	–	Fagundes et al. 2022 (MMC)
Rat; 42 days, GD 1–PND 22 +PNDs100–145	–	–	–	–	Anxiety ↑ (L: 0.4)	Rosa-Silva et al. 2020a, 2020b (MMC)
Rat; 60 days, PM–PND 21	↑ (L: 0.74)	–	↓ (L: 0.74)	↔ (N: 0.74)	–	Elsner 1991 (MMC)

Table 2-48. Neurobehavioral Effects in Rodents Following Intermediate-Duration Oral Exposure to Methylmercury Compounds During Development

Species; duration	Motor activity[a]	Motor coordi-nation[a]	Associative learning (OC, AA, PA)[a]	Spatial/ working learning, and memory[a]	Other[a]	Reference (compound)
Rat; 70–91 days, PM–PND 16	–	–	↓ (L: 0.045)	–	Reflex ontogeny (N: 0.6)	Newland and Reile 1999; Newland and Rasmussen 2000; Newland et al. 2004 (MMC)
Rat; 111 days PM–PND 55	–	↓ (L; 0.5)	↓ (L: 0.5)	↔ (N: 0.5)	–	Sakamoto et al. 2002 (MM)
Mouse; 35 days, GD8–PND 21	0 (N: 0.06)	–	–	–	–	Zhang et al. 2011 (MM)
Mouse[b]; 35 days, GD 8–PND 21	↑ (L: 0.06)	–	–	–	–	Zhang et al. 2011 (MM)
Mouse; 41 days, GD 2–PND 21	↓ (L: 0.9)	↔ (N: 1.7)	–	↓ (L: 0.9)	–	Goulet et al. 2003 (MMC)
Mouse; 42 days, GD 1–PND 21	–	↓ (L: 1)	–	–	–	Ghizoni et al. 2018 (MMC)
Mouse; 56 days, GD 14–PND 21	↓ (L: 1.3)	↔ (N: 1.3)	–	–	Motor strength, rearing ↓ (L: 1.3)	Rand et al. 2020 (MMC)
Mouse; 63–70 days, PM–PND 13	–	↓ (L: 0.2)	↔ (N: 0.6)	↓ (L: 0.2)	–	Weiss et al. 2005 (MMC)
Mouse; 70, PM–PND 21	↓ (L: 0.02)	(N: 0.02)	–	–	–	Huang et al. 2011 (MM)
Mouse; 119 days, PM–PND 70	↓ (L: 0.02)	↓ (L: 0.02)	–	–	–	Huang et al. 2011 (MM)
Postnatal exposure						
Rat; 30 days, PNDs 1–30	–	↓ (L: 4)	↓ (L: 0.8)	–	–	Sakamoto et al. 2004 (MMC)
Rat; 35 days PNDs 31–65	↓ (L: 0.037)	↓ (L: 0.037)	–	–	–	Oliveira et al. 2018 (MM)
Mouse[c]; 21 days PNDs 21–42	–	–	–	–	Socialization ↓ (L: 0.08) Stereotypy ↑ (L: 0.08)	Algahtani et al. 2023 (MMC)
Mouse; 21 days, PNDs 1–21	↓ (L: 4.7)	↓ (L: 4.7)	–	–	–	Franco et al. 2006 (MMC)

Table 2-48. Neurobehavioral Effects in Rodents Following Intermediate-Duration Oral Exposure to Methylmercury Compounds During Development

Species; duration	Motor activity[a]	Motor coordi-nation[a]	Associative learning (OC, AA, PA)[a]	Spatial/ working learning, and memory[a]	Other[a]	Reference (compound)
Mouse; 27 days, PNDs 2–28	↓ (L: 0.9)	–	↔ (N: 0.9)	↔ (N: 0.9)	Anxiety ↔ (N: 0.9)	Yoshida et al. 2018 (MMC)
Mouse; 37 days PNDs 22–59	–	–	↔ (N: 0.400)	–	Attention ↓ (L: 0.400)	Kendricks and Newland 2021 (MMC)
Mouse; 39 days PNDs 21–60	–	–	↔ (N: 0.320)	–	Attention ↔ (N: 0.320)	Kendricks et al. 2020a, 2020b (MMC)
Mouse; 39 days, PNDs 21–59	–	–	↓ (L: 0.032)	–	–	Boomhower and Newland 2019 (MMC)
Mouse; 39 days PNDs 24–62	–	–	↔ (N: 0.32)	–	–	Boomhower and Newland 2019 (MMC)
Mouse; 49 days, PNDs 21–70	↑ (L: 0.02)	↓ (L: 0.02)	–	–	–	Huang et al. 2011 (MM)

[a]NOAEL (N) or LOAEL (L) dose in mg Hg/kg/day for endpoint category.
[b]Autoimmune susceptible mouse strain.
[c]Exposure-related effects observed in BTBR mice (strain with increased baseline "autistic-like" traits of repetitive behavior and decreased socialization); exposure-related effects were not observed in similarly-exposed "social" C57BL/6 mice.

↑ = increased; ↓ = decreased; ↔ = no change; – = not assessed; AA = active avoidance learning, ASR = acoustic startle reflex; FOB = functional observation battery; GD = gestation day; LOAEL = lowest-observed-adverse-effect level; MM = methylmercury; MMC = methylmercuric chloride; MMH = methylmercury hydroxide; NOAEL = no-observed-adverse-effect level; OC = operant conditioning; PA = passive avoidance learning; PM = premating; PND = postnatal day

Evaluation of the oral neurodevelopmental database indicates that of the sensitive effects identified following acute- and intermediate-duration exposure to methylmercury compounds (Tables 2-47 and 2-48), the most consistently reported findings included impaired operant conditioning in rats, impaired spatial learning and memory in mice, motor incoordination in rats and mice, and hearing deficits in mice. Additional details on neurobehavioral testing and dose-response information for these consistently observed and sensitive neurodevelopmental effects in rodents following developmental exposure to methylmercury can be found in Table 2-49 and are discussed below.

Table 2-49. Dose-Response Data for Sensitive and Consistently Observed Neurobehavioral Effects in Rodents following Oral Exposure to Methylmercury During Development			
Reference; species; exposure duration	Assay/outcome measured (evaluation timing, sex)	Dose (mg Hg/kg/day)	Result (percent change compared to control)
Operant conditioning in rats			
Bornhausen et al. 1980 Rat; GDs 6–9	DRH [2/1] performance[a] (4 months, B)	0.004–0.008	↔
	DRH [4/2] performance (4 months, B)	0.004	↔
		0.008	M: ↓ (24.4)[b] F: ↓ (28.3)[b]
		0.035	M: ↓ (37.9)[b] F: ↓ (25.7)[b]
	DRH [8/4] performance (4 months, B)	0.004	↔
		0.008	M: ↓ (10.0)[b] F: ↓ (15.0)[b]
		0.035	M: ↓ (57.2)[b] F: ↓ (24.6)[b]
Kendricks et al. 2022 Rat; PNDs 1–10	SDR: time to acquisition of criterion for reversal learning[c] (PND 91, M)	0.064	↔
		0.280	↑ (138)[d]
Elsner 1991 Rat; 14 days premating through PND 21	DRF performance[e] at 60–120 or 60–100 g (PND 300, M)	0.19 or 0.74	↔
	DRF performance at 60–80 g (PND 300, M)	0.19	↓ (25)[b]
		0.74	↓ (25)[b]
Fagundes et al. 2022 Rat; GD 0–PND 21	Acquisition of inhibitory avoidance: latency of step down (PND 41, M; short-term memory at 1.5 hours)	0.03	↓ (67)[d]
	Acquisition of inhibitory avoidance: latency of step down (PND 41, M; long-term memory at 24 hours)	0.03	↓ (85)[d]
Newland and Rasmussen 2000 Rat; 10–13 weeks premating through PND 16	MFFR reinforcement rate (PND 120 or >400, F)	0.045	PND 120: ↔ PND >400: ↓ (13)[d]
		0.6	PND 120: 0 PND >400: ↓ (19)[d]

Table 2-49. Dose-Response Data for Sensitive and Consistently Observed Neurobehavioral Effects in Rodents following Oral Exposure to Methylmercury During Development

Reference; species; exposure duration	Assay/outcome measured (evaluation timing, sex)	Dose (mg Hg/kg/day)	Result (percent change compared to control)
Newland et al. 2004 Rat; 10–13 weeks premating through PND 16	CRI: acquisition of choice for 1:4 transition (half maximal reinforcers)[f] (1.7 or 2.3 years, B)	0.045	1.7 years: ↔ 2.3 years: ↑ (98)[d]
		0.6	1.7 years: ↔ 2.3 years: ↑ (118)[b]
	CRI: acquisition of choice for 1:4 transition (half maximal reinforcers) (1.7 or 2.3 years, B)	0.045	1.7 years: ↔ 2.3 years: ↑ (92)[b]
		0.6	1.7 years: ↔ 2.3 years: ↑ (76)[b]
Spatial learning and memory in mice			
Hughes and Annau 1976 Mouse, GD 8	MWM, escape latency [learning phase] (PND 56, NS)	1–5	↔
Fischer et al. 2008 Mouse; PND 10	MWM, escape latency on training day 4 (learning phase) (4 months, M)	0.37	↑ (36)[d]
		3.7	↑ (143)[d]
	MWM, escape latency on training day 5 (reversal learning) (4 months, M)	0.37	↔
		3.7	↑ (89)[d]
	Radial arm maze, time to acquire all pellets (5 months, M)	0.37	↔
		3.7	↑ (54)[b]
Dore et al. 2001 Mouse; GDs 7–9	T-maze, sessions to reach training criteria (PND 49, F)	3	↑ (110)[d]
		5	↑ (110)[d]
	Radial arm maze, correct arm choices/incorrect arm choices (PND 98, F)	3	↔
		5	↔
Dore et al. 2001 Mouse; GDs 12–14	T-maze, sessions to reach training criteria (PND 49, F)	3	↔
		5	↑ (70)[d]
	Radial arm maze, correct arm choices/incorrect arm choices (PND 98, F)	3	↔
		5	Trial 3: ↓ (15)[d]
Kim et al. 2000 Mouse; GDs 12–14	MWM, escape latency (learning phase) (PND 56, F)	3	↔
Kim et al. 2000 Mouse; GDs 12–14	MWM, escape latency (learning phase) (PND 56, F)	3	Day 1: ↔ Day 2: ↑ (12)[d] Day 3: ↑ (22)[d] Day 4: ↑ (27)[d] Day 5: ↑ (75)[d]

Table 2-49. Dose-Response Data for Sensitive and Consistently Observed Neurobehavioral Effects in Rodents following Oral Exposure to Methylmercury During Development

Reference; species; exposure duration	Assay/outcome measured (evaluation timing, sex)	Dose (mg Hg/kg/day)	Result (percent change compared to control)
Kim et al. 2000 Mouse; GDs 12–14	MWM, escape latency (learning phase) (PND 56, F)	3	Day 1: ↔ Day 2: ↑ (166)[d] Day 3: ↑ (57)[d] Day 4: ↑ (122)[d] Day 5: ↔
Montgomery et al. 2008 Mouse; GDs 8–18	MWM, escape latency (learning phase) (5–7 months, B)	0.009	Day 1: ↔ Day 2: ↔ Day 3: ↑ (27)[d] Day 4: ↑ (30)[d] Day 5: ↑ (34)[d] Day 6: ↑ (132)[d]
	MWM, time in cued quadrant (memory phase) (5–7 months, B)	0.009	Probe 1: ↓ (16)[d] Probe 2: ↓ (12)[d] Probe 3: ↓ (13)[d]
Yoshida et al. 2011; Mouse; GDs 0–18	MWM, escape latency (learning phase) (PND 56, B)	0.9	M: Day 4: ↑ (60)[d] Days 1–3, 5: ↔ F: ↔
Loan et al. 2023 Mouse; GDs 0–21	MWM, escape latency on training day 4 (learning phase) (PND 60, B)	0.05	↔
	MWM, time in cued quadrant (memory phase) (PND 60, B)	0.05	↔
	MWM, escape latency on training day 2 (reversal learning) (PND 60, B)	0.05	↔
	MWM, ratio of time spent in wrong (old) target during reversal probe (PND 60, B)	0.05	↑ (5)[d]
Yoshida et al. 2018 Mouse; PNDs 2–28	Radial arm maze, arm choice errors (PND 84, F)	0.9	↔
Goulet et al. 2003 Mouse: GD 2–PND 21	T-maze, sessions to reach training criteria (PND 42, B)	0.9	↔
		1.7	↔
Weiss et al. 2005 Mouse; 4 weeks premating through PND 13	T-maze, mice reaching training criteria within 55 sessions (5 or 15 months, M)	0.2	5 months: ↔ 15 months: ↓ (75)[b]
		0.6	5 or 15 months: ↓ (50)[b]

Table 2-49. Dose-Response Data for Sensitive and Consistently Observed Neurobehavioral Effects in Rodents following Oral Exposure to Methylmercury During Development

Reference; species; exposure duration	Assay/outcome measured (evaluation timing, sex)	Dose (mg Hg/kg/day)	Result (percent change compared to control)
Motor coordination in rats and mice			
Carratu et al. 2006 Rat; GD 8 or 15	Rotarod, fall latency (PND 40, B)	7	↔
Sakamoto et al. 2004 Rat; PNDs 1–3	Rotarod, fall latency (PND 35, M)	0.8 or 2	↔
		4	↓ (82)[b]
Sakamoto et al. 2020 Rat; PNDs 14–23	Rotarod, fall latency (PND 21, M)	6.3	↔
	Rotarod, fall latency (PND 24, M)	6.3	↓ (67)[d]
Oliveira et al. 2018 Rat; PNDs 31–65	Rotarod, latency to first fall on trial 1 (PND 66, F)	0.037	↓ (62)[d]
	Rotarod, latency to first fall on trial 2 (PND 66, F)	0.037	↓ (75)[d]
	Rotarod, latency to first fall on trial 3 (PND 66, F)	0.037	↔
	Vertical pole, descent latency (PND 66, F)	0.037	↑ (80)[d]
	Beam walking, crossing latency on 5 mm square beam (PND 66, F)	0.037	↑ (45)[d]
	Beam walking, crossing latency on 11 mm round beam (PND 66, F)	0.037	↑ (105)[d]
Cheng et al. 2015; Fujimura et al. 2012 Rat; GD 1–PND 21	Rotarod, % mice staying on rod for 60 seconds (PNDs 34–35, B)	0.05	↔
		0.23	M: ↓ (50)[b] F: ↓ (26)[b]
Fagundes et al. 2022 Rat; GD 0–PND 21	Rotarod, latency to first fall (PND 41, M)	0.03	↓ (84)[d]
	Rotarod, number of falls (PND 41, M)	0.03	↑ (200)[d]
Sakamoto et al. 2002 Rat; 8 weeks premating through PND 55	Rotarod, % mice staying on rod for 60 seconds (PND 35, B)	0.5	↓ (75)[b]
Dore et al. 2001 Mouse; GDs 7–9 or 12–14	Rotarod, fall latency (PND 42, F)	3 or 5	↔

Table 2-49. Dose-Response Data for Sensitive and Consistently Observed Neurobehavioral Effects in Rodents following Oral Exposure to Methylmercury During Development

Reference; species; exposure duration	Assay/outcome measured (evaluation timing, sex)	Dose (mg Hg/kg/day)	Result (percent change compared to control)
Bellum et al. 2007 Mouse; PNDs 29–33	Rotarod, fall latency (PND 38, B)	0.2	↔
		0.8	Day 1: ↓ (23)[d] Day 2: ↔ Day 3: ↓ (36)[d]
	Footprint analysis, angle of foot placement (PND 38, B)	0.2	↑ (55)[d]
		0.8	↔
	Vertical pole, percent of mice that fell before 90° (PND 38, B)	0.2	↑ (40)[b]
		0.8	↑ (37)[b]
Montgomery et al. 2008 Mouse; GDs 8–18	Rotarod, fall latency (2 months, B)	0.009	↔
	Rotarod, time spent on rod (2 months, B)	0.009	Day 1: ↓ (40)[d] Day 2: ↓ (20)[d] Day 3: ↓ (48)[d]
	Footprint analysis, foot angle (2 months, B)	0.009	↓ (40)[d]
Franco et al. 2006 Mouse; PNDs 1–21	Rotarod, fall latency (PND 21, B)	4.7	↓ (37)[b]
Rand et al. 2020 Mouse; 12 weeks prior to mating–PND 21	Rotarod, average time (PND 60, B)	0.12 or 1.3	↔
	Rotarod, average speed (PND 60, B)	0.13 or 1.3	↔
Goulet et al. 2003 Mouse; GD 2–PND 21	Rotarod, fall latency (PND 42, B)	0.9	↔
		1.7	↔
Ghizoni et al. 2018 Mouse; GD 0–PND 21	Rotarod, number of falls (PND 22, B)	1	↑ (110)[d]
Weiss et al. 2005 Mouse; 4 weeks premating through PND 13	Footprint analysis, hindlimb splay (5, 15, or 25 months, M)	0.2	5 months: ↔ 15 months: ↑ (12)[d] 25 months: ↔
		0.6	5 months: ↔ 15 months: ↑ (18)[d] 25 months: ↔
Huang et al. 2011 Mice; PNDs 21–70	Rotarod, fall latency (PND 70, M)	0.02	↓ (18)[d]
Huang et al. 2011 Mice; 4 weeks premating through PND 21	Rotarod, fall latency (PND 70, M)	0.02	↔

Table 2-49. Dose-Response Data for Sensitive and Consistently Observed Neurobehavioral Effects in Rodents following Oral Exposure to Methylmercury During Development

Reference; species; exposure duration	Assay/outcome measured (evaluation timing, sex)	Dose (mg Hg/kg/day)	Result (percent change compared to control)
Huang et al. 2011 Mice; 4 weeks premating through PND 70	Rotarod, fall latency (PND 70, M)	0.02	↓ (31)[d]
Auditory function in mice			
Huang et al. 2011 Mice; PNDs 21–70	Hearing threshold (PND 70, M)	0.02	↑ (698)[d]
	ABR absolute latency (PND 70, M)	0.02	Wave III: ↔ Wave V: ↑ (37)[d]
	ABR interwave latency [Waves I–V] (PND 70, M)]	0.02	↑ (9)[d]
Huang et al. 2011 Mice, 4 weeks premating through PND 21	Hearing threshold (PND 70, M)	0.02	↑ (637)[d]
	ABR absolute latency (PND 70, M)	0.02	Wave III: ↑ (6)[d] Wave V: ↑ (37)[d]
	ABR interwave latency [Waves I–V] (PND 70, M)]	0.02	↑ (10)[d]
Huang et al. 2011 Mice; 4 weeks premating through PND 70	Hearing threshold (PND 70, M)	0.02	↑ (1,096)[d]
	ABR absolute latency (PND 70, M)	0.02	Wave III: ↑ (6)[d] Wave V: ↑ (62)[d]
	ABR interwave latency [Waves I–V] (PND 70, M)]	0.02	↑ (15)[d]

[a]DRH performance was calculated by the following formula: [(number of reinforcements ×100)/lever presses during ON periods] x lever presses required for one reward.
[b]Calculated from quantitative data.
[c]Criterion for initial learning in the visual discrimination task was >85% correct responses on the reinforcing lever in each of three consecutive sessions; criterion for reversal learning was 85% correct responses on the newly designated "correct" lever for three consecutive trials.
[d]Estimated from graphically presented data.
[e]DRF performance was calculated by the following formula: number of correct responses/total number of trial responses.
[f]Acquisition of choice is defined as the allocation of behavior between two response alternatives, as it was undergoing a transition.

↑ = increased; ↓ = decreased; ↔ = no change; ABR = auditory brainstem response; B = both males and females; CRI = concurrent random interval (e.g., 180 seconds/180 seconds or 860 seconds/100 seconds) schedule of reinforcement; DRF = differential reinforcement of force range; DRH = differential reinforcement of high rates (lever presses/second) to gain food reward; F = female; GD = gestation day; M = male; MFFR = multiple fixed ratio food reward lever press task; MWM = Morris water maze; NS = not specified; PND = postnatal day; SDR = spatial discrimination reversal

Dose-related impairments in operant conditioning in rats were consistently observed following

developmental exposure to oral doses ≥0.008 mg Hg/kg/day (Bornhausen et al. 1980; Elsner 1991;

Fagundes et al. 2022; Kendricks et al. 2022; Newland and Rasmussen 2000; Newland et al. 2004). In contrast, while one study in male C57BL/6 mice reported deficiencies in associative learning via fixed-ratio operant conditioning following exposure to 0.032 mg Hg/kg/day from PND 21 to 59, no effect on learning was observed at 0.32 mg Hg/kg/day from PND 24 to 62 (Boomhower and Newland 2019). Other studies in mice did not observe deficits in operant training following developmental exposure to oral doses up to 0.9 mg Hg/kg/day (Kendricks and Newland 2021; Kendricks et al. 2020a, 2020b; Yoshida et al. 2018). However, transient effects on attention were reported in mice following developmental exposure to 0.400 mg Hg/kg/day, but not 0.320 mg Hg/kg/day (Kendricks and Newland 2021; Kendricks et al. 2020a, 2020b).

When assessed using the Morris water maze (MWM), impairments in spatial learning and/or memory were consistently observed in C57BL/6 mice following gestational exposure to oral doses ≥0.009 mg Hg/kg/day (Kim et al. 2000; Loan et al. 2023; Montgomery et al. 2008; Yoshida et al. 2011). In NMRI mice, impaired spatial learning in the MWM was observed following early postnatal exposure to oral doses ≥0.37 mg Hg/kg/day (Fischer et al. 2008). No changes in spatial learning were observed in BALB/c or CFW mice exposed to doses up to 3 or 5 mg Hg/kg/day, respectively, during gestation (Hughes and Annau 1976; Kim et al. 2000). Based on reported findings in the T-maze and radial arm maze following oral methylmercury exposure (Dore et al. 2001; Fischer et al. 2008; Goulet et al. 2003; Weiss et al. 2005; Yoshida et al. 2018), these tests appear to be less sensitive and/or less consistent measures of methylmercury-induced spatial learning impairments in mice compared to the MWM. Observed deficits in spatial learning were less consistent in rats. Impaired spatial learning and/or memory were observed in the MWM in adult Sprague-Dawley rats following developmental exposure to 0.56 mg Hg/kg/day from GD 5 to PND 1 (Wang et al. 2022a) or ≥0.2 mg Hg/kg/day on GDs 5–21 (Albores-Garcia et al. 2016). However, no spatial learning or memory impairments were observed in the MWM in Sprague-Dawley rats following exposure to 0.474 mg Hg/kg/day from GD 7 to PND 7 (Rossi et al. 1997) or Wistar rats following gestational exposure to doses up to 0.8 mg Hg/kg/day (Kakita et al. 2000; Sakamoto et al. 2002). Similar to mice, findings in arm-alternation mazes did not show spatial learning deficits in rats following oral methylmercury exposure during development (Cheng et al. 2015; Elsner 1991).

In rats, dose- and duration-dependent motor coordination impairments were observed during rotarod testing. In postnatal-only exposure studies, impairments were reported following exposure to 0.037 mg Hg/kg/day from PNDs 31 to 65 (Oliveira et al. 2018) or doses ≥4 mg Hg/kg/day administered during early neonatal (pre-weaning) periods (Sakamoto et al. 2004, 2020). Impaired motor coordination was

also observed following gestation plus postnatal exposure to doses ≥0.03 mg Hg/kg/day (Cheng et al.
2015; Fagundes et al. 2022; Fujimura et al. 2012; Sakamoto et al. 2002). No changes were observed
following a single exposure to 7 mg Hg/kg/day during gestation (Carratu et al. 2006). Findings in the
rotarod test were less consistent in mice, with varying findings between different strains and exposure
paradigms (Bellum et al. 2007; Dore et al. 2001; Franco et al. 2006; Ghizoni et al. 2018; Goulet et al.
2003; Huang et al. 2011; Montgomery et al. 2008; Rand et al. 2020). Data for other measures of
coordination in mice (footprint analysis, vertical pole) are limited (Bellum et al. 2007; Montgomery et al.
2008; Weiss et al. 2005).

One study evaluated auditory function in mice following developmental exposure to 0.02 mg Hg/kg/day
throughout gestation and lactation, during GD 1–PND 70, or postnatally only from PND 21–70 (Huang et
al. 2011). Observed hearing deficits were similar in the GD 1–PND 21 and PND 21–70 groups, and
markedly worse in the group with exposure during GD 1–PND 70.

Pathological changes in the rat brain have been reported following developmental exposure to
methylmercury at doses above those associated with neurobehavioral and neurophysiological effects,
primarily in regions associated with motor and movement control. An acute-duration gestational
exposure study observed dendritic spine abnormalities in the somatosensory cortex in rat offspring at
4 mg Hg/kg/day (Stoltenburg-Didinger and Markwort 1990). Exposure throughout gestation in rats
resulted in widespread neuronal degeneration (pyknosis, shrinkage of perikaryon, eosinophilic changes),
decreased cell numbers in amygdala and hippocampus, and reactive gliosis at 0.8 mg Hg/kg/day (Kakita
et al. 2000). Focal cerebellar dysplasia, including heterotopic location of Purkinje cells and granule cells,
and reactive gliosis were observed in rats following exposure to 0.5 mg Hg/kg/day throughout gestation,
lactation, and postweaning until PND 55 (Sakamoto et al. 2002). Loss of motor neurons and decreased
spinal cord myelination were observed on PND 42 in the offspring of rats exposed to 0.03 mg Hg/kg/day
throughout gestation and lactation (da Silva et al. 2022). Widespread neuronal damage in the central
nervous system was also observed in rats exposed to 4 mg Hg/kg/day from PND 1 to 30 (Sakamoto et al.
2004). Severe cerebral degeneration was reported in neonatal rats exposed to 6.3 mg Hg/kg/day on
PNDs 14–23, including neuronal loss and atrophy, degenerative eosinophilic neurons, and reactive gliosis
(Sakamoto et al. 2020).

Pathological changes in regions of the brain associated with motor and movement control have also been
observed in mice following developmental exposure to methylmercury at doses above those associated
with neurobehavioral and neurophysiological effects. Findings in acute-duration gestational exposure

studies included altered cerebellar development in mouse offspring at ≥1 mg Hg/kg/day (Inouye et al. 1985; Khera and Tabacova 1973) and a reduction in the size of "nucleus caudatus putamen" in mouse offspring at 16 mg Hg/kg/day (Inouye et al. 1985). Additionally, cerebellar inflammation was observed in an autoimmune susceptible mouse strain in offspring following maternal exposure to 0.06 mg Hg/kg/day during gestation and lactation (Zhang et al. 2011). Inflammation was not observed in similarly exposed wild-type mice.

Cerebellar damage has also been observed in hamsters following gestational exposure to methylmercury (no other neurological endpoints evaluated in hamsters). Exposure to 1.6 mg Hg/kg/day on GD 10 or GDs 10–15 resulted in degenerative changes in the cerebellum of hamster offspring examined between PND 1 and 25 (Reuhl et al. 1981a) or PND 275 and 300 (Reuhl et al. 1981b). In neonates, findings were most pronounced from PND 1 to 15, and included accumulation of lysosomes and areas of floccular cytoplasmic degradation in neuroblasts of the granular layer, pyknotic nuclei in the external granular layer, swollen developing dendrites packed with degenerating cytoplasmic material, and large aggregates of irregular debris, lysosomes, and large lipid droplets in astrocytes and perivascular macrophages. In older hamsters, findings included focal astrogliosis in the molecular layer, residual bodies in the perikarya and dendrites of granule and Purkinje neurons (sequalae of neonatal injuries), and degenerative changes of myelinated axons.

Predominant Mercury Form Unknown (General Populations). A large number of studies have been conducted on neurodevelopmental outcomes in general populations (Table 2-50). Most studies of general populations found no associations or inconsistent associations across outcome measures and biomarkers of exposure. These inconsistences may relate to the relatively low exposures in most of these populations (maternal or cord BHg <10 µg Hg/L; HHg <2 µg Hg/g), which may be near or below toxic thresholds, as well as other variables that may have affected outcomes and were not adequately controlled in models of association. These variables include multiple sources of exposure (e.g., diet, mercury amalgam dental restorations), fish consumption rates and related nutritional variables, and exposure to other chemicals (e.g., lead, PCBs).

Table 2-50. Results of Epidemiological Studies Evaluating General Population Exposure to Mercury (Predominant Mercury Form Unknown) and Neurodevelopmental Effects

Reference, study type, and population	Biomarker	Outcome evaluated	Result[a]

Al-Saleh et al. 2016
 	
Cross-sectional cohort of 944 mother-infant pairs evaluated at age 3–12 months; Saudi Arabia
	BHg median
	  Maternal: 0.635 µg/L
	
	HHg median
	  Maternal: 0.118 µg/g
	  Child: 0.101 µg/g
	
	HMeHg
	  Maternal: 0.132 µg/g
	  Child: 0.091 µg/g
		DDST-II	↓ (HMeHg, maternal)
			↔ (HHg, maternal)
			↔ (BHg, maternal)
			↔ (HMeHg, child)
			↔ (HHg, child)

		PEDS	↔ (HMeHg, maternal) ↓ (HHg, maternal) ↔ (BHg, maternal) ↔ (HMeHg, child) ↔ (HHg, child)

Al-Saleh et al. 2019
 	
Cross-sectional cohort of 206 mother-infant pairs evaluated at age 3–12 months; Saudi Arabia
	BMeHg median
	  Maternal: 0.455 µg/L
	
	BMMeHg
	  Maternal: 1.354 µg/dL
		DDST-II	↔ (BMeHg, maternal)
			↔ (BMMeHg, maternal)

		PEDS	↔ (BMeHg, maternal) ↔ (BMMeHg, maternal)

Barbone et al. 2019
 	
Prospective cohort of mother-infant pairs, follow-up at 18 months (n=1,308); Mediterranean Europe (Italy, Slovenia, Croatia, Greece)
	BHg median
	  Maternal: 0.0024 µg/g
	  Cord: 0.0036 µg/g
	
	HHg median
	  Maternal: 0.704 µg/g
		BSID cognitive composite score	↔ (BHg, cord)
			↔ (BHg, maternal)
			↔ (HHg, maternal)

		BSID language composite score	↔ (BHg, cord) ↑ (HHg, maternal)
		BSID motor composite score	↔ (BHg, cord) ↔ (BHg, maternal) ↔ (HHg, maternal)
		BSID receptive communication	↔ (BHg, cord) ↔ (BHg, maternal) ↑ (HHg, maternal)
		BSID expressive communication	↔ (BHg, cord) ↔ (BHg, maternal) ↔ (HHg, maternal)
Calamandrei et al. 2020 Prospective birth cohort, follow-up at age 18 months (n=984); Europe	HHg median Maternal: 0.292 µg/g	BSID (12 months)	↔ (HHg, maternal)
		BSID (24 months)	↔ (HHg, maternal)

Castriotta et al. 2020
 	
Prospective birth cohort, follow-up at age 40 months (n=470); Italy
	BHg median
	  Maternal: 3.4 µg/kg
	  Cord: 5.6 µg/kg
		BSID	↔ (BHg, cord)

Table 2-50. Results of Epidemiological Studies Evaluating General Population Exposure to Mercury (Predominant Mercury Form Unknown) and Neurodevelopmental Effects

Reference, study type, and population	Biomarker	Outcome evaluated	Result[a]

Cheuk and Wong 2006
 	
Case-control study of 52 ADHD cases and 59 controls, age <18 years; Hong Kong
	BHg geometric mean
	  Child case: 3.65 µg/L
	  Child control: 2.33 µg/L
		ADHD	↑ (BHg, child >5.8 µg/L)

Choi and Park 2017
 	
Cross-sectional study 853 adolescents (mean age 15 years) and 5,187 adults (mean age 45 years) (Republic of Korea; KNHANES 2010–2012)
	BHg geometric mean
	  Adults: 3.58 µg/L
	  Adolescents: 2.03 µg/L
		Speech-frequency hearing	↔ (BHg)

		High-frequency hearing	↔ (BHg)

Daniels et al. 2004
 	
Prospective cohort of mother-infant pairs, follow-up at age 15–18 months (n=1,054); United Kingdom
	Cord tissue mercury median
	  Wet weight: 0.01 µg/g
	  Dry weight: 0.04 µg/g
		MSCA	↔ (mercury, cord tissue)

		DDST	↔ (mercury, cord tissue)
Egwunye et al. 2023 Cross-sectional study of children evaluated at age 36 months (n=658); Vietnam	NHg median Child: 0.2 µg/g	BSID cognition	↔ (NHg, child)
		BISD language	↑ (NHg, child)
		BSID motor	↔ (NHg, child)
		BSID social-emotional	↔ (NHg, child)
Farías et al. 2022 Prospective cohort of mother-infant pairs, follow-up at age 1–12 months (n=253); Mexico	BHg median Maternal: 1.79 µg/L	BSID cognition	↔ (BHg, maternal)
		BISD language	↔ (BHg, maternal)
		BSID motor	↔ (BHg, maternal)
Feng et al. 2020 Cross-sectional study of children evaluated at age 8–10 years (n=314); China	HHg mean Child: 1.54 µg/g	WISC IQ	↔ (HHg, child)
		OR IQ<80	↑ (HHg, child)

Freire et al. 2010
 	
Prospective study of mother-child-infant pairs, follow-up at age 4 years (n=72); Spain
	HHg mean
	  Child (age 4 years):
	  0.96 µg/g
		MSCA cognitive	↓ (HHg, child≥1 µg/g)

		MSCA quantitative	↔ (HHg, child ≥1 µg/g)
		MSCA memory	↓ (HHg, child ≥1 µg/g)
		MSCA verbal	↓ (HHg, child ≥1 µg/g)
		MSCA performance	↔ (HHg, child ≥1 µg/g)
		MSCA motor	↔ (HHg, child ≥1 µg/g)

Table 2-50. Results of Epidemiological Studies Evaluating General Population Exposure to Mercury (Predominant Mercury Form Unknown) and Neurodevelopmental Effects

Reference, study type, and population	Biomarker	Outcome evaluated	Result[a]
Fruh et al. 2021 Prospective birth cohort, follow-up at age 6–11 years (n=1,009); Massachusetts	ErHg (median) Maternal: 3.1 ng/g	BRIEF GEC	↔ (ErHg, maternal)
		SDQ	↔ (ErHg, maternal)
Garí et al. 2022 Prospective birth cohort, follow-up at age 7 years (n=436); Poland	HHg (median) Maternal: 0.18µg/g	IDS	↔ (HHg, maternal)
		SDQ (hyperactivity/ inattention)	↑ (HHg, maternal)
Golding et al. 2016a Prospective birth cohort (ALSPAC) at ages 4–17 years (n=2,776); United Kingdom	BHg median Maternal: 1.86 µg/g	Hyperactivity	↔ (BHg, maternal)
		Conduct problems (SDQ)	↓ (BHg, maternal)
		Emotional problems	↓ (BHg, maternal)
		Peer problems	↓ (BHg, maternal)
		Prosocial	↔ (BHg, maternal)
Golding et al. 2016b Prospective birth cohort (ALSPAC) at ages 6–42 months (n=3,264); United Kingdom	BHg median Maternal: 1.86 µg/g	DDST (6 months)	↑ (BHg, maternal)
		DDST (18 months)	↑ (BHg, maternal)
		DDST (30 months)	↔ (BHg, maternal)
		DDST (42 months)	↑ (BHg, maternal)
Golding et al. 2017 Prospective birth cohort (ALSPAC) at age 8 years (n=4,285); United Kingdom	BHg median Maternal: 1.86 µg/g	WISC-III (verbal)	↔ (BHg, maternal)
		WISC-III (PIQ)	↔ (BHg, maternal)
		WISC-III (FSIQ)	↔ (BHg)
Golding et al. 2018 Prospective birth cohort (ALSPAC) at age 9–11 years (n=2,800); United Kingdom	BHg median Maternal: 1.86 µg/g	Signs of autism	↔ (BHg, maternal)
Guo et al. 2020a, 2020b Prospective birth cohort, follow-up at age 7.4 years (n=326); China	UHg (median) Maternal: 0.41µg/L	Chinese WISC IQ	↔ (UHg, maternal)
Gustin et al. 2017 Cross-sectional cohort of 1,434 children, age 10 years; Bangladesh	HHg median Child: 0.674 µg/g	WISC-IV	↔ (HHg, child)
		SDQ (behavior difficulties)	↓ (HHg, child)

Table 2-50. Results of Epidemiological Studies Evaluating General Population Exposure to Mercury (Predominant Mercury Form Unknown) and Neurodevelopmental Effects

Reference, study type, and population	Biomarker	Outcome evaluated	Result[a]
Ha et al. 2009 Cross-sectional cohort of 1,778 children, mean age 7 years; Republic of Korea	BHg geometric mean Child: 2.4 µg/L	ADHD symptoms	↔ (HHg, child)

Hu et al. 2016
 	
Prospective cohort of mother-infant pairs, follow-up at age 12 months (n=410); China
	BHg geometric mean
	  Maternal: 0.72 µg/L
	  Cord: 1.2 µg/L
		GDS gross motor	↔ (BHg, maternal)
			↔ (BHg, cord)

		GDS fine motor	↔ (BHg, maternal) ↔ (BHg, cord)
		GDS adaptive	↔ (BHg, maternal) ↑ (BHg, cord)
		GDS language	↔ (BHg, maternal) ↔ (BHg, cord)
		GDS social	↔ (BHg, maternal) ↑ (BHg, cord)

Hertz-Picciotto et al. 2010
 	
Case-control study of 332 autism cases at ages 2–5 years; California
	BHg median
	  Autism: 0.19 µg/L
	  Controls: 0.28 µg/L
		Autism	↔ (child BHg)

Hibbeln et al. 2018 Prospective birth cohort (ALSPAC), follow-up at age 7–9 years (n=2,224); United Kingdom	BHg median Maternal: 1.9 µg/L[b]	Scholastic achievement tests	↔ (BHg, maternal)

Jedrychowski et al. 2006
 	
Prospective cohort of mother-infants, follow up at age 12 months (n=233); Poland
	BHg geometric mean
	  Maternal: 0.55 µg/L
	  Cord: 0.88 µg/L
		BSID PDI or MDI	↓ (BHg, maternal ≥0.5 µg/g)
			↓ (BHg, cord ≥0.8 µg/g)

Jedrychowski et al. 2007 Prospective cohort of mother-infant pairs, follow-up at age 12 months (n=374), 24 months (n=353), and 36 months (n=270); Poland	BHg, "high" exposure Cord: >0.90 µg/L (n=177)	BSID PDI or MDI 12 months	↓ (BHg, cord)
		BSID PDI or MDI 24 months	↔ (BHg, cord)
		BSID PDI or MDI 36 months	↔ (BHg, cord)
Jeong et al. 2017 Prospective cohort of mother-infant pairs, follow-up at age 60 months (n=553); Republic of Korea	BHg geometric mean Maternal: 3.14 µg/L	WPPSI-RK (FSIQ)	↓ (BHg, maternal)
		WPPSI-RK (VIQ)	↓ (BHg, maternal)
		WPPSI-RK (PIQ)	↔ (BHg, maternal)

Table 2-50. Results of Epidemiological Studies Evaluating General Population Exposure to Mercury (Predominant Mercury Form Unknown) and Neurodevelopmental Effects

Reference, study type, and population	Biomarker	Outcome evaluated	Result[a]
Julvez et al. 2013 Prospective cohort (ALSPAC) of mother-infant pairs, follow-up at age 8 years (n=843); United Kingdom	Cord tissue mercury mean Dry weight: 0.026 µg/g	WISC-III (FSIQ)	↔ (Hg, cord tissue)
		WISC-III (VIQ)	↔ (Hg, cord tissue)
		WISC-III (PIQ)	↔ (Hg, cord tissue)
Julvez et al. 2019 Prospective birth cohort (ALSPAC), follow-up at age 8 years (n=1,051); United Kingdom	Cord tissue mercury mean Dry weight: 0.025 µg/g	WISC-III (FSIQ)	↔ (Hg, cord tissue)
		WISC-III (VIQ)	↔ (Hg, cord tissue)
		WISC-III (PIQ)	↔ (Hg, cord tissue)

Julvez et al. 2021
 	
Prospective birth cohort, follow-up at age 6–11 years (n=1,298); Europe
	BHg median
	  Maternal: 1.9 µg/L
	  Child: 0.9 µg/L
		RCPM	↑ (BHg, maternal)

Kvestad et al. 2018
 	
Cross-sectional study of children ages 4–6 years (n=210); Norway
	HHg mean
	  Fish diet: 0.529 µg/g
	  Meat diet: 0.315 µg/g
		WPPSI:	

		Full scale IQ	↔ (HHg, child)
		Verbal IQ	↔ (HHg, child)
		Performance IQ	↔ (HHg, child)
		Processing speed	↔ (HHg, child)

Kim et al. 2018
 	
Prospective cohort of mother-infant pairs, follow-up at age 6 months (n=662), 12 months (n=595), 24 months (n=523), and 36 months (n=438); Republic of Korea
	BHg geometric mean
	  Maternal (late pregnancy): 3.0 µg/L
	  Cord: 5.1 µg/L
		BSID 6 months	↔ (BHg, maternal)
			↔ (BHg, cord)

		BSID 12 months	↔ (BHg, maternal) ↔ (BHg, cord)
		BSID 24 months	↔ (BHg, maternal) ↔ (BHg, cord)
		BSID 36 months	↔ (BHg, maternal) ↔ (BHg, cord)

Kim et al. 2020a
 	
Prospective birth cohort, follow-up at age 36 months (n=451); Republic of Korea
	BHg median
	  Maternal: 3.15 µg/L
	  Cord: 5.42 µg/L
		BSID MDI:	↔ (BHg, maternal)

		MDI low folate	↓ (BHg, maternal) ↓ (BHg, cord)
		MDI high folate	↔ (BHg, maternal) ↔ (BHg, cord)
		PDI low folate	↓ (BHg, maternal) ↓ (BHg, cord)
		PDI high folate	↔ (BHg, maternal) ↔ (BHg, cord)

Table 2-50. Results of Epidemiological Studies Evaluating General Population Exposure to Mercury (Predominant Mercury Form Unknown) and Neurodevelopmental Effects

Reference, study type, and population	Biomarker	Outcome evaluated	Result[a]
Kobayashi et al. 2022 Prospective birth cohort, follow-up at ages 6 months to 4 years (n=48,731); Japan	BHg median Maternal: 3.64 µg/kg Cord: 7.56 µg/kg (n=3,083)	ASQ:	
		Communication	↔ (BHg, maternal) ↔ (BHg, cord)
		Gross motor	↔ (BHg, maternal) ↔ (BHg, cord)
		Fine motor	↔ (BHg, maternal) ↔ (BHg, cord)
		Problem solving	↔ (BHg, maternal) ↔ (BHg, cord)
		Social skills	↔ (BHg, maternal) ↔ (BHg, cord)
Lam et al. 2013 Prospective cohort of mother-infant pairs, follow-up at age 8 years (n=608); Hong Kong	BHg median Cord: 9.21 µg/L	WISC-HK (picture arrangement)	↓ (BHg, cord)
		WISC-HK (total)	↔ (BHg, cord)
		HKLLT (recall)	↓ (BHg, cord)
		TEACH	↔ (BHg, cord)
		BNT	↔ (BHg, cord)
		GPB	↔ (BHg, cord)
Lederman et al. 2008 Prospective cohort of mother-infant pairs, follow-up at ages 12, 24, and 36 months (n=280); New York	BHg mean Cord: 7.82 µg/L Maternal: 2.32 µg/L	BSID MDI, 12 months	↔ (BHg, cord)
		BSID PDI, 12 months	↔ (BHg, cord)
		BSID MDI, 24 months	↔ (BHg, cord)
		BSID PDI, 24 months	↔ (BHg, cord)
		BSID MDI, 36 months	↔ (BHg, cord)
		BSID PDI, 36 months	↓ (BHg, cord)
		WPPSI-R IQ, 48 months	↓ (BHg, cord)
Llop et al. 2012 Prospective cohort of mother-infant pairs (n=1,683) follow-up at age 14 months; Spain	BHg geometric mean Cord: 8.4 µg/L	BSID MDI	↔ (BHg, cord)
		BSID PDI	↔ (BHg, cord)

Table 2-50. Results of Epidemiological Studies Evaluating General Population Exposure to Mercury (Predominant Mercury Form Unknown) and Neurodevelopmental Effects

Reference, study type, and population	Biomarker	Outcome evaluated	Result[a]
Llop et al. 2012 Prospective cohort of mother-infant pairs (n=1,242) follow-up at age 4–5 years; Spain	HHg geometric mean Child: 0.98 µg/g	MSCA general	↑ (HHg, child)
		MSCA verbal	↑ (HHg, child)
		MSCA memory	↑ (HHg, child)
		MSCA numeric	↔ (HHg, child)
		MSCA motor	↔ (HHg, child)
Lozano et al. 2021 Prospective birth cohort, follow-up at ages 9 years (n=403) and 11 years (n=328); Spain	HHg geometric mean Child: 0.89 µg/g	ANT hit reaction time standard error	↔ (HHg, child)
		CBCL internalizing	↑ (HHg, child)
		CBCL externalizing	↔ (HHg, child)
		CPRS ADHD Index	↔ (HHg, child)

McKean et al. 2015
 	
Case-control study of 164 autism cases at ages 2–5 years; California
	BHg median
	  Neonatal autism:
	  3.41 µg/L
	  Neonatal controls:
	  3.48 µg/L
		Autism	↔ (BHg, child)

Murata et al. 2004b
 	
Cross-sectional cohort of 327 mother-child pairs, age 7 years; Japan
	HHg mean
	  Maternal: 1.63 µg/g
	  Child: 1.65 µg/g
		BAEPL	↔ (HHg, maternal)

Oken et al. 2008 Prospective cohort of mother-infant pairs, follow-up at age 38 months (n=341); Massachusetts	ErHg mean Maternal: 3.8 ng/g	PPVT	↓ (ErHg, maternal)
		WRAVMA	↓ (ErHg, maternal)
Oken et al. 2016 Prospective cohort of mother-infant pairs, follow-up at 8 years (n=872); Massachusetts	ErHg mean Maternal: 4.0 ng/g	KBIT	↔ (ErHg, maternal)
		WRAVMA	↔ (ErHg, maternal)
		WRAML	↔ (ErHg, maternal)
Orenstein et al. 2014 Prospective cohort of mother-infant pairs, follow-up at age 8 years (n=393); Massachusetts	HHg mean Maternal: 0.6 µg/g	WRAML verbal	↔ (HHg, maternal)
		WRAML visual	↓ (HHg, maternal)
		WRAML learning	↔ (HHg, maternal)

Table 2-50. Results of Epidemiological Studies Evaluating General Population Exposure to Mercury (Predominant Mercury Form Unknown) and Neurodevelopmental Effects

Reference, study type, and population	Biomarker	Outcome evaluated	Result[a]

Nakamura et al. 2023
 	
Cross-sectional study of children ages 7–8 years (n=134); Japan
	Cord tissue (CHg) Gmean 0.11 µg/g
	HHg Gmean
	  Maternal: 2.65 µg/g
	  (estimated from preserved cord tissue)
	  Child: 2.94 µg/g
		WISC full scale IQ	↔ (CHg, maternal)
			↔ (CHg, child)

		WISC verbal IQ	↔ (CHg, maternal)
		WISC performance IQ	↔ (CHg, maternal) ↔ (HHg, child)
		BNT	↔ (CHg, maternal) ↔ (HHg, child)
		BAEPL I–V interval	↔ (CHg, maternal, male) ↔ (CHg, maternal, female) ↑ (HHg, child, male) ↔ (HHg, child, female)
		BAEPL III–V interval	↑ (CHg, maternal, male) ↔ (CHg, maternal, female) ↑ (HHg, child, male) ↔ (HHg, child, female)
		VEP N145 latency	↑ (CHg, maternal, male) ↔ (CHg, maternal, female) ↔ (HHg, child, male) ↔ (HHg, child, female)
		Color vision	↔ (CHg, maternal, male) ↔ (CHg, maternal, female) ↔ (HHg, child, male) ↔ (HHg, child, female)

Table 2-50. Results of Epidemiological Studies Evaluating General Population Exposure to Mercury (Predominant Mercury Form Unknown) and Neurodevelopmental Effects

Reference, study type, and population	Biomarker	Outcome evaluated	Result[a]
Packull-McCormick et al. 2023 Prospective cohort of mother-infant pairs, follow-up at age 26–47 months (n=527); Canada	BHg median[c] Maternal: 0.68, 0.60 µg/L Cord: 0.91 0.62 µg/L Child: 0.18, 0.20 µg/L	Full-scale IQ	↔ (BHg, maternal; male) ↔ (BHg, maternal; female) ↔ (BHg, cord; male) ↑ (BHg, cord; female) ↔ (BHg, child; male) ↑ (BHg child; female)
		Verbal IQ	↔ (BHg, maternal; male) ↔ (BHg, maternal; female) ↔ (BHg, cord; male) ↔ (BHg, cord; female) ↔ (BHg, child; male) ↑ (BHg child; female)
		Performance IQ	↔ (BHg, maternal; male) ↔ (BHg, maternal; female) ↔ (BHg, cord; male) ↓(BHg, cord, male in lowest maternal fish consumption group) ↑ (BHg, cord; female) ↔ (BHg, child; male) ↔ (BHg child; female)
		Language	↔ (BHg, maternal; male) ↔ (BHg, maternal; female) ↔ (BHg, cord; male) ↔ (BHg, cord; female) ↔ (BHg, child; male) ↑ (BHg child; female)
Patel et al. 2019 Prospective birth cohort, follow-up at ages 2–8 years (n=389); Ohio	BHg median Maternal: 0.67 µg/L	BASC (behavior)	↔ (BHg, maternal)
		SCAS (anxiety)	↔ (BHg, maternal)
Polevoy et al. 2020 Prospective birth cohort, follow-up at age 6.6 months (n=429); Canada	BHg median Maternal: 0.6 µg/L Cord: 0.7µg/L	Visual acuity	↔ (BHg, maternal) ↔ (BHg, cord)

Table 2-50. Results of Epidemiological Studies Evaluating General Population Exposure to Mercury (Predominant Mercury Form Unknown) and Neurodevelopmental Effects

Reference, study type, and population	Biomarker	Outcome evaluated	Result[a]
Renzetti et al. 2021 Cross-sectional study of mother-child pairs, evaluation at age 6–11 years (n=299); Italy	HHg median Child: 0.477 µg/g	CBCL	↔ (HHg, child)
		SRS	↔ (HHg, child)
Rodríguez-Carrillo et al. 2022 Prosecutive birth cohort, follow-up at age 15–17 years (n=151); Spain	UHg median Child: 0.76 µg/L	CBCL	
		Withdrawn	↑ (UHg, child)
		Social problems	↑ (UHg, child)
		Internalizing	↔ (UHg, child)
		Externalizing	↔ (UHg, child)

Rothenberg et al. 2016b
 	
Prospective cohort of 270 mother-infant pairs, follow-up at age 12 months; China
	HHg Gmean
	  Maternal: 0.47 µg/g
	HMeHg Gmean
	  Maternal: 0.26 µg/g
	  (65%, range 30–108)
		BSID MDI	↓ (HHg, maternal)

		BSID PDI	↔ (HHg, maternal)
Rothenberg et al. 2021 Prospective cohort of 190 mother-infant pairs, follow-up at age 36 months; China	HHg median Maternal: 0.42 µg/g	BSID MDI	↔ (HHg, maternal)
		BSID PDI	↔ (HHg, maternal)

Ryu et al. 2017
 	
Prospective cohort of mother-infant pairs, follow-up at 5 years (n=458); Republic of Korea
	BHg geometric mean
	  Maternal (late pregnancy): 3.30 µg/L
	  Cord: 5.52 µg/L
	  Child (age 3 years): 2.16 µg/L
		SRS (autistic behaviors)	In male children:
			↑ (BHg, maternal)
			↑ (BHg, cord)
			↔ (BHg, child)
			
			In female children:
			↔ (BHg, maternal)
			↔ (BHg, cord)
			↔ (BHg, child)

Sagiv et al. 2012 Prospective study of mother-infant pairs, follow-up at age 8 years (n=421); Massachusetts	HHg median Maternal: 0.45 µg/g	CTRS (impulsive/ hyperactive)	↑ (HHg, maternal)
		NES CPT	↔ (HHg, maternal)
		WISC-III (processing speed)	↓ (HHg, maternal)

Shah-Kulkarni et al. 2020
 	
Prospective birth cohort, follow-up at 6 months (n=523); Republic of Korea
	BHg geometric mean
	  Early pregnancy; 3.30 µL
	  Late pregnancy: 3.13 µg/L
	  Cord: 5.21 µg/L
		BSID MDI	↔ (BHg, maternal)

		BSID PDI	↔ (BHg, maternal)

Table 2-50. Results of Epidemiological Studies Evaluating General Population Exposure to Mercury (Predominant Mercury Form Unknown) and Neurodevelopmental Effects

Reference, study type, and population	Biomarker	Outcome evaluated	Result[a]
Skogheim et al. 2021 Case-control study of mother-infant pairs, age >2 years (n=705 ADHD cases, 397 ASD cases, 1034 controls); Norway	BHg Gmean Maternal: 1.17	ADHD	↓ (BHg, maternal)
		ASD	↓ (BHg <1 µg/L, maternal)

Snoj Tratnik et al. 2017
 	
Prospective study of mother-infant pairs, follow-up at age 18 months (n=361); Slovenia
	BHg Gmean
	  Cord: 2.06 µg/L
	
	HHg Gmean
	  Maternal: 0.361 µg/g
		BSID III
		Cognitive
			↔ (BHg, cord)
			↔ (HHg, maternal)

		Language	↔ (BHg, cord) ↔ (HHg, maternal)
		Motor	↔ (BHg, cord) ↔ (HHg, maternal)
		Fine motor	↓ (BHg, cord) ↔ (HHg, maternal)
		Gross motor	↔ (BHg, cord) ↔ (HHg, maternal)
Stewart et al. 2003 Prospective study of mother-infant pairs, follow-up at age 38 months (n=194) and 54 months (n=197); New York	HHg median Maternal: 0.50 µg/g	MSCA 38 months	↓ (HHg, maternal, prenatal PCB detected)
		MSCA 54 months	↔ (HHg, maternal)
Taylor et al. 2018a Prospective study (ALSPAC) of mother-infant pairs, follow-up at age 7 years (n=1,558); United Kingdom	BHg median Maternal: 2.23 µg/L	ALSPAC CT (5 subtests)	↔ (BHg, maternal)
		DCD	↔ (BHg, maternal)

Valent et al. 2013
 	
Prospective cohort of mother-infant pairs, follow-up at age 18 months (n=606); Italy
	BHg median
	  Maternal: 0.00235 µg/g
	  Cord: 0.00397 µg/g
	
	HHg median
	  Maternal: 0.788 µg/g
		BSID composite scores (cognitive, language, motor, social-emotional, adaptive behavior)	↔ (HHg, maternal)
			↔ (BHg, maternal
			↔ (BHg, cord)

Vejrup et al. 2016
 	
Prospective cohort (MoBa) of mother-infant pairs, follow-up at age 3 years (n=46,750); Norway
	Dietary fish mercury median
	  Maternal: 1.3 µg/day
	  Maternal: 0.14 µg/kg/week
		DBGR (speech)	↓ (maternal dietary fish mercury >2.6 µg/day)

		ASQ (language)	↓ (maternal dietary fish mercury >2.6 µg/day)

Table 2-50. Results of Epidemiological Studies Evaluating General Population Exposure to Mercury (Predominant Mercury Form Unknown) and Neurodevelopmental Effects

Reference, study type, and population	Biomarker	Outcome evaluated	Result[a]
Vejrup et al. 2018 Prospective cohort (MoBa) of mother-infant pairs, follow-up at age 5 years (n=38,581); Norway	BHg median (n=2,232) Maternal: 1.03 µg/L Dietary fish mercury median Maternal: 0.15 µg/kg/week	ASQ (language)	↔ (BHg, maternal) ↓ (maternal dietary seafood ≤400 g/week) ↔ (maternal dietary seafood >400 g/week)
		SLAS (language)	↔ (BHg, maternal) ↓ (maternal dietary seafood ≤400 g/week) ↔ (maternal dietary seafood >400 g/week)
		Language 20	↔ (BHg, maternal) ↔ (maternal dietary seafood ≤400 g/week) ↔ (maternal dietary seafood >400 g/week)
Vejrup et al. 2022 Prospective cohort (MoBa) of mother-infant pairs, follow-up at age 3 and 5 years (n=51,238); Norway	BHg median (n=2,936) Maternal: 1.02 µg/L Dietary fish mercury median Maternal: 0.15 µg/kg/week	CBCL internalizing behavior	↔ (BHg, maternal) ↓ (maternal dietary)
		CBCL externalizing behavior	↔ (BHg, maternal) ↓ (maternal dietary)
Wang et al. 2019a Prospective birth cohort, follow-up at age 2 days and 18 months (n=286); China	BHg, geometric mean Cord: 2.00 µg/L	NBNA (3 days)	↓ (BHg, cord)
		NBNA (3 days)	↓ (BHg, cord, low DHA)
		NBNA (3 days)	↔ (BHg, cord, high DHA)
		BSID	↔ (BHg, cord)
Wu et al. 2014 Prospective cohort of mother-infant pairs, follow-up at age 3 days (n=418); China	BHg median Maternal: 5.00 µg/L Cord: 7.62 µg/L HHg median Maternal: 1.08 µg/g	NBNA (total)	↑ (BHg, cord)
		NBNA (behavior)	↔ (BHg, cord)
		NBNA (passive muscle tone)	↑ (BHg, cord)
		NBNA (active muscle tone)	↑ (BHg, cord)
Xu et al. 2016 Prospective cohort of mother-infant pairs, follow-up at age 5 weeks (n=344); Ohio	BHg geometric mean Maternal: 0.6 µg/L Cord: 0.72 µg/L	NICU NNS	↔ (HHg, maternal) ↔ (HHg, cord)
Yau et al. 2014 Retrospective cohort of 84 autism cases and 49 developmental delay cases at age 3–4 years; California	SHg geometric mean Maternal autism: 0.48 µg/L Maternal control: 0.32 µg/L	Autism	↔ (maternal serum Hg) ↔ (child BHg)

Table 2-50. Results of Epidemiological Studies Evaluating General Population Exposure to Mercury (Predominant Mercury Form Unknown) and Neurodevelopmental Effects

Reference, study type, and population	Biomarker	Outcome evaluated	Result[a]
	BHg geometric mean Neonatal autism: 3.52 µg/L Neonatal control: 2.85 µg/L		

[a]Interpretation of neurobehavioral test scores:
  ADHD: higher score = more behavioral problems
  ASD: higher score = more behavioral problems
  ALSPAC CT: higher score = higher performance
  ANT hit reaction time standard error: higher score = lower performance
  ASQ: higher score = more behavioral problems
  BASC: higher score = more behavioral problems
  BNT: higher score = higher performance
  BSID: higher score = higher performance
  CBCL: higher score = lower performance
  CPT: longer response time = lower performance
  CTRS: higher score = lower performance
  DBGR: higher score = higher performance
  DCD: higher score = more behavioral problems
  DDST-II: milestones evaluated against a standard; below standard = delayed development
  GDS: higher score = higher performance
  GPB: higher score = lower performance
  HKLLT: higher score = higher performance
  IDS: higher score = higher performance
  KBIT: higher score = higher performance
  Language 20: higher score = higher performance
  MSCA: higher score = higher performance
  MSCA: higher score = higher performance
  NBNA: higher score = higher performance
  NICU NNS: higher score = higher performance
  PEDS: higher score = higher performance
  PPRVT: higher score = higher performance
  RCPM: higher score = higher performance
  SCAS: higher score = more behavioral problems
  SDQ: higher score = more behavioral problems
  SLAS: higher score = higher performance
  SRS: higher score = more behavioral problems
  TEACH: higher score = higher performance
  WISC-III: higher score = higher performance
  WPPSI-RK: higher score = higher performance
  WRAVMA: higher score = higher performance
[b]Weighted mean of age group medians reported in Hibbeln et al. (2018) Appendix A, Table 1,
[c]Values are for pregnancies that resulted in male or female newborns (reported as male, female). Outcomes were assessed for associations with maternal, cord or concurrent child blood Hg concentrations.

↑ = positive association; ↓ = inverse association; ↔ = no association; ADHD = attention deficit/hyperactivity disorder; ALSPAC = Avon Longitudinal Study of Parents and Children; ANT = Attention Network Test; ASD = autism spectrum disorder; ASQ = Ages and Stages Communication Scale; BAEPL = brainstem auditory evoked potential latencies; BASC = Behavioral Assessment System for Children; BHg = blood mercury; BMMeHg = breastmilk mercury; BNT = Boston naming test; BRIEF GEC = Behavior Rating Inventory of Executive Function Global Executive Composite; BSID = Bayley Scales of Infant Development; CBCL = Child Behavior Checklist; CHg = cord mercury; CPRS = Connors' Teacher Rating Scale; CT = Coordination Test; CTRS = Connors' Teacher Rating Scale;

Table 2-50. Results of Epidemiological Studies Evaluating General Population Exposure to Mercury (Predominant Mercury Form Unknown) and Neurodevelopmental Effects

Reference, study type, and population	Biomarker	Outcome evaluated	Result[a]
DBGR = Dale and Bishop Grammar Rating; DCD = Development Coordination Disorder; DDST = Denver Developmental Screening Test; DHA = docosahexaenoic acid; ErHg = erythrocyte mercury; FSIQ = full scale intelligence quotient; GDS = Gesell Development Schedules; Gmean = geometric mean; GPB = grooved pegboard; HHg = hair mercury; HKLLT = Hong Kong List Learning Test; HMeHg = hair methylmercury; IDS = Intelligence and Development Scales; IQ = intelligence quotient; KBIT = Kauffman Brief Intelligence Test; KNHANES = Korea National Health and Nutrition Examination Survey; MDI = BSID Mental Development Index; MoBa = Norwegian Mother and Child Cohort Study; MSCA = McCarthy Scales of Children's Abilities; NBNA = Neonatal Behavioral Neurological Assessment; NES CPT = Neurobehavioral Evaluation Systems Continuous Performance Test; NHg = nail mercury; NICU NNS = Neonatal Intensive Care Unit Network Neurobehavioral Scale; OR = odds ratio; PCB = polychlorinated biphenyl; PDI = BSID Psychomotor Development Index; PEDS = Parents Evaluation of Developmental Status; PIQ = Performance Intelligence Quotient; PPVT = Peabody Picture Vocabulary Test; RCPM = Raven Coloured Progressive Matrices; SCAS = Spence Children's Anxiety Scale; SDQ = Strengths and Difficulties Questionnaire; SHg = serum mercury; SLAS = Speech and Language Assessment Scale; SRS = Social Responsiveness Scale; TEACH = Test for Everyday Attention for Children; UHg = urine mercury; VEP = visual evoked potential; VIQ = Verbal Intelligence Quotient; WISC = Wechsler Intelligence Scale; WISC-III = Wechsler Intelligence Scale, 3rd Edition; WISC-IV = Wechsler Intelligence Scale, 4th Edition; WISC-HK = Wechsler Intelligence Scale, Hong Kong; WPPSI = Wechsler Preschool and Primary Scale Intelligence; WPPSI-R = Wechsler Preschool and Primary Scale Intelligence, Revised; WPPSI-RK = Wechsler Preschool and Primary Scale Intelligence, Revised, Korean; WRAML = Wide Range Assessment of Memory and Learning; WRAVMA = Wide Range Assessment of Visual Motor Abilities			

In general populations, blood and HHg will be more greatly affected by exposures to other forms of mercury (e.g., mercury from amalgams) than in high fish consuming populations in which methylmercury is the dominant contributor to mercury body burden. Therefore, general population studies that estimated oral intake of methylmercury directly are stronger designs for the purpose of dose-response assessments of methylmercury. One study found associations between methylmercury intake and language proficiency (Vejrup et al. 2016, 2018).

General populations are exposed to a mixture of elemental, inorganic, and organic mercury. The relative contribution from each form of mercury in the studied populations is likely to vary with diet, number and state of mercury amalgam dental restorations, and extent of occupational exposures. Given the uncertainty in the source of exposure to mercury, the biomarkers used to represent exposure (e.g., total HHg, total BHg) cannot be confidently attributed to any specific form of mercury (Section 3.3.1, Biomarkers of exposure).

A possible exception to uncertainty about the mercury form in studies of general population exposures is a large prospective study conducted in Norway (Vejrup et al. 2016, 2018). This study examined a birth cohort consisting of 46,750 mother-infant pairs recruited during the period 1999–2008. Dietary intake of

mercury from fish consumption was estimated in each mother based on outcomes of a food frequency questionnaire (FFQ) completed during pregnancy and a survey of mercury levels in fish consumed by Norwegians (Jenssen et al. 2012). Median mercury intake from fish consumption was estimated to be 0.14 µg Hg/kg/week (range 0.0–1.68 µg Hg/kg/week). The 90th percentile was 0.29 µg Hg/kg/week. (Vejrup et al. 2016). The median intake of fish and seafood was 32 g/day with a range of 0–292 g/day (Vejrup et al. 2016). Since dietary intakes of mercury in fish (which is dominated by methylmercury) were estimated, this study did not use biomarkers for the dose metrics.

The Norwegian study (Vejrup et al. 2016, 2018) evaluated language proficiency and communication skills using parent-administered questionnaires. For the most part, Vejurp et al. (2018) found associations between increasing dietary intake of mercury from fish (µg/kg body weight/week), when maternal seafood consumption was ≤400 g/week, with decreasing performance on language proficiency tests administered at 5 years of age. At 3 years of age, high (>0.29 µg Hg/kg/week) maternal mercury exposure was associated with unintelligible speech (OR 2.22; 95% CI 1.31, 3.72) on the Dale and Bishop Grammar Rating (Vejrup et al. 2016). An association was also observed for high maternal mercury exposure and weak communication skills (OR 1.33; 95% 1.03, 1.70) on the Ages and Stages Communication Scale, ASQ (Vejrup et al. 2016).

Adjustment for known important confounders related to fish consumption, including fish consumption rate (adjustment strengthened the association with mercury), 3-omega LCPUFA consumption, and exposure to PCBs did not affect associations (Vejrup et al. 2016). Maternal mercury exposure (>0.29 µg Hg/kg/week) was associated with weak communication skills when LCPUFA (diet or from supplements) or PCBs were added to the analysis. However, there was a slight reduction in the association of maternal mercury and weak communication (OR 1.29; 95% 1.00, 1.67) when adjusted for exposure to dioxin and PCBs (Vejrup et al. 2016). Estimates of ORs were adjusted for parity, parental education, pre-pregnancy BMI (Vejrup et al. 2016, 2018), bilingual parents, age when child began speaking (Vejrup et al. 2016), maternal age, total energy intake, and two (EPA, DHA) LCPUFAs (Vejrup et al. 2018).

In a follow-up at age 5 years, children were assessed with three outcome tests: ASQ, Speech and Language Assessment Scale, and Twenty Statements about Language-Related Difficulties (Vejrup et al. 2018). No associations were observed with mid-pregnancy maternal BHg concentrations in a subcohort of the main cohort (2,232 subjects) in which BHg levels were measured (median 1.0 µg Hg/L; range 0–14 µg Hg/L). However, in the full cohort (n=38,397) among women who consumed ≤400 g fish/week, both fish consumption and mercury intake were associated with improvement of scores (negative error

scores) in the ASQ (adjusted β -0.16; 95% CI -0.3, -0.02) and Speech and Language Assessment Scale (-0.22; 95% CI -0.4, -.01).

When Vejrup et al. (2018) confined the analyses to matched siblings, dietary fish mercury intake at the 90th percentile level (>3.18 μg Hg/day) was associated with decreasing performance on the Speech and Language Assessment Scale (adjusted β 0.1; 95% CI 0.1, 0.2) but not on the Ages and Stages Communication Scale or Language-Related Difficulties scale. These results suggest that fish intake was a confounding variable in this study (correlation between dietary fish mercury intake and fish intake was 0.88) and may have attenuated associations between dietary methylmercury intake and delays in attainment of language skills. The absence of an association with maternal BHg may represent variance in BHg levels that is unrelated to dietary methylmercury intake (e.g., mercury from amalgam restorations).

Emotional behavior was also examined in the Norwegian birth cohort study (Vejrup et al. 2022). The Child Behavior Checklist was used to assess internalizing behavior (symptoms of anxiety or depression) and externalizing behavior (symptoms of aggressive behavior attention disorder) at age 3 and 5 years. Increasing dietary methylmercury intake (median 0.15 μg MeHg/kg/week) was associated with decreasing internalization and externalization scores (n=46,283). No association was evident between behavior and maternal BHg (median 1.02 μg Hg/L; n=2,744).

Similar to Vejrup et al. (2018), another large prospective study conducted in Japan (n=48,731) found no evidence for an association between maternal BHg levels (median 3.64 μg/kg) and neurodevelopment assessed from scores on the ASQ (Kobayashi et al. 2022). In a subset of the cohort (n=3,083), no association was found when the exposure biomarker was cord BHg (median 7.56 μg/kg).

Results from smaller studies that have examined associations between mercury exposure biomarkers and language proficiency have been inconsistent (Barbone et al. 2019; Freire et al. 2010; Hu et al. 2016; Jeong et al. 2017; Julvez et al. 2013, Kobayashi et al. 2022; Lederman et al. 2008; Orenstein et al. 2014; Rothenberg et al. 2016b; Snoj Tratnik et al. 2017; Valent et al. 2013). For example, Barbone et al. (2019) and Jeong et al. (2017) reported opposite outcomes for the association between BHg and language outcomes and most of the other studies reported no association (Table 2-50) for the same comparators. Further details are provided in the following paragraphs.

A large prospective study conducted in Japan (n=48,731) found no evidence for an association between maternal BHg levels (median 3.64 µg/kg) and neurodevelopment assessed from scores on the ASQ (Kobayashi et al. 2022). In a subset of the cohort (n=3,083), no association was found when the exposure biomarker was cord BHg.

A prospective study conducted in the Republic of North Korea (553 mother-infant pairs) found an inverse association between increasing maternal blood mercury (median 3.1 µg Hg/L) and verbal proficiency at age 5 years (Jeong et al. 2017). The effect size was estimated to be a 2.48 verbal IQ points (95% CI 0.72, 4.2) per doubling of maternal blood mercury. The Barbone et al. (2019) meta-analysis of populations in Mediterranean Europe (1,308 mother infant pairs) found an association between increasing prenatal (cord) blood mercury (median 3.6 µg Hg/L) and improved language performance at age 18 months, based on scores on the Bayley Scales of Infant Development. Mercury levels in the Barbone et al. (2019) study were similar to the Jeong et al. (2017) study (described above), which found an association between prenatal blood mercury and declining language proficiency. Other studies found declines in language or verbal performance (Freire et al. 2010) or no association (Hu et al. 2016; Julvez et al. 2013; Orenstein et al. 2014) with mercury exposure biomarkers.

A cross-sectional study examined associations between a short-term increase in exposure to methylmercury and IQ in children (Kvestad et al. 2018). In this study, children (n=210, age 4–6 years) were fed fish or meat lunches for 16 weeks. Mean HHg levels were 0.53 µg Hg/g in children who consumed fish lunches (0.16 µg Hg/g increase from pre-fish lunch diet). The mean HHg was 0.32 µg Hg/g in children who consumed meat lunches (-0.052 µg Hg/g change from pre-meat lunch diet). This study found no differences in scores on tests of IQ (full-scale, verbal, performance, or processing speed) between children who consumed fish or meat lunches and no association between HHg and IQ prior to starting the fish or meat lunch diets.

Several studies measured cognitive performance with the Bayley Scales of Infant Development at various ages, allowing comparison of the same outcomes across studies. Two of these studies found an inverse association with cord BHg (0.9 µg Hg/L) at age 12 months (Jedrychowski et al. 2006; Rothenberg et al. 2016b). One study found a positive association with cord BHg (median 3.6 µg Hg/L) at age 18 months (Barbone et al. 2019). However, an inverse association with cord BHg (mean 7.8 µg Hg/L) was observed at age 36 months, but not at younger ages (Lederman et al. 2008). Ten other studies found no association with cord or maternal BHg of HHg levels (median range >0.9–8.4 µg Hg/L) at ages 12–36 months (Table 2-50) .

When Jedrychowski et al. (2006) did not adjust for fish consumption or exposure to lead or PCBs, an inverse association was observed. When Jedrychowski et al. (2007) did adjust for fish consumption, there was no association. However, this was not the case for Rothenberg et al. (2016b) where the inverse association was strengthened after adjustment for maternal fish and shellfish consumption, rice consumption, and total energy intake. Other studies that found no association adjusted their regression models for fish consumption (Kim et al. 2018; Llop et al. 2012; Valent et al. 2013) and PCB and lead exposure (Llop et al. 2012). The inverse association observed in the Rothenberg et al. (2016b) study was strengthened after adjustment for maternal fish and shellfish consumption, rice consumptions, and total energy intake. Studies that found no association adjusted their regression models for fish consumption (Jedrychowski et al. 2007; Kim et al. 2018; Llop et al. 2012; Valent et al. 2013) and PCB and lead exposure (Llop et al. 2012).

Exposure to PCBs was found to be an important modifier of the association between cognitive performance measured with the McCarthy Scales of Children's Abilities at age 38 months (Stewart et al. 2003). Lederman et al. (2008) found an inverse association between cord BHg (mean 7.8 µg Hg/L) and IQ measured at age 48 months (Wechsler Preschool and Primary Scale Intelligence, Revised), after adjustment for fish and seafood consumption during pregnancy and other potential confounders (maternal age, race, education IQ, income, marital status, exposure to tobacco smoke, and material hardship; child sex, gestational age, and age at testing). The effect size was -3.6 IQ point per ln (µg/L), which corresponds to a 2.5-point decrease in IQ per doubling of cord BHg.

Latency of brainstem auditory evoked potentials was not associated with increasing maternal HHg in a prospective study (327 mother-infant pairs) conducted in Japan (Murata et al. 2004b). This observation is notable because increased latency of auditory evoked potentials was observed in the Faroe Islands and Madeira Portugal studies of high fish consumption populations (Grandjean et al. 1997, 1998, 2003; Murata et al. 1999a, 1999b). Maternal HHg was higher in the Faroe Islands cohort (median 4.3 µg Hg/g) and Madeira cohort (9.4) compared to the Japanese cohort (mean 2 µg Hg/g). A cross-sectional analysis of data from the KNHANES (853 adolescents) found no association between BHg levels in 853 adolescents (mean 2.0 µg Hg/L) or 5,187adults (mean 3.6 µg Hg/L) and speech-frequency or high-frequency hearing loss (Choi and Park 2017).

Several studies have examined associations between mercury exposure biomarkers (blood or urinary mercury) and signs of autism spectrum disorder (Golding et al. 2016a, 2016b, 2017, 2018; Hertz-Picciotto

et al. 2010; McKean et al. 2015; Ryu et al. 2017; Skogheim et al. 2021; Yau et al. 2014). In general, these studies found no associations between behaviors indicative of autism spectrum disorder and exposure to mercury. The largest prospective study reported (approximately 3,000 mother infant pairs) found no associations between maternal BHg levels (median 1.86 µg Hg/L) and signs of autism (Golding et al. 2016a, 2017, 2018). A smaller prospective study (450 mother-infant pairs) found an association between increasing maternal BHg levels (median 3.3 µg Hg/dL) and increasing scores for autistic behaviors on the Social Responsiveness Scales, in male children age 5 years, but not in females (Ryu et al. 2017). Several case-control studies have not found differences in covariate-adjusted BHg concentrations between autism cases and controls (Hertz-Picciotto et al. 2010; McKean et al. 2015; Yau et al. 2014). Skogheim et al. (2021) found an inverse association between maternal BHg concentrations and OR for autism spectrum and ADHD diagnosis, with elevated ORs at maternal BHg levels >1 µg/L. Meta-analyses have found elevated meta-ORs for autism spectrum disorder or ADHD in association with increasing mercury exposure (Nilsen and Tulve 2020; Yoshimasu et al. 2014).

2.16.2 Neurological Effects in Adults

Elemental Mercury—Epidemiological Studies. Studies of neurological function have been conducted in workers in various industries who were exposed to mercury vapor. Studies of neurological outcomes in workers are summarized in Table 2-51. The following populations exposed to elemental mercury were evaluated: chloralkali workers; florescent lamp workers; thermometer production workers; dental workers; workers in other industries; and populations with amalgam fillings. In some studies, work area or breathing zone mercury levels measured in a subset of the study group were reported. The most common biomarker reported was UHg (µg Hg/L or µg Hg/g creatinine). In cross-sectional studies, these were based on measurements made at the time of outcome assessment. In retrospective studies, UHg estimates were derived from historical industrial hygiene monitoring data and, in some studies, were aggregated into metrics of cumulative exposure (e.g., sum of quarterly average values for all exposure years) or exposure intensity (sum/exposure years). Most of the studies included in this discussion compared outcomes measured in exposed workers to a reference group of workers who were not exposed to elemental mercury. Potential selection bias and confounding were addressed by matching (e.g., age, sex, alcohol and smoking history, duration of exposure-related work) or by exclusion (e.g., head injuries, known neurological disease). However, other numerous potential variables that could have affected performance on tests of cognitive function (e.g., nutrition, exposure to other chemicals) were not evaluated (see discussion of characterization of effects on neurodevelopment). Collectively, these studies provide evidence for associations between exposure to mercury vapor and several categories of

neurological effects, including tremor, vision, nerve conduction, and cognitive performance (motor speed and coordination, memory, and integrative function).

Table 2-51. Results of Epidemiological Studies Evaluating Exposure to Elemental Mercury (Hg⁰) and Neurological Effects

Reference, study type, and population	Biomarker	Outcome evaluated[a]	Result
Chloralkali workers			
Albers et al. 1982 Retrospective cohort of 138 workers; United States	UHg working mean 36-months: normal: 80 µg/L polyneuropathy: 120 µg/L	Motor nerve conduction	↓ UHg
		Sensory nerve conduction	↓ UHg

Bast-Pettersen et al. 2005
 	
Retrospective cohort of 49 former workers and 49 referents; Norway
	UHg cumulative work mean:
	16.5 µg/g Cr/year
	
	UHg mean at testing
	  Workers: 2.93 µg/g Cr
	  Referents: 2.04 µg/g Cr
	
	BHg mean at testing
	  Workers: 4.63 µg/L
	  Referents: 3.51 µg/L
		Hand tremor	↔ (exposed versus referents)

		Digit span test	↔ (exposed versus referents)
		Digit symbol test	↔ (exposed versus referents)
		Trail making test	↔ (exposed versus referents)
		Visual retention test	↔ (exposed versus referents)
		Finger tapping test	↔ (exposed versus referents)
		NES CPT	↔ (exposed versus referents)
Bluhm et al. 1992 Cross-sectional study of 26 workers and referent population (n=27); United States	UHg mean: 100–200 µg/24 hours BHg mean: 50–100 µg/L	Trail making test	↓ UHg ↓ (exposed versus referents)
		Stroup color-word test	↓ UHg ↓ (exposed versus referents)
		Finger tapping test	↓ UHg ↓ (exposed versus referents)
		Grooved pegboard test	↓ UHg ↓ (exposed versus referents)

Chang et al. 1995
 	
Retrospective cohort of 26 workers; China
	UHg mean at testing
	  Workers: 40.5 µg/24 hours
	  Referents: NR
	
	UHg mean at testing
	  Workers: 358 µg/g Cr
	  Referents: NR
	
	BHg mean at testing
		Visual evoked potential N1-P1 interpeak amplitude	↑ (exposed versus referents)

		BAEP latency	↑ (exposed versus referents)

Table 2-51. Results of Epidemiological Studies Evaluating Exposure to Elemental Mercury (Hg⁰) and Neurological Effects

Reference, study type, and population	Biomarker	Outcome evaluated[a]	Result
	Workers: 28 µg/L Referents: NR		
Ellingsen et al. 2001 Retrospective cohort of 47 former workers and 47 referents; Norway	UHg cumulative work mean: 16.0 µg/g Cr/year UHg mean at testing Workers: 10.5 µg/g Cr Referents: 2.3 µg/g Cr BHg inorganic mean at testing Workers: 4.15 µg/L Referents: 1.1 µg/L	Hand steadiness	↔ (exposed versus referents)
		Digit span test	↔ (exposed versus referents)
		Digit symbol test	↓ (BHg inorganic)
		Trail making test	↔ (exposed versus referents)
		Visual retention test	↓ (BHg inorganic)
		Finger tapping test	↔ (exposed versus referents)
		NES CPT	↔ (exposed versus referents)
Frumkin et al. 2001 Retrospective cohort of 139 former workers and 107 referents; United States	UHg mean at testing Workers: 2.76 µg/g Cr Referents: 2.31 µg/g Cr UHg working mean: 72.1 µg/L Air mercury average: range: 2–106 µg/m³	Tremor	↑ (exposed versus referents)
		Vibration threshold	↑ (exposed versus referents)
		Finger tapping	↓ (exposed versus referents)
		Nerve conduction composite	↑ (exposed versus referents)
		Motor speed composite	↔ (exposed versus referents)
		Motor coordination composite	↔ (exposed versus referents)
		Memory composite	↔ (exposed versus referents)
		Integrative functions	↔ (exposed versus referents)
Langolf et al. 1978 Retrospective study of 79 workers and 51 referents; United States	UHg working mean Workers: 240 µg/L Referents: 30 µg/L	Forearm tremor	↑ (UHg)
		Forearm EMG bandwidth	↑ (UHg)
		Finger tapping rate	↓ UHg
		Hand-eye coordination	↓ UHg

Table 2-51. Results of Epidemiological Studies Evaluating Exposure to Elemental Mercury (Hg⁰) and Neurological Effects

Reference, study type, and population	Biomarker	Outcome evaluated[a]	Result

Langworth et al. 1992a
 	
Retrospective sectional cohort of 89 workers and 75 referents; Sweden
	UHg working median
	  Workers: 25.4 µg/g Cr
	  Referents: 1.9 µg/g Cr
	
	BHg working median
	  Workers: 11 µg/L
	  Referents: 3.0 µg/L
	
	Air mercury mean: 25 µg/m³
		Forearm tremor	↔ (exposed versus referents)

		Hand-eye coordination	↔ (exposed versus referents)
		Finger tapping	↔ (exposed versus referents)
		Simple reaction time	↔ (exposed versus referents)
		Symbol digit	↔ (exposed versus referents)
		Digit span	↔ (exposed versus referents)
		Sternberg memory task	↔ (exposed versus referents)

Levine et al. 1982
 	
Retrospective cohort of 18 workers; United States
	UHg working mean
	  12-month average:
	  290 µg/L
	  24-month average:
	  210 µg/L
		Motor nerve conduction latency	↑ UHg (24-month average)

		Sensory nerve conduction latency	↑ UHg (12- and 24-month average)

Mathiesen et al. 1999
 	
Retrospective cohort of 75 former workers and 52 referents; Norway
	UHg cumulative work mean: 108 µg/L/year
	
	UHg mean at testing
	  Workers: 0.36 µg/g Cr
	  Referents: 0.24 µg/g Cr
	
	BHg mean at testing
	  Workers: 5.24 µg/L
	  Referents: 5.54 µg/L
		Visual retention	↓ UHg (cumulative/year)

		Grooved pegboard test	↓ UHg (months of exposure)
		Trail making test	↓ UHg (cumulative/year)
		Digit symbol test	↑ UHg (≥50 µg/g Cr) ↑ BHg (≥10 µg/L UHg (cumulative/year)

Miller et al. 1975
 	
Cross-sectional cohort of 77 workers and 65 referents; United States
	UHg group mean range
	  Workers: 129–787 µg/L
	  Referents: 7.11–152 µg/L
	
	BHg group mean range
	  Workers: 3.97–17.11 µg/L
	  Referents: 0.90–5.89 µg/L
		Forearm tremor	↑ UHg

		Forearm EMG bandwidth	↑ UHg

Table 2-51. Results of Epidemiological Studies Evaluating Exposure to Elemental Mercury (Hg⁰) and Neurological Effects

Reference, study type, and population	Biomarker	Outcome evaluated[a]	Result

Piikivi et al. 1984
 	
Retrospective cohort of 36 workers and referents; Finland
	UHg mean at testing
	  Workers: 58.3 µg/L
	  Referents: NR
	
	BHg mean at testing
	  Workers: 20.0 µg/L
	  Referents: NR
		Picture similarity test	↓ UHg (TWA >110 µg/L)
			↓ UHg (highest >300 µg/L)

		Logical memory	0 UHg (TWA >110 µg/L) ↓ UHg (highest >300 µg/L)
		Santa Ana dexterity test	↓ UHg (TWA <110 µg/L) ↓ UHg (highest <300 µg/L) ↓ (exposed versus referents)

Piikivi and Hänninen 1989
 	
Retrospective cohort of 60 workers and referents; Finland
	UHg mean at testing
	  Workers: 17.9 µg/g Cr
	  Referents: 2.1 µg/g Cr
	
	BHg mean at testing
	  Workers: 6.78 µg/L
	  Referents: 0.92 µg/L
	
	BHg (inorganic) TWA working mean: 5.94 µg/L
		Hand-eye coordination	↑ (exposed versus referents)

		Finger tapping	↔ (exposed versus referents)
		Memory and learning	↔ (exposed versus referents)
		Continuous performance test	↔ (exposed versus referents)

Roels et al. 1982
 	
Cross-sectional cohort of 43 chloralkali and mercury battery workers and 47 referents; Belgium
	UHg median at testing
	  Workers: 71.0 µg/g Cr
	  Referents: 1.2 µg/g Cr
	
	BHg median at testing
	  Workers: 20.6 µg/L
	  Referents: 1.9 µg/L
		Hand tremor	↑ UHg (≥50 µg/g Cr)
			↑ BHg (≥10 µg/L)

		Hand-eye coordination	↓ UHg (≥50 µg/g Cr) ↓ BHg (≥10 µg/L

Smith et al. 1983
 	
Retrospective cohort of 86 workers; United States
	UHg working mean Plants 1 and 2 (n=26)
	  3 months: 195 µg/L
	  24 months: 143 µg/L
	
	Plants 3 and 4 (n=60)
	  3 months: 108 µg/L
	  24 months: 93 µg/L
		Short-term memory	↓ UHg

Urban et al. 2003
 	
Cross-sectional cohort of 24 workers and 24 referents; Czech Republic
	UHg mean
	  Workers: 20.5 µg/g Cr
	  Referents: 1 µg/L
	
	Air mercury 8 hours TWA: 59 µg/m³
		Visual color discrimination	↔ UHg
			↓ UHg (DMPS-provoked)
			↓ (exposed versus referents)

Table 2-51. Results of Epidemiological Studies Evaluating Exposure to Elemental Mercury (Hg^0) and Neurological Effects

Reference, study type, and population	Biomarker	Outcome evaluated[a]	Result

Wastensson et al. 2006, 2008
 	
Retrospective cohort of 43 workers and 22 referents; Sweden
	UHg cumulative work mean: 266 µg year/g Cr (mean 15 years), which corresponds to an average of 1.7 µg/g Cr
	
	UHg median at testing
	  Workers: 5.9 µg/g Cr
	  Referents: 0.7 µg/g Cr
		Postural tremor	↔ UHg at testing
			↔ UHg cumulative

		Hand tremor	↓ UHg at testing ↓ UHg cumulative
		Hand-eye coordination	↔ UHg at testing ↔ UHg cumulative
		Hand-eye coordination	↔ UHg at testing ↔ UHg cumulative
Florescent lamp workers			

Barboni et al. 2008
 	
Retrospective cohort of 35 former workers and 34 referents; Brazil
	UHg working mean: 41.15 µg/g Cr
	
	UHg mean at testing
	  Workers: 2.39 µg/g Cr
	  Referents: NR
		Visual field loss	↓ (exposed versus referents)

Fawer et al. 1983
 	
Cross-sectional cohort of 26 workers (12 chloralkali, 7 lamp and 7 acetaldehyde) and 25 referents; Belgium
	UHg mean
	  Workers: 20.1 µg/g Cr
	  Referents: 6.0 µg/g Cr
	
	Air mercury TWA: 26 µg/m^3
		Tremor	↑ (exposed versus referents)

Bagheri Hosseinabadi et al. 2020
 	
Cross-sectional cohort of 50 workers and 50 referents; Iran
	BHg mean
	  Workers: 22.59 µg/L
	  Referents: 1.28 µg/L
	
	Air mercury mean: 42 µg/m^3
		Tremor	↑ (exposed versus referents)

		Fatigue	↑ (exposed versus referents)
		Depression	↑ (exposed versus referents)
Milioni et al. 2017 Cross-sectional cohort of 31 workers and 31 referents; Brazil	NR	Recover of pupil contraction response to light	↓ (exposed versus referents)
Ventura et al. 2005 Retrospective cohort of 39 former workers and 21 referents; Brazil	UHg working mean: 41.09 µg/g Cr	Color vision loss	↓ (exposed versus referents)
Verberk et al. 1986 Retrospective cohort of 20 workers; The Netherlands	UHg mean at testing: 35.7 µg/g Cr	Tremor	↑ UHg

Table 2-51. Results of Epidemiological Studies Evaluating Exposure to Elemental Mercury (Hg⁰) and Neurological Effects

Reference, study type, and population	Biomarker	Outcome evaluated[a]	Result
Thermometer production workers			
Cavalleri and Gobba 1998 Cross-sectional cohort of 21 workers and 21 referents; Italy	Workers: 114.9 µg/g Cr Referents: NR UHg mean after chelation: 10.0 µg/g Cr	Color discrimination	↓ (exposed versus referents) ↓ UHg
Ehrenberg et al. 1991 Cross-sectional cohort of 83 workers and 79 referents; United States	UHg mean: 73 µg/g Cr Air mercury, 80-hour TWA, range: 9.3–75.6 µg/m³	Abnormal heal-to-toe walk	↑ (exposed versus referents)
Tang and Li 2006 Cross-sectional cohort of 143 workers; China	UHg mean: 30 µg/L Air workplace mean: 27 µg/m³	Tremor	↑ UHg (≥50 µg/L versus <10 µg/L)
		Neurasthenic symptoms (self-reported)	↑ UHg (≥50 µg/L versus <10 µg/L)
		Emotional changes (self-reported)	↑ UHg (≥50 µg/L versus <10 µg/L)
		Oral or gum inflammation	↑ UHg (≥50 µg/L versus <10 µg/L)
Dental workers			

Anglen et al. 2015
 	
Retrospective cohort of 13,906 dental workers; United States
	UHg mean
	  Year 1976: 20.1 µg/L
	  Year 2012: 2.04 µg/L
	  basis for OR: 4.7 µg/L
		Tremor	↑ UHg
			↔ Restorations per week

		Multiple sclerosis	↔ UHg ↔ Restorations per week
Bittner et al. 1998 Pooled study cohort of 230 dental workers; United States	UHg: 95% <55 µg/L	Hand steadiness	↓ UHg
		Finger tapping	↔ UHg
		One-hole test	↔ UHg
		Reaction time	↔ UHg
		Hand tremor	↔ UHg

Canto-Pereira et al. 2005
 	
Cross-sectional cohort of 15 dental workers and 13 referents; Brazil
	UHg Gmean testing
	  Workers: 1.54 µg/g Cr
	  Referents: 0.66 µg/g Cr
		Color contrast sensitivity	↓ (exposed versus referents)

		Color discrimination	↓ (exposed versus referents)
		Color confusion index	↔ (exposed versus referents)

Table 2-51. Results of Epidemiological Studies Evaluating Exposure to Elemental Mercury (Hg^0) and Neurological Effects

Reference, study type, and population	Biomarker	Outcome evaluated[a]	Result
Echeverria et al. 1998 Cross-sectional cohort of 49 dental workers (24 dentists, 15 assistants); United States	UHg mean Dentists: 0.89 µg/L Assistants: 1.07 µg/L	Mood symptoms	↑ UHg
		Motor coordination	↓ UHg
		Visual processing performance	↓ UHg
		Verbal processing and attention	↔ UHg
Echeverria et al. 2005 Cross-sectional cohort of 427 male dentists, 233 female dental assistants; United States	UHg mean Females: 1.98 µg/L Males: 3.32 µg/L	Attention	↓ UHg
		Working memory	↓ UHg
		Visual memory	↓ UHg
		Motor performance	↓ UHg
		Hand steadiness	↓ UHg
Franzblau et al. 2012 Longitudinal cohort of 2,767 dental workers, United States	UHg median 2.58 µg/L	Median NCV	↔ UHg
		Ulnar NCV	↔ UHg
Heyer et al. 2004 Cross-sectional cohort of 423 dental workers (193 male dentists, 230 female dental assistants); United States	UHg mean 2.32 µg/L	Mood symptoms	↑ UHg
		Neurologic symptoms	↑ UHg
Ngim et al. 1992 Cross-sectional cohort of 98 dental workers and 54 referents; Singapore	Air mercury Gmean 8-hour TWA: 13.6 µg/m^3 BHg geometric mean Dentists: 9.8 µg/L Referents: NR	Motor coordination	↓ UHg
		Visual processing performance	↓ UHg
		Working memory	↓ UHg
		Visual-motor performance	↓ UHg
Ritchie et al. 2002 Cross-sectional cohort of 170 dental workers and 179 referents; United Kingdom	UHg median Workers: 0.34 µg/g Cr Referents: 0.10 µg/g Cr Air mercury median range: 5.7–21.2 µg/m^3	Attention	↔ UHg
		Reaction time	↔ UHg
		Visual memory	↔ UHg
		Working memory	↔ UHg

Table 2-51. Results of Epidemiological Studies Evaluating Exposure to Elemental Mercury (Hg⁰) and Neurological Effects

Reference, study type, and population	Biomarker	Outcome evaluated[a]	Result
Sletvold et al. 2012 Cross-sectional cohort of 91 female dental workers; Norway	UHg median 12.0 µg/L	Motor function	↔ UHg
		Short-term memory	↔ UHg
		Working memory	↔ UHg
		Verbal long-term memory	↔ UHg
		Visual long-term memory	↓UHg
		Executive function	↔ UHg
		Mental flexibility	↔ UHg
Wang et al. 2012 Cross-sectional cohort of 513 dental workers (244 dentists and 269 dental assistants and hygienists); United States	UHg Gmean 0.65 µg/L HHg median: 0.28 µg/g	Sural nerve conduction onset latency	↓ UHg ↓ HHg
		Ulnar nerve conduction onset latency	↔ UHg ↓ HHg
Other workers			
Albers et al. 1988 Retrospective cohort of 247 lithium 6 workers and 255 referents; United States	UHg working mean 199.9 µg/L[b]	Tremor	↑ UHg ↑ (exposed versus referents)
Barboni et al. 2009 Cross-sectional cohort of 10 mercury recycling workers and 79 referents (10–20 referents per test); Brazil	UHg mean Workers: 22.3 µg/g Cr Referents: NR	Color discrimination	↓ (exposed versus referents)
		Visual field threshold	↓ (exposed versus referents)
		Visual contrast sensitivity	↓ (exposed versus referents)
Boogaard et al. 1996 Retrospective cohort of 40 natural gas workers and 19 referents; The Netherlands	UHg working median High exposure: 41 µg/L Low exposure: 12 µg/L UHg median at testing High exposure: 17 µg/L Low exposure: 5 µg/L Referents: 2 µg/L UHg median at testing high exposure: 17 µg/L low exposure: 5 µg/L	Tremor	↔ UHg ↔ (exposed versus referents)

Table 2-51. Results of Epidemiological Studies Evaluating Exposure to Elemental Mercury (Hg⁰) and Neurological Effects

Reference, study type, and population	Biomarker	Outcome evaluated[a]	Result
Cañadas et al. 2021 Cross-sectional cohort of 29 metal manufacture workers and 22 referents; Spain	UHg range (of individual maximums) during exposure Workers: 93.61– 245.57 µg/g Cr	Ocular (corneal) surface pathology	
		Sensitivity threshold	↑ (exposed versus referents)
		Nerve density	↓ (exposed versus referents)
	BHg range (of individual maximums) during exposure Workers: 252.62– 507.42 µg/L	Nerve branching	↓ (exposed versus referents)

Chapman et al. 1990
 	
Cross-sectional cohort of 18 battery workers and 18 referents; United States
	UHg mean at testing
	  Workers: 23.1 µg/L
	  Referents: NR
		Tremor	↑ (exposed versus referents)

Harari et al. 2012
 	
Cross-sectional cohort of 200 gold miners or processors, 37 gold merchants, and 72 referents; Ecuador
	UHg mean at testing
	  Merchants: 36.9 µg/g Cr
	  Miners: 3.3 µg/g Cr
	  Referents: 1.6 µg/g Cr
		Postural tremor	↑ UHg

		Postural sway	↑ UHg

	BHg mean at testing
	  Merchants: 30.1 µg/L
	  Miners: 5.3 µg/L
	  Referents: 5.0 µg/L
		Hand coordination	↔ UHg

Iwata et al. 2007
 	
Cross-sectional cohort 27 cinnabar miners and 52 referents; China
	UHg Gmean at testing
	  Workers: 228 µg/g Cr
	  Referents: 2.59 µg/g Cr
		Tremor	↔ UHg
			↑ (exposed versus referents)

		Postural sway	↑ UHg (transverse sway) ↔ (exposed versus referents)
Letz et al. 2000 Retrospective cohort of 104 lithium 6 workers and 101 referents; United States	UHg working median 180 µg/L	Polyneuropathy (tremor, decreased hand grip strength, slowed peripheral nerve conduction)	↑ UHg ↑ (exposed versus referents)
Mercury amalgam fillings			

Bilak et al. 2019
 	
Cross-sectional cohort of 56 people with amalgam fillings (age range 17– 35 years) and 44 referents
	BHg mean:
	  Amalgam group: 2.76 µg/L
	  Referents: 2.06 µg/L
	
	Mean number of amalgams: 2.77
		Retinal abnormalities:	

		Retinal nerve fiber layer thickness	↔ (amalgams versus no amalgams)
		Choroid ganglion layer volume	↓ (amalgams versus no amalgams)

Table 2-51. Results of Epidemiological Studies Evaluating Exposure to Elemental Mercury (Hg⁰) and Neurological Effects

Reference, study type, and population	Biomarker	Outcome evaluated[a]	Result
		Inner plexiform layer volume	↓ (amalgams versus no amalgams)
Factor-Litvak et al. 2003 Cross-sectional cohort of 550 health center employees not exposed occupationally (mean age 40 years); New York	UHg median: 1.3 µg/g Cr Median number of amalgams: 10 Median number of occlusal amalgam surfaces: 6	SRT (verbal memory)	↔ UHg ↔ number of amalgams ↔ number of occlusal amalgams
		BVRT (nonverbal memory)	↔ UHg ↔ number of amalgams ↔ number of occlusal amalgams
		WAIS trail making	↔ UHg ↔ number of amalgams ↔ number of occlusal amalgams
		WAIS digit symbol	↔ UHg ↔ number of amalgams ↔ number of occlusal amalgams
		Grooved pegboard (fine motor control)	↔ UHg ↔ number of amalgams ↔ number of occlusal amalgams
Hsu et al. 2016 Retrospective cohort of 10,236 people with amalgam restorations matched to referents without amalgam restorations (age >55 years); China	None	Parkinson's Disease at death	↑ (amalgams versus no amalgams)
Parkin Kullmann and Pamphlett 2018 Case-control study (age range 40–89 years) of 262 cases, 338 controls; international	None	ALS	↔ (amalgams versus no amalgams)
Sun et al. 2015 Retrospective cohort of 31,379 people with amalgam restorations and 176,208 without amalgam restorations (age >65 years); Taiwan	None	Alzheimer's disease at death	↑ (amalgams versus no amalgams)

Table 2-51. Results of Epidemiological Studies Evaluating Exposure to Elemental Mercury (Hg⁰) and Neurological Effects

Reference, study type, and population	Biomarker	Outcome evaluated[a]	Result
Tseng et al. 2020b Case-control study of 3,008 cases, 3,008 controls; China	Amalgams or no amalgams	Tremor	↔ (amalgams versus no amalgams)
Tseng et al. 2020a Case-control study of 612 cases, 612 controls; China	Amalgams or no amalgams	Multiple sclerosis	↔ (amalgams versus no amalgams)

[a]Interpretation of neurobehavioral test scores:
  BVRT: higher score = higher performance
  CPT: longer response time = lower performance
  Digit span: higher score = higher performance
  Digit symbol test: higher score = higher performance
  Finger tapping: higher score = higher performance
  Grooved pegboard: longer time = lower performance
  Picture similarity test: higher score = higher performance
  RVRT: higher score = higher performance
  Sant Ana dexterity test: higher score = higher performance
  SRT: higher score = higher performance
  Steinberg memory test: higher score = higher performance
  Stoop color-word test: higher score = higher performance
  Trail making: longer time = lower performance
  Visual retention test: higher score = higher performance
[b]The UHg working mean value was not reported by Albers et al. (1988) but was calculated based on data presented in Letz et al. (2000). There is substantial overlap between subjects in this study and the study by Letz et al. (2000); 89 exposed and 83 referents were examined in both studies.

↑ = positive association; ↓ = inverse association; ↔ = no association; ALS = amyotrophic lateral sclerosis
BAEP = brainstem auditory evoked potential; BHg = blood mercury; BVRT = Benton Visual Retention Test;
Cr = creatinine; DMPS = 2,3-dimercapto-1-propane sulfonate; EMG = Electromyography; Gmean = geometric mean;
HHg = hair mercury; NCV = nerve conduction velocity; NES CPT = Neurobehavioral Evaluation Systems Continuous
Performance Test; NR = not reported; SRT = Selective Reminder Test; TWA = time-weighted average; UHg = urine
mercury; WAIS = Wechsler Adult Intelligence Scale

Chloralkali workers. Chloralkali workers are exposed to mercury vapor during handling, processing, and storage of elemental mercury used in mercury electrolysis cells in the production of sodium hydroxide. These studies have found associations between exposure to mercury vapor or mercury biomarkers (UHg) and tremor, vision, peripheral nerve conduction and sensory evoked potentials, and performance on tests of hand-eye coordination and memory.

Several studies of chloralkali workers have found associations between exposure to mercury vapor and tremor (Chapman et al. 1990; Fawer et al. 1983; Frumkin et al. 2001; Bagheri Hosseinabadi et al. 2020; Langolf et al. 1978; Miller et al. 1975; Roels et al. 1982). UHg levels (mean or median) in these studies

ranged from approximately 20 to 240 µg Hg/g creatinine. The largest of these studies examined
139 former chloralkali workers and found increased tremor and increased threshold for sensing vibration
in workers compared to a referent group matched with workers for sex, age, race, educations (Frumkin et
al. 2001). The mean UHg level measured at the time of work in the plant was 72 µg Hg/L. Several
metrics of cognitive performance were also assessed in this study and were not found to be associated
with exposure to mercury. These included tests of motor speed and fine motor and visuomotor
coordination, memory, and integrated cognitive function. Bagheri Hosseinabadi et al. (2020) found that
scores on a survey of tremor severity were higher among chloralkali workers (mean BHg 23 µg/L, n=50)
compared to a reference group (mean BHg 1.3 µg/L, n=50). In this study, the mean air mercury level at
the workplace was 42 µg/m^3. Several studies that evaluated tremor in chloralkali workers did not find
associations with mercury exposure (Bast-Pettersen et al. 2005; Ellingsen et al. 2001; Langworth et al.
1992a; Wastensson et al. 2006, 2008). UHg levels (mean or median) in these studies ranged from
approximately 11 to 18 µg Hg/g creatinine.

A clinical study found decreased visual color discrimination in a group of chloralkali workers (n=24)
compared to a sex- and age-matched referent group (n=24; Urban et al. 2003). Color discrimination was
not associated with UHg levels (mean 21 µg Hg/g creatinine; range 0.15–62 µg Hg/g creatinine);
however, discrimination decreased in association with urinary mercury excretion provoked with
administration of 2,3-dimercapto-1-propane sulfonate (DMPS), a metric of mercury body burden. A
clinical study found changes in visual evoked potentials and increased brainstem auditory evoked
potentials in a group of chloralkali workers (n=26; mean UHg: 358 µg Hg/g creatinine) compared to sex-
and age-matched referents (Chang et al. 1995). Increased latency of ulnar nerve conduction was observed
in workers (n=18) in association with increasing UHg levels (mean 290 µg Hg/L; Levine et al. 1982).

Several studies of chloralkali workers have found associations between exposure to mercury and various
measures of cognitive function (Bluhm et al. 1992; Mathiesen et al. 1999; Piikivi et al. 1984 and Smith et
al. 1983). These studies found associations between increasing UHg and performance on various tests of
motor coordination, visual memory, and working memory. UHg levels (mean or median) in these studies
ranged from 100 to 140 µg Hg/L. A study of former chloralkali workers (n=49) found no differences
between cognitive performance of workers and a referent group (Bast-Pettersen et al. 2005). Mean UHg
at testing was 2.9 µg Hg/g creatinine (range 0.3–9.2 µg Hg/g creatinine) and the average over the working
period was 16.5 µg Hg/g creatinine per year (range 7–45 µg Hg/g creatinine per year).

Cessation of mercury exposure or chelation therapy to lower the mercury body burden resulted in improvement of outcomes (Bluhm et al. 1992; Langolf et al. 1978). A study of workers (n=26) who were exposed to mercury vapor while performing construction work in a chloralkali plant found lower performance on trial making and Stroup color word tests, relative to a reference group (Bluhm et al. 1992). The mean urinary mercury excretion rate measured 20–36 days after cessation of exposure was approximately 100–200 μg Hg/day and mean BHg level was approximately 50–100 μg Hg/L. Scores on trial making tests improved following treatment with DMSA which accelerated excretion of mercury in urine. A study of chloralkali workers (n=79) found increased tremor and lower performance on tests of hand coordination (Langolf et al. 1978). The mean UHg level was 240 μg Hg/L. Follow up of five subjects whose exposures were decreased showed that their neurological outcomes improved after exposures were decreased. UHg levels were 660 μg Hg/L during the high exposure period and 300 μg Hg/L after 6–10 months working in a lower exposure environment.

Mercury battery production workers. Studies of mercury battery production workers are summarized in Table 2-51. Increased prevalence of tremor was observed in workers exposed to mercury vapor in the production of mercury cell batteries (Chapman et al. 1990; Roels et al. 1982). A study of workers (n=43) that included battery production and chloralkali workers, found a higher prevalence (relative to a reference group) of hand tremor in workers who had UHg in the range of 50–100 μg Hg/g creatinine and BHg in the range of 10–20 μg Hg/L (Roels et al. 1982). Another study (n=15) found a shift in the power spectrum of finger tremor to higher tremor frequencies in battery workers compared to a reference group (Chapman et al. 1990). The mean UHg level was 23 μg Hg/L (range <10–121 μg Hg/L). A study of battery production workers (n=8) observed changes in brainstem auditory evoked potential latencies, relative to subjects in a reference group (Discalzi et al. 1993). The mean UHg level was 325 μg Hg/g creatinine.

Studies of fluorescent lamp production workers. Studies of fluorescent lamp production workers are summarized in Table 2-51. These studies compared signs and symptoms in workers and reference groups and found higher prevalence of tremor and impaired vision in workers. Increased prevalence of tremor was observed in workers exposed to mercury vapor in the production of mercury fluorescent lamps (Al-Batanony et al. 2013; Fawer et al. 1983; Verberk et al. 1986). In a study of lamp workers (n=25), hand tremor correlated with UHg level (mean 36 μg Hg/g creatinine; range 9–53 μg Hg/g creatinine) (Verberk et al. 1986). In a study that evaluated a combined cohort of workers in lamp, chloralkali, and acetaldehyde production (n=26); prevalence of hand tremor was higher in workers exposed to mercury vapor compared to a reference group not exposed to mercury vapor (Fawer et al. 1983). Mean UHg in

exposed workers was 20 µg Hg/g creatinine (SD 2.1) compared to the reference group (6.0±1.2 µg Hg/g creatinine). The mean time-weighted average mercury air level of the mercury workers was 26 µg Hg/m^3.

Decreased color discrimination and color vision loss was observed in lamp workers (Barboni et al. 2008; Feitosa-Santana et al. 2010; Ventura et al. 2004, 2005). Studies of former lamp workers (n=30–40) observed, relative to reference groups, lower red-green and blue-yellow discrimination and foveal visual field loss. Mean working urinary levels were 41 µg Hg/g creatinine (SD 1.7) and 2.4 µg Hg/g creatinine at the time of evaluation, approximately 7 years without occupational exposure (Barboni et al. 2008; Ventura et al. 2005). Recovery of pupillary contraction in response to a light flash (a sympathetic nervous system response) was prolonged in former lamp workers (n=31) relative to an age-matched reference group (Milioni et al. 2017). In this same study, mean scores on tests of working memory, spatial memory, and visual memory were lower in the lamp production workers compared to workers in the reference group.

Thermometer production workers. Studies of thermometer production workers are summarized in Table 2-51. Neurological effects have been studied in mercury thermometer production workers (Cavalleri and Gobba 1998; Ehrenberg et al. 1991; Tang and Li 2006). These studies compared signs and symptoms in workers and reference groups and found higher prevalence of tremor, impaired motor coordination, and impaired vision in workers.

The prevalence of neurological symptoms was evaluated in a group of workers (n=122) (Ehrenberg et al. 1991). Prevalence of difficulty in heel-to-toe walk was lower in workers compared to the reference group (relative risk 5.78; 95% CI 1.63, 20.50). Mean urinary mercury level was 73 µg Hg/g creatinine in workers (range 1–344 µg Hg/g creatinine) and 4.2 µg Hg/g creatinine (range: non-detected to 10 µg Hg/g creatinine) on reference workers. Mean 8-hour time-weighted average air mercury levels in the breathing zone ranged from 9.3 to 75.6 µg Hg/m^3.

The prevalence of neurological symptoms was evaluated in a group of workers (n=143) (Tang and Li 2006). Prevalence increased in workers who had urinary mercury levels ≥50 µg Hg/L compared to a group who had urine levels <10 µg Hg/L. The symptoms included tremor and self-reported neurasthenic symptoms (e.g., headache, dizziness, insomnia, memory loss, fatigue, weakness) and emotional changes (mood swings, irritability, nervousness, timidity, loss of confidence). The mean air mercury level measured in workplaces was 27 µg Hg/m^3 (range 11–57 µg Hg/m^3).

Decreased visual color discrimination was observed in a group of workers (n=21) who had a mean UHg of 115 µg Hg/g creatinine (range 34–287 µg Hg/g creatinine) relative to a matched reference group (matched for age, sex, alcohol consumption, and cigarette smoking) with mean UHg of 1.1 µg Hg/g creatinine (SD 0.13) (Cavalleri and Gobba 1998). Color discrimination was not different from the reference group following implementation of improved industrial hygiene procedures which resulted in mean urinary mercury levels of 10 µg Hg/g creatinine.

Dental practitioners. Several studies of dental practitioners have examined possible associations between exposures to mercury vapor and cognitive function and behavior; studies are summarized in Table 2-51. In these studies, exposures included elemental mercury released from during preparation, installation, or removal of mercury amalgam restorations, as well as exposures to methylmercury and inorganic mercury from other sources (e.g., diet). As a result, biomarkers such as urinary or BHg were not specific metrics of exposures to mercury vapor. Few studies reported estimates of exposure concentrations (Decharat et al. 2014; Ngim et al. 1992; Ritchie et al. 2002). Ritchie et al. (2002) measured breathing zone air concentrations in various areas of 180 active dental surgery facilities and reported median time-weighted average concentrations that ranged from 6 to 21 µg Hg/m^3. The median time-weighted average concentration measured in the breathing zones of 124 working dentists was 12 µg Hg/m^3 (range 2–38 µg Hg/m^3) (Decharat et al. 2014). Air mercury vapor concentrations are highly dynamic during some procedures, such as removal drilling of amalgam restorations (Warwick et al. 2019) and, as a result, time-weighted average concentrations may not reflect peak exposures experienced during the procedure.

Most studies of neurological outcomes in dentists have assessed exposure from biomarkers, typically urinary mercury in units of µg Hg/L or µg Hg/g creatinine. The largest study (n=13,905) matched historical records of urinary mercury and health survey data in which subjects self-reported experiencing tremor or diagnosis of multiple sclerosis (Anglen et al. 2015). Urinary mercury levels declined substantially during the survey period from a mean of 20.1 µg Hg/L in 1976 to 2.0 µg Hg/L in 2012. Increasing urinary mercury was associated with an increased OR of tremor per change in cohort mean UHg (OR 1.10 per 4.7 µg Hg/L urine; 95% CI 1.00, 1.22) but not with the number of mercury amalgam restorations placed or removed per week. No association was found with diagnosis of multiple sclerosis. Results of several smaller cross-sectional cohort studies that examined cognitive performance in dental practitioners were inconsistent. Some studies have found age-adjusted associations between increasing urinary mercury and decreasing performance on tests of motor coordination, visual processing, and working memory (Bittner et al. 1998; Echeverria et al. 1998, 2005; Ngim et al. 1992), while other studies have found no associations (Ritchie et al. 2002: Sletvold et al. 2012). Changes in self-reported mood

states or neurological symptoms were associated with increasing urinary mercury (Echeverria et al. 1998;
Heyer et al. 2004). Results of studies of nerve conduction have also been inconsistent (Franzblau et al.
2012; Wang et al. 2012). Clinical studies have compared neurosensory or cognitive performance in
dental practitioners compared to a reference group (Aydin et al. 2003; Canto-Pereira et al. 2005).
Decreased visual color discrimination and contrast sensitivity was observed in a group of 15 dentists
(median urinary mercury 1.54 µg Hg/g creatinine) compared to an age-matched reference group (0.66 µg
Hg/g creatinine) (Canto-Pereira et al. 2005). Decreased performance on tests of logical memory and
retention were found in a clinical study of 43 dental practitioners, compared to a reference group (hospital
workers) (Aydin et al. 2003).

*Other worker populations. S*tudies of other worker populations are summarized in Table 2-51. Increased
tremor was observed in cinnabar miners (n=27), relative to a referent group (Iwata et al. 2007). The
median UHg level in miners was 228 µg Hg/g creatinine (range 23–4,577 µg Hg/g creatinine). Increased
UHg was associated with increases in postural sway in workers exposed to mercury vapor during mining
(n=200) and processing of gold (n=37) (Harari et al. 2012). The mean UHg in merchants were 36.9 µg
Hg/g creatinine (range 3.2–420 µg Hg/g creatinine) and 3.3 µg Hg/g creatinine (range 0.3–170 µg Hg/g
creatinine) in miners. Exposures to mercury vapor occurred during handling, processing, and storage of
elemental mercury used in the COLEX process of lithium isotope separation. A study of workers
exposed to mercury vapor during production of lithium 6 (n=195) found increased tremor, decreased hand
grip strength, and changes in peripheral nerve conduction in association with increased UHg (Albers et al.
1988; Letz et al. 2000). The neurological outcomes were prominent when historic peak UHg levels were
>600 µg Hg/L (Albers et al. 1988). The median quarterly average UHg in exposed workers was 180 µg
Hg/L (range 64–7,000 µg Hg/L) (Letz et al. 2000). Neurologic outcomes were studied in workers (n=40)
in natural gas production (Boogaard et al. 1996). Exposures in gas production occurs typically during
maintenance and clean-up operations when mercury (from source materials) that has accumulated on
equipment surfaces can vaporize. In a comparison to a reference group, no differences were observed in
tests of tremor, hand-eye coordination, or peripheral never conduction velocity (Boogaard et al. 1996).
Median UHg were 41 µg Hg/L (range 7–72 µg Hg/L) in a high-exposure group and 17 µg Hg/L (range 7–
53 µg Hg/L) in a low-exposure group. Median air mercury concentration was 67 µg Hg/m^3 (range 10–
1,500 µg Hg/m^3). A study of workers in the mercury recycling industry (n=10) found changes to visual
field thresholds and contrast sensitivity color discrimination in workers compared to a reference group
(Barboni et al. 2009). Mean UHg at the time of examination was 22 µg Hg/g creatinine (range 9–35 µg
Hg/g creatinine). Performance improved after chelation with DMSA. Impaired vision and other ocular
disturbances were observed in workers who were exposed to mercury vapor at a metal manufacturing

plant and subsequently diagnosed with mercury intoxication (Cañadas et al. 2021). The maximum observed UHg levels in the patients ranged from 94 to 246 µg/g creatinine and BHg levels ranged from 250 to 500 µg/L.

Mercury released from amalgam dental restorations. Details of studies that examined associations between dental amalgams and neurological effects are summarized in Table 2-51. A cross-sectional study of 530 health center employees who had no known occupational exposure to mercury found no associations between urinary mercury (median 1.3 µg Hg/g creatinine) or number of mercury amalgam restorations and performance on tests of memory or fine motor control (Factor-Litvak et al. 2003). Two large retrospective studies found elevated hazard ratios for diagnosis at death of Parkinson's Disease (hazard ratio 1.58; 95% CI 1.12, 2.23; 20,000 subjects) or Alzheimer's Disease (hazard ratio 1.1; 95% CI 1.01, 1.19; 200,000 subjects) in adults who had mercury amalgam restorations (Hsu et al. 2016; Sun et al. 2015). Results from studies of associations between mercury amalgam restorations and multiple sclerosis have been inconsistent (Aminzadeh and Etminan 2007). A case-control study (143 cases, 128 controls) estimated the OR to be 1.05 (95% CL 1.19, 3.53) (Bangsi et al. 1998); however, other studies have found no association between amalgam restorations and multiple sclerosis (Bates et al. 2004; Casetta et al. 2001; McGrother et al. 1999; Tseng et al. 2020a). A case-control study (3,008 cases, 3,008 controls) found no evidence for an association between dental amalgams and tremor (Tseng et al. 2020b). A case-control study (262 cases, 338 controls) found no evidence for an association between dental amalgams and amyotrophic lateral sclerosis (ALS) (Parkin Kullmann and Pamphlett 2018). A cross-sectional comparison of retina tomography of adults who had dental amalgams (n=56) and 44 age- and sex-matched referents found decreased retinal choroid ganglion layers and inner plexiform layers in the amalgam group compared to referents (Bilak et al. (2019). Mean BHg levels in this study were 2.76 µg/L in the amalgam group and 2.05 µg/L in the referent group.

Several studies have reported improvement in self-reported signs of psychological disturbances following removal of mercury amalgam restorations; however, because placebo treatments are not possible in these types of studies, the association between the observed outcome changes and exposure to mercury is highly uncertain (Weidenhammer et al. 2010; Zwicker et al. 2014).

Other non-occupational exposures. A clinical study was conducted of families who had resided for up to 2 years in a florescent lamp factory that had been converted to apartments (Fiedler et al. (1999). Average air levels ranged from 5 µg/m^3 (adult breathing zone) to 888 µg/m^3 over visible pools of elemental mercury. The study included motor and cognitive testing of 19 adults and 6 children. The median adult

UHg was 19.4 μg/g creatinine. The study did not find significant differences in tremor between subjects who had UHg ≥19 μg/g creatinine, compared to subjects with UHg <19 μg/g creatinine. Hand-eye coordination errors (Neurobehavioral Evaluation System 2) were significantly higher in the higher UHg group. Results of other tests were not different between the high and low UHg groups (finger tapping, grooved pegboard, trail making, symbol-digit substitution, simple reaction time, continuous performance, verbal learning, and memory). Statistical comparison of test outcomes in children were not reported, and results were characterized as "no clinically significant deficits relative to age-adjusted normative values."

Elemental Mercury—Animal Studies. Two inhalation studies evaluated neurological effects in adult animals following acute-duration exposure to metallic mercury vapor. One study observed reduced grip strength in female mice when assessed 4–7 months after a single 4-hour exposure to 0.5 mg Hg/m^3 (Stankovic 2006). Upon necropsy at 7 months, decreased motor axon diameter was observed. The other acute-duration study observed clinical signs of neurotoxicity (mild tremor, lethargy, and unsteady gait) in maternal rats following exposure to 8 mg Hg/m^3 during GDs 6–15 for 2 hours/day (Morgan et al. 2002). These rats were sacrificed moribund on PND 1 based on excessive body weight loss and clinical signs. Similar effects were not observed at ≤4 mg Hg/m^3.

A limited number of intermediate-duration studies found clinical signs of toxicity, impaired learning, and pathological findings in the central nervous system following adult exposure to metallic mercury vapor. Tremors and impaired conditioned response learning (conditioned avoidance and escape response testing) were observed in rats intermittently exposed to 3 mg Hg/m^3 for 12–42 weeks (Kishi et al. 1978). Decreased cerebellar volume and cerebellar damage (gliosis, perineuronal vacuolization, decreased density of Purkinje cells) were observed in rats exposed to 1 mg Hg/m^3 for 9 hours/day for 45 days (Altunkaynak al. 2019). In another study, exaggerated reflexes, clonus, and tremors were observed in rabbits following intermittent exposure to 4 mg Hg/m^3 for 11–13 weeks (Fukuda 1971). Mild to moderate unspecified pathological brain lesions were observed in rabbits exposed to 0.86 mg Hg/m^3 for 2–12 weeks (7 hours/day, 5 days/week) (Ashe et al. 1953).

The size of the myelin sheath of the dorsal nerve root of the spinal cord was decreased in adult male rats intermittently exposed to 0.48 mg Hg/m^3 for 8 weeks (Schiønning et al. 1998b). Findings were not accompanied by clinical signs of neurotoxicity, obvious microscopic lesions, changes in ganglia volume, changes in number or size of motor neurons, or changes in the ventral nerve root. Therefore, the biological relevance of this finding is unclear, and a NOAEL/LOAEL determination for this study could not be made. In a companion study, male rats similarly exposed to 0.5 mg Hg/m^3 for 8 weeks showed

irritability and aggressiveness during the final 2 weeks of exposure (Sørensen et al. 2000). At necropsy, stereological changes in the cerebellum showed a reduction in the number of Purkinje and granular cells and a reduced volume of the granular cell layer. Based on these findings, the study authors concluded that elemental mercury vapor predominantly affects the central nervous system, rather than the peripheral nervous system.

Inorganic Mercury—Animal Studies. Available studies in adult rodents exposed to mercuric chloride indicate that exposure is potentially associated with altered neurobehavior (hyperactivity, impaired coordination, impaired learning and memory), damage to the dorsal root ganglion and cerebellum, and severe clinical signs of neurotoxicity with repeated, high-dose exposure. Neurological effects have also been reported in adult rodents following oral exposure to mercuric sulfide; doses associated with toxicity are much higher for mercuric sulfide compared to mercuric chloride. Available data following inhalation exposure to mercuric oxide are too limited to draw conclusions.

Sun et al. (2018) reported some evidence of altered pain sensitivity in rats following exposure to mercuric chloride; however, findings do not show a clear dose- or time-related pattern. After exposure for 1 week, responses in thermal and mechanical pain stimulation are comparable to control at doses up to 12.6 mg Hg/kg/day. At 2 weeks, increased sensitivity to thermal and mechanical pain were observed at 3.10 and 6.3 mg Hg/kg/day, but not at 12.6 mg Hg/kg/day (Sun et al. 2018). However, after 3 weeks, no changes in behavioral pain sensitivity were observed at doses up to 6.3 mg Hg/kg/day. Similar inconsistencies were observed in findings for the density of intraepidermal nerve fibers in hind paw skin samples, with decreased density at ≥6.3 mg Hg/kg/day at 1 week but only at 3.10 mg Hg/kg/day, but not higher doses, at 2 and 3 weeks (Sun et al. 2018).

A series of studies evaluated neurobehavior in adult male rats following intermediate-duration exposure to mercuric chloride. Rats exposed to 0.277 mg Hg/kg/day showed reduced total, horizontal, and vertical activity in an open field, impaired motor coordination and balance (rotarod, beam walking, inclined plane tests), and impaired spatial learning and memory in the Morris water maze (Bittencourt et al. 2021; Teixeira et al. 2014, 2018, 2019). No changes in social behavior were observed in the social recognition test (Teixeira et al. 2014). Alterations in behavior, not motor coordination, were associated with apoptosis and loss of neurons and astrocytes in the motor cortex and elevated glutamate uptake in the motor cortex and hippocampus (Teixeira et al. 2018, 2019). Impaired spatial learning in the Morris water maze was also reported in adult male rats at all evaluated doses (≥0.4 mg Hg/kg/day) following exposure for 21 days (Behzadfar et al. 2020).

No additional studies were available that were designed to evaluate neurobehavior in adult animals following exposure to mercuric chloride. However, severe clinical signs of neurotoxicity were observed in rats following acute-duration exposure to doses ≥3.10 mg Hg/kg/day or intermediate-duration exposure to doses ≥0.7 mg Hg/kg/day, including hindlimb spread and/or crossing, severe ataxia and abnormal gait, tremor, decreased activity, and partial paralysis (Chang and Hartmann 1972; Goldman and Blackburn 1979; Sun et al. 2018). No clinical signs of toxicity were observed in rats following acute-duration exposure to doses up to 9.24 mg Hg/kg/day (Chang and Hartmann 1972; Lecavalier et al. 1994). No exposure-related clinical signs were observed in mice following intermediate-duration exposure to doses up to 11 mg Hg/kg/day for 7 weeks (Dieter et al. 1983; Khan et al. 2004).

Ultrastructural changes were noted in the dorsal root ganglia (vacuole formation, focal cytoplasmic lesions) and cerebellum (vacuolation, degeneration of granule cells) of male rats following acute- or intermediate-duration exposure to mercuric chloride at doses of 0.7 mg Hg/kg/day (Chang and Hartmann 1972). No changes were observed in anterior horn motoneurons. Decreased cervical, thoracic, and lumbar motor neurons along with axonal damage in the spinal cord were observed in male rats exposed to mercuric chloride at doses of 0.277 mg Hg/kg/day for 45 days via gavage (Corrêa et al. 2020). No exposure-related changes in brain histology were observed in rats exposed to mercuric chloride at acute-duration doses up to 9.24 mg Hg/kg/day (Lecavalier et al. 1994) or intermediate- or chronic-duration doses up to 4 mg Hg/kg/day (Dieter et al. 1992; NTP 1993). No exposure-related changes in brain histology were observed in mice at intermediate-duration doses up to 15 mg Hg/kg/day (Dieter et al. 1983; Khan et al. 2004; NTP 1993) or chronic-duration doses up to 7.4 mg Hg/kg/day (NTP 1993).

A series of studies evaluated neurological function in adult laboratory animals following gavage exposure to mercuric sulfide. In rats, peripheral nerve conduction was altered following a 5- or 14-day exposure to 860 mg Hg/kg/day, specifically suppression and/or incomplete recovery of compound muscle action potentials (CMAPs) after induced tetany (Chuu et al. 2007). No changes in motor equilibrium or nociceptive testing were observed in exposed rats. In mice, increased thresholds for auditory brainstem responses were observed 5 weeks after a 7-day exposure to 860 mg Hg/kg/day, indicative of hearing loss (Chuu et al. 2001a). Thresholds returned to normal by 11 weeks post-exposure. No changes in thresholds were observed at 86 mg Hg/kg/day. In guinea pigs, an abnormal vestibular ocular reflex (VOR) and impaired equilibrium (measured using rotarod test) were observed after acute- or intermediate-duration exposure to mercuric sulfide at ≥86 mg Hg/kg/day (Chuu et al. 2001b). In the acute-duration study, outcomes were persistent 2 weeks after exposure at 860 mg Hg/kg/day and were

accompanied by Purkinje cell loss in the cerebellum (recovery and histopathology were not evaluated in
the intermediate-duration study).

The effects of inhaled mercuric oxide on the cerebellum of female rats were evaluated in a single study.
Following exposure to 1 mg Hg/m^3 for 45 days (9 hours/day), treated rats showed cerebellar gliosis and
perineuronal and perivascular vacuolization, reduced cerebellar volume, and decreased number and
density of Purkinje cells (Altunkaynak et al. 2019). Purkinje cells from treated animals showed irregular
cellular boundaries, eosinophilic cytoplasm, and heterochromatic nuclei.

Organic Mercury—Epidemiological Studies. Outbreaks of severe neurological effects have occurred in
association with ingestion of methylmercury in seafood (Minamata disease) and from ingestion of wheat
contaminated with a methylmercury fungicide (Iraq outbreak). Studies of associations between exposure
to methylmercury and neurological function in adults have also been conducted in populations that
consume large amounts of fish or marine mammals (Table 2-52); these populations include communities
from the Amazonian River basin, the St. Lawrence River, coastal Japan (whaling communities), and other
fish consuming populations. Collectively, these studies provide evidence for associations between
exposure to methylmercury and decreasing performance on tests of fine motor coordination and speed,
muscle strength, tactile sensation, color vision and visual contrast sensitivity, and memory and learning.

**Table 2-52. Results of Epidemiological Studies Evaluating Exposure to
Methylmercury or Ethylmercury and Neurological Effects in Adults**

Reference, study type, and population	Biomarker	Outcome evaluated[a]	Result
Amazonian River basin studies			
Feitosa-Santana et al. 2018 Cross-sectional cohort (n=36, age range 18–64 years) and 37 referents; Brazil	HHg median Exposed: 18.6 µg/g Referents: NA	Color vision	
		Lanthony desaturated error score	↑ HHg (exposed versus referents)
		Farnsworth-Munsell error score	↑ HHg (exposed versus referents)
Hoshino et al. 2015 Cross-sectional cohort (n=58, age range 1–47 years); Brazil	HHg median 10.91 µg/g	Tympanometry	↔ HHg
		Acoustic reflexes	↔ HHg
		Pure tone audiometry	↔ HHg
		Transient otoacoustic emissions	↔ HHg

Table 2-52. Results of Epidemiological Studies Evaluating Exposure to Methylmercury or Ethylmercury and Neurological Effects in Adults

Reference, study type, and population	Biomarker	Outcome evaluated[a]	Result

Khoury et al. 2015
 	
Cross-sectional cohort (n=108; age range 13–53 years) and 49 referents; Brazil
	HHg mean
	  Exposed: 8.8 µg/g
	  Referent: 0.73 µg/g
		Tactile sensation threshold	↑ HHg
			↑ (exposed versus referents)

		Vibration sensation duration	↔ HHg ↓ (exposed versus referents)
		2-point tactile discrimination threshold	↔ HHg ↑ (exposed versus referents)
Mergler 2002 (Dolbec et al. 2000, 2001; Lebel et al. 1996, 1998) Cross-sectional cohort (n=233, age >15 years); Brazil	HHg median: 11 µg/g	Fine motor coordination	↓ HHg
		Muscle strength	↓ HHg
		Vision (visual contrast, color vision)	↓ HHg
Oliveira et al. 2021 Cross-sectional cohort (n=110, mean age 28 years); Brazil	HHg median: 7.4 µg/g	Cognitive deficits (BCSB)	↑ (HHg >10 µg/g)
		Verbal fluency deficits	↑ (HHg >10 µg/g)
Yokoo et al. 2003 Cross-sectional cohort (n=129, age rage 17–81 years); Brazil	HHg median 3.7 µg/g	Fine motor speed	↓ HHg
		Memory	↓ HHg
		Learning	↓ HHg
St. Lawrence River studies			

McKeown-Eyssen et al. 1983
 	
Case-control study of 41 cases and 179 controls (age range: adults), Canada
	HMeHg mean:
	  Mistassini cases:
	    males: 15.9 µg/g
	    females: 16.7 µg/g
	  Great Whale cases:
	    males: 10.5 µg/g
	    females: 10.1 µg/g
		Bilateral coordination, visual field, nystagmus, tremor, sensory loss, or tactile discrimination	↓ HMeHg, males
			↓ HMeHg, females

Mergler 2002
 	
Cross-sectional cohort of 63 fish consumers and 63 non-fish-consumers (age range 20–69 years); Canada
	BMeHg median
	  Fish consumers: 37.3 µg/L
	  Non-consumers: 29.0 µg/L
		Auditory or visual memory	↓ (fish consumers versus non-consumers)

		Cognitive flexibility	↓ (fish consumers versus non-consumers)
		Fine motor coordination	↓ (fish consumers versus non-consumers)
		Reaction time	↓ (fish consumers versus non-consumers)
		Vision (visual color vision)	↔ (fish consumers versus non-consumers)

Table 2-52. Results of Epidemiological Studies Evaluating Exposure to Methylmercury or Ethylmercury and Neurological Effects in Adults

Reference, study type, and population	Biomarker	Outcome evaluated[a]	Result
Coastal Japan whaling communities			
Nakamura et al. 2014 Cross-sectional cohort (n=194, age range: 20–85 years); Japan	HHg geometric mean 14.9 µg/g	Sensorineural hearing loss	↑ HHg (>50 µg/g versus <50 µg/g)
		Gait disturbance	↑ HHg (>50 µg/g versus <50 µg/g)
		Muscular weakness	↔ HHg
		Tremor	↔ HHg
		Rigidity	↔ HHg
		Coordinated movements	↔ HHg
		Tactile, pain, vibration sensation	↔ HHg
Studies of other populations			
Carta et al. 2003 Cross-sectional cohort (n=22, median age 52 years) and 22 referents; Italy	Organic BHg median Exposed (n=10): 41.5 µg/L Referent (n=6): 2.6 µg/L	Digit-symbol reaction time	↑ BHg ↑ (exposed versus referents)
		Motor coordination	↓ BHg ↔ (exposed versus referents)
		Color word reaction time	↑ BHg ↑ (exposed versus referents)
		Finger tapping speed	↔ BHg ↓ (exposed versus referents)
		Digit span	↔ BHg ↔ (exposed versus referents)
		Tremor	↔ BHg ↔ (exposed versus referents)
Hoffman et al. 2021 Case-control study (age range: 50–65 years),165 cases, 330 controls; United States	Mercury consumption from fish mean: Cases: 355 mg/year Controls: 339 mg/year	ALS	↔ (Hg consumption from fish)

Table 2-52. Results of Epidemiological Studies Evaluating Exposure to Methylmercury or Ethylmercury and Neurological Effects in Adults

Reference, study type, and population	Biomarker	Outcome evaluated[a]	Result
Studies of other fish-eating populations or populations for which organic mercury was measured			
Geier et al. 2019 Cross-sectional study of data from NHANES 2011–2012 (n=NA; age range 60–80 years); Unites States	BEtHg mean Cohort: 0.3 µg/L	Digit symbol	↔ (BHg)
			↔ (BEtHg, BMeHg)
		Word fluency test	↓ (BEtHg)
		Word list learning	↓ (BEtHg)

Philibert et al. 2022
 	
Cross-sectional cohort (n=391, median age 54 years); Canada
	BHg median
	  Cord: 5 µg/L
	
	HHg median
	  Age 10 years: 1.1 µg/g
		Symptoms of neurological deficits:	

		Cranial nerve	↑ (HHg, age 10 years)
		Gross motor	↑ (HHg, age 10 years)
		Cognitive	↑ (HHg, age 10 years)
Rossa-Roccor and Karim 2021 Cross-sectional study of data from NHANES 2011–2016 (n=3,930; age >18 years); United States	BMeHg median: 0.36 µg/L	Depression	↔ (BMeHg)

[a]Interpretation of neurobehavioral tests:
  Word fluency: higher score = higher performance
  BCSB: higher score = lower performance
  Color word reaction time: longer reaction time = lower performance
  Digit span: higher score = higher performance
  Digit-symbol reaction time: longer reaction time = lower performance
  Finger tapping speed: higher speed = higher performance
  2-Point tactile discrimination threshold: higher threshold = lower performance
  Tactile sensation threshold: higher threshold = lower performance
  Vibration sensation duration: lower duration = lower performance
  Word list learning: higher score = higher performance

↑ = positive association; ↓ = inverse association; ↔ = no association; ALS = amyotrophic lateral sclerosis; BCSB = Brief Cognitive Screening Battery; BHg = blood mercury; BEtHg = blood ethylmercury; BMeHg = blood methylmercury; HHg = hair mercury; HMeHg = hair methylmercury; NA = not available; NHANES = National Health and Nutrition Examination Survey

Poisoning case studies. A lethal dose of dimethylmercury occurred to a 48-year-old female laboratory chemist following accidental contact of the dorsal surface of a latex gloved hand to "a few drops" of liquid dimethylmercury (Nierenberg et al. 1998; Siegler et al. 1999). Approximately 5 months after the exposure, the patient developed severe neurological symptoms that included deterioration of balance, gait and speech, paresthesia, and disturbances of vision and hearing; the patient died 298 days following the exposure (Nierenberg et al. 1998). Autopsy revealed thinning of the cerebral cortex and atrophy of the cerebellum (Siegler et al. 1999). The applied dose was reconstructed based on measurements of BHg made approximately 5 months following the accident and the estimated half-time of 75 days for HHg in

the subject (Nierenberg et al. 1998). The applied dose was estimated to have been approximately 1,344 mg mercury contained in approximately 0.48 mL of liquid dimethylmercury (density 3.2 g dimethylmercury/mL) (Nierenberg et al. 1998).

Minamata, Japan. Discharges of wastewater from an acetaldehyde production facility into the Shiranui Sea located in the Kumamato Prefecture of Japan resulted in exposure to methylmercury ingested in locally contaminated fish and shellfish (Harada 1995). An outbreak of what became known as Minamata disease occurred in the area. Patients diagnosed with Minamata disease showed a common set of signs which included: severe neuromotor (e.g., tremor, dysarthria, rigidity, ataxia), sensory disturbances (visual and auditory; paresthesia) and, in lethal cases, pathological changes in the cerebral cortex, cerebellar cortex, and dorsal root ganglia of the spinal cord (Ekino et al. 2007; Eto et al. 2002; Harada 1995).

Measurements of mercury in blood and hair were not made until several years following the period of most intense exposure and, therefore, do not provide reliable estimates of exposures that may have contributed to Minamata disease. HHg levels in Minamata disease patients measured 4–5 years following onset of Minamata disease ranged from 2 to 700 µg Hg/g (Harada 1995). In a study of fishermen of the Shiranui Sea coastline (n=191) conducted approximately 40 years following onset of Minamata disease, mean total HHg ranged from 1.9 to 3.7 µg Hg/g; the percent methylmercury ranged from 70 to 94% (Harada et al. 1998).

Follow-ups of Minamata disease patients conducted 40–60 years following onset of disease found evidence for persistence of neurological symptoms (Futatsuka et al. 2005; Nakamura et al. 2023; Uchino et al. 2005). Evidence for higher prevalence of neurological disorders in residents of the Minamata area has also been observed in follow-up studies (Yorifuji et al. 2008, 2009, 2011, 2016, 2023). Symptoms observed included paresthesia, ataxia, dysarthria, tremor, and abnormal reflexes (Yorifuji et al. 2008). Odds ratios for these symptoms were elevated in a study conducted 15–20 years following onset of Minamata disease (Yorifuji et al. 2016). Another 15–20-year follow-up study of residents of the Shiranui Sea coast (Minamata and Goshonoura) observed an association between increasing HHg and increasing ORs for perioral sensory loss (Yorifuji et al. 2009). HHg levels in the study group (n=120) ranged from 0 to 10 µg Hg/g (36% of subjects) to >50 µg Hg/g in 10% of subjects. Prevalence ORs were also elevated in Minamata residents (relative to a reference population) for impairment of intelligence and mood and behavior dysfunction (Yorifuji et al. 2011).

Cognitive deficits persisted in 25 Minamata residents who were exposed to methylmercury when evaluated in 2020 (Yorifuji et al. 2023). A study of brain morphology in 30 Minamata Disease patients conducted in 2021 found evidence for decreased gray matter volume of the calcarine, the cerebellum, and the thalamus and decreased white matter volume of the cerebrum and cerebellum, relative to an age- and sex-matched control group (Hirai et al. 2023).

Niigata, Japan. Discharges of wastewater from an acetaldehyde production facility into the mouth of the Agano River located in the Niigata Prefecture of Japan resulted in exposure to methylmercury from ingestion of locally contaminated fish and shellfish (Saito et al. 2020). Following discovery of Minamata Disease among local residents, 690 adults were subsequently diagnosed with methylmercury poisoning. HHg levels in some cases exceeded 50 μg/g (Saito et al. 2020). A follow-up of children of 50 cases (at age 40 years) found self-reported symptoms that included muscle cramps, irritability, headache, dizziness, impaired motor abilities, numbness, disturbed hearing or vision, delayed speech, and delayed walking (Saito et al. 2020). Medical examinations of 17 of these cases confirmed neurological deficits in cases in which maternal HHg at the time of exposure were >50 μg/g and, in some cases, in which maternal HHg ranged from 10 to 24 μg/g (Saito et al. 2020).

Iraq. An outbreak of methylmercury poisoning occurred in Iraq in as a result of widespread consumption of wheat that had been treated with a methylmercuric fungicide (Al-Mufti et al. 1976; Bakir et al. 1973; Clarkson et al. 1976). Approximately 6,500 cases of mercury poisoning occurred, with approximately 459 related deaths (Clarkson et al. 1976). BHg levels in poisoning cases measured approximately 65 days after exposure ranged from 10 to 3,000 μg Hg/L (Clarkson et al. 1976). Cases of poisonings occurred across all age ranges. Neurological symptoms included paresthesia, ataxia, visual disturbances, dysarthria, and hearing defects (Bakir et al. 1973). Prevalence of multiple symptoms increased with increasing BHg levels (Bakir et al. 1973). Based on measurements of methylmercury in flour used to bake contaminated bread and estimates of bread consumption, methylmercury intake was estimated to have ranged from 80 to 1,000 mg over a 3-month period (Al-Mufti et al. 1976).

Amazonian riverine populations. Studies of methylmercury exposure and neurological outcomes have been conducted in populations residing in Amazon River basins (Dolbec et al. 2000, 2001; Feitosa-Santana et al. 2018; Hoshino et al. 2015; Khoury et al. 2015; Lebel et al. 1996, 1998; Mergler 2002; Oliveira et al. 2021; Yokoo et al. 2003). Exposure to methylmercury in these populations derives primarily from methylation of inorganic mercury released to local aquatic ecosystems from alluvial gold mining (Mergler 2002). These studies have found associations between increasing HHg and decreasing

performance on tests of fine motor coordination and speed, muscle strength, tactile sensation, color vision and visual contrast sensitivity, and memory and learning (Feitosa-Santana et al. 2018; Khoury et al. 2015; Mergler 2002; Oliveira et al. 2021; Yokoo et al. 2003). Median HHg in these studies ranged from 4 to 19 µg Hg/g. One of the largest studies evaluated residents of the Tapjós River basin in Brazil (n=233) and found associations between increasing HHg (median 11 µg Hg/g; range <2–150) and decreasing performance on tests of fine motor coordination, muscle strength, color vision, and visual contrast sensitivity (Mergler 2002).

Other high fish or marine mammal consumers. A case-control study of fish and fish-eating mammal consumers (n=41 cases, 179 controls) who resided in Northern Quebec found increased ORs for neurologic symptoms (any of the following: impaired bilateral coordination, visual field, nystagmus, tremor, sensory loss, or tactile discrimination) in association with increasing hair methylmercury levels (McKeown-Eyssen et al. 1983). Adjusted ORs for a 20 µg/g increase in hair methylmercury level were 5.1 (95% CI 1.3, 20.8) in males and 2.9 (95% CI 1.1, 7.3 in females). Mean hair methylmercury levels measured at the time of evaluation were 15.9 and 10.5 µg/g in male cases (from subjects who resided in either of two locations) and 16.7 and 10.1 µg/g in female cases. A study of fish consumers (n=63) who resided in the St. Lawrence River basin found poorer performance on tests of auditory or visual memory, cognitive flexibility, and fine motor coordination among fish consumers compared to people who did not consume fish (Mergler 2002; Mergler et al. 1998). The median blood methylmercury levels were 37 µg Hg/L for fish consumers and 27 µg Hg/L for nonconsumers. A study of a whaling community in Japan (n=194) found associations between increasing HHg (median 19 µg Hg/g, range 1–102 µg Hg/g) and hearing loss and gait disturbances (Nakamura et al. 2014). A study of fish consumers who resided in St Peter Island, Sardinia, Italy (n=22 and 22 referents) found associations between increasing blood organic mercury levels (median 41 µg Hg/L, range 13–85 µg Hg/L) and digit-symbol reaction time and motor coordination (Carta et al. 2003). A study of residents of the Grassy Narrows watershed in western Ontario, Canada (n=391, age >18 years) found symptoms of neurological deficits in association with increasing HHg (median 1.1 µg/g measured at age 10 years) (Philibert et al. 2022).

Several studies have evaluated associations between fish consumption or organic mercury biomarkers in cross-sectional cohorts of adults in the United States. Geier et al. (2019) analyzed data from the 2011–2012 NHANES (U.S. population; age range 60–80 years) and found that increasing blood ethylmercury levels were associated with decreased performance on word learning and word fluency tests. An evaluation of data from the 2011–2016 NHANES (age >18 years) found no evidence for an association between blood methylmercury levels (n=3,930; median 0.36 µg/L) and risk of depression (OR 1.356,

95% CL: 0.85, 1.58) (Rossa-Roccor and Karim 2021). A case-control study of ALS (165 cases, 330 controls) found no evidence for an association between mercury consumption from fish (399 mg Hg/year) and ALS diagnosis (Hoffman et al. 2021).

Organic Mercury—Animal Studies. Methylmercury is neurotoxic to several species of experimental animals following acute-, intermediate-, and chronic-duration oral exposure. The major neurobehavioral effects that are seen across studies include sensorimotor dysfunction, vision and hearing deficits, and impaired learning and memory, with overt signs of neurotoxicity at higher doses. Methylmercury exposure is associated with degenerative brain changes (particularly in the cerebellum), spinal cord degenerations (particularly the sensory regions), and peripheral nerve degeneration. Effects observed in adult rodents following methylmercury exposure are consistent with findings observed in developing animals; however, effects generally occur at exposure levels higher than those associated with neurodevelopmental effects in animals.

Neurological effects have also been observed in adult macaque monkeys following exposure to methylmercury compounds (Table 2-53). Overt clinical signs of neurotoxicity (clumsiness, impaired fine motor coordination, insensitivity to touch), impaired high-frequency hearing function, and increased reactive gliosis in the brain were observed following intermediate- or chronic-duration exposure to 0.05 Hg/kg/day (Charleston et al. 1994, 1995, 1996; Rice 1989c; Rice and Gilbert 1992). No changes in visual function or operant training were observed at 0.05 mg Hg/kg/day (Rice 1998b; Rice and Hayward 1999). Chronic-duration exposure to 0.08 mg Hg/kg/day resulted in slight tremors and decreased sucking responses, followed by claw-like grasp, gross motor incoordination, and apparent blindness in monkeys (Burbacher and Mottet 1988; Burbacher et al. 1984, 2005). Overt signs of neurotoxicity were not observed in adult monkeys at doses ≤0.04 mg Hg/kg/day (Burbacher and Mottet 1988; Petruccioli and Turillazzi 1991); no other neurological endpoints were evaluated at doses <0.05 mg Hg/kg/day. In adult marmoset monkeys, exposure to 0.5 mg Hg/kg/day for 242 days resulted in clinical signs of neurotoxicity (restlessness, irritability, mild ataxia of the hindlimbs) and cortical findings consistent with anoxic-ischemic encephalopathy observed in Minamata disease, including white matter edema and compression near the calcarine fissure and astrogliosis and microcytic changes in the cortex (Eto et al. 2001).

Table 2-53. Neurological Effects[a] in Primates Following Oral Exposure to Methylmercury Compounds

Species (sex); exposure duration	Overt clinical signs	Learning/ memory	Auditory function	Visual function	Neuro-pathology	Reference (compound)
M. fascicularis (F); 150 days	↔ N: 0.04 (NR)[b]	–	–	–	–	Petruccioli and Turillazzi 1991 (MMC)
Marmoset (M); up to 242 days	+ L:0.5 (~10)	–	–	–	+ L:0.5 (~10)	Eto et al. 2001 (MM)
M. fascicularis (F); up to 395 days	+ L: 0.08 (1.56–2.209)	–	–	–	–	Burbacher and Mottet 1988; Burbacher et al. 1984, 2005 (MMH)
M. fascicularis (F); up to 548 days	0 N: 0.05 (1.1–2)	–	–	–	+ L: 0.05 (1.1–2)	Charleston et al. 1994, 1995, 1996; Vahter et al. 1994 (MMH)
M. fascicularis (M, F): up to 2,555 days (from birth)[c]	+ L: 0.05 (0.6–0.9)	↔	↓ L: 0.05 (0.6–0.9)	↔	–	Rice 1998b, 1989c; Rice and Gilbert 1992; Rice and Hayward 1999 (MMC)

[a]Studies with exposure in post-pubertal animals, including macaque monkey studies that include exposures, beginning during early neonatal periods and continuing through puberty (which occurs at ~5 years).
[b]NOAEL (N) or LOAEL (L) for dose administered in mg Hg/kg/day (blood level in mg Hg/L).
[c]Findings in studies with exposure extending from birth through adulthood may be due to developmental exposure, post-pubertal exposure, or both.

↓ = decreased; ↔ = no change; – = not assessed; + = present; F = female; LOAEL = lowest-observed-adverse-effect level; M = male; MM = methylmercury; MMC = methylmercuric chloride; MMH = methylmercury hydroxide; NOAEL = no-observed-adverse-effect level; NR = not reported

Numerous acute- and intermediate-duration studies have reported neurobehavioral and/or neuro-physiological changes in adult rodents following oral exposure to methylmercury, often at or below doses associated with frank neurotoxic signs. Effects observed have including altered motor function, impaired memory, decreased nociception, impaired reflexes, altered sleep patterns, and changes in peripheral and central nervous system electrophysiology (Table 2-54).

Table 2-54. Neurobehavioral and Neurophysiological Effects in Rodents Following Adult Oral Exposure to Methylmercury Compounds

Species; duration	Motor activity, coordination, strength[a]	Learning and memory[a]	Neuro-physiology[a]	Other[a]	Reference (compound)
Acute					
Rat; 1 day	↓ (L: 20)	↓ (L: 20)	–	–	Post et al. 1973 (MMC)
Rat; 2 days	–	–	–	↑ Altered sleep patterns (L: 4)	Arito and Takahashi 1991 (MMC)
Rat; 2 days	↓ (L: 10)	–	↓ PNS (L: 20)	–	Fehling et al. 1975 (MMC)
Rat; 5 or 14 days	↓ (L: 1.9)	–	↓ PNS (L: 1.9)	0 Nociception: ↔ (N: 1.9)	Chuu et al. 2007 (MM)
Mouse; 5 days	↓ (L: 0.9)	–	–	–	Bellum et al. 2013 (MMC)
Mouse; 7 days	–	–	↓ Auditory: (L: 0.2)	–	Chuu et al. 2001a (MM)
Mouse; 7 or 14 days	0 (N: 5.6)	–	–	–	Moreira et al. 2012 (MM)
Mouse; 7 or 14 days	0 (N: 4.6)	–	–	–	Kirkpatrick et al. 2015 (MM)
Mouse; 7 or 14 days	↓ (L: 8.7)	–	–	–	Dietrich et al. 2005 (MMC)
Mouse; 14 days	↓ (L: 3.2)	–	↔ Auditory (N: 3.2)	–	Ishihara et al. 2019 (MMC)
Intermediate					
Rat; 26 days	↓ (L: 1.6)	–	–	–	Tamashiro et al. 1986 (MMC)
Rat; 35 days	↓ (L: 0.5)	–	↓ Auditory, visual, SMS, hippocampal (L: 0.5)	↓ Reflexes (L: 0.5) 0 Pre-pulse inhibition (N: 2.0)	Vezér et al. 2005 (MMC)
Rat; 45 days	↑ (L:0.4)			↑ Anxiety (L:0.4)	Rosa-Silva et al. 2020a, 2020b (MMC)
Rat; 60 days	0 (N: 0.04)	↓ (L: 0.04)	–	↔ Anxiety, sociability: (N: 0.04)	Bittencourt et al. 2019 (MMC)

Table 2-54. Neurobehavioral and Neurophysiological Effects in Rodents Following Adult Oral Exposure to Methylmercury Compounds

Species; duration	Motor activity, coordination, strength[a]	Learning and memory[a]	Neuro-physiology[a]	Other[a]	Reference (compound)
Rat; 60 days	–	↓ (L: 0.04)	–	–	Bittencourt et al. 2019 (MMC)
Rat; 60 days	↓ (L: 0.04)	–	–	–	Bittencourt et al. 2022 (MMC)
Rat; 60 days	↓ (L: 0.03)	–	–	–	Freire et al. 2010
Rat; 60 days	↓ (L: 0.037)	–	–	↔ Anxiety (N: 0.037)	Santana et al. 2019 (MM)
Rat; 91 days	–	↓ (L: 0.09)	–	–	Wu et al. 2023
Mouse; 21 days	↓ (L: 4.7)	–	–	–	Dietrich et al. 2005 (MMC)
Mouse; 21 days	↔ (N: 4.6)	–	–	–	Kirkpatrick et al. 2015 (MM)
Mouse; 21 days	↓ (L: 5.6)	–	–	–	Moreira et al. 2012 (MM)
Mouse; 28 days	↓ (L: 4.6)	–	–	–	Kirkpatrick et al. 2015 (MM)
Mouse; 28 days	↔ (N: 3.2)	–	↓ Auditory (L: 3.2)	–	Ishihara et al. 2019 (MMC)
Mouse; 30 days	↓ (L:0.21)	↓ (L:0.21)	–	↑ Stereotypy (L:0.21)	Nascimento et al. 2022 (MMC)
Mouse; 35–56 days	↓ (L: 3.2)	–	–	–	Ishihara et al. 2019 (MMC)
Mouse; 60 days	–	↓ (L: 0.0073)	–	↔ Anxiety (N: 0.0073)	Bourdineaud et al. 2011 (MM)
Mouse; 60 days	↓ (L: 0.25)	–	–	–	Berthoud et al. 1976 (MMC)
Mouse; 196 days	↓ (L: 0.89)	–	–	–	MacDonald and Harbison 1977 (MMC)

[a]NOAEL (N) or LOAEL (L) dose in mg Hg/kg/day for endpoint category.

↑ = increased; ↓ = decreased; ↔ = no change; – = not assessed; LOAEL = lowest-observed-adverse-effect level; MM = methylmercury; MMC = methylmercuric chloride; NOAEL = no-observed-adverse-effect level; PNS = peripheral nervous system; SMS = somatosensory

Dose- and duration-dependent clinical signs of neurotoxicity have also been observed in adult rats following oral exposure to methylmercury compounds. Transient effects (lethargy, ataxia) were observed following a single exposure to 20 mg Hg/kg (Post et al. 1973). With repeated acute-duration exposure, mild effects (weakness, hindlimb crossing) were observed at ≥4 mg Hg/kg/day progressing to severe and persistent effects (spasms, ataxia, gait disturbances) at ≥6 mg Hg/kg/day for 8–10 days (Fuyuta et al. 1978; Miyakawa et al. 1974; Su et al. 1998; Usuki et al. 1998). In intermediate-duration studies, severe clinical signs of neurotoxicity were observed in rats following exposure to ≥1.6 mg Hg/kg/day for 2– 4 weeks or ≥0.8 mg Hg/kg/day for 5–6 weeks, including ataxia, tremor, unsteady/uncoordinated gait, partial paralysis, and hindlimb crossing (Chang and Hartmann 1972; Gandhi et al. 2013; Larsen and Brændgaard 1995; Schiønning et al. 1998a; Sitarek and Gralewicz 2009; Tamashiro et al. 1986; Tonk et al. 2010). No clinical signs of toxicity were observed in rats following chronic-duration exposure to doses up to 0.18 mg Hg/kg/day (Verschuuren et al. 1976).

Overt signs of neurotoxicity (e.g., ataxia, muscular incoordination, intention tremors, partial paralysis) were observed in mice exposed to intermediate-duration doses ≥0.89 mg Hg/kg/day (MacDonald and Harbison 1977; Mitsumori et al. 1981) and in male, but not female, mice chronically exposed to 0.686 mg Hg/kg/day (Mitsumori et al. 1990). However, another study did not report clinical signs of neurotoxicity in mice following intermediate- or chronic-duration exposure to doses up to 0.724 mg Hg/kg/day (Hirano et al. 1986). Severe clinical signs of neurotoxicity (e.g., ataxia, impaired gait, tremors, convulsions) were observed in cats following intermediate-duration exposure to ≥0.012 mg Hg/kg/day (Chang et al. 1974; Charbonneau et al. 1976; Khera et al. 1974) or chronic-duration exposure to ≥0.074 mg Hg/kg/day (Charbonneau et al. 1976). In rabbits, ataxia and intermittent convulsions were observed following intermediate-duration exposure to ≥0.49 mg Hg/kg/day (Koller et al. 1977).

Following acute-duration exposure to methylmercury compounds, the most sensitive effects were observed in mice, including impaired hearing at ≥0.2 mg Hg/kg/day (Chuu et al. 2001a) and decreased motor activity and impaired motor coordination at 0.9 mg Hg/kg/day (Bellum et al. 2013). Additional details on neurobehavioral testing and dose-response information for sensitive effects observed in mice following acute-duration oral exposure can be found in Table 2-55. For hearing impairment findings in mice of an unspecified strain following acute-duration exposure, degree and persistence of hearing impairment were dose-dependent when measured immediately following a 7-day exposure and 5 and 11 weeks post-exposure (Chuu et al. 2001a). However, no hearing impairment was observed in ICR mice following exposure to 3.2 mg Hg/kg/day for 2 weeks (Ishihara et al. 2019). Available data indicate that age and strain may influence exposure-related changes in motor activity and coordination. In C57BL/6

mice, no exposure-related changes in motor activity were observed following exposure to 5.6 mg
Hg/kg/day for 7 or 14 days starting at 3 months of age (Moreira et al. 2012); however, when exposure
started at 16–20 months of age (aged mice), five daily doses of 0.9 mg Hg/kg/day resulted in decreased
motor activity, altered gait, and impaired coordination/balance on the vertical pole test (Bellum et al.
2013). In 2-month-old Swiss mice, dose- and duration-dependent decreases in motor activity and
coordination were observed following exposure to 4.7 or 8.7 mg Hg/kg/day for 7 or 14 days (Dietrich et
al. 2005).

Table 2-55. Dose-Response Data for Sensitive Neurobehavioral Effects in Mice following Acute-Duration Oral Exposure to Methylmercury

Reference, study duration	Assay/ outcome measured	Dose (mg Hg/kg/day)	Result (% change compared to control)
Auditory function			
Chuu et al. 2001a 7 days	Hearing threshold	0.2	End of exposure: ↔ 5 weeks post-exposure: ↑ (180)[a] 11 weeks post-exposure: ↔
		1.9	End of exposure: ↑ (200)[a] 5 weeks post-exposure: ↑ (520)[a] 11 weeks post-exposure: ↑ (300)[a]
		9.3	End of exposure: ↑ (710)[a] Post-exposure: ND[b]

	ABR absolute latency	0.2	End of exposure:
			  Wave V: ↑ (10)[c]
			5 weeks post-exposure:
			  Wave V: ↑ (9)[c]
			11 week post-exposure: ↔

		1.9	End of exposure:
			  Wave V: ↑ (23)[c]
			5 weeks post-exposure:
			  Wave IV: ↑ (14)[c]
			  Wave V: ↑ (15)[c]
			11 weeks post-exposure:
			  Wave IV: ↑ (11)[c]
			  Wave V: ↑ (16)[c]

	ABR interwave latency (Waves I–V)	0.2	End of exposure: ↑ (19)[c] 5 weeks post-exposure: ↔ 11 weeks post-exposure: ↔
		1.9	End of exposure: ↑ (41)[c] 5 weeks post-exposure: ↑ (18)[c] 11 weeks post-exposure: ↑ (21)[c]

Table 2-55. Dose-Response Data for Sensitive Neurobehavioral Effects in Mice following Acute-Duration Oral Exposure to Methylmercury

Reference, study duration	Assay/ outcome measured	Dose (mg Hg/kg/day)	Result (% change compared to control)
Ishihara et al. 2019 2 weeks	Hearing threshold	3.2	End of exposure: ↔
	ABR amplitude	3.2	End of exposure: ↔
	ABR interwave latency (Waves I–V)	3.2	End of exposure: ↔
Motor activity and coordination			
Bellum et al. 2013 5 days; exposure began at 16–20 months; all tests were conducted 6 days post-exposure	Motor activity in open field (30 minutes)	0.9	First 5 minutes: ↓ (25)[a] Total 30 minutes: ↔
	Gait analysis	0.9	Angle of foot placement: ↓ (50)[a] Stride length: ↔ Base length: ↔
	Vertical pole test	0.9	% animals that didn't fall at 90°: ↓ (45)[c] % animals falling between 45 and 90°: ↑ (39)[c]
	Rotarod	0.9	↔
Kirkpatrick et al. 2015, 7 or 14 days	Rotarod	4.6	Latency to fall: ↔
Dietrich et al. 2005, 7 or 14 days; exposure began at 2 months	Motor activity in open field (20 minutes)	4.7	7 days: ↔ 14 days: ↓ (30)[a]
		8.7	7 days: ↓ (25)[a] 14 days: ↓ (45)[a]
	Beam walking (10 mm circle beam)	4.7	7 days: ↔ 14 days: ↑ (150)[a]
		8.7	Latency to cross beam: 7 days: ↔ 14 days: ↑ (500)[a]
Moreira et al. 2012, 7 or 14 days; exposure began at 3 months	Motor activity in open field (5 minutes)	5.6	↔

[a]Estimated from graphically presented data.
[b]All animals died prior to 5-week examination.
[c]Calculated from quantitative data.

↑ = increased; ↓ = decreased; ↔ = no change; ABR = auditory brainstem response; ND = no data

In intermediate-duration studies, mice were again more sensitive than rats, with impaired memory in the Y-maze observed at ≥0.0073 mg Hg/kg/day as the most sensitive effect following intermediate-duration exposure (Bourdineaud et al. 2011). In the Y-maze, the rate of spontaneous alteration was significantly decreased by 14% following exposure to 0.0073 mg Hg/kg/day for 2 months, compared to controls, suggesting that the animals had difficulty remembering which arm was entered last. No adverse effects in the Y-maze were observed in male mice following a shorter 30-day exposure to 0.21 mg Hg/kg/day; however, exposed mice showed impaired spatial learning and memory in the Barnes maze, compared to control (Nascimento et al. 2022). Memory impairments have also been reported in rats. Impaired spatial memory in the Morris water maze and impaired social memory in the social recognition task were observed following exposure to 0.04 mg Hg/kg/day for 60 days (Bittencourt et al. 2019). Open field and rotarod tests also indicated decreased motor activity, balance, and coordination in male rats exposed to 0.04 mg Hg/kg/day for 60 days (Bittencourt et al. 2022). Similarly, impaired spatial memory in the Morris water maze was reported in rats exposed to 0.09 mg Hg/kg/day for 3 months (Wu et al. 2023). Other effects reported in rodents at higher doses included decreased motor activity and exploration, impaired motor coordination and/or strength, impaired reflexes, impaired hearing and vision, and increased anxiety and stereotypical/repetitive behaviors (Table 2-54).

Data on neurobehavior following chronic-duration exposure is limited to a single study in cats, rats, and mice. The most sensitive finding was decreased nociception in cats exposed to dietary levels of 0.046 mg Hg/kg/day for 2 years; additional effects observed at 0.074 mg Hg/kg/day included muscle weakness, impaired balance and coordination (during beam walking), and impaired reflexes (righting, hopping, placing, optical, patellar) (Charbonneau et al. 1976). No adverse neurobehavioral effects were observed in cats at chronic-duration doses up to 0.02 mg Hg/kg/day. In the rat study, no changes in motor activity were observed following exposure to dietary doses up to 0.18 mg Hg/kg/day for 2 years (Verschuuren et al. 1976). In the mouse study, lifetime exposure to methylmercury (including gestation and lactation via dam) resulted in impaired spatial learning in the delayed alternation task and altered gait (increased hindlimb splay) at 5, 15, and/or 26 months of age at drinking water doses ≥0.2 mg Hg/kg/day (lowest dose tested); impaired operant training was observed at 0.6 mg Hg/kg/day (Weiss et al. 2005).

Histopathological changes in the brain have been reported in rats and mice following oral exposure to methylmercury; similar to neurodevelopmental studies, lesions were primarily in regions involved in motor and movement control. Ultrastructural changes were noted in the rat cerebellum (vacuolation, degeneration of granule cells) following acute- or intermediate-duration exposure to doses ≥0.8 mg Hg/kg/day (Chang and Hartmann 1972).

In acute-duration rat studies, degeneration of cortical and cerebellar neurons was observed in rats exposed
to 8 mg Hg/kg/day for 10 days (Su et al. 1998). Other studies observed no histopathological damage in
the brain at doses up to 20 mg/kg/day for 1 or 2 days or 7 mg Hg/kg/day for 10 days (Fehling et al. 1975;
Miyakawa et al. 1974; Post et al. 1973).

In intermediate-duration rat studies, no exposure-related histopathological changes were observed at
doses up to 9.72 mg Hg/kg/day for up to 35 days (Larsen and Brændgaard 1995; Sakamoto et al. 2017;
Schiønning et al. 1998a). However, a reduction in cellular number or density has been reported in several
brain regions of rats exposed to ≥0.03 mg Hg/kg/day for 60 days, including the motor cortex (neurons,
astrocytes), visual cortex (astrocytes), cerebellum (Purkinje cells, mature neurons, astrocytes, microglia,
oligodendrocytes), and hippocampus (neurons, mature neurons, astrocytes) (Bittencourt et al. 2019, 2022;
Freire et al. 2020; Santana et al. 2019). Reduced neuronal number in the pyramidal layer of the
hippocampus, resulting in thinning of the CA1 and CA3 regions, was also reported in rats following
exposure to 0.09 mg Hg/kg/day for 3 months (Wu et al. 2023). In mice, histopathological brain lesions
were observed following intermediate-duration exposures ≥0.89 mg Hg/kg/day, including neuronal
degeneration and microgliocytosis in subcortical regions (e.g., the putamen and corpus striatum, and to a
lesser extent, the thalamus, hypothalamus, and amygdala) and degenerative changes in Purkinje cells and
loss of granular cells in the cerebellum (Berthoud et al. 1976; MacDonald and Harbison 1977). The
number of reactive astrocytes was increased in the inferior colliculus of the midbrain in mice exposed to
3.2 mg Hg/kg/day for 2 or 4 weeks (Ishihara et al. 2019). Ventricular enlargement of the inferior
colliculus was also observed after 4 weeks of exposure.

No histopathological changes were observed in the mouse brain following intermediate- or chronic-
duration exposure to doses up to 0.724 mg Hg/kg/day (Hirano et al. 1986; Mitsumori et al. 1990). No
histopathological brain lesions were observed in rats at chronic-duration doses up to 0.18 mg Hg/kg/day
(Verschuuren et al. 1976).

Several studies have reported damage and degeneration of sensory regions of the spinal cord in rats (e.g.,
dorsal nerve root and ganglia, posterior column) following oral exposure to methylmercury at doses of
20 mg Hg/kg/day for 2 days (Fehling et al. 1975), 5.4 mg Hg/kg/day for 2 weeks (Shinoda et al. 2019), or
intermediate-duration doses ≥1.4 mg Hg/kg/day (Larsen and Brændgaard 1995; Sakamoto et al. 2017;
Schiønning et al. 1998a; Yip and Chang 1981). Ultrastructural changes were also noted in the dorsal root
ganglia (vacuole formation, focal cytoplasmic lesions) of rats following acute- or intermediate-duration

exposure to doses ≥0.8 mg Hg/kg/day (Chang and Hartmann 1972; Yip and Chang 1981). No changes were observed in anterior horn motor neurons in these studies. However, degeneration of the large motor neurons in spinal cord and myelinated fibers of spinal anterior roots was observed in rats exposed to 8 mg Hg/kg/day for 10 days (Su et al. 1998). No exposure-related histopathological changes in the spinal cord were observed in rats following chronic-duration exposure to 0.18 mg Hg/kg/day (Verschuuren et al. 1976) or in mice at intermediate- or chronic-duration doses up to 9.5 or 0.724 mg Hg/kg/day, respectively (Hirano et al. 1986; MacDonald and Harbison 1977; Mitsumori et al. 1990).

A few studies have reported damage to peripheral nerves in rats and mice exposed to methylmercury. Degeneration of peripheral nerves was also observed in rats following a 2-day exposure to 20 mg Hg/kg/day (Fehling et al. 1975) or a 10-day exposure to 7 mg Hg/kg/day (Miyakawa et al. 1974). No histopathological changes in peripheral nerves were observed in rats following chronic-duration exposure to doses up to 0.18 mg Hg/kg/day (Verschuuren et al. 1976). In mice, no histopathological changes in peripheral nerves were observed at intermediate-duration doses up to 0.724 mg Hg/kg/day for 26 weeks (Hirano et al. 1986). In chronic-duration studies, one study observed degeneration and fibrosis of the sciatic nerve in female mice at 0.627 mg Hg/kg/day, but not in males at doses up to 0.724 mg Hg/kg/day (Hirano et al. 1986). A second study observed peripheral nerve damage in males at 0.686 mg Hg/kg/day, but not females at doses up to 0.601 mg Hg/kg/day (Mitsumori et al. 1990).

Neuropathological data are limited for other laboratory animal species. Degeneration and/or necrosis of cerebellar granule and Purkinje cells and cortical neurons were observed in cats following intermediate-duration exposure to ≥0.012 mg Hg/kg/day (Chang et al. 1974; Khera et al. 1974). Degeneration of the cerebral cortex, cerebellum, and dorsal root ganglia was also observed in cats following intermediate- or chronic-duration exposure to 0.176 or 0.074 mg Hg/kg/day, respectively (Charbonneau et al. 1976). In rabbits, cerebellar degeneration was observed following intermediate-duration exposure to doses ≥1.0 mg Hg/kg/day (Koller et al. 1977).

Predominant Mercury Form Unknown (General Populations). An analysis of data from the 2011–2014 NHANES (n=6,199, age range 20–79 years) found no evidence for an association between BHg levels (median 0.8 µg/L) and grip strength (Gbemavo and Bouchard 2021) (Table 2-56). An analysis of data from the 2011–2014 NHANES restricted to age >60 years (n=2,002) found no evidence for an association between BHg levels and scores of tests for cognition (Lu et al. 2023). Kim et al. (2020b) analyzed data from the 2008–2013 Korean NHANES (n=11,754, age >19 years) and found an association between increasing BHg levels (5.01–168 µg/L) and symptoms of depression in adult females, but not in males. A

follow-up study of data from the 2009–2017 Korean NHANES (n=16,371, mean age 43 years) found no association between BHg levels and depression in females or males (Nguyen 2023). A cross-sectional study of adults in Korea (n=172; age range 20–65 years) found decreasing finger tapping speed in association with increasing UHg (median 1.2 µg/g creatinine; range 0–33 µg/g creatinine) (Kim et al. 2013a). Takeuchi et al. (2022a, 2022b) examined various metrics of cognitive function in a cross-sectional study of young adults (n=920, age range 18–27 years). In this study, increasing HHg (means: males 2.01 µg/g; females 1.85 µg/g) was associated with decreasing performance (lower score) on the Tanaka B-type intelligence test (total and perception score), color-word task, and Beck Depression Inventory Score (three of these measure processing speed). HHg was not associated with performance on other tests of general intelligence (e.g., Raven's Advanced Progressive Matrices) or on tasks that evaluated arithmetic, reading comprehension, inhibition or impulsivity, or creativity. A cross-sectional study of adults (n=436, mean age 59 years) found that increasing BHg levels (geometric mean 6.31 µg/L) were associated with decreasing performance on tests of attention, visual-spatial and executive function, and language based on the Montreal Cognitive Assessment (Sirivarasai et al. 2021). A cross-sectional study of adults (n=200, mean age 34 years) found that increasing HHg (median 8.5 µg/L) was associated with decreasing performance on the tests of visuomotor function or executive function (trail making test) (Rafiee et al. 2020).

Table 2-56. Results of Epidemiological Studies Evaluating General Population Exposure to Mercury (Predominant Mercury Form Unknown) and Neurological Effects

Reference, study type, and population	Biomarker	Outcome evaluated	Result[a]
Andrew et al. 2020 Case-control study (females age range 35–66 years), 70 cases, 210 controls; United States	NHg mean Cases 0.093 µg/g Controls: 0.074 µg/g	ALS	↔ (NHg, ≤0.21 µg/g) ↑ (NHg, ≥0.21 µg/g)
Gbemavo and Bouchard 2021 Cross-sectional study of data from NHANES 2011–2014 (n=6,199; mean age 46 years); United States	BHg median Female: 0.82 µg/L Male: 0.84 µg/L	Grip strength	↔ (BHg)
Kim et al. 2020b Cross-sectional study of data from KNHANES 2008–2013 (n=11,754; median age 44 years); Republic of Korea	BHg 5th quintile range: 5.01–168 µg/L	Depression	↑ (BHg, females) ↔ (BHg, males)

Table 2-56. Results of Epidemiological Studies Evaluating General Population Exposure to Mercury (Predominant Mercury Form Unknown) and Neurological Effects

Reference, study type, and population	Biomarker	Outcome evaluated	Result[a]
Lu et al. 2023 Cross-sectional study of data from NHANES 2011–2014 (n=2,002; age >60 years); United States	BHg median 0.94 µg/L	Animal fluency test	↔ (BHg)
		CERAD DSST	↔ (BHg)
		WAIS DSST	↔ (BHg)
Nguyen 2023 Cross-sectional study of data from KNHANES 2009–2017 (n=16,371; mean age 43 years); Republic of Korea	SHg mean: 4.06 µg/L	Depression	↔ (BHg, females) ↔ (BHg, males)
Peters et al. 2021 Prospective case-control study, 107 cases, 319 controls (median age 60 years); Europe	ErHg geometric mean Cases: 2.82 µg/kg Controls: 2.75 µg/kg	ALS	↔ (ErHg)
Rafiee et al. 2020 Cross-sectional cohort (n=200; mean age 34 years); Iran	HHg median: 8.5 µg/g	Trail making time (visuomotor function)	↑ HHg
		Trail making time (executive function)	↑ HHg
Sirivarasai et al. 2021 Cross-sectional cohort (n=436; mean age 59 years); Thailand	BHg geometric mean: 6.31 µg/L	Montreal Cognitive Assessment	↓ BHg
Takeuchi et al. 2022a, 2022b Cross-sectional cohort (n=920, age range 18–27 years); Japan	HHg mean: males: 2.01 µg/g females 1.85 µg/g	RAPM	↔ (HHg)
		TBIT total intelligence score	↓ (HHg)
		TBIT perception score	↓ (HHg)
		Arithmetic	↔ (HHg)
		Word-color task	↓ (HHg)
		Stroop	↔ (HHg)
		Reading comprehension	↔ (HHg)
		SA creativity task	↔ (HHg)
		Digit span	↔ (HHg)
		Beck Depression Inventory	↓ (HHg)

Table 2-56. Results of Epidemiological Studies Evaluating General Population Exposure to Mercury (Predominant Mercury Form Unknown) and Neurological Effects

Reference, study type, and population	Biomarker	Outcome evaluated	Result[a]
Xiong et al. 2022 Cross-sectional cohort (n=1,154, age >80 years); China	BHg Gmean 1.02 µg/L	Depression symptoms	↑ BHg (≥1.83 µg/L)

[a]Interpretation of neurobehavioral test scores:
  Animal Fluency Test: higher score = higher performance
  Beck Depression Inventory: higher score = more severe depression
  Digit symbol substitution test: higher score = higher performance
  Montreal Cognitive Assessment: higher score = higher performance
  TBIT: higher score = higher performance
  Trail-making: higher score = lower performance
  Word-color task: higher score = higher performance
  Word learning: higher score = higher performance

↑ = positive association; ↓ = inverse association; ↔ = no association; ALS = amyotrophic lateral sclerosis; BHg = blood mercury; CERAD = Consortium to Establish a Registry for Alzheimer's Disease; DSST = digit symbol substitution test; ErHg = erythrocyte mercury; HHg = hair mercury; KNHANES = Korean National Health and Nutrition Examination Survey; NHANES = National Health and Nutrition Examination Survey; NHg = toenail mercury; RAPM = Raven's Advance Progressive Matrices; RAVPM = Raven's Advanced Progressive Matrices; SHg = serum mercury; TBIT = Tanaka B-type Intelligence Test; WAIS = Wechsler Adult Intelligence Scale

Associations between mercury biomarkers and diagnosis of ALS have been examined in case-control studies of general population cohorts. A prospective case-control study (107 cases, 319 controls, median age 60 years) found no association between erythrocyte mercury levels (cases 2.82 µg/kg, controls 21.75 µg/g) and ALS diagnosis (Peters et al. (2021). Another case-control study (70 cases, 210 controls, age range 35–66 years) found an association between increasing NHg levels and ALS diagnosis when the analysis was restricted to comparing 0.38 to 0.21 µg/g (Andrew et al. 2020). In this study, no association was found for lower NHg strata (0.041–0.21 µg/g).

Mechanisms of Action. General mechanisms of toxicity of mercury (Section 2.21) are likely involved in adverse neurodevelopmental and neurological effects of mercury. Mercury is distributed to the fetus and has been measured in fetal tissues (Section 3.1.2, Distribution), providing a toxicokinetic mechanism for direct exposure of the placental tissues and fetus. Transfer of methylmercury across the placenta may be facilitated by amino acid or organic anion transporters that recognize CH_3Hg^{2+}-thiol conjugates of amino acids (Bridges and Zalups 2017). Amino acid transporters also participate in transfer of CH_3Hg^{2+}-S-cysteine conjugate across the blood brain barrier (Bridges and Zalups 2017).

A variety of toxicodynamic mechanisms contributing to neurological effects of methylmercury have been proposed. These include alteration or disruption in regulation of intracellular calcium homeostasis, the cytoskeleton, mitochondrial function, oxidative stress, neurotransmitter release, and DNA methylation (Aaseth et al. 2020; Cardenas et al. 2016, 2017a; Cediel Ulloa et al. 2021; Culbreth and Aschner 2016; Johansson et al. 2007; Patel and Reynolds 2013; dos Santos et al. 2016). Studies in humans, animals, and *in vitro* models have revealed that several potential mechanisms may contribute to neurological effects of methylmercury. Neurodegenerative mechanisms include tau hyperphosphorylation in the cerebral cortex, (Fujimura et al. 2009), neurite membrane disassembly, and neuron growth rate suppression (Leong et al. 2001). Methylmercury exposure has been shown to inhibit Na^+,K^+-ATPase and to decrease update of norepinephrine and dopamine in brain tissue (Rajanna and Hobson 1985). Song and Choi (2013) observed accumulation of amyloid beta protein through increased production of amyloid precursor protein and reduction of neprilysin and suggested it as a mechanism of mercury toxicity. Disruption of brain-derived neurotrophic factor mediation of growth and differentiation of nerve tissue may also contribute to neurological effects of methylmercury (Rodríguez-Carrillo et al. 2022; Zhou et al. 2021).

The vulnerability of the nervous system to mercury vapor is related to its pronounced distribution to the brain following inhalation. This is attributed, in part, to the high solubility of Hg^0 in lipid, its affinity for proteins such as hemoglobin, and its extracellular and intracellular oxidation, which can favor absorption from the lung and delivery to the brain (Hursh 1985; Magos 1967; Magos et al. 1978; U.S. Atomic Energy Commission 1961).

2.17 REPRODUCTIVE

Overview. The database for reproductive effects associated with exposure to mercury includes epidemiological studies and studies in laboratory animals. Epidemiological studies are available for workers exposed to elemental mercury, populations with high fish diets, and general populations. Few studies meeting inclusion criteria were identified for workers and populations with high fish diets, whereas the database for general populations was more robust (inclusion criteria summarized in Section 2.1). Few studies examined the same reproductive endpoints, and those that did often reported conflicting results. The available epidemiological studies do not provide convincing evidence that the reproductive system is a sensitive target of mercury exposure in males or females.

Studies evaluating reproductive function in animals (mating, fertility, pregnancy, and live birth indices) are available for inhalation exposure to elemental mercury or oral exposure to mercuric chloride or

methylmercury. Overall, oral studies indicate dose-dependent decreases in fertility in female monkeys exposed to methylmercury, in male rodents exposed to mercuric chloride and methylmercury, and in female rodents exposed to mercuric chloride. Data are inconsistent and/or inadequate to determine fertility effects in male monkeys and female rodents exposed to methylmercury. Supporting studies suggest that alterations in sperm parameters and/or estrous cyclicity may contribute to observed decreases in fertility. Evidence from inhalation studies are too limited to draw conclusions.

The following summarizes results of epidemiological and animal studies on reproductive outcomes.

- **Elemental mercury**
    - *Epidemiology studies*
        - It is not possible to determine if there are associations between elemental mercury exposure and adverse reproductive outcomes in males or females; few studies have been conducted, with most reporting no effects.
        - Studies in males show no effects on testosterone levels or increased risk of spontaneous abortion in their partners.
        - One study in females reported increased spontaneous abortion. This finding has not been corroborated.
    - *Animal studies*
        - Few studies investigated effects on reproductive function; data are insufficient to draw conclusions.
- **Inorganic mercury salts**
    - *Epidemiology studies*
        - No epidemiological studies evaluating associations between exposure to inorganic mercury salts and reproductive effects were identified.
    - *Animal studies*
        - Reproductive studies consistently reported dose-related impairments in fertility in male and female rodents following oral exposure.
        - Oral studies showed multiphasic changes in testosterone levels with respect to dose and duration, with initial decreases, followed by increases, followed by return to baseline/control levels. Few studies investigated effects of other male or female reproductive hormones. Data are insufficient to draw conclusions about effects on reproductive hormones other than testosterone.
        - Two oral studies have shown dose-related decreases in sperm motility and/or number in male rats.

- ▪ Evidence for histopathological lesions in testes is inconsistent in acute- and intermediate-duration oral studies, and reports are generally qualitative; no histopathological lesions were identified in male reproductive tissue following chronic-duration oral exposure.

- ▪ No histopathological lesions were identified in female reproductive tissue following acute-, intermediate-, or chronic-duration oral exposure.

- ▪ Few studies investigated effects of inhalation exposure on reproductive function; data are insufficient to draw conclusions.

- • *Organic mercury*
  - ▪ *Epidemiology studies*
    - ▪ Few epidemiology studies in populations with high fish diets have evaluated reproductive endpoints. Available data are not adequate to determine if methylmercury from high fish diets is associated with adverse reproductive effects.
    - ▪ In males, there were no adverse effects on sperm quality or serum levels of reproductive hormones; however, only one study was identified.
    - ▪ In females, results of two studies reported conflicting results for duration of gestation.
  - ▪ Animal studies
    - ▪ Reproductive studies consistently reported dose-related impairments in fertility in male rats and female monkeys following oral exposure; male monkeys were not assessed for fertility but showed alterations in sperm parameters.
    - ▪ Alterations in sperm parameters were observed in male rats following acute- or intermediate-duration exposure, but there is no clear evidence of increased magnitude of effect with dose or duration.
    - ▪ Evidence for exposure-related impairments in female rodent fertility following oral exposure is inconsistent.
    - ▪ Evidence for histopathological lesions in male reproductive organs in rodents is inconsistent; no histopathological lesions were identified in male reproductive organs in monkeys following intermediate-duration exposure.
    - ▪ No histopathological lesions were identified in female reproductive organs following intermediate- or chronic-duration oral exposure.

- • *Predominant mercury form unknown (general populations)*
  - ▪ No adverse effects of mercury exposure on sperm quality or serum levels of reproductive hormones were observed in males. Mercury exposure in general populations does not appear to adversely affect the male reproductive system.

- In nonpregnant women without known infertility, the female reproductive system does not appear to be a sensitive target for mercury. Most studies showed no associations between mercury biomarkers and serum levels of reproductive hormones. Other outcomes (e.g, menstrual cycle length, risk of endometriosis) were only assessed in a few studies, without compelling evidence of adverse effects.

- In pregnant women, most studies did not find associations between preterm birth, gestational age, or pre-eclampsia. No consistent effects were observed between mercury biomarkers and gestational diabetes or elevated blood glucose.

Confounding Factors. Numerous factors may add uncertainty in the interpretation of studies examining associations between mercury and reproductive effects, including overall health, body weight, nutrition, and SES. Exposures to other substances, including recreational drugs, alcohol, therapeutic agents, industrial chemicals, insecticides, and pesticides, also may affect fertility (Foster and Gray 2008). Failure to account for these factors may attenuate or strengthen the apparent associations between mercury exposure and the outcome, depending on the direction of the effect of the variable on the outcome.

Elemental Mercury—Epidemiological Studies. The effects of occupational exposure to elemental mercury have not been well-studied. Studies, summarized in Table 2-57, have been conducted in small populations (n≤147) of males and females exposed at chloralkali plants and dental offices. Small population sizes limit the power to detect effects. All studies quantified elemental mercury exposure using UHg, with or without adjustment for urine creatinine.

Table 2-57. Results of Epidemiological Studies Evaluating Exposure to Elemental Mercury (Hg^0) and Reproductive Effects

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Males			

Barregard et al. 1994a
 	
Cross-sectional; 41 male chloralkali workers and 41 matched controls (Sweden)
	UHg mean
	  Workers: 27 µg/g Cr
	  Controls: 3.3 µg/g Cr
		Testosterone	↔ (UHg, workers versus controls)

		Free testosterone	↔ (UHg, workers versus controls)
		Prolactin	↔ (workers versus controls)

Cordier et al. 1991
 	
Cross-sectional; 152 male chloralkali workers (France)
	UHg quartiles
	  Q1: 0 (reference)
	  Q2: 1–19 µg/L
	  Q3: 20–49 µg/L
	  Q4: ≥50 µg/L
		Spontaneous abortion	↔ (UHg, Q4)

Table 2-57. Results of Epidemiological Studies Evaluating Exposure to Elemental Mercury (Hg^0) and Reproductive Effects

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Erfurth et al. 1990 Cross-sectional; 9 male dentists 11 controls and 11 chloralkali workers and 10 controls (Sweden)	UHg mean, dentists Dentists: 2.3 µg/g Cr Controls: 0.71 µg/g Cr UHg mean, workers Workers: 46 µg/g Cr Controls: 1.1 µg/g Cr	Testosterone	↔ (UHg, workers or dentists versus respective controls)
Females			
El-Badry et al. 2018 Prospective; 64 pregnant dental workers and 60 pregnant controls (Egypt)	UHg mean, workers 1st trimester: 42.2 µg/g Cr 2nd trimester: 41.8 µg/g Cr 3rd trimester: 42.8 µg/g Cr UHg mean, control: 1st trimester: 6.2 µg/g Cr 2nd trimester: 6.3 µg/g Cr 3rd trimester: 7.1 µg/g Cr	Spontaneous abortion	↑ (UHg, relative to control)
		Pre-eclampsia	↑ (UHg, relative to control)
Louopou et al. 2020 Prospective cohort; 1,817 pregnant women with 1, 1–4, or ≥5 amalgam fillings (Canada)	BHg median, 1st trimester 0 amalgams: 0.58 µg/L 1–4 amalgams: 0.74 µg/L ≥5 amalgam: 0.90 µg/L BHg median, 3rd trimester 0 amalgams: 0.60 µg/L 1–4 amalgams:0.74 µg/L ≥5 amalgam: 0.90 µg/L	Gestational hypertension	↔ (BHg)
Males and females			
Frumkin et al. 2001 Retrospective cohort; 147 chloralkali workers (137 males and 10 females) and 132 controls (117 males and 15 females) (Brunswick, Georgia)	UHg mean Workers: 2.76 µg/g Cr Controls: 2.31 µg/g Cr	Spontaneous abortion	↔ (UHg)
		Preterm birth	↔ (UHg)

↑ = positive association or increased compared to controls; ↔ = no association or no increase compared to controls; BHg = blood mercury; Cr = creatinine; Q = quartile; UHg = urine mercury

Studies in male workers did not identify effects on reproductive hormones including testosterone and prolactin (Barregard et al. 1994a; Erfurth et al. 1990). In addition, exposure of males was not associated with risk of spontaneous abortion in their partners (Cordier et al. 1991). In females, a prospective study of dental workers found an increased risk of spontaneous abortion and pre-eclampsia, relative to controls (El-Badry et al. 2018). However, no increases in spontaneous abortion or preterm birth were observed in partners of males or in female chloralkali workers compared to controls. Given the small number of

studies, data are not adequate to determine if elemental mercury adversely affects reproductive function in males or females.

Elemental Mercury—Animal Studies. The effects of exposure to elemental mercury have not been well-studied in animals. A single study found significant testicular damage in male rats exposed to 1 mg/m^3 for 6 weeks (7 days/week, 9 hours/day), including seminiferous tubule atrophy; damage to spermatogenic cells; decreased volume of the testicles; decreased diameter and volume of the seminiferous tubules; and decreased Sertoli cells, spermatogonia, spermatocytes, and spermatids (Altunkaynak et al. 2015). In a series of experiments in female rats, Davis et al. (2001) found estrous cycle abnormalities following nose-only exposure to mercury vapor at concentrations ≥2 mg Hg/m^3 for 6–11 days (2 hours/day), including a concentration-related increase in the number of females with prolonged estrous cycles (≥5 days) and evidence of immature corpora lutea during estrus and metestrus phases. Significant alterations in reproductive hormone levels (decreased estradiol, increased progesterone) were observed at 4 mg Hg/m^3. However, no evidence of impaired fertility was observed when females were exposed to concentrations up to 2 mg Hg/m^3 for 8 days (2 hours/day) prior to mating to unexposed males; fertility was not assessed at 4 mg Hg/m^3 (Davis et al. 2001).

Inorganic Mercury Salts—Animal Studies. Studies in laboratory animals have evaluated effects of inorganic mercuric mercury (e.g., mercuric chloride) on reproductive function following intermediate-duration inhalation exposure and intermediate- and chronic-duration oral exposure. Additional data regarding reproductive endpoints (e.g., histology, organ weights, hormone levels, sperm parameters) are available from acute-, intermediate-, and chronic-duration oral studies. Available inhalation data are too limited to draw conclusions; however, results from oral studies indicate that exposure to mercuric chloride can impair male and female fertility in rodents.

The effects of inhaled mercuric oxide on the female rat reproductive system were evaluated in a single study. Following continuous exposure to 0.9 mg Hg/m^3 for 45 days, treated rats showed reduced ovary volume, decreased number of ovarian follicles, and various histopathological changes in the ovaries, including thickened tunica albuginea, increased fibrils within connective tissue, congested capillaries and blood vessels, thinned walls of large and dilated veins, fibrin deposits in veins, edema and maldeveloped follicles in the stroma, and irregular oocyte borders within follicles (Altunkaynak et al. 2016).

Reproductive capacity was reduced in a dose- and duration-related manner in generational studies in rats and mice following oral exposure to mercuric chloride (Table 2-58). In rats, exposure to both males and

females in a 2-generation study resulted in dose-related decreases in fertility index, live birth index, implantation efficiency, and number of live pups/litter in the F0 generation at all tested doses (≥0.37 Hg/kg/day in males; ≥0.55 Hg/kg/day in females); no significant impairments were observed in the F1 generation at doses up to 1.31 mg Hg/kg/day in males and 1.98 mg Hg/kg/day in females (Atkinson et al. 2001). In mice, premating exposure to mercuric chloride in a 1-generation study in males and females (40 and 16 days, respectively) resulted in a decreased fertility index at ≥0.18 mg Hg/kg/day and a decreased live birth index at 0.74 mg Hg/kg/day. Collectively, these studies indicate that mercuric chloride can impair rodent reproductive function; however, it is unclear if impaired fertility observed in generational studies was attributable to reproductive effects in males, females, or both. Findings from single-sex studies suggest that oral mercuric chloride exposure can alter reproductive function in both male and female rodents (Tables 2-59 and 2-60, respectively). Studies in male rats indicate dose-related impairments in reproductive function, including increased time to impregnate and decreased fertility at 1.5 mg Hg/kg/day, decreased viable embryos at ≥3 mg Hg/kg/day, and decreased mating index at 6 mg Hg/kg/day (Boujbiha et al. 2009, 2011; Heath et al. 2012). In females, decreased number of implantations and increased resorptions were observed in rats exposed to 1.5 mg Hg/kg/day prior to mating (Heath et al. 2012), decreased fetuses/litter by 58% in female rats exposed to 3 mg Hg/kg/day from GD 1 to 21 (Ismail and El-Meligy 2021), and decreased live pups per litter was observed in mice exposed to 0.4 mg Hg/kg/day prior to mating through lactation (Huang et al. 2011). No evidence of impaired fertility was observed in male or female rats exposed to ≤0.7 mg Hg/kg/day when mated to untreated animals (Heath et al. 2012; Szász et al. 2002).

Table 2-58. Reproductive Function in Rodents Orally Exposed to Mercuric Chloride when Both Sexes are Exposed

Species; duration	Dose (mg Hg/kg/day)	FI[a,b]	LBI[a,c]	IE[a,d]	Live pups/ litter[a]	Reference (study type)
Rat; 80 days	0.46[e]	F0: ↓ (32) F1: ↔	F0: ↓ (12) F1: ↔	F0: ↓ (38) F1: ↔	F0: ↓ (38) F1: ↔	Atkinson et al. 2001 (2-generation)
Rat; 80 days	0.93[e]	F0: ↓ (58) F1: ↔	F0: ↓ (10) F1: ↓ (6)	F0: ↓ (49) F1: ↓ (34)	F0: ↓ (49) F1: ↔	Atkinson et al. 2001 (2-generation)
Rat; 80 days	1.65[e]	F0 ↓ (83) F1: –	F0 ↓ (22) F1: –	F0 ↓ (56) F1: –	F0 ↓ (56) F1: –	Atkinson et al. 2001 (2-generation)
Mouse; 61–79 days	0.18	↓ (30)	↔	↔	↔	Khan et al. 2004 (1-generation)
Mouse; 61–79 days	0.37	↓ (30)	↔	↔	↔	Khan et al. 2004 (1-generation)

Table 2-58. Reproductive Function in Rodents Orally Exposed to Mercuric Chloride when Both Sexes are Exposed

Species; duration	Dose (mg Hg/kg/day)	FI[a,b]	LBI[a,c]	IE[a,d]	Live pups/ litter[a]	Reference (study type)
Mouse; 61–79 days	0.74	↓ (30)	↓ (81)	↔	↔	Khan et al. 2004 (1-generation)

[a]Numbers in ( ) are percent change compared to control, calculated from quantitative data.
[b]Fertility index = number of dams delivering/number of dams cohabited.
[c]Live birth index = number of live pups/total number of pups.
[d]Implantation efficiency = number of pups born/number of implants.
[e]Doses are the midpoint of estimated male and female doses for the F0 generation. Estimated F0 male doses were 0.37, 0.74, and 1.31 mg Hg/kg/day, respectively, and estimated F0 female doses were 0.55, 1.11, and 1.98 mg Hg/kg/day, respectively.

↓ = decreased; ↔ = no change; – = not assessed; FI = fertility index; IE = implantation efficiency; LBI = live birth index

Table 2-59. Reproductive Function in Male Rodents Orally Exposed to Mercuric Chloride Prior to Mating to Unexposed Females

Species; duration	Dose (mg Hg/kg/day)	MI[a,b]	Time-to-pregnant[a]	FI[a,c]	Live pups/ litter[a]	Reference
Rat; 60 days	0.7	–	↔	↔	–	Heath et al. 2012
Rat; 60 days	1.5	–	↑ (53[c])	↓ (30)	–	Heath et al. 2012
Rat; 90 days	3	↔	–	–	↓ (36)	Boujbiha et al. 2009, 2011
Rat; 90 days	6	↓ (50)	–	–	↓ (76)	Boujbiha et al. 2009, 2011

[a]Numbers in ( ) are percent change compared to control, calculated from quantitative data.
[b]Mating index = number of confirmed matings/number of pairs cohabited.
[c]Fertility index = number of dams delivering/number of dams cohabited.

↑ = increased; ↓ = decreased; ↔ = no change; – = not assessed; FI = fertility index; MI = mating index

Table 2-60. Reproductive Function in Female Rodents Orally Exposed to Mercuric Chloride Prior to Mating to Unexposed Males

Species duration	Dose (mg Hg/kg/day)	FI[a]	Live pups/ litter	Number of implants	Number of resorptions	Reference
Rat; 60 days	0.7	–	–	↔	↔	Heath et al. 2012
Rat; 60 days	1.5	–	–	↓ (15[b])	↑ (1,900[b])	Heath et al. 2012
Rat; 70–77 days	0.6	↔	↔	–	–	Szász et al. 2002

Table 2-60. Reproductive Function in Female Rodents Orally Exposed to Mercuric Chloride Prior to Mating to Unexposed Males

Species duration	Dose (mg Hg/kg/day)	FI[a]	Live pups/ litter	Number of implants	Number of resorptions	Reference
Mouse; 70 days	0.4	–	↓ (14[c])	–	–	Huang et al. 2011

[a]Fertility index = number of dams delivering/number of dams cohabited.
[b]Percent change compared to control, calculated from quantitative data.
[c]Percent change compared to control, estimated from graphically presented data.

↑ = increased; ↓ = decreased; ↔ = no change; – = not assessed; FI = fertility index

A 3-generation study in male and female rats with continuous breeding reported a decrease in the number of F3 litters and litter size (Lukacinova et al. 2012); however, reporting of the study design and results were inadequate for independent review and analysis of the results. Therefore, this study was not included in Table 2-60 or the LSE tables.

Alterations in sperm parameters and male reproductive hormones have also been reported following oral exposure to mercuric chloride (Table 2-61). Dose-related decreases in sperm number and mobility have been reported in rats following oral exposure to mercuric chloride at drinking water doses ≥3 Hg/kg/day for 3–90 days or gavage doses ≥0.7 Hg/kg/day for 60 days (Boujbiha et al. 2009, 2011; Heath et al. 2012); findings were generally duration-dependent, although there is some variation in the effect of exposure duration. In rats, alterations in serum testosterone levels show a multiphasic response with respect to dose and duration. Significant decreases in serum testosterone were observed after exposure to 3 mg Hg/kg/day for 3–15 days, 6 mg Hg/kg/day for 3 days, and 0.7 or 1.5 mg Hg/kg/day for 30 days. Similarly, significant increases were observed after exposure to 3 mg Hg/kg/day for 30 or 60 days or 6 mg Hg/kg/day for 7 days. However, no significant changes were observed after exposure to 3 mg Hg/kg/day for 90 days, 6 mg Hg/kg/day for 15–90 days, or 0.7 or 1.5 mg Hg/kg/day for 60 days (Boujbiha et al. 2009, 2011; Heath et al. 2012; Ramalingam et al. 2003). At 0.3 mg Hg/kg/day for 7 days, Albasher et al. (2020) also observed a significant decrease in serum testosterone in male rats. Similarly, testicular testosterone was significantly elevated following exposure to 0.7 or 1.5 mg Hg/kg/day for 60 days (Heath et al. 2012), but significantly decreased following exposure to ≥3 mg Hg/kg/day for 90 days (Boujbiha et al. 2009, 2011). Data on other male reproductive hormones is limited. Significant decreases in serum luteinizing hormone (LH) were observed in male rats following exposure to 0.7 mg Hg/kg/day for 30 days; serum prolactin and follicle-stimulating hormone (FSH) were also decreased at 1.5 mg Hg/kg/day (Ramalingam et al. 2003). Both serum and testicular estradiol (E2) levels were

significantly decreased in male rats after exposure to ≥3 mg/kg/day for 90 days (Boujbiha et al. 2009, 2011). Interpretation of observed serum hormone changes at higher doses is complicated based on known renal toxicity in animals (acute-duration exposures ≥7.4 mg Hg/kg/day, intermediate-duration exposures ≥0.923 mg Hg/kg/day; Section 2.11, Renal) because impaired renal function can alter testosterone production in humans and animals (e.g., Iglesias et al. 2012; Nakada and Adachi 1999) and the kidney participates in the metabolism and excretion of steroids (Schiffer et al. 2019).

Table 2-61. Sperm Parameters and Male Reproductive Hormones in Male Rodents Orally Exposed to Mercuric Chloride

Species; duration	Dose (mg Hg/kg/day)	Sperm No.	Sperm mobility	Serum T	Other hormone levels	Reference
Rat; 3 days	3	↓ (10[a])	↓ (10[a])	↓ (13[a])	–	Boujbiha et al. 2009
Rat; 3 days	6	↓ (35[a])	↓ (30[a])	↓ (22[a])	–	Boujbiha et al. 2009
Rat; 7 days	0.3	–	–	↓ (24[a])	–	Albasher et al. 2020
Rat; 7 days	3	↓ (24[a])	↓ (30[a])	↓ (40[a])	–	Boujbiha et al. 2009
Rat; 7 days	6	↓ (44[a])	↓ (38[a])	↑ (52[a])	–	Boujbiha et al. 2009
Rat; 15 days	3	↓ (27[a])	↓ (31[a])	↓ (52[a])	–	Boujbiha et al. 2009
Rat; 15 days	6	↓ (33[a])	↓ (34[a])	↔	–	Boujbiha et al. 2009
Rat; 30 days	0.7	–	–	↓ (35[a])	FSH: ↔ LH: ↓ (47[a]) PRL: ↔	Ramalingam et al. 2003
Rat; 30 days	1.5	–	–	↓ (63[a])	FSH: ↓ (15[a]) LH: ↓ (65[a]) PRL: ↓ (33[a])	Ramalingam et al. 2003
Rat; 30 days	3	↓ (16[a])	↔	↑ (93[a])	–	Boujbiha et al. 2009, 2011
Rat; 30 days	6	↓ (29[a])	↔	↔	–	Boujbiha et al. 2009, 2011
Rat; 60 days	0.7	↓ (10[b])	–	↔	TT: ↓ (30[b])	Heath et al. 2012
Rat; 60 days	1.5	↓ (10[b])	–	↔	TT: ↓ (30[b])	Heath et al. 2012
Rat; 60 days	3	↓ (9[a])	↓ (17[a])	↑ (103[a])	–	Boujbiha et al. 2009, 2011

Table 2-61. Sperm Parameters and Male Reproductive Hormones in Male Rodents Orally Exposed to Mercuric Chloride

Species; duration	Dose (mg Hg/kg/day)	Sperm No.	Sperm mobility	Serum T	Other hormone levels	Reference
Rat; 60 days	6	↓ (21[a])	↓ (34[a])	↔	–	Boujbiha et al. 2009, 2011
Rat 90 days	3	↓ (31[a])	↓ (16[a])	↔	TT: ↑ (23[a]) E2: ↓ (19[a]) TE2: ↓ (15[a])	Boujbiha et al. 2009, 2011
Rat; 90 days	6	↓ (38[a])	↓ (23[a])	↔	TT: ↑ (35[a]) E2: ↓ (37[a]) TE2: ↓ (26[a])	Boujbiha et al. 2009, 2011

[a]Percent change compared to control, calculated from quantitative data.
[b]Percent change compared to control, estimated from graphically reported data.

↑ = increased; ↓ = decreased; ↔ = no change; – = not assessed; E2 = serum estradiol; FSH = serum follicle-stimulating hormone; LH = serum luteinizing hormone; PRL = serum prolactin; T = testosterone; TE2 = testicular estradiol; TT = testicular testosterone

Evidence for histopathological damage to male reproductive organs is inconsistent in rats and mice following oral exposure to mercuric chloride. One study reported alterations to the seminiferous tubules that included vacuolation and degeneration of the spermatogenic cells and detachment of spermatogenic cells from the basement membrane in Wistar rats exposed to 0.3 Hg mg/kg/day for 7 days (Albasher et al. 2020). Boujbiha et al. (2009, 2011) reported changes in the histoarchitecture of the testes and seminiferous tubules in Wistar rats following drinking water exposure to mercuric chloride at doses of 3 or 6 mg Hg/kg/day for 3–90 days; the study authors reported that findings were "prominent" at the higher dose, but do not provide incidence data or additional dose- or time-specific details. Changes included interstitial effusion, increased space between seminiferous tubules, enlarged tubule lumen, degenerative and detachment of lining cells, reduced number of round spermatids, and an absence of mature spermatozoa in 48–70% of tubules. The only dose-specific quantitative data reported were increased degree of testicular edema (3.18 and 13.42% of tissue weight) and a 14 and 27% reduction in thickness of the germinative layer of the seminiferous tubules at 3 and 6 mg Hg/kg/day, respectively, after exposure for 90 days. In contrast, no exposure-related lesions were observed in male reproductive organs in F344 rats following intermediate- or chronic-duration gavage doses up to 4 mg Hg/kg/day (NTP 1993), in C57Bl/6 mice at intermediate-duration gavage doses up to 0.74 mg Hg/kg/day (Khan et al. 2004; NTP 1993), or in B6C3F1 mice at intermediate- or chronic-duration gavage doses up to 15 or 7.4 mg Hg/kg/day, respectively (NTP 1993).

Two additional studies in rodents qualitatively reported histopathological changes in the testes following acute- or intermediate-duration exposure to low doses of mercuric chloride; however, these studies were not included in the LSE tables due to reporting deficiencies that precluded independent evaluation of the data. Penna et al. (2009) reported time- and dose-related increases in testicular histopathology in male Sprague-Dawley rats exposed to mercuric chloride via drinking water for up to 90 days, with "mild" lesions in ≤10% of seminiferous tubules in <50% of animals (n=5) after exposure to 0.0133 mg Hg/kg/day for 30 days or 0.0011 mg Hg/kg/day for 60 days, and "moderate" lesions in 20–50% of seminiferous tubules in >50% of animals after exposure to ≥0.0059 mg Hg/kg/day for 60 days or ≥0.0011 mg Hg/kg/day for 90 days. Histopathological findings for control animals were not explicitly reported. Nagar and Bhattacharya (2001) reported various histopathological changes in the testes (detached tunica albuginea, hypertrophied and/or vacuolized spermatogenic and interstitial cells, luminal dilation) following gavage exposure to 0.006 mg Hg/kg/day (as mercuric chloride) for 7–21 days; incidence data were not reported, but effects reportedly became more pronounced with longer exposure duration (Nagar and Bhattacharya 2001). Control testes were "normal." Decreased diameter of seminiferous tubules, germ cells (spermatogonia, spermatocytes, spermatids, and/or sperm), Sertoli cells, and interstitial cells were also observed. The study authors also reported elevated testosterone; however, no measures of variance or statistics were reported.

A series of oral dosing studies in Wistar rats showed dose- and time-related 12–24% increases in relative testes weight following exposure to doses of 3 or 6 mg Hg/kg/day (as mercuric chloride) for 30, 60, or 90 days; no changes were observed in testes weight in rats similarly exposed for 3, 7, or 15 days (Boujbiha et al. 2009, 2011). In other studies, no exposure-related changes in testes weight were observed in Sprague-Dawley rats at intermediate-duration doses up to 1.31 mg Hg/kg/day (Atkinson et al. 2001) or F344 rats at intermediate- or chronic-duration doses up to 4 mg Hg/kg/day (NTP 1993). Significant, dose-related 15–20% decreases in seminal vesicle weight were reported in F0 male Sprague-Dawley rats exposed to ≥0.74 mg Hg/kg/day in a 2-generation study; no changes were observed in F1 males at doses up to 1.31 mg Hg/kg/day (Atkinson et al. 2001). No exposure-related changes were noted in epididymides or prostate weight in Sprague-Dawley rats exposed to intermediate-duration doses up to 1.31 mg Hg/kg/day (Atkinson et al. 2001). In mice, no exposure-related changes were noted in testes weight at intermediate-duration doses up to 15 mg Hg/kg/day (Khan et al. 2004; NTP 1993). Khan et al. (2004) also reported a lack of exposure-related changes in seminal vesicles, epididymides, and prostate weight in mice at intermediate-duration doses up to 0.74 mg Hg/kg/day.

Studies in female laboratory animals orally exposed to mercuric chloride provide no evidence of alterations to reproductive organs and minimal evidence of alterations in reproductive hormones. Histopathological lesions in female reproductive organs have not been reported following gavage exposure to mercuric chloride at acute-duration doses up to 9.24 mg Hg/kg/day in rats (Lecavalier et al. 1994), intermediate-duration doses up to 4 mg Hg/kg/day in rats or 15 mg Hg/kg/day in mice (Khan et al. 2004; NTP 1993), or chronic-duration doses up to 4 mg Hg/kg/day in rats or 7.4 mg Hg/kg/day in mice (NTP 1993). No changes in ovary or uterus weight were observed in F0 or F1 rats exposed to gavage doses up to 1.98 mg Hg/kg/day in a 2-generation study (Atkinson et al. 2001), and no changes in ovary weight were observed in mice exposed to gavage doses up to 0.74 mg Hg/kg/day for 79 days during premating, gestation, and lactation (Khan et al. 2004). Female reproductive hormone data are limited to a 60-day gavage study reporting an 18% decrease in serum progesterone and a 19% increase in pituitary LH levels at 1.5 mg Hg/kg/day, compared to control; these hormones were not altered at 0.7 mg Hg/kg/day and pituitary FSH was not altered at doses up to 1.5 mg Hg/kg/day (Heath et al. 2009).

One study reported reduced maternal care (increased latency to retrieve a pup removed from the nest) in dams exposed to mercuric chloride on GDs 1–21 at drinking water concentrations ≥6.1 mg Hg/kg/day (Chehimi et al. 2012). This may be secondary to altered pup behavior (e.g., decreased pup vocalizations), because foster dams also showed reduced maternal care; however, pup vocalizations were not measured.

Organic Mercury—Epidemiological Studies. Few epidemiological studies on male and female reproductive effects have been conducted in populations with high fish diets, with one study in males and two studies in females. Studies are summarized in Table 2-62. A study of male Inuit adults from Greenland examined comprehensive endpoints to evaluate male reproductive function (Mocevic et al. 2013). This study did not find adverse associations between BHg and sperm quality or serum levels of male reproductive hormones. The increase in serum levels of inhibin B, which reflects high Sertoli cell activity and high sperm counts, is not considered to be adverse. The single outcome evaluated for female reproductive function was duration of gestation, with studies reporting conflicting results (Dallaire et al. 2013; Murcia et al. 2016). A prospective study in Quebec Inuit mother-infant pairs reported an inverse association between umbilical cord BHg and the duration of gestation (Dallaire et al. 2013). In contrast, a cohort study of mother-infant pairs with high maternal fish consumption did not find an association (Murcia et al. 2016). Several factors may have contributed to these different observations: (1) differences may be due to differences in the types of fish consumed and corresponding intakes of methylmercury; (2) differences may exist in genetic predispositions between study populations; (3) mean cord BHg was higher in the Dallaire et al. (2013) study compared to the Murcia et al. (2016) study (21.3 versus

8.2 µg/L), although the Murcia study did not find an association between cord BHg and duration of
gestation for the highest cord BHg tertile (≥15.0 µg/L); (4) sample size in the Murcia study was
approximately 7 times larger than in the Dallaire et al. (2013) study; and (5) the Dallaire et al. (2013)
study considered additional confounding factors (exposure to PCBs and fatty acids from fish). Given
these conflicting data, it is unclear if methylmercury exposure from high fish diets is associated with
decreased gestational length.

Table 2-62. Epidemiological Studies Evaluating Associations between Mercury and Reproductive Effects in Populations with High Fish Diets

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Males			
Ai et al. 2019 Cross-sectional; 84 men (Taiwan)	BHg mean: 9.0 µg/L Tertiles: T1: <5.5 µg/L T2: 5.5–8.9 µg/L T3: >8.9 µg/L	Total sperm count	↔ (BHg)
		Normal sperm morphology	↓ (BHg, T2)
Mocevic et al. 2013 Cross-sectional; 194 male Inuits (Greenland)	BHg median: 9.2 µg/L	Semen volume	↔ (BHg)
		Sperm concentration	↔ (BHg)
		Total sperm count	↔ (BHg)
		Sperm motility	↔ (BHg)
		Normal sperm morphology	↔ (BHg)
		LH	↔ (BHg)
		FSH	↔ (BHg)
		Testosterone	↔ (BHg)
		Free androgen index	↔ (BHg)
		Inhibin B[a]	↑ (BHg)
Females			
Dallaire et al. 2013 Prospective longitudinal; 248 mother-infant pairs; Inuit (Arctic Quebec) (adjustments included PCBs and DHA acid from fish and seafood intake)	Cord BHg mean: 21.3 µg/L	Duration of gestation	↓ (BHg)
Murcia et al. 2016 Cohort; 1,756 mother-infant pairs with high maternal fish consumption (Spain)	Cord BHg Gmean: 8.2 µg/L Tertiles T1: 5.0–<8.5 µg/L T2: 8.5–<15.0 µg/L T3: ≥15.0 µg/L	Duration of gestation	↔ (BHg, T3)

Table 2-62. Epidemiological Studies Evaluating Associations between Mercury and Reproductive Effects in Populations with High Fish Diets

Reference, study type, and population	Biomarker	Outcome evaluated	Result

[a]Increased serum levels of inhibin B, which reflects high Sertoli cell activity and high sperm counts, is not considered to be adverse.

↑ = positive association; ↓ = inverse association; ↔ = no association; BHg = blood mercury; DHA = docosahexaenoic acid; FSH = follicle-stimulating hormone; Gmean = geometric mean; LH = luteinizing hormone; PCB = poly-chlorinated biphenyl; T = tertile

Organic Mercury—Animal Studies. Studies in laboratory animals have evaluated effects of methylmercury compounds on reproductive function following acute-, intermediate-, and chronic-duration oral exposure. Additional data regarding reproductive endpoints (e.g., histology, organ weights, hormone levels, sperm parameters) are available from acute-, intermediate-, and chronic-duration oral studies. Available oral data suggest that organic mercury can impair male and female fertility in monkeys and male fertility in rats. Data in male mice are too limited to draw conclusions. Available data in rodents do not provide consistent evidence of impaired female rodent fertility following oral exposure to organic mercury.

Studies in male rats found that acute- or intermediate-duration gavage exposure to methylmercury prior to mating with untreated females resulted in dose- and duration-dependent decreases in reproductive performance; no evidence of impaired fertility was observed in male mice following acute-duration gavage exposure (Table 2-63). In Wistar rats, decreased male fertility was observed after acute-duration exposure to 5 mg Hg/kg/day or intermediate-duration exposure to 1 mg Hg/kg/day (Khera 1973). Additionally, the number of viable embryos per litter (embryos/litter) was significantly decreased after acute-duration exposure to 5 mg Hg/kg/day or intermediate-duration exposure to ≥0.05 mg Hg/kg/day (Khera 1973). In male Brown Norway rats dosed 22 times over an 11-week period prior to mating, fertility rates were 36, 22, 11, and 0% at 0, 0.0008, 0.008, and 0.08 mg Hg/kg/day, respectively (Friedmann et al. 1998). No viable fetuses were observed in the single litter produced at 0.008 mg Hg/kg/day. In mice, no exposure-related changes in fertility indices or viable embryos/litter were observed following acute-duration exposure to doses up to 5 mg Hg/kg/day prior to mating (Khera 1973).

Table 2-63. Reproductive Function in Male Rodents Orally Exposed to Methylmercuric Chloride via Gavage Prior to Mating to Unexposed Females

Species; duration	Dose (mg Hg/kg/day)	FI[a]	Live fetuses/ embryos per litter	Reference
Rat; 7 days	1	↔	↔	Khera 1973
Rat; 7 days	2.5	↔	↔	Khera 1973
Rat; 7 days	5	↓ (8–15[b])	↓ (12–13[b])	Khera 1973
Rat; 77 days[c]	0.0008	↔	↔	Friedmann et al. 1998
Rat; 77 days[c]	0.008	↔	↓ (100[b])	Friedmann et al. 1998
Rat; 77 days	0.08	↓ (36[b])	NA	Friedmann et al. 1998
Rat; 95–125 days	0.1	↔	↔	Khera 1973
Rat; 95–125 days	0.5	↔	↓ (30[d])	Khera 1973
Rat; 95–125 days	1	↓ (>60[d])	↓ (70[d])	Khera 1973
Mouse; 7 days	1	↔	↔	Khera 1973
Mouse; 7 days	2.5	↔	↔	Khera 1973
Mouse; 7 days	5	↔	↔	Khera 1973

[a]Fertility index = number of dams confirmed pregnant/number of dams with successful matings.
[b]Percent change compared to control, calculated from quantitative data.
[c]Rats only dosed 2 times/week.
[d]Percent change compared to control, estimated from graphically reported data.

↓ = decreased; ↔ = no change; – = not assessed; FI = fertility index

There is no evidence for impaired ability to become pregnant in female monkeys or mice orally exposed to methylmercury prior to mating untreated males: however, there is evidence for dose-related decreases in the ability for exposed monkeys to bring a pregnancy to term and decreased live pups/litter in mice exposed via gavage (Table 2-64). In monkeys, no exposure-related changes in fertility, menstrual cyclicity, or gestation length were observed following exposure to methylmercury in apple juice over one or two breeding cycles at doses up to 0.08 mg Hg/kg/day; however, a 50–54% decrease in the number of viable pregnancies occurred following exposure to ≥0.06 mg Hg/kg/day (Burbacher and Mottet 1988; Burbacher et al. 1984, 2005). In rats, no changes in female fertility, live birth index, or number of live pups/litter were observed following intermediate-duration exposure to methylmercury at drinking water

doses up to 0.6 mg Hg/kg/day (Elsner 1991; Newland and Reile 1999; Newland and Rasmussen 2000; Newland et al. 2004; Szász et al. 2002) or dietary doses up to 0.25 mg Hg/kg/day over 2 generations (Khera and Tabacova 1973). There were also no exposure-related changes in the number of implantations, resorptions, or corpora lutea in a 2-generation study of female rats (Khera and Tabacova 1973). In mice, the number of live pups/litter were significantly decreased by 16% following exposure to methylmercury at a dose of 0.4 mg Hg/kg/day via gavage before mating and through gestation and lactation (Huang et al. 2011); however, no exposure-related changes in the number of live pups/litter were observed in mice similarly exposed to methylmercury at drinking water doses up to 0.6 mg Hg/kg/day (Weiss et al. 2005) or dietary doses up to 0.98 mg Hg/kg/day (Thuvander et al. 1996). Studies in mice did not evaluate any additional reproductive function parameters.

Table 2-64. Reproductive Function in Female Laboratory Animals Orally Exposed to Methylmercury Compounds

Species; duration	Dose (mg Hg/kg/day)	Viable pregnancies/LBI[a,b]	Live pups/ litter[a]	Reference (compound)
Exposure prior to mating with unexposed males and through gestation and lactation				
Monkey; 395 days	0.04	↔	–	Burbacher et al. 1984 (MMH)
Monkey; 395 days	0.08	↓ (50)	–	Burbacher et al. 1984 (MMH)
Monkey; 1,456 days	0.04	↔	–	Burbacher and Mottet 1988; Burbacher et al. 2005 (MMH)
Monkey; 1,456 days	0.06	↓ (54)	–	Burbacher and Mottet 1988; Burbacher et al. 2005 (MMH)
Monkey; 1,456 days	0.08	↓ (54)	–	Burbacher and Mottet 1988; Burbacher et al. 2005 (MMH)
Rat; 60 days	0.19	–	↔	Elsner 1991 (MMC)
Rat; 60 days	0.74	–	↔	Elsner 1991 (MMC)
Rat; 70–77 days	0.6	–	↔	Szász et al. 2002 (MMC)
Rat; 70–91 days	0.045–0.6	↔	↔	Newland and Reile 1999; Newland and Rasmussen 2000; Newland et al. 2004 (MMC)
Rat; 122 days	0.002–0.25	↔	↔	Khera and Tabacova 1973 (MMC)

Table 2-64. Reproductive Function in Female Laboratory Animals Orally Exposed to Methylmercury Compounds

Species; duration	Dose (mg Hg/kg/day)	Viable pregnancies/LBI[a,b]	Live pups/ litter[a]	Reference (compound)
Mouse; 70 days	0.2	–	↔	Weiss et al. 2005 (MM)
Mouse; 70 days	0.4	–	↓ (16)	Huang et al. 2011 (MMC)
Mouse; 70 days	0.6	–	↔	Weiss et al. 2005 (MM)
Mouse; 105–112 days	0.098–0.98	–	↔	Thuvander et al. 1996 (MMC)
Exposure throughout gestation and lactation only (GD 1–PND 21)				
Rat; 42 days	0.05–0.23	↔	↔	Fujimura et al. 2012 (MM)
Rat; 42 days	0.5	↓ (100)	↓ (100)	Fujimura et al. 2012 (MM)
Rat; 42 days	0.7	↔	↔	Chang et al. 2015 (MM)
Mouse; 42 days	0.9–1.3	–	↔	Goulet et al. 2003 (MMH)
Mouse; 42 days	1.7	–	↓ (18)	Goulet et al. 2003 (MMH)

[a]Numbers in ( ) are percent change compared to control, calculated from quantitative data.
[b]Viable pregnancies (monkeys) or Live birth index (rodents = number of live pups/number of pups).

↓ = decreased; ↔ = no change; – = not assessed; GD = gestation day; LBI = live birth index; MM = methylmercury; MMC = methylmercuric chloride; MMH = methylmercury hydroxide; PND = postnatal day

Evidence for reproductive effects in rodents following exposure to methylmercury throughout gestation and lactation (GD 1 to PND 21) is mixed (Table 2-64). In one gestational/lactational rat study, no viable litters were produced at a drinking water dose of 0.5 mg Hg/kg/day; no changes in live birth index or litter size were observed at drinking water doses ≤0.23 mg Hg/kg/day (Fujimura et al. 2012). However, in a second gestational/lactation study in rats, no exposure-related changes were observed in live birth index or litter size at drinking water doses up to 0.7 mg Hg/kg/day (Chang et al. 2015). In mice, exposure to methylmercury at a drinking water dose of 1.7 mg Hg/kg/day resulted in an 18% decrease in the number of live pups/litter (Goulet et al. 2003).

Alterations in sperm parameters have been reported in monkeys, rats, and mice following oral exposure to methylmercury (Table 2-65). In monkeys, morphological examination of semen smears indicated an increased incidence of tail defects (primarily bent and kinked tails) following intermediate-duration

exposure to methylmercury in apple juice at doses ≥0.046 mg Hg/kg/day; at 0.065 mg Hg/kg/day, additional sperm effects included a decrease in the mean percentage of motile spermatozoa and the mean sperm speed (Mohamed et al. 1987). No changes in the sperm count in monkey semen were observed at doses up to 0.065 mg Hg/kg/day.

Table 2-65. Sperm Parameters in Male Laboratory Animals Orally Exposed to Methylmercury Compounds

Species; duration	Dose (mg Hg/kg/day)	Number	Mobility	Percent immobile	Speed	Percent abnormal	Reference
Monkey; 140 days	0.046	↔	↔	–	↔	↑ (17[a])	Mohamed et al. 1987 (MM)
Monkey; 140 days	0.065	↔	↔	–	↓ (33[a])	↑ (16[a])	Mohamed et al. 1987 (MM)
Rat; 5 days	9	↓ (17–45[b,c])	–	↑ (11–32[b,c])	–	–	Chen et al. 2019a (MMC)
Rat; 14 days	0.5	↓ (17[b])	↓ (50[a])	↑ (30[a])	–	↑ (350[b])	Fossato da Silva et al. 2011 (MM)
Rat; 14 days	0.93	↓ (18[b])	↓ (43[a])	↑ (20[a])	–	0	Fossato da Silva et al. 2011 (MM)
Rat; 14 days	2.8	↓ (16[b])	↓ (36[a])	↔	–	↔	Fossato da Silva et al. 2011 (MM)
Rat; 56 days	3.2	↔	–	–	–	–	Moussa et al. 2010 (M)
Rat; 133 days[d]	0.0008–0.008	↔	–	–	–	–	Friedmann et al. 1998 (MMC)
Rat; 133 days[d]	0.08	↓ (17[a])	–	–	–	–	Friedmann et al. 1998 (MMC)
Mouse; 728 days	0.03–0.15	↔	–	–	–	–	Hirano et al. 1986 (MMC)
Mouse; 728 days	0.724	↓ (NR[e])	–	–	–	–	Hirano et al. 1986 (MMC)

[a]Percent change compared to control, estimated from graphically reported data.
[b]Percent change compared to control, calculated from quantitative data.
[c]Alterations in sperm parameters observed 19–26 days after initial exposure.
[d]Rats only dosed 2 times/week.
[e]"Decreased spermatogenesis" reported in the testes; no quantitative data reported.

↑ = increased; ↓ = decreased; ↔ = no change; – = not assessed; MM = methylmercury; MMC = methylmercuric chloride; NR = not reported

In rats, decreased sperm number (in the cauda epididymides) and/or decreased sperm mobility were observed following acute-duration exposure to doses ≥0.5 mg Hg/kg/day (Fossato da Silva et al. 2011; Chen et al. 2019a) or intermediate-duration exposure to 0.08 mg Hg/kg/day (Friedmann et al. 1998). Acute-duration findings do not appear to be strongly dose-related; however, effects persisted and worsened post-exposure following higher exposure levels (9 mg Hg/kg/day) (Chen et al. 2019a). Fossato da Silva et al. (2011) also reported an increase in the proportion of sperm with head abnormalities following acute-duration gavage exposure to 0.5 mg Hg/kg/day, but not at higher doses (≥0.93 mg Hg/kg/day). In mice, decreased spermatogenesis was qualitatively reported in the testes of mice exposed to methylmercury at a dietary dose of 0.724 mg Hg/kg/day for 2 years (Hirano et al. 1986).

No exposure-related changes in serum testosterone levels or Leydig cell testosterone secretion were observed in monkeys following intermediate-duration exposure to methylmercury in apple juice at doses up to 0.065 mg Hg/kg/day (Mohamed et al. 1987). In rats, a limited number of studies reported dose- and duration-related decreases in serum testosterone following acute- or intermediate-duration exposures to methylmercury. Acute-duration gavage exposure to 2.8 mg Hg/kg/day resulted in a 65% decrease in serum testosterone (Fossato da Silva et al. 2011) and intermediate-duration drinking water exposure to 3.2 mg Hg/kg/day resulted in a 98% decrease in serum testosterone (Moussa et al. 2010). No exposure-related changes were observed for serum testosterone following gavage exposure to methylmercury at acute-duration doses up to 0.93 mg Hg/kg/day (Fossato da Silva et al. 2011) or intermediate-duration doses up to 0.08 mg Hg/kg/day (Friedmann et al. 1998). Decreased testicular (interstitial) testosterone levels were also reported following intermediate-duration exposure to methylmercury at a drinking water dose of 3.2 mg Hg/kg/day (-74%) (Moussa et al. 2010) or a gavage dose of 0.08 mg Hg/kg/day (-44%) (Friedmann et al. 1998). No changes in serum FSH or LH were reported in rats following acute-duration gavage exposure to methylmercury at doses up to 2.8 mg Hg/kg/day (Fossato da Silva et al. 2011).

No exposure-related changes in testicular histology were observed in monkeys following intermediate-duration exposure to methylmercury in apple juice at doses up to 0.065 mg Hg/kg/day (Mohamed et al. 1987). In rats, the only reported damage to the testes was reported 26 days after the start of a 5-day exposure to 9 mg Hg/kg/day via gavage as methylmercury (Chen et al. 2019a). Treatment-related findings included significant disruption of the germinal epithelium of the seminiferous tubules and few spermatozoa; these findings were not evident 12 or 19 days after the start of exposure. In other rat studies, no histopathological changes in the testes were observed following oral exposure to methylmercury at acute-duration doses up to 2.8 mg Hg/kg/day (Fossato da Silva et al. 2011), intermediate-duration doses up to 3.2 mg Hg/kg/day (Moussa et al. 2010), or chronic-duration exposure to

doses up to 0.16 mg Hg/kg/day (Verschuuren et al. 1976). In B6C3F1 mice, chronic-duration exposure to methylmercury at a dietary dose of 0.686 mg Hg/kg/day resulted in increased incidence of tubular atrophy of the testes; this increase was not observed at doses up to 0.139 mg Hg/kg/day (Mitsumori et al. 1990). However, no exposure-related testicular lesions were observed in ICR mice similarly exposed to intermediate- or chronic-duration dietary doses up to 0.724 mg Hg/kg/day (Hirano et al. 1986).

A single study in rats reported numerous histopathological lesions in the prostate following 14-day gavage exposure to methylmercury (Fossato da Silva et al. 2012). Alterations in prostate histology included increased incidence of inflammatory foci in 6/10 at 0.5 mg Hg/kg/day, periacinar connective tissue causing epithelial folds at 0.93 mg Hg/kg/day, and apparent thinning of the glandular epithelium, dilation of glandular acini, and higher nuclear-to-cytoplasmic ratio at 2.8 mg Hg/kg/day. Stereological measurements showed 40 and 34% increases in the epithelial component of the prostate at 0.5 and 0.93 mg Hg/kg/day, respectively; 46 and 56% decreases in the stromal component at 0.93 and 2.8 mg Hg/kg/day, respectively; and a 25% increase in the size of the lumen at 2.8 mg Hg/kg/day. In other studies, no evidence of pathological lesions in the prostate were observed following dietary exposure to methylmercury for up to 2 years at doses up to 0.16 mg Hg/kg/day in rats (Verschuuren et al. 1976) or 0.724 mg Hg/kg/day in mice (Hirano et al. 1986; Mitsumori et al. 1990).

There is no consistent evidence for alterations in male reproductive organ weights in rats following exposure to methylmercury. One study reported a significant 8% decrease in absolute testes weight following exposure to methylmercury at a gavage dose of 0.08 mg; relative testes weight was not reported, but no body weight effects were noted in the study (Friedmann et al. 1998). However, other studies reported no exposure-related changes in testes weight at acute-duration doses up to 2.8 mg Hg/kg/day (Fossato da Silva et al. 2011), intermediate-duration doses up to 3.2 mg Hg/kg/day (Moussa et al. 2010), or chronic-duration doses up to 0.16 mg Hg/kg/day (Verschuuren et al. 1976). A significant 28% decrease in relative seminal vesicle weight was reported in rats following acute-duration gavage exposure to 2.8 mg Hg/kg/day, but not ≤0.93 mg Hg/kg/day (Fossato da Silva et al. 2011); no other available studies evaluated seminal vesicle weight. No dose-related changes in prostate weight were observed at acute-duration doses up to 2.8 mg Hg/kg/day (Fossato da Silva et al. 2012) or chronic-duration doses up to 0.16 mg Hg/kg/day (Verschuuren et al. 1976), and no dose-related changes in epididymides weights were observed at acute-duration doses up to 2.8 mg Hg/kg/day (Fossato da Silva et al. 2011) or intermediate-duration doses up to 0.08 mg Hg/kg/day (Friedmann et al. 1998).

Studies in female laboratory animals provide no evidence of alterations to reproductive organ weight and/or histology following dietary exposure to methylmercury for up to 2 years at doses up to 0.18 mg Hg/kg/day in rats (Verschuuren et al. 1976) or 0.627 mg Hg/kg/day in mice (Hirano et al. 1986; Mitsumori et al. 1990).

Predominant Mercury Form Unknown (General Populations). Studies evaluating reproductive effects of mercury in general populations are summarized in Table 2-66. Studies of male reproductive effects used cross-sectional designs and evaluated sperm quality and serum reproductive hormones. Most studies had small study populations (n=30–394), although two studies examined larger populations (n=1,940–2,763) (Lee et al. 2019; Liu et al. 2023). One study evaluating serum hormone levels was conducted in adolescent males (Castiello et al. 2020). Studies were also conducted in male partners of infertile couples for which other causes for decreased fertility may have been effect modifiers. The most common biomarker was BHg. In males, a large range for mean or median BHg was reported (0.72–14.3 µg/L). In women, several study designs were used to evaluate reproductive effects, including several prospective studies. Reproductive effects were primarily assessed by measurement of serum levels of reproductive hormones and incidence of preterm birth, with some studies evaluating other reproductive effects (e.g., endometriosis, pre-eclampsia) and effects on ovarian stimulation in sub- or infertile women. Studies evaluating reproductive effects in females were generally larger (n=30–77,341) than in males. The most common biomarkers were BHg or HHg, with a range of BHg of 0.24–5.3 µg/L. In addition, a few studies evaluated reproductive success in couples. Two studies evaluated reproductive endpoints based on maternal and cord biomarkers (Sarzo et al. 2022; Wang et al. 2021a).

Table 2-66. Overview of Epidemiological Studies Evaluating Associations between Mercury (Predominant Mercury Form Unknown) and Reproductive Effects in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Male reproductive effects			
Calogero et al. 2021	BHg median: 5.42 µg/L	Sperm concentration	↔ (BHg)
		Sperm count	↑ (BHg)
Cross-sectional; 179 men (Italy)		Progressive motility	↔ (BHg)
		Normal sperm	↑ (BHg)
Castiello et al. 2020	UHg Gmean: 0.03 µg/g creatinine	Total testosterone	↔ (UHg)
		FSH	↔ (UHg)
Cross-sectional; 133 male adolescents (ages 15–17 years) (Spain)		LH	↑ (UHg)

Table 2-66. Overview of Epidemiological Studies Evaluating Associations between Mercury (Predominant Mercury Form Unknown) and Reproductive Effects in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Choy et al. 2002 Cross-sectional; 111 subfertile men (Hong Kong)	BHg mean: 8.3 µg/L	Sperm concentration	↔ (BHg)
		% motile sperm	↔ (BHg)
Lee et al. 2019 Cross sectional; 2,763 men (KoNEHS)	BHg median: 3.80 µg/L	FSH	↔ (BHg)
Liu et al. 2023 Cross-sectional; 1,940 men males (NHANES 2013–2016)	BHg Gmean: 0.81 mg/L	Total testosterone	↔ (BHg)
		Estradiol	↔ (BHg)
		SHBG	↔ (BHg)
		Free androgen index	↔ (BHg)
		Total testosterone/ estradiol ratio	↔ (BHg)
Leung et al. 2001 Cross-sectional; 51 male partners of infertile couples (Hong Kong)	BHg median Low mercury: 6.32 µg/L High mercury: 14.3 µg/L	Sperm concentration	↔ (BHg, low versus high BHg)
		Normal sperm morphology	↔ (BHg, low versus high BHg)
		Sperm velocity	↔ (BHg, low versus high BHg)
		FSH	↔ (BHg, low versus high BHg)
		LH	↔ (BHg, low versus high BHg)
		Testosterone	↔ (BHg, low versus high BHg)
		Prolactin	↔ (BHg, low versus high BHg)
Meeker et al. 2008 Cross-sectional; 219 men (Michigan)	BHg median: 1.10 µg/L	Sperm concentration	↔ (BHg)
		Sperm motility	↔ (BHg)
		Sperm morphology	↔ (BHg)
Mendiola et al. 2011 Case-control; 30 infertile men and 31 controls (Spain)	BHg mean Cases: 5.8 µg/L Control: 6.2 µg/L	FSH	↔ (BHg)
		LH	↔ (BHg)
		Testosterone	↔ (BHg)
		Sperm concentration	↔ (BHg)
		Sperm motility	↔ (BHg)
		Sperm morphology	↔ (BHg)

Table 2-66. Overview of Epidemiological Studies Evaluating Associations between Mercury (Predominant Mercury Form Unknown) and Reproductive Effects in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Mínguez-Alarcón et al. 2018 Cross-sectional; 129 men enrolled in a study for infertile couples (Massachusetts)	HHg median: 0.72 µg/g Quartiles Q1: 0.03–0.37 µg/g Q2: 0.38–0.67 µg/g Q3: 0.70–1.25 µg/g Q4: 1.26–8.01 µg/g	Semen volume	↔ (HHg, Q1 versus Q4) ↔ (HHg, continuous)
		Sperm concentration	↔ (HHg, Q1 versus Q4) ↑ (HHg, continuous)
		Total sperm count	↔ (HHg, Q1 versus Q4) ↑ (HHg, continuous)
		Sperm motility	↔ (HHg, Q1 versus Q4) ↑ (HHg, continuous)
		Normal sperm morphology	↔ (HHg, Q1 versus Q4) ↔ (HHg, continuous)
Shi et al. 2021 Cross-sectional; 288 men, 28–57 years of age (Hong Kong)	BHg quartiles Q1: ≤3.85 µg/L Q2: >3.85–5.36 µg/L Q3: >5.37–7.22 µg/L Q4: >7.22 µg/L	Semen volume	↔ (BHg, Q4)
		Sperm concentration	↔ (BHg, Q4)
		Sperm count	↔ (BHg, Q4)
		Sperm motility	↔ (BHg, Q4)
		Motile sperm count	↔ (BHg, Q4)
		Sperm morphology	↔ (BHg, Q4)
		Sperm vitality	↔ (BHg, Q4)
Sukhn et al. 2018 Cross-sectional; 116 male partners of infertile couples (Lebanon)	BHg quartiles Q1: ≤4.35 µg/L Q2: 4.36–11.05 µg/L Q3: 11.06–21.47 µg/L Q4: ≥21.48 µg/L	Semen volume	↔ (BHg, Q4)
		Sperm concentration	↔ (BHg, Q4)
		Sperm count	↔ (BHg, Q4)
		Sperm motility	↔ (BHg, Q4)
		Sperm motility	↔ (BHg, Q4)
		Sperm viability	↔ (BHg, Q4)
		Sperm morphology	↔ (BHg, Q4)
Zeng et al. 2013 Cross-sectional; 118 men from an infertility clinic (China)	UHg median: 1.98 µg/L Cr	Testosterone	↔ (UHg)
Zeng et al. 2015 Cross-sectional; 394 men from an infertility clinic (China)	UHg median: 1.21 µg/L Cr	Sperm concentration	↔ (UHg)
		Sperm count	↔ (UHg)
		Sperm motility	↔ (UHg)
		Sperm morphology	↔ (UHg)

Table 2-66. Overview of Epidemiological Studies Evaluating Associations between Mercury (Predominant Mercury Form Unknown) and Reproductive Effects in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Female reproductive effects			

An et al. 2021
 	
Nested case-control; 126 cases, 348 controls (China)
	BHg median
	  Cases: 0.46 µg/L
	  Controls: 0.43 µg/L
	
	SHg median
	  Cases: 0.26 µg/L
	  Controls: 0.24 µg/L
	
	ErHg median
	  Cases: 0.64
	  Controls: 0.66
		Preterm birth	↔ BHg
			↔ SHg
			↑ (ratio of SHg:ErHg, first trimester only)

Arakawa et al. 2006 Retrospective; 198 women (Japan)	HHg Gmean: 2.01 µg/g	TTP	↔ (HHg)
Ashrap et al. 2020 Prospective cohort; 731 pregnant women (Puerto Rico)	BHg median: 1.3 µg/L	Preterm birth	↔ (BHg)

Borghese et al. 2023
 	
Cohort; 1,560 pregnant women (Canada)
	BHg median (µg/L)
	  Normotensive: 7.2
	  Gestational hypertension: 6.4
	  Pre-eclampsia: 6.6
		Gestational hypertension	↔ (BHg)

		Pre-eclampsia	↔ (BHg)

Bloom et al. 2015
 	
Prospective longitudinal; 253 couples with singleton deliveries (Michigan and Texas)
	BHg
	Maternal tertiles
	  T1 (33%): 0.66 µg/L
	  T2 (median): 0.94 µg/L
	  T3 (67%): 1.38 µg/L
	Paternal tertiles
	  T1 (33%): 0.76 µg/L
	  T2 (median): 1.11 µg/L
	  T3 (67%): 1.76 µg/L
		Gestational age	↑ (BHg, maternal T3; paternal T3)

Dickerson et al. 2011 Prospective; 30 subfertile women undergoing IVF (United Kingdom)	HHg mean: 0.89 µg/g	Oocyte yield after ovarian stimulation	↓ (HHg)
		Follicle number after ovarian stimulation	↓ (HHg)
		IVF fertilization rate	↔ (HHg)
Garcia-Fortea et al. 2018 Prospective; 194 subfertile women undergoing IVF (Spain)	HHg mean: 1.145 µg/g	Probability of mature oocytes	↓ (HHg)

Table 2-66. Overview of Epidemiological Studies Evaluating Associations between Mercury (Predominant Mercury Form Unknown) and Reproductive Effects in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Gerald et al. 2023 Cross-sectional; 1,618 women, age, mean age 43.43 years (NHANES 2013–2016)	BHg median: 0.73 µg/L	Estrogen	↔ (BHg)
Gokoel et al. 2020 Cross-sectional; 1,143 pregnant women (Suriname)	HHg median: 0.826 µg/g Low HHg: < 1.1 µg/g High HHg: ≥1.1 µg/g	Preterm birth	↑ (HHg, high)
Jackson et al. 2008 Cross-sectional; 1,425 premenopausal women (NHANES)	BHg mean: 1.00 µg/L	Endometriosis	↔ (BHg)
		Uterine fibroids	↔ (BHg)
Jackson et al. 2011; Pollack et al. 2011 Cross-sectional; 252 premenopausal women (Buffalo, New York)	BHg median: 1.10 µg/L	Menstrual cycle length	↔ (BHg)
		FSH	↔ (BHg)
		LH	↔ (BHg)
		Estradiol	↔ (BHg)
		Progesterone	↔ (BHg)
Lee et al. 2019 Cross sectional; 1,926 postmenopausal women (KoNEHS)	BHg median: 2.81 µg/L	FSH	↔ (BHg)

Liu et al. 2019
 	
Birth cohort; 1,274 women 24–72 hours post-partum (Boston)
	ErHg quintiles
	  Qi1: 0.58–1.56 mg/L
	  Qi2: 1.57–2.10 mg/L
	  Qi3: 2.12–2.80 mg/L
	  Qi4: 2.81–4.28 mg/L
	  Qi5: 4.40–24.80 mg/L
		Pre-eclampsia	↔ (BHg, Qu5)

Liu et al. 2023 Cross-sectional; 1,559 females (NHANES 2013–2016)	BHg Gmean: 0.79 mg/L	Total testosterone	↔ (BHg)
		Estradiol	↔ (BHg)
		SHBG	↔ (BHg)
		Free androgen index	↔ (BHg)
		Total testosterone/estradiol ratio	↔ (BHg)

Table 2-66. Overview of Epidemiological Studies Evaluating Associations between Mercury (Predominant Mercury Form Unknown) and Reproductive Effects in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated	Result

Ma et al. 2022
 	
Nested case control;
146 cases with pre-eclampsia or gestational hypertension and 292 controls (China)
	SHg median
	  Cases: 0.33 µg/L
	  Controls: 0.28 µg/L
		Pre-eclampsia or gestational hypertension	↑ (SHg)

Maeda et al. 2019
 	
Case-control; 98 infertile women and 43 controls (Japan)
	BHg mean
	  Infertile: 5.3 µg/L
	  Control: 5.0 µg/L
		Infertility	↑ (BHg)

		DHRA-S	↔ (BHg)
		Testosterone	↔ (BHg)
		Estradiol	↔ (BHg)
		Prolactin	↔ (BHg)
McClam et al. 2023 Cross-sectional; 1,919 women (amenorrhea), 1,900 (infertility) (NHANES 2013–2018)	BHg median: 0.61 µg/L	Amenorrhea	↔ (BHg)
		Infertility	↔ (BHg)

Mínguez-Alarcón et al. 2021
 	
Prospective cohort;
353 women attending a fertility center (Massachusetts)
	HHg tertiles
	  T1: 0.001–0.39 µg/g
	  T2: 0.40–0.99 µg/g
	  T3: 1.00–8.60 µg/g
		Antral follicle count (measure of ovarian reserve)	↑ (HHg, T2), only in the high n3PUFA group

Nyanza et al. 2020 Prospective longitudinal; 961 pregnant women (Tanzania)	BHg median: 1.2 µg/L	Spontaneous abortion	↔ (BHg)
		Preterm birth	↑ (BHg)

Ren et al. 2022
 	
Prospective nested case-control; 82 cases of preterm birth and 415 controls (China)
	HHg median
	  Cases: 0.397 µg/g
	  Controls: 0.410 µg/g
		Preterm birth	↔ (HHg)

Rezaei et al. 2021
 	
Cross-sectional; 102 pregnant women (60 with gestational diabetes and 42 without gestational diabetes) (Iran)
	BHg mean
	  With GDM: 2.60 µg/L
	  No GDM 0.90 µg/L
		GDM	↑ (BHg)

Shen et al. 2023
 	
Case-control; 451 women, 217 controls and 234 cases (China)
	BHg tertiles:
	  T1: 0.010–1,207 µg/L
	  T2: 1.208–1.893 µg/L
	  T3: 1.894–5.205 µg/L
		Risk of endometriosis	↑ (BHg, T2)

Table 2-66. Overview of Epidemiological Studies Evaluating Associations between Mercury (Predominant Mercury Form Unknown) and Reproductive Effects in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Tatsuta et al. 2022 Cross-sectional; 78,964 pregnant women (1,624 with GDM and 77,341 without GDM) participating in JECS (Japan)	BHg median: 3.6 µg/L Quintiles Qi1: 0.18–2.31 Qi2: 2.32–3.16 µg/L Qi3: 3.17–4.12 µg/L Qi4: 4.13–5.62 µg/L Qi5: 5.63–58.8 µg/L	GDM	↑ (BHg, Qi4)
Tsuji et al. 2018 Cohort; 18,847 pregnant women (Japan)	BHg quartiles Q1: ≤2.57 µg/L Q2: 2.58–3.65 µg/L Q3: 3.66–5.16 µg/L Q4: ≥5.17 µg/L	Preterm birth	↔ (BHg, Q4)
Tsuji et al. 2019 Cross-sectional; 16,019 pregnant women (Japan)	BHg median: 3.65 µg/L BHg quartiles: Q1: ≤2.56 µg/L Q2: 2.57–3.64 µg/L Q3: 3.65–5.15 µg/L Q4: ≥5.16 µg/L	Placenta previa Placenta accreta	↔ (BHg, Q4) ↔ (BHg, Q4)
Wang et al. 2019b Nested case-control; 776 women with GDM and 776 without GDM	BHg median: All: 1.339 µg/L With GDM: 1.370 µg/L Without GDM: 1.300 µg/L Tertiles (all) T1: <0.99 T2: 0.99–1,73 T3: ≥1,73	GDM	↑ (BHg, T3)
Wang et al. 2020 Case-control; 427 women with pre-eclampsia and 427 controls (China)	BHg tertiles T1: <1,01 µg/L T2: 1.01–1.89 µg/L T3: ≥1.89 µg/L	Pre-eclampsia	↑ (BHg, T3)
Wang et al. 2023c Prospective cohort; 1,355 women, ages 45–56 years (United States)	UHg mean: 1.22 µg/L	Estradiol FSH SHBG	↓ (UHg) ↔ (UHg) ↔ (UHg)
Wells et al. 2016 Cross-sectional; 271 mother-infant pairs (Baltimore, Maryland)	Cord BMeHg Gmean: 0.94 µg/L	Gestational age	↔ (BMeHg)

Table 2-66. Overview of Epidemiological Studies Evaluating Associations between Mercury (Predominant Mercury Form Unknown) and Reproductive Effects in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Wright et al. 2015 Prospective; 205 subfertile women undergoing IVF (Massachusetts)	HHg median: 0.62 µg/g	Oocyte yield after ovarian stimulation	↔ (HHg)
		IVF fertilization rate	↔ (HHg)
		Successful implantation	↔ (HHg)
		Live birth	↔ (HHg)
Xue et al. 2007 Prospective, 1,024 pregnant women (Michigan)	Maternal HHg median: 0.23 µg/g ≥90th percentile: 0.55–2.50 µg/g	Preterm birth (<35 weeks)	↑ (HHg, ≥90th percentile)

Yildirim et al. 2019
 	
Case-control; 30 preterm delivery women and 20 term delivery women (Turkey)
	Maternal BHg mean
	  Preterm: 2.60 µg/L
	  Term: 2.41 µg/L
		Preterm birth	↔ (BHg)

Xu et al. 2022a
 	
Nested case-control; 74 cases of preterm birth and 74 controls (China)
	SHg median
	  Cases: 0.33 µg/L
	  Controls: 0.25 µg/L
	  Q4 range: 0.58–1.13 µg/L
		Preterm birth	↑ (SHg, Q4)

Xu et al. 2022b Cross-sectional; 696 women at parturition (Argentina)	BHg Gmean: 0.52 µg/L	Preterm birth	↔ (BHg)

Yu et al. 2019
 	
Nested case-control; 147 cases of preterm birth and 381 controls (China)
	SHg mean
	  Cases: 0.275 µg/L
	  Controls: 0.242 µg/L
		Preterm birth	↔ (SHg)

Zhang et al. 2023a Cross-sectional; 614 women (NHANES 2013–2016)	BHg median: 0.74 µg/L	Estradiol	↔ (BHg)
		Free estradiol	↔ (BHg)
		Total testosterone	↔ (BHg)
		Free testosterone	↔ (BHg)
		SHBG	↔ (BHg)
		Total testosterone/ estradiol ratio	↔ (BHg)
Zhao et al. 2023 Prospective cohort; 292 mother-infant pairs (China)	SHg mean (maternal in 2nd trimester): 0.69 µg/L	Gestational age	↑ (SHg)

Table 2-66. Overview of Epidemiological Studies Evaluating Associations between Mercury (Predominant Mercury Form Unknown) and Reproductive Effects in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Zheng et al. 2021 Prospective; 1,311 pregnant women (Boston, Massachusetts)	ErHg median: 3.25 ng/g	Gestational glucose concentration	↔ (ErHg)

Zhu et al. 2020
 	
Cross-sectional; 1,592 fertile and 204 ever infertile women (NHANES)
	BHg mean:
	  Infertile: 1.00 µg/L
	  Fertile: 1.32 µg/L
	Stratified as <5.278 and >5.278 µg/L
		Infertility	↔ (BHg, all BHg)
			↑ (BHg, >5.278 µg/L)

Reproductive effects in couples			

Buck Louis et al. 2012
 	
Prospective; 401 couples (United States)
	BHg Gmean
	  Males: 1.81 µg/L
	  Females: 1.40 µg/L
		Fecundity	↔ (BHg, males)
			↔ (BHg, females)
			↔ (BHg, couple)

Buck Louis et al. 2017
 	
Cohort; 344 couples (United States)
	BHg median
	  Men: 1.18 µg/L
	  Women: 0.98 µg/L
		Pregnancy loss	↔ (BHg, men and women)

Cole et al. 2006
 	
Cross-sectional; 41 couples (Canada)
	BHg quartiles, women
	  Q1: 0.4–0.6 µg/L
	  Q2: 0.7–1.0 µg/L
	  Q3: 1.1–1.2 µg/L
	  Q4: 1.3–3.6 µg/L
	BHg quartiles, men
	  Q1: 0–0.6 µg/L
	  Q2: 0.7–1.0 µg/L
	  Q3: 1.1–1.8 µg/L
	  Q4: 1.9–4.8 µg/L
		TTP	↑ (BHg, women Q4)
			↔ (BHg, men Q4)

Reproductive effects following gestational exposure			

Sarzo et al. 2022
 	
Prospective; 412 children, 9 years of age (Spain)
	Males (medians)
	Cord BHg: 2.3 µg/L
	HHg
	  Age 4 years: 2.8 µg/g
	  Age 9 years: 2.9 µg/g
		Estradiol	↔ (BHg, cord, males and females)
			↔ (HHg, males and females at 4 and 9 years)

	Females (medians)
	Cord BHg: 2.2 µg/L
	HHg
	  Age 4 years: 2.5 µg/g
	  Age 9 years: 2.3 µg/g
		Testosterone	↔ (BHg, cord, males and females)
			↔ (HHg, males 4 years, and females at 4 and 9 years)
			↓ (HHg, males at 9 years)

Table 2-66. Overview of Epidemiological Studies Evaluating Associations between Mercury (Predominant Mercury Form Unknown) and Reproductive Effects in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated	Result
		Tanner evaluation	↔ (BHg, cord female) ↓ (BHg, cord males) ↔ (HHg, males and females at 4 and 6 years)
Wang et al. 2021a Prospective birth cohort; 1,512 mother-child pairs (Boston)	Maternal ErHg tertiles T1: 0.30–1.37 µg/L T2: 1.38–3.06 µg/L T3: 3.08–27.8 µg/L	Precocious puberty	↑ (ErHg, maternal, T3)

↑ = positive association; ↓ = inverse association; ↔ = no association; BHg = blood mercury; Cr = creatinine; DHRA-S = dehydroepiandrosterone sulfate; ErHg = erythrocyte mercury; FSH = follicle-stimulating hormone; GDM = gestational diabetes mellitus; Gmean = geometric mean; HHg = hair mercury; IVF = *in vitro* fertilization; JECS = Japan Environment and Children's Study national birth cohort; KoNEHS = Korean National Environmental Health Survey; LH = luteinizing hormone; n3PUFA = long chain omega-3 polyunsaturated fatty acids; NHANES = National Health and Nutrition Examination Survey; Q = quartile; Qi = quintile; SHBG = sex hormone binding globulin; SHg = serum mercury; T = tertile; TTP = time to pregnancy; UHg = urine mercury

Male reproductive effects. Several studies on male reproductive function have been conducted in general populations. Study populations include men with no known pre-existing reproductive system abnormalities (Calogero et al. 2021; Lee et al. 2019; Liu et al. 2023; Meeker et al. 2008; Shi et al. 2021), sub- or infertile males (Choy et al. 2002; Mendiola et al. 2011; Zeng et al. 2013, 2015), and male partners of infertile couples (Leung et al. 2001; Mínguez-Alarcón et al. 2018; Sukhn et al. 2018). Results show no inverse associations between mercury and sperm quality. One study showed a positive association between BHg and sperm count and normal sperm (Calogero et al. 2021). Similarly, no associations between mercury biomarkers and serum levels of reproductive hormones in males were observed, except for one study in adolescent males that showed an inverse association between UHg and LH, but not total testosterone or LSH (Castiello et al. 2020). In male partners of infertile couples, the only association that was observed was positive associations between HHg and sperm concentration, total sperm count, and sperm motility (Mínguez-Alarcón et al. 2018); these effects are not adverse. Based on these findings, mercury exposure in general populations did not appear to adversely affect the male reproductive system in the populations studied.

Female reproductive effects. Epidemiological studies on female reproductive function have been conducted in different subpopulations: women with no known fertility issues (Arakawa et al. 2006;

Jackson et al. 2008, 2011; Pollack et al. 2011); sub- or infertile women (Dickerson et al. 2011; Garcia-Fortea et al. 2018; Maeda et al. 2019; Wright et al. 2015); and pregnant women (Tsuji et al. 2018; Wells et al. 2016; Yildirim et al. 2019). Outcomes assessed in nonpregnant women with no fertility issues include serum reproductive hormone levels, menstrual cycle length, and reproductive disorders (e.g., amenorrhea, endometriosis, uterine fibroids). In sub- or infertile women, serum reproductive hormones and other reproductive parameters to assess fertility were evaluated. Assessments in pregnant women included spontaneous abortion, preterm birth, and other pregnancy associated disorders (e.g., pre-eclampsia, gestational diabetes). Several study types were used to evaluate reproductive effects, including prospective, case-control, retrospective, cohort, and cross-sectional designs. As discussed below, taken together, epidemiological studies on females provide conflicting results, with no clear evidence of adverse reproductive effects.

Results of studies in nonpregnant women with no known fertility issues indicate that the female reproductive system is not a sensitive target for mercury. No associations between mercury biomarkers and serum reproductive hormones (e.g., estradiol, FSH, LH, progesterone, testosterone) were observed in available studies (Gerald et al. 2023; Jackson et al. 2011; Liu et al. 2023; Wang et al. 2023c; Zhang et al. 2023a), except for one prospective study showing an inverse association between UHg and estradiol (Wang et al. 2023c). No associations have been observed between BHg and menstrual cycle length (Jackson et al. 2011; Pollack et al. 2011), amenorrhea (McClam et al. 2023), or uterine fibroids (Jackson et al. 2008). Results of two studies on endometriosis were conflicting, with one study finding no association between BHg (0.61 µg/L) and endometriosis (Jackson et al. 2008), and another study showing an increased risk of endometriosis at a BHg range of 1.2–5.2 µg/L (Shen et al. 2023). No associations were observed between HHg and time to pregnancy (Arakawa et al. 2006) or infertility (McClam et al. 2023). However, in a study of combined fertile and "ever infertile" women, the risk of infertility was increased at BHg levels >5.278 µg/L (Zhu et al. 2020).

In sub- or infertile women, a case-control study reported a positive association between BHg and infertility, but no associations were observed between BHg and reproductive hormones (Maeda et al. 2019). Three prospective studies evaluated associations between mercury and ovarian response to stimulation in sub- or infertile women, with studies reporting conflicting results (Dickerson et al. 2011; Garcia-Fortea et al. 2018; Wright et al. 2015). Inverse associations were observed between HHg and oocyte yield, follicle number and probability of mature oocytes (Dickerson et al. 2011; Garcia-Fortea et al. 2018), whereas Wright et al. (2015) did not find an association between HHg and oocyte yield. A prospective study of women attending a fertility clinic found a positive association between HHg (range

0.04–8.6 µg/g) and antral follicle count (a measure of ovarian reserve); however, these associations were only observed in the group of women with higher long-chain omega-3 polyunsaturated fatty acids (n3PUFA) levels than the median, suggesting that the positive association may be due to the beneficial effects of n-3 PUFA rather than mercury (Mínguez-Alarcón et al. 2021). No associations were observed for *in vitro* fertilization (IVF) rate or successful implantation (Garcia-Fortea et al. 2018; Wright et al. 2015).

Several studies in pregnant women examined associations between mercury and preterm birth (<35 weeks of gestation) or gestational age; results are conflicting. Three prospective studies observed positive associations between mercury biomarkers and preterm birth (Nyanza et al. 2020; Xue et al. 2007; Zhao et al. 2023). A prospective study in a U.S. population observed a positive association for HHg and preterm birth (Xue et al. 2007) and a prospective study in a small Chinese population showed a positive association between SHg and gestational age (Zhao et al. 2023). Nyanza et al. (2020) also reported a positive association between BHg and preterm birth, but no association for spontaneous abortion. In contrast, other prospective studies did not find associations between BHg or HHg and preterm birth (Ashrap et al. 2020; Ren et al. 2022). Other case-control, cohort, and cross-sectional studies did not show associations between biomarkers and preterm birth or gestational age, except for a small, nested case-control study showing a positive association for the highest quartile of SHg (0.058–1.13 µg/L) (Xu et al. 2022a).

Studies also assessed associations between mercury biomarkers and other disorders during pregnancy, including pre-eclampsia and gestational hypertension, gestational diabetes, and placenta previa or accreta. One case-control study (427 cases and 427 controls) showed an association between BHg and pre-eclampsia at the highest exposure tertile (≥1.89 µg/L) (Wang et al. 2020). However, other studies of larger populations (1,274–1,560) did not find associations (Borghese et al. 2023; Liu et al. 2019). Three cross-sectional studies and one case-control study showed positive associations between BHg and gestational diabetes (Rezaei et al. 2021; Tatsuta et al. 2022; Wang et al. 2019b), although a prospective study of an NHANES population did not find an association between erythrocyte mercury and gestational glucose concentration. A larger cross-sectional study of a Japanese population did not observed associations between BHg and placenta previa or accreta (Tsuji et al. 2019). Given the conflicting results of studies in pregnant women, inadequate data were identified to determine if mercury exposure in general populations adversely affects the female reproductive system.

Reproductive effects in couples. Studies evaluating reproductive effects in couples show no associations between fecundity or pregnancy loss (Buck Louis et al. 2012, 2017), although an association was observed for time to pregnancy based on BHg in women, but not in men. Data are inadequate to determine if exposure to mercury adversely affects reproductive success.

Reproductive effects in offspring following gestational exposure. Two studies evaluated reproductive effects using biomarkers that reflect gestational exposure (Sarzo et al. 2022; Wang et al. 2021a). Sarzo et al. (2022) did not find associations between cord BHg and serum estradiol or testosterone measured at 9 years of age. However, tanner evaluation showed an inverse association between cord BHg in males, but not females. Wang et al. (2021a) observed a positive association between maternal erythrocyte mercury and precocious puberty at the highest exposure tertile. However, findings of these studies have not been corroborated.

Mechanisms of Action. General mechanisms of toxicity of mercury, including oxidative stress and inflammation are likely involved in the toxicity to male and female reproductive systems (Section 2.21). Several mechanisms may be involved in the toxicity of mercury compounds to the reproductive system (Ferguson and Chin 2017; Lu et al. 2018; Schuurs 1999; Tan et al. 2009; Wirth and Mijal 2010). Proposed mechanisms include the following: (1) altered hormonal regulation of the hypothalamic-pituitary-gonadal axis; (2) disruption of steroidogenesis; (3) enzyme inhibition; (4) inhibition of DNA, RNA, and protein synthesis; (5) decreased mitochondrial energy production and alterations of microtubule assembly in sperm tails; (6) altered estrogen production resulting in decreased numbers, size, and quality of ova; (7) agonist activity at estrogen receptors; (8) genetic polymorphisms; and (9) DNA methylation in sperm. In addition, mercury has been shown to accumulate in the hypothalamic-pituitary-gonadal axis.

2.18 DEVELOPMENTAL

A large body of literature addresses the potential for mercury exposure to produce neurological effects following exposure during early development. Similarly, several animal studies address the potential for mercury exposure to produce immunological effects following exposure during early development. Studies that have evaluated neurodevelopmental outcomes in humans and animal models are discussed in Section 2.16 (Neurological) and studies that have evaluated altered immune system development in animal models are discussed in Section 2.15 (Immunological) to facilitate comparison with effects observed following adult exposure. This section discusses developmental effects of mercury other than

neurodevelopmental and immunodevelopmental effects. The term "developmental" used in the discussion that follows refers to effects other than neurodevelopmental and immunodevelopmental.

Overview. Data on developmental effects of mercury are available from epidemiology studies and studies in animals. Epidemiological studies have assessed effects in workers exposed to elemental mercury, populations with high fish diets, and general populations. These studies examined possible associations between mercury exposure and anthropometric measures in newborns (e.g., birth weight and size) and postnatal growth in children. The studies reported conflicting results, with no strong evidence of associations between mercury exposure and *in utero* or postnatal growth.

Studies evaluating developmental toxicity in animals are available for inhalation exposure to elemental mercury or oral exposure to mercuric chloride, mercuric acetate, or methylmercury. Overall, oral studies indicate dose- and duration-dependent developmental toxicity (increased offspring mortality, increased malformations and variations, decreased body weight) in rodents exposed to methylmercury, predominantly at maternally toxic doses. Oral studies with exposure to inorganic mercury salts are limited but suggest potential decreases in postnatal growth and survival following exposure to mercuric chloride, primarily at maternally toxic doses. Evidence from inhalation studies are too limited to draw conclusions.

The following summarizes results of epidemiological and animal studies on developmental outcomes.

- ***Elemental mercury***
  - *Epidemiology studies*
    - Few studies have evaluated effects of exposure to elemental mercury and developmental outcomes.
    - One study reported an increased risk of small for gestational age (SGA) infants in dental workers versus controls; this outcome was not evaluated in other studies.
    - No associations were observed between exposure and anthropometric measures in neonates, neonatal mortality, or congenital malformations.
    - Available data are not sufficient to determine if exposure to elemental mercury is associated with adverse developmental outcomes.
  - *Animal studies*
    - Few studies investigated effects on developmental toxicity; one study reported developmental toxicity in rats (increased resorptions, decreased birth weight) following exposure to maternally toxic exposure levels.

- ***Inorganic mercury salts***
  - *Epidemiology studies*
    - No epidemiological studies evaluating associations between exposure to inorganic mercury salts and developmental effects were identified.
  - *Animal studies*
    - Developmental endpoints evaluated in available studies are primarily limited to survival and growth parameters.
    - Decreased postnatal growth and survival have been reported in two multigenerational studies at doses associated with maternal toxicity; a few additional studies have reported decreased body weight in offspring following gestational exposure.
    - Available data are not sufficient to determine if exposure is associated with adverse developmental outcomes at oral exposures below those associated with maternal toxicity.
- ***Organic mercury***
  - *Epidemiology studies*
    - In the Minamata population, congenital defects were observed in infants.
    - Results of studies evaluating birth size and postnatal growth in populations with high maternal fish diets were inconsistent, with most results reporting no associations.
    - Available studies do not provide evidence of adverse effects on *in utero* or postnatal growth.
  - *Animal studies*
    - Developmental studies consistently reported dose- and duration-dependent decreases in offspring survival and increases in malformations and variations in rats and mice. Common malformations observed in both rats and mice at high doses include cleft palate, skeletal malformations (ribs, sternebrae), and hydronephrosis.
    - Developmental studies in mice consistently reported dose- and duration-dependent decreases in offspring body weight; findings in rat were less consistent.
    - The majority of effects were noted at maternally toxic doses, but some effects were observed below doses associated with maternal toxicity.
- ***Predominant mercury form unknown (general populations)***
  - Evidence for effects on mercury exposure on birth size in general populations is inconclusive, with studies reporting inconsistent results. Most studies did not observe associations between mercury biomarkers and birth size.

▪ Few studies have evaluated effects of mercury exposure on postnatal growth in general populations. The study results were inconsistent and do not provide clear evidence that mercury exposure in general populations is associated with decreased postnatal growth.

Confounding Factors. Numerous complicating factors may add uncertainty in the interpretation of studies examining associations between mercury exposure and developmental effects if not homogenously distributed in the study population. These factors include nutrition during pregnancy, prenatal care, adequate nutrition during infancy and childhood, socio-economic factors, intercurrent diseases, alcohol consumption, smoking status, and potential exposure to other chemicals. Failure to account for these factors may attenuate or strengthen the apparent associations between mercury exposure and the outcome, depending on the direction of the effect of the variable on the outcome.

Elemental Mercury—Epidemiological Studies. Few studies have evaluated effects of occupational exposure and developmental effects; studies are summarized in Table 2-67. Developmental outcomes evaluated were birth size, congenital malformations, and mortality. Two prospective studies examined small populations of females exposed through dental work or amalgam fillings (Bedir Findik et al. 2016; El-Badry et al. 2018) and one retrospective study evaluated neonates of male and female chloralkali workers (Frumkin et al. 2001). The only adverse effect observed was an increased risk (risk ratio 6.2; 95% CI 2.3, 16.4) of SGA infants in dental workers versus controls (El-Badry et al. 2018). SGA was not evaluated in the other studies. No other adverse associations between biomarkers (cord BHg or UHg) were observed for anthropometric measures, congenital malformations, or neonatal mortality. Data are not adequate to determine if exposure to elemental mercury is associated with adverse developmental outcomes.

Table 2-67. Results of Epidemiological Studies Evaluating Exposure to Elemental Mercury (Hg^0) and Developmental Effects

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Bedir Findik et al. 2016 Prospective case-control; 28 pregnant women with amalgam fillings and 32 pregnant women with no amalgam fillings (Turkey)	BHg mean, cord Amalgam: 0.5 µg/L No amalgam: 0.3 µg/L BHg mean, maternal Amalgam: 0.50 µg/L No amalgam: 0.27 µg/L	Weight	↔ (BHg amalgam versus no amalgam)
		Length	↔ (BHg, amalgam versus no amalgam)
		Head circumference	↔ (BHg, amalgam versus no amalgam)
		Gender	↔ (BHg, amalgam versus no amalgam)

Table 2-67. Results of Epidemiological Studies Evaluating Exposure to Elemental Mercury (Hg^0) and Developmental Effects

Reference, study type, and population	Biomarker	Outcome evaluated	Result
		Neonatal mortality	↔ (BHg, amalgam versus no amalgam)
El-Badry et al. 2018 Prospective; 64 pregnant dental workers and 60 pregnant controls (Egypt)	UHg mean, workers 1st trimester: 42.2 µg/g Cr 2nd trimester: 41.8 µg/g Cr 3rd trimester: 42.8 µg/g Cr UHg mean, control: 1st trimester: 6.2 µg/g Cr 2nd trimester: 6.3 µg/g Cr 3rd trimester: 7.1 µg/g Cr	SGA	↑ (UHg, workers versus controls)
		Congenital malformations	↔ (UHg, workers versus controls)
Frumkin et al. 2001 Retrospective cohort; 147 chloralkali workers and 132 controls (Brunswick, Georgia)	UHg mean Workers: 2.76 µg/g Cr Controls: 2.31 µg/g Cr	Birth weight	↔ (UHg)
		Fetal malformation	↔ (UHg)

↑ = positive association or increased compared to controls; ↔ = no association; BHg = blood mercury; Cr = creatinine; SGA = small for gestational age; UHg = urine mercury

Elemental Mercury—Animal Studies. The developmental effects of exposure to elemental mercury have not been well-studied in animals. An increase in the number of resorptions, decreased litter size, and decreased pup weight on PND 1 was observed in rats following inhalation exposure to 8 mg Hg/m^3 for 2 hours/day on GDs 6–15; maternal toxicity (body weight loss) was observed in this group (Morgan et al. 2002). These effects were not observed in groups similarly exposed to ≤4 mg Hg/m^3 on GDs 6–15 or ≤8 mg Hg/m^3 on GD 6 or GDs 6–10 (Morgan et al. 2002). In other acute-duration inhalation studies, no exposure-related changes in litter size or birth weight were observed in rats following exposure to 1.8 mg Hg/m^3 for 1 or 3 hours/day on GDs 11–14 plus GDs 17–20 or 1–5 hours/per day on GDs 14–19 (Danielsson et al. 1993; Fredriksson et al. 1996). No changes in postnatal growth were observed in rats following direct postnatal inhalation exposure to 0.05 mg Hg/m^3 for 1 or 4 hours/day on PNDs 11–17 (Fredriksson et al. 1992). In mice, no changes in PND 10 body weight were observed following gestational exposure to 0.03 mg Hg/m^3 for 6 hours/day on GDs 0–18 (Yoshida et al. 2011). In squirrel monkeys, no exposure-related differences in birth weight, weight gain, or body weight through 4 years of age were observed in offspring following exposure to 0.5 or 1 mg Hg/m^3 for 4 or 7 hours/day, 5 days/week during the last two-thirds of gestation (Newland et al. 1996).

No exposure-related changes in emergence of developmental landmarks (e.g., pinna unfolding, tooth eruption) or reflex ontogeny (e.g., surface righting, negative geotaxis) were observed in rats following acute-duration gestational inhalation exposure to 1.8 mg Hg/m^3 for 1–5 hours per day (Danielsson et al. 1993; Fredriksson et al. 1996).

Inorganic Mercury Salts—Animal Studies. A limited number of developmental endpoints have been evaluated in laboratory animals exposed to mercuric chloride in multigenerational, gestational, gestational plus lactational, and early postnatal exposure studies. Most available studies were focused on neurological or immune development, which are discussed in Section 2.16 (Neurological) or Section 2.15 (Immunological), respectively, with limited information on systemic developmental toxicity (e.g., body weight). No comprehensive developmental toxicity evaluations were available (e.g., examinations for skeletal or visceral malformations); therefore, oral data are too limited to draw conclusions. However, some studies indicate that growth and survival of offspring may be impacted following developmental exposure to mercuric chloride, generally at oral doses associated with maternal toxicity in rodents.

Reduced postnatal survival has been reported in rats following developmental exposure to mercuric chloride at high oral doses. In a 2-generation gavage study in rats, neonatal survival to PND 4 decreased by 59% in F1 offspring at 1.98 mg Hg/kg/day and 19% in F2 offspring at 1.11 mg Hg/kg/day (F1 dams were not mated at 1.98 mg Hg/kg/day due to low F1 birth and survival rates); maternal toxicity (decreased body weight, decreased survival) were observed in F0 dams at ≥1.11 mg Hg/kg/day (Atkinson et al. 2001). In a gestation-only study, pup mortality was increased by 16% following maternal drinking water exposure to 9.6 mg Hg/kg/day on GDs 1–21; no maternal toxicity was observed (Chehimi et al. 2012). In mice, no exposure-related changes in postnatal survival were observed following exposure to gavage doses up to 0.74 mg Hg/kg/day in a 1-generation study (Khan et al. 2004) or drinking water exposure to 1.5 mg Hg/kg/day on GDs 0–21 (Pilones et al. 2009).

No gross malformations were seen in rat offspring following gestational exposure to gavage doses up to 1.6 mg Hg/kg/day on GDs 5–15 (Papp et al. 2005). No changes in reflex ontogeny were observed in rat offspring following drinking water exposure to doses up to 3.8 mg Hg/kg/day from GD 0 to PND 21 (Oliveira et al. 2016). No other identified studies specifically evaluated malformations or reflex ontogeny following developmental exposure to mercuric chloride.

Body weight effects in rat offspring have been reported following gestational and/or postnatal exposure to mercuric chloride; findings were often associated with maternal toxicity. In a 2-generation gavage study,

birth weight was decreased by 30% in F1 offspring at 1.98 mg Hg/kg/day and dose-related decreases in body weight were observed at all doses by PND 21 (20, 30, and 35% reductions at 0.55, 1.11, and 1.98 mg Hg/kg/day, respectively); F0 dam body weights were decreased at ≥1.11 mg Hg/kg/day (Atkinson et al. 2001). No exposure-related decreases were observed in F2 offspring at doses up to 1.11 mg Hg/kg/day (no F2 litters at 1.98 mg Hg/kg/day). A gavage study in rats exposed to 3 mg Hg/kg/day on GDs 1–21 reported a 17% decreased birth weight of offspring (Ismail and El-Meligy 2021). A non-specified "slight" decrease in birth weight was reported in female rat pups following gestational exposure to gavage doses ≥0.8 mg Hg/kg/day on GDs 5–15; no exposure-related changes were observed in male birth weight and no exposure-related changes were observed in body weights of either sex at 12 weeks of age at gestational doses up to 1.6 mg Hg/kg/day (Papp et al. 2005). Similarly, no body weight effects at 12 weeks of age were observed in similarly treated rats with continued postnatal exposure on PNDs 2–28 (via dam) or PNDs 2–28 (via dam) plus direct exposure on PNDs 29–84 (Papp et al. 2005). In a drinking water study, no changes in fetal body weight on GD 20 were observed in rats following exposure doses up to 0.0301 mg Hg/kg/day on GDs 0–20 (Oliveira et al. 2012). However, maternal exposure to higher drinking water doses of 6.1 or 9.6 mg Hg/kg/day on GDs 1–21 resulted in offspring body weight decreases of approximately 10–15 and 20–30%, respectively, through PND 17 (Chehimi et al. 2012). No postnatal body weight effects were noted in rats following maternal exposure to doses up to 0.094 mg Hg/kg/day throughout gestation and lactation; body weights were monitored through PND 40 (Galiciolli et al. (2022).

Developmental body weight data in mice exposed to mercuric chloride are limited and inconsistent. In ICR mice, a 6% decrease in birth weights and a 12% decrease in PND 70 body weights were observed in offspring following gavage exposure to 0.4 mg Hg/kg/day during gestation plus lactation (GD 0 to PND 21); body weight decreases were slightly more (15%) if direct exposure continued postweaning through PND 70 (Huang et al. 2011). No changes were observed in birth weights of SfvF1 or FvSF1 (autoimmune-susceptible) mice following drinking water exposure to 2.7 mg Hg/kg/day from GD 8 to PND 21 (Zhang et al. 2013). In a gestation-only study, no changes in birth weight were noted in DBF1 mouse offspring following drinking water exposure to 1.5 mg Hg/kg/day on GDs 0–21 (Pilones et al. 2009).

One study evaluated developmental toxicity in hamster offspring on GD 12 or 14 following a single maternal exposure to oral mercuric acetate on GD 8 (Gale 1974). The number of resorptions was increased in a dose-related manner at doses ≥22.1 mg Hg/kg/day, with 99% resorption at 63 mg Hg/kg/day. Additionally, the percentage of "malformed" embryos was increased at ≥15.8 mg Hg/kg/day,

and the crown-rump length was decreased at ≥5 mg Hg/kg/day. Maternal toxicity (weight loss, diarrhea, tremor, somnolence, liver and kidney damage) was qualitatively reported; however, the dose(s) associated with effects were not reported. While no malformations were reported, one study reported ultrastructural changes in fetal lungs that included collapsed alveoli and cellular degeneration in the offspring of dams exposed to 3 mg Hg/kg/day on GDs 1–21 (Ismail and El-Meligy 2021).

Organic Mercury—Epidemiological Studies. Congenital malformations were reported in infants of Minamata mothers who consumed fish contaminated with very high levels of methylmercury (Harada 1995; Rice et al. 2014). Malformations included polydactyly, syndactyly, craniofacial malformations, microcornea, undescended testicles, enlarged colon, and protrusion of the coccyx.

Epidemiological studies investigating effects of mercury exposure on developmental outcomes in populations with high fish diets are summarized in Table 2-68. Studies include populations from the Faroe Islands and Seychelles Islands, an Inuit population, and other populations with high maternal fish consumption. Most studies evaluated populations with <300 participants, although a few studies evaluated larger populations (1,756–2,152 participants). Most studies used prospective designs and one study was a pooled analysis of prospective studies (Timmermann et al. 2017). Outcomes evaluated included anthropometric measures at birth (weight, length, head circumference), and postnatal growth, sex ratio, and heart rate variability. Most studies assessed mercury exposure using maternal and/or umbilical cord BHg. Collectively, these studies do not provide strong evidence for associations between maternal mercury exposure and birth weight or length; however, some studies found associations with head circumference and postnatal growth.

Table 2-68. Epidemiological Studies Evaluating Associations between Mercury and Developmental Effects in Populations with High Maternal Fish Diets

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Faroe Islands			

Grandjean et al. 2001
 	
Prospective birth cohort; 182 pregnant women (Faroe Islands)
	Cord BHg tertiles
	  T1: <14 µg/L
	  T2: 14–33 µg/L
	  T3: >33 µg/L
		Birth weight	↔ (BHg, T3)

Table 2-68. Epidemiological Studies Evaluating Associations between Mercury and Developmental Effects in Populations with High Maternal Fish Diets

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Grandjean et al. 2003 Prospective birth cohort; 171 children evaluated at 18 months and 154 evaluated at 42 months (Faroe Islands)	Cord BHg mean: 20.4 µg/L	Postnatal weight	↓ (BHg, 18 months) ↔ (BHg, 42 months)
		Postnatal height	↔ (BHg, 18 months) ↔ (BHg, 42 months

Timmermann et al. 2017
 	
Pooled data from 3 prospective birth cohorts; 2,152 mother-child pairs (Faroe Islands)
	Maternal HHg median
	  Cohort 1: 4.49 µg/g
	  Cohort 3: 2.20 µg/g
	  Cohort 5: 0.71 µg/g
		Sex ratio (male:female)[a]	↑ (HHg, combined cohorts)
			↔ (HHg, cohort 1)
			↔ (HHg, cohort 3)
			↑ (HHg, cohort 5)

Seychelles Islands			
van Wijngaarden et al. 2014 Prospective birth cohort; 230 mother-infant pairs (Seychelles Islands)	Maternal HHg mean: 5.9 µg/g	Birth weight	↔ (HHg)
Yeates et al. 2020 Prospective birth cohort; 1,236 mother-infant pairs (Seychelles Islands)	Maternal HHg mean (prenatal) Mothers of males: 3.96 µg/g Mothers of females: 3.90 µg/g	Birth weight	↔ (HHg)
		Birth length	↔ (HHg)
		Head circumference	↔ (HHg)
Zareba et al. 2019 Prospective birth cohort; 514 mother-child pairs participating; assessments made in offspring at 19 years of age (Sechelles)	Maternal HHg mean: 6.92 µg/g Offspring HHg mean at age 19 years: 10.21 µg/g	Heart rate variability	↔ (HHg, maternal) ↔ (HHg, offspring age 19 years)
Inuit populations			
Dallaire et al. 2013 Prospective longitudinal; 248 mother-infant pairs; Inuit (Arctic Quebec) (adjusted for DHA fatty acids from fish)	Cord BHg mean: 21.3 µg/L	Birth weight	↔ (BHg)
		Birth length	↔ (BHg)
		Head circumference	↔ (BHg)
Other populations			
Murcia et al. 2016 Prospective birth cohort; 1,756 mother-infant pairs with high maternal fish consumption (Spain)	Cord BHg Gmean: 8.2 µg/L Tertiles T1: 5.0–<8.5 µg/L T2: 8.5–<15.0 µg/L T3: ≥15.0 µg/L	Birth weight	↔ (BHg, T3)
		Birth length	↔ (BHg, T3)
		Head circumference	↓ (BHg, T3)

Table 2-68. Epidemiological Studies Evaluating Associations between Mercury and Developmental Effects in Populations with High Maternal Fish Diets

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Tang et al. 2016 Cross-sectional; 103 mother-infant pairs with high maternal fish consumption (China)	Cord BHg median: 21.94 µg/L	Birth weight	↔ (BHg)
		Birth length	↔ (BHg)
		Head circumference	↔ (BHg)
Tatsuta et al. 2017 Prospective birth cohort; 289 mother-infant pairs (252 male newborns and 237 female newborns) with high maternal fish consumption (Japan)	Cord BHg mean: 10.1 µg/L	Birth weight	↑ (BHg, males) ↔ (BHg, females) ↔ (BHg, males and females)

[a]The toxicological significance of a positive association between HHg and male:female sex ratio is not established.

↑ = positive association, indicating an increase in the measured parameter; ↓ = inverse association, indicating a decrease in the measured parameter; ↔ = no association; BHg = blood mercury; DHA = docosahexaenoic acid; Gmean = geometric mean; HHg = hair mercury; T = tertile

Results of studies evaluating anthropometric measures in populations with high maternal fish diets do not provide evidence of adverse effects. The largest prospective study (n=1,236) from the Seychelle Islands (Nutrition cohort 2) found that maternal HHg was not associated with birth weight, length, or head circumference (Yeates et al. 2020). This outcome is consistent with results from the smaller (n=230) main Seychelle Islands cohort (van Wijngaarden et al. 2014) and from the Faroe Islands prospective cohort (Grandjean et al. 2001). Another large prospective study conducted in Spain (n=1,756) also did not find an association between mercury exposure (cord BHg) and birth weight or birth length (Murcia et al. 2016). However, this study did find an association with decreasing head circumference at birth (-0.052 cm per doubling of total BHg; 95% CI 0.109, 0.005)). Other smaller prospective studies did not find associations between increasing with birth weight and/or birth length (Dallaire et al. 2013; Tatsuta et al. 2017). One prospective study of a Faroe Islands birth cohort evaluated postnatal growth in children from birth to 18 and 42 months of age (Grandjean et al. 2003). Results showed an inverse association between umbilical cord BHg and postnatal weight at 18 months, with a 0.8 kg (95% CI -1.56, -0.04) decrease per 10-fold increase in umbilical cord BHg. However, no association was observed at 42 months, and no associations were observed for postnatal height at 18 or 42 months.

A large pooled analysis of data from three prospective birth cohorts in the Faroe Islands, found a positive association between maternal HHg and male:female sex ratio (Timmermann et al. 2017). Examination of individual cohorts showed that this association only occurred in the cohort with the lowest HHg. One prospective study evaluated heart rate variability in children (age 19 years) from the Seychelle Islands cohort and found no association with maternal HHg (Zareba et al. 2019).

Organic Mercury—Animal Studies. Decreased offspring survival and increased malformations and variations are associated with developmental exposure to methylmercury compounds in rats and mice in a dose- and duration-dependent manner. Offspring body weight decreases in mice are also dose- and duration-dependent, while body weight findings in rats are less consistent. While the majority of effects are noted at maternally toxic doses, some effects were observed below doses associated with maternal toxicity, indicating that the developing organism may be susceptible to methylmercury toxicity.

Several studies have reported increased fetal death/resorption, decreased litter size, and/or decreased neonatal survival in rats following gestational exposure to methylmercury, predominantly at doses associated with maternal toxicity (Table 2-69). Increased fetal death and decreased live litter size were observed in rats in a dose- and duration-dependent manner following gestational exposure to a single dose ≥8 mg Hg/kg/day, repeat acute-duration doses ≥6 mg Hg/kg/day, or an intermediate-duration dose of 1.9 mg Hg/kg/day; these findings were associated with maternal toxicity (decreased body weight, clinical signs of toxicity) (Fuyuta et al. 1978; Gandhi et al. 2013; Lee and Han 1995). Decreased postnatal survival to weaning was observed following gestational exposure to 7 mg Hg/kg/day on GD 8 or 15, with increased mortality following exposure on GD 15, compared to GD 8; no maternal toxicity was noted (Carratu et al. 2006). No change in postnatal survival was observed in rats exposed to 6.4 mg Hg/kg/day on GD 15 (Cagiano et al. 1990), 1.9 mg Hg/kg/day on GDs 6–9 (Fredriksson et al. 1996), or doses up to 0.9 mg Hg/kg/day on GDs 5–21 (Gandhi et al. 2013).

Table 2-69. Pre- and Postnatal Survival in Rats Following Gestation-Only Exposure to Methylmercury Compounds

Duration; dose (mg Hg/kg/day)	Dead/ resorbed[a]	Live litter size[a]	Postnatal survival[a]	Reference (compound)
1 day, GD 15; dose: 6.4	–	–	↔ PND 21	Cagiano et al. 1990 (MMC)
1 day, GD 8; dose: 7	–	↔	↓ PND 21 (8)	Carratu et al. 2006 (MM)

Table 2-69. Pre- and Postnatal Survival in Rats Following Gestation-Only Exposure to Methylmercury Compounds

Duration; dose (mg Hg/kg/day)	Dead/ resorbed[a]	Live litter size[a]	Postnatal survival[a]	Reference (compound)
1 day, GD 15; dose: 7	–	↔	↓ PND 21 (16)	Carratu et al. 2006 (MM)
1 day GD 7; dose: 8[b]	↑ (17)	↓ (19)	–	Lee and Han 1995 (MMC)
1 day, GD 7; dose: 16[b]	↑ (19)	↓ (41)	–	Lee and Han 1995 (MMC)
1 day, GD 7; dose: 24[b]	↑ (41)	↓ (91)	–	Lee and Han 1995 (MMC)
4 day, GDs 6–9; dose: 0.02–0.4	–	↔	–	Stoltenburg-Didinger and Markwort 1990 (MMC)
4 days, GDs 6–9; dose: 1.9	–	–	↔	Fredriksson et al. 1996 (MM)
4 days, GDs 6–9; dose: 4	–	↔	–	Stoltenburg-Didinger and Markwort 1990 (MMC)
8 days, GDs 7–14; dose: 2[b] or 4[b]	↔	↔	–	Fuyuta et al. 1978 (MMC)
8 days, GDs 7–14; dose: 6[b]	↑ (38)	↓ (45)	–	Fuyuta et al. 1978 (MMC)
9 days, GDs 6–14; dose: 0.024–4.6[b]	↔	↔	–	Nolen et al. 1972 (MMC)
17 days, GDs 5–21; dose: 0.5–0.9	↔	↔	↔	Gandhi et al. 2013 (MM)
17 days, GDs 5–21; dose: 1.9[b]	↑ (100)	↓ (100)	NA	Gandhi et al. 2013 (MM)

[a]Numbers in ( ) are percent change compared to control, calculated from quantitative data.
[b]Dose associated with maternal toxicity (e.g., decreased body weight, clinical signs).

↑ = increased; ↓ = decreased; ↔ = no change; – = not assessed; GD = gestation day; MM = methylmercury; MMC = methylmercuric chloride; NA = not applicable; PND = postnatal day

In gestation plus lactation studies in rats, one study reported an unspecified increase in the number of stillbirths and decreased postnatal survival following gavage exposure to methylmercury at 1.6 mg Hg/kg/day from GD 6 to PND 6, a dose associated with maternal toxicity (Tonk et al. 2010). Exposure to methylmercury at gavage doses up to 1.2 mg Hg/kg/day or drinking water doses up to 1.9 mg Hg/kg/day during gestation and lactation did not result in exposure-related changes in live litter size or postnatal survival (Albores-Garcia et al. 2016; Cheng et al. 2015; Fujimura et al. 2012; Giménez-Llort et al. 2001; Rossi et al. 1997; Sitarek and Gralewicz 2009; Tonk et al. 2010). Additionally, no exposure-related

changes in live litter size or postnatal survival were observed in 1- or 2-generational studies in rats at
doses up to 0.9 mg Hg/kg/day (Beyrouty et al. 2006; Elsner 1991; Khera and Tabacova 1973; Newland
and Reile 1999; Szász et al. 2002).

In mice, increased fetal death/resorption, decreased litter size, and/or decreased neonatal survival have
also been observed following gestation or gestation plus lactation exposure to methylmercury at doses
below those associated with maternal toxicity (Table 2-70). Increased fetal death was observed in mice
following repeat acute-duration exposures ≥4.8 mg Hg/kg/day and following an intermediate-duration
dose of 5 mg Hg/kg/day; in both studies, fetal effects were observed (Fuyuta et al. 1978; Khera and
Tabacova 1973). No changes in fetal death/resorption were observed in mice following single gestational
methylmercury exposure to doses up to 20 mg Hg/kg/day (Fuyuta et al. 1979; Belles et al. 2002; Yasuda
et al. 1985).

Table 2-70. Pre- and Postnatal Survival in Mice Following Gestation-Only or Gestation plus Lactation Exposure to Methylmercury Compounds

Duration; dose (mg Hg/kg/day)	Dead/resorbed[a]	Live litter size[a]	Neonatal survival[a]	Reference (compound)
1 day, GD 8; dose: 1–2	–	↔	–	Hughes and Annau 1976 (MMH)
1 day, GD 8; dose: 3[b]	–	↓ (35)	–	Hughes and Annau 1976 (MMH)
1 day, GD 8; dose: 5[b]	–	↓ (40)	–	Hughes and Annau 1976 (MMH)
1 day, GD 10; dose: 8	↔	↓ (13)	–	Fuyuta et al. 1979 (MMC)
1 day, GD 10; dose: 9.99	↔	–	–	Belles et al. 2002 (MMC)
1 day, GD 8; dose: 10	–	↓ (73)	–	Hughes and Annau 1976 (MMH)
1 day, GD 10; dose: 12–16	↔	↔	–	Fuyuta et al. 1979 (MMC)
1 day, GD 13, 14, 15, 16, or 17; dose: 16[b]	–	↔	PND 56: ↓ (67–94%)	Inouye et al. 1985 (MMC)
1 day, GD 10 or 12; dose: 10–20	↔	↔	–	Yasuda et al. 1985 (MMC)
1 day, GD 10; dose: 20[c]	↔	↓ (15)	–	Fuyuta et al. 1979 (MMC)
3 days, GDs 7–9 or 12–14; dose: 3	–	↔	↔	Dore et al. 2001 (MMC)
3 days, GDs 7–9; dose: 5[b]	–	↔	PND 35: ↓ (28)	Dore et al. 2001 (MMC)

Table 2-70. Pre- and Postnatal Survival in Mice Following Gestation-Only or Gestation plus Lactation Exposure to Methylmercury Compounds

Duration; dose (mg Hg/kg/day)	Dead/resorbed[a]	Live litter size[a]	Neonatal survival[a]	Reference (compound)
3 days, GDs 12–14; dose: 5[b]	—	↔	PND 35: ↓ (26)	Dore et al. 2001 (MMC)
8 days, GDs 6–13; dose: 2–4	↔	↔	—	Fuyuta et al. 1978 (MMC)
8 days, GDs 6–13; dose: 4.8	↑ (25)	↔	—	Fuyuta et al. 1978 (MMC)
8 days, GDs 6–13; dose: 6[c]	↑ (89)	↔	—	Fuyuta et al. 1978 (MMC)
12 days, GDs 6–17; dose: 0.0001–1	↔	↔	↔	Khera and Tabacova 1973 (MMC)
12 days, GDs 6–17; dose: 5	↑ (100)	NA	NA	Khera and Tabacova 1973 (MMC)
41 days, GD 2–PND 21; dose: 0.9–1.3	—		↔	Goulet et al. 2003 (MMC)
41 days, GD 2–PND 21; dose: 1.7[b]	—	↓ (18)	↓ (14)	Goulet et al. 2003 (MMC)
63–70 days, premating through PND 13; dose: 0.2–6	—	↔	↔	Weiss et al. 2005 (MMC)
112 days, premating through PND 15; dose: 0.098–0.98	—	↔	↔	Thuvander et al. 1996 (MMC)
119 days, premating through PND 70; dose: 0.02	—	↓ (16)	↔	Huang et al. 2011 (MM)

[a]Numbers in ( ) are percent change compared to control, calculated from quantitative data.
[b]Maternal health not reported.
[c]Dose associated with maternal toxicity (e.g., decreased body weight, clinical signs).

↑ = increased; ↓ = decreased; ↔ = no change; – = not assessed; GD = gestation day; MM = methylmercury; MMC = methylmercuric chloride; MMH = methylmercury hydroxide; NA = not applicable; PND = postnatal day

Decreased postnatal survival to PND 56 was observed following gestational exposure to 16 mg Hg/kg/day on GD 13, 14, 15, 16, or 17, with the highest mortality after exposure on GD 15 or 16 (Inouye et al. 1985). Decreased postnatal survival to PND 35 was also observed in mice exposed to 5 mg Hg/kg/day on GDs 7–9 or 12–14, but not 3 mg Hg/kg/day; mortality was comparable for both exposure paradigms (Dore et al. 2001). No change in postnatal survival was observed in mice exposed to doses up to 1 mg Hg/kg/day on GDs 6–17 (Khera and Tabacova 1973). No exposure-related changes in postnatal

survival were observed in the 1-generation studies (Huang et al. 2011; Thuvander et al. 1996; Weiss et al. 2005).

There is inconsistent evidence for decreased live litter size following single exposures to methylmercury during gestation. No changes were observed in litter sizes following repeated gestational exposure to methylmercury at doses below those associated with 100% fetal death (12-day exposure to 5 mg Hg/kg/day; Khera and Tabacova 1973). In a mouse study with gestational plus lactational exposure, live litter size and postnatal survival were both decreased at 1.7 mg Hg/kg/day, but not at doses ≤1.3 mg Hg/kg/day (Goulet et al. 2003). A 1-generation study in mice reported decreased live litter size following exposure to 0.02 mg Hg/kg/day (Huang et al. 2011); however, no change in live litter size was reported in two other 1-generation studies at doses up to 6 mg Hg/kg/day (Thuvander et al. 1996; Weiss et al. 2005).

A single study in guinea pigs reported 100% fetal death in 20, 50, 67, 50, and 20% of dams following exposure to 11.5 mg Hg/kg/day once on GD 21, 28, 35, 42, or 49, respectively, compared to 0% of control dams (Inouye and Kajiwara 1988). Exposed dams showed clinical signs of toxicity.

Dose- and duration-related increases in malformations and variations have been observed in rats and mice following gestational exposure to methylmercury compounds; some findings were observed at doses below those associated with maternal toxicity and/or offspring lethality (Tables 2-71 and 2-72, respectively). In rats, total gross malformations, including cleft palate and generalized edema were observed after repeated oral exposures to doses ≥4 mg Hg/kg/day during gestation (Fuyuta et al. 1978; Nolen et al. 1972). Cleft palate was also observed in mice following repeated oral exposures to doses ≥4 mg Hg/kg/day during gestation (Fuyuta et al. 1978) or single gestational exposures ≥9.99 mg Hg/kg/day (Belles et al. 2002; Fuyuta et al. 1979; Yasuda et al. 1985). Observed skeletal malformations and variations in rats included spinal curvature, sternal absence or defects, wavy ribs, absent or bilobed vertebral centra, and delayed ossification at single doses ≥8 mg Hg/kg/day and repeat doses ≥0.024 mg Hg/kg/day (Abd El-Aziz et al. 2012; Fuyuta et al. 1978; Lee and Han 1995; Nolen et al. 1972). Similar effects (delayed ossification, sternal and vertebral defects) were observed in mice following single doses ≥8 mg Hg/kg/day and repeat doses ≥2 mg Hg/kg/day (Belles et al. 2002; Fuyuta et al. 1978, 1979; Yasuda et al. 1985). Visceral malformations in rats included hydrocephaly following exposure to ≥4 mg Hg/kg/day on GDs 7–14 (Fuyuta et al. 1978) and defects in the urinary system (bladder defects, hydronephrosis, and/or hydroureter) following exposure to ≥0.024 mg Hg/kg/day on GDs 6–14 (Nolen et al. 1972). Hydronephrosis and/or dilatation of the renal pelvis were observed in mice following single

doses ≥16 mg Hg/kg/day; hydronephrosis was also observed following repeat doses of 4.8 mg Hg/kg/day
(Belles et al. 2002; Fuyuta et al. 1978, 1979; Yasuda et al. 1985).

Table 2-71. Malformations and Variations in Rats Following Gestation-Only Exposure to Methylmercury Compounds

Duration; dose (mg Hg/kg/day)	Gross malformations	Skeletal malformation/ variation	Visceral malformation/ variation	Reference (compound)
1 day, GD 7; dose: 8[a,b]	↔	Decreased ossification centers ↓ (9–12[c]) Spinal curvature ↑ (NR)	↔	Lee and Han 1995 (MMC)
1 day, GD 7; dose: 16[a,b]	↔	Decreased ossification centers ↓ (25–63[c]) Spinal curvature ↑ (NR)	↔	Lee and Han 1995 (MMC)
1 day, GD 7; dose: 24[a,b]	↔	Decreased ossification centers ↓ (55–100[c]) Spinal curvature ↑ (NR)	↔	Lee and Han 1995 (MMC)
8 days, GDs 7–14; dose: 2[a]	↔	↔	↔	Fuyuta et al. 1978 (MMC)
8, GDs 7–14; dose: 4[a]	Total malformations ↑ (7[d])	Wavy ribs ↑ (7[d])	Hydrocephaly ↑ (6[d])	Fuyuta et al. 1978 (MMC)
8 days, GDs 7–14; dose: 6[a,b]	Total malformations ↑ (80[d]) Cleft palate ↑ (18[d]) General edema ↑ (79[d])	Wavy ribs ↑ (27[d]) Sternal defects/ absence ↑ (20–61[d]) Absence or bilobed vertebral centra ↑ (6–13[d])	Hydrocephaly ↑ (67[d])	Fuyuta et al. 1978 (MMC)
9 days, GDs 6–14; dose: 0.024	↔	Missing 5th sternebra ↑ (7[c]) Incomplete calcification ↑ (15[c])	Bladder defect ↑ (8[c])	Nolen et al. 1972 (MMC)
9 days, GDs 6–14; dose: 0.23	↔	Missing 5th sternebra ↑ (8[c])	Bladder defect ↑ (16[c]) Hydronephrosis ↑ (11[c])	Nolen et al. 1972 (MMC)

Table 2-71. Malformations and Variations in Rats Following Gestation-Only Exposure to Methylmercury Compounds

Duration; dose (mg Hg/kg/day)	Gross malformations	Skeletal malformation/ variation	Visceral malformation/ variation	Reference (compound)
9 days, GDs 6–14; dose: 4.6[a]	Total malformations ↑ (61[c])	Missing 5th sternebra ↑ (22[c])	Bladder defect ↑ (54[c]) Hydronephrosis ↑ (36[c]) Hydroureter ↑ (9[c])	Nolen et al. 1972 (MMC)
21 days, GDs 0–20; dose: 0.9	–	Delayed ossification ↑ (12[d])	–	Abd El-Aziz et al. 2012 (MMC)
21 days, GDs 0–20; dose: 1.8[e]	–	Delayed ossification ↑ (18[d])	–	Abd El-Aziz et al. 2012 (MMC)

[a]Dose associated with maternal toxicity (e.g., decreased body weight, clinical signs).
[b]Dose associated with increased fetal/neonatal death.
[c]Percent change compared to control, calculated from quantitative data.
[d]Percent difference in fetal incidence, compared to control.
[e]Maternal health not reported.

↑ = increased; ↓ = decreased; ↔ = no change; – = not assessed; GD = gestation day; MMC = methylmercuric chloride; NR = not reported

Table 2-72. Malformations and Variations in Mice Following Gestation-Only Exposure to Methylmercury Compounds

Duration; dose (mg Hg/kg/day)	Gross malformations[a]	Skeletal malformation/ variation[a]	Visceral malformation/ variation[a]	Reference (compound)
1 day, GD 10; dose: 8	↔	Incomplete fusion sternebrae ↑ (5)	↔	Fuyuta et al. 1979 (MMC)
1 day, GD 10; dose: 9.99	Cleft palate ↑ (61)	Delayed ossification ↑ (69)	↔	Belles et al. 2002 (MMC)
1 day, GD 10 or 12; dose: 10–12	↔	↔	–	Yasuda et al. 1985 (MMC)
1 day, GD 10; dose: 12	Total malformations ↑ (29) Cleft palate ↑ (28)	Incomplete fusion sternebrae ↑ (65)	↔	Fuyuta et al. 1979 (MMC)
1 day, GD 10; dose: 16	Total malformations ↑ (61) Cleft palate ↑ (59)	Incomplete fusion sternebrae ↑ (74)	Hydronephrosis ↑ (19)	Fuyuta et al. 1979 (MMC)

Table 2-72. Malformations and Variations in Mice Following Gestation-Only Exposure to Methylmercury Compounds

Duration; dose (mg Hg/kg/day)	Gross malformations[a]	Skeletal malformation/ variation[a]	Visceral malformation/ variation[a]	Reference (compound)
1 day, GD 13, 14, 15, 16, or 17; dose: 16[b]	↔	–	–	Inouye et al. 1985 (MMC)
1 day, GD 10 or 12; dose: 16	Cleft palate GD 10: ↑ (70) GD 12: (81)	↔	Dilatation of renal pelvis GD 10: ↑ (22) GD 12: (25)	Yasuda et al. 1985 (MMC)
1 day, GD 10 or 12; dose: 20	Cleft palate GD 10: ↑ (99.9) GD 12: (98)	↔	Dilatation of renal pelvis GD 10: ↑ (41) GD 12: (36)	Yasuda et al. 1985 (MMC)
1 day, GD 10; dose: 20[c]	Total malformations ↑ (97) Cleft palate ↑ (100)	Incomplete fusion sternebrae ↑ (88)	Hydronephrosis ↑ (24)	Fuyuta et al. 1979 (MMC)
8 days, GDs 6–13; dose: 2	Total malformations ↑ (11)	Delayed ossification ↑ (36) Absent sternebra ↑ (18)	↔	Fuyuta et al. 1978 (MMC)
8 days, GDs 6–13; dose: 4	Total malformations ↑ (76) Cleft palate ↑ (57)	Fused thoracic vertebra ↑ (63) Delayed ossification ↑ (72) Absent sternebra ↑ (80)	↔	Fuyuta et al. 1978 (MMC)
8 days, GDs 6–13; dose: 4.8[a]	Total malformations ↑ (98) Cleft palate ↑ (98)	Fused thoracic vertebra ↑ (61) Delayed ossification ↑ (80) Absent sternebra ↑ (91)	Hydronephrosis ↑ (24)	Fuyuta et al. 1978 (MMC)
8 days, GDs 6–13; dose: 6[b,c]	Total malformations[d] ↑ (100) Cleft palate[d] ↑ (100)	↔[d]	↔[d]	Fuyuta et al. 1978 (MMC)

[a]Numbers in ( ) are percent difference in fetal incidence, compared to control.
[b]Dose associated with increased fetal/neonatal death.
[c]Dose associated with maternal toxicity (e.g., decreased body weight, clinical signs).
[d]Based on a single live fetus.

↑ = increased; ↔ = no change; – = not assessed; GD = gestation day; MMC = methylmercuric chloride

In a 2-generation study in rats, delayed eye opening, suborbital edema, and corneal opacity were observed in offspring following exposure to 0.25 mg Hg/kg/day, but not ≤0.05 mg Hg/kg/day. Delays in developmental landmark acquisitions were not observed at gestation-only doses up to 1.9 mg Hg/kg/day (Fredriksson et al. 1996; Gandhi et al. 2013) or at doses up to 0.6 mg Hg/kg/day in a 1-generation study in rats (Newland and Reile 1999). Decreased pup vocalization was reported in rat offspring in a 1-generation study at doses ≥0.19 mg Hg/kg/day (Elsner 1991). No other available study examined this endpoint.

No changes in postnatal body weight were observed in monkey offspring following exposure to methylmercury in a 1-generation study (premating through gestation) at a dose of 0.04 mg Hg/kg/day (Burbacher et al. 1984).

Body weight effects in rats following developmental exposure to methylmercury are inconsistent; observed effects were often associated with maternal toxicity (Table 2-73). Rat fetal body weight and length on GD 20 were decreased in a dose-related manner following gestational exposure to methylmercury at doses ≥8 and 16 mg Hg/kg/day, respectively, on GD 7 (Lee and Han 1995). However, findings from repeat-dose gestational exposure studies in rats do not show consistent dose- or duration-dependent effects for fetal/birth weight (Table 2-73). Postnatal body weight on PND 21 was decreased following exposure to 7 mg Hg/kg/day on GD 15, but not on GD 8 (Carratu et al. 2006), and no change in postnatal weight was observed in another study following exposure to 6.4 mg Hg/kg/day on GD 15 (Cagiano et al. 1990). No exposure-related changes in postnatal weight were observed following repeated gestation-only exposures up to 1.9 mg Hg/kg/day (Abd El-Aziz et al. 2012; Fredriksson et al. 1996). When exposure continued during lactation, dose-related decreases were observed in postnatal weight during lactation at doses ≥0.8 mg Hg/kg/day (Sitarek and Gralewicz 2009; Tonk et al. 2010).

Table 2-73. Body Weight and Length Effects in Rats Following Gestation or Gestation Plus Lactation Exposure to Methylmercury Compounds

Duration; dose (mg Hg/kg/day)	Fetal/birth weight	Fetal length	Postnatal birth weight	Reference (compound)
1 day, GD 15; dose: 6.4	↔	–	↔	Cagiano et al. 1990 (MMC)
1 day, GD 8; dose: 7[a]	↔	–	↔	Carratu et al. 2006 (MM)
1 day, GD 15; dose: 7[a]	↔	–	PND 21: ↓ (18)[b]	Carratu et al. 2006 (MM)

Table 2-73. Body Weight and Length Effects in Rats Following Gestation or Gestation Plus Lactation Exposure to Methylmercury Compounds

Duration; dose (mg Hg/kg/day)	Fetal/birth weight	Fetal length	Postnatal birth weight	Reference (compound)
1 day, GD 7; dose: 8[a,c]	GD 20: ↓ (12)[b]	↔	–	Lee and Han 1995 (MMC)
1 day, GD 7; dose: 16[a,c]	GD 20: ↓ (24)[b]	GD 20: ↓ (22)[b]	–	Lee and Han 1995 (MMC)
1 day, GD 7; dose: 24[a,c]	GD 20: ↓ (49)[b]	GD 20: ↓ (37)[b]	–	Lee and Han 1995 (MMC)
4 days, GDs 6–9; dose: 1.9	↔	–	↔	Fredriksson et al. 1996 (MM)
8 days, GDs 7–14; dose: 2[c]	↔	–	–	Fuyuta et al. 1978 (MMC)
8 days, GDs 7–14; dose: 4[c]	M: ↓ (9)[b] F: ↓ (8)[b]	–	–	Fuyuta et al. 1978 (MMC)
8 days, GDs 7–14; dose: 6[a,c]	↔	–	–	Fuyuta et al. 1978 (MMC)
9 days, GDs 6–14; dose: 0.024–4.6[c]	↔	–	–	Nolen et al. 1972 (MMC)
17 days, GDs 5–21; dose: 0.5	PND 1: ↓ (12)[b]	–	↔	Gandhi et al. 2013 (MM)
17 days, GDs 5–21; dose: 0.9	PND 1: ↓ (14)[b]	–	↔	Gandhi et al. 2013 (MM)
21 days, GDs 0–20; dose: 0.9	↔	↔	–	Abd El-Aziz et al. 2012 (MMC)
21 days, GDs 0–20; dose: 1.8[d]	GD 20: ↓ (14)[b]	GD 20: ↓ (14)[b]	–	Abd El-Aziz et al. 2012 (MMC)
22 days, GD 7–PND 7; dose: 0.5	↔	–	↔	Giménez-Llort et al. 2001; Rossi et al. 1997 (MMH)
26 days, GD 6–PND 10; dose: 0.08–0.6	–	–	↔	Tonk et al. 2010 (MMC)
26 days, GD 6–PND 10; dose: 0.8	–	–	PND 10: M: ↓ (7)[e] F: 0	Tonk et al. 2010 (MMC)
26 days, GD 6–PND 10; dose: 1.2	–	–	PND 10: M: ↓ (9)[e] F: 0	Tonk et al. 2010 (MMC)
26 days, GD 6–PND 10; dose: 1.6[a,c]	–	–	PND 10: M: ↓ (10)[e] F: ↓ (15)[e]	Tonk et al. 2010 (MMC)
36 days, GD 7–PND 21; dose: 0.5	↔	–	↔	Sitarek and Gralewicz 2009 (MMC)
36 days, GD 7–PND 21; dose: 1.9[c]	↔	–	PND 21: ↓ (23)[e]	Sitarek and Gralewicz 2009 (MMC)

Table 2-73. Body Weight and Length Effects in Rats Following Gestation or Gestation Plus Lactation Exposure to Methylmercury Compounds

Duration; dose (mg Hg/kg/day)	Fetal/birth weight	Fetal length	Postnatal birth weight	Reference (compound)
38 days, GD 5–PND 21 dose: 0.2–0.4	↔	–	↔	Albores-Garcia et al. 2016 (MMC)
42 days, GD 1–PND 21; dose: 0.05–0.23	↔	–	↔	Cheng et al. 2015; Fujimura et al. 2012 (MM)

[a]Dose associated with increased fetal/neonatal death.
[b]Percent change compared to control, calculated from quantitative data.
[c]Dose associated with maternal toxicity (e.g., decreased body weight, clinical signs).
[d]Maternal health not reported.
[e]Percent change compared to control, estimated from graphically reported data.

↓ = decreased; ↔ = no change; – = not assessed; F = female; GD = gestation day; M = male; MM = methylmercury; MMC = methylmercuric chloride; MMH = methylmercury hydroxide; PND = postnatal day

Findings regarding alterations in birth and postnatal weight following methylmercury exposure in 1-generation rat studies are inconsistent. One study reported an 11% decrease in birth weight at a drinking water dose of 0.3 mg Hg/kg/day (Szász et al. 2002), but no changes in birth weight were observed in other studies at drinking water doses up to 0.74 mg Hg/kg/day or gavage doses up to 0.9 mg Hg/kg/day (Beyrouty et al. 2006: Elsner 1991; Newland and Reile 1999). No decreases in offspring postnatal body weight were observed at drinking water doses up to 0.74 mg Hg/kg/day (Elsner 1991; Newland and Reile 1999; Szász et al. 2002). One study reported a >20% increase in body weight at postnatal week 6 in offspring following F0 drinking water exposure to doses ≥0.0006 mg Hg/kg/day; this finding was no longer observed at postnatal week 12 (Wild et al. 1997). The adversity of this transient increase in offspring body weight is unclear; therefore, it is not included in the LSE tables or Table 2-73. In gavage and dietary studies, 6–12% decreases in postnatal body weight were observed at 0.9 and 0.37 mg Hg/kg/day, respectively (Beyrouty et al. 2006; Ilback et al. 1991). No changes in birth or postnatal weight were observed in a 2-generation study in rats at dietary doses up to 0.25 mg Hg/kg/day (Khera and Tabacova 1973).

Observed decreases in late gestation or birth weight in mice were generally dose- and duration-dependent following gestational exposure to methylmercury and occurred below maternally toxic doses (Table 2-74). Decreased weights were consistently observed following single exposures to ≥9.99 mg Hg/kg/day or repeat exposures ≥4 mg Hg/kg/day (Belles et al. 2002; Fuyuta et al. 1979; Hughes and Annau 1976), although one study did not report body weight effects on GD 18 following exposure until doses ≥16 mg Hg/kg/day were administered on GD 10 or 12 (Yasuda et al. 1985). Decreased postnatal

weight or decreased weight gain was reported during lactation following single gestational exposures to doses ≥5 mg Hg/kg/day (Hughes and Annau 1976; Inouye et al. 1985). No changes in postnatal weight were observed following repeated exposure to methylmercury during gestation at doses up to 1 mg Hg/kg/day (Khera and Tabacova 1973; Yoshida et al. 2011).

Table 2-74. Body Weight Effects in Mice Following Gestation-Only Exposure to Methylmercury Compounds

Duration; dose (mg Hg/kg/day)	Fetal/birth weight[a]	Postnatal body weight[a]	Reference (compound)
1 day, GD 8; dose: 1–2	↔	↔	Hughes and Annau 1976 (MMH)
1 day, GD 8; dose: 3[b,c]	↔	PND 21: ↓ (13)[c]	Hughes and Annau 1976 (MMH)
1 day, GD 8; dose: 5[b,c]	↔	PND 21: ↓ (17)	Hughes and Annau 1976 (MMH)
1 day, GD 10; dose: 8[c]	↔	–	Fuyuta et al. 1979 (MMC)
1 day, GD 10; dose: 9.99	GD 18: ↓ (17)	–	Belles et al. 2002 (MMC)
1 day, GD 10 or 12; dose: 10–12	↔	–	Yasuda et al. 1985 (MMC)
1 day, GD 8; dose: 10	PND 1: ↓ (6)	PND 21: ↓ (16)	Hughes and Annau 1976 (MMH)
1 day, GD 10; dose: 12	GD 18: ↓ (M) (9) ↓ (F) (11)	–	Fuyuta et al. 1979 (MMC)
1 day, GD 10; dose: 16	GD 18: ↓ (M) (9) ↓ (F) (11)	–	Fuyuta et al. 1979 (MMC)
1 day, GD 10 or 12; dose: 16	GD 18: ↓ (10–16)	–	Yasuda et al. 1985 (MMC)
1 day, GD 13, 14, 15, 16, or 17; dose: 16[b,c]	–	PND 14: ↓ (NR)	Inouye et al. 1985 (MMC)
1 day, GD 10; dose: 20[c,d]	GD 18: ↓ (M) (16) ↓ (F) (19)	–	Fuyuta et al. 1979 (MMC)
1 day, GD 10 or 12; dose: 20	GD 18: ↓ (21–27)	–	Yasuda et al. 1985 (MMC)
8 days, GDs 6–13; dose: 2	↔	–	Fuyuta et al. 1978 (MMC)
8 days, GDs 6–13; dose: 4	GD 18: ↓ (M) (18) ↓ (F) (20)	–	Fuyuta et al. 1978 (MMC)

Table 2-74. Body Weight Effects in Mice Following Gestation-Only Exposure to Methylmercury Compounds

Duration; dose (mg Hg/kg/day)	Fetal/birth weight[a]	Postnatal body weight[a]	Reference (compound)
8 days, GDs 6–13; dose: 4.8[c]	GD 18: ↓ (M) (21) ↔ (F)	–	Fuyuta et al. 1978 (MMC)
12 days, GDs 6–17; dose: 0.0001–1	↔	↔	Khera and Tabacova 1973 (MMC)
19 days, GDs 0–18; dose: 0.9	–	↔	Yoshida et al. 2011 (MM)

[a]Numbers in ( ) are percent change compared to control, calculated from quantitative data.
[b]Maternal health not reported.
[c]Dose associated with increased fetal/neonatal death.
[d]Dose associated with maternal toxicity (e.g., decreased body weight, clinical signs).

↓ = decreased; ↔ = no change; – = not assessed; GD = gestation day; F = female; M = male; MM = methylmercury; MMC = methylmercuric chloride; MMH = methylmercury hydroxide; NR = not reported; PND = postnatal day

A single study in guinea pigs reported 12, 23, and 30% decreases in GD 63 fetal body weight following methylmercury exposure at 11.5 mg Hg/kg/day once on GD 35, 42, or 49, respectively, compared to controls (Inouye and Kajiwara 1988). No effects on fetal body weight were observed in fetuses following similar exposures on GD 21 or 28. Exposed dams showed clinical signs of toxicity.

A few studies reported body weight effects in laboratory animals following postnatal-only exposure to methylmercury. In monkeys, an approximate 13% decrease in body weight was observed at PND 45 following exposure to 0.5 mg Hg/kg/day from PND 0 to 29 (Willes et al. 1978); no body weight effects were observed in monkeys exposed to 0.05 mg Hg/kg/day for the first 4 years of life (Rice and Gilbert 1982). Inconsistent findings were observed in rats, with a 7% decrease in body weight at PND 15 following exposure to 0.37 mg Hg/kg/day on PNDs 1–15 (Ilback et al. 1991) and by an unspecified amount at PND 33 following exposure to 4 mg Hg/kg/day on PNDs 1–30, but not doses up to 2 mg Hg/kg/day (Sakamoto et al. 2004). No changes in postnatal weight were observed in rats exposed to 0.6 mg Hg/kg/day on PNDs 14–23 (Coluccia et al. 2007). No effects on postnatal weight were observed in mice following acute- or intermediate-duration postnatal exposure to doses up to 3.7 or 4.7 mg Hg/kg/day, respectively (Bellum et al. 2007; Fischer et al. 2008; Franco et al. 2006; Huang et al. 2011).

Predominant Mercury Form Unknown (General Populations). Several studies have evaluated relationships between mercury exposure and neonatal anthropometric measures and postnatal growth. The main outcomes assessed in newborns were birth weight, height, and head circumference; for

postnatal growth, main outcomes were weight and height for age. Study designs include prospective and cross-sectional studies. Several different biomarkers were used to assess exposure, with BHg as the most common biomarker. Studies have also assessed congenital defects, although little information is available.

Anthropometric measures at birth. Studies evaluating effects of *in utero* exposure on anthropometric measures in newborns are summarized in Table 2-75. Evidence for effects of mercury exposure on birth size in general populations is inconclusive, with studies reporting inconsistent results. Several prospective and cross-sectional studies did not observe associations between mercury biomarkers and birth weight, birth length, head circumference, and/or SGA. Two large prospective studies evaluated birth size in cohorts consisting of >70,000 births (Okubo and Nakayama 2023; Takatani et al. 2022). The Takatani et al. (2022) study found an association between increasing maternal BHg (median BHg 3.63 µg/L) and head circumference, with a doubling of maternal BHg associated with a 0.02-cm decrease in head circumference. No associations were observed for SGA, birth weight, birth length, or chest circumference. The Okubo and Nakayama (2023) study found an association between maternal BHg >3.63 µg/L and risk of low birth weight. Another large prospective study (n=15,444) did not find an association between maternal BHg and birth weight or SGA (highest quartile BHg 5.18– 30.1 µg/L). Twelve other smaller prospective studies (n<1,000) did not find associations between maternal mercury exposure and birth size metrics or found mixed results for these outcomes (associations with length but not weight or head circumference, Table 2-75). Collectively, results from larger prospective studies and conflicting results from smaller prospective studies and cross-sectional studies do not provide conclusive evidence that birth size is adversely affected by mercury exposure in general populations.

Table 2-75. Overview of Epidemiological Studies Evaluating Associations between Mercury (Predominant Mercury Form Unknown) and Anthropometric Measures in Newborns in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Al-Saleh et al. 2014 Cross-sectional; 1,578 pregnant women (Saudi Arabia)	BHg (mean) Maternal: 3.005 µg/L Cord: 3.354 µg/L	Birth weight	↔ (BHg, maternal and cord)
		Birth length	↔ (BHg, maternal and cord)
		SGA	↔ (BHg, maternal and cord)
		Head circumference	↔ (BHg, maternal and cord)

Table 2-75. Overview of Epidemiological Studies Evaluating Associations between Mercury (Predominant Mercury Form Unknown) and Anthropometric Measures in Newborns in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Ashrap et al. 2020 Prospective cohort; 731 pregnant women (Puerto Rico)	Maternal BHg median: 1.3 µg/L	Gestational age	↔ (BHg)
		Z-score birth weight	↔ (BHg)
		SGA	↔ (BHg)
		LGA	↔ (BHg)

Bloom et al. 2015
 	
Prospective longitudinal; 253 couples with singleton deliveries (Michigan and Texas)
	BHg
	Maternal tertiles
	  T1 (33%): 0.66 µg/L
	  T2 (median): 0.94 µg/L
	  T3 (67%): 1.38 µg/L
	Paternal tertiles
	  T1 (33%): 0.76 µg/L
	  T2 (median): 1.11 µg/L
	  T3 (67%): 1.76 µg/L
		Birth weight	↔ (BHg, maternal T3; paternal T3)

		Birth length	↑ (BHg, maternal T3; paternal T3)
		Head circumference	↔ (BHg, maternal T3; paternal T3)
		Ponderal index	↔ (BHg, maternal T3; paternal T3)
		Sex	↔ (BHg, maternal T3; paternal, T3)
Chang et al. 2015 Cross-sectional; 252 infants (Korea)	Infant BHg mean: 0.94 µg/L Infant HHg: 0.22 µg/g	Z-score birth weight	↔ (BHg, HHg)
		Z-score weight for age	↔ (BHg, HHg)
		Z-score height for age	↔ (BHg, HHg)
		Weight percentiles difference between body weight and weight at time of study	↔ (BHg) ↓ (HHg)
Choi et al. 2022 Cross-sectional; 182 pregnant women (South Korea)	Maternal UHg median: 1.80 µg/g Cr	Birth weight	↔ (UHg)
		Birth length	↑ (UHg)
		Head circumference	↔ (UHg)
		Ponderal index	↓ (UHg)
Dack et al. 2023 Birth cohort; 544 mother-child pairs; child weight assessed at ages 4–61 months (United Kingdom)	Maternal BHg median: 1.88 µg/L	Birth weight	↔ (BHg)

Ding et al. 2013
 	
Prospective birth cohort; 258 mother-infant pairs (China)
	BHg Gmean
	  Cord: 1.46 µg/L
	  Maternal: 0.84 µg/L
		Birth weight	↔ (BHg, maternal and cord)

		Birth length	↔ (BHg, maternal and cord)
		Head circumference	↔ (maternal and cord BHg)

Table 2-75. Overview of Epidemiological Studies Evaluating Associations between Mercury (Predominant Mercury Form Unknown) and Anthropometric Measures in Newborns in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Dou et al. 2022 Prospective; pregnant women, 1,030 at GW 22–24, 1,082 at GWs 30–32, and 860 at GWs 34–36 (China)	Maternal UHg median: 0.36 µg/L	Estimated fetal weight	↔ (UHg, GW 22–24 and 30–32 ↓ (UHg, GW 34–36)
Gokoel et al. 2020 Cross-sectional; 1,143 pregnant women (Suriname)	Maternal HHg median: 0.826 µg/g Low HHg: < 1.1 µg/g High HHg: ≥1.1 µg/g	Birth weight	↔ (HHg, high HHg)
		Apgar score	↔ (HHg, high HHg)
Gao et al. 2018 Cross-sectional; 14,202 children ages 0–6 years (China)	Child BHg mean: 1.39 µg/L	Weight	↔ (BHg)
		Z-height	↔ (BHg)
		Height	↔ (BHg)
		Z-weight	↔ (BHg)
		BMI	↑ (BHg)
		Z-BMI	↑ (BHg)
Govarts et al. 2016 Cohort; 248 mother-child pairs (Belgium)	Maternal HMeHg Gmean: 0.255 µg/g	Birth weight	↔ (HMeHg)
Guo et al. 2013 Prospective cohort; 213 mother-infant pairs (China)	Gmean Cord BHg: 1.54 µg/L Maternal HHg: 0.497 µg/kg Fetal HHg: 0.234 µg/g	Birth weight	↔ (BHg, HHg)
		Birth length	↔ (BHg, HHg)
		Head circumference	↔ (BHg, HHg)
Gustin et al. 2020 Prospective cohort; 584 pregnant women (Sweden)	Maternal ErHg median: 1.5 µg/g stratified as <1.0 and >1.0 µg/g	Birth weight	↑ (ErHg, <1.0 µg/g) ↓ (ErHg, >1.0 µg/g)
		Birth length	↑ (ErHg, <1.0 µg/g) ↓ (ErHg, >1.0 µg/g)
		Head circumference	↔ (ErHg, <1.0 µg/g) ↔ (ErHg, >1.0 µg/g)
Howe et al. 2022 Prospective pooled analysis; 1,002 pregnant women (California, New Hampshire, Puerto Rico)	Maternal UHg mean: 1.22 µg/L	Birthweight for gestational age	↔ (UHg)

Table 2-75. Overview of Epidemiological Studies Evaluating Associations between Mercury (Predominant Mercury Form Unknown) and Anthropometric Measures in Newborns in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Kim et al. 2017 Pooled analysis (2 prospective birth cohorts); 1,147 mother-infant pairs (Taiwan and Korea)	BHg median Cord: 5.75 µg/L Maternal: 3.27 µg/L BHg 25th percentile Cord: 4.18 µg/L Maternal: 2.29 µg/L	Birth weight	↔ (BHg, median) ↓ (BHg, >25th percentile)
Kim et al. 2020c Prospective cohort; 390 pregnant women (Boston, Massachusetts)	Maternal UHg median (at ~GW 26): 0.27 µg/L	Estimated fetal weight	↔ (UHg)
		Fetal head circumference	↔ (UHg)
		Fetal abdominal circumference	↔ (UHg)
Kobayashi et al. 2019 Prospective birth cohort; 15,444 pregnant women for birth weight assessment, 12,632 pregnant women for SGA assessment	Maternal BHg quartiles Q1: 0.334–<2.59 Q2: 2.58–<3.66 Q3: 3.66–<5.18 Q4: 5.18–30.1	Birth weight	↔ (BHg)
		SGA	↔ (BHg)
Lee et al. 2010 Prospective cohort; 417 mother-infant pairs (South Korea)	BHg Gmean Maternal: 3.30 µg/L Cord: 5.53 µg/L	Birth weight	↔ (maternal and cord BHg)
Lee et al. 2020b Prospective birth cohort; 719 mother-infant pairs (466 with BHg at <20 GW and 542 with BHg at >20 weeks) (South Korea)	Maternal BHg mean <20 GW: 3.15 µg/L >20 GW: 2.96 µg/L	Birth weight	↔ (BHg, <20 GW and >20 GW)
Nyanza et al. 2020 Prospective longitudinal; 961 pregnant women (Tanzania)	Maternal BHg median: 1.2 µg/L	Low birth weight	↔ (BHg)
Okubo and Nakayama 2023 Birth cohort; 72,317 mother-child pairs (Japan)	Maternal BHg quartiles: Q1: 0.25–2.54 Q2: 2.55–3.63 Q3: 3.64–5.18 Q4: 5.19–43.7	Risk of low birth weight	↑ (BHg, Q3)

Table 2-75. Overview of Epidemiological Studies Evaluating Associations between Mercury (Predominant Mercury Form Unknown) and Anthropometric Measures in Newborns in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated	Result

Ou et al. 2015
 	
Prospective; 50 mother-infant pairs (China)
	Total BHg mean
	  Cord: 2.93 µg/L
	  Maternal: 2.36 µg/L
	BMeHg mean
	  Cord: 2.11 µg/L
	  Maternal: 1.11 µg/L
	BIHg mean
	  Cord: 0.84 µg/L
	  Maternal: 1.22 µg/L
	Maternal UIHg mean:
	0.76 µg/g Cr
		Birth weight	↓ (BHg, BIHg, maternal)
			↔ (BMeHg, UIHg, maternal)
			↔ (BHg, BMeHg, BIHg, cord)

		Birth length	↓ (BHg, UIHg, maternal) ↔ (BMeHg BIHg, maternal) ↔ (BHg, BMeHg, BIHg, cord)
Takatani et al. 2022 Prospective birth cohort; 91,739 pregnant women (Japan)	Maternal BHg median: 3.63 µg/L	Birth weight	↔ (BHg)
		Small for gestational age	↔ (BHg)
		Birth length	↔ (BHg)
		Head circumference	↓ (BHg)
		Chest circumference	↔ (BHg)
Taylor et al. 2016 Prospective; 4,044 mother-infant pairs (United Kingdom)	Maternal BHg: 2.07 µg/L	Birth weight	↔ (BHg)
		Crown-heel length	↔ (BHg)
		Head circumference	↔ (BHg)

Vigeh et al. 2018
 	
Prospective birth cohort; 334 mother-infant pairs (Japan)
	Maternal BHg mean
	  1st trimester: 6.06 µg/L
	  2nd trimester: 4.99 µg/L
	  3rd trimester: 4.97 µg/L
		Birth weight	↓ (BHg, $\log_{10}$, 1st trimester)
			↓ (BHg, $\log_{10}$, 2nd trimester)
			↔ (BHg, $\log_{10}$, 3rd trimester)

Wells et al. 2016
 	
Cross-sectional;
271 newborns (Baltimore, Maryland)
	Cord BHg Gmean
	  BIHg: 0.13 µg/L
	  BMeHg: 0.94 µg/L
		Birth weight	↔ (BMeHg)

		Birth length	↔ (BMeHg)
		Head circumference	↔ (BMeHg)
		Ponderal index	↓ (BMeHg)
Zhao et al. 2023 Prospective cohort; 292 mother-infant pairs (China)	Maternal SHg mean (in 2nd trimester): 0.69 µg/L	Birth weight	↑ (SHg)

Table 2-75. Overview of Epidemiological Studies Evaluating Associations between Mercury (Predominant Mercury Form Unknown) and Anthropometric Measures in Newborns in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Zhang et al. 2023b Prospective cohort 919 mother-infant pairs (China)	Maternal BHg median: 2.80 µg/L	Z-score weight	↔ (BHg, maternal)
		Z-score length	↔ (BHg, maternal)
		Z-score BMI	↔ (BHg, maternal)
		Z-score head circumference	↔ (BHg, maternal)

↑ = positive association; ↓ = inverse association; ↔ = no association; BHg = blood mercury; BIHg = blood inorganic mercury; BMeHg = blood methylmercury; BMI = body mass index; Cr = creatinine; ErHg = erythrocyte mercury; Gmean = geometric mean; GW = gestational week; HHg = hair mercury; HMeHg = hair methylmercury; calculated as [(birth weight; g)/(birth length; cm)3] × 100; LGA = large for gestational age; Q = quartile; SGA = small for gestational age; T = tertile; UHg = urine mercury; UIHg = urine inorganic mercury

Postnatal growth. Few studies have evaluated effects of mercury exposure on postnatal growth in general populations; studies are summarized in Table 2-76. Results of studies on postnatal growth are inconsistent. The largest prospective study (n=2,227) prospective study assessed associations between maternal BHg and BMI in children from 1 month through 8 years of age (Papadopoulou et al. 2021). No associations were observed between maternal BHg in the top 10th percentile and BMI in girls ages 1 month through 3 years. However, inverse associations were observed between maternal BHg in the top 10th percentile and BMI in girls at ages 4, 5, 6, 7, and 8 years of age. Another large prospective study (n=921) found an association between increasing maternal or cord BHg and growth measured at age 24 months, although this effect was not observed at 12 months (Kim et al. 2011). A much smaller prospective study (n=50) did not observe an association between maternal or cord BHg and weight for age (Ou et al. 2015); however, this study did find that increasing maternal or cord BHg was associated decreased height for age. A prospective study of mother-child pairs found an association between maternal erythrocyte mercury and overweight or obesity in children aged 2–15 years (Wang et al. 2019c). Cross-sectional studies did not find associations between BHg and/or HHg and measures of postnatal growth (weight, height) in infants or children ages 6 months to 6 years (Chang et al. 2015; Gao et al. 2018). Chang et al. (2015) observed an inverse association between child HHg and postnatal growth measured as the difference between body weight z-score at birth and at age of postnatal observation (6–20 months). However, the weight z-score difference was also independently inversely associated with duration of breastfeeding, and was no longer associated with child HHg when adjusted for duration of breastfeeding. Gao et al. (2018) observed a positive association between child BHg and BMI; however, other studies did not assess this endpoint. Results of these studies do not provide clear evidence that

mercury exposure in general populations is associated with decreased postnatal growth. Collectively, results from larger prospective studies and conflicting results from smaller prospective studies and cross-sectional studies do not provide conclusive evidence that postnatal growth is adversely affected by mercury exposure in general populations.

Table 2-76. Overview of Epidemiological Studies Evaluating Associations between Mercury (Predominant Mercury Form Unknown) and Postnatal Growth in General Populations

Reference, study type, and population	Biomarker	Weight for age	Weight percent difference[a]	Height for age	BMI
Chang et al. 2015 Cross-sectional; 252 infants (age: 6–24 months) (Korea)	Infant Gmean BHg: 0.94 µg/L HHg: 0.22 µg/g	↔ (BHg) ↔ (HHg)	↔ (BHg ↓ (HHg)	↔ (BHg ↔ (HHg)	–
Gao et al. 2018 Cross-sectional; 14,202 children (age: 0–6 years) (China)	Child BHg mean: 1.39 µg/L	↔ (BHg)	–	↔ (BHg)	↑ (BHg)
Kim et al. 2011 Prospective; 921 mother-infant pairs (South Korea)	Gmean Maternal BHg: 3.1 µg/L Cord BHg Gmean: 5.2 µg/L	12 months: ↔ (BHg, M, C) 24 months: ↓ (BHg, M, C)	–	–	–
Ou et al. 2015 Prospective; 50 mother-infant pairs (age: 12 months) (China)	Maternal mean BHg: 2.36 µg/L BIHg: 1.25 µg/L BMeHg: 1.11 µg/L UIHg: 0.76 µg/g Cr Cord mean BHg: 2.93 µg/L BIHg: 0.82 µg/L BMeHg: 2.11 µg/L	↔ (BHg, M) ↔ (BIHg, M) ↔ (BMeHg, M) ↔ (UIHg, M) ↔ (BHg, C) ↔ BIHg, C) ↔ (BMeHg, C)	–	↓ (BHg, M) ↓ (BIHg, M) ↔ (BMeHg, M) ↔ (UIHg, M) ↔ (BHg, C) ↓ (BIHg, C) ↔ (BMeHg, C)	–

Table 2-76. Overview of Epidemiological Studies Evaluating Associations between Mercury (Predominant Mercury Form Unknown) and Postnatal Growth in General Populations

Reference, study type, and population	Biomarker	Weight for age	Weight percent difference[a]	Height for age	BMI

Papadopoulou et al. 2021
 	
Prospective study; 2,277 mother-child pairs (n=227 in the 90th percentile maternal BHg), assessed from 1 month to 8 years of age (Norway)
	Maternal BHg
	  Median: 1.03 µg/L
	  90th percentile: 2.23 µg/L
		–	–	–	BMI trajectory
					
					↓ (BHg, 90th percentile, females)
					
					↔ (BHg, 90th percentile, males)
					
					↔ (BHg, 90th percentile, males and females combined)

Signes-Pastor et al. 2021 Cross-sectional; 1,634 children, ages 6–11 years of age (NHANES)	Child BHg median: 0.3 µg/L	–	–	–	↔ (BHg)
Wang et al. 2019c Prospective, longitudinal birth cohort; 1,442 mother-child pairs; children assessed at 2–15 years of age	Maternal ErHg quartiles (measured at parturition) Q1: 0.39–1.04 µg/L Q2: 1.04–2.10 µg/L Q3: 2.12–3.68 µg/L Q4: 3.70–27.8 µg/L	Overweight or obesity ↑ (ErHg, maternal, Q4)	–	–	–

[a]Weight percentiles difference between birth weight and postnatal birth weight at time of study.

↑ = positive association; ↓ = inverse association; ↔ = no association; – = not assessed; BHg = blood mercury; BIHg = blood inorganic mercury; BMeHg = blood methylmercury; C = umbilical cord; Cr = creatinine; ErHg = erythrocyte mercury; Gmean = geometric mean; HHg = hair mercury; M = maternal; NHANES = National Health and Nutrition Examination Survey; Q = quartile; UIHg = urine inorganic mercury

Congenital defects. The effects of gestational exposure on congenital defects in general populations have not been well-studied. Available studies are summarized in Table 2-77. A very large prospective cohort study (n=89,273) did not find associations between maternal BHg and abdominal congenital malformations (Miyashita et al. 2021). Other smaller case-control studies did not find associations between gestational exposure and neural tube defect (Tian et al. 2021; n=273 cases) or cleft palate

(Takeuchi et al. 2022c; n=192 cases). A small case-control study found an association between increasing maternal SHg and congenital heart defects (specific heart defects were not reported) (Wang et al. 2022c). The results from these studies are mixed and have not been sufficiently corroborated to conclude whether or not gestational exposure to mercury is associated with congenital defects.

Table 2-77. Overview of Epidemiological Studies Evaluating Associations between Mercury (Predominant Mercury Form Unknown) and Congenital Defects in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Miyashita et al. 2021 Prospective cohort; 89,273 mother-infant pairs (139 with abdominal congenital malformations)	Maternal BHg median: 3.64 µg/L	Abdominal congenital malformations	↔ (BHg, maternal)

Tian et al. 2021
 	
Case-control; 273 women with neural tube defect-affected pregnancies and 477 controls (China)
	Maternal SHg median
	  Cases: 0.25 µg/L
	  Controls: 0.23 µg/L
		Neural tube defect	↔ (SHg, maternal)

Takeuchi et al. 2022c
 	
Nested case-control; maternal-infant pairs; 192 offspring with cleft palate and 1,920 controls (Japan)
	Maternal BHg median
	  Cases: 3.64 µg/L
	  Controls: 3.54 µg/L
		Cleft palate	↔ (BHg, maternal)

Wang et al. 2022c
 	
Case-control; maternal-infant pairs; 303 with congenital heart defect and 303 controls (China)
	Maternal SHg median
	  CHD Cases: 4.92 µg/L
	  Controls: 3.03 µg/L
		Congenital heart defect	↑ (SHg, maternal)

↑ = positive association; ↔ = no association; BHg = blood mercury; SHg = serum mercury

Mechanisms of Action. Specific mechanisms for developmental effects of mercury exposure have not been established. Kim et al. (2013b) have shown that BHg is inversely associated with serum folate levels. Folate has an important role in preventing neural tube defects and intrauterine growth restriction; therefore, decreased folate levels could contribute to developmental effects, including neurotoxicity and decreased anthropometric measures. Prenatal exposure to mercury has been shown to alter DNA methylation in pregnant women and infants (Cardenas et al. 2017b; Weyde et al. 2021). General

mechanisms of toxicity of mercury (reviewed in Section 2.21) are also likely involved in adverse developmental effects. Mercury is distributed to the fetus and has been measured in fetal tissues (Section 3.1.2, Distribution), providing a toxicokinetic mechanism for direct exposure of the placenta and fetus.

2.19 CANCER

Cancer Classifications of Mercury and Mercury Compounds. The U.S. Department of Health and Human Services (NTP 2016) has not categorized the carcinogenicity of mercury and mercury compounds. IARC (1993) has developed cancer classifications for metallic and inorganic mercury compounds and methylmercury compounds as follows.

- Metallic and inorganic mercury compounds: "not classifiable as to their carcinogenicity to humans (Group 3)," based on inadequate evidence in humans, inadequate evidence for elemental mercury in experimental animals, and limited evidence for mercuric chloride in experimental animals.

- Methylmercury compounds: "possibly carcinogenic to humans (Group 2B)," based on inadequate evidence in humans and sufficient evidence in experimental animals.

IRIS (1995a, 1995b, 2001) classified the carcinogenicity of mercury and mercury compounds as follows:

- Elemental mercury: not classifiable as to human carcinogenicity (Group D), "based on inadequate human and animal data."

- Mercuric chloride: possible human carcinogen (Group C), "based on the absence of data in humans and limited evidence in rats and mice."

- Methylmercury: possible human carcinogen (Group C), "based on inadequate data in humans and limited evidence of carcinogenicity in animals."

Overview. A limited number of epidemiological studies have evaluated the potential carcinogenicity of mercury exposure. Consistent with the IARC (1993) and IRIS (1995a, 1995b, 2001) classifications noted above, available epidemiological data do not provide adequate evidence that mercury exposure is associated with cancer in humans.

Carcinogenicity has been assessed in rats and mice following chronic-duration oral exposure to mercuric chloride, methylmercury, and phenylmercuric acetate. Mercuric chloride induced forestomach and thyroid tumors in male rats and methylmercury induced renal tumors in male mice. There is limited

evidence of renal tumors in male rats exposed to phenylmercuric acetate. There are no animal inhalation cancer data available.

The following summarizes results of epidemiological and animal studies on cancer outcomes.

- ***Elemental mercury***
  - *Epidemiology studies*
    - No epidemiology studies on cancer outcomes associated with exposure to elemental mercury reporting data on mercury biomarkers were identified.
  - *Animal studies*
    - No studies evaluating cancer following exposure to elemental mercury were identified.
- ***Inorganic mercury salts***
  - *Epidemiology studies*
    - No epidemiological studies evaluating associations between exposure to inorganic mercury salts and cancer outcomes were identified.
  - *Animal studies*
    - Mercuric chloride showed some evidence of carcinogenicity in male rats (forestomach and thyroid tumors), equivocal evidence of carcinogenicity in female rats and male mice (low incidence of forestomach and renal tumors, respectively), and no evidence of carcinogenicity in female mice in an NTP (1993) bioassay.
- ***Organic mercury***
  - *Epidemiology studies*
    - Two studies on the Minamata population found elevated SMRs for liver cancer. However, results were not adjusted for alcohol consumption or other confounding factors, and mercury biomarkers were not reported.
    - One cross-sectional study reported a positive association between blood methylmercury levels in the general population and increased prevalence of non-melanoma skin cancer after adjustment for several confounders.
  - *Animal studies*
    - Methylmercury is associated with induction of renal tumors in male mice.
    - Methylmercury did not induce tumors in female mice or male or female rats.
    - There are limited data that phenylmercuric mercury induces renal tumors in male rats.
- ***Predominant mercury form unknown (general populations)***
  - One prospective cohort study reported a positive association between NHg levels and incidence of various skin cancers.

- ▪ Findings from four case-control studies are mixed regarding potential associations between urinary mercury levels and risk of thyroid cancer.
- ▪ Additional epidemiological studies did not find an association between mercury biomarkers and death due to cancer, prevalence of breast cancer, or risk of glioma.

Confounding Factors. Numerous factors can influence results of epidemiological studies evaluating associations between mercury exposure and cancer if they are not homogenously distributed in the study population. These factors include age, smoking status, family history of cancer, and co-exposure to other carcinogens that are also risk factors for cancer but may not be homogenous between exposure groups in the study population. Some of the studies reviewed in this section did not adjust for some or all of these factors.

Elemental Mercury—Epidemiological Studies. Studies that evaluated associations between occupational exposure to elemental mercury and cancer did not report quantitative mercury biomarker data.

Elemental Mercury—Animal Studies. No studies were located regarding cancer in animals after exposure to elemental mercury.

Inorganic Mercury Salts—Animal Studies. The carcinogenicity of mercuric chloride was investigated in a 2-year gavage study in rats and mice (NTP 1993). In rats, statistically significant increases in the incidence of forestomach squamous cell papillomas in males (12/50 versus 0/50 in control) and thyroid follicular cell carcinomas in male rats (6/50 versus 0.50 control) were observed at 4 mg Hg/kg/day. Forestomach squamous cell papillomas were also observed in 3/50 males at 1.8 mg Hg/kg/day and in 2/50 females at 4 mg Hg/kg/day. In mice, potentially exposure-related tumors were limited to low incidence renal tumors in males at 7.4 mg Hg/kg/day, including renal tubule adenoma (2/50) and adenocarcinoma (1/50). NTP (1993) concluded that there was some evidence for carcinogenicity in male rats (increased forestomach tumors, marginally increased thyroid follicular cell tumors); equivocal evidence of carcinogenic activity in female rats (low incidence of forestomach tumors) and male mice (low incidence of renal tumors); and no evidence of carcinogenic activity in female mice.

Organic Mercury—Epidemiological Studies. No studies evaluating cancer in populations with high fish diets and reporting exposures based on mercury biomarkers were identified. Two studies evaluating cancer outcomes in the Minamata population found elevated SMRs for liver cancer (Futatsuka et al. 2005; Tamashiro et al. 1986). However, these studies are of limited usefulness as results were not adjusted for alcohol consumption or other confounding factors, and mercury biomarkers were not reported.

A large cross-sectional study in NHANES adults found a positive association between blood methylmercury levels and increased prevalence of non-melanoma skin cancer after adjusting for age, sex, ethnicity, BMI, smoking history, income status, and survey year (Rhee et al. 2020). Individuals included in the study population were exposed to both inorganic and organic forms of mercury; however, based on blood biomarker levels, the predominant exposure was organic mercury (BHg means: 0.3 μg/L inorganic mercury and 1.3 μg/L methylmercury).

Organic Mercury—Animal Studies. Renal cell adenomas were increased in male rats exposed to phenylmercuric acetate at drinking water doses of 3.7 mg Hg/kg/day for 2 years (Solecki et al. 1991). The report is limited because the assay was not intended as a carcinogenicity assay and utilized small animal groups; however, renal tumors were observed in 10/20 treated males compared to 0/18 controls. In a 2-year methylmercury study, no increase in tumor incidence was observed in rats exposed to dietary doses as high as 0.18 mg Hg/kg/day (Verschuuren et al. 1976).

Chronic-duration dietary exposure to methylmercury has resulted in significant increases in renal epithelial cell tumors in male mice in three cancer bioassays (Hirano et al. 1986; Mitsumori et al. 1981, 1990). In B6C3F1 mice, significant increases in renal epithelial cell adenomas and carcinomas were observed in males exposed to 0.686 mg Hg/kg/day for 2 years (Mitsumori et al. 1990). In ICR mice, a significant increase in the incidence of renal epithelial cell adenocarcinomas was observed in males exposed to 0.724 mg Hg/kg/day for 2 years (Hirano et al. 1986) and an increase in kidney adenomas and adenocarcinomas were observed in males exposed to 2.1 mg/kg/day for 78 weeks (Mitsumori et al. 1981). No exposure-related tumors were observed in similarly exposed female mice (Hirano et al. 1986; Mitsumori et al. 1981, 1990).

Predominant Mercury Form Unknown (General Populations). Studies of general populations have examined associations between mercury biomarkers and general mortality associated with cancer as well as specific forms of cancer (Table 2-78). A large population-based cohort in the United States did not observe an association between cancer mortality and BHg (Duan et al. 2020). Similarly, an excess of

cancer deaths was not associated with SHg in a prospective study in Swedish women with amalgam

fillings (Ahlqwist et al. 1999). In a prospective cohort, positive associations between NHg and different

types of skin cancer were observed (Matthews et al. 2019). Positive associations were observed between

NHg and basal cell carcinoma incidence in men and women, squamous cell carcinoma in women only,

and melanoma in men only. A cross-sectional study in NHANES adult women did not observe an

association between UHg levels and breast cancer prevalence (Bell et al. 2023).

Table 2-78. Results of Epidemiological Studies Evaluating Exposure to Mercury (Predominant Mercury Form Unknown) and Cancer in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Ahlqwist et al. 1999 Prospective cohort; 1,462 women with amalgam fillings, enrolled in 1968–1969, and followed through 1980–1981(n=135 at follow-up) (Sweden)	SHg mean: 17 µg/L	Cancer deaths	↔ (SHg)
Bell et al. 2023 Cross-sectional with nested case-control; 3,352 women, including 106 cases of breast cancer and 3,246 without (United States; NHANES 2007–2016)	UHg quartiles (µg/g Cr): Q1: <0.20 Q2: 0.20–<0.40 Q3: 0.40–<0.79 Q4: ≥0.79 Cases (Gmean): 0.53 Controls (Gmean): 0.41	Breast cancer prevalence	↔ (UHg; case versus control, Q4 versus Q1)
Creed et al. 2019 Case-control; 300 cases of glioma and 300 matched controls (Southeastern United States)	NHg quintiles (µg/g) Qi1: <0.030 Qi2: 0.031–0.055 Qi3: 0.056–0.084 Qi4: 0.084–0.161 Qi5: >0.162 Cases (median): 0.066 Controls (median): 0.069	Glioma risk	↔ (NHg; case versus control, Qi5 versus Qi1)
Duan et al. 2020 Population-based cohort; 12,129 men and 13,927 women (United States[a])	BHg median: 0.90 µg/L	Cancer mortality	↔ (BHg)

Table 2-78. Results of Epidemiological Studies Evaluating Exposure to Mercury (Predominant Mercury Form Unknown) and Cancer in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated	Result

Liu et al. 2021b
 	
Case-control; 197 patients with papillary thyroid microcarcinoma, papillary thyroid carcinoma, and nodular goiter and 197 matched controls (China)
	UHg median
	  Cases: 0.27 µg/L
	  Controls: 0.38 µg/L
		Thyroid tumor risk	↔ (UHg)

Matthews et al. 2019
 	
Prospective cohort; 3,730 males (HPFS cohort) and 6,708 women (NHS cohort) (United States)
	NHg mean
	  Men: 0.54 µg/g
	  Women: 0.31 µg/g
		Basal cell carcinoma incidence	M: ↑ (NHg)
			F: ↑ (NHg)

		Squamous cell carcinoma incidence	M: ↔ (NHg) F: ↑ (NHg)
		Melanoma incidence	M: ↑ (NHg) F: ↔ (NHg)

Rezaei et al. 2019
 	
Case-control; 11 cases (3 men, 8 women) of thyroid cancer and 33 healthy controls (22 men, 11 women) (Iran)
	SHg mean
	  Case: 37.7 µg/g
	  Control: 18.9 µg/g
		Thyroid cancer risk	↔ (SHg)

Zhang et al. 2019
 	
Case-control; 262 cases of papillary thyroid cancer and 262 matched controls (China)
	UHg median
	  Cases: 21.38 µg/g Cr
	  Controls: 14.89 µg/g Cr
	
	UHg, by quartile (µg/g Cr)
	  Q1: ≤2.67
	  Q2: 2.67–14.89
	  Q3: 14.89–34.81
	  Q4>34.81
		Thyroid cancer risk	↑ (UHg, Q2, Q3, or Q4 versus Q1; trend; case versus control)

Table 2-78. Results of Epidemiological Studies Evaluating Exposure to Mercury (Predominant Mercury Form Unknown) and Cancer in General Populations

Reference, study type, and population	Biomarker	Outcome evaluated	Result
Zhang et al. 2021d Case-control; 308 cases of thyroid cancer and 308 matched controls (China)	UHg median Cases: 29.75 µg/g Cr Controls: 15.73 µg/g Cr UHg, exposure groups (µg/g Cr) low: <2.44 moderate: 2.44–34.97 high: >34.97	Thyroid cancer risk	↑ (UHg, high versus low; trend; case versus control)

[a]Exposure information obtained from historical NHANES data.

↑ = positive association; ↔ = no association; BHg = blood mercury; Cr = creatinine; Gmean = geometric mean; HPFS = Health Professionals Follow-up Study; NHANES = United States National Health and Nutrition Examination Survey; NHg = toenail mercury; NHS = Nurses' Health Study; Q = quartile; Qi = quintile; SHg = serum mercury; UHg = urine mercury

Four case-control studies present mixed results regarding potential associations between mercury biomarkers and thyroid tumors. Two studies from China observed a positive association between the risk of thyroid cancer and UHg (Zhang et al. 2019, 2021d); however, one observed the association at UHg levels ≥2.67 µg/g Cr (Zhang et al. 2019) while the other only observed an association at levels >34.97 µg/g Cr (Zhang et al. 2021d). A third case-control study from China did not observe an association between the risk of thyroid tumors and UHg levels (Liu et al. 2021b). A small case-control study from Iran did not observe an association between the risk of thyroid cancer and SHg levels (Rezaei et al. 2019).

A case-control study of glioma did not observe an association between NHg levels and risk of glioma in the Southeastern United States (Creed et al. 2019).

Mechanisms of Action. As reviewed in Section 2.20 (Genotoxicity), elemental mercury has been shown to produce oxidative damage to DNA. There is limited evidence that inorganic and organic mercury are mutagenic. These findings provide a plausible mechanism for carcinogenesis. In addition, a recent review proposed that mercury may act as an epigenetic tumor promoter (Zefferino et al. 2017).

Mechanisms of Action. As reviewed in Section 2.20 (Genotoxicity), elemental mercury has been shown to produce oxidative damage to DNA. There is limited evidence that inorganic and organic mercury are

mutagenic. These findings provide a plausible mechanism for carcinogenesis. In addition, a recent review proposed that mercury may act as an epigenetic tumor promoter (Zefferino et al. 2017).

2.20 GENOTOXICITY

Overview. Available data indicate that elemental mercury may cause oxidative DNA damage; findings regarding chromosomal effects are inconclusive. There is limited evidence that inorganic and organic mercury are mutagenic. Inorganic and organic mercury are consistently clastogenic and DNA damaging in mammalian cells.

The following summarizes results of *in vitro* and *in vivo* studies on genotoxic effects.

- *Elemental mercury (in vivo studies only)*
    - Inconclusive evidence for chromosome aberrations in exposed workers.
    - Limited evidence of oxidative DNA damage in the general population.
- *Inorganic mercury salts*
    - *In vitro* studies
        - Limited evidence of mutagenicity in mammalian cells.
        - Consistent evidence of clastogenicity in mammalian cells.
        - Consistent evidence of DNA binding and damage in mammalian cells.
    - *In vivo* studies
        - Induced dominant lethal mutations in rats with oral exposure.
        - Inconclusive evidence for chromosome aberrations in exposed workers.
        - Oral, but not intraperitoneal, exposure is associated with chromosome aberrations and micronuclei in rodents.
        - Consistent evidence of DNA binding and damage in rodents following oral exposure.
- *Organic mercury*
    - *In vitro* studies
        - Limited evidence of mutagenicity in mammalian cells.
        - Consistent evidence of clastogenicity in human, hamster, and rat cells; no evidence in mouse cells.
        - Consistent evidence of DNA damage in bacteria and mammalian cells.
    - *In vivo* studies
        - Induced dominant lethal mutations in one mouse strain with oral exposure.

- ▪ Inconclusive evidence for chromosome aberrations from occupational and general population studies in humans and *in vivo* studies in animals.
- ▪ Consistent evidence of DNA damage in mammals and chicken embryos.

Elemental Mercury. There is inconclusive evidence that occupational inhalation exposure to metallic mercury causes structural and numerical chromosome aberrations in human lymphocytes. However, most human studies have significant limitations, precluding clear conclusions. There is limited evidence that exposure to elemental mercury causes oxidative DNA damage. Available genotoxicity studies are reviewed in Table 2-79.

Table 2-79. Genotoxicity of Elemental Mercury in Epidemiological Studies

Species (exposure route)	Mercury compound	Endpoint	Results	Reference
Human (occupational exposure)	Metallic mercury	Aneuploidy in peripheral lymphocytes	–	Popescu et al. 1979
Human (occupational exposure)	Metallic mercury	Aneuploidy in peripheral lymphocytes	(+)	Verschaeve et al. 1976
Human (occupational exposure)	Metallic mercury	Aneuploidy in peripheral lymphocytes	–	Verschaeve et al. 1979
Human (occupational exposure)	Metallic mercury	Chromosome aberrations in peripheral lymphocytes	(+)	Popescu et al. 1979
Human (occupational exposure)	Metallic mercury	Chromosome aberrations in peripheral lymphocytes	(+)	Verschaeve et al. 1976
Human (occupational exposure)	Metallic mercury	Chromosome aberrations in peripheral lymphocytes	–	Verschaeve et al. 1979
Human (occupational exposure)	Amalgams	Chromosome aberrations in peripheral lymphocytes	(+)	Verschaeve et al. 1976
Human (occupational exposure)	Mercury amalgamated with zinc	Chromosome aberrations in peripheral lymphocytes	–	Mabille et al. 1984
Human (occupational exposure)	Mercury	Micronuclei induction in peripheral lymphocytes	+[a]	Barregard et al. 1991
Human (general population exposure)	Unspecified mercury	Oxidative DNA damage (urine 8-OHdG)	+	Al-Saleh et al. 2017
Human (oral)	Amalgams	Oxidative DNA damage (urine 8-OHdG)	+	Al-Saleh et al. 2012

[a]Positive response only in stimulated T-lymphocytes.

+ = positive result; – = negative result; (+) = reported as positive but study was either seriously compromised or findings did not provide valid evidence of a positive response; 8-OHdG = 8-hydroxydeoxyguanosine; DNA = deoxyribonucleic acid

One study reported increased aneuploidy in peripheral lymphocytes of 28 subjects exposed to various types of mercury (including 14 exposed to metallic mercury vapor and 3 exposed via amalgams), compared to 7 unexposed controls (Verschaeve et al. 1976). However, the study was not well controlled (i.e., not matched for sex, smoking habits, or sample size). Additionally, these data should be interpreted with caution since age has an influence on aneuploidy, and in this study, there was a general trend toward a higher incidence of aneuploidy in the older exposed workers (ages 36–63 years). It is noteworthy that in a subsequent study performed by these investigators (Verschaeve et al. 1979), no adverse effect on the number of chromosomes was demonstrated in 28 workers exposed to moderate levels of metallic mercury (mean urine levels of 35 µg/L; range 7–175 µg/L), compared to 8 unexposed controls from the plant (e.g., clerks; urine level range <5–11 µg/L) and 12 general population controls (UHg levels not reported). The study authors concluded that the results from their 1976 study suggesting a potential association between increased chromosomal aberrations and occupational exposure to mercury may have been affected by factors other than exposure to mercury compounds. No evidence of aneuploidy was observed in four workers exposed to high concentrations of metallic mercury (range 0.15–0.44 mg/m^3) (Popescu et al. 1979).

The study described above by Verschaeve et al. (1976) also reported an increase in structural chromosomal aberrations in mercury-exposed workers; as discussed above, data should be interpreted with caution. As with aneuploidy, no adverse effect on the structure of chromosomes was demonstrated in the subsequent study by Verschaeve et al. (1979) in 28 workers exposed to moderate levels of metallic mercury. Another study reported significant increases in the frequency of acentric fragments (chromosome breaks) in four workers exposed to high concentrations of metallic mercury (range 0.15–0.44 mg/m^3); the urinary excretion level of mercury for both exposed groups was 0.890 µg/L (Popescu et al. 1979). However, the findings of this study are suspect because the control group was not matched for sex, smoking habits, or sample size. Additionally, one of the four exposed individuals had a history of benzene poisoning, which was reflected in the unusually high frequency of abnormal chromosome morphology seen in this individual. Chromosomal aberrations were not observed in peripheral lymphocytes of 22 workers exposed to mercury amalgamated with zinc; the mean urine and blood mercury levels in the exposed group were 117 µg/g creatinine and 0.031 µg/mL, respectively (Mabille et al. 1984). Another study evaluated micronuclei induction in peripheral lymphocytes from 26 workers exposed to mercury vapors (25–50 µg/m^3) for a mean exposure time of 10 years, compared to 26 unexposed controls (Barregard et al. 1991). Groups were matched for age (within 7 years) and smoking habits; plasma, erythrocyte, and UHg levels were determined. Parallel lymphocyte cultures from each donor group were incubated in the presence of pokeweed mitogen, which stimulates both B- and

T-lymphocytes, and phytohemagglutinin, which primarily activates T-cells. The analysis showed no significant increase in the frequency or the size of micronuclei in the exposed versus the control group. Nor was there a correlation between micronuclei induction and plasma, erythrocyte, or urine levels of mercury. Within the exposed group, however, there was a significant correlation between micronuclei induction in phytohemagglutinin in stimulated lymphocytes and cumulative exposure (whole-blood mercury level over employment time); the response was independent of age or smoking habits. These results, suggesting a genotoxic effect on T-lymphocytes, are unusual since there is evidence that B-lymphocytes may be more sensitive indicators of chemically induced clastogenesis than T-lymphocytes (Högstedt et al. 1988). Barregard et al. (1991) stated that the evidence of a genotoxic response confined to T-lymphocytes could have been a random finding but hypothesized that long-term exposure to mercury may cause an accumulation of cytogenetic effects.

Oxidative DNA damage was significantly associated with the UHg levels in children aged 5–15.5 years with dental amalgam fillings (Al-Saleh et al. 2017). Oxidative DNA damage was also significantly associated with increased UHg levels in mothers and young children; however, environmental mercury exposure source(s) and form(s) are unknown in this study population (Al-Saleh et al. 2017).

Inorganic Mercury Salts. There is limited evidence that inorganic mercury salts are mutagenic in mammalian cells. *In vitro* data in mammalian cells and *in vivo* oral data in rodents show clear, consistent evidence of clastogenicity and DNA damage associated with inorganic mercury exposure. Available *in vitro* and *in vivo* genotoxicity studies for inorganic mercury salts are reviewed in Tables 2-80 and 2-81, respectively.

Table 2-80. Genotoxicity of Inorganic Mercury Salts *In Vitro* Studies

Species (test system)	Mercury compound	Endpoint	Results		Reference
			With activation	Without activation	
Prokaryotic organisms					
Salmonella typhimurium (TA1535, TA1537, TA98, TA102)	Mercuric chloride	Gene mutation	–	–	Wong 1988
Bacillus subtilis (H17, M45)	Mercuric chloride	DNA damage	NT	+	Kanematsu et al. 1980
Mammalian cells					
Mouse lymphoma cells L5178Y	Mercuric chloride	Gene mutation	+/–	–	Oberly et al. 1982
NIH 3T3 cells	Mercuric chloride	Gene mutation	NT	+	Schurz et al. 2000

Table 2-80. Genotoxicity of Inorganic Mercury Salts *In Vitro* Studies

Species (test system)	Mercury compound	Endpoint	Results With activation	Without activation	Reference
Human (peripheral lymphocytes)	Mercuric chloride	Aneuploidy	NT	+	Patel and Rao 2018
Human (peripheral lymphocytes)	Mercuric chloride	Chromosome aberrations	NT	–	Rao et al. 2001
Human (peripheral lymphocytes)	Mercuric chloride	Chromosome aberrations	NT	+	Patel and Rao 2018
CHO cells	Mercuric chloride	Chromosome aberrations	NT	+	Howard et al. 1991
Human (peripheral lymphocytes)	Mercury nitrate	Sister chromatid exchange	NT	–	Lee et al. 1997
Human (peripheral lymphocytes)	Mercuric chloride	Sister chromatid exchange	NT	+	Patel and Rao 2015
Human (peripheral lymphocytes)	Mercuric chloride	Sister chromatid exchange	NT	+	Purohit and Rao 2014
Human (peripheral lymphocytes)	Mercuric chloride	Sister chromatid exchange	NT	+	Rao et al. 2001
CHO cells	Mercuric chloride	Sister chromatid exchange	NT	+	Howard et al. 1991
Human (peripheral lymphocytes)	Mercuric chloride	Micronuclei induction	NT	+	Patel and Rao 2018
Chinese hamster V79 cells	Mercuric chloride	Micronuclei induction	NT	+	Stoiber et al. 2004
Rat embryo fibroblasts	Mercuric chloride	DNA binding	NT	+	Rozalski and Wierzbicki 1983
CHO cells	Mercuric chloride	DNA binding	NT	+	Cantoni et al. 1984a
Human (U-937 monocyte-like cells)	Mercuric chloride	DNA damage	NT	+	Ben-Ozer et al. 2000
Human (WRL-68 hepatocytes)	Mercuric chloride	DNA damage	NT	+	Bucio et al. 1999
Human (TK6 lymphoblastoid cells)	Mercuric chloride	DNA damage	NT	+	Guillamet et al. 2008
Human (peripheral lymphocytes)	Mercuric chloride	DNA damage	NT	+	Patel and Rao 2018
Human (salivary gland tissue cells)	Mercuric chloride	DNA damage	NT	+	Schmid et al. 2007
Human (lymphocytes)	Mercuric chloride	DNA damage	NT	+	Schmid et al. 2007
Human KB cells	Mercuric acetate	DNA damage	NT	+	Williams et al. 1987
Rat embryo fibroblasts	Mercuric chloride	DNA damage	NT	+	Zasukhina et al. 1983

Table 2-80. Genotoxicity of Inorganic Mercury Salts *In Vitro* Studies

Species (test system)	Mercury compound	Endpoint	Results With activation	Without activation	Reference
Mouse embryo fibroblasts CHO cells	Mercuric chloride	DNA damage	NT	+	Zasukhina et al. 1983
	Mercuric chloride	DNA damage	NT	+	Cantoni and Costa 1983
CHO cells	Mercuric chloride	DNA damage	NT	+	Cantoni et al. 1982, 1984a, 1984b
CHO cells	Mercuric chloride	DNA damage	NT	+	Christie et al. 1984, 1986

+ = positive result; – = negative result; +/– = weakly positive (2- to 3-fold increase in mutations); CHO = Chinese hamster ovary; DNA = deoxyribonucleic acid; NT = not tested

Table 2-81. Genotoxicity of Inorganic Mercury Salts *In Vivo* Animal Studies

Species (exposure route)	Mercury compound	Endpoint	Results	Reference
Mammals				
(101xC3H)F1 mouse (intraperitoneal)	Mercuric chloride	Dominant lethal mutations in oocytes	+/–	Suter 1975
Rat (oral)	Mercuric chloride	Dominant lethal mutations in spermatogonia	+	Zasukhina et al. 1983
Human (occupational exposure)	Mixture of mercuric chloride, methylmercuric chloride, and ethylmercuric chloride	Aneuploidy in peripheral lymphocytes	–	Popescu et al. 1979
Swiss mouse (intraperitoneal)	Mercuric chloride	Aneuploidy in spermatogonia	–	Poma et al. 1981
Swiss mouse (intraperitoneal)	Mercuric acetate	Aneuploidy in oocytes	–	Jagiello and Lin 1973
Human (occupational exposure)	Mixture of mercuric chloride, methylmercuric chloride, and ethylmercuric chloride	Chromosome aberrations in peripheral lymphocytes	(+)	Popescu et al. 1979
Rat (gavage)	Mercuric chloride	Chromosome aberrations in bone marrow cells	+	Bhowmik and Patra 2015
Rat (drinking water)	Mercuric chloride	Chromosome aberrations in bone marrow cells	+	Boujbiha et al. 2012

Table 2-81. Genotoxicity of Inorganic Mercury Salts *In Vivo* Animal Studies

Species (exposure route)	Mercury compound	Endpoint	Results	Reference
Swiss mouse (intraperitoneal)	Mercuric chloride	Chromosome aberrations in bone marrow cells	–	Poma et al. 1981
Swiss mouse (gavage)	Mercuric chloride	Chromosome aberrations in bone marrow cells	+	Ghosh et al. 1991
Rat (gavage)	Mercuric chloride	Micronuclei induction in reticulocytes	+	Rozgaj et al. 2005
Golden Syrian hamsters (intraperitoneal)	Mercurous chloride	Micronuclei induction in bone marrow cells	–	Cortés-Gutiérrez et al. 2004
Swiss mouse (drinking water)	Mercuric chloride	DNA binding in liver	+	Bryan et al. 1974
Rat (gavage)	Mercuric chloride	DNA damage in lymphocytes	+	Bhowmik and Patra 2015
Rat (gavage)	Mercuric chloride	DNA damage in lymphocytes	+	Rozgaj et al. 2005
Rat (oral intubation)	Mercuric chloride	DNA damage in peripheral leukocytes	+	Grover et al. 2001
Non-mammalian eukaryotic organisms				
Drosophila melanogaster (diet)	Mercuric chloride	Somatic mutation and recombination	–	Carmona et al. 2008

+ = positive result; – = negative result; +/– = inconclusive; (+) = reported as positive but study was either seriously compromised or findings did not provide valid evidence of a positive response; DNA = deoxyribonucleic acid

Mercuric chloride is not mutagenic in bacteria (Wong 1988). In mammalian cells, mercuric chloride was weakly mutagenic with activation in mouse lymphoma cells (Oberly et al. 1982) and mutagenic without activation in mouse fibroblasts (Schurz et al. 2000). An *in vivo* study in rats showed dominant lethal mutations in spermatogonia following oral exposure to mercuric chloride (Zasukhina et al. 1983). Evidence for dominant lethal mutations in oocytes was inconclusive following intraperitoneal exposure to mercuric chloride in mice (Suter 1975). There is no evidence for somatic mutation or recombination in *Drosophila melanogaster* following dietary exposure to mercuric chloride (Carmona et al. 2008).

Several studies have reported clastogenic effects in human peripheral lymphocytes following exposure to mercuric chloride (without metabolic activation). One study reported aneuploidy (Patel and Rao 2018), one reported chromosomal aberrations (Patel and Rao 2018), three reported sister chromatid exchanges (Patel and Rao 2015; Purohit and Rao 2014; Rao et al. 2001), and one reported micronuclei induction (Patel and Rao 2018). However, one study reported a lack of chromosomal aberrations in human peripheral lymphocytes exposed to mercuric chloride (Rao et al. 2001) and another reported a lack of sister chromatid exchanges in human peripheral lymphocytes exposed to mercuric nitrate (Lee et al.

1997). In hamster cells, chromosome aberrations, sister chromatid exchanges, and micronuclei were induced following exposure to mercuric chloride in the absence of metabolic activation (Howard et al. 1991; Stoiber et al. 2004).

Evidence for clastogenicity of mercuric chloride is less consistent *in vivo*. In humans, one study reported significant increases in the frequency of acentric fragments (chromosome breaks) in 18 workers exposed to a mixture of mercuric chloride, methylmercuric chloride, and ethylmercuric chloride (Popescu et al. 1979). The urinary excretion level of mercury for the exposed group was 0.890 μg/L. The findings of this study should be interpreted with caution because the control group was not matched for sex, smoking habits, or sample size. No difference in the incidence of aneuploidy was found between the exposed workers and the controls. In rodents, there is no evidence of aneuploidy in spermatogonia or oocytes following intraperitoneal exposure to mercuric chloride or acetate, respectively (Jagiello and Lin 1973; Poma et al. 1981). Chromosomal aberrations in bone marrow were reported in rats and mice following oral exposure to mercuric chloride (Bhowmik and Patra 2015; Boujbiha et al. 2012; Ghosh et al. 1991), but not in mice following intraperitoneal exposure (Poma et al. 1981). Oral exposure to mercuric chloride also induced micronuclei in rat reticulocytes (Rozgaj et al. 2005), but intraperitoneal exposure to mercurous chloride did not induce micronuclei in hamster bone marrow (Cortés-Gutiérrez et al. 2004).

Mercuric chloride does not cause DNA damage in bacteria (Kanematsu et al. 1980). However, numerous studies consistently reported DNA damage in human, rat, mouse, and hamster cells exposed to mercuric chloride (Table 2-80 for citations), and mercuric chloride binds to rat and hamster DNA (Cantoni et al. 1984a; Rozalski and Wierzbicki 1983). Mercuric acetate also induced DNA damage in human cells (Williams et al. 1987). *In vivo* studies in rodents show DNA damage in rat lymphocytes and leukocytes and DNA binding in mouse liver following oral exposure to mercuric chloride (Bhowmik and Patra 2105; Bryan et al. 1974; Grover et al. 2001; Rozgaj et al. 2005).

Organic Mercury. There is limited evidence that exposure to organic mercury is mutagenic in mammalian cells. Evidence for clastogenicity is inconclusive in mammals following *in vivo* exposure; *in vitro* data in mammalian cells generally show evidence of clastogenicity associated with organic mercury exposure. DNA damage is consistently observed in both *in vivo* and *in vitro* studies in mammals; there is limited evidence for DNA damage in bacteria and chicken embryos. Available *in vitro* and *in vivo* genotoxicity studies for organic mercury are reviewed in Tables 2-82 and 2-83, respectively.

Table 2-82. Genotoxicity of Organic Mercury *In Vitro*

Species (test system)	Mercury compound	Endpoint	Results With activation	Without activation	Reference
Prokaryotic organisms					
Bacillus subtilis (H17, M45)	Methylmercury chloride	DNA damage	NT	+	Kanematsu et al. 1980
B. subtilis (H17, M45)	Phenylmercuric acetate	DNA damage	NT	+	Kanematsu et al. 1980
Non-mammalian eukaryotic organisms					
Saccharomyces cerevisiae	Methylmercury chloride	Gene mutation	NT	–	Nakai and Machida 1973
S. cerevisiae	Methylmercury chloride	Chromosome nondisjunction	NT	(+)	Nakai and Machida 1973
S. cerevisiae	Methylmercury chloride	Recombination	NT	–	Nakai and Machida 1973
Mammalian cells					
Chinese hamster V79 cells	Methylmercury chloride	Gene mutation	NT	+/–	Fiskesjo 1979
Chinese hamster V79 cells	Methoxyethyl mercury chloride	Gene mutation	NT	+/–	Fiskesjo 1979
Human peripheral lymphocytes	Methylmercury chloride	Aneuploidy	NT	+	Betti et al. 1992
Human peripheral lymphocytes	Dimethyl mercury	Aneuploidy	NT	+	Betti et al. 1992
Human peripheral lymphocytes	Methylmercury chloride	Chromosome aberrations	NT	+	Betti et al. 1992
Human peripheral lymphocytes	Dimethyl mercury	Chromosome aberrations	NT	+	Betti et al. 1992
CHO cells	Methylmercury chloride	Chromosome aberrations	NT	+	Ehrenstein et al. 2002
Human lymphocytes	Phenylmercury acetate	Sister chromatid exchange	NT	+	Lee et al. 1997
Human lymphocytes	Methylmercury chloride	Sister chromatid exchange	NT	+	Lee et al. 1997
Early mouse embryos (blastocysts)	Methylmercury	Sister chromatid exchange	NT	-	Matsumoto and Spindle 1982
CHO cells	Methylmercury chloride	Sister chromatid exchange	NT	+	Ehrenstein et al. 2002
Human glioblastoma cell line	Methylmercury	Micronuclei induction	NT	+	Crespo-López et al. 2007
Human neuroblastoma cell line	Methylmercury	Micronuclei induction	NT	+	Crespo-López et al. 2007
Human lymphocytes	Methylmercury chloride	Micronuclei induction	NT	+	Migliore et al. 1999

Table 2-82. Genotoxicity of Organic Mercury *In Vitro*

Species (test system)	Mercury compound	Endpoint	Results		Reference
			With activation	Without activation	
Rat glioma C6 cells	Methylmercury	Micronuclei induction	NT	+	Crespo-Lopez et al. 2016
Human nerve cells	Methylmercury chloride	DNA damage	NT	+	Costa et al. 1991
Human lung cells	Methylmercury chloride	DNA damage	NT	+	Costa et al. 1991
Human leukocytes	Methylmercury chloride	DNA damage	NT	+	Frenzilli et al. 2000
Human TK6 lymphoblastoid cells	Methylmercury chloride	DNA damage	NT	+	Guillamet et al. 2008
Rat glioblastoma cells	Methylmercury chloride	DNA damage	NT	+	Costa et al. 1991
Rat glioma C6 cells	Methylmercury	DNA damage	NT	+	Crespo-Lopez et al. 2016
Mouse wild-type and OGG1-null (Ogg1$^{-/-}$) embryonic fibroblasts	Methylmercury	DNA damage	NT	+	Ondovcik et al. 2012
Chinese hamster V79 cells	Methylmercury chloride	DNA damage	NT	+	Costa et al. 1991

+ = positive result; – = negative result; +/– = weakly positive at concentrations with >50% survival (2–3-fold increase in mutations); (+) = reported as slightly increased, but quantitative data were not reported; CHO = Chinese hamster ovary; DNA = deoxyribonucleic acid; NT = not tested

Table 2-83. Genotoxicity of Organic Mercury Following *In Vivo* Exposure

Species (exposure route)	Mercury compound	Endpoint	Results	Reference
Mammals				
(101xC3H)F1 mouse (intraperitoneal)	Methylmercuric hydroxide	Dominant lethal mutations in spermatogonia	–	Suter 1975
(101xC3H)F1 mouse (intraperitoneal)	Mercuric chloride	Dominant lethal mutations in oocytes	–	Suter 1975
(SECxC57BL)F1 mouse (intraperitoneal)	Methylmercuric hydroxide	Dominant lethal mutations in spermatogonia	+	Suter 1975
Human (occupational exposure)	Mixture of mercuric chloride, methylmercuric chloride, and ethylmercuric chloride	Aneuploidy in peripheral lymphocytes	–	Popescu et al. 1979

Table 2-83. Genotoxicity of Organic Mercury Following *In Vivo* Exposure

Species (exposure route)	Mercury compound	Endpoint	Results	Reference
Human (diet, fish consumption)	Methylmercury	Aneuploidy in peripheral lymphocytes	(+)	Skerfving et al. 1970
Human (diet, fish consumption)	Methylmercury	Aneuploidy in peripheral lymphocytes	(+)	Skerfving et al. 1974
Human (occupational exposure)	Ethylmercury	Aneuploidy in peripheral lymphocytes	(+)	Verschaeve et al. 1976
Human (occupational exposure)	Phenylmercury	Aneuploidy in peripheral lymphocytes	(+)	Verschaeve et al. 1976
Human (occupational exposure)	Mercury fulminate	Aneuploidy in peripheral lymphocytes	–	Anwar and Gabal 1991
Swiss mouse (intraperitoneal)	Dimethyl-mercury	Aneuploidy in oocytes	–	Jagiello and Lin 1973
Swiss mouse (intraperitoneal)	Mercaptomerin (as Thiomerin)	Aneuploidy in oocytes	–	Jagiello and Lin 1973
Syrian hamsters (intraperitoneal)	Methylmercury	Aneuploidy in oocytes	+	Mailhes 1983
Human (occupational exposure)	Mixture of mercuric chloride, methylmercuric chloride, and ethylmercuric chloride	Chromosome aberrations in peripheral lymphocytes	(+)	Popescu et al. 1979
Human (diet, fish consumption)	Methylmercury	Chromosome aberrations in peripheral lymphocytes	(+)	Skerfving et al. 1970
Human (diet, fish consumption)	Methylmercury	Chromosome aberrations in peripheral lymphocytes	(+)	Skerfving et al. 1974
Human (occupational exposure)	Ethylmercury	Chromosome aberrations in peripheral lymphocytes	(+)	Verschaeve et al. 1976
Human (occupational exposure)	Phenylmercury	Chromosome aberrations in peripheral lymphocytes	(+)	Verschaeve et al. 1976
Human (occupational exposure)	Mercury fulminate	Chromosome aberrations in peripheral lymphocytes	+[a]	Anwar and Gabal 1991
Cat (diet)	Methylmercury	Chromosome aberrations in bone marrow cells	+/-	Miller et al. 1979
Syrian hamsters (intraperitoneal)	Methylmercury	Chromosome aberrations in oocytes	–	Mailhes 1983
Human (diet, seal consumption)	Mercury	Sister chromatid exchange in peripheral lymphocytes	(+)	Wulf et al. 1986
Human (occupational exposure)	Mercury fulminate	Micronuclei induction in peripheral lymphocytes	+[a]	Anwar and Gabal 1991
Cat (diet)	Methylmercury	Micronuclei induction in bone marrow cells	–	Miller et al. 1979
CBA mouse (intraperitoneal)	Methylmercury hydroxide	Micronuclei induction in bone marrow cells	–	Jenssen and Ramel 1980

Table 2-83. Genotoxicity of Organic Mercury Following *In Vivo* Exposure

Species (exposure route)	Mercury compound	Endpoint	Results	Reference
Human (diet, fish consumption)	Methylmercury	Mitochondrial DNA copy number and damage in white blood cells	–	Berky et al. 2019 (all regions)
Human (diet, fish consumption)	Methylmercury	Mitochondrial DNA copy number and damage in white blood cells	+	Berky et al. 2019 (outside capital region)
Cat (diet)	Methylmercury	UDS in peripheral leukocytes	–	Miller et al. 1979
Rat (gavage)	Methylmercury	DNA damage in peripheral leukocytes	+	Barcelos et al. 2011
Rat (gavage)	Methylmercury	DNA damage in hepatocytes	+	Barcelos et al. 2011
Rat (gavage)	Methylmercury	DNA damage in peripheral leukocytes	+	Barcelos et al. 2012
Rat (gavage)	Methylmercury	DNA damage in hepatocytes	+	Barcelos et al. 2012
Rat (oral)	Methylmercury	DNA damage in testes	+	Chen et al. 2019a
Rat (gavage)	Methylmercury	DNA damage in whole blood	+	de Oliveira Lopes et al. 2021
Rat (gavage)	Methylmercury	DNA damage in whole blood	+	Grotto et al. 2009b
Rat (gavage)	Methylmercury	DNA damage in liver and kidneys	+	Jin et al. 2008
Rat (oral via intragastric catheter)	Methylmercury	DNA damage in liver, kidneys, and brain	+	Joshi et al. 2014
Rat (stereotaxic injection)	Methylmercury	DNA damage in frontal cortex	+	Juárez et al. 2005
Rat (gavage)	Methylmercury	DNA damage in leukocytes	+	Manzolli et al. 2015
Rat (gavage)	Methylmercury	DNA damage in hepatocytes	+	Manzolli et al. 2015
Mice (gavage)	Methylmercury	DNA damage in hepatocytes	+	Maqbool et al. 2019
Non-mammalian eukaryotic organisms				
Drosophila melanogaster (diet)	Methylmercury chloride	Somatic mutation and recombination	–	Carmona et al. 2008
Chicken embryos (injection)	Methylmercury	DNA damage	+	Ferreira et al. 2015

[a]Positive response but no correlation to urine mercury levels or duration of exposure.

+ = positive result; – = negative result; +/– = weakly positive or marginal result; (+) = reported as positive but study was either seriously compromised or findings did not provide valid evidence of a positive response; DNA = deoxyribonucleic acid; UDS = unscheduled DNA synthesis

Methylmercury is not mutagenic in yeast cells (Nakai and Machida 1973). In hamster cells, both

methylmercury and methoxyethyl mercury chloride are weakly mutagenic without metabolic activation

(Fiskesjo 1979). An *in vivo* study in (SEC × C57BL)F1 mice showed dominant lethal mutations in

spermatogonia following intraperitoneal exposure to methylmercury; dominant lethal mutations were not

induced in spermatogonia or oocytes in similarly exposed (101 × C3H)F1 mice (Suter 1975). There is no evidence for somatic mutation or recombination in *D. melanogaster* following dietary exposure to methylmercury (Carmona et al. 2008).

In yeast, methylmercury exposure is a weak inducer of chromosome nondisjunction, but does not cause recombination (Nakai and Machida 1973). *In vitro* studies show consistent evidence of clastogenicity (aneuploidy, chromosome aberrations, sister chromatid exchanges, and micronuclei) in human, rat, and hamster cell lines exposed to various organic mercury compounds in the absence of metabolic activation (Betti et al. 1992; Crespo-López et al. 2007; Ehrenstein et al. 2002; Lee et al. 1997; Migliore et al. 1999). Sister chromatid exchanges were not observed in early mouse embryos (blastocysts) exposed to methylmercury in the absence of metabolic activation (Matsumoto and Spindle 1982).

The overall findings from cytogenetic monitoring studies of workers occupationally exposed to organic mercury compounds (Anwar and Gabal 1991; Popescu et al. 1979; Verschaeve et al. 1976) or the general population exposed via diet (Skerfving et al. 1970; Wulf et al. 1986) provided no convincing evidence that mercury adversely affects the number or structure of chromosomes in human somatic cells. Studies reporting a positive result (Anwar and Gabal 1991; Popescu et al. 1979; Skerfving et al. 1970, 1974; Verschaeve et al. 1976; Wulf et al. 1986) were compromised either by technical problems, a lack of consideration of confounding factors, or a failure to demonstrate a relationship between mercury exposure and induced aberrations. Therefore, none of these studies can be used to predict the potential genetic hazard to humans associated with exposure to mercury or mercury compounds. In hamsters, the number of aneuploid oocytes was significantly increased following intraperitoneal exposure to methylmercury, but not to dimethylmercury or mercaptomerin; structural chromosomal alterations were not induced (Jagiello and Lin 1973; Mailhes 1983). The number of chromosomal alterations was increased in cat bone marrow following oral exposure to methylmercury; however, findings were not clearly dose-related (Miller et al. 1979). Micronuclei were not induced in mouse bone marrow cells following intraperitoneal exposure to methylmercury (Mailhes 1983) or in cat bone marrow cells following oral exposure to methylmercury (Miller et al. 1979).

Methylmercury and phenylmercuric acetate both induced DNA damage in bacteria (Kanematsu et al. 1980). Various organic mercury compounds consistently induced DNA damage in human, rat, mouse, and hamster cells lines *in vitro* in the absence of metabolic activation (Costa et al. 1991; Crespo-Lopez et al. 2016; Frenzilli et al. 2000; Guillamet et al. 2008; Ondovcik et al. 2012). Oral exposure to organic mercury compounds consistently induced DNA damage in various tissues in rats (Barcelos et al. 2011,

2012; Chen et al. 2019a; Grotto et al. 2009b; Jin et al. 2008; Joshi et al. 2014; Juárez et al. 2005; Manzolli et al. 2015). DNA damage was also observed in chicken embryos injected with methylmercury (Ferreira et al. 2015). Unscheduled DNA synthesis was not induced in cats following oral exposure to methylmercury (Miller et al. 1979).

The potential association between exposure to mercury and mitochondrial DNA copy number or damage in WBCs was assessed in Peruvian subjects living various distances from artisanal and small-scale gold mining operations outside the capital city of Puerto Maldonado (Berky et al. 2019). Exposure to mercury in these populations was attributed to consumption of methylmercury contaminated fish. Overall, HHg were similar across regions and no associations were observed between HHg and mitochondrial DNA copy number or damage. Additionally, no associations were found when the data were stratified by relationship to mining operations (upriver, near Puerto Maldonado, downriver). However, when evaluated just in individuals who lived >20 miles outside of the capital city, HHg levels were significantly associated with increased mitochondrial DNA damage.

2.21 GENERAL MECHANISMS OF ACTION

A diverse list of toxic mechanisms for mercury compounds has been described. This includes alteration or disruption of the regulation of intracellular calcium homeostasis, cytoskeleton, mitochondrial function, oxidative stress, neurotransmitter release, and DNA methylation. Mercury is a soft electrophile and will interact with soft nucleophiles, including thiols (R-SH) and selenols (R-Se) in proteins (Carty and Malone 1979). A contributor to the diversity of activity of mercury in biological systems is the high affinity of Hg^{2+} and CH_3Hg^{2+} for thiolate (R-S⁻) and selenolate (R-Se⁻) groups in proteins (Carty and Malone 1979; Parks and Smith 2016; Ralston and Raymond 2018). This enables mercury to bind to and disrupt structure and activity of enzymes, transporters, and other proteins whose activity is dependent on functional thiol or selenol groups. These include a diverse set of important transporters and enzymes that participate in the regulation of cell structure and function such as ATPases; hemoglobin and myoglobin; tubulin; numerous oxidoreductases, transferases, hydrolases and isomerases; and selenoenzymes (Khan and Wang 2009; Nagahara 2011). Low molecular weight thiols also serve as important ligands for mercury transport in and out of cells. Conjugates of Hg^{2+} and CH_3Hg^{2+} with extracellular thiols (e.g., cysteine, glycinyl-cysteine, glutathione) are recognized by physiological transport systems for amino acids (e.g., molecular mimicry) and, once in cells, mercury can distribute to other critical intracellular thiol and selenol groups. Transport of mercury S-conjugates has been shown to be important in a variety of tissues, including, brain, intestines, kidneys, liver, placenta, and RBCs (Ballatori 2002; Bridges and

Zalups 2010, 2017; Clarkson et al. 2007; Lohren et al. 2015). Molecular mimicry may contribute to tissue target specificity of methylmercury and inorganic mercuric mercury, primarily to brain, fetus, and kidneys (Bridges and Zalups 2017). General mechanisms by mercury form (elemental, inorganic, organic) are discussed in more detail below.

Elemental Mercury. Toxic actions of elemental mercury are related to mercury levels in the target tissues, primarily (e.g., brain). The relatively high lipid solubility of Hg^0 contributes to the partitioning of inhaled mercury vapor into blood and delivery of Hg^0 and Hg^{2+}-thiol conjugates to the central nervous system. Vascular proximity of the brain, coupled with a limiting oxidation rate of Hg^0 in blood, contributes to a first-pass effect on uptake of mercury into the brain following inhalation of Hg^0 (Magos et al. 1989). Transfer of inhaled Hg^0 into the brain results from several processes: (1) diffusion of Hg^0 vapor into blood; (2) physical partitioning (dissolving) of Hg^0 into plasma, RBCs, and other tissues; (3) extracellular and intracellular oxidation of Hg^0 to Hg^{2+}; (4) formation of Hg^{2+} complexes with proteins and non-protein species (primarily with sulfhydryls, including sulfhydryl amino acids); and (5) transport and distribution of Hg^{2+} complexes. Toxicity of absorbed Hg^0 in target tissues is related to inorganic mercury (primarily mercuric) levels in the target tissues (see discussion of mechanisms of toxicity of inorganic mercuric mercury below).

Inorganic Mercuric Mercury. Toxic actions of inorganic mercuric mercury are related to mercury levels in the target tissues (e.g., brain, kidneys, red blood cells). Delivery of inorganic mercuric mercury to target tissues is facilitated by membrane transporters that recognize S-conjugates of Hg^2. The Hg^{2+} ion has a strong tendency to form conjugates with two sulfur ligands (e.g., R-S-Hg-S-R′) (Carty and Malone 1979; Parks and Smith 2016). This distinguishes S-conjugates of inorganic Hg^{2+} from those formed by CH_3Hg^{2+} (CH_3Hg-S-R). Transporters implicated in the uptake of Hg^{2+}-S conjugates in the mammalian renal proximal tubule include the organic anion transporter, OAT1, located in the basolateral membrane of the proximal tubule and amino acid transporter system, $b^{0,+}$, located in the luminal membrane (Bridges and Zalups 2005; Bridges et al. 2004; Wei et al. 1999; Zalups and Ahmad 2004; Zalups et al. 2004). Both systems transport thiol conjugates of Hg^{2+} with the amino acid cysteine (Cys-S-Hg-S-Cys). On the luminal side of the proximal tubule, formation of the cysteine S-conjugate is facilitated by the catabolism of a glutathione S-conjugate (GluGlyCys-S-Hg-S-CysGlyGlu), which is catalyzed by the luminal membrane enzymes, GGT and cysteinylglycinase (Berndt et al. 1985; de Ceaurriz et al. 1994; Tanaka et al. 1990; Tanaka-Kagawa et al. 1993; Zalups 1995; Zalups and Lash 1997). Kinetics of reversible binding of Hg^{2+} to thiols is sufficiently fast enough to allow the Hg^{2+} in transported S-conjugates of Hg^{2+}

to exchange with other thiol or selenol ligands, including thiolate or selenolate groups in proteins (Carty and Malone 1979; Parks and Smith 2016; Ralston and Raymond 2018).

Interactions of mercury with transporters, enzymes, and other proteins are thought to be the primary mechanisms by which inorganic mercuric mercury disrupts cell function. Several specific systems have been identified as targets of inorganic mercuric mercury. Mercuric mercury binds to and inhibits selenoenzymes, including thioredoxin reductases, enzymes that function in regulation of the oxidation state of protein thiols (Branco and Carvalho 2019). Inhibition of thioredoxin reductases is considered to be an important mechanism by which inorganic mercuric mercury impairs cellular antioxidant systems and produces oxidative damage to cells (Branco et al. 2012). Disruption of antioxidant systems leads to formation of ROS, lipid peroxidation, necrosis, and apoptosis, and in RBCs, promotes the formation of methemoglobin (Ahmad and Mahmood 2019; dos Santos et al. 2016; Branco et al. 2012). Mercuric mercury binds to thiol groups in heme-thiolate proteins, which include cytochrome P450 and nitric oxide synthase (Ynalvez et al. 2016). Inhibition of nitric oxide synthase is thought to be an important mechanism by which mercuric chloride disrupts regulation of vascular resistance (Omanwar et al. 2014; Vassallo et al. 2011; Wiggers et al. 2008). Altered expression of cytochrome P450 in cardiac tissue is thought to be a contributing mechanism to mercuric chloride-induced cardiotoxicity (Amara et al. 2014).

The Hg^{2+} ion can displace cationic metals (copper, zinc) from binding sites on metallothionein (and other metalloproteins) and induces the synthesis of metallothionine (Aschner et al. 2006; Kagi et al. 1984, Yasutake and Nakamura 2011).

Methylmercury. Toxic actions of methylmercury are related to mercury levels in the target tissues, which primarily include the brain and kidneys. Delivery of methylmercury to target tissues is facilitated by membrane transporters that recognize S-conjugates of methylmercury with cysteine and other thiols (Ballatori 2002; Bridges and Zalups 2010, 2017; Clarkson et al. 2007; Lohren et al. 2015). The high affinity of CH_3Hg^{2+} for thiols enables mercury to bind to and perturb the function of a wide variety of proteins. These include ATPases; globins (e.g., hemoglobin, myoglobin); tubulin; and numerous oxidoreductases, transferases, hydrolases, and isomerases (Nagahara 2011). Methylmercury also forms stable complexes with selenols (R-Se) (Khan and Wang 2009). Formation of complexes with selenocysteine residues can alter the function of selenoenzymes (e.g., GPX and thioreductase). Direct complexation of selenium with methylmercury may also sequester selenium, making it unavailable for incorporation into protein or other selenium-dependent physiological processes (Ralston and Raymond 2018).

Interactions of mercury with transporters and enzymes are thought to be the primary mechanisms by which methylmercury disrupts cell differentiation and function. Several specific systems have been identified as targets of methylmercury. Methylmercury disrupts cellular antioxidant systems and promotes generation of ROS (Aaseth et al. 2020; Farina and Aschner 2017; Garza-Lombo et al. 2018). Several mechanisms contribute to the pro-oxidative action of mercury, including direct binding to cysteine and glutathione, depletion of glutathione, and inhibition of selenoenzymes that function in maintaining cell redox potential (Farina and Aschner 2017; Ralston and Raymond 2018; Spiller 2018). These include the selenoenzymes, GPX and thioreductase. In mitochondria, disruption of antioxidant systems leads to loss of mitochondrial membrane integrity, apoptotic cell cytokine cascade, and cell death (Ceccatelli et al. 2010; Roos et al. 2012). Methylmercury stimulates neuronal excitatory N-methyl-D-aspartate (NMDA) glutamate receptors (Aaseth et al. 2020; Colon-Rodriguez et al. 2017; Farina and Aschner 2017). This can lead to dysregulation of intracellular calcium levels and production of ROS (Aschner et al. 2007). Methylmercury binds to thiols on neuronal gamma-aminobutyric acid (GABA) receptors and inhibits GABA signaling (Basu et al. 2010; Fonfria et al. 2001). Methylmercury disrupts cell signaling pathways, including phospholipase C, calcium, and phosphatidylinosito-3-kinases/protein kinases (Fretham et al. 2012; Kang et al. 2006). Disruption of cell signaling is thought to contribute to increased production of ROS and inflammatory responses to methylmercury in neuronal tissues (Chang 2011; Hwang et al. 2011). Methylmercury forms complexes with thiols in microtubule-associated proteins, disrupting tubulin organization, and cellular architecture dependent on microtubules (Aaseth et al. 2020, Sager et al. 1983; Vogel et al. 1985). Methylmercury changes expression and post-translational modification of genes involved in neuronal cell differentiation, antioxidant responses, and inflammation (Fujimura and Usuki 2014; Hwang et al. 2011; Ke et al. 2019; Onishchenko et al. 2008; Robinson et al. 2011; Theunissen et al. 2011).

CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

3.1 TOXICOKINETICS

Overview. Humans are exposed to a variety of forms of mercury that exhibit route-dependent and chemical species dependent toxicokinetics. The major categories discussed in this section include:

- elemental mercury (Hg^0, e.g., mercury vapor);
- inorganic mercuric compounds (Hg^{2+}, e.g., mercuric chloride);
- inorganic mercurous compounds (Hg^+, calomel); and
- organic mercuric compounds (Hg^{2+}, e.g., methylmercury, dimethylmercury, phenylmercury).

Elemental Mercury
- *Absorption:*
  - Respiratory tract: Absorption of inhaled mercury vapor was estimated to range from 69 to 85% in human adults.
  - Gastrointestinal tract: Absorption of elemental mercury ingested as mercury amalgam was estimated to be 0.04% in human adults.
  - Dermal: Systemic absorption of mercury has been shown to occur in adult humans following skin exposure to mercury vapor. Systemic dermal absorption during a full-body immersion in mercury vapor was estimated to be 2% of the amount absorbed from inhalation during the immersion.
- *Distribution:*
  - Following inhalation exposure to mercury vapor, mercury distributes throughout the body, with the highest concentrations occurring in the kidneys.
  - Vascular proximity of the heart and brain coupled with a limiting oxidation rate of Hg^0 in blood contributes to a first-pass effect on uptake of Hg^0 in these tissues following inhalation of mercury vapor.
  - Mercury from inhalation exposure to mercury vapor can be transferred from the mother to the fetus and also from the mother to infants via maternal milk.
- *Metabolism:*
  - Absorbed Hg^0 is rapidly oxidized in blood and tissues to mercuric mercury (Hg^{2+}).
  - The major oxidative pathway for Hg^0 is catalyzed by the enzyme catalase.

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

- o   Oxidation removes Hg^0 from blood, limiting its transfer from blood to exhaled air and its distribution to other tissues.

- *Excretion:*
  - o   The major routes of excretion of absorbed mercury vapor are excretion of unmetabolized Hg^0 in exhaled air and urinary and fecal excretion of mercuric Hg^{2+} following oxidation of Hg^0 in blood and other tissues.
  - o   Kinetics of elimination of mercury following exposure to inhalation mercury vapor shows multiple phases. The terminal half-time, thought to largely reflect urinary and fecal excretion of Hg^{2+}, has been estimated in humans to range from 30 to 90 days.

- *Toxicokinetics models:*
  - o   Several pharmacokinetics models of inorganic mercury have been published. Of these, two models were developed to predict the absorption and distribution of inhaled mercury vapor (Jonsson et al. 1999; Leggett et al. 2001).

Inorganic Mercuric Mercury

- *Absorption:*
  - o   Respiratory tract: Following accidental inhalation exposures to mercuric oxide (^{203}HgO), mercury was detected in various body regions, including the head, kidneys, pelvis, and legs; indicating systemic absorption.
  - o   Gastrointestinal tract: Absorption of ingested inorganic mercuric mercury was estimated to range from 1 to 16% in human adults. Studies conducted in rodents have found that gastrointestinal absorption is higher in younger rats (age 8 weeks compared to adults).
  - o   Dermal: Inorganic mercuric mercury was absorbed across isolated human and pig skin.

- *Distribution:*
  - o   Following ingestion of inorganic mercuric mercury (e.g., mercuric chloride), mercury distributes throughout the body, with the highest concentrations occurring in the kidneys and liver.
  - o   Inorganic mercury is found in human cord blood, placenta, and breast milk indicating potential routes of transfer to the fetus and nursing infant.

- *Metabolism:*
  - o   Exhaled Hg^0 was observed in mice following parenteral doses of mercuric chloride, suggesting that Hg^{2+} had been reduced to Hg^0.

- o   Salivary and gastrointestinal bacteria have been shown to methylate Hg^{2+}; however, the quantitative significance of methylation in the disposition of absorbed Hg^{2+} remains uncertain.

- *Excretion:*
  - o   The major routes of excretion of absorbed mercuric mercury are feces and urine.
  - o   Kinetics of elimination of absorbed inorganic mercuric mercury exhibits multiple phases.
  - o   The terminal half-time has been estimated in humans to range from 49 to 120 days.

- *Toxicokinetics models:*
  - o   Several pharmacokinetics models for inorganic mercury have been published. These models are based on studies of the pharmacokinetics of absorbed inorganic mercuric mercury.

Inorganic Mercurous Mercury

- o   No studies were located that provide quantitative information on the absorption, distribution, metabolism, or excretion of inorganic mercurous mercury.

- o   Pharmacological and cosmetic use of calomel (mercurous sulfide) ointments (skin lightening, acne) has resulted in elevated urinary mercury levels and mercury poisoning, indicating that absorption of mercury can occur following oral and/or dermal exposure to inorganic mercurous mercury.

- o   Toxicity may have been from absorbed inorganic mercuric mercury, as the low pH and high chloride concentration of the gastric environment favor oxidation of ingested Hg^1 to Hg^{2+}.

Organic Mercuric Mercury

- *Absorption:*
  - o   Respiratory tract: No studies were found that have estimated absorption of inhaled organic mercuric mercury.
  - o   Gastrointestinal tract: Studies conducted in humans, monkeys, and rodents have shown that gastrointestinal absorption of mercury is close to 100% following ingestion of methylmercury as the chloride salt or when incorporated into fish or other ingested protein.
  - o   Dermal: Dimethylmercury is rapidly absorbed through human skin. A study conducted in guinea pigs showed that mercury was absorbed following application of methylmercuric dicyandiamide.

- *Distribution:*
  - o   Following ingestion of methylmercury, mercury distributes throughout the body, with the highest concentrations occurring in the liver, kidneys, and brain.

o   Methylmercury is found in human cord blood, placenta, and breast milk indicating potential routes of transfer to the fetus and nursing infants.

- *Metabolism:*
  o   Studies conducted in humans and in a variety of other mammalian species have observed methylmercury and inorganic mercury in tissues and excreta following exposure to methylmercury.
  o   During repeated exposures to methylmercury, the rate of demethylation is not sufficient to completely eliminate the entire absorbed dose of methylmercury. As a result, a mix of methylmercury and inorganic mercuric mercury occurs in the body following exposures to methylmercury.

- *Excretion:*
  o   The major routes of excretion of absorbed methylmercury are feces, urine, and hair.
  o   Following exposure to phenylmercury, absorbed mercury is eliminated in bile, feces, urine, and hair.
  o   Kinetics of elimination of absorbed methylmercury exhibits multiple phases. The terminal half-time has been estimated in humans to be 80 days (2.5–97.5 percentile range: 64–97).

- *Toxicokinetics models:*
  o   Pharmacokinetics models of methylmercury have been developed for humans and a variety of other animal species.

3.1.1 Absorption

Inhalation Exposure

Elemental Mercury. Inhaled elemental mercury vapor (Hg^0 vapor) is absorbed from the respiratory tract. Absorption has been estimated in human clinical studies in which subjects (adults) inhaled measured amounts of Hg^0 vapor over periods of several minutes and retention was estimated from blood or whole-body mercury elimination kinetics. Absorption was estimated to range from 69 to 85% in humans exposed to concentrations ranging from 0.05 to 0.4 mg Hg/m^3 (Hursh et al. 1976, 1980; Nielsen-Kudsk 1965a, 1965b; Sandborgh-Englund et al. 1998; Teisinger and Fiserova-Bergerova 1965). Kinetics of absorption from the respiratory tract exhibits multiple phases: a more rapid phase attributed to diffusion and partitioning into blood and a slower phase attributed to absorption of mercury oxidized to Hg^{2+} in lung tissues (Hursh 1985; Leggett et al. 2001; Sandborgh-Englund et al. 1998). Based on sequential measurements of plasma mercury following a 15-minute inhalation exposure to Hg^0 vapor (0.4 mg/m³),

an absorption half-time was estimated to be approximately 4.5 hours (Sandborgh-Englund et al. 1998).
Leggett et al. (2001) assigned three components to absorption of Hg^0 from the lung with approximate
half-time values of 1 minute, 8 hours, and 5 days (Section 3.1.5 provides a more detailed description of
the Leggett et al. 2001 respiratory tract model).

Mercury vapor released from dental amalgams can be absorbed by inhalation (Clarkson et al. 1988).
Evidence that mercury released from amalgams can be absorbed comes from numerous studies that have
shown associations between amalgam number and other factors that affect release of mercury from
amalgams, and BHg or UHg levels. For example, levels of mercury in these biological media increased
with increasing number of dental amalgams (Al-Saleh et al. 2011; Barany et al. 2003; Gul et al. 2016;
Maserejian et al. 2008; Yin et al. 2016). Children who received amalgam restorations showed higher
urinary mercury levels than children who received resin restorations (Woods et al. 2007). Plasma and
urinary levels of mercury declined after replacement of amalgams with resin restorations (Halbach et al.
2000). Studies conducted in rodents have also shown that mercury released from dental amalgam
restorations is excreted in urine (Galic et al. 2001). Quantification of absorption of amalgam mercury
from the inhalation pathway is complicated by multiple routes of absorption, including ingestion of Hg^0
dissolved in saliva and Hg^0 particulate (Bjorkman et al. 1997; Halbach et al. 2000; Leistevuo et al. 2001;
Mackert and Berglund 1997). Based on results from measurements of releases of Hg^0 vapor and
particulate Hg^0 from amalgams and models of intake and absorption of mercury released from amalgams,
the inhalation pathway was estimated to account for approximately two-thirds of total absorption of
amalgam mercury (Mackert and Berglund 1997). Rates of absorption from inhalation were estimated to
be 2 µg Hg/day (range 0.3–6.1 µg Hg/day; 33 adults). Estimated rates of absorption of mercury from
inhalation ranged from 3 to 18 µg Hg/day for four studies of Hg^0 release from dental amalgams (Clarkson
et al. 1988). The wide range reflects, at least in part, the methodological differences used in estimating
Hg^0 release rates and different conditions of the amalgams (e.g., number, wear, active chewing during
measurement) (Clarkson et al. 1988).

Inter-species variation in regional deposition of inhaled Hg^0 vapor has been observed (Leggett et al.
2001). A larger fraction of inhaled mercury was deposited in bronchial regions of the respiratory tract in
rodents and monkeys compared to humans (Berlin et al. 1969a; Hayes and Rothstein 1962; Khayat and
Dencker 1984). Absorption kinetics of inhaled Hg^0 exhibits multiple phases in monkeys, guinea pigs,
mice, rabbits, and rats (Berlin et al. 1966, 1969b; Hayes and Rothstein 1962; Hursh et al. 1980; Khayat
and Dencker 1983, 1984; Nordberg and Serenius 1969). In general, all species show a rapid phase of

absorption of most of the deposited mercury (50–70% with a half-time of several minutes) with a slower component accounting for the remaining portion.

Mechanisms of absorption. The primary mechanism contributing to absorption of inhaled Hg^0 vapor is thought to be deposition primarily in alveolar and bronchial regions of the respiratory tract followed by diffusion and partitioning of mercury vapor into blood (Leggett et al. 2001). Transfer to blood is facilitated by the relatively high solubility of Hg^0 in blood and a diffusion gradient maintained by uptake and oxidation of Hg^0 in RBCs (Hursh 1985; Magos et al. 1978).

Inorganic Mercuric Mercury. Retention of mercury was measured in two adult workers following three incidents of accidental inhalation exposures to ^{203}HgO (Newton and Fry 1978). The total inhaled dose could not be estimated as the exposures were discovered from urinary measurements several days following the actual inhalation exposures. Whole-body and regional mercury retentions were estimated from measurements of external gamma activity over periods extending from 3 to 256 days following exposure. In one subject, based on thorax measurements made between days 3 and 212 following exposure, lung retention kinetics exhibited two phases with half-times of approximately 2 days for the fast phase and 20–26 days for the slow phase. Following all three incidents, absorption of mercury was indicated from measurements of ^{203}Hg in the head, kidney, pelvis, and leg regions. Following nose-only exposures of dogs to aerosols of mercuric oxide (^{202}HgO, 5 mg/m^3, count median diameter 0.16 μm), approximately 45% of the deposited mercury was cleared from the lower respiratory tract with a half-time that was <24 hours and the remaining portion was cleared with a half-time of 33 days (Morrow et al. 1964). Absorption of more soluble mercuric compounds (e.g., mercuric chloride) following inhalation is also expected but has not been studied.

Inorganic Mercurous Mercury. No information was located on absorption of mercury following inhalation exposures to inorganic mercurous mercury.

Organic Mercuric Mercury. No information was located on absorption of mercury following inhalation exposures to methylmercury. In mice, approximately 100% of inhaled dimethylmercury (4.5–9.0 mg Hg/kg) was initially retained during the first 5 minutes following the inhaled dose (Ostlund 1969).

Oral Exposure

Elemental Mercury. Ingested Hg^0 is absorbed from the gastrointestinal tract (af Geijersstam et al. 2001; Engqvist et al. 1998; Sandborgh-Englund et al. 2004). Following ingestion of water that had been equilibrated with Hg^0 vapor, approximately 40% of the mercury dose (0.03 mg, one adult subject) was excreted in feces over a 12-hour observation period (Engqvist et al. 1998). An elevation of plasma mercury concentrations was observed following ingestion of liquid Hg^0 contained in a rubber bile-sampling balloon, indicating that Hg^0 vapor that diffused out of the sampling balloon was absorbed (Sandborgh-Englund et al. 2004). Gastrointestinal absorption of ingested Hg^0 vapor is greater than absorption of mercury from ingested mercury amalgam.

Fecal excretion in two adult subjects who ingested powdered mercury amalgam (0.31–0.56 mg Hg) accounted for approximately 80% of the ingested dose of mercury (Engqvist et al. 1998). Absorption was estimated in a human clinical study in which 11 adult subjects ingested capsules containing powdered mercury amalgam and absorption was estimated from mercury elimination kinetics (af Geijersstam et al. 2001). Following a single dose of 1 mg amalgam mercury, absorption was estimated to be 0.04% of the ingested dose and was sufficient to result in transient elevations of plasma mercury concentrations. In rats, absorption of mercury was detected (but not quantified) as elevated tissue mercury levels following 4 weeks of exposure to diets amended with pulverized mercury amalgam (8.3 or 25 mg amalgam per week) (Song et al. 2002). Based on results from measurements of releases of Hg^0 vapor and particulate Hg^0 from amalgams and models of intake and absorption of mercury released from amalgams, the ingestion pathway was estimated to account for approximately one-third of total absorption of amalgam mercury (Mackert and Berglund 1997). Rates of absorption from inhalation were estimated to be 1 μg Hg/day (range 0.2–3.2 μg Hg/day; 33 adults).

Mechanisms of absorption. Following ingestion of Hg^0, absorption of mercury is likely to occur, in part as Hg^{2+} and in part as Hg^0 vapor released from Hg^0 particulates (Mackert and Berglund 1997). The low pH and high chloride concentration of the gastric environment favor oxidation of ingested Hg^0 to Hg^{2+} (Mousavi 2015; Nikolaychuk 2016). Mechanisms that contribute to absorption of Hg^{2+} are summarized in the section on absorption of inorganic mercuric mercury. Mechanisms that contribute to gastrointestinal absorption of Hg^0 vapor are likely to be those that operate in absorption across the lung. These include diffusion and partitioning of mercury vapor into blood, with diffusion gradients maintained by oxidization to Hg^{2+} and uptake of Hg^{2+} into tissues.

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

Inorganic Mercuric Mercury. Few studies quantify mercury absorption in humans following ingestion of Hg^{2+}. Rahola et al. (1972, 1973) measured whole-body elimination kinetics and excretion in adult subjects following ingestion of a single tracer dose of mercury (6 µg), as $^{203}Hg(NO_3)_2$, in drinking water (two subjects) or mixed with calf liver paste (eight subjects). Based on the mean recovery of 85% of the mercury dose in feces during the first 4–5 days following dosing (range 75–92 days), absorption was estimated to have been approximately 15%. This estimate would not have accounted for mercury that was excreted in feces following absorption. Rahola et al. (1973) also reported for each subject the parameters for a two-compartment model of elimination of whole-body radioactivity. If it is assumed that the fast elimination component consisted entirely of fecal excretion of unabsorbed mercury, occurring largely during the first 10–15 days after the dose, then extrapolation of the slow component to zero time yields an estimate of the absorbed dose fraction. Parameter estimates from the study are presented in Table 3-1. The mean value for absorbed dose fraction (percent of administered dose) for the subjects who consumed mercury in calf liver was 6.2±2.7% (range 4–8.7%; n=7); the mean values for the two subjects who consumed mercury in drinking water were 4.7 and 15.6%. The mean value for all subjects (n=10) was 7.0% (range 1.4–15.6%).

Table 3-1. Whole-Body Retention and Excretion of Mercuric Chloride in Human Subjects

Medium	Subject	Sex	Age	BW	$T_{1/2}a$	%$T_{1/2}a$	$T_{1/2}b$	%$T_{1/2}b$	FE	UR
Food	AE	F	35	60	1.7	32	29	4	82	0.11
Food	AN	F	23	48	3.0	22	36	7.4	ND	0.21
Food	TP	F	23	51	2.2	54	39	6.6	ND	ND
Food	AH	M	32	75	1.9	19	50	4.0	91	0.06
Food	PK	M	40	72	1.9	27	60	8.7	75	0.15
Food	JM	M	49	85	2.9	6	51	1.4	88	0.05
Food	MR	M	30	56	3.3	8	45	8.5	91	0.21
Food	IV	M	29	69	1.0	5	32	8.7	92	0.23
Water	MG	F	48	72	2.5	45	38	4.7	ND	0.11
Water	KR	F	29	61	2.5	35	41	15.6	75	0.38
AM			34	65	2.3	25	42	7.0	85	0.17
SD			9.2	12	0.7	17	9.5	3.9	7.5	0.10
SE			2.9	3.7	0.2	5.3	3.0	1.2	2.8	0.03

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

Table 3-1. Whole-Body Retention and Excretion of Mercuric Chloride in Human Subjects

Medium	Subject	Sex	Age	BW	$T_{1/2}a$	$\%T_{1/2}a$	$T_{1/2}b$	$\%T_{1/2}b$	FE	UR
AM food			33	65	2.2	22	43	6.2	87	0.15
SD food			8.7	13	0.8	16	11	2.7	6.7	0.07
SE food			3.1	4.5	0.3	5.8	3.8	1.0	2.7	0.03
AM water			39	67	2.5	40	39.5	10	75	0.30

AM = arithmetic mean; F = female; FE = cumulative fecal excretion measured on days 4–5 after the dose; M = male; ND = no data; SD = standard deviation; SE = standard error; $T_{1/2}a$ = first-order elimination half-time for the rapid phase of elimination, respectively; $T_{1/2}b$ = first-order elimination half-time for the slower phase of elimination; %T = fractions of the body burden attributed to fast or slow phase of elimination; UR = urinary excretion measured on days 4–5 after the dose; the administered dose was 6 μg Hg, as [^{203}Hg]-mercuric chloride.

Source: Rahola et al. 1973

Absorption of Hg^{2+} has been studied more extensively in rodents. Studies that provide quantitative estimates of the fraction of dose absorbed are summarized in Table 3-2. The estimates for ingested mercuric chloride range from 0.4 to 42%. Differences in methods used to arrive at these estimates make it difficult to compare values across studies. For example, mass balance studies that estimate absorption as the difference between the oral dose and cumulative fecal excretion are likely to underestimate absorption because mercury excreted in feces after absorption cannot be distinguished from excretion of unabsorbed mercury. Within-study comparisons provide some insights about variables that affect absorption of Hg^{2+}. In rats, absorption was substantially higher in nursing pups (38%) compared to adults maintained on rat chow (1%) (Kostial et al. 1978). Young rats (130 g or 8 weeks of age) also showed higher absorption than older rats (Kostial et al. 1997; Piotrowski et al. 1992). A repeated-dose study in which rats were exposed to mercuric chloride in drinking water estimated the absorption fraction to range from 31 to 43% (Morcillo and Santamaria 1995). Estimates of the absorption fraction following ingestion of mercuric chloride in mice also showed wide variability (2–30%). The large difference in the estimates provided by Nielsen and Andersen (1990), 17–30%, and Revis et al. (1990), 2.1%, may reflect the substantial underestimate of the absorption fraction provided by fecal mass-balance studies on the lower end of the range (Revis et al. 1990). Of the mouse studies reported in Table 3-2, the Nielsen and Andersen (1990) study would not have been biased downward by fecal excretion of absorbed mercury and may represent a more accurate estimate of the absorption fraction in adult mice (17–30%). Estimates from the Revis et al. (1990) study suggest that the absorption fraction for ingested mercuric chloride (2.1%) is larger than that for mercuric sulfide (0.4%). This is supported by studies in mice that have found lower tissue levels of mercury following ingestion of mercuric sulfide and/or cinnabar in which the predominant mercury species is mercuric sulfide, compared to tissue levels following ingestion of

Table 3-2. Summary of Estimates of Gastrointestinal Absorption in Mice and Rats

Species	Sex	Age or BW	Hg Form	EF	Dose	Route	Diet	AF (%)	Source
Mouse	F	7–8 weeks	$HgCl_2$	1 dose	0.2–1 mg/kg	Gavage	Standard diet	17–30[a]	Nielsen and Andersen 1990
Mouse	ND	3 months	$HgCl_2$	1 dose	Trace	Gavage (in feed)	Standard diet	2.1[a]	Revis et al. 1990
Mouse	ND	3 months	HgS	1 dose	Trace	Gavage (in feed)	Standard diet	0.4[b]	Revis et al. 1990
Mouse	B	3 months	Soil[c]	1 day	0.002–0.4 mg	5% soil in diet	Standard diet	4–16[b]	Revis et al. 1990
Mouse	B	1–21 days	$HgCl_2$	21 days	0.0002 mg/pup	Nursing	Nursing	15[d]	Sundberg et al. 1999
Rat	ND	1 weeks	$HgCl_2$	1 dose	ND	Gavage	Nursing	38[e]	Kostial et al. 1978
Rat	ND	18 weeks	$HgCl_2$	1 dose	ND	Gavage	Cow milk diet	7[e]	Kostial et al. 1978
Rat	ND	18 weeks	$HgCl_2$	1 dose	ND	Gavage	Standard diet	1[e]	Kostial et al. 1978
Rat	F	8 weeks	$HgCl_2$	1 dose	0.5 mg/kg	Gavage	Standard diet	42[f]	Kostial et al. 1997
Rat	M	130 g	$HgCl_2$	Daily for 8 weeks	0.1–7.3 mg/kg day	Drinking water	Standard diet	31–43[g]	Morcillo and Santamaria 1995
Rat	F	160–250 g	$HgCl_2$	1 dose	0.2–12.5 mg/kg	Gavage	Standard diet	3–4[h]	Piotrowski et al. 1992
Rat	F	160–250 g	$HgCl_2$	1 dose	17–20 mg/kg	Gavage	Standard diet	6–9[h]	Piotrowski et al. 1992

AF = absorption fraction; B = both males and females; BW = body weight; EF = exposure frequency; F = female; M = male; ND = no data

[a]Oral/intraperitoneal ratio of whole-body retention.
[b]Dose minus cumulative excretion in feces measured over a period of 96 hours, minus mercury in gastrointestinal tract mercury at termination of exposure.
[c]5% soil in diet.
[d]Whole-body minus gastrointestinal tract/cumulative dose from nursing.
[e]Whole-body retention 6 days after dosing.
[f]Whole-body retention 4 days after dosing.
[g]Whole-body retention/whole-body elimination rate.
[h]Whole-body retention minus gastrointestinal tract 4 hours after dosing.

mercuric chloride (Sin et al. 1983, 1989; Wang et al. 2013). The lower absorption fraction is likely to result from the lower solubility of mercuric sulfide and the higher stability of the Hg^{2+}-S^{-2} complex under physiological conditions (Carty and Malone 1979).

Mechanisms of absorption. Studies conducted in mice and rats indicate that the predominant site of absorption of Hg^{2+} is the small intestine (Endo et al. 1984, 1986, 1990, 1991; Foulkes 1993; Foulkes and Bergman 1993; Nielsen et al. 1992; Zalups 1998). The mechanism of absorption of Hg^{2+} has not been fully characterized. Bile flow and bile constituents increase absorption in the rat (Endo et al. 1984; Nielsen et al. 1992; Zalups 1998). Absorption is dependent on pH of the luminal contents of the intestine (Endo et al. 1986). In a study in rats that compared intestinal absorption of a series of Hg^{2+} compounds, absorption decreased with increasing stability constant of the Hg^{2+} complex (Endo et al. 1990). These observations suggest that ligand interactions are important variables affecting absorption. These interactions include formation of Hg^{2+} S-conjugates, which have been found to be important in the transport of Hg^{2+} in kidneys, liver, and brain (Bridges and Zalups 2017). Studies conducted in mice and in cultured enterocytes have shown that Hg^{2+} can be a substrate for the divalent metal transporter, DMT1, which resides on the apical membrane of enterocytes and, therefore, may participate in the absorption of Hg^{2+} (Ilback et al. 2008; Vazquez et al. 2015). Analogous to Hg^{2+} transport in kidneys, amino acid transporters may also participate in the uptake of Hg^{2+} into hepatocytes (Bridges and Zalups 2017).

Inorganic Mercurous Mercury. No studies were located that provide estimates of absorption of ingested mercurous mercury compounds, although pharmacological use of calomel (mercurous sulfide) as a purgative and teething ointment has resulted in mercury poisoning (Davis 2000). Mercurous sulfide has a substantially lower solubility than mercuric chloride, which is likely to limit absorption of Hg^{1+}. However, the low pH and high chloride concentration of the gastric environment favor oxidation of solubilized Hg^{1+} to Hg^{2+}; therefore, absorption of Hg^{2+} may have contributed to toxicity observed in cases of calomel poisoning (Mousavi 2015; Nikolaychuk 2016).

Organic Mercuric Mercury. Studies conducted in humans, monkeys, and rodents have shown that gastrointestinal absorption of mercury is close to 100% following ingestion of methylmercury as the chloride salt or when incorporated into fish or other ingested protein (Aberg et al. 1969; Berlin et al. 1975; Clarkson 1971; Clarkson and Shapiro 1971; Li and Wang 2019: Miettinen et al. 1971; Mori et al. 2012; Nielsen 1992; Nielsen and Andersen 1991; Nielsen et al. 1992; Sundberg et al. 1999; Yannai and Sachs 1993).

Mechanisms of absorption. Studies conducted in rats and intestinal cell cultures have shown that absorption of methylmercury from the small intestine involves facilitated transport of S-conjugates of methylmercury out of the intestinal lumen (Bridges and Zalups 2017; Mori et al. 2012; Urano et al. 1990; Vazquez et al. 2014). The CH_3Hg-S-CysGly and CH_3Hg-S-Cys were more avidly taken up from the lumen of the rat small intestine than CH_3Hg-S-CysGlyGlu, suggesting that the transported species may be CH_3Hg-S-CysGly and CH_3Hg-S-Cys (Urano et al. 1990). In rats, orally administered methylmercury and CH_3Hg-S-Cys had similar absorption fractions and absorption kinetics (Mori et al. 2012), and inhibition of intestinal GGT suppressed absorption of orally administered methylmercury (Urano et al. 1990).

Dermal Exposure

Elemental Mercury. Hg^0 vapor is absorbed through the skin. Absorption was estimated in a human clinical study in which the forearms of subjects (adults) were exposed to $^{203}Hg^0$ vapor (0.88–2.14 mg Hg/m^3) and absorption was estimated from whole-body gamma counting (Hursh et al. 1989). Absorption into skin was estimated to range from 0.01 to 0.04 ng Hg/cm^2 skin per mg Hg/m^3 air. Approximately one-half of the mercury uptake into skin was eliminated by desquamation (skin shedding) over a period of 60 days. The remaining portion was absorbed into the systemic circulation, with the highest amounts of systemic mercury observed 10–30 days post-exposure. The rate constant for systemic absorption from skin was estimated to be approximately 0.05 day^{-1}, which corresponds to a half-time of 14 days. Based on the measured rate of dermal absorption and 80% absorption of inhaled mercury vapor, the relative contributions of the dermal and inhalation absorption routes during a full body immersion in mercury vapor were estimated to be 2.6 and 97.4%, respectively (Hursh et al. 1989).

Inorganic Mercuric Mercury. Dermal penetration of Hg^{2+} has been studied in preparations of isolated human and pig skin and in guinea pigs (Moody et al. 2009; Sartorelli et al. 2003; Skowronski et al. 2000). These studies showed that mercury from mercuric chloride was transferred across the skin and retained in skin, and that retention substantially exceeded transdermal transfer over the period of observation (16–72 hours). Transdermal transfer was of similar magnitude in the three studies. Sartorelli et al. (2003) estimated the permeability coefficient (K_p) for transdermal transfer across isolated human breast skin to be 1.4×10^{-2} cm/hour when the initial mercury concentration was 0.0088 $nmol/cm^3$ (1.8 µg Hg/L) and 3.0×10^{-3} cm/hour when the initial concentration was 0.0607 $nmol/cm^3$ (12.2 µg/L). At the lower concentration, 4.8% of the applied dose was transferred across the skin over a 72-hour period (1.64% over a 24-hour period) and 19% was retained in skin. At the higher concentration, transdermal transfer was 0.93% over a 72-hour period (0.34% in 24 hours) and 45% was retained in skin. In a study of isolated

human abdomen skin, transdermal transfer over a 24-hour period was 1.4% of the applied mercury dose
(1.1 µg Hg/cm^2), while 77% was retained in the skin (Moody et al. 2009). Transdermal transfer across
pig skin was 0.18% of the applied dose (0.25 µg/cm^2) when measured over a period of 16 hours and 66%
of the applied dose was retained in skin. Transdermal transfer and skin retention were lower after mixing
mercuric chloride with soil, and more substantially decreased if the mercury-soil mixture was allowed to
age (stored in the dark in a sealed vial) for a period of 3 months (Sartorelli et al. 2003, Skowronski et al.
2000). In guinea pigs, a dermal dose of 95 mg mercury as mercuric chloride applied to a 3.1 cm^2 area of
skin resulted in 65% mortality (Wahlberg 1965).

Inorganic Mercurous Mercury. No studies were located that estimated absorption of dermally applied
inorganic mercurous mercury. Pharmacological and cosmetic use of calomel (mercurous sulfide)
ointments (skin lightening, acne) has resulted in elevated urinary mercury levels and mercury poisoning
(Copan et al. 2015; Davis 2000).

Organic Mercuric Mercury. A study conducted in guinea pigs showed that methylmercuric
dicyandiamide (a fungicide) applied to skin was absorbed (Friberg et al. 1961). Following dermal
exposures to 2.6 or 5.3 mg Hg/cm^2, absorption was estimated to be 0.44 and 1.2% per hour.
Methylmercuric dicyandiamide is not a dissociable salt of methylmercury.

Dimethylmercury is rapidly absorbed through human skin. A lethal dose of dimethylmercury occurred
following accidental contact of the dorsal surface of a latex gloved hand to "a few drops" of liquid
dimethylmercury (Nierenberg et al. 1998; Siegler et al. 1999). The applied dose was reconstructed based
on measurements of BHg made approximately 5 months following the accident and the estimated half-
time of 75 days for HHg in the subject (Nierenberg et al. 1998). The applied dose was estimated to have
been approximately 1,344 mg mercury contained in approximately 0.48 mL of liquid dimethylmercury
(density 3.2 g dimethylmercury/mL) (Nierenberg et al. 1998).

Phenylmercury is absorbed through the skin. Estimates of the magnitude of absorption were not located;
however, cases of mercury toxicity (acrodynia) and elevated urinary mercury excretion have been
reported in infants exposed to phenylmercury that had been applied to cloth diapers as a fungicide (Gotelli
et al. 1985).

3.1.2 Distribution

Elemental Mercury. The distribution of absorbed mercury following inhalation of Hg^0 vapor reflects several processes: (1) diffusion of Hg^0 vapor into blood; (2) physical partitioning (dissolving) of Hg^0 into plasma, RBCs, and other tissues; (3) extracellular and intracellular oxidation of Hg^0 to Hg^{2+}; (4) formation of Hg^{2+} complexes with proteins and non-protein species (primarily with sulfhydryls, including sulfhydryl amino acids); and (5) and transport and distribution of Hg^{2+} complexes. Although Hg^{2+} is the dominant species of mercury retained in tissues, the distribution of mercury following exposure to Hg^0 vapor differs from the distribution observed following exposure to inorganic Hg^{2+} compounds (Berlin et al. 1966, 1969b; Khayat and Dencker 1983; Magos et al. 1989). These differences are attributed, in part, to the high solubility of Hg^0 in lipid as well its affinity for proteins such as hemoglobin (Hursh 1985; Magos 1967; Magos et al. 1978; U.S. Atomic Energy Commission 1961). Particularly relevant to the vulnerability of the nervous system to Hg^0 vapor is the pronounced distribution of mercury in the brain following Hg^0 vapor exposure. The distribution of inorganic Hg^{2+} is discussed in greater detail in the section on inorganic mercuric mercury.

Whole-body distribution. Following inhalation exposure to Hg^0 vapor, mercury distributes to the blood and other tissues. Hursh et al. (1976) measured regional external gamma activity following 14–24-minute exposures to $^{203}Hg^0$ vapor (0.1 mg Hg/m^3) and estimated that approximately 7% (range 6.3–8.3%; five adult subjects) initially distributed to the head region and that mercury levels in the kidney region were approximately 10-fold higher than levels in the head region. Studies conducted in monkeys and rodents have found that the largest portion of the absorbed dose and highest concentrations of mercury occur in the kidneys following inhalation exposure to Hg^0 vapor (Berlin et al. 1969b; Hayes and Rothstein 1962; Khayat and Dencker 1984). In monkeys, immediately after a 1-hour exposure to Hg^0 vapor, the rank order of mercury concentration in tissues was kidneys, lungs, myocardium, spleen, thymus, liver, brain, salivary glands, pancreas, skeletal muscles, whole blood, and testes (Khayat and Dencker 1984). Following a 4-hour exposure in mice (4–50 mg/m³), the rank order of mercury concentration in tissues was lungs, kidneys, thyroid, myocardium, adrenal glands, brain, eyes, liver, plasma, blood, testes, and abdominal fat (Khayat and Dencker 1983).

Vascular proximity of the heart and brain, coupled with a limiting oxidation rate of Hg^0 in blood, contributes to a first-pass effect on uptake in these tissues following inhalation of Hg^0 (Magos et al. 1989). In rats, uptake into the lungs, brain, and heart and exhalation of mercury were greater when Hg^0 was injected directly into the jugular vein than when the same dose was injected into the tail vein (Magos

et al. 1989). The time of first appearance of mercury in exhaled air, indicative of the transit time to the lungs, was 0.6 seconds following jugular vein injection and 1.8 seconds following tail vein injection, whereas the half-time for oxidation of Hg^0 in rat blood was estimated to be 3.3 seconds. The first-pass effect is also evident from differences in tissue distribution observed in monkeys and rodents following inhalation of Hg^0 vapor compared to similar doses of Hg^{2+} administered intravenously (Berlin et al. 1966, 1969b; Khayat and Dencker 1983; Magos et al. 1989). Studies conducted in monkeys and rodents have found that uptake of mercury into the brain and heart tissues is greater following an inhalation exposure to Hg^0 vapor compared to the same intravenous dose of mercuric chloride (Berlin et al. 1966, 1969b). In rats, higher initial mercury levels were observed in the adrenal cortex, brown fat, epididymides, eyes, ovaries, and thyroid gland following inhalation of Hg^0 vapor compared to the distribution following an intravenous dose of mercuric chloride (Khayat and Dencker 1983).

Distribution in blood. Mercury absorbed following inhalation of Hg^0 vapor distributes into plasma and RBCs (Berlin et al. 1969b; Cherian et al. 1978; Hursh et al. 1980; Khayat and Dencker 1983). Concentrations in the RBC fraction of blood exceeds that of plasma. The RBC-to-plasma ratio (RBC/plasma) has been measured in human clinical studies and in studies conducted in monkeys and rodents (Berlin et al. 1969b; Cherian et al. 1978; Hursh et al. 1980). In a human clinical study, the RBC/plasma ratio was >10 within minutes of inhaling Hg^0 vapor (0.1 mg/m^3 for 14–24 minutes), after which the ratio declined to a value of approximately 2 within 20 hours following exposure and remained at that ratio over the 5-day observation period. (Cherian et al. 1978). An RBC/plasma ratio of approximately 1.3 for total mercury was observed in Hg^0 workers (Suzuki et al. 1970). An RBC/plasma ratio of 2 corresponds to a whole blood/plasma ratio of approximately 1.45 if the hematocrit is 0.45. Sandborgh-Englund et al. (1998) measured whole blood and plasma concentrations in human subjects over a 30-day period following inhalation of mercury vapor (0.4 mg/m^3 for 25 minutes). The ratio of the area under the curve (AUC) for mercury in the RBCs to that in plasma (AUC_{RBC}/AUC_{plasma}) was approximately 1.33, consistent with an RBC/plasma ratio of approximately 1.7. A whole blood/plasma ratio of 1.3 was observed in workers exposed to Hg^0 vapor (Lundgren et al. 1967). The RBC/plasma ratios immediately after exposure to Hg^0 vapor were 2 in monkeys and >5 in rabbits (Berlin et al. 1969b). Following exposure of whole blood or plasma to Hg^0 vapor, mercury was found to be associated with proteins, including albumin, hemoglobin and other globulins, and non-protein sulfhydryls (NPSH) (Cember et al. 1968; U.S. Atomic Energy Commission 1961).

The decrease in the RBC/plasma ratio observed in the initial few minutes following exposure to Hg^0 vapor is thought to reflect an initial partitioning of Hg^0 into blood followed by distribution of its oxidation product, Hg^{2+}, between plasma, RBCs, and other tissues (Hursh et al. 1976; Magos 1967; Magos et al.

1978; U.S. Atomic Energy Commission 1961). Partitioning of Hg^0 into blood involves both the physical dissolving of Hg^0 into aqueous and lipid components of blood as well as an interaction with hemoglobin (Hursh et al. 1976; Magos 1967; U.S. Atomic Energy Commission 1961). The blood:air partition coefficient for Hg^0 in human whole blood ranged from approximately 10 to 4.2 over a range of temperatures extending from 10 to 37°C and ranged from 5.6 to 2.4 in plasma over the same temperature range (Hursh et al. 1980). The partition coefficient in lipid (sunflower oil) was approximately 80 (Hursh et al. 1980).

Distribution in brain and nervous tissue. Studies of regional and cellular distribution of mercury in the brain principally have relied on two techniques imaging the distribution of mercury. In studies in which exposures were to ^{203}Hg, the regional distribution of mercury can be observed by autoradiography, which maps the location of gamma emission from ^{203}Hg. Spatial resolution of this technique is limited by the path length between the tissue section and the radiography plate. Detection is also limited by the gamma emission decay of ^{203}Hg, which has a half-life of 37 days. Mercury can be visualized at the cellular and subcellular levels using autometallography. In this technique, the tissue section is placed in contact with a developing agent containing silver ion and a reducing agent. The silver reacts with Hg-sulfides in the tissue to form localized deposits of elemental silver that can be imaged by light or electron microscopy (Danscher and Moller-Madsen 1985; Nørgaard et al. 1989).

Mercury does not uniformly distribute in all areas of the brain following inhalation exposure to Hg^0 vapor. Autopsy studies of patients poisoned with mercury vapor found mercury deposited primarily in neuron vascular walls and brainstem and in deep nuclei of the cerebrum and cerebellum (O'Donoghue et al. 2020). Autopsy studies of Parkinson's Disease patients found mercury deposited in neurons of the substantia nigra, motor cortex, striatum, thalamus, and cerebellum (Pamphlett and Bishop 2022). Studies conducted in monkeys and rodents have found higher levels in gray matter compared to white matter and heterogenous distribution among brain nuclei (Berlin et al. 1969b; Nordberg and Serenius 1969; Warfvinge 2000; Warfvinge et al. 1994a). Higher mercury levels were found in the dentate nucleus in the cerebellum, inferior olivary nucleus, subthalamic nucleus, choroid plexus, and superior colliculus. Within the cerebral cortex, higher levels were found in the ganglionic layer, and mercury was found in both neurons and astrocytes. In the cerebellum, uptake was higher in the granular and Purkinje cell layers, and mercury was found in neurons and glial cells. In monkeys and mice, mercury was observed in the spinal cord following inhalation exposure to Hg^0 vapor, in association with motor neurons (Pamphlett and Coote 1998; Roos and Dencker 2012; Stankovic 2006). In a study conducted in mice, mercury was observed in association with spinal motor neurons 30 weeks after a single 12-hour exposure to 0.025 mg/m^3 or a 30-

minute exposure to 0.5 mg/m^3 (Pamphlett and Coote 1998). Studies conducted in monkeys have shown uptake of mercury into the retina, including optic disk, pigment epithelium, ganglion cells, and vessel walls (Khayat and Dencker 1983, 1984; Warfvinge and Bruun 1996, 2000). Analyses of tissues from autopsies of mercury minors have found concentrations in the thyroid and pituitary higher than in the kidneys, liver, or whole brain (Kosta et al. 1975).

Maternal-fetal-infant transfer. Mercury is transferred to the fetus and to nursing infants from breast milk following exposures to Hg^0. Concentrations of inorganic mercury in maternal blood, cord blood, placenta, and breast milk were higher in women who had been occupationally exposed to vapor compared to a control group, and the inorganic fraction of breast milk mercury was higher in the exposed group (Yang et al. 1997). Studies conducted in monkeys and rodents have shown that mercury absorbed following maternal inhalation exposures to Hg^0 vapor distributes to the placenta and fetus, including the fetal brain, kidneys, and liver (Clarkson et al. 1972; Ishitobi et al. 2010; Morgan et al. 2002; Pamphlett and Kum-Jew 2001, 2019: Pamphlett et al. 2019; Shimada et al. 2004; Warfvinge 2000; Yoshida et al. 2002). In mice, mercury was found associated with neonatal brain vasculature, sensory ganglia, and facial and spinal motor neurons following maternal exposure (0.5 mg/m^3, 4 hours/day) during GDs 14–18, but not when exposure occurred earlier in pregnancy (GDs 1–10) (Pamphlett and Kum-Jew 2001). A study conducted in monkeys exposed animals to 0.5 or 1 mg/m^3, 5 days/week during gestation (Warfvinge 2000; Warfvinge and Bruun 2000). In this study, mercury was detected in maternal and offspring cerebellum 3 years after maternal exposure. Mercury was found in Bergmann glia and Purkinje cells, granular and Golgi cells, and medullary astrocytes. The highest amounts of mercury were found in cerebellar nuclei. Areas of the retina where mercury distributed in adult monkeys were also sites of accumulation of mercury in offspring of monkeys exposed to Hg^0 vapor (Warfvinge and Bruun 2000). These areas included the optic nerve, retinal pigment epithelium, inner plexiform layer, ganglion cells, and vessel walls. Studies conducted in mice have examined eye tissues of mouse neonates following maternal exposures in late pregnancy (0.5 mg/m^3, 4 hours/day, GDs 14–18) and found deposits of mercury in the retinal ganglion cells, endothelial cells, and retinal pigment epithelium and optic nerve (Pamphlett et al. 2019). Following the same exposure protocol, deposits of mercury were found in skeletal connective tissues, including synovial cells, articular chondrocytes, and periosteal and tracheal cartilage cells (Pamphlett and Kum-Jew 2019).

Mercury released from dental amalgam restorations can be transferred to the placenta, fetuses, and newborns during nursing. Dental amalgam restorations in pregnant women increased placenta and cord levels of mercury compared to a control group with no amalgam restorations (Bedir Findik et al. 2016).

In rats and sheep, dental amalgam restorations installed during gestation increased mercury levels in the placenta and amniotic fluid; fetal brain, kidneys, and liver; and maternal milk (Takahashi et al. 2001; Vimy et al. 1990).

Elimination from tissues. Kinetics of elimination of mercury from plasma following exposure to Hg^0 vapor exhibits multiple phases. In a human clinical study, following a 15-minute inhalation exposure to Hg^0 vapor (0.4 mg/m^3), half-times for elimination from plasma were estimated to be 1.2 days (range 0.26–2.5 days) and 10.4 days (range 0.6–2.5 days; n=9 adult subjects) (Sandborgh-Englund et al. 1998). In another human clinical study in which subjects (adults) ingested capsules containing powdered mercury amalgam, the terminal elimination half-time for plasma mercury was estimated to be 37 days (af Geijersstam et al. 2001). In workers exposed to mercury vapor and monitored for a 600-day period following cessation of exposure, the elimination half-time for mercury in blood was estimated to be 45 days and the half-time for mercury in urine was estimated to be 56 days (Bluhm et al. 1992).

Studies conducted in rats have found that mercury concentrations decrease faster in most tissues compared to the kidneys and, as a result, several weeks following exposure, most of the body burden of mercury resides in the kidneys (Berlin et al. 1969b; Hayes and Rothstein 1962). In rats, mercury concentrations in the brain declined more slowly than either the body burden or the concentrations in the kidneys (Magos 1967). The same may not apply to humans. Following a brief exposure to $^{203}Hg^0$ (0.1 mg/m^3), the mean half-time for externally measured gamma activity in the head region was estimated to be 21 days (range 16–29 days; n=5 subjects) compared to 64 days (range 47–83 days) in the kidney region (Hursh et al. 1976).

Inorganic Mercuric Mercury. The distribution of absorbed Hg^{2+} reflects formation of Hg^{2+} complexes with proteins and non-protein species (primarily sulfhydryls, including sulfhydryl amino acids) and transport and distribution of Hg^{2+} complexes.

Whole-body distribution following inhalation. Studies conducted in rodents have found that the kidneys and liver retain the largest fractions of the absorbed dose following an oral dose of mercuric chloride and mercuric sulfide (Ekstrand et al. 2010; Feng et al. 2004; Højbjerg et al. 1992; Khan et al. 2001; Kostial et al. 1978, 1984; Lu et al. 2020; Nielsen and Andersen 1990, Nielsen et al. 1992; Nielsen and Hultman 1998; Nielsen et al. 1992; Piotrowski et al. 1992; Sin et al. 1983, 1989; Zhang et al. 2017). In mice, on day 14 following a single oral dose of mercuric chloride (1 mg Hg/kg), 40–50% of the residual body burden was in the kidneys, 10–20% in the liver, and 1% the in brain; other tissues retained <1% (Højbjerg et al. 1992; Nielsen and Andersen 1990, Nielsen et al. 1992). Following repeated exposure of mice to

mercuric chloride (2 or 3.7 mg Hg/L in drinking water for 6–12 weeks), mercury levels in the kidneys ranged from 10 to 100 times that of the liver, depending on the mouse strain and sex (Ekstrand et al. 2010; Nielsen and Hultman 1998). In some mouse strains, differences in whole-body retention of mercury have been shown to be associated with increased retention of mercury in the kidneys (Ekstrand et al. 2010; Nielsen 1992; Nielsen and Andersen 1990; Nielsen and Hultman 1998). Within-strain sex differences in whole-body and kidney retention have also been observed in mice, with males showing greater whole-body and kidney retention than females (Ekstrand et al. 2010). Following 14 days of daily gavage dosing of rats with mercuric chloride (2 mg/kg/day), the highest quantifiable concentration of mercury was found in the kidneys and liver, with the concentration in the kidneys approximately 60 times that of the liver (Khan et al. 2001).

Whole-body distribution following ingestion. Studies conducted in rodents have found that the kidneys and liver retain the largest fractions of the absorbed dose following an oral dose of mercuric chloride and mercuric sulfide (Ekstrand et al. 2010; Feng et al. 2004; Højbjerg et al. 1992; Khan et al. 2001; Kostial et al. 1978, 1984; Nielsen and Andersen 1990, Nielsen et al. 1992; Nielsen and Hultman 1998; Nielsen et al. 1992; Piotrowski et al. 1992; Sin et al. 1983, 1989; Zhang et al. 2017). In mice, on day 14 following a single oral dose of mercuric chloride (1 mg Hg/kg), 40–50% of the residual body burden was in the kidneys, 10–20% in the liver, and 1% the in brain; other tissues retained <1% (Højbjerg et al. 1992; Nielsen and Andersen 1990, Nielsen et al. 1992). Following repeated exposure of mice to mercuric chloride (2 or 3.7 mg Hg/L in drinking water for 6–12 weeks), mercury levels in the kidneys ranged from 10 to 100 times that of the liver, depending on the mouse strain and sex (Ekstrand et al. 2010; Nielsen and Hultman 1998). In some mouse strains, differences in whole-body retention of mercury have been shown to be associated with increased retention of mercury in the kidneys (Ekstrand et al. 2010; Nielsen 1992; Nielsen and Andersen 1990; Nielsen and Hultman 1998). Within-strain sex differences in whole-body and kidney retention have also been observed in mice, with males showing greater whole-body and kidney retention than females (Ekstrand et al. 2010). Following 14 days of daily gavage dosing of rats with mercuric chloride (2 mg/kg/day), the highest quantifiable concentration of mercury was found in the kidneys and liver, with the concentration in the kidneys approximately 60 times that of the liver (Khan et al. 2001).

Distribution in blood. The distribution of absorbed Hg^{2+} is strongly influenced by the high affinity of Hg^{2+} for the thiolate anion and formation of Hg^{2+} S-conjugates (Carty and Malone 1979). In plasma, the predominant sulfhydryls available to form S-conjugates with Hg^{2+} include albumin (approximately 1 mM) (Brown and Shockley 1982; Ikegaya et al. 2010) and low molecular weight thiols such as

glutathione and cysteine (approximately 10 μM) (Lash and Jones 1985). Within cells, Hg^{2+} forms
complexes with intracellular thiols, including glutathione, cysteine, glycinyl-cysteine, metallothionein,
and RBC hemoglobin (Cherian and Clarkson 1976; Hursh 1985; Kagi et al. 1984; Komsta-Szumska et al.
1976; Magos 1967; Magos et al. 1978; Piotrowski et al. 1974a, 1974b; U.S. Atomic Energy Commission
1961). The Hg^{2+} ion has a strong tendency to form conjugates with two sulfur ligands (e.g., R-S-Hg-S-
R′) (Carty and Malone 1979). This distinguishes S-conjugates of inorganic Hg^{2+} from those formed by
CH_3Hg^{2+} (CH_3Hg-S-R). In rats that received an injection of mercuric chloride (0.02 or 0.2 mg Hg)
approximately half of the mercury in blood was associated with RBCs, and mercury bound to protein in
plasma was associated with albumin and globulins (Cember et al. 1968). In mice administered mercuric
chloride, the concentration of Hg^{2+} in plasma was similar to that in whole blood (Sundberg et al. 1998).
In workers who were exposed to Hg^0 for varying lengths of time, the RBC/plasma mercury ratio was
observed to be approximately 1.3 (Suzuki et al. 1970). This ratio probably reflects the distribution of
Hg^{2+} formed from oxidation of absorbed Hg^0.

Distribution in the kidneys. Following a dose of mercuric chloride, absorbed mercury distributes to the
renal cortex and outer strip of the outer medulla in association with proximal tubules (Bergstrand et al.
1958; Berlin and Ullberg 1963a, 1963b, 1963c; Hultman and Enestrom 1986; Hultman et al. 1985; Rodier
et al. 1988; Zalups and Barfuss 1990). This non-uniform distribution within the kidney is the result of
membrane transporters in the proximal tubule that participate in the bi-directional transport of Hg^{2+}
(Cannon et al. 2000, 2001; Wei et al. 1999; Zalups and Lash 1997; Zalups and Minor 1995; Zalups et al.
1993). Transporters implicated in the uptake of Hg^{2+} in the mammalian proximal tubule include the
organic anion transporter, OAT1, located in the basolateral membrane of the proximal tubule and amino
acid transporter system, $b^{0,+}$, located in the luminal membrane (Bridges and Zalups 2005; Bridges et al.
2004; Wei et al. 1999; Zalups and Ahmad 2004; Zalups et al. 2004). Both systems transport sulfhydryl
conjugates of Hg^{2+} with the amino acid cysteine (Cys-S-Hg-S-Cys). On the luminal side of the proximal
tubule, formation of the cysteine S-conjugate is facilitated by the catabolism of a glutathione S-conjugate
(GluGlyCys-S-Hg-S-CysGlyGlu), which is catalyzed by the luminal membrane enzymes, GGT and
cysteinylglycinase (Berndt et al. 1985; de Ceaurriz et al. 1994; Tanaka et al. 1990; Tanaka-Kagawa et al.
1993; Zalups 1995; Zalups and Lash 1997). Luminal uptake of Hg^{2+} in the rat has been estimated to be
approximately half of total uptake (Zalups and Minor 1995). Within kidney cells, Hg^{2+} forms conjugates
with non-protein and protein sulfhydryls, including metallothionein (Cherian and Clarkson 1976;
Komsta-Szumska et al. 1976; Piotrowski et al. 1974a, 1974b).

Distribution in the liver. Studies conducted in rodents dosed with mercuric chloride have found higher accumulation in the periportal region of the liver (Berlin and Ullberg 1963a, 1963c). Mercury can distribute to the liver from the systemic circulation by way of the hepatic artery or from the gastrointestinal tract by way of the portal vein. Either route, in addition to transport of mercury into the bile duct, could contribute to higher concentrations in the periportal region. Several mechanisms may contribute to the uptake of mercury into the liver, including endocytosis of Hg^{2+} conjugates with albumin or other proteins in the sinusoidal space, and transport of Hg^{2+} or Hg^{2+} S-conjugates by carriers in the hepatic sinusoidal membrane (Bridges and Zalups 2017). Several transporters in the hepatic sinusoidal membrane may participate in transfer of Hg^{2+} from the sinusoidal space into hepatocytes; these include organic anion transporter, OAT2, and amino acid transporters (Bridges and Zalups 2017).

Maternal-fetal-infant transfer. Inorganic mercury is found in human cord blood, placenta, and breast milk, indicating potential routes of transfer to the fetus and infant (Ask et al. 2002; Bjornberg et al. 2003, 2005; Ou et al. 2014; Sakamoto et al. 2013; Sandborgh-Englund et al. 2001; Vahter et al. 2000). The appearance of inorganic mercury in fetal or neonatal tissues could represent direct transfer of inorganic mercuric mercury absorbed into the maternal system or could result from transfer of Hg^0 or methylmercury and subsequent oxidation and demethylation, respectively. Studies conducted in rodents dosed with mercuric chloride provide direct evidence of placental and lactational transfer of inorganic mercuric mercury (Dock et al. 1994; Feng et al. 2004; Mansour et al. 1974; Oliveira et al. 2001, 2015; Sundberg et al. 1998, 1999; Suzuki et al. 1967). Mechanisms of placental transfer of inorganic mercuric mercury have not been characterized and may involve transport of Hg^{2+} and Hg^{2+} S-conjugates in the kidneys and other tissues (Bridges and Zalups 2017).

Elimination from tissues. Whole-body retention kinetics of absorbed inorganic mercuric mercury in humans was estimated in a clinical study in which five adult subjects received a single intravenous dose of $^{203}Hg(NO_3)_2$ (0.6–2.8 Hg) (Hall et al. 1995). Although short-term kinetics following intravenous administration of Hg^{2+} may differ from that following the oral route of administration, the terminal half-time can be expected to reflect the elimination kinetics of inorganic mercuric mercury following its initial systemic distribution. The whole-body elimination half-time in the five subjects ranged from 49 to 96 days based on observations made over the period of 13–73 days following dosing. The corresponding blood half-time ranged from 23 to 66 days. Farris et al. (2008) reanalyzed the data from Hall et al. (1995) and reported the whole-body half-time for the interval 21–70 days following dosing; based on the combined data for the five subjects, the whole-body half-time was 75.9 days (range 49–120 days).

Whole-body elimination of mercury following ingestion of mercuric chloride exhibited multiple phases in rodents (Ekstrand et al. 2010; Nielsen and Hultman 1998). Three half-times estimated in four different mouse strains were 1.5–2.5 days for the fast phase, 10–12 days for the second phase, and 44–83 days for the slowest phase, when mice were observed for a period of 10 weeks following a 12-week period of exposure to mercuric chloride in drinking water (3.7 mg Hg/L) (Nielsen and Hultman 1998). Whole-body elimination half-times in four strains of mice were 0.98–2.04 days for the fast phase and 3.97–5.39 days for the slower phase, when measured over a 5-week period following 6 weeks of exposure to mercuric chloride in drinking water (2 mg Hg/L) (Ekstrand et al. 2010). The fast phase of elimination is due, in part, to excretion of unabsorbed mercury in feces and the slow phase is attributed to elimination from the kidneys and other tissues (Piotrowski et al. 1992). Since the kidneys are the major site of accumulation of mercury following ingestion of inorganic mercuric mercury, the rate of elimination of mercury from the kidneys is the major determinant of the rate of elimination of the absorbed dose.

Inorganic Mercurous Mercury. No studies were located that provide information on the distribution of absorbed inorganic mercurous mercury.

Organic Mercuric Mercury Similar to Hg^{2+}, CH_3Hg^{2+} has a high affinity for the thiolate anion and readily forms CH_3Hg^{2+} S-conjugates with protein and non-protein sulfhydryls (Carty and Malone 1979; see discussion of the distribution and elimination of inorganic mercuric mercury from blood). However, the CH_3Hg^{2+} ion has a strong tendency to form conjugates with a single sulfur ligand (e.g., CH_3Hg-S-R), unlike inorganic Hg^{2+}, which tends to form ligands with two sulfur ligands (R-S-Hg-S-R′) (Carty and Malone 1979). The difference in structure of S-conjugates may explain, at least in part, differences in the toxicokinetics of methylmercury and inorganic mercuric mercury. In particular, the larger oral absorption fraction of methylmercury, greater accumulation of methylmercury in the brain, and greater accumulation of inorganic mercury in the kidneys (Berlin et al. 2015; Bridges and Zalups 2005; Clarkson and Magos 2006).

Whole-body distribution. Studies of postmortem tissue mercury concentrations have revealed a non-uniform distribution of mercury and the methylmercury fraction in tissues (Bjorkman et al. 2007; Magos 1967; Matsuo et al. 1989; Sumino et al. 1975). Most notably, concentrations of methylmercury were highest in the liver (approximately 2–3-fold higher than in other tissues, including the brain, heart, kidneys, and spleen); however, the methylmercury fraction was highest in the brain, heart, and spleen (80%) and lower in the liver (38%) and kidneys (11–16%) (Matsuo et al. 1989). Postmortem measurements of mercury in tissues reflect the combined effects of exposure to inorganic and

methylmercury as well as changes to mercury concentrations that may have occurred postmortem. Postmortem measurements of mercury in tissues made after formalin fixation (embalming) are subject to errors from loss of mercury to tissue leakage and demethylation of methylmercury (Matsuo et al. 1989).

In three adult subjects who ingested a single oral dose of ^{203}Hg-labeled methylmercuric nitrate (9 μg Hg), measurements of external radiation indicated that approximately 10% of the body burden was detected in the head region and approximately 50% was in the region of the liver (Aberg et al. 1969). Studies conducted in monkeys and rodents have found that the liver, kidneys, and brain retain the largest fractions of the absorbed dose following an oral dose of methylmercury, while the highest concentrations occurred in the kidneys (Berlin et al. 1975; Clarkson and Shapiro 1971; Li et al. 2020; Nielsen and Andersen 1991; Nielsen et al. 1992; Rice et al. 1989; Sundberg et al. 1999; Yasutake et al. 1997).

The distribution of absorbed mercury following dosing with methylmercury has been studied in a variety of other mammalian species (Young et al. 2001), including cats (Charbonneau et al. 1976; Hollins et al. 1975), cows (Ansari et al. 1973; Sell and Davison 1975), goats (Sell and Davison 1975), guinea pigs (Iverson et al. 1973), hamsters (Omata et al. 1986), pigs (Charette et al. 2021; Gyrd-Hansen 1981), rabbits (Petersson et al. 1991), and sheep (Kostyniak 1983).

Dimethylmercury distributed to the brain, kidneys, and liver following a lethal dose of dimethylmercury resulting from accidental contact of the dorsal surface of a latex gloved hand to liquid dimethylmercury (Nierenberg et al. 1998; Siegler et al. 1999). In mice, absorbed dimethylmercury that was not exhaled distributed to tissues, with highest concentrations in the liver and kidneys (Ostlund 1969). Other sites of retention in mice were adipose tissue, adrenal cortex, brain, Harderian glands, lens of the eyes, intestines, oral mucosa, salivary glands, pituitary, spleen, and hair follicles (Ostlund 1969).

Distribution in blood. Most of the mercury in blood (>90%) following absorption of methylmercury is found in RBCs (Berglund et al. 2005; Kawasaki et al. 1986). Several factors contribute to the accumulation of methylmercury in RBCs. The S-conjugates of methylmercury with cysteine (CH_3Hg-S-Cys) and glutathione (CH_3Hg-S-CysGlyGlu) are substrates for organic anion transporters that facilitated uptake and concentration of methylmercury in the RBC (Wu 1995, 1996, 1997). Methylmercury readily exchanges between sulfhydryl ligands, which allows it to complex with hemoglobin, trapping methylmercury (temporarily) in the RBCs (Carty and Malone 1979; Rabenstein et al. 1982).

Distribution of mercury in blood following ingestion of methylmercury has been studied in several human clinical and occupational studies in which adult subjects ingested a tracer dose of ^{203}Hg-labeled methylmercury, or methylmercury incorporated in fish (Aberg et al. 1969; Birke et al. 1972; Kershaw et al. 1980; Lundgren et al. 1967; Miettinen et al. 1971; Sherlock et al. 1984), or received an intravenous dose of ^{203}Hg-labeled methylmercury (Smith et al. 1994). Following a fish meal (18–20 µg Hg/kg body weight), the concentration of mercury in blood increased above baseline; however, the concentration of inorganic mercury remained unchanged, indicating that the mercury absorbed from the fish meal was predominantly methylmercury (Kershaw et al. 1980). BHg accounted for approximately 5–7% of the absorbed dose (Kershaw et al. 1980; Sherlock et al. 1984; Smith et al. 1994). Within blood, most of the mercury was located in RBCs (Birke et al. 1972; Kershaw et al. 1980; Lundgren et al. 1967; Miettinen et al. 1971). The RBC/plasma ratio ranged from 17 to 26 and was nearly identical to the ratio for organic mercury, indicating that nearly all of the mercury in the RBC was organic mercury (Kershaw et al. 1980).

Following a lethal dermal dose of dimethylmercury (estimated dose approximately 1344 mg Hg), mercury concentrations in RBCs were approximately10–20-fold higher than concentrations in plasma (Nierenberg et al. 1998).

Distribution in the brain. Mercury does not uniformly distribute in all areas of the brain following inhalation exposure to methylmercury. Autopsy studies of people exposed to methylmercury found mercury deposited in glial and endothelial cells more prominently than in neurons (O'Donoghue et al. 2020). In monkeys, methylmercury was observed in the cerebral cortex and cerebellum located on the exterior of neurons and glial cells (Berlin et al. 1975; Kawasaki et al. 1986; Rice 1989b). Mercury concentrations in the cerebral cortex and cerebellum ranged from 2 to 7 times that of blood. Rice (1989c) measured regional brain levels of mercury in brains of monkeys 210–260 days following cessation of 800–1,000 days of oral dosing with methylmercury (25 or 50 µg Hg/kg). Mercury was distributed throughout the brain, with highest concentrations found in the hypothalamus and pons. Following exposure to methylmercury, mercury in the brain was found to be associated with protein and as S-conjugates with non-protein sulfhydryls, including glutathione, cysteine, homocysteine, and N-acetylcysteine (Clarkson 1993; Thomas and Smith 1979). Entry of methylmercury into the brain is facilitated by transport of the cysteine S-conjugate (CH$_3$Hg-S-Cys) by a neutral amino acid transporter (system L) in brain capillary endothelial cells (Aschner and Clarkson 1988, 1989; Aschner et al. 1990, 1991; Bridges and Zalups 2017; Kerper et al. 1992; Mokrzan et al. 1995; Simmons-Willis et al. 2002). The S-cysteine conjugate may be as substrate for system L as a structural analog of methionine (Bridges

and Zalups 2017; Kerper et al. 1992; Simmons-Willis et al. 2002). Following exposure to ethylmercury, mercury has been detected in the brain (reviewed by Kern et al. 2020).

Autopsy findings 10 months following a lethal dermal dose of dimethylmercury (estimated dose approximately 1,344 mg Hg), showed elevated levels of mercury in the frontal lobe and visual cortex (3.1 µg/g), atrophy of the cerebral cortex and cerebellum, and neuron loss in the visual and auditory cortices (Nierenberg et al. 1998).

Distribution in the kidneys. A large fraction (60–70%) of the mercury found in monkey kidneys following an oral dose of methylmercuric hydroxide (0.8 mg/kg, 0.7 mg Hg/kg) was identified as inorganic mercury (Berlin et al. 1975). Mercury concentrations in the renal cortex of monkeys were approximately 20 times higher than in the blood 210–260 days following cessation of 800–1,000 days of oral dosing (25 or 50 µg Hg/kg) (Rice 1989b). In a study conducted in rats, 40–50% of the mercury administered as methylmercury (5 mg Hg/kg) was identified in the kidneys as inorganic mercury, whereas <1% of mercury in blood was inorganic (Zalups et al. 1992). In mice, organic mercury in the kidneys has been identified as methylmercury protein complexes and S-conjugates with glutathione and cysteine (Yasutake et al. 1989). This suggests the possibility that renal uptake of absorbed methylmercury may reflect a combination of the renal handling of methylmercury and inorganic mercuric mercury formed from methylmercury in or external to the kidneys. Mercury accumulates in the renal cortex following exposures to methylmercury (Rice 1989b; Zalups et al. 1992). Studies conducted in rats that received doses of methylmercury (5 mg Hg/kg) found the distribution of mercury within the kidneys to be similar to that following a dose of inorganic mercuric mercury, with the highest concentrations in the renal cortex and outer stripe of the outer medulla (Zalups et al. 1992). Uptake of methylmercury into the kidneys is facilitated by transporters in the luminal (system $b^{0,+}$) and basolateral (OAT1) membranes of the proximal tubules that transport S-conjugates of methylmercury with cysteine or homocysteine (Berlin et al. 2015; Bridges and Zalups 2017; Koh et al. 2002; Tanaka et al. 1992; Zalups and Ahmad 2005a, 2005b, 2005c).

Autopsy findings 10 months following a lethal dermal dose of dimethylmercury (estimated dose of approximately 1,344 mg Hg) showed elevated levels of mercury in the renal cortex (34.8 µg/g) (Nierenberg et al. 1998).

In rats that received a subcutaneous dose of phenylmercury (2.95 mg phenylmercuric acetate, 1.76 mg Hg), the inorganic fraction of mercury in the kidneys increased from 41% at 2 hours to 80% at 24 hours

after the administered dose (Daniel et al. 1972). Total mercury concentration in the kidneys at 24 hours was 22 µg/g.

Distribution in the liver. A large fraction (70–90%) of the mercury found in monkey liver following an oral dose of methylmercuric hydroxide (0.8 mg/kg, 0.7 mg Hg/kg) was identified as organic mercury (Berlin et al. 1975). This suggests the possibility that hepatic uptake of absorbed methylmercury may reflect a combination of the hepatic handling of methylmercury and inorganic mercuric mercury formed from methylmercury in or external to the liver. Several mechanisms may contribute to the uptake of methylmercury into liver, including endocytosis of S-conjugates with albumin or other proteins in the sinusoidal space, and transport of S-conjugates by carriers in the hepatic sinusoidal membrane (Ballatori and Truong 1995; Berlin et al. 2015; Bridges and Zalups 2017; Thomas and Smith 1982; Wang et al. 2000).

Autopsy findings 10 months following a lethal dermal dose of dimethylmercury (estimated dose of approximately 1,344 mg Hg), showed elevated levels of mercury in the liver (20.1 µg/g) (Nierenberg et al. 1998).

In rats that received a subcutaneous dose of phenylmercury (2.95 mg phenylmercuric acetate, 1.76 mg Hg), the inorganic fraction of mercury in the liver increased from 26% at 2 hours to 76% at 24 hours after the administered dose (Daniel et al. 1972). Total mercury concentration in the liver at 24 hours was 7.4 µg/g.

Maternal-fetal-infant transfer. Methylmercury is found in human cord blood, placenta, and breast milk, indicating potential routes of transfer to the fetus and nursing infant (Ask et al. 2002; Bjornberg et al. 2003, 2005; Gundacker et al. 2021; Hadavifar et al. 2020; Iwai-Shimada et al. 2015; Kim et al. 2011; Marques et al. 2013c; Ou et al. 2014; Sakamoto et al. 2018; Stern and Smith 2003; Vahter et al. 2000; Vollset et al. 2019; Wells et al. 2016). Studies conducted in monkeys and rodents provide direct evidence of placental and lactational transfer of mercury following exposure to methylmercury (Gilbert et al. 1993, 1996; Harry et al. 2004; Hu et al. 2010; Kajiwara et al. 1997; Newland and Reile 1999; Nordenhall et al. 1998; Oliveira et al. 2001, 2017; Oskarsson et al. 1995; Rice 1992; Stern et al. 2001; Sundberg et al. 1991, 1998, 1999). A cross-fostering study conducted in hamsters found that *in utero* transfer of mercury following gestational exposure to methylmercury was approximately 0.9% of the maternal mercury dose (0.32 mg Hg/kg) and lactational transfer was approximately 4.5% of the maternal body burden at the start of nursing (Nordenhall et al. 1998).

Studies conducted in rodents have shown that methylmercury transferred to the fetus distributes to the brain, liver, and kidneys, with the highest concentrations in these tissues observed in the liver (Inouye et al. 1986; Nordenhall et al. 1998; Oliveira et al. 2001; Sundberg et al. 1999). In mice and rats, *in utero* exposure to methylmercury resulted in mercury concentrations in the fetal brain that exceeded concentrations in fetal blood or the maternal brain (Inouye et al. 1986; Stern et al. 2001). In rats following *in utero* exposure to methylmercury, the rank order of mercury concentrations in the fetal brain was cerebrum > cerebellum > hippocampus (Hu et al. 2010). Mechanisms of placental transfer of methylmercury have not been fully characterized; however, a contributing mechanism involves transport of the cysteine S-conjugate, $CH_3Hg-S-Cys$ (Berlin et al. 2015; Bridges and Zalups 2017; Bridges et al. 2012; Kajiwara et al. 1996).

Mercury can be transferred to the fetus following absorption of dimethylmercury. In mice, following an intravenous dose of ^{203}Hg-labeled dimethylmercury, mercury distributed to the fetus, with highest levels detected in the bronchi, nasal and oral mucosa, and lens of the eyes (Ostlund 1969).

Elimination from tissues. A human clinical study measured whole-body mercury for a period of 3 months following an oral dose of ^{203}Hg-labeled methylmercuric nitrate (9 µg Hg). The whole-body half-time ranged from 70.4 to 74.3 days (three adult subjects) (Aberg et al. 1969). The whole-body half-time was estimated to be 134 days (SD 2.7 days, n=7) in monkeys that were monitored for a period of 115 days following an oral dose of 0.8 mg/kg methylmercuric hydroxide (0.7 mg Hg/kg) (Berlin et al. 1975). Whole-body retention kinetics of absorbed methylmercury in humans was estimated in a clinical study in which seven adult subjects received a single intravenous dose of ^{203}Hg-labeled methylmercury (0.6–2.8 Hg) (Smith et al. 1994). Although short-term kinetics following intravenous administration may differ from that following the oral route of administration, the terminal elimination half-time can be expected to reflect the elimination kinetics of mercury following its initial systemic distribution. Whole-body elimination half-time in the seven subjects ranged from 40 to 53 days (geometric mean 42.7±1.2 SD) based on observations made over the period of 10–70 days following dosing. The whole-body elimination half-time corresponded to elimination of 1.6±1.2% of the total mercury body burden per day.

Several clinical studies have estimated blood elimination half-times of mercury following exposure to methylmercury. Elimination of mercury from blood was biphasic; the estimated half-time for the fast phase was 7.6 days (SE 0.8) and 51.9 days (SE 3.7) for the slower phase (Kershaw et al. 1980). The

terminal half-time was estimated to be 50 days based on measurements of BHg in 20 adult subjects during and following cessation of consumption of mercury in fish (43–233 µg Hg/day) (Sherlock et al. 1984). Terminal-plasma elimination half-times for mercury following ingestion of methylmercury ranged from 47 to 130 days (Birke et al. 1972) and from 99 to 120 days for RBCs (Birke et al. 1972). A human clinical study measured clearances of mercury from the whole body and of total mercury and methylmercury from blood in seven adult subjects following a single intravenous dose of ^{203}Hg-labeled methylmercury (0.6–2.8 Hg) (Smith et al. 1994). Blood was estimated to contain 7.5% of the injected mercury dose, of which >90% was identified as methylmercury. The blood elimination half-time for methylmercury measured from day 10 to day 70 following the dose, ranged from 32 to 60 days (seven adult subjects; geometric mean 44.8±1.2 days) and was nearly identical to the whole-body mercury elimination half-time (43.7±1.2 days). A study conducted in monkeys estimated the elimination half-time to be 49.1 days (SD 2.8) for mercury in blood monitored for a period of 115 days following an oral dose of methylmercury (0.8 mg/kg, 0.7 mg Hg/kg) (Berlin et al. 1975). Similar to humans, the RBC/plasma mercury concentration ratio in monkeys was approximately 20 (Berlin et al. 1975).

A population study estimated blood half-times for methylmercury in 125 pregnant women (Albert et al. (2010). Scalp and whole hair mercury levels were measured at weeks 12 and 32 of pregnancy. Dietary mercury intakes were estimated in each subject from a food frequency questionnaire with seafood items paired to a national (France) database on methylmercury content of foods (Verger et al. 2007). The following one-compartment model was solved to estimate blood half-time:

$$MeHg_b = \frac{d \cdot t_{1/2} \cdot Abs \cdot f_b \cdot w}{\ln(2) \cdot V_b}$$

where d is the daily dietary intake (µg/kg body weight/day), $t_{1/2}$ is the blood methylmercury half-time (day), Abs is the gastrointestinal absorption fraction, f_b is the blood fraction of the body burden (the fraction of the total amount of methylmercury in the body that is in the blood), w is the body weight (kg), and V_b is the blood volume (L). Values for parameters were assigned prior distributions based on various sources (Albert et al. 2010) and posterior distributions were estimated in Markov Chain Monte Carlo simulations. When estimated assuming a point estimate for the population dietary intake, the mean half-time was 65.4 days (SD 6.0; 95% CI 54, 78). When interindividual variability in dietary mercury intake was included in the estimation of the half-time, the population mean half-time was 103 days (SD 9.5; 95% CI 83, 121).

Jo et al. (2015) used a similar approach to estimate half-times in 304 adults who were randomly selected from BHg quartiles of the Korean Research Project on Integrated Exposure Assessment to Hazardous Materials for Food Safety (KRIEFS) cohort (Jo et al. 2015). Values for parameters were assigned prior distributions (based on Albert et al. 2010; Stern 1997) and posterior distributions were estimated in Markov Chain Monte Carlo simulations. The estimated population mean half-time (n=304) was 80.2 days (2.5[th]–97.5[th] percentile range: 64.0–97.4 days). The estimated mean half-time for males (n=167) was 81.6 days (range 66.0–98.8 days); for females (n=137), the estimated mean half-time was 78.9 days (range 62.8–96.4 days).

In monkeys, elimination of mercury from blood following oral doses of methylmercury was biphasic (Rice 1989a, 1989b; Rice et al. 1989). Terminal BHg half-times in monkeys ranged from 10 to 15 days when followed for a period of 50 days following a single dose of 50 or 500 g Hg/kg as methylmercury. With repeated dosing of 10, 20, or 50 g Hg/kg/day, time to 95% of BHg steady state was estimated to range from 76 to 103 days. In monkeys followed for a period of 210–260 days following cessation of 800–1,000 days of oral dosing with methylmercury (25 or 50 µg Hg/kg), the estimated BHg half-time ranged from 9 to 17 days (9 monkeys) and the mean was 14 days. Estimated elimination half-times for the brain ranged from 38 to 79 days (nine monkeys) and were substantially greater than estimated half-times for blood, which ranged from 9 to 14 days (Rice 1989b).

Elimination of mercury from blood was measured following a lethal dermal dose of dimethylmercury (estimated dose of approximately 1,344 mg Hg) (Nierenberg et al. 1998). Measurements began approximately 170 days following the exposure and continued for a period of 95 days. The estimated elimination half-times were 33 days in whole blood, 37 days in RBCs, and 29 days in plasma. In mice, the whole-body elimination half-time was estimated to be 70 days when measured over a 25-day period following an inhaled dose of dimethylmercury (from 4–5 to 9 Hg/kg) and 95 days following an intravenous dose (12–15 mg Hg/kg) (Ostlund 1969).

3.1.3 Metabolism

Elemental Mercury. Absorbed Hg^0 is rapidly oxidized to mercuric mercury (Hg^{2+}) in tissues. Oxidation removes Hg^0 from blood and limits its distribution to other tissues and elimination in exhaled air. Oxidation occurs in the brain, RBCs, lungs, liver, and other tissues (Clarkson 1989; Dencker et al. 1983; Hursh et al. 1980; Magos et al. 1978; Satoh et al. 1981). The major oxidative pathway for Hg^0 is catalyzed by the enzyme, catalase (Halbach and Clarkson 1978; Hursh et al. 1980; Nielsen-Kudsk 1973;

Magos et al. 1978). Metabolism of Hg^0 through the catalase pathway is saturable, in part, due to limitations in availability of intracellular hydrogen peroxide (Magos et al. 1989; Nielsen-Kudsk 1973). Saturation of metabolism in RBCs alters the distribution of absorbed Hg^0, increasing its distribution to extravascular tissues (Magos et al. 1989).

Inorganic Mercuric Mercury. Exhaled Hg^0 was observed in mice following parenteral doses of mercuric chloride, suggesting that Hg^{2+} had been reduced to Hg^0 (Clarkson and Rothstein 1964; Dunn et al. 1978). The mechanism for reduction of Hg^{2+} in mammalian tissues has not been characterized and may be non-enzymatic or of bacterial origin. A Hg^{2+} reductase is found in various forms of bacteria (Boyd and Barkay 2012; Fox and Walsh 1982). Salivary and gastrointestinal bacteria have been shown to methylate Hg^{2+}; however, the quantitative significance of methylation in the disposition of absorbed Hg^{2+} remains uncertain (Barregard et al. 1994b; Li et al. 2019b; Rowland et al. 1975a, 1975b).

Inorganic Mercurous Mercury. No studies were located that provide information on the metabolism of absorbed inorganic mercurous mercury. The low pH and high chloride concentration of the gastric environment favor oxidation of ingested Hg^1 to Hg^{2+} (Mousavi 2015; Nikolaychuk 2016).

Organic Mercuric Mercury. Studies conducted in humans and in a variety of other mammalian species have observed methylmercury and inorganic mercury in tissues and excreta following exposure to methylmercury (Berlin et al. 1975; Caito et al. 2018; Farris et al. 1993; Havarinasab et al. 2007; Iverson and Hierlihy 1974; Li et al. 2020; Norseth 1971; Norseth and Clarkson 1970; Oliveira et al. 1998; Smith et al. 1994; Zorn and Smith 1989). In rats that received a single oral dose of ^{203}Hg-labeled methylmercury (4.5 µg Hg), 69% of the administered dose was demethylated over a 98-day observation period (Farris et al. 1993). Gastrointestinal bacteria are a major contributor to demethylation and degrade ingested methylmercury as well as absorbed methylmercury that is secreted into the small intestine (Caito et al. 2018; Farris et al. 1993; Li et al. 2019b; Norseth and Clarkson 1970). Demethylation also occurs in the liver, phagocytes, brain, and other tissues (Charleston et al. 1995; Nagano et al. 2010; Shapiro and Chan 2008; Suda et al. 1992, 1993; Uchikawa et al. 2016; Vahter et al. 1995; Yasutake and Hirayama 2001). In the liver, demethylation occurs in the microsomal fraction catalyzed by NADPH-cytochrome P-450 reductase and by other free radical driven mechanisms (Suda and Hirayama 1992). Salivary and gastrointestinal flora can methylate Hg^{2+}; however, the quantitative significance of this pathway to net methylmercury production remains uncertain (Barregard et al. 1994b; Li et al. 2019b). In the liver and gastrointestinal tract, methylmercury can react with reactive sulfur species (e.g., glutathione, hydrogen sulfide and hydrogen persulfide) to form bismethylmercury sulfide ($[MeHg]_2S$) (Abiko et al. 2021;

Yoshida et al. 2011). The reaction in the gastrointestinal tract is thought to be mediated by intestinal bacteria (Abiko et al. 2021; Seki et al. 2021).

Dimethylmercury has been shown to be demethylated in mice. Following inhalation or intravenous exposure to ^{203}Hg-labled dimethylmercury (20 mg Hg/kg), mercury retained in the kidneys and liver 24 hours following exposure was identified as methylmercury, while mercury excreted in exhaled air was identified as dimethylmercury (Ostlund 1969).

A study conducted in rats showed that following a subcutaneous dose of phenylmercury (2.95 mg phenylmercuric acetate, 1.76 mg Hg), approximately 80–90% of the mercury excreted (bile, urine, feces) and retained in the kidneys and liver was inorganic mercury (Daniel et al. 1972). The time for conversion to inorganic mercury was approximately 1 day, based on measurements of the inorganic fraction in excreta and tissues. In the kidneys and liver, the inorganic fraction increased during the first day after dosing to 80 and 76% in the kidneys and liver, respectively (Daniel et al. 1972). Phenylmercury was demethylated in the soluble fraction of rat liver homogenates, in a reaction that did not require NADPH or NADH (Daniel et al. 1972).

3.1.4   Excretion

Elemental Mercury. The major routes of excretion of absorbed Hg^0 are excretion of unmetabolized Hg^0 in exhaled air and urinary and fecal excretion of mercuric Hg^{2+} following oxidation of Hg^0 in blood and other tissues. A more detailed discussion of the excretion of mercuric mercury is present in the section on mercuric compounds. Mercury has also been detected in sweat following exposure to Hg^0 (Bjorkman et al. 1997; Lovejoy et al. 1973; Sunderman 1978). Mercury excretion following inhalation of Hg^0 has been measured in several clinical studies conducted in adults (Cherian et al. 1978; Hursh et al. 1976, 1980; Sandborgh-Englund et al. 1998; Teisinger and Fiserova-Bergerova 1965). Exhaled air was the dominant excretion pathway shortly after inhalation of Hg^0 vapor and accounted for approximately 10% of the inhaled dose (Cherian et al. 1978; Hursh et al. 1976, 1980; Sandborgh-Englund et al. 1998). Over a 7-day observation period following a 14–24-minute inhalation exposure to Hg^0 vapor (1 mg Hg/m^3), 7% of the initially retained dose was exhaled, 2.4% (range 1.9, 2.5%, n=5 adults) was excreted in urine, and 9.2% (range 7.7=11.9%) was excreted in feces (Cherian et al. 1978). When monitored over longer periods that exceed the time for excretion of Hg^0 vapor in exhaled air, a larger fraction of the inhaled dose is excreted in urine (Sandborgh-Englund et al. 1998). This later phase represents mercury (primarily inorganic mercuric mercury) excreted from blood, kidneys, and other tissues. In a study that monitored subjects for

30 days postexposure (0.4 mg Hg/m^3 for 15 minutes), 7.5–12% (n=9 adults) of the inhaled dose was exhaled during the first 3 days following dosing and approximately 1% was excreted in urine, whereas 13% (range 8–40%) was excreted in urine over the 30-day observation period (Sandborgh-Englund et al. 1998). Based on the data from the Sandborgh-Englund et al. (1998) study, Jonsson et al. (1999) estimated that, over a period of 1 year, 14% of the initially retained dose of inhaled Hg^0 vapor would be exhaled and 55% would be excreted in urine.

Half-times for decline in urinary excretion of mercury following inhalation of Hg^0 vapor have been measured in human clinical studies and in workers exposed to Hg^0 vapor (Barregard et al. 1992, 1996; Harari et al. 2012; Jonsson et al. 1999; Sallsten et al. 1994). Jonsson et al. (1999) estimated the urinary excretion half-time to be 63.1 days (range 12.8–98.9 days; eight adult subjects) over a 30-day period following a 15-minute exposure to 0.4 mg Hg/m^3 Hg^0 vapor (data from Sandborgh-Englund et al. 1998). These estimates are consistent with half-times estimated in chloralkali workers (range 10–210 days) who were exposed to Hg^0 vapor (Barregard et al. 1992, 1996; Sallsten et al. 1994). The half-time for decrease in urinary mercury following a decrease in exposure to Hg^0 vapor varied with genotype of the enzyme glutamate-cysteine ligase modifier subunit (GCLM-588). The half-time was estimated to be 77 days for the CC genotype and 34 days for the CT/TT genotype (Harari et al. 2012).

Fecal excretion of mercury following inhalation of Hg^0 vapor has been observed in human clinical studies and in rats (Hayes and Rothstein 1962; Hursh et al. 1980). In a human clinical study, cumulative excretion over a 7-day period following exposure to Hg^0 vapor (range 0.06–0.08 mg Hg/m^3, n=2 adult subjects) was approximately 4% in urine and 11% in feces (Hursh et al. 1980). In rats, fecal excretion was the dominant excretory pathway during the first 6 days following exposure (6% of body burden per day); however, some of fecal excretion may have derived from ingestion of mercury that adhered to the body surface following whole-body exposure (Hayes and Rothstein 1962). After 6 days, fecal and urinary excretion occurred at similar rates (approximately 0.7–1% of the body burden per day).

Based on human clinical studies and animal studies, fecal and urinary excretion are dominant long-term routes of excretion and elimination of mercury absorbed following inhalation of Hg^0 vapor (Barregard et al. 1992, 1996; Hayes and Rothstein 1962; Hursh et al. 1980; Jonsson et al. 1999; Sallsten et al. 1994; Sandborgh-Englund et al. 1998). Therefore, long-term kinetics of the body burden (e.g., terminal half-time) provide estimates of the combined rates of excretion in feces and urine. The terminal whole-body half-time has been measured in humans and rodents (Hayes and Rothstein 1962; Hursh et al. 1976). The half-time in humans was estimated to be 58 days (range 35–90 days, n=5 adult subjects) when assessed

over a period that ranged from 9 to 48 days (Hursh et al. 1976). This value is close to the terminal half-time estimated for the decline in urinary mercury after an exposure to Hg^0 vapor (Jonsson et al. 1999). In rats, the terminal whole-body half-time was estimated to be 15–24 days when assessed over a period of 1–16 days (Hayes and Rothstein 1962).

Inorganic Mercuric Mercury. Absorbed inorganic mercuric mercury is excreted in feces and urine. In a clinical study in which five adult subjects received a single intravenous dose of $^{203}Hg(NO_3)_2$ (0.6–2.8 Hg), fecal excretion measured over a 70-day period following dosing ranged from 18 to 38% of the administered dose and urinary excretion ranged from 6 to 35% of the dose (Hall et al. 1995). Farris et al. (2008) reanalyzed the data from Hall et al. (1995) and, based on the combined data for the five subjects, estimated that approximately 30% of the dose was excreted in feces and 25% was excreted in urine. In humans, absorbed mercury is also excreted in sweat (Genuis et al. 2011; Robinson and Skelly 1983; Sears et al. 2012) and saliva (Bjorkman et al. 1997; Joselow et al. 1968). Studies conducted in rodents have found that mercury absorbed following an oral dosing with mercuric chloride is excreted in feces and urine (Morcillo and Santamaria 1995). In rats, mercury has been observed in salivary and lacrimal glands following exposure to mercuric chloride (Warfvinge et al. 1994b). Absorbed inorganic mercuric mercury is not appreciably accumulated in hair (Berglund et al. 2005; George et al. 2010; Yasutake and Hachiya 2006).

Excretion following inhalation. Following an accidental inhalation exposure to ^{203}HgO, urinary excretion was estimated to account for elimination of all absorbed mercury (Newton and Fry 1978). Following nose-only exposures of dogs to aerosols of mercuric oxide (^{203}HgO, 5 mg/m^3, count median diameter 0.16 µm), mercury was excreted in feces and urine. The fecal/urine ratio ranged from 0.06 on the first day following exposure to 0.3 on day 5 of exposure (Morrow et al. 1964).

Excretion following ingestion. Rahola et al. (1972, 1973) measured mercury excretion in adult subjects following ingestion of a single tracer dose of $^{203}Hg(NO_3)_2$ (6 µg) mercury in drinking water (two subjects) or mixed with calf liver paste (eight subjects). Immediately after dosing and during the absorption phase, feces was the dominant route of excretion of mercury. Within 5 days following dosing, the rate of fecal excretion declined to be similar to the rate of urinary excretion (0.05–0.15% of the administered dose per day). At 50 days following the administered dose, fecal and urinary excretion were each approximately 0.02% of the administered dose per day. Fecal mercury observed following an oral dose of inorganic mercuric mercury results from a combination of unabsorbed and absorbed mercury.

Mechanisms of fecal and urinary excretion. Studies conducted in rodents have shown that fecal excretion of absorbed inorganic mercuric mercury derives from secretion from the liver into bile as well as secretion from blood across the gastrointestinal epithelium (Ballatori and Clarkson 1984, 1985; Sugawara et al. 1998; Zalups 1998; Zalups et al. 1999). Secretion into bile is dependent on intracellular glutathione, suggesting that mercury may be transported in the liver as a Hg^{2+} S-conjugate of glutathione (Ballatori and Clarkson 1984, 1985). Several transporters in the bile canalicular membrane may participate in the transfer of Hg^{2+} from hepatocytes into bile; these include multidrug resistance proteins, MDR1, MRP2, and MRP3; and the breast cancer resistant protein, BCRP (Bridges and Zalups 2017).

Studies conducted in rodents and mammalian kidney cell cultures have shown that several processes in the kidneys contribute to excretion of inorganic mercuric mercury in urine. These include glomerular filtration of Hg^{2+} S-conjugates (e.g., albumin cysteine, glutathione), transport of Hg^{2+} S-conjugates (e.g., Cys-Hg-Cys) out of the tubular fluid into proximal tubule cells, and transport of Hg^{2+} S-conjugates (e.g., Cys-Hg-Cys) from peritubular blood into proximal tubule cells (Berlin et al. 2015). The relative contributions of these three processes may vary with dose and other factors that may affect such variables as binding of Hg^{2+} to plasma proteins, glomerular sieving of protein, levels of intra- and extracellular glutathione and metallothionein in proximal tubule cells, and presence of other non-physiological ligands that can form transportable S-conjugates with Hg^{2+} (Berlin et al. 2015; Zalups 2000; Zalups and Bridges 2012). Net secretion of Hg^{2+} from blood to urine has been shown to be mediated by the multidrug resistance protein, MRP2 (Bridges et al. 2011, 2013).

Organic Mercuric Mercury. Following a dose of methylmercury, the major routes of excretion of mercury are feces, urine, and hair (Berlin et al. 1975; Cernichiari et al. 1995; Farris et al. 1993; Johnsson et al. 2005; Kawasaki et al. 1986; Kershaw et al. 1980; Li et al. 2020; Mottet et al. 1987; Nordenhall et al. 1998; Smith et al. 1994; Yaginuma-Sakurai et al. 2012). Most of the mercury excreted in feces and urine is inorganic mercury, while the dominant form in hair is organic mercury (Berlin et al. 1975; Caito et al. 2018; Cernichiari et al. 1995; Farris et al. 1993; Giovanoli-Jakubczak et al. 1974; George et al. 2010; Ishihara 2000; Norseth and Clarkson 1970; Rothenberg et al. 2016b; Smith et al. 1994). A human clinical study measured excretion of mercury in seven adult subjects following a single intravenous dose of [203]Hg-labled methylmercury (0.6–2.8 Hg) (Smith et al. 1994). During the 70-day observation period, 31% of the dose was excreted in feces and 4% was excreted in urine. A study conducted in monkeys found that 85 days following a single oral dose of methylmercury (0.8 mg/kg, 0.7 mg Hg/kg), approximately 70% of the initial body burden remained in the body, of which 50% of the total body burden was in hair (Berlin et al. 1975). In rats, 98 days following a single oral dose of methylmercury

(4.5 µg Hg), 90% of the remaining body burden (12% of the dose) was associated with hair (Farris et al. 1993).

Methylmercury is secreted from the liver into bile and transported into the gastrointestinal tract, where it can be reabsorbed into the blood or demethylated and excreted in feces as inorganic mercuric mercury (Ballatori and Clarkson 1984; Dutczak and Ballatori 1994; Dutczak et al. 1991). Biliary secretion of methylmercury is dependent on glutathione and metabolism of glutathione by the enzyme, GGT (Ballatori and Clarkson 1982, 1985; Omata et al. 1978; Refsvik 1983; Refsvik and Norseth 1975). In rats, development of biliary secretion of methylmercury occurs at age 2–4 weeks, in association with the development of biliary secretion of glutathione (Ballatori and Clarkson 1982). Inhibition of (or absence of) hepatic GGT disrupts biliary secretion of methylmercury and accelerates excretion of methylmercury in urine (Ballatori et al. 1998). Secretion of methylmercury is thought to involve the following processes: formation of an S-conjugate of methylmercury with glutathione (CH_3Hg-S-CysGlyGlu), metabolism of the CH_3Hg-S-CysGlyGlu by GGT, and transport of CH_3Hg S-Cys or CH_3Hg-S-CysGlyGlu across the canalicular membrane (Dutczak and Ballatori 1994; Wang et al. 2000). CH_3Hg-Cys in bile can be reabsorbed in the gall bladder or small intestine (Dutczak and Ballatori 1992; Dutczak et al. 1991). Demethylation of methylmercury by intestinal bacteria contributes to the excretion of inorganic mercuric mercury in feces (Farris et al. 1993; Li et al. 2019b; Norseth and Clarkson 1970).

Most of the mercury excreted in urine following absorption of methylmercury is inorganic mercury (Berlin et al. 1975; Farris et al. 1993; Smith et al. 1994). Urinary excretion of methylmercury is limited by a resorptive pathway for methylmercury in the proximal tubule facilitated by metabolism of the S-conjugate of glutathione (CH_3Hg-S-CysGlyGlu) and reabsorptive transport of the S-conjugate of cysteine (CH_3Hg-S-Cys). Inhibition of GGT increases urinary excretion of glutathione and methylmercury (Berndt et al. 1985; Gregus et al. 1987; Mulder and Kostyniak 1985a, 1985b; Tanaka et al. 1992; Tanaka-Kagawa et al. 1993; Yasutake et al. 1989).

In a case of dimethylmercury poisoning, mercury was excreted in urine following dermal absorption of dimethylmercury (Nierenberg et al. 1998). In mice, respiratory exhalation was the major route of excretion of mercury following an intravenous injection of radiolabeled [203]Hg-labeled dimethylmercury and accounted for approximately 65% of the dose (1.3 µg Hg) (Ostlund 1969). Following inhalation of [203]Hg-labeled dimethylmercury (20 mg/kg) in mice, all exhaled mercury was identified as dimethylmercury (Ostlund 1969).

Methylmercury enters hair follicles and is incorporated into hair during keratinization and remains associated with hair as the hair strand grows (Cernichiari et al. 2007; Shi et al. 1990; Zareba et al. 2008). Mercury in hair collected from women in a marine fish-eating population was shown to be predominantly CH_3Hg-S-Cys (80% of total mercury) and inorganic Hg^{2+} S-conjugates (20%) (George et al. 2010). A study of HHg in a sample for a general population found that >90% of the mercury in hair was organic mercury (Berglund et al. 2005). Following exposures to methylmercury, HHg concentrations exceed that of blood and approach a steady-state ratio of 200–400 (Clarkson et al. 1988; Yaginuma-Sakurai et al. 2012). Hair appears to uptake mercury corresponding to methylmercury blood concentrations at the time of hair keratinization. As a result, the kinetics of accumulation and elimination of mercury in hair is similar to that of methylmercury in blood (Clarkson et al. 1988; Yaginuma-Sakurai et al. 2012). Caito et al. (2018) estimated the halftime for elimination of mercury from hair of adults following a fish meal. The estimated mean halftime was 44 days (range: 28–62 days, n=37). Interspecies variability in uptake of methylmercury into hair has been observed (Farris et al. 1993; Kawasaki et al. 1986; Mottet et al. 1987). The hair/blood ratio is lower in monkeys compared to humans (Kawasaki et al. 1986; Mottet et al. 1987). Species differences may arise from several different variables including cysteine content of keratins and hair growth patterns and rates (Mottet et al. 1987).

Mercury levels in hair were measured following a lethal dermal dose of dimethylmercury (estimated dose of approximately 1,344 mg Hg) (Nierenberg et al. 1998). Sequential analysis of mercury in a single hair strand provided a time series of HHg concentrations. Levels of mercury became elevated after approximately 17 days following exposure and reached the highest observed level (1,100 µg/g) at approximately 40 days following exposure; the half-time to peak hair level was 5.6 days. Based on the declining phase of HHg (40–170 days), the elimination half-time was estimated to have been 75 days.

Following exposure to phenylmercury, absorbed mercury is eliminated in bile, feces, urine, and hair (Daniel et al. 1972; Gotelli et al. 1985). Phenylmercury was detected in hair of infants exposed to phenylmercury that had been applied to cloth diapers as a fungicide (Gotelli et al. 1985). More than 90% of the mercury excreted in urine in the exposed infants was inorganic mercury. In rats that received a subcutaneous dose of phenylmercury (2.95 mg phenylmercuric acetate, 1.76 mg Hg), 13% of the administered mercury dose was excreted in urine and 52% was excreted in feces over an 8-day observation period (Daniel et al. 1972). Approximately 80% of the mercury in urine or bile was inorganic mercury.

3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models

Models are simplified representations of a system with the intent of reproducing or simulating its structure, function, and behavior. PBPK models are more firmly grounded in principles of biology and biochemistry. They use mathematical descriptions of the processes determining uptake and disposition of chemical substances as a function of their physicochemical, biochemical, and physiological characteristics (Andersen and Krishnan 1994; Clewell 1995; Mumtaz et al. 2012a; Sweeney and Gearhart 2020). PBPK models have been developed for both organic and inorganic pollutants (Ruiz et al. 2011) and are increasingly used in risk assessments, primarily to predict the concentration of potentially toxic moieties of a chemical that will be delivered to any given target tissue following various combinations of route, dose level, and test species (Mumtaz et al. 2012b; Ruiz et al. 2011; Sweeney and Gearhart 2020; Tan et al. 2020). PBPK models can also be used to more accurately extrapolate from animal to human, high dose to low dose, route to route, and various exposure scenarios and to study pollutant mixtures (El-Masri et al. 2004). Physiologically based pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to quantitatively describe the relationship between target tissue dose and toxic endpoints (Clewell 1995).

Several pharmacokinetics models of inorganic mercury have been published (Abass et al. 2018; Farris et al. 2008; Jonsson et al. 1999; Leggett et al. 2001). Of these, three models were developed to predict the absorption and distribution of inhaled mercury vapor (Jonsson et al. 1999; Leggett et al. 2001; Pierrehumbert et al. 2002) and one model (Abass et al. 2018) includes an absorption fraction for Hg^0 and simulates the kinetics of absorbed Hg^0 as inorganic mercury using the Farris et al. (2008) model. Pharmacokinetic models of methylmercury have been developed for humans (Byczkowski and Lipscomb 2001; Carrier et al. 2001a; Gearhart et al. 1995; Young et al. 2001) and a variety of other animal species (Carrier et al. 2001b; Farris et al. 1993; Young et al. 2001).

Farris et al. 2008 Model

Farris et al. (2008) developed a model to simulate the pharmacokinetics of intravenously injected inorganic mercuric mercury. The model includes a mobile compartment that receives the intravenous dose and an immobile compartment that exchanges mercury with the mobile compartment. Exchange between compartments is governed by first-order rate coefficients (day^{-1}). Both compartments contribute to excretion of mercury in feces and urine (day^{-1}). The model was calibrated with data on fecal and urinary mercury excretion measured over a period of 70 days in five adult subjects who received

intravenous injections of tracer amounts of ^{203}Hg(NO$_3$)$_2$ (0.6–2.8 µg Hg) (Hall et al. 1995). The model was then evaluated for predicting whole body burden measured in the same study. The model predicted observed kinetics and cumulative fecal excretion (approximately 30% of the administered dose) and urinary excretion of mercury (approximately 25% of the administered dose) when parameters were fit to the individual subject data on fecal and urinary mercury. The model also predicted the observed whole-body elimination kinetics for each subject. Terminal elimination half-times for the five subjects ranged from 56 to 120 days, based on data for days 21–70 following the dose. When data for individual subjects were averaged, the terminal half-time was estimated to be 75.9 days.

The Farris et al. (2008) model was incorporated into a model for simulating pharmacokinetics of inorganic and organic mercury (Abass et al. 2018; Carrier et al. 2001a, 2001b). The Abass et al. (2018) model included a blood compartment for inorganic mercury, which transferred absorbed mercury (from food and mercury amalgams) to tissues with a half-time of 2 days. The absorption fractions used in the model were 0.8 for inhaled Hg^0 and 0.15 for inorganic mercury in food.

Jonsson et al. 1999 Model

Jonsson et al. (1999) developed a model to simulate the pharmacokinetics of inhaled Hg^0 vapor in humans. The model includes compartments representing the respiratory tract, a central distributing compartment in equilibrium with blood plasma, kidney (referred to as the excretion depot), and a lumped peripheral tissue compartment representing mercury in all other tissues. Transfers of mercury between compartments are governed by first-order rate coefficients (k, day^{-1}) and deposition fractions (f). Values for these parameters are presented in Jonsson et al. (1999).

Inhaled mercury deposits in the respiratory compartment and is removed from the respiratory tract by absorption and exhalation. Mercury in the central compartment exchanges with mercury in the peripheral compartment and is eliminated by direct transfer to urine, transfer to kidney and then to urine, or to a lumped elimination compartment representing other elimination pathways. Total clearance from the central compartment was estimated to be 0.123 L/day/kg body weight. The ratio of the rate coefficients for exchange between the central and peripheral compartments leads to a steady state in which the amount of mercury in the peripheral compartment is approximately 20 times the amount in the central compartment.

Total transfer from the central compartment to excretory pathways is apportioned approximately as follows: transfer to kidney (60%), direct transfer to urine (3%), and transfer to other excretory pathways (37%). The model predicts that over a period of 1 year following an acute-duration exposure to Hg^0 vapor, 14% of the initially retained inhaled mercury dose is lost to exhaled air (half-time 1.81 days) while 55% is excreted in urine (half-time 63.2 days). The remining portion, 31%, is retained in tissues or eliminated by other pathways (Jonsson et al. 1999).

The model was calibrated using data collected in a clinical study in which eight adult subjects inhaled Hg^0 (0.4 mg Hg/m^3) for a single 15-minute period and mercury levels in plasma and urine were measured over a period of 30–35 days (Sandborgh-Englund et al. 1998). The calibrated model was evaluated against observations of urinary mercury excretion in two clinical studies of acute-duration inhalation exposures to Hg^0 vapor (Cherian et al. 1978; Hursh et al. 1980). Simulations of the Cherian et al. (1978) study (0.1 mg Hg/m^3 for 14–24 minutes) predicted a daily rate of mercury excretion of approximately 0.5%/day from days 2 to 12 post-exposure compared to observed rates which ranged from approximately 0.2 to 0.45%. The model predicted cumulative urinary mercury excretion to be approximately 3.5% of the dose 7 days post-exposure compared to observations that ranged from 1.9 to 3% (n=4 subjects). Simulations of the Hursh et al. (1980) study predicted cumulative excretion of approximately 5% of the dose at day 10 post-exposure, compared to observations that ranged from approximately 3.6 to 4.2% (n=2 subjects).

Leggett et al. 2001 (ICRP 1980) Model

Leggett et al. (2001) developed a respiratory tract model for depositions and absorption of inhaled Hg^0 in humans. The respiratory tract model was developed to predict absorbed doses from inhalation as inputs to the International Commission on Radiological Protection (ICRP) Human Respiratory Tract Model (HRTM, ICRP 1994) and a systemic biokinetics model for inorganic mercury (ICRP 1980). The generic ICRP HRTM model simulates transport and absorption of inhaled particles or vapors deposited in regions of the respiratory tract. The model simulates surface transport (e.g., mucociliary) and sequestration into tissues.

The Leggett et al. (2001) model assumes that 80% of inhaled Hg^0 is deposited in the respiratory tract with the following apportionments: 2% to the extrathoracic region, 1% to the bronchial region, 2% to the bronchiolar region, and 75% to the alveolar-interstitial region. Absorption to blood is governed by three first-order rate coefficients (day^{-1}) that simulate a slower phase of absorption from all regions and a faster phase of absorption from the alveolar-interstitial region. The alveolar-interstitial pathway absorbs 70% of

total deposition with a half-time of approximately 1 minute. Of the remaining mercury in all regions, 80% is absorbed with a half-time of 8 hours and 20% with a half-time of 5 days.

In the systemic model, mercury absorbed from the respiratory tract is transferred to a central compartment, which distributes 8% of the mercury in the central compartment to the kidney and 92% to a lumped compartment representing all other tissues (ICRP 1980). Mercury is eliminated from both the kidney and other tissue compartments at the same rates: 95% is eliminated with a half-time of 40 days and 5% with a half-time of 10,000 days.

The model was developed based on the results of human clinical studies in which adult subjects were exposed acutely to Hg^0 vapor (Cherian et al. 1978; Hursh et al. 1976, 1980; Nielsen-Kudsk 1965a, 1965b; Sandborgh-Englund et al. 1998; Teisinger and Fiserova-Bergerova 1965). The model was evaluated against data on retention of mercury in the respiratory tract following exposures to Hg^0 vapor in humans (Hursh et al. 1976), monkeys (Berlin et al. 1969b; Khayat and Dencker 1984), and rodents (Berlin et al. 1966, 1969a, 1969b; Hayes and Rothstein 1962; Hursh et al. 1980; Khayat and Dencker 1984; Magos 1967; Nordberg and Serenius 1969). The model predicted the observed temporal pattern of elimination over a period of 30 days following acute-duration exposure in which approximately 70% of mercury initially deposited in the respiratory tract was absorbed within minutes of exposure and, of the remaining 30%, 80% was absorbed with a half-time of 8 hours and 20% was absorbed with a half-time of 5 days (Leggett et al. 2001).

Pierrehumbert et al. 2002 Model

Pierrehumbert et al. (2002) developed a model to simulate the pharmacokinetics of inorganic mercury absorbed from inhalation of Hg^0 vapor in humans. The model is a modification of a generic model for simulating the pharmacokinetics of several other chemicals (lead, phenol, toluene). The model includes compartments representing a central distributing compartment in equilibrium with blood and kidney. Transfers of mercury between compartments are governed by compartment blood flows, partition coefficients, and permeability coefficients. Values for these parameters are presented in Pierrehumbert et al. (2002).

Although Pierrehumbert et al. (2002) describes parameters governing alveolar absorption and excretion (alveolar ventilation, blood/air partition coefficients), values for the blood/air partition coefficient for mercury are not reported; therefore, it is not clear how the alveolar exchange of mercury is actually

represented in the model. Two pathways of excretion are simulated. Excretion in urine occurs from the
kidney compartment and is governed by a first-order rate constant (minute^{-1}). Biliary excretion is
represented as first-order transfer from the central compartment.

Pierrehumbert et al. (2002) do not report or cite evaluations of the mercury model against observations
made in humans. Berthet et al. (2010) applied the Pierrehumbert et al. (2002) model to predict blood
urinary mercury levels for hypothetical workweek exposures and compared the results to American
Conference of Governmental Industrial Hygienists (ACGIH) Biological Exposure Indices (BEI)
corresponding to the same workweek exposure assumptions. The predicted levels were similar to the
BEIs.

Farris et al. 1993 Model

Farris et al. (1993) developed a PBPK model for simulating the kinetics of methylmercury in rats. The
model includes compartments for blood, brain, gastrointestinal tract, liver, kidney, skin, hair, and a
lumped compartment representing all other tissues (carcass). Growth is simulated as a time-dependent
increase in compartment volumes (expressed in units of g), governed by a rate coefficient (minute^{-1}). The
model simulates the disposition of absorbed methylmercury as well as inorganic mercury formed from
demethylation in the liver and lumen of the gastrointestinal tract. Transfers of mercury between blood
and tissue compartments are governed by first-order clearance coefficients (mL/minute/g tissue) and the
concentration gradients between systemic blood and tissue blood, where the tissue blood concentrations
are calculated as the ratio of the tissue concentration and tissue/blood concentration equilibrium
ratios (R).

The gastrointestinal tract has two compartments representing lumen and tissue. Absorption of
methylmercury and inorganic mercury are simulated as direct transfers from gastrointestinal tissue to the
liver and exchanges between gastrointestinal tissue and blood. Methylmercury is assumed to undergo
bidirectional transfer between gastrointestinal tissue and the gastrointestinal lumen, with transfer
governed by a first-order clearance coefficient (mL/minute/g tissue) and concentration gradient between
systemic blood and tissue blood, where the tissue blood concentration is calculated as the ratio of the
tissue concentration and a lumen/tissue concentration equilibrium ratio. The gastrointestinal lumen also
receives methylmercury from the oral dose, methylmercury and inorganic mercury from bile, and
inorganic mercury from demethylation of methylmercury in the gastrointestinal lumen. Demethylation in
the gastrointestinal lumen is assumed to occur in regions of the gastrointestinal tract distal to the site of

absorption and is not reabsorbed. Unabsorbed methylmercury and inorganic mercury are cleared to feces
at a rate governed by a fecal flow rate (mL/minute/g lumen).

Flows of methylmercury and inorganic mercury in the liver compartment include exchange with blood,
transfer from gastrointestinal tissue, transfer to bile, and demethylation in the liver. Biliary transfers of
methylmercury and inorganic mercury are governed by clearance coefficients (mL/minute/g tissue) and
the biliary clearance of non-protein sulfhydryls (Ballatori and Clarkson 1985). Flows of methylmercury
and inorganic mercury in the kidney compartment include exchange with blood and transfer to urine.
Two pathways for urinary excretion are simulated representing "filtration clearance" and "exfoliation of
renal tubular cells." The exfoliation pathway is governed by the kidney concentration, urine flow rate
mL/minute/g kidney, and a urine/kidney equilibrium concentration ratio. The filtration pathway applies
only to inorganic mercury and is governed by the inorganic mercury concentration in the kidneys and a
filtration clearance term (mL blood/minute/g kidney).

The model includes a skin compartment, which exchanges methylmercury and inorganic mercury with
blood and through which methylmercury and inorganic mercury can be transferred to hair. Skin-to-hair
transfer is governed by a clearance coefficient (mL/minute/g skin). Mercury is assumed to be retained in
hair until the hair is shed. Hair shedding is represented as a first-order elimination rate constant
(minute^{-1}). HHg is assumed to be partially ingested during fur grooming in rats at a rate also governed by
a rate coefficient (minute^{-1}).

The model was developed and calibrated to simulate results from a study in which adult rats were
administered a single oral dose of ^{203}Hg-labeled methylmercuric chloride (4.5 µg, approximately 14.9 µg
Hg/kg) and monitored for methylmercury and inorganic mercury in tissue, feces, and urine; and mercury
in hair and skin for a period of 98 days (Farris et al. 1993). Comparisons of observed and predicted
mercury levels are reported in figures with no statistical evaluation of model fit to the observations.
Based on the figures, the models simulated the observed levels (percent dose/g) and rates of decline of
methylmercury and inorganic mercury in the blood, brain, kidney, and liver, as well as the distinct
differences between kinetics of methylmercury and inorganic mercury in these tissues. For example,
levels of inorganic mercury in the kidney peaked 28 days after the time of peak levels of methylmercury
(day 1) and, by day 98, levels of inorganic mercury exceeded that of methylmercury in the kidney. The
model also predicted the observed pattern of cumulative fecal and urinary excretion of methylmercury
and inorganic mercury in which inorganic mercury was the dominant form of mercury in feces (65% of
dose) compared to methylmercury (15% of dose), whereas urine was a relatively minor excretory route,

accounting for approximately 4% of the dose (methylmercury 3.5%, inorganic mercury 1%). The model predicted the observed levels of mercury in hair as approximately 1–2% of the dose/g hair, with little attenuation during the 98-day observation period.

Carrier et al. 2001 Model

Carrier et al. (2001a, 2001b) developed a PBPK model for simulating the kinetics of methylmercury in rats and humans. The model includes compartments for blood, brain, gastrointestinal tract, kidney, liver, hair, and a lumped compartment representing all other tissues. The model is structured as two submodels, which simulate the disposition of absorbed organic mercury and inorganic mercury formed from demethylation.

The organic mercury model simulates whole-body elimination of organic mercury as the sum of the elimination rates for fecal and urinary excretion, transfer to hair, and demethylation, with each elimination pathway governed by a first-order rate coefficient (day^{-1}). Organic mercury in tissue compartments is apportioned from whole-body organic mercury based on proportionality constants (tissue/blood) for each tissue. The gastrointestinal tract compartment receives organic mercury from the ingested dose as well as from organic mercury in hair ingested during fur grooming (rat model only). Absorption of organic mercury is simulated as a direct transfer from gastrointestinal tissue to whole body governed by a rate coefficient (day^{-1}). Demethylation of inorganic mercury is assumed to occur in the liver and brain.

The inorganic mercury submodel simulates the disposition of inorganic mercury formed in the brain and liver from organic mercury transferred to these compartments from blood (passed to the inorganic mercury submodel). Transfers of organic mercury to the brain and blood are governed by rate coefficients (day^{-1}) that combine rates for transfer and demethylation. Bi-directional exchanges of inorganic mercury between blood and tissues are governed by rate coefficients (day^{-1}). Hair receives inorganic mercury from blood and loses inorganic mercury to feces, representing ingestion of hair during fur grooming (i.e., ingested hair inorganic mercury is not absorbed). Excretion of inorganic mercury in feces includes direct transfer from blood, transfer from liver representing biliary transfer, and transfer from hair (rodent only), each governed by rate coefficients (day^{-1}). Urinary excretion of inorganic mercury includes direct transfer from blood and transfer from the kidney compartment, both governed by rate coefficients (day^{-1}). Mass balance between the organic mercury and inorganic mercury submodels is

achieved by setting the transfer rate coefficients to ensure that the blood-to-brain and blood-to-liver mass transfers for inorganic mercury equal the rate of demethylation of whole-body organic mercury.

The model was developed and calibrated to simulate results from a study in which adult rats were administered a single oral dose of [203]Hg-labeled methylmercuric chloride (4.5 µg, approximately 14.9 µg Hg/kg) and monitored for methylmercury and inorganic mercury in tissue, feces, and urine; and total mercury in hair and skin for a period of 98 days (Farris et al. 1993). Comparisons of observed and predicted mercury levels are reported in figures with no statistical evaluation of model fit to the observations. Based on the figures, the models simulated the observed levels (percent dose/g) and rates of decline of methylmercury and inorganic mercury in the blood, brain, kidney, and liver, as well as the distinct differences between kinetics of methylmercury and inorganic mercury in these tissues. The model also predicted the observed pattern of cumulative fecal and urinary excretion of methylmercury and inorganic mercury in which inorganic mercury was the dominant form of mercury in feces (65% of dose) compared to methylmercury (15% of dose), whereas urine was a relatively minor excretory route, accounting for approximately 4% of the dose (methylmercury 3.5%, inorganic mercury 1%). The model predicted the observed levels of mercury in hair, approximately 1–2% of the dose/g hair, with little attenuation during the 98-day observation period.

The rat model was evaluated by comparing predictions to observations made in studies conducted in rats that were not used in model development (Norseth and Clarkson 1970; Thomas et al. 1986). In the Norseth and Clarkson (1970) study, rats received single intravenous doses of 1 mg of mercury as [203]Hg-labeled methylmercury and were monitored for a period of 60 days. In the Thomas et al. (1986) study, rats received a single subcutaneous dose of 0.2 mg Hg/kg as [203]Hg-labeled methylmercury and were monitored for a period of 98 days. Comparisons of observed and predicted mercury levels are reported in figures with no statistical evaluation of model fit to the observations. Based on the figures, the model predicted the observed patterns of elimination of total mercury (percent of dose) in the blood, brain, kidney, and liver, and the cumulative excretion in feces, urine, and hair, observed in both studies.

The human model was developed by adjusting transfer coefficients (Carrier et al. 2001b). The model was calibrated to simulate results from a study conducted in which three adult subjects ingest a single oral dose of [203]Hg-labeled methylmercury (9 µg Hg) and whole body [203]Hg and [203]Hg in blood urine and feces were measured over a period of 3 months (Aberg et al. 1969). The calibrated model was evaluated by comparing predictions to observations made in studies conducted in humans that were not used in model development (Birke et al. 1972; Kershaw et al. 1980; Miettinen et al. 1971; Sherlock et al. 1984; Smith et

al. 1994). In the Birke et al. (1972) study, 26 adults consumed fish meals for doses of 5–800 µg mercury as methylmercury.

Total mercury and organic mercury were measured in blood. Mercury was measured before and following switching to a diet having a lower mercury level. In the Kershaw et al. (1980) study, six adults consumed a meal of fish (6–10 µg Hg/g fish) for an oral mercury dose of 18–20 µg Hg/kg body weight, and total mercury and organic mercury in blood were measured for a period of 160 days following the meal. In the Miettinen et al. (1971) study, 15 adults consumed a meal of fish that had been fed ^{202}Hg-labeled methylmercury for an oral dose of 22 µg mercury and ^{203}Hg in whole body and blood were measured periodically over a period of 28 weeks.

In the Sherlock et al. (1984) study, 20 adults consumed fish periodically for a period of 96 days for an average oral dose that ranged from 43 to 233 µg Hg/day. In the Smith et al. (1994) study, seven adults received a single intravenous dose of ^{203}Hg-labeled methylmercury (0.6–2.8 Hg) and whole-body retention kinetics of absorbed methylmercury in humans was measured for a period of 70 days. Comparisons of observed and predicted mercury levels are reported in figures with no statistical evaluation of model fit to the observations. Based on the figures, the model predicted the observed patterns of whole body and blood retention of mercury observed in all of the above studies. The model predicted the observed buildup of total mercury blood concentration during a 3-month period of fish ingestion and the elimination kinetics in the subjects following cessation of fish meals that ranged from 43 to 223 µg Hg/day (Sherlock et al. 1984).

Gosselin et al. (2006) applied the Carrier et al. (2001b) model to reconstruct methylmercury intakes from measurements of HHg in high fish and marine mammal consumers in the Inuvik region of Canada and the Amazonian River Basin. Reconstructed methylmercury intakes in the Inuvik population (mean 0.03±0.05 SD µg/kg/day) were lower than intakes estimated from food questionnaires (0.20±0.35 µg/kg/day). BHg-time profiles predicted with the model from HHg-time profiles agreed with observed BHg levels.

Reconstructed methylmercury intakes for two Amazonian subjects ranged from approximately 0.5 to 1.4 µg/kg/day and were substantially higher than the intakes reconstructed for the Inuvik population. Noisel et al. (2011) applied the Carrier et al. (2001b) model to reconstruct methylmercury intakes from measurements of HHg in fishermen in northern Quebec. Reconstructed methylmercury intakes (mean 0.07 µg/kg/day, range 0–0.26 µg/kg/day) were lower than intakes estimated from food questionnaires (0.43 µg/kg/day, range 0.09–2.78 µg/kg/day).

Abass et al. (2018) combined the Carrier et al. (2001b) human model with a model of inorganic mercury (Farris et al. 2008) to estimate dietary mercury intakes corresponding to mercury blood concentrations and methylmercury/inorganic mercury ratios from the diet measured in a Norwegian food consumption survey (Jenssen et al. 2012). The correlation was 0.38 between dietary mercury intakes predicted from the PBPK model (median 0.043 µg Hg/kg/day) and the food consumption survey (median 0.050 µg Hg/kg/day). Residuals for estimates of dietary intake from the PBPK model indicated the model provided estimates that tended to be higher than the estimates from the food consumption survey, particularly at ages >40 years.

Gearhart et al. 1995 Model

Gearhart et al. (1995; Clewell et al. 1999) developed a PBPK model to simulate maternal-fetal transfer of methylmercury in humans. The Clewell et al. (1999) model is the same as the Gearhart et al. (1995) human model, with parameter values representing U.S. women (age 14–45 years) derived from an analysis of NHANES (1988–1994). Population parameter values for the model were subsequently re-estimated for U.S. women ages 16–49 years based on Bayesian analysis of NHANES (1999–2000) and data on dietary intake of methylmercury in the U.S. population for the same population stratum (Allen et al. 2007; Carrington and Bolger 2002). The PBPK model has been applied to human methylmercury dosimetry (Allen et al. 2007; Clewell et al. 1999; Gearhart et al. 1995; Lee et al. 2017b; Shipp et al. 2000).

The PBPK model includes maternal compartments for blood (with plasma and RBC compartments), brain, fat, intestine, kidney, liver, placenta, hair, and lumped compartments representing all other rapidly and slowly-perfused tissues. The fetal model includes compartments for plasma, RBCs, brain, and a lumped compartment representing all other fetal tissues (fetal body). The model simulates demethylation of methylmercury in the brain, intestine, and liver as elimination pathways; disposition of the inorganic mercury produced from demethylation is not simulated.

Exchanges between plasma and all tissues are either flow- or diffusion-limited. Flow-limited exchanges are governed by tissue plasma flows (L/hour), the tissue-plasma partition coefficient, and the concentration gradient for methylmercury between plasma and tissue. Diffusion-limited exchanges are governed by first-order plasma-tissue diffusion coefficients (L/hour), tissue-plasma concentration gradients, and tissue/plasma partition coefficients. Exchanges between plasma and all tissues except

RBCs and the brain are flow-limited. The diffusion-limited (L/hour) RBC-plasma model results in a steady state of approximately 88% of BHg residing in RBCs and a plasma/RBC concentration ratio of approximately 0.08. Approximately 6% of the post-absorption mercury body burden resides in whole blood.

Maternal model. Methylmercury enters brain tissue by diffusion (L/hour) from brain blood, which receives methylmercury from central plasma by flow-limited exchange. Mercury in the brain has several possible fates: conversion of methylmercury to inorganic mercury (L/hour); incorporation of inorganic mercury in brain tissue (L/hour); and loss of incorporated inorganic mercury from brain (L/hour). Incorporated inorganic mercury can be lost from the brain; however, it cannot become unincorporated. As a result, incorporated inorganic mercury that is lost from the brain is lost from systemic distribution (e.g., it is not returned to central plasma), and its fate is not described in the model.

Exchanges of methylmercury between the liver and central plasma are flow-limited. Methylmercury in the liver has two potential fates: biliary secretion into the intestine (L/hour) or conversion to inorganic mercury (L/hour). Demethylation in the liver serves solely as an elimination pathway for methylmercury in the model. The fate of the inorganic mercury produced in the liver is not simulated. Exchanges of methylmercury between the kidneys and central plasma are flow-limited.

Exchanges of methylmercury between plasma and all other tissues (fat, richly perfused, slowly perfused) are flow-limited. Urinary excretion of methylmercury is simulated as clearance from central plasma (L/hour). The default value for the clearance coefficient is zero, representing typical conditions in which methylmercury makes a negligible contribution to urinary mercury.

Elimination pathways for methylmercury from the maternal system include: (1) fecal excretion of unabsorbed or biliary methylmercury and inorganic mercury produced in the intestine; (2) demethylation of methylmercury in the brain and liver; (3) transfer of methylmercury to hair; (4) transfer of methylmercury from plasma to urine (nominally set to zero); (5) transfer of methylmercury to the fetus; and (6) transfer to breast milk. The demethylation and urinary pathways were described previously in Section 3.1.1, in the discussions of absorption in the brain, kidneys, and liver. Conversion of methylmercury to mercury is simulated in the brain and liver with rate coefficients (hour^{-1}). All demethylation not occurring in the brain is attributed to the liver.

There are no atomic/molecular weight conversions in the model so the rate coefficients account for the mass fraction of mercury in methylmercury. Methylmercury enters hair from the slowly perfused tissue compartment (which includes skin). The transfer is assumed to be diffusion-limited and governed by a clearance coefficient (L/hour), concentration of methylmercury in slowly perfused venous plasma, and a hair/blood partition coefficient. Appearance of methylmercury in hair is subject to a time delay (day), representing the time for between-exposure of the hair follicle and appearance of hair on the body surface. The nominal delay is set to 7 days. The model also includes a first-order elimination pathway for methylmercury in hair (L/hour), representing loss from hair to the environment. Methylmercury lost from hair is lost from the systemic distribution. The nominal value for the clearance rate from hair is set equal to the clearance rate from slowly perfused tissue to hair.

Pregnancy-fetal model. The duration of pregnancy is nominally set to 270 days. Pregnancy initiates growth of the placenta and fetus, and expansion of the maternal blood volume by approximately 50%. Exchange of methylmercury between maternal plasma and the placenta is flow-limited, with plasma flow to the placenta scaled to the growing placenta volume (L).

The fetal model includes compartments representing central plasma, RBCs, and a lumped compartment representing all other fetal tissues. Volumes of these compartments scale with the fetal blood volume, which scales with fetal volume (L). Entry of methylmercury into the fetus is from the placenta to fetal central plasma. Transfer to fetal plasma is diffusion limited and governed by a clearance coefficient (L/hour) and the concentration gradient between placenta and fetus.

Similar to the maternal model, exchange between fetal plasma and RBCs is diffusion-limited (L/hour). The fetal brain compartment is simpler than the maternal model and includes only a single compartment. Exchanges of methylmercury between plasma and brain, and between plasma and the lumped other fetal tissue (body) compartment, are flow-limited.

The model was calibrated with data from studies conducted in monkeys (Kawasaki et al. 1986; Rice et al. 1989) and humans (Birke et al. 1972; Sherlock et al. 1984). In the Kawasaki et al. (1986) study, monkeys received oral doses of methylmercury (10, 30, or 100 µg Hg/kg/day) for periods ranging from 18 to 54 months. In the Rice et al. (1989) study, monkeys received oral doses of methylmercury (10, 25, or 50 µg Hg/day, 3 days/week) for a period of 35–100 weeks. The model predicted the observed buildup to steady state of blood methylmercury observed in the Rice et al. (1989) study and the buildup of HHg

observed in the Kawasaki et al. (1986) study. The model predicted the buildup and decline in blood methylmercury levels observed in adults who consumed fish periodically for a period of 96 days for an average oral dose that ranged from 43 to 233 µg Hg/day (Sherlock et al. 1984), and the decline in methylmercury concentrations in plasma, RBCs, and hair in an adult following cessation of consumption of methylmercury in fish (2.14 µg Hg/kg/day) (Birke et al. 1972).

Byczkowski and Lipscomb 2001 Model

Byczkowski and Lipscomb (2001) extended the Gearhart (1995; Clewell et al. 1999) model to include parameters for simulation of lactational transfer of methylmercury to a nursing human infant. The lactation model simulates transfer of methylmercury into breast milk, transfer to the nursing infant, and biokinetics of methylmercury in the infant. Transfer of methylmercury into breast milk begins on the day of conception. The model can be run with or without a nursing infant. Transfer to breast milk is flow-limited, with plasma flow to breast tissue being a fraction (10%) of flow to rapidly perfused tissue, and a breast/plasma partition coefficient of 0.172. Production of breast milk is an exponential function of infant body weight. Milk consumption by the infant is a fraction of total milk production (nominally set to 1).

The infant model includes compartments representing plasma, RBCs, brain, kidney, gastrointestinal tract, and other tissues (body). Infant growth is simulated using the same body weight growth algorithm applied to the maternal model, with separate parameters for F0 and F1 generations, allowing maternal and infant growth to be independently controlled. Weight at conception can be set to represent the fetal volume at the end conception. Infant tissue plasma flows and volumes are scaled from maternal values to infant volume (L), which is scaled to infant body weight (kg). Methylmercury ingested in breast milk is absorbed from the gastrointestinal tract directly to fetal plasma (hour^{-1}). Similar to the maternal model, exchange between infant plasma and RBCs is diffusion-limited (L/hour). The infant brain model is identical to the maternal model, with: (1) flow-limited transfer of methylmercury from infant plasma to brain plasma; (2) diffusion-limited transfer of methylmercury from brain plasma to brain tissue (L/day); (3) first-order conversion of methylmercury to inorganic mercury (day^{-1}); and (4) first-order loss of incorporated mercury (day^{-1}). The infant kidney model is identical to the maternal model with flow-limited exchange between methylmercury in plasma and the kidney. As in the maternal model, urinary excretion of methylmercury in the infant is represented as clearance from plasma (L/day). The default value for the clearance coefficient is zero, representing typical conditions in which methylmercury makes a negligible contribution to urinary mercury. Exchanges of methylmercury between the lumped other tissue compartment and plasma are flow-limited.

Elimination pathways for methylmercury from the infant include: (1) fecal excretion of unabsorbed or biliary methylmercury; (2) demethylation of methylmercury in the brain; (3) transfer of methylmercury to hair; and (4) transfer of methylmercury from plasma to urine (nominally set to zero). The infant hair model is identical to the maternal hair model. The start of infant hair growth is specified by the number of days following birth when hair growth begins, which is nominally set to the day of birth. Methylmercury enters hair from the slowly perfused tissue compartment (which includes skin). The transfer is assumed to be diffusion-limited and governed by a clearance coefficient (L/hour), the concentration of methylmercury in slowly perfused venous plasma and a hair/blood partition coefficient. Appearance of methylmercury in hair is subject to a time delay (nominal value 7 days), representing the time between exposure of the hair follicle and appearance of hair on the body surface. The model also includes a first-order elimination pathway for methylmercury in hair (L/hour), representing fugitive loss. The nominal value for the clearance rate is set equal to the clearance rate from tissue to hair.

The model was initially calibrated with data from studies conducted in rodents (Oskarsson et al. 1995; Sundberg et al. 1991); however, comparisons to observation made in these studies are not reported in Byczkowski and Lipscomb (2001). The model was evaluated by comparing predictions with observations from studies of mother-infant pairs following exposures to methylmercury (Amin-Zaki et al. 1976; Fujita and Takabatake 1977). The Amin-Zaki et al. (1976) study measured methylmercury in maternal hair, breast milk, and infant blood following an outbreak of poisonings in Iraq related to consumption of methylmercury in grain. The estimated intake was 0.12 mg methylmercury/kg/day for a period of 4 months during lactation. The model predicted the observed buildup and decline of methylmercury in hair during and following the exposure period as well as the observed decline in breast milk and infant blood levels (Amin-Zaki et al. 1976). The model also predicted concentrations of total mercury in maternal blood, hair, and breast milk, and infant blood and hair, within 1 SD of observations in a group of 34 mother-infant pairs (Fujita and Takabatake 1977).

Ou et al. 2018 Model

Ou et al. (2018) extended the Byczkowski and Lipscomb (2001) model to include additional compartments in the fetal and infant models. The fetal and infant models were expanded to include compartments representing placenta, plasma, RBCs, brain, fat, kidney, liver, slowly and richly perfused tissues, and hair. Infant growth rates were derived from data on Chinese children. Tissue volumes of infants were assigned values based on Bjorkman (2004). Other compartments and exchanges are

identical to Byczkowski and Lipscomb (2001) and Gearhart et al. (1995). Exchanges between plasma and all tissues are either flow- or diffusion-limited. Flow-limited exchanges are governed by tissue plasma flows (L/hour), the tissue-plasma partition coefficient, and the concentration gradient for methylmercury between plasma and tissue venous plasma. Diffusion-limited exchanges are governed by first-order plasma-tissue diffusion coefficients (L/hour), tissue-plasma concentration gradients, and tissue/plasma partition coefficients. Exchanges between plasma and all tissues except RBCs and the brain are flow-limited.

Elimination pathways for methylmercury from the maternal system include: (1) fecal excretion of unabsorbed or biliary methylmercury and inorganic mercury produced in the intestine; (2) demethylation of methylmercury in the brain and liver; (3) transfer of methylmercury to hair; (4) transfer of methylmercury from plasma to urine; (5) transfer of methylmercury to the placenta and fetus; and (6) transfer of methylmercury to breast milk. Conversion of methylmercury to mercury is simulated in the brain and liver with clearance coefficients (L/hour). Disposition of the inorganic mercury produced from demethylation is not simulated. Methylmercury enters hair from the slowly perfused tissue compartment (which includes skin). The transfer is assumed to be diffusion-limited and governed by a clearance coefficient (L/hour), concentration of methylmercury in slowly perfused venous plasma, and a hair/blood partition coefficient. The model also includes a first-order elimination pathway for methylmercury in hair (L/hour), representing loss from hair to the environment. Methylmercury lost from hair is lost from the systemic distribution.

The lactation model simulates transfer of methylmercury into breast milk, transfer to the nursing infant, and biokinetics of methylmercury in the infant. Transfer of methylmercury into breast milk begins on the day of conception. Transfer to breast milk is flow-limited, governed by plasma flow to breast tissue, a breast/plasma partition coefficient. The plasma flow to breast tissue was assigned a value that was 7% of cardiac output. The breast/plasma partition coefficient varied with time during lactation, reflecting time-dependency of breast milk protein content. Production of breast milk is an exponential function of infant body weight. Milk consumption by the infant is dependent on age.

The model was evaluated with data on methylmercury levels in infant hair, maternal hair, cord blood, and maternal venous blood collected from 40 pregnancies (Ou et al. 2018). The maternal model was assigned inputs to agree with measured levels of methylmercury in maternal hair and venous blood. These inputs were then used to simulate the pregnancy and lactation periods. Predicted methylmercury levels in breast milk and infant hair were compared to observations. The model predicted observations made during the

first 3 months of lactation. At later times during lactation (days 90–400) predictions diverged from observations to a greater extent.

Pope and Rand 2021 Model

Pope and Rand (2021) developed a PBPK model for simulating the kinetics of methylmercury in humans. The structure of the model was similar to the Gearhart et al. (1995; Clewell et al. 1999) model without the maternal-fetal transfer compartments. The PBPK model includes compartments for blood (with plasma and RBC compartments), brain, fat, intestine, kidney, liver, hair, and lumped compartments representing all other rapidly and slowly perfused tissues. The model simulates demethylation of methylmercury in the intestine and liver as elimination pathways; disposition of the inorganic mercury produced from demethylation is not simulated. Exchanges between plasma and all tissues are flow-limited governed by tissue plasma flows (L/hour), the tissue-plasma partition coefficient, and the concentration gradient for methylmercury between plasma and tissue venous plasma. Within blood, exchanges between RBCs and plasma are first order and governed by rate coefficients (hour^{-1}). Transfers between the intestinal lumen and intestinal tissue are also governed by first-order rate coefficients (hour^{-1}). Transfers to bile, feces, and hair are governed by first-order clearance coefficients (L/hour). Demethylation activity is assigned to the intestinal lumen and liver, the latter representing all other sites of demethylation. The rate of demethylation is first-order, with the rate coefficients in the liver being 0.0125 of the rate in the intestinal lumen.

The model was calibrated by adjusting methylmercury transfer coefficients to observations of HHg elimination kinetics measured in two adult subjects who repeatedly ingested fish meals (Caito et al. 2018). The parameters that were adjusted included the rate coefficient for demethylation in the intestinal lumen, rate coefficients for exchange of methylmercury between intestinal lumen and intestinal tissue, and clearance coefficients for biliary transfer, fecal excretion, and transfer from plasma to hair. The model was independently calibrated to observations made in two subjects. The calibrated model predicted HHg elimination half-times of 40.1 days in a female subject and 51.8 days in a male subject. The corresponding half-times derived from the observations made on the same subjects were 45 and 44 days, respectively (Caito et al. 2018).

The calibrated model was then used to simulate blood methylmercury concentrations corresponding to various exposure scenarios. The model predicted blood methylmercury elimination half-times of 46.9 days in an adult man, 38.9 days in an adult female, and 31.5 days in a child. A simulation of

elimination of methylmercury during a 50-day period following a single oral dose administered to an adult female predicted that 73% would be demethylated in the intestinal lumen, 13% would be eliminated in hair, 9% would be demethylated in other tissues, and 6% would be eliminated in feces. The contribution of hair as an elimination pathway for methylmercury was predicted to be higher (18%) in children.

Young et al. 2001 Model

Young et al. (2001) developed a PBPK model for simulating the kinetics of methylmercury in humans and 11 other animal species (cat, cow, goat, guinea pig, hamster, monkey, mouse, pig, rabbit, rat, and sheep). The methylmercury model provides methylmercury parameter values and species-specific physiological parameters for a generic model for simulating maternal and fetal kinetics of a parent chemical and metabolite in humans and rats (Luecke et al. 1994, 1997). The generic model includes 24 maternal tissue compartments and 17 fetal tissue compartments. The Young et al. (2001) model includes only the maternal compartments. Transfers between plasma and tissues are governed by tissue plasma flow; the concentration difference between tissue plasma and plasma, where the tissue plasma concentrations are calculated as the ratio of the tissue concentration and tissue/plasma concentration equilibrium ratios (referred to as binding constants); and a diffusion constant that represents the fraction of arterial-plasma concentration equilibrium achieved in the tissue. Transfers are flow-limited if the diffusion constant is 1 and diffusion-limited if the constant is <1. Methylmercury parameters for the various animal species are not reported in Young et al. (2001); however, diffusion-limit transfers of both methylmercury and inorganic mercury are discussed. Demethylation of methylmercury to inorganic mercury is assumed to occur in the liver and is governed by a first-order rate coefficient (time^{-1}). The excretion pathways for methylmercury and inorganic mercury are not described in Young et al. (2001), although based on Luecke et al. (1994), the model simulates transfer from the liver to the gastrointestinal tract (biliary) and transfer from the kidney to elimination. Young et al. (2001) refer to elimination rate constants for the liver and kidney and note that the methylmercury model does not simulate reabsorption of mercury transferred to the gastrointestinal tract, as it was not needed to predict observations of blood and tissue mercury kinetics. Young et al. (2001) do not discuss transfer to hair or demethylation in the gastrointestinal tract.

Models were fit to observations of blood and tissue mercury levels by applying allometric scaling derived from regression analysis of body weight and scaled parameter values estimated in mice, rats, monkeys, and humans. Values for other species were interpolated. The allometrically scaled parameters included

the demethylation rate constant, elimination rate constants for methylmercury and inorganic mercury, and binding tissue/blood coefficients for methylmercury and inorganic mercury in the brain, kidney, and liver. In some cases, rates for specific species were not included in deriving allometric scaling factors if the species was considered to be an outlier (e.g., tissue/blood coefficients for the brain, kidney, and liver in rats). Comparisons of predicted and observed blood and tissue levels of methylmercury and inorganic mercury are presented in Figures 1 through 11 of Young et al. (2001); quantitative estimates of goodness of fit were not reported. Based on the Figures 1 through 11 of Young et al. (2001), the model predicted the temporal patterns of blood and tissue methylmercury, inorganic mercury, and total mercury (depending on data available from the study) in all species evaluated. Data from the studies of the various animal species are described in Young et al. (2001) and included humans (Sherlock et al. 1984), cats (Charbonneau et al. 1976; Hollins et al. 1975), cows (Ansari et al. 1973; Sell and Davison 1975), goats (Sell and Davison 1975), guinea pigs (Iverson et al. 1973), hamsters (Omata et al. 1986), pigs (Gyrd-Hansen 1981), rabbits (Petersson et al. 1991), and sheep (Kostyniak 1983).

3.2   CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE

This section discusses potential health effects from exposures during the period from conception to maturity at 18 years of age in humans. Potential effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect effects on the fetus and neonate resulting from maternal exposure during gestation and lactation. Children may be more or less susceptible than adults to health effects from exposure to hazardous substances and the relationship may change with developmental age.

This section also discusses unusually susceptible populations. A susceptible population may exhibit different or enhanced responses to certain chemicals than most persons exposed to the same level of these chemicals in the environment. Factors involved with increased susceptibility may include genetic makeup, age, health and nutritional status, and exposure to other toxic substances (e.g., cigarette smoke). These parameters can reduce detoxification or excretion or compromise organ function.

Populations at greater exposure risk to unusually high exposure levels to mercury compounds are discussed in Section 5.7, Populations with Potentially High Exposures.

Age. Children and older adults (≥65 years of age) are likely to have increased susceptibility to mercury compared to younger adults as it is generally accepted that developing and aging systems are more susceptible than mature, but not yet declining, systems. As reviewed in Section 3.1.2 (Distribution),

mercury that crosses the placenta is distributed to the fetus, and nursing neonates may also be exposed to mercury in breast milk. Epidemiological studies show that umbilical cord BHg and maternal mercury biomarkers measured during gestation or at parturition (reflective of neonatal mercury exposure) are associated with adverse health outcomes during childhood, including decrements in neurological function (reviewed in Chapter 2). Outbreaks of severe neurodevelopmental effects occurred in association with maternal ingestion of methylmercury in seafood (congenital Minamata disease) and from ingestion of wheat contaminated with a methylmercury fungicide (Iraq outbreak). The vulnerability of the developing nervous system to mercury is supported with abundant evidence of animal studies (reviewed in Chapter 2). Differences in elimination kinetics may also contribute to differences in susceptibility of children and adults (Pope and Rand 2021).

Regarding older adults, it is well-established that physiological functions (e.g., renal, neurological) decline with age. Thus, populations with age-related compromises in physiological function would be anticipated to be more susceptible to mercury than younger populations.

Nutritional Status. As discussed in Section 3.4 (Interactions with other Chemicals), interactions of mercury with selenium, selenocysteine, and selenoenzymes are thought to be important mechanisms by which inorganic mercuric and methylmercury exert cellular toxicity (Section 2.21 General Mechanisms of Action). These interactions provide mechanisms for possible associations between susceptibility to mercury toxicity and selenium nutritional status. Mercury can displace copper and zinc from binding sites on metallothionein (and other metalloproteins) and induce the synthesis of metallothionine (Section 2.21 General Mechanisms of Action). These interactions provide mechanisms for possible associations between susceptibility to mercury toxicity and copper and zinc nutritional status.

Pre-existing Conditions, Diseases, and Exposure to Other Substances. Epidemiological and animal studies have identified neurological and renal systems as the most sensitive targets for all forms of mercury. Therefore, it is assumed that any condition or disease that compromises physiological function of these organ systems could increase susceptibility to mercury toxicity. Examples of underlying conditions include individuals with compromised renal function (e.g., glomerular nephritis) and atypical neurological function (e.g., cerebral palsy). Studies in laboratory animals have also identified cardiovascular, hematological, immunological, reproductive, and developmental effect as targets for mercury; thus, underlying diseases or compromised function of these systems may increase susceptibility to mercury toxicity. Increased sensitivity to mercury may also occur due to use of alcohol, tobacco, or any other substance that causes deficits in physiological function. Available information on toxic actions

provides support for possible synergism between co-exposure to PCBs and methylmercury in disrupting regulation of brain levels of dopamine that may influence neurological function and development (ATSDR 2004). Mercury induces the synthesis of metallothionine (Section 2.21 General Mechanisms of Action). This may provide mechanisms for potential toxicologic interactions between mercury and other metals that bind to and induce synthesis of metallothionine such as cadmium and lead.

Genetic Polymorphisms. Numerous genetic polymorphisms that may alter susceptibility to mercury through altered toxicokinetics (e.g., absorption, distribution, and retention of mercury) or toxicodynamics (e.g., effects) have been identified. The most well-studied polymorphisms are glutathione-associated genes and genes associated with mercury transport and elimination. Several other polymorphisms that may alter susceptibility to mercury have been identified, although little data are available. Unless otherwise indicated, information below was obtained from reviews by Andreoli and Sprovieri (2017), Basu et al. (2014), and Gundacker et al. (2010).

Glutamate cysteine ligase (GCL) and glutathione S-transferases (GST). Glutathione is an intracellular scavenger of oxidants and electrophiles, and glutathione conjugation is an important detoxification pathway for mercury. GCL is an enzyme involved in glutathione synthesis, it is encoded by two polymorphic genes (GCLC, GCLM), while glutathione transferases, which catalyze glutathione conjugation, are encoded by several other genes (GSTM1, GSTT1, GSTA1, GSTP1). Genetic alterations in glutathione-related genes could result in altered detoxification and elimination of mercury. Studies in humans indicate that some GCL and GST genetic variants are associated with increased biomarkers of mercury exposure (blood, plasma, or hair mercury levels), while others are associated with decreased biomarkers of mercury exposure (Harari et al. 2012; Medina Pérez et al. 2021; Silva et al. 2023; Wahlberg et al. 2018). For example, the half-time for decrease in urinary mercury following a decrease in exposure to Hg^0 vapor varied with genotype of GCLM-588; 77 days for the CC genotype and 34 days for the CT/TT genotype (Harari et al. 2012). Specific findings included increased risk of low birth weight in mercury-exposed mothers with GSTT1 and/or GSTM1 deletions, increased retention of mercury in the umbilical cord with a minor GCLC allele, and increased risk of myocardial infarction in mercury-exposed individuals with a specific GCLM variant.

L Amino Acid Transporters (LAT). LAT1 and LAT2, encoded by human polymorphic genes, SLC7A5 and SLC7A8, respectively, actively transport mercury across cell membranes. Genetic alterations in SLC7 genes could result in altered uptake of mercury. However, no significant differences in BHg levels were observed in individuals with different SLC7A5 phenotypes (Parajuli et al. 2018).

Organic anion transporters (OAT). Members of the OAT family are responsible for proximal tubular uptake of mercury in the kidney. Limited genetic and functional diversity of the gene encoding OAT1 (SLC22A6) indicate that it may not contribute substantially to interindividual differences in renal elimination of mercury. In contrast, the gene encoding OAT3 (SLC22A8) shows a number of functional variants, some of which show reduced or complete loss of function, while others have no apparent effect on function. Studies in humans indicate that some OAT1 and OAT3 genetic variants are associated with decreased blood, plasma, or hair biomarkers of inorganic mercury exposure.

Metallothionein (MT). MT proteins bind to and sequester mercury. Genetic alterations in MT genes could result in altered distribution and retention. A functional polymorphism of MT4 was associated with increased HHg levels in medical students, while polymorphisms of MT1 and MT2 had no apparent effect on mercury levels. However, other human studies show that some MT1 and MT2 genetic variants are associated with increased biomarkers of mercury exposure, while others are associated with decreased biomarkers of mercury exposure. Significant associations have been reported between MT1 and MT2 variants and altered neurobehavior or cognitive performance in mercury-exposed children.

Selenoprotein. Selenoproteins bind to and sequester mercury as well as provide an antioxidant function. They are encoded by the polymorphic SEP and GPX genes. Genetic alterations in these genes could result in altered distribution and retention. A SEPP1 variant in humans has been associated with lower levels of biomarkers of methylmercury exposure, but with increased levels of biomarkers of inorganic mercury exposure. SEPHS2 and GPX3 variants in humans have been associated with increased levels of biomarkers of mercury exposure (Parajuli et al. 2018).

ATP binding cassette (ABC) transporters. ABC transporters, also known as multidrug resistance-associated proteins (MRPs) are involved in mercury elimination via active transport across biological membranes. Genetic alterations in ABC genes could result in altered elimination of mercury. Studies in humans indicate that some MRP2 genetic variants are associated with increased levels of biomarkers (blood, plasma, or hair mercury levels) of inorganic mercury exposure, while others are associated with decreased levels of biomarkers of inorganic mercury exposure. Significant associations have been reported between an ABCC1 variant and altered mental and psychomotor development in mercury-exposed infants.

Other polymorphisms

- Epidemiological studies show increased risk of mercury-associated cognitive or neurobehavioral effects in children and/or adults with one or more genetic variants of the following genes: apolipoprotein E (APOE), brain-derived neurotrophic factor (BDNF), catechol-O-methyltransferase (COMT), CPOX, paraoxonase1 (PON1), progesterone receptor (PGR), serotonin-transporter-linked polymorphic region (5-HTTLPR or SLC6A4), and transferrin (TF). Several of these polymorphisms showed synergistic effects when two or more were present.

- A limited number of epidemiological studies reported potential associations between genetic variants and increased risk of mercury-associated cardiovascular effects (e.g., hypertension, coronary artery disease, cardiac events), including metalloproteinase (MMP-2, MMP-9) and nitric oxide synthase (NOS).

- Certain genetic variants of heat shock protein 70 (HSPA1A, HSPA1B) in former workers with occupational exposure to mercury vapor were associated with increased risk of chronic mercury intoxication (CMI) diagnosis (Chernyak and Merinova 2017). CMI is characterized by a range of cognitive, personality, and sensorimotor disorders.

- Variants of genes involved in the folate pathway (CBS, MTRR) have been associated with increased levels of biomarkers of mercury exposure, while variants of genes involved in mediation of oxidative stress (NOS, TXNRD2) have been associated with decreased levels of biomarkers of mercury exposure (Parajuli et al. 2018).

3.3   BIOMARKERS OF EXPOSURE AND EFFECT

Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have been classified as biomarkers of exposure, biomarkers of effect, and biomarkers of susceptibility (NAS/NRC 2006).

The National Report on Human Exposure to Environmental Chemicals provides an ongoing assessment of the exposure of a generalizable sample of the U.S. population to environmental chemicals using biomonitoring (see http://www.cdc.gov/exposurereport/). If available, biomonitoring data for mercury from this report are discussed in Section 5.6, General Population Exposure.

A biomarker of exposure is a xenobiotic substance or its metabolite(s) or the product of an interaction between a xenobiotic agent and some target molecule(s) or cell(s) that is measured within a compartment of an organism (NAS/NRC 2006). The preferred biomarkers of exposure are generally the substance

itself, substance-specific metabolites in readily obtainable body fluid(s), or excreta. Biomarkers of exposure to mercury are discussed in Section 3.3.1.

Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an organism that (depending on magnitude) can be recognized as an established or potential health impairment or disease (NAS/NRC 2006). This definition encompasses biochemical or cellular signals of tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung capacity. Note that these markers are not often substance specific. They also may not be directly adverse, but can indicate potential health impairment (e.g., DNA adducts). Biomarkers of effect caused by mercury are discussed in Section 3.3.2.

A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability to respond to the challenge of exposure to a specific xenobiotic substance. It can be an intrinsic genetic or other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the biologically effective dose, or a target tissue response. If biomarkers of susceptibility exist, they are discussed in Section 3.2, Children and Other Populations that are Unusually Susceptible.

3.3.1 Biomarkers of Exposure

Humans are exposed to a mixture of methylmercury and inorganic mercury (primarily mercuric and elemental) in their local environments, with either being more or less pronounced under certain circumstances (e.g., occupational exposure to Hg^0 vapor, consumption of methylmercury in fish). Exposure to mercury that leads to absorption of mercury in any form can be detected from measurement of total mercury (inorganic plus organic) in blood or urine. A change in exposure to either form of mercury will be reflected in a change in blood or urine total mercury (Awata et al. 2017; Birch et al. 2014; Jain 2017; Kim et al. 2017; Mahaffey et al. 2009; Nielsen et al. 2014; Razzaghi et al. 2014; Yin et al. 2016). Measurements of total mercury in blood and urine can be considered biomarkers of total exposure to all forms of mercury and do not provide information to confidently estimate the magnitude of exposures specific to methylmercury, inorganic mercury compounds, or elemental mercury. Mercurialentis, a clinically distinct discoloration of the anterior capsule of the lens observable via slit-lamp examination, is also a diagnostic biomarker of mercury exposure (Byrns and Pennings 2017; El-Sherbeeny et al. 2006). However, as this is a qualitative biomarker (exposure levels cannot be estimated), it is not further discussed below.

As discussed below, biomarkers that are more strongly correlated to methylmercury exposure are methylmercury concentration in whole blood, or total mercury concentration in RBCs or hair; these are more significant depots for accumulation of methylmercury than inorganic mercury. Biomarkers that are more strongly correlated to exposure to inorganic forms of mercury are inorganic mercury in blood (or plasma) and inorganic mercury or total mercury in urine. Berglund et al. (2005) found that approximately 5% of the methylmercury in hair was converted to inorganic mercury during sample processing. Additionally, demethylation after absorption contributes inorganic mercury to blood and urine; this complicates distinguishing exposures to inorganic forms of mercury from exposures to methylmercury based solely on measurements of total mercury in blood or urine.

Biomarkers of Exposure to Inorganic Mercury

Urine. Mercuric inorganic mercury is the dominant species of mercury excreted in urine (Section 3.1.4, Excretion) and reflects the contributions of inorganic mercury intake (inhalation, ingestion) and inorganic mercury formed from demethylation of absorbed methylated mercury (Sherman et al. 2013). In populations in which the main source of exposure was to inorganic mercury, urinary mercury has been shown to correlate with inorganic mercury exposure. Measurement of total mercury in urine has been used as a biomarker for exposure to Hg^0 vapor. Studies of exposed production and processing workers and dentists have shown that urinary mercury correlates with Hg^0 concentrations in air (Barregard 1993; Ehrenberg et al. 1991; Nordhagen et al. 1994; Roels et al. 1987). Tsuji et al. (2003) found that urinary inorganic mercury was also correlated with Hg^0 vapor exposures in unexposed workers and in populations from the general public, in which Hg^0 vapor exposures were considerably lower than in exposed workers. Urinary total mercury and inorganic mercury levels have also been shown to correlate with number of Hg^0 amalgam dental surface restorations (Berglund et al. 2005; Jarosinska et al. 2008; Maserejian et al. 2008; Tuček et al. 2020; Vahter et al. 2000; Woods et al. 2007; Yin et al. 2013). Urinary total mercury was found to correlate with kidney mercury concentrations measured in kidney donors (Akerstrom et al. 2017).

Urinary mercury can be measured as a rate of urinary excretion of mercury (µg/day) based on a timed sample with a measured urine volume, or as a concentration (µg/L) based on a timed to untimed sample, with or without adjustments for urine creatinine concentration or specific gravity (Araki et al. 1986; Barber and Wallis 1986). The creatinine and specific gravity adjustments are intended to standardize a measured concentration for variations in urine volume, which by itself can result in concentration or

dilution of urinary mercury (Diamond 1988; Lee et al. 1996; MacPherson et al. 2018; Martin et al. 1996; Trachtenberg et al. 2010). Lee et al. (1996) found similar correlations (r>0.8) between Hg^0 vapor concentrations in air and the various urine metrics in mercury workers who had worked for >2 years, including mercury excretion rate and mercury concentration with or without adjustment for creatinine concentration or specific gravity. Urinary mercury concentrations (µg/L) decrease with decreasing eGFR (Jin et al. 2018).

Urinary porphyrins have been studied for utility as biomarkers of mercury body burden (Geier et al. 2011; Woods et al. 2005, 2009). Mercury can inhibit various enzymes in the heme synthesis pathway, leading to increased urinary excretion of pentacarboxyporphyrin, precoproporphyrin, and coproporphyrin (Geier et al. 2011). Urinary excretion of porphyrins had been shown to correlate with urinary excretion of mercury in humans and rats (Pingree et al. 2001; Woods et al. 2005). Urinary excretion of porphyrins in children was shown to correlate with the number of mercury amalgam restorations (Geier et al. 2011). Clinical testing of urinary porphyrins is typically performed to diagnose porphyria; a disruption of heme metabolism.

Blood. Mercury in blood is predominantly a mixture of methylmercury and inorganic mercury. The geometric means of total mercury (range 0.678–0.703 µg/L) and methylmercury (range 0.431–0.489 µg/L) estimated for the U.S. population based on data from NHANES for the period 2011–2016 suggested that methylmercury comprised approximately 61–70% of blood total mercury (CDC 2019). The bulk of the remaining fraction (30–39%) is likely to be inorganic mercury; however, the geometric mean concentration of inorganic mercury was below the limit of detection (0.27 µg/L). Based on data reported in NHANES (2011–2012), the number of Hg^0 amalgam dental surface restorations and amount of fish consumed were significant variables in explaining blood total mercury, inorganic mercury, and methylmercury concentrations (Yin et al. 2016, 2022). In a clinical study (28 adult subjects), blood inorganic mercury, but not blood organic mercury, was found to correlate with number of Hg^0 amalgam dental surface restorations; however, blood organic mercury, but not blood inorganic mercury, correlated with fish consumption (Berglund et al. 2005).

Biomarkers of Exposure to Methylmercury. Exposure to methylmercury can be detected from measurements of methylmercury in blood and measurements of total mercury in hair and nails. The concentration of total mercury in blood is not considered to be a specific metric for methylmercury exposure because exposure to inorganic mercury will contribute to BHg. However, blood total mercury can be used as a metric for methylmercury exposure in populations in which methylmercury is the

dominant source of exposure to mercury. Measurement of total mercury in RBCs can also serve as a metric of exposure to methylmercury, because most of the methylmercury in whole blood resides in RBCs. A high RBC/plasma ratio (>10) for total mercury is indicative of methylmercury exposure. For the same reason, measurements of total mercury in plasma are less useful as exposure metrics of methylmercury, since most of the mercury in plasma is inorganic mercury, regardless of the contributions of methylmercury or inorganic mercury to total mercury exposure. Measurement of urine total mercury is not considered to be a useful biomarker for exposure to methylmercury, because mercury excreted in urine is predominantly inorganic following exposure to methylmercury or inorganic mercury.

Blood. The concentration of methylmercury in whole blood and RBCs has been shown to correlate with methylmercury consumption (Airaksinen et al. 2011; Berglund et al. 2005). Following absorption of methylmercury, methylmercury is the dominant mercury species in blood, with most of the methylmercury associated with RBCs (Section 3.1.2, Distribution). It follows that, in populations in which methylmercury is the dominant source of mercury intake, total mercury in blood will be dominated by methylmercury and the blood total mercury concentration will reflect methylmercury intake. This would not apply to populations in which the dominant form of exposure is to elemental mercury or other forms of inorganic mercury. Total BHg should be interpreted as a biomarker of exposure to methylmercury only if other information is available that supports methylmercury being the dominant form of exposure in the population.

In populations where fish are a major contributor to the diet, total mercury concentrations in blood correlate with fish intake (Grandjean et al. 1992). Numerous studies have found that blood (or RBC) total mercury concentrations correlate with dietary fish or marine mammal consumption, a metric for methylmercury intake (Awata et al. 2017; Donohue et al. 2018; McKelvey et al. 2018; Wells et al. 2020; Yin et al. 2021). In populations in which fish is a major contributor to the diet, methylmercury accounts for nearly all of the mercury in umbilical cord blood and, as a result, methylmercury and total mercury concentrations in cord blood are correlated (Donohue et al. 2018; Lukina et al. 2021; Sakamoto et al. 2007).

Measurement of total mercury in plasma is not widely used as a biomarker for exposure to methylmercury. The reason for this is that plasma methylmercury typically makes a relatively small contribution to total mercury in blood. However, within the plasma compartment, methylmercury and inorganic mercury are in a ratio close to one (Berglund et al. 2005; Carneiro et al. 2014).

Hair. The concentration of total mercury in hair is correlated with blood methylmercury concentration (Berglund et al. 2005; Budtz-Jorgensen et al. 2004; Liberda et al. 2014; Morrissette et al. 2004; Phelps et al. 1980). Total HHg concentrations correlate with dietary consumption of mercury from fish and marine mammals (Berglund et al. 2005; Castano et al. 2015; Johnsson et al. 2005; Karatela et al. 2019; Tian et al. 2011; Yaginuma-Sakurai et al. 2012). The correlation between BHg and HHg in association with methylmercury consumption was demonstrated in a clinical study that measured the time-course for changes in total mercury in blood and new-grown hair during and following consumption of methylmercury in fish (Yaginuma-Sakurai et al. 2012). This study measured total mercury in blood and new-grown hair (repeatedly sampled close to the scalp) of 27 adults who consumed methylmercury in fish (3.4 µg methylmercury/kg/week) for a period of 14 weeks with continued measurements for a 15-week period following cessation of the exposure. Concentrations of total mercury in blood and new-grown hair increased during exposure and decreased following exposure with similar half-times for blood (57±18 [SD] days) and hair (64±22 days). Hair/blood ratios (µg/kg hair per µg/L blood) remained relatively constant during the study. The median ratio at the start of exposure was 354 (5th–95th percentile range: 267–475) and just prior to cessation of exposure, the median ratio was 321 (5th–95th percentile range: 264–451). The mean HHg half-time was estimated to be 44 days (95% CI 41, 48) based on longitudinal measurements of mercury in hair of 37 adults following a period of fish meals (Caito et al. 2018).

The correlation between total mercury in hair and blood methylmercury derives from several factors. Methylmercury is accumulated in hair to a much greater extent than is inorganic mercury (Shi et al. 1990; Yasutake and Hachiya 2006). Based on studies conducted in rats, the mercuric chloride dose would have to be approximately 400 times the dose of methylmercury to achieve the same HHg level (Yasutake and Hachiya 2006). The Rothenberg et al. (2016a) study found that the dominant form of mercury in hair was methylmercury (65% of total). In populations in which methylmercury is the dominant form of exposure, the methylmercury contribution has been found to be higher (e.g., >80%; Akagi et al. 1995; Cernichiari et al. 2007; George et al. 2010; Harada et al. 1998; Marinho et al. 2014). A portion of the inorganic mercury in human hair has been attributed, in part, to demethylation that occurs in processing the hair sample for analysis, absorbed inorganic mercury, and demethylation of methylmercury within the hair follicle. Berglund et al. (2005) found that approximately 5% of the methylmercury in hair was converted to inorganic mercury during sample processing.

The relationship between HHg and BHg has been modeled as a linear relationship with estimated slopes (µg/kg hair per µg/L blood) that have large inter-study variability, ranging from 140 to 370 with

estimated means across studies of approximately 250 (Clarkson and Magos 2006; Clarkson et al. 1988). The hair/blood concentration ratio has been measured in numerous studies and shows high inter-individual variability, with population means ranging from 100 to 400 (Albert et al. 2010; Budtz-Jorgensen et al. 2004; Clarkson et al. 1988; Liberda et al. 2014;Yaginuma-Sakurai et al. 2012). The World Health Organization (WHO) and United Nations (WHO 1990, 2004) recommend a hair/blood ratio of 250 for interconverting HHg and BHg concentrations.

Mercury in hair is retained until the hair strand is shed. As a result, the mercury content of a hair reflects the history of blood methylmercury levels. Since methylmercury enters hair during keratinization in the hair follicle, and hair grows from the hair follicle outward, analysis of hair strand segments can provide a basis for reconstructing a temporal history of blood methylmercury concentrations, providing that the ratio of concentrations (hair/blood) and rate of hair growth are known (Boischio et al. 2000; Caito et al. 2018; Cox et al. 1989; Sakamoto et al. 2008, 2016). Maternal HHg and neonatal HHg are correlated, reflecting transfer of maternal methylmercury to the newborn during gestation and nursing (Castano et al. 2015; Gundacker et al. 2010; Marques et al. 2013a; Ramirez et al. 2000).

Several sources of error can affect measurements of total mercury and methylmercury in hair. External contamination of hair with mercury can result in an overestimate of mercury incorporated into hair. Hair waving and permanents can decrease HHg levels (Dakeishi et al. 2005; Yamaguchi et al. 1975; Yamamoto and Suzuki 1978; Yasutake et al. 2003).

Nails. Similar to hair, nails are composed largely of keratin, which provides abundant sulfhydryl ligands for formation of S-conjugates with methylmercury (Baden et al. 1973; Baswan et al. 2017; Gupchup and Zatz 1999). Methylmercury has been identified in human nails (Krystek et al. 2012; Zhang et al. 2022). A study of total mercury and inorganic mercury in human nails found that the inorganic mercury fraction ranged from 10 to 16%; the corresponding range of organic mercury (total mercury minus inorganic mercury) was 85 to 90% (Suzuki et al. 1989). The total mercury concentration of fingernails and toenails correlate with total mercury in hair and methylmercury in blood (Alfthan 1997; Bjorkman et al. 2007; Hinners et al. 2012; Ohno et al. 2007; Sakamoto et al. 2015; Zhang et al. 2022). The total mercury concentration in nails has also been shown to correlate with dietary mercury consumption and dietary fish consumption (Ohno et al. 2007; Rees et al. 2007; Yoshizawa et al. 2002).

3.3.2   Biomarkers of Effect

No specific biomarkers of effect have been identified for any category of mercury compounds. Effects of mercury are not unique to mercury; thus, it is not possible to identify exposure without measurement of mercury biomarkers. For example, in workers with known exposure to elemental mercury, signs of neurological effects may suggest that exposure has occurred; however, clinical findings need to be coupled with biomarkers of exposure.

3.4   INTERACTIONS WITH OTHER CHEMICALS

Dietary fish is an important source of exposure to methylmercury in most populations. As a result, dietary exposure to methylmercury will occur with exposures to other chemicals that bioaccumulate in fish. ATSDR (2004) assessed evidence for potential toxicity interactions between methylmercury, chlorinated dibenzodioxins (CDDs), hexachlorobenzene, *p,p'*-DDE, and PCBs, all of which are fish contaminants. Available information on toxic actions of the individual components provided support for possible synergism between PCBs and methylmercury in disrupting regulation of brain levels of dopamine that may influence neurological function and development (ATSDR 2004).

Oceanic fish and marine mammals are major sources of dietary intakes of both selenium and methylmercury. Interactions of mercury with selenium, selenocysteine, and selenoenzymes are thought to be important mechanisms by which inorganic mercuric and methylmercury exert cellular toxicity (Section 2.21 General Mechanisms of Action). These interactions provide mechanisms for potential toxicologic interactions between methylmercury and selenium (Ralston and Raymond 2018; Ralston et al. 2008; reviewed by Wesolowska et al. 2023).

Fish contain other nutrients that have been shown to be important modifiers of development. These include 3-omega LCPUFAs, folate, iodine, and iron (Cheatham 2008; Choi et al. 2008a; Kim et al. 2020a; Mao et al. 2019; Muldoon et al. 2014). Nutritional benefits of fish consumption are a source of negative confounding in epidemiological studies that assess potential associations between prenatal methylmercury exposure and neurodevelopmental outcomes (Choi et al. 2008a).

Mercury can displace copper and zinc from binding sites on metallothionein (and other metalloproteins) and induces the synthesis of metallothionine (Section 2.21 General Mechanisms of Action). These interactions provide mechanisms for potential toxicologic interactions between mercury and other metals

that bind to and induce synthesis of metallothionine such as cadmium, copper, lead, and zinc (Aschner et al. 2006; Wu et al. 2016; Yasutake and Nakamura 2011; Zalups and Cherian 1992).

CHAPTER 4. CHEMICAL AND PHYSICAL INFORMATION

4.1   CHEMICAL IDENTITY

Information regarding the chemical identity of mercury compounds is presented in Table 4-1. For this profile, mercury compounds are classified into three general categories: (1) elemental mercury; (2) inorganic mercury compounds (e.g., mercuric chloride); and (3) organic mercury compounds (e.g., methylmercury). An inorganic mercury compound is a compound of mercury that does not contain a chemical bond between mercury and carbon. Inorganic mercury salts are inorganic mercury compounds that can dissociate into a mercury cation (e.g., mercuric chloride, mercuric sulfide). Inorganic mercury compounds that are not salts include mercury oxides (e.g., mercuric oxide). Organic mercury compounds contain bonds between mercury and carbon (e.g., methylmercuric chloride, phenylmercuric acetate). Mercuric acetate has been included as an organic form of mercury. However, the bonds of the salt are not covalent and, in aqueous solution, the mercury behaves like an inorganic form.

Table 4-1. Chemical Identity of Selected Inorganic and Organic Mercury Compounds[a]

Characteristic	Elemental	Inorganic	Inorganic
Chemical name	Mercury	Mercuric (II) chloride	Mercuric (II) sulfide
Synonym(s) and registered trade name(s)	Colloidal mercury; liquid silver; mercury, metallic; quicksilver; metallic mercury[b]; hydrargyrum	Bichloride of mercury; mercury bichloride[c]; mercury chloride[c]; mercury dichloride; mercury perchloride; mercury (II) chloride; perchloride of mercury; corrosive sublimate[c]; corrosive mercury chloride; dichloromercury; Calochlor; Fungchex; TL 898	Etiops mineral[d]; mercury sulfide, black[c]; vermillion; Chinese red; C.I. Pigment Red 106; C.I. 77766[d]; quicksilver vermillion; Chinese vermillion; red mercury sulfide; artificial cinnabar; red mercury sulfuret[d]
SMILES	[Hg]	Cl[Hg]Cl	S=[Hg]
Chemical formula	Hg[d]	$HgCl_2$[d]	HgS[d]
Chemical structure	Hg	Hg[++] Cl[−] Cl[−]	Hg=S
CAS Registry Number	7439-97-6[d]	7487-94-7[d]	1344-48-5[d]

Table 4-1. Chemical Identity of Selected Inorganic and Organic Mercury Compounds[a]

Characteristic	Inorganic	Inorganic	Organic
Chemical name	Mercurous (I) chloride	Mercuric (II) acetate[e]	Methylmercury
Synonym(s) and registered trade name(s)	Calomel; mild mercury chloride; mercury monochloride; mercury protochloride; mercury subchloride; calogree; cyclosan[d]; mercury chloride[c]; Calogreen; Calomel Calotab; Cylosan	Acetic acid, mercury (2+ salt); bis(acetyloxy) mercury; diacetocymercury; mercury diacetate; mercury (II) acetate; mercury (2+) acetate; mercury acetate[d]	Methylmercury cation; methylmercury II; mercury(1+), methyl; methylmercury ion; methylmercury(II) cation; monomethylmercury cation
SMILES	Cl[Hg]Cl	CC(=O)[O-].CC(=O)[O-].[Hg+2]	C[Hg]
Chemical formula	Hg_2Cl_2[b]	$HgC_4H_6O_4$[b]	CH_3Hg
Chemical structure	Cl–Hg–Hg–Cl		
CAS Registry Number	10112-91-1	1600-27-7	22967-92-6

Table 4-1. Chemical Identity of Selected Inorganic and Organic Mercury Compounds[a]

Characteristic	Organic	Organic	Organic
Chemical name	Methylmercuric chloride	Dimethyl mercury	Phenylmercuric acetate
Synonym(s) and registered trade name(s)	Chloromethylmercury; monomethyl mercury chloride; methylmercury chloride; methylmercury monochloride[b]; Caspan	Mercury, dimethyl; methyl mercury[d]	(Acetato)phenylmercury; acetoxyphenylmercury; phenylmercury acetate[d]; acetophenylmercucy; mercury (II) acetate, phenyl-; mercury, (acetato)phenyl-; phenylmercury acetate; phenylmercuriactetate; PMA; PMAC; Pmacetate; Cerasan Slaked Lime; Gollitox; liquiphene; Mersolite; Tag Fungicide; Tag HL-331; Nylmerate; Scutl; Riogen; PMAS
SMILES	C[Hg]Cl	C[Hg]C	CC(=O)O[Hg]C1=CC=CC=C1
Chemical formula	CH_3HgCl^f	$C_2H_6Hg^d$	$C_8H_8HgO_2^d$
Chemical structure	Hg / \ Cl	Hg / \	O \ O Hg phenyl
CAS Registry Number	115-09-3	593-74-8[d]	62-38-4[d]

[a]All information obtained from NLM (2020), except where noted.
[b]RTECS 1997.
[c]Lewis 1993.
[d]Budavari 1989.
[e]Although organic moieties are associated with the mercury atom, the mercury-carbon bonds are ionic, not covalent, in nature; in aqueous solution, Hg^{2+} is released. Therefore, based on chemical properties, mercuric acetate is classified as an inorganic compound for this profile. Due to the presence of carbon in the acetate moiety, mercuric acetate could also be classified as an organic compound.
[f]ASTER 1997.

CAS = Chemical Abstracts Service; SMILES = simplified molecular-input line-entry system

4.2   PHYSICAL AND CHEMICAL PROPERTIES

Information regarding the physical and chemical properties of mercury compounds is located in Table 4-2. Mercury has seven naturally occurring isotopes, with the most common being mercury-202 (Gonzalez-Raymat et al. 2017). The fate and properties of mercury are greatly dependent upon its oxidation state which are mainly: elemental mercury Hg^0, mercurous Hg^+ (I), and mercuric Hg^{2+} (II).

Table 4-2. Physical and Chemical Properties of Selected Inorganic and Organic Mercury Compounds[a]

Property	Elemental Mercury	Inorganic		
		Mercuric (II) chloride	Mercuric (II) sulfide	Mercurous (I) chloride
Molecular weight	200.59	271.52	232.68	472.09
Color	Silver-white (liquid metal); tin-white (solid mercury)	White	Black or grayish-black (mercuric sulfide, black); bright scarlet-red blackens on exposure to light (mercury sulfide, red)	White
Physical state	Heavy, mobile, liquid metal; solid mercury is a ductile, malleable mass that may be cut with a knife	Crystals, granules, or powder; rhombic crystalline solid[b]	Heavy amorphous powder, also occurs as black cubic crystals (mercury sulfide, black); powder, lumps, hexagonal crystals (mercury sulfide, red)	Heavy powder; rhombic crystals or crystalline powder[c]
Melting point	-38.87°C	277°C	Transition temperature (red to black) 386°C; sublimes at 446°C (mercuric sulfide, black)[c]; sublimes at 583°C (mercuric sulfide, red)	Sublimes at 400–500°C without melting; 302°C[c]
Boiling point	357.72°C	302°C	502°C (predicted)[d]	384°C[c]
Density (g/cm^3)	13.534 at 25°C	5.4 at 25°C	7.55–7.70 (mercuric sulfide, black); 8.06–8.12 g/cc (mercuric sulfide, red)[c]	7.15 g/cc; 6.993 g/cc[c]
Odor	Odorless[b]	Odorless[c]	Odorless	Odorless
Odor threshold:				
Water	No data	No data	No data	No data
Air	No data	No data	No data	No data

4. CHEMICAL AND PHYSICAL INFORMATION

Table 4-2. Physical and Chemical Properties of Selected Inorganic and Organic Mercury Compounds[a]

Property	Elemental Mercury	Inorganic		
		Mercuric (II) chloride	Mercuric (II) sulfide	Mercurous (I) chloride
Solubility:				
Water	0.28 µmoles/L at 25°C	69 g/L at 20°C[e]	Insoluble (mercuric sulfide, black), soluble in aqua regia with separation of sulfur, in warm hydriodic acid with evolution of hydrogen sulfide (mercuric sulfide, red)	$2x10^{-4}$ g/100 mL at 25°C
Organic solvents	Soluble in H_2SO_4 upon boiling in lipids; readily soluble in HCl[c]; soluble in 2.7 mg/L pentane[b]	1 g/3.8 mL alcohol, 1 g/200 mL C_6H_6, 22 mL ether, 12 mL glycerol, 40 mL CH_3COOH, acetone, CH_3OH, ethyl acetate; 33 g/100 cc alcohol at 25°C, slightly soluble in carbon disulfide, pyridine[b]	Insoluble in alcohol, dilute mineral acids	Insoluble in alcohol, ether
Partition coefficients:				
Log K_{ow}	5.95[f]	No data	1.53 (predicted)[d]	-0.550 (predicted)[d]
Log K_{oc}	No data	No data	No data	No data
Vapor pressure	$2x10^3$ mmHg at 25°C	1 mmHg at 136.2°C	No data	No data
Henry's law constant	No data	No data	No data	No data
Autoignition temperature	Not flammable[b]	No data	No data	No data
Flashpoint	Not flammable[b]	Not flammable[b]	No data	No data
Flammability limits	Not flammable[b]	Not flammable[b]	No data	No data
Conversion factors	1 ppm=8.18 mg/m³ 1 mg/m³=0.122 ppm	1 ppm=11.1 mg/m³; 1 mg/m³=0.09 ppm	1 ppm=9.5 mg/m³; 1 mg/m³=0.11 ppm	1 ppm=19.3 mg/m³; 1 mg/m³=0.052 ppm
Explosive limits	Non-combustible[b]	Non-combustible[b]	No data	No data
Valence states	+1, +2	+2	+2	+2

4. CHEMICAL AND PHYSICAL INFORMATION

Table 4-2. Physical and Chemical Properties of Selected Inorganic and Organic Mercury Compounds[a]

Property	Inorganic Mercuric (II) acetate	Organic			
		Methylmercury	Methylmercuric chloride[g]	Dimethyl mercury	Phenylmercuric acetate
Molecular weight	318.70	216.63	251.1[h]	230.66	366.75
Color	White[c]	White (chloride salt)[e]	White[i]	Colorless	White to cream[c]
Physical state	Crystals or crystalline powder; solid at 25°C and 1 atm[b]	Crystalline solid (chloride salt)[e]	Crystals[i]	Liquid	Small lustrous prisms; crystalline powder, small prisms or leaflets[b]
Melting point	178–180°C	-60.5°C (predicted)[d]	170°C[h]	-56.6°C (predicted)[d]	149°C; 148–150°C[c]
Boiling point	118°C (predicted)[d]	83.0°C (predicted)[d]	117°C (predicted)[d]	92°C	291°C (predicted)[d]
Density (g/cm^3)	3.28	4.06 g/mL at 25°C (chloride salt)[e]	4.06 g/mL at 25°C[i]	3.1874 g/mL at 20°C	No data
Odor	Slight acetic odor	Disagreeable odor[e]	No data	No data	Odorless[j]
Odor threshold:					
Water	No data	No data	No data	No data	No data
Air	No data	No data	No data	No data	No data
Solubility:					
Water	1 g in 2.5 mL cold; 1 mL boiling water; 25 g/100 mL at 10°C, 100 g/100 mL at 100°C[b]	0.145 mol/L (predicted)[d]	<0.1 mg/mL at 21°C[i]	Insoluble 1.00x10^3 mg/L[h]	Soluble in about 600 parts water; 1 g/180 mL[b]
Organic solvents	Soluble in alcohol, acetic acid[b]	No data	DMSO ≥100 mg/mL at 27°C, 95% C$_2$H$_5$OH 10–50 mg/mL at 27°C; acetone ≥100 mg/mL at 27°C[i]	Easily soluble in ether, alcohol	Soluble in alcohol, benzene, acetone; 6.8 mL CHCl$_3$, 200 mL ether[b]
Partition coefficients:					
Log K$_{ow}$	-0.662 (predicted)[d]	0.08 (predicted)[d]	0.390 (predicted)[d]	2.28[b]	0.71[b]
Log K$_{oc}$	No data	No data	No data	2.73[h]	1.72[h]

Table 4-2. Physical and Chemical Properties of Selected Inorganic and Organic Mercury Compounds[a]

	Inorganic	Organic			
Property	Mercuric (II) acetate	Methylmercury	Methylmercuric chloride[g]	Dimethyl mercury	Phenylmercuric acetate
Vapor pressure	13.9–15.6 mmHg at 25°C (predicted)[d]	0.0085 mmHg at 25°C (chloride salt)[e]	0.0085 mmHg at 25°C[i]	62.3 mmHg at 25°C[j]	1.20×10^{-4} mmHg at 25°C[b]
Henry's law constant at 25°C	1.00×10^{-7} atm m^3/mol (predicted)[d]	No data	No data	No data	1.22×10^{-8} atm m^3/mol[b]
Autoignition temperature	No data	No data	Probably nonflammable[i]	Easily inflammable	No data
Flashpoint	Not flammable[b]	No data	Probably nonflammable[i]	Easily inflammable	No data
Flammability limits	Not flammable[b]	No data	Probably nonflammable[i]	Easily inflammable	No data
Conversion factors	No data	No data	1 ppm=10.27 mg/m^3 1 mg/m^3=0.097413 ppm	1 ppm=9.43 mg/m^3 1 mg/m^3=0.106 ppm	No data
Explosive limits	Noncombustible[b]	No data	No data	No data	Probably combustible[i]
Valence state	+2	+2	+2	+2	+2

[a]All information obtained from Budavari (1989) except where noted.
[b]NLM 2020.
[c]Lewis 1993.
[d]EPA 2021a, 2021b, 2021c, 2021d, 2021e.
[e]Grandjean and Yorifuji 2012.
[f]Stein et al. 1996.
[g]Commonly occurring form of methylmercury; proprietary names include bis-methylmercuric sulfate (cerewet), methylmercury cyanoguianidine or methylmercury dicyanodiamide (agrosol, morsodren, panogen, panospray), methylmercury nitrile (chipcote), and methylmercury proprionate (metasol MP).
[h]ASTER 1997.
[i]NTP 1997.
[j]Long and Cattanach 1961.

CHAPTER 5. POTENTIAL FOR HUMAN EXPOSURE

5.1   OVERVIEW

Mercury or mercury compounds have been identified in at least 847 of the 1,867 hazardous waste sites
that have been proposed for inclusion on the EPA National Priorities List (NPL) (ATSDR 2022).
However, the number of sites in which mercury has been evaluated is not known. The number of sites in
each state is shown in Figure 5-1. Of these sites, 837 are located within the United States, 1 is located in
Guam, 2 are located in the Virgin Islands, and 7 are located in Puerto Rico (not shown).

**Figure 5-1. Number of NPL Sites with Mercury or Mercury Compound
Contamination**

Source: ATSDR 2022

- The general population is primarily exposed to mercury through the ingestion of foods,
  particularly fish.
- The general population may also be exposed to mercury by inhalation of ambient air. Exposure
  from ingestion of drinking water is a minor exposure pathway. Mercury released from mercury
  amalgam restorations can also contribute to mercury exposure.
- Occupational exposure for persons working with mercury or mercury compounds, such as
  mercury recycling and reprocessing facilities or dental offices where mercury is used in dental
  amalgams, may occur through inhalation or dermal contact.

- Most mercury in the atmosphere is in the gaseous elemental form, which can remain suspended in air for long periods of time and is subject to long-range atmospheric transport. When released or deposited to land or water, mercury can be transformed to methylated forms by anaerobic microorganisms. Methylmercury is highly bioaccumulative and biomagnifies in the food chain.

Mercury occurs naturally as a mineral and is distributed throughout the environment by both natural and anthropogenic processes. The natural global bio-geochemical cycling of mercury is characterized by degassing of the element from soils and surface waters, followed by atmospheric transport, deposition of mercury back to land, vegetation and surface water, and sorption of the compound to soil or sediment particulates. Mercury deposited on land and open water is, in part, revolatilized back into the atmosphere. This emission, deposition, and revolatilization creates difficulties in tracing the movement of mercury to its sources. Major anthropogenic sources of mercury releases to the environment include mining and smelting; industrial processes involving the use of mercury, including chloralkali production facilities; combustion of fossil fuels, primarily coal; production of cement; and medical and municipal waste incinerators and industrial/commercial boilers. Natural sources include volcanic activity, wildfires that release sequestered mercury from biomass, and weathering of mercury-containing rocks.

The element has three valence states and is found in the environment in the metallic form and in the form of various inorganic and organic complexes. The major features of the bio-geochemical cycle of mercury include degassing of mineral mercury from the lithosphere and hydrosphere, long-range transport in the atmosphere, wet and dry deposition to land and surface water, sorption to soil and sediment particulates, revolatilization from land and surface water, and bioaccumulation in both terrestrial and aquatic food chains.

Potential sources of general population exposure to mercury include inhalation of mercury vapors in ambient air, ingestion of drinking water and foodstuffs contaminated with mercury, and exposure to mercury through dental and medical treatments. Dietary intake is the most important source of nonoccupational exposure to mercury, with fish and other seafood products being the dominant source of mercury in the diet. Most of the mercury consumed in fish or other seafood is the highly absorbable methylmercury form. Consumption of rice can also make a substantial contribution to dietary mercury intake. Intake of elemental mercury from dental amalgams is another important contributing source to the total mercury body burden in humans in the general population. This is expected to decline as use of dental amalgams is being phased-out in many countries.

Mercury is present in a variety of human tissues. Mercury has also been detected in urine, human breast milk, nails, hair, and placenta in individuals in the general population. Inhalation of mercury vapor in workplace atmospheres is the main route of occupational exposure to the compound. Mercury has a long history of use in industrial processes and as a therapeutic agent (Clarkson and Magos 2006). Occupational exposure to mercury has occurred in a variety of industries that process or use the element (e.g., felting, chloralkali processing, fluorescent lamp production, gold mining and processing, lithium-6 purification, dentistry applications of mercury amalgam, mercury battery production, natural gas production, recycling, and thermometer production).

Members of the general public with potentially high exposures include individuals who live in proximity to former mercury mining or production sites, secondary production (recycling) facilities, municipal or medical incinerators, or coal-fired power plants. Other populations at risk of exposure include recreational and subsistence fishers who routinely consume meals of fish that may be contaminated; subsistence hunters who routinely consume the meat and organ tissues of marine mammals; individuals with a large number of dental amalgams; fetuses by maternal-fetal transfer and breastfed infants through maternal-breast milk transfer; medical exposure (e.g., ethylmercury used as a preservative in vaccines); occupational sources; individuals who use consumer products containing mercury (e.g., traditional or herbal remedies, or cosmetics, including skin lightening creams); and individuals where intentional (religious or cultural use) or unintentional mercury spills have occurred. Historically, mercury compounds were also used as pharmaceutical agents (e.g., antibiotics, antiseptics, diuretics) (Clarkson and Magos 2006).

5.2   PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL

5.2.1   Production

Mercury is a naturally occurring element that is usually found as mercuric sulfide (cinnabar), an insoluble, stable compound. It occurs in soils at a concentration of approximately 80 ng/g (0.080 ppm) but the actual levels in different locations can vary considerably (Gonzalez-Raymat et al. 2017). Mercury is mined using both open pit (10% of production) and underground mining techniques (90%) (Drake 1981).

Mercury ores are processed inexpensively to produce metallic mercury. Due to the low boiling point of elemental mercury, mercury can be refined by heating the ore and condensing the vapor to form metallic

mercury. This method is 95% efficient and yields mercury that is 99.9% pure. The methods used to refine mercury ores are uncomplicated. Smaller refineries use simple firing and condensing equipment, while larger operations use continuous rotary kilns or mechanically feeding and discharging multiple-hearth furnaces (DOI 1985).

According to the U.S. Geological Survey (USGS), mercury has not been produced as a principal mineral commodity in the United States since 1992; however, it is recovered as a byproduct from processing gold-silver ore at mines located in Nevada (USGS 2023a). Metals in the gold ores are extracted with an aqueous cyanide solution, with typical mercury recoveries of between 10 and 20% (DOI 1993; USGS 1997). In addition, mercury can be recovered from batteries, compact and traditional fluorescent lamps, dental amalgam, medical devices, old thermostats, and mercury-contaminated soils. It was estimated that in 2019, <40 metric tons of mercury were consumed domestically in the United States (USGS 2020). In 2021, the reported domestic consumption of mercury and mercury in compounds in products was 16 metric tons (USGS 2023a). The USGS reported that, in 2022, eight facilities operated by six companies in the United States accounted for the majority of secondary mercury produced and were authorized by the U.S. Department of Energy to temporarily store mercury (USGS 2023a). Typically, mercury-containing products such as automobile convenience switches, barometers, mercury containing lightbulbs, computers, dental amalgams, medical devices, and thermostats are retrieved by smaller companies and transported to the refining establishments for mercury reclamation. Due to the continued phase-out of compact and traditional fluorescent lighting for light-emitting-diode (LED) lighting, mercury recycling has increased.

Annual global mine production of mercury was estimated to be around 4,000 metric tons in 2019 (USGS 2020) and 2,200 metric tons in 2020 and 2021 (USGS 2023a). China is the overwhelming producer of mined mercury (~2,000 metric tons in 2020). Other nations with mine production of mercury include Argentina, Kyrgyzstan, Mexico, Norway, Peru, and Tajikistan (USGS 2023a). Gold mining may produce mercury. In 1995, there were eight U.S. mines that produced mercury when aqueous cyanide solution was used to recover metals (DOI 1993; USGS 1997). It is unclear whether this production occurs today as production volumes for this use are no longer disclosed.

Tables 5-1 and 5-2 summarize information on companies that reported the production, import, or use of elemental mercury and mercury compounds, respectively, for the Toxics Release Inventory (TRI) in 2021 (TRI22 2024). TRI data should be used with caution since only certain types of industrial facilities are required to report. This is not an exhaustive list.

Table 5-1. Facilities that Produce, Process, or Use Elemental Mercury

State[a]	Number of facilities	Minimum amount on site in pounds[b]	Maximum amount on site in pounds[b]	Activities and uses[c]
AK	4	0	99	1, 5, 12, 14
AL	8	0	999	1, 5, 8, 12, 13, 14
AR	6	0	99	1, 5, 12, 13, 14
AZ	11	0	9,999	1, 4, 5, 6, 8, 9, 12, 13, 14
CA	31	0	9,999	1, 2, 5, 8, 10, 11, 12, 13, 14
CO	6	0	99	1, 5, 12, 13, 14
CT	5	0	999	6, 7, 8, 9, 12, 14
DC	1	0	99	14
DE	1	100	999	8
FL	3	0	9,999	1, 4, 5, 8, 12, 13, 14
GA	8	0	999	1, 2, 3, 4, 5, 6, 8, 12, 13, 14
GU	1	0	99	1, 5, 12
IA	6	0	99	1, 5, 8, 12, 13, 14
ID	2	1,000	9,999	1, 5, 12, 13, 14
IL	23	0	9,999	1, 5, 6, 9, 11, 12, 13, 14
IN	9	0	499,999,999	1, 2, 5, 8, 12, 13, 14
KS	3	0	999	1, 2, 5, 12, 13, 14
KY	5	0	99	7, 12, 14
LA	11	0	9,999,999	1, 2, 5, 12, 13, 14
MA	7	0	9,999	8, 9, 11, 12, 14
MD	4	0	999	11, 12, 14
ME	1	0	99	12
MI	6	0	9,999	1, 5, 8, 12, 13, 14
MN	13	0	9,999	1, 2, 5, 7, 8, 12, 13, 14
MO	5	0	99	1, 2, 5, 7, 9, 12, 13, 14
MS	3	0	99	1, 5, 9, 12, 14
MT	2	0	99	1, 10, 13
NC	9	0	999	1, 12, 13, 14
NE	7	0	9,999	1, 5, 12, 13, 14
NJ	4	0	9,999	8, 12, 14
NM	1	10,000	99,999	1, 5, 12
NV	9	0	9,999,999	1, 3, 5, 8, 9, 12, 14
NY	8	0	49,999,999	1, 5, 7, 11, 12, 14
OH	20	0	9,999	1, 2, 5, 7, 8, 12, 13, 14
OK	4	0	99	1, 2, 5, 8, 9, 12, 13, 14
OR	2	0	999	12, 14
PA	12	0	99,999	1, 2, 3, 4, 5, 8, 9, 12, 13, 14
RI	1	0	99	12, 14

Table 5-1. Facilities that Produce, Process, or Use Elemental Mercury

State[a]	Number of facilities	Minimum amount on site in pounds[b]	Maximum amount on site in pounds[b]	Activities and uses[c]
SC	4	0	99	1, 5, 12, 14
SD	4	0	99	1, 5, 7, 12, 14
TN	5	0	99	1, 5, 12, 14
TX	38	0	9,999	1, 2, 4, 5, 7, 8, 9, 11, 12, 13, 14
UT	9	0	999	1, 5, 9, 12, 13, 14
VA	6	0	999	1, 5, 11, 12, 14
VT	1	0	99	8
WA	4	0	999	1, 5, 6, 8, 9, 11, 12
WI	7	0	999	1, 5, 14
WV	7	0	999	1, 5, 12, 13, 14
WY	5	0	9,999	1, 2, 5, 8, 9, 12, 13, 14

[a]Post office state abbreviations used.
[b]Amounts on site reported by facilities in each state.
[c]Activities/Uses:

1. Produce	6. Reactant	11. Manufacture Aid
2. Import	7. Formulation Component	12. Ancillary
3. Used Processing	8. Article Component	13. Manufacture Impurity
4. Sale/Distribution	9. Repackaging	14. Process Impurity
5. Byproduct	10. Chemical Processing Aid	

Source: TRI22 2024 (Data are from 2022)

Table 5-2. Facilities that Produce, Process, or Use Mercury Compounds

State[a]	Number of facilities	Minimum amount on site in pounds[b]	Maximum amount on site in pounds[b]	Activities and uses[c]
AK	18	0	99,999	1, 2, 5, 7, 8, 9, 12, 13, 14
AL	29	0	999,999	1, 3, 4, 5, 6, 8, 12, 13, 14
AR	16	0	99,999	1, 2, 3, 4, 5, 6, 9, 11, 12, 13, 14
AZ	16	0	99,999	1, 3, 4, 5, 8, 9, 12, 13, 14
CA	63	0	99,999	1, 2, 4, 5, 6, 7, 8, 9, 11, 12, 13, 14
CO	18	0	9,999,999	1, 4, 5, 6, 7, 8, 12, 13, 14
CT	1	0	99	8, 12, 14
DC	1	0	99	14
DE	3	0	99	1, 2, 3, 5, 7, 12, 13, 14
FL	31	0	99,999	1, 2, 3, 4, 5, 8, 9, 11, 12, 13, 14
GA	18	0	999	1, 3, 4, 5, 7, 8, 12, 13, 14
GU	1	0	99	7, 9, 0
HI	6	0	99	1, 2, 5, 9, 13, 14
IA	20	0	9,999	1, 3, 4, 5, 7, 8, 9, 12, 13, 14

Table 5-2. Facilities that Produce, Process, or Use Mercury Compounds

State[a]	Number of facilities	Minimum amount on site in pounds[b]	Maximum amount on site in pounds[b]	Activities and uses[c]
ID	11	0	99,999	1, 5, 7, 8, 11, 12, 13, 14
IL	34	0	9,999	1, 2, 3, 4, 5, 7, 8, 9, 12, 13, 14
IN	34	0	9,999	1, 2, 3, 4, 5, 7, 9, 11, 12, 13, 14
KS	16	0	9,999	1, 3, 4, 5, 6, 7, 8, 9, 12, 13, 14
KY	25	0	9,999	1, 2, 3, 4, 5, 8, 9, 12, 13, 14
LA	44	0	99,999	1, 2, 3, 4, 5, 9, 11, 12, 13, 14
MA	1	100	999	2, 3, 4, 9, 0
MD	9	0	999	1, 3, 4, 5, 9, 12, 13, 14
ME	3	0	999	1, 5, 12, 14
MI	24	0	99,999	1, 4, 5, 7, 8, 9, 12, 13, 14
MN	18	0	9,999	1, 2, 3, 4, 5, 7, 8, 9, 11, 12, 13, 14
MO	23	0	9,999	1, 3, 4, 5, 6, 7, 8, 9, 12, 13, 14
MP	1	0	99	7, 9, 0
MS	12	0	999	1, 2, 3, 4, 5, 8, 12, 13, 14
MT	13	0	999	1, 2, 5, 6, 12, 13, 14
NC	38	0	999,999	1, 2, 3, 5, 7, 8, 9, 12, 13, 14
ND	16	0	9,999	1, 2, 4, 5, 7, 9, 12, 13, 14
NE	14	0	99,999	1, 3, 4, 5, 7, 9, 12, 13, 14
NH	2	0	99	1, 2, 5, 9, 12, 13, 14
NJ	13	0	9,999	1, 2, 3, 4, 5, 7, 9, 12, 13, 14
NM	8	0	999	1, 3, 4, 5, 9, 12, 13, 14
NV	37	0	9,999,999	1, 2, 3, 5, 9, 12, 13, 14
NY	10	0	9,999	1, 5, 12, 13, 14
OH	35	0	9,999	1, 2, 3, 4, 5, 7, 9, 11, 12, 13, 14
OK	22	0	99,999	1, 2, 3, 4, 5, 8, 9, 12, 13, 14
OR	10	0	99	1, 2, 5, 8, 12, 13, 14
PA	50	0	99,999	1, 2, 3, 4, 5, 7, 8, 9, 11, 12, 13, 14
PR	2	0	99	1, 2, 5, 12, 14
RI	2	0	999	7, 8, 14
SC	27	0	99,999	1, 3, 4, 5, 6, 7, 8, 12, 13, 14
SD	3	0	99,999	1, 5, 9, 12, 13, 14
TN	23	0	999	1, 2, 5, 8, 9, 12, 13, 14
TX	94	0	999,999	1, 2, 3, 4, 5, 7, 8, 9, 11, 12, 13, 14
UT	27	0	999,999	1, 2, 3, 4, 5, 7, 8, 9, 12, 13, 14
VA	15	0	999	1, 3, 4, 5, 6, 7, 9, 12, 13, 14
WA	22	0	999	1, 2, 3, 5, 7, 8, 9, 12, 13, 14
WI	22	0	99,999	1, 3, 4, 5, 7, 8, 9, 12, 13, 14

Table 5-2. Facilities that Produce, Process, or Use Mercury Compounds

State[a]	Number of facilities	Minimum amount on site in pounds[b]	Maximum amount on site in pounds[b]	Activities and uses[c]
WV	16	0	999,999	1, 3, 4, 5, 6, 8, 9, 12, 13, 14
WY	13	0	999	1, 2, 3, 4, 5, 7, 8, 9, 12, 13, 14

[a]Post office state abbreviations used.
[b]Amounts on site reported by facilities in each state.
[c]Activities/Uses:

1. Produce	6. Reactant	11. Manufacture Aid
2. Import	7. Formulation Component	12. Ancillary
3. Used Processing	8. Article Component	13. Manufacture Impurity
4. Sale/Distribution	9. Repackaging	14. Process Impurity
5. Byproduct	10. Chemical Processing Aid	

Source: TRI22 2024 (Data are from 2022)

5.2.2   Import/Export

Until 1989, the United States was a net importer of mercury. After that, market values of mercury
fluctuated and consumption diminished, leading to a decreased need for imported mercury (DOI 1985;
Drake 1981). U.S. imports of mercury fell sharply between 1987 and 1990 (DOI 1990, 1993). The
import volumes were: 636 metric tons in 1987, 329 metric tons in 1988, 131 metric tons in 1989, and
15 metric tons in 1990. However, imports of mercury began increasing after 1990: 56 metric tons in
1991, 92 metric tons in 1992, 40 metric tons in 1993, 129 metric tons in 1994, and 277 metric tons in
1995 (USGS 1997). Most recent data show low import volume as compared to the 1990s. In 2015, 2016,
2017, 2018, and 2019, mercury imports were reported as 26, 24, 20, 6, and 10 metric tons, respectively
(USGS 2020). According to USGS (2020) for the period 2016−2018, imports were from Canada (39%),
France (32%), Switzerland (13%), China (8%), and other countries (8%) (USGS 2020). From 2018 to
2021, most imports were from Canada (69%) and China (31%) (USGS 2023a).

Exports of elemental mercury were effectively eliminated on January 1, 2013, as a result of the Mercury
Export Ban passed by Congress in 2008 (DeVito and Brooks 2013; EPA 2023). In addition, beginning on
January 1, 2020, exports of five mercury compounds have also been banned (Mercury (I) chloride or
calomel; mercury (II) oxide; mercury (II) sulfate; mercury (II) nitrate; and cinnabar or mercury sulphide)
(EPA 2020b, 2023). In 2008, 2009, 2010, 2011, and 2012, U.S. exports of mercury were 732, 753, 459,
132, and 110 metric tons, respectively (USGS 2013).

5.2.3   Use

Mercury has many applications in industry due to its unique properties, such as its fluidity, its uniform volume expansion over the entire liquid temperature range, its high surface tension, and its ability to alloy with other metals. However, domestic consumption of mercury has shown a downward trend since the early 1970s. In 1995, consumption was 463 metric tons, down 10% from 1994. In 2019, consumption was estimated as <40 metric tons (USGS 2020). The EPA reported a revised domestic production of 45 metric tons in 2018, and about 82 metric tons of mercury was stored by manufacturers or producers. The reported domestic consumption of mercury in products was 16 metric tons (USGS 2023a).

The leading domestic end uses of mercury and mercury compounds were dental amalgam, 43%; relays, sensors, switches, and valves, 41%; bulbs, lamps, and lighting, 8%; formulated products (buffers, catalysts, fixatives, and vaccination uses), 7%; and batteries and other end uses, 1%. A large quantity of mercury (about 245 metric tons) is used domestically in manufacturing processes such as catalysts or as a cathode in the chlorine-caustic soda (chloralkali) process. Almost all the mercury is reused in the process (USGS 2023a).

In 2020, the use of mercury in the production of chloralkali decreased when one of the two operating facilities in the United States converted to a non-mercury process. Comparing data from 2018 to 2021, there has been an approximate 26% decrease in the amount of mercury sold in the United States and a >20% decrease in the amount of mercury used in products manufactured in the United States (EPA 2023). In 2021, 29,255 pounds of mercury were used for the domestic manufacture of mercury-added products (EPA 2023). Of this total, 27,276 pounds of elemental mercury were used to manufacture elemental mercury-added products and 1,979 pounds of mercury compounds were used to manufacture mercury compound-added products (EPA 2023).

Many past uses of mercury, such as in automobile convenience switches, alkaline batteries, paints and pigments, fungicides and pesticides, thermometers, and other scientific and medical devices, have been discontinued or significantly reduced, although these historical uses still represent a significant emission source (CDC 2015). For example, it has been estimated that 150–200 tons of mercury are still contained in old automobiles in the United States and up to 10 tons of mercury per year may be released from shredded vehicles (DeVito and Brooks 2013). Another historical use of note is the former use of mercury in the making of felt hats starting during the industrial revolution through the early 20th century (Beauchamp et al. 2021; Byrns and Pennings 2017). Hatters using this process were often exposed to

high levels of mercury, which resulted in a characteristic neurological syndrome referred to "Mad
Hatter's Disease" (Section 2.16).

Historically and even presently, gold mining uses mercury and may even produce it (Section 5.2.1).
Amalgamation is the process where mercury is added to substrates containing gold to form a complex.
The mercury-gold complex/amalgam is then heated to release the mercury, resulting in gold. There is
industrial scale gold mining and artisanal and small-scale gold mining (ASGM). ASGM uses mercury to
extract gold. Large-scale operations may use mercury and other processes in gold extraction, although
ASGM can occur anywhere, the activity seems to be more predominant in developing countries.
Populations in the Amazon River basin, some African countries, Slovenia, and India (Subhavana et al.
2019) are undertaking artisanal mining, as evidenced by some recent neurological studies of mercury
exposed workers (Section 2.16.1 and Table 2-45).

Religious and Cultural Rituals, Ceremonies, and Practices. Most medicinal and pharmaceutical uses of
mercury compounds have been discontinued. However, individuals in some cultural or religious groups
may still use mercury in various rituals, practices, and ceremonies, resulting in exposure to elevated
mercury concentrations in homes and confined spaces. Media reports (Sawyer 2015; Vasquez 2012;
Washam 2011), case reports, and scientific papers indicate that mercury is still being used in this way and
can cause health effects (Pandalai and Morgan 2011; Rhee et al. 2020; Tarabar and Su 2003; Weinstein
and Bernstein 2003).

Metallic mercury has been used in Latin American and Caribbean communities as part of certain religious
practices (e.g., Voodoo, Santeria, and Espiritismo), predominantly in domestic settings (Riley et al. 2001;
Wendroff 1990; WHO 2010). Vietnamese and Indian people may also use mercury as alternative
medicine. There are few instances in the literature where external or internal exposure measures have
been quantified along with the health effect(s) observed. One case report details a Vietnamese person
heating 'pellets' to vaporize the contents. After onset of malaise, dry skin, and poor appetite, the person
saw a physician and blood tests indicated 409 μg mercury/L at 1-week postexposure. At 4 weeks
postexposure, BHg was 61 μg/L, with 497 μg mercury/g creatinine in the urine (Pandalai and Morgan
2011). An unintentional poisoning occurred when 20-month-old Indian twins were given mercury
'teething powder' over the course of months. This resulted in the twins becoming weak; exhibiting a
rash; and having swollen, red, painful hands and feet (these symptoms are consistent with acrodynia; see
Section 2.15 for additional information). Testing indicated diminished reflexes with BHg levels of

176 and 209 µmol/L (Weinstein and Bernstein 2003). For more information about ritualistic mercury use, recommendations, and how the EPA has addressed this, please refer to EPA (2002b, 2006).

Electrical Applications. Mercury was a critical element in alkaline batteries; however, mercury use in batteries has been discontinued in the United States, with a few exceptions. The Mercury-Containing and Rechargeable Battery Management Act of 1996 began the phase out of mercury in batteries in the United States. Common AAA, AA, C, and D alkaline batteries no longer contain mercury. The total amount of mercury sold in batteries has declined from 5,585 pounds in 2001 to 1,203 pounds in 2013 (IMERC 2015). Currently, the only types of batteries in the United States that contain mercury are specialty button cell batteries and mercuric oxide batteries used for military and medical applications that that require a high-energy density and a flat voltage curve (IMERC 2015). The EPA estimated that, in 2018, approximately 8,915 pounds of mercury were used to produce switches, relays, and sensors in the United States and an additional 1,637 pounds of mercury were used in lighting lamps and bulbs (EPA 2020b). For 2021, it was estimated that 162 pounds were used for linear fluorescent lighting, lamps, and bulbs, with about 16 pounds exported for these purposes (EPA 2023). Another 16 pounds were used for high-pressure sodium and metal halide bulbs (EPA 2023). In 2021, 19,116 pounds of mercury were used in switches, relays, sensors, and bulbs (EPA 2023).

Medical Applications. Although many medical and laboratory uses of mercury are being phased out, mercury has been used domestically in laboratories and in a number of medical devices such as gastrointestinal dilators, manometers, sphygmomanometers, and thermometers (DeVito and Brooks 2013). It is also widely used in dental amalgam fillings, which contain approximately 50% metallic mercury, 35% silver, 9% tin, 6% copper, and trace amounts of zinc. The EPA reported that, in 2018, approximately 9,287 pounds of elemental mercury were used to produce dental amalgam in the United States (EPA 2020b). In 2021, that total was 7,995 pounds (EPA 2023). Thimerosal is a mercury-containing compound that prevents the growth of bacteria and fungus and is still used as a preservative for flu vaccines in multi-dose vials to keep the vaccine free from contamination (CDC 2011). It is no longer used in childhood vaccines. The last children's vaccines that used thimerosal as a preservative expired in 2003 (CDC 2020). In 2018, it was estimated that approximately 290 pounds of mercury were used in vaccine usage in the United States (EPA 2020b). In 2021, 1,955 pounds were used in medical formulated products such as animal vaccines, preservatives, reagents, testing kits, etc. (EPA 2023).

Chemical/Mining Applications. Mercury is a catalyst in reactions to form polymers, such as vinyl chloride and urethane foams. The preparation of chlorine and caustic soda (NaOH) from brines also uses

mercury as a catalyst. In this process, mercury is used as a moving cathode to separate sodium and chlorine (Rieber and Harris 1994). This mercury can be recycled with 95% efficiency (Drake 1981). Consumption occurs as mercury is lost in wastewater treatment, recaptured, reprocessed, and sent to landfills (Rieber and Harris 1994).

5.2.4   Disposal

Mercury is an element; thus, its chemical structure cannot be further broken down. In its elemental form, mercury is highly toxic when its vapors are inhaled. Therefore, incineration of mercury is not recommended as a disposal method. Mercury-containing waste products include waste effluents from chloralkali plants and discarded mercury-containing mechanical and electrical devices (DOI 1985). Under current federal guidelines, mercury and its compounds are considered hazardous substances, and various regulations are in effect to control the emission of mercury into the environment (especially organic compounds) (DOI 1985). Emissions from mercury ore processing facilities and mercury cell chloralkali plants are limited to 2.3 kg/day/facility. Emissions of mercury from the incineration or drying of wastewater sludges is limited to 3.2 kg/day/facility (EPA 1975a, 1975b). In addition, dumping wastes containing more than trace amounts of mercury is prohibited. There is currently no commercial capacity for disposal of high-concentration mercury containing hazardous waste. Management options in the United States for high-concentration mercury wastes of all types are limited. Despite the Department of Energy's (DOE) efforts to open and operate a long-term storage facility for elemental mercury, no such facility is currently available (EPA 2023); therefore, there are eight facilities operated by six companies in the United States that are authorized by the DOE to temporarily store mercury (USGS 2023a).

Recycling of mercury-containing compounds is an important method of disposal. Recycling (retorting) is a treatment for five categories of mercury wastes including: (D009) characteristic mercury; (K106) chlor-alkali waste; (P065) mercury fulminate; (P092) phenylmercuric acetate; and (U151) elemental mercury. From 1987 to 1991, annual production of mercury from old scrap averaged nearly 180 metric tons, equivalent to 16% of the average reported consumption during that period (DOI 1993). Virtually all mercury can be reclaimed from mercury cell chloralkali plants, electrical apparatuses, and control instruments when plants are dismantled or scrapped (DOI 1985). Increased recycling would decrease the mercury load from waste sites and treatment plants. As environmental concerns increase with respect to the disposal of mercury, the recovery by recycling and industrial processes will become a more significant source of domestic supply (DOI 1985).

5.3   RELEASES TO THE ENVIRONMENT

The Toxics Release Inventory (TRI) data should be used with caution because only certain types of facilities are required to report (EPA 2022). This is not an exhaustive list. Manufacturing and processing facilities are required to report information to the TRI only if they employ ≥10 full-time employees; if their facility's North American Industry Classification System (NAICS) codes is covered under EPCRA Section 313 or is a federal facility; and if their facility manufactures (defined to include importing) or processes any TRI chemical in excess of 25,000 pounds, or otherwise uses any TRI chemical in excess of 10,000 pounds, in a calendar year (EPA 2022).

Mercury is released to the environment by both natural processes (e.g., volcanic activity, wildfires that release sequestered mercury from biomass, and weathering of mercury-containing rocks) and anthropogenic sources. Pyle and Mather (2003) analyzed data from active volcanoes and estimated that annual mercury emissions from volcanic activity was approximately 700 Mg/year (700 metric tons/year), which accounts for roughly 20–40% of all natural emissions. Studies of 11 western U.S. states between 2000 and 2013 estimated that the average annual emission of mercury due to wildfires in these states was 3,100±1,900 kg/year (3.1 metric tons/year) (Webster et al. 2016).

Anthropogenic releases have historically been primarily to the atmosphere; however, in the United States, these levels have been decreasing as regulations and engineering controls on point source and fugitive emissions limit the amount of mercury released to air. On-site land disposal now accounts for the majority of all of the releases of mercury from facilities that are required to report to the TRI (EPA 2020a). Streets et al. (2017) performed a comprehensive temporal review of worldwide anthropogenic emission sources of mercury and estimated that a cumulative total of 1,540 Gigagrams (1,540,000 metric tons) of mercury have been released to the environment from human activity, the bulk of which (24%) occurred from silver mining and smelting. The cumulative anthropogenic emission budget of mercury to the environment is shown in Table 5-3.

Table 5-3. Cumulative Worldwide Man-made Releases of Mercury to Air, Land, and Water Until 2010

Emission source	Amount released to air (Gg)	Amount released to land/water (Gg)	Total amount (Gg)
Copper smelting	4.91	12.6	17.5
Zinc smelting	10.5	25.3	35.8
Lead smelting	6.04	8.57	14.6
Iron making	1.2	1.45	2.65
Steel making	0.41	2.41	2.82
Mercury production	91.7	321	413
Gold, large-scale production	21	114	135
Gold, artisanal	34.4	51.6	86
Silver production	146	219	365
Cement production	3.29	3.47	6.76
Caustic soda production	8.80	63.6	72.4
Coal combustion	26.4	11.4	37.8
Oil combustion	0.77	0	0.77
Municipal waste incineration	34.6	0	34.6
Other waste burning	27.8	0	27.8
Electrical and measuring equipment	5.52	97.7	179
Chemicals manufacturing	47.5	131	179
Dental	1.06	5.69	6.75
Total Gg (metric tons)	472 (472,000)	1,070 (1,070,000)	1,540 (1,540,000)

Source: Adapted with permission from Streets et al. 2017. Copyright (2017) American Chemical Society.

5.3.1 Air

Estimated releases of 4,289 pounds (~1.95 metric tons) of elemental mercury to the atmosphere from 351 facilities reporting to TRI domestic manufacturing and processing facilities in 2022, accounted for about 6.7% of the estimated total environmental releases from facilities required to report to the TRI (TRI22 2024). Estimated releases of 30,136 pounds (~13.67 metric tons) of mercury compounds to the atmosphere from 1,007 facilities reporting to TRI domestic manufacturing and processing facilities in 2022, accounted for about 0.72% of the estimated total environmental releases from facilities required to report to the TRI (TRI22 2024). These releases are summarized in Tables 5-4 and 5-5.

Table 5-4. Releases to the Environment from Facilities that Produce, Process, or Use Elemental Mercury[a]

							Total release		
State[c]	RF[d]	Air[e]	Water[f]	UI[g]	Land[h]	Other[i]	On-site[j]	Off-site[k]	On- and off-site
AL	8	710	0	0	266	0	964	12	976
AK	4	5	0	0	39	0	5	39	44
AZ	11	37	0	0	109	41	144	43	187
AR	6	59	0	0	209	0	268	0	268
CA	31	318	7	0	11,538	2	11,854	11	11,865
CO	6	21	0	0	0	0	21	0	21
CT	5	0	0	0	118	47	0	165	165
DE	1	0	0	0	0	0	0	0	0
DC	1	0	0	0	0	0	0	0	0
FL	3	56	0	0	5	0	56	5	61
GA	8	5	1	0	23	0	7	23	30
ID	2	1	0	0	2,834	2,538	2,835	2,538	5,373
IL	23	34	1	0	2,889	10	2,727	206	2,933
IN	9	89	19	0	109	0	195	22	218
IA	6	280	0	0	21	0	281	19	300
KS	3	50	0	1	18	2	51	20	71
KY	5	8	5	0	632	10	623	32	655
LA	11	673	160	0	2,703	361	3,456	442	3,898
ME	1	0	0	0	0	0	0	0	0
MD	4	0	0	0	0	25	0	25	25
MA	7	0	0	0	0	21	0	21	21
MI	6	86	0	143	9	0	238	0	238
MN	13	7	1	0	33	0	8	33	41
MS	3	4	0	0	1	0	4	1	4
MO	5	34	0	0	7	0	40	1	40
MT	2	1	0	0	0	0	1	0	1
NE	6	30	1	0	53	169	31	222	252
NV	9	271	0	0	3,453	20	3,724	20	3,744
NJ	4	1	1	0	90	0	2	90	92
NM	1	5	0	0	121	49	5	170	175
NY	8	38	5	0	802	13	838	20	859
NC	9	17	0	0	0	1	17	1	18
OH	20	738	36	0	614	91	1,334	144	1,478
OK	4	9	0	0	1	0	10	0	10
OR	2	0	0	0	415	325	415	325	741
PA	12	34	0	0	765	18,287	392	18,695	19,087
RI	1	0	0	0	0	0	0	1	1

Table 5-4. Releases to the Environment from Facilities that Produce, Process, or Use Elemental Mercury[a]

							Reported amounts released in pounds (metric tons) per year[b]		
								Total release	
State[c]	RF[d]	Air[e]	Water[f]	UI[g]	Land[h]	Other[i]	On-site[j]	Off-site[k]	On- and off-site
SC	4	33	0	0	7	0	40	0	40
SD	4	41	0	0	2	0	42	0	42
TN	5	21	0	0	22	21	21	43	64
TX	38	145	5	1	4,288	921	4,419	941	5,360
UT	9	34	0	0	90	6	120	9	130
VT	1	0	0	0	0	1	0	1	1
VA	6	2	1	0	2	13	2	16	18
WA	4	3	0	0	14	5	16	6	22
WV	7	16	0	0	3,079	0	3,094	1	3,095
WI	7	12	0	0	242	10	12	252	264
WY	5	355	0	0	461	0	815	1	816
GU	1	6	0	0	0	0	6	0	6
Total	351	4,289	245	145	36,081	22,988	39,133	24,615	63,748

[a]The TRI data should be used with caution since only certain types of facilities are required to report. This is not an exhaustive list. Data are rounded to nearest whole number.
[b]Data in TRI are maximum amounts released by each facility.
[c]Post office state abbreviations are used.
[d]Number of reporting facilities.
[e]The sum of fugitive and point source releases are included in releases to air by a given facility.
[f]Surface water discharges, wastewater treatment (metals only), and publicly owned treatment works (POTWs) (metal and metal compounds).
[g]Class I wells, Class II-V wells, and underground injection.
[h]Resource Conservation and Recovery Act (RCRA) subtitle C landfills; other onsite landfills, land treatment, surface impoundments, other land disposal, other landfills.
[i]Storage only, solidification/stabilization (metals only), other off-site management, transfers to waste broker for disposal, unknown.
[j]The sum of all releases of the chemical to air, land, water, and underground injection wells.
[k]Total amount of chemical transferred off-site, including to POTWs.

RF = reporting facilities; UI = underground injection

Source: TRI22 2024 (Data are from 2022)

Table 5-5. Releases to the Environment from Facilities that Produce, Process, or Use Mercury Compounds[a]

							Reported amounts released in pounds (metric tons) per year[b]		
								Total release	
State[c]	RF[d]	Air[e]	Water[f]	UI[g]	Land[h]	Other[i]	On-site[j]	Off-site[k]	On- and off-site
AL	29	1,636	17	0	126,456	329	127,698	740	128,438

Table 5-5. Releases to the Environment from Facilities that Produce, Process, or Use Mercury Compounds[a]

| | | | | | | Reported amounts released in pounds (metric tons) per year[b] | | | |
| | | | | | | | Total release | | |
State[c]	RF[d]	Air[e]	Water[f]	UI[g]	Land[h]	Other[i]	On-site[j]	Off-site[k]	On- and off-site
AK	18	62	0	0	92,634	61	92,686	72	92,758
AZ	16	561	2	0	40,562	5,693	36,499	10,318	46,818
AR	16	1,577	10	22	310,385	3	309,033	2,965	311,998
CA	59	663	52	0	26,625	1,276	25,931	2,685	28,616
CO	18	376	0	0	2,384	20	2,624	155	2,779
CT	1	0	0	0	1	0	1	0	1
DE	3	11	1	0	21	1	33	1	34
DC	1	5	0	0	0	0	5	0	5
FL	31	827	688	0	8,355	134	9,817	186	10,003
GA	18	209	29	0	342	8	536	52	588
HI	6	24	0	1	12	0	26	12	38
ID	11	740	6	0	7,165	0	7,910	1	7,910
IL	31	898	12	0	1,247	478	2,002	633	2,635
IN	33	3,792	11	0	2,211	139	5,804	348	6,153
IA	20	189	10	0	693	86	791	187	978
KS	16	226	1	0	608	201	813	223	1,036
KY	25	878	4	2	3,100	7	3,978	12	3,990
LA	42	513	18	17	1,980	352	1,744	1,136	2,879
ME	3	32	49	0	15	1	87	9	96
MD	9	140	0	0	424	0	140	424	564
MA	1	0	0	0	0	11	0	11	11
MI	23	275	2	0	3,045	117	3,194	244	3,438
MN	18	172	0	0	794	1	868	100	967
MS	12	388	15	29	464	22	605	313	918
MO	23	1,040	5	1	969	413	1,937	491	2,428
MT	12	163	0	0	1,301	10	1,441	33	1,474
NE	13	299	1	0	49,552	28	47,896	1,984	49,880
NV	33	1,876	0	5	3,075,211	284,349	3,076,115	285,327	3,361,441
NH	2	2	0	0	95	0	3	94	97
NJ	13	25	1,243	0	109	318	25	1,671	1,695
NM	8	84	0	1	1,117	350	1,201	351	1,552
NY	10	84	0	0	2,464	2	2,528	23	2,551
NC	38	914	12	0	4,342	93	2,105	3,256	5,361
ND	15	925	1	0	564	41	1,335	196	1,531
OH	35	1,006	47	166	3,223	65	3,297	1,210	4,507
OK	21	323	2	0	887	529	1,169	572	1,741
OR	10	54	4	0	2,309	0	59	2,308	2,366

Table 5-5. Releases to the Environment from Facilities that Produce, Process, or Use Mercury Compounds[a]

State[c]	RF[d]	Air[e]	Water[f]	UI[g]	Land[h]	Other[i]	On-site[j]	Off-site[k]	On- and off-site
							Total release		
PA	50	1,295	20	0	2,600	885	2,459	2,342	4,801
RI	2	6	0	0	0	0	6	0	6
SC	27	1,298	11	0	938	110	2,186	171	2,357
SD	3	11	0	0	4,640	0	4,650	0	4,650
TN	23	704	80	0	1,827	226	2,255	582	2,837
TX	93	3,617	19	47	13,017	903	15,364	2,239	17,604
UT	25	628	200	0	57,450	96	52,516	5,858	58,375
VA	15	333	6	23	348	0	660	49	709
WA	22	167	2	0	158	14	279	63	342
WV	16	441	8	0	7,470	19	5,065	2,873	7,938
WI	21	168	145	0	978	171	900	561	1,460
WY	13	355	0	0	637	9	807	194	1,001
GU	1	0	0	0	0	0	0	0	0
MP	1	0	0	0	0	0	0	0	0
PR	2	126	0	0	192	0	126	192	318
Total	1,007	30,136	2,735	315	3,861,917	297,572	3,859,208	333,467	4,192,675

The heading row also carries the span label *Reported amounts released in pounds (metric tons) per year[b]*.

[a]The TRI data should be used with caution since only certain types of facilities are required to report. This is not an exhaustive list. Data are rounded to nearest whole number.
[b]Data in TRI are maximum amounts released by each facility.
[c]Post office state abbreviations are used.
[d]Number of reporting facilities.
[e]The sum of fugitive and point source releases are included in releases to air by a given facility.
[f]Surface water discharges, wastewater treatment (metals only), and publicly owned treatment works (POTWs) (metal and metal compounds).
[g]Class I wells, Class II-V wells, and underground injection.
[h]Resource Conservation and Recovery Act (RCRA) subtitle C landfills; other onsite landfills, land treatment, surface impoundments, other land disposal, other landfills.
[i]Storage only, solidification/stabilization (metals only), other off-site management, transfers to waste broker for disposal, unknown.
[j]The sum of all releases of the chemical to air, land, water, and underground injection wells.
[k]Total amount of chemical transferred off-site, including to POTWs.

RF = reporting facilities; UI = underground injection

Source: TRI22 2024 (Data are from 2022)

In the United States, atmospheric releases of mercury have been declining for the last 2 decades as fugitive and stack source emissions have been reduced. Figure 5-2 shows the atmospheric emissions of facilities required to report to the TRI from 2007 to 2018 (EPA 2020a).

**Figure 5-2. Temporal Atmospheric Emissions of Mercury from Facilities Required
to Report to the Toxics Release Inventory**

Source EPA 2020a

The bulk of these emissions (>90%) arise from stack emissions rather than fugitive emissions. Releases
of mercury and mercury compounds to air decreased by 71% from 2007 to 2018, with electric utility
providers having a decline in mercury air emissions of approximately 90% during this period (EPA
2020b).

The United Nations Global Mercury Assessment for 2018 estimated that the global inventory of mercury
emissions to the atmosphere from anthropogenic sources in 2015 was approximately 2,220 metric tons
(UNEP 2018), which is approximately 20% greater than in 2010 (Dastoor et al. 2022). Artisanal and
small-scale gold mining is the greatest emission source, representing approximately 38% of the total
followed by stationary combustion of coal from power plants (13.1%), cement production (10.5%), and
non-ferrous metal production, principally aluminum, copper, lead, and zinc (10.3%). Anthropogenic
emissions by sector source type are illustrated in Table 5-6. Globally, the greatest amount of atmospheric
emissions of mercury are estimated to come from Asia (49%, of which 39% is from East and South-east
Asia), followed by South America (18%), and Sub-Saharan Africa (16%). Mercury emissions from
cremation, which contributed 0.17% of the total global anthropogenic mercury emissions in 2019 (UNEP
2018), are expected to increase as global cremations increase (Tibau and Grube 2019).

Table 5-6. Global Anthropogenic Emissions of Mercury to the Atmosphere by Sector

Sector	Mercury emissions (range), metric tons	Percentage of total amount
Artisanal and small-scale gold mining	838 (675–1,000)	37.7
Stationary combustion of coal from power plants	292 (255–346)	13.1
Cement production (raw materials and fuel, excluding coal)	233 (117–782)	10.5
Non-ferrous metal production (principally aluminum, copper, lead, and zinc)	228 (154–338)	10.3
Waste	147 (120–223)	6.6
Stationary combustion of coal (industrial)	126 (106–146)	5.67
Large-scale gold production	84.5 (72.3–97.4)	3.8
Vinyl-chloride monomer (mercury catalyst)	58.2 (28.0–88.8)	2.6
Stationary combustion of coal (domestic/residential, transportation)	55.8 (36.7–69.4)	2.51
Biomass burning (domestic, industrial, and power plant)	51.9 (44.3–62.1)	2.33
Pig iron and steel production (primary)	29.8 (19.1–76.0)	1.34
Chloralkali production (mercury process)	15.1 (12.2–18.3)	0.68
Waste incineration (controlled burning)	15.0 (8.9–32.3)	0.67
Oil refining	14.4 (11.5–17.2)	0.65
Mercury production	13.8 (7.9–19.7)	0.62
Secondary steel production	10.1 (7.65–18.1)	0.46
Cremation	3.77 (3.51–4.02)	0.17
Stationary combustion of oil (domestic/residential, transportation)	2.70 (2.33–3.21)	0.12
Stationary combustion of oil (power plants)	2.45 (2.17–2.84)	0.11
Stationary combustion of oil (industrial)	1.40 (1.18–1.69)	0.06
Stationary combustion of gas (power plants)	0.349 (0.285–0.435)	0.02
Stationary combustion of gas (domestic/residential, transportation)	0.165 (0.13–0.22)	0.01
Stationary combustion of gas (industrial)	0.123 (0.10–0.15)	0.01
Total	2,220 (2,000, 3,820)	100

Source: UNEP 2018

5.3.2   Water

Estimated releases of 245 pounds (~0.1 metric tons) of elemental mercury to water from 351 facilities reporting to TRI domestic manufacturing and processing facilities in 2022, accounted for <1% of the estimated total environmental releases from facilities required to report to the TRI (TRI22 2024).

Estimated releases of 2,735 pounds (~1.1 metric tons) of mercury compounds to water from
1,007 facilities reporting to TRI domestic manufacturing and processing facilities in 2022, accounted for
<1% of the estimated total environmental releases from facilities required to report to the TRI (TRI22
2024). These releases are summarized in Tables 5-4 and 5-5.

Natural weathering of mercury-bearing minerals in igneous rocks can contribute substantially to
environmental mercury. An analysis conducted in 1972 estimated that this source directly released about
800 metric tons of mercury per year to surface waters of the earth (Gavis and Ferguson 1972).
Atmospheric deposition of elemental mercury from both natural and anthropogenic sources has been
identified as an indirect source of mercury to surface waters (WHO 1991). Mercury associated with soils
can be directly washed into surface waters during rain events. Surface runoff is an important mechanism
for transporting mercury from soil into surface waters, particularly for soils with high humic content
(Meili 1991). Mercury may also be released to surface waters in effluents from industrial processes
(Dean et al. 1972; EPA 1971; UNEP 2018).

Atmospheric deposition is a significant source of mercury emissions to water bodies. Gaseous elemental
mercury can remain suspended in the atmosphere for many months and is susceptible to long-range
atmospheric transport. While the United States and Canada have reduced mercury emissions significantly
over the last several decades, anthropogenic emissions arising from outside of North America continue to
deposit mercury into the Great Lakes Basin. The International Joint Commission (IJC) reported that
Environment Canada estimates that 95% of anthropogenic deposition in Canada arises from foreign
sources (IJC 2015). Cohen et al. (2016) developed a model to estimate atmospheric deposition of
mercury to the Great Lakes and calculated that the United States contributed the most anthropogenic
emissions (25%), followed by China (6%). Canada's deposition of mercury to the Great Lakes in 2005
was estimated to approximately 2%, while 15% was attributed to India, Russia, and Mexico. All other
nations combined were estimated to contribute a little over 4% of the total atmospheric deposition of
mercury to the Great Lakes. The rest of the deposition arose from oceanic natural emissions and re-
emissions of previously deposited mercury (32%), terrestrial natural emissions and re-emissions (17%),
biomass burning (5.1%), and geogenic emissions such as those coming from volcanoes (6.4%).

The Mercury Deposition Network (MDN) provides long-term temporal records of total mercury
deposition in precipitation across the United States and Canada. Annual deposition data from the MDN
are provided in Table 5-7 for select years for the previous 2 decades.

Table 5-7. Mercury Deposition Data from the Mercury Deposition Network for North America

Year	Deposition ($\mu g/m^2$)
1998	10.56
2005	9.08
2010	8.96
2015	8.91
2018	8.78

Source: MDN 2020

According to the United Nations Global Mercury Assessment, anthropogenic global mercury emissions to waters from artisanal and small-scale gold mining was approximately 1,220 metric tons in 2015 (UNEP 2018). The majority of releases occurred in South America (53%), East and Southeast Asia (36%), and Sub-Saharan Africa (8%). Additionally, another 580 metric tons of mercury were released to water from other anthropogenic activities, primarily waste treatment, ore mining and processing, and from the energy sector.

5.3.3   Soil

Estimated releases of 36,081 pounds (~16.4 metric tons) of elemental mercury to soil from 351 facilities reporting to TRI domestic manufacturing and processing facilities in 2022, accounted for about 62% of the estimated total environmental releases from facilities required to report to the TRI (TRI22 2024). An additional 145 pounds (~0.07 metric tons), accounted for <1% of the total environmental emissions, were released via underground injection (TRI22 2024). These releases are summarized in Table 5-4.

Estimated releases of 3,861,917 pounds (~1,751.7 metric tons) of mercury compounds to soil from 1,007 facilities reporting to TRI domestic manufacturing and processing facilities in 2022, accounted for about 92% of the estimated total environmental releases from facilities required to report to the TRI (TRI22 2024). An additional 315 pounds (~0.1 metric tons), accounted for <1% of the total environmental emissions, were released via underground injection (TRI22 2024). These releases are summarized in Table 5-5.

Atmospheric deposition of mercury from both natural and anthropogenic sources has been identified as an indirect source of mercury to soil and sediments (Dastoor et al. 2022; MDN 2020;). Since vapor-phase mercury is subject to long-range transport, it can be deposited to remote areas such as the Arctic. Atmospheric deposition of mercury in the Arctic was estimated as 133±9 metric tons per year in 1990 and decreased to 119±10 metric tons in 2005 (Goodsite et al. 2013). The contributions to Arctic deposition of anthropogenic mercury were dominated by sources in East Asia (32%), Commonwealth of Independent States (12%), and Africa (12%) (Dastoor et al. 2022). Risch et al. (2017) compiled data from the National Atmospheric Deposition Program for years 2007–2014 and determined that the annual deposition flux rate in deciduous-coniferous forests in 16 states in the eastern United States was approximately 11.7 $\mu g/m^2$-year (range 2.2–23.4 $\mu g/m^2$-year). Mercury is released to cultivated soils through the direct application of inorganic and organic fertilizers (e.g., sewage sludge and compost), and lime (Andersson 1979). The use of biosolids as a nutrient for agricultural soils has the potential to release mercury to soils. Lomonte et al. (2010) studied the levels of mercury in biosolids from a wastewater treatment plant in Melbourne, Australia and found concentrations between 3.5 and 8.4 mg/kg.

5.4   ENVIRONMENTAL FATE

The natural global bio-geochemical cycling of mercury is characterized by degassing of the element from soils and surface waters, followed by atmospheric transport, deposition of mercury back to land and surface waters, and sorption of the compound to soil or sediment particulates. Figure 5-3 summarizes the approximate global contributions of natural and anthropogenic sources to the mercury cycle (UNEP2018). Mercury deposited on land and open water is, in part, revolatilized back into the atmosphere. This emission, deposition, and revolatilization creates difficulties in tracing the movement of mercury to its sources (WHO 1990). Particulate-bound mercury can be converted to insoluble mercury sulfide and precipitated or bioconverted into more volatile or soluble forms that re-enter the atmosphere or are bioaccumulated in aquatic and terrestrial food chains (EPA 1984).

Figure 5-3. Global Mercury Budget: Impact of Human Activities on the Mercury Cycle and the Resulting Increase in Mercury Accumulated in Soils and Oceans

Source: UNEP (2018)

5.4.1   Transport and Partitioning

Air. Mercury has three valence states. The specific state and form of the compound found in an
environmental medium is dependent upon a number of factors, including the redox potential and pH of
the medium. The most reduced form is metallic or elemental mercury, which is a liquid at ambient
temperatures, but readily vaporizes. Although point source emissions of mercury to the environment
affects ecosystems locally, these large sources of mercury pollution can contribute to the global
atmospheric level of mercury since it is a volatile substance. Deposition can occur far distances from
emission sources and impact remote ecosystems (Sizmur et al. 2018). Over 95% of the mercury found in
the atmosphere is gaseous mercury (Hg^0), the form involved in long-range (global) transport of the
element. Residence time in the atmosphere has been estimated to range from 6 days (Andren and Nriagu
1979) to 2 years (EPA 1984). Approximately 5% of atmospheric mercury is associated with particulates,
which have a shorter atmospheric residence time, are removed by dry or wet deposition, and may show a
regional or local distribution pattern (Nater and Grigal 1992). Atmospheric inputs may be more
significant in areas where other sources of contamination, such as contaminated rivers, are less important
or nonexistent (Kelly et al. 1991). Although local sources are important, a 72-hour travel time trajectory
for mercury indicates that some mercury found in rain may originate from sources up to 2,500 km
(1,550 miles) away (Glass et al. 1991).

Metallic mercury released in vapor form to the atmosphere can be transported long distances before it is
converted to other forms of mercury, and wet and dry deposition processes return it to land and water
surfaces. Dry deposition may account for approximately 70% of the total atmospheric deposition of
mercury during the summer, although on an annual basis, wet and dry deposition may be of equal
importance (Lindberg et al. 1991). Up to 22% of the annual input of mercury to Lake Erie is from dry
deposition of mercury-containing atmospheric particles or from precipitation (Kelly et al. 1991). Wet
deposition is the primary method of removal of mercury from the atmosphere (approximately 66%)
(Fitzgerald et al. 1991; Lindqvist et al. 1991) and may account for virtually all of the mercury content in
remote lakes that do not receive inputs from other sources (e.g., industrial effluents) (Hurley et al. 1991;
Swain et al. 1992). Most inert mercury (Hg+2) in precipitation is bound to aerosol particulates, which are
relatively immobile when deposited on soil or water (Meili et al. 1991). Wet deposition has high spatial
variability globally; however, a general trend of highest wet deposition in the lower and mid-latitudes of
the Northern Hemisphere, with lower deposition rates in the Arctic and the Southern Hemisphere, have
been observed (Lyman et al. 2020). In North America, wet deposition tends to be highest in the
southeastern United States. Dry deposition flux rates of mercury have been reported as approximately

10 µg/m^2-year in Asia and approximately 6 µg/m^2-year in North America (Lyman et al. 2020). The difference is due to much higher anthropogenic emissions, and thus ambient concentrations, in Asia.

Mercury is also present in the atmosphere to a limited extent in unidentified soluble forms associated with particulate matter. In addition to wet and dry deposition processes, mercury may also be removed from the atmosphere by sorption of the vapor form to soil or water surfaces (EPA 1984). Cloud water chemical properties also affect the speciation of inorganic mercury compounds (Lyman et al. 2020). Highly acidic (pH <4) cloud water displayed 10–20 times higher total mercury concentrations than cloud water at pH >4.

Water. In soils and surface waters, mercury can exist in the mercuric (Hg^{+2}) and mercurous (Hg^{+1}) states as a number of complex ions with varying water solubilities. Mercuric mercury, present as complexes and chelates with ligands, is probably the predominant form of mercury present in surface waters. The transport and partitioning of mercury in surface waters and soils are influenced by the particular form of the compound. More than 97% of the dissolved gaseous mercury found in water consists of elemental mercury (Vandal et al. 1991). Hydrologic transport and geochemical cycling of mercury in water is an important part of the mercury global transport cycle. Wetlands, particularly estuarine marshes, are environments with biogeochemical settings that are favorable to elevated activity of the anaerobic bacteria responsible for the conversion of inorganic mercury into methylmercury (Turner et al. 2018). Conditions that favor methylmercury production in wetlands and other aquatic ecosystems include anoxic sediments, plentiful sources of labile carbon, and levels of sulfate that are neither too low to inhibit the activity of sulfate-reducing bacteria or too high, wherein significant sulfide is produced and mercury bioavailability for methylation is reduced. Turner et al. (2018) measured net fluxes of mercury from the mercury-contaminated Penobscot River and Bay system located in Maine. Over four tidal cycles on the South Marsh River, it was demonstrated that the marsh was a consistent sink over typical 12-hour tidal periods for total mercury with a flux rate of 9.2–47 µg/m^2-day and a total methylmercury flux rate of 0.2– 1.4 µg/m^2-day. It was noted that the marsh was a source of methylmercury to the Penobscot River during large spring tides; however, it was concluded that Mendall Marsh is not a significant source of mercury or methylmercury to Penobscot River and Bay system.

Volatile forms (e.g., metallic mercury and dimethylmercury) are expected to evaporate to the atmosphere, whereas solid forms partition to particulates in the soil or water column and are transported downward in the water column to the sediments (Hurley et al. 1991). Vaporization of mercury from soils may be controlled by temperature, with emissions from contaminated soils being greater in warmer weather when

soil microbial reduction of Hg^{+2} to the more volatile elemental mercury is greatest (Lindberg et al. 1991). Vapor-phase mercury volatilized from surface waters has been measured (Schroeder and Fanaki 1988); however, the dominant process controlling the distribution of mercury compounds in the environment appears to be the sorption of nonvolatile forms to soil and sediment particulates, with little resuspension from the sediments back into the water column (Bryan and Langston 1992). Cossa et al. (1988) found that 70% of the dissolved mercury in St. Lawrence River water was associated with organic matter. The study authors reported that the removal mechanism was flocculation of organic mercury colloids in freshwater. Methylmercury and other mercury fractions are strongly bound to organic matter in water and may be transported in runoff water from contaminated lakes to other surface waters and soils (Lee and Iverfeldt 1991). Small amounts (2–4 ng/L [ppt]) of mercury are able to move from contaminated groundwater into overlying lakes, with concentrations reaching a maximum near the sediment/water interface; however, since most of the mercury in the groundwater is derived from atmospheric sources, this low range of values indicates that most of the mercury deposited on soil (92–96% of the 10.3 $\mu g/m^2$/year of mercury deposited) is absorbed to the soil and does not leach down into the groundwater (Krabbenhoft and Babiarz 1992).

Sediment and Soil. The sorption process has been found to be related to the organic matter content of the soil or sediment. Mercury is strongly sorbed to humic materials and sesquioxides in soil at a pH >4 (Blume and Brümmer 1991) and to the surface layer of peat (Lodenius and Autio 1989). Mercury has been shown to volatilize from the surface of more acidic soils (i.e., soil pH <3.0) (Warren and Dudas 1992). Adsorption of mercury to mineral surfaces increases with increasing pH; however, increases in chloride concentration reduces the extent of adsorption (Schuster 1991). Mercury is sorbed to soil with high iron and aluminum content up to a maximum loading capacity of 15 g/kg (15,000 ppm) (Ahmad and Qureshi 1989). Inorganic mercury sorbed to particulate material is not readily desorbed. Thus, freshwater and marine sediments are important repositories for inorganic forms of the element, and leaching is a relatively insignificant transport process in soils. However, surface runoff is an important mechanism for moving mercury from soil to water, particularly for soils with high humic content (Meili 1991). Mobilization of sorbed mercury from particulates can occur through chemical or biological reduction to elemental mercury and bioconversion to volatile organic forms (Andersson 1979; EPA 1979, 1984). Metallic mercury may move through the top 3–4 cm of dry soil at atmospheric pressure; however, it is unlikely that further penetration would occur (Eichholz et al. 1988). Bachand et al. (2019) demonstrated that addition of coagulants, such as polyaluminum chloride and ferric sulfate, to soils contaminated with mercury reduced the transfer into aquatic systems by sequestering mercury into insoluble particulate forms resulting in enhanced settling of particles.

The volatilization and leaching of various forms of mercury (elemental, mercuric sulfide, mercuric oxide, and mercurous oxide) from soils or wastes were examined using the headspace method for volatilization and the Resource and Conservation Recovery Act (RCRA) leaching protocols for leaching through soil to determine if the leachates exceeded the RCRA limit of 200 µg/L (ppb) (Willett et al. 1992). With the exception of mercuric sulfide, the other forms of mercury increased in concentrations in the headspace vapor and in the leachate as the soil concentrations increased, although the elemental mercury concentrations never exceeded the RCRA limit, indicating that it was relatively nonleachable. Mercuric sulfide also did not exceed the background level for the leachate and was consistently <0.001 mg/m^3 for the vapor concentrations, indicating that it was also nonleachable and did not readily volatilize. This study also showed that concentrations of mercury in leachate could not be correlated with the concentration of mercury in the soil or in the headspace vapors (Willett et al. 1992). Mercuric sulfide has been found to strongly adsorb to soil, and even with weathering, any mercury released from the mercuric sulfide is readsorbed by the soil (Harsh and Doner 1981).

Other Media. Mercury emitted to the atmosphere is primarily in an inorganic form and it remains primarily in the inorganic form when deposition occurs to water bodies. However, in water and sediments, inorganic mercury can be transformed into methylmercury, which is very prone to bioaccumulate and biomagnify as it moves through the food chain (Riisgard and Hansen 1990; UNEP 2018). In a study of bioaccumulation of mercury in aquatic organisms, it was shown that fish had lower methylmercury bioaccumulation factors in sites with high organic carbon, especially sites with large coastal wetlands and large variability in dissolved organic carbon levels in the water column (Taylor et al. 2018b). Methylmercury in surface waters is rapidly accumulated by aquatic organisms; concentrations in carnivorous fish (e.g., pike, shark, and swordfish) at the top of both freshwater and marine food chains are biomagnified on the order of 10,000–100,000 times the concentrations found in ambient waters (EPA 1979, 1984; WHO 1990, 1991). The range in experimentally determined bioconcentration factor (BCF) values is shown in Table 5-8. The bioaccumulation potential for methylmercury in fish is influenced by the pH of the water, with a greater bioaccumulation seen in waters with lower pH (BDI 2011; Ponce and Bloom 1991). Mercury concentrations in fish have also been negatively correlated with other water quality factors, such as alkalinity and dissolved oxygen content (Ontario Ministry of the Environment 1991). Biogeochemical and ecological mechanisms are responsible for the transfer of mercury from near-shore contaminated sediments to higher trophic levels in offshore environments. Anoxic conditions in estuaries favor the production of methylmercury; however, sediments high in total organic carbon and iron sulfides tend to reduce the bioavailability of mercury in these areas. Trophic relay or bioadvection of

methylmercury from sediments in contaminated estuaries to offshore pelagic organisms may occur

through predator-prey relationships or the movement of juvenile species to deeper waters (Chen et al.

2009).

Table 5-8. Bioconcentration of Various Mercury Compounds by Freshwater and Saltwater Organisms

Species	Tissue	Chemical	Duration (days)	Bioconcentration factor[a]
Freshwater species				
Mercury (II)				
Rainbow trout *Salmo gairdneri*	Whole body	Mercuric chloride	60	1,800
Fathead minnow *Pimphales promelas*	Whole body	Mercuric chloride	287	4,994[b]
Organomercury compounds				
Rainbow trout *S. gairdneri*	Whole body	Methylmercuric chloride	60	11,000
Rainbow trout *S. gairdneri*	Whole body	Methylmercuric chloride	75	85,700
Brook trout *Salvelinus fontinalis*	Muscle	Methylmercuric chloride	273	11,000–33,000
Brook trout *S. fontinalis*	Whole body	Methylmercuric chloride	273	10,000–23,000
Brook trout *S. fontinalis*	Muscle and whole body	Methylmercuric chloride	756	12,000
Fathead minnow *P. promelas*	Whole body	Methylmercuric chloride	336	44,130–81,570
Saltwater species				
Mercury (II)				
Eastern oyster (adult) *Crassostrea virginica*	Soft parts	Mercuric chloride	73	10,000
American lobster (adult) *Homarus americanus*	Soft parts	Mercuric chloride	30	129
Organomercury compounds				
Eastern oyster (adult) *C. virginica*	Soft parts	Methylmercuric chloride	74	40,000
Eastern oyster (adult) *C. virginica*	Soft parts	Phenylmercuric chloride	74	40,000

[a]Results are based on the concentration of mercury, not the concentration of the mercury compound to which the animal was exposed.
[b]From concentrations that caused adverse effects in a life-cycle test.

Source: ASTER 1997

Mercury levels in freshwater fish have been shown to be elevated in areas impacted by gold mining operations (Diringer et al. 2015; Salazar-Camacho et al. 2021). A study of fish impacted by gold mining in the Atrato River Basin, Columbia identified a correlation between total mercury levels with fish length and trophic level, indicating that mercury was biomagnifying in the ecosystem. The median total mercury level in all carnivorous fish (n=533) was 225.4±344.3 μg/kg and the median level in all non-carnivorous fish (n=289) was 82.4±91.3 μg/kg. Total mercury concentrations (median±SD) in the fish categorized by trophic level are shown in Table 5-9.

Table 5-9. Mercury Concentrations Found in Fish

Species	Total mercury median (±SD) μg/kg	Trophic level
Doncella *Ageneiosus pardalis*	678.5±344.9	3.8
Moncholo *Hoplias malabaricus*	401.4±278.5	4.5
Caga *Trachelyopterus fisheri*	374.3±250.0	3.5
Bagre sapo *Pseudopimelodus schultzi*	432.7±897.0	3.7
Agujeta *Ctenolucius beani*	270.9±289.1	4
Majarra Negra *Caquetaia umbrifera*	218.5±221.1	3.8
Mayupa *Sternopygus macrurus*	177.0±452.2	3.2
Mojarra Amarilla *Caquetaia kraussii*	218.0±200.6	3.4
Liso *Rhamdia quelen*	145.8±211.6	3.9
Sardina colirroja *Astyanax fasciatus*	117.2±113.7	3
Charre *Pimelodus punctatus*	100.5±66.9	3.3
Cocobolo *Andinoacara pulcher*	116.7±59.7	3.3
Dentón *Leporinus muyscorum*	116.7±68.0	2.2
Bocachico *Prochilodus magdalenae*	93.1±113.2	2.1
Guacuco *Hypostomus hondae*	56.0±55.5	2
Viejita *Cyphocharax magdalenae*	32.0±53.2	2

Source: Salazar-Camacho et al. 2021

Ruus et al. (2015) analyzed different species in the Kongsfjorden food web system in Norway and found that tissue concentrations of methylmercury increased with increasing trophic level and were highly correlated with total mercury levels. The highest levels of total mercury and methylmercury were observed in birds (95–1,108 ng/g), which were at the highest trophic level in the food web, and the lowest levels were found in zooplankton (4.7–7.5 ng/g), the lowest trophic level in the foodweb.

Biomagnification factors for methylmercury in the food webs of Lake Ontario were lowest for the transfer of methylmercury from mysids to amphipods (1.1), plankton to amphipods (1.8), and plankton to mysids (2.4); intermediate for the transfer from mysids to fish (5.1) and amphipods to fish (6.5); and highest for the transfer from plankton to fish (10.4) (Evans et al. 1991). The biomagnification of methylmercury from water through several trophic levels is compared to the biomagnification of inorganic mercury in Table 5-10. Watras and Bloom (1992) reported that biomagnification of methylmercury in Little Rock Lake seems to be the result of two processes: the higher affinity of inorganic mercury in lower trophic level organisms and the high affinity of methylmercury in fish. Fish appear to accumulate methylmercury from both food sources and the water column. However, Hall et al. (1997) found that food was the predominant source of mercury uptake in fish. The BCF of methylmercury in fish in Little Rock Lake was $3x10^6$ (Porcella 1994). Mason et al. (1995) also compared bioaccumulation of inorganic mercury and methylmercury and found that passive uptake of the mercury complexes ($HgCl_2$ and CH_3HgCl) results in high concentrations of both the inorganic and methylated mercury in phytoplankton. However, differences in partitioning within phytoplankton cells between inorganic mercury (which is principally membrane-bound) and methylmercury (which accumulated in the cytoplasm) led to a greater assimilation of methylmercury during zooplankton grazing.

Table 5-10. Comparison of the Biomagnification of Methylmercury and Inorganic Mercury in a Freshwater Food Chain (Little Rock Lake)

Medium or trophic level	Methylmercury	Inorganic mercury	Percent methylmercury
Water	1	10	10
Phytoplankton	10^5	$10^{5.7}$	15
Zooplankton	$10^{5.5}$	$10^{5.9}$	30
Fish	$10^{6.5}$	10^5	95

Source: Watras and Bloom 1992

Rumbold et al. (2018) studied biomagnification of mercury in two different locations along the Florida Keys using 50 different species of fish to determine whether the high biodiversity in coral reefs in these complex food webs reduces the biomagnification potential in these regions. It was determined that the Trophic Magnification Slopes (TMS) were very similar for the two sites and that these TMS were also within the ranges of slopes reported for food webs in other ecosystems; therefore, biomagnification of mercury in fish muscle tissue was not reduced in this complex ecosystem. In a similar study conducted along the coast of the Florida Keys, Thera and Rumbold (2014) assessed the trophic biomagnification factor of mercury using 57 species of invertebrates. They concluded that the levels of mercury increased by a factor of 5 with each unit increase in trophic level.

Most of the discrimination between inorganic and methylmercury thus occurs during trophic transfer, while the major enrichment factor is between water and the phytoplankton. This also has been reported for the diatom, *Thalassiosura weissflogii*, in a marine food chain (Mason et al. 1996). Methylmercury was accumulated in the cell cytoplasm, and its assimilation by copepods was 4 times more efficient than the assimilation of inorganic mercury. Bioaccumulation has been demonstrated for predator fish in both freshwater and marine systems and in marine mammals.

Aquatic macrophytes have been found to bioconcentrate methylmercury in almost direct proportion to the mercury concentration in the water (Ribeyre et al. 1991). Mortimer (1985) reported BCFs for several species of submerged aquatic plants exposed to inorganic mercury in laboratory aquaria of 3,300, 1.3, 0.9, and 1.3 for *Utricularia*, *Ceratophyllum*, *Najas*, and *Nitella*, respectively. The concentration factors used by this author was based on $\mu g\ g^{-1}$ dry weight in the plant/$\mu g\ mL^{-1}$ water day^{-1}.

The potential for bioaccumulation in terrestrial food chains is demonstrated by the uptake of mercury by the edible mushroom, *Pleurotus ostreatus*, grown on compost and containing mercury at concentrations of up to 0.2 mg/kg (ppm). The bioaccumulation factors reported ranged from 65 to 140, indicating that there are potential risks to human health if these mushrooms are eaten in large quantities (Bressa et al. 1988). Elevated concentrations of mercury in 149 samples of mushrooms representing 11 different species were reported by Kalač et al. (1991). The study authors collected mushrooms within 6 km of a lead smelter in Czechoslovakia in operation since 1786. Mercury was accumulated by *Lepista nuda* and *Lepiota rhacodes* at 11.9 mg/kg (ppm) and 6.5 mg/kg (ppm) (dry weight), respectively. The mean concentration of other species ranged from 0.3 to 2.4 mg/kg (ppm). Concentrations of mercury in most of the mushroom species collected in that location were higher than in mushrooms collected in other parts of the country.

Data from higher plants indicate that virtually no mercury is taken up from the soil into the shoots of plants such as peas, although mercury concentrations in the roots may be significantly elevated and reflect the mercury concentrations of the surrounding soil (Lindqvist et al. 1991). In a study by Granato et al. (1995), municipal solid waste sludge mercury concentrations from the Metropolitan Water Reclamation District of Greater Chicago were found to range from 1.1 to 8.5 mg/kg (ppm), with a mean concentration of 3.3 mg/kg (ppm). From 1971 to 1995, sludge applications were made to a Fulton County, Illinois sludge utilization site. About 80–100% of the mercury applied to the soils in sewage sludge since 1971 still resided in the top 15 cm of soil. The study authors reported that sewage sludge applications did not increase plant tissue mercury concentrations in corn or wheat raised on the sludge utilization site.

Earthworms, *Lumbricus sp.*, bioaccumulate mercury under laboratory and field conditions in amounts that are dependent on soil concentrations and exposure duration (Cocking et al. 1994). Maximum mercury tissue concentrations in laboratory cultures were only 20% of the 10–14.8 µg/g (ppm) (dry weight) observed in individual worms collected from contaminated soils (21 µg/g) on the South River flood plain at Waynesboro, Virginia. Bioconcentration occurred under field conditions in uncontaminated control soil (0.2 µg Hg/g); however, total tissue mercury concentrations (0.4–0.8 µg/g dry weight) were only 1–5% of those for earthworms collected on contaminated soils. Uptake by the earthworms appeared to be enhanced in slightly acidic soils (pH 5.9–6.0) in laboratory cultures. Soil and earthworm tissue mercury contents were positively correlated under both field and laboratory conditions. Predation of earthworms contaminated with mercury could pass the contamination to such predators as moles and ground-feeding birds, such as robins (Cocking et al. 1994).

5.4.2 Transformation and Degradation

Mercury is transformed in the environment by biotic and abiotic oxidation and reduction, bioconversion of inorganic and organic forms, and photolysis of organomercurials. Inorganic mercury can be methylated by microorganisms indigenous to soils, fresh water, and salt water (Blanc et al. 2018). This process is mediated by various microbial populations under both aerobic and anaerobic conditions. The most probable mechanism for this reaction involves the nonenzymatic methylation of mercuric mercury ions by methyl cobalamin compounds produced as a result of bacterial synthesis. Mercury forms stable complexes with organic compounds. Monoalkyl mercury compounds (e.g., methylmercuric chloride) are relatively soluble; however, the solubility of methylmercury is decreased with increasing dissolved organic carbon content, indicating that it is bound by organic matter in water (Miskimmin 1991). Dialkyl

mercury compounds (e.g., dimethyl-mercury) are relatively insoluble (EPA 1979, 1984). Dimethyl-mercury is volatile, although it makes up <3% of the dissolved gaseous mercury found in water (Andersson et al. 1990; Vandal et al. 1991). The major pathways for transformation of mercury and various mercury compounds in air, water, and soil are shown in Figure 5-4.

Figure 5-4. Transformation of Mercury in Air, Water, and Sediment

Dashed lines represent the boundary between environmental compartments.

Air. Lyman et al. (2020) published an updated review of the atmospheric transport, partitioning, and transformation of mercury. Oxidation by ozone and hydroxyl radicals has historically been assumed to be the dominant oxidation mechanism for ambient elemental mercury; however, recent evidence suggests that oxidation by bromine radicals may be a globally important oxidation mechanism. Ye et al. (2016), showed that in the marine boundary layer, bromine and bromine oxide were the dominant gaseous elemental mercury oxidants, with mixing ratios reaching 0.1 and 1 pptv, respectively, and contributing approximately 70% of the total gaseous oxidized mercury production during midday, while ozone dominated oxidation (50–90 % of gaseous oxidized mercury production) over the remaining day when bromine and bromine oxide mixing ratios decreased.

The overall residence time of elemental mercury in the atmosphere has been estimated to be 6 days to
2 years, although in clouds, a fast oxidation reaction on the order of hours may occur between elemental
mercury and ozone. Some mercury compounds, such as mercuric sulfide, are quite stable in the
atmosphere as a result of their binding to particles in the aerosol phase (Lindqvist et al. 1991). Other
mercury compounds, such as mercuric hydroxide ($Hg[OH]^2$), which may be found in the aqueous phase
of the atmosphere (e.g., rain), are rapidly reduced to monovalent mercury in sunlight (Munthe and
McElroy 1992). The main atmospheric transformation process for organomercurials appears to be
photolysis (EPA 1984; Johnson and Braman 1974; Williston 1968).

Water. The most important transformation process in the environmental fate of mercury in surface
waters is the methylation and demethylation cycle. The methylation of mercury in surface waters is
largely driven by the presence of sulphate-reducing bacteria, and demethylation can occur through both
abiotic and biotic means (Ouddane et al. 2015; Turner et al. 2018). The photochemical degradation of
methylmercury is the most important process of the demethylation cycle at the surface or in shallow
waters. Demethylation by biotic oxidation and reduction reactions are the dominant pathways at deeper
depths and in sediments.

Any form of mercury entering surface waters can be microbially converted to methylmercury, given
favorable conditions. The major factors that influence the rate of methylation are the abundance of
anaerobic microorganisms that have the biochemistry to methylate mercury and the bioavailability of
inorganic Hg(II) in these microorganisms (SERDP 2014). Sulfur-reducing bacteria are responsible for
most of the mercury methylation in the environment (Gilmour and Henry 1991; Ouddane et al. 2015;
Turner et al. 2018), with anaerobic conditions favoring their activity (Regnell and Tunlid 1991). Yeasts,
such as *Candida albicans* and *Saccharomyces cerevisiae*, whose growth is favored by low pH conditions,
are able to methylate mercury and are also able to reduce ionic mercury to elemental mercury (Yannai et
al. 1991). Methyl cobalamin compounds produced by bacterial synthesis appear to be involved in the
nonenzymatic methylation of inorganic mercury ions (Regnell and Tunlid 1991). The rate of
methylmercury formation by this process is largely determined by the concentration of methyl cobalamin
compounds, inorganic mercuric ions, and the oxygen concentration of the water, with the rate increasing
as the conditions become anaerobic. Volatile elemental mercury may be formed through the
demethylation of methylmercury or the reduction of inorganic mercury, with anaerobic conditions again
favoring the demethylation of the methylmercury (Barkay et al. 1989; EPA 1979; Regnell and Tunlid
1991). Increased dissolved organic carbon levels reduce methylation of mercury in the water column
(Gilmour and Henry 1991), possibly as a result of the binding of free mercury ions to the dissolved

organic carbon at low pH, thus reducing their availability for methylation, or the dissolved organic carbon may inhibit the methylating bacteria (Miskimmin et al. 1992). Alternatively, low pH favors the methylation of mercury in the water column, particularly in acid deposition lakes, while inhibiting its demethylation (Gilmour and Henry 1991). It has also been shown that the methylation rate is not affected by addition of sulfate in softwater lakes (Kerry et al. 1991). Even in polar marine systems, methylation of mercury can occur. Sea water and ice samples were collected in the East Antarctic Sea and analyzed for total mercury and methylmercury (Gionfriddo et al. 2016). The marine nitrite-oxidizing bacterium, Nitrospina, was identified as the most likely source for microbially induced methylation of mercury in polar ice and water.

At a pH of 4–9 and a normal sulfide concentration, mercury will form mercuric sulfide. This compound is relatively insoluble in aqueous solution (11×10^{-17} ppb), and it will therefore precipitate out and remove mercury ions from the water, reducing the availability of mercury to fish. Under acidic conditions, however, the activity of the sulfide ion decreases, thus inhibiting the formation of mercuric sulfide and favoring the formation of methylmercury (Bjornberg et al. 1988). Low pH and high mercury sediment concentrations favor the formation of methylmercury, which has greater bioavailability potential for aquatic organisms than inorganic mercury compounds. Methylmercury may be ingested by aquatic organisms lower in the food chain, such as yellow perch, which in turn are consumed by piscivorous fish higher in the food chain (Cope et al. 1990; Wiener et al. 1990). Mercury cycling occurs in freshwater lakes, with the concentrations and speciation of the mercury being dependent on limnological features and water stratification. Surface waters may be saturated with volatile elemental mercury, whereas sediments are the primary source of the mercury in surface waters. During the summer months, surface concentrations of methyl and elemental mercury decline as a result of evaporation, although they remain relatively constant in deeper waters (Bloom and Effler 1990).

Abiotic reduction of inorganic mercury to metallic mercury in aqueous systems can also occur, particularly in the presence of soluble humic substances (i.e., acidic waters containing humic and fulvic acids). This reduction process is enhanced by light, occurs under both aerobic and anaerobic conditions, and is inhibited by competition from chloride ions (Allard and Arsenie 1991).

Sediment and Soil. Mercury compounds in soils may undergo the same chemical and biological transformations described for surface waters. Mercuric mercury usually forms various complexes with chloride and hydroxide ions in soils; the specific complexes formed depend on the pH, salt content, and composition of the soil solution. Formation and degradation of organic mercurials in soils appear to be

mediated by the same types of microbial processes occurring in surface waters and may also occur through abiotic processes (Andersson 1979). Elevated levels of chloride ions reduce methylation of mercury in river sediments, sludge, and soil (Olson et al. 1991), although increased levels of organic carbon and sulfate ions increase methylation in sediments (Gilmour and Henry 1991). In freshwater and estuarine ecosystems, the presence of chloride ions (0.02 M) may accelerate the release of mercury from sediments (Wang et al. 1991). Cesario et al. (2017) studied the methylation and demethylation kinetics of mercury in sediments, with and without salt-marsh plant vegetation, obtained from the Guadiana and Tagus Estuaries, Portugal. Methylation and demethylation rates varied between sediments of the estuaries depending upon the presence of vegetation and the macrophyte species present. The highest methylation rate constant was observed in *Sarcocornia fruticosa* vegetated sediments at the Castro Marim site in Guadiana (Km = 0.160 day^{-1},) and the lowest rate constant was observed in non-vegetated sediments at the Alcochete site in Tagus (Km = 0.009 day^{-1}). The role that vegetation plays in methylation cycling of mercury was studied by examining the seasonal variation of methylmercury production in three types of flooded agricultural wetlands (white rice, wild rice, and fallow fields), and two permanently flooded, non-agricultural managed wetland areas in the Yolo Bypass Wildlife Unit California (Windham-Myers et al. 2014). In addition to transport and transformation reactions that occur in air, water, soil and sediment, plant biomass also plays an indirect role in the methylation and demethylation cycle of mercury. Inorganic mercury may be taken up through plant roots in contaminated soils or deposited on leafy surfaces following atmospheric deposition, whereas methylmercury appears to be primarily taken up by plants via the root system (Windham-Myers et al. 2014). Thus, the transport of methylmercury into plants in wetland environments provides a temporary storage sink and reduces the levels in the surrounding aquatic environments. However, decomposition of plant tissue, deforestation, clearing of wetlands, and fires can release stored methylmercury to other environmental media. Methylmercury levels in rice leaves tended to increase from summer to fall during the growing season and were shown to correlate with root methylmercury levels. Degrading litter residue was shown to correlate with increased methylmercury production during the winter months in the wetlands.

The rates of mercury methylation and demethylation were studied in sediments obtained from the Deûle River, France (Ouddane et al. 2015). Sampling was conducted at two locations that were contaminated with mercury from previous industrial activity. At the first location, demethylation, rather than methylation, was the dominant process. The study authors surmised that high levels of mercury found in this heavily contaminated site resulted in an increase in the rate of bacterial demethylation, either by reduction producing Hg^0 or oxidation yielding Hg^{2+} and CO_2. For the second site sampled, where total mercury levels were lower than the first site, the average net methylation potential was positive

(methylation occurred at a greater rate than demethylation) even though there were sediments obtained at some depths where the rate of demethylation was greater than methylation.

In the late 1950s, unknown quantities of mercuric nitrate and elemental mercury were released into East Fork Poplar Creek from a government facility in Oak Ridge, Tennessee. Total mercury concentrations in the flood plain soil along the creek ranged from 0.5 to 3,000 ppm (Revis et al. 1989). The form of that mercury has been reported to be primarily mercuric sulfide (85–88%), with 6–9% present as elemental mercury (Revis et al. 1989, 1990). A very small amount was detected in the form of methylmercury (<0.02%). The reported presence of the mercuric sulfide suggests that the predominant biological reaction in soil for mercury is the reduction of Hg^{+2} to mercuric sulfide by sulfate-reducing bacteria under anaerobic conditions (Revis et al. 1989, 1990). Mercuric sulfide has very limited water solubility $(4.5 \times 10^{-24}$ mol/L), and thus, in the absence of other solvents, is likely to have limited mobility in soil. Aerobic microorganisms can solubilize Hg^{+2} from mercuric sulfide by oxidizing the sulfide through sulfite to sulfate, with the Hg^{+2} being reduced to elemental mercury (Wood 1974). However, examination of the weathering of mercuric sulfide indicated that mercuric sulfide does not undergo significant weathering when bound to riverwash soil with a pH of 6.8, although degradation may be increased in the presence of chloride and iron (Harsh and Doner 1981).

Mercury, frequently present in mine tailings, was toxic to bacteria isolated from a marsh treatment system used to treat municipal wastewaters. The minimum concentration that inhibited the bacteria (as determined by intracellular ATP levels) was approximately 0.07 ± 0.15 mg/L (ppm) (Desjardins et al. 1988).

5.5   LEVELS IN THE ENVIRONMENT

Reliable evaluation of the potential for human exposure to mercury depends, in part, on the reliability of supporting analytical data from environmental samples and biological specimens. Concentrations of mercury in unpolluted atmospheres and in pristine surface waters are often so low as to be near the limits of current analytical methods. In reviewing data on mercury levels monitored or estimated in the environment, it should also be noted that the amount of chemical identified analytically is not necessarily equivalent to the amount that is bioavailable.

Table 5-11 shows the lowest limit of detections that are achieved by analytical analysis in environmental media. An overview summary of the ranges of concentrations detected worldwide in environmental media is presented in Table 5-12.

Table 5-11. Lowest Limit of Detection Based on Standards[a,b]

Media	Detection limit	Reference
Air	30 pg/m^3 (particulate); 45 pg/m^3 (vapor)	EPA 1999a (Method IO-5)
Drinking water	0.2 ng/L	EPA 2002a (Method 1631E)
Surface water and groundwater	0.2 ng/L	EPA 2002a (Method 1631E)
Soil	4.8 µg/kg	Frentiu et al. 2013
Sediment	4.8 µg/kg	Frentiu et al. 2013
Whole blood	0.2–0.33 µg/L	CDC 2024

[a]Detection limits based on using appropriate preparation and analytics. These limits may not be possible in all situations.
[b]A review of analytical methods to detect mercury in environmental matrices has been published by Suvarapu and Baek (2017).

Table 5-12. Summary of Environmental Levels of Mercury Worldwide

Media	Low	High	For more information
Outdoor air (ng/m^3)	0.000161 (particulate)	174,000 (vapor)	Section 5.5.1
Indoor air (ng/m^3)	<3	1,500	Section 5.5.1
Surface water (ppb)	<0.002	0.09	Section 5.5.2
Ground water (ppb)	0.21	300	Section 5.5.2
Drinking water (ppb)	<0.025	300	Section 5.5.2
Food (ppm)	<0.01	0.509	Section 5.5.4
Soil (ppm)	0.063	141,000	Section 5.5.3

Detections of mercury in air, water, and soil at NPL sites are summarized in Table 5-13.

Table 5-13. Mercury Levels in Water, Soil, and Air at National Priorities List (NPL) Sites

Medium	Median[a]	Geometric mean[a]	Geometric standard deviation[a]	Number of quantitative measurements	NPL sites
Water (ppb)	2	3.50	16.3	316	188
Soil (ppb)	1,800	2,730	28.2	381	220

Table 5-13. Mercury Levels in Water, Soil, and Air at National Priorities List (NPL) Sites

Medium	Median[a]	Geometric mean[a]	Geometric standard deviation[a]	Number of quantitative measurements	NPL sites
Air (ppbv)	0.301	0.282	75.4	26	18

[a]Concentrations found in ATSDR site documents from 1981 to 2022 for 1,868 NPL sites (ATSDR 2022). Maximum concentrations were abstracted for types of environmental media for which exposure is likely. Pathways do not necessarily involve exposure or levels of concern.

5.5.1 Air

The vast majority of mercury found in the atmosphere occurs in the form of Hg^0 (gaseous elemental mercury). Total gaseous mercury (TGM) represents the sum of all gaseous compounds and gaseous elemental mercury and has been reported to have a global background concentration typically in the range of 1.5–2.0 ng/m^3, although levels can vary due to local sources (Gworek et al. 2017). Decreases in gaseous elemental mercury levels have been reported globally as mercury emissions have declined in many parts of the world. Annual decreasing trends of 1.4 and 2.7% per year in the Northern and Southern Hemispheres from 1996 to 2009, respectively, have been reported (Lyman et al. 2020). The Global Mercury Observation System (GMOS) is a European Union project consisting of 43 globally distributed monitoring stations that measure ambient atmospheric mercury levels on a global scale (Sprovieri et al. 2016). Results from GMOS data for 2013 and 2014 had reported mean background levels of 1.22 and 1.23 ng/m^3, respectively, in tropical zones and 0.93 and 0.97 ng/m^3, respectively, in the Southern Hemisphere. The 2013 and 2014 annual mean mercury concentrations were reported as 1.55 and 1.51 ng/m^3, respectively, in the Northern Hemisphere (Sprovieri et al. 2016).

Data on mercury air levels are available at the Air Quality System (AQS) database, which contains ambient air quality data collected by EPA, state, local, and tribal air pollution control agencies from monitors throughout the country. For 2019, the arithmetic mean vapor phase levels ranged from 1.11 to 2.22 ng/m^3, with a maximum level of 248 ng/m^3 reported in Milwaukee, Wisconsin (EPA 2019). The arithmetic mean mercury concentration of total suspended particulates (TSP) ranged from 0.009 to 0.0025 ng/m^3. The arithmetic mean mercury levels associated with PM_{10} (particulate matter ≤10-micron diameters) ranged from 0.00619 to 1.50 ng/m^3, while the arithmetic means for mercury associated with $PM_{2.5}$ were 0.000161–0.000317 ng/m^3. For 2023, the arithmetic mean TSP ranged from 0.00032 to 2 ng/m^3 (EPA 2024).

The Atmospheric Mercury Network (AMN) and the National Atmospheric Deposition Program (NADP) operate monitoring sites to record temporal atmospheric concentrations of mercury and deposition rates in North America. The average gaseous elemental mercury concentrations from the AMN from 2012 to 2022 are shown in Table 5-14.

Table 5-14. Atmospheric Mercury Network (AMN) Average Gaseous Elemental Mercury Concentrations, 2012–2022

Year	Averaged gaseous elemental mercury level (ng/m^3)
2012	1.45
2013	1.46
2014	1.47
2015	1.42
2016	1.44
2017	1.80
2018	1.73
2019	1.61
2020	1.76
2021	1.72
2022	1.40

Source: NADP 2024

As mercury is subject to long-range transport, it has been detected in Arctic atmospheric samples. The median (±SD) concentrations of mercury at Alert, Canada in the fall, winter, spring, and summer were 1.49 (±0.11), 1.59 (±0.17), 1.24 (±0.53), and 1.80 (±0.35) ng/m^3, respectively (Kirk et al. 2012). Atmospheric mercury trends in the Arctic from 1995 to 2018 have shown seasonal variability and generally decreasing levels after 2010 (MacSween et al. 2022). For example, over the sampling period the location at Villum Research Station, Greenland showed the largest decrease in total gaseous mercury, averaging about a 4.55 % decline per year during winter months.

Several decades ago, ambient atmospheric levels of mercury could have been an order of magnitude higher than current expected background levels. In 1990, metallic mercury concentrations in the gas and aerosol phases of the atmosphere in Sweden were 2–6 and 0.01–0.1 ng/m^3, respectively (Brosset and Lord 1991). Higher levels (10–15 µg/m^3) have been detected near point emission sources, such as mercury mines, refineries, and agricultural fields treated with mercury fungicides. Atmospheric concentrations of mercury over lakes in Wisconsin averaged 2.0 ng/m^3 (Wiener et al. 1990). Mercury levels ranged from

6.3 to 16.0 ng/m^3 above the water surface of the mercury-contaminated Wabigoon River in Ontario (Schroeder and Fanaki 1988). The mean vapor concentration of mercury in air over a forested watershed (Walker Branch Watershed) in Tennessee was 5.5 ng/m^3 in 1988–1989, while the particle-associated aerosol mercury concentration was determined to be 0.03 ng/m^3, or approximately 0.5% of the total atmospheric mercury (Lindberg et al. 1991). Lindberg et al. (1994) measured mercury vapor at concentrations of 2–6 ng/m^3 and particulate mercury at 0.002–0.06 ng/m^3 at Walker Branch Watershed, Tennessee, from August 1991 to April 1992. Particulate mercury concentrations are greater in precipitation than in ambient air. In the St. Louis River estuary, mercury levels in precipitation averaged 22 ng/L (ppt), although ambient air levels averaged 3 ng/m^3 (Glass et al. 1990).

Total gaseous mercury was measured (1992–1993) as part of the Florida Atmospheric Mercury Study (FAMS) (Gill et al. 1995). Average total gaseous mercury concentrations for 3–6-day integrated samples ranged from 1.43 to 3.11 ng/m^3 (mean 1.64 ng/m^3). In the same study, Dvonch et al. (1995) reported that the mean concentrations of total gaseous mercury measured at two inland Florida sites were significantly higher (3.3 and 2.8 ng/m^3) than measurements at an Atlantic coastal site (1.8 ng/m^3). The mean concentrations of particle-phase mercury collected at the inland sites (51 and 49 pg/m^3) were 50% higher than those at the coastal site (34 pg/m^3). The mean mercury concentration in rain samples was 44 ng/L (ppt) (range 14–130 ng/L). Guentzel et al. (1995) also reported results of the FAMS from 1992 to 1994. Particle-phase measurements ranged from 2 to 18 pg/m^3 at all sites. Measurements of monomethylmercury in precipitation ranged from <0.005 to 0.020 ng/L (ppt).

Keeler et al. (1994) measured atmospheric mercury in the Great Lakes Basin. The study authors reported that vapor-phase mercury levels were 4 times higher in Chicago, Illinois, than in South Haven, Michigan (8.7 versus 2.0 ng/m^3). Furthermore, a diurnal pattern was observed in the vapor-phase mercury levels measured at the Chicago site. The average concentration (ng/m^3) was 3.3 times greater for the daytime samples (8 AM to 2 PM) than for the night samples (8 PM to 8 AM), and the average concentration for the afternoon samples (2 PM to 8 PM) was 2.1 times greater than the night samples (average, 3.7 ng/m^3). Particulate-phase mercury concentrations were also higher at the Chicago site than at the South Haven site (98 versus 19 pg/m^3). Burke et al. (1995) reported that the concentration of mercury in vapor-phase samples measured over Lake Champlain was consistent with other rural areas (mean 2.0 ng/m^3; range 1.2–4.2 ng/m^3), and the concentrations were consistent across all seasons. Particulate-phase mercury concentrations averaged 11 pg/m^3, with the highest concentrations detected during the winter.

In the past, mercury was a component of indoor and outdoor, water-based latex paints; however, in 1990, most uses of mercury for interior and exterior paints and coatings were voluntarily cancelled by the manufacturers (DeVito and Brooks 2013). Prior to this cancellation, mercury levels in homes and buildings that were recently painted could be much higher than background levels. Indoor air mercury concentrations were determined in 37 houses in Ohio that had been painted with latex paint (Beusterien et al. 1991). Of the 37 homes studied, 21 homes had been painted with interior latex paint containing mercury a median of 86 days earlier, while the 16 control homes had not been recently painted with mercury-containing latex paints. Paint samples from the exposed homes contained a median concentration of 210 mg/L mercury (ppm) (range 120–610 mg/L). The median air mercury concentration (0.3 µg/m^3) was found to be significantly higher (p<0.0001) in the exposed homes (range: not detectable to 1.5 µg/m^3) than in the unexposed homes (range: not detectable to 0.3 µg/m^3). Among the exposed homes, there were seven in which paint containing <200 mg/L mercury had been applied. In these homes, the median air mercury concentration was 0.2 µg/m^3 (range: not detectable to 1 µg/m^3). Six exposed homes had air mercury concentrations >0.5 µg/m^3. The study authors reported that elemental mercury was the form of mercury released to the air and that potentially hazardous mercury exposure could occur in homes recently painted with paint containing <200 mg Hg/L (Beusterien et al. 1991). In an indoor exposure study of families of workers at a chloralkali plant in Charleston, Tennessee, mercury levels in the air of the workers' homes averaged 0.92 µg/m^3 (ATSDR 1990).

A monitoring program established at a facility at Oak Ridge National Laboratories found that the major sources of mercury release to the air were vaporization from soil, burning of coal for a steam plant, and fugitive exhaust from a former lithium isotope separation facility contaminated with mercury (DOI 1991). When the monitoring program began in 1986, ambient air mercury vapor concentrations at the facility ranged from 0.011 to 0.108 µg/m^3. These values decreased to 0.006–0.071 µg/m^3 by 1990, while background levels near the facility remained at 0.006 µg/m^3. The decrease in mercury vapor concentrations occurred primarily as a result of an 80% reduction in coal burning at the steam plant; however, periods of drought and activities such as moving contaminated soil for construction were found to increase the atmospheric mercury concentrations on a transient basis (DOI 1991). Turner and Bogle (1993) monitored ambient air for mercury around the same industrial complex site at Oak Ridge, Tennessee. Elemental mercury was used in large quantities at the nuclear weapons plant between 1950 and 1963 in a process similar to chloralkali production. Soil and water contamination had been found at the site. The results of weekly ambient monitoring for gaseous mercury from 1986 through 1990 showed that gaseous mercury levels were well below the National Emission Standard for Hazardous Air Pollutants (1.0 mg/m^3) with the exception of one station. Mean mercury levels at the control site ranged

from 5 to 6 μg/m^3, while levels at the on-site stations ranged from 6–11, 11–143, 68–174, 71–109, and 4–46 μg/m^3, depending on the station. Mean particulate mercury levels were 0.00003 μg/m^3 at the control site, compared with mean concentrations at the on-site stations ranging from 0.00006 to 0.00024 μg/m^3 (Turner and Bogle 1993).

5.5.2 Water

The EPA maintains a Water Quality Portal (WQP) database that aggregates environmental monitoring data from the National Water Information System (NWIS) and STORage and RETrieval (STORET) system, providing ample data for assessment of current conditions and trends in mercury concentrations in waters of the United States. A summary of the data for ambient surface and groundwater from recent years is reported in Table 5-15 (WQP 2024).

Table 5-15. Summary of Concentrations of Dissolved Total Mercury (μg/L) Measured in Surface Water and Groundwater Across the United States

Year	Average	Maximum	Number of samples	Percent detected
Surface water				
2018	0.005	0.82	2358	44%
2019	0.030	2.59	2155	44%
2020	0.003	0.26	1821	54%
2021	0.020	4.9	1600	59%
2022	0.090	23.2	1384	54%
2023	0.044	21.0	1235	52%
Groundwater				
2018	0.11	3.3	495	29%
2019	0.33	3.4	375	23%
2020	0.12	0.86	288	11%
2021	0.09	0.69	337	15%
2022	0.17	0.95	238	5%
2023	0.32	2.39	247	8%

Source: WQP 2024

Rainwater collected in monitoring stations in the U.S Great Lakes region (2002–2008) found annual average mean concentrations at 37 sites to range from 5.6 to 13.6 ng/L (ppt) and temporal trends for decreasing and increasing concentrations, depending on location (Risch et al. 2012). Average total mercury and methylmercury levels in cloud water above the Pacific Ocean near the coast of California were 9.2±6.0 and 0.87 ±0.66 ng/L, respectively, during a sampling period from the summer of 2016

(Weiss-Penzias et al. 2018). Fitzgerald et al. (1991) measured total mercury in rainwater from May through August 1989 at Little Rock Lake, Wisconsin. The total mercury concentrations ranged from 3.2 to 15.2 ng/L (ppt). Mercury concentrations in precipitation collected in Minnesota during 1988 and 1989 averaged 18 ng/L (ppt) for an average annual mercury deposition of 15 μg/m² (Glass et al. 1991). Antarctic surface snow contained a mean mercury concentration of <1 pg/g (ppt) (Dick et al. 1990). Snowpack from the Muskeg watershed in Alberta, Canada contained total mercury and methylmercury levels of 0.5–38.2 and 0.01–0.27 ng/L, respectively (Wasiuta et al. 2019). In Ontario, Canada, mercury present in precipitation at an average concentration of 10 ng/L (ppt) accounted for more than half of the mercury inputs to surface waters compared with inputs from stream runoff, suggesting that atmospheric deposition is a significant source of mercury in surface waters (Mierle 1990). Lindberg et al. (1994) measured total mercury in rain collected at Walker Branch Watershed, Tennessee from August 1991 to April 1992. Rain concentrations of total mercury ranged from 7.57 ng/L (ppt) in February 1992 to 17.4 ng/L (ppt) in April 1992. Burke et al. (1995) reported that the average concentration of mercury in precipitation samples measured over Lake Champlain was 8.3 ng/L (ppt) for the sampling year, and the average amount of mercury deposited per precipitation event was 0.069 μg/m². The highest concentrations of mercury in precipitation samples occurred during spring and summer months. Guentzel et al. (1995) reported results of the Florida Atmospheric Monitoring Study from 1992 to 1994. The study authors found that the wet season in south Florida accounted for 80–90% of the annual rainfall mercury deposition. Depositional rates in south Florida are 30–50% higher than those in central Florida. Measurements of monomethylmercury in precipitation samples ranged from <0.005 to 0.020 ng/L (ppt).

Bowman et al. (2020) analyzed data on mercury levels in the oceans. They determined that greater levels were observed in surface waters (<150 meters) in the Arctic Ocean, but higher levels were observed in deeper layers (150–1,000 m) for other oceans. Average concentrations in the upper surface in the Arctic Ocean ranged from about 1.1 to 1.3 picomoles/L (pM) and from 0.71 to 0.81 pM in the deeper layers. Opposite trends were observed in the Atlantic and Pacific Oceans. For example, the levels in the upper layers of the Pacific Ocean averaged about 0.19–0.99 pM in the <150 m layers and 0.59–1.35 pM in the 150–1,000 m layers. Chen and Li (2019) reported average total mercury levels in the central tropical Pacific Ocean of 0.29–0.54 pM at the thermocline layer (the transition layer between the warmer water at the surface and the cooler deep water below) and 0.98–1.70 pM in deeper layers.

The natural occurrence of mercury in the environment means that mercury is likely to occur in surface waters, even when anthropogenic sources of mercury are absent. Median total mercury levels in 23 streams in the northeastern United States ranged from 0.48 to 10.2 ng/L and median values of

methylmercury ranged from below the detection limit of 0.04 ng/L to 0.63 ng/L (Janssen et al. 2019).
Methylated mercury levels averaged 0.024 (±0.009 SD) ng/L in Canadian Arctic waters and 0.023 ng/L
(±0.011 SD) in the Hudson Bay (Kirk et al. 2012). The USGS conducted sampling from 2012 to 2015 at
six locations of the Brownlee Reservoir, Boise, and Snake River in Idaho (USGS 2016). Mercury levels
in the water ranged from 0.48 to 8.8 ng/L, with the highest concentration observed in the Brownlee
Reservoir. The concentration and speciation of mercury were measured in nine tributaries to Lake
Ontario in two independent field sampling programs (Denkenberger et al. 2020). Mean total mercury
concentrations were 0.9–2.6 ng/L. Mean total dissolved and particulate phase total mercury levels were
0.5–1.5 and 0.3–2.0 ng/L, respectively in the 9 different tributaries. Mean methylmercury levels were
0.06–0.14 ng/L. Correlations were observed between the levels and speciation of mercury in water and
the watershed characteristics and surrounding land use types. For example, total suspended solids in the
water column were strongly correlated with the percentage of agricultural land in the watershed and
methylmercury as a percentage of total mercury was positively correlated to percent open-water coverage
in the watershed.

The baseline concentration of mercury in unpolluted marine waters is typically approximately 0.3 ng/L
(Gonzalez-Raymat et al. 2017). In contrast, the New York Bight, an inshore coastal area near the
industrialized areas of New York Harbor and northern New Jersey, contained dissolved mercury
concentrations in the range of 10–90 ng/L (ppt) (Fowler 1990).

Near-surface groundwaters in remote areas of Wisconsin were found to contain approximately 2–4 ng/L
(ppt) of mercury, of which only a maximum of 0.3 ng/L (ppt) was determined to be methylmercury,
indicating that groundwater was not a source of methylmercury in the lake (Krabbenhoft and Babiarz
1992). Mercury was found at levels >0.5 µg/L (ppb) in 15–30% of wells tested in some groundwater
surveys (EPA 1985). Drinking water is generally assumed to contain <0.025 µg/L (ppb) (EPA 1984). A
chemical monitoring study of California's public drinking water from groundwater sources was
conducted by Storm (1994). This author reported that mercury was analyzed in 6,856 samples, with
225 positive detections and 27 exceedances of the maximum contaminant level (0.002 mg/L [200 ppb]).
The mean mercury concentration was 6.5 ppb (median, 0.62 ppb; range, 0.21 to 300 ppb).

5.5.3   Sediment and Soil

Mercury is a natural constituent of soils occurring at a concentration of approximately 80 ng/g
(0.080 ppm) (Gonzalez-Raymat et al. 2017). In a review of the mercury content of virgin and cultivated

surface soils from a number of countries, it was found that the average concentrations ranged from 20 to 625 ng/g (0.020–0.625 ppm) (Andersson 1979). The highest concentrations were generally found in soils from urban locations and in organic, versus mineral, soils. The mercury content of most soils varies with depth, with the highest mercury concentrations generally found in the surface layers. A study conducted in 26 European Union countries collected 21,951 topsoil samples (0–20-cm depth) and used a Deep Neural Network (DNN) algorithm to map out the distribution of mercury in European soils (Ballabio et al. 2021). An estimated median level of 38.3 ng/g (0.0383 ppm) was calculated if known contaminated sites were excluded. The study found that mercury concentrations in soil increased with latitude from south to north and with altitude and higher levels were observed around coal use in large power plants. The study authors identified 209 "hotspots" in which soil concentrations exceeded 422 ng/g (0.422 ppm), and nearly half of these (42%) were associated with mining operations.

Median total mercury and methylmercury levels in soil of a remote watershed in the Adirondack Mountains, New York (Fishing Brook) were 170–235 and 0.28–0.94 ng/g (0.170–0.235 and 0.00028–0.00094 ppm), respectively (Burns et al. 2014). The same authors also studied total mercury and methylmercury levels of a coastal watershed (McTier Creek) in South Carolina. Median total mercury and methylmercury levels in these soils were 40–106 and 0.20–1.50 ng/g (0.040–0.106 and 0.00020–0.0015 ppm), respectively. Mercury levels in surface sediment (upper 10 cm) sampled in 10 lakes or watersheds from the Upper Columbia River Watershed in 2012 ranged from 0.01 to 0.28 mg/kg (ppm) (Washington State Department of Ecology 2013). Total mercury levels in 36 samples of soil obtained from a heavily contaminated site near a chloralkali production facility in Romania ranged from 0.08 to 114 mg/kg (ppm), with a mean value of 13.1 mg/kg (ppm; Frentiu et al. 2013). The total mercury concentration in a soil from a polluted chlor-alkali production facility was reported as 1,346 mg/kg (Wang et al. 2023d).

Granato et al. (1995) reported that municipal solid waste sludge mercury concentrations from the Metropolitan Water Reclamation District of Greater Chicago ranged from 1.1 to 8.5 mg/kg (ppm), with a mean concentration of 3.31 mg/kg (ppm). Sludge applications to a sludge utilization site in Fulton County, Illinois, significantly increased extractable soil mercury concentrations from 1971 to 1995. In addition, 80–100% of the mercury applied to the soils in sewage sludge since 1971 still resided in the top 15 cm of soil.

Mercury levels in sediment the Penobscot River, Maine were reported to range from approximately 400 to 1,400 ng/g (range 0.400–1.4 ppm) over a 35-km area, with some samples exceeding 3,000 ng/g (Bodaly

2018). It was estimated that this river received approximately 6–12 metric tons of mercury emitted from a nearby chloralkali plant that was operational from 1967 to 2000. Peat cores obtained from two micro-tidal marshes in the Sacramento-San Joaquin Delta of California were used to reconstruct mercury levels over an approximate 6,000-year period (Drexler et al. 2016). Pre-anthropogenic levels of mercury were estimated to range from approximately 6.9 to 71 ng/g (0.0069–0.071 ppm) and the first man-made sources of mercury introduced to this watershed occurred around 1425 AD. Mercury levels peaked at 990 ng/g around the time of the California gold rush (~1850) as mercury is used to separate gold from its ore by forming an amalgam. A USGS monitoring program in the Great Lakes found that in 2021, 30 sites in Lake Superior had mercury surface sediment levels ranging from 1.1 to 161.2 ng/g and in Lake Huron, mercury sediment concentrations ranged from 0.7 to 113.7 ng/g across all samples (USGS 2023b). Sediment samples collected from Lake Ontario had mercury levels of 19–2,001.1 ng/g (USGS 2023b). The median concentration of total mercury in bed sediments from 23 streams in the northeast United States ranged from 1.3 to 47.6 ng/g normalized to percent organic matter, while the median concentration of methylmercury ranged from 0.04 to 1.8 ng/g normalized to percent organic matter (Janssen et al. 2019). Bulk sediments collected from Galveston Bay, Texas from 2017 to 2019 at four sampling locations had mean levels of 0.01–0.08 µg/g (10–80 ng/g) (Lopez et al. 2022).

Facemire et al. (1995) reported industrial contamination of soils and sediment in several states in the southeastern United States. The study authors reported soil concentrations up to 141,000 ppm (mg/kg) associated with contamination in northeastern Louisiana from mercury-charged manometers (i.e., gas regulators) used to measure pressure and delivery from natural gas wells. In Tennessee, a maximum mercury concentration of 1,100 ppm (associated with previous operations of the Oak Ridge nuclear facility) was found in wetland soils adjacent to the East Fork Poplar Creek. A pharmaceutical company's effluents enriched sediments in a localized area of Puerto Rico to 88 ppm (mg/kg) mercury (Facemire et al. 1995). Rule and Iwashchenko (1998) reported that mean soil mercury concentrations of 1.06 ppm were collected within 2 km of a former chlor-alkali plant in Saltsville, Virginia, and that these concentrations were 17 times higher than regional background soil samples (0.063 ppm [mg/kg]). The study authors further reported that soil organic content, topographic factors, wind patterns, and elevation were variables significantly related to mercury concentration as determined by regression analysis. Soil mercury levels decreasing with distance from the former plant were indicative of a point source distribution pattern. A man-made land soil type (Udorthent), which appears to be a byproduct of the chloralkali manufacturing process, was found proximal to the former plant site and contained about 68 times (4.31 ppm [mg/kg]) the regional background concentration.

A summary of the data for ambient soil/sediment monitoring from the WQP reported in Table 5-16.

Table 5-16. Summary of Concentrations of Total Mercury (ng/g) Measured in Soil and Sediment Across the United States

Year	Average	Maximum	Number of samples	Percent detected
Soil				
2018	33	180	93	94%
2019	120	700	122	21%
2020	96	570	15	100%
2021	100	100	10	40%
2022	100	100	1	100%
2023	0.04	0.05	7	100%
Sediment				
2018	934	79,600	1,676	66%
2019	672	194,000	1,271	73%
2020	588	72,900	2,281	65%
2021	483	18,900	1,105	58%
2022	107	1,600	517	76%
2023	70	184	31	100

Source: WQP 2024

5.5.4   Other Media

Foods. The U.S. Food and Drug Administration (FDA) conducted a Total Diet Study (April 1982 to April 1984) to determine dietary intakes of selected industrial chemicals (including mercury) from retail purchases of foods representative of the total diet of the U.S. population (Gunderson 1988). The data were collected as part of eight food collections, termed Market Basket Surveys collected in regional metropolitan areas during the 2-year study and involved individual analysis of 234 food items representing the diets of eight different population groups. Mercury was detected in 129 adult foods; seafood, the major contributing food group, accounted for 77% (3.01 of the 3.9 µg of mercury) of the total mercury intake for 25–30-year-old males (Gunderson 1988). Minyard and Roberts (1991) reported results of a survey conducted on food samples analyzed at 10 state food laboratories between 1988 and 1989. These laboratories conducted food regulatory programs and analyzed findings of pesticides and related chemical residues for 27,065 food samples. In 1988, these laboratories reported methylmercury residues in 13 (0.09%) of 13,980 samples, with 1 sample exceeding federal or state tolerances. Similarly, in 1989, methylmercury was detected in 25 (0.19%) of 13,085 samples, with 1 sample exceeding federal or state tolerances. A survey of 220 cans of tuna, conducted in 1991 by the FDA, found an average

methylmercury content (expressed as mercury) of 0.17 mg/kg (range <0.10–0.75 mg/kg) (Yess 1993).
Levels of methylmercury were higher in solid white tuna (0.26 mg/kg) and chunk white tuna (0.31 mg/kg)
than in chunk light tuna (0.10 mg/kg) or chunk tuna (0.10 mg/kg). Previously, the FDA had determined
methylmercury concentrations in 42 samples of canned tuna between 1978 and 1990 (Yess 1993) to range
from <0.01 to 0.67 mg/kg methylmercury (expressed as mercury), with an average concentration of
0.14 mg/kg. These earlier results are similar to those obtained in the 1991 survey (Yess 1993).

Data from the Market Basket Surveys are included in the FDA Total Diet Study for mercury in consumed
food items. Data from the 2006–2013 Total Diet Study are shown in Table 5-17. Data from the 2018–
2020 Total Diet Study showed that mercury was not detected in most of the samples (245 detects out of
3,276 analyzed samples) (FDA 2022). Only 33 of the 307 different food items tested for mercury had
detectable levels. The highest mean mercury concentrations were in fish samples. Canned tuna, baked
cod, and baked salmon had mean concentrations of 230 ppb (0.230 mg/kg), 83 ppb (0.083 mg/kg), and
21 ppb (0.021 mg/kg), respectively. Of the 33 foods with detectable results, 28 had mean concentrations
<10 ppb (0.010 mg/kg), and all detectable mercury (total mercury) results (mostly seafood) were below
the 1 mg/kg (1,000 ppb) action level for methylmercury established for fish, shellfish, crustaceans, and
other aquatic animals (FDA 2022). Mercury was only detected in 6% of vegetables analyzed, with a
maximum concentration of 1.8 ppb (0.0018 mg/kg) and in 1% of fruit items tested at a maximum level of
1.3 ppb (0.0013 mg/kg). Mercury was not detected in any dairy products from the 2018–2020 survey. It
was only detected in 3% of 384 baby food samples and all detections were <3 ppb (0.003 mg/kg).

The use of fish meal as a food for poultry and other animals used for human consumption may result in
increased mercury levels in these animals. In Germany, poultry and eggs were found to contain average
mercury concentrations of 0.04 and 0.03 mg/kg, respectively. Cattle are able to demethylate mercury in
the rumen and thus absorb less mercury; therefore, beef (meat) and cow's milk contained only 0.001–
0.02 and 0.01 mg/kg of mercury, respectively (Hapke 1991). A survey of raw foods in Germany in 1986
found that grains, potatoes, vegetables, and fruits contained average mercury concentrations of 0.005–
0.05 mg/kg (fresh weight); however, wild mushrooms contained up to 8.8 mg/kg of mercury. Cocoa
beans, tea leaves, and coffee beans contained average mercury concentrations of 0.005, 0.025, and
0.04 mg/kg, respectively. In all cases where the mercury content was high, selenium was also found in
measurable, but lower, concentrations (Weigert 1991).

Table 5-17. Mercury Concentrations in Food from the FDA Total Diet Study 2006–2013

Food	Number of analyses	Number of non-detects	Number of trace	Mean (mg/kg)	SD (mg/kg)	Median (mg/kg)	Minimum (mg/kg)	Maximum (mg/kg)	LOD (mg/kg)	LOQ (mg/kg)
Milk, whole, fluid	16	16	0	0	0	0	0	0	0.010	0.040
Milk, lowfat (2%), fluid	16	16	0	0	0	0	0	0	0.010	0.040
Turkey breast, oven-roasted	15	13	2	0.0001	0.0004	0	0	0.001	0.010	0.040
Liver (beef/calf), pan-cooked with oil	15	10	5	0.001	0.001	0	0	0.003	0.010	0.040
Fish sticks or patty, frozen, oven-cooked	15	6	8	0.004	0.004	0.005	0	0.012	0.010	0.040
Eggs, scrambled with oil	14	14	0	0	0	0	0	0	0.010	0.040
Eggs, boiled	16	15	1	0.0001	0.0003	0	0	0.001	0.010	0.040
Peanut butter, smooth/creamy	16	15	1	0.0002	0.0008	0	0	0.003	0.020	0.070
Rice, white, enriched, cooked	16	10	6	0.0004	0.0006	0	0	0.002	0.010	0.040
Oatmeal, plain, cooked	16	15	1	0.0001	0.0005	0	0	0.002	0.010	0.040
Bread, white, enriched	16	15	1	0.0001	0.0005	0	0	0.002	0.020	0.070
Fruit-flavored cereal, presweetened	16	12	4	0.0004	0.0008	0	0	0.002	0.020	0.070
Crisped rice cereal	16	8	8	0.001	0.002	0.001	0	0.004	0.020	0.070
Raisins	16	10	6	0.001	0.001	0	0	0.003	0.020	0.050
Avocado, raw	16	15	1	0.0001	0.0003	0	0	0.001	0.020	0.070
Orange juice, frozen concentrate, reconstituted	14	14	0	0	0	0	0	0	0.010	0.040
Apple juice, bottled	15	15	0	0	0	0	0	0	0.010	0.040
Prune juice, bottled	16	14	2	0.0001	0.0003	0	0	0.001	0.010	0.040
Spinach, fresh/frozen, boiled	16	11	5	0.0003	0.0005	0	0	0.001	0.010	0.040
Collards, fresh/frozen, boiled	16	9	7	0.001	0.001	0	0	0.002	0.010	0.040
Cauliflower, fresh/frozen, boiled	15	15	0	0	0	0	0	0	0.010	0.040
Tomato, raw	16	16	0	0	0	0	0	0	0.010	0.040
Ice cream, light, vanilla	16	16	0	0	0	0	0	0	0.010	0.040
Fruit drink, from powder	16	16	0	0	0	0	0	0	0.010	0.040

Table 5-17. Mercury Concentrations in Food from the FDA Total Diet Study 2006–2013

Food	Number of analyses	Number of non-detects	Number of trace	Mean (mg/kg)	SD (mg/kg)	Median (mg/kg)	Minimum (mg/kg)	Maximum (mg/kg)	LOD (mg/kg)	LOQ (mg/kg)
Baby food, infant formula, milk-based, iron fortified ready to feed (formerly high iron)	16	16	0	0	0	0	0	0	0.010	0.040
Baby food, infant formula, milk-based, low iron, ready to feed	8	8	0	0	0	0	0	0	0.010	0.040
Baby food, chicken and broth/gravy	16	16	0	0	0	0	0	0	0.010	0.040
Baby food, vegetables and beef	16	16	0	0	0	0	0	0	0.010	0.040
Baby food, mixed vegetables	16	16	0	0	0	0	0	0	0.010	0.040
Baby food, pears	16	16	0	0	0	0	0	0	0.010	0.040
Baby food, juice, apple	16	16	0	0	0	0	0	0	0.010	0.040
Yogurt, lowfat, fruit-flavored	16	16	0	0	0	0	0	0	0.010	0.040
Chicken breast, oven-roasted (skin removed)	16	16	0	0	0	0	0	0	0.010	0.040
Chicken nuggets, fast-food	16	16	0	0	0	0	0	0	0.010	0.040
Shrimp, boiled	15	7	8	0.006	0.006	0.007	0	0.016	0.010	0.040
Mushrooms, raw	16	9	7	0.001	0.001	0	0	0.003	0.010	0.040
Tuna noodle casserole, homemade	16	3	9	0.016	0.017	0.011	0	0.067	0.010	0.040
Fish sandwich on bun, fast-food	15	8	7	0.002	0.003	0	0	0.009	0.010	0.040
Clam chowder, New England, canned, condensed, prepared with whole milk	16	12	4	0.0003	0.0004	0	0	0.001	0.010	0.040
Syrup, chocolate	15	13	2	0.0003	0.0008	0	0	0.003	0.010	0.040
Jelly, any flavor	16	15	1	0.0001	0.0003	0	0	0.001	0.010	0.040
Carbonated beverage, fruit-flavored, regular	15	15	0	0	0	0	0	0	0.010	0.040
Baby food, infant formula, soy-based, ready to feed	16	16	0	0	0	0	0	0	0.010	0.040
Baby food, bananas	16	16	0	0	0	0	0	0	0.010	0.040
Salmon, steaks/fillets, baked	16	0	10	0.021	0.009	0.021	0.006	0.039	0.010	0.040

Table 5-17. Mercury Concentrations in Food from the FDA Total Diet Study 2006–2013

Food	Number of analyses	Number of non-detects	Number of trace	Mean (mg/kg)	SD (mg/kg)	Median (mg/kg)	Minimum (mg/kg)	Maximum (mg/kg)	LOD (mg/kg)	LOQ (mg/kg)
Baby food, cereal, rice, dry, prepared with water	15	12	3	0.0003	0.0006	0	0	0.002	0.010	0.040
Baby food, cereal, rice with apples, dry, prepared with water	6	6	0	0	0	0	0	0	0.010	0.040
Chicken breast, fried, fast-food (with skin)	15	15	0	0	0	0	0	0	0.010	0.040
Chicken thigh, oven-roasted (skin removed)	15	15	0	0	0	0	0	0	0.010	0.040
Chicken leg, fried, fast-food (with skin)	15	15	0	0	0	0	0	0	0.010	0.040
Catfish, pan-cooked with oil	15	7	8	0.003	0.004	0.002	0	0.016	0.010	0.040
Tuna, canned in water, drained	15	0	1	0.136	0.114	0.118	0.035	0.509	0.010	0.040
Cranberry juice cocktail, canned/bottled	15	15	0	0	0	0	0	0	0.010	0.040
Beef with vegetables in sauce, from Chinese carry-out	15	12	3	0.0003	0.0006	0	0	0.002	0.010	0.040
Fried rice, meatless, from Chinese carry-out	15	8	7	0.001	0.001	0	0	0.002	0.010	0.040

FDA = U.S. Food and Drug Administration; LOD = limit of detection; LOQ = limit of quantification; SD = standard deviation

Source: FDA 2017a

Pedersen et al. (1994) conducted a monitoring study to assess the levels of trace metals, including

mercury, in table wine, fortified wine, beer, soft drinks, and various juices. The study authors reported

that in all samples tested, mercury concentrations were at or below the detection limit (6 µg/L).

Fish and Shellfish. Consumption of fish is a major contributor to methylmercury exposure in most

populations (EFSA 2012; Kim et al. 2016b; Vejrup et al. 2016; You et al. 2014; Zhang et al. 2010).

Mercury levels in Great Lakes aquatic organisms have generally been trending lower since the 1970s;

however, since about 1990, they have leveled off or even increased slightly (Grieb et al. 2020; IJC 2015).

The initial decrease was likely due to decreasing atmospheric deposition from North America; however,

increasing emissions from other parts of the world and climate change, along with many other factors are

likely responsible for recent changes (Grieb et al. 2020). The Great Lakes Commission (GLC) reported

that fish mercury levels in the Great Lakes region are positively correlated with areas of high forest cover

and wetlands because forested areas in these regions of the Great Lakes receive higher dry deposition of

mercury and have other watershed features that worsen the impacts of mercury emissions and deposition

(BDI 2011). The report also found that fish in waterbodies near agricultural areas tended to have lower

mercury levels since increased algal biomass in the aquatic food web tends to reduce methylmercury

levels. They also noted that mercury levels in predatory fish such as walleye and largemouth bass are

55 and 25% lower, respectively, in the Great Lakes as compared to inland lakes nearby, which likely

occurs due to dissimilarities in the food web structure, land-water linkages, and methylating potential

variations between the larger and smaller water bodies. Total mercury levels obtained from fish in

23 streams located in the northeastern United States ranged from 19.5 ng/g (bluegill) to 774.7 ng/g

(largemouth bass) (Janssen et al. 2019).

The USGS compiled data from state and federal programs to study the temporal mercury levels in fish in

rivers and lakes in the United States from 1969 to 2005 (Chalmers et al. 2011). They observed that

declining mercury levels in sediment cores during the 1970s and 1980s correlated with the period of

downward mercury levels in fish. Overall, from 1969 to 2005 in 90 rivers and lakes, mercury

concentrations had no temporal trends at 57% of the sites, decreasing mercury levels in fish at 32% of the

sites, and increasing levels at 11% of the sites. Data from the late 1980s to 2005 showed increasing levels

of mercury in fish in some southeastern states, while no trend or decreasing levels in upper midwestern

states were observed. These data are summarized in Table 5-18. Another report from the USGS

concluded that methylmercury levels in fish exceeded the EPA criterion for protection of human health

(0.3 ppm) in predator fish from about 25% of streams sampled nationwide during 1998–2005. Fish

methylmercury concentrations tended to be greatest in wetland-dominated streams in the southeastern

United States or in streams draining basins that had been mined for mercury or gold in the West (USGS
2014).

Table 5-18. Trends in Mercury Concentrations Based on Fish Data Aggregated by State from 1988 to 2005[a]

State	Sites	Number	Species	Begin year	End year	Median mercury (mg/kg)	p-Value	Percent change	Trend
Southeastern United States									
<u>Georgia</u>	<u>112</u>	<u>266</u>	<u>LMB</u>	<u>1991</u>	<u>2001</u>	<u>0.24</u>	<u><0.001</u>	<u>7.43</u>	<u>Up</u>
Georgia	56	105	CCF	1991	2001	0.10	0.063	6.76	None
<u>Louisiana</u>	<u>324</u>	<u>1,049</u>	<u>LMB</u>	<u>1994</u>	<u>2005</u>	<u>0.39</u>	<u><0.001</u>	<u>3.78</u>	<u>Up</u>
Louisiana	113	168	CCF	1994	2004	0.10	0.007	11.2	Up
<u>Louisiana</u>	<u>178</u>	<u>328</u>	<u>FD</u>	<u>1994</u>	<u>2004</u>	<u>0.37</u>	<u>0.013</u>	<u>6.23</u>	<u>Up</u>
Louisiana	72	125	RS	1994	2004	0.16	0.075	11.4	None
Louisiana	158	383	WC	1994	2004	0.21	0.601	1.14	None
Louisiana	178	378	BC	1995	2004	0.24	0.686	0.83	None
Louisiana	**169**	**444**	**B**	**1994**	**2004**	**0.52**	**0.019**	**-3.26**	**Down**
Louisiana	*42*	*66*	*BMBU*	*1995*	*2004*	*0.28*	*0.045*	*-6.66*	*Down*
North Carolina	37	61	BG	1989	1999	0.10	0.771	0.76	None
South Carolina	**129**	**963**	**B**	**1993**	**2004**	**0.80**	**0.003**	**3.02**	**Up**
South Carolina	70	194	CCF	1994	2004	<0.25	0.277	-2.29	None
South Carolina	**188**	**1,556**	**LMB**	**1993**	**2004**	**0.38**	**<0.001**	**-3.13**	**Down**
Midwestern United States									
Iowa	31	34	LMB	1994	2005	0.13	0.947	0.25	None
Iowa	44	60	CC	1993	2005	0.10	0.005	-6.11	Down
Iowa	87	142	CCF	1988	2005	0.09	<0.001	-6.14	Down
Indiana	194	285	CC	1988	2004	0.17	0.856	-0.11	None
Indiana	56	74	CCF	1988	2004	0.14	0.316	-1.04	None
Indiana	75	91	LMB	1991	2004	0.19	0.999	0.00	None
Michigan	55	158	LMB	1988	1997	0.31	0.632	-0.75	None
Minnesota	43	81	CCF	1990	2000	0.21	0.364	1.80	None
Minnesota	78	157	CC	1990	2001	0.13	0.085	-2.16	None

Table 5-18. Trends in Mercury Concentrations Based on Fish Data Aggregated by State from 1988 to 2005[a]

State	Sites	Number	Species	Begin year	End year	Median mercury (mg/kg)	p-Value	Percent change	Trend
Minnesota	*53*	*142*	*NP*	*1988*	*2001*	*0.27*	*0.001*	*-4.86*	*Down*
Minnesota	75	202	W	1989	2001	0.23	0.036	-3.16	Down

[a]Trends above the U.S. Environmental Protection Agency (EPA) advisory guideline (0.3 µg/g methylmercury) are in bold text. Upward trends starting below and ending above EPA guideline are underlined. Downward trends starting above and ending below EPA guideline are in italics. Trends below EPA guideline are in regular text.

B = bowfin; BC = black crappie; BG = bluegill; BMBU = bigmouth buffalo; CC = common carp; CCF = channel catfish; FD = freshwater drum; LMB = largemouth bass; NP = northern pike; RS = redear sunfish; W = walleye; WC = white crappie

Source: Chalmers et al. 2011

From 2012 to 2015, the USGS collected and analyzed individual fillets of mountain whitefish (*Prosopium williamsoni*), rainbow trout (*Oncorhynchus mykiss*), smallmouth bass (*Micropterus dolomieu*), and channel catfish (*Ictalurus punctatus*) for mercury in the Brownlee Reservoir and Snake River in Idaho (USGS 2016). Mercury levels in rainbow trout were analyzed for one site (Eckert) and had a median concentration of 0.02 mg/kg. Median mercury levels in mountain whitefish were 0.18 mg/kg at the Eckert sampling location and ranged from 0.11 to 0.18 mg/kg at the Middleton site during the 3-year sampling period. Channel catfish collected at three locations had median mercury levels that ranged from 0.11 to 0.28 mg/kg for all three sites. Smallmouth Bass collected from the Brownlee Reservoir in 2013 had median levels of 0.32 mg/kg, which exceeded Idaho water-quality criterion.

Sampling was conducted for different species of fish from 2006 to 2012 in the lower Penobscot River and upper estuary in Maine (Kopec et al. 2019). This river was contaminated by mercury discharges from a chloralkali plant that was operational from 1967 to 2000. Mercury levels were shown to be greatest in fish and shellfish near the plant and downstream from the plant as opposed to upstream or more distant locations. In the most heavily contaminated locations near the chloralkali facility, mean total mercury concentrations in fish muscle adjusted for size or age were 0.521 (95% CI 0.480, 0.566) mg/kg wet weight in American eels, 0.321 (95% CI 0.261, 0.395) in mummichog, 0.121 (95% CI 0.104, 0.140) in rainbow smelt, 0.155 (95% CI 0.142, 0.169) in tomcod, 0.0552 (95% C: 0.0427, 0.0714) in winter flounder, and 0.328 (95% CI 0.259, 0.413) in American lobster tail, and 0.522 (95% CI 0.488, 0.557) mg/kg dw in blue mussel.

Rumbold et al. (2018) studied mercury levels in 50 species of fish at two locations off the coast of the
Florida Keys. The first location, Tennessee Reef Lighthouse (TRL), is a bank reef with moderate cover
of hard coral, soft-coral, sponge, and macroalgae on a sandy bottom and the second location was a
slightly shallower water, Long Key Hard Bottom (LKH), characterized by exposed hard substrate with
soft-coral, sponge, and macroalgal cover. These data are presented in Table 5-19.

Table 5-19. Mercury Levels in 50 Species of Fish Obtained at Two Sites Along the Florida Reef Tract from April 2012 to December 2013

Common name	Scientific name	Mean (ng/g)	SD (ng/g)	Maximum (ng/g)	CV (%)
Tennessee Reef Lighthouse					
Bermuda chub	*Kyphosus sectatrix*	78.64	44.87	135.6	57.1
Bicolor damsel	*Stegastes partitus*	26.60	2.96	29.55	11.1
Black grouper	*Mycteroperca bonaci*	347.2	85.95	445.2	24.8
Blue runner	*Caranx crysos*	40.95	NR	NR	NR
Blue stripe grunt	*Haemulon sciurus*	390.9	108.8	506.1	27.8
Blue tang	*Acanthurus coeruleus*	35.28	5.32	44.08	15.1
Brown chromis damsel	*Chromis multilineata*	113.0	NR	NR	NR
Doctorfish tang	*Acanthurus chirurgus*	52.97	7.58	60.98	14.3
French angelfish	*Pomacanthus paru*	43.42	22.11	65.53	50.9
Gray angelfish	*Pomacanthus arcuatus*	58.11	26.34	91.63	45.3
Graysby grouper	*Cephalopholis cruentata*	322.0	68.33	417.4	21.2
Great barracuda	*Sphyraena barracuda*	1,713.8	882.3	3,401.4	51.5
Hogfish	*Lachnolaimus maximus*	129.6	41.44	200.0	31.9
Knobbed porgy	*Calamus nodosus*	153.0	50.23	203.2	32.8
Porkfish	*Anisotremus virginicus*	1,555.1	1,970.9	6,842.3	126.7
Princess parrotfish	*Scarus taeniopterus*	66.84	NR	NR	NR
Red lionfish	*Pterois volitans*	174.9	44.75	225.8	1.7
Redband parrotfish	*Sparisoma aurofrenatum*	42.52	10.17	56.91	23.9
Rock Beauty angelfish	*Holacanthus tricolor*	20.53	1.52	22.04	7.4
Saucereye porgy	*Calamus*	114.6	NR	NR	NR
Schoolmaster snapper	*Lutjanus apodus*	143.1	NR	NR	NR
Scrawled filefish	*Aluterus scriptus*	76.79	6.24	82.57	8.1
Sergeant major damsel	*Abudefduf saxatilis*	57.19	NR	NR	NR
Spanish grunt	*Haemulon macrostomum*	505.9	25.55	531.5	5.0

Table 5-19. Mercury Levels in 50 Species of Fish Obtained at Two Sites Along the Florida Reef Tract from April 2012 to December 2013

Common name	Scientific name	Mean (ng/g)	SD (ng/g)	Maximum (ng/g)	CV (%)
Spanish hogfish	*Bodianus rufus*	300.8	95.90	392.1	31.9
Spotted goatfish	*Pseudupeneus maculatus*	102.2	48.03	184.1	46.9
Stoplight parrotfish	*Sparisoma viride*	30.22	3.33	32.58	11.0
Trumpetfish	*Aulostomus maculatus*	133.3	NR	NR	NR
White grunt	*Haemulon plumierii*	304.1	53.05	340.1	10.6
Yellowtail damsel	*Chrysiptera parasema*	35.91			
Yellowtail snapper	*Ocyurus chrysurus*	104.4	45.45	149.8	43.5
Long Key Hard Bottom					
Atlantic spadefish	*Chaetodipterus faber*	242.6	66.47	310.9	27.4
Bermuda chub	*Kyphosus sectatrix*	50.99	23.80	97.41	46.7
Black grouper	*Mycteroperca bonaci*	343.1	13.14	356.3	3.8
Blue runner	*Caranx crysos*	252.2	166.0	460.7	65.8
Blue stripe grunt	*Haemulon sciurus*	265.4	65.28	356.1	24.6
Blue tang	*Acanthurus coeruleus*	40.90	NR	NR	NR
Cocoa damsel	*Stegastes variabilis*	118.4	NR	NR	NR
Doctorfish tang	*Acanthurus chirurgus*	96.37	NR	NR	NR
French angelfish	*Pomacanthus paru*	53.31	NR	NR	NR
Gray angelfish	*Pomacanthus arcuatus*	17.49	0.16	17.65	0.9
Gray snapper	*Lutjanus griseus*	190.2	31.10	216.1	16.4
Graysby grouper	*Cephalopholis cruentata*	152.5	NR	NR	NR
Great barracuda	*Sphyraena barracuda*	3,317.5	NR	NR	NR
Hogfish	*Lachnolaimus maximus*	142.3	55.66	257.5	39.1
Horse-eye jack	*Caranx latus*	147.8	NR	NR	NR
Lane snapper	*Lutjanus synagris*	256.2	NR	NR	NR
Leatherjacket	*Oligoplites saurus*	747.7	43.99	791.7	5.9
Lookdown	*Selene vomer*	234.9	90.64	322.3	38.5
Mutton snapper	*Lutjanus analis*	196.9	NR	NR	NR
Ocean surgeon	*Acanthurus bahianus*	41.41	0.02	41.43	0.0
Pigfish	*Orthopristis chrysoptera*	857.5	NR	NR	NR
Planehead filefish	*Stephanolepis hispidus*	77.57	NR	NR	NR
Porkfish	*Anisotremus virginicus*	501.6	151.1	702.5	30.1
Red grouper	*Epinephelus morio*	197.8	24.77	232.8	12.5
Red lionfish	*Pterois volitans*	239.3	25.01	264.4	10.4
Rock hind grouper	*Epinephelus adscensionis*	144.0	9.35	153.4	6.5

Table 5-19. Mercury Levels in 50 Species of Fish Obtained at Two Sites Along the Florida Reef Tract from April 2012 to December 2013

Common name	Scientific name	Mean (ng/g)	SD (ng/g)	Maximum (ng/g)	CV (%)
White grunt	*Haemulon plumierii*	320.5	78.05	494.7	24.3
Yellow jack	*Carangoides bartholomaei*	236.4	129.6	366.0	54.8
Yellowtail snapper	*Ocyurus chrysurus*	142.5	38.52	223.2	27.0

CV = coefficient of variation (SD/mean); NR = not reported; SD = standard deviation for means based on ≥2 fish

Source: Rumbold et al. 2018

From 1986 to 1989, the National Study of Chemical Residues in Fish (NSCRF) was conducted by the EPA to assess the concentrations of 60 toxic pollutants (including mercury) in the tissues of benthic and predatory gamefish nationwide (EPA 1992). Benthic species were analyzed as whole-body samples, while game fish species were analyzed as fillet samples, and all concentrations were reported on a wet weight basis. Mercury was detected at 92% of the 374 sites surveyed nationwide at a mean concentration of 0.260 mg/kg (median concentration of 0.17 mg/kg and maximum concentration of 1.8 mg/kg), and at 2% of the sites, measured mercury concentrations exceeded 1 mg/kg. Most of the higher mercury concentrations in fish were collected in the Northeast. Ten of the sites in the top 10th percentile for high mercury concentrations were near pulp and paper mills, four were near Superfund sites, and most of the remaining sites were near industrial areas. However, the mercury sources could not be identified at all of these sites. Five sites were considered to represent background conditions and six USGS National Stream Quality Accounting Network (NASQAN) sites were also among the sites in the top 10th percentile (EPA 1992).

A national survey conducted by the EPA solicited data on mercury concentrations in fish collected by the states as part of their fish contaminant monitoring programs (EPA 1999b). The EPA asked all states to submit mercury residue data collected from their fish sampling programs from 1990 through 1995 to assess whether there were geographic variations or trends in fish tissue concentrations of mercury. Thirty-nine states provided information on the levels of contamination in their fish. The study included the following: information on the tissue concentrations of mercury, including the number of fish sampled (by species); the mean mercury concentration; and the minimum, median, and maximum concentrations reported for each species by state. Residue information for the three most abundant species sampled in

each state included such species as the largemouth and smallmouth bass; channel, flathead, and blue

catfish; brown and yellow bullhead; rainbow and lake trout; carp; walleye; north pike; and white sucker.

A summary of the mean, minimum, and maximum tissue concentrations of mercury detected for two of

the sampled species with the widest geographical distribution; the largemouth bass and the channel catfish

are given in Tables 5-20 and 5-21, respectively. As Table 5-20 shows, the maximum mercury residues

reported for the largemouth bass exceeded the FDA action level (1 ppm [1 mg/kg]) in 16 states that

collected and analyzed tissue samples for this species. The highest maximum mercury concentration

reported for this species was 8.94 mg/kg, reported by New Jersey. Table 5-21 shows the maximum

mercury residue reported for another widely distributed species, the channel catfish. While the maximum

mercury residues reported for this species are not consistently as high as those for the largemouth bass,

maximum residues in channel catfish from six states still exceeded the FDA action level (1 ppm

[1 mg/kg]). Consumption of large amounts of feral fish containing these high mercury residues exposes

high volume fish consuming populations (those that consume >100 g fish/day) to potentially greater risk

of mercury exposure than members of the general population.

Table 5-20. Mercury Concentrations (mg/kg) for Largemouth Bass Collected in Various States Throughout the United States (1990–1995)

State	Number of fish	Minimum	Mean[a]	Maximum[b]
Alabama	914	0.100	0.393	**1.630**
Arizona	35	0.700	**1.369**	**2.620**
Arkansas	1,190	0.030	0.675	**3.170**
California	517	0.030	0.291	**1.800**
Connecticut	507	0.032	0.505	**2.645**
District of Columbia	11	0.037	0.153	0.458
Florida	2,000	0.020	0.645	**4.360**
Georgia	968	0.010	0.274	**2.286**
Illinois	305	0.010	0.018	0.880
Louisiana	452	0.001	0.391	**1.883**
Maine	137	0.071	0.634	**1.343**
Massachusetts	152	0.045	0.399	**1.100**
Mississippi	505	0.090	0.651	**2.630**
Missouri	106	0.002	0.257	0.608
Nebraska	182	0.080	0.343	0.920
New Hampshire	35	0.210	0.573	**1.400**
New Jersey	173	0.030	0.664	**8.940**
New York	53	0.050	0.462	0.950
North Carolina	1,569	0.020	0.532	**3.600**

Table 5-20. Mercury Concentrations (mg/kg) for Largemouth Bass Collected in Various States Throughout the United States (1990–1995)

State	Number of fish	Minimum	Mean[a]	Maximum[b]
Oregon	140	0.030	0.332	0.980
Pennsylvania	139	0.090	0.293	0.750
South Carolina	505	0.230	0.994	**3.330**
Tennessee	64	0.100	0.255	0.830
Texas	58	0.043	0.237	0.657
Vermont	1	0.150	0.802	**1.200**
Washington	20	0.024	0.137	0.350

[a]Weighted average of composite samples where the weight is the number of fish in each composite ($\Sigma(C_i \times N_i)/N_t$, where C_i and N_i are the concentrations and number of fish in each composite sample, respectively, and N_t is the total number of fish in all composites).
[b]Tissue concentrations shown in **bold type** exceed the U.S. Food and Drug Administration (FDA) action level of 1 ppm (1 mg/kg).

Source: EPA 1999b

Table 5-21. Mercury Concentrations (mg/kg) for Channel Catfish Collected in Various States Throughout the United States (1990–1995)

State	Number of fish	Minimum	Mean[a]	Maximum[b]
Alabama	702	0.100	0.214	0.660
Delaware	19	0.020	0.050	0.133
District of Columbia	17	0.055	0.091	0.240
Georgia	658	0.010	0.084	**1.1143**
Iowa	323	0.030	0.104	0.410
Kansas	56	0.029	0.125	0.314
Louisiana	76	0.001	0.111	0.732
Maryland	157	0.006	0.033	0.256
Michigan	964	0.014	0.047	0.710
Mississippi	157	0.040	0.272	2.100
Missouri	198	0.002	0.052	0.350
Nebraska	238	0.001	0.109	0.643
New Mexico	78	0.100	0.297	**1.800**
Ohio	574	0.018	0.118	1.040
Oklahoma	324	0.100	0.193	0.640
South Carolina	42	0.250	0.345	**1.610**
Tennessee	138	0.100	0.173	0.650

Table 5-21. Mercury Concentrations (mg/kg) for Channel Catfish Collected in Various States Throughout the United States (1990–1995)

State	Number of fish	Minimum	Mean[a]	Maximum[b]
Texas	44	0.043	0.193	**1.186**
West Virginia	65	0.030	0.139	**1.583**

[a]Weighted average of composite samples where the weight is the number of fish in each composite ($\Sigma(C_i \times N_i)/N_t$, where C_i and N_i are the concentrations and number of fish in each composite sample, respectively, and N_t is the total number of fish in all composites).
[b]Tissue concentrations shown in **bold type** exceed the U.S. Food and Drug Administration (FDA) action level of 1 ppm (1 mg/kg).

Source: EPA 1999b

The Northeast states and Eastern Canadian provinces issued their own mercury study, including a comprehensive analysis of current mercury concentrations in a variety of freshwater sportfish species (NESCAUM 1998). This study involved a large number of fish sampling sites in each state, many of which were remote lake sites that did not receive point source discharges. Top level piscivores (i.e., predatory fish) such as walleye, chain pickerel, and large and smallmouth bass were typically found to exhibit some of the highest concentrations, with average tissue residues >0.5 mg/kg and maximum residues >2 mg/kg. One largemouth bass sample was found to contain 8.94 mg/kg of mercury, while one smallmouth bass sampled contained 5.0 mg/kg. A summary of the mean and minimum–maximum (range) of mercury concentrations in eight species of fish sampled is shown in Table 5-22. This study also identified a relationship between elevated mercury levels in fish and certain water quality parameters, including low pH, high conductivity, and elevated levels of dissolved organic carbon.

Table 5-22. Combined Data on Mercury Concentrations in Selected Fish Species Sampled in the Northeast[a]

Species	Number of samples[b]	Mean mercury concentration	Minimum–maximum mercury[c] concentration range (mg/kg)
Largemouth bass	1,019	0.51	0–**8.94**
Smallmouth bass	738	0.53	0.08–**5.0**
Yellow perch	1,346	0.40	0–**3.15**
Eastern chain pickerel	157	0.63	0–**2.81**
Lake trout	877	0.32	0–**2.70**
Walleye[d]	257	0.77	0.10–**2.04**

Table 5-22. Combined Data on Mercury Concentrations in Selected Fish Species Sampled in the Northeast[a]

Species	Number of samples[b]	Mean mercury concentration	Minimum–maximum mercury[c] concentration range (mg/kg)
Brown bullhead	421	0.20	0–**1.10**
Brook trout	200	0.26	0–0.98

[a]Northeastern states include Main, Vermont, New Hampshire, Massachusetts, Rhode Island, Connecticut, New York, and New Jersey.
[b]In some cases, states reported an average of values from a given location; thus, the number of samples indicated may not represent the number of individual fish sampled.
[c]Maximum tissue concentrations shown in **bold type** exceed the U.S. Food and Drug Administration action level of 1 mg/kg (1 ppm).
[d]Walleye data are from New York State only and may not be representative of walleye mercury concentrations in other parts of the northeast.

Source: NESCAUM 1998

Methylmercury constitutes over 99% of the total mercury detected in fish muscle tissue, with no detection of inorganic or dimethylmercury (Bloom 1992; Grieb et al. 1990). Mercury levels were examined in aquatic organisms taken from the Calcasieu River/Lake Complex in Louisiana. The order of enrichment was as follows: shrimp (0.2 mg/kg) < mussel (0.3 mg/kg) < fish (0.4 mg/kg) = oyster (0.4 mg/kg) < zooplankton (1.4 mg/kg) (Ramelow et al. 1989). Average mercury concentrations for aquatic organisms collected from the Wabigoon/English/Winnipeg River system in Canada were as follows: 0.06–2.2 mg/kg for crayfish, 0.01–0.55 mg/kg for perch, and 0.04–1.2 mg/kg for pike. Methylmercury concentrations were found to increase with distance from the pollutant source, possibly as a result of the increased bioavailability of organic mercury produced by aquatic microorganisms, whereas inorganic mercury was the predominant form at the source (Parks et al. 1991).

In a study of sportfish collected in San Francisco Bay, Fairey et al. (1997) reported that the highest concentrations of mercury were detected in leopard shark muscle tissue (1.26 mg/kg). Bluefin tuna caught in the Northwest Atlantic Ocean in 1990 contained mercury at a mean muscle concentration of 3.41 mg/kg dry weight (Hellou et al. 1992). Arctic cod (*Arctogadus glacialis*) that were obtained during the spring season under ice layers in the Amundsen Gulf/Franklin Bay had average mercury levels of 0.37 mg/kg dry weight and were significantly higher than those collected from the shallow coastal shelf region of the Beaufort Sea, near the Mackenzie Delta, suggesting differences in regional food webs (Kirk et al. 2012).

Marine Mammals. Consumption of marine mammals can be an important source of exposure to methylmercury in populations that are high consumers of marine mammals (Grandjean et al. 1992). Mercury concentrations have been analyzed in various tissues (i.e., muscle, liver, kidneys) from several species of marine mammals, including beluga whales, narwhal, white-toothed dolphins, pilot whales, ringed seals, harp seals, and walruses in the western and eastern Canadian Arctic (Wagemann et al. 1995). The mean mercury concentration (mg/kg dry weight) in liver tissue was highest in pilot whales (78 mg/kg), harp seals (36 mg/kg), Eastern Arctic ringed seals (29 mg/kg), narwhal (25 mg/kg), and Eastern Arctic beluga (22 mg/kg), with lesser amounts in Arctic walrus (5 mg/kg) and dolphins (4 mg/kg). Of the three tissues analyzed, mercury was most concentrated in the liver, with successively lower concentrations in the kidney and muscle tissue. This pattern prevails in most marine mammals. The concentration of total mercury is greater by a factor of 3 in the liver than in the kidney but can be significantly higher in some species (Table 5-23). Mean tissue residues in ringed seals from the western Arctic had significantly higher concentrations of mercury than those from the eastern Arctic. The study authors reported higher mercury levels in sediment (0.068–0.243 mg/kg dry weight) and water (11– 29 ng/L) from the western Arctic, as compared to sediment (0.040–0.060 mg/kg dry weight) and water (3.7 ng/L) from the eastern Arctic. These differences in sediment and water mercury levels may be responsible for some of the observed differences in mercury tissue concentrations in the seals.

Table 5-23. Total Mercury Concentrations in Tissues of Marine Mammals in Alaska and Canada (mg/kg, Wet Weight)

Species	Date collected (location)	Muscle concentration (n)	Liver concentration (n)	Source
Polar bear	1972 (West Alaska)	0.043±0.001 (16)	4.235±1.385 (25)	ADFG 1976
	1972 (North Alaska)	0.168±0.089 (30)	29.914±22.547 (38)	
Beluga whale	1977 (South Beaufort Sea)	2.12±0.15 (11)	30.62±20.53 (8)	Muir et al. 1992
Ringed seal	1972 (Southeast Beaufort Sea)	0.23±0.11 (13)	1.0±1.16 (13)	Smith and Armstrong 1975
	1972–1973 (Amundsen Gulf)	0.72±0.33 (83)	27.50±30.10 (83)	Smith and Armstrong 1975, 1978
	1976 (Barrow Strait)	0.91±0.38 (27)	16.14±13.84 (27)	Smith and Armstrong 1978
	1976 (Strathcona Sound)	0.08±0.07 (37)	0.32±0.080 (36)	
	1976 (North Baffin Island)	0.31±0.17 (33)	3.76±3.42 (33)	

Table 5-23. Total Mercury Concentrations in Tissues of Marine Mammals in Alaska and Canada (mg/kg, Wet Weight)

Species	Date collected (location)	Muscle concentration (n)	Liver concentration (n)	Source
Bearded seal	1973 (Amundsen Gulf)	0.53±0.35 (3)	143±170 (6)	Smith and Armstrong 1975, 1978
	1974 (East Hudson Bay)	0.09±0.04 (55)	26.18±26.13 (56)	Smith and Armstrong 1978

Mercury tissue concentrations were detected in 17 adult and 8 fetal pilot whales from two stranding episodes off Cape Cod, Massachusetts (Meador et al. 1993). Total mercury occurred in high concentrations in both the liver and kidney, and liver concentrations were significantly correlated with the animal's length. Methylmercury, as a percentage of total mercury, varied inversely with total mercury, indicating that demethylation was occurring. Mean adult mercury concentrations in mg/kg dry weight in liver and kidneys were 176 mg/kg (range 1.9–626 mg/kg dry weight) and 27.5 mg/kg (range 6.8–49.7 mg/kg dry weight), respectively. Mean fetal mercury concentrations in mg/kg dry weight in liver and kidneys were 2.3 mg/kg (range 0.9–5.4 mg/kg dry weight) and 1.9 mg/kg (range, 0.6–3.9 mg/kg dry weight), respectively. The mean methylmercury concentration in mg/kg dry weight in adult liver tissue was 8 mg/kg (range 5.6–10 mg/kg). Aguilar and Borrell (1995) studied mercury tissue levels (1970–1988) in harbor porpoises in the eastern North Atlantic. The study authors reported that in most tissues of harbor porpoises, the mercury was virtually all in the form of methylmercury; however, the fraction of organic mercury in the liver was much lower than in the rest of the body tissues. The study authors found that for a given tissue, the concentrations detected were extremely variable between localities and years. Mercury concentrations in harbor porpoises ranged from 0.62 to 70 mg/kg in liver and from 0.66 to 22 mg/kg in muscle. The mean mercury concentration in liver for the eastern harbor porpoise population was 11.2 mg/kg. Mercury tissue levels progressively increased with the age of the animal; no significant differences were found between the sexes (Aguilar and Borrell 1995).

Plants. Consumption of rice can also make a substantial contribution to dietary mercury intake, and, in some populations, rice has been shown to be the dominant sources of dietary mercury intake (Zhang et al. 2010). Rice is a particularly susceptible crop for mercury accumulation since it grows in wet, often flooded, anaerobic conditions, which are favorable to the transformation of elemental mercury into methylmercury (Sizmur et al. 2018). Mortimer (1985) reported that total mercury in the roots of five species of freshwater vascular plants in the polluted Ottawa River was 10–40% higher than in the shoots. Speciation may be important in determining the patterns of mercury uptake, translocation, and excretion

in macrophytes. Shoots of *Elodea densa* more readily accumulated methylmercury than inorganic

mercury, and also excreted more inorganic mercury than methylmercury (Czuba and Mortimer 1980).

Significant translocation of inorganic mercury from shoots to roots occurred in *E. densa* (Czuba and

Mortimer 1980). In this species, methylmercury and inorganic mercury moved in opposite directions,

with methylmercury moving towards the young shoot apex and inorganic mercury moving towards lower

(older) parts of the shoot (Czuba and Mortimer 1980). Dolar et al. (1971) noted the same methylmercury

pattern in the water milfoil (*Myriophyllum spicatum*). Using solution culture experiments, the study

authors showed that mercury accumulation was greater when plants were exposed to inorganic mercury

($HgCl_2$) than organic methylmercury (CH_3HgCl) and that mercury accumulation from the nutrient

solution was rapid and approached maximum values in 2 hours. Organomercury compounds

(methylmercury chloride, phenylmercuric acetate, phenylmercuric chloride, and phenylmercuric

hydroxide) were more available than inorganic compounds (HgF_2 and $HgCl_2$) from lake sediments. The

various organomercury and inorganic mercury compounds were added to sediment at concentrations of 0,

46, 230, and 460 mg/kg prior to rooting water milfoil. After 20 days, concentration of mercury in the

plant tissues exposure to 46, 230, and 460 mg/kg of the inorganic mercury compounds in the sediment

were 1.71–4.01, 4.81–6.03, and 6.61–10.2 mg/kg, respectively. In contrast, the concentrations of mercury

in plant tissues exposed to 46, 230, and 460 mg/kg of the organic mercury compounds in the sediment

were 2.40–7.15, 36–84.5, and 114.6–243.1 mg/kg, respectively. The control plants (no mercury

compounds added to the sediments) contained 0.3 mg/kg mercury. It is clear from this experiment that

organomercury compounds may accumulate significantly in the above-ground parts of some macrophytes.

Mortimer (1985) found that although *E. densa* shoots had lower total mercury contents than roots, with

32% of the mercury in the shoots in the form of methylmercury, compared to only 10% in the roots.

Grasses sampled downwind of a municipal waste incinerator contained up to 0.20 µg/g (ppm) of mercury,

with concentrations decreasing with increasing distance from the facility (Bache et al. 1991). Background

mercury levels in vegetation were usually <0.1 mg/kg dry weight (Lindqvist et al. 1991); however,

mushrooms collected 1 km from a lead smelter in Czechoslovakia contained between 0.3 and 12 mg/kg

dry weight (Kalač et al. 1991).

Consumer and Medicinal Products. Various consumer and medicinal products may contain mercury or

mercury compounds (e.g., skin lightening creams and soaps, herbal remedies, laxatives, tattooing dyes,

fingerpaints, artists paints, and make-up paints), but all of these products originate from outside of the

United States (Barr et al. 1973; DeVito and Brooks 2013; Dyall-Smith and Scurry 1990; Lauwerys et al.

1987; McKelvey et al. 2011; Rastogi 1992; Wendroff 1990). The EPA maintains a website that lists the

consumer products that may contain mercury (https://www.epa.gov/mercury/mercury-consumer-products#list).

Barr et al. (1973) reported elevated mercury levels in the blood of women using skin lightening creams, although the mercury compound and concentrations in the skin cream were not determined. Dyall-Smith and Scurry (1990) reported that one skin lightening cosmetic cream contained 17.5% mercuric ammonium chloride. Lauwerys et al. (1987) reported a case of mercury poisoning in a 3-month-old infant whose mother frequently used a skin lightening cream and soap containing inorganic mercury during her pregnancy and during the 1-month lactation period following birth. However, the mercury concentration and specific mercury compound in the cream and soap were not determined. Al-Saleh and Al-Doush (1997) analyzed the inorganic mercury content of 38 skin lightening creams in Saudi Arabian markets. The creams were manufactured in a variety of countries, including India and Pakistan, other Arab countries, Thailand, Taiwan, Indonesia, England, and Germany. Almost 50% of the creams tested exceeded the tolerance limit of 1 ppm. The mean concentration of mercury in the 38 creams was 994 mg/kg, with a range of 0–5,650 mg/kg. It is not known whether any of these products are available in the United States.

Metallic mercury was also the source of two cases of mercury poisoning caused by the dermal application of an over-the-counter anti-lice product (Bourgeois et al. 1986). The more severely poisoned individual applied 30 g of ointment containing 9 g of metallic mercury (300,000 mg/kg) to his entire body. Wands et al. (1974) also reported the deaths of two individuals due to the excessive use of a laxative preparation containing mercurous chloride (calomel).

Metallic mercury has been used by Mexican-American and Asian populations in traditional remedies for chronic stomach disorders (Espinoza et al. 1995, 1996; Geffner and Sandler 1980; Trotter 1985). Perharic et al. (1994) reported cases of poisonings resulting from exposure to traditional remedies and food supplements reported to the National Poisons Unit in London, England. From 1989 to 1991, elemental mercury was implicated in several poisonings following exposure to traditional Asian medicines. In one case, the mercury concentration in the medicinal product taken orally was 540,000 mg/kg. The mercury was in its elemental or metallic form. Espinoza et al. (1995, 1996) reported that while examining imported Chinese herbal balls for the presence of products from endangered species, the study authors detected potentially toxic levels of arsenic and mercury in certain herbal ball preparations. Herbal balls are aromatic, malleable, earth-toned, roughly spherical, hand-rolled mixtures primarily composed of herbs and honey that are used to make medicinal teas. These herbal balls are used as a self-medication for a

wide variety of conditions, including fever, rheumatism, apoplexy, and cataracts. Herbal balls similar to those analyzed are readily available in specialty markets throughout the United States. Mercury (probably mercury sulfide) was detected in eight of the nine herbal balls tested. The recommended adult dose for the herbal balls is two per day. Ingesting two herbal balls could theoretically provide a dose of up to 1,200 mg of mercury.

Samudralwar and Garg (1996) conducted trace metal analysis on a variety of plants used in Indian herbal remedies and other medicinal preparations. The study authors reported mercury concentrations of 0.139, 0.180, 0.027, 0.0125, 0.0117, and <0.010 mg/kg for Bowen's kale, Neem leaves, Gulvei leaves, Kanher bark, Vekhand root, and orange peel, respectively.

Hoet and Lison (1997) reported on an unusual non-occupational source of mercury exposure in a woman who used prescription nasal drops that contained 300 mg/L borate phenylmercury. The study authors reported that the woman, who had used the nasal drops over a long period of time, had high urinary levels of mercury (82 mg/kg), but that blood levels were not abnormal (5.5 µg/L).

Mercuric sulfide, or cinnabar, was reported to be used in tattooing dyes to produce a red pigmentation (Bagley et al. 1987; Biro and Klein 1967). An analysis of finger paints and make-up paints manufactured in Europe showed that they all contained <1 mg/kg mercury (Rastogi 1992). Rastogi and Pritzl (1996) conducted another study to assess the migration of several toxic metals from crayons, watercolor paints, and water-based paints. Migration of mercury from the art materials was determined by scraping flakes of the products into dichloromethane for 2 hours at 54°C. The degreased material was then placed in an aqueous HCl solution, shaken, and centrifuged. The supernatant was then filtered through a 0.45 µm membrane filter and analyzed. The study authors reported that the migration of mercury from these art supplies was 0.24–5.98 mg/kg for red paint, 0.26–3.63 mg/kg for blue paint, 0.20–4.79 mg/kg for yellow paint, 0.22–5.68 mg/kg for green paint, and 0.17–3.63 mg/kg for white paint. Migration of mercury from the product occurred in 57% of the samples tested. The migration limit set by European Standard EN71-3 for mercury is 60 mg/kg. This value was not exceeded in any of the art supplies tested. The study authors, however, believe that children might be exposed not only to mercury, but to several other metals that also co-migrated from the paints. Mercury is not allowed in the manufacture of any paint products in the United States (DeVito and Brooks 2013).

Cigarettes. In a study conducted in West Germany, Pesch et al. (1992) analyzed mercury concentrations in 50 brands of cigarettes manufactured in two Western and six Eastern European countries. The study

authors reported that in 1987, the average mercury concentration detected in cigarettes was 0.098 mg/kg (dry weight) (range 0.06–0.14 mg/kg dry weight). In 1991, the mean mercury concentrations for cigarettes were 0.034 mg/kg dry weight (range 0.007–0.092 mg/kg dry weight) for Eastern Europe and 0.015 mg/kg dry weight (range 0.006–0.037 mg/kg dry weight) for Western European countries. The study authors attributed the decline in mercury content of cigarettes to environmental protection measures instituted in the intervening years (Pesch et al. 1992).

Religious and Cultural Rituals, Ceremonies, and Practices. Some practitioners of religious, folk, cultural, or ritualistic practices such as Santeria, Voodoo, Palo Mayombe, and Espiritismo have used mercury in their practices (WHO 2010). In the United States, people may obtain metallic mercury (sometimes under the name azogue) in shops called botanicas. Botanicas typically dispense mercury in gelatin capsules or sometimes in small glass vials.

Some people carry a small amount of mercury in a vial, or mix mercury in bath water or perfumed soaps, devotional candles, ammonia, or camphor. Other people's religious practices involve sprinkling metallic mercury on the floor of a dwelling or car, mixing metallic mercury with soap and water to wash the floor, or placing it in an open container to rid the house of evil spirits. Any of these practices can liberate mercury vapor into the room air, exposing the occupants to elevated levels of mercury vapors (ATSDR 1997; Wendroff 1990, 1991). This use of mercury can contaminate a dwelling or automobile if the mercury is not completely removed from flooring, carpeting, and woodwork in an appropriate manner.

In addition to the individuals who intentionally use mercury in their dwellings, the opportunity exists for non-users to be inadvertently exposed when they visit the dwelling, or purchase or rent dwellings in which the former tenants used mercury for religious purposes (NJDEP 2007; Riley et al. 2006). In one study, mean mercury levels were significantly ($p<0.05$) elevated at 9.8 ng/m^3 in 60 building common areas with suspected cultural mercury use. The referent community buildings (n=40) recorded 5.0 ng Hg/m^3 in their common areas. Likewise, the maximum mercury levels in buildings with suspected cultural mercury use were also significantly elevated compared to the referent community buildings, with values of 13.3 and 6.4 ng Hg/m^3, respectively (Garetano et al. 2008). The issuance of cautionary notices and information by health departments to members of these user populations is appropriate (Rogers et al. 2007).

5.6   GENERAL POPULATION EXPOSURE

Humans can be exposed to mercury in air, water, soil, and food. Diet is typically the major source of mercury absorption in the general population (non-occupational). However, mercury released from mercury amalgam dental restorations can also contribute to mercury absorption (Langworth et al. 1988; Mackert and Berglund 1997; Nylander et al. 1987). The dominant source of mercury intake and absorption from the diet derives from consumption of fish (Davis et al. 2014; De Winter-Sorkina et al. 2003; EFSA 2012; Kim et al. 2016b; Lescord et al. 2018;), in part because of the relative high concentrations of methylmercury in fish and shellfish (Bloom 1992; Lescord et al. 2018; Storelli et al. 2003; Wells et al. 2020) and near complete absorption of methylmercury in the human gastrointestinal tract (Section 3.1 Toxicokinetics).

Consumption of rice can also make a substantial contribution to dietary mercury intake and, in some populations, rice has been shown to be the dominant sources of dietary intake (Rothenberg et al. 2016b; Sizmur et al. 2018; Wells et al. 2020; Zhang et al. 2010). Dietary mercury intake has been estimated from food surveys in various populations and, as can be expected, varies with diet and, in particular, the contribution of fish and shellfish and rice to the total diet (De Winter-Sorkina et al. 2003; EFSA 2012; Kim et al. 2016b; Vejrup et al. 2016; WHO 1990; You et al. 2014; Zhang et al. 2010). Total diet studies conducted in Asia, United States, and Europe suggest that intakes of total mercury ranging from 1 to 10 µg/day are typical (Carrington and Bolger 2002; EFSA 2014; EPA 1999b; Jenssen et al. 2012; Kim et al. 2016b; Sanga et al. 2001; WHO 1990). Intakes can be substantially higher in populations that consume higher amounts of fish (Dong et al. 2015; Juric et al. 2017; Marien and Patrick 2001; Passos et al. 2008).

The relative contribution of mercury released from dental amalgams has been estimated based on studies of release rates and assumptions regarding the fate and absorption of amalgam mercury. The contributions of mercury from dental amalgams were estimated based on results from measurements of releases of Hg^0 vapor and particulate Hg^0 from amalgams and models of intake and absorption of mercury released from amalgams (Mackert and Berglund 1997). Total mercury absorption in a person having 13 mercury amalgam dental restorations was estimated to be approximately 3 µg/day (range 0.6– 9.3 µg/day), of which approximately one-third was absorbed from the gastrointestinal tract. Following removal of all dental amalgams, mean blood total mercury decreased 1.13 µg/L (SD 0.6) from a baseline of 2.18 µg/L (SD 0.90) over an 18-week period, a 49% decrease, in subjects who had an average of seven occlusal surfaces with amalgam restorations (Snapp et al. 1989). This would be consistent with

amalgams contributing to approximately half of total mercury absorption. Removal of mercury amalgams can release Hg^0 to air and saliva (Halbach et al. 2000; Warwick et al. 2019).

The general population may also be exposed to mercury vapor released from liquid elemental mercury from breakage or spills of older mercury-containing items at home or at school, such as medical/scientific equipment, batteries, fluorescent lamps, electrical switches, and paints made prior to 1992 (CDC 2015). Disposal of older items and proper clean-up of spills reduces the change of exposure (CDC 2013, 2015).

Various consumer (e.g., skin lightening creams and soaps, herbal remedies, laxatives, tattooing dyes, fingerpaints, artists paints, and make-up paints) and medicinal products (e.g., thimerosal, an ethylmercury-containing compound that was used as a preservative in vaccines) that contain mercury or mercury compounds can also contribute to exposure to consumers (DeVito and Brooks 2013; McKelvey et al. 2011; Rastogi 1992; Wendroff 1990). Any mercury released into air, water, or soil via consumer use or disposal of mercury-containing products would contribute to exposures detected in environmental media.

Mercury levels in blood and urine are measured as part of the NHANES (CDC 2024) (Tables 5-24–5-33). Based on survey data for the period 2017–2018 (the most recent data available in CDC 2024), the geometric mean total BHg level in the adult U.S. population was estimated to be 0.730 µg/L (95% CI 0.620, 0.840). The geometric mean methylmercury blood level was 0.500 µg/L (95% CI 0.420, 0.610). Total and methylmercury blood levels in young children were lower than in adults. The 50th percentiles for total BHg levels in children 1–5 years of age were less than the detection limit (0.28 µg/L) in 2017–2018. For the 2011–2012 period, the detection limits for total mercury were lower, reporting a geometric mean total BHg level of 0.262 µg/L (95% CI 0.237, 0.291) in children 1–5 years of age. The 50th percentiles for methylmercury blood levels in children 1–5 years of age were less than the detection limit (0.12 µg/L) during both time periods. For the 2017–2018 period, the 50th percentiles of total urinary mercury were below the detection limit (0.13 µg/L) in children 3–5 years of age and adults.

Table 5-24. Geometric Mean and Selected Percentiles of Total Mercury Blood Concentrations (in µg/L) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 2003–2010

	Survey years	Geometric mean (95% CI)	Selected percentiles (95% CI)[a]				Sample size
			50th	75th	90th	95th	
Total	2003–2004	0.797 (0.703–0.903)	0.800 (0.700–0.900)	1.70 (1.50–1.90)	3.30 (2.90–3.90)	4.90 (4.30–5.50)	8,373
	2005–2006	0.863 (0.787–0.946)	0.830 (0.760–0.920)	1.66 (1.48–1.93)	3.20 (2.87–3.54)	4.64 (4.17–5.25)	8,407
	2007–2008	0.769 (0.689–0.859)	0.740 (0.660–0.830)	1.48 (1.29–1.69)	2.95 (2.46–3.59)	4.64 (3.74–5.79)	8,266
	2009–2010	0.863 (0.792–0.941)	0.790 (0.730–0.880)	1.68 (1.49–1.91)	3.43 (3.07–3.84)	5.13 (4.57–5.67)	8,793
Age group							
1–5 years	2003–2004	0.326 (0.285–0.372)	0.300 (0.300–0.300)	0.500 (0.500–0.700)	1.00 (0.800–1.60)	1.80 (1.30–2.50)	911
	2005–2006	NC	<LOD	0.500 (0.470–0.550)	.940 (0.820–1.24)	1.43 (1.25–1.59)	968
	2007–2008	NC	<LOD	0.440 (0.380–0.540)	.830 (0.620–1.12)	1.32 (0.960–2.40)	817
	2009–2010	NC	<LOD	0.490 (0.430–0.590)	.890 (0.740–1.08)	1.30 (1.08–1.52)	836
6–11 years	2003–2004	0.419 (0.363–0.484)	0.400 (0.400–0.500)	0.700 (0.700–0.900)	1.30 (1.00–1.60)	1.90 (1.40–3.50)	856
	2005–2006	NC	0.410 (0.330–0.460)	0.740 (0.630–1.00)	1.43 (1.21–1.87)	2.34 (1.53–3.42)	934
	2007–2008	NC	0.380 (0.340–0.440)	0.700 (0.600–0.790)	1.21 (0.970–1.36)	1.56 (1.34–1.80)	1,011
	2009–2010	NC	0.360 (<LOD–0.400)	0.670 (0.590–0.770)	1.22 (1.05–1.45)	1.88 (1.43–2.61)	1,009
12–19 years	2003–2004	0.490 (0.418–0.574)	0.500 (0.400–0.600)	1.00 (0.800–1.20)	1.80 (1.40–2.30)	2.60 (2.10–3.30)	2,081
	2005–2006	0.513 (0.461–0.570)	0.460 (0.390–0.530)	0.850 (0.740–1.04)	1.66 (1.31–1.98)	2.41 (2.12–2.90)	1,996
	2007–2008	0.469 (0.426–0.516)	0.440 (0.390–0.490)	0.800 (0.670–0.970)	1.55 (1.30–1.72)	2.05 (1.77–2.34)	1,074
	2009–2010	0.534 (0.473–0.602)	0.450 (0.370–0.540)	0.910 (0.770–1.11)	2.04 (1.53–2.55)	3.01 (2.53–3.63)	1,183
≥20 years	2003–2004	0.979 (0.860–1.12)	1.00 (0.800–1.10)	2.00 (1.70–2.30)	3.80 (3.20–4.40)	5.40 (4.60–6.70)	4,525
	2005–2006	1.06 (0.967–1.15)	1.03 (0.930–1.15)	1.98 (1.73–2.22)	3.64 (3.33–4.01)	5.31 (4.82–5.67)	4,509
	2007–2008	0.944 (0.833–1.07)	0.890 (0.780–1.03)	1.73 (1.47–2.09)	3.41 (2.82–4.17)	5.32 (4.32–6.72)	5,364
	2009–2010	1.04 (0.956–1.14)	0.970 (0.870–1.08)	2.00 (1.80–2.20)	3.96 (3.55–4.27)	5.75 (5.14–6.50)	5,765
Gender							
Males	2003–2004	0.814 (0.714–0.927)	0.800 (0.700–0.900)	1.80 (1.50–2.00)	3.70 (3.20–4.30)	5.40 (4.60–6.50)	4,132
	2005–2006	0.864 (0.783–0.954)	0.810 (0.720–0.940)	1.69 (1.48–2.01)	3.30 (2.86–3.73)	4.83 (4.08–5.45)	4,092
	2007–2008	0.809 (0.709–0.923)	0.760 (0.670–0.850)	1.56 (1.31–1.81)	3.21 (2.72–4.06)	5.16 (4.12–6.97)	4,147
	2009–2010	0.883 (0.810–0.962)	0.790 (0.730–0.870)	1.75 (1.54–2.02)	3.84 (3.35–4.26)	5.65 (5.13–6.34)	4,366
Females	2003–2004	0.781 (0.689–0.886)	0.800 (0.700–0.900)	1.60 (1.40–1.80)	3.00 (2.50–3.50)	4.40 (3.60–5.30)	4,241
	2005–2006	0.864 (0.791–0.943)	0.850 (0.770–0.920)	1.63 (1.44–1.89)	3.09 (2.75–3.46)	4.51 (4.01–5.28)	4,315
	2007–2008	0.748 (0.677–0.827)	0.720 (0.660–0.810)	1.42 (1.24–1.60)	2.70 (2.27–3.27)	3.93 (3.17–5.16)	4,119
	2009–2010	0.845 (0.772–0.924)	0.800 (0.720–0.880)	1.61 (1.43–1.81)	3.13 (2.76–3.48)	4.43 (4.04–5.11)	4,427

Table 5-24. Geometric Mean and Selected Percentiles of Total Mercury Blood Concentrations (in µg/L) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 2003–2010

	Survey years	Geometric mean (95% CI)	Selected percentiles (95% CI)[a]				Sample size
			50th	75th	90th	95th	
Race/ethnicity							
Mexican Americans	2003–2004	0.563 (0.472–0.672)	0.600 (0.500–0.700)	1.00 (0.800–1.30)	1.90 (1.60–2.40)	3.00 (2.20–3.80)	2,085
	2005–2006	0.597 (0.524–0.679)	0.580 (0.490–0.670)	1.04 (0.870–1.24)	1.70 (1.40–2.12)	2.58 (1.96–3.31)	2,236
	2007–2008	0.594 (0.536–0.658)	0.580 (0.520–0.670)	1.03 (0.900–1.17)	1.73 (1.49–2.04)	2.48 (2.10–2.91)	1,712
	2009–2010	0.613 (0.571–0.659)	0.580 (0.540–0.630)	1.01 (0.890–1.15)	1.63 (1.47–1.90)	2.45 (2.03–2.93)	1,966
Non-Hispanic blacks	2003–2004	0.877 (0.753–1.02)	0.900 (0.800–1.00)	1.60 (1.40–1.80)	3.00 (2.30–4.00)	4.40 (3.30–6.00)	2,293
	2005–2006	0.823 (0.697–0.972)	0.800 (0.670–0.940)	1.50 (1.21–1.92)	2.72 (2.14–3.59)	4.09 (3.22–5.16)	2,193
	2007–2008	0.766 (0.711–0.825)	0.780 (0.710–0.830)	1.32 (1.23–1.42)	2.25 (1.99–2.58)	3.42 (2.74–3.90)	1,746
	2009–2010	0.928 (0.805–1.07)	0.900 (0.800–1.02)	1.67 (1.38–1.96)	2.93 (2.20–4.21)	4.56 (3.34–6.69)	1,593
Non-Hispanic whites	2003–2004	0.776 (0.655–0.919)	0.800 (0.700–0.900)	1.70 (1.40–2.00)	3.20 (2.60–3.90)	4.70 (4.00–5.60)	3,478
	2005–2006	0.891 (0.801–0.992)	0.870 (0.770–1.00)	1.74 (1.50–2.10)	3.37 (2.88–3.76)	4.76 (4.18–5.37)	3,310
	2007–2008	0.743 (0.651–0.847)	0.720 (0.620–0.820)	1.43 (1.18–1.70)	2.79 (2.33–3.41)	4.18 (3.57–4.83)	3,461
	2009–2010	0.856 (0.766–0.957)	0.790 (0.690–0.920)	1.70 (1.46–1.98)	3.43 (2.94–3.94)	4.92 (4.30–5.65)	3,760

[a]The limits of detection for survey years 2003–2004, 2005–2006, 2007–2008, and 2009–2010 were 0.2, 0.33, 0.33, and 0.33 µg/L, respectively.

CI = confidence interval; LOD = limit of detection; NC = not calculated (proportion of results below limit of detection was too high to provide a valid result)

Source: CDC 2024

5. POTENTIAL FOR HUMAN EXPOSURE

Table 5-25. Geometric Mean and Selected Percentiles of Total Mercury Blood Concentrations (in µg/L) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 2011–2018

	Survey years	Geometric mean (95% CI)	Selected percentiles (95% CI)[a]				Sample size
			50th	75th	90th	95th	
Total	2011–2012	0.703 (0.617–0.801)	0.640 (0.580–0.730)	1.38 (1.14–1.72)	2.87 (2.39–3.62)	4.40 (3.50–5.71)	7,920
	2013–2014	0.683 (0.621–0.751)	0.620 (0.540–0.690)	1.29 (1.14–1.46)	2.65 (2.32–3.08)	4.36 (3.65–4.97)	5,215
	2015–2016	0.678 (0.619–0.743)	0.600 (0.540–0.690)	1.26 (1.07–1.47)	2.55 (2.17–3.10)	4.25 (3.44–4.94)	4,988
	2017–2018	0.643 (0.577–0.715)	0.580 (0.490–0.690)	1.22 (1.08–1.38)	2.52 (2.17–2.91)	3.87 (3.41–4.61)	7,513
Age group							
1–5 years	2011–2012	0.262 (0.237–0.291)	0.250 (0.020–0.270)	0.390 (0.340–0.450)	0.680 (0.540–0.880)	0.99 (0.790–1.21)	713
	2013–2014	NC	<LOD	0.410 (0.370–0.450)	0.810 (0.710–0.990)	1.21 (1.05–1.48)	818
	2015–2016	NC	<LOD	0.380 (0.340–0.430)	0.690 (0.540–0.830)	1.06 (0.840–1.36)	790
	2017–2018	NC	<LOD	0.350 (0.310–0.420)	0.640 (0.520–0.790)	0.960 (0.750–1.22)	629
6–11 years	2011–2012	0.330 (0.287–0.379)	0.320 (0.280–0.360)	0.530 (0.0480–0.600)	0.930 (0.0780–1.20)	1.40 (1.02–2.17)	1,048
	2013–2014	NC	0.300 (<LOD–0.360)	0.570 (0.0470–0.680)	1.12 (0.0980–1.36)	1.62 (1.38–2.19)	1,075
	2015–2016	NC	0.310 (0.290–0.340)	0.480 (0.0430–0.570)	0.920 (0.0750–1.13)	1.33 (1.01–2.28)	1,023
	2017–2018	NC	<LOD	0.450 (0.380–0.550)	0.930 (0.710–1.11)	1.71 (1.02–2.41)	883
12–19 years	2011–2012	0.411 (0.355–0.476)	0.370 (0.320–0.450)	0.680 (0.0590–0.800)	1.32 (1.08–1.75)	2.25 (1.46–2.87)	1,129
	2013–2014	0.412 (0.367–0.463)	0.350 (0.310–0.420)	0.630 (0.0530–0.750)	1.20 (0.0900–1.67)	1.87 (1.30–2.38)	627
	2015–2016	0.395 (0.356–0.439)	0.340 (0.300–0.370)	0.590 (0.0470–0.750)	1.00 (0.0850–1.35)	1.89 (1.02–3.34)	565
	2017–2018	NC	0.310 (<LOD–0.370)	0.590 (0.500–0.700)	1.14 (0.890–1.47)	1.71 (1.31–2.73)	1,030
≥20 years	2011–2012	0.863 (0.753–0.990)	0.790 (0.690–0.940)	1.68 (1.36–2.12)	3.35 (2.71–4.31)	5.02 (3.94–6.96)	5,030
	2013–2014	0.814 (0.736–0.900)	0.740 (0.650–0.850)	1.54 (1.36–1.71)	3.08 (2.73–3.56)	4.88 (4.36–5.21)	2,695
	2015–2016	0.810 (0.740–0.886)	0.740 (0.660–0.830)	1.47 (1.28–1.75)	2.86 (2.50–3.44)	4.66 (3.91–5.96)	2,610
	2017–2018	0.764 (0.685–0.815)	0.730 (0.620–0.840)	1.40 (1.24–1.62)	3.00 (2.58–3.29)	4.36 (3.78–5.02)	5,021
Gender							
Males	2011–2012	0.712 (0.623–0.815)	0.650 (0.570–0.730)	1.40 (1.17–1.72)	3.00 (2.44–3.91)	4.94 (3.50–6.79)	3,968
	2013–2014	0.688 (0.617–0.767)	0.620 (0.530–0.720)	1.30 (1.12–1.54)	2.76 (2.36–3.34)	4.52 (3.65–5.23)	2,587
	2015–2016	0.679 (0.621–0.743)	0.610 (0.530–0.700)	1.29 (1.06–1.60)	2.45 (2.06–3.31)	4.67 (3.77–5.39)	2,488
	2017–2018	0.655 (0.577–0.743)	0.580 (0.470–0.730)	1.24 (1.05–1.52)	2.83 (2.41–3.18)	4.03 (3.53–4.56)	3,666
Females	2011–2012	0.694 (0.609–0.791)	0.640 (0.580–0.740)	1.36 (1.09–1.75)	2.81 (2.28–3.50)	4.03 (3.29–5.08)	3,952
	2013–2014	0.678 (0.617–0.745)	0.610 (0.530–0.700)	1.27 (1.14–1.42)	2.56 (2.17–3.08)	4.15 (3.37–4.93)	2,628
	2015–2016	0.677 (0.608–0.754)	0.600 (0.530–0.700)	1.23 (1.02–1.42)	2.57 (2.20–3.10)	3.95 (3.10–4.55)	2,500
	2017–2018	0.631 (0.573–0.695)	0.580 (0.500–0.560)	1.19 (1.08–1.35)	2.23 (1.96–2.69)	3.78 (3.13–4.68)	3,847

Table 5-25. Geometric Mean and Selected Percentiles of Total Mercury Blood Concentrations (in µg/L) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 2011–2018

	Survey years	Geometric mean (95% CI)	Selected percentiles (95% CI)[a]				Sample size
			50th	75th	90th	95th	
Race/ethnicity							
Mexican Americans	2011–2012	0.483 (0.424–0.550)	0.480 (0.400–0.560)	0.810 (0.720–0.900)	1.44 (1.16–1.63)	1.90 (1.57–2.19)	1,077
	2013–2014	0.487 (0.433–0.547)	0.430 (0.390–0.510)	0.760 (0.690–0.870)	1.41 (1.14–1.69)	1.98 (1.70–2.38)	969
	2015–2016	0.540 (0.522–0.559)	0.530 (0.470–0.570)	0.840 (0.790–0.920)	1.41 (1.19–1.60)	1.81 (1.54–2.33)	994
	2017–2018	0.513 (0.444–0.593)	0.430 (0.370–0.500)	0.910 (0.680–1.15)	1.68 (1.38–2.11)	2.92 (1.98–4.41)	1,134
Non-Hispanic blacks	2011–2012	0.679 (0.542–0.852)	0.630 (0.500–0.790)	1.24 (0.0880–1.72)	2.45 (1.84–3.14)	3.80 (2.70–5.37)	2,195
	2013–2014	0.699 (0.614–0.796)	0.650 (0.570–0.750)	1.20 (1.08–1.40)	2.30 (1.65–2.96)	3.34 (2.35–5.93)	1,119
	2015–2016	0.698 (0.587–0.829)	0.630 (0.510–0.760)	1.21 (1.04–1.47)	2.49 (2.01–3.51)	4.51 (2.74–5.87)	1,070
	2017–2018	0.655 (0.558–0.769)	0.580 (0.460–0.730)	1.20 (0.980–1.51)	2.54 (1.93–3.38)	4.35 (3.40–5.09)	1,708
Non-Hispanic whites	2011–2012	0.688 (0.582–0.813)	0.630 (0.550–0.750)	1.38 (1.09–1.82)	2.83 (2.18–3.82)	4.25 (3.02–6.24)	2,493
	2013–2014	0.672 (0.598–0.755)	0.620 (0.520–0.720)	1.30 (1.12–1.51)	2.61 (2.18–3.08)	4.15 (3.35–4.98)	1,848
	2015–2016	0.638 (0.563–0.723)	0.570 (0.500–0.670)	1.22 (0.940–1.47)	2.29 (1.82–2.72)	3.95 (2.56–4.55)	1,511
	2017–2018	0.623 (0.546–0.711)	0.580 (0.470–0.730)	1.19 (1.03–1.35)	2.23 (1.93–2.64)	3.46 (2.89–4.13)	2,536
All Hispanics	2011–2012	0.612 (0.527–0.710)	0.590 (0.490–0.700)	1.08 (0.890–1.33)	1.96 (1.60–2.68)	3.03 (2.37–3.86)	1,931
	2013–2014	0.551 (0.486–0.624)	0.490 (0.420–0.580)	0.910 (0.820–1.10)	1.76 (1.44–2.12)	2.59 (2.06–3.14)	1,481
	2015–2016	0.607 (0.546–0.675)	0.570 (0.520–0.640)	1.00 (0.870–1.17)	1.75 (1.38–2.33)	2.60 (1.85–3.25)	1,664
	2017–2018	0.591 (0.522–0.669)	0.520 (0.430–0.620)	1.07 (0.910–1.27)	2.04 (1.72–2.58)	3.23 (2.65–4.41)	1,816
Asians	2011–2012	1.86 (1.58–2.19)	2.30 (1.84–2.64)	4.32 (3.71–5.21)	7.71 (6.38–8.79)	10.3 (8.85–12.0)	1,005
	2013–2014	1.72 (1.46–2.03)	1.77 (1.42–2.26)	3.92 (3.35–4.55)	7.78 (6.39–9.16)	9.99 (9.16–13.7)	510
	2015–2016	1.73 (1.41–2.12)	2.03 (1.40–2.70)	4.21 (3.31–5.50)	7.66 (6.17–9.91)	11.3 (9.12–13.8)	479
	2017–2018	1.24 (0.964–1.60)	1.28 (0.930–1.73)	3.28 (2.49–4.01)	5.87 (4.83–8.44)	9.51 (6.97–12.2)	946

[a]The limits of detection for survey years 2011–2012, 2013–2014, 2015–2016, and 2017–2018 were 0.16, 0.28, 0.28, and 0.28 µg/L, respectively.

CI = confidence interval; LOD = limit of detection; NC = not calculated (proportion of results below limit of detection was too high to provide a valid result)

Source: CDC 2024

Table 5-26. Geometric Mean and Selected Percentiles of Inorganic Mercury Blood Concentrations (in µg/L) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 2003–2010

	Survey years	Geometric mean (95% CI)	Selected percentiles (95% CI)[a]				Sample size
			50th	75th	90th	95th	
Total	2003–2004	NC	<LOD	<LOD	0.600 (0.500–0.600)	0.700 (0.700–0.700)	8,147
	2005–2006	NC	<LOD	<LOD	0.540 (0.500–0.580)	0.660 (0.620–0.710)	8,371
	2007–2008	NC	<LOD	0.350 (<LOD–0.370)	0.520 (0.500–0.540)	0.650 (0.620–0.690)	8,162
	2009–2010	NC	<LOD	<LOD	0.390 (0.360–0.430)	0.510 (0.480–0.570)	8,733
Age group							
1–5 years	2003–2004	NC	<LOD	<LOD	<LOD	0.500 (<LOD–0.600)	792
	2005–2006	NC	<LOD	<LOD	0.430 (<LOD–0.470)	0.510 (0.430–0.670)	948
	2007–2008	NC	<LOD	<LOD	0.350 (<LOD–0.450)	0.500 (0.410–0.550)	726
	2009–2010	NC	<LOD	<LOD	<LOD	0.360 (<LOD–0.460)	789
6–11 years	2003–2004	NC	<LOD	<LOD	<LOD	0.600 (0.500–0.600)	842
	2005–2006	NC	<LOD	<LOD	0.450 (<LOD–0.520)	0.560 (0.470–0.640)	932
	2007–2008	NC	<LOD	<LOD	0.380 (0.350–0.410)	0.470 (0.420–0.520)	1,010
	2009–2010	NC	<LOD	<LOD	<LOD	0.380 (0.350–0.440)	1,006
12–19 years	2003–2004	NC	<LOD	<LOD	0.500 (<LOD–0.500)	0.600 (0.500–0.600)	2,060
	2005–2006	NC	<LOD	<LOD	0.430 (0.410–0.460)	0.540 (0.480–0.590)	1,984
	2007–2008	NC	<LOD	<LOD	0.370 (<LOD–0.400)	0.480 (0.410–0.530)	1,069
	2009–2010	NC	<LOD	<LOD	<LOD	0.420 (0.350–0.500)	1,184
≥20 years	2003–2004	NC	<LOD	<LOD	0.600 (0.500–0.600)	0.700 (0.700–0.800)	4,453
	2005–2006	NC	<LOD	<LOD	0.570 (0.530–0.610)	0.690 (0.650–0.750)	4,507
	2007–2008	NC	<LOD	0.380 (0.360–0.390)	0.550 (0.530–0.570)	0.700 (0.660–0.730)	5,357
	2009–2010	NC	<LOD	<LOD	0.420 (0.390–0.450)	0.540 (0.490–0.600)	5,754
Gender							
Males	2003–2004	NC	<LOD	<LOD	0.500 (0.500–0.600)	0.600 (0.600–0.700)	4,015
	2005–2006	NC	<LOD	<LOD	0.480 (0.450–0.520)	0.600 (0.550–0.640)	4,076
	2007–2008	NC	<LOD	<LOD	0.500 (0.470–0.520)	0.600 (0.570–0.650)	4,093
	2009–2010	NC	<LOD	<LOD	0.370 (<LOD–0.420)	0.500 (0.440–0.560)	4,336
Females	2003–2004	NC	<LOD	<LOD	0.600 (0.500–0.600)	0.700 (0.700–0.800)	4,132
	2005–2006	NC	<LOD	<LOD	0.580 (0.550–0.640)	0.700 (0.670–0.780)	4,295
	2007–2008	NC	<LOD	0.380 (0.360–0.390)	0.550 (0.520–0.570)	0.700 (0.670–0.740)	4,069
	2009–2010	NC	<LOD	<LOD	0.410 (0.380–0.440)	0.530 (0.490–0.600)	4,397

Table 5-26. Geometric Mean and Selected Percentiles of Inorganic Mercury Blood Concentrations (in µg/L) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 2003–2010

| | Survey years | Geometric mean (95% CI) | Selected percentiles (95% CI)[a] | | | | Sample size |
			50th	75th	90th	95th	
Race/ethnicity							
Mexican Americans	2003–2004	NC	<LOD	<LOD	0.500 (0.500–0.600)	0.700 (0.600–0.800)	2,007
	2005–2006	NC	<LOD	<LOD	0.530 (0.470–0.580)	0.670 (0.560–0.830)	2,224
	2007–2008	NC	<LOD	<LOD	0.430 (0.400–0.480)	0.560 (0.520–0.610)	1,685
	2009–2010	NC	<LOD	<LOD	<LOD	0.470 (0.390–0.530)	1,947
Non-Hispanic blacks	2003–2004	NC	<LOD	<LOD	0.600 (0.500–0.600)	0.700 (0.600–0.800)	2,240
	2005–2006	NC	<LOD	<LOD	0.530 (0.470–0.600)	0.670 (0.600–0.760)	2,183
	2007–2008	NC	<LOD	<LOD	0.490 (0.450–0.530)	0.610 (0.560–0.650)	1,729
	2009–2010	NC	<LOD	<LOD	0.370 (0.350–0.390)	0.480 (0.410–0.530)	1,580
Non-Hispanic whites	2003–2004	NC	<LOD	<LOD	0.600 (0.500–0.600)	0.700 (0.600–0.700)	3,406
	2005–2006	NC	<LOD	<LOD	0.540 (0.500–0.580)	0.650 (0.610–0.710)	3,298
	2007–2008	NC	<LOD	0.360 (<LOD–0.390)	0.530 (0.500–0.550)	0.660 (0.620–0.700)	3,421
	2009–2010	NC	<LOD	<LOD	0.410 (0.370–0.450)	0.520 (0.480–0.590)	3,739

[a]The limits of detection for survey years 2003–2004, 2005–2006, 2007–2008, and 2009–2010 were 0.42, 0.4, 0.35, and 0.35 µg/L, respectively.

CI = confidence interval; LOD = limit of detection; NC = not calculated (proportion of results below limit of detection was too high to provide a valid result)

Source: CDC 2024

5. POTENTIAL FOR HUMAN EXPOSURE

Table 5-27. Geometric Mean and Selected Percentiles of Inorganic Mercury Blood Concentrations (in µg/L) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 2011–2018

	Survey years	Geometric mean (95% CI)	Selected percentiles (95% CI)[a]				Sample size
			50th	75th	90th	95th	
Total	2011–2012	NC	<LOD	<LOD	0.440 (0.390–0.480)	0.600 (0.520–0.680)	7,841
	2013–2014	NC	<LOD	<LOD	0.410 (0.380–0.440)	0.530 (0.490–0.570)	5,175
	2015–2016	NC	<LOD	<LOD	0.350 (0.300–0.400)	0.480 (0.430–0.530)	4,938
	2017–2018	NC	<LOD	<LOD	0.320 (0.300–0.350)	0.450 (0.400–0.510)	7,480
Age group							
1–5 years	2011–2012	NC	<LOD	<LOD	<LOD	0.280 (<LOD–0.360)	657
	2013–2014	NC	<LOD	<LOD	<LOD	<LOD	779
	2015–2016	NC	<LOD	<LOD	<LOD	0.270 (<LOD–0.340)	749
	2017–2018	NC	<LOD	<LOD	<LOD	<LOD	611
6–11 years	2011–2012	NC	<LOD	<LOD	0.280 (<LOD–0.320)	0.360 (0.290–0.450)	1,044
	2013–2014	NC	<LOD	<LOD	<LOD	0.340 (<LOD–0.420)	1,074
	2015–2016	NC	<LOD	<LOD	<LOD	0.330 (<LOD–0.450)	1,022
	2017–2018	NC	<LOD	<LOD	<LOD	0.280 (0.230–0.390)	831
12–19 years	2011–2012	NC	<LOD	<LOD	0.280 (<LOD–0.350)	0.400 (0.300–0.540)	1,121
	2013–2014	NC	<LOD	<LOD	<LOD	0.360 (0.290–0.420)	627
	2015–2016	NC	<LOD	<LOD	<LOD	0.400 (<LOD–0.510)	565
	2017–2018	NC	<LOD	<LOD	<LOD	0.280 (0.240–0.350)	1,027
≥20 years	2011–2012	NC	<LOD	0.290 (0.270–0.310)	0.470 (0.420–0.530)	0.630 (0.550–0.760)	5,019
	2013–2014	NC	<LOD	0.270 (<LOD–0.300)	0.440 (0.410–0.470)	0.560 (0.510–0.660)	2,695
	2015–2016	NC	<LOD	<LOD	0.380 (0.330–0.430)	0.500 (0.450–0.560)	2,602
	2017–2018	NC	<LOD	0.210 (<LOD–0.230)	0.350 (0.320–0.370)	0.500 (0.420–0.560)	5,011
Gender							
Males	2011–2012	NC	<LOD	<LOD	0.420 (0.370–0.480)	0.600 (0.490–0.680)	3,925
	2013–2014	NC	<LOD	<LOD	0.400 (0.340–0.430)	0.510 (0.450–0.560)	2,570
	2015–2016	NC	<LOD	<LOD	0.330 (0.280–0.400)	0.430 (0.400–0.490)	2,460
	2017–2018	NC	<LOD	<LOD	0.310 (0.280–0.330)	0.430 (0.380–0.480)	3,650
Females	2011–2012	NC	<LOD	0.280 (<LOD–0.300)	0.450 (0.390–0.490)	0.610 (0.520–0.700)	3,916
	2013–2014	NC	<LOD	<LOD	0.420 (0.390–0.450)	0.550 (0.510–0.590)	2,605
	2015–2016	NC	<LOD	<LOD	0.370 (0.320–0.450)	0.530 (0.450–0.620)	2,478
	2017–2018	NC	<LOD	<LOD	0.330 (0.300–0.370)	0.480 (0.400–0.550)	3,380

Table 5-27. Geometric Mean and Selected Percentiles of Inorganic Mercury Blood Concentrations (in µg/L) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 2011–2018

	Survey years	Geometric mean (95% CI)	Selected percentiles (95% CI)[a]				Sample size
			50th	75th	90th	95th	
Race/ethnicity							
Mexican Americans	2011–2012	NC	<LOD	<LOD	0.390 (0.330–0.460)	0.580 (0.460–0.710)	1,058
	2013–2014	NC	<LOD	<LOD	0.380 (0.330–0.410)	0.540 (0.420–0.640)	958
	2015–2016	NC	<LOD	<LOD	0.420 (0.290–0.600)	0.560 (0.430–0.820)	988
	2017–2018	NC	<LOD	<LOD	0.370 (0.290–0.490)	0.590 (0.450–0.800)	1,129
Non-Hispanic blacks	2011–2012	NC	<LOD	<LOD	0.410 (0.370–0.470)	0.570 (0.480–0.670)	2,170
	2013–2014	NC	<LOD	<LOD	0.380 (0.330–0.430)	0.530 (0.440–0.630)	1,110
	2015–2016	NC	<LOD	<LOD	0.330 (0.270–0.380)	0.430 (0.370–0.490)	1,058
	2017–2018	NC	<LOD	<LOD	0.320 (0.280–0.370)	0.430 (0.380–0.520)	1,129
Non-Hispanic whites	2011–2012	NC	<LOD	0.270 (<LOD–0.300)	0.430 (0.370–0.490)	0.590 (0.480–0.690)	2,477
	2013–2014	NC	<LOD	<LOD	0.420 (0.360–0.450)	0.510 (0.460–0.570)	1,835
	2015–2016	NC	<LOD	<LOD	0.320 (0.280–0.400)	0.460 (0.400–0.540)	1,500
	2017–2018	NC	<LOD	<LOD	0.300 (0.260–0.360)	0.410 (0.360–0.500)	2,525
All Hispanics	2011–2012	NC	<LOD	<LOD	0.430 (0.370–0.490)	0.630 (0.540–0.760)	1,902
	2013–2014	NC	<LOD	<LOD	0.380 (0.330–0.410)	0.540 (0.440–0.650)	1,467
	2015–2016	NC	<LOD	<LOD	0.380 (0.300–0.490)	0.510 (0.430–0.650)	1,648
	2017–2018	NC	<LOD	<LOD	0.360 (0.310–0.430)	0.540 (0.450–0.650)	1,810
Asians	2011–2012	NC	<LOD	0.350 (0.310–0.390)	0.550 (0.500–0.590)	0.700 (0.630–0.760)	997
	2013–2014	NC	<LOD	0.330 (0.270–0.390)	0.570 (0.420–0.680)	0.750 (0.580–1.10)	508
	2015–2016	NC	<LOD	<LOD	0.430 (0.360–0.540)	0.600 (0.470–0.730)	473
	2017–2018	NC	<LOD	0.240 (<LOD–0.310)	0.420 (0.310–0.540)	0.550 (0.420–0.800)	944

[a]The limits of detection for survey years 2011–2012, 2013–2014, 2015–2016, and 2017–2018 were 0.27, 0.27, 0.27, and 0.27 µg/L, respectively.

CI = confidence interval; LOD = limit of detection; NC = not calculated (proportion of results below limit of detection was too high to provide a valid result)

Source: CDC 2024

Table 5-28. Geometric Mean and Selected Percentiles of Ethyl Mercury Blood Concentrations (in µg/L) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 2011–2018

	Survey years	Geometric mean (95% CI)	Selected percentiles (95% CI)[a]				Sample size
			50th	75th	90th	95th	
Total	2011–2012	NC	<LOD	<LOD	<LOD	<LOD	7,841
	2013–2014	NC	<LOD	<LOD	<LOD	<LOD	5,175
	2015–2016	NC	<LOD	<LOD	<LOD	<LOD	4,936
	2017–2018	NC	<LOD	<LOD	<LOD	<LOD	7,480
Age group							
1–5 years	2011–2012	NC	<LOD	<LOD	<LOD	<LOD	657
	2013–2014	NC	<LOD	<LOD	<LOD	<LOD	779
	2015–2016	NC	<LOD	<LOD	<LOD	<LOD	749
	2017–2018	NC	<LOD	<LOD	<LOD	<LOD	611
6–11 years	2011–2012	NC	<LOD	<LOD	<LOD	<LOD	1,044
	2013–2014	NC	<LOD	<LOD	<LOD	<LOD	1,074
	2015–2016	NC	<LOD	<LOD	<LOD	<LOD	1,022
	2017–2018	NC	<LOD	<LOD	<LOD	<LOD	831
12–19 years	2011–2012	NC	<LOD	<LOD	<LOD	<LOD	1,121
	2013–2014	NC	<LOD	<LOD	<LOD	<LOD	627
	2015–2016	NC	<LOD	<LOD	<LOD	<LOD	565
	2017–2018	NC	<LOD	<LOD	<LOD	<LOD	1,027
≥20 years	2011–2012	NC	<LOD	<LOD	<LOD	<LOD	5,019
	2013–2014	NC	<LOD	<LOD	<LOD	<LOD	2,695
	2015–2016	NC	<LOD	<LOD	<LOD	<LOD	2,600
	2017–2018	NC	<LOD	<LOD	<LOD	<LOD	5,011
Gender							
Males	2011–2012	NC	<LOD	<LOD	<LOD	<LOD	3,925
	2013–2014	NC	<LOD	<LOD	<LOD	<LOD	2,570
	2015–2016	NC	<LOD	<LOD	<LOD	<LOD	2,458
	2017–2018	NC	<LOD	<LOD	<LOD	<LOD	3,650
Females	2011–2012	NC	<LOD	<LOD	<LOD	<LOD	3,916
	2013–2014	NC	<LOD	<LOD	<LOD	<LOD	2,605
	2015–2016	NC	<LOD	<LOD	<LOD	<LOD	2,478
	2017–2018	NC	<LOD	<LOD	<LOD	<LOD	3,830

Table 5-28. Geometric Mean and Selected Percentiles of Ethyl Mercury Blood Concentrations (in µg/L) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 2011–2018

	Survey years	Geometric mean (95% CI)	Selected percentiles (95% CI)[a]				Sample size
			50th	75th	90th	95th	
Race/ethnicity							
Mexican Americans	2011–2012	NC	<LOD	<LOD	<LOD	<LOD	1,058
	2013–2014	NC	<LOD	<LOD	<LOD	<LOD	958
	2015–2016	NC	<LOD	<LOD	<LOD	<LOD	988
	2017–2018	NC	<LOD	<LOD	<LOD	<LOD	1,129
Non-Hispanic blacks	2011–2012	NC	<LOD	<LOD	<LOD	<LOD	2,170
	2013–2014	NC	<LOD	<LOD	<LOD	<LOD	1,110
	2015–2016	NC	<LOD	<LOD	<LOD	<LOD	1,057
	2017–2018	NC	<LOD	<LOD	<LOD	<LOD	1,699
Non-Hispanic whites	2011–2012	NC	<LOD	<LOD	<LOD	<LOD	2,477
	2013–2014	NC	<LOD	<LOD	<LOD	<LOD	1,835
	2015–2016	NC	<LOD	<LOD	<LOD	<LOD	1,500
	2017–2018	NC	<LOD	<LOD	<LOD	<LOD	2,525
All Hispanics	2011–2012	NC	<LOD	<LOD	<LOD	<LOD	1,902
	2013–2014	NC	<LOD	<LOD	<LOD	<LOD	1,467
	2015–2016	NC	<LOD	<LOD	<LOD	<LOD	1,647
	2017–2018	NC	<LOD	<LOD	<LOD	<LOD	1,180
Asians	2011–2012	NC	<LOD	<LOD	<LOD	0.160 (<LOD–0.280)	997
	2013–2014	NC	<LOD	<LOD	<LOD	<LOD	508
	2015–2016	NC	<LOD	<LOD	<LOD	<LOD	473
	2017–2018	NC	<LOD	<LOD	<LOD	<LOD	944

[a]The limits of detection for survey years 2011–2012, 2013–2014, 2015–2016, and 2017–2018 were 0.16, 0.16, 0.16, and 0.064 µg/L, respectively.
.

CI = confidence interval; LOD = limit of detection; NC = not calculated (proportion of results below limit of detection was too high to provide a valid result)

Source: CDC 2024

Table 5-29. Geometric Mean and Selected Percentiles of Methylmercury Blood Concentrations (in µg/L) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 2011–2018

	Survey years	Geometric mean (95% CI)	Selected percentiles (95% CI)[a]				Sample size
			50th	75th	90th	95th	
Total	2011–2012	0.498 (0.423–0.587)	0.480 (0.400–0.570)	1.25 (0.950–1.61)	2.81 (2.29–3.55)	4.43 (3.46–5.49)	7,841
	2013–2014	0.434 (0.381–0.495)	0.420 (0.340–0.510)	1.09 (0.940–1.27)	2.62 (2.18–3.04)	4.28 (3.74–4.93)	5,175
	2015–2016	0.413 (0.361–0.472)	0.380 (0.320–0.490)	1.02 (0.860–1.22)	2.30 (1.92–2.78)	3.92 (3.35–4.81)	4,938
	2017–2018	0.480 (0.431–0535)	0.390 (0.210–0.470)	0.980 (0.830–1.15)	2.23 (1.88–2.57)	3.49 (3.05–4.01)	7,480
Age group							
1–5 years	2011–2012	NC	0.140 (0.120–0.170)	0.270 (0.220–0.350)	0.540 (0.420–0.780)	0.970 (0.590–1.14)	657
	2013–2014	NC	<LOD	0.260 (0.230–0.310)	0.660 (0.550–0.810)	1.11 (0.960–1.48)	779
	2015–2016	NC	<LOD	0.200 (0.170–0.240)	0.470 (0.350–0.630)	0.830 (0.590–1.21)	749
	2017–2018	NC	<LOD	<LOD	0.460 (0.380–0.600)	0.790 (0.600–0.930)	611
6–11 years	2011–2012	0.209 (0.182–0.241)	0.180 (0.150–0.220)	0.400 (0.330–0.490)	0.820 (0.630–1.06)	1.34 (0.940–1.84)	1,044
	2013–2014	NC	0.150 (<LOD–0.200)	0.380 (0.280–0.530)	0.960 (0.700–1.26)	1.58 (1.26–2.11)	1,074
	2015–2016	NC	0.140 (<LOD–0.180)	0.290 (0.260–0.340)	0.730 (0.530–0.950)	1.11 (0.870–1.91)	1,022
	2017–2018	NC	<LOD	0.280 (<LOD–0.340)	0.710 (0.490–0.960)	1.40 (0.830–2.02)	831
12–19 years	2011–2012	0.276 (0.237–0.322)	0.270 (0.210–0.310)	0.570 (0.460–0.670)	1.27 (0.870–1.67)	2.15 (1.40–2.81)	1121
	2013–2014	0.233 (0.202–0.269)	0.190 (0.140–0.260)	0.480 (0.380–0.560)	1.02 (0.730–1.60)	1.84 (1.20–2.57)	627
	2015–2016	0.212 (0.180–0.249)	0.160 (0.120–0.220)	0.420 (0.310–0.620)	0.800 (0.690–1.23)	1.81 (0.800–3.14)	565
	2017–2018	NC	<LOD	0.410 (0.340–0.510)	0.990 (0.730–1.27)	1.52 (1.05–2.41)	1,027
≥20 years	2011–2012	0.624 (0.523–0.746)	0.610 (0.500–0.760)	1.53 (1.18–2.00)	3.28 (2.56–4.31)	4.97 (3.91–6.89)	5,019
	2013–2014	0.541 (0.473–0.618)	0.540 (0.450–0.630)	1.32 (1.17–1.54)	3.05 (2.64–3.60)	4.92 (4.34–5.41)	2,695
	2015–2016	0.518 (0.456–0.588)	0.530 (0.420–0.630)	1.23 (1.05–1.46)	2.59 (2.25–3.36)	4.42 (3.66–5.58)	2,602
	2017–2018	0.566 (0.505–0.635)	0.500 (0.420–0.610)	1.17 (1.01–1.34)	2.61 (2.23–2.93)	3.89 (3.31–4.53)	5,011
Gender							
Males	2011–2012	0.509 (0.433–0.598)	0.490 (0.400–0.590)	1.30 (0.990–1.62)	2.84 (2.29–3.68)	4.77 (3.44–6.74)	3,925
	2013–2014	0.448 (0.390–0.515)	0.430 (0.350–0.530)	1.10 (0.940–1.37)	2.67 (2.22–3.33)	4.44 (3.88–5.40)	2,570
	2015–2016	0.429 (0.379–0.486)	0.400 (0.330–0.520)	1.11 (0.900–1.33)	2.24 (1.85–2.86)	4.42 (3.60–5.05)	2,460
	2017–2018	0.496 (0.434–0.567)	0.390 (0.300–0.510)	1.04 (0.820–1.28)	2.51 (2.07–2.78)	3.69 (3.19–4.13)	3,650
Females	2011–2012	0.489 (0.413–0.580)	0.470 (0.380–0.560)	1.19 (0.900–1.61)	2.72 (2.18–3.46)	3.99 (3.28–4.99)	3,916
	2013–2014	0.422 (0.367–0.485)	0.400 (0.330–0.490)	1.08 (0.900–1.22)	2.46 (2.03–2.92)	3.91 (3.32–4.93)	2,605
	2015–2016	0.399 (0.338–0.470)	0.370 (0.300–0.470)	0.950 (0.760–1.18)	2.36 (1.91–2.81)	3.58 (2.92–4.24)	2,478
	2017–2018	0.465 (0.424–0.511)	0.370 (0.310–0.450)	0.960 (0.810–1.10)	1.92 (1.64–2.43)	3.32 (2.77–3.90)	3,830

Table 5-29. Geometric Mean and Selected Percentiles of Methylmercury Blood Concentrations (in µg/L) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 2011–2018

	Survey years	Geometric mean (95% CI)	Selected percentiles (95% CI)[a]				Sample size
			50th	75th	90th	95th	
Race/ethnicity							
Mexican Americans	2011–2012	0.320 (0.264–0.387)	0.330 (0.260–0.410)	0.610 (0.500–0.770)	1.23 (0.920–1.40)	1.66 (1.33–2.06)	1,058
	2013–2014	0.276 (0.239–0.318)	0.260 (0.210–0.310)	0.540 (0.440–0.650)	1.06 (0.770–1.43)	1.72 (1.27–2.34)	958
	2015–2016	0.292 (0.276–0.309)	0.290 (0.260–0.330)	0.610 (0.550–0.690)	1.13 (0.870–1.47)	1.54 (1.34–2.02)	988
	2017–2018	NC	0.270 (<LOD–0.320)	0.620 (0.460–0.820)	1.33 (0.990–1.87)	2.24 (1.51–3.08	1,129
Non-Hispanic blacks	2011–2012	0.517 (0.392–0.681)	0.510 (0.380–0.660)	1.13 (0.750–1.61)	2.37 (1.66–3.08)	3.63 (2.57–5.16)	2,170
	2013–2014	0.481 (0.407–0.569)	0.460 (0.370–0.580)	1.03 (0.900–1.22)	2.08 (1.55–2.72)	3.33 (2.15–5.12)	1,110
	2015–2016	0.461 (0.376–0.565)	0.430 (0.330–0.580)	1.05 (0.830–1.25)	2.34 (1.71–3.31)	4.08 (2.80–5.58)	1,058
	2017–2018	0.492 (0.412–0.589)	0.410 (0.290–0.540)	0.970 (0.740–1.28)	2.31 (1.68–2.94)	3.69 (3.04–4.45)	1,699
Non-Hispanic whites	2011–2012	0.478 (0.392–0.583)	0.470 (0.360–0.580)	1.25 (0.870–1.69)	2.76 (2.06–3.69)	4.24 (2.92–6.38)	2,477
	2013–2014	0.420 (0.357–0.495)	0.420 (0.310–0.530)	1.10 (0.910–1.32)	2.62 (2.07–3.12)	4.01 (3.46–5.00)	1,835
	2015–2016	0.380 (0.319–0.451)	0.350 (0.270–0.490)	0.960 (0.750–1.22)	2.04 (1.55–2.51)	3.50 (2.32–4.49)	1,500
	2017–2018	NC	0.380 (0.300–0.470)	0.950 (0.800–1.12)	1.91 (1.62–2.46)	3.19 (2.56–3.75)	2,525
All Hispanics	2011–2012	0.429 (0.350–0.525)	0.420 (0.340–0.520)	0.890 (0.700–1.17)	1.81 (1.39–2.46)	2.94 (2.19–3.71)	1,902
	2013–2014	0.326 (0.278–0.382)	0.310 (0.250–0.350)	0.680 (0.580–0.790)	1.50 (1.15–1.89)	2.34 (1.79–3.00)	1,467
	2015–2016	0.353 (0.305–0.409)	0.350 (0.300–0.390)	0.760 (0.630–0.930)	1.53 (1.14–1.98)	2.26 (1.60–3.03)	1,648
	2017–2018	NC	0.330 (0.270–0.410)	0.810 (0.670–0.990)	1.65 (1.32–2.23)	2.68 (2.08–3.86)	1,810
Asians	2011–2012	1.58 (1.29–1.94)	2.16 (1.68–2.55)	4.35 (3.64–5.13)	7.57 (6.21–8.61)	10.5 (8.48–12.5)	997
	2013–2014	1.42 (1.16–1.74)	1.71 (1.17–2.07)	3.90 (3.31–4.54)	7.93 (6.42–9.21)	10.8 (9.57–13.6)	508
	2015–2016	1.37 (1.08–1.73)	1.85 (1.18–2.51)	3.80 (3.11–4.83)	7.52 (5.60–9.63)	11.0 (8.65–12.4)	473
	2017–2018	0.996 (0.791–1.25)	1.07 (0.760–1.47)	2.90 (2.13–3.57)	5.35 (4.49–7.33)	8.67 (6.45–11.0)	994

[a]The limits of detection for survey years 2011–2012, 2013–2014, 2015–2016, and 2018–2018 were 0.12, 0.12, 0.12, and 0.26 µg/L, respectively.

CI = confidence interval; LOD = limit of detection; NC = not calculated (proportion of results below limit of detection was too high to provide a valid result)

Source: CDC 2024

	Survey years	Geometric mean (95% CI)	Selected percentiles (95% CI)[a]				Sample size
			50th	75th	90th	95th	
Total	2003–2004	0.447 (0.406–0.492)	0.420 (0.360–0.480)	1.00 (0.870–1.14)	2.08 (1.78–2.42)	3.19 (2.76–3.55)	2,538
	2005–2006	0.468 (0.426–0.514)	0.460 (0.410–0.510)	1.03 (0.900–1.12)	2.11 (1.88–2.36)	2.94 (2.58–3.26)	2,578
	2007–2008	0.443 (0.408–0.482)	0.440 (0.400–0.470)	0.880 (0.760–1.00)	1.74 (1.62–1.96)	2.66 (2.29–3.08)	2,634
	2009–2010	NC	0.400 (0.360–0.450)	0.850 (0.770–0.910)	1.53 (1.30–1.81)	2.42 (2.07–2.72)	2,865
Age group							
6–11 years	2003–2004	0.254 (0.213–0.304)	0.200 (0.160–0.250)	0.440 (0.330–0.580)	1.16 (0.610–1.61)	1.96 (1.13–2.97)	287
	2005–2006	0.333 (0.267–0.416)	0.320 (0.250–0.390)	0.650 (0.470–0.840)	1.32 (0.930–1.88)	2.18 (1.28–3.40)	355
	2007–2008	0.301 (0.260–0.347)	0.290 (0.230–0.340)	0.520 (0.430–0.620)	1.03 (0.770–1.23)	1.87 (1.03–3.48)	398
	2009–2010	NC	0.260 (0.220–0.320)	0.510 (0.430–0.620)	1.03 (0.730–1.31)	1.58 (1.18–1.88)	379
12–19 years	2003–2004	0.358 (0.313–0.408)	0.330 (0.290–0.370)	0.700 (0.530–0.840)	1.60 (1.14–2.52)	2.93 (1.88–3.66)	722
	2005–2006	0.372 (0.286–0.486)	0.350 (0.270–0.470)	0.740 (0.580–0.920)	1.61 (0.970–2.81)	2.59 (1.40–4.45)	703
	2007–2008	0.364 (0.326–0.406)	0.380 (0.320–0.450)	0.590 (0.550–0.650)	1.24 (0.830–1.71)	1.82 (1.41–2.29)	375
	2009–2010	NC	0.290 (0.230–0.360)	0.530 (0.470–0.630)	1.09 (0.890–1.31)	1.73 (1.28–2.31)	455
≥20 years	2003–2004	0.495 (0.442–0.555)	0.480 (0.410–0.570)	1.12 (0.930–1.29)	2.20 (1.85–2.65)	3.33 (2.76–3.88)	1,529
	2005–2006	0.505 (0.468–0.545)	0.510 (0.460–0.560)	1.11 (1.04–1.16)	2.23 (1.97–2.50)	3.11 (2.64–3.37)	1,520
	2007–2008	0.477 (0.435–0.523)	0.470 (0.430–0.520)	0.970 (0.850–1.10)	1.89 (1.69–2.20)	2.82 (2.33–3.56)	1,861
	2009–2010	NC	0.450 (0.390–0.510)	0.890 (0.810–1.00)	1.66 (1.40–2.01)	2.53 (2.21–2.84)	2,031
Gender							
Males	2003–2004	0.433 (0.405–0.463)	0.400 (0.350–0.460)	0.940 (0.840–1.05)	1.88 (1.63–2.18)	2.68 (2.34–3.05)	1,266
	2005–2006	0.464 (0.411–0.523)	0.450 (0.400–0.520)	0.980 (0.860–1.11)	2.03 (1.57–2.48)	3.00 (2.48–3.37)	1,270
	2007–2008	0.457 (0.417–0.501)	0.460 (0.400–0.520)	0.880 (0.780–1.01)	1.68 (1.53–1.77)	2.40 (2.11–2.76)	1,326
	2009–2010	NC	0.410 (0.340–0.480)	0.860 (0.750–0.950)	1.46 (1.29–1.66)	2.21 (1.93–2.53)	1,404
Females	2003–2004	0.460 (0.396–0.534)	0.430 (0.330–0.530)	1.07 (0.870–1.28)	2.26 (1.77–2.90)	3.54 (2.76–4.31)	1,272
	2005–2006	0.472 (0.424–0.525)	0.470 (0.390–0.550)	1.07 (0.900–1.19)	2.14 (1.84–2.50)	2.89 (2.60–3.38)	1,308
	2007–2008	0.431 (0.388–0.478)	0.430 (0.380–0.460)	0.870 (0.710–1.05)	1.88 (1.55–2.38)	2.92 (2.27–4.17)	1,308
	2009–2010	NC	0.390 (0.360–0.450)	0.840 (0.730–0.940)	1.61 (1.29–2.03)	2.61 (2.16–3.12)	1,461
Race/ethnicity							
Mexican Americans	2003–2004	0.416 (0.340–0.509)	0.360 (0.280–0.430)	0.960 (0.700–1.23)	2.19 (1.39–3.24)	3.16 (1.99–6.30)	619
	2005–2006	0.451 (0.369–0.551)	0.420 (0.310–0.560)	1.01 (0.780–1.25)	2.22 (1.48–2.64)	3.00 (2.27–4.01)	651
	2007–2008	0.409 (0.349–0.480)	0.370 (0.330–0.450)	0.780 (0.700–0.950)	1.82 (1.26–1.97)	2.55 (1.87–3.08)	514
	2009–2010	NC	0.350 (0.280–0.430)	0.670 (0.520–0.890)	1.53 (1.06–1.84)	2.29 (1.81–2.76)	615

Table 5-30. Geometric Mean and Selected Percentiles of Total Mercury Urinary Concentrations (in µg/L) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 2003–2010

Table 5-30. Geometric Mean and Selected Percentiles of Total Mercury Urinary Concentrations (in µg/L) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 2003–2010

	Survey years	Geometric mean (95% CI)	Selected percentiles (95% CI)[a]				Sample size
			50th	75th	90th	95th	
Non-Hispanic blacks	2003–2004	0.476 (0.413–0.549)	0.430 (0.360–0.530)	0.890 (0.770–1.00)	1.96 (1.60–2.31)	3.09 (2.03–4.89)	713
	2005–2006	0.453 (0.384–0.533)	0.450 (0.380–0.550)	0.890 (0.710–1.13)	1.78 (1.34–2.29)	2.57 (2.21–3.15)	691
	2007–2008	0.478 (0.411–0.556)	0.460 (0.380–0.540)	0.910 (0.770–1.06)	1.85 (1.42–2.41)	2.76 (1.97–4.19)	589
	2009–2010	NC	0.410 (0.340–0.490)	0.840 (0.650–1.08)	1.66 (1.34–1.95)	2.64 (1.88–3.30)	546
Non-Hispanic whites	2003–2004	0.441 (0.382–0.509)	0.420 (0.330–0.520)	1.01 (0.840–1.23)	2.08 (1.67–2.46)	3.24 (2.67–3.60)	1,066
	2005–2006	0.459 (0.409–0.513)	0.440 (0.400–0.510)	1.00 (0.860–1.12)	2.07 (1.77–2.40)	2.81 (2.47–3.37)	1,044
	2007–2008	0.431 (0.378–0.493)	0.430 (0.380–0.480)	0.880 (0.700–1.07)	1.71 (1.50–2.18)	2.70 (2.18–3.59)	1,100
	2009–2010	NC	0.390 (0.330–0.470)	0.850 (0.750–0.950)	1.52 (1.26–2.01)	2.42 (1.93–2.85)	1,225

[a]The limits of detection for survey years 2003–2004, 2005–2006, 2007–2008, and 2009–2010 were 0.14, 0.11, 0.08, and 0.08 µg/L, respectively.

CI = confidence interval; LOD = limit of detection; NC = not calculated (proportion of results below limit of detection was too high to provide a valid result)

Source: CDC 2024

Table 5-31. Geometric Mean and Selected Percentiles of Total Mercury Urinary Concentrations (in µg/L) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 2011–2018

	Survey years	Geometric mean (95% CI)	Selected percentiles (95% CI)[a]				Sample size
			50th	75th	90th	95th	
Total	2011–2012	0.324 (0.285–0.368)	0.320 (0.280–0.370)	0.660 (0.580–0.770)	1.37 (1.15–1.59)	1.83 (1.62–2.14)	2,507
	2013–2014	0.246 (0.221–0.273)	0.200 (0.170–0.240)	0.470 (0.400–0.570)	1.07 (0.900–1.22)	1.64 (1.35–1.96)	2,666
	2015–2016	NC	<LOD	0.280 (0.250–0.320)	0.680 (0.570–0.780)	1.18 (0.920–1.29)	3,080
	2017–2018	NC	<LOD	0.300 (0.250–0.379)	0.680 (0.600–0.770)	1.05 (0.850–1.23)	2,812
Age group							
3–5 years	2015–2016	NC	<LOD	<LOD	0.160 (<LOD–0.240)	0.280 (0.190–0.510)	496
	2017–2018	NC	<LOD	<LOD	0.190 (<LOD–0.360)	0.390 (0.210–1.19)	407
6–11 years	2011–2012	0.241 (0.206–0.283)	0.220 (0.190–0.270)	0.450 (0.390–0.530)	0.930 (0.680–1.36)	1.37 (0.990–2.03)	401
	2013–2014	NC	<LOD	0.220 (0.150–0.310)	0.560 (0.340–0.840)	0.890 (0.640–1.10)	401
	2015–2016	NC	<LOD	<LOD	0.300 (0.200–0.380)	0.520 (0.360–0.700)	380
	2017–2018	NC	<LOD	<LOD	0.270 (0.210–0.550)	0.570 (0.430–0.879)	333
12–19 years	2011–2012	0.257 (0.212–0.312)	0.270 (0.220–0.340)	0.490 (0.390–0.600)	0.840 (0.650–1.24)	1.31 (0.920–1.75)	390
	2013–2014	NC	<LOD	0.240 (0.200–0.310)	0.560 (0.400–0.860)	1.02 (0.610–1.81)	452
	2015–2016	NC	<LOD	0.130 (<LOD–0.160)	0.350 (0.200–0.470)	0.610 (0.380–1.14)	402
	2017–2018	NC	<LOD	0.160 (<LOD–0.250)	0.330 (0.310–0.520)	0.700 (0.400–0.940)	364
≥20 years	2011–2012	0.346 (0.303–0.396)	0.340 (0.290–0.400)	0.720 (0.620–0.850)	1.49 (1.20–1.67)	1.93 (1.67–2.29)	1,716
	2013–2014	0.274 (0.246–0.305)	0.240 (0.200–0.280)	0.540 (0.450–0.630)	1.16 (1.00–1.33)	1.76 (1.44–2.04)	1,813
	2015–2016	NC	0.140 (0.130–0.150)	0.340 (0.310–0.380)	0.740 (0.650–0.890)	1.22 (0.970–1.43)	1,802
	2017–2018	NC	<LOD	0.370 (0.310–0.410)	0.750 (0.620–0.840)	1.16 (0.950–1.34)	1,708
Gender							
Males	2011–2012	0.342 (0.293–0.399)	0.330 (0.290–0.380)	0.670 (0.580–0.810)	1.34 (1.03–1.67)	1.91 (1.54–2.51)	1,260
	2013–2014	0.243 (0.219–0.268)	0.200 (0.170–0.220)	0.480 (0.390–0.600)	1.07 (0.840–1.33)	1.55 (1.28–1.96)	1,319
	2015–2016	NC	<LOD	0.280 (0.230–0.330)	0.620 (0.540–0.710)	0.900 (0.760–1.18)	1,533
	2017–2018	NC	<LOD	0.290 (0.220–0.380)	0.620 (0.550–0.780)	1.04 (0.760–1.39)	1,382
Females	2011–2012	0.307 (0.262–0.360)	0.300 (0.250–0.360)	0.660 (0.540–0.770)	1.37 (1.17–1.54)	1.82 (1.54–2.14)	1,247
	2013–2014	0.249 (0.218–0.284)	0.210 (0.170–0.260)	0.470 (0.390–0.570)	1.07 (0.820–1.27)	1.75 (1.25–2.26)	1,347
	2015–2016	NC	<LOD	0.290 (0.250–0.350)	0.730 (0.570–0.980)	1.27 (0.940–1.88)	1,547
	2017–2018	NC	<LOD	0.310 (0.230–0.390)	0.720 (0.590–0.820)	1.07 (0.840–1.25)	1,430

Table 5-31. Geometric Mean and Selected Percentiles of Total Mercury Urinary Concentrations (in µg/L) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 2011–2018

	Survey years	Geometric mean (95% CI)	Selected percentiles (95% CI)[a]				Sample size
			50th	75th	90th	95th	
Race/ethnicity							
Mexican Americans	2011–2012	0.301 (0.261–0.348)	0.300 (0.200–0.400)	0.620 (0.510–0.680)	1.25 (0.910–1.53)	1.75 (1.32–2.25)	317
	2013–2014	0.229 (0.198–0.265)	0.160 (0.150–0.210)	0.450 (0.300–0.620)	1.12 (0.780–1.35)	1.47 (0.970–2.38)	454
	2015–2016	NC	<LOD	0.230 (0.170–0.280)	0.530 (0.440–0.640)	0.900 (0.650–1.22)	586
	2017–2018	NC	<LOD	0.280 (0.200–0.400)	0.770 (0.480–1.36)	1.36 (0.720–3.95)	436
Non-Hispanic blacks	2011–2012	0.360 (0.316–0.410)	0.360 (0.320–0.400)	0.670 (0.570–0.800)	1.33 (1.06–1.60)	1.99 (1.48–3.06)	671
	2013–2014	0.279 (0.228–0.340)	0.250 (0.190–0.320)	0.530 (0.400–0.690)	1.10 (0.900–1.49)	1.82 (1.11–2.48)	580
	2015–2016	NC	0.140 (<LOD–0.180)	0.370 (0.270–0.510)	0.800 (0.620–1.19)	1.38 (0.870–1.72)	676
	2017–2018	NC	<LOD	0.370 (.0280–0.480)	0.900 (2.02–1.86)	1.31 (1.01–1.86)	641
Non-Hispanic whites	2011–2012	0.308 (0.260–0.365)	0.290 (0.260–0.360)	0.630 (0.510–0.810)	1.37 (1.09–1.64)	1.77 (1.49–2.14)	819
	2013–2014	0.240 (0.211–0.271)	0.200 (0.160–0.230)	0.460 (0.370–0.580)	1.06 (0.840–1.24)	1.64 (1.24–2.04)	988
	2015–2016	NC	<LOD	0.260 (0.210–0.330)	0.700 (0.480–0.870)	1.18 (0.860–1.40)	932
	2017–2018	NC	<LOD	0.280 (0.200–0.370)	0.620 (0.570–0.750)	0.840 (0.680–1.16)	918
All Hispanics	2011–2012	0.330 (0.299–0.364)	0.330 (0.270–0.390)	0.680 (0.610–0.760)	1.30 (1.15–1.53)	1.98 (1.61–2.42)	574
	2013–2014	0.239 (0.207–0.276)	0.180 (0.150–0.240)	0.460 (0.360–0.620)	1.14 (0.800–1.35)	1.57 (1.24–2.15)	702
	2015–2016	NC	<LOD	0.260 (0.210–0.330)	0.600 (0.470–0.740)	1.03 (0.730–1.37)	986
	2017–2018	NC	<LOD	0.310 (0.250–0.420)	0.810 (0.580–0.990)	1.34 (0.910–2.03)	677
Asians	2011–2012	0.430 (0.351–0.527)	0.450 (0.330–0.580)	0.910 (0.750–1.12)	1.69 (1.31–2.06)	2.41 (1.77–3.53)	355
	2013–2014	0.313 (0.269–0.363)	0.270 (0.220–0.340)	0.620 (0.520–0.710)	1.18 (0.890–1.66)	1.78 (1.20–3.10)	291
	2015–2016	NC	0.180 (<LOD–0.250)	0.390 (0.330–0.510)	0.720 (0.610–0.820)	0.960 (0.790–1.49)	333
	2017–2018	NC	0.190 (<LOD–0.280)	0.430 (0.350–0.600)	0.990 (0.640–1.29)	1.49 (1.05–2.46)	365

[a]The limits of detection for survey years 2011–2012, 2013–2014, 2015–2016, and 2017–2018 were 0.05, 0.13, 0.13 and 0.13 µg/L, respectively.

CI = confidence interval; LOD = limit of detection; NC = not calculated (proportion of results below limit of detection was too high to provide a valid result)

Source: CDC 2024

Table 5-32. Geometric Mean and Selected Percentiles of Total Mercury Creatinine Corrected Urinary Concentrations (µg/g of Creatinine) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 2003–2010

	Survey years	Geometric mean (95% CI)	Selected percentiles (95% CI)[a]				Sample size
			50th	75th	90th	95th	
Total	2003–2004	0.443 (0.404–0.486)	0.447 (0.392–0.498)	0.909 (0.785–1.00)	1.65 (1.40–1.86)	2.35 (1.88–2.85)	2,537
	2005–2006	0.460 (0.414–0.511)	0.450 (0.410–0.510)	0.870 (0.790–1.00)	1.63 (1.44–1.75)	2.26 (2.12–2.50)	2,578
	2007–2008	0.462 (0.425–0.502)	0.450 (0.400–0.490)	0.820 (0.750–0.960)	1.57 (1.38–1.73)	2.32 (2.00–2.89)	2,634
	2009–2010	NC	0.409 (0.367–0.459)	0.793 (0.691–0.893)	1.43 (1.24–1.67)	2.09 (1.79–2.39)	2,865
Age group							
6–11 years	2003–2004	0.297 (0.246–0.358)	0.276 (0.208–0.347)	0.485 (0.391–0.630)	1.25 (0.667–1.79)	1.79 (1.11–2.61)	286
	2005–2006	0.411 (0.323–0.524)	0.390 (0.290–0.500)	0.710 (0.510–0.960)	1.30 (0.990–2.12)	2.55 (1.38–3.50)	355
	2007–2008	0.393 (0.351–0.440)	0.350 (0.300–0.440)	0.630 (0.540–0.770)	1.15 (0.860–1.50)	1.68 (1.18–2.99)	398
	2009–2010	NC	0.357 (0.306–0.406)	0.632 (0.500–0.750)	1.04 (0.863–1.26)	1.62 (1.19–1.98)	379
12–19 years	2003–2004	0.255 (0.225–0.289)	0.217 (0.196–0.275)	0.464 (0.376–0.535)	1.06 (0.714–1.39)	1.67 (1.13–2.03)	722
	2005–2006	.286 (0.230–0.356)	0.260 (0.200–0.320)	0.500 (0.380–0.660)	1.09 (0.660–1.70)	1.76 (1.11–2.67)	703
	2007–2008	0.284 (0.251–0.320)	0.280 (0.230–0.300)	0.500 (0.400–0.550)	.890 (0.620–1.08)	1.18 (0.980–1.36)	375
	2009–2010	NC	0.226 (0.202–0.287)	0.481 (0.429–0.553)	.917 (0.736–1.18)	1.41 (1.12–1.62)	455
≥20 years	2003–2004	0.508 (0.455–0.566)	0.525 (0.447–0.616)	1.00 (0.875–1.09)	1.76 (1.46–2.11)	2.54 (2.04–3.00)	1,529
	2005–2006	0.503 (0.461–0.549)	0.510 (0.470–0.550)	0.940 (0.850–1.07)	1.69 (1.50–1.86)	2.31 (2.12–2.54)	1,520
	2007–2008	0.507 (0.463–0.555)	0.500 (0.450–0.550)	0.940 (0.810–1.02)	1.69 (1.51–2.01)	2.56 (2.09–3.17)	1,861
	2009–2010	NC	0.454 (0.395–0.517)	0.861 (0.731–0.988)	1.51 (1.29–1.85)	2.15 (1.88–2.57)	2,031
Gender							
Males	2003–2004	0.365 (0.333–0.400)	0.362 (0.309–0.417)	0.696 (0.620–0.784)	1.31 (1.18–1.44)	1.87 (1.51–2.30)	1,266
	2005–2006	0.380 (0.336–0.431)	0.390 (0.330–0.440)	0.740 (0.600–0.890)	1.27 (1.09–1.47)	1.73 (1.62–1.85)	1,270
	2007–2008	0.408 (0.374–0.445)	0.390 (0.350–0.450)	0.730 (0.650–0.810)	1.22 (1.11–1.36)	1.69 (1.54–2.11)	1,326
	2009–2010	NC	0.337 (0.298–0.391)	0.675 (0.585–0.802)	1.19 (1.06–1.29)	1.50 (1.33–1.78)	1,404
Females	2003–2004	0.532 (0.472–0.599)	0.545 (0.455–0.652)	1.06 (0.969–1.21)	1.88 (1.64–2.30)	2.77 (2.12–3.56)	1,271
	2005–2006	0.552 (0.494–0.617)	0.540 (0.490–0.620)	1.09 (0.850–1.27)	1.96 (1.72–2.14)	2.78 (2.35–3.17)	1,308
	2007–2008	0.520 (0.469–0.576)	0.490 (0.460–0.540)	0.960 (0.820–1.11)	1.92 (1.58–2.24)	2.83 (2.24–3.50)	1,308
	2009–2010	NC	0.475 (0.423–0.552)	0.890 (0.771–1.07)	1.81 (1.43–2.09)	2.57 (2.09–2.94)	1,461

Table 5-32. Geometric Mean and Selected Percentiles of Total Mercury Creatinine Corrected Urinary Concentrations (µg/g of Creatinine) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 2003–2010

	Survey years	Geometric mean (95% CI)	Selected percentiles (95% CI)[a]				Sample size
			50th	75th	90th	95th	
Race/ethnicity							
Mexican Americans	2003–2004	0.384 (0.307–0.480)	0.365 (0.280–0.455)	0.768 (0.619–0.990)	1.62 (1.23–2.16)	2.32 (1.78–4.01)	618
	2005–2006	0.425 (0.337–0.536)	0.400 (0.310–0.490)	0.840 (0.560–1.29)	1.82 (1.30–2.47)	2.63 (2.22–3.20)	651
	2007–2008	0.409 (0.350–0.479)	0.380 (0.310–0.480)	0.790 (0.690–0.850)	1.55 (1.08–1.98)	2.03 (1.55–2.70)	514
	2009–2010	NC	0.333 (0.272–0.400)	0.660 (0.494–0.861)	1.29 (1.02–1.54)	1.95 (1.52–2.89)	615
Non-Hispanic blacks	2003–2004	0.343 (0.301–0.391)	0.306 (0.265–0.368)	0.587 (0.522–0.687)	1.28 (0.964–1.63)	2.13 (1.41–2.87)	713
	2005–2006	0.328 (0.285–0.378)	0.320 (0.270–0.370)	0.610 (0.470–0.780)	1.15 (0.930–1.40)	1.64 (1.29–1.96)	691
	2007–2008	0.350 (0.303–0.404)	0.330 (0.280–0.380)	0.590 (0.490–0.690)	1.10 (0.840–1.46)	1.85 (1.13–2.77)	589
	2009–2010	NC	0.317 (0.259–0.393)	0.582 (0.500–0.659)	1.05 (0.900–1.30)	1.55 (1.18–1.96)	546
Non-Hispanic whites	2003–2004	0.463 (0.400–0.537)	0.476 (0.385–0.588)	0.970 (0.800–1.07)	1.67 (1.32–2.11)	2.40 (1.88–2.90)	1,066
	2005–2006	0.475 (0.426–0.531)	0.490 (0.440–0.540)	0.890 (0.820–1.02)	1.61 (1.42–1.75)	2.23 (1.98–2.50)	1,044
	2007–2008	0.481 (0.423–0.546)	0.480 (0.390–0.540)	0.890 (0.750–1.03)	1.58 (1.34–2.02)	2.49 (1.89–3.18)	1,100
	2009–2010	NC	0.434 (0.370–0.500)	0.833 (0.689–1.04)	1.50 (1.26–1.87)	2.12 (1.80–2.64)	1,225

[a]The limits of detection were based on non-creatinine corrected urinary concentrations, which were 0.14, 0.11, 0.08, and 0.08 µg/L for survey years 2003–2004, 2005–2006, 2007–2008, and 2009–2010, respectively.

CI = confidence interval; NC = not calculated (proportion of results below limit of detection was too high to provide a valid result)

Source: CDC 2024

5. POTENTIAL FOR HUMAN EXPOSURE

Table 5-33. Geometric Mean and Selected Percentiles of Total Mercury Creatinine Corrected Urinary Concentrations (µg/g of Creatinine) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 2011–2018

	Survey years	Geometric mean (95% CI)	Selected percentiles (95% CI)[a]				Sample size
			50th	75th	90th	95th	
Total	2011–2012	0.367 (0.333–0.405)	0.353 (0.306–0.394)	0.676 (0.623–0.754)	1.33 (1.13–1.50)	1.75 (1.49–2.32)	2,505
	2013–2014	0.283 (0.260–0.309)	0.270 (0.250–0.290)	0.571 (0.511–0.644)	1.20 (1.05–1.36)	1.61 (1.47–1.81)	2,665
	2015–2016	NC	<LOD	0.356 (0.318–0.391)	0.708 (0.628–0.817)	1.10 (0.912–1.25)	3,077
	2017–2018	NC	<LOD	0.362 (0.327–0.402)	0.683 (0.579–0.761)	0.962 (0.841–1.13)	2,810
Age group							
3–5 years	2015–2016	NC	<LOD	<LOD	0.667 (<LOD–0.818)	0.994 (0.818–1.13)	495
	2017–2018	NC	<LOD	<LOD	0.692 (<LOD–0.818)	0.923 (0.735–1.46)	407
6–11 years	2011–2012	0.345 (0.298–0.398)	0.306 (0.276–0.344)	0.537 (0.441–0.613)	1.08 (0.884–1.43)	1.62 (1.07–2.34)	400
	2013–2014	NC	<LOD	0.429 (0.310–0.529)	0.750 (0.563–0.897)	1.11 (0.713–1.72)	401
	2015–2016	NC	<LOD	<LOD	0.474 (0.409–0.529)	0.643 (0.500–1.00)	380
	2017–2018	NC	<LOD	<LOD	0.529 (0.450–0.745)	0.961 (0.635–1.29)	332
12–19 years	2011–2012	0.246 (0.219–0.277)	0.221 (0.190–0.269)	0.405 (0.368–0.453)	0.735 (0.571–1.11)	1.21 (0.742–1.49)	390
	2013–2014	NC	<LOD	0.257 (0.200–0.281)	0.580 (0.391–0.735)	0.846 (0.580–1.07)	452
	2015–2016	NC	<LOD	0.194 (<LOD–0.220)	0.320 (0.246–0.568)	0.650 (0.385–0.967)	402
	2017–2018	NC	<LOD	0.205 (<LOD–0.500)	0.353 (0.281–0.500)	0.642 (0.353–1.12)	364
≥20 years	2011–2012	0.393 (0.351–0.439)	0.383 (0.330–0.437)	0.750 (0.673–0.805)	1.38 (1.17–1.63)	1.95 (1.50–2.48)	1,715
	2013–2014	0.318 (0.291–0.349)	0.304 (0.281–0.333)	0.644 (0.561–0.741)	1.32 (1.13–1.47)	1.76 (1.50–1.88)	1,812
	2015–2016	NC	0.198 (0.184–0.210)	0.391 (0.349–0.449)	0.776 (0.692–0.886)	1.15 (1.00–1.32)	1,800
	2017–2018	NC	<LOD	0.388 (0.344–0.441)	0.714 (0.563–0.859)	1.00 (0.841–1.32)	1,707
Gender							
Males	2011–2012	0.320 (0.278–0.368)	0.294 (0.267–0.358)	0.558 (0.478–0.667)	1.11 (0.791–1.44)	1.57 (1.21–2.00)	1,259
	2013–2014	0.242 (0.223–0.263)	0.231 (0.206–0.259)	0.476 (0.429–0.542)	0.902 (0.779–1.11)	1.31 (1.13–1.49)	1,318
	2015–2016	NC	<LOD	0.274 (0.246–0.300)	0.563 (0.490–0.628)	0.818 (0.705–0.994)	1,533
	2017–2018	NC	<LOD	0.316 (0.265–0.360)	0.501 (0.433–0.623)	0.692 (0.551–0.948)	1,381
Females	2011–2012	0.418 (0.374–0.466)	0.409 (0.355–0.453)	0.800 (0.706–0.900)	1.46 (1.29–1.65)	2.00 (1.63–2.60)	1,246
	2013–2014	0.330 (0.297–0.367)	0.315 (0.273–0.356)	0.692 (0.600–0.822)	1.44 (1.18–1.68)	1.83 (1.60–2.12)	1,347
	2015–2016	NC	<LOD	0.415 (0.375–0.473)	0.875 (0.750–1.00)	1.30 (1.06–1.86)	1,544
	2017–2018	NC	<LOD	0.429 (0.368–0.482)	0.841 (0.701–0.948)	1.13 (1.00–1.45)	1,429

Table 5-33. Geometric Mean and Selected Percentiles of Total Mercury Creatinine Corrected Urinary Concentrations (μg/g of Creatinine) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 2011–2018

	Survey years	Geometric mean (95% CI)	Selected percentiles (95% CI)[a]				Sample size
			50th	75th	90th	95th	
Race/ethnicity							
Mexican Americans	2011–2012	0.339 (0.288–0.399)	0.286 (0.225–0.393)	0.641 (0.433–0.789)	1.17 (1.00–1.42)	1.70 (1.31–2.24)	317
	2013–2014	0.261 (0.231–0.295)	0.237 (0.209–0.273)	0.516 (0.409–0.709)	1.04 (0.810–1.48)	1.62 (1.11–2.55)	454
	2015–2016	NC	<LOD	0.283 (0.236–0.360)	0.692 (0.530–0.810)	1.04 (0.791–1.30)	585
	2017–2018	NC	<LOD	0.346 (0.257–0.447)	0.788 (0.477–1.22)	1.68 (0.745–4.66)	434
Non-Hispanic blacks	2011–2012	0.280 (0.245–0.320)	0.261 (0.224–0.294)	0.467 (0.411–0.529)	0.896 (0.638–1.14)	1.43 (1.10–1.57)	671
	2013–2014	0.211 (0.169–0.264)	0.202 (0.152–0.269)	0.409 (0.333–0.516)	0.794 (0.643–1.10)	1.34 (0.880–1.52)	580
	2015–2016	NC	0.136 (<LOD–0.163)	0.303 (0.237–0.367)	0.642 (0.450–0.848)	0.901 (0.695–1.18)	674
	2017–2018	NC	<LOD	0.294 (0.225–0.360)	0.616 (0.478–0.762)	0.889 (0.667–1.39)	641
Non-Hispanic whites	2011–2012	0.372 (0.323–0.428)	0.364 (0.294–0.433)	0.700 (0.619–0.805)	1.35 (1.05–1.63)	1.75 (1.41–2.48)	817
	2013–2014	0.295 (0.269–0.323)	0.278 (0.257–0.310)	0.602 (0.516–0.689)	1.27 (1.08–1.45)	1.64 (1.46–1.82)	987
	2015–2016	NC	<LOD	0.349 (0.300–0.400)	0.708 (0.563–0.886)	1.10 (0.827–1.32)	932
	2017–2018	NC	<LOD	0.368 (0.310–0.441)	0.621 (0.514–0.745)	0.867 (0.683–1.09)	918
All Hispanics	2011–2012	0.369 (0.342–0.399)	0.331 (0.283–0.384)	0.674 (0.612–0.772)	1.24 (1.13–1.44)	1.86 (1.47–2.92)	574
	2013–2014	0.267 (0.237–0.300)	0.237 (0.214–0.273)	0.541 (0.448–0.634)	1.07 (0.837–1.36)	1.61 (1.24–1.86)	702
	2015–2016	NC	<LOD	0.348 (0.284–0.408)	0.717 (0.574–0.917)	1.15 (0.948–1.36)	985
	2017–2018	NC	<LOD	0.358 (0.310–0.426)	0.788 (0.605–0.976)	1.17 (0.929–2.25)	675
Asians	2011–2012	0.577 (0.473–0.705)	0.562 (0.467–0.700)	1.16 (0.872–1.44)	1.82 (1.54–2.00)	2.29 (1.90–3.12)	355
	2013–2014	0.488 (0.422–0.565)	0.475 (0.373–0.600)	0.917 (0.779–1.06)	1.88 (1.35–2.19)	2.57 (1.88–4.24)	291
	2015–2016	NC	0.290 (<LOD–0.375)	0.594 (0.457–0.706)	1.02 (0.808–1.22)	1.38 (1.11–1.80)	333
	2017–2018	NC	0.300 (<LOD–0.367)	0.566 (0.474–0.731)	1.05 (0.848–1.45)	1.47 (1.07–1.94)	365

[a]The limits of detection were based on non-creatinine corrected urinary concentrations, which were 0.05, 0.13, 0.13, and 0.13 μg/L for survey years 2011–2012, 2013–2014, 2015–2016, and 2017–2018 respectively.

CI = confidence interval; LOD = limit of detection; NC = not calculated (proportion of results below limit of detection was too high to provide a valid result)

Source: CDC 2024

5.7   POPULATIONS WITH POTENTIALLY HIGH EXPOSURES

In addition to workers exposed to mercury (primarily mercury vapor) in the workplace, other population groups are at risk for potential exposure to high levels of mercury. These include: (1) people who live in proximity to former mercury mining or production sites, secondary production (recycling) facilities, municipal or medical incinerators, or coal-fired power plants; (2) people who consume large amounts of fish or marine mammals (Grandjean et al. 1992); (3) people who have mercury amalgam dental restorations (Mackert and Berglund 1997; Snapp et al. 1989); (4) people who use consumer products containing mercury such as traditional or herbal remedies, or cosmetics, including skin lightening creams (McKelvey et al. 2011); and (5) people who use mercury as part of spiritual practices (Riley et al. 2001).

Mercury levels were measured in air samples at several recycling operations in Brazil (Gouveia et al. 2019). Highest levels tended to be near the recycling piles (0.032 μg/m^3) and conveyer belts (0.032 μg/m^3); however, only 14.5% of the samples had levels above the limit of quantification. People involved in artisanal and small-scale gold mining are potentially exposed to higher levels of mercury than the general population. Total mercury and methylmercury levels in blood, urine, and hair, were monitored from 238 participants with occupational exposure to mercury from ASGM activities in Colombia (Calao-Ramos et al. 2021). The median values of total mercury in blood (3.70 μg/L), urine (4.00 μg/L), and hair (1.37 mg/kg), and methylmercury concentrations in hair (1.47 mg/kg) for the study group were below allowed concentrations set by WHO. The study results did, however, show that 40% of the miners had levels in blood, urine, and/or hair above the WHO thresholds. Burning of amalgam and fish consumption was correlated with the highest mercury levels in biological matrices.

CHAPTER 6. ADEQUACY OF THE DATABASE

Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the Administrator of EPA and agencies and programs of the Public Health Service) to assess whether adequate information on the health effects of mercury is available. Where adequate information is not available, ATSDR, in conjunction with NTP, is required to ensure the initiation of a program of research designed to determine the adverse health effects (and techniques for developing methods to determine such health effects) from exposure to mercury.

Data needs are defined as substance-specific informational needs that, if met, would reduce the uncertainties of human health risk assessment. This definition should not be interpreted to mean that all data needs discussed in this section must be filled. In the future, the identified data needs will be evaluated and prioritized, and a substance-specific research agenda will be proposed.

6.1   INFORMATION ON HEALTH EFFECTS

Studies evaluating the health effects of inhalation, oral, and dermal exposure of humans and animals to mercury that are discussed in Chapter 2 are summarized in Figure 6-1 for elemental mercury, Figure 6-2 for inorganic mercury, Figure 6-3 for organic mercury, and Figure 6-4 for predominant form of mercury exposure unknown in general populations. The purpose of these figures is to illustrate the information concerning the health effects of mercury compounds. The number of human and animal studies examining each endpoint is indicated regardless of whether an effect was found and the quality of the study or studies.

6.2   IDENTIFICATION OF DATA NEEDS

Missing information in Figures 6-1, 6-2, 6-3, and 6-4 should not be interpreted as a "data need." A data need, as defined in ATSDR's *Decision Guide for Identifying Substance-Specific Data Needs Related to Toxicological Profiles* (ATSDR 1989), is substance-specific information necessary to conduct comprehensive public health assessments. Generally, ATSDR defines a data gap more broadly as any substance-specific information missing from the scientific literature.

Figure 6-1. Summary of Existing Health Effects Studies on Elemental Mercury by Route and Endpoint*

The most studied endpoints (in humans & animals) were potential neurological, developmental, and renal effects resulting from inhalation exposure

Inhalation exposure studies in humans comprised the majority of elemental mercury health effects research

Inhalation Studies

Endpoint	Human	Animal
Death	3	4
Body weight	11	
Respiratory	10	8
Cardiovascular	8	
Gastrointestinal	7	
Hematological	2	
Musculoskeletal	—	
Hepatic	1	5
Renal	17	7
Dermal	1	
Ocular	—	
Endocrine	4	
Immunological	7	1
Neurological	72	7
Reproductive	5	5
Developmental	18	11
Other Noncancer	—	
Cancer	—	

Inhalation Route Duration

Acute 15%
Intermediate 10%
Chronic 76%

*Includes studies discussed in Chapter 2; the number of studies include those finding no effect. Most studies examined multiple endpoints. No oral or dermal studies in humans or animals were located.

Figure 6-2. Summary of Existing Health Effects Studies on Inorganic Mercuric Salts by Route and Endpoint*

The most studied endpoints (in humans & animals) were potential hematological, immune, neurological, renal, and cardiac system effects resulting from oral exposure in animals
Oral exposure studies in animals comprised the majority of inorganic mercury health effects research

*Includes studies discussed in Chapter 2; the number of studies include those finding no effect. Most studies examined multiple endpoints. No dermal studies in humans or animals were located.

Figure 6-3. Summary of Existing Health Effects Studies on Organic Mercury by Route and Endpoint*

The most studied endpoints (in humans & animals) were potential developmental, neurological, and body weight effects resulting from oral exposure

Oral exposure studies in humans and animals comprised the majority of inorganic mercury health effects research

*Includes studies discussed in Chapter 2; the number of studies include those finding no effect. Most studies examined multiple endpoints. No inhalation studies in humans or animals were located.

Figure 6-4. Summary of Existing Health Effects Studies on General Population Exposure to Mercury (Unspecified Route and Form)*

The most studied endpoints (in humans) were potential developmental, cardiovascular, and reproductive effects resulting from unknown exposure sources

*Includes studies discussed in Chapter 2; the number of studies include those finding no effect.
Most studies examined multiple endpoints.

Elemental Mercury Inhalation MRLs. A chronic-duration inhalation MRL was developed for elemental mercury based on neurological effects (tremor) in mercury workers. Additional data may provide further definition of the NOAEL-LOAEL boundary.

The acute-duration animal inhalation database identified neurodevelopmental effects as the critical effect in animals. However, the database was not considered adequate for identification of a point of departure. The studies that identified the lowest LOAEL values involved whole-body exposure for relative short daily durations (1 or 4 hours/day) and did not control for potential oral exposure from preening or volatilization of mercury deposited on the skin/fur. Studies limiting the inhalation exposure to nose-only that examine neurodevelopmental endpoints, test multiple concentrations, and are for longer daily durations would be useful for establishing an acute-duration inhalation MRL for elemental mercury.

The available data from animal intermediate-duration inhalation studies suggest that neurodevelopmental toxicity is the most sensitive target of toxicity. However, most of the studies in the database only tested one concentration and were not considered adequate for establishing concentration-response relationships. Additional studies evaluating neurodevelopmental endpoints and testing several concentrations would be useful for developing an intermediate-duration inhalation MRL for elemental mercury.

Elemental Mercury Oral MRLs. No oral MRLs for elemental mercury have been derived for any exposure duration due to lack of data. The primary route of exposure to elemental mercury is inhalation. Oral exposure to elemental mercury is not considered an important route of environmental exposure. Therefore, there is not a data need for elemental mercury and oral exposure.

Inorganic Mercury Salts Inhalation MRLs. No inhalation MRLs for inorganic mercury salts have been derived for any exposure duration due to lack of data. The primary route of exposure to inorganic mercury salts is oral. While inorganic salts can release mercury vapor into the air, inhalation exposure to inorganic mercury compounds is not currently considered an important route of environmental exposure. Therefore, there is not a data need for inorganic mercury compounds and inhalation exposure.

Inorganic Mercury Salts Oral MRLs. Acute- and immediate-duration oral MRLs were derived for inorganic mercury salts based on renal effects in rats (Apaydin et al. 2016; Dieter et al. 1992; NTP 1993). However, data for chronic-duration exposure are insufficient to derive an MRL. For chronic-duration exposure, the lowest LOAEL identified is 0.66 mg Hg/kg/day for increased systolic blood pressure in rats

exposed to mercuric chloride in drinking water for 1 year, with a NOAEL of 0.33 mg Hg/kg/day (Perry and Erlanger 1974). Thus, the lowest chronic-duration LOAEL is 44-fold higher than the lowest intermediate-duration LOAEL of 0.015 mg Hg/kg/day, which was identified in the study used in development of the intermediate-duration oral MRL. Studies examining effects of chronic-duration oral exposure at lower levels, particularly ones evaluating sensitive systems identified in Section 1.2 (neurological and neurodevelopmental, renal, cardiovascular, hematological, immunological, and male reproductive), may provide sufficient data to derive a chronic-duration oral MRL.

Organic Mercury Inhalation MRLs. No inhalation MRLs for organic mercury have been derived for any exposure duration due to lack of data. The primary route of exposure to organic mercury compounds is oral. Inhalation exposure to organic mercury is not considered an important route of environmental exposure. Therefore, there is not a data need for organic mercury compounds and inhalation exposure.

Organic Mercury Oral MRLs. A chronic-duration oral MRL for methylmercury was derived based on a meta-analysis of three epidemiological studies for neurodevelopmental effects. Additional data may lead to more accurate definition of the NOAEL-LOAEL boundary.

No acute- or intermediate-duration oral MRLs were derived for organic mercury compounds. The human database is limited to dietary exposure for chronic-durations. The animal database provides data for acute- and intermediate-duration oral exposure. However, if MRLs were based on available animal data, the acute- and intermediate-duration oral MRLs would be lower than the chronic-duration oral MRLs based on data in humans. Additional studies in animals would provide important information regarding effects of organic mercury at low levels of exposure, but additional animal data would not be useful to derive acute- and intermediate-duration oral MRLs for organic mercury.

Health Effects.

> ***Neurological and Neurodevelopmental.*** The nervous system, including the developing nervous system, is well-established as a sensitive target for all forms of mercury. Epidemiological studies have identified associations between exposure to elemental mercury and neurological effects and between methylmercury exposure and neurodevelopmental effects. Additional studies evaluating neurological and neurodevelopmental effects at low exposures would provide additional data to better define population NOAELs.

The oral database evaluating neurological effects in animals following exposure to inorganic or organic mercury compounds clearly identifies the developing and the adult nervous system as a sensitive target of mercury toxicity. Additional studies conducted at low doses for inorganic mercury compounds would provide additional information to define NOAELs and LOAELs at the low end of the dose-response curve. Evidence for neurological effects in animals following inhalation exposure to elemental mercury is less robust, particularly regarding neuro-developmental effects. Additional inhalation studies in adult and developing animals may better inform dose-response relationships following exposure to mercury vapor.

Renal. The kidney is a well-established target of mercury in humans and animals. Additional epidemiological studies for elemental mercury and organic mercury would provide additional data to define the low end of the dose-response curve for these mercury classes. The renal toxicity of inorganic mercury salts has been well-characterized in animal studies. Additional low-dose, oral studies on inorganic mercury salts in animals would provide important information to define NOAEL and LOAEL values for renal effects.

Cardiovascular. Results of epidemiological studies on populations exposed to elemental mercury and methylmercury do not provide conclusive evidence that the cardiovascular system is a sensitive target in humans exposed to mercury.

Epidemiological studies are inconsistent, with some studies showing an association between biomarkers and cardiovascular effects and other studies showing no associations. Additional study populations exposed to elemental mercury and methylmercury would provide important information to determine if the cardiovascular system is a target of mercury at occupational (elemental mercury) and environmental (general populations and populations with high fish diets) exposure levels.

The majority of animal studies show that oral exposure to mercuric chloride or methylmercury is associated with altered cardiovascular function (increased blood pressure, positive cardiac inotropism, decreased baroreflex sensitivity). Mechanistic studies would help to determine mechanisms of action and human relevance of cardiovascular findings in animals.

Hematological. Few epidemiological studies have evaluated hematological effects of mercury compounds. Although there are plausible mechanisms for mercury to adversely affect

erythrocytes, data from epidemiological studies are insufficient to determine if exposure to mercury produces adverse hematological effects in humans. Additional epidemiological studies on elemental and methylmercury would provide important information to determine if the hematological system is a target of occupational or environmental exposure to mercury.

There is limited evidence of impaired clotting, decreases in RBC parameters, and increases in WBC counts in animals following oral exposure to inorganic mercury salts. However, biological relevance of available findings is unclear due to limited data, small magnitude of effect, and/or inconsistent findings. Additional multi-dose studies of various durations in multiple species are needed to better define potential hematological effects and inform dose-response relationships for inorganic mercury salts. Additional animal studies on hematological effects of elemental and organic mercury compounds could provide information on the potential for hematological effects.

Immunological. Immunological effects of mercury compounds have not been well-investigated in epidemiological studies, and there is currently no clear evidence that elemental or methylmercury is associated with altered immune function. Epidemiological studies of populations exposed to elemental and organic mercury could provide information on potential associations between exposure and immune system function.

Mercury-induced autoimmunity has been reported in autoimmune-susceptible mice following oral exposure to mercuric chloride or methylmercury, including autoimmune-susceptible mice exposed during development. Data in non-susceptible animal strains exposed to methylmercury generally report immune suppression following oral exposure; however, there are limited data suggesting that very low exposure levels may stimulate the immune system. Additional low-dose studies of mercuric chloride or methylmercury in non-susceptible strains may help elucidate potential non-monotonic immune responses associated with mercury exposure. Mechanistic studies would help determine mechanisms of action and human relevance of findings in autoimmune susceptible mice.

Reproductive. Epidemiological studies are available for workers exposed to elemental mercury, populations with high fish diets, and general populations. Few studies have examined the same reproductive endpoints, and those that did often reported conflicting results. The available epidemiological studies do not provide convincing evidence that the reproductive system is a sensitive target of mercury exposure in males or females. Additional epidemiological

studies could provide evidence to determine if reproductive effects are associated with environmental exposures in humans.

Laboratory animal studies evaluating reproductive endpoints following oral exposure to mercuric chloride or methylmercury consistently reported dose-related impairments in fertility. A few inorganic mercuric chloride studies suggest that the male reproductive system may be a sensitive target of toxicity at very low oral doses; however, findings from these studies need to be confirmed with additional low-exposure, multi-dose oral studies reporting quantitative endpoints to better define potential male reproductive effects and inform dose-response relationships.

Developmental. Epidemiological studies have assessed effects in workers exposed to elemental mercury, populations with high fish diets, and general populations. These studies examined mercury exposure and anthropometric measures in newborns (e.g., birth weight and size) and postnatal growth in children. Results are conflicting, with no strong evidence of associations between mercury exposure and *in utero* or postnatal growth. Additional epidemiological studies would provide important information to determine if gestational exposure to elemental or organic mercury alters the developing fetus.

Laboratory animal studies evaluating developmental endpoints following oral exposure to methylmercury reported adverse effects (decreased offspring weight and survival, increased fetal malformations and variations) at concentrations 3–4-fold higher than the lowest LOAELs associated with neurodevelopmental or immunodevelopmental effects. Since the nervous and immune systems appear to be the most sensitive targets during development, additional studies evaluating standard developmental effects are not a high priority.

Epidemiology and Human Dosimetry Studies. Most epidemiology studies of associations between exposure to mercury and health outcomes have relied on biomarkers (blood, hair, urine) as exposure metrics. Use of these studies for estimating risks from exposures to mercury require applications of dosimetry models for converting biomarkers into equivalent exposures. Steady-state mass balance models have been used to convert BHg or HHg levels into equivalent daily average intakes of methylmercury (ATSDR 1997; IRIS 2001). Additional studies would be helpful for addressing uncertainties in key parameters in these models. These include central estimates of population variability for the following parameters, including during pregnancy: (1) fraction of ingested methylmercury absorbed; (2) fraction of mercury body burden in blood; (3) terminal elimination half-time of mercury

from blood; and (4) hair-blood mercury ratio. Steady-state mass-balance models can also be used to convert urinary mercury levels to equivalent exposure concentrations of elemental mercury vapor in air. Additional studies would be helpful for addressing uncertainties in key parameters of these models. These include central estimates and population variability for the following parameters: (1) fraction of inhaled mercury absorbed; (2) fraction of absorbed dose excreted in urine; and (3) relationship between steady-state urinary mercury (µg/g creatinine or µg/L) and urinary excretion rate (µg/day).

Steady-state models can be used for dosimetry extrapolations of exposures that are constant for a period of approximately 1 year, the exposure duration needed to achieve >95% of steady state (Section 3.1). Dosimetry extrapolations for exposures of shorter duration (e.g., acute-duration MRLs) require PBPK models that can reliably predict the kinetics of change in BHg levels prior to achieving steady state. Several pharmacokinetics models of inorganic mercury (mercury vapor, mercuric) in humans have been published (Abass et al. 2018; Farris et al. 2008; Jonsson et al. 1999; Leggett et al. 2001 (Section 3.1.5). Pharmacokinetics models of methylmercury have been developed for humans (Byczkowski and Lipscomb 2001; Carrier et al. 2001a; Gearhart et al. 1995; Young et al. 2001) and a variety of other animal species (Carrier et al. 2001b; Farris et al. 1993; Young et al. 2001). The developing fetus and neonate are highly sensitive to exposures to methylmercury; therefore, predictions of exposures during fetal and postnatal development are potentially valuable for improving dosimetry extrapolations (Byczkowski and Lipscomb 2001; Gearhart et al. 1995). Additional studies that evaluate performance of these models for predicting maternal BHg and HHg levels during pregnancy and fetal (cord) blood levels would be helpful for assessing uncertainty in application of these models to human dosimetry extrapolation.

PBPK models for inorganic mercuric mercury in humans have been developed (Abass et al. 2018; Farris et al. 2008); however, no models are available for use in interspecies dosimetry extrapolation. PBPK models of inorganic mercuric mercury in monkeys, mice, and rats would be helpful for extrapolating external dose-response relationships (e.g., NOAELs, LOAELs) observed in these species to equivalent external doses in humans.

Biomarkers of Exposure and Effect. Epidemiology studies of health effects of mercury have relied on mercury levels in blood and hair as biomarkers of exposure to methylmercury and mercury in urine as a biomarker of exposure to inorganic (elemental or mercuric) mercury (Section 3.3.1, Biomarkers of Exposure). These biomarkers are most useful in studies of populations in which the dominant exposures are to methylmercury (e.g., high fish consumers) or inorganic mercury (e.g., workers exposed to relatively

high levels of mercury vapor). In high fish consumers, most of the mercury in hair and blood will derive from methylmercury, whereas in workers exposed to high levels of mercury vapor, most of the mercury in urine will derive from exposure to mercury vapor. Interpretation of biomarkers measured in general populations that experience relatively low exposures to all forms of mercury is more uncertain because exposure to any form of mercury will contribute mercury to blood, hair, and urine. Additional studies would be helpful for identifying biomarkers of exposure to methylmercury and inorganic mercury (elemental and mercuric) in general populations, to facilitate studies of dose-response relationships at the lower exposure levels expected in these populations.

No biomarkers specific for the health effects of mercury are available. Exposure biomarkers that reflect mercury body burden (mercury levels in blood, hair, urine) are used to attribute signs and symptoms to mercury exposure.

Absorption, Distribution, Metabolism, and Excretion. Mercury toxicokinetics have been extensively studied in humans and animals (Section 3.1, Toxicokinetics). However, additional studies would be helpful for increasing confidence in estimates of certain toxicokinetics parameters that are important in dosimetry models, in particular, conversion of biomarker measurements, such as mercury in blood, hair, or urine, to equivalent exposures (see Epidemiology and Human Dosimetry Studies section above). These include, for all forms of mercury, the absorption fractions for oral and inhalation exposure, fractions of absorbed mercury distributed to blood, and half-time for elimination of mercury from blood.

Comparative Toxicokinetics. Mercury toxicokinetics have been studied in the animal models used to estimate dose-response relationships for methylmercury, elemental mercury vapor, and inorganic mercury compounds (humans, monkeys, mice, rats). Toxicokinetics models of methylmercury for a variety of animal species have been developed (Section 3.1.5). Models of mercury vapor and inorganic mercuric mercury in monkeys, mice, and rats would be helpful for extrapolating external dose-response relationships (e.g., NOAELs, LOAELs) observed in these species to equivalent external doses in humans.

Children's Susceptibility. All forms of mercury are toxic to the developing nervous system and studies conducted in humans and animals suggest that the developing nervous system is more vulnerable than the fully-developed nervous system. Additional epidemiological studies of neurodevelopmental outcomes in populations exposed to low levels of methylmercury (levels experienced in general populations) would be helpful for establishing toxicity thresholds, if they exist. Outcomes of particular interest are attainment of language proficiency, which was found to be inversely associated with mercury

intake from dietary fish in a large general population prospective study (Vejrup et al. 2016, 2018), but was not studied in two other important prospective studies of high fish consumers who experienced higher exposures to methylmercury (Faroe Islands, Seychelle Islands).

Physical and Chemical Properties. The physical and chemical properties of metallic mercury and its inorganic and organic compounds have been well characterized to permit estimation of their environmental fate (Budavari 1989; Lewis 1993; Osol 1980; Spencer and Voigt 1968; Verschueren 1983; Weast 1988; Weiss 1986). Most values are available for the log K_{ow}, log K_{oc}, Henry's law constant, vapor pressure, and solubility in water. Experimental data exist that allow characterization of the environmental fate of metallic mercury and inorganic and organic mercury compounds in a variety of environmental media. No data needs are identified.

Production, Import/Export, Use, Release, and Disposal. Information on mercury production, import/export, and use are well documented (EPA 2020b, 2023; USGS 2020, 2023a).

Information on disposal methods and recycling of mercury and mercury containing wastes are available (DOI 1985, 1989, 1993).

One area that requires additional study is the use of elemental mercury by members of specific religious or cultural groups in their ceremonies, rituals, and practices so an assessment of the magnitude of these activities can be made. In addition, information on how mercury is used in these ceremonies and rituals, as well as the methods of mercury disposal used, would be helpful in assessing the potential pathways for human exposure and environmental releases.

Environmental Fate. Mercury released to the atmosphere may be transported long distances before being removed by wet or dry deposition. Residence time in the atmosphere has been estimated to range from 60–90 days to 0.3–2 years (EPA 1984; Glass et al. 1991). Volatile forms of mercury released in water or soil can enter the atmosphere, but most mercury is adsorbed to soil and sediment (EPA 1984; Meili et al. 1991). Sorbed mercury may be reduced to elemental mercury or bioconverted to volatile organic forms (EPA 1984). The major transport and transformation processes involved in the environmental fate of mercury have been fairly well defined; the most important fate process for human exposure, bioaccumulation of methylmercury in aquatic food chains is also well defined (EPA 1979, 1984; Stein et al. 1996; UNEP 2018). Additional information on mercury transport and flux in waterbodies and in tropical environments, in general, would be helpful.

Bioavailability from Environmental Media. Metallic mercury vapors in the air are readily absorbed through the lungs following inhalation exposure, while inorganic and organic mercury compounds are poorly absorbed via this route (Berlin et al. 1969a). Gastrointestinal absorption of methylmercury is nearly 100%, while gastrointestinal absorption of inorganic mercury is low (typically <10%) (Clarkson 1989; Friberg and Nordberg 1973). Metallic mercury vapor can be absorbed following dermal exposure; however, dermal absorption of the vapor accounts for a much smaller percentage (2.6% of the total absorbed through the lungs) than absorption through the inhalation route (Hursh et al. 1989). Toxicokinetic data indicate that inorganic mercury salts and organomercury compounds are dermally absorbed to some extent (Friberg et al. 1961; Moody et al. 2009; Sartorelli et al. 2003; Skowronski et al. 2000); however, certain organomercury compounds (dimethylmercury, phenylmercury) are readily absorbed through the skin (Blayney et al. 1997; Gotelli et al. 1985; Nierenberg et al. 1998; Siegler et al. 1999; Toribara et al. 1997). Data are needed regarding the bioavailability of elemental, inorganic, and organic mercury forms from contaminated surface water, groundwater, soil, or plant material. Data are also needed regarding the bioavailability of mercuric chloride in air because of the possibility of inhalation of volatilized mercuric chloride near emission sources. Additional data on the bioavailability of elemental mercury, inorganic mercury compounds, and organic mercury compounds (specifically, methylmercury) in soil would also be useful in assessing the risks from dermal and oral exposures at mining, industrial, or hazardous waste sites.

Food Chain Bioaccumulation. Mercury is known to bioconcentrate in aquatic organisms and biomagnify in aquatic food chains (ASTER 1997; EPA 1984; Kohler et al. 1990; Watras and Bloom 1992; UNEP 2018). While bioconcentration in the aquatic food chain is well studied, little is known about the bioaccumulation potential for terrestrial food chains, although it appears to be smaller than in aquatic systems (Lindqvist et al. 1991). Additional information on the potential for terrestrial food chain biomagnification would be useful since mercury binds to organic matter in soils and sediment. Information on foliar uptake of mercury and of plant/mercury chemistry is needed to determine whether plants convert elemental or divalent mercury into other forms of mercury that are more readily bioaccumulated and whether plants are able to emit these different forms to the air. Additional information is also needed to improve biotransfer factors for mercury from soil to plants to animals.

Exposure Levels in Environmental Media. Environmental monitoring data are available for mercury in ambient air, surface water, groundwater, drinking water, soils, sediments, and foodstuffs

(Section 3.3.1 for citations); however, additional monitoring data on mercury levels in all environmental media, particularly drinking water, would be helpful in determining current exposure levels.

Estimates of human intake from inhalation of ambient air and ingestion of contaminated foods and drinking water are available (Burger et al. 1992), although the estimates may be based on specific intake scenarios (e.g., information is most extensive for fish and other seafood products). Better estimates of fish consumption rates for high-volume consumers (subsistence fishers) and recreational fishers are needed, as is information on fish-specific consumption rates by these populations.

Additional information on the levels of mercury in foods other than fish and seafood would be very useful in determining total dietary intakes. Additional research is needed to characterize mercury exposures via consumption of marine mammal species. Available data indicate that the ratio of methylmercury to total mercury varies within tissues, and that only a small portion of mercury is methylated in the marine mammal liver. Also, other trace metal constituents of marine mammal tissues such as selenium, cadmium, and other metals may interact with and influence the bioavailability of mercury. Additional studies are needed to understand why the relatively high concentrations of mercury measured in marine mammal tissues do not appear to result in elevation of HHg levels among Alaskan natives that consume marine mammal tissues.

Reliable monitoring data for the levels of mercury in contaminated media at hazardous waste sites are needed so that the information obtained on levels of mercury in the environment can be used in combination with the known body burden of mercury to assess the potential risk of adverse health effects in populations living in the vicinity of hazardous waste sites.

Exposure Levels in Humans. Mercury has been measured in human blood, hair, breast milk, urine, feces, and saliva (Section 3.3.1). Continued biomonitoring data are needed to determine the temporal trends of mercury exposure to the U.S. population and for integrating these data into existing health information systems.

Exposures of Children. Children are exposed to mercury by a variety of exposure pathways depending on their age. The most important pathways appear to be ingestion of methylmercury in foods, primarily fish and shellfish (FDA 2017a), intake of inorganic mercury associated with dental amalgams in children up to 18 years old, and inhalation of metallic mercury vapors. These are the same important pathways of exposure for adults as well. Nursing infants can also be exposed to mercury in breastmilk.

More data are needed on the levels of mercury exposure in nursing women from inhalation of metallic mercury in occupational or domestic situations, including religious and ethnic uses (ATSDR 1997; Riley et al. 2006; Wendroff 1990, 1991; Zayas and Ozuah 1996); from use of commercial or hobby arts and crafts (Grabo 1997; Rastogi and Pritzl 1996); from mercury-containing herbal remedies, cosmetics, and prescription drugs (Al-Saleh and Al-Doush 1997; Espinoza et al. 1996; Lauwerys et al. 1987; Perharic et al. 1994; Washam 2011); and from consumption of mercury-contaminated fish and wildlife, including marine mammals (ADPH 1998; CRITFC 1994; Oskarsson et al. 1996).

6.3   ONGOING STUDIES

There are numerous ongoing studies supported by the National Institutes of Health (NIH) evaluating the potential adverse effects of mercury exposure in humans and laboratory animals, as well as underlying mechanisms of toxicity (Table 6-1) (RePORTER 2024). Most ongoing human studies are focused on neurodevelopmental endpoints, while most ongoing animal studies are focused on autoimmune effects.

Table 6-1. Ongoing Studies on Mercury Sponsored by the National Institutes of Health (NIH)

Investigator	Affiliation	Research description	Sponsor
Human studies			
Andres Cardenas	University of California Berkeley	Prenatal and postnatal exposure to environmental mixtures: neurodevelopment and DNA methylation biomarkers	NIEHS
Celia Chen	Dartmouth College	Sources and protracted effects of early life exposure to arsenic and mercury	NIEHS
Danielle Fallin	Johns Hopkins University	Prenatal exposure to metals and risk for autism spectrum disorder in MARBLES and EARLI	NIEHS
Ka He	Columbia University Health Sciences	Trace mineral levels, metabolomics, and diabetes risk	NIDDK
Irva Hertz-Picciotto	University of California at Davis	The CHARGE Study: Childhood Autism Risks from Genetics and the Environment	NIEHS
Sek Won Kong	Boston Children's Hospital	An environment-wide association study in autism spectrum disorders using novel bioinformatics methods and metabolomics via mass spectrometry	NIMH
Jonathan Levy	Boston University Medical Campus	Assessing the relation of chemical and non-chemical stressors with risk-taking behavior and related outcomes among adolescents living near the New Bedford Harbor Superfund Site	NIEHS
Simin Liu	Brown University	Environmental heavy metals and risk of ischemic heart disease and stroke in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil)	NIEHS

Table 6-1. Ongoing Studies on Mercury Sponsored by the National Institutes of Health (NIH)

Investigator	Affiliation	Research description	Sponsor
Mohammad Rahbar	University of Texas Health Science Center Houston	Epidemiological research on autism in Jamaica, Phase II	NIEHS
Sarah Rothenberg	Oregon State University	Exploratory use of stable mercury isotopes to distinguish dietary sources of methylmercury and their relation to neurodevelopment	NIEHS
Alison Sanders	Icahn School of Medicine at Mount Sinai	Children's exposure to metals, micro RNAs and biomarkers of renal health	NIEHS
Dale Sandler	NIEHS	Environmental and genetic risk factors for breast cancer: the sister study	NIEHS
James Saunders	Dartmouth-Hitchcock Clinic	Central auditory processing abnormalities as an indicator of pediatric heavy metal neurotoxicity	NIDCD
Mary Ellen Turyk	University of Illinois at Chicago	Endocrine disruption by perfluoroalkyl substances and mercury	NIEHS
Edwin van Wijngaarden	University of Rochester	Factors modifying the toxicity of methylmercury in a fish-eating population	NIEHS
Edwin van Wijngaarden	University of Rochester	Leveraging investments in the Seychelles Child Development Study to enable novel investigations of long-term methylmercury exposure, toxicity mechanisms, and health across the life course	NIEHS
Guoying Wang	Johns Hopkins University	*In utero* exposure to metals and vitamin b on placenta and child cardiometabolic outcomes	NIEHS
Xiaobin Wang	Johns Hopkins University	Maternal exposure to low level mercury, metabolome, and child cardiometabolic risk in multi-ethnic prospective birth cohorts	NIEHS
Ganesa Rebecca Wegienka	Henry Ford Health System	Environmental risk factors for uterine fibroids: a prospective ultrasound study	NIEHS
Clarice Weinberg	NIEHS	The Two Sister Study (breast cancer)	NIEHS
Alexandra White	NIEHS	Environment and cancer epidemiology	NIEHS
Tongzhang Zheng	Brown University	A nested case-control study of exposure to toxic metals, essential metals and their interaction on the risk of Type 2 diabetes	NIEHS
Wilco Zijlmans	Academisch Ziekenhuis Paramaribo	Neurotoxicant exposures: impact on maternal and child health in Suriname	FIC
Animal toxicity studies (some with associated mechanistic studies)			
William Atchison	Michigan State University	Environmental metals, excitotoxicity, and ALS (methylmercury)	NIEHS
David Lawrence	Wadsworth Center	Prenatal environmental toxicants induce neuroinflammation causing autistic behaviors (mercuric chloride)	NIEHS

Table 6-1. Ongoing Studies on Mercury Sponsored by the National Institutes of Health (NIH)

Investigator	Affiliation	Research description	Sponsor
Kenneth Michael Pollard	Scripts Research Institute	The effect of age on xenobiotic-induced autoimmunity (mercuric chloride)	NIEHS
Kenneth Michael Pollard	Scripts Research Institute	Do xenobiotics exacerbate idiopathic autoimmunity	NIEHS
Kenneth Michael Pollard	Scripts Research Institute	Modeling xenobiotic-induced autoimmunity using collaborative cross strains (mercuric chloride)	NIEHS
Allen Rosenspire	Wayne State University	Understanding the connection between exposure to mercury, autoimmunity, and tolerance in B cells	NIEHS
Mechanistic studies			
Michael Aschner	Albert Einstein College of Medicine	Mechanisms of methylmercury induced neuronal toxicity	NIEHS
Christy Bridges	Mercer University Macon	Uptake of mercury at the basolateral membrane of isolated proximal tubules	NIEHS
Lawrence Lash	Wayne State University	Mitochondrial and cellular biomarkers of renal injury from environmental and therapeutic agents	NIEHS
Stuart Macdonald	University of Kansas Lawrence	Toxicogenomics of metal response in genetically-variable *Drosophila* populations	NIEHS
Joel Newman Meyer	Duke University	Exposure to mitochondrial toxicants during germ cell development result in lifeline alterations in mitochondrial function mediated by epigenetic changes (methylmercury)	NIEHS
Mathew Pitts	University of Hawaii at Manoa	Mechanisms of neurotoxicity and interactions with selenium	NIEHS
Kenneth Pollard	The Scripps Research Institute	Mechanisms of mercury-induced autoimmunity	NIEHS
Matthew Rand	University of Rochester	Mechanisms of methylmercury toxicity in neuromuscular development	NIEHS
Caren Weinhouse	Oregon Health & Science University	Understanding the causes of DNA methylation response to methylmercury: a novel approach to quantify genetic, environmental, and stochastic factors	NIEHS
Toxicokinetics			
Matthew Rand	University of Rochester	Microbial mechanisms of methylmercury metabolism in humans	NIEHS

Table 6-1. Ongoing Studies on Mercury Sponsored by the National Institutes of Health (NIH)

Investigator	Affiliation	Research description	Sponsor
Biomarkers			
Joe Schwartz	Harvard School of Public Health	Air particulate, metals, and cognitive performance in aging cohort-roles of circulating extracellular vesicles and non-coding RNAs	NIEHS

ALS = Amyotrophic lateral sclerosis; DNA = deoxyribonucleic acid; EARLI = Early Autism Risk Longitudinal Investigation; FIC = Fogarty International Center; MARBLES = Markers of Autism Risk in Babies-Learning Early Signs; NIDDK = National Institute of Diabetes and Digestive and Kidney Diseases; NIDCD = National Institute on Deafness and Other Communication Disorders; NIEHS = National Institute of Environmental Health Sciences; NIMH = National Institute of Mental Health; RNA = ribonucleic acid

Source: RePORTER 2024

CHAPTER 7. REGULATIONS AND GUIDELINES

Pertinent international and national regulations, advisories, and guidelines regarding mercury in air, water, and other media are summarized in Table 7-1. This table is not an exhaustive list, and current regulations should be verified by the appropriate regulatory agency.

ATSDR develops MRLs, which are substance-specific guidelines intended to serve as screening levels by ATSDR health assessors and other responders to identify contaminants and potential health effects that may be of concern at hazardous waste sites. See Section 1.3 and Appendix A for detailed information on the MRLs for mercury.

Table 7-1. Regulations and Guidelines Applicable to Mercury (Hg)

Agency	Description	Information	Reference
Air			
EPA	RfC		IRIS 1995a
	Mercury, elemental	$3x10^{-4}$ mg/m^3 (0.00004 ppm)	
WHO	Air quality guidelines		WHO 2000
	Mercury vapor	1 µg/m^3 annual average (0.0001 ppm)	
Water & Food			
EPA	Drinking water standards and health advisories		EPA 2018a
	Mercury, inorganic		
	1-Day health advisory (10-kg child)	0.002 mg/L	
	10-Day health advisory (10-kg child)	0.002 mg/L	
	DWEL	0.01 mg/L	
	Lifetime health advisory	0.002 mg/L	
	National primary drinking water regulations	No data	EPA 2009
	Mercury, inorganic		
	MCL	0.002 mg/L	
	RfD		
	Mercuric chloride	$3x10^{-4}$ mg/kg/day	IRIS 1995b
	Methylmercury	$1x10^{-4}$ mg/kg/day	IRIS 2001
	Phenylmercuric acetate	$8x10^{-5}$ mg/kg/day	IRIS 1987
WHO	Drinking water quality guidelines		WHO 2022
	Mercury, inorganic		
	Guideline value	0.006 mg/L	
	TDI	2 µg/kg body weight	

Table 7-1. Regulations and Guidelines Applicable to Mercury (Hg)

Agency	Description	Information	Reference
	Provisional tolerable weekly intake		
	Mercury, inorganic	4 µg/kg body weight	WHO 2011
	Methylmercury	1.6 µg/kg body weight	WHO 2007
FDA	Substances added to food[a]	No data	FDA 2023
	Action level in human food and animal feed		
	Mercury		FDA 2018a
	Wheat (pink kernels only)	1 ppm on pink kernels and an average of 10 or more pink kernels/500 g	
	Methylmercury (as Hg)		FDA 2018b
	Fish, shellfish, crustaceans, other aquatic animals (fresh, frozen, or processed)	1 ppm in edible portion	
	Allowable level in bottled water		
	Mercury	0.002 mg/L	FDA 2017b
Cancer			
HHS	Carcinogenicity classification	Not evaluated	NTP 2021
EPA	Carcinogenicity classification		
	Mercury, elemental	D[b]	IRIS 1995a
	Mercuric chloride	C[c]	IRIS 1995b
	Methylmercury	C[c]	IRIS 2001
IARC	Carcinogenicity classification		IARC 1993
	Mercury and inorganic mercury compounds	Group 3[d]	
	Methylmercury compounds	Group 2B[e]	
Occupational			
OSHA	PEL (8-hour TWA) for general industry, shipyards, and construction		OSHA 2005, 2021a, 2021b, 2021c
	Mercury, except (organo) alkyl compounds (as Hg)	1 mg/10 m³ (0.1 mg/m³)[f]	
	Mercury (organo) alkyl compounds	0.01 mg/m³ [f]	
	PEL (ceiling) for general industry		
	Mercury (organo) alkyl compounds	0.04 mg/m³ [f]	
NIOSH	REL (up to 10-hour TWA)		
	Mercury vapor	0.05 mg/m³ [f]	NIOSH 2019a
	Mercury (organo) alkyl compounds (as Hg)	0.01 mg/m³ [f]	NIOSH 2019b
	REL (ceiling)		
	Mercury compounds except (organo) alkyls (as Hg)	0.1 mg/m³ [f]	NIOSH 2019a
	STEL[g]		
	Mercury (organo) alkyl compounds (as Hg)	0.03 mg/m³ [f]	NIOSH 2019b

Table 7-1. Regulations and Guidelines Applicable to Mercury (Hg)

Agency	Description	Information	Reference
	IDLH		
	Mercury compounds except (organo) alkyls (as Hg)	10 mg/m^3	NIOSH 1994a
	Mercury (organo) alkyl compounds (as Hg)	2 mg/m^3	NIOSH 1994b
	Emergency Criteria		
EPA	AEGLs-air		EPA 2018b
	Mercury vapor		
	AEGL 1[h]	Not recommended	
	AEGL 2[h]		
	10-minute	3.1 mg/m^3	
	30-minute	2.1 mg/m^3	
	60-minute	1.7 mg/m^3	
	4-hour	0.67 mg/m^3	
	8-hour	0.33 mg/m^3	
	AEGL 3[h]		
	10-minute	16 mg/m^3	
	30-minute	11 mg/m^3	
	60-minute	8.9 mg/m^3	
	4-hour	2.2 mg/m^3	
	8-hour	2.2 mg/m^3	
DOE	PACs-air		DOE 2018a
	Mercury vapor		
	PAC-1[i]	0.15 mg/m^3	
	PAC-2[i]	1.7 mg/m^3	
	PAC-3[i]	8.9 mg/m^3	
	Mercury(II) chloride		
	PAC-1[i]	0.1 mg/m^3	
	PAC-2[i]	0.14 mg/m^3	
	PAC-3[i]	38 mg/m^3	
	Mercury(I) chloride		
	PAC-1[i]	0.088 mg/m^3	
	PAC-2[i]	0.12 mg/m^3	
	PAC-3[i]	33 mg/m^3	
	Mercuric acetate		
	PAC-1[i]	0.048 mg/m^3	
	PAC-2[i]	0.64 mg/m^3	
	PAC-3[i]	3.2 mg/m^3	
	Dimethylmercury		
	PAC-1[i]	0.034 mg/m^3	
	PAC-2[i]	0.046 mg/m^3	
	PAC-3[i]	2.3 mg/m^3	

Table 7-1. Regulations and Guidelines Applicable to Mercury (Hg)

Agency	Description	Information	Reference
	Phenylmercury acetate		
	PAC-1[i]	2 mg/m^3	
	PAC-2[i]	22 mg/m^3	
	PAC-3[i]	47 mg/m^3	
	Methylmercury		
	PAC-1[i]	0.032 mg/m^3	
	PAC-2[i]	0.043 mg/m^3	
	PAC-3[i]	2.1 mg/m^3	

[a]The Substances Added to Food inventory replaces EAFUS and contains the following types of ingredients: food and color additives listed in FDA regulations, flavoring substances evaluated by FEMA or JECFA, GRAS substances listed in FDA regulations, substances approved for specific uses in food prior to September 6, 1958, substances that are listed in FDA regulations as prohibited from use in food, delisted color additives, and some substances "no longer FEMA GRAS".
[b]D: not classifiable as to human carcinogenicity.
[c]C: possible human carcinogen.
[d]Group 3: not classifiable as to its carcinogenicity to humans.
[e]Group 2B: possibly carcinogenic to humans.
[f]Skin notation.
[g]Short-term exposure limit, a 15-minute TWA exposure that should not be exceeded at any time during a workday.
[h]Definitions of AEGL terminology are available from EPA (2018c).
[i]Definitions of PAC terminology are available from DOE (2018b).

AEGL = acute exposure guideline levels; DOE = Department of Energy; DWEL = drinking water equivalent level; EAFUS = Everything Added to Food in the United States; EPA = U.S. Environmental Protection Agency; FDA = Food and Drug Administration; FEMA = Flavor and Extract Manufacturers Association of the United States; GRAS = generally recognized as safe; HHS = Department of Health and Human Services; IARC = International Agency for Research on Cancer; IDLH = immediately dangerous to life or health; IRIS = Integrated Risk Information System; JECFA = Joint FAO/WHO Expert Committee on Food Additives; MCL = maximum contaminant level; NIOSH = National Institute for Occupational Safety and Health; NTP = National Toxicology Program; OSHA = Occupational Safety and Health Administration; PAC = protective action criteria; PEL = permissible exposure limit; REL = recommended exposure limit; RfC = inhalation reference concentration; RfD = oral reference dose; STEL = short-term exposure limit; TDI = tolerable daily intake; TWA = time-weighted average; WHO = World Health Organization

CHAPTER 8. REFERENCES

Aaseth J, Wallace DR, Vejrup K, et al. 2020. Methylmercury and developmental neurotoxicity: A global concern. Curr Opin Toxicol 19:80-87. https://doi.org/10.1016/j.cotox.2020.01.005.

Abass K, Huusko A, Knutsen HK, et al. 2018. Quantitative estimation of mercury intake by toxicokinetic modelling based on total mercury levels in humans. Environ Int 114:1-11. https://doi.org/10.1016/j.envint.2018.02.028.

Abd El-Aziz GS, El-Fark MM, Saleh HA. 2012. The prenatal toxic effect of methylmercury on the development of the appendicular skeleton of rat fetuses and the protective role of vitamin E. Anat Rec 295(6):939-949. https://doi.org/10.1002/ar.22485.

Aberg B, Ekman L, Falk R, et al. 1969. Metabolism of methyl mercury (^{203}Hg) compounds in man. Arch Environ Health 19(4):478-484.

Abiko Y, Katayama Y, Zhao W, et al. 2021. The fate of methylmercury through the formation of bismethylmercury sulfide as an intermediate in mice. Sci Rep 11(1):17598. https://doi.org/10.1038/s41598-021-96579-y.

ADFG. 1976. Environmental contaminants and parasites in polar bears. Juneau, AK: Alaska Department of Fish and Game. http://www.adfg.alaska.gov/static/home/library/pdfs/wildlife/research_pdfs/76_pbear_contam_lentfer.pdf. January 13, 2021.

ADPH. 1998. The use of traditional foods in a healthy diet in Alaska. Anchorage, AK: Alaska Division of Public Health. http://www.epi.alaska.gov/bulletins/docs/rr1998_01.pdf. January 13, 2021.

af Geijersstam E, Sandborgh-Englund G, Jonsson F, et al. 2001. Mercury uptake and kinetics after ingestion of dental amalgam. J Dent Res 80(9):1793-1796. https://doi.org/10.1177/00220345010800090401.

Afrifa J, Essien-Baidoo S, Ephraim RKD, et al. 2017. Reduced eGFR, elevated urine protein and low level of personal protective equipment compliance among artisanal small scale gold miners at Bibiani-Ghana: a cross-sectional study. BMC Public Health 17(1):601. https://doi.org/10.1186/s12889-017-4517-z.

Afrifa J, Ogbordjor WD, Duku-Takyi R. 2018. Variation in thyroid hormone levels is associated with elevated blood mercury levels among artisanal small-scale miners in Ghana. PLoS ONE 13(8):e0203335. https://doi.org/10.1371/journal.pone.0203335.

Agrawal R, Chansouria JP. 1989. Chronic effects of mercuric chloride ingestion on rat adrenocortical function. Bull Environ Contam Toxicol 43(3):481-484. https://doi.org/10.1007/BF01701886.

Agrawal S, Flora G, Bhatnagar P, et al. 2014. Comparative oxidative stress, metallothionein induction and organ toxicity following chronic exposure to arsenic, lead and mercury in rats. Cell Mol Biol (Noisy-le-grand) 60(2):13-21.

Aguilar A, Borrell A. 1995. Pollution and harbour porpoises in the Eastern North Atlantic: A review. In: Biology of the phocoenids: A collection of papers. Report of the International Whaling Commission, Special issue 16. Cambridge: International Whaling Commission, 231-242.

Ahlqwist M, Bengtsson C, Lapidus L, et al. 1999. Serum mercury concentration in relation to survival, symptoms, and diseases: Results from the prospective population study of women in Gothenburg, Sweden. Acta Odontol Scand 57(3):168-174. https://doi.org/10.1080/000163599428913.

Ahmad S, Qureshi IH. 1989. Fast mercury removal from industrial effluent. J Radioanal Nucl Chem 130(2):347-352. https://doi.org/10.1007/bf02041354.

Ahmad S, Mahmood R. 2019. Mercury chloride toxicity in human erythrocytes: enhanced generation of ROS and RNS, hemoglobin oxidation, impaired antioxidant power, and inhibition of plasma membrane redox system. Environ Sci Pollut Res Int 26(6):5645-5657. https://doi.org/10.1007/s11356-018-04062-5.

8. REFERENCES

Ai CE, Li CJ, Tsou MC, et al. 2019. Blood and seminal plasma mercury levels and predatory fish intake in relation to low semen quality. Environ Sci Pollut Res Int 26(19):19425-19433. https://doi.org/10.1007/s11356-019-04592-6.

Airaksinen R, Turunen AW, Rantakokko P, et al. 2011. Blood concentration of methylmercury in relation to food consumption. Public Health Nutr 14(3):480-489. https://doi.org/10.1017/s1368980010001485.

Akagi H, Malm O, Branches F, et al. 1995. Human exposure to mercury due to goldmining in the Tapajos River Basin, Amazon, Brazil: Speciation of mercury in human hair, blood and urine. Water Air Soil Pollut 80(1-4):85-94.

Akerstrom M, Barregard L, Lundh T, et al. 2017. Relationship between mercury in kidney, blood, and urine in environmentally exposed individuals, and implications for biomonitoring. Toxicol Appl Pharmacol 320:17-25. https://doi.org/10.1016/j.taap.2017.02.007.

Albasher G, Alkahtani S, Alarifi S. 2020. Berberine mitigates oxidative damage associated with testicular impairment following mercury chloride intoxication. J Food Biochem 44(9):e13385. https://doi.org/10.1111/jfbc.13385.

Al-Batanony MA, Abdel-Rasul GM, Abu-Salem MA, et al. 2013. Occupational exposure to mercury among workers in a fluorescent lamp factory, Quisna Industrial Zone, Egypt. Int J Occup Environ Med 4(3):149-156.

Albers JW, Cavender GD, Levine SP, et al. 1982. Asymptomatic sensorimotor polyneuropathy in workers exposed to elemental mercury. Neurology 32(10):1168-1174. https://doi.org/10.1212/wnl.32.10.1168.

Albers JW, Kallenbach LR, Fine LJ, et al. 1988. Neurological abnormalities associated with remote occupational elemental mercury exposure. Ann Neurol 24(5):651-659. https://doi.org/10.1002/ana.410240510.

Albert I, Villeret G, Paris A, et al. 2010. Integrating variability in half-lives and dietary intakes to predict mercury concentration in hair. Regul Toxicol Pharmacol 58(3):482-489. https://doi.org/10.1016/j.yrtph.2010.08.020.

Albores-Garcia D, Acosta-Saavedra LC, Hernandez AJ, et al. 2016. Early developmental low-dose methylmercury exposure alters learning and memory in periadolescent but not young adult rats. BioMed Res Int 2016:6532108. https://doi.org/10.1155/2016/6532108.

Alfthan GV. 1997. Toenail mercury concentration as a biomarker of methylmercury exposure. Biomarkers 2(4):233-238. https://doi.org/10.1080/135475097231607.

Algahtani MM, Ahmad SF, Alkharashi LA, et al. 2023. Exposure to methylmercury at juvenile stage worsens autism-like symptoms in adult BTBR T+tf/J mice due to lack of nuclear factor erythroid 2-related factor 2 signaling upregulation in periphery and brain. Toxics 11(6):546. https://doi.org/10.3390/toxics11060546.

Ali Z, Ulrik CS. 2013. Obesity and asthma: A coincidence or a causal relationship? A systematic review. Respir Med 107(9):1287-1300. https://doi.org/10.1016/j.rmed.2013.03.019.

Aligne CA, Auinger P, Byrd RS, et al. 2000. Risk factors for pediatric asthma. Am J Respir Crit Care Med 162(3):873-877. https://doi.org/10.1164/ajrccm.162.3.9908085.

Allard B, Arsenie I. 1991. Abiotic reduction of mercury by humic substances in aquatic system: An important process for the mercury cycle. Water Air Soil Pollut 56(0):457-464.

Allen BC, Hack CE, Clewell HJ. 2007. Use of Markov Chain Monte Carlo analysis with a physiologically-based pharmacokinetic model of methylmercury to estimate exposures in US women of childbearing age. Risk Anal 27(4):947-959. https://doi.org/10.1111/j.1539-6924.2007.00934.x.

Al-Mazroua HA, Nadeem A, Ansari MA, et al. 2022. Methylmercury chloride exposure exacerbates existing neurobehavioral and immune dysfunctions in the BTBR T(+) Itpr3(tf)/J mouse model of autism. Immunol Lett 244:19-27. https://doi.org/10.1016/j.imlet.2022.03.001.

Al-Mufti AW, Copplestone JF, Kazantzis G, et al. 1976. Epidemiology of organomercury poisoning in Iraq. I. Incidence in a defined area and relationship to the eating of contaminated bread. Bull World Health Organ 53(Suppl):23-36.

8. REFERENCES

Al-Saleh I, Al-Doush I. 1997. Mercury content in skin-lightening creams and potential hazards to the health of Saudi women. J Toxicol Environ Health 51(2):123-130. https://doi.org/10.1080/00984109708984016.

Al-Saleh I, Shinwari N, Mashhour A, et al. 2006. Cadmium and mercury levels in Saudi women and its possible relationship with hypertension. Biol Trace Elem Res 112(1):13-29. https://doi.org/10.1385/bter:112:1:13.

Al-Saleh I, Shinwari N, Mashhour A, et al. 2011. Heavy metals (lead, cadmium and mercury) in maternal, cord blood and placenta of healthy women. Int J Hyg Environ Health 214(2):79-101. https://doi.org/10.1016/j.ijheh.2010.10.001.

Al-Saleh I, Al-Sedairi A, Elkhatib R. 2012. Effect of mercury (Hg) dental amalgam fillings on renal and oxidative stress biomarkers in children. Sci Total Environ 431:188-196. https://doi.org/10.1016/j.scitotenv.2012.05.036.

Al-Saleh I, Abduljabbar M, Al-Rouqi R, et al. 2013. Mercury (Hg) exposure in breast-fed infants and their mothers and the evidence of oxidative stress. Biol Trace Elem Res 153(1-3):145-154. https://doi.org/10.1007/s12011-013-9687-7.

Al-Saleh I, Shinwari N, Mashhour A, et al. 2014. Birth outcome measures and maternal exposure to heavy metals (lead, cadmium and mercury) in Saudi Arabian population. Int J Hyg Environ Health 217(2-3):205-218. https://doi.org/10.1016/j.ijheh.2013.04.009.

Al-Saleh I, Nester M, Abduljabbar M, et al. 2016. Mercury (Hg) exposure and its effects on Saudi breastfed infant's neurodevelopment. Int J Hyg Environ Health 219(1):129-141. https://doi.org/10.1016/j.ijheh.2015.10.002.

Al-Saleh I, Al-Rouqi R, Elkhatib R, et al. 2017. Risk assessment of environmental exposure to heavy metals in mothers and their respective infants. Int J Hyg Environ Health 220(8):1252-1278. https://doi.org/10.1016/j.ijheh.2017.07.010.

Al-Saleh I, Al-Mohawes S, Al-Rouqi R, et al. 2019. Selenium status in lactating mothers-infants and its potential protective role against the neurotoxicity of methylmercury, lead, manganese, and DDT. Environ Res 176:108562. https://doi.org/10.1016/j.envres.2019.108562.

Altunkaynak ME, Akgul N, Yahyazadeh A, et al. 2015. A stereological and histopathological study of the effects of exposure of male rat testes to mercury vapor. Biotech Histochem 90(7):529-534. https://doi.org/10.3109/10520295.2015.1024739.

Altunkaynak BZ, Akgul N, Yahyazadeh A, et al. 2016. Effect of mercury vapor inhalation on rat ovary: Stereology and histopathology. J Obstet Gynaecol Res 42(4):410-416. https://doi.org/10.1111/jog.12911.

Altunkaynak BZ, Akgül N, Yahyazedeh A, et al. 2019. A stereological study of the effects of mercury inhalation on the cerebellum. Biotech Histochem 94(1):42-47. https://doi.org/10.1080/10520295.2018.1493224.

Amara IE, Elshenawy OH, Abdelrady M, et al. 2014. Acute mercury toxicity modulates cytochrome P450, soluble epoxide hydrolase and their associated arachidonic acid metabolites in C57B1/6 mouse heart. Toxicol Lett 226(1):53-62. https://doi.org/10.1016/j.toxlet.2014.01.025.

Aminzadeh KK, Etminan M. 2007. Dental amalgam and multiple sclerosis: A systematic review and meta-analysis. J Public Health Dent 67(1):64-66.

Amin-Zaki L, Elhassani S, Majeed MA, et al. 1974. Intra-uterine methylmercury poisoning in Iraq. Pediatrics 54(5):587-595.

Amin-Zaki L, Elhassani S, Majeed MA, et al. 1976. Perinatal methylmercury poisoning in Iraq. Am J Dis Child 130(10):1070-1076.

Amin-Zaki L, Majeed MA, Clarkson TW, et al. 1978. Methylmercury poisoning in Iraqi children: Clinical observations over two years. Br Med J 1(6113):613-616.

Amin-Zaki L, Majeed MA, Greenwood MR, et al. 1981. Methylmercury poisoning in the Iraqi suckling infant: a longitudinal study over five years. J Appl Toxicol 1(4):210-214.

8. REFERENCES

Amirhosseini M, Alkaissi H, Hultman PA, et al. 2021. Autoantibodies in outbred Swiss Webster mice following exposure to gold and mercury. Toxicol Appl Pharmacol 412:115379. https://doi.org/10.1016/j.taap.2020.115379.

An H, Wang B, Li Z, et al. 2021. Distribution of mercury in serum and blood cells and risk of spontaneous preterm birth: A nested case-control study in China. Ecotoxicol Environ Saf 217:112228. https://doi.org/10.1016/j.ecoenv.2021.112228.

Andersen ME, Krishnan K. 1994. Relating in vitro to in vivo exposures with physiologically based tissue dosimetry and tissue response models. In: Salem H, ed. Animal test alternatives: Refinement, reduction, replacement. New York, NY: Marcel Dekker, Inc., 9-25.

Andersson AB. 1979. Mercury in soils. In: Nriagu JO, ed. The biogeochemistry of mercury in the environment. New York, NY: Elsevier/North Holland Biomedical Press, 79-112.

Andersson I, Parkman H, Jernelov A. 1990. The role of sediments as sink or source for environmental contaminants: A case study of mercury and chlorinated organic compounds. Limnologica 20(2):347-360.

Andren AW, Nriagu JO. 1979. The global cycle of mercury. In: Nriagu JO, ed. The biogeochemistry of mercury in the environment. New York, NY: Elsevier/North Holland Biomedical Press, 1-22.

Andreoli V, Sprovieri F. 2017. Genetic aspects of susceptibility to mercury toxicity: An overview. Int J Environ Res Public Health 14:93. https://doi.org/10.3390/ijerph14010093.

Andrew AS, O'Brien KM, Jackson BP, et al. 2020. Keratinous biomarker of mercury exposure associated with amyotrophic lateral sclerosis risk in a nationwide U.S. study. Amyotroph Lateral Scler Frontotemporal Degener 21(5-6):420-427. https://doi.org/10.1080/21678421.2020.1753777.

Anglen J, Gruninger SE, Chou HN, et al. 2015. Occupational mercury exposure in association with prevalence of multiple sclerosis and tremor among US dentists. J Am Dent Assoc 146(9):659-668 e651. https://doi.org/10.1016/j.adaj.2015.05.016.

Ansari MS, Miller WJ, Gentry RP, et al. 1973. Tissue 203 Hg distribution in young Holstein calves after single tracer oral doses in organic and inorganic forms. J Anim Sci 36(2):415-419.

Anwar WA, Gabal MS. 1991. Cytogenetic study in workers occupationally exposed to mercury fulminate. Mutagenesis 6(3):189-192.

Apaydin FG, Bas H, Kalender S, et al. 2016. Subacute effects of low dose lead nitrate and mercury chloride exposure on kidney of rats. Environ Toxicol Pharmacol 41:219-224. https://doi.org/10.1016/j.etap.2015.12.003.

Arakawa C, Yoshinaga J, Okamura K, et al. 2006. Fish consumption and time to pregnancy in Japanese women. Int J Hyg Environ Health 209(4):337-344. https://doi.org/10.1016/j.ijheh.2006.02.004.

Araki S, Aono H, Murata K. 1986. Adjustment of urinary concentration to urinary volume in relation to erythrocyte and plasma concentrations: an evaluation of urinary heavy metals and organic substances. Arch Environ Health 41(3):171-177. https://doi.org/10.1080/00039896.1986.9935773.

Arbi S, Oberholzer HM, Van Rooy MJ, et al. 2017. Effects of chronic exposure to mercury and cadmium alone and in combination on the coagulation system of Sprague-Dawley rats. Ultrastruct Pathol 41(4):275-283. https://doi.org/10.1080/01913123.2017.1327909.

Arito H, Takahashi M. 1991. Effect of methylmercury on sleep patterns in the rat. In: Suzuki T, Imura N, Clarkson TW, eds. Advances in mercury toxicology. New York, NY: Plenum Press, 381-394.

Aschner M, Clarkson TW. 1988. Uptake of methylmercury in the rat brain: Effects of amino acids. Brain Res 462(1):31-39.

Aschner M, Clarkson TW. 1989. Methyl mercury uptake across bovine brain capillary endothelial cells in vitro: The role of amino acids. Pharmacol Toxicol 64(3):293-297. https://doi.org/10.1111/j.1600-0773.1989.tb00650.x.

Aschner M, Eberle NB, Goderie S, et al. 1990. Methylmercury uptake in rat primary astrocyte cultures: The role of the neutral amino acid transport system. Brain Res 521(1-2):221-228.

Aschner M, Eberle NB, Kimelberg HK. 1991. Interactions of methylmercury with rat primary astrocyte cultures: Methylmercury efflux. Brain Res 554(1-2):10-14.

8. REFERENCES

Aschner M, Syversen T, Souza DO, et al. 2006. Metallothioneins: Mercury species-specific induction and their potential role in attenuating neurotoxicity. Exp Biol Med 231(9):1468-1473.

Aschner M, Syversen T, Souza DO, et al. 2007. Involvement of glutamate and reactive oxygen species in methylmercury neurotoxicity. Braz J Med Biol Res 40(3):285-291.

Asgary S, Movahedian A, Keshvari M, et al. 2017. Serum levels of lead, mercury and cadmium in relation to coronary artery disease in the elderly: A cross-sectional study. Chemosphere 180:540-544. https://doi.org/10.1016/j.chemosphere.2017.03.069.

Ashe WF, Largent EJ, Dutra FR, et al. 1953. Behavior of mercury in the animal organism following inhalation. AMA Arch Ind Hyg Occup Med 7(1):19-43.

Ashrap P, Watkins DJ, Mukherjee B, et al. 2020. Maternal blood metal and metalloid concentrations in association with birth outcomes in Northern Puerto Rico. Environ Int 138:105606. https://doi.org/10.1016/j.envint.2020.105606.

Ask K, Akesson A, Berglund M, et al. 2002. Inorganic mercury and methylmercury in placentas of Swedish women. Environ Health Perspect 110(5):523-526.

ASTER. 1997. ASTER (assessment tools for the evaluation of risk) ecotoxicity profile. Duluth, MN: U.S. Environmental Protection Agency.

Atkinson A, Thompson SJ, Khan AT, et al. 2001. Assessment of a two-generation reproductive and fertility study of mercuric chloride in rats. Food Chem Toxicol 39(1):73-84. https://doi.org/10.1016/s0278-6915(00)00096-x.

ATSDR. 1989. Decision guide for identifying substance-specific data needs related to toxicological profiles. Atlanta, GA: Agency for Toxic Substances and Disease Registry.

ATSDR. 1990. Technical assistance to the Tennessee Department of Health and Environment. Mercury exposure study Charleston, Tennessee. Atlanta, GA: Agency for Toxic Substances and Disease Registry. ATDR/HS-91/11. PB91151142. https://ntrl.ntis.gov/NTRL/dashboard/searchResults/titleDetail/PB91151142.xhtml. January 13, 2021.

ATSDR. 1997. Press release: ATSDR and EPA warn the public about continuing patterns of metallic mercury exposure. Atlanta, GA: Agency for Toxic Substances and Disease Registry. https://www.cdc.gov/media/pressrel/mercury.htm. January 13, 2021.

ATSDR. 2004. Interaction profile for: Persistent chemicals found in fish (chlorinated dibenzo-p-dioxins, hexachlorobenzene, p,p'-DDE, methylmercury, and polychlorinated biphenyls). Atlanta, GA: Agency for Toxic Substances and Disease Registry. https://www.atsdr.cdc.gov/interactionprofiles/ip-fish/ip01.pdf. December 14, 2020.

ATSDR. 2012. Toxicological profile for cadmium. Agency for Toxic Substances and Disease Registry. PB2013105787. https://ntrl.ntis.gov/NTRL/dashboard/searchResults/titleDetail/PB2013105787.xhtml. March 15, 2021.

ATSDR. 2022. Mercury. Full SPL data. Substance priority list (SPL) resource page. Agency for Toxic Substances and Disease Registry. https://www.atsdr.cdc.gov/SPL/resources/index.html. April 1, 2024.

Awata H, Linder S, Mitchell LE, et al. 2017. Association of dietary intake and biomarker levels of arsenic, cadmium, lead, and mercury among Asian populations in the United States: NHANES 2011-2012. Environ Health Perspect 125(3):314-323. https://doi.org/10.1289/ehp28.

Axelrad DA, Bellinger DC, Ryan LM, et al. 2007a. Dose-response relationship of prenatal mercury exposure and IQ: An integrative analysis of epidemiologic data. Environ Health Perspect 115(4):609-615. https://doi.org/10.1289/ehp.9303.

Axelrad DA, Bellinger DC, Ryan LM, et al. 2007b. Supplemental material: Dose-response relationship of prenatal mercury exposure and IQ: An integrative analysis of epidemiologic data. Environ Health Perspect 115 https://doi.org/10.1289/ehp.9303.

Axtell CD, Myers GJ, Davidson PW, et al. 1998. Semiparametric modeling of age at achieving developmental milestones after prenatal exposure to methylmercury in the Seychelles child

development study. Environ Health Perspect 106(9):559-564. https://doi.org/10.1289/ehp.106-1533142.

Axtell CD, Cox C, Myers GJ, et al. 2000. Association between methylmercury exposure from fish consumption and child development at five and a half years of age in the Seychelles Child Development Study: an evaluation of nonlinear relationships. Environ Res 84(2):71-80. https://doi.org/10.1006/enrs.2000.4082.

Aydin N, Karaoglanoglu S, Yigit A, et al. 2003. Neuropsychological effects of low mercury exposure in dental staff in Erzurum, Turkey. Int Dent J 53(2):85-91.

Bachand PAM, Kraus TEC, Stumpner EB, et al. 2019. Mercury sequestration and transformation in chemically enhanced treatment wetlands. Chemosphere 217:496-506. https://doi.org/10.1016/j.chemosphere.2018.10.144.

Bache CA, Gutenmann WH, Rutzke M, et al. 1991. Concentrations of metals in grasses in the vicinity of a municipal refuse incinerator. Arch Environ Contam Toxicol 20(4):538-542. https://doi.org/10.1007/bf01065846.

Baden HP, Goldsmith LA, Fleming B. 1973. A comparative study of the physicochemical properties of human keratinized tissues. Biochim Biophys Acta 322(2):269-278. https://doi.org/10.1016/0005-2795(73)90303-6.

Bae S, Park SJ, Yeum KJ, et al. 2016. Cut-off values of blood mercury concentration in relation to increased body mass index and waist circumference in Koreans. J Investig Med 64(4):867-871. https://doi.org/10.1136/jim-2015-000039.

Bagheri Hosseinabadi M, Khanjani N, Mobarake MD, et al. 2020. Neuropsychological effects of long-term occupational exposure to mercury among chloralkali workers. Work 66(3):491-498. https://doi.org/10.3233/wor-203194.

Bagley MP, Schwartz RA, Lambert WC. 1987. Hyperplastic reaction developing within a tattoo. Diagnosis: Granulomatous tattoo reaction, probably to mercuric sulfide (cinnabar). Arch Dermatol 123(11):1557, 1560-1561. https://doi.org/10.1001/archderm.123.11.1557b.

Bakir F, Damluji SF, Amin-Zaki L, et al. 1973. Methylmercury poisoning in Iraq. Science 181(4096):230-241.

Ballabio C, Jiskra M, Osterwalder S, et al. 2021. A spatial assessment of mercury content in the European Union topsoil. Sci Total Environ 769:144755. https://doi.org/10.1016/j.scitotenv.2020.144755.

Ballatori N. 2002. Transport of toxic metals by molecular mimicry. Environ Health Perspect 110(Suppl 5):689-694.

Ballatori N, Clarkson TW. 1982. Developmental changes in the biliary excretion of methylmercury and glutathione. Science 216(4541):61-63.

Ballatori N, Clarkson TW. 1984. Inorganic mercury secretion into bile as a low molecular weight complex. Biochem Pharmacol 33(7):1087-1092.

Ballatori N, Clarkson TW. 1985. Biliary secretion of glutathione and of glutathione-metal complexes. Fundam Appl Toxicol 5(5):816-831.

Ballatori N, Truong AT. 1995. Mechanisms of hepatic methylmercury uptake. J Toxicol Environ Health 46(3):343-353. https://doi.org/10.1080/15287399509532040.

Ballatori N, Wang W, Lieberman MW. 1998. Accelerated methylmercury elimination in gamma-glutamyl transpeptidase-deficient mice. Am J Pathol 152(4):1049-1055.

Bangsi D, Ghadirian P, Ducic S, et al. 1998. Dental amalgam and multiple sclerosis: a case-control study in Montreal, Canada. Int J Epidemiol 27(4):667-671. https://doi.org/10.1093/ije/27.4.667.

Barany E, Bergdahl IA, Bratteby LE, et al. 2003. Mercury and selenium in whole blood and serum in relation to fish consumption and amalgam fillings in adolescents. J Trace Elem Med Biol 17(3):165-170. https://doi.org/10.1016/s0946-672x(03)80021-4.

Barber TE, Wallis G. 1986. Correction of urinary mercury concentration by specific gravity, osmolality, and creatinine. J Occup Med 28(5):354-359.

8. REFERENCES

Barbone F, Rosolen V, Mariuz M, et al. 2019. Prenatal mercury exposure and child neurodevelopment outcomes at 18 months: Results from the Mediterranean PHIME cohort. Int J Hyg Environ Health 222(1):9-21. https://doi.org/10.1016/j.ijheh.2018.07.011.

Barboni MT, da Costa MF, Moura AL, et al. 2008. Visual field losses in workers exposed to mercury vapor. Environ Res 107(1):124-131. https://doi.org/10.1016/j.envres.2007.07.004.

Barboni MT, Feitosa-Santana C, Zachi EC, et al. 2009. Preliminary findings on the effects of occupational exposure to mercury vapor below safety levels on visual and neuropsychological functions. J Occup Environ Med 51(12):1403-1412. https://doi.org/10.1097/JOM.0b013e3181bca9ea.

Barcelos GR, Grotto D, Serpeloni JM, et al. 2011. Protective properties of quercetin against DNA damage and oxidative stress induced by methylmercury in rats. Arch Toxicol 85(9):1151-1157. https://doi.org/10.1007/s00204-011-0652-y.

Barcelos GR, Grotto D, Serpeloni JM, et al. 2012. Bixin and norbixin protect against DNA-damage and alterations of redox status induced by methylmercury exposure in vivo. Environ Mol Mutagen 53(7):535-541. https://doi.org/10.1002/em.21715.

Barkay T, Liebert C, Gillman M. 1989. Environmental significance of the potential for mer(Tn-21)-mediated reduction of Hg^{2+} to Hg^0 in natural waters. Appl Environ Microbiol 55(5):1196-1202.

Barnes DG, Dourson M. 1988. Reference dose (RfD): Description and use in health risk assessments. Regul Toxicol Pharmacol 8(4):471-486.

Barnes DM, Hanlon PR, Kircher EA. 2003. Effects of inorganic $HgCl_2$ on adipogenesis. Toxicol Sci 75(2):368-377. https://doi.org/10.1093/toxsci/kfg195.

Barnett LMA, Cummings BS. 2018. Nephrotoxicity and renal pathophysiology: A contemporary perspective. Toxicol Sci 164(2):379-390. https://doi.org/10.1093/toxsci/kfy159.

Barr RD, Woodger BA, Rees PH. 1973. Levels of mercury in urine correlated with the use of skin lightening creams. Am J Clin Pathol 59(1):36-40. https://doi.org/10.1093/ajcp/59.1.36.

Barregard L. 1993. Biological monitoring of exposure to mercury vapor. Scand J Work Environ Health 19(Suppl 1):45-49.

Barregard L, Sallsten G, Jarvholm B. 1990. Mortality and cancer incidence in chloralkali workers exposed to inorganic mercury. Br J Ind Med 47(2):99-104.

Barregard L, Trachtenberg F, McKinlay S. 2008. Renal effects of dental amalgam in children: The New England children's amalgam trial. Environ Health Perspect 116(3):394-399. https://doi.org/10.1289/ehp.10504.

Barregard L, Hogstedt B, Schutz A, et al. 1991. Effects of occupational exposure to mercury vapor on lymphocyte micronuclei. Scand J Work Environ Health 17(4):263-268. https://doi.org/10.5271/sjweh.1704.

Barregard L, Sallsten G, Schutz A, et al. 1992. Kinetics of mercury in blood and urine after brief occupational exposure. Arch Environ Health 47(3):176-184. https://doi.org/10.1080/00039896.1992.9938347.

Barregard L, Lindstedt G, Schutz A, et al. 1994a. Endocrine function in mercury exposed chloralkali workers. Occup Environ Med 51(8):536-540. https://doi.org/10.1136/oem.51.8.536.

Barregard L, Horvat M, Schutz A. 1994b. No indication of in vivo methylation of inorganic mercury in chloralkali workers. Environ Res 67(2):160-167. https://doi.org/10.1006/enrs.1994.1071.

Barregard L, Quelquejeu G, Sallsten G, et al. 1996. Dose-dependent elimination kinetics for mercury in urine: Observations in subjects with brief but high-level exposure. Int Arch Occup Environ Health 68(5):345-348. https://doi.org/10.1007/bf00409421.

Barregard L, Eneström S, Ljunghusen O, et al. 1997. A study of autoantibodies and circulating immune complexes in mercury-exposed chloralkali workers. Int Arch Occup Environ Health 70(2):101-106. https://doi.org/10.1007/s004200050193.

Barregard L, Horvat M, Mazzolai B, et al. 2006. Urinary mercury in people living near point sources of mercury emissions. Sci Total Environ 368(1):326-334. https://doi.org/10.1016/j.scitotenv.2005.08.048.

8. REFERENCES

Basta PC, Viana PVS, Vasconcellos ACS, et al. 2021. Mercury exposure in Munduruku indigenous communities from Brazilian Amazon: Methodological background and an overview of the principal results. Int J Environ Res Public Health 18(17):9222. https://doi.org/10.3390/ijerph18179222.

Bast-Pettersen R, Ellingsen DG, Efskind J, et al. 2005. A neurobehavioral study of chloralkali workers after the cessation of exposure to mercury vapor. Neurotoxicology 26(3):427-437. https://doi.org/10.1016/j.neuro.2005.03.006.

Basu N, Scheuhammer AM, Rouvinen-Watt K, et al. 2010. In vitro and whole animal evidence that methylmercury disrupts GABAergic systems in discrete brain regions in captive mink. Comp Biochem Physiol C Toxicol Pharmacol 151(3):379-385. https://doi.org/10.1016/j.cbpc.2010.01.001.

Basu N, Goodrich JM, Head J. 2014. Ecogenetics of mercury: From genetic polymorphisms and epigenetics to risk assessment and decision-making. Environ Toxicol Chem 33(6):1248-1258. https://doi.org/10.1002/etc.2375.

Baswan S, Kasting GB, Li SK, et al. 2017. Understanding the formidable nail barrier: A review of the nail microstructure, composition and diseases. Mycoses 60(5):284-295. https://doi.org/10.1111/myc.12592.

Bates MN, Fawcett J, Garrett N, et al. 2004. Health effects of dental amalgam exposure: A retrospective cohort study. Int J Epidemiol 33(4):894-902. https://doi.org/10.1093/ije/dyh164.

Bautista LE, Stein JH, Morgan BJ, et al. 2009. Association of blood and hair mercury with blood pressure and vascular reactivity. WMJ 108(5):250-252.

BDI. 2011. Great Lakes mercury connections: The extent and effects of mercury pollution in the Great Lakes region. Gorham, ME: Biodiversity Research Institute. https://www.glc.org/library/2011-great-lakes-mercury-connections. January 19, 2021.

Beauchamp G, Kusin S, Elinder CG. 2021. Mercury toxicity. UpToDate. Wolters Kluwer.

Bedir Findik R, Celik HT, Ersoy AO, et al. 2016. Mercury concentration in maternal serum, cord blood, and placenta in patients with amalgam dental fillings: Effects on fetal biometric measurements. J Matern Fetal Neonatal Med 29(22):3665-3669. https://doi.org/10.3109/14767058.2016.1140737.

Behzadfar L, Hassani S, Feizpour H, et al. 2020. Effects of mercuric chloride on spatial memory deficit-induced by beta-amyloid and evaluation of mitochondrial function markers in the hippocampus of rats. Metallomics 12(1):144-153. https://doi.org/10.1039/c9mt00161a.

Bell BC, Zhu J, Wei Y. 2023. Urinary concentrations of endocrine-disrupting metals and prevalent breast cancer in US women. Biol Trace Elem Res 201(9):4230-4237. https://doi.org/10.1007/s12011-022-03512-z.

Bellanger M, Pichery C, Aerts D, et al. 2013. Economic benefits of methylmercury exposure control in Europe: Monetary value of neurotoxicity prevention. Environ Health 12:3. https://doi.org/10.1186/1476-069x-12-3.

Belles M, Albina ML, Sanchez DJ, et al. 2002. Interactions in developmental toxicology: Effects of concurrent exposure to lead, organic mercury, and arsenic in pregnant mice. Arch Environ Contam Toxicol 42(1):93-98. https://doi.org/10.1007/s002440010296.

Bellinger DC. 2012. Comparing the population neurodevelopmental burdens associated with children's exposures to environmental chemicals and other risk factors. Neurotoxicology 33(4):641-643. https://doi.org/10.1016/j.neuro.2012.04.003.

Bellinger DC, Trachtenberg F, Barregard L, et al. 2006. Neuropsychological and renal effects of dental amalgam in children: a randomized clinical trial. JAMA 295(15):1775-1783. https://doi.org/10.1001/jama.295.15.1775.

Bellinger DC, Daniel D, Trachtenberg F, et al. 2007a. Dental amalgam restorations and children's neuropsychological function: the New England Children's Amalgam Trial. Environ Health Perspect 115(3):440-446. https://doi.org/10.1289/ehp.9497.

Bellinger DC, Trachtenberg F, Daniel D, et al. 2007b. A dose-effect analysis of children's exposure to dental amalgam and neuropsychological function: the New England Children's Amalgam Trial. J Am Dent Assoc 138(9):1210-1216. https://doi.org/10.14219/jada.archive.2007.0345.

8. REFERENCES

Bellinger DC, Trachtenberg F, Zhang A, et al. 2008. Dental amalgam and psychosocial status: the New England Children's Amalgam Trial. J Dent Res 87(5):470-474. https://doi.org/10.1177/154405910808700504.

Bellinger DC, Devleesschauwer B, O'Leary K, et al. 2019. Global burden of intellectual disability resulting from prenatal exposure to methylmercury, 2015. Environ Res 170:416-421. https://doi.org/10.1016/j.envres.2018.12.042.

Bellum S, Thuett KA, Grajeda R, et al. 2007. Coordination deficits induced in young adult mice treated with methylmercury. Int J Toxicol 26(2):115-121. https://doi.org/10.1080/10915810701225190.

Bellum S, Thuett KA, Bawa B, et al. 2013. The effect of methylmercury exposure on behavior and cerebellar granule cell physiology in aged mice. J Appl Toxicol 33(9):959-969. https://doi.org/10.1002/jat.2786.

Ben-Ozer EY, Rosenspire AJ, McCabe MJ, et al. 2000. Mercuric chloride damages cellular DNA by a non-apoptotic mechanism. Mutat Res 470(1):19-27.

Bergdahl IA, Ahlqwist M, Barregard L, et al. 2013. Mercury in serum predicts low risk of death and myocardial infarction in Gothenburg women. Int Arch Occup Environ Health 86(1):71-77. https://doi.org/10.1007/s00420-012-0746-8.

Berglund M, Lind B, Bjornberg KA, et al. 2005. Inter-individual variations of human mercury exposure biomarkers: a cross-sectional assessment. Environ Health 4:20. https://doi.org/10.1186/1476-069x-4-20.

Bergstrand A, Friberg L, Odeblad E. 1958. Localization of mercury in the kidneys after subcutaneous administration. A study on rabbits with mercuric chloride and phenylmercuric acetate. Arch Ind Health 17(3):253-256.

Berky AJ, Ryde IT, Feingold B, et al. 2019. Predictors of mitochondrial DNA copy number and damage in a mercury-exposed rural Peruvian population near artisanal and small-scale gold mining: An exploratory study. Environ Mol Mutagen 60(2):197-210. https://doi.org/10.1002/em.22244.

Berlin M, Ullberg S. 1963a. Accumulation and retention of mercury in the mouse. I. An autoradiographic study after a single intravenous injection of mercuric chloride. Arch Environ Health 6:589-601. https://doi.org/10.1080/00039896.1963.10663447.

Berlin M, Ullberg S. 1963b. Accumulation and retention of mercury in the mouse. II. An autoradiographic comparison of phenylmercuric acetate with inorganic mercury. Arch Environ Health 6:602-609. https://doi.org/10.1080/00039896.1963.10663448.

Berlin M, Ullberg S. 1963c. Accumulation and retention of mercury in the mouse. III. An autoradiographic comparison of methylmercuric dicyandiamide with inorganic mercury. Arch Environ Health 6:610-616. https://doi.org/10.1080/00039896.1963.10663449.

Berlin M, Jerksell LG, von Ubisch H. 1966. Uptake and retention of mercury in the mouse brain. A comparison of exposure to mercury vapor and intravenous injection of mercuric salt. Arch Environ Health 12(1):33-42.

Berlin MH, Nordberg GF, Serenius F. 1969a. On the site and mechanism of mercury vapor resorption in the lung. A study in the guinea pig using mercuric nitrate Hg 203. Arch Environ Health 18(1):42-50.

Berlin M, Fazackerley J, Nordberg G. 1969b. The uptake of mercury in the brains of mammals exposed to mercury vapor and to mercuric salts. Arch Environ Health 18(5):719-729.

Berlin M, Carlson J, Norseth T. 1975. Dose-dependence of methylmercury metabolism: A study of distribution: Biotransformation and excretion in the squirrel monkey. Arch Environ Health 30(6):307-313.

Berlin M, Zalups RK, Fowler BA. 2015. Mercury. In: Nordberg GF, Fowler BA, Nordberg M, eds. Handbook on the toxicology of metals. Boston, MA: Academic Press, 1013-1075. https://doi.org/10.1016/B978-0-444-59453-2.00046-9.

Berndt WO, Baggett JM, Blacker A, et al. 1985. Renal glutathione and mercury uptake by kidney. Fundam Appl Toxicol 5(5):832-839. https://doi.org/10.1016/0272-0590(85)90166-6.

8. REFERENCES

Berthet A, de Batz A, Tardif R, et al. 2010. Impact of biological and environmental variabilities on biological monitoring--an approach using toxicokinetic models. J Occup Environ Hyg 7(3):177-184. https://doi.org/10.1080/15459620903530052.

Berthoud HR, Garman RH, Weiss B. 1976. Food intake, body weight, and brain histopathology in mice following chronic methylmercury treatment. Toxicol Appl Pharmacol 36(1):19-30. https://doi.org/10.1016/0041-008x(76)90023-5.

Betti C, Davini T, Barale R. 1992. Genotoxic activity of methyl mercury chloride and dimethyl mercury in human lymphocytes. Mutat Res 281(4):255-260.

Beusterien KM, Etzel RA, Agocs MM, et al. 1991. Indoor air mercury concentrations following application of interior latex paint. Arch Environ Contam Toxicol 21(1):62-64. https://doi.org/10.1007/bf01055557.

Beyrouty P, Stamler CJ, Liu JN, et al. 2006. Effects of prenatal methylmercury exposure on brain monoamine oxidase activity and neurobehaviour of rats. Neurotoxicol Teratol 28(2):251-259. https://doi.org/10.1016/j.ntt.2005.12.007.

Bhan A, Sarkar NN. 2005. Mercury in the environment: effect on health and reproduction. Rev Environ Health 20(1):39-56.

Bhowmik N, Patra M. 2015. Assessment of genotoxicity of inorganic mercury in rats in vivo using both chromosomal aberration and comet assays. Toxicol Ind Health 31(7):588-594. https://doi.org/10.1177/0748233712469656.

Bilak Ş, Önderci M, Şimşek A. 2019. Evaluation of amalgam-related retinal neurotoxicity with optical coherence tomography findings. Hum Exp Toxicol 38(7):814-822. https://doi.org/10.1177/0960327119842637.

Birch RJ, Bigler J, Rogers JW, et al. 2014. Trends in blood mercury concentrations and fish consumption among U.S. women of reproductive age, NHANES, 1999-2010. Environ Res 133:431-438. https://doi.org/10.1016/j.envres.2014.02.001.

Birke G, Johnels AG, Plantin LO, et al. 1972. Studies on humans exposed to methyl mercury through fish consumption. Arch Environ Health 25(2):77-91.

Biro L, Klein WP. 1967. Unusual complications of mercurial (cinnabar) tattoo. Arch Dermatol 96(2):165. https://doi.org/10.1001/archderm.1967.01610020057017.

Bittencourt LO, Dionizio A, Nascimento PC, et al. 2019. Proteomic approach underlying the hippocampal neurodegeneration caused by low doses of methylmercury after long-term exposure in adult rats. Metallomics 11(2):390-403. https://doi.org/10.1039/c8mt00297e.

Bittencourt LO, Chemelo VS, Aragão WAB, et al. 2021. From molecules to behavior in long-term inorganic mercury intoxication: Unraveling proteomic features in cerebellar neurodegeneration of rats. Int J Mol Sci 23(1):111. https://doi.org/10.3390/ijms23010111.

Bittencourt LO, Matta PPM, Nascimento PC, et al. 2022. Deciphering the global proteomic profile involved in methylmercury-induced cerebellar neurodegeneration and motor dysfunction in adult rats. Toxics 10(9):531. https://doi.org/10.3390/toxics10090531.

Bittner AC, Echeverria D, Woods JS, et al. 1998. Behavioral effects of low-level exposure to Hg^0 among dental professionals: a cross-study evaluation of psychomotor effects. Neurotoxicol Teratol 20(4):429-439. https://doi.org/10.1016/s0892-0362(98)00006-3.

Bjorkman S. 2004. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. Br J Clin Pharmacol 59(6):691-704. https://doi.org/10.1111/j.1365-2125.2004.02225.x.

Bjorkman L, Sandborgh-Englund G, Ekstrand J. 1997. Mercury in saliva and feces after removal of amalgam fillings. Toxicol Appl Pharmacol 144(1):156-162. https://doi.org/10.1006/taap.1997.8128.

Bjorkman L, Lundekvam BF, Laegreid T, et al. 2007. Mercury in human brain, blood, muscle and toenails in relation to exposure: an autopsy study. Environ Health 6:30. https://doi.org/10.1186/1476-069x-6-30.

Bjornberg A, Hakanson L, Lundbergh K. 1988. A theory on the mechanisms regulating the bioavailability of mercury in natural waters. Environ Pollut 49(1):53-62.

8. REFERENCES

Bjornberg KA, Vahter M, Petersson-Grawe K, et al. 2003. Methyl mercury and inorganic mercury in Swedish pregnant women and in cord blood: influence of fish consumption. Environ Health Perspect 111(4):637-641.

Bjornberg KA, Vahter M, Berglund B, et al. 2005. Transport of methylmercury and inorganic mercury to the fetus and breast-fed infant. Environ Health Perspect 113(10):1381-1385.

Blakley BR, Sisodia CS, Mukkur TK. 1980. The effect of methylmercury, tetraethyl lead, and sodium arsenite on the humoral immune response in mice. Toxicol Appl Pharmacol 52(2):245-254. https://doi.org/10.1016/0041-008x(80)90111-8.

Blanc P, Burnol A, Marty N, et al. 2018. Methylmercury complexes: Selection of thermodynamic properties and application to the modelling of a column experiment. Sci Total Environ 621:368-375. https://doi.org/10.1016/j.scitotenv.2017.11.259.

Blanchet C, Rochette L. 2008. Qanuippitaa? How are we? Nutrition and food consumption among the Inuit of Nunavik. Quebec: Institut National de Santé Publique du Québec. https://www.inspq.qc.ca/pdf/publications/762_ESI_Nutrition_Report_MA.pdf. January 18, 2021.

Blayney MB, Winn JS, Nierenberg DW. 1997. Handling dimethylmercury. Chem Eng News 75(19):7.

Bloom NS. 1992. On the chemical form of mercury in edible fish and marine invertebrate tissue. Can J Fish Aquat Sci 49(5):1010-1017. https://doi.org/10.1139/f92-113.

Bloom NS, Effler SW. 1990. Seasonal variability in the mercury speciation of Onondaga Lake (New York). Water Air Soil Pollut 53(3-4):251-265. https://doi.org/10.1007/bf00170741.

Bloom MS, Buck Louis GM, Sundaram R, et al. 2015. Birth outcomes and background exposures to select elements, the Longitudinal Investigation of Fertility and the Environment (LIFE). Environ Res 138:118-129. https://doi.org/10.1016/j.envres.2015.01.008.

Bluhm RE, Bobbitt RG, Welch LW, et al. 1992. Elemental mercury vapour toxicity, treatment, and prognosis after acute, intensive exposure in chloralkali plant workers. Part I: History, neuropsychological findings and chelator effects. Hum Exp Toxicol 11(3):201-210. https://doi.org/10.1177/096032719201100308.

Blume HP, Brümmer G. 1991. Prediction of heavy metal behavior in soil by means of simple field tests. Ecotoxicol Environ Saf 22(2):164-174. https://doi.org/10.1016/0147-6513(91)90056-u.

Bodaly RAD. 2018. Mercury contamination of the Penobscot River Estuary, Maine, USA. Sci Total Environ 639:1077-1078. https://doi.org/10.1016/j.scitotenv.2018.05.127.

Boersma ER, Lanting CI. 2000. Environmental exposure to polychlorinated biphenyls (PCBs) and dioxins. Consequences for longterm neurological and cognitive development of the child lactation. Adv Exp Med Biol 478:271-287.

Boischio AA, Cernichiari E, Henshel D. 2000. Segmental hair mercury evaluation of a single family along the upper Madeira basin, Brazilian Amazon. Cad Saude Publica 16(3):681-686.

Boogaard PJ, Houtsma AT, Journee HL, et al. 1996. Effects of exposure to elemental mercury on the nervous system and the kidneys of workers producing natural gas. Arch Environ Health 51(2):108-115. https://doi.org/10.1080/00039896.1996.9936002.

Boomhower SR, Newland MC. 2019. Adolescent methylmercury exposure: Behavioral mechanisms and effects of sodium butyrate in mice. Neurotoxicology 70:33-40. https://doi.org/10.1016/j.neuro.2018.10.011.

Borghese MM, Fisher M, Ashley-Martin J, et al. 2023. Individual, independent, and joint associations of toxic metals and manganese on hypertensive disorders of pregnancy: Results from the MIREC Canadian pregnancy cohort. Environ Health Perspect 131(4):47014. https://doi.org/10.1289/ehp10825.

Bornhausen M, Musch HR, Greim H. 1980. Operant behavior performance changes in rats after prenatal methylmercury exposure. Toxicol Appl Pharmacol 56(3):305-310. https://doi.org/10.1016/0041-008x(80)90062-9.

Boscolo P, Carmignani M, Giuliano G, et al. 1989. Peripheral catecholaminergic mechanisms and baroreflex pathways are involved in vascular and cardiac effects of long-term exposure to inorganic

mercury in rats. In: Strano A, Novo S, eds. Advances in vascular pathology. Amsterdam: Elsevier Science Publisher, 1061-1066.

Boucher O, Bastien CH, Saint-Amour D, et al. 2010. Prenatal exposure to methylmercury and PCBs affects distinct stages of information processing: an event-related potential study with Inuit children. Neurotoxicology 31(4):373-384. https://doi.org/10.1016/j.neuro.2010.04.005.

Boucher O, Burden MJ, Muckle G, et al. 2012a. Response inhibition and error monitoring during a visual go/no-go task in Inuit children exposed to lead, polychlorinated biphenyls, and methylmercury. Environ Health Perspect 120(4):608-615. https://doi.org/10.1289/ehp.1103828.

Boucher O, Jacobson SW, Plusquellec P, et al. 2012b. Prenatal methylmercury, postnatal lead exposure, and evidence of attention deficit/hyperactivity disorder among Inuit children in Arctic Quebec. Environ Health Perspect 120(10):1456-1461. https://doi.org/10.1289/ehp.1204976.

Boucher O, Muckle G, Jacobson JL, et al. 2014. Domain-specific effects of prenatal exposure to PCBs, mercury, and lead on infant cognition: Results from the Environmental Contaminants and Child Development Study in Nunavik. Environ Health Perspect 122(3):310-316. https://doi.org/10.1289/ehp.1206323.

Boucher O, Muckle G, Ayotte P, et al. 2016. Altered fine motor function at school age in Inuit children exposed to PCBs, methylmercury, and lead. Environ Int 95:144-151. https://doi.org/10.1016/j.envint.2016.08.010.

Boujbiha MA, Hamden K, Guermazi F, et al. 2009. Testicular toxicity in mercuric chloride treated rats: Association with oxidative stress. Reprod Toxicol 28(1):81-89. https://doi.org/10.1016/j.reprotox.2009.03.011.

Boujbiha MA, Hamden K, Guermazi F, et al. 2011. Impairment of spermatogenesis in rats by mercuric chloride: Involvement of low 17beta-estradiol level in induction of acute oxidative stress. Biol Trace Elem Res 142(3):598-610. https://doi.org/10.1007/s12011-010-8774-2.

Boujbiha MA, Ben Salah G, Ben Feleh A, et al. 2012. Hematotoxicity and genotoxicity of mercuric chloride following subchronic exposure through drinking water in male rats. Biol Trace Elem Res 148(1):76-82. https://doi.org/10.1007/s12011-012-9342-8.

Bourdineaud JP, Fujimura M, Laclau M, et al. 2011. Deleterious effects in mice of fish-associated methylmercury contained in a diet mimicking the Western populations' average fish consumption. Environ Int 37(2):303-313. https://doi.org/10.1016/j.envint.2010.09.003.

Bourgeois M, Dooms-Goossens A, Knockaert D, et al. 1986. Mercury intoxication after topical application of a metallic mercury ointment. Dermatology 172(1):48-51. https://doi.org/10.1159/000249292.

Bowman KL, Lamborg CH, Agather AM. 2020. A global perspective on mercury cycling in the ocean. Sci Total Environ 710:136166. https://doi.org/10.1016/j.scitotenv.2019.136166.

Boyd ES, Barkay T. 2012. The mercury resistance operon: from an origin in a geothermal environment to an efficient detoxification machine. Front Microbiol 3:349. https://doi.org/10.3389/fmicb.2012.00349.

Branco V, Carvalho C. 2019. The thioredoxin system as a target for mercury compounds. Biochim Biophys Acta Gen Subj 1863(12):129255. https://doi.org/10.1016/j.bbagen.2018.11.007.

Branco V, Ramos P, Canario J, et al. 2012. Biomarkers of adverse response to mercury: Histopathology versus thioredoxin reductase activity. J Biomed Biotechnol 2012:1-9. https://doi.org/10.1155/2012/359879.

Bressa G, Cima L, Costa P. 1988. Bioaccumulation of mercury in the mushroom Pleurotus ostreatus. Ecotoxicol Environ Saf 16(2):85-89.

Bridges CC, Zalups RK. 2005. Molecular and ionic mimicry and the transport of toxic metals. Toxicol Appl Pharmacol 204(3):274-308. https://doi.org/10.1016/j.taap.2004.09.007.

Bridges CC, Zalups RK. 2010. Transport of inorganic mercury and methylmercury in target tissues and organs. J Toxicol Environ Health B Crit Rev 13(5):385-410. https://doi.org/10.1080/10937401003673750.

8. REFERENCES

Bridges CC, Zalups RK. 2017. Mechanisms involved in the transport of mercuric ions in target tissues. Arch Toxicol 91(1):63-81. https://doi.org/10.1007/s00204-016-1803-y.

Bridges CC, Bauch C, Verrey F, et al. 2004. Mercuric conjugates of cysteine are transported by the amino acid transporter system $b^{0,+}$: implications of molecular mimicry. J Am Soc Nephrol 15(3):663-673.

Bridges CC, Joshee L, Zalups RK. 2011. MRP2 and the handling of mercuric ions in rats exposed acutely to inorganic and organic species of mercury. Toxicol Appl Pharmacol 251(1):50-58. https://doi.org/10.1016/j.taap.2010.11.015.

Bridges CC, Joshee L, Zalups RK. 2012. Placental and fetal disposition of mercuric ions in rats exposed to methylmercury: Role of Mrp2. Reprod Toxicol 34(4):628-634. https://doi.org/10.1016/j.reprotox.2012.10.001.

Bridges CC, Joshee L, van den Heuvel JJ, et al. 2013. Glutathione status and the renal elimination of inorganic mercury in the $Mrp2^{-/-}$ mouse. PLoS ONE 8(9):e73559. https://doi.org/10.1371/journal.pone.0073559.

Brosset C, Lord E. 1991. Mercury in precipitation and ambient air: A new scenario. Water Air Soil Pollut 56(0):493-506.

Brown JR, Shockley P. 1982. Serum albumin: structure and characterization of its ligand binding sites. In: Jost PC, Griffith OH, eds. Lipid-protein interactions. Vol. 1. New York, NY: Wiley, Inc., 25-68.

Brown E, Hopper J, Hodges JL, et al. 1962. Red cell, plasma, and blood volume in healthy women measured by radiochromium cell-labeling and hematocrit. J Clin Invest 41(12):2182-2190. https://doi.org/10.1172/jci104677.

Bryan GW, Langston WJ. 1992. Bioavailability, accumulation and effects of heavy metals in sediments with special reference to United Kingdom estuaries: A review. Environ Pollut 76(2):89-131.

Bryan SE, Guy AL, Hardy KJ. 1974. Metal constituents of chromatin. Interaction of mercury in vivo. Biochemistry 13(2):313-319. https://doi.org/10.1021/bi00699a013.

Bucio L, Garcia C, Souza V, et al. 1999. Uptake, cellular distribution and DNA damage produced by mercuric chloride in a human fetal hepatic cell line. Mutat Res 423(1-2):65-72.

Buck Louis GM, Sundaram R, Schisterman EF, et al. 2012. Heavy metals and couple fecundity, the LIFE Study. Chemosphere 87(11):1201-1207. https://doi.org/10.1016/j.chemosphere.2012.01.017.

Buck Louis GM, Smarr MM, Sundaram R, et al. 2017. Low-level environmental metals and metalloids and incident pregnancy loss. Reprod Toxicol 69:68-74. https://doi.org/10.1016/j.reprotox.2017.01.011.

Budavari S, ed. 1989. Mercury. In: Merck index: an encyclopedia of chemicals, drugs, and biologicals. Rahway, NJ: Merck & Co., Inc., 923-927.

Budtz-Jorgensen E, Grandjean P, Jorgensen PJ, et al. 2004. Association between mercury concentrations in blood and hair in methylmercury-exposed subjects at different ages. Environ Res 95(3):385-393. https://doi.org/10.1016/j.envres.2003.11.001.

Buhari O, Dayyab FM, Igbinoba O, et al. 2020. The association between heavy metal and serum cholesterol levels in the US population: National Health and Nutrition Examination Survey 2009-2012. Hum Exp Toxicol 39(3):355-364. https://doi.org/10.1177/0960327119889654.

Bulat P, Dujic I, Potkonjak B, et al. 1998. Activity of glutathione peroxidase and superoxide dismutase in workers occupationally exposed to mercury. Int Arch Occup Environ Health 71(Suppl):S37-S39.

Bulka CM, Persky VW, Daviglus ML, et al. 2019. Multiple metal exposures and metabolic syndrome: A cross-sectional analysis of the National Health and Nutrition Examination Survey 2011-2014. Environ Res 168:397-405. https://doi.org/10.1016/j.envres.2018.10.022.

Burbacher TM, Mottet NK. 1988. The long-term physical, behavioral, and sexual maturation of Macaca fascicularis exposed in utero to methylmercury [abstract]. Teratology 37(5):524.

Burbacher TM, Monnett C, Grant KS, et al. 1984. Methylmercury exposure and reproductive dysfunction in the nonhuman primate. Toxicol Appl Pharmacol 75(1):18-24. https://doi.org/10.1016/0041-008x(84)90071-1.

Burbacher TM, Grant KS, Mayfield DB, et al. 2005. Prenatal methylmercury exposure affects spatial vision in adult monkeys. Toxicol Appl Pharmacol 208(1):21-28. https://doi.org/10.1016/j.taap.2005.01.011.

Burger J, Cooper K, Gochfeld M. 1992. Exposure assessment for heavy metal ingestion from a sport fish in Puerto Rico: Estimating risk for local fishermen. J Toxicol Environ Health 36(4):355-365. https://doi.org/10.1080/15287399209531644.

Burke J, Hoyer M, Keeler G, et al. 1995. Wet deposition of mercury and ambient mercury concentrations at a site in the Lake Champlain basin. Water Air Soil Pollut 80:353-362.

Burns DA, Woodruff LG, Bradley PM, et al. 2014. Mercury in the soil of two contrasting watersheds in the eastern United States. PLoS ONE 9(2):e86855. https://doi.org/10.1371/journal.pone.0086855.

Byczkowski JZ, Lipscomb JC. 2001. Physiologically based pharmacokinetic modeling of the lactational transfer of methylmercury. Risk Anal 21(5):869-882.

Byrns MC, Pennings TM. 2017. Environmental toxicology: Carcinogens and heavy metals. In: Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman & Gilman's: The pharmacological basis of therapeutics. 13th ed. McGraw Hill,

Cagiano R, De Salvia MA, Renna G, et al. 1990. Evidence that exposure to methyl mercury during gestation induces behavioral and neurochemical changes in offspring of rats. Neurotoxicol Teratol 12(1):23-28. https://doi.org/10.1016/0892-0362(90)90108-o.

Caito SW, Jackson BP, Punshon T, et al. 2018. Editor's highlight: Variation in methylmercury metabolism and elimination status in humans following fish consumption. Toxicol Sci 161(2):443-453. https://doi.org/10.1093/toxsci/kfx226.

Cakmak S, Mitchell K, Lukina A, et al. 2023. Do blood metals influence lipid profiles? Findings of a cross-sectional population-based survey. Environ Res 231(Pt 2):116107. https://doi.org/10.1016/j.envres.2023.116107.

Calamandrei G, Ricceri L, Meccia E, et al. 2020. Pregnancy exposome and child psychomotor development in three European birth cohorts. Environ Res 181:108856. https://doi.org/10.1016/j.envres.2019.108856.

Calao-Ramos C, Bravo AG, Paternina-Uribe R, et al. 2021. Occupational human exposure to mercury in artisanal small-scale gold mining communities of Colombia. Environ Int 146:106216. https://doi.org/10.1016/j.envint.2020.106216.

Callan AC, Devine A, Qi L, et al. 2015. Investigation of the relationship between low environmental exposure to metals and bone mineral density, bone resorption and renal function. Int J Hyg Environ Health 218(5):444-451. https://doi.org/10.1016/j.ijheh.2015.03.010.

Calogero AE, Fiore M, Giacone F, et al. 2021. Exposure to multiple metals/metalloids and human semen quality: A cross-sectional study. Ecotoxicol Environ Saf 215:112165. https://doi.org/10.1016/j.ecoenv.2021.112165.

Cañadas P, Lantigua Y, Enríquez-de-Salamanca A, et al. 2021. Ocular surface pathology in patients suffering from mercury intoxication. Diagnostics (Basel) 11(8):1326. https://doi.org/10.3390/diagnostics11081326.

Cannon VT, Barfuss DW, Zalups RK. 2000. Molecular homology and the luminal transport of Hg^{2+} in the renal proximal tubule. J Am Soc Nephrol 11(3):394-402.

Cannon VT, Zalups RK, Barfuss DW. 2001. Amino acid transporters involved in luminal transport of mercuric conjugates of cysteine in rabbit proximal tubule. J Pharmacol Exp Ther 298(2):780-789.

Cantoni O, Costa M. 1983. Correlations of DNA strand breaks and their repair with cell survival following acute exposure to mercury(II) and X-rays. Mol Pharmacol 24(1):84-89.

Cantoni O, Evans RM, Costa M. 1982. Similarity in the acute cytotoxic response of mammalian cells to mercury (II) and X-rays: DNA damage and glutathione depletion. Biochem Biophys Res Commun 108(2):614-619. https://doi.org/10.1016/0006-291x(82)90873-7.

Cantoni O, Christie NT, Robison SH, et al. 1984a. Characterization of DNA lesions produced by $HgCl_2$ in cell culture systems. Chem Biol Interact 49(1-2):209-224.

Cantoni O, Christie NT, Swann A, et al. 1984b. Mechanism of HgCl$_2$ cytotoxicity in cultured
    mammalian cells. Mol Pharmacol 26(2):360-368.

Canto-Pereira LH, Lago M, Costa MF, et al. 2005. Visual impairment on dentists related to occupational
    mercury exposure. Environ Toxicol Pharmacol 19(3):517-522.
    https://doi.org/10.1016/j.etap.2004.12.015.

Cappelletti S, Piacentino D, Fineschi V, et al. 2019. Mercuric chloride poisoning: symptoms, analysis,
    therapies, and autoptic findings. A review of the literature. Crit Rev Toxicol 49(4):329-341.
    https://doi.org/10.1080/10408444.2019.1621262.

Cardenas A, Roels H, Bernard AM, et al. 1993. Markers of early renal changes induced by industrial
    pollutants. I. Application to workers exposed to mercury vapour. Br J Ind Med 50(1):17-27.
    https://doi.org/10.1136/oem.50.1.17.

Cardenas A, Allard C, Doyon M, et al. 2016. Validation of a DNA methylation reference panel for the
    estimation of nucleated cells types in cord blood. Epigenetics 11(11):773-779.
    https://doi.org/10.1080/15592294.2016.1233091.

Cardenas A, Rifas-Shiman SL, Agha G, et al. 2017a. Persistent DNA methylation changes associated
    with prenatal mercury exposure and cognitive performance during childhood. Sci Rep 7(1):288.
    https://doi.org/10.1038/s41598-017-00384-5.

Cardenas A, Rifas-Shiman SL, Godderis L, et al. 2017b. Prenatal exposure to mercury: Associations
    with global DNA methylation and hydroxymethylation in cord blood and in childhood. Environ
    Health Perspect 125(8):087022. https://doi.org/10.1289/EHP1467.

Carmignani M, Boscolo P. 1984. Cardiovascular homeostasis in rats chronically exposed to mercuric
    chloride. Arch Toxicol Suppl 7:383-388. https://doi.org/10.1007/978-3-642-69132-4_66.

Carmignani M, Boscolo P, Preziosi P. 1989. Renal ultrastructural alterations and cardiovascular
    functional changes in rats exposed to mercuric chloride. Arch Toxicol Suppl 13:353-356.
    https://doi.org/10.1007/978-3-642-74117-3_68.

Carmignani M, Boscolo P, Artese L, et al. 1992. Renal mechanisms in the cardiovascular effects of
    chronic exposure to inorganic mercury in rats. Br J Ind Med 49(4):226-232.
    https://doi.org/10.1136/oem.49.4.226.

Carmona ER, Kossatz E, Creus A, et al. 2008. Genotoxic evaluation of two mercury compounds in the
    Drosophila wing spot test. Chemosphere 70(10):1910-1914.
    https://doi.org/10.1016/j.chemosphere.2007.07.032.

Carneiro MF, Grotto D, Barbosa F. 2014. Inorganic and methylmercury levels in plasma are
    differentially associated with age, gender, and oxidative stress markers in a population exposed to
    mercury through fish consumption. J Toxicol Environ Health A 77(1-3):69-79.
    https://doi.org/10.1080/15287394.2014.865584.

Carocci A, Rovito N, Sinicropi MS, et al. 2014. Mercury toxicity and neurodegenerative effects. Rev
    Environ Contam Toxicol 229:1-18. https://doi.org/10.1007/978-3-319-03777-6_1.

Carrasco P, Estarlich M, Iñiguez C, et al. 2021. Pre and postnatal exposure to mercury and respiratory
    health in preschool children from the Spanish INMA Birth Cohort Study. Sci Total Environ
    782:146654. https://doi.org/10.1016/j.scitotenv.2021.146654.

Carratu MR, Borracci P, Coluccia A, et al. 2006. Acute exposure to methylmercury at two
    developmental windows: Focus on neurobehavioral and neurochemical effects in rat offspring.
    Neuroscience 141(3):1619-1629. https://doi.org/10.1016/j.neuroscience.2006.05.017.

Carratu MR, Coluccia A, Modafferi AM, et al. 2008. Prenatal methylmercury exposure: Effects on
    stress response during active learning. Bull Environ Contam Toxicol 81(6):539-542.
    https://doi.org/10.1007/s00128-008-9557-8.

Carrier G, Bouchard M, Brunet RC, et al. 2001a. A toxicokinetic model for predicting the tissue
    distribution and elimination of organic and inorganic mercury following exposure to methyl mercury
    in animals and humans. II. Application and validation of the model in humans. Toxicol Appl
    Pharmacol 171(1):50-60. https://doi.org/10.1006/taap.2000.9113.

8. REFERENCES

Carrier G, Brunet RC, Caza M, et al. 2001b. A toxicokinetic model for predicting the tissue distribution and elimination of organic and inorganic mercury following exposure to methyl mercury in animals and humans. I. Development and validation of the model using experimental data in rats. Toxicol Appl Pharmacol 171(1):38-49. https://doi.org/10.1006/taap.2000.9112.

Carrington CD, Bolger MP. 2002. An exposure assessment for methylmercury from seafood for consumers in the United States. Risk Anal 22(4):689-699.

Carta P, Flore C, Alinovi R, et al. 2003. Sub-clinical neurobehavioral abnormalities associated with low level of mercury exposure through fish consumption. Neurotoxicology 24(4-5):617-623. https://doi.org/10.1016/s0161-813x(03)00080-9.

Carty AJ, Malone SF. 1979. The chemistry of mercury in biological systems. In: Nriagu JO, ed. The biogeochemistry of mercury in the environment. New York, NY: Elsevier/North Holland Biomedical Press, 433-480.

Casetta I, Invernizzi M, Granieri E. 2001. Multiple sclerosis and dental amalgam: Case-control study in Ferrara, Italy. Neuroepidemiology 20(2):134-137. https://doi.org/10.1159/000054773.

Castano A, Cutanda F, Esteban M, et al. 2015. Fish consumption patterns and hair mercury levels in children and their mothers in 17 EU countries. Environ Res 141:58-68. https://doi.org/10.1016/j.envres.2014.10.029.

Castiello F, Olmedo P, Gil F, et al. 2020. Association of urinary metal concentrations with blood pressure and serum hormones in Spanish male adolescents. Environ Res 182:108958. https://doi.org/10.1016/j.envres.2019.108958.

Castoldi AF, Johansson C, Onishchenko N, et al. 2008. Human developmental neurotoxicity of methylmercury: impact of variables and risk modifiers. Regul Toxicol Pharmacol 51(2):201-214. https://doi.org/10.1016/j.yrtph.2008.01.016.

Castriotta L, Rosolen V, Biggeri A, et al. 2020. The role of mercury, selenium and the Se-Hg antagonism on cognitive neurodevelopment: A 40-month follow-up of the Italian mother-child PHIME cohort. Int J Hyg Environ Health 230:113604. https://doi.org/10.1016/j.ijheh.2020.113604.

Cavalleri A, Gobba F. 1998. Reversible color vision loss in occupational exposure to metallic mercury. Environ Res 77(2):173-177. https://doi.org/10.1006/enrs.1997.3814.

CDC. 2002. Urine output. Centers for Disease Control and Prevention. https://www.cdc.gov/dengue/training/cme/ccm/page57297.html. December 16, 2020.

CDC. 2011. Understanding thimerosal, mercury, and vaccine safety. Centers for Disease Control and Prevention: https://www.cdc.gov/vaccines/hcp/patient-ed/conversations/downloads/vacsafe-thimerosal-color-office.pdf. December 14, 2020.

CDC. 2013. What to do when mercury spills at school. Centers for Disease Control and Prevention. https://www.atsdr.cdc.gov/dontmesswithmercury/pdfs/mercury-spill-instructions.pdf. December 23, 2021.

CDC. 2015. Mercury-containing objects: In schools and your home. Centers for Disease Control and Prevention. https://www.atsdr.cdc.gov/dontmesswithmercury/pdfs/Mercury-containing-objects-in-schools-and-homes_teachers.pdf. December 20, 2021.

CDC. 2019. Fourth national report on human exposure to environmental chemicals, updated tables, January 2019. Atlanta, GA: Centers for Disease Control and Prevention. https://www.cdc.gov/exposurereport/index.html. December 16, 2020.

CDC. 2020. Timeline of thimerosal in vaccines. Centers for Disease Control and Prevention. https://www.cdc.gov/vaccinesafety/concerns/thimerosal/timeline.html. March 15, 2021.

CDC. 2024. Mercury. Biomonitoring data tables for environmental chemicals. Centers for Disease Control and Prevention. https://www.cdc.gov/exposurereport/data_tables.html. April 4, 2024.

Ceccatelli S, Dare E, Moors M. 2010. Methylmercury-induced neurotoxicity and apoptosis. Chem Biol Interact 188(2):301-308. https://doi.org/10.1016/j.cbi.2010.04.007.

Cediel Ulloa A, Gliga A, Love TM, et al. 2021. Prenatal methylmercury exposure and DNA methylation in seven-year-old children in the Seychelles Child Development Study. Environ Int 147:106321. https://doi.org/10.1016/j.envint.2020.106321.

8. REFERENCES

Cember H, Gallagher P, Faulkner A. 1968. Distribution of mercury among blood fractions and serum proteins. Am Ind Hyg Assoc J 29(3):233-237. https://doi.org/10.1080/00028896809342994.

Cernichiari E, Toribara TY, Liang L, et al. 1995. The biological monitoring of mercury in the Seychelles study. Neurotoxicology 16(4):613-628.

Cernichiari E, Myers GJ, Ballatori N, et al. 2007. The biological monitoring of prenatal exposure to methylmercury. Neurotoxicology 28(5):1015-1022. https://doi.org/10.1016/j.neuro.2007.02.009.

Cesario R, Hintelmann H, Mendes R, et al. 2017. Evaluation of mercury methylation and methylmercury demethylation rates in vegetated and non-vegetated saltmarsh sediments from two Portuguese estuaries. Environ Pollut 226:297-307. https://doi.org/10.1016/j.envpol.2017.03.075.

Chalmers AT, Argue DM, Gay DA, et al. 2011. Mercury trends in fish from rivers and lakes in the United States, 1969-2005. Environ Monit Assess 175(1-4):175-191. https://doi.org/10.1007/s10661-010-1504-6.

Chan HM, Egeland GM. 2004. Fish consumption, mercury exposure, and heart diseases. Nutr Rev 62(2):68-72.

Chan PHY, Kwok KM, Chan MHM, et al. 2021. Prenatal methylmercury exposure is associated with decrease heart rate variability in children. Environ Res 200:111744. https://doi.org/10.1016/j.envres.2021.111744.

Chang JY. 2011. Methylmercury-induced IL-6 release requires phospholipase C activities. Neurosci Lett 496(3):152-156. https://doi.org/10.1016/j.neulet.2011.04.004.

Chang LW, Hartmann HA. 1972. Ultrastructural studies of the nervous system after mercury intoxication. I. Pathological changes in the nerve cell bodies. Acta Neuropathol (Berl) 20(2):122-138. https://doi.org/10.1007/bf00691129.

Chang LW, Mak L, Martin AH. 1974. Effects of methylmercury on the limb regeneration of newts Triturus-viridescens. Anat Rec 178(2):509. https://doi.org/10.1016/0013-9351(76)90091-8.

Chang YC, Yeh CY, Wang JD. 1995. Subclinical neurotoxicity of mercury vapor revealed by a multimodality evoked potential study of chloralkali workers. Am J Ind Med 27(2):271-279. https://doi.org/10.1002/ajim.4700270211.

Chang JW, Chen HL, Su HJ, et al. 2011. Simultaneous exposure of non-diabetics to high levels of dioxins and mercury increases their risk of insulin resistance. J Hazard Mater 185(2-3):749-755. https://doi.org/10.1016/j.jhazmat.2010.09.084.

Chang JY, Park JS, Shin S, et al. 2015. Mercury exposure in healthy Korean weaning-age infants: Association with growth, feeding and fish intake. Int J Environ Res Public Health 12(11):14669-14689. https://doi.org/10.3390/ijerph121114669.

Chapman LJ, Sauter SL, Henning RA, et al. 1990. Differences in frequency of finger tremor in otherwise asymptomatic mercury workers. Br J Ind Med 47(12):838-843. https://doi.org/10.1136/oem.47.12.838.

Charbonneau SM, Munro IC, Nera EA, et al. 1976. Chronic toxicity of methylmercury in the adult cat. Interim report. Toxicology 5(3):337-349. https://doi.org/10.1016/0300-483x(76)90052-4.

Charette T, Bueno Dalto D, Rosabal M, et al. 2021. Assessment of in vitro bioaccessibility and in vivo oral bioavailability as complementary tools to better understand the effect of cooking on methylmercury, arsenic, and selenium in tuna. Toxics 9(2):27. https://doi.org/10.3390/toxics9020027.

Charleston JS, Bolender RP, Mottet NK, et al. 1994. Increases in the number of reactive glia in the visual cortex of Macaca fascicularis following subclinical long-term methyl mercury exposure. Toxicol Appl Pharmacol 129(2):196-206. https://doi.org/10.1006/taap.1994.1244.

Charleston JS, Body RL, Mottet NK, et al. 1995. Autometallographic determination of inorganic mercury distribution in the cortex of the calcarine sulcus of the monkey Macaca fascicularis following long-term subclinical exposure to methylmercury and mercuric chloride. Toxicol Appl Pharmacol 132(2):325-333. https://doi.org/10.1006/taap.1995.1114.

8. REFERENCES

Charleston JS, Body RL, Bolender RP, et al. 1996. Changes in the number of astrocytes and microglia in the thalamus of the monkey Macaca fascicularis following long-term subclinical methylmercury exposure. Neurotoxicology 17(1):127-138.

Cheatham C. 2008. Omega-3 fatty acids and the development of cognitive abilities: A review of DHA supplementation studies. CAB Rev Perspect Agric Vet Sci Nutr Nat Resour 3(001):1-15. https://doi.org/10.1079/pavsnnr20083001.

Chehimi L, Roy V, Jeljeli M, et al. 2012. Chronic exposure to mercuric chloride during gestation affects sensorimotor development and later behaviour in rats. Behav Brain Res 234(1):43-50. https://doi.org/10.1016/j.bbr.2012.06.005.

Chemelo VS, Nascimento PC, Bittencourt LO, et al. 2022. In utero and lactational exposure to methylmercury elicits physical-chemical and morphological damages in the alveolar bone of offspring rats: The first toxicological findings. Chemosphere 308(Pt 3):136453. https://doi.org/10.1016/j.chemosphere.2022.136453.

Chen L, Li Y. 2019. A review on the distribution and cycling of mercury in the pacific ocean. Bull Environ Contam Toxicol 102(5):665-671. https://doi.org/10.1007/s00128-019-02560-x.

Chen CY, Dionne M, Mayes BM, et al. 2009. Mercury bioavailability and bioaccumulation in estuarine food webs in the Gulf of Maine. Environ Sci Technol 43(6):1804-1810.

Chen KL, Liu SH, Su CC, et al. 2012. Mercuric compounds induce pancreatic islets dysfunction and apoptosis in vivo. Int J Mol Sci 13(10):12349-12366. https://doi.org/10.3390/ijms131012349.

Chen A, Kim SS, Chung E, et al. 2013. Thyroid hormones in relation to lead, mercury, and cadmium exposure in the National Health and Nutrition Examination Survey, 2007-2008. Environ Health Perspect 121(2):181-186. https://doi.org/10.1289/ehp.1205239.

Chen C, Xun P, McClure LA, et al. 2018. Serum mercury concentration and the risk of ischemic stroke: The REasons for Geographic and Racial Differences in Stroke Trace Element Study. Environ Int 117:125-131. https://doi.org/10.1016/j.envint.2018.05.001.

Chen N, Lin M, Liu N, et al. 2019a. Methylmercury-induced testis damage is associated with activation of oxidative stress and germ cell autophagy. J Inorg Biochem 190:67-74. https://doi.org/10.1016/j.jinorgbio.2018.10.007.

Chen R, Xu Y, Xu C, et al. 2019b. Associations between mercury exposure and the risk of nonalcoholic fatty liver disease (NAFLD) in US adolescents. Environ Sci Pollut Res Int 26(30):31384-31391. https://doi.org/10.1007/s11356-019-06224-5.

Chen KH, Yu HC, Chang YC. 2021. Analysis of dental amalgam fillings on primary Sjögren's syndrome: A population-based case-control study in Taiwan. Medicine (Baltimore) 100(47):e28031. https://doi.org/10.1097/md.0000000000028031.

Chen C, Zhang S, Yang T, et al. 2023a. Associations between environmental heavy metals exposure and preserved ratio impaired spirometry in the U.S. adults. Environ Sci Pollut Res Int 30(49):108274-108287. https://doi.org/10.1007/s11356-023-29688-y.

Chen Y, Zhao A, Li R, et al. 2023b. Independent and combined associations of multiple-heavy-metal exposure with lung function: a population-based study in US children. Environ Geochem Health 45(7):5213-5230. https://doi.org/10.1007/s10653-023-01565-0.

Chen T, Li Y, Liu J, et al. 2023c. The burden of mild intellectual disability attributed to prenatal exposure to methylmercury in China, 2017. Ecotoxicol Environ Saf 254:114748. https://doi.org/10.1016/j.ecoenv.2023.114748.

Cheng J, Fujimura M, Bo D. 2015. Assessing pre/post-weaning neurobehavioral development for perinatal exposure to low doses of methylmercury. J Environ Sci (China) 38:36-41. https://doi.org/10.1016/j.jes.2015.05.027.

Cherian MG, Clarkson TW. 1976. Biochemical changes in rat kidney on exposure to elemental mercury vapor: Effect on biosynthesis of metallothionein. Chem Biol Interact 12(2):109-120. https://doi.org/10.1016/0009-2797(76)90093-4.

8. REFERENCES

Cherian MG, Hursh JB, Clarkson TW, et al. 1978. Radioactive mercury distribution in biological fluids and excretion in human subjects after inhalation of mercury vapor. Arch Environ Health 33(3):109-114. https://doi.org/10.1080/00039896.1978.10667318.

Chernyak YI, Merinova AP. 2017. HSP70 (HSPA1) polymorphisms in former workers with chronic mercury vapor exposure. Int J Occup Med Environ Health 30(1):77-85. https://doi.org/10.13075/ijomeh.1896.00732.

Cheuk DK, Wong V. 2006. Attention-deficit hyperactivity disorder and blood mercury level: a case-control study in Chinese children. Neuropediatrics 37(4):234-240. https://doi.org/10.1055/s-2006-924577.

Chevrier C, Sullivan K, White RF, et al. 2009. Qualitative assessment of visuospatial errors in mercury-exposed Amazonian children. Neurotoxicology 30(1):37-46. https://doi.org/10.1016/j.neuro.2008.09.012.

Cho KY. 2021. Association of blood mercury levels with the risks of overweight and high waist-to-height ratio in children and adolescents: Data from the Korean National Health and Nutrition Examination Survey. Children (Basel) 8(12):1087. https://doi.org/10.3390/children8121087.

Cho HW, Kim SH, Park MJ. 2020. An association of blood mercury levels and hypercholesterolemia among Korean adolescents. Sci Total Environ 709:135965. https://doi.org/10.1016/j.scitotenv.2019.135965.

Cho GJ, Park HT, Shin JH, et al. 2012. The relationship between blood mercury level and osteoporosis in postmenopausal women. Menopause 19(5):576-581. https://doi.org/10.1097/gme.0b013e3182377294.

Choi YH, Park SK. 2017. Environmental exposures to lead, mercury, and cadmium and hearing loss in adults and adolescents: KNHANES 2010-2012. Environ Health Perspect 125(6):1-8. https://doi.org/10.1289/ehp565.

Choi AL, Cordier S, Weihe P, et al. 2008a. Negative confounding in the evaluation of toxicity: the case of methylmercury in fish and seafood. Crit Rev Toxicol 38(10):877-893. https://doi.org/10.1080/10408440802273164.

Choi AL, Budtz-Jorgensen E, Jorgensen PJ, et al. 2008b. Selenium as a potential protective factor against mercury developmental neurotoxicity. Environ Res 107(1):45-52. https://doi.org/10.1016/j.envres.2007.07.006.

Choi AL, Weihe P, Budtz-Jorgensen E, et al. 2009. Methylmercury exposure and adverse cardiovascular effects in Faroese whaling men. Environ Health Perspect 117(3):367-372. https://doi.org/10.1289/ehp.11608.

Choi B, Yeum KJ, Park SJ, et al. 2015. Elevated serum ferritin and mercury concentrations are associated with hypertension; analysis of the fourth and fifth Korea national health and nutrition examination survey (KNHANES IV-2, 3, 2008-2009 and V-1, 2010). Environ Toxicol 30(1):101-108. https://doi.org/10.1002/tox.21899.

Choi J, Bae S, Lim H, et al. 2017. Mercury exposure in association with decrease of liver function in adults: A longitudinal study. J Prev Med Public Health 50(6):377-385. https://doi.org/10.3961/jpmph.17.099.

Choi S, Lee A, Choi G, et al. 2022. Free cortisol mediates associations of maternal urinary heavy metals with neonatal anthropometric measures: A cross-sectional study. Toxics 10(4):167. https://doi.org/10.3390/toxics10040167.

Chowdhury R, Ramond A, O'Keeffe LM, et al. 2018. Environmental toxic metal contaminants and risk of cardiovascular disease: Systematic review and meta-analysis. BMJ 362:k3310. https://doi.org/10.1136/bmj.k3310.

Choy CM, Yeung QS, Briton-Jones CM, et al. 2002. Relationship between semen parameters and mercury concentrations in blood and in seminal fluid from subfertile males in Hong Kong. Fertil Steril 78(2):426-428. https://doi.org/10.1016/s0015-0282(02)03232-6.

Christensen H, Krogh M, Nielsen M. 1937. Acute mercury poisoning in a respiration chamber. Nature 139(3519):626-627. https://doi.org/10.1038/139626b0.

8. REFERENCES

Christie NT, Cantoni O, Evans RM, et al. 1984. Use of mammalian DNA repair-deficient mutants to assess the effects of toxic metal compounds on DNA. Biochem Pharmacol 33(10):1661-1670. https://doi.org/10.1016/0006-2952(84)90289-2.

Christie NT, Cantoni O, Sugiyama M, et al. 1986. Differences in the effects of Hg(II) on DNA repair induced in Chinese hamster ovary cells by ultraviolet or X-rays. Mol Pharmacol 29(2):173-178.

Chung SH, Myong JP. 2016. Are higher blood mercury levels associated with dry eye symptoms in adult Koreans? A population-based cross-sectional study. BMJ Open 6(4):e010985. https://doi.org/10.1136/bmjopen-2015-010985.

Chung SM, Moon JS, Yoon JS, et al. 2020. The sex-specific effects of blood lead, mercury, and cadmium levels on hepatic steatosis and fibrosis: Korean nationwide cross-sectional study. J Trace Elem Med Biol 62:126601. https://doi.org/10.1016/j.jtemb.2020.126601.

Chung JW, Acharya D, Singh JK, et al. 2023. Association of blood mercury level with liver enzymes in Korean adults: An analysis of 2015-2017 Korean National Environmental Health Survey. Int J Environ Res Public Health 20(4):3290. https://doi.org/10.3390/ijerph20043290.

Chuu JJ, Hsu CJ, Lin-Shiau SY. 2001a. Abnormal auditory brainstem responses for mice treated with mercurial compounds: Involvement of excessive nitric oxide. Toxicology 162(1):11-22. https://doi.org/10.1016/s0300-483x(01)00348-1.

Chuu JJ, Young YH, Liu SH, et al. 2001b. Neurotoxicity of mercury sulfide in the vestibular ocular reflex system of guinea pigs. Naunyn Schmiedebergs Arch Pharmacol 364(3):249-258. https://doi.org/10.1007/s002100000279.

Chuu JJ, Liu SH, Lin-Shiau SY. 2007. Differential neurotoxic effects of methylmercury and mercuric sulfide in rats. Toxicol Lett 169(2):109-120. https://doi.org/10.1016/j.toxlet.2006.12.006.

Clarkson TW. 1971. Epidemiological and experimental aspects of lead and mercury contamination of food. Food Cosmet Toxicol 9(2):229-243. https://doi.org/10.1016/0015-6264(71)90308-7.

Clarkson TW. 1989. Mercury. J Am Coll Toxicol 8(7):1291-1295.

Clarkson TW. 1993. Molecular and ionic mimicry of toxic metals. Annu Rev Pharmacol Toxicol 32:545-571.

Clarkson TW. 2006. The three modern faces of mercury. Birth Defects Res A Clin Mol Teratol 76(5):359.

Clarkson T, Rothstein A. 1964. The excretion of volatile mercury by rats injected with mercuric salts. Health Phys 10:1115-1121. https://doi.org/10.1097/00004032-196412000-00032.

Clarkson TW, Shapiro RE. 1971. The absorption of mercury from food, its significance and new methods of removing mercury from the body. In: Proceedings of special symposium on mercury in man's environment. Ottawa, Canada: The Royal Society of Canada, 124-130.

Clarkson TW, Magos L. 2006. The toxicology of mercury and its chemical compounds. Crit Rev Toxicol 36(8):609-662. https://doi.org/10.1080/10408440600845619.

Clarkson TW, Magos L, Greenwood MR. 1972. The transport of elemental mercury into fetal tissues. Neonatology 21(3-4):239-244. https://doi.org/10.1159/000240512.

Clarkson TW, Amin-Zaki L, Al-Tikriti SK. 1976. An outbreak of methylmercury poisoning due to consumption of contaminated grain. Fed Proc 35(12):2395-2399.

Clarkson TW, Friberg L, Hursh JB, et al. 1988. The prediction of intake of mercury vapor from amalgams. In: Biological monitoring of toxic metals. New York, NY: Plenum Press, 247-264.

Clarkson TW, Magos L, Myers GJ. 2003. The toxicology of mercury--current exposures and clinical manifestations. N Engl J Med 349(18):1731-1737. https://doi.org/10.1056/NEJMra022471.

Clarkson TW, Vyas JB, Ballatori N. 2007. Mechanisms of mercury disposition in the body. Am J Ind Med 50(10):757-764. https://doi.org/10.1002/ajim.20476.

Clewell HJ. 1995. The application of physiologically based pharmacokinetic modeling in human health risk assessment of hazardous substances. Toxicol Lett 79(1-3):207-217. https://doi.org/10.1016/0378-4274(95)03372-r.

Clewell HJ, Gearhart JM, Gentry PR, et al. 1999. Evaluation of the uncertainty in an oral reference dose for methylmercury due to interindividual variability in pharmacokinetics. Risk Anal 19(4):547-558.

Cocking D, King ML, Ritchie L, et al. 1994. Earthworm bioaccumulation of mercury from contaminated flood plain soils. In: Watras CJ, Huckabee JW, eds. Mercury pollution integration and synthesis. Boca Raton, FL: Lewis Publishers, 381-394.

Cohen JT, Bellinger DC, Shaywitz BA. 2005. A quantitative analysis of prenatal methyl mercury exposure and cognitive development. Am J Prev Med 29(4):353-365. https://doi.org/10.1016/j.amepre.2005.06.007.

Cohen MD, Draxler RR, Artz RS, et al. 2016. Modeling the global atmospheric transport and deposition of mercury to the Great Lakes. Elementa 4:000118. https://doi.org/10.12952/journal.elementa.000118.

Cole DC, Wainman B, Sanin LH, et al. 2006. Environmental contaminant levels and fecundability among non-smoking couples. Reprod Toxicol 22(1):13-19. https://doi.org/10.1016/j.reprotox.2005.12.001.

Colon-Rodriguez A, Hannon HE, Atchison WD. 2017. Effects of methylmercury on spinal cord afferents and efferents. A review. Neurotoxicology 60:308-320. https://doi.org/10.1016/j.neuro.2016.12.007.

Coluccia A, Borracci P, Giustino A, et al. 2007. Effects of low dose methylmercury administration during the postnatal brain growth spurt in rats. Neurotoxicol Teratol 29(2):282-287. https://doi.org/10.1016/j.ntt.2006.10.005.

Copan L, Fowles J, Barreau T, et al. 2015. Mercury toxicity and contamination of households from the use of skin creams adulterated with mercurous chloride (calomel). Int J Environ Res Public Health 12(9):10943-10954. https://doi.org/10.3390/ijerph120910943.

Cope WG, Wiener JG, Rada RG. 1990. Mercury accumulation in yellow perch in Wisconsin seepage lakes: Relation to lake characteristics. Environ Toxicol Chem 9(7):931-940. https://doi.org/10.1002/etc.5620090711.

Cordier S, Deplan F, Mandereau L, et al. 1991. Paternal exposure to mercury and spontaneous abortions. Br J Ind Med 48(6):375-381. https://doi.org/10.1136/oem.48.6.375.

Cordier S, Garel M, Mandereau L, et al. 2002. Neurodevelopmental investigations among methylmercury-exposed children in French Guiana. Environ Res 89(1):1-11. https://doi.org/10.1006/enrs.2002.4349.

Cordier S, Anassour-Laouan-Sidi E, Lemire M, et al. 2020. Association between exposure to persistent organic pollutants and mercury, and glucose metabolism in two Canadian Indigenous populations. Environ Res 184:109345. https://doi.org/10.1016/j.envres.2020.109345.

Corrêa MG, Bittencourt LO, Nascimento PC, et al. 2020. Spinal cord neurodegeneration after inorganic mercury long-term exposure in adult rats: Ultrastructural, proteomic and biochemical damages associated with reduced neuronal density. Ecotoxicol Environ Saf 191:110159. https://doi.org/10.1016/j.ecoenv.2019.110159.

Cortés-Gutiérrez EI, Cerda-Flores RM, Gonzalez-Ramirez D, et al. 2004. Evaluation of the mutagenic and cytotoxic effects of mercurous chloride by the micronuclei technique in golden Syrian hamsters. Mutagenesis 19(3):203-205.

Cortes-Maramba N, Reyes JP, Francisco-Rivera AT, et al. 2006. Health and environmental assessment of mercury exposure in a gold mining community in Western Mindanao, Philippines. J Environ Manage 81(2):126-134. https://doi.org/10.1016/j.jenvman.2006.01.019.

Cossa D, Gobeil C, Courau P. 1988. Dissolved mercury behaviour in the Saint Lawrence estuary. Estuarine Coastal Shelf Sci 26(2):227-230. https://doi.org/10.1016/0272-7714(88)90052-2.

Costa M, Christie NT, Cantoni O, et al. 1991. DNA damage by mercury compounds: An overview. In: Suzuki T, Imura N, Clarkson TW, eds. Advances in mercury toxicology. New York, NY: Plenum Press, 255-273.

Counter SA. 2003. Neurophysiological anomalies in brainstem responses of mercury-exposed children of Andean gold miners. J Occup Environ Med 45(1):87-95.

Counter SA, Buchanan LH, Laurell G, et al. 1998. Blood mercury and auditory neuro-sensory responses in children and adults in the Nambija gold mining area of Ecuador. Neurotoxicology 19(2):185-196.

Counter SA, Buchanan LH, Ortega F. 2006. Neurocognitive screening of mercury-exposed children of Andean gold miners. Int J Occup Environ Health 12(3):209-214. https://doi.org/10.1179/oeh.2006.12.3.209.

Counter SA, Buchanan LH, Ortega F. 2012. Acoustic stapedius muscle reflex in mercury-exposed Andean children and adults. Acta Oto-Laryngologica 132(1):51-63. https://doi.org/10.3109/00016489.2011.617778.

Counter SA, Buchanan LH, Ortega F, et al. 2002. Elevated blood mercury and neuro-otological observations in children of the Ecuadorian gold mines. J Toxicol Environ Health A 65(2):149-163. https://doi.org/10.1080/152873902753396785.

Cox C, Clarkson TW, Marsh DO, et al. 1989. Dose-response analysis of infants prenatally exposed to methyl mercury: An application of a single compartment model to single-strand hair analysis. Environ Res 49(2):318-332.

Cragle DL, Hollis DR, Qualters JR, et al. 1984. A mortality study of men exposed to elemental mercury. J Occup Med 26(11):817-821. https://doi.org/10.1097/00043764-198411000-00011.

Creed JH, Peeri NC, Anic GM, et al. 2019. Methylmercury exposure, genetic variation in metabolic enzymes, and the risk of glioma. Sci Rep 9(1):10861. https://doi.org/10.1038/s41598-019-47284-4.

Crespo-López ME, Lima de Sa A, Herculano AM, et al. 2007. Methylmercury genotoxicity: a novel effect in human cell lines of the central nervous system. Environ Int 33(2):141-146. https://doi.org/10.1016/j.envint.2006.08.005.

Crespo-Lopez ME, Costa-Malaquias A, Oliveira EH, et al. 2016. Is low non-lethal concentration of methylmercury really safe? A report on genotoxicity with delayed cell proliferation. PLoS ONE 11(9):e0162822. https://doi.org/10.1371/journal.pone.0162822.

CRITFC. 1994. A fish consumption survey of the Umatilla, Nez Perce, Yakima and Warm Springs tribes of the Columbia River Basin. Columbia River Inter-Tribal Fish Commission. 1-105. Technical Report 94-3.

Crowe W, Doherty L, Watson G, et al. 2015. Mercury in hair is inversely related to disease associated damage in systemic lupus erythematosus. Int J Environ Res Public Health 13(1):0075. https://doi.org/10.3390/ijerph13010075.

Crump K, Viren J, Silvers A, et al. 1995. Reanalysis of dose-response data from the Iraqi methylmercury poisoning episode. Risk Anal 15(4):523-532.

Crump KS, Kjellstrom T, Shipp AM, et al. 1998. Influence of prenatal mercury exposure upon scholastic and psychological test performance: benchmark analysis of a New Zealand cohort. Risk Anal 18(6):701-713.

Crump KS, Van Landingham C, Shamlaye C, et al. 2000. Benchmark concentrations for methylmercury obtained from the Seychelles Child Development Study. Environ Health Perspect 108(3):257-263.

Culbreth M, Aschner M. 2016. Dysregulation of glutamate cycling mediates methylmercury-induced neurotoxicity. Adv Neurobiol 13:295-305. https://doi.org/10.1007/978-3-319-45096-4_11.

Czuba M, Mortimer DC. 1980. Stability of methylmercury and inorganic mercury in aquatic plants (Elodea densa). Can J Bot 58(3):316-320.

da Cunha Martins A, Carneiro MFH, Grotto D, et al. 2018. Arsenic, cadmium, and mercury-induced hypertension: mechanisms and epidemiological findings. J Toxicol Environ Health B Crit Rev 21(2):61-82. https://doi.org/10.1080/10937404.2018.1432025.

da Silva DCB, Bittencourt LO, Baia-da-Silva DC, et al. 2022. Methylmercury causes neurodegeneration and downregulation of myelin basic protein in the spinal cord of offspring rats after maternal exposure. Int J Mol Sci 23(7):3777. https://doi.org/10.3390/ijms23073777.

Dack K, Wootton RE, Taylor CM, et al. 2023. Prenatal mercury exposure and infant weight trajectories in a UK observational birth cohort. Toxics 11(1):10. https://doi.org/10.3390/toxics11010010.

Dakeishi M, Nakai K, Sakamoto M, et al. 2005. Effects of hair treatment on hair mercury-The best biomarker of methylmercury exposure? Environ Health Prev Med 10(4):208-212. https://doi.org/10.1007/bf02897712.

8. REFERENCES

Dallaire R, Dewailly E, Ayotte P, et al. 2013. Exposure to organochlorines and mercury through fish and marine mammal consumption: associations with growth and duration of gestation among Inuit newborns. Environ Int 54:85-91. https://doi.org/10.1016/j.envint.2013.01.013.

Daneshmand R, Kurl S, Tuomainen TP, et al. 2016. Associations of serum n-3 and n-6 PUFA and hair mercury with the risk of incident stroke in men: the Kuopio Ischaemic Heart Disease Risk Factor Study (KIHD). Br J Nutr 115(10):1851-1859. https://doi.org/10.1017/S0007114516000982.

Daniel JW, Gage JC, Lefevre PA. 1972. The metabolism of phenylmercury by the rat. Biochem J 129(4):961-967. https://doi.org/10.1042/bj1290961.

Daniels JL, Longnecker MP, Rowland AS, et al. 2004. Fish intake during pregnancy and early cognitive development of offspring. Epidemiology 15(4):394-402. https://doi.org/10.1097/01.ede.0000129514.46451.ce.

Danielsson BR, Fredriksson A, Dahlgren L, et al. 1993. Behavioural effects of prenatal metallic mercury inhalation exposure in rats. Neurotoxicol Teratol 15(6):391-396. https://doi.org/10.1016/0892-0362(93)90056-t.

Danscher G, Moller-Madsen B. 1985. Silver amplification of mercury sulfide and selenide: a histochemical method for light and electron microscopic localization of mercury in tissue. J Histochem Cytochem 33(3):219-228. https://doi.org/10.1177/33.3.2579122.

Das RM, Ahmed MK, Oulton MR, et al. 1997. Methylmercury-induced alterations in lung and pulmonary surfactant properties of adult mice. Chem Phys Lipids 89(2):107-117. https://doi.org/10.1016/s0009-3084(97)00072-8.

Dastoor A, Wilson SJ, Travnikov O, et al. 2022. Arctic atmospheric mercury: Sources and changes. Sci Total Environ 839:156213. https://doi.org/10.1016/j.scitotenv.2022.156213.

Davidson PW, Meyers GJ, Cox C, et al. 1995. Longitudinal neurodevelopmental study of Seychellois children following in utero exposure to methylmercury from maternal fish ingestion: Outcomes at 19 and 29 months. Neurotoxicology 16(4):677-688.

Davidson PW, Myers GJ, Cox C, et al. 1998. Effects of prenatal and postnatal methylmercury exposure from fish consumption on neurodevelopment: Outcomes at 66 months of age in the Seychelles Child Development Study. JAMA 280(8):701-707. https://doi.org/10.1001/jama.280.8.701.

Davidson PW, Myer GJ, Shamlaye C, et al. 1999. Association between prenatal exposure to methylmercury and developmental outcomes in Seychellois children: effect modification by social and environmental factors. Neurotoxicology 20(5):833-841.

Davidson PW, Myers GJ, Shamlaye C, et al. 2004. Prenatal exposure to methylmercury and child development: influence of social factors. Neurotoxicol Teratol 26(4):553-559. https://doi.org/10.1016/j.ntt.2004.03.007.

Davidson PW, Myers GJ, Cox C, et al. 2006a. Methylmercury and neurodevelopment: Longitudinal analysis of the Seychelles child development cohort. Neurotoxicol Teratol 28(5):529-535. https://doi.org/10.1016/j.ntt.2006.06.002.

Davidson PW, Myers GJ, Weiss B, et al. 2006b. Prenatal methyl mercury exposure from fish consumption and child development: a review of evidence and perspectives from the Seychelles Child Development Study. Neurotoxicology 27(6):1106-1109. https://doi.org/10.1016/j.neuro.2006.03.024.

Davidson PW, Jean Sloane R, Myers GJ, et al. 2008a. Association between prenatal exposure to methylmercury and visuospatial ability at 10.7 years in the Seychelles Child Development Study. Neurotoxicology 29(3):453-459. https://doi.org/10.1016/j.neuro.2008.02.009.

Davidson PW, Strain JJ, Myers GJ, et al. 2008b. Neurodevelopmental effects of maternal nutritional status and exposure to methylmercury from eating fish during pregnancy. Neurotoxicology 29(5):767-775. https://doi.org/10.1016/j.neuro.2008.06.001.

Davidson PW, Leste A, Benstrong E, et al. 2010. Fish consumption, mercury exposure, and their associations with scholastic achievement in the Seychelles Child Development Study. Neurotoxicology 31(5):439-447. https://doi.org/10.1016/j.neuro.2010.05.010.

8. REFERENCES

Davidson PW, Cory-Slechta DA, Thurston SW, et al. 2011. Fish consumption and prenatal methylmercury exposure: cognitive and behavioral outcomes in the main cohort at 17 years from the Seychelles child development study. Neurotoxicology 32(6):711-717. https://doi.org/10.1016/j.neuro.2011.08.003.

Davis LE. 2000. Unregulated potions still cause mercury poisoning. West J Med 173(1):19.

Davis BJ, Price HC, O'Connor RW, et al. 2001. Mercury vapor and female reproductive toxicity. Toxicol Sci 59(2):291-296. https://doi.org/10.1093/toxsci/59.2.291.

Davis MA, Gilbert-Diamond D, Karagas MR, et al. 2014. A dietary-wide association study (DWAS) of environmental metal exposure in US children and adults. PLoS ONE 9(9):e104768. https://doi.org/10.1371/journal.pone.0104768.

de Burbure C, Buchet JP, Leroyer A, et al. 2006. Renal and neurologic effects of cadmium, lead, mercury, and arsenic in children: evidence of early effects and multiple interactions at environmental exposure levels. Environ Health Perspect 114(4):584-590. https://doi.org/10.1289/ehp.8202.

de Ceaurriz J, Payan JP, Morel G, et al. 1994. Role of extracellular glutathione and gamma-glutamyltranspeptidase in the disposition and kidney toxicity of inorganic mercury in rats. J Appl Toxicol 14(3):201-206.

de Oliveira Lopes G, Aragão WAB, Bittencourt LO, et al. 2021. Imaging microstructural damage and alveolar bone loss in rats systemically exposed to methylmercury: first experimental evidence. Biol Trace Elem Res 199(10):3707-3717. https://doi.org/10.1007/s12011-020-02492-2.

de Winter-Sorkina R, Bakker MI, van Donkersgoed G, et al. 2003. Dietary intake of heavy metals (cadmium, lead and mercury) by the Dutch population. Wageningen, Netherlands: Institute of Food Safety. 1-49. RIVM report 320103001. RIKILT-report 2003.016.

Dean JG, Bosqui FL, Lanouette KH. 1972. Removing heavy metals from waste water. Environ Sci Technol 6(6):518-522. https://doi.org/10.1021/es60065a006.

Debes F, Budtz-Jorgensen E, Weihe P, et al. 2006. Impact of prenatal methylmercury exposure on neurobehavioral function at age 14 years. Neurotoxicol Teratol 28(5):536-547. https://doi.org/10.1016/j.ntt.2006.02.005.

Debes F, Weihe P, Grandjean P. 2016. Cognitive deficits at age 22 years associated with prenatal exposure to methylmercury. Cortex 74:358-369. https://doi.org/10.1016/j.cortex.2015.05.017.

Decharat S, Phethuayluk P, Maneelok S, et al. 2014. Determination of mercury exposure among dental health workers in Nakhon Si Thammarat Province, Thailand. J Toxicol 2014:1-8. https://doi.org/10.1155/2014/401012.

Dencker L, Danielsson B, Khayat A, et al. 1983. Deposition of metals in the embryo and fetus. In: Clarkson TW, Nordberg GG, Sager PR, eds. Reproductive and developmental toxicity of metals. New York, NY: Plenum Press, 607-631.

Denkenberger JS, Fakhraei H, Branfireun B, et al. 2020. Watershed influences on mercury in tributaries to Lake Ontario. Ecotoxicology 29(10):1614-1626. https://doi.org/10.1007/s10646-019-02157-4.

DeRouen TA, Martin MD, Leroux BG, et al. 2006. Neurobehavioral effects of dental amalgam in children: A randomized clinical trial. JAMA 295(15):1784-1792. https://doi.org/10.1001/jama.295.15.1784.

Desai G, Niu Z, Luo W, et al. 2021. Low-level exposure to lead, mercury, arsenic, and cadmium, and blood pressure among 8-17-year-old participants of the 2009-2016 National Health and Nutrition Examination Survey. Environ Res 197:111086. https://doi.org/10.1016/j.envres.2021.111086.

Desjardins RM, Bradbury WC, Seyfried PL. 1988. Effects of metals from mine tailings on the microflora of a marsh treatment system. In: Adams WJ, Chapman GA, Landis WG, eds. Aquatic toxicology and hazard assessment. Vol. 10th. Philadelphia, PA: American Society for Testing and Materials, 491-502.

Despres C, Beuter A, Richer F, et al. 2005. Neuromotor functions in Inuit preschool children exposed to Pb, PCBs, and Hg. Neurotoxicol Teratol 27(2):245-257. https://doi.org/10.1016/j.ntt.2004.12.001.

DeVito SC, Brooks WE. 2013. Mercury. In: Kirk-Othmer encyclopedia of chemical technology. Hoboken, NJ: Wiley, 1-23.

Diamond GL. 1988. Biological monitoring of urine for exposure to toxic metals. In: Clarkson TW, Friberg L, Nordberg GF, et al., eds. Biological monitoring of toxic metals. New York, NY: Plenum Press, 515-529.

Dick AL, Sheppard DS, Patterson JE. 1990. Mercury content of Antarctic surface snow: Initial results. Atmos Environ 24A(4):973-978. https://doi.org/10.1016/0960-1686(90)90299-3.

Dickerson EH, Sathyapalan T, Knight R, et al. 2011. Endocrine disruptor & nutritional effects of heavy metals in ovarian hyperstimulation. J Assist Reprod Genet 28(12):1223-1228. https://doi.org/10.1007/s10815-011-9652-3.

Dieter MP, Luster MI, Boorman GA, et al. 1983. Immunological and biochemical responses in mice treated with mercuric chloride. Toxicol Appl Pharmacol 68(2):218-228. https://doi.org/10.1016/0041-008x(83)90006-6.

Dieter MP, Boorman GA, Jameson CW, et al. 1992. Development of renal toxicity in F344 rats gavaged with mercuric chloride for 2 weeks, or 2, 4, 6, 15, and 24 months. J Toxicol Environ Health 36(4):319-340. https://doi.org/10.1080/15287399209531642.

Dieter MP, Goehl TJ, Jameson CW, et al. 1993. Comparison of the toxicity of citral in F344 rats and B6C3F1 mice when administered by microencapsulation in feed or by corn-oil gavage. Food Chem Toxicol 31(7):463-474. https://doi.org/10.1016/0278-6915(93)90105-8.

Dietrich MO, Mantese CE, Anjos GD, et al. 2005. Motor impairment induced by oral exposure to methylmercury in adult mice. Environ Toxicol Pharmacol 19(1):169-175. https://doi.org/10.1016/j.etap.2004.07.004.

Ding G, Cui C, Chen L, et al. 2013. Prenatal low-level mercury exposure and neonatal anthropometry in rural northern China. Chemosphere 92(9):1085-1089. https://doi.org/10.1016/j.chemosphere.2013.01.045.

Diringer SE, Feingold BJ, Ortiz EJ, et al. 2015. River transport of mercury from artisanal and small-scale gold mining and risks for dietary mercury exposure in Madre de Dios, Peru. Environ Sci Process Impacts 17(2):478-487. https://doi.org/10.1039/c4em00567h.

Discalzi G, Fabbro D, Meliga F, et al. 1993. Effects of occupational exposure to mercury and lead on brainstem auditory evoked potentials. Int J Psychophysiol 14(1):21-25. https://doi.org/10.1016/0167-8760(93)90080-9.

Dock L, Rissanen RL, Vahter M. 1994. Demethylation and placental transfer of methyl mercury in the pregnant hamster. Toxicology 94(1):131-142. https://doi.org/10.1016/0300-483X(94)90033-7.

DOE. 2018a. Table 3: Protective action criteria (PAC) rev. 29a based on applicable 60-minute AEGLs, ERPGs, or TEELs. The chemicals are listed by CASRN. June 2018. U.S. Department of Energy. https://edms3.energy.gov/pac/docs/Revision_29A_Table3.pdf. July 6, 2022.

DOE. 2018b. Protective action criteria (PAC) with AEGLs, ERPGs, & TEELs: Rev. 29A, June 2018. U.S. Department of Energy. https://edms3.energy.gov/pac/. July 6, 2022.

DOI. 1985. Mercury. Mineral facts and problems. Washington, DC: U.S. Department of the Interior. 499-508. Bureau of Mines Bulletin 675.

DOI. 1989. Mercury. In: Minerals yearbook. Washington, DC: U.S. Department of the Interior, 705-708.

DOI. 1990. Mercury. In: Minerals yearbook. Washington, DC: U.S. Department of the Interior, 743-747.

DOI. 1991. Mineral commodity summaries, 1991: Mercury. Washington, DC: Department of the Interior.

DOI. 1993. Mineral commodity summaries, 1993: Mercury. Washington, DC: U.S. Department of the Interior.

Dolar SG, Keeney DR, Chesters G. 1971. Mercury accumulation by Myriophyllum spicatum L. Environ Lett 1(3):191-198. https://doi.org/10.1080/00139307109434981.

Dolbec J, Mergler D, Sousa Passos CJ, et al. 2000. Methylmercury exposure affects motor performance of a riverine population of the Tapajos river, Brazilian Amazon. Int Arch Occup Environ Health 73(3):195-203. https://doi.org/10.1007/s004200050027.

8. REFERENCES

Dolbec J, Mergler D, Larribe F, et al. 2001. Sequential analysis of hair mercury levels in relation to fish diet of an Amazonian population, Brazil. Sci Total Environ 271(1-3):87-97. https://doi.org/10.1016/s0048-9697(00)00835-4.

Dong Z, Jim RC, Hatley EL, et al. 2015. A longitudinal study of mercury exposure associated with consumption of freshwater fish from a reservoir in rural south central USA. Environ Res 136:155-162. https://doi.org/10.1016/j.envres.2014.09.029.

Donohue A, Wagner CL, Burch JB, et al. 2018. Blood total mercury and methylmercury among pregnant mothers in Charleston, South Carolina, USA. J Expo Sci Environ Epidemiol 28(5):494-504. https://doi.org/10.1038/s41370-018-0033-1.

Dore FY, Goulet S, Gallagher A, et al. 2001. Neurobehavioral changes in mice treated with methylmercury at two different stages of fetal development. Neurotoxicol Teratol 23(5):463-472. https://doi.org/10.1016/s0892-0362(01)00167-2.

Dorea JG, Marques RC, Isejima C. 2012. Neurodevelopment of Amazonian infants: antenatal and postnatal exposure to methyl- and ethylmercury. J Biomed Biotechnol 2012:1-9. https://doi.org/10.1155/2012/132876.

Dorea JG, Marques RC, Abreu L. 2014. Milestone achievement and neurodevelopment of rural Amazonian toddlers (12 to 24 months) with different methylmercury and ethylmercury exposure. J Toxicol Environ Health A 77(1-3):1-13. https://doi.org/10.1080/15287394.2014.861335.

dos Santos AA, Appel Hort M, Culbreth M, et al. 2016. Methylmercury and brain development: A review of recent literature. J Trace Elem Med Biol 38:99-107. https://doi.org/10.1016/j.jtemb.2016.03.001.

dos Santos Freitas J, da Costa Brito Lacerda EM, da Silva Martins ICV, et al. 2018. Cross-sectional study to assess the association of color vision with mercury hair concentration in children from Brazilian Amazonian riverine communities. Neurotoxicology 65:60-67. https://doi.org/10.1016/j.neuro.2018.02.006.

dos Santos-Lima C, Mourão DS, Carvalho CF, et al. 2020. Neuropsychological effects of mercury exposure in children and adolescents of the Amazon region, Brazil. Neurotoxicology 79:48-57. https://doi.org/10.1016/j.neuro.2020.04.004.

dos Santos Chemelo V, Bittencourt LO, Aragão WAB, et al. 2021. Long-term exposure to inorganic mercury leads to oxidative stress in peripheral blood of adult rats. Biol Trace Elem Res 199(8):2992-3000. https://doi.org/10.1007/s12011-020-02411-5.

Dou Y, Yin Y, Li Z, et al. 2022. Maternal exposure to metal mixtures during early pregnancy and fetal growth in the Jiangsu Birth Cohort, China. Environ Res 215(Pt 2):114305. https://doi.org/10.1016/j.envres.2022.114305.

Downer MK, Martínez-González MA, Gea A, et al. 2017. Mercury exposure and risk of cardiovascular disease: a nested case-control study in the PREDIMED (PREvention with MEDiterranean Diet) study. BMC Cardiovasc Disord 17:9. https://doi.org/10.1186/s12872-016-0435-8.

Drake HJ. 1981. Mercury. In: Mark HF, Othmer DF, Overberger CG, eds. Kirk-Othmer encyclopedia of chemical technology. New York, NY: John Wiley and Sons, Inc., 143-156.

Drexler JZ, Alpers CN, Neymark LA, et al. 2016. A millennial-scale record of Pb and Hg contamination in peatlands of the Sacramento-San Joaquin Delta of California, USA. Sci Total Environ 551-552:738-751. https://doi.org/10.1016/j.scitotenv.2016.01.201.

Druet P, Druet E, Potdevim F, et al. 1978. Immune type glomerulonephritis induced by $HgCl_2$ in the Brown Norway rat. Ann Immunol 129(6):777-792.

Duan W, Xu C, Liu Q, et al. 2020. Levels of a mixture of heavy metals in blood and urine and all-cause, cardiovascular disease and cancer mortality: A population-based cohort study. Environ Pollut 263(Pt A):114630. https://doi.org/10.1016/j.envpol.2020.114630.

Dunn JD, Clarkson TW, Magos L. 1978. Ethanol-increased exhalation of mercury in mice. Br J Ind Med 35(3):241-244. https://doi.org/10.1136/oem.35.3.241.

Dutczak WJ, Ballatori N. 1992. gamma-Glutamyltransferase-dependent biliary-hepatic recycling of methyl mercury in the guinea pig. J Pharmacol Exp Ther 262(2):619-623.

8. REFERENCES

Dutczak WJ, Ballatori N. 1994. Transport of the glutathione-methylmercury complex across liver canalicular membranes on reduced glutathione carriers. J Biol Chem 269(13):9746-9751.

Dutczak WJ, Clarkson TW, Ballatori N. 1991. Biliary-hepatic recycling of a xenobiotic: Gallbladder absorption of methyl mercury. Am J Physiol 260(6 Pt 1):G873-880. https://doi.org/10.1152/ajpgi.1991.260.6.G873.

Dvonch JT, Vette AF, Keeler GJ. 1995. An intensive multi-site pilot study investigating atmospheric mercury in Broward County, Florida. In: Porcella DB, Wheatley B, eds. Mercury as a global pollutant. Proceedings of the third International Conference Whistler, British Columbia, July 10-14, 1994. Boston, MA: Kluwer Academic Publishers, 169-178.

Dyall-Smith DJ, Scurry JP. 1990. Mercury pigmentation and high mercury levels from the use of a cosmetic cream. Med J Aust 153(7):409-410 to 414-405.

Echeverria D, Aposhian HV, Woods JS, et al. 1998. Neurobehavioral effects from exposure to dental amalgam Hg^0: new distinctions between recent exposure and Hg body burden. FASEB J 12(11):971-980. https://doi.org/10.1096/fasebj.12.11.971.

Echeverria D, Woods JS, Heyer NJ, et al. 2005. Chronic low-level mercury exposure, BDNF polymorphism, and associations with cognitive and motor function. Neurotoxicol Teratol 27(6):781-796. https://doi.org/10.1016/j.ntt.2005.08.001.

EFSA. 2012. Scientific Opinion on the risk for public health related to the presence of mercury and methylmercury in food. EFSA J 10(12):2985. https://doi.org/10.2903/j.efsa.2012.2985.

EFSA. 2014. Scientific Opinion on health benefits of seafood (fish and shellfish) consumption in relation to health risks associated with exposure to methylmercury. EFSA J 12(7):3761. https://doi.org/10.2903/j.efsa.2014.3761.

Egwunye J, Cardoso BR, Braat S, et al. 2023. The role of fingernail selenium in the association between arsenic, lead and mercury and child development in rural Vietnam: a cross-sectional analysis. Br J Nutr 129(9):1589-1597. https://doi.org/10.1017/s0007114522001374.

Ehrenberg RL, Vogt RL, Smith AB, et al. 1991. Effects of elemental mercury exposure at a thermometer plant. Am J Ind Med 19(4):495-507.

Ehrenstein C, Shu P, Wickenheiser EB, et al. 2002. Methyl mercury uptake and associations with the induction of chromosomal aberrations in Chinese hamster ovary (CHO) cells. Chem Biol Interact 141(3):259-274.

Eichholz GG, Petelka MF, Kury RL. 1988. Migration of elemental mercury through soil from simulated burial sites. Water Res 22(1):15-20. https://doi.org/10.1016/0043-1354(88)90126-1.

Ekino S, Susa M, Ninomiya T, et al. 2007. Minamata disease revisited: an update on the acute and chronic manifestations of methyl mercury poisoning. J Neurol Sci 262(1-2):131-144. https://doi.org/10.1016/j.jns.2007.06.036.

Ekstrand J, Nielsen JB, Havarinasab S, et al. 2010. Mercury toxicokinetics-dependency on strain and gender. Toxicol Appl Pharmacol 243(3):283-291. https://doi.org/10.1016/j.taap.2009.08.026.

El-Badry A, Rezk M, El-Sayed H. 2018. Mercury-induced oxidative stress may adversely affect pregnancy outcome among dental staff: A cohort study. Int J Occup Environ Med 9(3):113-119. https://doi.org/10.15171/ijoem.2018.1181.

Ellingsen DG, Holland RI, Thomassen Y, et al. 1993. Mercury and selenium in workers previously exposed to mercury vapour at a chloralkali plant. Br J Ind Med 50(8):745-752.

Ellingsen DG, Efskind J, Berg KJ, et al. 2000a. Renal and immunologic markers for chloralkali workers with low exposure to mercury vapor. Scand J Work Environ Health 26(5):427-435. https://doi.org/10.5271/sjweh.564.

Ellingsen DG, Efskind J, Haug E, et al. 2000b. Effects of low mercury vapour exposure on the thyroid function in chloralkali workers. J Appl Toxicol 20(6):483-489. https://doi.org/10.1002/1099-1263(200011/12)20:6<483::aid-jat722>3.0.co;2-i.

Ellingsen DG, Bast-Pettersen R, Efskind J, et al. 2001. Neuropsychological effects of low mercury vapor exposure in chloralkali workers. Neurotoxicology 22(2):249-258. https://doi.org/10.1016/s0161-813x(01)00012-2.

8. REFERENCES

El-Masri HA, Mumtaz MM, Yushak ML. 2004. Application of physiologically-based pharmacokinetic modeling to investigate the toxicological interaction between chlorpyrifos and parathion in the rat. Environ Toxicol Pharmacol 16(1-2):57-71. https://doi.org/10.1016/j.etap.2003.10.002.

El-Sherbeeny AM, Odom JV, Smith JE. 2006. Visual system manifestations due to systemic exposure to mercury. Cutan Ocul Toxicol 25(3):173-183. https://doi.org/10.1080/15569520600860215.

Elsner J. 1991. Tactile-kinesthetic system of rats as an animal model for minimal brain dysfunction. Arch Toxicol 65(6):465-473. https://doi.org/10.1007/BF01977358.

Emeny RT, Korrick SA, Li Z, et al. 2019. Prenatal exposure to mercury in relation to infant infections and respiratory symptoms in the New Hampshire Birth Cohort Study. Environ Res 171:523-529. https://doi.org/10.1016/j.envres.2019.01.026.

Endo T, Nakaya S, Kimura R, et al. 1984. Gastrointestinal absorption of inorganic mercuric compounds in vivo and in situ. Toxicol Appl Pharmacol 74(2):223-229.

Endo T, Nakaya S, Kimura R, et al. 1986. Gastrointestinal absorption of inorganic mercuric compounds in vitro. Toxicol Appl Pharmacol 83(2):187-196.

Endo T, Nakaya S, Kimura R. 1990. Mechanisms of absorption of inorganic mercury from rat small intestine. III. Comparative absorption studies of inorganic mercuric compounds in vitro. Pharmacol Toxicol 66(5):347-353.

Endo T, Nakaya S, Kimura R. 1991. Mechanisms of absorption of inorganic mercury from rat small intestine. IV: Effect of chelating agents and cysteine on absorption of mercuric chloride in situ and in vitro. Pharmacol Toxicol 68(3):171-176.

Engqvist A, Colmsjo A, Skare I. 1998. Speciation of mercury excreted in feces from individuals with amalgam fillings. Arch Environ Health 53(3):205-213. https://doi.org/10.1080/00039899809605697.

Engstrom K, Love TM, Watson GE, et al. 2016. Polymorphisms in ATP-binding cassette transporters associated with maternal methylmercury disposition and infant neurodevelopment in mother-infant pairs in the Seychelles Child Development Study. Environ Int 94:224-229. https://doi.org/10.1016/j.envint.2016.05.027.

Eom SY, Choi SH, Ahn SJ, et al. 2014. Reference levels of blood mercury and association with metabolic syndrome in Korean adults. Int Arch Occup Environ Health 87(5):501-513. https://doi.org/10.1007/s00420-013-0891-8.

EPA. 1971. Water quality criteria data book. Washington, DC: U.S. Environmental Protection Agency.

EPA. 1975a. Emission standards. U.S. Environmental Protection Agency. Code of Federal Regulations. 40 CFR 61.52.

EPA. 1975b. National emission standards for hazardous air pollutants, emissions standard. U.S. Environmental Protection Agency. Fed Regist 40:48302.

EPA. 1979. Water related environmental fate of 129 priority pollutants, introduction and technical background, metals and inorganics, pesticides and PCBs. Washington, DC: U.S. Environmental Protection Agency. EPA440479029a.

EPA. 1984. Pesticide assessment guidelines: Subdivision F. Hazard evaluation: human and domestic animals. Washington, DC: U.S. Environmental Protection Agency. EPA540984014. https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=910129CT.txt. March 15, 2021.

EPA. 1985. Drinking water criteria document for mercury. Washington, DC: U.S. Environmental Protection Agency. EPA600X841781. PB86117827.

EPA. 1992. National study of chemical residues in fish. Volume I. Washington, DC: U.S. Environmental Protection Agency. EPA823R92008a.

EPA. 1998. Hazard standard risk analysis - TSCA section 403: Risk analysis to support standards for lead in paint, dust, and soil. Washington, DC: U.S. Environmental Protection Agency. EPA747R97006. https://www.epa.gov/lead/hazard-standard-risk-analysis-tsca-section-403. January 15, 2021.

EPA. 1999a. Method IO-5: Sampling and analysis for vapor and particle phase mercury in ambient air utilizing cold vapor atomic fluorescence spectrometry (CVAFS). Compendium of methods for the

determination of inorganic compounds in ambient air. Cincinnati, OH: U.S. Environmental
Protection Agency. EPA625R96010a. https://www.epa.gov/sites/production/files/2015-
07/documents/epa-io-5.pdf. January 15, 2021.

EPA. 1999b. National survey of mercury concentrations in fish data base summary 1990-1995.
Washington, DC: U.S. Environmental Protection Agency. EPA823R99014.

EPA. 2002a. Method 1631, Revision E: Mercury in water by oxidation, purge and trap, and cold vapor
atomic fluorescence spectrometry. Washington, DC: U.S. Environmental Protection Agency.
EPA821R02019. https://www.epa.gov/sites/production/files/2015-
08/documents/method_1631e_2002.pdf. December 16, 2020.

EPA. 2002b. Task force on ritualistic use of mercury report. Washington, DC: U.S. Environmental
Protection Agency. EPA540R01005. https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=90100I00.txt.
June 24, 2024.

EPA. 2006. Report: EPA is properly addressing the risks of using mercury in rituals. Washington, DC:
U.S. Environmental Protection Agency. EPA2006P00031. https://www.epaoig.gov/report-epa-
properly-addressing-risks-using-mercury-rituals. June 24, 2024.

EPA. 2008. Regulatory impact analysis of the proposed revisions to the National Ambient Air Quality
Standards. U.S. Environmental Protection Agency.

EPA. 2009. National primary drinking water regulations. Washington, DC: U.S. Environmental
Protection Agency. EPA816F09004. https://www.epa.gov/sites/production/files/2016-
06/documents/npwdr_complete_table.pdf. August 2, 2019.

EPA. 2011. Exposure factors handbook: 2011 edition. Washington, DC: U.S. Environmental
Protection Agency. EPA600R09052F.

EPA. 2018a. 2018 Edition of the drinking water standards and health advisories. Washington, DC: U.S.
Environmental Protection Agency. EPA822F18001.
https://www.epa.gov/system/files/documents/2022-01/dwtable2018.pdf. June 15, 2022.

EPA. 2018b. Compiled AEGL values. U.S. Environmental Protection Agency.
https://www.epa.gov/sites/production/files/2018-
08/documents/compiled_aegls_update_27jul2018.pdf. April 12, 2020.

EPA. 2018c. About acute exposure guideline levels (AEGLs). U.S. Environmental Protection Agency.
https://www.epa.gov/aegl/about-acute-exposure-guideline-levels-aegls. July 26, 2018.

EPA. 2019. Air quality system (AQS) data. U.S. Environmental Protection Agency.
https://www.epa.gov/aqs/obtaining-aqs-data. December 18, 2020.

EPA. 2020a. Introduction to the 2018 TRI National Analysis. U.S. Environmental Protection Agency.
https://www.epa.gov/trinationalanalysis/introduction-2018-tri-national-analysis. December 18,
2020.

EPA. 2020b. Inventory of mercury supply, use, and trade in the United States 2020 report. U.S.
Environmental Protection Agency.

EPA. 2021a. CompTox data: Mercuric (II) acetate. U.S. Environmental Protection Agency.
https://comptox.epa.gov/dashboard/dsstoxdb/results?search=DTXSID4042123#details. May 17,
2021.

EPA. 2021b. CompTox data: Methylmercuric chloride. U.S. Environmental Protection Agency.
https://comptox.epa.gov/dashboard/dsstoxdb/results?search=DTXSID5020813. May 17, 2021.

EPA. 2021c. CompTox data: Dimethyl mercury. U.S. Environmental Protection Agency.
https://comptox.epa.gov/dashboard/dsstoxdb/results?search=DTXSID5047742. May 17, 2021.

EPA. 2021d. CompTox data: Phenylmercuric acetate. U.S. Environmental Protection Agency.
https://comptox.epa.gov/dashboard/dsstoxdb/results?search=DTXSID7021150. May 17, 2021.

EPA. 2021e. CompTox data: Methyl mercury. U.S. Environmental Protection Agency.
https://comptox.epa.gov/dashboard/dsstoxdb/results?search=methyl%20mercury. May 17, 2021.

EPA. 2022. Toxic chemical release inventory reporting forms and instructions: Revised 2021 version.
U.S. Environmental Protection Agency. EPA740B22002.

https://ordspub.epa.gov/ords/guideme_ext/guideme_ext/guideme/file/ry_2021_rfi.pdf. August 22, 2023.

EPA. 2023. Inventory of mercury supply, use, and trade in the United States 2023 report. U.S. Environmental Protection Agency. https://www.epa.gov/chemicals-under-tsca/epa-publishes-2023-mercury-inventory-report. April 4, 2024.

EPA. 2024. Annual summary data: Mercury. Air quality system (AQS): Concentration by monitor. U.S. Environmental Protection Agency. https://www.epa.gov/aqs. April 4, 2024.

Erfurth EM, Schutz A, Nilsson A, et al. 1990. Normal pituitary hormone response to thyrotrophin and gonadotrophin releasing hormones in subjects exposed to elemental mercury vapour. Occup Environ Med 47(9):639-644. https://doi.org/10.1136/oem.47.9.639.

Espinoza EO, Mann MJ, Bleasdell B. 1995. Arsenic and mercury in traditional Chinese herbal balls. N Engl J Med 333(12):803-804. https://doi.org/10.1056/nejm199509213331217.

Espinoza EO, Mann M-J, Bleasdell B, et al. 1996. Toxic metals in selected traditional Chinese medicinals. J Forensic Sci 41(3):453-456. https://doi.org/10.1520/jfs13934j.

Ethier AA, Muckle G, Bastien C, et al. 2012. Effects of environmental contaminant exposure on visual brain development: A prospective electrophysiological study in school-aged children. Neurotoxicology 33(5):1075-1085. https://doi.org/10.1016/j.neuro.2012.05.010.

Eti S, Weisman R, Hoffman R, et al. 1995. Slight renal effect of mercury from amalgam fillings. Pharmacol Toxicol 76(1):47-49. https://doi.org/10.1111/j.1600-0773.1995.tb00101.x.

Eto K, Yasutake A, Kuwana T, et al. 2001. Methylmercury poisoning in common marmosets-a study of selective vulnerability within the cerebral cortex. Toxicol Pathol 29(5):565-573. https://doi.org/10.1080/019262301317226375.

Eto K, Tokunaga H, Nagashima K, et al. 2002. An autopsy case of Minamata disease (methylmercury poisoning)-pathological viewpoints of peripheral nerves. Toxicol Pathol 30(6):714-722. https://doi.org/10.1080/019262230290166805.

Evans MS, Noguchi GE, Rice CP. 1991. The biomagnification of polychlorinated biphenyls, toxaphene, and DDT compounds in a Lake Michigan offshore food web. Arch Environ Contam Toxicol 20(1):87-93. https://doi.org/10.1007/bf01065333.

Facemire CF, Gross TS, Guillette LJ. 1995. Reproductive impairment in the Florida panther: nature or nurture? Environ Health Perspect 103(Suppl 4):79-86.

Factor-Litvak P, Hasselgren G, Jacobs D, et al. 2003. Mercury derived from dental amalgams and neuropsychologic function. Environ Health Perspect 111(5):719-723. https://doi.org/10.1289/ehp.5879.

Fagundes BHF, Nascimento PC, Aragão WAB, et al. 2022. Methylmercury exposure during prenatal and postnatal neurodevelopment promotes oxidative stress associated with motor and cognitive damages in rats: an environmental-experimental toxicology study. Toxicol Rep 9:563-574. https://doi.org/10.1016/j.toxrep.2022.02.014.

Fairey R, Taberski K, Lamerdin S, et al. 1997. Organochlorines and other environmental contaminants in muscle tissues of sportfish collected from San Francisco Bay. Mar Pollut Bull 34(12):1058-1071. https://doi.org/10.1016/s0025-326x(97)00084-2.

Fan Y, Zhang C, Bu J. 2017. Relationship between selected serum metallic elements and obesity in children and adolescent in the U.S. Nutrients 9(2):104. https://doi.org/10.3390/nu9020104.

Farías P, Hernández-Bonilla D, Moreno-Macías H, et al. 2022. Prenatal co-exposure to manganese, mercury, and lead, and neurodevelopment in children during the first year of life. Int J Environ Res Public Health 19(20):13020. https://doi.org/10.3390/ijerph192013020.

Farina M, Aschner M. 2017. Methylmercury-induced neurotoxicity: Focus on pro-oxidative events and related consequences. Adv Neurobiol 18:267-286. https://doi.org/10.1007/978-3-319-60189-2_13.

Farris FF, Dedrick RL, Allen PV, et al. 1993. Physiological model for the pharmacokinetics of methyl mercury in the growing rat. Toxicol Appl Pharmacol 119(1):74-90. https://doi.org/10.1006/taap.1993.1046.

8. REFERENCES

Farris FF, Kaushal A, Strom JG. 2008. Inorganic mercury pharmacokinetics in man: A two-
    compartment model. Toxicol Environ Chem 90(3):519-533.
    https://doi.org/10.1080/02772240701602736.

Farzan SF, Howe CG, Chen Y, et al. 2021. Prenatal and postnatal mercury exposure and blood pressure
    in childhood. Environ Int 146:106201. https://doi.org/10.1016/j.envint.2020.106201.

Fawer RF, de Ribaupierre Y, Guillemin MP, et al. 1983. Measurement of hand tremor induced by
    industrial exposure to metallic mercury. Br J Ind Med 40(2):204-208.
    https://doi.org/10.1136/oem.40.2.204.

FDA. 2017a. Total diet study: Elements results summary statistics. Market baskets 2006 through 2013.
    U.S. Food and Drug Administration. https://www.fda.gov/media/77948/download. December 14,
    2020.

FDA. 2017b. Subpart B - Requirements for specific standardized beverages. Bottled water. U.S. Food
    and Drug Administration. Code of Federal Regulations. 21 CFR 165.110.
    https://www.gpo.gov/fdsys/pkg/CFR-2017-title21-vol2/pdf/CFR-2017-title21-vol2-sec165-110.pdf.
    September 7, 2017.

FDA. 2018a. CPG sec 578.400 Treated grain seed - mercury residue. U.S. Food and Drug
    Administration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-
    sec-578400-treated-grain-seed-mercury-residue. November 18, 2020.

FDA. 2018b. CPG sec. 540.600 Fish, shellfish, crustaceans and other aquatic animals - fresh, frozen or
    processed - methyl mercury. U.S. Food and Drug Administration. https://www.fda.gov/regulatory-
    information/search-fda-guidance-documents/cpg-sec-540600-fish-shellfish-crustaceans-and-other-
    aquatic-animals-fresh-frozen-or-processed-methyl. November 18, 2020.

FDA. 2022. Total diet study report: Fiscal years 2018-2020 elements data. U.S. Food and Drug
    Administration. https://www.fda.gov/food/fda-total-diet-study-tds/fda-total-diet-study-tds-results.
    April 4, 2024.

FDA. 2023. Substances added to food. U.S. Food and Drug Administration.
    https://www.cfsanappsexternal.fda.gov/scripts/fdcc/?set=FoodSubstances. March 14, 2023.

Fehling C, Abdulla M, Brun A, et al. 1975. Methylmercury poisoning in the rat: a combined
    neurological, chemical, and histopathological study. Toxicol Appl Pharmacol 33(1):27-37.
    https://doi.org/10.1016/0041-008x(75)90240-9.

Feitosa-Santana C, Bimler DL, Paramei GV, et al. 2010. Color-space distortions following long-term
    occupational exposure to mercury vapor. Ophthalmic Physiol Opt 30(5):724-730.
    https://doi.org/10.1111/j.1475-1313.2010.00764.x.

Feitosa-Santana C, Souza GDS, Sirius EVP, et al. 2018. Color vision impairment with low-level
    methylmercury exposure of an Amazonian population - Brazil. Neurotoxicology 66:179-184.
    https://doi.org/10.1016/j.neuro.2018.01.010.

Feng W, Wang M, Li B, et al. 2004. Mercury and trace element distribution in organic tissues and
    regional brain of fetal rat after in utero and weaning exposure to low dose of inorganic mercury.
    Toxicol Lett 152(3):223-234. https://doi.org/10.1016/j.toxlet.2004.05.001.

Feng L, Zhang C, Liu H, et al. 2020. Impact of low-level mercury exposure on intelligence quotient in
    children via rice consumption. Ecotoxicol Environ Saf 202:110870.
    https://doi.org/10.1016/j.ecoenv.2020.110870.

Ferguson KK, Chin HB. 2017. Environmental chemicals and preterm birth: Biological mechanisms and
    the state of the science. Curr Epidemiol Rep 4(1):56-71. https://doi.org/10.1007/s40471-017-0099-
    7.

Ferreira FF, Ammar D, Bourckhardt GF, et al. 2015. MeHg developing exposure causes DNA double-
    strand breaks and elicits cell cycle arrest in spinal cord cells. J Toxicol 2015:1-10.
    https://doi.org/10.1155/2015/532691.

Fiedler N, Udasin I, Gochfeld M, et al. 1999. Neuropsychological and stress evaluation of a residential
    mercury exposure. Environ Health Perspect 107(5):343-347.

Fillion M, Mergler D, Sousa Passos CJ, et al. 2006. A preliminary study of mercury exposure and blood pressure in the Brazilian Amazon. Environ Health 5:29. https://doi.org/10.1186/1476-069x-5-29.

Fischer C, Fredriksson A, Eriksson P. 2008. Coexposure of neonatal mice to a flame retardant PBDE 99 (2,2',4,4',5-pentabromodiphenyl ether) and methyl mercury enhances developmental neurotoxic defects. Toxicol Sci 101(2):275-285. https://doi.org/10.1093/toxsci/kfm271.

Fiskesjo G. 1979. Two organic mercury compounds tested for mutagenicity in mammalian cells by use of the cell line V 79-4. Hereditas 90(1):103-109.

Fitzgerald WF, Mason RP, Vandal GM. 1991. Atmospheric cycling and air-water exchange of mercury over mid-continental lacustrine regions. Water Air Soil Pollut 56(1):745-767. https://doi.org/10.1007/bf00342314.

Fonfria E, Rodriguez-Farre E, Sunol C. 2001. Mercury interaction with the GABA(A) receptor modulates the benzodiazepine binding site in primary cultures of mouse cerebellar granule cells. Neuropharmacology 41(7):819-833.

Forbes GB, Bruining GJ. 1976. Urinary creatinine excretion and lean body mass. Am J Clin Nutr 29(12):1359-1366. https://doi.org/10.1093/ajcn/29.12.1359.

Fossato da Silva DA, Teixeira CT, Scarano WR, et al. 2011. Effects of methylmercury on male reproductive functions in Wistar rats. Reprod Toxicol 31(4):431-439. https://doi.org/10.1016/j.reprotox.2011.01.002.

Fossato da Silva DA, Barbosa F, Scarano WR. 2012. Oral exposure to methylmercury modifies the prostatic microenvironment in adult rats. Int J Exp Pathol 93(5):354-360. https://doi.org/10.1111/j.1365-2613.2012.00825.x.

Foster P, Gray LE. 2008. Toxic responses of the reproductive system. In: Klaassen CD, ed. Casarett and Doull's toxicology: The basic science of poisons. New York, NY: The McGraw-Hill Companies, Inc, 761-806.

Foulkes EC. 1993. Metallothionein and glutathione as determinants of cellular retention and extrusion of cadmium and mercury. Life Sci 52(20):1617-1620. https://doi.org/10.1016/0024-3205(93)90042-2.

Foulkes EC, Bergman D. 1993. Inorganic mercury absorption in mature and immature rat jejunum: Transcellular and intercellular pathways in vivo and in everted sacs. Toxicol Appl Pharmacol 120(1):89-95. https://doi.org/10.1006/taap.1993.1090.

Fournie GJ, Saoudi A, Druet P, et al. 2002. Th2-type immunopathological manifestations induced by mercury chloride or gold salts in the rat: signal transduction pathways, cellular mechanisms and genetic control. Autoimmun Rev 1(4):205-212.

Fowler SW. 1990. Critical review of selected heavy metal and chlorinated hydrocarbon concentrations in the marine environment. Mar Environ Res 29(1):1-64. https://doi.org/10.1016/0141-1136(90)90027-l.

Fox B, Walsh CT. 1982. Mercuric reductase. Purification and characterization of a transposon-encoded flavoprotein containing an oxidation-reduction-active disulfide. J Biol Chem 257(5):2498-2503.

Franco JL, Teixeira A, Meotti FC, et al. 2006. Cerebellar thiol status and motor deficit after lactational exposure to methylmercury. Environ Res 102(1):22-28. https://doi.org/10.1016/j.envres.2006.02.003.

Franko A, Budihna MV, Dodic-Fikfak M. 2005. Long-term effects of elemental mercury on renal function in miners of the Idrija Mercury Mine. Ann Occup Hyg 49(6):521-527. https://doi.org/10.1093/annhyg/mei022.

Franzblau A, d'Arcy H, Ishak MB, et al. 2012. Low-level mercury exposure and peripheral nerve function. Neurotoxicology 33(3):299-306. https://doi.org/10.1016/j.neuro.2012.02.009.

Fredriksson A, Dahlgren L, Danielsson B, et al. 1992. Behavioural effects of neonatal metallic mercury exposure in rats. Toxicology 74(2-3):151-160. https://doi.org/10.1016/0300-483x(92)90135-2.

Fredriksson A, Dencker L, Archer T, et al. 1996. Prenatal coexposure to metallic mercury vapour and methylmercury produce interactive behavioural changes in adult rats. Neurotoxicol Teratol 18(2):129-134. https://doi.org/10.1016/0892-0362(95)02059-4.

8. REFERENCES

Freire C, Ramos R, Lopez-Espinosa MJ, et al. 2010. Hair mercury levels, fish consumption, and cognitive development in preschool children from Granada, Spain. Environ Res 110(1):96-104. https://doi.org/10.1016/j.envres.2009.10.005.

Freire MAM, Lima RR, Nascimento PC, et al. 2020. Effects of methylmercury on the pattern of NADPH diaphorase expression and astrocytic activation in the rat. Ecotoxicol Environ Saf 201:110799. https://doi.org/10.1016/j.ecoenv.2020.110799.

Frentiu T, Pintican BP, Butaciu S, et al. 2013. Determination, speciation and distribution of mercury in soil in the surroundings of a former chlor-alkali plant: assessment of sequential extraction procedure and analytical technique. Chem Cent J 7(1):178. https://doi.org/10.1186/1752-153x-7-178.

Frenzilli G, Bosco E, Barale R. 2000. Validation of single cell gel assay in human leukocytes with 18 reference compounds. Mutat Res 468(2):93-108.

Fretham SJ, Caito S, Martinez-Finley EJ, et al. 2012. Mechanisms and modifiers of methylmercury-induced neurotoxicity. Toxicol Res 1(1):32-38. https://doi.org/10.1039/c2tx20010d.

Friberg L, Nordberg F. 1973. Inorganic mercury-a toxicological and epidemiological appraisal. In: Miller MW, Clarkson TW, eds. Mercury, mercurials and mercaptans. Springfield, IL: Charles C. Thomas, 5-22.

Friberg L, Skog E, Wahlberg JE. 1961. Resorption of mercuric chloride and methyl mercury dicyandiamide in guinea-pigs through normal skin and through skin pretreated with acetone, alkylaryl-sulphonate and soap. Acta Derm Venereol 41:40-52.

Friedmann AS, Chen H, Rabuck LD, et al. 1998. Accumulation of dietary methylmercury in the testes of the adult Brown Norway rat: Impaired testicular and epididymal function. Environ Toxicol Chem 17(5):867-871.

Fruh V, Rifas-Shiman SL, Coull BA, et al. 2021. Prenatal exposure to a mixture of elements and neurobehavioral outcomes in mid-childhood: Results from Project Viva. Environ Res 201:111540. https://doi.org/10.1016/j.envres.2021.111540.

Frumkin H, Letz R, Williams PL, et al. 2001. Health effects of long-term mercury exposure among chloralkali plant workers. Am J Ind Med 39(1):1-18. https://doi.org/10.1002/1097-0274(200101)39:1<1::aid-ajim1>3.0.co;2-n.

Fujimura M, Usuki F. 2014. Low in situ expression of antioxidative enzymes in rat cerebellar granular cells susceptible to methylmercury. Arch Toxicol 88(1):109-113. https://doi.org/10.1007/s00204-013-1089-2.

Fujimura M, Usuki F, Sawada M, et al. 2009. Methylmercury induces neuropathological changes with tau hyperphosphorylation mainly through the activation of the c-jun-N-terminal kinase pathway in the cerebral cortex, but not in the hippocampus of the mouse brain. Neurotoxicology 30(6):1000-1007. https://doi.org/10.1016/j.neuro.2009.08.001.

Fujimura M, Cheng J, Zhao W. 2012. Perinatal exposure to low-dose methylmercury induces dysfunction of motor coordination with decreases in synaptophysin expression in the cerebellar granule cells of rats. Brain Res 1464:1-7. https://doi.org/10.1016/j.brainres.2012.05.012.

Fujita M, Takabatake E. 1977. Mercury levels in human maternal and neonatal blood, hair and milk. Bull Environ Contam Toxicol 18(2):205-209. https://doi.org/10.1007/bf01686068.

Fukuda K. 1971. Metallic mercury induced tremor in rabbits and mercury content of the central nervous system. Br J Ind Med 28(3):308-311. https://doi.org/10.1136/oem.28.3.308.

Futatsuka M, Kitano T, Nagano M, et al. 1992. An epidemiological study with risk analysis of liver diseases in the general population living in a methyl mercury polluted area. J Epidemiol Community Health 46(3):237-240.

Futatsuka M, Kitano T, Shono M, et al. 2000. Health surveillance in the population living in a methyl mercury-polluted area over a long period. Environ Res 83(2):83-92. https://doi.org/10.1006/enrs.1999.4014.

Futatsuka M, Kitano T, Shono M, et al. 2005. Long-term follow-up study of health status in population living in methylmercury-polluted area. Environ Sci 12(5):239-282.

8. REFERENCES

Fuyuta M, Fujimoto T, Hirata S. 1978. Embryotoxic effects of methylmercuric chloride administered to mice and rats during organogenesis. Teratology 18(3):353-365. https://doi.org/10.1002/tera.1420180310.

Fuyuta M, Fujimoto T, Kiyofuji E. 1979. Teratogenic effects of a single oral administration of methylmercuric chloride in mice. Acta Anat (Basel) 104(3):356-362. https://doi.org/10.1159/000145084.

Gale TF. 1974. Embryopathic effects of different routes of administration of mercuric acetate in the hamster. Environ Res 8(2):207-213. https://doi.org/10.1016/0013-9351(74)90052-8.

Galic N, Prpic-Mehiic G, Prester LJ, et al. 2001. Elimination of mercury from amalgam in rats. J Trace Elem Med Biol 15(1):1-4.

Galiciolli MEA, Pedroso TF, Mesquita M, et al. 2022. Biochemical parameters of female Wistar rats and their offspring exposed to inorganic mercury in drinking water during the gestational and lactational periods. Toxics 10(11):664. https://doi.org/10.3390/toxics10110664.

Gallagher CM, Meliker JR. 2012. Mercury and thyroid autoantibodies in U.S. women, NHANES 2007-2008. Environ Int 40:39-43. https://doi.org/10.1016/j.envint.2011.11.014.

Gallagher CM, McElroy AE, Smith DM, et al. 2013. Polychlorinated biphenyls, mercury, and antinuclear antibody positivity, NHANES 2003-2004. Int J Hyg Environ Health 216(6):721-727. https://doi.org/10.1016/j.ijheh.2013.01.004.

Gandhi DN, Panchal GM, Dhull DK. 2013. Influence of gestational exposure on the effects of prenatal exposure to methyl mercury on postnatal development in rats. Cent Eur J Public Health 21(1):30-35. https://doi.org/10.21101/cejph.a3773.

Gao ZY, Li MM, Wang J, et al. 2018. Blood mercury concentration, fish consumption and anthropometry in Chinese children: A national study. Environ Int 110:14-21. https://doi.org/10.1016/j.envint.2017.08.016.

Gao W, Tong L, Zhao S, et al. 2022. Exposure to Cadmium, lead, mercury, and arsenic and uric acid levels: Results from NHANES 2007-2016. Biol Trace Elem Res 201(4):1659-1669. https://doi.org/10.1007/s12011-022-03309-0.

Garcia-Fortea P, Cohen-Corcia I, Cordoba-Dona JA, et al. 2018. Toxic elements in hair and in vitro fertilization outcomes: A prospective cohort study. Reprod Toxicol 77:43-52. https://doi.org/10.1016/j.reprotox.2018.02.001.

Garetano G, Stern AH, Robson M, et al. 2008. Mercury vapor in residential building common areas in communities where mercury is used for cultural purposes versus a reference community. Sci Total Environ 397(1-3):131-139. https://doi.org/10.1016/j.scitotenv.2008.02.034.

Garí M, Grzesiak M, Krekora M, et al. 2022. Prenatal exposure to neurotoxic metals and micronutrients and neurodevelopmental outcomes in early school age children from Poland. Environ Res 204(Pt B):112049. https://doi.org/10.1016/j.envres.2021.112049.

Garza-Lombo C, Posadas Y, Quintanar L, et al. 2018. Neurotoxicity linked to dysfunctional metal ion homeostasis and xenobiotic metal exposure: Redox signaling and oxidative stress. Antioxid Redox Signal 28:1669-1703. https://doi.org/10.1089/ars.2017.7272.

Gavis J, Ferguson JF. 1972. The cycling of mercury through the environment. Water Res 6:989-1008.

Gbemavo MCJ, Bouchard MF. 2021. Concentrations of lead, mercury, selenium, and manganese in blood and hand grip strength among adults living in the United States (NHANES 2011-2014). Toxics 9(8):189. https://doi.org/10.3390/toxics9080189.

Gearhart JM, Clewell HJ, Crump KS, et al. 1995. Pharmacokinetic dose estimates of mercury in children and dose-response curves of performance tests in a large epidemiological study. Water Air Soil Pollut 80(1-4):49-58.

Geffner ME, Sandler A. 1980. Oral metallic mercury: A folk medicine remedy for gastroenteritis. Clin Pediatr (Phila) 19(6):435-437. https://doi.org/10.1177/000992288001900611.

Geier DA, Carmody T, Kern JK, et al. 2011. A significant relationship between mercury exposure from dental amalgams and urinary porphyrins: A further assessment of the Casa Pia children's dental amalgam trial. Biometals 24(2):215-224. https://doi.org/10.1007/s10534-010-9387-0.

8. REFERENCES

Geier DA, Kern JK, Homme KG, et al. 2019. A cross-sectional study of blood ethylmercury levels and cognitive decline among older adults and the elderly in the United States. J Alzheimers Dis 72(3):901-910. https://doi.org/10.3233/jad-190894.

Genchi G, Sinicropi MS, Carocci A, et al. 2017. Mercury exposure and heart diseases. Int J Environ Res Public Health 14(1):1-13. https://doi.org/10.3390/ijerph14010074.

Genuis SJ, Birkholz D, Rodushkin I, et al. 2011. Blood, urine, and sweat (BUS) study: Monitoring and elimination of bioaccumulated toxic elements. Arch Environ Contam Toxicol 61(2):344-357. https://doi.org/10.1007/s00244-010-9611-5.

George CR. 2011. Mercury and the kidney. J Nephrol 24(Suppl 17):S126-132. https://doi.org/10.5301/jn.2011.6486.

George GN, Singh SP, Myers GJ, et al. 2010. The chemical forms of mercury in human hair: a study using X-ray absorption spectroscopy. J Biol Inorg Chem 15(5):709-715. https://doi.org/10.1007/s00775-010-0638-x.

Gerald AC, Ganapathy S, Zhu J, et al. 2023. Exposure to endocrine-disrupting metals and serum estrogen levels among US women. Reprod Toxicol 118:108392. https://doi.org/10.1016/j.reprotox.2023.108392.

Ghizoni H, Ventura M, Colle D, et al. 2018. Effects of perinatal exposure to n-3 polyunsaturated fatty acids and methylmercury on cerebellar and behavioral parameters in mice. Food Chem Toxicol 120:603-615. https://doi.org/10.1016/j.fct.2018.08.004.

Ghosh AK, Sen S, Sharma A, et al. 1991. Effect of chlorophyllin on mercuric chloride-induced clastogenicity in mice. Food Chem Toxicol 29(11):777-779.

Gilbert SG, Burbacher TM, Rice DC. 1993. Effects of in utero methylmercury exposure on a spatial delayed alternation task in monkeys. Toxicol Appl Pharmacol 123(1):130-136. https://doi.org/10.1006/taap.1993.1229.

Gilbert SG, Rice DC, Burbacher TM. 1996. Fixed interval/fixed ratio performance in adult monkeys exposed in utero to methylmercury. Neurotoxicol Teratol 18(5):539-546.

Gill GA, Guentzel JL, Landing WM, et al. 1995. Total gaseous mercury measurements in Florida: the FAMS project (1992-1994). In: Porcella DB, Wheatley B, eds. Mercury as a global pollutant. Proceedings of the Third International Conference Whistler, British Columbia, July 10-14, 1994. Boston, MA: Kluwer Academic Publishers, 235-244.

Gilmour CC, Henry EA. 1991. Mercury methylation in aquatic systems affected by acid deposition. Environ Pollut 71(2-4):131-170.

Giménez-Llort L, Ahlbom E, Dare E, et al. 2001. Prenatal exposure to methylmercury changes dopamine-modulated motor activity during early ontogeny: age and gender-dependent effects. Environ Toxicol Pharmacol 9(3):61-70. https://doi.org/10.1016/s1382-6689(00)00060-0.

Gionfriddo CM, Tate MT, Wick RR, et al. 2016. Microbial mercury methylation in Antarctic sea ice. Nat Microbiol 1(10):1-12. https://doi.org/10.1038/nmicrobiol.2016.127.

Giovanoli-Jakubczak T, Greenwood MR, Smith JC, et al. 1974. Determination of total and inorganic mercury in hair by flameless atomic absorption, and of methylmercury by gas chromatography. Clin Chem 20(2):222-229.

Glass GE, Sorensen JA, Schmidt KW, et al. 1990. New source identification of mercury contamination in the Great Lakes. Environ Sci Technol 24(7):1059-1069. https://doi.org/10.1021/es00077a017.

Glass GE, Sorensen JA, Schmidt KW, et al. 1991. Mercury deposition and sources for the upper Great Lakes region. Water Air Soil Pollut 56(1):235-249. https://doi.org/10.1007/bf00342274.

Gokoel AR, Zijlmans W, Covert HH, et al. 2020. Influence of prenatal exposure to mercury, perceived stress, and depression on birth outcomes in Suriname: Results from the MeKiTamara Study. Int J Environ Res Public Health 17(12):4444. https://doi.org/10.3390/ijerph17124444.

Golding J, Gregory S, Emond A, et al. 2016a. Prenatal mercury exposure and offspring behaviour in childhood and adolescence. Neurotoxicology 57:87-94. https://doi.org/10.1016/j.neuro.2016.09.003.

Golding J, Gregory S, Iles-Caven Y, et al. 2016b. Associations between prenatal mercury exposure and early child development in the ALSPAC study. Neurotoxicology 53:215-222. https://doi.org/10.1016/j.neuro.2016.02.006.

Golding J, Hibbeln JR, Gregory SM, et al. 2017. Maternal prenatal blood mercury is not adversely associated with offspring IQ at 8 years provided the mother eats fish: A British prebirth cohort study. Int J Hyg Environ Health 220(7):1161-1167. https://doi.org/10.1016/j.ijheh.2017.07.004.

Golding J, Rai D, Gregory S, et al. 2018. Prenatal mercury exposure and features of autism: a prospective population study. Mol Autism 9:30. https://doi.org/10.1186/s13229-018-0215-7.

Goldman M, Blackburn P. 1979. The effect of mercuric chloride on thyroid function in the rat. Toxicol Appl Pharmacol 48(1 Pt 1):49-55. https://doi.org/10.1016/s0041-008x(79)80007-1.

Gonzalez-Raymat H, Liu G, Liriano C, et al. 2017. Elemental mercury: Its unique properties affect its behavior and fate in the environment. Environ Pollut 229:69-86. https://doi.org/10.1016/j.envpol.2017.04.101.

Goodrich JM, Wang Y, Gillespie B, et al. 2013. Methylmercury and elemental mercury differentially associate with blood pressure among dental professionals. Int J Hyg Environ Health 216(2):195-201. https://doi.org/10.1016/j.ijheh.2012.03.001.

Goodsite ME, Outridge PM, Christensen JH, et al. 2013. How well do environmental archives of atmospheric mercury deposition in the Arctic reproduce rates and trends depicted by atmospheric models and measurements? Sci Total Environ 452-453:196-207. https://doi.org/10.1016/j.scitotenv.2013.02.052.

Gore I, Harding SM. 1987. Sinker lung: Acute metallic mercury poisoning associated with the making of fishing weights. Ala J Med Sci 24(3):267-269.

Gosselin NH, Brunet RC, Carrier G, et al. 2006. Reconstruction of methylmercury intakes in indigenous populations from biomarker data. J Expo Sci Environ Epidemiol 16(1):19-29. https://doi.org/10.1038/sj.jea.7500433.

Gotelli CA, Astolfi E, Cox C, et al. 1985. Early biochemical effects of an organic mercury fungicide on infants: "Dose makes the poison". Science 227(4687):638. https://doi.org/10.1126/science.2857500.

Goulet S, Dore FY, Mirault ME. 2003. Neurobehavioral changes in mice chronically exposed to methylmercury during fetal and early postnatal development. Neurotoxicol Teratol 25(3):335-347. https://doi.org/10.1016/s0892-0362(03)00007-2.

Gouveia N, Buzzo ML, Grossi MGL, et al. 2019. Occupational exposure to mercury in recycling cooperatives from the metropolitan region of São Paulo, Brazil. Cien Saude Colet 24(4):1517-1526. https://doi.org/10.1590/1413-81232018244.01332017.

Govarts E, Remy S, Bruckers L, et al. 2016. Combined effects of prenatal exposures to environmental chemicals on birth weight. Int J Environ Res Public Health 13(5):495. https://doi.org/10.3390/ijerph13050495.

Grabo TN. 1997. Unknown toxic exposures. Arts and crafts materials. AAOHN J 45(3):124-130.

Granato TC, Pietz RI, Gschwind J, et al. 1995. Mercury in soils and crops from fields receiving high cumulative sewage sludge applications: Validation of U.S. EPA's risk assessment for human ingestion. In: Porcella DB, Wheatley B, eds. Mercury as a global pollutant. Proceedings of the Third International Conference Whistler, British Columbia, July 10-14, 1994. Boston, MA: Kluwer Academic Publishers, 1119-1127.

Grandjean P, Budtz-Jorgensen E. 2007. Total imprecision of exposure biomarkers: implications for calculating exposure limits. Am J Ind Med 50(10):712-719. https://doi.org/10.1002/ajim.20474.

Grandjean P, Yorifuji T. 2012. Mercury. In: Bingham E, Cohrssen B, eds. Patty's toxicology. New York, NY: Wiley, 213-227.

Grandjean P, Weihe P, White RF. 1995. Milestone development in infants exposed to methylmercury from human milk. Neurotoxicology 16(1):27-33.

Grandjean P, Weihe P, Jorgensen PJ, et al. 1992. Impact of maternal seafood diet on fetal exposure to mercury, selenium, and lead. Arch Environ Health 47(3):185-195. https://doi.org/10.1080/00039896.1992.9938348.

Grandjean P, Weihe P, White RF, et al. 1997. Cognitive deficit in 7-year-old children with prenatal exposure to methylmercury. Neurotoxicol Teratol 19(6):417-428. https://doi.org/10.1016/s0892-0362(97)00097-4.

Grandjean P, Weihe P, White RF, et al. 1998. Cognitive performance of children prenatally exposed to "safe" levels of methylmercury. Environ Res 77(2):165-172. https://doi.org/10.1006/enrs.1997.3804.

Grandjean P, Budtz-Jorgensen E, White RF, et al. 1999. Methylmercury exposure biomarkers as indicators of neurotoxicity in children aged 7 years. Am J Epidemiol 150(3):301-305. https://doi.org/10.1093/oxfordjournals.aje.a010002.

Grandjean P, Bjerve KS, Weihe P, et al. 2001. Birthweight in a fishing community: Significance of essential fatty acids and marine food contaminants. Int J Epidemiol 30(6):1272-1278. https://doi.org/10.1093/ije/30.6.1272.

Grandjean P, Budtz-Jorgensen E, Steuerwald U, et al. 2003. Attenuated growth of breast-fed children exposed to increased concentrations of methylmercury and polychlorinated biphenyls. FASEB J 17(6):699-701. https://doi.org/10.1096/fj.02-0661fje.

Grandjean P, Murata K, Budtz-Jorgensen E, et al. 2004a. Cardiac autonomic activity in methylmercury neurotoxicity: 14-year follow-up of a Faroese birth cohort. J Pediatr 144(2):169-176. https://doi.org/10.1016/j.jpeds.2003.10.058.

Grandjean P, Budtz-Jorgensen E, Keiding N, et al. 2004b. Underestimation of risk due to exposure misclassification. Int J Occup Med Environ Health 17(1):131-136.

Grandjean P, Poulsen LK, Heilmann C, et al. 2010. Allergy and sensitization during childhood associated with prenatal and lactational exposure to marine pollutants. Environ Health Perspect 118(10):1429-1433. https://doi.org/10.1289/ehp.1002289.

Grandjean P, Weihe P, Debes F, et al. 2014. Neurotoxicity from prenatal and postnatal exposure to methylmercury. Neurotoxicol Teratol 43:39-44. https://doi.org/10.1016/j.ntt.2014.03.004.

Greenwood MR. 1985. Methylmercury poisoning in Iraq. An epidemiological study of the 1971-1972 outbreak. J Appl Toxicol 5(3):148-159.

Gregory S, Iles-Caven Y, Hibbeln JR, et al. 2016. Are prenatal mercury levels associated with subsequent blood pressure in childhood and adolescence? The Avon prebirth cohort study. BMJ Open 6(10):e012425. https://doi.org/10.1136/bmjopen-2016-012425.

Gregus Z, Stein AF, Klaassen CD. 1987. Effect of inhibition of gamma-glutamyltranspeptidase on biliary and urinary excretion of glutathione-derived thiols and methylmercury. J Pharmacol Exp Ther 242(1):27-32.

Gribble MO, Cheng A, Berger RD, et al. 2015. Mercury exposure and heart rate variability: A systematic review. Curr Environ Health Rep 2(3):304-314. https://doi.org/10.1007/s40572-015-0053-0.

Grieb TM, Driscoll CT, Gloss SP, et al. 1990. Factors affecting mercury accumulation in fish in the upper Michigan peninsula. Environ Toxicol Chem 9(7):919-930.

Grieb TM, Fisher NS, Karimi R, et al. 2020. An assessment of temporal trends in mercury concentrations in fish. Ecotoxicology 29(10):1739-1749. https://doi.org/10.1007/s10646-019-02112-3.

Griffiths C, McGartland A, Miller M. 2007. A comparison of the monetized impact of IQ decrements from mercury emissions. Environ Health Perspect 115(6):841-847. https://doi.org/10.1289/ehp.9797.

Grotto D, de Castro MM, Barcelos GR, et al. 2009a. Low level and sub-chronic exposure to methylmercury induces hypertension in rats: nitric oxide depletion and oxidative damage as possible mechanisms. Arch Toxicol 83(7):653-662. https://doi.org/10.1007/s00204-009-0437-8.

Grotto D, Barcelos GR, Valentini J, et al. 2009b. Low levels of methylmercury induce DNA damage in rats: protective effects of selenium. Arch Toxicol 83(3):249-254. https://doi.org/10.1007/s00204-008-0353-3.

8. REFERENCES

Grover P, Banu BS, Devi KD, et al. 2001. In vivo genotoxic effects of mercuric chloride in rat peripheral blood leucocytes using comet assay. Toxicology 167(3):191-197.

Guallar E, Sanz-Gallardo MI, van't Veer P, et al. 2002. Mercury, fish oils, and the risk of myocardial infarction. N Engl J Med 347(22):1747-1754. https://doi.org/10.1056/NEJMoa020157.

Guan T, Wu Z, Xu C, et al. 2023. The association of trace elements with arthritis in US adults: NHANES 2013-2016. J Trace Elem Med Biol 76:127122. https://doi.org/10.1016/j.jtemb.2022.127122.

Guentzel JL, Landing WM, Gill GA, et al. 1995. Atmospheric deposition of mercury in Florida: the FAMS project (1992-1994). In: Porcella DB, Huckabee JW, eds. Mercury as a global pollutant. Proceedings of the third International Conference Whistler, British Columbia, July 10-14, 1994. Boston, MA: Kluwer Academic Publishers, 393-402.

Guillamet E, Creus A, Farina M, et al. 2008. DNA-damage induction by eight metal compounds in TK6 human lymphoblastoid cells: results obtained with the alkaline Comet assay. Mutat Res 654(1):22-28. https://doi.org/10.1016/j.mrgentox.2008.04.005.

Gul N, Khan S, Khan A, et al. 2016. Quantification of Hg excretion and distribution in biological samples of mercury-dental-amalgam users and its correlation with biological variables. Environ Sci Pollut Res Int 23(20):20580-20590. https://doi.org/10.1007/s11356-016-7266-0.

Gundacker C, Gencik M, Hengstschlager M. 2010. The relevance of the individual genetic background for the toxicokinetics of two significant neurodevelopmental toxicants: mercury and lead. Mutat Res 705(2):130-140. https://doi.org/10.1016/j.mrrev.2010.06.003.

Gundacker C, Graf-Rohrmeister K, Gencik M, et al. 2021. Gene variants determine placental transfer of perfluoroalkyl substances (PFAS), mercury (Hg) and lead (Pb), and birth outcome: findings from the UmMuKi Bratislava-Vienna Study. Front Genet 12:664946. https://doi.org/10.3389/fgene.2021.664946.

Gunderson EL. 1988. FDA Total Diet Study, April 1982-April 1984, dietary intakes of pesticides, selected elements, and other chemicals. J Assoc Off Anal Chem 71(6):1200-1209.

Guo BQ, Cai SZ, Guo JL, et al. 2013. Levels of prenatal mercury exposure and their relationships to neonatal anthropometry in Wujiang City, China. Environ Pollut 182:184-189. https://doi.org/10.1016/j.envpol.2013.07.023.

Guo J, Wu C, Zhang J, et al. 2020a. Prenatal exposure to mixture of heavy metals, pesticides and phenols and IQ in children at 7 years of age: The SMBCS study. Environ Int 139:105692. https://doi.org/10.1016/j.envint.2020.105692.

Guo J, Wu C, Zhang J, et al. 2020b. Supplemental material: Prenatal exposure to mixture of heavy metals, pesticides and phenols and IQ in children at 7 years of age: The SMBCS study. Environ Int 139 https://doi.org/10.1016/j.envint.2020.105692.

Guo X, Li N, Wang H, et al. 2022. Combined exposure to multiple metals on cardiovascular disease in NHANES under five statistical models. Environ Res 215(Pt 3):114435. https://doi.org/10.1016/j.envres.2022.114435.

Guo Y, Lv Y, Liu X, et al. 2023. Association between heavy metal mercury in body fluids and tissues and diabetes mellitus: a systematic review and meta-analysis. Ann Transl Med 11(2):114. https://doi.org/10.21037/atm-22-6404.

Gupchup GV, Zatz J. 1999. Structural characteristics and permeability properties of the human nail: A review. J Cosmet Sci 50(6):363-385.

Gustin K, Tofail F, Mehrin F, et al. 2017. Methylmercury exposure and cognitive abilities and behavior at 10 years of age. Environ Int 102:97-105. https://doi.org/10.1016/j.envint.2017.02.004.

Gustin K, Barman M, Stråvik M, et al. 2020. Low-level maternal exposure to cadmium, lead, and mercury and birth outcomes in a Swedish prospective birth-cohort. Environ Pollut 265(Pt B):114986. https://doi.org/10.1016/j.envpol.2020.114986.

Gworek B, Dmuchowski W, Baczewska AH, et al. 2017. Air contamination by mercury, emissions and transformations-a review. Water Air Soil Pollut 228(4):123. https://doi.org/10.1007/s11270-017-3311-y.

8. REFERENCES

Gyrd-Hansen N. 1981. Toxicokinetics and methyl mercury in pigs. Arch Toxicol 48(2-3):173-181.

Ha M, Kwon HJ, Lim MH, et al. 2009. Low blood levels of lead and mercury and symptoms of attention deficit hyperactivity in children: A report of the children's health and environment research (CHEER). Neurotoxicology 30(1):31-36. https://doi.org/10.1016/j.neuro.2008.11.011.

Hadavifar M, Rastakhiz M, Souvizi B, et al. 2020. Biomonitoring of maternal and fetal exposure to mercury in Sabzevar and its affecting risk factors. J Hazard Mater 388:121781. https://doi.org/10.1016/j.jhazmat.2019.121781.

Haddad JK, Stenberg E. 1963. Bronchitis due to acute mercury inhalation. Report of two cases. Am Rev Respir Dis 88:543-535. https://doi.org/10.1164/arrd.1963.88.4.543.

Halbach S, Clarkson TW. 1978. Enzymatic oxidation of mercury vapor by erythrocytes. Biochim Biophys Acta Enzymol 523(2):522-531. https://doi.org/10.1016/0005-2744(78)90055-4.

Halbach S, Welzl G, Kremers L, et al. 2000. Steady-state transfer and depletion kinetics of mercury from amalgam fillings. Sci Total Environ 259(1-3):13-21.

Hales CM, Carroll MD, Fryar CD, et al. 2020. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. Centers for Disease Control and Prevention. NCHS Data Brief No. 360. https://www.cdc.gov/nchs/products/databriefs/db360.htm. March 15, 2021.

Hall LL, Allen PV, Fisher HL, et al. 1995. The kinetics of intravenously administered inorganic mercury in humans. In: Subramanian KN, Wastney ME, eds. Kinetic models of trace element and mineral metabolism. Boca Raton, FL: CRC Press, 265-280.

Hall BD, Bodaly RA, Fudge RJP, et al. 1997. Food as the dominant pathway of methylmercury uptake by fish. Water Air Soil Pollut 100(1-2):13-24.

Hallee TJ. 1969. Diffuse lung disease caused by inhalation of mercury vapor. Am Rev Repir Dis 99(3):430-436. https://doi.org/10.1164/arrd.1969.99.3.430.

Hallgren CG, Hallmans G, Jansson JH, et al. 2001. Markers of high fish intake are associated with decreased risk of a first myocardial infarction. Br J Nutr 86(3):397-404. https://doi.org/10.1079/bjn2001415.

Han DH, Lim SY, Sun BC, et al. 2009. Mercury exposure and periodontitis among a Korean population: The Shiwha-Banwol environmental health study. J Periodontol 80(12):1928-1936. https://doi.org/10.1902/jop.2009.090293.

Handley J, Todd D, Burrows D. 1993. Mercury allergy in a contact dermatitis clinic in Northern Ireland. Contact Dermatitis 29(5):258-261. https://doi.org/10.1111/j.1600-0536.1993.tb03561.x.

Hapke HJ. 1991. Metals accumulation in the food chain and load of feed and food. In: Merian E, ed. Metals and their compounds in the environment. Weinheim, Germany: VCH, 469-479.

Harada M. 1995. Minamata disease: Methylmercury poisoning in Japan caused by environmental pollution. Crit Rev Toxicol 25(1):1-24. https://doi.org/10.3109/10408449509089885.

Harada M, Nakanishi J, Konuma S, et al. 1998. The present mercury contents of scalp hair and clinical symptoms in inhabitants of the Minamata area. Environ Res 77(2):160-164. https://doi.org/10.1006/enrs.1998.3837.

Harada M, Akagi H, Tsuda T, et al. 1999. Methylmercury level in umbilical cords from patients with congenital Minamata disease. Sci Total Environ 234(1-3):59-62.

Harari R, Harari F, Gerhardsson L, et al. 2012. Exposure and toxic effects of elemental mercury in gold-mining activities in Ecuador. Toxicol Lett 213(1):75-82. https://doi.org/10.1016/j.toxlet.2011.09.006.

Harry GJ, Harris MW, Burka LT. 2004. Mercury concentrations in brain and kidney following ethylmercury, methylmercury and Thimerosal administration to neonatal mice. Toxicol Lett 154(3):183-189. https://doi.org/10.1016/j.toxlet.2004.07.014.

Harsh JB, Doner HE. 1981. Characterization of mercury in a river wash soil. J Environ Qual 10(3):333-337.

Havarinasab S, Hultman P. 2005. Organic mercury compounds and autoimmunity. Autoimmun Rev 4(5):270-275. https://doi.org/10.1016/j.autrev.2004.12.001.

8. REFERENCES

Havarinasab S, Bjorn E, Nielsen JB, et al. 2007. Mercury species in lymphoid and non-lymphoid tissues after exposure to methyl mercury: correlation with autoimmune parameters during and after treatment in susceptible mice. Toxicol Appl Pharmacol 221(1):21-28. https://doi.org/10.1016/j.taap.2007.02.009.

Hayes AD, Rothstein A. 1962. The metabolism of inhaled mercury vapor in the rat studied by isotope techniques. J Pharmacol Exp Ther 138:1-10.

He K, Xun P, Liu K, et al. 2013. Mercury exposure in young adulthood and incidence of diabetes later in life: The CARDIA trace element study. Diabetes Care 36(6):1584-1589. https://doi.org/10.2337/dc12-1842.

He J, Zhao Y, Zhu T, et al. 2021. Mercury chloride impacts on the development of erythrocytes and megakaryocytes in mice. Toxics 9(10):252. https://doi.org/10.3390/toxics9100252.

Heath JC, Abdelmageed Y, Braden TD, et al. 2009. The effects of chronic mercuric chloride ingestion in female Sprague-Dawley rats on fertility and reproduction. Food Chem Toxicol 47(7):1600-1605. https://doi.org/10.1016/j.fct.2009.04.007.

Heath JC, Abdelmageed Y, Braden TD, et al. 2012. The effects of chronic ingestion of mercuric chloride on fertility and testosterone levels in male Sprague Dawley rats. J Biomed Biotechnol 2012:1-9. https://doi.org/10.1155/2012/815186.

Heinrich J, Guo F, Trepka MJ. 2017. Brief report: Low-level mercury exposure and risk of asthma in school-age children. Epidemiology 28(1):116-118. https://doi.org/10.1097/ede.0000000000000576.

Hellou J, Fancey LL, Payne JF. 1992. Concentrations of twenty-four elements in bluefin tuna, from the Northwest Atlantic. Chemosphere 24(2):211-218. https://doi.org/10.1016/0045-6535(92)90394-7.

Hernández-Mendoza H, Álvarez-Loredo HE, Romero-Guzmán ET, et al. 2022. Relationship between serum levels of arsenic, cadmium, and mercury and body mass index and fasting plasma glucose in a Mexican adult population. Biol Trace Elem Res 200:4916-4923. https://doi.org/10.1007/s12011-021-03081-7.

Herr DW, Chanda SM, Graff JE, et al. 2004. Evaluation of sensory evoked potentials in Long Evans rats gestationally exposed to mercury (Hg0) vapor. Toxicol Sci 82(1):193-206. https://doi.org/10.1093/toxsci/kfh246.

Herrstrom P, Schutz A, Raihle G, et al. 1995. Dental amalgam, low-dose exposure to mercury, and urinary proteins in young Swedish men. Arch Environ Health 50(2):103-107. https://doi.org/10.1080/00039896.1995.9940886.

Hertz-Picciotto I, Green PG, Delwiche L, et al. 2010. Blood mercury concentrations in CHARGE Study children with and without autism. Environ Health Perspect 118(1):161-166. https://doi.org/10.1289/ehp.0900736.

Heyer NJ, Echeverria D, Bittner AC, et al. 2004. Chronic low-level mercury exposure, BDNF polymorphism, and associations with self-reported symptoms and mood. Toxicol Sci 81(2):354-363. https://doi.org/10.1093/toxsci/kfh220.

Hibbeln J, Gregory S, Iles-Caven Y, et al. 2018. Total mercury exposure in early pregnancy has no adverse association with scholastic ability of the offspring particularly if the mother eats fish. Environ Int 116:108-115. https://doi.org/10.1016/j.envint.2018.03.024.

Hinners T, Tsuchiya A, Stern AH, et al. 2012. Chronologically matched toenail-Hg to hair-Hg ratio: Temporal analysis within the Japanese community (U.S.). Environ Health 11:81. https://doi.org/10.1186/1476-069x-11-81.

Hirai T, Abe O, Nakamura M, et al. 2023. Brain structural changes in patients with chronic methylmercury poisoning in Minamata. Brain Res 1805:148278. https://doi.org/10.1016/j.brainres.2023.148278.

Hirano M, Mitsumori K, Maita K, et al. 1986. Further carcinogenicity study on methylmercury chloride in ICR mice. Nihon Juigaku Zasshi 48(1):127-135. https://doi.org/10.1292/jvms1939.48.127.

Hirzy JW, Connett P, Xiang Q, et al. 2016. Developmental neurotoxicity of fluoride: A quantitative risk analysis towards establishing a safe daily dose of fluoride for children. Fluoride 49(4 Pt 1):379-400.

Hoet P, Lison D. 1997. A nonoccupational source of mercury intoxication. Clin Chem 43(7):1248.

Hoffman HI, Bradley WG, Chen CY, et al. 2021. Amyotrophic lateral sclerosis risk, family income, and fish consumption estimates of mercury and omega-3 PUFAs in the United States. Int J Environ Res Public Health 18(9):4528. https://doi.org/10.3390/ijerph18094528.

Högstedt B, Bratt I, Holmen A, et al. 1988. Frequency and size distribution of micronuclei in lymphocytes stimulated with phytohemagglutinin and pokeweed mitogen in workers exposed to piperazine. Hereditas 109(1):139-142. https://doi.org/10.1111/j.1601-5223.1988.tb00194.x.

Højbjerg S, Nielsen JB, Andersen O. 1992. Effects of dietary lipids on whole-body retention and organ distribution of organic and inorganic mercury in mice. Food Chem Toxicol 30(8):703-708. https://doi.org/10.1016/0278-6915(92)90166-i.

Hollins JG, Willes RF, Bryce FR, et al. 1975. The whole body retention and tissue distribution of [^{203}Hg]methylmercury in adult cats. Toxicol Appl Pharmacol 33(3):438-449.

Hoshino A, Pacheco-Ferreira H, Sanches SG, et al. 2015. Mercury exposure in a riverside Amazon population, Brazil: A study of the ototoxicity of methylmercury. Int Arch Otorhinolaryngol 19(2):135-140. https://doi.org/10.1055/s-0034-1544115.

Houston MC. 2011. Role of mercury toxicity in hypertension, cardiovascular disease, and stroke. J Clin Hypertens (Greenwich) 13(8):621-627. https://doi.org/10.1111/j.1751-7176.2011.00489.x.

Howard W, Leonard B, Moody W, et al. 1991. Induction of chromosome changes by metal compounds in cultured CHO cells. Toxicol Lett 56(1-2):179-186.

Howe CG, Nozadi SS, Garcia E, et al. 2022. Prenatal metal(loid) mixtures and birth weight for gestational age: A pooled analysis of three cohorts participating in the ECHO program. Environ Int 161:107102. https://doi.org/10.1016/j.envint.2022.107102.

Hsu YC, Chang CW, Lee HL, et al. 2016. Association between history of dental amalgam fillings and risk of Parkinson's disease: A population-based retrospective cohort study in Taiwan. PLoS ONE 11(12):e0166552. https://doi.org/10.1371/journal.pone.0166552.

Hu G, Jin M, Lin X, et al. 2010. Mercury distribution in neonatal rat brain after intrauterine methylmercury exposure. Environ Toxicol Pharmacol 29(1):7-11. https://doi.org/10.1016/j.etap.2009.08.006.

Hu Y, Chen L, Wang C, et al. 2016. Prenatal low-level mercury exposure and infant neurodevelopment at 12 months in rural northern China. Environ Sci Pollut Res Int 23(12):12050-12059. https://doi.org/10.1007/s11356-016-6395-9.

Hu XF, Eccles KM, Chan HM. 2017. High selenium exposure lowers the odds ratios for hypertension, stroke, and myocardial infarction associated with mercury exposure among Inuit in Canada. Environ Int 102:200-206. https://doi.org/10.1016/j.envint.2017.03.002.

Hu XF, Singh K, Chan HM. 2018. Mercury exposure, blood pressure, and hypertension: a systematic review and dose-response meta-analysis. Environ Health Perspect 126(7):076002. https://doi.org/10.1289/ehp2863.

Hu XF, Lowe M, Chan HM. 2021. Mercury exposure, cardiovascular disease, and mortality: A systematic review and dose-response meta-analysis. Environ Res 193:110538. https://doi.org/10.1016/j.envres.2020.110538.

Huang LS, Cox C, Wilding GE, et al. 2003. Using measurement error models to assess effects of prenatal and postnatal methylmercury exposure in the Seychelles Child Development Study. Environ Res 93(2):115-122.

Huang LS, Cox C, Myers GJ, et al. 2005. Exploring nonlinear association between prenatal methylmercury exposure from fish consumption and child development: evaluation of the Seychelles Child Development Study nine-year data using semiparametric additive models. Environ Res 97(1):100-108. https://doi.org/10.1016/j.envres.2004.05.004.

Huang LS, Myers GJ, Davidson PW, et al. 2007. Is susceptibility to prenatal methylmercury exposure from fish consumption non-homogeneous? Tree-structured analysis for the Seychelles Child Development Study. Neurotoxicology 28(6):1237-1244. https://doi.org/10.1016/j.neuro.2007.08.009.

8. REFERENCES

Huang CF, Liu SH, Hsu CJ, et al. 2011. Neurotoxicological effects of low-dose methylmercury and mercuric chloride in developing offspring mice. Toxicol Lett 201(3):196-204. https://doi.org/10.1016/j.toxlet.2010.12.016.

Huang LS, Cory-Slechta DA, Cox C, et al. 2018. Analysis of nonlinear associations between prenatal methylmercury exposure from fish consumption and neurodevelopmental outcomes in the Seychelles main cohort at 17 years. Stoch Environ Res Risk Assess 32(4):893-904. https://doi.org/10.1007/s00477-017-1451-7.

Hughes JA, Annau Z. 1976. Postnatal behavioral effects in mice after prenatal exposure to methylmercury. Pharmacol Biochem Behav 4(4):385-391. https://doi.org/10.1016/0091-3057(76)90052-6.

Hui LL, Chan MHM, Lam HS, et al. 2016. Impact of fetal and childhood mercury exposure on immune status in children. Environ Res 144(Pt A):66-72. https://doi.org/10.1016/j.envres.2015.11.005.

Hultman P, Enestrom S. 1986. Localization of mercury in the kidney during experimental acute tubular necrosis studied by the cytochemical Silver Amplification method. Br J Exp Pathol 67(4):493-503.

Hultman P, Johansson U. 1991. Strain differences in the effect of mercury on murine cell-mediated immune reactions. Food Chem Toxicol 29(9):633-638. https://doi.org/10.1016/0278-6915(91)90146-x.

Hultman P, Enestrom S. 1992. Dose-response studies in murine mercury-induced autoimmunity and immune-complex disease. Toxicol Appl Pharmacol 113(2):199-208. https://doi.org/10.1016/0041-008x(92)90115-9.

Hultman P, Nielsen JB. 2001. The effect of dose, gender, and non-H-2 genes in murine mercury-induced autoimmunity. J Autoimmun 17(1):27-37. https://doi.org/10.1006/jaut.2001.0521.

Hultman P, Enestrom S, von Schenck H. 1985. Renal handling of inorganic mercury in mice. The early excretion phase following a single intravenous injection of mercuric chloride studied by the Silver Amplification method. Virchows Arch B Cell Pathol Incl Mol Pathol 49(3):209-224.

Hurley JP, Watras CJ, Bloom NS. 1991. Mercury cycling in a northern Wisconsin seepage lake: The role of particulate matter in vertical transport. Water Air Soil Pollut 56(1):543-551. https://doi.org/10.1007/bf00342298.

Hursh JB. 1985. Partition coefficients of mercury (203Hg) vapor between air and biological fluids. J Appl Toxicol 5(5):327-332. https://doi.org/10.1002/jat.2550050512.

Hursh JB, Clarkson TW, Cherian MG, et al. 1976. Clearance of mercury (Hg-197, Hg-203) vapor inhaled by human subjects. Arch Environ Health 31:302-309.

Hursh JB, Greenwood MR, Clarkson TW, et al. 1980. The effect of ethanol on the fate of mercury vapor inhaled by man. J Pharmacol Exp Ther 214(3):520-527.

Hursh JB, Clarkson TW, Miles EF, et al. 1989. Percutaneous absorption of mercury vapor by man. Arch Environ Health 44(2):120-127. https://doi.org/10.1080/00039896.1989.9934385.

Hwang GW, Lee JY, Ryoke K, et al. 2011. Gene expression profiling using DNA microarray analysis of the cerebellum of mice treated with methylmercury. J Toxicol Sci 36(3):389-391.

Hytten F. 1985. Blood volume changes in normal pregnancy. Clin Haematol 14(3):601-612.

IARC. 1993. Mercury and mercury compounds. In: IARC monographs on the evaluation of carcinogenic risks to humans. Volume 58. Beryllium, cadmium, mercury, and exposures in the glass manufacturing industry. Lyon, France: International Agency for Research on Cancer, 239-345. https://publications.iarc.fr/76. November 11, 2020.

ICRP. 1980. Metabolic data for mercury. In: Limits for intakes of radionuclides by workers. Oxford, England: Pergamon Press, 59-63.

ICRP. 1981. Report of the task group on reference man. New York, NY: International Commission on Radiological Protection. ICRP Publication 23.

ICRP. 1994. Human respiratory tract model for radiological protection. International Commission on Radiological Protection. ICRP Publication 66.

8. REFERENCES

Iesato K, Wakashin M, Wakashin Y, et al. 1977. Renal tubular dysfunction in Minamata disease. Detection of renal tubular antigen and beta-2-microglobin in the urine. Ann Intern Med 86(6):731-737. https://doi.org/10.7326/0003-4819-86-6-731.

Igata A. 1993. Epidemiological and clinical features of Minamata disease. Environ Res 63(1):157-169.

Iglesias P, Carrero JJ, Díez JJ. 2012. Gonadal dysfunction in men with chronic kidney disease: Clinical features, prognostic implications and therapeutic options. J Nephrol 25(1):31-42. https://doi.org/10.5301/jn.2011.8481.

IJC. 2015. Atmospheric deposition of mercury in the Great Lakes basin. Washington, DC: International Joint Commission: Canada and United States. https://legacyfiles.ijc.org/tinymce/uploaded/documents/Atmospheric-Deposition-of-Mercury-in-the-Great-Lakes-Basin-December-2015.pdf. December 14, 2020.

Ikegaya K, Nokihara K, Yasuhara T. 2010. Characterization of sulfhydryl heterogeneity in human serum albumin and recombinant human serum albumin for clinical use. Biosci Biotechnol Biochem 74(11):2232-2236. https://doi.org/10.1271/bbb.100423.

Ilback NG. 1991. Effects of methyl mercury exposure on spleen and blood natural killer (NK) cell activity in the mouse. Toxicology 67(1):117-124. https://doi.org/10.1016/0300-483x(91)90169-2.

Ilback NG, Sundberg J, Oskarsson A. 1991. Methyl mercury exposure via placenta and milk impairs natural killer (NK) cell function in newborn rats. Toxicol Lett 58(2):149-158. https://doi.org/10.1016/0378-4274(91)90169-7.

Ilback N-G, Frisk P, Tallkvist J, et al. 2008. Gastrointestinal uptake of trace elements are changed during the course of a common human viral (Coxsackievirus B3) infection in mice. J Trace Elem Med Biol 22(2):120-130. https://doi.org/10.1016/j.jtemb.2007.12.001.

IMERC. 2015. IMERC fact sheet: Mercury use in batteries. Interstate Mercury Education and Reduction Clearinghouse.

Inoue S, Yorifuji T, Tsuda T, et al. 2012. Short-term effect of severe exposure to methylmercury on atherosclerotic heart disease and hypertension mortality in Minamata. Sci Total Environ 417-418:291-293. https://doi.org/10.1016/j.scitotenv.2011.11.076.

Inouye M, Kajiwara Y. 1988. Developmental disturbances of the fetal brain in guinea-pigs caused by methylmercury. Arch Toxicol 62(1):15-21. https://doi.org/10.1007/BF00316251.

Inouye M, Murao K, Kajiwara Y. 1985. Behavioral and neuropathological effects of prenatal methylmercury exposure in mice. Neurobehav Toxicol Teratol 7(3):227-232.

Inouye M, Kajiwara Y, Hirayama K. 1986. Dose- and sex-dependent alterations in mercury distribution in fetal mice following methylmercury exposure. J Toxicol Environ Health 19(3):425-435. https://doi.org/10.1080/15287398609530940.

IRIS. 1987. Phenylmercuric acetate. CASRN 62-38-4. Integrated Risk Information System. Chemical assessment summary. Washington, DC: U.S. Environmental Protection Agency. https://cfpub.epa.gov/ncea/iris/iris_documents/documents/subst/0089_summary.pdf. November 10, 2020.

IRIS. 1995a. Mercury, elemental. CASRN 7439-97-6. Integrated Risk Information System. Chemical assessment summary. Washington, DC: U.S. Environmental Protection Agency. https://cfpub.epa.gov/ncea/iris/iris_documents/documents/subst/0370_summary.pdf. November 10, 2020.

IRIS. 1995b. Mercuric chloride (HgCl2). CASRN 7487-94-7. Integrated Risk Information System. Chemical assessment summary. Washington, DC: U.S. Environmental Protection Agency. https://cfpub.epa.gov/ncea/iris/iris_documents/documents/subst/0692_summary.pdf. November 10, 2020.

IRIS. 2001. Methylmercury (MeHg). CASRN 22967-92-6. Integrated Risk Information System. Chemical assessment summary. Washington, DC: U.S. Environmental Protection Agency. https://cfpub.epa.gov/ncea/iris/iris_documents/documents/subst/0073_summary.pdf. November 10, 2020.

8. REFERENCES

Ishihara N. 2000. Excretion of methyl mercury in human feces. Arch Environ Health 55(1):44-47. https://doi.org/10.1080/00039890009603384.

Ishihara Y, Itoh K, Oguro A, et al. 2019. Neuroprotective activation of astrocytes by methylmercury exposure in the inferior colliculus. Sci Rep 9(1):13899. https://doi.org/10.1038/s41598-019-50377-9.

Ishitobi H, Stern S, Thurston SW, et al. 2010. Organic and inorganic mercury in neonatal rat brain after prenatal exposure to methylmercury and mercury vapor. Environ Health Perspect 118(2):242-248. https://doi.org/10.1289/ehp.0900956.

Ismail OI, El-Meligy MMS. 2021. Could vitamin C protect against mercuric chloride induced lung toxicity in the offspring rat: A histological and immunohistochemical study. Ultrastruct Pathol 45(3):197-211. https://doi.org/10.1080/01913123.2021.1954118.

Iverson F, Hierlihy SL. 1974. Biotransformation of methyl mercury in the guinea pig. Bull Environ Contam Toxicol 11(1):85-91.

Iverson F, Downie RH, Paul C, et al. 1973. Methyl mercury: acute toxicity, tissue distribution and decay profiles in the guinea pig. Toxicol Appl Pharmacol 24(4):545-554.

Iwai-Shimada M, Satoh H, Nakai K, et al. 2015. Methylmercury in the breast milk of Japanese mothers and lactational exposure of their infants. Chemosphere 126:67-72. https://doi.org/10.1016/j.chemosphere.2014.12.086.

Iwata T, Sakamoto M, Feng X, et al. 2007. Effects of mercury vapor exposure on neuromotor function in Chinese miners and smelters. Int Arch Occup Environ Health 80(5):381-387. https://doi.org/10.1007/s00420-006-0144-1.

Iwata T, Takaoka S, Sakamoto M, et al. 2016. Characteristics of hand tremor and postural sway in patients with fetal-type Minamata disease. J Toxicol Sci 41(6):757-763. https://doi.org/10.2131/jts.41.757.

Jackson LW, Zullo MD, Goldberg JM. 2008. The association between heavy metals, endometriosis and uterine myomas among premenopausal women: National Health and Nutrition Examination Survey 1999-2002. Hum Reprod 23(3):679-687. https://doi.org/10.1093/humrep/dem394.

Jackson LW, Howards PP, Wactawski-Wende J, et al. 2011. The association between cadmium, lead and mercury blood levels and reproductive hormones among healthy, premenopausal women. Hum Reprod 26(10):2887-2895. https://doi.org/10.1093/humrep/der250.

Jacobson JL, Muckle G, Ayotte P, et al. 2015. Relation of prenatal methylmercury exposure from environmental sources to childhood IQ. Environ Health Perspect 123(8):827-833. https://doi.org/10.1289/ehp.1408554.

Jagiello G, Lin JS. 1973. An assessment of the effects of mercury on the meiosis of mouse ova. Mutat Res 17(1):93-99. https://doi.org/10.1016/0027-5107(73)90257-1.

Jain RB. 2017. Trends in and factors affecting the observed levels of urinary inorganic and total blood mercury among US children, adolescents, adults, and senior citizens over 2005-2012. Environ Toxicol Pharmacol 56:268-281. https://doi.org/10.1016/j.etap.2017.09.003.

Jalili C, Kazemi M, Taheri E, et al. 2020a. Exposure to heavy metals and the risk of osteopenia or osteoporosis: a systematic review and meta-analysis. Osteoporos Int 31(9):1671-1682. https://doi.org/10.1007/s00198-020-05429-6.

Jalili C, Akhshi N, Rashidi I, et al. 2020b. Harmine protects mercuric chloride kidney-induced injury by antioxidant activity in male mice: a biochemical and histological study. Res Pharm Sci 15(6):541-550. https://doi.org/10.4103/1735-5362.301339.

Jan AT, Ali A, Haq Q. 2011. Glutathione as an antioxidant in inorganic mercury induced nephrotoxicity. J Postgrad Med 57(1):72-77. https://doi.org/10.4103/0022-3859.74298.

Janse van Rensburg M, van Rooy MJ, Bester MJ, et al. 2020. Ultrastructural alterations of whole blood by copper, manganese and mercury metal mixtures using a chronic in vivo model of coagulation. Environ Toxicol Pharmacol 75:103314. https://doi.org/10.1016/j.etap.2019.103314.

8. REFERENCES

Janssen SE, Riva-Murray K, DeWild JF, et al. 2019. Chemical and physical controls on mercury source signatures in stream fish from the northeastern United States. Environ Sci Technol 53(17):10110-10119. https://doi.org/10.1021/acs.est.9b03394.

Jao-Tan C, Pope E. 2006. Cutaneous poisoning syndromes in children: A review. Curr Opin Pediatr 18(4):410-416. https://doi.org/10.1097/01.mop.0000236391.49086.34.

Jarosinska D, Horvat M, Sallsten G, et al. 2008. Urinary mercury and biomarkers of early renal dysfunction in environmentally and occupationally exposed adults: a three-country study. Environ Res 108(2):224-232. https://doi.org/10.1016/j.envres.2008.06.005.

Jedrychowski W, Jankowski J, Flak E, et al. 2006. Effects of prenatal exposure to mercury on cognitive and psychomotor function in one-year-old infants: epidemiologic cohort study in Poland. Ann Epidemiol 16(6):439-447. https://doi.org/10.1016/j.annepidem.2005.06.059.

Jedrychowski W, Perera F, Jankowski J, et al. 2007. Fish consumption in pregnancy, cord blood mercury level and cognitive and psychomotor development of infants followed over the first three years of life: Krakow epidemiologic study. Environ Int 33(8):1057-1062. https://doi.org/10.1016/j.envint.2007.06.001.

Jensen TK, Grandjean P, Jorgensen EB, et al. 2005. Effects of breast feeding on neuropsychological development in a community with methylmercury exposure from seafood. J Expo Anal Environ Epidemiol 15(5):423-430. https://doi.org/10.1038/sj.jea.7500420.

Jenssen D, Ramel C. 1980. The micronucleus test as part of a short-term mutagenicity test program for the prediction of carcinogenicity evaluated by 143 agents tested. Mutat Res 75:191-202.

Jenssen MT, Brantsaeter AL, Haugen M, et al. 2012. Dietary mercury exposure in a population with a wide range of fish consumption-self-capture of fish and regional differences are important determinants of mercury in blood. Sci Total Environ 439:220-229. https://doi.org/10.1016/j.scitotenv.2012.09.024.

Jeon J, Morris JS, Park K. 2021. Toenail mercury levels positively correlate with obesity and abdominal obesity among Korean adults. J Trace Elem Med Biol 64:126678. https://doi.org/10.1016/j.jtemb.2020.126678.

Jeong KS, Park H, Ha E, et al. 2017. High maternal blood mercury level is associated with low verbal IQ in children. J Korean Med Sci 32(7):1097-1104. https://doi.org/10.3346/jkms.2017.32.7.1097.

Jeppesen C, Valera B, Nielsen NO, et al. 2015. Association between whole blood mercury and glucose intolerance among adult Inuit in Greenland. Environ Res 143(Pt A):192-197. https://doi.org/10.1016/j.envres.2015.10.013.

Jin X, Chan HM, Lok E, et al. 2008. Dietary fats modulate methylmercury-mediated systemic oxidative stress and oxidative DNA damage in rats. Food Chem Toxicol 46(5):1706-1720. https://doi.org/10.1016/j.fct.2008.01.015.

Jin R, Zhu X, Shrubsole MJ, et al. 2018. Associations of renal function with urinary excretion of metals: Evidence from NHANES 2003-2012. Environ Int 121(Pt 2):1355-1362. https://doi.org/10.1016/j.envint.2018.11.002.

Jin T, Park EY, Kim B, et al. 2021. Association between blood mercury concentration and prevalence of borderline hypercholesterolemia among adolescents: The Korea National Health and Nutrition Examination Survey (KNHANES) 2010-2013 and 2016. Toxics 9(10):242. https://doi.org/10.3390/toxics9100242.

Jindal M, Garg GR, Mediratta PK, et al. 2011. Protective role of melatonin in myocardial oxidative damage induced by mercury in murine model. Hum Exp Toxicol 30(10):1489-1500. https://doi.org/10.1177/0960327110391685.

Jo S, Woo HD, Kwon HJ, et al. 2015. Estimation of the biological half-life of methylmercury using a population toxicokinetic model. Int J Environ Res Public Health 12(8):9054-9067. https://doi.org/10.3390/ijerph120809054.

Johansson C, Castoldi AF, Onishchenko N, et al. 2007. Neurobehavioural and molecular changes induced by methylmercury exposure during development. Neurotox Res 11(3-4):241-260.

Johnson DL, Braman RS. 1974. Distribution of atmospheric mercury species near ground. Environ Sci Technol 8(12):1003-1009.

Johnsson C, Schutz A, Sallsten G. 2005. Impact of consumption of freshwater fish on mercury levels in hair, blood, urine, and alveolar air. J Toxicol Environ Health A 68(2):129-140. https://doi.org/10.1080/15287390590885992.

Jonker D, Woutersen RA, van Bladeren PJ, et al. 1993. Subacute (4-wk) oral toxicity of a combination of four nephrotoxins in rats: comparison with the toxicity of the individual compounds. Food Chem Toxicol 31(2):125-136. https://doi.org/10.1016/0278-6915(93)90126-j.

Jonsson F, Sandborgh-Englund G, Johanson G. 1999. A compartmental model for the kinetics of mercury vapor in humans. Toxicol Appl Pharmacol 155(2):161-168. https://doi.org/10.1006/taap.1998.8585.

Joo SH, Seo S, Cho MH, et al. 2022. Environmental exposure to lead, mercury, and cadmium is not associated with abnormal kidney function in Korean adolescents. Pediatr Nephrol 37(3):625-631. https://doi.org/10.1007/s00467-021-05215-4.

Joselow MM, Ruiz R, Goldwater LJ. 1968. Absorption and excretion of mercury in man. XIV. Salivary excretion of mercury and its relationship to blood and urine mercury. Arch Environ Health 17(1):39-43.

Joshi D, Kumar MD, Kumar SA, et al. 2014. Reversal of methylmercury-induced oxidative stress, lipid peroxidation, and DNA damage by the treatment of N-acetyl cysteine: a protective approach. J Environ Pathol Toxicol Oncol 33(2):167-182.

Juárez BI, Portillo-Salazar H, Gonzalez-Amaro R, et al. 2005. Participation of N-methyl-D-aspartate receptors on methylmercury-induced DNA damage in rat frontal cortex. Toxicology 207(2):223-229. https://doi.org/10.1016/j.tox.2004.09.007.

Julvez J, Debes F, Weihe P, et al. 2010. Sensitivity of continuous performance test (CPT) at age 14 years to developmental methylmercury exposure. Neurotoxicol Teratol 32(6):627-632. https://doi.org/10.1016/j.ntt.2010.08.001.

Julvez J, Smith GD, Golding J, et al. 2013. Prenatal methylmercury exposure and genetic predisposition to cognitive deficit at age 8 years. Epidemiology 24(5):643-650. https://doi.org/10.1097/EDE.0b013e31829d5c93.

Julvez J, Davey Smith G, Ring S, et al. 2019. A birth cohort study on the genetic modification of the association of prenatal methylmercury with child cognitive development. Am J Epidemiol 188(10):1784-1793. https://doi.org/10.1093/aje/kwz156.

Julvez J, Lopez-Vicente M, Warembourg C, et al. 2021. Early life multiple exposures and child cognitive function: A multi-centric birth cohort study in six European countries. Environ Pollut 284:117404. https://doi.org/10.1016/j.envpol.2021.117404.

Jung RC, Aaronson J. 1980. Death following inhalation of mercury vapor at home. West J Med 132(6):539-543.

Jung SJ, Lee SH. 2019. Association between three heavy metals and dry eye disease in Korean adults: Results of the Korean National Health and Nutrition Examination Survey. Korean J Ophthalmol 33(1):26-35. https://doi.org/10.3341/kjo.2018.0065.

Jung W, Kim Y, Lihm H, et al. 2019. Associations between blood lead, cadmium, and mercury levels with hyperuricemia in the Korean general population: A retrospective analysis of population-based nationally representative data. Int J Rheum Dis 22(8):1435-1444. https://doi.org/10.1111/1756-185x.13632.

Juric AK, Batal M, David W, et al. 2017. A total diet study and probabilistic assessment risk assessment of dietary mercury exposure among First Nations living on-reserve in Ontario, Canada. Environ Res 158:409-420. https://doi.org/10.1016/j.envres.2017.06.025.

Kagi JHR, Vasak M, Lerch K, et al. 1984. Structure of mammalian metallothionein. Environ Health Perspect 54:93. https://doi.org/10.2307/3429795.

Kajiwara Y, Yasutake A, Adachi T, et al. 1996. Methylmercury transport across the placenta via neutral amino acid carrier. Arch Toxicol 70(5):310-314.

8. REFERENCES

Kajiwara Y, Yasutake A, Hirayama K. 1997. Strain difference in methylmercury transport across the placenta. Bull Environ Contam Toxicol 59(5):783-787.

Kakita A, Wakabayashi K, Su M, et al. 2000. Intrauterine methylmercury intoxication. Consequence of the inherent brain lesions and cognitive dysfunction in maturity. Brain Res 877(2):322-330. https://doi.org/10.1016/s0006-8993(00)02717-7.

Kalač P, Burda J, Stakova I. 1991. Concentrations of lead, cadmium, mercury and copper in mushrooms in the vicinity of a lead smelter. Sci Total Environ 105:109-119. https://doi.org/10.1016/0048-9697(91)90333-a.

Kalish BT, Rifas-Shiman SL, Wright RO, et al. 2014. Associations of prenatal maternal blood mercury concentrations with early and mid-childhood blood pressure: a prospective study. Environ Res 133:327-333. https://doi.org/10.1016/j.envres.2014.06.004.

Kamycheva E, Goto T, Camargo CA. 2017. Blood levels of lead and mercury and celiac disease seropositivity: the US National Health and Nutrition Examination Survey. Environ Sci Pollut Res Int 24(9):8385-8391. https://doi.org/10.1007/s11356-017-8545-0.

Kanematsu N, Hara M, Kada T. 1980. Rec assay and mutagenicity studies on metal compounds. Mutat Res 77:109-116.

Kang MS, Jeong JY, Seo JH, et al. 2006. Methylmercury-induced toxicity is mediated by enhanced intracellular calcium through activation of phosphatidylcholine-specific phospholipase C. Toxicol Appl Pharmacol 216(2):206-215. https://doi.org/10.1016/j.taap.2006.04.016.

Kang P, Shin HY, Kim KY. 2021. Association between dyslipidemia and mercury exposure in adults. Int J Environ Res Public Health 18(2):775. https://doi.org/10.3390/ijerph18020775.

Kanluen S, Gottlieb CA. 1991. A clinical pathologic study of four adult cases of acute mercury inhalation toxicity. Arch Pathol Lab Med 115(1):56-60.

Karatela S, Ward N, Paterson J. 2019. Mercury exposure in mother-children pairs in a seafood eating population: Body burden and related factors. Int J Environ Res Public Health 16(12):2238. https://doi.org/10.3390/ijerph16122238.

Karita K, Iwata T, Maeda E, et al. 2018. Assessment of cardiac autonomic function in relation to methylmercury neurotoxicity. Toxics 6:38. https://doi.org/10.3390/toxics6030038.

Kawahara D, Oshima H, Kosugi H, et al. 1993. Further epidemiologic study of occupational contact dermatitis in the dental clinic. Contact Dermatitis 28(2):114-115. https://doi.org/10.1111/j.1600-0536.1993.tb03357.x.

Kawasaki Y, Ikeda Y, Yamamoto T, et al. 1986. Long-term toxicity study of methylmercury chloride in monkeys. J Food Hyg Soc Jpn 27(5):528-552.

Ke T, Gonçalves FM, Gonçalves CL, et al. 2019. Post-translational modifications in MeHg-induced neurotoxicity. Biochim Biophys Acta Mol Basis Dis 1865(8):2068-2081. https://doi.org/10.1016/j.bbadis.2018.10.024.

Keeler GJ, Hoyner ME, Lamborg CH. 1994. Measurements of atmospheric mercury in the Great Lakes basin. In: Watras CJ, Huckabee JW, eds. Mercury pollution integration and synthesis. Boca Raton, FL: Lewis Publishers, 231-241.

Kelly TJ, Czuczwa JM, Sticksel PR, et al. 1991. Atmospheric and tributary inputs of toxic substances to Lake Erie. J Great Lakes Res 17(4):504-516. https://doi.org/10.1016/s0380-1330(91)71386-5.

Kendricks DR, Newland MC. 2021. Selective dopaminergic effects on attention and memory in male mice exposed to Methylmercury during adolescence. Neurotoxicol Teratol 87:107016. https://doi.org/10.1016/j.ntt.2021.107016.

Kendricks DR, Boomhower SR, Newland MC. 2020a. Methylmercury, attention, and memory: baseline-dependent effects of adult d-amphetamine and marginal effects of adolescent methylmercury. Neurotoxicology 80:130-139. https://doi.org/10.1016/j.neuro.2020.07.009.

Kendricks DR, Boomhower SR, Arnold MA, et al. 2020b. Adolescent methylmercury exposure alters short-term remembering, but not sustained attention, in male Long-Evans rats. Neurotoxicology 78:186-194. https://doi.org/10.1016/j.neuro.2020.03.009.

8. REFERENCES

Kendricks DR, Bhattacharya S, Reed MN, et al. 2022. Impacts of neonatal methylmercury on behavioral flexibility and learning in spatial discrimination reversal and visual signal detection tasks. Neurotoxicology 93:9-21. https://doi.org/10.1016/j.neuro.2022.08.013.

Kern JK, Geier DA, Homme KG, et al. 2020. Examining the evidence that ethylmercury crosses the blood-brain barrier. Environ Toxicol Pharmacol 74:103312. https://doi.org/10.1016/j.etap.2019.103312.

Kerper LE, Ballatori N, Clarkson TW. 1992. Methylmercury transport across the blood-brain barrier by an amino acid carrier. Am J Physiol 262(5 Pt 2):R761-765. https://doi.org/10.1152/ajpregu.1992.262.5.R761.

Kerry A, Welbourn PM, Prucha B, et al. 1991. Mercury methylation by sulphate-reducing bacteria from sediments of an acid stressed lake. Water Air Soil Pollut 56(1):565-575. https://doi.org/10.1007/bf00342300.

Kershaw TG, Clarkson TW, Dhahir PH. 1980. The relationship between blood levels and dose of methylmercury in man. Arch Environ Health 35(1):28-36.

Khan MA, Wang F. 2009. Mercury-selenium compounds and their toxicological significance: Toward a molecular understanding of the mercury-selenium antagonism. Environ Toxicol Chem 28(8):1567-1577. https://doi.org/10.1897/08-375.1.

Khan MF, Wang H. 2020. Environmental exposures and autoimmune diseases: contribution of gut microbiome. Front Immunol 10:3094. https://doi.org/10.3389/fimmu.2019.03094.

Khan AT, Atkinson A, Graham TC, et al. 2001. Uptake and distribution of mercury in rats after repeated administration of mercuric chloride. J Environ Sci Health A Tox Hazard Subst Environ Eng 36(10):2039-2045.

Khan AT, Atkinson A, Graham TC, et al. 2004. Effects of inorganic mercury on reproductive performance of mice. Food Chem Toxicol 42(4):571-577. https://doi.org/10.1016/j.fct.2003.10.018.

Khayat A, Dencker L. 1983. Whole body and liver distribution of inhaled mercury vapor in the mouse: Influence of ethanol and aminotriazole pretreatment. J Appl Toxicol 3(2):66-74. https://doi.org/10.1002/jat.2550030203.

Khayat A, Dencker L. 1984. Organ and cellular distribution of inhaled metallic mercury in the rat and marmoset monkey (Callithrix jacchus): Influence of ethyl alcohol pretreatment. Acta Pharmacol Toxicol 55(2):145-152. https://doi.org/10.1111/j.1600-0773.1984.tb01977.x.

Khera KS. 1973. Reproductive capability of male rats and mice treated with methyl mercury. Toxicol Appl Pharmacol 24:167-177. https://doi.org/10.1016/0041-008x(73)90136-1.

Khera KS, Tabacova SA. 1973. Effects of methylmercuric chloride on the progeny of mice and rats treated before or during gestation. Food Cosmet Toxicol 11(2):245-254. https://doi.org/10.1016/s0015-6264(73)80491-2.

Khera KS, Iverson F, Hierlihy L, et al. 1974. Toxicity of methylmercury in neonatal cats. Teratology 10(1):69-76. https://doi.org/10.1002/tera.1420100110.

Khoury ED, Souza Gda S, da Costa CA, et al. 2015. Somatosensory psychophysical losses in inhabitants of riverside communities of the Tapajos River Basin, Amazon, Brazil: Exposure to methylmercury is possibly involved. PLoS ONE 10(12):e0144625. https://doi.org/10.1371/journal.pone.0144625.

Kim Y, Lee BK. 2012. Associations of blood lead, cadmium, and mercury with estimated glomerular filtration rate in the Korean general population: Analysis of 2008-2010 Korean National Health and Nutrition Examination Survey data. Environ Res 118:124-129. https://doi.org/10.1016/j.envres.2012.06.003.

Kim K, Park H. 2023. Association of mercury exposure with the serum high-sensitivity C-reactive protein level in Korean adults. Front Public Health 11:1062741. https://doi.org/10.3389/fpubh.2023.1062741.

Kim CY, Nakai K, Kasanuma Y, et al. 2000. Comparison of neurobehavioral changes in three inbred strains of mice prenatally exposed to methylmercury. Neurotoxicol Teratol 22(3):397-403. https://doi.org/10.1016/s0892-0362(99)00077-x.

8. REFERENCES

Kim SH, Johnson VJ, Sharma RP. 2003. Oral exposure to inorganic mercury alters T lymphocyte phenotypes and cytokine expression in BALB/c mice. Arch Toxicol 77(11):613-620. https://doi.org/10.1007/s00204-003-0497-0.

Kim BM, Lee BE, Hong YC, et al. 2011. Mercury levels in maternal and cord blood and attained weight through the 24 months of life. Sci Total Environ 410-411:26-33. https://doi.org/10.1016/j.scitotenv.2011.08.060.

Kim RB, Kim BG, Kim YM, et al. 2013a. Association between low-level mercury exposure and neurobehavioral functions in Korean adults living in a coastal city. Environ Health Toxicol 28:e2013015. https://doi.org/10.5620/eht.2013.28.e2013015.

Kim H, Kim KN, Hwang JY, et al. 2013b. Relation between serum folate status and blood mercury concentrations in pregnant women. Nutrition 29(3):514-518. https://doi.org/10.1016/j.nut.2012.08.012.

Kim YN, Kim YA, Yang AR, et al. 2014. Relationship between blood mercury level and risk of cardiovascular diseases: Results from the fourth Korea National Health and Nutrition Examination Survey (KNHANES IV) 2008-2009. Prev Nutr Food Sci 19(4):333-342. https://doi.org/10.3746/pnf.2014.19.4.333.

Kim KN, Bae S, Park HY, et al. 2015a. Low-level mercury exposure and risk of asthma in school-age children. Epidemiology 26(5):733-739. https://doi.org/10.1097/ede.0000000000000351.

Kim NH, Hyun YY, Lee KB, et al. 2015b. Environmental heavy metal exposure and chronic kidney disease in the general population. J Korean Med Sci 30(3):272-277. https://doi.org/10.3346/jkms.2015.30.3.272.

Kim KN, Park SJ, Choi B, et al. 2015c. Blood mercury and insulin resistance in nondiabetic Koreans (KNHANES 2008-2010). Yonsei Med J 56(4):944-950. https://doi.org/10.3349/ymj.2015.56.4.944.

Kim JH, Lee KH, Hong SC, et al. 2015d. Association between serum mercury concentration and leukocyte differential count in children. Pediatr Hematol Oncol 32(2):109-114. https://doi.org/10.3109/08880018.2013.853222.

Kim YH, Shim JY, Seo MS, et al. 2016a. Relationship between blood mercury concentration and bone mineral density in Korean men in the 2008-2010 Korean National Health and Nutrition Examination Survey. Korean J Fam Med 37(5):273-278. https://doi.org/10.4082/kjfm.2016.37.5.273.

Kim SA, Kwon Y, Kim S, et al. 2016b. Assessment of dietary mercury intake and blood mercury levels in the Korean population: Results from the Korean National Environmental Health Survey 2012-2014. Int J Environ Res Public Health 13(9):13090877. https://doi.org/10.3390/ijerph13090877.

Kim BM, Chen MH, Chen PC, et al. 2017. Path analysis of prenatal mercury levels and birth weights in Korean and Taiwanese birth cohorts. Sci Total Environ 605-606:1003-1010. https://doi.org/10.1016/j.scitotenv.2017.06.151.

Kim Y, Ha EH, Park H, et al. 2018. Prenatal mercury exposure, fish intake and neurocognitive development during first three years of life: Prospective cohort mothers and Children's environmental health (MOCEH) study. Sci Total Environ 615:1192-1198. https://doi.org/10.1016/j.scitotenv.2017.10.014.

Kim B, Shah S, Park HS, et al. 2020a. Adverse effects of prenatal mercury exposure on neurodevelopment during the first 3 years of life modified by early growth velocity and prenatal maternal folate level. Environ Res 191:109909. https://doi.org/10.1016/j.envres.2020.109909.

Kim KW, Sreeja SR, Kwon M, et al. 2020b. Association of blood mercury level with the risk of depression according to fish intake level in the general Korean population: Findings from the Korean National Health and Nutrition Examination Survey (KNHANES) 2008-2013. Nutrients 12(1):189. https://doi.org/10.3390/nu12010189.

Kim SS, Meeker JD, Aung MT, et al. 2020c. Urinary trace metals in association with fetal ultrasound measures during pregnancy. Environ Epidemiol 4(2):e075. https://doi.org/10.1097/ee9.0000000000000075.

Kim DW, Ock J, Moon KW, et al. 2021a. Association between Pb, Cd, and Hg exposure and liver injury among Korean adults. Int J Environ Res Public Health 18(13):6783. https://doi.org/10.3390/ijerph18136783.

Kim MJ, Kim S, Choi S, et al. 2021b. Association of exposure to polycyclic aromatic hydrocarbons and heavy metals with thyroid hormones in general adult population and potential mechanisms. Sci Total Environ 762:144227. https://doi.org/10.1016/j.scitotenv.2020.144227.

Kim DW, Ock J, Moon KW, et al. 2022a. Association between heavy metal exposure and dyslipidemia among Korean adults: From the Korean National Environmental Health Survey, 2015-2017. Int J Environ Res Public Health 19(6):3181. https://doi.org/10.3390/ijerph19063181.

Kim K, Argos M, Persky VW, et al. 2022b. Associations of exposure to metal and metal mixtures with thyroid hormones: Results from the NHANES 2007-2012. Environ Res 212(Pt C):113413. https://doi.org/10.1016/j.envres.2022.113413.

King G. 1954. Acute pneumonitis due to accidental exposure to mercury vapor. Ariz Med 11:335.

Kirk JL, Lehnherr I, Andersson M, et al. 2012. Mercury in Arctic marine ecosystems: sources, pathways and exposure. Environ Res 119:64-87. https://doi.org/10.1016/j.envres.2012.08.012.

Kirkpatrick M, Benoit J, Everett W, et al. 2015. The effects of methylmercury exposure on behavior and biomarkers of oxidative stress in adult mice. Neurotoxicology 50:170-178. https://doi.org/10.1016/j.neuro.2015.07.001.

Kishi R, Hashimoto K, Shimizu S, et al. 1978. Behavioral changes and mercury concentrations in tissues of rats exposed to mercury vapor. Toxicol Appl Pharmacol 46(3):555-566. https://doi.org/10.1016/0041-008x(78)90303-4.

Kjellstrom T, Kennedy P, Wallis S, et al. 1986. Physical and mental development of children with prenatal exposure to mercury from fish. Stage I: Preliminary tests at age 4. Solna, Sweden: National Swedish Environmental Board. Report 3080.

Kjellstrom T, Kennedy P, Wallis S, et al. 1989. Physical and mental development of children with prenatal exposure to mercury from fish. Stage 2: Interviews and psychological tests at age 6. Solna, Sweden: National Swedish Environmental Protection Board. Report 3642.

Kobal AB, Horvat M, Prezelj M, et al. 2004. The impact of long-term past exposure to elemental mercury on antioxidative capacity and lipid peroxidation in mercury miners. J Trace Elem Med Biol 17(4):261-274. https://doi.org/10.1016/s0946-672x(04)80028-2.

Kobayashi S, Kishi R, Saijo Y, et al. 2019. Association of blood mercury levels during pregnancy with infant birth size by blood selenium levels in the Japan Environment and Children's Study: A prospective birth cohort. Environ Int 125:418-429. https://doi.org/10.1016/j.envint.2019.01.051.

Kobayashi S, Itoh S, Miyashita C, et al. 2022. Impact of prenatal exposure to mercury and selenium on neurodevelopmental delay in children in the Japan environment and Children's study using the ASQ-3 questionnaire: A prospective birth cohort. Environ Int 168:107448. https://doi.org/10.1016/j.envint.2022.107448.

Koch P, Bahmer FA. 1999. Oral lesions and symptoms related to metals used in dental restorations: a clinical, allergological, and histologic study. J Am Acad Dermatol 41(3 Pt 1):422-430. https://doi.org/10.1016/s0190-9622(99)70116-7.

Koh AS, Simmons-Willis TA, Pritchard JB, et al. 2002. Identification of a mechanism by which the methylmercury antidotes N-acetylcysteine and dimercaptopropanesulfonate enhance urinary metal excretion: transport by the renal organic anion transporter-1. Mol Pharmacol 62(4):921-926.

Kohler CC, Heidinger RC, Call T. 1990. Levels of PCBs and trace metals in crab orchard lake sediment, benthos, zooplankton and fish. Carbondale, IL: University of South Illinois. HWRICRR-043.

Koller LD, Exon JH, Arbogast B. 1977. Methylmercury: Effect on serum enzymes and humoral antibody. J Toxicol Environ Health 2(5):1115-1123. https://doi.org/10.1080/15287397709529509.

Komsta-Szumska E, Chmielnicka J, Piotrowski JK. 1976. Binding of inorganic mercury by subcellar fractions and proteins of rat kidneys. Arch Toxicol 37(1):57-66. https://doi.org/10.1007/bf00353355.

Koopsamy Naidoo SV, Bester MJ, Arbi S, et al. 2019. Oral exposure to cadmium and mercury alone and in combination causes damage to the lung tissue of Sprague-Dawley rats. Environ Toxicol Pharmacol 69:86-94. https://doi.org/10.1016/j.etap.2019.03.021.

Kopec AD, Kidd KA, Fisher NS, et al. 2019. Spatial and temporal trends of mercury in the aquatic food web of the lower Penobscot River, Maine, USA, affected by a chlor-alkali plant. Sci Total Environ 649:770-791. https://doi.org/10.1016/j.scitotenv.2018.08.203.

Kort SAR, Wickliffe J, Shankar A, et al. 2022. The association between mercury and lead exposure and liver and kidney function in pregnant Surinamese women enrolled in the Caribbean Consortium for Research in Environmental and Occupational Health (CCREOH) environmental epidemiologic cohort study. Toxics 10(10):584. https://doi.org/10.3390/toxics10100584.

Kosta L, Byrne AR, Zelenko V. 1975. Correlation between selenium and mercury in man following exposure to inorganic mercury. Nature 254(5497):238-239. https://doi.org/10.1038/254238a0.

Kostial K, Kargačin B, Landeka M. 1984. Influence of dietary ingredients on the body retention of strontium, cadmium and mercury in suckling rats. Toxicol Lett 23(2):163-168. https://doi.org/10.1016/0378-4274(84)90121-8.

Kostial K, Kello D, Jugo S, et al. 1978. Influence of age on metal metabolism and toxicity. Environ Health Perspect 25:81-86. https://doi.org/10.1289/ehp.782581.

Kostial K, Restek-Samarzija N, Blanusa M, et al. 1997. Racemic-2,3-dimercaptosuccinic acid for inorganic mercury mobilization in rats. J Appl Toxicol 17(1):71-74.

Kostyniak PJ. 1983. Pharmacokinetics of methylmercury in sheep. J Appl Toxicol 3(1):35-38.

Krabbenhoft DP, Babiarz CL. 1992. The role of groundwater transport in aquatic mercury cycling. Water Resour Res 28(12):3119-3128. https://doi.org/10.1029/92wr01766.

Krystek P, Favaro P, Bode P, et al. 2012. Methyl mercury in nail clippings in relation to fish consumption analysis with gas chromatography coupled to inductively coupled plasma mass spectrometry: a first orientation. Talanta 97:83-86. https://doi.org/10.1016/j.talanta.2012.03.065.

Kvestad I, Vabø S, Kjellevold M, et al. 2018. Fatty fish, hair mercury and cognitive function in Norwegian preschool children: Results from the randomized controlled trial FINS-KIDS. Environ Int 121(Pt 2):1098-1105. https://doi.org/10.1016/j.envint.2018.10.022.

Laine J, Kalimo K, Happonen RP. 1997. Contact allergy to dental restorative materials in patients with oral lichenoid lesions. Contact Dermatitis 36(3):141-146. https://doi.org/10.1111/j.1600-0536.1997.tb00396.x.

Lam HS, Kwok KM, Chan PH, et al. 2013. Long term neurocognitive impact of low dose prenatal methylmercury exposure in Hong Kong. Environ Int 54:59-64. https://doi.org/10.1016/j.envint.2013.01.005.

Langolf GD, Chaffin DB, Henderson R, et al. 1978. Evaluation of workers exposed to elemental mercury using quantitative tests of tremor and neuromuscular functions. Am Ind Hyg Assoc J 39(12):976-984. https://doi.org/10.1080/0002889778507898.

Langworth S, Kölbeck KG, Akesson A. 1988. Mercury exposure from dental fillings. II. Release and absorption. Swed Dent J 12(1-2):71-72.

Langworth S, Almkvist O, Soderman E, et al. 1992a. Effects of occupational exposure to mercury vapour on the central nervous system. Occup Environ Med 49(8):545-555. https://doi.org/10.1136/oem.49.8.545.

Langworth S, Elinder CG, Sundquist KG, et al. 1992b. Renal and immunological effects of occupational exposure to inorganic mercury. Br J Ind Med 49(6):394-401. https://doi.org/10.1136/oem.49.6.394.

Larsen JO, Brændgaard H. 1995. Structural preservation of cerebellar granule cells following neurointoxication with methyl mercury: A stereological study of the rat cerebellum. Acta Neuropathol 90:251-256. https://doi.org/10.1007/BF00296508.

Larsen TJ, Jørgensen ME, Larsen CVL, et al. 2018. Whole blood mercury and the risk of cardiovascular disease among the Greenlandic population. Environ Res 164:310-315. https://doi.org/10.1016/j.envres.2018.03.003.

Lash LH, Jones DP. 1985. Uptake of the glutathione conjugate S-(1,2-dichlorovinyl)glutathione by renal basal-lateral membrane vesicles and isolated kidney cells. Mol Pharmacol 28(3):278-282.

Laue HE, Moroishi Y, Jackson BP, et al. 2020. Nutrient-toxic element mixtures and the early postnatal gut microbiome in a United States longitudinal birth cohort. Environ Int 138:105613. https://doi.org/10.1016/j.envint.2020.105613.

Lauwerys R, Bonnier C, Evrard P, et al. 1987. Prenatal and early postnatal intoxication by inorganic mercury resulting from the maternal use of mercury containing soap. Hum Toxicol 6(3):253-256. https://doi.org/10.1177/096032718700600316.

Lebel J, Mergler D, Lucotte M, et al. 1996. Evidence of early nervous system dysfunction in Amazonian populations exposed to low-levels of methylmercury. Neurotoxicology 17(1):157-167.

Lebel J, Mergler D, Branches F, et al. 1998. Neurotoxic effects of low-level methylmercury contamination in the Amazonian Basin. Environ Res 79(1):20-32.

Lecavalier PR, Chu I, Villeneuve D, et al. 1994. Combined effects of mercury and hexachlorobenzene in the rat. J Environ Sci Health B 29(5):951-961. https://doi.org/10.1080/03601239409372911.

Lederman SA, Jones RL, Caldwell KL, et al. 2008. Relation between cord blood mercury levels and early child development in a World Trade Center cohort. Environ Health Perspect 116(8):1085-1091. https://doi.org/10.1289/ehp.10831.

Lee Y, Iverfeldt A. 1991. Measurement of methylmercury and mercury in run-off, lake and rain waters. Water Air Soil Pollut 56(1):309-321. https://doi.org/10.1007/bf00342279.

Lee JH, Han DH. 1995. Maternal and fetal toxicity of methylmercuric chloride administered to pregnant Fischer 344 rats. J Toxicol Environ Health 45(4):415-425. https://doi.org/10.1080/15287399509532005.

Lee E, Park HK, Kim HJ. 1996. Adjustment of urinary mercury in health risk assessment of mercury. J Korean Med Sci 11(4):319-325. https://doi.org/10.3346/jkms.1996.11.4.319.

Lee CH, Lin RH, Liu SH, et al. 1997. Distinct genotoxicity of phenylmercury acetate in human lymphocytes as compared with other mercury compounds. Mutat Res 392(3):269-276.

Lee BE, Hong YC, Park H, et al. 2010. Interaction between GSTM1/GSTT1 polymorphism and blood mercury on birth weight. Environ Health Perspect 118(3):437-443. https://doi.org/10.1289/ehp.0900731.

Lee H, Kim Y, Sim CS, et al. 2014. Associations between blood mercury levels and subclinical changes in liver enzymes among South Korean general adults: analysis of 2008-2012 Korean national health and nutrition examination survey data. Environ Res 130:14-19. https://doi.org/10.1016/j.envres.2014.01.005.

Lee S, Yoon JH, Won JU, et al. 2016. The association between blood mercury levels and risk for overweight in a general adult population: Results from the Korean National Health and Nutrition Examination Survey. Biol Trace Elem Res 171(2):251-261. https://doi.org/10.1007/s12011-015-0530-1.

Lee MR, Lim YH, Lee BE, et al. 2017a. Blood mercury concentrations are associated with decline in liver function in an elderly population: a panel study. Environ Health 16(1):17. https://doi.org/10.1186/s12940-017-0228-2.

Lee S, Tan YM, Phillips MB, et al. 2017b. Estimating methylmercury intake for the general population of South Korea using physiologically based pharmacokinetic modeling. Toxicol Sci 159(1):6-15. https://doi.org/10.1093/toxsci/kfx111.

Lee DH, Keum N, Hu FB, et al. 2017c. Development and validation of anthropometric prediction equations for lean body mass, fat mass and percent fat in adults using the National Health and Nutrition Examination Survey (NHANES) 1999–2006. Br J Nutr 118(10):858-866. https://doi.org/10.1017/s0007114517002665.

Lee SH, Choi B, Park SJ, et al. 2017d. The cut-off value of blood mercury concentration in relation to insulin resistance. J Obes Metab Syndr 26(3):197-203. https://doi.org/10.7570/jomes.2017.26.3.197.

8. REFERENCES

Lee TW, Kim DH, Ryu JY. 2019. The effects of exposure to lead, cadmium and mercury on follicle-stimulating hormone levels in men and postmenopausal women: data from the Second Korean National Environmental Health Survey (2012-2014). Ann Occup Environ Med 31:e21. https://doi.org/10.35371/aoem.2019.31.e21.

Lee S, Cho SR, Jeong I, et al. 2020a. Mercury exposure and associations with hyperlipidemia and elevated liver enzymes: A nationwide cross-sectional survey. Toxics 8(3):47. https://doi.org/10.3390/toxics8030047.

Lee S, Hong YC, Park H, et al. 2020b. Combined effects of multiple prenatal exposure to pollutants on birth weight: The Mothers and Children's Environmental Health (MOCEH) study. Environ Res 181:108832. https://doi.org/10.1016/j.envres.2019.108832.

Leggett RW, Munro NB, Eckerman KF. 2001. Proposed revision of the ICRP model for inhaled mercury vapor. Health Phys 81(4):450-455.

Leistevuo J, Leistevuo T, Helenius H, et al. 2001. Dental amalgam fillings and the amount of organic mercury in human saliva. Caries Res 35(3):163-166. https://doi.org/10.1159/000047450.

Leong CC, Syed NI, Lorscheider FL. 2001. Retrograde degeneration of neurite membrane structural integrity of nerve growth cones following in vitro exposure to mercury. Neuroreport 12(4):733-737.

Lescord GL, Johnston TA, Branfireun BA, et al. 2018. Percentage of methylmercury in the muscle tissue of freshwater fish varies with body size and age and among species. Environ Toxicol Chem 37(10):2682-2691. https://doi.org/10.1002/etc.4233.

Letz R, Gerr F, Cragle D, et al. 2000. Residual neurologic deficits 30 years after occupational exposure to elemental mercury. Neurotoxicology 21(4):459-474.

Leung TY, Choy CM, Yim SF, et al. 2001. Whole blood mercury concentrations in sub-fertile men in Hong Kong. Aust N Z J Obstet Gynaecol 41(1):75-77. https://doi.org/10.1111/j.1479-828x.2001.tb01298.x.

Levey AS, Stevens LA, Schmid CH, et al. 2009. A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604. https://doi.org/10.7326/0003-4819-150-9-200905050-00006.

Levine SP, Cavender GD, Langolf GD, et al. 1982. Elemental mercury exposure: Peripheral neurotoxicity. Occup Environ Med 39(2):136-139. https://doi.org/10.1136/oem.39.2.136.

Lewis RJ. 1993. Mercury. In: Hawley's condensed chemical dictionary. 12th ed. New York, NY: John Wiley & Sons, Inc., 739-741, 743-745, 901.

Li W, Wang WX. 2019. In vivo oral bioavailability of fish mercury and comparison with in vitro bioaccessibility. Sci Total Environ 683:648-658. https://doi.org/10.1016/j.scitotenv.2019.05.290.

Li Y, Zhang B, Yang L, et al. 2013. Blood mercury concentration among residents of a historic mercury mine and possible effects on renal function: a cross-sectional study in southwestern China. Environ Monit Assess 185(4):3049-3055. https://doi.org/10.1007/s10661-012-2772-0.

Li P, Du B, Chan HM, et al. 2015. Human inorganic mercury exposure, renal effects and possible pathways in Wanshan mercury mining area, China. Environ Res 140:198-204. https://doi.org/10.1016/j.envres.2015.03.033.

Li S, Baiyun R, Lv Z, et al. 2019a. Exploring the kidney hazard of exposure to mercuric chloride in mice: Disorder of mitochondrial dynamics induces oxidative stress and results in apoptosis. Chemosphere 234:822-829. https://doi.org/10.1016/j.chemosphere.2019.06.096.

Li H, Lin X, Zhao J, et al. 2019b. Intestinal methylation and demethylation of mercury. Bull Environ Contam Toxicol 102(5):597-604. https://doi.org/10.1007/s00128-018-2512-4.

Li P, Yin R, Du B, et al. 2020. Kinetics and metabolism of mercury in rats fed with mercury contaminated rice using mass balance and mercury isotope approach. Sci Total Environ 736:139687. https://doi.org/10.1016/j.scitotenv.2020.139687.

Li W, Li X, Su J, et al. 2023. Associations of blood metals with liver function: Analysis of NHANES from 2011 to 2018. Chemosphere 317:137854. https://doi.org/10.1016/j.chemosphere.2023.137854.

Liang JH, Pu YQ, Liu ML, et al. 2023. Joint effect of whole blood metals exposure with dyslipidemia in representative US adults in NHANES 2011-2020. Environ Sci Pollut Res Int 30(42):96604-96616. https://doi.org/10.1007/s11356-023-28903-0.

8. REFERENCES

Liberda EN, Tsuji LJ, Martin ID, et al. 2014. The complexity of hair/blood mercury concentration ratios and its implications. Environ Res 134:286-294. https://doi.org/10.1016/j.envres.2014.08.007.

Lilis R, Miller A, Lerman Y. 1985. Acute mercury poisoning with severe chronic pulmonary manifestations. Chest 88(2):306-309. https://doi.org/10.1378/chest.88.2.306.

Lim HS, Lee HH, Kim TH, et al. 2016. Relationship between heavy metal exposure and bone mineral density in Korean adult. J Bone Metab 23(4):223-231. https://doi.org/10.11005/jbm.2016.23.4.223.

Lin YS, Ginsberg G, Caffrey JL, et al. 2014a. Association of body burden of mercury with liver function test status in the U.S. population. Environ Int 70:88-94. https://doi.org/10.1016/j.envint.2014.05.010.

Lin YS, Ginsberg G, Lin JW, et al. 2014b. Mercury exposure and omega-3 fatty acid intake in relation to renal function in the US population. Int J Hyg Environ Health 217(4-5):465-472. https://doi.org/10.1016/j.ijheh.2013.09.004.

Lin PD, Cardenas A, Rifas-Shiman SL, et al. 2023. Non-essential and essential trace element mixtures and kidney function in early pregnancy - A cross-sectional analysis in project viva. Environ Res 216(Pt 4):114846. https://doi.org/10.1016/j.envres.2022.114846.

Lindberg SE, Turner RR, Meyers TP, et al. 1991. Atmospheric concentrations and deposition of Hg to a deciduous forest at Walker Branch Watershed, Tennessee, USA. Water Air Soil Pollut 56(1):577-594. https://doi.org/10.1007/bf00342301.

Lindberg SE, Owens JG, Stratton WJ. 1994. Application of throughfall methods to estimate dry deposition of mercury. In: Watras CJ, Huckabee JW, eds. Mercury pollution integration and synthesis. Boca Raton, FL: Lewis Publishers, 261-271.

Lindqvist O, Johansson K, Bringmark L, et al. 1991. Mercury in the Swedish environment - Recent research on causes, consequences and corrective methods. Water Air Soil Pollut 55(1-2):xi-261. https://doi.org/10.1007/bf00542429.

Liu T, Zhang M, Guallar E, et al. 2019. Trace minerals, heavy metals, and preeclampsia: Findings from the Boston Birth Cohort. J Am Heart Assoc 8(16):e012436. https://doi.org/10.1161/jaha.119.012436.

Liu J, Portnoy J, Um P, et al. 2021a. Blood lead and mercury levels are associated with low resting heart rate in community adolescent boys. Int J Hyg Environ Health 233:113685. https://doi.org/10.1016/j.ijheh.2020.113685.

Liu M, Song J, Jiang Y, et al. 2021b. A case-control study on the association of mineral elements exposure and thyroid tumor and goiter. Ecotoxicol Environ Saf 208:111615. https://doi.org/10.1016/j.ecoenv.2020.111615.

Liu Y, Zhang C, Qin Z, et al. 2022. Analysis of threshold effect of urinary heavy metal elements on the high prevalence of nephrolithiasis in men. Biol Trace Elem Res 200(3):1078-1088. https://doi.org/10.1007/s12011-021-02740-z.

Liu Q, Hu S, Fan F, et al. 2023. Association of blood metals with serum sex hormones in adults: A cross-sectional study. Environ Sci Pollut Res Int 30(26):69628-69638. https://doi.org/10.1007/s11356-023-27384-5.

Livardjani F, Ledig M, Kopp P, et al. 1991. Lung and blood superoxide dismutase activity in mercury vapor exposed rats: Effect of N-acetylcysteine treatment. Toxicology 66(3):289-295. https://doi.org/10.1016/0300-483x(91)90200-k.

Llop S, Guxens M, Murcia M, et al. 2012. Prenatal exposure to mercury and infant neurodevelopment in a multicenter cohort in Spain: study of potential modifiers. Am J Epidemiol 175(5):451-465. https://doi.org/10.1093/aje/kwr328.

Llop S, Lopez-Espinosa MJ, Murcia M, et al. 2015. Synergism between exposure to mercury and use of iodine supplements on thyroid hormones in pregnant women. Environ Res 138:298-305. https://doi.org/10.1016/j.envres.2015.02.026.

Loan A, Leung JW, Cook DP, et al. 2023. Prenatal low-dose methylmercury exposure causes premature neuronal differentiation and autism-like behaviors in a rodent model. iScience 26(3):106093. https://doi.org/10.1016/j.isci.2023.106093.

Lodenius M, Autio S. 1989. Effects of acidification on the mobilization of cadmium and mercury from soils. Arch Environ Contam Toxicol 18(1-2):261-267. https://doi.org/10.1007/bf01056212.

Lohren H, Bornhorst J, Galla H-J, et al. 2015. The blood–cerebrospinal fluid barrier – first evidence for an active transport of organic mercury compounds out of the brain. Metallomics 7(10):1420-1430. https://doi.org/10.1039/c5mt00171d.

Lomonte C, Doronila AI, Gregory D, et al. 2010. Phytotoxicity of biosolids and screening of selected plant species with potential for mercury phytoextraction. J Hazard Mater 173(1-3):494-501. https://doi.org/10.1016/j.jhazmat.2009.08.112.

Long LH, Cattanach J. 1961. Antoine vapour-pressure equations and heats of vaporization for the dimethyls of zinc, cadmium and mercury. J Inorg Nucl Chem 20(3-4):340-342. https://doi.org/10.1016/0022-1902(61)80285-6.

Lopez AM, Fitzsimmons JN, Adams HM, et al. 2022. A time-series of heavy metal geochemistry in sediments of Galveston Bay estuary, Texas, 2017-2019. Sci Total Environ 806(Pt 3):150446. https://doi.org/10.1016/j.scitotenv.2021.150446.

Louopou RC, Trottier H, Arbuckle TE, et al. 2020. Dental amalgams and risk of gestational hypertension in the MIREC study. Pregnancy Hypertens 21:84-89. https://doi.org/10.1016/j.preghy.2020.04.015.

Love TM, Thurston SW, Davidson PW. 2017. Finding vulnerable subpopulations in the Seychelles Child Development Study: Effect modification with latent groups. Stat Methods Med Res 26(2):809-822. https://doi.org/10.1177/0962280214560044.

Lovejoy HB, Bell ZG, Vizena TR. 1973. Mercury exposure evaluations and their correlation with urine mercury excretions. 4. Elimination of mercury by sweating. J Occup Med 15(7):590-591.

Lozano M, Murcia M, Soler-Blasco R, et al. 2021. Exposure to mercury among 9-year-old children and neurobehavioural function. Environ Int 146:106173. https://doi.org/10.1016/j.envint.2020.106173.

Lu Z, Ma Y, Gao L, et al. 2018. Urine mercury levels correlate with DNA methylation of imprinting gene H19 in the sperm of reproductive-aged men. PLoS ONE 13(4):e0196314. https://doi.org/10.1371/journal.pone.0196314.

Lu YT, Qi WZ, Wang S, et al. 2020. Toxicity and risk assessment of mercury exposures from cinnabar and Baizi Yangxin Pills based on pharmacokinetic and tissue distribution studies. J Ethnopharmacol 250:112489. https://doi.org/10.1016/j.jep.2019.112489.

Lu K, Liu T, Wu X, et al. 2023. Association between serum iron, blood lead, cadmium, mercury, selenium, manganese and low cognitive performance in old adults from National Health and Nutrition Examination Survey (NHANES): a cross-sectional study. Br J Nutr 130(10):1743-1753. https://doi.org/10.1017/s0007114523000740.

Luecke RH, Wosilait WD, Pearce BA, et al. 1994. A physiologically based pharmacokinetic computer model for human pregnancy. Teratology 49(2):90-103. https://doi.org/10.1002/tera.1420490205.

Luecke RH, Wosilait WD, Pearce BA, et al. 1997. A computer model and program for xenobiotic disposition during pregnancy. Comput Methods Programs Biomed 53(3):201-224.

Lukacinova A, Benacka R, Sedlakova E, et al. 2012. Multigenerational lifetime low-dose exposure to heavy metals on selected reproductive parameters in rats. J Environ Sci Health A Tox Hazard Subst Environ Eng 47(9):1280-1287. https://doi.org/10.1080/10934529.2012.672132.

Lukina AO, Fisher M, Khoury C, et al. 2021. Temporal variation of total mercury levels in the hair of pregnant women from the Maternal-Infant Research on Environmental Chemicals (MIREC) study. Chemosphere 264(Pt 1):128402. https://doi.org/10.1016/j.chemosphere.2020.128402.

Lundgren KD, Swensson Å, Ulfvarson U. 1967. Studies in humans on the distribution of mercury in the blood and the excretion in urine after exposure to different mercury compounds. Scand J Clin Lab Invest 20(2):164-166. https://doi.org/10.3109/00365516709076937.

Lyman SN, Cheng I, Gratz LE, et al. 2020. An updated review of atmospheric mercury. Sci Total Environ 707:135575. https://doi.org/10.1016/j.scitotenv.2019.135575.

8. REFERENCES

Ma J, Zhang H, Zheng T, et al. 2022. Exposure to metal mixtures and hypertensive disorders of pregnancy: A nested case-control study in China. Environ Pollut 306:119439. https://doi.org/10.1016/j.envpol.2022.119439.

Ma Y, Liang C, Wang Z, et al. 2023. Association between prenatal metals exposure and blood pressure in 5-6 years children: A birth cohort study. Environ Res 219:114974. https://doi.org/10.1016/j.envres.2022.114974.

Mabille V, Roels H, Jacquet P, et al. 1984. Cytogenetic examination of leucocytes of workers exposed to mercury vapour. Int Arch Occup Environ Health 53(3):257-260. https://doi.org/10.1007/bf00398818.

MacDonald JS, Harbison RD. 1977. Methyl mercury-induced encephalopathy in mice. Toxicol Appl Pharmacol 39(2):195-205. https://doi.org/10.1016/0041-008x(77)90153-3.

Mackert JR, Berglund A. 1997. Mercury exposure from dental amalgam fillings: Absorbed dose and the potential for adverse health effects. Crit Rev Oral Biol Med 8(4):410-436.

MacPherson S, Arbuckle TE, Fisher M. 2018. Adjusting urinary chemical biomarkers for hydration status during pregnancy. J Expo Sci Environ Epidemiol 28(5):481-493. https://doi.org/10.1038/s41370-018-0043-z.

MacSween K, Stupple G, Aas W, et al. 2022. Updated trends for atmospheric mercury in the Arctic: 1995-2018. Sci Total Environ 837:155802. https://doi.org/10.1016/j.scitotenv.2022.155802.

Maeda E, Murata K, Kumazawa Y, et al. 2019. Associations of environmental exposures to methylmercury and selenium with female infertility: A case-control study. Environ Res 168:357-363. https://doi.org/10.1016/j.envres.2018.10.007.

Magos L. 1967. Mercury-blood interaction and mercury uptake by the brain after vapor exposure. Environ Res 1(4):323-337.

Magos L, Clarkson TW. 2006. Overview of the clinical toxicity of mercury. Ann Clin Biochem 43(Pt 4):257-268. https://doi.org/10.1258/000456306777695654.

Magos L, Halbach S, Clarkson TW. 1978. Role of catalase in the oxidation of mercury vapor. Biochem Pharmacol 27(9):1373-1377. https://doi.org/10.1016/0006-2952(78)90122-3.

Magos L, Clarkson TW, Hudson AR. 1989. The effects of dose of elemental mercury and first-pass circulation time on exhalation and organ distribution of inorganic mercury in rats. Biochim Biophys Acta 991(1):85-89. https://doi.org/10.1016/0304-4165(89)90032-9.

Mahaffey KR, Clickner RP, Jeffries RA. 2009. Adult women's blood mercury concentrations vary regionally in the United States: association with patterns of fish consumption (NHANES 1999-2004). Environ Health Perspect 117(1):47-53. https://doi.org/10.1289/ehp.11674.

Mahour K, Saxena PN. 2009. Assessment of haematotoxic potential of mercuric chloride in rat. J Environ Biol 30(5 Suppl):927-928.

Mailhes JB. 1983. Methylmercury effects on Syrian hamster metaphase II oocyte chromosomes. Environ Mutagen 5(5):679-686.

Malqui H, Anarghou H, Ouardi FZ, et al. 2018. Continuous exposure to inorganic mercury affects neurobehavioral and physiological parameters in mice. J Mol Neurosci 66(2):291-305. https://doi.org/10.1007/s12031-018-1176-1.

Mansour MM, Dyer NC, Hoffman LH, et al. 1974. Placental transfer of mercuric nitrate and methyl mercury in the rat. Am J Obstet Gynecol 119(4):557-562. https://doi.org/10.1016/0002-9378(74)90220-8.

Manzolli ES, Serpeloni JM, Grotto D, et al. 2015. Protective effects of the flavonoid chrysin against methylmercury-induced genotoxicity and alterations of antioxidant status, in vivo. Oxid Med Cell Longev 2015:1-7. https://doi.org/10.1155/2015/602360.

Mao X, Chen C, Xun P, et al. 2019. Effects of seafood consumption and toenail mercury and selenium levels on cognitive function among American adults: 25 y of follow up. Nutrition 61:77-83. https://doi.org/10.1016/j.nut.2018.11.002.

Maqbool F, Niaz K, Hassan FI, et al. 2017. Immunotoxicity of mercury: Pathological and toxicological
     effects. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 35(1):29-46.
     https://doi.org/10.1080/10590501.2016.1278299.

Maqbool F, Bahadar H, Hassani S, et al. 2019. Biochemical evidence on the potential role of methyl
     mercury in hepatic glucose metabolism through inflammatory signaling and free radical pathways. J
     Cell Biochem 120(9):16195-16205. https://doi.org/10.1002/jcb.28899.

Marien K, Patrick GM. 2001. Exposure analysis of five fish-consuming populations for overexposure to
     methylmercury. J Expo Anal Environ Epidemiol 11(3):193-206.
     https://doi.org/10.1038/sj.jea.7500160.

Marinho JS, Lima MO, de Oliveira Santos EC, et al. 2014. Mercury speciation in hair of children in
     three communities of the Amazon, Brazil. BioMed Res Int 2014:1-9.
     https://doi.org/10.1155/2014/945963.

Marques RC, Garrofe Dorea J, Rodrigues Bastos W, et al. 2007. Maternal mercury exposure and neuro-
     motor development in breastfed infants from Porto Velho (Amazon), Brazil. Int J Hyg Environ
     Health 210(1):51-60. https://doi.org/10.1016/j.ijheh.2006.08.001.

Marques RC, Bernardi JV, Dórea JG, et al. 2013a. Mercury transfer during pregnancy and breastfeeding:
     hair mercury concentrations as biomarker. Biol Trace Elem Res 154(3):326-332.
     https://doi.org/10.1007/s12011-013-9743-3.

Marques RC, Bernardi JV, Dórea JG, et al. 2013b. Fish consumption during pregnancy, mercury
     transfer, and birth weight along the Madeira River Basin in Amazonia. Int J Environ Res Public
     Health 10(6):2150-2163. https://doi.org/10.3390/ijerph10062150.

Marques RC, Moreira Mde F, Bernardi JV, et al. 2013c. Breast milk lead concentrations of mothers
     living near tin smelters. Bull Environ Contam Toxicol 91(5):549-554.
     https://doi.org/10.1007/s00128-013-1093-5.

Marques RC, Bernardi JV, Abreu L, et al. 2015. Neurodevelopment outcomes in children exposed to
     organic mercury from multiple sources in a tin-ore mine environment in Brazil. Arch Environ
     Contam Toxicol 68(3):432-441. https://doi.org/10.1007/s00244-014-0103-x.

Marsh DO, Clarkson TW, Cox C, et al. 1987. Fetal methylmercury poisoning: Relationship between
     concentration in single strands of maternal hair and child effects. Arch Neurol 44(10):1017-1022.

Martin MD, McCann T, Naleway C, et al. 1996. The validity of spot urine samples for low-level
     occupational mercury exposure assessment and relationship to porphyrin and creatinine excretion
     rates. J Pharmacol Exp Ther 277(1):239-244.

Maserejian NN, Trachtenberg FL, Assmann SF, et al. 2008. Dental amalgam exposure and urinary
     mercury levels in children: The New England Children's Amalgam Trial. Environ Health Perspect
     116(2):256-262. https://doi.org/10.1289/ehp.10440.

Mason RP, Reinfelder JR, Morel FM. 1995. Bioaccumulation of mercury and methylmercury. In:
     Porcella DB, Wheatley B, eds. Proceedings of the third international Conference Whistler, British
     Columbia, July 10-14, 1994. Boston, MA: Kluwer Academic Publishers, 915-921.

Mason RP, Reinfelder JR, Morel FM. 1996. Uptake, toxicity, and trophic transfer of mercury in a
     coastal diatom. Environ Sci Technol 30(6):1835-1845.

Mathiesen T, Ellingsen DG, Kjuus H. 1999. Neuropsychological effects associated with exposure to
     mercury vapor among former chloralkali workers. Scand J Work Environ Health 25(4):342-350.
     https://doi.org/10.5271/sjweh.444.

Matsumoto N, Spindle A. 1982. Sensitivity of early mouse embryos to methylmercury toxicity. Toxicol
     Appl Pharmacol 64(1):108-117.

Matsuo N, Suzuki T, Akagi H. 1989. Mercury concentration in organs of contemporary Japanese. Arch
     Environ Health 44(5):298-303.

Matthews NH, Koh M, Li WQ, et al. 2019. A prospective study of toenail trace element levels and risk
     of skin cancer. Cancer Epidemiol Biomarkers Prev 28(9):1534-1543. https://doi.org/10.1158/1055-
     9965.EPI-19-0214.

8. REFERENCES

McClam M, Liu J, Fan Y, et al. 2023. Associations between exposure to cadmium, lead, mercury and mixtures and women's infertility and long-term amenorrhea. Arch Public Health 81(1):161. https://doi.org/10.1186/s13690-023-01172-6.

McGrother CW, Dugmore C, Phillips MJ, et al. 1999. Multiple sclerosis, dental caries and fillings: a case-control study. Br Dent J 187(5):261-264. https://doi.org/10.1038/sj.bdj.4800255.

McKean SJ, Bartell SM, Hansen RL, et al. 2015. Prenatal mercury exposure, autism, and developmental delay, using pharmacokinetic combination of newborn blood concentrations and questionnaire data: a case control study. Environ Health 14:62. https://doi.org/10.1186/s12940-015-0045-4.

McKelvey W, Jeffery N, Clark N, et al. 2011. Population-based inorganic mercury biomonitoring and the identification of skin care products as a source of exposure in New York City. Environ Health Perspect 119(2):203-209. https://doi.org/10.1289/ehp.1002396.

McKelvey W, Alex B, Chernov C, et al. 2018. Tracking declines in mercury exposure in the New York City adult population, 2004-2014. J Urban Health 95(6):813-825. https://doi.org/10.1007/s11524-018-0269-z.

McKeown-Eyssen GE, Ruedy J, Neims A. 1983. Methyl mercury exposure in northern Quebec. II. Neurologic findings in children. Am J Epidemiol 118(4):470-479. https://doi.org/10.1093/oxfordjournals.aje.a113652.

McSorley EM, Yeates AJ, Mulhern MS, et al. 2018. Associations of maternal immune response with MeHg exposure at 28 weeks' gestation in the Seychelles Child Development Study. Am J Reprod Immunol 80(5):e13046. https://doi.org/10.1111/aji.13046.

McSorley EM, van Wijngaarden E, Yeates AJ, et al. 2020. Methylmercury and long chain polyunsaturated fatty acids are associated with immune dysregulation in young adults from the Seychelles child development study. Environ Res 183:109072. https://doi.org/10.1016/j.envres.2019.109072.

MDN. 2020. Mercury deposition network data. National Atmospheric Deposition Program. http://nadp.slh.wisc.edu/MDN/. December 16, 2020.

Meador JP, Varanasi U, Robisch PA, et al. 1993. Toxic metals in pilot whales (Globicephala melaena) from strandings in 1986 and 1990 on Cape Cod, Massachusetts. Can J Fish Aquat Sci 50(12):2698-2706.

Medina Pérez OM, Flórez-Vargas O, Rincón Cruz G, et al. 2021. Glutathione-related genetic polymorphisms are associated with mercury retention and nephrotoxicity in gold-mining settings of a Colombian population. Sci Rep 11(1):8716. https://doi.org/10.1038/s41598-021-88137-3.

Meeker JD, Rossano MG, Protas B, et al. 2008. Cadmium, lead, and other metals in relation to semen quality: Human evidence for molybdenum as a male reproductive toxicant. Environ Health Perspect 116(11):1473-1479. https://doi.org/10.1289/ehp.11490.

Meili M. 1991. The coupling of mercury and organic matter in the biogeochemical cycle - towards a mechanistic model for the boreal forest zone. Water Air Soil Pollut 56(1):333-347. https://doi.org/10.1007/bf00342281.

Meili M, Iverfeldt A, Håkanson L. 1991. Mercury in the surface water of Swedish forest lakes - concentrations, speciation and controlling factors. Water Air Soil Pollut 56(1):439-453. https://doi.org/10.1007/bf00342290.

Mendiola J, Moreno JM, Roca M, et al. 2011. Relationships between heavy metal concentrations in three different body fluids and male reproductive parameters: a pilot study. Environ Health 10(1):6. https://doi.org/10.1186/1476-069X-10-6.

Mergler D. 2002. Review of neurobehavioral deficits and river fish consumption from the Tapajos (Brazil) and St. Lawrence (Canada). Environ Toxicol Pharmacol 12(2):93-99. https://doi.org/10.1016/s1382-6689(02)00027-3.

Mergler D, Belanger S, Larribe F, et al. 1998. Preliminary evidence of neurotoxicity associated with eating fish from the Upper St. Lawrence River Lakes. Neurotoxicology 19(4-5):691-702.

8. REFERENCES

Miao J, Feng S, Dou S, et al. 2023. Association between mercury exposure and lung function in young adults: A prospective cohort study in Shandong, China. Sci Total Environ 878:162759. https://doi.org/10.1016/j.scitotenv.2023.162759.

Mierle G. 1990. Aqueous inputs of mercury to Precambrian shield lakes in Ontario. Environ Toxicol Chem 9(7):843-851. https://doi.org/10.1002/etc.5620090704.

Miettinen JK, Rahola T, Hattula T, et al. 1971. Elimination of 203-Hg-methylmercury in man. Ann Clin Res 3(2):116-122.

Migliore L, Cocchi L, Nesti C, et al. 1999. Micronuclei assay and FISH analysis in human lymphocytes treated with six metal salts. Environ Mol Mutagen 34(4):279-284.

Milioni ALV, Nagy BV, Moura ALA, et al. 2017. Neurotoxic impact of mercury on the central nervous system evaluated by neuropsychological tests and on the autonomic nervous system evaluated by dynamic pupillometry. Neurotoxicology 59:263-269. https://doi.org/10.1016/j.neuro.2016.04.010.

Miller JM, Chaffin DB, Smith RG. 1975. Subclinical psychomotor and neuromuscular changes in workers exposed to inorganic mercury. Am Ind Hyg Assoc J 36(10):725-733. https://doi.org/10.1080/0002889758507331.

Miller CT, Zawidzka Z, Nagy E, et al. 1979. Indicators of genetic toxicity in leucocytes and granulocytic precursors after chronic methylmercury ingestion by cats. Bull Environ Contam Toxicol 21(3):296-303.

Miller C, Karimi R, Silbernagel S, et al. 2018. Mercury, omega-3 fatty acids, and seafood intake are not associated with heart rate variability or QT interval. Arch Environ Occup Health 73(4):251-257. https://doi.org/10.1080/19338244.2017.1315360.

Milne J, Christophers A, Silva PD. 1970. Acute mercurial pneumonitis. Occup Environ Med 27(4):334-338. https://doi.org/10.1136/oem.27.4.334.

Mínguez-Alarcón L, Afeiche MC, Williams PL, et al. 2018. Hair mercury (Hg) levels, fish consumption and semen parameters among men attending a fertility center. Int J Hyg Environ Health 221(2):174-182. https://doi.org/10.1016/j.ijheh.2017.10.014.

Mínguez-Alarcón L, Williams PL, Souter I, et al. 2021. Hair mercury levels, intake of omega-3 fatty acids and ovarian reserve among women attending a fertility center. Int J Hyg Environ Health 237:113825. https://doi.org/10.1016/j.ijheh.2021.113825.

Minyard JP, Roberts EW. 1991. State findings on pesticide residues in foods-1988 and 1989. J AOAC Int 74(3):438-452. https://doi.org/10.1093/jaoac/74.3.438.

Miskimmin BM. 1991. Effect of natural levels of dissolved organic carbon doc on methyl mercury formation and sediment-water partitioning. Bull Environ Contam Toxicol 47(5):743-750.

Miskimmin BM, Rudd JW, Kelly CA. 1992. Influence of dissolved organic carbon, pH, and microbial respiration rates on mercury methylation and demethylation in lake water. Can J Fish Aquat Sci 49(1):17-22.

Mitsumori K, Maita K, Saito T, et al. 1981. Carcinogenicity of methylmercury chloride in ICR mice: Preliminary note on renal carcinogenesis. Cancer Lett 12(4):305-310. https://doi.org/10.1016/0304-3835(81)90172-5.

Mitsumori K, Hirano M, Ueda H, et al. 1990. Chronic toxicity and carcinogenicity of methylmercury chloride in B6C3F1 mice. Fundam Appl Toxicol 14(1):179-190. https://doi.org/10.1016/0272-0590(90)90243-d.

Miyakawa T, Sumiyoshi S, Deshimaru M. 1974. Late changes in sciatic nerve of rats after a small dose of methyl methylmercury sulfide. Acta Neuropathol (Berl) 30(1):33-41. https://doi.org/10.1007/BF00685320.

Miyake Y, Tanaka K, Yasutake A, et al. 2011. Lack of association of mercury with risk of wheeze and eczema in Japanese children: the Osaka Maternal and Child Health Study. Environ Res 111(8):1180-1184. https://doi.org/10.1016/j.envres.2011.07.003.

Miyashita C, Saijo Y, Ito Y, et al. 2021. Association between the concentrations of metallic elements in maternal blood during pregnancy and prevalence of abdominal congenital malformations: The Japan

Environment and Children's study. Int J Environ Res Public Health 18(19):10103.
https://doi.org/10.3390/ijerph181910103.

Miyazaki J, Ikehara S, Tanigawa K, et al. 2023. Prenatal exposure to selenium, mercury, and manganese
during pregnancy and allergic diseases in early childhood: The Japan Environment and Children's
study. Environ Int 179:108123. https://doi.org/10.1016/j.envint.2023.108123.

Mocevic E, Specht IO, Marott JL, et al. 2013. Environmental mercury exposure, semen quality and
reproductive hormones in Greenlandic Inuit and European men: a cross-sectional study. Asian J
Androl 15(1):97-104. https://doi.org/10.1038/aja.2012.121.

Mohamed MK, Burbacher TM, Mottet NK. 1987. Effects of methyl mercury on testicular functions in
Macaca fascicularis monkeys. Pharmacol Toxicol 60(1):29-36. https://doi.org/10.1111/j.1600-
0773.1987.tb01715.x.

Mohammad Abu-Taweel G, Al-Fifi Z. 2021. Protective effects of curcumin towards anxiety and
depression-like behaviors induced mercury chloride. Saudi J Biol Sci 28(1):125-134.
https://doi.org/10.1016/j.sjbs.2020.09.011.

Mokrzan EM, Kerper LE, Ballatori N, et al. 1995. Methylmercury-thiol uptake into cultured brain
capillary endothelial cells on amino acid system L. J Pharmacol Exp Ther 272(3):1277-1284.

Møller L, Kristensen TS. 1992. Blood lead as a cardiovascular risk factor. Am J Epidemiol
136(9):1091-1100. https://doi.org/10.1093/oxfordjournals.aje.a116574.

Monastero RN, Karimi R, Nyland JF, et al. 2017. Mercury exposure, serum antinuclear antibodies, and
serum cytokine levels in the Long Island Study of Seafood Consumption: A cross-sectional study in
NY, USA. Environ Res 156:334-340. https://doi.org/10.1016/j.envres.2017.03.037.

Montgomery KS, Mackey J, Thuett K, et al. 2008. Chronic, low-dose prenatal exposure to
methylmercury impairs motor and mnemonic function in adult C57/B6 mice. Behav Brain Res
191(1):55-61. https://doi.org/10.1016/j.bbr.2008.03.008.

Moody RP, Joncas J, Richardson M, et al. 2009. Contaminated soils (II): In vitro dermal absorption of
nickel (Ni-63) and mercury (Hg-203) in human skin. J Toxicol Environ Health A 72(8):551-559.
https://doi.org/10.1080/15287390802706322.

Moon S. 2013. Association of lead, mercury and cadmium with diabetes in the Korean population: the
Korea National Health and Nutrition Examination Survey (KNHANES) 2009-2010. Diabet Med
30(4):e143-148. https://doi.org/10.1111/dme.12103.

Moon S. 2017. Association between blood mercury level and visceral adiposity in adults. Diabetes
Metab J 41(2):96-98. https://doi.org/10.4093/dmj.2017.41.2.96.

Moon SH, Kang Y, Park KM. 2017. A one-dimensional Hg(II) coordination polymer based on bis-
(pyridin-3-ylmeth-yl)sulfane. Acta Crystallogr E Crystallogr Commun 73(Pt 12):1871-1874.
https://doi.org/10.1107/s205698901701619x.

Moon MK, Lee I, Lee A, et al. 2022. Lead, mercury, and cadmium exposures are associated with obesity
but not with diabetes mellitus: Korean National Environmental Health Survey (KoNEHS) 2015-
2017. Environ Res 204(Pt A):111888. https://doi.org/10.1016/j.envres.2021.111888.

Morcillo MA, Santamaria J. 1995. Whole-body retention, and urinary and fecal excretion of mercury
after subchronic oral exposure to mercuric chloride in rats. Biometals 8(4):301-308.

Mordukhovich I, Wright RO, Hu H, et al. 2012. Associations of toenail arsenic, cadmium, mercury,
manganese, and lead with blood pressure in the normative aging study. Environ Health Perspect
120(1):98-104. https://doi.org/10.1289/ehp.1002805.

Moreira EL, de Oliveira J, Dutra MF, et al. 2012. Does methylmercury-induced hypercholesterolemia
play a causal role in its neurotoxicity and cardiovascular disease? Toxicol Sci 130(2):373-382.
https://doi.org/10.1093/toxsci/kfs252.

Morgan DL, Chanda SM, Price HC, et al. 2002. Disposition of inhaled mercury vapor in pregnant rats:
Maternal toxicity and effects on developmental outcome. Toxicol Sci 66(2):261-273.
https://doi.org/10.1093/toxsci/66.2.261.

Mori T, Sato K, Kusaka Y, et al. 2007. Positive patch test for mercury possibly from exposure to
amalgam. Environ Health Prev Med 12(4):172-177. https://doi.org/10.1007/bf02897987.

8. REFERENCES

Mori N, Yamamoto M, Tsukada E, et al. 2012. Comparison of in vivo with in vitro pharmacokinetics of mercury between methylmercury chloride and methylmercury cysteine using rats and Caco2 cells. Arch Environ Contam Toxicol 63(4):628-636. https://doi.org/10.1007/s00244-012-9800-5.

Morris GE. 1960. Dermatoses from phenylmercuric salts. Arch Environ Health 1:53-55.

Morrissette J, Takser L, St-Amour G, et al. 2004. Temporal variation of blood and hair mercury levels in pregnancy in relation to fish consumption history in a population living along the St. Lawrence River. Environ Res 95(3):363-374. https://doi.org/10.1016/j.envres.2003.12.007.

Morrow PE, Gibb FR, Johnson LA. 1964. Clearance of insoluble dust from the lower respiratory tract. Health Phys 10(8):543-555. https://doi.org/10.1097/00004032-196408000-00003.

Mortada WL, Sobh MA, El-Defrawy MM, et al. 2002. Mercury in dental restoration: is there a risk of nephrotoxicity? J Nephrol 15(2):171-176.

Mortimer DC. 1985. Freshwater aquatic macrophytes as heavy metal monitors - the Ottawa River experience. Environ Monit Assess 5(3):311-324.

Mottet NK, Body RL, Wilkens V, et al. 1987. Biologic variables in the hair uptake of methylmercury from blood in the macaque monkey. Environ Res 42(2):509-523.

Mousavi A. 2015. Mercury(I) chloride in vivo oxidation: a thermodynamic study. Main Group Metal Chem 38(3-4):121-124. https://doi.org/10.1515/mgmc-2015-0012.

Moussa H, Hachfi L, Trimeche M, et al. 2010. Accumulation of mercury and its effects on testicular functions in rats intoxicated orally by methylmercury. Andrologia 43(1):23-27. https://doi.org/10.1111/j.1439-0272.2009.01003.x.

Movassagh H, Halchenko Y, Sampath V, et al. 2021. Maternal gestational mercury exposure in relation to cord blood T cell alterations and placental gene expression signatures. Environ Res 201:111385. https://doi.org/10.1016/j.envres.2021.111385.

Mozaffarian D. 2009. Fish, mercury, selenium and cardiovascular risk: current evidence and unanswered questions. Int J Environ Res Public Health 6(6):1894-1916. https://doi.org/10.3390/ijerph6061894.

Mozaffarian D, Rimm EB. 2006. Fish intake, contaminants, and human health: Evaluating the risks and the benefits. JAMA 296(15):1885-1899. https://doi.org/10.1001/jama.296.15.1885.

Mozaffarian D, Shi P, Morris JS, et al. 2011. Mercury exposure and risk of cardiovascular disease in two U.S. cohorts. N Engl J Med 364(12):1116-1125. https://doi.org/10.1056/NEJMoa1006876.

Mozaffarian D, Shi P, Morris JS, et al. 2012. Mercury exposure and risk of hypertension in US men and women in 2 prospective cohorts. Hypertension 60(3):645-652. https://doi.org/10.1161/hypertensionaha.112.196154.

Mozaffarian D, Shi P, Morris JS, et al. 2013. Methylmercury exposure and incident diabetes in U.S. men and women in two prospective cohorts. Diabetes Care 36(11):3578-3584. https://doi.org/10.2337/dc13-0894.

Muckle G, Dewailly E, Ayotte P. 1998. Prenatal exposure of Canadian children to polychlorinated biphenyls and mercury. Can J Public Health 89:S20-S25.

Muckle G, Ayotte P, Dewailly EE, et al. 2001. Prenatal exposure of the northern Québec Inuit infants to environmental contaminants. Environ Health Perspect 109(12):1291-1299. https://doi.org/10.1289/ehp.011091291.

Muir DCG, Wagemann R, Hargrave BT, et al. 1992. Arctic marine ecosystem contamination. Sci Total Environ 122(1-2):75-134. https://doi.org/10.1016/0048-9697(92)90246-o.

Mulder KM, Kostyniak PJ. 1985a. Effect of L-(alpha S,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid on urinary excretion of methylmercury in the mouse. J Pharmacol Exp Ther 234(1):156-160.

Mulder KM, Kostyniak PJ. 1985b. Involvement of glutathione in the enhanced renal excretion of methyl mercury in CFW Swiss mice. Toxicol Appl Pharmacol 78(3):451-457.

Muldoon MF, Ryan CM, Yao JK, et al. 2014. Long-chain omega-3 fatty acids and optimization of cognitive performance. Mil Med 179(11S):95-105. https://doi.org/10.7205/milmed-d-14-00168.

8. REFERENCES

Mumtaz MM, Ray M, Crowell SR, et al. 2012a. Translational research to develop a human PBPK models tool kit-volatile organic compounds (VOCs). J Toxicol Environ Health A 75(1):6-24. https://doi.org/10.1080/15287394.2012.625546.

Mumtaz M, Fisher J, Blount B, et al. 2012b. Application of physiologically based pharmacokinetic models in chemical risk assessment. J Toxicol 2012:904603. https://doi.org/10.1155/2012/904603.

Munthe J, McElroy WJ. 1992. Some aqueous reactions of potential importance in the atmospheric chemistry of mercury. Atmos Environ 26A(4):553-557.

Murata K, Weihe P, Renzoni A, et al. 1999a. Delayed evoked potentials in children exposed to methylmercury from seafood. Neurotoxicol Teratol 21(4):343-348.

Murata K, Weihe P, Araki S, et al. 1999b. Evoked potentials in Faroese children prenatally exposed to methylmercury. Neurotoxicol Teratol 21(4):471-472.

Murata K, Budtz-Jorgensen E, Grandjean P. 2002. Benchmark dose calculations for methylmercury-associated delays on evoked potential latencies in two cohorts of children. Risk Anal 22(3):465-474.

Murata K, Weihe P, Budtz-Jorgensen E, et al. 2004a. Delayed brainstem auditory evoked potential latencies in 14-year-old children exposed to methylmercury. J Pediatr 144(2):177-183. https://doi.org/10.1016/j.jpeds.2003.10.059.

Murata K, Sakamoto M, Nakai K, et al. 2004b. Effects of methylmercury on neurodevelopment in Japanese children in relation to the Madeiran study. Int Arch Occup Environ Health 77(8):571-579. https://doi.org/10.1007/s00420-004-0542-1.

Murcia M, Ballester F, Enning AM, et al. 2016. Prenatal mercury exposure and birth outcomes. Environ Res 151:11-20. https://doi.org/10.1016/j.envres.2016.07.003.

Myers GJ, Marsh DO, Davidson PW, et al. 1995. Main neurodevelopmental study of Seychellois children following in utero exposure to methylmercury from a maternal fish diet: outcome at six months. Neurotoxicology 16(4):653-664.

Myers GJ, Davidson PW, Shamlaye CF, et al. 1997. Effects of prenatal methylmercury exposure from a high fish diet on developmental milestones in the Seychelles Child Development Study. Neurotoxicology 18(3):819-829.

Myers GJ, Davidson PW, Palumbo D, et al. 2000. Secondary analysis from the Seychelles Child Development Study: the child behavior checklist. Environ Res 84(1):12-19. https://doi.org/10.1006/enrs.2000.4085.

Myers GJ, Davidson PW, Cox C, et al. 2003. Prenatal methylmercury exposure from ocean fish consumption in the Seychelles child development study. Lancet 361(9370):1686-1692. https://doi.org/10.1016/s0140-6736(03)13371-5.

Myers GJ, Thurston SW, Pearson AT, et al. 2009. Postnatal exposure to methyl mercury from fish consumption: a review and new data from the Seychelles Child Development Study. Neurotoxicology 30(3):338-349. https://doi.org/10.1016/j.neuro.2009.01.005.

Myers GJ, Davidson PW, Shamlaye C, et al. 2020. The Seychelles Child Development Study of methyl mercury from fish consumption: analysis of subscales from the Child Behaviour Checklist at age 107 months in the main cohort. Neurotoxicology 81:331-338. https://doi.org/10.1016/j.neuro.2020.09.025.

NADP. 2024. AMNet: Atmospheric mercury data. National Atmospheric Deposition Program. http://nadp.slh.wisc.edu/data/AMNet/. April 4, 2024.

Nagahara N. 2011. Catalytic site cysteines of thiol enzyme: Sulfurtransferases. J Amino Acids 2011:1-7. https://doi.org/10.4061/2011/709404.

Nagano M, Yasutake A, Miura K. 2010. Demethylation of methylmercury in human neuroblastoma, glioblastoma and liver cells. J Health Sci 56(3):326-330. https://doi.org/10.1248/jhs.56.326.

Nagar RN, Bhattacharya L. 2001. Effect of mercuric chloride on testicular activities in mice, Musculus albinus. J Environ Biol 22(1):15-18.

Nakada Y, Adachi T. 1999. Effect of experimentally induced renal failure on testicular testosterone synthesis in rats. Arch Androl 43(1):37-45. https://doi.org/10.1080/014850199262715.

Nakai S, Machida I. 1973. Genetic effect of organic mercury on yeast. Mutat Res 21(6):348.

8. REFERENCES

Nakamura M, Hachiya N, Murata KY, et al. 2014. Methylmercury exposure and neurological outcomes in Taiji residents accustomed to consuming whale meat. Environ Int 68:25-32. https://doi.org/10.1016/j.envint.2014.03.005.

Nakamura M, Tatsuta N, Murata K, et al. 2023. Neurodevelopmental associations of prenatal and postnatal methylmercury exposure among first-grade children in the Kinan region, Japan. Environ Res 235:116688. https://doi.org/10.1016/j.envres.2023.116688.

Nan Y, Yang J, Yang J, et al. 2024. Associations between individual and combined metal exposures in whole blood and kidney function in U.S. adults aged 40 years and older. Biol Trace Elem Res 202(3):850-865. https://doi.org/10.1007/s12011-023-03722-z.

NAS/NRC. 2006. Human biomonitoring for environmental chemicals. Washington, DC: The National Academies Press, National Research Council. https://doi.org/10.17226/11700.

Nascimento S, Goethel G, Gauer B, et al. 2018. Exposure to environment chemicals and its possible role in endocrine disruption of children from a rural area. Environ Res 167:488-498. https://doi.org/10.1016/j.envres.2018.07.039.

Nascimento TS, Pinto DV, Dias RP, et al. 2022. Chronic methylmercury intoxication induces systemic inflammation, behavioral, and hippocampal amino acid changes in C57Bl6J adult mice. Int J Mol Sci 23(22):13837. https://doi.org/10.3390/ijms232213837.

Nater EA, Grigal DF. 1992. Regional trends in mercury distribution across the Great Lakes states, north central USA. Nature 358(6382):139-141. https://doi.org/10.1038/358139a0.

Neghab M, Choobineh A, Hassan Zadeh J, et al. 2011. Symptoms of intoxication in dentists associated with exposure to low levels of mercury. Ind Health 49(2):249-254.

NESCAUM. 1998. Northeast states and eastern Canadian provinces - mercury study - a framework for action. Boston, MA: Northeast States for Coordinated Air Use Management.

Newland MC, Reile PA. 1999. Blood and brain mercury levels after chronic gestational exposure to methylmercury in rats. Toxicol Sci 50(1):106-116. https://doi.org/10.1093/toxsci/50.1.106.

Newland MC, Rasmussen EB. 2000. Aging unmasks adverse effects of gestational exposure to methylmercury in rats. Neurotoxicol Teratol 22(6):819-828. https://doi.org/10.1016/s0892-0362(00)00107-0.

Newland MC, Warfvinge K, Berlin M. 1996. Behavioral consequences of in utero exposure to mercury vapor: Alterations in lever-press durations and learning in squirrel monkeys. Toxicol Appl Pharmacol 139(2):374-386. https://doi.org/10.1006/taap.1996.0178.

Newland MC, Reile PA, Langston JL. 2004. Gestational exposure to methylmercury retards choice in transition in aging rats. Neurotoxicol Teratol 26(2):179-194. https://doi.org/10.1016/j.ntt.2003.12.004.

Newton D, Fry FA. 1978. The retention and distribution of radioactive mercuric oxide following accidental inhalation. Ann Occup Hyg 21(1):21-32.

Ngim CH, Foo SC, Boey KW, et al. 1992. Chronic neurobehavioural effects of elemental mercury in dentists. Br J Ind Med 49(11):782-790. https://doi.org/10.1136/oem.49.11.782.

Nguyen HD. 2023. Cadmium, lead, and mercury interactions on obstructive lung function in pre- and postmenopausal women. Environ Sci Pollut Res Int 30(29):73485-73496. https://doi.org/10.1007/s11356-023-27503-2.

Nguyen HD, Oh H, Hoang NHM, et al. 2022. Environmental science and pollution research role of heavy metal concentrations and vitamin intake from food in depression: a national cross-sectional study (2009-2017). Environ Sci Pollut Res Int 29(3):4574-4586. https://doi.org/10.1007/s11356-021-15986-w.

Nielsen JB. 1992. Toxicokinetics of mercuric chloride and methylmercuric chloride in mice. J Toxicol Environ Health 37(1):85-122. https://doi.org/10.1080/15287399209531659.

Nielsen JB, Andersen O. 1990. Disposition and retention of mercuric chloride in mice after oral and parenteral administration. J Toxicol Environ Health 30(3):167-180. https://doi.org/10.1080/15287399009531420.

8. REFERENCES

Nielsen JB, Andersen O. 1991. Methyl mercuric chloride toxicokinetics in mice. I: Effects of strain,
    sex, route of administration and dose. Pharmacol Toxicol 68(3):201-207.

Nielsen JB, Hultman P. 1998. Strain dependence of steady-state retention and elimination of mercury in
    mice after prolonged exposure to mercury(II) chloride. Analyst 123(1):87-90.

Nielsen JB, Hultman P. 2002. Mercury-induced autoimmunity in mice. Environ Health Perspect
    110(Suppl 5):877-881. https://doi.org/10.1289/ehp.02110s5877.

Nielsen JB, Andersen HR, Andersen O, et al. 1991. Mercuric chloride-induced kidney damage in mice:
    Time course and effect of dose. J Toxicol Environ Health 34(4):469-483.
    https://doi.org/10.1080/15287399109531583.

Nielsen JB, Andersen HL, Sorensen JA, et al. 1992. Localization of gastrointestinal deposition of
    mercuric chloride studied in vivo. Pharmacol Toxicol 70(4):262-267.

Nielsen AB, Davidsen M, Bjerregaard P. 2012. The association between blood pressure and whole blood
    methylmercury in a cross-sectional study among Inuit in Greenland. Environ Health 11:44.
    https://doi.org/10.1186/1476-069x-11-44.

Nielsen SJ, Kit BK, Aoki Y, et al. 2014. Seafood consumption and blood mercury concentrations in
    adults aged ≥20 y, 2007-2010. Am J Clin Nutr 99(5):1066-1070.
    https://doi.org/10.3945/ajcn.113.077081.

Nielsen-Kudsk F. 1965a. Absorption of mercury vapour from the respiratory tract in man. Acta
    Pharmacol Toxicol 23(2):250-262. https://doi.org/10.1111/j.1600-0773.1965.tb03592.x.

Nielsen-Kudsk F. 1965b. The influence of ethyl alcohol on the absorption of mercury vapour from the
    lungs in man. Acta Pharmacol Toxicol 23(2):263-274. https://doi.org/10.1111/j.1600-
    0773.1965.tb03593.x.

Nielsen-Kudsk F. 1973. Biological oxidation of elemental mercury. In: Miller MW, Clarkson TW, eds.
    Mercury, mercurials and mercaptans. Springfield, IL: Charles C. Thomas, 355.

Nierenberg DW, Nordgren RE, Chang MB, et al. 1998. Delayed cerebellar disease and death after
    accidental exposure to dimethylmercury. N Engl J Med 338(23):1672-1676.
    https://doi.org/10.1056/nejm199806043382305.

Nikolaychuk PA. 2016. Is calomel truly a poison and what happens when it enters the human stomach?
    A study from the thermodynamic viewpoint. Main Group Metal Chem 39(1-2):41-47.
    https://doi.org/10.1515/mgmc-2015-0040.

Nilsen FM, Tulve NS. 2020. A systematic review and meta-analysis examining the interrelationships
    between chemical and non-chemical stressors and inherent characteristics in children with ADHD.
    Environ Res 180:108884. https://doi.org/10.1016/j.envres.2019.108884.

NIOSH. 1994a. Mercury (organo) alkyl compounds (as Hg). Immediately dangerous to life or health
    concentrations (IDLH). Atlanta, GA: National Institute for Occupational Safety and Health, Centers
    for Disease Control and Prevention. https://www.cdc.gov/niosh/idlh/merc-hg.html. November 12,
    2020.

NIOSH. 1994b. Mercury compounds [except (organo) alkyls] (as Hg). Immediately dangerous to life or
    health concentrations (IDLH). Atlanta, GA: National Institute for Occupational Safety and Health,
    Centers for Disease Control and Prevention. https://www.cdc.gov/niosh/idlh/7439976.html.
    November 12, 2020.

NIOSH. 2010. NIOSH backgrounder: Alice's Mad Hatter & work-related illness. National Institute for
    Occupational Safety and Health. https://www.cdc.gov/niosh/updates/upd-03-04-10.html. January 5,
    2022.

NIOSH. 2019a. Mercury (organo) alkyl compounds (as Hg). NIOSH pocket guide to chemical hazards.
    Atlanta, GA: National Institute for Occupational Safety and Health, Centers for Disease Control and
    Prevention. https://www.cdc.gov/niosh/npg/npgd0384.html. November 12, 2020.

NIOSH. 2019b. Mercury compounds [except (organo) alkyls] (as Hg). NIOSH pocket guide to chemical
    hazards. Atlanta, GA: National Institute for Occupational Safety and Health, Centers for Disease
    Control and Prevention. https://www.cdc.gov/niosh/npg/npgd0383.html. November 12, 2020.

8. REFERENCES

NJDEP. 2007. Cultural uses of mercury in New Jersey - year 2 mercury vapor in residential buildings - Comparison of communities that use mercury for cultural purposes with a reference community. Trenton, NJ: New Jersey Department of Environmental Protection. https://www.nj.gov/dep/dsr/research/mercury-cultural-yr2.pdf. May 17, 2021.

NLM. 2020. PubChem compound summary: Mercury. National Library of Medicine. https://pubchem.ncbi.nlm.nih.gov/compound/Mercury. January 11, 2021.

Noisel N, Bouchard M, Carrier G, et al. 2011. Comparison of a toxicokinetic and a questionnaire-based approach to assess methylmercury intake in exposed individuals. J Expo Sci Environ Epidemiol 21(3):328-335. https://doi.org/10.1038/jes.2010.33.

Nolen GA, Buchler EV, Geil RG, et al. 1972. Effects of trisodium nitrotriacetate on cadmium and methylmercury toxicity and teratogenicity in rats. Toxicol Appl Pharmacol 23(2):222-223. https://doi.org/10.1016/0041-008x(72)90186-x.

Nonaka H, Nakada T, Iijima M, et al. 2011. Metal patch test results from 1990-2009. J Dermatol 38(3):267-271. https://doi.org/10.1111/j.1346-8138.2010.00980.x.

Nordberg GF, Serenius F. 1969. Distribution of inorganic mercury in the guinea pig brain. Acta Pharmacol Toxicol (Copenh) 27:269-283.

Nordenhall K, Dock L, Vahter M. 1998. Cross-fostering study of methyl mercury retention, demethylation and excretion in the neonatal hamster. Pharmacol Toxicol 82(3):132-136.

Nordhagen HP, Ellingsen DG, Kjuus H. 1994. Production and surveillance of mercury exposure over 40 years at a chloralkali plant. Ann Occup Hyg 38(5):777-788. https://doi.org/10.1093/annhyg/38.5.777.

Nordlind K, Liden S. 1992. Patch test reactions to metal salts in patients with oral mucosal lesions associated with amalgam restorations. Contact Dermatitis 27(3):157-160. https://doi.org/10.1111/j.1600-0536.1992.tb05245.x.

Nørgaard JO, Møller-Madsen B, Hertel N, et al. 1989. Silver enhancement of tissue mercury: Demonstration of mercury in autometallographic silver grains from rat kidneys. J Histochem Cytochem 37(10):1545-1547. https://doi.org/10.1177/37.10.2778309.

Norseth T. 1971. Biotransformation of methyl mercuric salts in the mouse studied by specific determination of inorganic mercury. Acta Pharmacol Toxicol (Copenh) 29(4):375-384. https://doi.org/10.1111/j.1600-0773.1971.tb00597.x.

Norseth T, Clarkson TW. 1970. Studies on the biotransformation of 203Hg-labeled methyl mercury chloride in rats. Arch Environ Health 21(6):717-727.

NTP. 1993. Toxicology and carcinogenesis studies of mercuric chloride (CAS no. 7487-94-7) in F344/N rats and B6C3F1 mice (gavage studies). Research Triangle Park, NC: National Toxicology Program. NTP TR 408. NIH publication no. 91-3139.

NTP. 1997. Chemical repository (Radian Corporation August 29, 1991) phenylmercuric acetate. National Toxicology Program.

NTP. 2016. Substances listed in the fourteenth report on carcinogens. 14th Report on carcinogens. National Toxicology Program. https://ntp.niehs.nih.gov/whatwestudy/assessments/cancer/roc/index.html. January 19, 2021.

NTP. 2021. CASRN index. In: Report on carcinogens. 15th ed. National Toxicology Program, https://ntp.niehs.nih.gov/go/roc15. January 10, 2022.

Nunes PBO, Ferreira MKM, Ribeiro Frazão D, et al. 2022. Effects of inorganic mercury exposure in the alveolar bone of rats: an approach of qualitative and morphological aspects. PeerJ 10:e12573. https://doi.org/10.7717/peerj.12573.

Nyanza EC, Dewey D, Manyama M, et al. 2020. Maternal exposure to arsenic and mercury and associated risk of adverse birth outcomes in small-scale gold mining communities in Northern Tanzania. Environ Int 137:105450. https://doi.org/10.1016/j.envint.2019.105450.

Nyanza EC, Bernier FP, Martin JW, et al. 2021. Effects of prenatal exposure and co-exposure to metallic or metalloid elements on early infant neurodevelopmental outcomes in areas with small-scale gold

mining activities in Northern Tanzania. Environ Int 149:106104.
https://doi.org/10.1016/j.envint.2020.106104.

Nyland JF, Wang SB, Shirley DL, et al. 2011. Fetal and maternal immune responses to methylmercury
exposure: a cross-sectional study. Environ Res 111(4):584-589.
https://doi.org/10.1016/j.envres.2011.02.010.

Nylander M, Friberg L, Lind B. 1987. Mercury concentrations in the human brain and kidneys in
relation to exposure from dental amalgam fillings. Swed Dent J 11(5):179-187.

Oberly TJ, Piper CE, McDonald DS. 1982. Mutagenicity of metal salts in the L51784 mouse lymphoma
assay. J Toxicol Environ Health 9(3):367-376.

O'Donoghue JL, Watson GE, Brewer R, et al. 2020. Neuropathology associated with exposure to
different concentrations and species of mercury: A review of autopsy cases and the literature.
Neurotoxicology 78:88-98. https://doi.org/10.1016/j.neuro.2020.02.011.

Ohno T, Sakamoto M, Kurosawa T, et al. 2007. Total mercury levels in hair, toenail, and urine among
women free from occupational exposure and their relations to renal tubular function. Environ Res
103(2):191-197. https://doi.org/10.1016/j.envres.2006.06.009.

Oken E, Radesky JS, Wright RO, et al. 2008. Maternal fish intake during pregnancy, blood mercury
levels, and child cognition at age 3 years in a US cohort. Am J Epidemiol 167(10):1171-1181.
https://doi.org/10.1093/aje/kwn034.

Oken E, Rifas-Shiman SL, Amarasiriwardena C, et al. 2016. Maternal prenatal fish consumption and
cognition in mid childhood: Mercury, fatty acids, and selenium. Neurotoxicol Teratol 57:71-78.
https://doi.org/10.1016/j.ntt.2016.07.001.

Okubo H, Nakayama SF. 2023. Periconceptional maternal diet quality influences blood heavy metal
concentrations and their effect on low birth weight: the Japan Environment and Children's Study.
Environ Int 173:107808. https://doi.org/10.1016/j.envint.2023.107808.

Oliveira RB, Gomes-Leal W, do-Nascimento JL, et al. 1998. Methylmercury intoxication and
histochemical demonstration of NADPH-diaphorase activity in the striate cortex of adult cats. Braz J
Med Biol Res 31(9):1157-1161.

Oliveira RB, Malm O, Guimaraes JR. 2001. Distribution of methylmercury and inorganic mercury in
neonate hamsters dosed with methylmercury during fetal life. Environ Res 86(1):73-79.
https://doi.org/10.1006/enrs.2001.4220.

Oliveira CS, Oliveira VA, Ineu RP, et al. 2012. Biochemical parameters of pregnant rats and their
offspring exposed to different doses of inorganic mercury in drinking water. Food Chem Toxicol
50(7):2382-2387. https://doi.org/10.1016/j.fct.2012.04.046.

Oliveira CS, Joshee L, Zalups RK, et al. 2015. Disposition of inorganic mercury in pregnant rats and
their offspring. Toxicology 335:62-71. https://doi.org/10.1016/j.tox.2015.07.006.

Oliveira CS, Oliveira VA, Costa LM, et al. 2016. Inorganic mercury exposure in drinking water alters
essential metal homeostasis in pregnant rats without altering rat pup behavior. Reprod Toxicol
65:18-23. https://doi.org/10.1016/j.reprotox.2016.06.013.

Oliveira C, Joshee L, George H, et al. 2017. Oral exposure of pregnant rats to toxic doses of
methylmercury alters fetal accumulation. Reprod Toxicol 69:265-275.
https://doi.org/10.1016/j.reprotox.2017.03.008.

Oliveira AN, Pinheiro AM, Belém-Filho IJA, et al. 2018. Unravelling motor behaviour hallmarks in
intoxicated adolescents: methylmercury subtoxic-dose exposure and binge ethanol intake paradigm
in rats. Environ Sci Pollut Res Int 25(22):21937-21948. https://doi.org/10.1007/s11356-018-2235-4.

Oliveira RAA, Pinto BD, Rebouças BH, et al. 2021. Neurological impacts of chronic methylmercury
exposure in Munduruku indigenous adults: Somatosensory, motor, and cognitive abnormalities. Int J
Environ Res Public Health 18(19):10270. https://doi.org/10.3390/ijerph181910270.

Olson BH, Cayless SM, Ford S, et al. 1991. Toxic element contamination and the occurrence of
mercury-resistant bacteria in Hg-Contaminated soil, sediments, and sludges. Arch Environ Contam
Toxicol 20(2):226-233. https://doi.org/10.1007/bf01055908.

8. REFERENCES

Omanwar S, Fahim M. 2015. Mercury exposure and endothelial dysfunction: An interplay between nitric oxide and oxidative stress. Int J Toxicol 34(4):300-307. https://doi.org/10.1177/1091581815589766.

Omanwar S, Saidullah B, Ravi K, et al. 2014. Vasorelaxant effects of mercury on rat thoracic aorta: the nitric oxide signaling mechanism. Hum Exp Toxicol 33(9):904-910. https://doi.org/10.1177/0960327113512341.

Omata S, Sakimura K, Ishii T, et al. 1978. Chemical nature of a methylmercury complex with a low molecular weight in the liver cytosol of rats exposed to methylmercury chloride. Biochem Pharmacol 27(12):1700-1702.

Omata S, Kasama H, Hasegawa H, et al. 1986. Species difference between rat and hamster in tissue accumulation of mercury after administration of methylmercury. Arch Toxicol 59(4):249-254.

Ondovcik SL, Tamblyn L, McPherson JP, et al. 2012. Oxoguanine glycosylase 1 (OGG1) protects cells from DNA double-strand break damage following methylmercury (MeHg) exposure. Toxicol Sci 128(1):272-283. https://doi.org/10.1093/toxsci/kfs138.

Onishchenko N, Karpova N, Sabri F, et al. 2008. Long-lasting depression-like behavior and epigenetic changes of BDNF gene expression induced by perinatal exposure to methylmercury. J Neurochem 106(3):1378-1387. https://doi.org/10.1111/j.1471-4159.2008.05484.x.

Ontario Ministry of the Environment. 1991. Relationship of mercury levels in sportfish with lake sediment and water quality variables. Toronto, Ontario: Ontario Environmental Research Program. PIBS 1261. https://archive.org/details/RELATIONSHIPOFME00WREN08121.ome/page/n1/mode/2up. January 19, 2021.

Orenstein ST, Thurston SW, Bellinger DC, et al. 2014. Prenatal organochlorine and methylmercury exposure and memory and learning in school-age children in communities near the New Bedford Harbor Superfund site, Massachusetts. Environ Health Perspect 122(11):1253-1259. https://doi.org/10.1289/ehp.1307804.

Orlando MS, Dziorny AC, Harrington D, et al. 2014. Associations between prenatal and recent postnatal methylmercury exposure and auditory function at age 19 years in the Seychelles Child Development Study. Neurotoxicol Teratol 46:68-76. https://doi.org/10.1016/j.ntt.2014.10.003.

Orlando MS, Love T, Harrington D, et al. 2023. The association of auditory function measures with low-level methylmercury from oceanic fish consumption and mercury vapor from amalgam: The Seychelles Child Development Study Nutrition 1 Cohort. Neurotoxicology 95:46-55. https://doi.org/10.1016/j.neuro.2022.12.010.

Ortega HG, Lopez M, Salvaggio JE, et al. 1997a. Lymphocyte proliferative response and tissue distribution of methylmercury sulfide and chloride in exposed rats. J Toxicol Environ Health 50(6):605-616. https://doi.org/10.1080/15287399709532058.

Ortega HG, Lopez M, Takaki A, et al. 1997b. Neuroimmunological effects of exposure to methylmercury forms in the Sprague-Dawley rats. Activation of the hypothalamic-pituitary-adrenal axis and lymphocyte responsiveness. Toxicol Ind Health 13(1):57-66. https://doi.org/10.1177/074823379701300105.

OSHA. 2005. Memorandum: PEL for inorganic mercury. Occupational Safety and Health Administration. https://www.osha.gov/laws-regs/standardinterpretations/1996-09-03-0. November 19, 2020.

OSHA. 2021a. Occupational safety and health standards. Subpart Z - Toxic and hazardous substances. Air contaminants. Table Z-1: Limits for air contaminants. Occupational Safety and Health Administration. Code of Federal Regulations. 29 CFR 1910.1000. https://www.govinfo.gov/content/pkg/CFR-2021-title29-vol6/pdf/CFR-2021-title29-vol6-sec1910-1000.pdf. August 28, 2022.

OSHA. 2021b. Occupational safety and health standards for shipyard employment. Subpart Z - Toxic and hazardous substances. Air contaminants. Occupational Safety and Health Administration.

Code of Federal Regulations. 29 CFR 1915.1000. https://www.govinfo.gov/content/pkg/CFR-2021-title29-vol7/pdf/CFR-2021-title29-vol7-sec1915-1000.pdf. August 28, 2022.

OSHA. 2021c. Safety and health regulations for construction. Subpart D - Occupational health and environment controls. Gases, vapors, fumes, dusts, and mists. Occupational Safety and Health Administration. Code of Federal Regulations. 29 CFR 1926.55. https://www.govinfo.gov/content/pkg/CFR-2021-title29-vol8/pdf/CFR-2021-title29-vol8-sec1926-55.pdf. August 28, 2022.

Oskarsson A, Palminger Hallen I, Sundberg J. 1995. Exposure to toxic elements via breast milk. Analyst 120(3):765-770.

Oskarsson A, Schütz A, Skerfving S, et al. 1996. Total and inorganic mercury in breast milk and blood in relation to fish consumption and amalgam fillings in lactating women. Arch Environ Health 51(3):234-241. https://doi.org/10.1080/00039896.1996.9936021.

Osol A. 1980. Mercury. In: Remington's pharmaceutical sciences. 16th ed. Easton, PA: Mack Publishing Co., 1106.

Ostlund K. 1969. Studies on the metabolism of methyl mercury and dimethyl mercury in mice. Acta Pharmacol Toxicol (Copenh) 27(1):5-132.

Ou L, Chen L, Chen C, et al. 2014. Associations of methylmercury and inorganic mercury between human cord blood and maternal blood: a meta-analysis and its application. Environ Pollut 191:25-30. https://doi.org/10.1016/j.envpol.2014.04.016.

Ou L, Chen C, Chen L, et al. 2015. Low-level prenatal mercury exposure in north China: an exploratory study of anthropometric effects. Environ Sci Technol 49(11):6899-6908. https://doi.org/10.1021/es5055868.

Ou L, Wang H, Chen C, et al. 2018. Physiologically based pharmacokinetic (PBPK) modeling of human lactational transfer of methylmercury in China. Environ Int 115:180-187. https://doi.org/10.1016/j.envint.2018.03.018.

Ouddane B, Monperrus M, Kadlecova M, et al. 2015. Mercury methylation and demethylation in highly contaminated sediments from the Deule River in Northern France using species-specific enriched stable isotopes. Environ Sci Process Impacts 17(1):145-155. https://doi.org/10.1039/c4em00398e.

Oulhote Y, Shamim Z, Kielsen K, et al. 2017a. Children's white blood cell counts in relation to developmental exposures to methylmercury and persistent organic pollutants. Reprod Toxicol 68:207-214. https://doi.org/10.1016/j.reprotox.2016.08.001.

Oulhote Y, Debes F, Vestergaard S, et al. 2017b. Aerobic fitness and neurocognitive function scores in young Faroese adults and potential modification by prenatal methylmercury exposure. Environ Health Perspect 125(4):677-683. https://doi.org/10.1289/ehp274.

Oulhote Y, Coull B, Bind MA, et al. 2019. Joint and independent neurotoxic effects of early life exposures to a chemical mixture: A multi-pollutant approach combining ensemble learning and g-computation. Environ Epidemiol 3(5):e063. https://doi.org/10.1097/ee9.0000000000000063.

Packull-McCormick S, Ashley-Martin J, Singh K, et al. 2023. Prenatal and concurrent blood mercury concentrations and associations with IQ in Canadian preschool children. Environ Res 233:116463. https://doi.org/10.1016/j.envres.2023.116463.

Palumbo DR, Cox C, Davidson PW, et al. 2000. Association between prenatal exposure to methylmercury and cognitive functioning in Seychellois children: a reanalysis of the McCarthy Scales of Children's Ability from the main cohort study. Environ Res 84(2):81-88. https://doi.org/10.1006/enrs.2000.4095.

Pamphlett R, Coote P. 1998. Entry of low doses of mercury vapor into the nervous system. Neurotoxicology 19(1):39-47.

Pamphlett R, Kum-Jew S. 2001. Mercury vapor uptake into the nervous system of developing mice. Neurotoxicol Teratol 23(2):191-196.

Pamphlett R, Kum Jew S. 2019. Mercury is taken up selectively by cells involved in joint, bone, and connective tissue disorders. Front Med (Lausanne) 6:168. https://doi.org/10.3389/fmed.2019.00168.

8. REFERENCES

Pamphlett R, Kum Jew S, Cherepanoff S. 2019. Mercury in the retina and optic nerve following prenatal exposure to mercury vapor. PLoS ONE 14(8):e0220859. https://doi.org/10.1371/journal.pone.0220859.

Pamphlett R, Bishop DP. 2022. Mercury is present in neurons and oligodendrocytes in regions of the brain affected by Parkinson's disease and co-localises with Lewy bodies. PLoS ONE 17(1):e0262464. https://doi.org/10.1371/journal.pone.0262464.

Pan Z, Guo Y, Xiang H, et al. 2020. Effects of lead, mercury, and cadmium co-exposure on children's pulmonary function. Biol Trace Elem Res 194(1):115-120. https://doi.org/10.1007/s12011-019-01772-w.

Pandalai SL, Morgan BW. 2011. Case files of the Emory University Medical Toxicology Fellowship: inhalational mercury toxicity from a traditional Vietnamese product. J Med Toxicol 7(4):295-305. https://doi.org/10.1007/s13181-011-0180-4.

Papadopoulou E, Botton J, Caspersen IH, et al. 2021. Maternal seafood intake during pregnancy, prenatal mercury exposure and child body mass index trajectories up to 8 years. Int J Epidemiol 50(4):1134-1146. https://doi.org/10.1093/ije/dyab035.

Papp A, Nagymajtenyi L, Vezer T. 2005. Subchronic mercury treatment of rats in different phases of ontogenesis: functional effects on the central and peripheral nervous system. Food Chem Toxicol 43(1):77-85. https://doi.org/10.1016/j.fct.2004.08.014.

Parajuli RP, Goodrich JM, Chan LHM, et al. 2018. Genetic polymorphisms are associated with exposure biomarkers for metals and persistent organic pollutants among Inuit from the Inuvialuit Settlement Region, Canada. Sci Total Environ 634:569-578. https://doi.org/10.1016/j.scitotenv.2018.03.331.

Park H, Kim K. 2011. Association of blood mercury concentrations with atopic dermatitis in adults: a population-based study in Korea. Environ Res 111(4):573-578. https://doi.org/10.1016/j.envres.2011.02.003.

Park JD, Zheng W. 2012. Human exposure and health effects of inorganic and elemental mercury. J Prev Med Public Health 45(6):344-352. https://doi.org/10.3961/jpmph.2012.45.6.344.

Park S, Lee BK. 2013. Body fat percentage and hemoglobin levels are related to blood lead, cadmium, and mercury concentrations in a Korean Adult Population (KNHANES 2008-2010). Biol Trace Elem Res 151(3):315-323. https://doi.org/10.1007/s12011-012-9566-7.

Park S, Choi NK. 2016. Associations of blood heavy metal levels with intraocular pressure. Ann Epidemiol 26(8):546-550 e541. https://doi.org/10.1016/j.annepidem.2016.07.002.

Park K, Seo E. 2017. Toenail mercury and dyslipidemia: Interaction with selenium. J Trace Elem Med Biol 39:43-49. https://doi.org/10.1016/j.jtemb.2016.07.005.

Park J, Kim Y. 2021. Associations of blood heavy metals with uric acid in the Korean general population: analysis of data from the 2016-2017 Korean National Health and Nutrition Examination Survey. Biol Trace Elem Res 199(1):102-112. https://doi.org/10.1007/s12011-020-02152-5.

Park IH, Park KM, Lee SS. 2010. Preparation and characterisation of divalent hard and soft metal (M = Ca, Co, Cu, Zn, Cd, Hg and Pb) complexes of 1,10-dithia-18-crown-6: structural versatility. Dalton Trans 39(40):9696-9704. https://doi.org/10.1039/c0dt00696c.

Park SK, Lee S, Basu N, et al. 2013. Associations of blood and urinary mercury with hypertension in U.S. adults: the NHANES 2003-2006. Environ Res 123:25-32. https://doi.org/10.1016/j.envres.2013.02.003.

Park JS, Ha KH, He K, et al. 2017. Association between blood mercury level and visceral adiposity in adults. Diabetes Metab J 41(2):113-120. https://doi.org/10.4093/dmj.2017.41.2.113.

Park KC, Kim KS, Jung BS, et al. 2022. Hair methylmercury levels are inversely correlated with arterial stiffness. Atherosclerosis 357:14-19. https://doi.org/10.1016/j.atherosclerosis.2022.08.003.

Parkin Kullmann JA, Pamphlett R. 2018. A comparison of mercury exposure from seafood consumption and dental amalgam fillings in people with and without amyotrophic lateral sclerosis (ALS): An international online case-control study. Int J Environ Res Public Health 15(12):2874. https://doi.org/10.3390/ijerph15122874.

8. REFERENCES

Parks JM, Smith JC. 2016. Modeling mercury in proteins. Methods Enzymol 578:103-122. https://doi.org/10.1016/bs.mie.2016.05.041.

Parks JW, Curry C, Romani D, et al. 1991. Young northern pike, yellow perch and crayfish as bioindicators in a mercury contaminated watercourse. Environ Monit Assess 16(1):39-73. https://doi.org/10.1007/bf00399593.

Passos CJ, Da Silva DS, Lemire M, et al. 2008. Daily mercury intake in fish-eating populations in the Brazilian Amazon. J Expo Sci Environ Epidemiol 18(1):76-87. https://doi.org/10.1038/sj.jes.7500599.

Pastor-Idoate S, Coco-Martin RM, Zabalza I, et al. 2021. Long-term visual pathway alterations after elemental mercury poisoning: report of a series of 29 cases. J Occup Med Toxicol 16(1):49. https://doi.org/10.1186/s12995-021-00341-z.

Patel E, Reynolds M. 2013. Methylmercury impairs motor function in early development and induces oxidative stress in cerebellar granule cells. Toxicol Lett 222(3):265-272. https://doi.org/10.1016/j.toxlet.2013.08.002.

Patel TA, Rao MV. 2015. Ameliorative effect of certain antioxidants against mercury induced genotoxicity in peripheral blood lymphocytes. Drug Chem Toxicol 38(4):408-414. https://doi.org/10.3109/01480545.2014.975354.

Patel TA, Rao MV. 2018. Antigenotoxic effect of melatonin against mercuric chloride in human peripheral blood lymphocytes. Toxicol Ind Health 34(11):778-786. https://doi.org/10.1177/0748233718795747.

Patel NB, Xu Y, McCandless LC, et al. 2019. Very low-level prenatal mercury exposure and behaviors in children: the HOME Study. Environ Health 18(1):4. https://doi.org/10.1186/s12940-018-0443-5.

Pedersen GA, Mortensen GK, Larsen EH. 1994. Beverages as a source of toxic trace element intake. Food Addit Contam 11(3):351-363. https://doi.org/10.1080/02652039409374234.

Penna S, Pocino M, Marval MJ, et al. 2009. Modifications in rat testicular morphology and increases in IFN-gamma serum levels by the oral administration of subtoxic doses of mercuric chloride. Syst Biol Reprod Med 55(2):69-84. https://doi.org/10.1080/19396360802562678.

Perharic L, Shaw D, Colbridge M, et al. 1994. Toxicological problems resulting from exposure to traditional remedies and food supplements. Drug Saf 11(4):284-294. https://doi.org/10.2165/00002018-199411040-00006.

Periard D, Beqiraj B, Hayoz D, et al. 2015. Associations of baroreflex sensitivity, heart rate variability, and initial orthostatic hypotension with prenatal and recent postnatal methylmercury exposure in the Seychelles Child Development Study at age 19 years. Int J Environ Res Public Health 12(3):3395-3405. https://doi.org/10.3390/ijerph120303395.

Perry HM, Erlanger MW. 1974. Metal-induced hypertension following chronic feeding of low doses of cadmium and mercury. J Lab Clin Med 83(4):541-547.

Pesch HJ, Bloss S, Schubert J, et al. 1992. The mercury, cadmium and lead content of cigarette tobacco: Comparative analytical-statistical studies in 1987 and 1991 employing Zeeman-AAS. Fresenius J Anal Chem 343(1):152-153. https://doi.org/10.1007/bf00332087.

Peters S, Broberg K, Gallo V, et al. 2021. Blood metal levels and amyotrophic lateral sclerosis risk: a prospective cohort. Ann Neurol 89(1):125-133. https://doi.org/10.1002/ana.25932.

Petersson K, Dock L, Soderling K, et al. 1991. Distribution of mercury in rabbits subchronically exposed to low levels of radiolabeled methyl mercury. Pharmacol Toxicol 68(6):464-468.

Petruccioli L, Turillazzi P. 1991. Effect of methylmercury on acetylcholinesterase and serum cholinesterase activity in monkeys, Macaca fascicularis. Bull Environ Contam Toxicol 46(5):769-773. https://doi.org/10.1007/BF01689966.

Phelps RW, Clarkson TW, Kershaw TG, et al. 1980. Interrelationships of blood and hair mercury concentrations in a North American population exposed to methylmercury. Arch Environ Health 35(3):161-168.

8. REFERENCES

Philibert A, Fillion M, Mergler D. 2020. Mercury exposure and premature mortality in the Grassy Narrows First Nation community: a retrospective longitudinal study. Lancet Planet Health 4(4):e141-e148. https://doi.org/10.1016/s2542-5196(20)30057-7.

Philibert A, Fillion M, Da Silva J, et al. 2022. Past mercury exposure and current symptoms of nervous system dysfunction in adults of a First Nation community (Canada). Environ Health 21(1):34. https://doi.org/10.1186/s12940-022-00838-y.

Pierrehumbert G, Droz PO, Tardif R, et al. 2002. Impact of human variability on the biological monitoring of exposure to toluene, phenol, lead, and mercury: II. Compartmental based toxicokinetic modelling. Toxicol Lett 134(1-3):165-175. https://doi.org/10.1016/s0378-4274(02)00186-8.

Piikivi L. 1989. Cardiovascular reflexes and low long-term exposure to mercury vapour. Int Arch Occup Environ Health 61(6):391-395. https://doi.org/10.1007/bf00381030.

Piikivi L, Hänninen H. 1989. Subjective symptoms and psychological performance of chlorine-alkali workers. Scand J Work Environ Health 15(1):69-74. https://doi.org/10.5271/sjweh.1880.

Piikivi L, Ruokonen A. 1989. Renal function and long-term low mercury vapor exposure. Arch Environ Health 44(3):146-149. https://doi.org/10.1080/00039896.1989.9935878.

Piikivi L, Hanninen H, Martelin T, et al. 1984. Psychological performance and long-term exposure to mercury vapors. Scand J Work Environ Health 10(1):35-41. https://doi.org/10.5271/sjweh.2365.

Pilones K, Tatum A, Gavalchin J. 2009. Gestational exposure to mercury leads to persistent changes in T-cell phenotype and function in adult DBF1 mice. J Immunotoxicol 6(3):161-170. https://doi.org/10.1080/15476910903084021.

Pingree SD, Simmonds PL, Rummel KT, et al. 2001. Quantitative evaluation of urinary porphyrins as a measure of kidney mercury content and mercury body burden during prolonged methylmercury exposure in rats. Toxicol Sci 61(2):234-240.

Piotrowski JK, Trojanowska B, Sapota A. 1974a. Binding of cadmium and mercury by metallothionein in the kidneys and liver of rats following repeated administration. Arch Toxicol 32(4):351-360. https://doi.org/10.1007/bf00330118.

Piotrowski JK, Trojanowska B, Wisniewska-Knypl JM, et al. 1974b. Mercury binding in the kidney and liver of rats repeatedly exposed to mercuric chloride: induction of metallothionein by mercury and cadmium. Toxicol Appl Pharmacol 27(1):11-19. https://doi.org/10.1016/0041-008x(74)90169-0.

Piotrowski JK, Szymanska JA, Skrzypinska-Gawrysiak M, et al. 1992. Intestinal absorption of inorganic mercury in rat. Pharmacol Toxicol 70(1):53-55.

Polevoy C, Arbuckle TE, Oulhote Y, et al. 2020. Prenatal exposure to legacy contaminants and visual acuity in Canadian infants: a maternal-infant research on environmental chemicals study (MIREC-ID). Environ Health 19(1):14. https://doi.org/10.1186/s12940-020-0567-2.

Pollack AZ, Schisterman EF, Goldman LR, et al. 2011. Cadmium, lead, and mercury in relation to reproductive hormones and anovulation in premenopausal women. Environ Health Perspect 119(8):1156-1161. https://doi.org/10.1289/ehp.1003284.

Pollack AZ, Mumford SL, Wactawski-Wende J, et al. 2013. Bone mineral density and blood metals in premenopausal women. Environ Res 120:76-81. https://doi.org/10.1016/j.envres.2012.06.001.

Pollack AZ, Mumford SL, Mendola P, et al. 2015. Kidney biomarkers associated with blood lead, mercury, and cadmium in premenopausal women: a prospective cohort study. J Toxicol Environ Health A 78(2):119-131. https://doi.org/10.1080/15287394.2014.944680.

Poma K, Kirsch-Volders M, Susanne C. 1981. Mutagenicity study on mice given mercuric chloride. J Appl Toxicol 1(6):314-316. https://doi.org/10.1002/jat.2550010609.

Ponce RA, Bloom NS. 1991. Effect of pH on the bioaccumulation of low level, dissolved methylmercury by rainbow trout (Oncorhynchus mykiss). Water Air Soil Pollut 56(0):631-640.

Pope Q, Rand MD. 2021. Variation in methylmercury metabolism and elimination in humans: physiological pharmacokinetic modeling highlights the role of gut biotransformation, skeletal muscle, and hair. Toxicol Sci 180(1):26-37. https://doi.org/10.1093/toxsci/kfaa192.

Popescu HI, Negru L, Lancranjan I. 1979. Chromosome aberrations induced by occupational exposure to mercury. Arch Environ Health 34(6):461-463. https://doi.org/10.1080/00039896.1979.10667450.

Porcella DB. 1994. Mercury in the environment: Biogeochemistry. In: Watras CJ, Huckabee JW, eds. Mercury pollution integration and synthesis. Boca Raton, FL: Lewis Publishers, 3-19.

Poreba R, Skoczynska A, Gac P, et al. 2012. Left ventricular diastolic function in workers occupationally exposed to mercury vapour without clinical presentation of cardiac involvement. Toxicol Appl Pharmacol 263(3):368-373. https://doi.org/10.1016/j.taap.2012.07.012.

Post EM, Yang MG, King JA, et al. 1973. Behavioral changes of young rats force-fed methyl mercury chloride. Proc Soc Exp Biol Med 143(4):1113-1116. https://doi.org/10.3181/00379727-143-37480.

Pouzaud F, Ibbou A, Blanchemanche S, et al. 2010. Use of advanced cluster analysis to characterize fish consumption patterns and methylmercury dietary exposures from fish and other sea foods among pregnant women. J Expo Sci Environ Epidemiol 20(1):54-68. https://doi.org/10.1038/jes.2009.2.

Purohit AR, Rao MV. 2014. Mitigative role of melatonin and alpha-tocopherol against mercury-induced genotoxicity. Drug Chem Toxicol 37(2):221-226. https://doi.org/10.3109/01480545.2013.838774.

Puty B, Leão LKR, Crespo-Lopez ME, et al. 2019. Association between methylmercury environmental exposure and neurological disorders: A systematic review. J Trace Elem Med Biol 52:100-110. https://doi.org/10.1016/j.jtemb.2018.12.001.

Pyle DM, Mather TA. 2003. The importance of volcanic emissions for the global atmospheric mercury cycle. Atmos Environ 37(36):5115-5124. https://doi.org/10.1016/j.atmosenv.2003.07.011.

Rabenstein DL, Isab AA, Reid RS. 1982. A proton nuclear magnetic resonance study of the binding of methylmercury in human erythrocytes. Biochim Biophys Acta 720(1):53-64.

Raeeszadeh M, Moradi M, Ayar P, et al. 2021. The antioxidant effect of Medicago sativa L. (Alfalfa) ethanolic extract against mercury chloride (HgCl2) toxicity in rat liver and kidney: An in vitro and in vivo study. Evid Based Complement Alternat Med 2021:8388002. https://doi.org/10.1155/2021/8388002.

Rafiee A, Delgado-Saborit JM, Sly PD, et al. 2020. Environmental chronic exposure to metals and effects on attention and executive function in the general population. Sci Total Environ 705:135911. https://doi.org/10.1016/j.scitotenv.2019.135911.

Raffee LA, Alawneh KZ, Alassaf RA, et al. 2021. Effects of elemental mercury vapor inhalation on arterial blood gases, lung histology, and interleukin-1 expression in pulmonary tissues of rats. ScientificWorldJournal 2021:4141383. https://doi.org/10.1155/2021/4141383.

Rahola T, Aaran RK, Miettinen JK. 1972. Half-time studies of mercury and cadmium by whole-body counting. Assess Radioactiv Contam March:553-562.

Rahola T, Hattula T, Korolainen A, et al. 1973. Elimination of free and protein-bound ionic mercury 203Hg2+ in man. Ann Clin Res 5(4):214-219.

Rajaee M, Sanchez BN, Renne EP, et al. 2015. An investigation of organic and inorganic mercury exposure and blood pressure in a small-scale gold mining community in Ghana. Int J Environ Res Public Health 12(8):10020-10038. https://doi.org/10.3390/ijerph120810020.

Rajanna B, Hobson M. 1985. Influence of mercury on uptake of (3H)dopamine and (3H)norepinephrine by rat brain synaptosomes. Toxicol Lett 27:7-14.

Ralston NVC, Raymond LJ. 2018. Mercury's neurotoxicity is characterized by its disruption of selenium biochemistry. Biochim Biophys Acta Gen Subj 1862:2405-2416. https://doi.org/10.1016/j.bbagen.2018.05.009.

Ralston NV, Ralston CR, Blackwell JL, et al. 2008. Dietary and tissue selenium in relation to methylmercury toxicity. Neurotoxicology 29(5):802-811. https://doi.org/10.1016/j.neuro.2008.07.007.

Ramalingam V, Vimaladevi V, Rajeswary S, et al. 2003. Effect of mercuric chloride on circulating hormones in adult albino rats. J Environ Biol 24(4):401-404.

Ramelow GJ, Webre CL, Mueller CS, et al. 1989. Variations of heavy metals and arsenic in fish and other organisms from the Calcasieu River and Lake, Louisiana. Arch Environ Contam Toxicol 18(6):804-818. https://doi.org/10.1007/bf01160294.

8. REFERENCES

Ramirez GB, Cruz MC, Pagulayan O, et al. 2000. The Tagum study I: analysis and clinical correlates of mercury in maternal and cord blood, breast milk, meconium, and infants' hair. Pediatrics 106(4):774-781.

Ramirez GB, Pagulayan O, Akagi H, et al. 2003. Tagum study II: follow-up study at two years of age after prenatal exposure to mercury. Pediatrics 111(3):e289-295.

Rand MD, Conrad K, Marvin E, et al. 2020. Developmental exposure to methylmercury and resultant muscle mercury accumulation and adult motor deficits in mice. Neurotoxicology 81:1-10. https://doi.org/10.1016/j.neuro.2020.07.007.

Rao MV, Chinoy NJ, Suthar MB, et al. 2001. Role of ascorbic acid on mercuric chloride-induced genotoxicity in human blood cultures. Toxicol in Vitro 15(6):649-654.

Rastogi SC. 1992. Cadmium, chromium, lead, and mercury residues in finger-paints and make-up paints. Bull Environ Contam Toxicol 48(2):289-294. https://doi.org/10.1007/bf00194386.

Rastogi SC, Pritzl G. 1996. Migration of some toxic metals from crayons and water colors. Bull Environ Contam Toxicol 56(4):527-533. https://doi.org/10.1007/s001289900076.

Raymond MR, Christensen KY, Thompson BA, et al. 2016. Associations between fish consumption and contaminant biomarkers with cardiovascular conditions among older male anglers in Wisconsin. J Occup Environ Med 58(7):676-682. https://doi.org/10.1097/jom.0000000000000757.

Razzaghi H, Tinker SC, Crider K. 2014. Blood mercury concentrations in pregnant and nonpregnant women in the United States: National Health and Nutrition Examination Survey 1999-2006. Am J Obstet Gynecol 210(4):357 e351-357 e359. https://doi.org/10.1016/j.ajog.2013.10.884.

Rees JR, Sturup S, Chen C, et al. 2007. Toenail mercury and dietary fish consumption. J Expo Sci Environ Epidemiol 17(1):25-30. https://doi.org/10.1038/sj.jes.7500516.

Refsvik T. 1983. The mechanism of biliary excretion of methyl mercury: Methylthiols. Acta Pharmacol Toxicol (Copenh) 53(2):153-158.

Refsvik T, Norseth T. 1975. Methyl mercuric compounds in rat bile. Acta Pharmacol Toxicol (Copenh) 36(1):67-78.

Regencia ZJG, Dalmacion GV, Baja ES. 2022. Effect of heavy metals on ventricular repolarization and depolarization in the Metropolitan Manila Development Authority (MMDA) traffic enforcers' health study. Arch Environ Occup Health 77(2):87-95. https://doi.org/10.1080/19338244.2020.1853017.

Regnell O, Tunlid A. 1991. Laboratory study of chemical speciation of mercury in lake sediment and water under aerobic and anaerobic conditions. Appl Environ Microbiol 57(3):789-795. https://doi.org/10.1128/aem.57.3.789-795.1991.

Ren M, Zhao J, Wang B, et al. 2022. Associations between hair levels of trace elements and the risk of preterm birth among pregnant women: A prospective nested case-control study in Beijing Birth Cohort (BBC), China. Environ Int 158:106965. https://doi.org/10.1016/j.envint.2021.106965.

Renzetti S, Cagna G, Calza S, et al. 2021. The effects of the exposure to neurotoxic elements on Italian schoolchildren behavior. Sci Rep 11(1):9898. https://doi.org/10.1038/s41598-021-88969-z.

RePORTER. 2024. Mercury and mercury compounds. Research Portfolio Online Reporting Tools. National Institutes of Health. https://reporter.nih.gov/. March 14, 2024.

Reuben A, Frischtak H, Berky A, et al. 2020. Elevated hair mercury levels are associated with neurodevelopmental deficits in children living near artisanal and small-scale gold mining in Peru. Geohealth 4(5):e2019GH000222. https://doi.org/10.1029/2019gh000222.

Reuhl KR, Chang LW, Townsend JW. 1981a. Pathological effects of in utero methylmercury exposure on the cerebellum of the golden hamster (Mesocricetus auratus): 1. Early effects on the neonatal cerebellar cortex. Environ Res 26(2):281-306. https://doi.org/10.1016/0013-9351(81)90205-x.

Reuhl KR, Chang LW, Townsend JW. 1981b. Pathological effects of in utero methylmercury exposure on the cerebellum of the golden hamster (Mesocricetus auratus): 2. Residual effects on the adult cerebellum. Environ Res 26(2):307-327. https://doi.org/10.1016/0013-9351(81)90206-1.

Revis NW, Osborne TR, Holdsworth G, et al. 1989. Distribution of mercury species in soil from a mercury-contaminated site. Water Air Soil Pollut 45(1-2):105-114.

8. REFERENCES

Revis NW, Osborne TR, Holdsworth G, et al. 1990. Mercury in soil: A method for assessing acceptable limits. Arch Environ Contam Toxicol 19(2):221-226.

Rezaei M, Javadmoosavi SY, Mansouri B, et al. 2019. Thyroid dysfunction: how concentration of toxic and essential elements contribute to risk of hypothyroidism, hyperthyroidism, and thyroid cancer. Environ Sci Pollut Res Int 26(35):35787-35796. https://doi.org/10.1007/s11356-019-06632-7.

Rezaei M, Blaszczyk M, Tinkov AA, et al. 2021. Relationship between gestational diabetes and serum trace element levels in pregnant women from Eastern Iran: a multivariate approach. Environ Sci Pollut Res Int 28(33):45230-45239. https://doi.org/10.1007/s11356-021-13927-1.

Rhee J, Vance TM, Lim R, et al. 2020. Association of blood mercury levels with nonmelanoma skin cancer in the U.S.A. using National Health and Nutrition Examination Survey data (2003-2016). Br J Dermatol 183(3):480-487. https://doi.org/10.1111/bjd.18797.

Ribeyre F, Boudou A, Maury-Brachet R. 1991. Multicompartment ecotoxicological models to study mercury bioaccumulation and transfer in freshwater systems. Water Air Soil Pollut 56(1):641-652. https://doi.org/10.1007/bf00342306.

Rice DC. 1989a. Blood mercury concentrations following methyl mercury exposure in adult and infant monkeys. Environ Res 49(1):115-126. https://doi.org/10.1016/s0013-9351(89)80026-x.

Rice DC. 1989b. Brain and tissue levels of mercury after chronic methylmercury exposure in the monkey. J Toxicol Environ Health 27(2):189-198. https://doi.org/10.1080/15287398909531290.

Rice DC. 1989c. Delayed neurotoxicity in monkeys exposed developmentally to methylmercury. Neurotoxicology 10(4):645-650.

Rice DC. 1992. Effects of pre- plus postnatal exposure to methylmercury in the monkey on fixed interval and discrimination reversal performance. Neurotoxicology 13(2):443-452.

Rice DC. 1998a. Age-related increase in auditory impairment in monkeys exposed in utero plus postnatally to methylmercury. Toxicol Sci 44(2):191-196. https://doi.org/10.1006/toxs.1998.2487.

Rice DC. 1998b. Lack of effect of methylmercury exposure from birth to adulthood on information processing speed in the monkey. Neurotoxicol Teratol 20(3):275-283.

Rice DC, Gilbert SG. 1982. Early chronic low-level methylmercury poisoning in monkeys impairs spatial vision. Science 216(4547):759-761. https://doi.org/10.1126/science.7079739.

Rice DC, Gilbert SG. 1990. Effects of developmental exposure to methyl mercury on spatial and temporal visual function in monkeys. Toxicol Appl Pharmacol 102(1):151-163. https://doi.org/10.1016/0041-008x(90)90092-9.

Rice DC, Gilbert SG. 1992. Exposure to methyl mercury from birth to adulthood impairs high-frequency hearing in monkeys. Toxicol Appl Pharmacol 115(1):6-10. https://doi.org/10.1016/0041-008x(92)90361-u.

Rice DC, Hayward S. 1999. Comparison of visual function at adulthood and during aging in monkeys exposed to lead or methylmercury. Neurotoxicology 20(5):767-784.

Rice DC, Krewski D, Collins BT, et al. 1989. Pharmacokinetics of methylmercury in the blood of monkeys (Macaca fascicularis). Fundam Appl Toxicol 12(1):23-33.

Rice KM, Walker EM, Wu M, et al. 2014. Environmental mercury and its toxic effects. J Prev Med Public Health 47(2):74-83. https://doi.org/10.3961/jpmph.2014.47.2.74.

Rieber M, Harris DP. 1994. Mercury pollution: The impact of U.S. government stockpile releases. In: Watras CJ, Huckabee JW, eds. Mercury pollution integration and synthesis. Boca Raton, FL: Lewis Publishers, 615-620.

Riisgard HU, Hansen S. 1990. Biomagnification of mercury in a marine grazing food-chain: Algal cells Phaeodactylum tricornutum, mussels Mytilus edulis and flounders Platichthys flesus studied by means of a stepwise-reduction-CVAA method. Mar Ecol Prog Ser 62(3):259-270.

Riley DM, Newby CA, Leal-Almeraz TO, et al. 2001. Assessing elemental mercury vapor exposure from cultural and religious practices. Environ Health Perspect 109(8):779-784. https://doi.org/10.1289/ehp.01109779.

Riley DM, Newby CA, Leal-Almeraz TO. 2006. Incorporating ethnographic methods in multidisciplinary approaches to risk assessment and communication: cultural and religious uses of

mercury in Latino and Caribbean communities. Risk Anal 26(5):1205-1221. https://doi.org/10.1111/j.1539-6924.2006.00809.x.

Risch MR, Gay DA, Fowler KK, et al. 2012. Spatial patterns and temporal trends in mercury concentrations, precipitation depths, and mercury wet deposition in the North American Great Lakes region, 2002-2008. Environ Pollut 161:261-271. https://doi.org/10.1016/j.envpol.2011.05.030.

Risch MR, DeWild JF, Gay DA, et al. 2017. Atmospheric mercury deposition to forests in the eastern USA. Environ Pollut 228:8-18. https://doi.org/10.1016/j.envpol.2017.05.004.

Ritchie KA, Gilmour WH, Macdonald EB, et al. 2002. Health and neuropsychological functioning of dentists exposed to mercury. Occup Environ Med 59(5):287-293. https://doi.org/10.1136/oem.59.5.287.

Robinson JW, Skelly EM. 1983. The direct determination of mercury in sweat. Spectrosc Lett 16(2):133-150. https://doi.org/10.1080/00387018308062329.

Robinson JF, Theunissen PT, van Dartel DA, et al. 2011. Comparison of MeHg-induced toxicogenomic responses across in vivo and in vitro models used in developmental toxicology. Reprod Toxicol 32(2):180-188. https://doi.org/10.1016/j.reprotox.2011.05.011.

Rodier PM, Kates B, Simons R. 1988. Mercury localization in mouse kidney over time: Autoradiography versus silver staining. Toxicol Appl Pharmacol 92(2):235-245.

Rodriguez LH, Rodriguez-Villamizar LA, Florez-Vargas O, et al. 2017. No effect of mercury exposure on kidney function during ongoing artisanal gold mining activities in Colombia. Toxicol Ind Health 33(1):67-78. https://doi.org/10.1177/0748233716659031.

Rodríguez-Carrillo A, Mustieles V, D'Cruz SC, et al. 2022. Exploring the relationship between metal exposure, BDNF, and behavior in adolescent males. Int J Hyg Environ Health 239:113877. https://doi.org/10.1016/j.ijheh.2021.113877.

Rodríguez-Viso P, Domene A, Vélez D, et al. 2023. Oral exposure to inorganic mercury or methylmercury elicits distinct pro-inflammatory and pro-oxidant intestinal responses in a mouse model system. Food Chem Toxicol 177:113801. https://doi.org/10.1016/j.fct.2023.113801.

Roels H, Lauwerys R, Buchet JP, et al. 1982. Comparison of renal function and psychomotor performance in workers exposed to elemental mercury. Int Arch Occup Environ Health 50(1):77-93. https://doi.org/10.1007/bf00432495.

Roels H, Abdeladim S, Ceulemans E, et al. 1987. Relationships between the concentrations of mercury in air and in blood or urine in workers exposed to mercury vapour. Ann Occup Hyg 31(2):135-145. https://doi.org/10.1093/annhyg/31.2.135.

Rogers HS, McCullough J, Kieszak S, et al. 2007. Exposure assessment of young children living in Chicago communities with historic reports of ritualistic use of mercury. Clin Toxicol 45(3):240-247. https://doi.org/10.1080/15563650601031643.

Roman HA, Walsh TL, Coull BA, et al. 2011. Evaluation of the cardiovascular effects of methylmercury exposures: current evidence supports development of a dose-response function for regulatory benefits analysis. Environ Health Perspect 119(5):607-614. https://doi.org/10.1289/ehp.1003012.

Roman-Franco AA, Turiello M, Albini B, et al. 1978. Anti-basement membrane antibodies and antigen-antibody complexes in rabbits injected with mercuric chloride. Clin Immunol Immunopathol 9(4):464-481. https://doi.org/10.1016/0090-1229(78)90143-5.

Roos PM, Dencker L. 2012. Mercury in the spinal cord after inhalation of mercury. Basic Clin Pharmacol Toxicol 111(2):126-132. https://doi.org/10.1111/j.1742-7843.2012.00872.x.

Roos D, Seeger R, Puntel R, et al. 2012. Role of calcium and mitochondria in MeHg-mediated cytotoxicity. J Biomed Biotechnol 2012:1-15. https://doi.org/10.1155/2012/248764.

Rosa-Silva HTD, Panzenhagen AC, Schmidtt V, et al. 2020a. Hepatic and neurobiological effects of foetal and breastfeeding and adulthood exposure to methylmercury in Wistar rats. Chemosphere 244:125400. https://doi.org/10.1016/j.chemosphere.2019.125400.

Rosa-Silva HTD, Panzenhagen AC, Espitia-Pérez P, et al. 2020b. Effects of foetal and breastfeeding exposure to methylmercury (MeHg) and retinol palmitate (Vitamin A) in rats: Redox parameters and

susceptibility to DNA damage in liver. Mutat Res Genet Toxicol Environ Mutagen 858-860:503239.
https://doi.org/10.1016/j.mrgentox.2020.503239.

Rossa-Roccor V, Karim ME. 2021. Are US adults with low-exposure to methylmercury at increased risk
for depression? A study based on 2011-2016 National Health and Nutrition Examination Surveys
(NHANES). Int Arch Occup Environ Health 94(3):419-431. https://doi.org/10.1007/s00420-020-
01592-9.

Rossi AD, Ahlbom E, Ogren SO, et al. 1997. Prenatal exposure to methylmercury alters locomotor
activity of male but not female rats. Exp Brain Res 117(3):428-436.
https://doi.org/10.1007/s002210050237.

Rothenberg SE, Keiser S, Ajami NJ, et al. 2016a. The role of gut microbiota in fetal methylmercury
exposure: Insights from a pilot study. Toxicol Lett 242:60-67.
https://doi.org/10.1016/j.toxlet.2015.11.022.

Rothenberg SE, Yu X, Liu J, et al. 2016b. Maternal methylmercury exposure through rice ingestion and
offspring neurodevelopment: A prospective cohort study. Int J Hyg Environ Health 219(8):832-842.
https://doi.org/10.1016/j.ijheh.2016.07.014.

Rothenberg SE, Wagner CL, Hamidi B, et al. 2019. Longitudinal changes during pregnancy in gut
microbiota and methylmercury biomarkers, and reversal of microbe-exposure correlations. Environ
Res 172:700-712. https://doi.org/10.1016/j.envres.2019.01.014.

Rothenberg SE, Korrick SA, Liu J, et al. 2021. Maternal methylmercury exposure through rice ingestion
and child neurodevelopment in the first three years: a prospective cohort study in rural China.
Environ Health 20(1):50. https://doi.org/10.1186/s12940-021-00732-z.

Rowens B, Guerrero-Betancourt D, Gottlieb CA, et al. 1991. Respiratory failure and death following
acute inhalation of mercury vapor. Chest 99(1):185-190. https://doi.org/10.1378/chest.99.1.185.

Rowland IR, Davies MJ, Grasso P. 1975a. The methylation of mercury by the gastro-intestinal contents
of the rat. Biochem Soc Trans 3(4):502-504.

Rowland IR, Grasso P, Davies MJ. 1975b. The methylation of mercuric chloride by human intestinal
bacteria. Experientia 31(9):1064-1065.

Rozalski M, Wierzbicki R. 1983. Effect of mercuric chloride on cultured rat fibroblasts: survival, protein
biosynthesis and binding of mercury to chromatin. Biochem Pharmacol 32(13):2124-2126.

Rozgaj R, Kasuba V, Blanusa M. 2005. Mercury chloride genotoxicity in rats following oral exposure,
evaluated by comet assay and micronucleus test. Arh Hig Rada Toksikol 56(1):9-15.

RTECS. 1997. Mercury. Registry of Toxic Effects of Chemical Substances, Micromedex, Inc.

Ruiz P, Ray M, Fisher J, et al. 2011. Development of a human physiologically based pharmacokinetic
(PBPK) toolkit for environmental pollutants. Int J Mol Sci 12(11):7469-7480.
https://doi.org/10.3390/ijms12117469.

Rule JH, Iwashchenko MS. 1998. Mercury concentrations in soils adjacent to a former chlor-alkali plant.
J Environ Qual 27(1):31-37.

Rumbold DG, Lienhardt CT, Parsons ML. 2018. Mercury biomagnification through a coral reef
ecosystem. Arch Environ Contam Toxicol 75(1):121-133. https://doi.org/10.1007/s00244-018-
0523-0.

Ruus A, Overjordet IB, Braaten HF, et al. 2015. Methylmercury biomagnification in an Arctic pelagic
food web. Environ Toxicol Chem 34(11):2636-2643. https://doi.org/10.1002/etc.3143.

Ryan L. 2008. Combining data from multiple sources, with applications to environmental risk
assessment. Stat Med 27(5):698-710. https://doi.org/10.1002/sim.3053.

Ryu J, Ha EH, Kim BN, et al. 2017. Associations of prenatal and early childhood mercury exposure with
autistic behaviors at 5years of age: The Mothers and Children's Environmental Health (MOCEH)
study. Sci Total Environ 605-606:251-257. https://doi.org/10.1016/j.scitotenv.2017.06.227.

Sabir S, Saleem U, Akash MSH, et al. 2022. Thymoquinone induces Nrf2 mediated adaptive
homeostasis: implication for mercuric chloride-induced nephrotoxicity. ACS Omega 7(8):7370-
7379. https://doi.org/10.1021/acsomega.2c00028.

8. REFERENCES

Sager PR, Doherty RA, Olmsted JB. 1983. Interaction of methylmercury with microtubules in cultured cells and in vitro. Exp Cell Res 146(1):127-137.

Sagiv SK, Thurston SW, Bellinger DC, et al. 2012. Prenatal exposure to mercury and fish consumption during pregnancy and attention-deficit/hyperactivity disorder-related behavior in children. Arch Pediatr Adolesc Med 166(12):1123-1131. https://doi.org/10.1001/archpediatrics.2012.1286.

Saint-Amour D, Roy MS, Bastien C, et al. 2006. Alterations of visual evoked potentials in preschool Inuit children exposed to methylmercury and polychlorinated biphenyls from a marine diet. Neurotoxicology 27(4):567-578. https://doi.org/10.1016/j.neuro.2006.02.008.

Saito H, Sekikawa T, Taguchi J, et al. 2020. Prenatal and postnatal methyl mercury exposure in Niigata, Japan: adult outcomes. Neurotoxicology 81:364-372. https://doi.org/10.1016/j.neuro.2020.09.031.

Sakamoto M, Kakita A, Wakabayashi K, et al. 2002. Evaluation of changes in methylmercury accumulation in the developing rat brain and its effects: a study with consecutive and moderate dose exposure throughout gestation and lactation periods. Brain Res 949(1-2):51-59. https://doi.org/10.1016/s0006-8993(02)02964-5.

Sakamoto M, Kakita A, de Oliveira RB, et al. 2004. Dose-dependent effects of methylmercury administered during neonatal brain spurt in rats. Brain Res Dev Brain Res 152(2):171-176. https://doi.org/10.1016/j.devbrainres.2004.06.016.

Sakamoto M, Kaneoka T, Murata K, et al. 2007. Correlations between mercury concentrations in umbilical cord tissue and other biomarkers of fetal exposure to methylmercury in the Japanese population. Environ Res 103(1):106-111. https://doi.org/10.1016/j.envres.2006.03.004.

Sakamoto M, Kubota M, Murata K, et al. 2008. Changes in mercury concentrations of segmental maternal hair during gestation and their correlations with other biomarkers of fetal exposure to methylmercury in the Japanese population. Environ Res 106(2):270-276. https://doi.org/10.1016/j.envres.2007.10.002.

Sakamoto M, Yasutake A, Domingo JL, et al. 2013. Relationships between trace element concentrations in chorionic tissue of placenta and umbilical cord tissue: potential use as indicators for prenatal exposure. Environ Int 60:106-111. https://doi.org/10.1016/j.envint.2013.08.007.

Sakamoto M, Chan HM, Domingo JL, et al. 2015. Significance of fingernail and toenail mercury concentrations as biomarkers for prenatal methylmercury exposure in relation to segmental hair mercury concentrations. Environ Res 136:289-294. https://doi.org/10.1016/j.envres.2014.09.034.

Sakamoto M, Murata K, Domingo JL, et al. 2016. Implications of mercury concentrations in umbilical cord tissue in relation to maternal hair segments as biomarkers for prenatal exposure to methylmercury. Environ Res 149:282-287. https://doi.org/10.1016/j.envres.2016.04.023.

Sakamoto M, Kakita A, Domingo JL, et al. 2017. Stable and episodic/bolus patterns of methylmercury exposure on mercury accumulation and histopathologic alterations in the nervous system. Environ Res 152:446-453. https://doi.org/10.1016/j.envres.2016.06.034.

Sakamoto M, Chan HM, Domingo JL, et al. 2018. Placental transfer and levels of mercury, selenium, vitamin E, and docosahexaenoic acid in maternal and umbilical cord blood. Environ Int 111:309-315. https://doi.org/10.1016/j.envint.2017.11.001.

Sakamoto M, Kakita A, Sakai K, et al. 2020. Methylmercury exposure during the vulnerable window of the cerebrum in postnatal developing rats. Environ Res 188:109776. https://doi.org/10.1016/j.envres.2020.109776.

Salazar-Camacho C, Salas-Moreno M, Paternina-Uribe R, et al. 2021. Mercury species in fish from a tropical river highly impacted by gold mining at the Colombian Pacific region. Chemosphere 264(Pt 2):128478. https://doi.org/10.1016/j.chemosphere.2020.128478.

Sallsten G, Barregard L, Schutz A. 1994. Clearance half life of mercury in urine after the cessation of long term occupational exposure: influence of a chelating agent (DMPS) on excretion of mercury in urine. Occup Environ Med 51(5):337-342. https://doi.org/10.1136/oem.51.5.337.

Salonen JT, Seppanen K, Nyyssonen K, et al. 1995. Intake of mercury from fish, lipid peroxidation, and the risk of myocardial infarction and coronary, cardiovascular, and any death in eastern Finnish men. Circulation 91(3):645-655. https://doi.org/10.1161/01.cir.91.3.645.

Salonen JT, Seppanen K, Lakka TA, et al. 2000. Mercury accumulation and accelerated progression of carotid atherosclerosis: a population-based prospective 4-year follow-up study in men in eastern Finland. Atherosclerosis 148(2):265-273. https://doi.org/10.1016/s0021-9150(99)00272-5.

Samudralwar DL, Garg AN. 1996. Minor and trace elemental determination in the Indian herbal and other medicinal preparations. Biol Trace Elem Res 54(2):113-121. https://doi.org/10.1007/bf02786258.

Sanchez Rodriguez LH, Florez-Vargas O, Rodriguez-Villamizar LA, et al. 2015. Lack of autoantibody induction by mercury exposure in artisanal gold mining settings in Colombia: Findings and a review of the epidemiology literature. J Immunotoxicol 12(4):368-375. https://doi.org/10.3109/1547691x.2014.986591.

Sandborgh-Englund G, Elinder CG, Johanson G, et al. 1998. The absorption, blood levels, and excretion of mercury after a single dose of mercury vapor in humans. Toxicol Appl Pharmacol 150(1):146-153. https://doi.org/10.1006/taap.1998.8400.

Sandborgh-Englund G, Ask K, Belfrage E, et al. 2001. Mercury exposure in utero and during infancy. J Toxicol Environ Health A 63(5):317-320. https://doi.org/10.1080/15287390152103634.

Sandborgh-Englund G, Einarsson C, Sandstrom M, et al. 2004. Gastrointestinal absorption of metallic mercury. Arch Environ Health 59(9):449-454. https://doi.org/10.1080/00039890409603424.

Sanders AP, Mazzella MJ, Malin AJ, et al. 2019. Combined exposure to lead, cadmium, mercury, and arsenic and kidney health in adolescents age 12-19 in NHANES 2009-2014. Environ Int 131:104993. https://doi.org/10.1016/j.envint.2019.104993.

Sanga RN, Bartell SM, Ponce RA, et al. 2001. Effects of uncertainties on exposure estimates to methylmercury: a Monte Carlo analysis of exposure biomarkers versus dietary recall estimation. Risk Anal 21(5):859-868. https://doi.org/10.1111/0272-4332.215157.

Santana L, Bittencourt LO, Nascimento PC, et al. 2019. Low doses of methylmercury exposure during adulthood in rats display oxidative stress, neurodegeneration in the motor cortex and lead to impairment of motor skills. J Trace Elem Med Biol 51:19-27. https://doi.org/10.1016/j.jtemb.2018.09.004.

Sapin C, Druet E, Druet P. 1977. Induction of anti-glomerular basement membrane antibodies in the Brown-Norway rat by mercuric chloride. Clin Exp Immunol 28(1):173-179.

Sartorelli P, Montomoli L, Sisinni AG, et al. 2003. Percutaneous penetration of inorganic mercury from soil: an in vitro study. Bull Environ Contam Toxicol 71(6):1091-1099.

Sarzo B, Ballester F, Soler-Blasco R, et al. 2022. Pre and postnatal exposure to mercury and sexual development in 9-year-old children in Spain: The role of brain-derived neurotrophic factor. Environ Res 213:113620. https://doi.org/10.1016/j.envres.2022.113620.

Satoh H, Hursh JB, Clarkson TW, et al. 1981. Selective determination of elemental mercury in blood and urine exposed to mercury vapor in vitro. J Appl Toxicol 1(3):177-181. https://doi.org/10.1002/jat.2550010309.

Sawyer J. 2015. Hartford man had skeletal remains in apartment for religious reasons: PD. NBC Connecticut. https://www.nbcconnecticut.com/news/local/Skeletal-Remains-of-Five-Bodies-Stolen-From-Massachusetts-Cemetery-Found-in-Hartford-Apartment-Police-360669131.html. May 17, 2021.

Schiffer L, Barnard L, Baranowski ES, et al. 2019. Human steroid biosynthesis, metabolism and excretion are differentially reflected by serum and urine steroid metabolomes: A comprehensive review. J Steroid Biochem Mol Biol 194:1-25. https://doi.org/10.1016/j.jsbmb.2019.105439.

Schiønning JD, Larsen JO, Eide R. 1998a. A stereological study of dorsal root ganglion cells and nerve root fibers from rats exposed to mercury vapor. Acta Neuropathol (Berl) 96(2):185-190. https://doi.org/10.1007/s004010050880.

Schiønning JD, Larsen JO, Tandrup T, et al. 1998b. Selective degeneration of dorsal root ganglia and dorsal nerve roots in methyl mercury-intoxicated rats: a stereological study. Acta Neuropathol (Berl) 96(2):191-201.

8. REFERENCES

Schmid K, Sassen A, Staudenmaier R, et al. 2007. Mercuric dichloride induces DNA damage in human salivary gland tissue cells and lymphocytes. Arch Toxicol 81(11):759-767. https://doi.org/10.1007/s00204-007-0208-3.

Schroeder WH, Fanaki FH. 1988. Field measurements of water-air exchange of mercury in freshwater systems. Environ Technol Lett 9(5):369-374. https://doi.org/10.1080/09593338809384579.

Schumacher L, Abbott LC. 2017. Effects of methyl mercury exposure on pancreatic beta cell development and function. J Appl Toxicol 37(1):4-12. https://doi.org/10.1002/jat.3381.

Schurz F, Sabater-Vilar M, Fink-Gremmels J. 2000. Mutagenicity of mercury chloride and mechanisms of cellular defence: The role of metal-binding proteins. Mutagenesis 15(6):525-530.

Schuster E. 1991. The behavior of mercury in the soil with special emphasis on complexation and adsorption processes - A review of the literature. Water Air Soil Pollut 56(1):667-680. https://doi.org/10.1007/bf00342308.

Schuurs AH. 1999. Reproductive toxicity of occupational mercury. A review of the literature. J Dent 27(4):249-256.

Sears ME, Kerr KJ, Bray RI. 2012. Arsenic, cadmium, lead, and mercury in sweat: A systematic review. J Environ Public Health 2012:1-10. https://doi.org/10.1155/2012/184745.

Seki N, Akiyama M, Yamakawa H, et al. 2021. Adverse effects of methylmercury on gut bacteria and accelerated accumulation of mercury in organs due to disruption of gut microbiota. J Toxicol Sci 46(2):91-97. https://doi.org/10.2131/jts.46.91.

Sell JL, Davison KL. 1975. Metabolism of mercury, administered as methylmercuric chloride or mercuric chloride, by lactating ruminants. J Agric Food Chem 23(4):803-808.

SERDP. 2014 Bioavailability and methylation potential of mercury sulfides in sediments. Alexandria, VA: Strategic Environmental Research and Development Program. ER1744.

Shaheen SO, Newson RB, Henderson AJ, et al. 2004. Umbilical cord trace elements and minerals and risk of early childhood wheezing and eczema. Eur Respir J 24(2):292-297. https://doi.org/10.1183/09031936.04.00117803.

Shah-Kulkarni S, Lee S, Jeong KS, et al. 2020. Prenatal exposure to mixtures of heavy metals and neurodevelopment in infants at 6 months. Environ Res 182:109122. https://doi.org/10.1016/j.envres.2020.109122.

Shamalaye C, Davidson PW, Myers GJ. 2004. The Seychelles Child Development Study: Two decades of collaboration. Seychelles Med Dent J 7(1):92-99.

Shapiro AM, Chan HM. 2008. Characterization of demethylation of methylmercury in cultured astrocytes. Chemosphere 74(1):112-118. https://doi.org/10.1016/j.chemosphere.2008.09.019.

Shen Y, Laue HE, Shrubsole MJ, et al. 2022. Associations of childhood and perinatal blood metals with children's gut microbiomes in a Canadian gestation cohort. Environ Health Perspect 130(1):17007. https://doi.org/10.1289/EHP9674.

Shen L, Liang C, Li D, et al. 2023. The association between exposure to multiple toxic metals and the risk of endometriosis: Evidence from the results of blood and follicular fluid. Sci Total Environ 855:158882. https://doi.org/10.1016/j.scitotenv.2022.158882.

Shenker BJ, Maserejian NN, Zhang A, et al. 2008. Immune function effects of dental amalgam in children: a randomized clinical trial. J Am Dent Assoc 139(11):1496-1505. https://doi.org/10.14219/jada.archive.2008.0076.

Sherlock JC, Lindsay DG, Evans WH, et al. 1982. Duplication diet study on mercury intake by fish consumers in the UK. Arch Environ Health 37(5):271-278.

Sherlock J, Hislop J, Newton D, et al. 1984. Elevation of mercury in human blood from controlled chronic ingestion of methylmercury in fish. Hum Toxicol 3(2):117-131.

Sherman LS, Blum JD, Franzblau A, et al. 2013. New insight into biomarkers of human mercury exposure using naturally occurring mercury stable isotopes. Environ Sci Technol 47(7):3403-3409. https://doi.org/10.1021/es305250z.

Shi CY, Lane AT, Clarkson TW. 1990. Uptake of mercury by the hair of methylmercury-treated newborn mice. Environ Res 51(2):170-181.

8. REFERENCES

Shi X, Chan CPS, Man GKY, et al. 2021. Associations between blood metal/ metalloid concentration and human semen quality and sperm function: A cross-sectional study in Hong Kong. J Trace Elem Med Biol 65:126735. https://doi.org/10.1016/j.jtemb.2021.126735.

Shimada A, Yamamoto E, Morita T, et al. 2004. Ultrastructural demonstration of mercury granules in the placenta of metallothionein-null pregnant mice after exposure to mercury vapor. Toxicol Pathol 32(5):519-526. https://doi.org/10.1080/01926230490496302.

Shin YY, Ryu IK, Park MJ, et al. 2018. The association of total blood mercury levels and overweight among Korean adolescents: analysis of the Korean National Health and Nutrition Examination Survey (KNHANES) 2010-2013. Korean J Pediatr 61(4):121-128. https://doi.org/10.3345/kjp.2018.61.4.121.

Shinoda Y, Ehara S, Tatsumi S, et al. 2019. Methylmercury-induced neural degeneration in rat dorsal root ganglion is associated with the accumulation of microglia/macrophages and the proliferation of Schwann cells. J Toxicol Sci 44(3):191-199. https://doi.org/10.2131/jts.44.191.

Shipp AM, Gentry PR, Lawrence G, et al. 2000. Determination of a site-specific reference dose for methylmercury for fish-eating populations. Toxicol Ind Health 16(9-10):335-438. https://doi.org/10.1177/074823370001600901.

Siblerud RL. 1990. The relationship between mercury from dental amalgam and the cardiovascular system. Sci Total Environ 99(1-2):23-35. https://doi.org/10.1016/0048-9697(90)90207-b.

Siegler RW, Nierenberg DW, Hickey WF. 1999. Fatal poisoning from liquid dimethylmercury: A neuropathologic study. Hum Pathol 30(6):720-723.

Signes-Pastor AJ, Desai G, García-Villarino M, et al. 2021. Exposure to a mixture of metals and growth indicators in 6-11-year-old children from the 2013-16 NHANES. Expo Health 13(2):173-184. https://doi.org/10.1007/s12403-020-00371-8.

Silbergeld EK, Silva IA, Nyland JF. 2005. Mercury and autoimmunity: Implications for occupational and environmental health. Toxicol Appl Pharmacol 207(2 Suppl):282-292. https://doi.org/10.1016/j.taap.2004.11.035.

Silva JL, Leocádio PCL, Reis JM, et al. 2021. Oral methylmercury intoxication aggravates cardiovascular risk factors and accelerates atherosclerosis lesion development in ApoE knockout and C57BL/6 mice. Toxicol Res 37(3):311-321. https://doi.org/10.1007/s43188-020-00066-x.

Silva MCD, Oliveira RAA, Vasconcellos ACS, et al. 2023. Chronic mercury exposure and GSTP1 polymorphism in Munduruku indigenous from Brazilian Amazon. Toxics 11(2):138. https://doi.org/10.3390/toxics11020138.

Simmons-Willis TA, Koh AS, Clarkson TW, et al. 2002. Transport of a neurotoxicant by molecular mimicry: the methylmercury-L-cysteine complex is a substrate for human L-type large neutral amino acid transporter (LAT) 1 and LAT2. Biochem J 367(Pt 1):239-246. https://doi.org/10.1042/bj20020841.

Sin YM, Teh WF. 1992. Effect of long-term uptake of mercuric sulphide on thyroid hormones and glutathione in mice. Bull Environ Contam Toxicol 49(6):847-854. https://doi.org/10.1007/BF00203157.

Sin YM, Lim YF, Wong MK. 1983. Uptake and distribution in mice from ingesting soluble and insoluble mercury compounds. Bull Environ Contam Toxicol 31(5):605-612.

Sin YM, Teh WF, Wong MK. 1989. Absorption of mercuric chloride and mercuric sulphide and their possible effects on tissue glutathione in mice. Bull Environ Contam Toxicol 42(2):307-314.

Sin YM, Teh WF, Wong MK, et al. 1990. Effect of mercury on glutathione and thyroid hormones. Bull Environ Contam Toxicol 44(4):616-622. https://doi.org/10.1007/BF01700885.

Sirivarasai J, Chaisungnern K, Panpunuan P, et al. 2021. Role of MT1A polymorphism and environmental mercury exposure on the Montreal Cognitive Assessment (MoCA). Neuropsychiatr Dis Treat 17:2429-2439. https://doi.org/10.2147/ndt.S320374.

Sirot V, Guerin T, Mauras Y, et al. 2008. Methylmercury exposure assessment using dietary and biomarker data among frequent seafood consumers in France CALIPSO study. Environ Res 107(1):30-38. https://doi.org/10.1016/j.envres.2007.12.005.

8. REFERENCES

Sitarek K, Gralewicz S. 2009. Early developmental effects of separate or combined perinatal exposure to methylmercury (MeHg) and 2,2',4,4',5,5'-hexachlorobiphenyl (PCB 153) in the rat. Int J Occup Med Environ Health 22(2):89-105. https://doi.org/10.2478/v10001-009-0015-6.

Sizmur T, O'Driscoll N, Cai Y. 2018. JES Special issue in mercury biogeochemistry and fate. J Environ Sci (China) 68:1-4. https://doi.org/10.1016/j.jes.2018.05.020.

Skerfving S, Hansson K, Lindsten J. 1970. Chromosome breakage in humans exposed to methyl mercury through fish consumption. Arch Environ Health 21:133-139.

Skerfving S, Hansson K, Mangs C, et al. 1974. Methylmercury-induced chromosome damage in man. Environ Res 7(1):83-98.

Skogheim TS, Weyde KVF, Engel SM, et al. 2021. Metal and essential element concentrations during pregnancy and associations with autism spectrum disorder and attention-deficit/hyperactivity disorder in children. Environ Int 152:106468. https://doi.org/10.1016/j.envint.2021.106468.

Skoglund A, Egelrud T. 1991. Hypersensitivity reactions to dental materials in patients with lichenoid oral mucosal lesions and in patients with burning mouth syndrome. Scand J Dent Res 99(4):320-328. https://doi.org/10.1111/j.1600-0722.1991.tb01035.x.

Skowronski GA, Turkall RM, Abdel-Rahman MS. 2000. In vitro penetration of soil-aged mercury through pig skin. J Toxicol Environ Health A 61(3):189-200.

Skröder H, Kippler M, Tofail F, et al. 2017. Early-life selenium status and cognitive function at 5 and 10 years of age in Bangladeshi children. Environ Health Perspect 125(11):1-13. https://doi.org/10.1289/ehp1691.

Sletvold H, Svendsen K, Aas O, et al. 2012. Neuropsychological function and past exposure to metallic mercury in female dental workers. Scand J Psychol 53(2):136-143. https://doi.org/10.1111/j.1467-9450.2011.00929.x.

Smith TG, Armstrong FAJ. 1975. Mercury in seals, terrestrial carnivores, and principal food items of the Inuit, from Holman, N.W.T. J Fish Res Board Can 32(6):795-802.

Smith TG, Armstrong FAJ. 1978. Mercury and selenium in ringed and bearded seal tissues from Arctic Canada. J Arctic Inst North Am 31(2):75-84.

Smith PJ, Langolf GD, Goldberg J. 1983. Effects of occupational exposure to elemental mercury on short term memory. Br J Ind Med 40(4):413-419.

Smith JC, Allen PV, Turner MD, et al. 1994. The kinetics of intravenously administered methyl mercury in man. Toxicol Appl Pharmacol 128(2):251-256. https://doi.org/10.1006/taap.1994.1204.

Smith KM, Barraj LM, Kantor M, et al. 2009. Relationship between fish intake, n-3 fatty acids, mercury and risk markers of CHD (National Health and Nutrition Examination Survey 1999-2002). Public Health Nutr 12(8):1261-1269. https://doi.org/10.1017/s1368980008003844.

Snapp KR, Boyer DB, Peterson LC, et al. 1989. The contribution of dental amalgam to mercury in blood. J Dent Res 68(5):780-785. https://doi.org/10.1177/00220345890680050501.

Snoj Tratnik J, Falnoga I, Trdin A, et al. 2017. Prenatal mercury exposure, neurodevelopment and apolipoprotein E genetic polymorphism. Environ Res 152:375-385. https://doi.org/10.1016/j.envres.2016.08.035.

Sohn SH, Heo HC, Jo S, et al. 2020. The association between mercury concentrations and lipid profiles in the Korean National Environmental Health Survey (KoNEHS) cycle 3. Ann Occup Environ Med 32:e19. https://doi.org/10.35371/aoem.2020.32.e19.

Soldin OP, O'Mara DM, Aschner M. 2008. Thyroid hormones and methylmercury toxicity. Biol Trace Elem Res 126(1-3):1-12. https://doi.org/10.1007/s12011-008-8199-3.

Solecki R, Hothorn L, Holzweissig M, et al. 1991. Computerised analysis of pathological findings in longterm trials with phenylmercuric acetate in rats. Arch Toxicol Suppl 14:100-103. https://doi.org/10.1007/978-3-642-74936-0_21.

Somers EC, Ganser MA, Warren JS, et al. 2015. Mercury exposure and antinuclear antibodies among females of reproductive age in the United States: NHANES. Environ Health Perspect 123(8):792-798. https://doi.org/10.1289/ehp.1408751.

8. REFERENCES

Sommar JN, Svensson MK, Bjor BM, et al. 2013. End-stage renal disease and low level exposure to lead, cadmium and mercury; a population-based, prospective nested case-referent study in Sweden. Environ Health 12:9. https://doi.org/10.1186/1476-069x-12-9.

Son HY, Lee S, Park SB, et al. 2010. Toxic effects of mercuric sulfide on immune organs in mice. Immunopharmacol Immunotoxicol 32(2):277-283. https://doi.org/10.3109/08923970903305499.

Song JW, Choi BS. 2013. Mercury induced the accumulation of amyloid beta (abeta) in PC12 cells: The role of production and degradation of abeta. Toxicol Res 29(4):235-240. https://doi.org/10.5487/tr.2013.29.4.235.

Song KB, Lee YE, Jeong SH, et al. 2002. Mercury distribution and concentration in rats fed powdered dental amalgam. Arch Oral Biol 47(4):307-313.

Sørensen N, Murata K, Budtz-Jorgensen E, et al. 1999. Prenatal methylmercury exposure as a cardiovascular risk factor at seven years of age. Epidemiology 10(4):370-375.

Sørensen FW, Larsen JO, Eide R, et al. 2000. Neuron loss in cerebellar cortex of rats exposed to mercury vapor: A stereological study. Acta Neuropathol (Berl) 100(1):95-100. https://doi.org/10.1007/s004010051198.

Spencer JN, Voigt AF. 1968. Thermodynamics of the solution of mercury metal. I. Tracer determination of the solubility in various liquids. J Phys Chem 72(2):464-470. https://doi.org/10.1021/j100848a012.

Spiller HA. 2018. Rethinking mercury: the role of selenium in the pathophysiology of mercury toxicity. Clin Toxicol (Phila) 56(5):313-326. https://doi.org/10.1080/15563650.2017.1400555.

Sprovieri F, Pirrone N, Bencardino M, et al. 2016. Atmospheric mercury concentrations observed at ground-based monitoring sites globally distributed in the framework of the GMOS network. Atmos Chem Phys 16(18):11915-11935. https://doi.org/10.5194/acp-16-11915-2016.

Stankovic R. 2006. Atrophy of large myelinated motor axons and declining muscle grip strength following mercury vapor inhalation in mice. Inhal Toxicol 18(1):57-69. https://doi.org/10.1080/08958370500282902.

Stein ED, Cohen Y, Winer AM. 1996. Environmental distribution and transformation of mercury compounds. Crit Rev Environ Sci 26(1):1-43. https://doi.org/10.1080/10643389609388485.

Stern AH. 1997. Estimation of the interindividual variability in the one-compartment pharmacokinetic model for methylmercury: implications for the derivation of a reference dose. Regul Toxicol Pharmacol 25(3):277-288. https://doi.org/10.1006/rtph.1997.1105.

Stern AH. 2005. Balancing the risks and benefits of fish consumption. Ann Intern Med 142(11):949.

Stern AH, Smith AE. 2003. An assessment of the cord blood:maternal blood methylmercury ratio: implications for risk assessment. Environ Health Perspect 111(12):1465-1470.

Stern S, Cox C, Cernichiari E, et al. 2001. Perinatal and lifetime exposure to methylmercury in the mouse: blood and brain concentrations of mercury to 26 months of age. Neurotoxicology 22(4):467-477.

Steuerwald U, Weihe P, Jorgensen PJ, et al. 2000. Maternal seafood diet, methylmercury exposure, and neonatal neurologic function. J Pediatr 136(5):599-605. https://doi.org/10.1067/mpd.2000.102774.

Stewart PW, Reihman J, Lonky EI, et al. 2003. Cognitive development in preschool children prenatally exposed to PCBs and MeHg. Neurotoxicol Teratol 25(1):11-22. https://doi.org/10.1016/s0892-0362(02)00320-3.

Stoiber T, Bonacker D, Bohm KJ, et al. 2004. Disturbed microtubule function and induction of micronuclei by chelate complexes of mercury(II). Mutat Res 563(2):97-106. https://doi.org/10.1016/j.mrgentox.2004.06.009.

Stoltenburg-Didinger G, Markwort S. 1990. Prenatal methylmercury exposure results in dendritic spine dysgenesis in rats. Neurotoxicol Teratol 12(6):573-576. https://doi.org/10.1016/0892-0362(90)90064-j.

Storelli MM, Giacominelli Stuffler R, Storelli A, et al. 2003. Total mercury and methylmercury content in edible fish from the Mediterranean Sea. J Food Prot 66(2):300-303.

8. REFERENCES

Storm DL. 1994. Chemical monitoring of California's public drinking water sources: Public exposures and health impacts. In: Wang RG, ed. Water contamination and health. New York, NY: Marcel Dekker, Inc, 67-124.

Strain JJ, Davidson PW, Bonham MP, et al. 2008. Associations of maternal long-chain polyunsaturated fatty acids, methyl mercury, and infant development in the Seychelles Child Development Nutrition Study. Neurotoxicology 29(5):776-782. https://doi.org/10.1016/j.neuro.2008.06.002.

Strain JJ, Davidson PW, Thurston SW, et al. 2012. Maternal PUFA status but not prenatal methylmercury exposure is associated with children's language functions at age five years in the Seychelles. J Nutr 142(11):1943-1949. https://doi.org/10.3945/jn.112.163493.

Strain JJ, Yeates AJ, van Wijngaarden E, et al. 2015. Prenatal exposure to methyl mercury from fish consumption and polyunsaturated fatty acids: associations with child development at 20 mo of age in an observational study in the Republic of Seychelles. Am J Clin Nutr 101(3):530-537. https://doi.org/10.3945/ajcn.114.100503.

Strain JJ, Love TM, Yeates AJ, et al. 2021. Associations of prenatal methylmercury exposure and maternal polyunsaturated fatty acid status with neurodevelopmental outcomes at 7 years of age: results from the Seychelles Child Development Study Nutrition Cohort 2. Am J Clin Nutr 113(2):304-313. https://doi.org/10.1093/ajcn/nqaa338.

Stratakis N, Golden-Mason L, Margetaki K, et al. 2021. In utero exposure to mercury is associated with increased susceptibility to liver injury and inflammation in childhood. Hepatology 74(3):1546-1559. https://doi.org/10.1002/hep.31809.

Streets DG, Horowitz HM, Jacob DJ, et al. 2017. Total mercury released to the environment by human activities. Environ Sci Technol 51(11):5969-5977. https://doi.org/10.1021/acs.est.7b00451.

Su M, Wakabayashi K, Kakita A, et al. 1998. Selective involvement of large motor neurons in the spinal cord of rats treated with methylmercury. J Neurol Sci 156(1):12-17. https://doi.org/10.1016/s0022-510x(98)00030-6.

Subhavana KL, Qureshi A, Roy A. 2019. Mercury levels in human hair in South India: baseline, artisanal goldsmiths and coal-fired power plants. J Expo Sci Environ Epidemiol 29(5):697-705. https://doi.org/10.1038/s41370-018-0107-0.

Suda I, Hirayama K. 1992. Degradation of methyl and ethyl mercury into inorganic mercury by hydroxyl radical produced from rat liver microsomes. Arch Toxicol 66(6):398-402.

Suda I, Totoki S, Uchida T, et al. 1992. Degradation of methyl and ethyl mercury into inorganic mercury by various phagocytic cells. Arch Toxicol 66(1):40-44.

Suda I, Suda M, Hirayama K. 1993. Phagocytic cells as a contributor to in vivo degradation of alkyl mercury. Bull Environ Contam Toxicol 51(3):394-400. https://doi.org/10.1007/bf00201758.

Sugawara N, Lai YR, Sugaware C, et al. 1998. Decreased hepatobiliary secretion of inorganic mercury, its deposition and toxicity in the Eisai hyperbilirubinemic rat with no hepatic canalicular organic anion transporter. Toxicology 126(1):23-31.

Sukhn C, Awwad J, Ghantous A, et al. 2018. Associations of semen quality with non-essential heavy metals in blood and seminal fluid: Data from the environment and male infertility (EMI) study in Lebanon. J Assist Reprod Genet 35:1691-1701. https://doi.org/10.1007/s10815-018-1236-z.

Sumino K, Hayakawa K, Shibata T, et al. 1975. Heavy metals in normal Japanese tissues: Amounts of 15 heavy metals in 30 subjects. Arch Environ Health 30(10):487-494.

Sun YH, Nfor ON, Huang JY, et al. 2015. Association between dental amalgam fillings and Alzheimer's disease: a population-based cross-sectional study in Taiwan. Alzheimers Res Ther 7(1):65. https://doi.org/10.1186/s13195-015-0150-1.

Sun B, Fan S, Yao K, et al. 2018. Changes in intraepidermal nerve fiber and Langerhans cell densities in the plantar skin of rats after mercuric chloride exposure. J Peripher Nerv Syst 23(1):17-22. https://doi.org/10.1111/jns.12246.

Sun Y, Zhou Q, Zheng J. 2019. Nephrotoxic metals of cadmium, lead, mercury and arsenic and the odds of kidney stones in adults: An exposure-response analysis of NHANES 2007-2016. Environ Int 132:105115. https://doi.org/10.1016/j.envint.2019.105115.

8. REFERENCES

Sun Y, Liu B, Rong S, et al. 2021. Association of seafood consumption and mercury exposure with cardiovascular and all-cause mortality among US adults. JAMA Netw Open 4(11):e2136367. https://doi.org/10.1001/jamanetworkopen.2021.36367.

Sundberg J, Oskarsson A, Albanus L. 1991. Methylmercury exposure during lactation: milk concentration and tissue uptake of mercury in the neonatal rat. Bull Environ Contam Toxicol 46(2):255-262.

Sundberg J, Jonsson S, Karlsson MO, et al. 1998. Kinetics of methylmercury and inorganic mercury in lactating and nonlactating mice. Toxicol Appl Pharmacol 151(2):319-329. https://doi.org/10.1006/taap.1998.8456.

Sundberg J, Jonsson S, Karlsson MO, et al. 1999. Lactational exposure and neonatal kinetics of methylmercury and inorganic mercury in mice. Toxicol Appl Pharmacol 154(2):160-169. https://doi.org/10.1006/taap.1998.8566.

Sunderman FW. 1978. Clinical response to therapeutic agents in poisoning from mercury vapor. Ann Clin Lab Sci 8(4):259-269.

Surkan PJ, Wypij D, Trachtenberg F, et al. 2009. Neuropsychological function in school-age children with low mercury exposures. Environ Res 109(6):728-733. https://doi.org/10.1016/j.envres.2009.04.006.

Suter KE. 1975. Studies on the dominant-lethal and fertility effects of the heavy metal compounds methylmercuric hydroxide, mercuric chloride, and cadmium chloride in male and female mice. Mutat Res 30(3):365-374.

Suvarapu LN, Baek SO. 2017. Recent studies on the speciation and determination of mercury in different environmental matrices using various analytical techniques. Int J Anal Chem 2017:1-28. https://doi.org/10.1155/2017/3624015.

Suzuki T, Matsumoto N, Miyama T, et al. 1967. Placental transfer of mercuric chloride, phenyl mercury acetate and methyl mercury acetate in mice. Ind Health 5:149-155.

Suzuki T, Miyama T, Katsunuma H. 1970. Comparison of mercury contents in maternal blood, umbilical cord blood, and placental tissues. Bull Environ Contam Toxicol 5(6):502-508. https://doi.org/10.1007/bf01539978.

Suzuki T, Watanabe S, Matsuo N. 1989. Comparison of hair with nail as index media for biological monitoring of mercury. Sangyo Igaku 31(4):235-238. https://doi.org/10.1539/joh1959.31.235.

Swain EB, Engstrom DR, Brigham ME, et al. 1992. Increasing rates of atmospheric mercury deposition in midcontinental North America. Science 257(5071):784-787. https://doi.org/10.1126/science.257.5071.784.

Sweeney LM, Gearhart JM. 2020. Examples of physiologically based pharmacokinetic modeling applied to risk assessment. In: Fisher JW, Gearhart JM, Lin Z, eds. Physiologically based pharmacokinetic (PBPK) modeling. Elsevier, Inc., 281-299. https://doi.org/10.1016/B978-0-12-818596-4.00011-4.

Syversen T, Kaur P. 2012. The toxicology of mercury and its compounds. J Trace Elem Med Biol 26(4):215-226. https://doi.org/10.1016/j.jtemb.2012.02.004.

Szász A, Barna B, Gajda Z, et al. 2002. Effects of continuous low-dose exposure to organic and inorganic mercury during development on epileptogenicity in rats. Neurotoxicology 23(2):197-206. https://doi.org/10.1016/s0161-813x(02)00022-0.

Takahashi H, Takahashi H, Nomiyama K. 2000a. Mercury exposure does not elevate systolic blood pressure in normotensive rats. J Trace Elem Exp Med 13:239-247.

Takahashi H, Nomiyama H, Nomiyama K. 2000b. Mercury elevates systolic blood pressure in spontaneously hypertensive rats. J Trace Elem Exp Med 13:227-237.

Takahashi Y, Tsuruta S, Hasegawa J, et al. 2001. Release of mercury from dental amalgam fillings in pregnant rats and distribution of mercury in maternal and fetal tissues. Toxicology 163(2-3):115-126.

Takatani T, Eguchi A, Yamamoto M, et al. 2022. Individual and mixed metal maternal blood concentrations in relation to birth size: An analysis of the Japan Environment and Children's Study (JECS). Environ Int 165:107318. https://doi.org/10.1016/j.envint.2022.107318.

8. REFERENCES

Takeuchi H, Shiota Y, Yaoi K, et al. 2022a. Mercury levels in hair are associated with reduced neurobehavioral performance and altered brain structures in young adults. Commun Biol 5(1):529. https://doi.org/10.1038/s42003-022-03464-z.

Takeuchi H, Shiota Y, Yaoi K, et al. 2022b. Supplemental material: Mercury levels in hair are associated with reduced neurobehavioral performance and altered brain structures in young adults. Commun Biol 5(1) https://doi.org/10.1038/s42003-022-03464-z.

Takeuchi M, Yoshida S, Kawakami C, et al. 2022c. Association of maternal heavy metal exposure during pregnancy with isolated cleft lip and palate in offspring: Japan Environment and Children's Study (JECS) cohort study. PLoS ONE 17(3):e0265648. https://doi.org/10.1371/journal.pone.0265648.

Tamashiro H, Arakaki M, Akagi H, et al. 1985. Mortality and survival for Minamata disease. Int J Epidemiol 14(4):582-588. https://doi.org/10.1093/ije/14.4.582.

Tamashiro H, Arakaki M, Akagi H, et al. 1986. Effects of ethanol on methyl mercury toxicity in rats. J Toxicol Environ Health 18(4):595-605. https://doi.org/10.1080/15287398609530897.

Tan SW, Meiller JC, Mahaffey KR. 2009. The endocrine effects of mercury in humans and wildlife. Crit Rev Toxicol 39(3):228-269. https://doi.org/10.1080/10408440802233259.

Tan YM, Chan M, Chukwudebe A, et al. 2020. PBPK model reporting template for chemical risk assessment applications. Regul Toxicol Pharmacol 115:104691. https://doi.org/10.1016/j.yrtph.2020.104691.

Tan Y, Fu Y, Huang F, et al. 2023. Association between blood metal exposures and hyperuricemia in the U.S. general adult: A subgroup analysis from NHANES. Chemosphere 318:137873. https://doi.org/10.1016/j.chemosphere.2023.137873.

Tanaka T, Naganuma A, Imura N. 1990. Role of gamma-glutamyltranspeptidase in renal uptake and toxicity of inorganic mercury in mice. Toxicology 60(3):187-198. https://doi.org/10.1016/0300-483x(90)90142-4.

Tanaka T, Naganuma A, Imura N. 1992. Routes for renal transport of methylmercury in mice. Eur J Pharmacol 228(1):9-14.

Tanaka-Kagawa T, Naganuma A, Imura N. 1993. Tubular secretion and reabsorption of mercury compounds in mouse kidney. J Pharmacol Exp Ther 264(2):776-782.

Tang N, Li YM. 2006. Neurotoxic effects in workers of the clinical thermometer manufacture plant. Int J Occup Med Environ Health 19(3):198-202. https://doi.org/10.2478/v10001-006-0023-8.

Tang M, Xu C, Lin N, et al. 2016. Lead, mercury, and cadmium in umbilical cord serum and birth outcomes in Chinese fish consumers. Chemosphere 148:270-275. https://doi.org/10.1016/j.chemosphere.2016.01.058.

Tang J, Zhu Q, Xu Y, et al. 2022a. Total arsenic, dimethylarsinic acid, lead, cadmium, total mercury, methylmercury and hypertension among Asian populations in the United States: NHANES 2011-2018. Ecotoxicol Environ Saf 241:113776. https://doi.org/10.1016/j.ecoenv.2022.113776.

Tang Y, Yi Q, Wang S, et al. 2022b. Normal concentration range of blood mercury and bone mineral density: a cross-sectional study of National Health and Nutrition Examination Survey (NHANES) 2005-2010. Environ Sci Pollut Res Int 29(5):7743-7757. https://doi.org/10.1007/s11356-021-16162-w.

Tarabar AF, Su M. 2003. Mercury and cadmium toxicity in a Haitian voodoo minister that resulted in acute renal failure. J Toxicol Clin Toxicol 41(5):741-742.

Tatsuta N, Kurokawa N, Nakai K, et al. 2017. Effects of intrauterine exposures to polychlorinated biphenyls, methylmercury, and lead on birth weight in Japanese male and female newborns. Environ Health Prev Med 22(1):39. https://doi.org/10.1186/s12199-017-0635-6.

Tatsuta N, Iwai-Shimada M, Nakayama SF, et al. 2022. Association between whole blood metallic elements concentrations and gestational diabetes mellitus in Japanese women: The Japan environment and Children's study. Environ Res 212(Pt B):113231. https://doi.org/10.1016/j.envres.2022.113231.

8. REFERENCES

Taylor CM, Golding J, Emond AM. 2016. Blood mercury levels and fish consumption in pregnancy: Risks and benefits for birth outcomes in a prospective observational birth cohort. Int J Hyg Environ Health 219(6):513-520. https://doi.org/10.1016/j.ijheh.2016.05.004.

Taylor CM, Emond AM, Lingam R, et al. 2018a. Prenatal lead, cadmium and mercury exposure and associations with motor skills at age 7 years in a UK observational birth cohort. Environ Int 117:40-47. https://doi.org/10.1016/j.envint.2018.04.032.

Taylor VF, Buckman KL, Seelen EA, et al. 2018b. Organic carbon content drives methylmercury levels in the water column and in estuarine food webs across latitudes in the Northeast United States. Environ Pollut 246:639-649. https://doi.org/10.1016/j.envpol.2018.12.064.

Teisinger J, Fiserova-Bergerova V. 1965. Pulmonary retention and excretion of mercury vapors in man. Ind Med Surg 34:580-584.

Teixeira FB, Fernandes RM, Farias-Junior PM, et al. 2014. Evaluation of the effects of chronic intoxication with inorganic mercury on memory and motor control in rats. Int J Environ Res Public Health 11(9):9171-9185. https://doi.org/10.3390/ijerph110909171.

Teixeira FB, de Oliveira ACA, Leão LKR, et al. 2018. Exposure to inorganic mercury causes oxidative stress, cell death, and functional deficits in the motor cortex. Front Mol Neurosci 11:1-11. https://doi.org/10.3389/fnmol.2018.00125.

Teixeira FB, Leão LKR, Bittencourt LO, et al. 2019. Neurochemical dysfunction in motor cortex and hippocampus impairs the behavioral performance of rats chronically exposed to inorganic mercury. J Trace Elem Med Biol 52:143-150. https://doi.org/10.1016/j.jtemb.2018.12.008.

Teng CT, Brennan JC. 1959. Acute mercury vapor poisoning. Radiology 73(3):354-361. https://doi.org/10.1148/73.3.354.

Tennant R, Johnston HJ, Wells JB. 1961. Acute bilateral pneumonitis associated with the inhalation of mercury vapor. Report of five cases. Conn Med 25:106-109.

Thanyavuthi A, Boonchai W, Kasemsarn P. 2016. Amalgam contact allergy in oral lichenoid lesions. Dermatitis 27(4):215-221. https://doi.org/10.1097/der.0000000000000204.

Thera JC, Rumbold DG. 2014. Biomagnification of mercury through a subtropical coastal food web off southwest Florida. Environ Toxicol Chem 33(1):65-73. https://doi.org/10.1002/etc.2416.

Theunissen PT, Pennings JL, Robinson JF, et al. 2011. Time-response evaluation by transcriptomics of methylmercury effects on neural differentiation of murine embryonic stem cells. Toxicol Sci 122(2):437-447. https://doi.org/10.1093/toxsci/kfr134.

Thomas DJ, Smith JC. 1979. Partial characterization of a low-molecular weight methylmercury complex in rat cerebrum. Toxicol Appl Pharmacol 47(3):547-556.

Thomas DJ, Smith JC. 1982. Effects of coadministered low-molecular-weight thiol compounds on short-term distribution of methyl mercury in the rat. Toxicol Appl Pharmacol 62(1):104-110.

Thomas DJ, Fisher HL, Sumler MR, et al. 1986. Sexual differences in the distribution and retention of organic and inorganic mercury in methyl mercury-treated rats. Environ Res 41(1):219-234.

Thurston SW, Bovet P, Myers GJ, et al. 2007. Does prenatal methylmercury exposure from fish consumption affect blood pressure in childhood? Neurotoxicology 28(5):924-930. https://doi.org/10.1016/j.neuro.2007.06.002.

Thurston SW, Myers G, Mruzek D, et al. 2022. Associations between time-weighted postnatal methylmercury exposure from fish consumption and neurodevelopmental outcomes through 24 years of age in the Seychelles Child Development Study Main Cohort. Neurotoxicology 91:234-244. https://doi.org/10.1016/j.neuro.2022.05.016.

Thuvander A, Sundberg J, Oskarsson A. 1996. Immunomodulating effects after perinatal exposure to methylmercury in mice. Toxicology 114(2):163-175. https://doi.org/10.1016/s0300-483x(96)03486-5.

Tian W, Egeland GM, Sobol I, et al. 2011. Mercury hair concentrations and dietary exposure among Inuit preschool children in Nunavut, Canada. Environ Int 37(1):42-48. https://doi.org/10.1016/j.envint.2010.05.017.

Tian T, Yin S, Jin L, et al. 2021. Single and mixed effects of metallic elements in maternal serum during pregnancy on risk for fetal neural tube defects: A Bayesian kernel regression approach. Environ Pollut 285:117203. https://doi.org/10.1016/j.envpol.2021.117203.

Tibau AV, Grube BD. 2019. Mercury contamination from dental amalgam. J Health Pollut 9(22):190612. https://doi.org/10.5696/2156-9614-9.22.190612.

Timmermann CAG, Choi AL, Petersen MS, et al. 2017. Secondary sex ratio in relation to exposures to polychlorinated biphenyls, dichlorodiphenyl dichloroethylene and methylmercury. Int J Circumpolar Health 76(1):1-8. https://doi.org/10.1080/22423982.2017.1406234.

Tiwari SM, Gebauer K, Frydrych AM, et al. 2018. Dental patch testing in patients with undifferentiated oral lichen planus. Australas J Dermatol 59:188-193. https://doi.org/10.1111/ajd.12692.

Tonk EC, de Groot DM, Penninks AH, et al. 2010. Developmental immunotoxicity of methylmercury: the relative sensitivity of developmental and immune parameters. Toxicol Sci 117(2):325-335. https://doi.org/10.1093/toxsci/kfq223.

Toribara TY, Clarkson TW, Nierenberg DW. 1997. More on working with dimethylmercury. Chem Eng News 75(24):3, 6, 11, 12.

Trachtenberg F, Barregard L, McKinlay S. 2010. The influence of urinary flow rate on mercury excretion in children. J Trace Elem Med Biol 24(1):31-35. https://doi.org/10.1016/j.jtemb.2009.06.003.

Trasande L, Landrigan PJ, Schechter C. 2005. Public health and economic consequences of methyl mercury toxicity to the developing brain. Environ Health Perspect 113(5):590-596.

TRI22. 2024. TRI explorer: Providing access to EPA's toxics release inventory data. Washington, DC: Toxics Release Inventory. U.S. Environmental Protection Agency. http://www.epa.gov/triexplorer/. March 15, 2023.

Trotter R. 1985. Greta and azarcon: A survey of episodic lead poisoning from a folk remedy. Hum Organ 44(1):64-72. https://doi.org/10.17730/humo.44.1.u448k01428282555.

Tsai TL, Kuo CC, Pan WH, et al. 2019. Type 2 diabetes occurrence and mercury exposure - From the National Nutrition and Health Survey in Taiwan. Environ Int 126:260-267. https://doi.org/10.1016/j.envint.2019.02.038.

Tseng CF, Chen KH, Yu HC, et al. 2020a. Dental amalgam fillings and multiple sclerosis: A nationwide population-based case-control study in Taiwan. Int J Environ Res Public Health 17(8):2637. https://doi.org/10.3390/ijerph17082637.

Tseng CF, Chen KH, Yu HC, et al. 2020b. Association between dental amalgam filling and essential tremor: A nationwide population-based case control study in Taiwan. Int J Environ Res Public Health 17(3):780. https://doi.org/10.3390/ijerph17030780.

Tsuji JS, Williams PR, Edwards MR, et al. 2003. Evaluation of mercury in urine as an indicator of exposure to low levels of mercury vapor. Environ Health Perspect 111(4):623-630.

Tsuji M, Shibata E, Morokuma S, et al. 2018. The association between whole blood concentrations of heavy metals in pregnant women and premature births: The Japan Environment and Children's Study (JECS). Environ Res 166:562-569. https://doi.org/10.1016/j.envres.2018.06.025.

Tsuji M, Shibata E, Askew DJ, et al. 2019. Associations between metal concentrations in whole blood and placenta previa and placenta accreta: the Japan Environment and Children's Study (JECS). Environ Health Prev Med 24(1):40. https://doi.org/10.1186/s12199-019-0795-7.

Tuček M, Bušová M, Čejchanová M, et al. 2020. Exposure to mercury from dental amalgam: actual contribution for risk assessment. Cent Eur J Public Health 28(1):40-43. https://doi.org/10.21101/cejph.a5965.

Turner RR, Bogle MA. 1993. Ambient air monitoring for mercury around an industrial complex. In: Chow W, Connor KK, eds. Managing hazardous air pollutants state of the art. Boca Raton, FL: Lewis Publishers, 162-172.

Turner RR, Mitchell CPJ, Kopec AD, et al. 2018. Tidal fluxes of mercury and methylmercury for Mendall Marsh, Penobscot River estuary, Maine. Sci Total Environ 637-638:145-154. https://doi.org/10.1016/j.scitotenv.2018.04.395.

8. REFERENCES

U.S. Atomic Energy Commission. 1961. Studies on the equilibration of mercury vapor with blood. UR
        Reports. U.S. Atomic Energy Commission. UR-582.

Uchikawa T, Kanno T, Maruyama I, et al. 2016. Demethylation of methylmercury and the enhanced
        production of formaldehyde in mouse liver. J Toxicol Sci 41(4):479-487.
        https://doi.org/10.2131/jts.41.479.

Uchino M, Hirano T, Satoh H, et al. 2005. The severity of Minamata disease declined in 25 years:
        temporal profile of the neurological findings analyzed by multiple logistic regression model.
        Tohoku J Exp Med 205(1):53-63.

UNEP. 2018. Global mercury assessment 2018. Geneva, Switzerland: United Nations Environment
        Programme. https://www.unep.org/resources/publication/global-mercury-assessment-2018. August
        20, 2021.

Urano T, Iwasaki A, Himeno S, et al. 1990. Absorption of methylmercury compounds from rat intestine.
        Toxicol Lett 50(2-3):159-164.

Urban P, Gobba F, Nerudova J, et al. 2003. Color discrimination impairment in workers exposed to
        mercury vapor. Neurotoxicology 24(4-5):711-716. https://doi.org/10.1016/s0161-813x(03)00036-6.

Ursitti F, Marano M, Locatelli CA, et al. 2022. Developmental regression, hypertension, and pink
        extremities in childhood mercury poisoning. Neuropediatrics 53(6):448-450.
        https://doi.org/10.1055/a-1788-7340.

USGS. 1997. Mercury. United States Geological Survey.

USGS. 2013. Mineral commodity summaries, January 2013. U.S. Geological Survey.
        https://doi.org/10.3133/mineral2013.

USGS. 2014. Mercury in the nation's streams - levels, trends, and implications. Reston, VA: U.S.
        Geological Survey. Circular 1395. https://doi.org/10.3133/cir1395.

USGS. 2016. Mercury concentrations in water and mercury and selenium concentrations in fish from
        Brownlee Reservoir and selected sites in Boise and Snake Rivers, Idaho and Oregon, 2013-15. U.S.
        Geological Survey. Open-File Report 2016–1098. https://doi.org/10.3133/ofr20161098.

USGS. 2020. Mineral commodity summaries, January 2020. U.S. Geological Survey.
        https://pubs.usgs.gov/periodicals/mcs2020/mcs2020.pdf. January 21, 2021.

USGS. 2023a. Mineral commodity summaries 2023. Reston, VA: U.S. Geological Survey.
        https://doi.org/10.3133/mcs2023.

USGS. 2023b. Great lakes sediment surveillance program: mercury concentrations and mercury stable
        isotopes in sediments of the Laurentian Great Lakes. U.S. Geological Survey.
        https://doi.org/10.5066/P9VB8GO6.

Usuki F, Yasutake A, Matsumoto M, et al. 1998. The effect of methylmercury on skeletal muscle in the
        rat: A histopathological study. Toxicol Lett 94(3):227-232. https://doi.org/10.1016/s0378-
        4274(98)00022-8.

Vahter M, Mottet NK, Friberg L, et al. 1994. Speciation of mercury in the primate blood and brain
        following long-term exposure to methyl mercury. Toxicol Appl Pharmacol 124(2):221-229.
        https://doi.org/10.1006/taap.1994.1026.

Vahter ME, Mottet NK, Friberg LT, et al. 1995. Demethylation of methyl mercury in different brain
        sites of Macaca fascicularis monkeys during long-term subclinical methyl mercury exposure.
        Toxicol Appl Pharmacol 134(2):273-284. https://doi.org/10.1006/taap.1995.1193.

Vahter M, Akesson A, Lind B, et al. 2000. Longitudinal study of methylmercury and inorganic mercury
        in blood and urine of pregnant and lactating women, as well as in umbilical cord blood. Environ Res
        84(2):186-194. https://doi.org/10.1006/enrs.2000.4098.

Valcke M, Ouellet N, Dubé M, et al. 2019. Biomarkers of cadmium, lead and mercury exposure in
        relation with early biomarkers of renal dysfunction and diabetes: Results from a pilot study among
        aging Canadians. Toxicol Lett 312:148-156. https://doi.org/10.1016/j.toxlet.2019.05.014.

Valent F, Mariuz M, Bin M, et al. 2013. Associations of prenatal mercury exposure from maternal fish
        consumption and polyunsaturated fatty acids with child neurodevelopment: a prospective cohort
        study in Italy. J Epidemiol 23(5):360-370. https://doi.org/10.2188/jea.je20120168.

8. REFERENCES

Valera B, Dewailly E, Poirier P. 2008. Cardiac autonomic activity and blood pressure among Nunavik Inuit adults exposed to environmental mercury: a cross-sectional study. Environ Health 7:29. https://doi.org/10.1186/1476-069x-7-29.

Valera B, Dewailly E, Poirier P. 2009. Environmental mercury exposure and blood pressure among Nunavik Inuit adults. Hypertension 54(5):981-986. https://doi.org/10.1161/hypertensionaha.109.135046.

Valera B, Dewailly E, Poirier P, et al. 2011a. Influence of mercury exposure on blood pressure, resting heart rate and heart rate variability in French Polynesians: a cross-sectional study. Environ Health 10:99. https://doi.org/10.1186/1476-069x-10-99.

Valera B, Dewailly E, Poirier P. 2011b. Impact of mercury exposure on blood pressure and cardiac autonomic activity among Cree adults (James Bay, Quebec, Canada). Environ Res 111(8):1265-1270. https://doi.org/10.1016/j.envres.2011.09.001.

Valera B, Muckle G, Poirier P, et al. 2012. Cardiac autonomic activity and blood pressure among Inuit children exposed to mercury. Neurotoxicology 33(5):1067-1074.

Valera B, Dewailly E, Poirier P. 2013. Association between methylmercury and cardiovascular risk factors in a native population of Quebec (Canada): a retrospective evaluation. Environ Res 120:102-108. https://doi.org/10.1016/j.envres.2012.08.002.

van Wijngaarden E, Beck C, Shamlaye CF, et al. 2006. Benchmark concentrations for methyl mercury obtained from the 9-year follow-up of the Seychelles Child Development Study. Neurotoxicology 27(5):702-709. https://doi.org/10.1016/j.neuro.2006.05.016.

van Wijngaarden E, Myers GJ, Thurston SW, et al. 2009. Interpreting epidemiological evidence in the presence of multiple endpoints: an alternative analytic approach using the 9-year follow-up of the Seychelles child development study. Int Arch Occup Environ Health 82(8):1031-1041. https://doi.org/10.1007/s00420-009-0402-0.

van Wijngaarden E, Davidson PW, Smith TH, et al. 2013. Autism spectrum disorder phenotypes and prenatal exposure to methylmercury. Epidemiology 24(5):651-659. https://doi.org/10.1097/EDE.0b013e31829d2651.

van Wijngaarden E, Harrington D, Kobrosly R, et al. 2014. Prenatal exposure to methylmercury and LCPUFA in relation to birth weight. Ann Epidemiol 24(4):273-278. https://doi.org/10.1016/j.annepidem.2014.01.002.

van Wijngaarden E, Thurston SW, Myers GJ, et al. 2017. Methyl mercury exposure and neurodevelopmental outcomes in the Seychelles Child Development Study Main cohort at age 22 and 24 years. Neurotoxicol Teratol 59:35-42. https://doi.org/10.1016/j.ntt.2016.10.011.

Vandal GM, Mason RP, Fitzgerald WF. 1991. Cycling of volatile mercury in temperate lakes. Water Air Soil Pollut 56(1):791-803. https://doi.org/10.1007/bf00342317.

Vas J, Monestier M. 2008. Immunology of mercury. Ann N Y Acad Sci 1143:240-267. https://doi.org/10.1196/annals.1443.022.

Vasquez C. 2012. Human skull, bones found at site of horse slaughter investigation. Local10. http://www.local10.com/news/Human-skull-bones-found-at-site-of-horse-slaughter-investigation/-/1717324/10536270/-/foq2vmz/-/index.html. May 17, 2021.

Vassallo DV, Simoes MR, Furieri LB, et al. 2011. Toxic effects of mercury, lead and gadolinium on vascular reactivity. Braz J Med Biol Res 44(9):939-946.

Vazquez M, Velez D, Devesa V. 2014. In vitro characterization of the intestinal absorption of methylmercury using a Caco-2 cell model. Chem Res Toxicol 27(2):254-264. https://doi.org/10.1021/tx4003758.

Vazquez M, Velez D, Devesa V, et al. 2015. Participation of divalent cation transporter DMT1 in the uptake of inorganic mercury. Toxicology 331:119-124. https://doi.org/10.1016/j.tox.2015.03.005.

Vejrup K, Schjolberg S, Knutsen HK, et al. 2016. Prenatal methylmercury exposure and language delay at three years of age in the Norwegian Mother and Child Cohort Study. Environ Int 92-93:63-69. https://doi.org/10.1016/j.envint.2016.03.029.

8. REFERENCES

Vejrup K, Brandlistuen RE, Brantsaeter AL, et al. 2018. Prenatal mercury exposure, maternal seafood consumption and associations with child language at five years. Environ Int 110:71-79. https://doi.org/10.1016/j.envint.2017.10.008.

Vejrup K, Brantsæter AL, Meltzer HM, et al. 2022. Prenatal mercury exposure, fish intake and child emotional behavioural regulation in the Norwegian Mother, Father and Child Cohort Study. BMJ Nutr Prev Health 5(2):313-320. https://doi.org/10.1136/bmjnph-2021-000412.

Venter C, Olivier A, Taute H, et al. 2020. Histological analysis of the effects of cadmium, chromium and mercury alone and in combination on the spleen of male Sprague-Dawley rats. J Environ Sci Health A Tox Hazard Subst Environ Eng 55(8):925-934. https://doi.org/10.1080/10934529.2020.1756158.

Ventura DF, Costa MT, Costa MF, et al. 2004. Multifocal and full-field electroretinogram changes associated with color-vision loss in mercury vapor exposure. Vis Neurosci 21(3):421-429.

Ventura DF, Simoes AL, Tomaz S, et al. 2005. Colour vision and contrast sensitivity losses of mercury intoxicated industry workers in Brazil. Environ Toxicol Pharmacol 19(3):523-529. https://doi.org/10.1016/j.etap.2004.12.016.

Verberk MM, SallÉ HJA, Kemper CH. 1986. Tremor in workers with low exposure to metallic mercury. Am Ind Hyg Assoc J 47(9):559-562. https://doi.org/10.1080/15298668691390232.

Verger P, Houdart S, Marette S, et al. 2007. Impact of a risk-benefit advisory on fish consumption and dietary exposure to methylmercury in France. Regul Toxicol Pharmacol 48(3):259-269. https://doi.org/10.1016/j.yrtph.2007.04.005.

Verschaeve L, Kirsch-Volders M, Susanne C, et al. 1976. Genetic damage induced by occupationally low mercury exposure. Environ Res 12(3):306-316.

Verschaeve L, Tassignon JP, Lefevre M, et al. 1979. Cytogenetic investigation on leukocytes of workers exposed to metallic mercury. Environ Mutagen 1(3):259-268. https://doi.org/10.1002/em.2860010308.

Verschueren K. 1983. Mercury. In: Handbook of environmental data on organic chemicals. 2nd ed. New York, NY: Van Nostrand Reinhold Co, 991-992.

Verschuuren HG, Kroes R, Den Tonkelaar EM, et al. 1976. Toxicity of methylmercury chloride in rats. III. Long-term toxicity study. Toxicology 6(1):107-123. https://doi.org/10.1016/0300-483x(76)90012-3.

Vezér T, Papp A, Kurunczi A, et al. 2005. Behavioral and neurotoxic effects seen during and after subchronic exposure of rats to organic mercury. Environ Toxicol Pharmacol 19(3):785-796. https://doi.org/10.1016/j.etap.2004.12.045.

Vigeh M, Nishioka E, Ohtani K, et al. 2018. Prenatal mercury exposure and birth weight. Reprod Toxicol 76:78-83. https://doi.org/10.1016/j.reprotox.2018.01.002.

Vilagi I, Doczi J, Banczerowski-Pelyhe I. 2000. Altered electrophysiological characteristics of developing rat cortical neurones after chronic methylmercury chloride treatment. Int J Dev Neurosci 18(6):493-499. https://doi.org/10.1016/s0736-5748(00)00027-7.

Vimercati L, Santarelli L, Pesola G, et al. 2001. Monocyte-macrophage system and polymorphonuclear leukocytes in workers exposed to low levels of metallic mercury. Sci Total Environ 270(1-3):157-163. https://doi.org/10.1016/s0048-9697(00)00780-4.

Vimy MJ, Takahashi Y, Lorscheider FL. 1990. Maternal-fetal distribution of mercury (203Hg) released from dental amalgam fillings. Am J Physiol Regul Integr Comp Physiol 258(4):R939-R945. https://doi.org/10.1152/ajpregu.1990.258.4.R939.

Virtanen JK, Voutilainen S, Rissanen TH, et al. 2005. Mercury, fish oils, and risk of acute coronary events and cardiovascular disease, coronary heart disease, and all-cause mortality in men in eastern Finland. Arterioscler Thromb Vasc Biol 25(1):228-233. https://doi.org/10.1161/01.atv.0000150040.20950.61.

Virtanen JK, Rissanen TH, Voutilainen S, et al. 2007. Mercury as a risk factor for cardiovascular diseases. J Nutr Biochem 18(2):75-85. https://doi.org/10.1016/j.jnutbio.2006.05.001.

8. REFERENCES

Virtanen JK, Laukkanen JA, Mursu J, et al. 2012a. Serum long-chain n-3 polyunsaturated fatty acids, mercury, and risk of sudden cardiac death in men: A prospective population-based study. PLoS ONE 7(7):e41046. https://doi.org/10.1371/journal.pone.0041046.

Virtanen JK, Nyantika AN, Kauhanen J, et al. 2012b. Serum long-chain n-3 polyunsaturated fatty acids, methylmercury and blood pressure in an older population. Hypertens Res 35(10):1000-1004. https://doi.org/10.1038/hr.2012.80.

Vogel DG, Margolis RL, Mottet NK. 1985. The effects of methyl mercury binding to microtubules. Toxicol Appl Pharmacol 80(3):473-486. https://doi.org/10.1016/0041-008x(85)90392-8.

Vollset M, Iszatt N, Enger Ø, et al. 2019. Concentration of mercury, cadmium, and lead in breast milk from Norwegian mothers: Association with dietary habits, amalgam and other factors. Sci Total Environ 677:466-473. https://doi.org/10.1016/j.scitotenv.2019.04.252.

Vupputuri S, Longnecker MP, Daniels JL, et al. 2005. Blood mercury level and blood pressure among US women: results from the National Health and Nutrition Examination Survey 1999-2000. Environ Res 97(2):195-200. https://doi.org/10.1016/j.envres.2004.05.001.

Wagemann R, Lockhart WL, Welch H, et al. 1995. Arctic marine mammals as integrators and indicators of mercury in the arctic. In: Porcella DB, Wheatley B, eds. Mercury as a global pollutant. Proceedings of the Third International Conference Whistler, British Columbia, July 10-14, 1994. Boston, MA: Kluwer Academic Publishers, 683-693.

Wahlberg JE. 1965. Percutaneous toxicity of metal compounds. A comparative investigation in guinea pigs. Arch Environ Health 11(2):201-204. https://doi.org/10.1080/00039896.1965.10664198.

Wahlberg K, Love TM, Pineda D, et al. 2018. Maternal polymorphisms in glutathione-related genes are associated with maternal mercury concentrations and early child neurodevelopment in a population with a fish-rich diet. Environ Int 115:142-149. https://doi.org/10.1016/j.envint.2018.03.015.

Wakita Y. 1987. Hypertension induced by methyl mercury in rats. Toxicol Appl Pharmacol 89(1):144-147. https://doi.org/10.1016/0041-008x(87)90185-2.

Walker EV, Girgis S, Yuan Y, et al. 2021. Community-driven research in the Canadian Arctic: dietary exposure to methylmercury and gastric health outcomes. Int J Circumpolar Health 80(1):1889879. https://doi.org/10.1080/22423982.2021.1889879.

Wands JR, Weiss SW, Yardley JH, et al. 1974. Chronic inorganic mercury poisoning due to laxative abuse: A clinical and ultrastructural study. Am J Med 57(1):92-101. https://doi.org/10.1016/0002-9343(74)90773-6.

Wang JS, Huang PM, Liaw WK, et al. 1991. Kinetics of the desorption of mercury from selected freshwater sediments as influenced by chloride. Water Air Soil Pollut 56(1):533-542. https://doi.org/10.1007/bf00342297.

Wang W, Clarkson TW, Ballatori N. 2000. gamma-Glutamyl transpeptidase and l-cysteine regulate methylmercury uptake by HepG2 cells, a human hepatoma cell line. Toxicol Appl Pharmacol 168(1):72-78. https://doi.org/10.1006/taap.2000.9018.

Wang Y, Goodrich JM, Werner R, et al. 2012. An investigation of modifying effects of single nucleotide polymorphisms in metabolism-related genes on the relationship between peripheral nerve function and mercury levels in urine and hair. Sci Total Environ 417-418:32-38. https://doi.org/10.1016/j.scitotenv.2011.12.019.

Wang Q, Yang X, Zhang B, et al. 2013. Cinnabar is different from mercuric chloride in mercury absorption and influence on the brain serotonin level. Basic Clin Pharmacol Toxicol 112(6):412-417. https://doi.org/10.1111/bcpt.12045.

Wang X, Mukherjee B, Park SK. 2018. Associations of cumulative exposure to heavy metal mixtures with obesity and its comorbidities among U.S. adults in NHANES 2003-2014. Environ Int 121(Pt 1):683-694. https://doi.org/10.1016/j.envint.2018.09.035.

Wang J, Wu W, Li H, et al. 2019a. Relation of prenatal low-level mercury exposure with early child neurobehavioral development and exploration of the effects of sex and DHA on it. Environ Int 126:14-23. https://doi.org/10.1016/j.envint.2019.02.012.

Wang Y, Zhang P, Chen X, et al. 2019b. Multiple metal concentrations and gestational diabetes mellitus in Taiyuan, China. Chemosphere 237:124412. https://doi.org/10.1016/j.chemosphere.2019.124412.

Wang G, DiBari J, Bind E, et al. 2019c. In utero exposure to mercury and childhood overweight or obesity: counteracting effect of maternal folate status. BMC Med 17(1):216. https://doi.org/10.1186/s12916-019-1442-2.

Wang Y, Wang K, Han T, et al. 2020. Exposure to multiple metals and prevalence for preeclampsia in Taiyuan, China. Environ Int 145:106098. https://doi.org/10.1016/j.envint.2020.106098.

Wang G, Tang WY, Ji H, et al. 2021a. Prenatal exposure to mercury and precocious puberty: a prospective birth cohort study. Hum Reprod 36(3):712-720. https://doi.org/10.1093/humrep/deaa315.

Wang X, Karvonen-Gutierrez CA, Herman WH, et al. 2021b. Urinary heavy metals and longitudinal changes in blood pressure in midlife women: the study of women's health across the nation. Hypertension 78(2):543-551. https://doi.org/10.1161/hypertensionaha.121.17295.

Wang W, Zhang L, Deng C, et al. 2022a. In utero exposure to methylmercury impairs cognitive function in adult offspring: Insights from proteomic modulation. Ecotoxicol Environ Saf 231:113191. https://doi.org/10.1016/j.ecoenv.2022.113191.

Wang J, Yin J, Hong X, et al. 2022b. Exposure to heavy metals and allergic outcomes in children: a systematic review and meta-analysis. Biol Trace Elem Res 200(11):4615-4631. https://doi.org/10.1007/s12011-021-03070-w.

Wang C, Pi X, Yin S, et al. 2022c. Maternal exposure to heavy metals and risk for severe congenital heart defects in offspring. Environ Res 212(Pt C):113432. https://doi.org/10.1016/j.envres.2022.113432.

Wang K, Mao Y, Liu Z, et al. 2023a. Association of blood heavy metal exposure with atherosclerotic cardiovascular disease (ASCVD) among white adults: evidence from NHANES 1999-2018. Biol Trace Elem Res 201(9):4321-4333. https://doi.org/10.1007/s12011-022-03537-4.

Wang G, Fang L, Chen Y, et al. 2023b. Association between exposure to mixture of heavy metals and hyperlipidemia risk among U.S. adults: A cross-sectional study. Chemosphere 344:140334. https://doi.org/10.1016/j.chemosphere.2023.140334.

Wang X, Ding N, Harlow SD, et al. 2023c. Exposure to heavy metals and hormone levels in midlife women: The Study of Women's Health Across the Nation (SWAN). Environ Pollut 317:120740. https://doi.org/10.1016/j.envpol.2022.120740.

Wang YL, Tsou MM, Lai LC, et al. 2023d. Oral and inhalation bioaccessibility of mercury in contaminated soils and potential health risk to the kidneys and neurodevelopment of children in Taiwan. Environ Geochem Health 45(8):6267-6286. https://doi.org/10.1007/s10653-023-01633-5.

Warfvinge K. 2000. Mercury distribution in the neonatal and adult cerebellum after mercury vapor exposure of pregnant squirrel monkeys. Environ Res 83(2):93-101. https://doi.org/10.1006/enrs.1999.4013.

Warfvinge K, Bruun A. 1996. Mercury accumulation in the squirrel monkey eye after mercury vapour exposure. Toxicology 107(3):189-200. https://doi.org/10.1016/0300-483x(95)03257-g.

Warfvinge K, Bruun A. 2000. Mercury distribution in the squirrel monkey retina after in utero exposure to mercury vapor. Environ Res 83(2):102-109. https://doi.org/10.1006/enrs.1999.4029.

Warfvinge K, Hua J, Logdberg B. 1994a. Mercury distribution in cortical areas and fiber systems of the neonatal and maternal adult cerebrum after exposure of pregnant squirrel monkeys to mercury vapor. Environ Res 67(2):196-208. https://doi.org/10.1006/enrs.1994.1074.

Warfvinge G, Warfvinge K, Larsson A. 1994b. Histochemical visualization of mercury in the oral mucosa, salivary and lacrimal glands of BN rats with HgCl2-induced autoimmunity. Exp Toxicol Pathol 46(4):329-334. https://doi.org/10.1016/S0940-2993(11)80112-0.

Warfvinge K, Hansson H, Hultman P. 1995. Systemic autoimmunity due to mercury vapor exposure in genetically susceptible mice: dose-response studies. Toxicol Appl Pharmacol 132(2):299-309. https://doi.org/10.1006/taap.1995.1111.

8. REFERENCES

Warren CJ, Dudas MJ. 1992. Acidification adjacent to an elemental sulfur stockpile: II. Trace element redistribution. Can J Soil Sci 72(2):127-134. https://doi.org/10.4141/cjss92-012.

Warwick D, Young M, Palmer J, et al. 2019. Mercury vapor volatilization from particulate generated from dental amalgam removal with a high-speed dental drill – a significant source of exposure. J Occup Med Toxicol 14(1):22. https://doi.org/10.1186/s12995-019-0240-2.

Washam C. 2011. Beastly beauty products: Exposure to inorganic mercury in skin-lightening creams. Environ Health Perspect 119(2):A80.

Washington State Department of Ecology. 2013. Metals concentrations in sediments of lakes and wetlands in the Upper Columbia River watershed: Lead, zinc, arsenic, cadmium, antimony, and mercury. Washington State Department of Ecology. PB2013109530. Publication No. 13-03-012. https://apps.ecology.wa.gov/publications/SummaryPages/1303012.html. January 19, 2021.

Wasiuta V, Kirk JL, Chambers PA, et al. 2019. Accumulating mercury and methylmercury burdens in watersheds impacted by oil sands pollution. Environ Sci Technol 53(21):12856-12864. https://doi.org/10.1021/acs.est.9b02373.

Wastensson G, Lamoureux D, Sallsten G, et al. 2006. Quantitative tremor assessment in workers with current low exposure to mercury vapor. Neurotoxicol Teratol 28(6):681-693. https://doi.org/10.1016/j.ntt.2006.09.001.

Wastensson G, Lamoureux D, Sallsten G, et al. 2008. Quantitative assessment of neuromotor function in workers with current low exposure to mercury vapor. Neurotoxicology 29(4):596-604. https://doi.org/10.1016/j.neuro.2008.03.005.

Watras CJ, Bloom NS. 1992. Mercury and methylmercury, in individual zooplankton: Implications for bioaccumulation. Limnol Oceanogr 37(6):1313-1318. https://doi.org/10.4319/lo.1992.37.6.1313.

Watson GE, Lynch M, Myers GJ, et al. 2011. Prenatal exposure to dental amalgam: Evidence from the Seychelles Child Development Study main cohort. J Am Dent Assoc 142(11):1283-1294. https://doi.org/10.14219/jada.archive.2011.0114.

Watson GE, Evans K, Thurston SW, et al. 2012. Prenatal exposure to dental amalgam in the Seychelles Child Development Nutrition Study: associations with neurodevelopmental outcomes at 9 and 30 months. Neurotoxicology 33(6):1511-1517. https://doi.org/10.1016/j.neuro.2012.10.001.

Weast RC. 1988. Mercury. In: CRC handbook of chemistry and physics. 69th ed. Boca Raton, FL: CRC Press Inc., B-106 to B-108, F-103.

Webster JP, Kane TJ, Obrist D, et al. 2016. Estimating mercury emissions resulting from wildfire in forests of the Western United States. Sci Total Environ 568:578-586. https://doi.org/10.1016/j.scitotenv.2016.01.166.

Wei H, Qiu L, Divine KK, et al. 1999. Toxicity and transport of three synthesized mercury-thiol-complexes in isolated rabbit renal proximal tubule suspensions. Drug Chem Toxicol 22(2):323-341. https://doi.org/10.3109/01480549909017838.

Wei MH, Cui Y, Zhou HL, et al. 2021. Associations of multiple metals with bone mineral density: A population-based study in US adults. Chemosphere 282:131150. https://doi.org/10.1016/j.chemosphere.2021.131150.

Wei Y, Lyu Y, Cao Z, et al. 2022. Association of low cadmium and mercury exposure with chronic kidney disease among Chinese adults aged ≥80 years: A cross-sectional study. Chin Med J (Engl) 135(24):2976-2983. https://doi.org/10.1097/cm9.0000000000002395.

Weidenhammer W, Bornschein S, Zilker T, et al. 2010. Predictors of treatment outcomes after removal of amalgam fillings: associations between subjective symptoms, psychometric variables and mercury levels. Community Dent Oral Epidemiol 38(2):180-189. https://doi.org/10.1111/j.1600-0528.2009.00523.x.

Weigert P. 1991. Metal loads of food of vegetable origin including mushrooms. In: Merian E, ed. Metals and their compounds in the environment. Weinheim, Germany: VCH, 449-468.

Weihe P, Grandjean P, Debes F, et al. 1996. Health implications for Faroe Islanders of heavy metals and PCBs from pilot whales. Sci Total Environ 186(1-2):141-148.

8. REFERENCES

Weinhouse C, Ortiz EJ, Berky AJ, et al. 2017. Hair mercury level is associated with anemia and micronutrient status in children living near artisanal and small-scale gold mining in the Peruvian Amazon. Am J Trop Med Hyg 97(6):1886-1897. https://doi.org/10.4269/ajtmh.17-0269.

Weinstein M, Bernstein S. 2003. Pink ladies: mercury poisoning in twin girls. Can Med Assoc J 168(2):201.

Weiss G. 1986. Mercury. In: Hazardous chemicals data book. 2nd ed. Rahway, NJ: Noyes Data Corp, 650-662.

Weiss B, Stern S, Cox C, et al. 2005. Perinatal and lifetime exposure to methylmercury in the mouse: behavioral effects. Neurotoxicology 26(4):675-690. https://doi.org/10.1016/j.neuro.2005.05.003.

Weiss-Penzias P, Sorooshian A, Coale K, et al. 2018. Aircraft measurements of total mercury and monomethyl mercury in summertime marine stratus cloudwater from Coastal California, USA. Environ Sci Technol 52(5):2527-2537. https://doi.org/10.1021/acs.est.7b05395.

Wells EM, Herbstman JB, Lin YH, et al. 2016. Cord blood methylmercury and fetal growth outcomes in Baltimore newborns: Potential confounding and effect modification by omega-3 fatty acids, selenium, and sex. Environ Health Perspect 124(3):373-379. https://doi.org/10.1289/ehp.1408596.

Wells EM, Herbstman JB, Lin YH, et al. 2017. Methyl mercury, but not inorganic mercury, associated with higher blood pressure during pregnancy. Environ Res 154:247-252. https://doi.org/10.1016/j.envres.2017.01.013.

Wells EM, Kopylev L, Nachman R, et al. 2020. Seafood, wine, rice, vegetables, and other food items associated with mercury biomarkers among seafood and non-seafood consumers: NHANES 2011-2012. J Expo Sci Environ Epidemiol 30(3):504-514. https://doi.org/10.1038/s41370-020-0206-6.

Wen J, Giri M, Xu L, et al. 2023. Association between exposure to selected heavy metals and blood eosinophil counts in asthmatic adults: Results from NHANES 2011-2018. J Clin Med 12(4):1543. https://doi.org/10.3390/jcm12041543.

Wendroff AP. 1990. Domestic mercury pollution. Nature 347(6294):623-623. https://doi.org/10.1038/347623a0.

Wendroff AP. 1991. Bringing attention to mercury threat. SfAA News 2(1):3-5. https://www.appliedanthro.org/application/files/6815/8870/3319/Feb_1991.pdf. January 15, 2021.

Wennberg M, Bergdahl IA, Hallmans G, et al. 2011. Fish consumption and myocardial infarction: a second prospective biomarker study from northern Sweden. Am J Clin Nutr 93(1):27-36. https://doi.org/10.3945/ajcn.2010.29408.

Wennberg M, Stromberg U, Bergdahl IA, et al. 2012. Myocardial infarction in relation to mercury and fatty acids from fish: a risk-benefit analysis based on pooled Finnish and Swedish data in men. Am J Clin Nutr 96(4):706-713. https://doi.org/10.3945/ajcn.111.033795.

Wesolowska M, Yeates AJ, McSorley EM, et al. 2023. Potential role of selenium in modifying the effect of maternal methylmercury exposure on child neurodevelopment - A review. Neurotoxicology 99:59-69. https://doi.org/10.1016/j.neuro.2023.08.003.

Weyde KVF, Olsen AK, Duale N, et al. 2021. Gestational blood levels of toxic metal and essential element mixtures and associations with global DNA methylation in pregnant women and their infants. Sci Total Environ 787:147621. https://doi.org/10.1016/j.scitotenv.2021.147621.

WHO. 1990. Methyl mercury. Environmental health criteria. Geneva, Switzerland: World Health Organization. EHC 101. http://www.inchem.org/documents/ehc/ehc/ehc101.htm. January 15, 2021.

WHO. 1991. Inorganic mercury. Environmental health criteria. Geneva, Switzerland: World Health Organization. EHC 118. http://www.inchem.org/documents/ehc/ehc/ehc118.htm January 15, 2021.

WHO. 2000. Air quality guidelines for Europe. Geneva, Switzerland: World Health Organization. https://apps.who.int/iris/handle/10665/107335. April 18, 2023.

WHO. 2004. Methylmercury (addendum). World Health Organization. WHO Food Additives Series 52. http://www.inchem.org/documents/jecfa/jecmono/v52je23.htm. January 19, 2021.

WHO. 2007. Methyl mercury. Safety evaluation of certain food additives and contaminants: prepared by the sixty-seventh meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA). Geneva, Switzerland: World Health Organization. WHO food additives series 58.

https://apps.who.int/food-additives-contaminants-jecfa-database/Document/Index/9006. April 18, 2023.

WHO. 2010. Children's exposure to mercury compounds. Geneva, Switzerland: World Health Organization. https://www.who.int/publications/i/item/9789241500456. January 15, 2021.

WHO. 2011. Mercury (addendum). Safety evaluation of certain contaminants in food: prepared by the seventy-second meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA). Geneva, Switzerland: World Health Organization. WHO Food Additives Series 63. https://apps.who.int/food-additives-contaminants-jecfa-database/Document/Index/8996. April 18, 2023.

WHO. 2022. Guidelines for drinking-water quality. Fourth edition incorporating the first and second addenda. World Health Organization. https://www.who.int/publications/i/item/9789240045064. June 22, 2022.

Wiener JG, Fitzergerald WF, Watras CJ, et al. 1990. Partitioning and bioavailability of mercury in an experimentally acidified Wisconsin Lake. Environ Toxicol Chem 9(7):909-918.

Wiggers GA, Pecanha FM, Briones AM, et al. 2008. Low mercury concentrations cause oxidative stress and endothelial dysfunction in conductance and resistance arteries. Am J Physiol Heart Circ Physiol 295(3):H1033-H1043. https://doi.org/10.1152/ajpheart.00430.2008.

Wild LG, Ortega HG, Lopez M, et al. 1997. Immune system alteration in the rat after indirect exposure to methyl mercury chloride or methyl mercury sulfide. Environ Res 74(1):34-42. https://doi.org/10.1006/enrs.1997.3748.

Wildemann TM, Mirhosseini N, Siciliano SD, et al. 2015a. Cardiovascular responses to lead are biphasic, while methylmercury, but not inorganic mercury, monotonically increases blood pressure in rats. Toxicology 328:1-11. https://doi.org/10.1016/j.tox.2014.11.009.

Wildemann TM, Weber LP, Siciliano SD. 2015b. Combined exposure to lead, inorganic mercury and methylmercury shows deviation from additivity for cardiovascular toxicity in rats. J Appl Toxicol 35(8):918-926. https://doi.org/10.1002/jat.3092.

Wildemann TM, Siciliano SD, Weber LP. 2016. The mechanisms associated with the development of hypertension after exposure to lead, mercury species or their mixtures differs with the metal and the mixture ratio. Toxicology 339:1-8. https://doi.org/10.1016/j.tox.2015.11.004.

Willes RF, Truelove JF, Nera EA. 1978. Neurotoxic response of infant monkeys to methylmercury. Toxicology 9(1-2):125-135. https://doi.org/10.1016/0300-483x(78)90037-9.

Willett KL, Turner RR, Beauchamp JJ. 1992. Effect of chemical form of mercury on the performance of dosed soils in standard leaching protocols: EP and TCLP. Hazard Waste Hazard Mater 9(3):275-288.

Williams MV, Winters T, Waddell KS. 1987. In-vivo effects of mercury (II) on deoxyuridine triphosphate nucleotidohydrolase, DNA polymerase (α, β), and uracil-DNA glycosylase activities in cultured human cells: Relationship to DNA damage, DNA repair, and cytotoxicity. Mol Pharmacol 31(2):200-207.

Williston SH. 1968. Mercury in the atmosphere. J Geophys Res 73:7051-7055.

Windham-Myers L, Marvin-DiPasquale M, Kakouros E, et al. 2014. Mercury cycling in agricultural and managed wetlands of California, USA: seasonal influences of vegetation on mercury methylation, storage, and transport. Sci Total Environ 484:308-318. https://doi.org/10.1016/j.scitotenv.2013.05.027.

Wirth JJ, Mijal RS. 2010. Adverse effects of low level heavy metal exposure on male reproductive function. Syst Biol Reprod Med 56(2):147-167. https://doi.org/10.3109/19396360903582216.

Wong PK. 1988. Mutagenicity of heavy metals. Bull Environ Contam Toxicol 40(4):597-603. https://doi.org/10.1007/bf01688386.

Wood JM. 1974. Biological cycles for toxic elements in the environment. Science 183(4129):1049-1052. https://doi.org/10.1126/science.183.4129.1049.

8. REFERENCES

Woods JS, Echeverria D, Heyer NJ, et al. 2005. The association between genetic polymorphisms of coproporphyrinogen oxidase and an atypical porphyrinogenic response to mercury exposure in humans. Toxicol Appl Pharmacol 206(2):113-120. https://doi.org/10.1016/j.taap.2004.12.016.

Woods JS, Martin MD, Leroux BG, et al. 2007. The contribution of dental amalgam to urinary mercury excretion in children. Environ Health Perspect 115(10):1527-1531. https://doi.org/10.1289/ehp.10249.

Woods JS, Martin MD, Leroux BG, et al. 2008. Biomarkers of kidney integrity in children and adolescents with dental amalgam mercury exposure: findings from the Casa Pia children's amalgam trial. Environ Res 108(3):393-399. https://doi.org/10.1016/j.envres.2008.07.003.

Woods JS, Martin MD, Leroux BG, et al. 2009. Urinary porphyrin excretion in children with mercury amalgam treatment: findings from the Casa Pia Children's Dental Amalgam Trial. J Toxicol Environ Health A 72(14):891-896. https://doi.org/10.1080/15287390902959557.

Woods JS, Heyer NJ, Echeverria D, et al. 2012. Modification of neurobehavioral effects of mercury by a genetic polymorphism of coproporphyrinogen oxidase in children. Neurotoxicol Teratol 34(5):513-521. https://doi.org/10.1016/j.ntt.2012.06.004.

Woods JS, Heyer NJ, Russo JE, et al. 2013. Modification of neurobehavioral effects of mercury by genetic polymorphisms of metallothionein in children. Neurotoxicol Teratol 39:36-44. https://doi.org/10.1016/j.ntt.2013.06.004.

Woods JS, Heyer NJ, Russo JE, et al. 2014. Genetic polymorphisms affecting susceptibility to mercury neurotoxicity in children: summary findings from the Casa Pia Children's Amalgam clinical trial. Neurotoxicology 44:288-302. https://doi.org/10.1016/j.neuro.2014.07.010.

WQP. 2024. Mercury. Water quality portal. Advisory Committee on Water Information (ACWI); Agricultural Research Service (ARS); Environmental Protection Agency (EPA); National Water Quality Monitoring Council (NWQMC); United States Geological Survey (USGS). https://www.waterqualitydata.us/portal/. February 26, 2024.

Wright DL, Afeiche MC, Ehrlich S, et al. 2015. Hair mercury concentrations and in vitro fertilization (IVF) outcomes among women from a fertility clinic. Reprod Toxicol 51:125-132. https://doi.org/10.1016/j.reprotox.2015.01.003.

Wu G. 1995. Screening of potential transport systems for methyl mercury uptake in rat erythrocytes at 5 degrees by use of inhibitors and substrates. Pharmacol Toxicol 77(3):169-176.

Wu G. 1996. Methylmercury-cysteine uptake by rat erythrocytes: evidence for several transport systems. J Appl Toxicol 16(1):77-83. https://doi.org/10.1002/(sici)1099-1263(199601)16:1<77::aid-jat319>3.0.co;2-c.

Wu G. 1997. Effect of probenecid on the transport of methyl mercury in erythrocytes by the organic anion transport system. Arch Toxicol 71(4):218-222.

Wu J, Ying T, Shen Z, et al. 2014. Effect of low-level prenatal mercury exposure on neonate neurobehavioral development in China. Pediatr Neurol 51(1):93-99. https://doi.org/10.1016/j.pediatrneurol.2014.03.018.

Wu X, Cobbina SJ, Mao G, et al. 2016. A review of toxicity and mechanisms of individual and mixtures of heavy metals in the environment. Environ Sci Pollut Res Int 23(9):8244-8259. https://doi.org/10.1007/s11356-016-6333-x.

Wu P, Kainz MJ, Bravo AG, et al. 2019. The importance of bioconcentration into the pelagic food web base for methylmercury biomagnification: A meta-analysis. Sci Total Environ 646:357-367. https://doi.org/10.1016/j.scitotenv.2018.07.328.

Wu B, Qu Y, Lu Y, et al. 2022. Mercury may reduce the protective effect of sea fish consumption on serum triglycerides levels in Chinese adults: Evidence from China National Human Biomonitoring. Environ Pollut 311:119904. https://doi.org/10.1016/j.envpol.2022.119904.

Wu X, Li P, Tao J, et al. 2023. Subchronic low-dose methylmercury exposure accelerated cerebral telomere shortening in relevant with declined urinary aMT6s level in rats. Toxics 11(2):191. https://doi.org/10.3390/toxics11020191.

8. REFERENCES

Wulf HC, Kromann N, Kousgaard N, et al. 1986. Sister chromatid exchange (SCE) in Greenlandic
    Eskimos. Dose-response relationship between SCE and seal diet, smoking, and blood cadmium and
    mercury concentrations. Sci Total Environ 48(1-2):81-94. https://doi.org/10.1016/0048-
    9697(86)90155-5.

Wyatt L, Permar SR, Ortiz E, et al. 2019. Mercury exposure and poor nutritional status reduce response
    to six expanded program on immunization vaccines in children: an observational cohort study of
    communities affected by gold mining in the Peruvian Amazon. Int J Environ Res Public Health
    16(4):638. https://doi.org/10.3390/ijerph16040638.

Xiong J, Lv Y, Wei Y, et al. 2022. Association of blood mercury exposure with depressive symptoms in
    the Chinese oldest old. Ecotoxicol Environ Saf 243:113976.
    https://doi.org/10.1016/j.ecoenv.2022.113976.

Xu Y, Khoury JC, Sucharew H, et al. 2016. Low-level gestational exposure to mercury and maternal fish
    consumption: Associations with neurobehavior in early infancy. Neurotoxicol Teratol 54:61-67.
    https://doi.org/10.1016/j.ntt.2016.02.002.

Xu J, Engel LS, Rhoden J, et al. 2021. The association between blood metals and hypertension in the
    GuLF study. Environ Res 202:111734. https://doi.org/10.1016/j.envres.2021.111734.

Xu R, Meng X, Pang Y, et al. 2022a. Associations of maternal exposure to 41 metals/metalloids during
    early pregnancy with the risk of spontaneous preterm birth: Does oxidative stress or DNA
    methylation play a crucial role? Environ Int 158:106966.
    https://doi.org/10.1016/j.envint.2021.106966.

Xu S, Hansen S, Sripada K, et al. 2022b. Maternal blood levels of toxic and essential elements and birth
    outcomes in Argentina: The EMASAR study. Int J Environ Res Public Health 19(6):3643.
    https://doi.org/10.3390/ijerph19063643.

Xu J, Zhu X, Hui R, et al. 2022c. Associations of metal exposure with hyperuricemia and gout in general
    adults. Front Endocrinol (Lausanne) 13:1052784. https://doi.org/10.3389/fendo.2022.1052784.

Xu W, Park SK, Gruninger SE, et al. 2023a. Associations between mercury exposure with blood
    pressure and lipid levels: A cross-sectional study of dental professionals. Environ Res 220:115229.
    https://doi.org/10.1016/j.envres.2023.115229.

Xu K, Gao B, Liu T, et al. 2023b. Association of blood mercury levels with bone mineral density in
    adolescents aged 12-19. Environ Sci Pollut Res Int 30(16):46933-46939.
    https://doi.org/10.1007/s11356-023-25701-6.

Xue F, Holzman C, Rahbar MH, et al. 2007. Maternal fish consumption, mercury levels, and risk of
    preterm delivery. Environ Health Perspect 115(1):42-47. https://doi.org/10.1289/ehp.9329.

Yaginuma-Sakurai K, Murata K, Iwai-Shimada M, et al. 2012. Hair-to-blood ratio and biological half-
    life of mercury: experimental study of methylmercury exposure through fish consumption in
    humans. J Toxicol Sci 37(1):123-130.

Yahyazedeh A, Altunkaynak BZ, Akgul N, et al. 2017. A histopathological and stereological study of
    liver damage in female rats caused by mercury vapor. Biotech Histochem 92(5):338-346.
    https://doi.org/10.1080/10520295.2017.1312527.

Yalçin SS, Erdal İ, Oğuz B, et al. 2022. Associations between toxic elements and blood pressure
    parameters in adolescents. J Trace Elem Med Biol 71:126949.
    https://doi.org/10.1016/j.jtemb.2022.126949.

Yamaguchi S, Matsumoto H, Kaku S, et al. 1975. Factors affecting the amount of mercury in human
    scalp hair. Am J Public Health 65(5):484-488.

Yamamoto R, Suzuki T. 1978. Effects of artificial hair-waving on hair mercury values. Int Arch Occup
    Environ Health 42(1):1-9. https://doi.org/10.1007/bf00385706.

Yang J, Jiang Z, Wang Y, et al. 1997. Maternal-fetal transfer of metallic mercury via the placenta and
    milk. Ann Clin Lab Sci 27:135-141.

Yang YJ, Yang EJ, Park K, et al. 2021. Association between blood mercury levels and non-alcoholic
    fatty liver disease in non-obese populations: The Korean National Environmental Health Survey

(KoNEHS) 2012-2014. Int J Environ Res Public Health 18(12):6412. https://doi.org/10.3390/ijerph18126412.

Yang D, Zhu H, Chen H, et al. 2023. Association between serum trace heavy metals and liver function among adolescents. J Occup Environ Med 65(3):e155-e160. https://doi.org/10.1097/jom.0000000000002778.

Yannai S, Sachs KM. 1993. Absorption and accumulation of cadmium, lead and mercury from foods by rats. Food Chem Toxicol 31(5):351-335.

Yannai S, Berdicevsky I, Duek L. 1991. Transformations of inorganic mercury by Candida albicans and Saccharomyces cerevisiae. Appl Environ Microbiol 57(1):245-247.

Yao B, Lu X, Xu L, et al. 2020. Relationship between low-level lead, cadmium and mercury exposures and blood pressure in children and adolescents aged 8-17 years: An exposure-response analysis of NHANES 2007-2016. Sci Total Environ 726:138446. https://doi.org/10.1016/j.scitotenv.2020.138446.

Yasuda Y, Datu AR, Hirata S, et al. 1985. Characteristics of growth and palatal shelf development in ICR mice after exposure to methylmercury. Teratology 32(2):273-286. https://doi.org/10.1002/tera.1420320216.

Yasutake A, Hirayama K. 2001. Evaluation of methylmercury biotransformation using rat liver slices. Arch Toxicol 75(7):400-406.

Yasutake A, Hachiya N. 2006. Accumulation of inorganic mercury in hair of rats exposed to methylmercury or mercuric chloride. Tohoku J Exp Med 210(4):301-306.

Yasutake A, Nakamura M. 2011. Induction by mercury compounds of metallothioneins in mouse tissues: inorganic mercury accumulation is not a dominant factor for metallothionein induction in the liver. J Toxicol Sci 36(3):365-372.

Yasutake A, Hirayama K, Inoue M. 1989. Mechanism of urinary excretion of methylmercury in mice. Arch Toxicol 63(6):479-483.

Yasutake A, Hirayama Y, Inouye M. 1991. Sex difference of nephrotoxicity by methylmercury in mice. In: Bach PH, Ulrich KJ, eds. Nephrotoxicity: Mechanisms, early diagnosis, and therapeutic management; Fourth International symposium on nephrotoxicity, Guilford, England, UK, 1989. New York, NY: Marcel Dekker, Inc., 389-396.

Yasutake A, Nakano A, Miyamoto K, et al. 1997. Chronic effects of methylmercury in rats. I. Biochemical aspects. Tohoku J Exp Med 182(3):185-196.

Yasutake A, Matsumoto M, Yamaguchi M, et al. 2003. Current hair mercury levels in Japanese: survey in five districts. Tohoku J Exp Med 199(3):161-169.

Yau VM, Green PG, Alaimo CP, et al. 2014. Prenatal and neonatal peripheral blood mercury levels and autism spectrum disorders. Environ Res 133:294-303. https://doi.org/10.1016/j.envres.2014.04.034.

Yawei S, Jianhai L, Junxiu Z, et al. 2021. Epidemiology, clinical presentation, treatment, and follow-up of chronic mercury poisoning in China: a retrospective analysis. BMC Pharmacol Toxicol 22(1):25. https://doi.org/10.1186/s40360-021-00493-y.

Ye X, Qian H, Xu P, et al. 2009. Nephrotoxicity, neurotoxicity, and mercury exposure among children with and without dental amalgam fillings. Int J Hyg Environ Health 212(4):378-386. https://doi.org/10.1016/j.ijheh.2008.09.004.

Ye Z, Mao H, Lin CJ, et al. 2016. Investigation of processes controlling summertime gaseous elemental mercury oxidation at midlatitudinal marine, coastal, and inland sites. Atmos Chem Phys 16(13):8461-8478. https://doi.org/10.5194/acp-16-8461-2016.

Yeates KO, Mortensen ME. 1994. Acute and chronic neuropsychological consequences of mercury vapor poisoning in two early adolescents. J Clin Exp Neuropsychol 16(2):209-222. https://doi.org/10.1080/01688639408402632.

Yeates AJ, Zavez A, Thurston SW, et al. 2020. Maternal long-chain polyunsaturated fatty acid status, methylmercury exposure, and birth outcomes in a high-fish-eating mother-child cohort. J Nutr 150(7):1749-1756. https://doi.org/10.1093/jn/nxaa131.

8. REFERENCES

Yen CC, Chen HH, Hsu YT, et al. 2022. Effects of heavy metals in acute ischemic stroke patients: A cross-sectional study. Medicine (Baltimore) 101(9):e28973. https://doi.org/10.1097/md.0000000000028973.

Yess NJ. 1993. U.S. Food and Drug Administration survey of methyl mercury in canned tuna. J AOAC Int 76(1):36-38.

Yildirim E, Derici MK, Demir E, et al. 2019. Is the Concentration of Cadmium, Lead, Mercury, and Selenium Related to Preterm Birth? Biol Trace Elem Res 191(2):306-312. https://doi.org/10.1007/s12011-018-1625-2.

Yilmaz OH, Karakulak UN, Tutkun E, et al. 2016. Assessment of the cardiac autonomic nervous system in mercury-exposed individuals via post-exercise heart rate recovery. Med Princ Pract 25(4):343-349. https://doi.org/10.1159/000445322.

Yin R, Feng X, Meng B. 2013. Stable mercury isotope variation in rice plants (Oryza sativa L.) from the Wanshan mercury mining district, SW China. Environ Sci Technol 47(5):2238-2245. https://doi.org/10.1021/es304302a.

Yin L, Yu K, Lin S, et al. 2016. Associations of blood mercury, inorganic mercury, methyl mercury and bisphenol A with dental surface restorations in the U.S. population, NHANES 2003-2004 and 2010-2012. Ecotoxicol Environ Saf 134P1:213-225. https://doi.org/10.1016/j.ecoenv.2016.09.001.

Yin L, Lin S, Summers AO, et al. 2021. Children with amalgam dental restorations have significantly elevated blood and urine mercury levels. Toxicol Sci 184(1):104-126. https://doi.org/10.1093/toxsci/kfab108.

Yin L, Lin S, Summers AO, et al. 2022. Corrigendum to: Children with amalgam dental restorations have significantly elevated blood and urine mercury levels. Toxicol Sci 186(1):174. https://doi.org/10.1093/toxsci/kfab156.

Yip RK, Chang LW. 1981. Vulnerability of dorsal root neurons and fibers toward methylmercury toxicity: a morphological evaluation. Environ Res 26(1):152-167. https://doi.org/10.1016/0013-9351(81)90194-8.

Ynalvez R, Gutierrez J, Gonzalez-Cantu H. 2016. Mini-review: toxicity of mercury as a consequence of enzyme alteration. Biometals 29(5):781-788. https://doi.org/10.1007/s10534-016-9967-8.

Yokoo EM, Valente JG, Grattan L, et al. 2003. Low level methylmercury exposure affects neuropsychological function in adults. Environ Health 2(1):8. https://doi.org/10.1186/1476-069x-2-8.

Yoo JI, Ha YC, Lee YK, et al. 2016. High levels of heavy metals increase the prevalence of sarcopenia in the elderly population. J Bone Metab 23(2):101-109. https://doi.org/10.11005/jbm.2016.23.2.101.

Yorifuji T, Tsuda T, Takao S, et al. 2008. Long-term exposure to methylmercury and neurologic signs in Minamata and neighboring communities. Epidemiology 19(1):3-9. https://doi.org/10.1097/EDE.0b013e31815c09d2.

Yorifuji T, Tsuda T, Takao S, et al. 2009. Total mercury content in hair and neurologic signs: historic data from Minamata. Epidemiology 20(2):188-193. https://doi.org/10.1097/EDE.0b013e318190e73f.

Yorifuji T, Tsuda T, Kashima S, et al. 2010. Long-term exposure to methylmercury and its effects on hypertension in Minamata. Environ Res 110(1):40-46. https://doi.org/10.1016/j.envres.2009.10.011.

Yorifuji T, Tsuda T, Inoue S, et al. 2011. Long-term exposure to methylmercury and psychiatric symptoms in residents of Minamata, Japan. Environ Int 37(5):907-913. https://doi.org/10.1016/j.envint.2011.03.008.

Yorifuji T, Murata K, Bjerve KS, et al. 2013. Visual evoked potentials in children prenatally exposed to methylmercury. Neurotoxicology 37:15-18. https://doi.org/10.1016/j.neuro.2013.03.009.

Yorifuji T, Kato T, Kado Y, et al. 2015. Intrauterine exposure to methylmercury and neurocognitive functions: Minamata disease. Arch Environ Occup Health 70(5):297-302. https://doi.org/10.1080/19338244.2014.904268.

8. REFERENCES

Yorifuji T, Kado Y, Diez MH, et al. 2016. Neurological and neurocognitive functions from intrauterine methylmercury exposure. Arch Environ Occup Health 71(3):170-177. https://doi.org/10.1080/19338244.2015.1080153.

Yorifuji T, Takaoka S, Grandjean P. 2018. Accelerated functional losses in ageing congenital Minamata disease patients. Neurotoxicol Teratol 69:49-53. https://doi.org/10.1016/j.ntt.2018.08.001.

Yorifuji T, Kadowaki T, Yasuda M, et al. 2023. Neurological and neurocognitive impairments in adults with a history of prenatal methylmercury poisoning: Minamata disease. Int J Environ Res Public Health 20(12):6173. https://doi.org/10.3390/ijerph20126173.

Yoshida M, Satoh M, Shimada A, et al. 2002. Maternal-to-fetus transfer of mercury in metallothionein-null pregnant mice after exposure to mercury vapor. Toxicology 175(1-3):215-222. https://doi.org/10.1016/s0300-483x(02)00084-7.

Yoshida M, Suzuki M, Satoh M, et al. 2011. Neurobehavioral effects of combined prenatal exposure to low-level mercury vapor and methylmercury. J Toxicol Sci 36(1):73-80. https://doi.org/10.2131/jts.36.73.

Yoshida M, Watanabe C, Honda A, et al. 2013. Emergence of delayed behavioral effects in offspring mice exposed to low levels of mercury vapor during the lactation period. J Toxicol Sci 38(1):1-6. https://doi.org/10.2131/jts.38.1.

Yoshida M, Lee JY, Satoh M, et al. 2018. Neurobehavioral effects of postnatal exposure to low-level mercury vapor and/or methylmercury in mice. J Toxicol Sci 43(1):11-17. https://doi.org/10.2131/jts.43.11.

Yoshimasu K, Kiyohara C, Takemura S, et al. 2014. A meta-analysis of the evidence on the impact of prenatal and early infancy exposures to mercury on autism and attention deficit/hyperactivity disorder in the childhood. Neurotoxicology 44:121-131. https://doi.org/10.1016/j.neuro.2014.06.007.

Yoshizawa K, Rimm EB, Morris JS, et al. 2002. Mercury and the risk of coronary heart disease in men. N Engl J Med 347(22):1755-1760. https://doi.org/10.1056/NEJMoa021437.

You CH, Kim BG, Kim YM, et al. 2014. Relationship between dietary mercury intake and blood mercury level in Korea. J Korean Med Sci 29(2):176-182. https://doi.org/10.3346/jkms.2014.29.2.176.

You SH, Wang SL, Pan WH, et al. 2018. Risk assessment of methylmercury based on internal exposure and fish and seafood consumption estimates in Taiwanese children. Int J Hyg Environ Health 221(4):697-703. https://doi.org/10.1016/j.ijheh.2018.03.002.

Young JF, Wosilait WD, Luecke RH. 2001. Analysis of methylmercury disposition in humans utilizing a PBPK model and animal pharmacokinetic data. J Toxicol Environ Health A 63(1):19-52. https://doi.org/10.1080/152873901750128344.

Young EC, Davidson PW, Wilding G, et al. 2020. Association between prenatal dietary methyl mercury exposure and developmental outcomes on acquisition of articulatory-phonologic skills in children in the Republic of Seychelles. Neurotoxicology 81:353-357. https://doi.org/10.1016/j.neuro.2020.09.028.

Yu Y, Gao M, Wang X, et al. 2019. Recommended acceptable levels of maternal serum typical toxic metals from the perspective of spontaneous preterm birth in Shanxi Province, China. Sci Total Environ 686:599-605. https://doi.org/10.1016/j.scitotenv.2019.05.413.

Zalups RK. 1995. Organic anion transport and action of gamma-glutamyl transpeptidase in kidney linked mechanistically to renal tubular uptake of inorganic mercury. Toxicol Appl Pharmacol 132(2):289-298. https://doi.org/10.1006/taap.1995.1110.

Zalups RK. 1998. Intestinal handling of mercury in the rat: Implications of intestinal secretion of inorganic mercury following biliary ligation or cannulation. J Toxicol Environ Health A 53(8):615-636. https://doi.org/10.1080/009841098159079.

Zalups RK. 2000. Molecular interactions with mercury in the kidney. Pharmacol Rev 52(1):113-143.

Zalups RK, Barfuss D. 1990. Accumulation of inorganic mercury along the renal proximal tubule of the rabbit. Toxicol Appl Pharmacol 106(2):245-253. https://doi.org/10.1016/0041-008x(90)90244-o.

8. REFERENCES

Zalups RK, Cherian MG. 1992. Renal metallothionein metabolism after a reduction of renal mass. II. Effect of zinc pretreatment on the renal toxicity and intrarenal accumulation of inorganic mercury. Toxicology 71(1-2):103-117.

Zalups RK, Minor KH. 1995. Luminal and basolateral mechanisms involved in the renal tubular uptake of inorganic mercury. J Toxicol Environ Health 46(1):73-100. https://doi.org/10.1080/15287399509532019.

Zalups RK, Lash LH. 1997. Binding of mercury in renal brush-border and basolateral membrane-vesicles. Biochem Pharmacol 53(12):1889-1900. https://doi.org/10.1016/s0006-2952(97)00138-x.

Zalups RK, Ahmad S. 2004. Homocysteine and the renal epithelial transport and toxicity of inorganic mercury: role of basolateral transporter organic anion transporter 1. J Am Soc Nephrol 15(8):2023-2031. https://doi.org/10.1097/01.asn.0000135115.63412.a9.

Zalups RK, Diamond GL. 2005. Nephrotoxicology of metals. In: Tarloff JB, Lash LH, eds. Toxicology of the kidney. 3rd ed. Boca Raton, FL: CRC Press, 767-814.

Zalups RK, Ahmad S. 2005a. Handling of cysteine S-conjugates of methylmercury in MDCK cells expressing human OAT1. Kidney Int 68(4):1684-1699. https://doi.org/10.1111/j.1523-1755.2005.00585.x.

Zalups RK, Ahmad S. 2005b. Handling of the homocysteine S-conjugate of methylmercury by renal epithelial cells: role of organic anion transporter 1 and amino acid transporters. J Pharmacol Exp Ther 315(2):896-904. https://doi.org/10.1124/jpet.105.090530.

Zalups RK, Ahmad S. 2005c. Transport of N-acetylcysteine s-conjugates of methylmercury in Madin-Darby canine kidney cells stably transfected with human isoform of organic anion transporter 1. J Pharmacol Exp Ther 314(3):1158-1168. https://doi.org/10.1124/jpet.105.086645.

Zalups RK, Bridges CC. 2012. Relationships between the renal handling of DMPS and DMSA and the renal handling of mercury. Chem Res Toxicol 25(9):1825-1838. https://doi.org/10.1021/tx3001847.

Zalups RK, Barfuss DW, Kostyniak PJ. 1992. Altered intrarenal accumulation of mercury in uninephrectomized rats treated with methylmercury chloride. Toxicol Appl Pharmacol 115(2):174-182.

Zalups RK, Knutson KL, Schnellmann RG. 1993. In vitro analysis of the accumulation and toxicity of inorganic mercury in segments of the proximal tubule isolated from the rabbit kidney. Toxicol Appl Pharmacol 119(2):221-227.

Zalups RK, Barfuss DW, Lash LH. 1999. Disposition of inorganic mercury following biliary obstruction and chemically induced glutathione depletion: dispositional changes one hour after the intravenous administration of mercuric chloride. Toxicol Appl Pharmacol 154(2):135-144. https://doi.org/10.1006/taap.1998.8562.

Zalups RK, Aslamkhan AG, Ahmad S. 2004. Human organic anion transporter 1 mediates cellular uptake of cysteine-S conjugates of inorganic mercury. Kidney Int 66(1):251-261. https://doi.org/10.1111/j.1523-1755.2004.00726.x.

Zanoli P, Truzzi C, Veneri C, et al. 1994. Methyl mercury during late gestation affects temporarily the development of cortical muscarinic receptors in rat offspring. Pharmacol Toxicol 75(5):261-264. https://doi.org/10.1111/j.1600-0773.1994.tb00358.x.

Zareba G, Cernichiari E, Goldsmith LA, et al. 2008. Validity of methyl mercury hair analysis: mercury monitoring in human scalp/nude mouse model. J Appl Toxicol 28(4):535-542. https://doi.org/10.1002/jat.1307.

Zareba W, Thurston SW, Zareba G, et al. 2019. Prenatal and recent methylmercury exposure and heart rate variability in young adults: the Seychelles Child Development Study. Neurotoxicol Teratol 74:106810. https://doi.org/10.1016/j.ntt.2019.106810.

Zasukhina GD, Vasilyeva IM, Sdirkova NI, et al. 1983. Mutagenic effect of thallium and mercury salts on rodent cells with different repair activities. Mutat Res 124(2):163-173.

Zayas LH, Ozuah PO. 1996. Mercury use in espiritismo: a survey of botanicas. Am J Public Health 86(1):111-112. https://doi.org/10.2105/ajph.86.1.111.

8. REFERENCES

Zefferino R, Piccoli C, Ricciardi N, et al. 2017. Possible mechanisms of mercury toxicity and cancer
    promotion: Involvement of gap junction intercellular communications and inflammatory cytokines.
    Oxid Med Cell Longev 2017:1-6. https://doi.org/10.1155/2017/7028583.
Zeng Q, Zhou B, Feng W, et al. 2013. Associations of urinary metal concentrations and circulating
    testosterone in Chinese men. Reprod Toxicol 41:109-114.
    https://doi.org/10.1016/j.reprotox.2013.06.062.
Zeng Q, Feng W, Zhou B, et al. 2015. Urinary metal concentrations in relation to semen quality: A
    cross-sectional study in China. Environ Sci Technol 49(8):5052-5059.
    https://doi.org/10.1021/es5053478.
Zhai Q, Cen S, Jiang J, et al. 2019. Disturbance of trace element and gut microbiota profiles as
    indicators of autism spectrum disorder: A pilot study of Chinese children. Environ Res 171:501-509.
    https://doi.org/10.1016/j.envres.2019.01.060.
Zhang Y, Bolivar VJ, Lawrence DA. 2013. Maternal exposure to mercury chloride during pregnancy
    and lactation affects the immunity and social behavior of offspring. Toxicol Sci 133(1):101-111.
    https://doi.org/10.1093/toxsci/kft023.
Zhang H, Feng X, Larssen T, et al. 2010. In inland China, rice, rather than fish, is the major pathway for
    methylmercury exposure. Environ Health Perspect 118(9):1183-1188.
    https://doi.org/10.1289/ehp.1001915.
Zhang Y, Gao D, Bolivar VJ, et al. 2011. Induction of autoimmunity to brain antigens by developmental
    mercury exposure. Toxicol Sci 119(2):270-280. https://doi.org/10.1093/toxsci/kfq334.
Zhang BB, Li WK, Hou WY, et al. 2017. Zuotai and HgS differ from HgCl2 and methyl mercury in Hg
    accumulation and toxicity in weanling and aged rats. Toxicol Appl Pharmacol 331:76-84.
    https://doi.org/10.1016/j.taap.2017.05.021.
Zhang C, Wu HB, Cheng MX, et al. 2019. Association of exposure to multiple metals with papillary
    thyroid cancer risk in China. Environ Sci Pollut Res Int 26(20):20560-20572.
    https://doi.org/10.1007/s11356-019-04733-x.
Zhang Y, Huo X, Lu X, et al. 2020a. Exposure to multiple heavy metals associate with aberrant immune
    homeostasis and inflammatory activation in preschool children. Chemosphere 257:127257.
    https://doi.org/10.1016/j.chemosphere.2020.127257.
Zhang C, Gan C, Ding L, et al. 2020b. Maternal inorganic mercury exposure and renal effects in the
    Wanshan mercury mining area, southwest China. Ecotoxicol Environ Saf 189:109987.
    https://doi.org/10.1016/j.ecoenv.2019.109987.
Zhang J, Wang J, Hu J, et al. 2021a. Associations of total blood mercury and blood methylmercury
    concentrations with diabetes in adults: An exposure-response analysis of 2005-2018 NHANES. J
    Trace Elem Med Biol 68:126845. https://doi.org/10.1016/j.jtemb.2021.126845.
Zhang M, Liu T, Wang G, et al. 2021b. In utero exposure to heavy metals and trace elements and
    childhood blood pressure in a U.S. urban, low-income, minority birth cohort. Environ Health
    Perspect 129(6):67005. https://doi.org/10.1289/EHP8325.
Zhang Y, Chen T, Zhang Y, et al. 2021c. Contribution of trace element exposure to gestational diabetes
    mellitus through disturbing the gut microbiome. Environ Int 153:106520.
    https://doi.org/10.1016/j.envint.2021.106520.
Zhang Q, Hu M, Wu H, et al. 2021d. Plasma polybrominated diphenyl ethers, urinary heavy metals and
    the risk of thyroid cancer: A case-control study in China. Environ Pollut 269:116162.
    https://doi.org/10.1016/j.envpol.2020.116162.
Zhang W, Li F, Gao L, et al. 2022. Understanding the excretion rates of methylmercury and inorganic
    mercury from human body via hair and fingernails. J Environ Sci (China) 119:59-67.
    https://doi.org/10.1016/j.jes.2022.01.041.
Zhang W, Cui Y, Liu J. 2023a. The association between blood heavy metals level and sex hormones
    among postmenopausal women in the US. Front Endocrinol (Lausanne) 14:1175011.
    https://doi.org/10.3389/fendo.2023.1175011.

8. REFERENCES

Zhang X, Wei H, Guan Q, et al. 2023b. Maternal exposure to trace elements, toxic metals, and longitudinal changes in infancy anthropometry and growth trajectories: a prospective cohort study. Environ Sci Technol 57(32):11779-11791. https://doi.org/10.1021/acs.est.3c02535.

Zhao Y, Zhou C, Wu C, et al. 2020. Subchronic oral mercury caused intestinal injury and changed gut microbiota in mice. Sci Total Environ 721:137639. https://doi.org/10.1016/j.scitotenv.2020.137639.

Zhao Y, Zhou C, Guo X, et al. 2021. Exposed to mercury-induced oxidative stress, changes of intestinal microflora, and association between them in mice. Biol Trace Elem Res 199(5):1900-1907. https://doi.org/10.1007/s12011-020-02300-x.

Zhao S, Yang X, Xu Q, et al. 2023. Association of maternal metals exposure, metabolites and birth outcomes in newborns: A prospective cohort study. Environ Int 179:108183. https://doi.org/10.1016/j.envint.2023.108183.

Zheng Y, Lin PD, Williams PL, et al. 2021. Early pregnancy essential and non-essential metal mixtures and gestational glucose concentrations in the 2nd trimester: Results from project viva. Environ Int 155:106690. https://doi.org/10.1016/j.envint.2021.106690.

Zheng L, Yu Y, Tian X, et al. 2023. The association between multi-heavy metals exposure and lung function in a typical rural population of Northwest China. Environ Sci Pollut Res Int 30(24):65646-65658. https://doi.org/10.1007/s11356-023-26881-x.

Zhou CC, Fu H, Zhang GY, et al. 2021. Effects of low-level mercury exposure on brain-derived neurotrophic factor in preschool children. Ecotoxicol Environ Saf 208:111642. https://doi.org/10.1016/j.ecoenv.2020.111642.

Zhou X, Feng Y, Gong Z. 2022. Associations between lead, cadmium, mercury, and arsenic exposure and alanine aminotransferase elevation in the general adult population: an exposure-response analysis. Environ Sci Pollut Res Int 29(35):53633-53641. https://doi.org/10.1007/s11356-022-19698-7.

Zhu X, Kusaka Y, Sato K, et al. 2000. The endocrine disruptive effects of mercury. Environ Health Prev Med 4(4):174-183. https://doi.org/10.1007/bf02931255.

Zhu XJ, Wang JJ, Mao JH, et al. 2019. Relationships of cadmium, lead, and mercury levels with albuminuria in US adults: Results from the National Health and Nutrition Examination Survey database, 2009-2012. Am J Epidemiol 188(7):1281-1287. https://doi.org/10.1093/aje/kwz070.

Zhu F, Chen C, Zhang Y, et al. 2020. Elevated blood mercury level has a non-linear association with infertility in U.S. women: Data from the NHANES 2013-2016. Reprod Toxicol 91:53-58. https://doi.org/10.1016/j.reprotox.2019.11.005.

Zorn NE, Smith JT. 1989. In vivo methylation of inorganic mercury in guinea pigs. Biochem Arch 5:141-146.

Zuk AM, Liberda EN, Tsuji LJS. 2021. Environmental contaminant body burdens and the relationship with blood pressure measures among indigenous adults. Environ Epidemiol 5(2):e137. https://doi.org/10.1097/ee9.0000000000000137.

Zwicker JD, Dutton DJ, Emery JC. 2014. Longitudinal analysis of the association between removal of dental amalgam, urine mercury and 14 self-reported health symptoms. Environ Health 13:95. https://doi.org/10.1186/1476-069x-13-95.

APPENDIX A. ATSDR MINIMAL RISK LEVEL WORKSHEETS

MRLs are derived when reliable and sufficient data exist to identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a given route of exposure. An MRL is an estimate of the daily human exposure to a hazardous substance that is likely to be without appreciable risk of adverse noncancer health effects over a specified route and duration of exposure. MRLs are based on noncancer health effects only; cancer effects are not considered. These substance-specific estimates, which are intended to serve as screening levels, are used by ATSDR health assessors to identify contaminants and potential health effects that may be of concern at hazardous waste sites. It is important to note that MRLs are not intended to define clean-up or action levels.

MRLs are derived for hazardous substances using the NOAEL/uncertainty factor approach. They are below levels that might cause adverse health effects in the people most sensitive to such chemical-induced effects. MRLs are derived for acute (1–14 days), intermediate (15–364 days), and chronic (≥365 days) durations and for the oral and inhalation routes of exposure. Currently, MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method suitable for this route of exposure. MRLs are generally based on the most sensitive substance-induced endpoint considered to be of relevance to humans. LOAELs for serious health effects (such as irreparable damage to the liver or kidneys, or serious birth defects) are not used as a basis for establishing MRLs. Exposure to a level above the MRL does not mean that adverse health effects will occur.

MRLs are intended only to serve as a screening tool to help public health professionals decide where to look more closely. They may also be viewed as a mechanism to identify those hazardous waste sites that are not expected to cause adverse health effects. Most MRLs contain a degree of uncertainty because of the lack of precise toxicological information on the people who might be most sensitive (e.g., infants, elderly, nutritionally or immunologically compromised) to the effects of hazardous substances. ATSDR uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health principle of prevention. Although human data are preferred, MRLs often must be based on animal studies because relevant human studies are lacking. In the absence of evidence to the contrary, ATSDR assumes that humans are more sensitive to the effects of hazardous substances than animals and that certain persons may be particularly sensitive. Thus, the resulting MRL may be as much as 100-fold below levels that have been shown to be nontoxic in laboratory animals.

APPENDIX A

Proposed MRLs undergo a rigorous review process: Health Effects/MRL Workgroup reviews within the Office of Innovation and Analytics, Toxicology Section, expert panel peer reviews, and agency-wide MRL Workgroup reviews, with participation from other federal agencies and comments from the public. They are subject to change as new information becomes available concomitant with updating the toxicological profiles. Thus, MRLs in the most recent toxicological profiles supersede previously published MRLs. For additional information regarding MRLs, please contact the Office of Innovation and Analytics, Toxicology Section, Agency for Toxic Substances and Disease Registry, 1600 Clifton Road NE, Mailstop S106-5, Atlanta, Georgia 30329-4027.

APPENDIX A

MINIMAL RISK LEVEL (MRL) WORKSHEET

Chemical Name: Elemental mercury
CAS Number: 7439-97-6
Date: October 2024
Profile Status: Final
Route: Inhalation
Duration: Acute

MRL Summary: There are insufficient data for derivation of an acute-duration inhalation MRL for elemental mercury.

Rationale for Not Deriving an MRL: No epidemiological studies investigating effects of acute-duration exposure to inhaled elemental mercury were identified. Acute-duration inhalation studies in humans are limited to accidental or intentional exposure to fatal or near-fatal levels of elemental mercury vapor.

Studies in rats and mice have identified several targets of toxicity including neurological alterations, neurodevelopmental effects, and renal effects. Acute-duration studies have also reported developmental outcome effects and reproductive effects in rats; however, given the limited number of studies reporting these effects, the data are insufficient to draw conclusions as to whether reproductive and developmental outcome effects are sensitive targets for elemental mercury. It is noted that the reported developmental and reproductive effects occur at higher elemental mercury concentrations than the neurological effects. Summaries of the lowest LOAELs for neurological, neurodevelopmental, renal, developmental, and reproductive endpoints are presented in Table A-1.

Table A-1. Selected NOAEL and LOAEL Values in Animals Acutely Exposed to Inhaled Elemental Mercury

Species	Duration	NOAEL/LOAEL (mg Hg/m³)		Effect	Reference
		NOAEL	LOAEL		
Neurodevelopmental					
Rat	7 days PNDs 11–17 1 hour/day (WB)	ND	0.05	Increased spontaneous locomotion and total activity and decreased rearing counts at 4 months of age; impaired spatial learning at 6 months of age	Fredriksson et al. 1992
Rat	7 days PNDs 11–17 4 hours/day (WB)	ND	0.05	Increased spontaneous locomotion and total activity and decreased rearing counts at 2 months of age; decreased spontaneous locomotion, total activity, and rearing counts at 4 months of age; and impaired spatial learning at 6 months of age	Fredriksson et al. 1992
Rat	6 days GDs 14–19 1.5 hours/day (WB)	ND	1.8	Increased spontaneous locomotion, rearing, and total activity at 4 months of age; impaired spatial learning	Fredriksson et al. 1996

APPENDIX A

Table A-1. Selected NOAEL and LOAEL Values in Animals Acutely Exposed to Inhaled Elemental Mercury

Species	Duration	NOAEL/LOAEL (mg Hg/m³)		Effect	Reference
		NOAEL	LOAEL		
Rat	8 days GDs 11–14 + GDs 17–20 1 or 3 hours/day (WB)	ND	1.8	Decreased spontaneous locomotion, rearing, and total activity at 3 months; reduced novel environment habituation at 7 months	Danielsson et al. 1993
Neurological					
Mouse	4 hours (WB)	ND	0.5	Reduced grip strength 4–7 months post-exposure, decreased motor axon diameter 7 months post-exposure	Stankovic 2006
Rat	GDs 6–15 2 hours/day (N)	4	8	Mild tremor, lethargy, unsteady gait	Morgan et al. 2002
Reproductive					
Rat	11 days 2 hours/day (N)	1	2	Prolonged estrous cycle	Davis et al. 2001
Rat	1–8 days 2 hours/day (N)	ND	2	Prolonged estrous cycle after 6–8 days exposure; immature corpora lutea during estrus and metestrus phases	Davis et al. 2001
Renal					
Rat	GDs 6–15 2 hours/day (N)	2	4	Elevated maternal relative kidney weight (32% on GD 15); increased urinary protein (80%) and ALP (943%)	Morgan et al. 2002
Developmental					
Rat	GDs 6–15 2 hours/day (N)	4	8	Increased resorptions, decreased litter size, decreased pup weight	Morgan et al. 2002

ALP = alkaline phosphatase; GD = gestation day; LOAEL = lowest-observed-adverse-effect level; (N) = nose-only exposure; ND = not determined; NOAEL = no-observed-adverse-effect level; PND = postnatal day; (WB) = whole-body exposure

The lowest LOAEL is 0.05 mg Hg/m³ for neurodevelopmental effects in rats exposed on PNDs 11–17 for 1 or 4 hours/day (Fredriksson et al. 1992). When the animals exposed for 4 hours/day were examined at 2 months of age, increased spontaneous locomotion and total activity and decreased rearing were observed. At 4 months of age, spontaneous locomotion and total activity were decreased in the group exposed for 4 hours/day and increased in the group exposed for 1 hour/day. At 6 months of age, impaired spatial learning was observed in the groups exposed for 1 and 4 hours/day. Similar effects were also observed in offspring of rats exposed to 1.8 mg Hg/m³ for 1.5 hours/day on GDs 14–19 and tested at 4 months of age (Fredriksson et al. 1996). Neurological effects consisting of reduced grip strength and

decreased motor axon diameter were reported in adult mice 4–7 months after a single 4-hour exposure (Stankovic 2006). At higher concentrations, non-neurological effects such as prolonged estrus cycle (Davis et al. 2001), increased resorptions and decreased pup weight (Morgan et al. 2002), and evidence of renal damage (Morgan et al. 2002) were observed.

Although there is strong evidence from epidemiological studies involving chronic exposure and acute- and intermediate-duration animal studies supporting the identification of neurotoxicity/ neuro-developmental toxicity as the critical effect, the acute-duration inhalation database was not considered adequate for derivation of an MRL. The Fredriksson et al. (1992) study, which identified the lowest LOAEL was not considered a suitable principal study for several reasons: (1) the daily exposure was short (1 or 4 hours/day) and there is uncertainty that the observed effects may not be predictive of continuous exposure; (2) the control group treatment was not identical to the exposed groups (i.e., the controls were placed in exposure chamber for 2 hours/day compared to 1 or 4 hours/day for the exposed groups); and (3) animals received whole-body exposure and no measures were taken to prevent mercury ingestion during preening or inhalation exposure from volatilization of mercury deposited on fur/skin.

Agency Contacts (Chemical Manager): Rae Benedict

MINIMAL RISK LEVEL (MRL) WORKSHEET

Chemical Name: Elemental mercury
CAS Number: 7439-97-6
Date: October 2024
Profile Status: Final
Route: Inhalation
Duration: Intermediate

MRL Summary: There are insufficient data for derivation of an intermediate-duration inhalation MRL for elemental mercury.

Rationale for Not Deriving an MRL: No intermediate-duration epidemiological studies were identified for elemental mercury. A number of animal studies have evaluated the toxicity of elemental mercury following intermediate-duration inhalation exposure. The results of these studies suggest that neurological and/or neurodevelopmental effects are the most sensitive outcomes. At higher concentrations, renal and male reproductive effects have also been reported. Neurological and/or neurodevelopmental effects observed in monkeys, rats, mice, and rabbits include decreased motor activity, impairments in learning and memory, and tremors (Fukuda 1971; Kishi et al. 1978; Newland et al. 1996; Yoshida et al. 2018). Renal effects include slight degenerative changes in the renal tubular epithelium (Kishi et al. 1978). The male reproductive effects included seminiferous tubule atrophy, and decreased spermatocyte and spermatids (Altunkaynak et al. 2015); it is noted that this is the only reproductive toxicity study on elemental mercury that examined male reproductive effects and the database is considered insufficient to draw conclusions.

Selected NOAEL and LOAEL values are presented in Table A-2. The lowest LOAEL is 0.188 mg Hg/m^3 for decreased motor activity on PND 77 in the offspring of mice continuously exposed to elemental mercury on PNDs 2–28 (Yoshida et al. 2018); the study only tested one concentration (in addition to a control group). The study did not find alterations in passive avoidance tests or working memory tests. Earlier studies by this group found no alterations in motor activity, learning, or memory in the offspring of mice exposed to 0.03 mg Hg/m^3 during GDs 0–18 (Yoshida et al. 2011) or in mice exposed to 0.057 mg Hg/m^3 on PNDs 1–20 (Yoshida et al. 2013).

Table A-2. Selected NOAEL and LOAEL Values in Animals Exposed to Inhaled Elemental Mercury for Intermediate Durations

Species	Duration	NOAEL/LOAEL (mg Hg/m^3)		Effect	Reference
		NOAEL	LOAEL		
Neurodevelopmental					
Mouse	PNDs 2–28 24 hours/day (WB)	ND	0.188	Decreased motor activity at PND 77	Yoshida et al. 2018
Monkey	15–17 weeks gestational exposure 5 days/week 4 or 7 hours/day (WB)	ND	0.5	Impaired operant training in offspring tested at 0.8–4 years of age	Newland et al. 1996

Table A-2. Selected NOAEL and LOAEL Values in Animals Exposed to Inhaled Elemental Mercury for Intermediate Durations

Species	Duration	NOAEL/LOAEL (mg Hg/m^3)		Effect	Reference
		NOAEL	LOAEL		
Mouse	GDs 0–18 6 hours/day (WB)	0.03	ND	No effect on motor activity, learning, or memory assessed on PND56	Yoshida et al. 2011
Mouse	PNDs 1–20 24 hours/day (WB)	0.057	ND	No effect on motor activity, learning, or memory assessed at 3 or 15 months of age	Yoshida et al. 2013
Neurological					
Rat	8 weeks 4–5 days/week 5 hours/day (WB)	ND	0.5	Irritability, aggressiveness; loss of Purkinje and granular cells in cerebellum	Sørensen et al. 2000
Reproductive					
Rat	6 weeks 7 days/week 9 hours/day (WB)	ND	1	Seminiferous tubule atrophy; damage to spermatogenic cells; decreased testicular and seminiferous tubule volume, decreased seminiferous tubule diameter; decreased Sertoli cells, spermatogonia, spermatocytes, and spermatids	Altunkaynak et al. 2015
Renal					
Rat	12–42 weeks 5 days/week 3 hour/day (WB)	ND	3	Slight degenerative changes (i.e., dense deposits in tubule cells and lysosomal inclusions) in the renal tubular epithelium	Kishi et al. 1978

GD = gestation day; LOAEL = lowest-observed-adverse-effect level ND = not determined; NOAEL = no-observed-adverse-effect level; PND = postnatal day; (WB) = whole-body exposure

The intermediate-duration inhalation database for elemental mercury was not considered adequate for MRL derivation. Although several studies have identified NOAELs and LOAELs for neuro-developmental effects (the presumed critical effect), most of the studies only tested a single concentration and the database was considered insufficient for establishing concentration-response relationships. It should also be noted that the highest NOAEL (0.057 mg Hg/m^3) for the intermediate-duration database is similar to the lowest LOAEL (0.05 mg Hg/m^3) identified for neurodevelopmental effects in the acute-duration inhalation database; this may be due to, but not limited to, species differences (mice versus rats) and/or differences in the study design (e.g., age at dosing and assessment, exposure duration, total exposure concentration, etc.).

Agency Contacts (Chemical Managers): Rae Benedict

APPENDIX A

MINIMAL RISK LEVEL (MRL) WORKSHEET

Chemical Name: Elemental mercury
CAS Number: 7439-97-6
Date: October 2024
Profile Status: Final
Route: Inhalation
Duration: Chronic
MRL   0.3 µg Hg/m^3 (3×10^{-4} mg Hg/m^3)
Critical Effect: Tremors
Reference: Bast-Pettersen et al. 2005; Boogaard et al. 1996; Chapman et al. 1990; Ellingsen
                          et al. 2001; Fawer et al. 1983; Langworth et al. 1992a; Wastensson et al. 2006,
                          2008
Point of Departure: 2.84 µg Hg/m^3 (95% lower confidence limit of weighted median of seven
principal   studies)
Uncertainty Factor: 10
LSE Graph Key: 29
Species: Human

MRL Summary: A chronic-duration inhalation MRL of 0.3 µg Hg/m^3 was derived for elemental mercury
based on tremors reported in several occupational exposure studies. The MRL is based on 2.84 µg
Hg/m^3, which is the 95% lower confidence limit of the weighted median of 4.92 µg Hg/m^3 calculated
using estimated air concentrations from seven studies, reported in eight publications (Bast-Pettersen et al.
2005; Boogaard et al. 1996; Chapman et al. 1990; Ellingsen et al. 2001; Fawer et al. 1983; Langworth et
al. 1992a; Wastensson et al. 2006, 2008) and a total uncertainty factor of 10 for human variability.

Selection of the Critical Effect: The available information on the toxicity of elemental mercury vapor
comes from numerous epidemiological studies of workers in the chloralkali, fluorescent lamp, lithium-6
purification, natural gas production, gold mining and processing, and thermometer industries and of
dental workers. Most epidemiological studies used urinary mercury levels (expressed as µg Hg/L or µg
Hg/g creatinine) as a biomarker of exposure, and some studies also provided work area or breathing zone
mercury levels. Reported UHg levels were converted to equivalent exposure concentrations by applying
a steady-state mass balance model (see the *Calculation of Estimated Air Concentration* section below for
additional information). No reliable chronic-duration animal studies were identified.

The epidemiological studies provide consistent evidence of neurological effects, specifically alterations in
color vision, tremor, nerve conduction velocity, and cognitive function. There is also suggestive evidence
of renal effects, particularly glomerular function decrements and tubular injury from epidemiological
studies. Neurotoxicity was selected as the critical effect based on the stronger weight of evidence
supporting an association with elemental mercury exposure.

Over 35 epidemiological studies have evaluated neurological outcomes among workers exposed to
mercury vapor; the most commonly assessed endpoints were decrements or loss in color vision, tremors,
and alterations in motor speed and fine motor coordination, and cognitive function (memory, and
integrative function), typically compared to a reference group. A list of the studies examining these
neurological effects is presented in Table A-3. For each study, observed biomarkers of exposure (e.g.,
UHg) were converted to estimates of exposure air concentrations and categorized as either an adverse-
effect level (AEL) if an adverse effect was observed or a no-adverse-effect level (NAEL) if no adverse
effect was observed (Appendix E has for definitions of AEL and NAEL). The aggregate median AEL
estimated air concentrations for the types of effects observed are similar, ranging from 8.8 to 13.9 µg

Hg/m^3 (for more details on how air concentrations were estimated, see the *Calculation of Estimated Air Concentration* section below).

Table A-3. Summary of Adverse Effect Levels for Neurological Effects Reported in Epidemiological Studies of Elemental Mercury

	Median (range) estimated air concentrations (µg Hg/m^3)	Number of exposed workers examined in each study	References
Color vision			
NAEL	ND (2.58)	21	Cavalleri and Gobba 1998
AEL	8.76 (0.914–8.74)	15–40	Barboni et al. 2008, 2009; Canto-Pereira et al. 2005; Cavalleri and Gobba 1998; Urban et al. 2003; Ventura et al. 2005
Tremor			
NAEL	4.75 (0.914–8.74)	43–200	Bast-Pettersen et al. 2005; Boogaard et al. 1996; Ellingsen et al. 2001; Harari et al. 2012; Langworth et al. 1992a; Wastensson et al. 2006, 2008
AEL	11.72 (0.422–63.1)	15–13,905	Albers et al. 1988; Anglen et al. 2015; Bittner et al. 1998; Chapman et al. 1990; Echeverria et al. 2005; Fawer et al. 1983; Frumkin et al. 2001; Harari et al. 2012; Iwata et al. 2007; Langolf et al. 1978; Letz et al. 2000; Miller et al. 1975; Roels et al. 1982; Tang and Li 2006; Verberk et al. 1986
Cognitive function			
NAEL	1.44 (0.072–4.57)	49–550	Bast-Pettersen et al. 2005; Factor-Litvak et al. 2003; Ritchie et al. 2002; Sletvold et al. 2012
AEL	13.9 (0.405–30.5)	26–426	Bluhm et al. 1992; Echeverria et al. 1998, 2005; Mathiesen et al. 1999; Ngim et al. 1992; Piikivi and Hanninen 1989; Piikivi et al. 1984; Sletvold et al. 2012; Smith et al. 1983

AEL = adverse-effect level; NAEL = no-adverse-effect level

The tremor endpoint was selected as the critical effect because more studies (20 studies) with larger populations have evaluated tremor compared to color vision (5 studies). Alterations in cognitive function was not selected as the critical effect because the studies evaluated various domains of cognitive function and the number of studies evaluating similar domains is small, as compared to the number of studies evaluating tremors. The NAELs and AELs for the epidemiological studies evaluating tremors are presented in Table A-4.

APPENDIX A

Table A-4. NAEL and AEL Values for Epidemiological Studies Evaluating Tremor

Study	Population	Number of subjects	Estimated air concentration (µg Hg/m^3) NAEL	AEL
Albers et al. 1988	Lithium 6 workers	247		42.6
Anglen et al. 2015	Dental workers	13,906		1.00
Bast-Pettersen et al. 2005	Chloralkali workers	49	4.57	
Bittner et al. 1998	Dental workers	230		11.7
Boogaard et al. 1996	Gas production	40	8.74	
Chapman et al. 1990	Chloralkali workers	18		4.92
Echeverria et al. 2005	Dental workers	427		0.422
Ellingsen et al. 2001	Chloralkali workers	47	4.43	
Fawer et al. 1983	Lamp and chloralkali workers	26		5.57
Frumkin et al. 2001	Chloralkali workers	139		18.7
Harari et al. 2012	Gold miners	200	0.914	
Harari et al. 2012	Gold merchants	37		10.2
Iwata et al. 2007	Cinnabar miners and smelters	27		63.1
Langolf et al. 1978	Chloralkali workers	79		51.1
Langworth et al. 1992a	Chloralkali workers	85	7.03	
Letz et al. 2000	Lithium 6 workers	104		38.4
Miller et al. 1975	Chloralkali workers	77		27.5
Roels et al. 1982	Chloralkali workers	43		13.8
Tang and Li 2006	Thermometer workers	143		10.7
Verberk et al. 1986	Lamp workers	20		9.88
Wastensson et al. 2006, 2008	Chloralkali workers	43	4.90	

AEL = adverse-effect level; NAEL = no-adverse-effect level

Selection of the Principal Study: Rather than selecting an individual study as the principal study, a group of seven studies, reported in eight publications, that provide information on the NAEL/AEL boundary were selected as the principal studies (see the *Selection of the Point of Departure* section for information on criteria for selecting these studies). Citations for the principal studies are listed below; summaries of these studies are included in Table A-5.

Bast-Pettersen R, Ellingsen DG, Efskind J, et al. 2005. A neurobehavioral study of chloralkali workers after the cessation of exposure to mercury vapor. Neurotoxicology 26(3):427-437.

Boogaard PJ, Houtsma A-T AJ, Journée HL, et al. 1996. Effects of exposure to elemental mercury on the nervous system and the kidneys of workers producing natural gas. Arch Environ Health 51(2):108-115.

Chapman LJ, Sauter SL, Henning RA, et al. 1990. Differences in frequency of finger tremor in otherwise asymptomatic mercury workers. Br J Ind Med 47(12):838-843.

APPENDIX A

Ellingsen DG, Bast-Pettersen R, Efskind J, et al. 2001. Neuropsychological effects of low mercury vapor exposure in chloralkali workers. Neurotoxicology 22(2):249-258.

Fawer RF, DeRibaupierre Y, Guillemin M, et al. 1983. Measurement of hand tremor induced by industrial exposure to metallic mercury. Br J Ind Med 40:204-208.

Langworth S, Almkvist O, Soderman E, et al. 1992a. Effects of occupational exposure to mercury vapour on the central nervous system. Br J Ind Med 49(8):545-555.

Wastensson G, Lamoureux D, Sällsten G, et al. 2006. Quantitative tremor assessment in workers with current low exposure to mercury vapor. Neurotoxicol Teratol 28(6):681-693.

Wastensson, G, Lamoureux, D, Sallsten G, et al. 2008. Quantitative assessment of neuromotor function in workers with current low exposure to mercury vapor. Neurotoxicol 29(4):596-604.

Table A-5. Summary of the Principal Studies Examining Tremor in Workers Exposed to Elemental Mercury

Reference: Bast-Pettersen et al. 2005

Study type and population: Retrospective cohort of 49 former chloralkali workers and 49 referents from Norway. Average duration of exposure of workers was 13.1 years. Average time elapsed since exposure ceased was 4.8 years.

Biomarkers:

UHg working (average µg Hg/g Cr/year, range)
  Referent: NA
  Exposed: 16.5 (7.1–45)

UHg at testing (mean µg Hg/g Cr, range)
  Referent: 2.0 (0.6–5.7)
  Exposed: 2.9 (0.4–9.2)

Estimated air concentration[a]: 4.57 µg Hg/m^3 (based on exposed working average)

Analysis: Subjects were excluded for history of alcohol abuse, major head injuries; or metabolic, major psychiatric or neurological disease that caused severe disability. Data were analyzed using ANOVA for comparison of means between exposure groups and referents.

Results:

Mean (range) of tremor intensity (m/s^2)
- Dominant hand, NS
  - Exposed: 0.12 (0.07–0.33)
  - Referent: 0.13 (0.07–0.40)
  - Mean ratio: 0.96 (95% CI 0.85, 1.10)
- Non-dominant hand, NS
  - Exposed: 0.12 (0.07–0.31)
  - Referent: 0.12 (0.06–0.51)
  - Mean ratio: 1.01 (95% CI 0.87, 1.17)

Mean (range) of frequency dispersion (Hz)
- Dominant hand, NS
  - Exposed: 2.9 (1.2–4.4)

Mean (range) of center frequency (Hz)
- Dominant hand, NS
  - Exposed: 7.4 (6.0–9.6)
  - Referent: 7.5 (5.8–10.6)
  - Mean difference: -0.1 (95% CI -0.5, 0.3)
- Non-dominant hand, NS
  - Exposed: 7.6 (5.9–10.8)
  - Referent: 7.4 (2.4–9.9)
  - Mean difference: 0.2 (95% CI -0.3, 0.6)

Mean (range) of harmonic index
- Dominant hand, NS
  - Exposed: 0.92 (0.80–0.97)
  - Referent: 0.91 (0.82–0.98)
  - Mean difference: 0.01 (95% CI -0.01, 0.02)

Table A-5. Summary of the Principal Studies Examining Tremor in Workers Exposed to Elemental Mercury

- o   Referent: 2.8 (0.9–4.3)
- o   Mean difference: 0.1 (95% CI -0.2, 0.4)
- Non-dominant hand, NS
  - o   Exposed: 3.3 (1.0–4.9)
  - o   Referent: 3.3 (1.1–6.4)
  - o   Mean difference: 0 (95% CI -0.3, 0.3)

- Non-dominant hand, NS
  - o   Exposed: 0.89 (0.82–0.98)
  - o   Referent: 0.89 (0.78–0.97)
  - o   Mean difference: 0 (95% CI -0.02, 0.02)

Interpretation: Tremor was not significantly different between exposed and referent groups; therefore, the working mean UHg in the exposed group (16.5 µg/g Cr) was considered to be a NAEL for tremor. The equivalent air mercury concentration (4.57 µg Hg/m^3) was weighted by the number of subjects in the exposed group (49).

Reference: Boogaard et al. 1996

Study type and population: Retrospective cohort of 40 natural gas workers (18 with "high" exposure; 22 with "low" exposure) and 19 referents from the Netherlands. Median (range) exposure time for high- and low-exposure workers was 9 years (1–15 years) and 10 years (3–20 years), respectively. Time elapsed since exposure ceased was not reported.

Biomarkers:

UHg working (median µg Hg/L, range)
  Referent: 3 (1–8)
  High exposure: 41 (7–72)
  Low exposure: 12 (7–53)

UHg at testing (median µg Hg/L, range)
  Referent: 2 (0.5–6.8)
  High exposure: 17 (3.5–71.9)
  Low exposure: 5 (0.6–8.8)

Estimated air concentration[a]: 8.74 µg Hg/m^3 (based on high working median)

Analysis: Subjects were excluded for history of nonoccupational neuropathies or disorders with potential renal sequelae. Data were analyzed using MANOVA for comparison of means between exposure groups and referents. Multivariate regression analysis was performed for the entire population (referents plus exposed).

Results:

Mean (median; range) of resting tremor
- Right hand, NS
  - o   High exposed: 6.49 (6.5; 1.4–10.3)
  - o   Low exposed: 6.45 (5.95; 2.3–10.2)
  - o   Referent: 6.34 (6.0; 3.9–9.2)
- Left hand, NS
  - o   High exposed: 5.94 (4.9; 2.9–10.4)
  - o   Low exposed: 6.60 (6.8; 2.9–10.5)
  - o   Referent: 6.64 (6.8; 3.6–10.1)

Mean (median; range) of intention tremor
- Right hand, NS
  - o   High exposed: 5.09 (4.85; 3.9–8.0)
  - o   Low exposed: 5.38 (5.2; 3.7–10.8)
  - o   Referent: 5.22 (5.2; 3.9–6.7)
- Left hand, NS
  - o   High exposed: 5.15 (4.9; 4.2–8.0)
  - o   Low exposed: 5.50 (5.3; 4.2–10.6)
  - o   Referent: 5.39 (5.6; 3.9–6.2)

No significant correlation between tremor measures and present or historical UHg levels (data not shown).

APPENDIX A

Table A-5. Summary of the Principal Studies Examining Tremor in Workers Exposed to Elemental Mercury

Mean (median; range) of action tremor
- Right hand, NS
  - High exposed: 6.61 (7.05; 2.2–10.3) (lower end of range reported as 97.05)
  - Low exposed: 7.39 (7.4; 2.0–12.3)
  - Referent: 6.67 (7.5; 2.4–9.0)
- Left hand, NS
  - High exposed: 6.76 (6.8; 2.3–12.0
  - Low exposed: 7.75 (7.55; 1.6–11.4)
  - Referent: 7.00 (7.7; 2.5–9.5)

Interpretation: No significant association between UHg and tremor; therefore, the working median UHg in the high exposure group (41 µg/L) is a NAEL for tremor. The equivalent air mercury concentration (8.74 µg Hg/m^3) was weighted by the number of subjects in the high exposure group (40).

Reference: Chapman et al. 1990

Study type and population: Cross-sectional cohort of 18 mercury battery workers and 18 referents from the United States. Average exposure time (range) for workers was 5.3 (0.3–32) years.

Biomarkers:
UHg at testing (mean µg Hg/L, SD)
  Exposed: 23.1 (28.3)
  Referent: Not measured

Estimated air concentration[a]: 4.92 µg Hg/m^3

Analysis: Subjects were excluded for previous or current injuries or illnesses with neuropathic potential and neurotoxic drug or chemical exposures. Data were analyzed using non-parametric Mann-Whitney test to compare means between exposed and referent subjects, adjusted for the four comparison metrics.

Results:

Mean (SD) of hand tremor amplitude, NS
- Exposed: 35.6 (2.5)
- Referent: 23.0 (6.5)

Mean (SD) of hand tremor power, p<0.01
- Exposed: 315.0 (37.0)
- Referent: 68.0 (5.0)

Mean (SD) of hand tremor half power frequency, NS
- Exposed: 7.8 (0.9) Hz
- Referent: 7.5 (0.6) Hz

Mean (SD) of tremor highest band power (5–15 Hz), p<0.001
- Exposed: 2.6 (2.3)
- Referent: 1.5 (0.6)

Interpretation: Tremor was significantly higher in the exposed group; therefore, the mean UHg in the exposed group (23.1 µg/L) is an AEL for tremor. The equivalent air mercury concentration (4.92 µg Hg/m^3) was weighted by the number of subjects in the exposed group (18).

APPENDIX A

Table A-5. Summary of the Principal Studies Examining Tremor in Workers Exposed to Elemental Mercury

Reference: Ellingsen et al. 2001

Study type and population: Retrospective cohort of 47 former chloralkali workers exposed for at least one year, and 47 referents; from Norway. Average exposure duration of 13.3 years.

Biomarkers:
UHg working (average µg Hg/g Cr/year, range)
  Referent: NA
  Exposed: 16.0 (7.1–35)

UHg at testing (mean µg Hg/g Cr, range)
  Referent: 2.3 (0.4–8.9)
  Exposed: 10.5 (2.0–30)

Estimated air concentration[a]: 4.43 µg Hg/m^3 (exposed)

Analysis: Subjects were excluded for alcohol abuse, major heads injuries; or metabolic, psychiatric, neurologic or other diseases causing severe disability. Data on intentional hand steadiness were analyzed by ANOVA of means between exposed and referents.

Results:
Mean (SD) of static steadiness (number of hits)
- Dominant hand, NS
  - Exposed: 126.5 (113.3)
  - Referent: 123.4 (117.0)

- Non-dominant hand, NS
  - Exposed: 112.5 (71.6)
  - Referent: 120.0 (90.7)

Mean (SD) of static steadiness (duration of hits, s)
- Dominant hand, NS
  - Exposed: 7.2 (5.5)
  - Referent: 6.8 (4.4)

- Non-dominant hand, NS
  - Exposed: 7.6 (5.0)
  - Referent: 7.9 (5.1)

Interpretation: Tremor was not significantly different between exposed and referent groups; therefore, the working mean UHg in the exposed group (16.0 µg/g Cr) is a NAEL for tremor. The equivalent air mercury concentration (4.43 µg Hg/m^3) was weighted by the number of subjects in the exposed group (47).

Reference: Fawer et al. 1983

Study type and population: Cross-sectional cohort of florescent lamp workers (n=7), chloralkali workers (n=12), acetaldehyde production workers (n=7), and 25 referents from Belgium. Average exposure time (±SE) for workers was 15.3±2.6 years

Biomarkers:
UHg at testing (mean µg Hg/g Cr, SE)[b]
  Referent: 6.0 (1.2)
  Exposed: 20.1 (2.1)

Estimated air concentration: 5.57 µg Hg/m^3

Analysis: Criteria for excluding participation in the study were not reported. Data were analyzed by t-test of means between exposed and referents or paired t-test for changes between rest and load.

APPENDIX A

Table A-5. Summary of the Principal Studies Examining Tremor in Workers Exposed to Elemental Mercury

---

Results:

Mean (SE) for highest peak frequency of hand tremor

- At rest, p<0.001
  - Referent: 6.40 (0.19) Hz
  - Exposed: 7.60 (0.22) Hz
- Changes between rest and load, p<0.001
  - Referent: 2.69 (0.19) Hz
  - Exposed: 3.62 (0.29) Hz

Mean (SE) for second moment

- At rest, p>0.002
  - Referent: 10.9 (1.1) Hz
  - Exposed: 13.3 (0.9) Hz
- Changes between rest and load, p<0.002
  - Referent: 0.9 (1.1) Hz
  - Exposed: 4.1 (1.2) Hz

Interpretation: Tremor was significantly higher in the exposed group; therefore, the mean UHg in the exposed group (20.1 µg/g Cr) is an AEL for tremor. The equivalent air mercury concentration (5.57 µg Hg/m³) was weighted by the number of subjects in the exposed group (26).

Reference: Langworth et al. 1992a

Study type and population: Cross-sectional cohort of 89 chloralkali workers and 75 referents from Sweden. Average exposure time (±SD) for workers was 13.5±8.7 years.

Biomarkers:
UHg at testing and while working[b] (median µg Hg/g Cr, range)
  Referent: 1.9 (0–7.6)
  Exposed: 25.4 (0.5–83.3)

Estimated air concentration[a]: 7.03 µg Hg/m³

Analysis: Subjects were excluded for alcohol abuse, exposure to other heavy metals or organic solvents; or chronic neurological or kidney disease. Data analyzed using the Student's t test.

Results:

Incidence of slight finger tremor, NS

- Referent: 13/75 (17%)
- Exposed: 17/89 (19%)

Forearm tremor (exposed vs referents), NS

- Tremor frequency spectrum
- Tremor acceleration amplitude

Interpretation: Tremor was not significantly different in the exposed and referent group; therefore, the median UHg in the exposed group (24.4 µg/g Cr) is a NAEL for tremor. The equivalent air concentration (7.03 µg Hg/m³) was weighted by the number of subjects in the exposed group who were evaluated for tremor (85 of 89).

APPENDIX A

Table A-5. Summary of the Principal Studies Examining Tremor in Workers Exposed to Elemental Mercury

Reference: Wastensson et al. 2006, 2008

Study type and population: Retrospective cohort of 43 chloralkali workers and 22 referents from Sweden. The average exposure time for workers was 15 years.

Biomarkers:
UHg cumulative work index (mean µg year/g Cr, range)
  266 (8–1,440)
UHg average (calculated as 266/15 mean years worked)
17.7 µg/g Cr
UHg at testing (median µg Hg/g Cr, range)
  Exposed: 5.9 (1.3–25)
  Referent: 0.7 (0.2–4.1)

Estimated air concentration: 4.90 µg Hg/m^3 (based on cumulative work mean/mean years worked)

Analysis: Subjects were excluded based on medications, diseases (e.g., diabetes), essential tremor, skull or whiplash injury, or other circumstances that could affect tremor or coordination (e.g., pain in upper limb, lack of sleep, nervousness, colds). Data were analyzed using Student's t-test (n >20), Wilcoxon's rank sum test, chi-squared test, or Fisher's exact test to compare means between exposed and referents. Associations between the tremor measures and UHg were evaluated using Spearman's correlation coefficients (exposed and referent subjects combined). Multivariate linear regression was conducted, adjusting for age, shift work, and smoking.

Results:
Incidence (%) of clinically diagnosed tremor, NS
- Any tremor
  - Referent: 3/22 (14)
  - Exposed: 7/43 (16)
- Rest tremor
  - Referent: 0/22 (0)
  - Exposed: 1/43 (2)
- Postural tremor
  - Referent: 3/22 (14)
  - Exposed: 5/43 (12)
- Intention tremor
  - Referent: 2/22 (9)
  - Exposed: 5/43 (12)

Spearman's correlation coefficients for:
Postural hand tremor in laser-based system
- Amplitude (RMS), NS
  - Dominant hand: -0.01
  - Non-dominant hand: -0.11
- Proportional power (4–6 Hz), p<0.05
  - Dominant hand: -0.07
  - Non-dominant hand: 0.26
    - Adjusted linear regression NS after exclusion of one outlier

Spearman's correlation coefficients for:
Postural hand tremor in CATSYS system
- Tremor intensity (RMS), NS
  - Dominant hand: 0.00
  - Non-dominant hand: 0.03
- Tremor index, NS
  - Dominant hand: -0.06
  - Non-dominant hand: 0.04
Static hand tremor in laser-based system (1st recording, 2nd recording)
- Amplitude (RMS), NS
  - Dominant hand: -0.05, -0.07
  - Non-dominant hand: -0.10, -0.17
Kinetic hand tremor in laser-based system
- Mean tracking error, NS
  - Dominant hand: 0.00
  - Non-dominant hand: 0.01
Hand tremor detected during rapid pointing movements
- Tremor, NS
  - Dominant hand: -0.03
  - Non-dominant hand: -0.09

APPENDIX A

Table A-5. Summary of the Principal Studies Examining Tremor in Workers Exposed to Elemental Mercury

---

Interpretation: The outcome was designated as a NAEL because the weight of evidence did not support a significant difference in tremor between exposed and referents. Tremor based on all laser measurements was not significant. The only metric that was significant based on the CATSYS measurement was tremor index, which was different when means were assessed by the t-test, but was not significant when medians were assessed by the Wilcoxon rank sum test. Therefore, the UHg average in the workers (17.7 µg/g Cr) is a NAEL for tremor. The equivalent air concentration (4.90 µg Hg/m^3) was weighted by the number of subjects in the exposed group (43).

---

[a]See the *Calculation of Estimated Air Concentration* section below for how air concentrations were calculated.
[b]Reported as µmol Hg/mol creatinine and converted to µg Hg/g creatinine as follows: (µmol Hg/mol Cr x µg Hg/µmol Hg)/g Cr/mol Cr.

AEL = adverse-effect level; ANOVA = analysis of variance; CI = confidence interval; Cr = creatinine; MANOVA = multivariate analysis of variance; NAEL = no-adverse-effect level; NS = not significant; RMS = root mean square; SD = standard deviation; SE = standard error; UHg = urine mercury

Selection of the Point of Departure: The MRL was based on a 95% lower confidence limit of the weighted median estimated air concentration of 2.84 µg Hg/m^3, based on the seven principal studies.

Typically, the point of departure (POD) would be highest NAEL or lowest AEL. The problem with this approach being applied to the occupational worker tremor studies is that there is substantial overlap in reported NAELs and AELs. The overlap between the lower end of the AEL range and the NAEL range does not support selection of any single NAEL or AEL as a POD. As an alternative approach, the following was assumed:

1. A NAEL/AEL boundary exists and is located somewhere within the range of overlapping NAELs and AELs.
2. Each NAEL and AEL in this range represents an independent estimate of the NAEL/AEL boundary.
3. The best estimate of the NAEL/AEL boundary is the weighted median of the set of overlapping NAELs and AELs (weighted for study size which assumes greater confidence in estimates from larger studies).
4. The lower 95% confidence limit on the median was selected as the POD, to account for uncertainty in the estimated weighted median.

This approach avoids having to make a highly uncertain selection of a single study as the basis for the POD and, instead, utilizes information from multiple studies to identify an exposure that is most likely to be the NAEL/AEL boundary.

Overlapping NAELs and AELs include all AELs that are less than or equal to the highest NAEL for the outcome, plus all NAELs that are greater than or equal to the lowest AEL. For tremor, the highest NAEL is 8.74 µg Hg/m^3 (Boogaard et al. 1996) and the lowest reliable AEL is 4.90 µg Hg/m^3 (Wastensson et al. 2006, 2008). For selection of the studies to include in the estimate of the POD, all AELs that were <9 µg/m^3 and all NAELs that were >4 µg/m^3 were included in the calculation of the weighted mean. The NAELs and AELs for the principal studies that met the selection criteria are presented in Table A-6. Note that the Anglen et al. (2015) study was omitted for the following reasons: (1) during the 32-year retrospective period, mean UHg levels declined from 20 to 2 µg Hg/L, making it difficult to assign a central estimate UHg level to the outcome; and (2) tremor outcome was self-reported. The Echeverria et

al. (2005) study was omitted because of the extremely low AEL and low confidence in the reported mean
UHg levels being representative of the steady state, given the expected highly intermittent exposures of
dentists to mercury vapor.

Table A-6. NAEL and AEL Values for Studies Defining the NAEL/AEL Boundary for Tremor

Study	Population	Number of subjects	POD	Estimated air concentration ($\mu g\ Hg/m^3$)
Bast-Pettersen et al. 2005	Chloralkali workers	49	NAEL	4.57
Boogaard et al. 1996	Gas production	40	NAEL	8.74
Ellingsen et al. 2001	Chloralkali workers	47	NAEL	4.43
Langworth et al. 1992a	Chloralkali workers	85	NAEL	7.03
Wastensson et al. 2006, 2008	Chloralkali workers	43	NAEL	4.90
Chapman et al. 1990	Chloralkali workers	18	AEL	4.92
Fawer et al. 1983	Lamp and chloralkali workers	26	AEL	5.57
Median: 4.92 $\mu g/m^3$ (95% CI 3.02, 6.82)				
Weighted median: 4.92 $\mu g/m^3$ (95% CI 2.84, 7.00)				

AEL = adverse-effect level; CI = confidence interval; NAEL = no-adverse-effect level; POD = point of departure

For the principal studies, the unweighted median estimated air concentration is 4.92 $\mu g\ Hg/m^3$ (95% CI
3.02, 6.82) and the weighted median estimated air concentration is 4.92 $\mu g\ Hg/m^3$ (95% CI 2.84, 7.00).
The 95% lower confidence limit of the weighted median is 2.84 $\mu g\ Hg/m^3$, which was selected as the
POD for the MRL to account for uncertainty in the estimate of the median. Sensitivity of the POD to
individual studies was tested by recomputing the POD after removing one of the studies. The POD was
not highly influenced by removal of any single study. The mean of PODs calculated from censored data
sets was 3.30 (range: 2.51–3.86).

Calculation of Estimated Air Concentration: Total mercury levels in urine ($\mu g\ Hg/L$ or $\mu g\ Hg/g$
creatinine) were used as the exposure metric for estimating human exposures ($\mu g\ Hg/m^3$) to mercury
vapor. The urine biomarker is considered to be a more accurate reflection of mercury body burden than
reported measurements of room air or breathing zone mercury concentrations, which were likely to be
highly intermittent and variable. Non-occupational sources, including diet and mercury amalgam dental
restorations, are likely to have contributed to the urinary mercury observed in the occupational studies
that provide the basis for the chronic inhalation MRL. However, occupational exposures are likely to
have been the dominant source of urinary mercury in the principal studies and support the use of urinary
mercury for estimating air exposure concentrations. For example, it is unlikely that diet could account for
the urinary mercury levels observed in the principal studies. Based on the urinary levels, the estimated
inhaled mercury doses in the principal studies ranged from 1 to 2 $\mu g/kg/day$ (approximately 70–
140 $\mu g/day$ for a 70-kg adult). By contrast, dietary mercury intakes have been estimated to range from
1 to 10 $\mu g/day$ (Section 5.6, General Population Exposure). Another possible contributor to urinary
mercury in the occupational studies would have been mercury released from mercury amalgam
restorations. However, total mercury absorption in a person having 13 restorations was estimated to be
approximately 3 $\mu g/day$ (range 0.6–9.3; Section 5.6, General Population Exposure). Based on these
estimates, it is likely that the dominant source of urinary mercury in the principal studies was
occupational exposure to mercury, predominantly inhalation of mercury vapor, given the working
environments described in these studies.

Reported UHg levels (mean or median for the study population) were converted to equivalent exposure concentrations by applying a steady-state mass balance model which did the following: (1) converted the reported urine level (assumed to represent steady state) to an equivalent steady-state excretion rate (µg Hg/day/kg body weight), and (2) converted the steady-state excretion rate to an equivalent steady-state exposure (µg Hg/m^3). The assumption of steady state requires that the exposures were relatively constant for periods >272 days. This is the exposure duration that would achieve 95% of steady-state body burden, assuming a terminal elimination half-time of 62 days (Jonsson et al. 1999; Equation 1):

$$Time\ to\ steady\ state = \frac{\ln(1-0.95)}{k_e}$$ Eq. (1)

where 0.95 is the fraction of steady state and k_e is ln(2)/half-time.

An alternative to the steady-state mass balance model would be to implement the complete biokinetics model described by Jonsson et al. (1999). However, this is not needed for the epidemiology or clinical studies used in the derivation of the MRL because the steady-state assumption can be reasonably assured for the exposures in these study groups. However, it must be assumed that the mean or median urine levels in each study adequately represent the corresponding steady-state exposures. Although there is an unknown level of uncertainty in this assumption, the same assumption would also apply to the application of the complete biokinetic model.

The calculated exposure concentration represents the continuous exposure that would achieve a steady-state UHg level equal to the observed mean urinary mercury level. Calculated exposure concentrations based on urinary levels are likely to be less than measured air concentrations observed during the workday by at least a factor of 3, assuming an 8-hour workday, because continuous exposure is assumed to occur 7 days/week 24 hours/day.

Conversion of UHg levels to equivalent steady-state excretion rates. UHg levels reported as µg Hg/g creatinine were converted to equivalent excretion rates (µg Hg/day) assuming a standard steady-state excretion rate of creatinine per kg of lean body mass. A more detailed example of this approach is given in ATSDR (2012) where it was used in the derivation of MRLs for cadmium. The rate of excretion of mercury (Hg$_{ur}$, µg Hg/day) was calculated as the product of the urinary level (µg Hg/g creatinine) and the urinary excretion rate of creatinine (g creatinine/day; Equation 2).

$$Hg_{ur} = Hg\ conc_{ur} \cdot Cr_{ur}$$ Eq. (2)

where Hg_{ur} is the rate of excretion of mercury (µg/day), $Hg\ conc_{ur}$ is the mercury concentration (µg/g creatinine) and Cr_{ur} is the rate of excretion of creatinine (g creatinine/day).

The rate of creatinine excretion (Cr$_{ur}$; g creatinine/day) was calculated from the relationship between lean body mass (LBM) and Cr$_{ur}$ (Equation 3):

$$LBM = 27.2 \cdot Cr_{ur} + 8.58$$ Eq. (3)

where the constants 27.2 and 8.58 are the sample size-weighted arithmetic mean of estimates of these variables from eight studies reported in Forbes and Bruining (1976). LBM was estimated as follows (ICRP 1981; Equation 4 and 5):

$$LBM\ of\ adult\ females = BW \cdot 0.85$$ Eq. (4)

APPENDIX A

$$LBM\ of\ adult\ males = BW\ \cdot 0.88 \qquad\qquad \text{Eq. (5)}$$

where the central tendency for adult body weight for males and females were assumed to be 70 and 58 kg for adult European/American males and females, respectively (ICRP 1981). Equation 5 predicts a lean body mass of 61.6 kg for a 70-kg male, which is similar to a mean lean body mass of 58.3 kg estimated for adults in the NHANES 1999–2006 (Lee et al. 2017c). These equations are applicable to higher average U.S. adult body weights (EPA 2011) because increases in average body weight in the United States derive primarily from increased body fat rather than increased average lean body mass (Hales et al. 2020). UHg levels reported as µg Hg/L were converted to equivalent excretion rates (µg Hg/day) assuming a standard rate of urine output of 1.5 L/day (approximately 1 L/day/kg body weight; CDC 2002; Equation 6).

$$Hg_{ur} = Hg\ conc_{ur} \cdot V_{ur} \qquad\qquad \text{Eq. (6)}$$

where $Hg\ conc_{ur}$ is the mercury concentration (µg/L) and V_{ur} is the urine output (L/day).

The validity of the above approach was evaluated based on data reported in Frumkin et al. (2001) that reported mean UHg levels in units of µg Hg/g creatinine and µg Hg/L for 147 exposed chloralkali workers and 132 referents. For workers, the mean urinary levels were 3.42 µg Hg/L and 2.76 µg Hg/creatinine. The model predicted 3.6 µg Hg/L for an assumed 2.76 µg Hg/g creatinine. For referents, the mean urinary levels were 3.12 µg Hg/L and 2.31 µg Hg/creatinine, and the model predicted 3.0 µg Hg/L for an assumed 2.31 µg Hg/g creatinine.

Conversion of mercury excretion rate (µg Hg/day/kg) to an equivalent steady-state exposure (µg Hg/m³). Steady-state exposures corresponding to steady-state rates of urinary excretion of mercury were calculated based on a simplified steady-state mass balance implementation of the biokinetic models reported by Jonsson et al. (1999). The simplified model is given by Equation 7:

$$Hg_{air} = \frac{Hg_{ur}}{f_r \cdot f_u \cdot IR} \qquad\qquad \text{Eq. (7)}$$

where Hg_{ur} is the mercury excretion rate (µg Hg/day) calculated from UHg levels reported as µg Hg/g creatinine or µg Hg/L as described above; f_r is the fraction of the inhaled dose initially retained in the body (0.80; Leggett et al. 2001); f_u is the fraction of the retained mercury excreted in urine (0.55; Jonsson et al. 1999); and IR is the inhalation rate (16 m³/day; EPA 2011).

Results from the mass balance model were compared to the results obtained from the Jonsson et al. (1999) biokinetics model (implemented in MATLAB). Both models predicted 0.5 for the inhalation dose (µg Hg/day)/UHg excretion rate (µg Hg/day) ratio.

Predictions of dose conversion coefficients from the steady-state mass balance model. The model predicts the following steady-state relationships between exposure levels and UHg levels:

Steady-state air concentration (µg Hg/m³) = steady-state UHg (µg Hg/g creatinine) × 0.258
Steady-state air concentration (µg Hg/m³) = steady-state UHg (µg Hg/L) × 0.198

APPENDIX A

Example of conversion of steady-state UHg levels (20.1 µg Hg/g creatinine; Fawer et al. 1983) to equivalent steady-state air mercury levels (5.57 µg Hg/m³):

Convert body weight (BW, kg) to lean body mass (LBM, kg; Equation 5):

$$LBM \; of \; adult \; males = BW \; \times 0.88$$

$$LBM = 70 \; \times 0.88 = 61.6$$

where 0.88 is the proportionality coefficient for males at 70 kg body weight (ICRP 1981).

Convert lean body mass (LBM, kg) to rate of urinary excretion of creatinine (Cr$_{ur}$; g creatinine/day; Equation 3):

$$LBM = 27.2 \; \times Cr_{ur} + 8.58$$

which rearranges to:

$$Cr_{ur} = \frac{LBM - 8.58}{27.2}$$

$$Cr_{ur} = \frac{61.6 - 8.58}{27.2} = 1.949$$

where the constants 27.2 and 8.58 are the sample size-weighted arithmetic mean of estimates of these variables from eight studies reported in (Forbes and Bruining 1976).

Convert urinary mercury (UHg$_{cr}$, 20.1 µg Hg/g creatinine, Fawer et al. 1983) to rate of urinary excretion of mercury (Hg$_{ur}$, µg/day; Equation 2):

$$Hg_{ur} = UHg_{cr} \times Cr_{ur}$$

$$Hg_{ur} = 20.1 \times 1.949 = 39.17$$

where f_r is the fraction of the inhaled dose initially retained in the body (0.80; Leggett et al. [2001]); f_u is the fraction of the retained mercury excreted in urine (0.55; Jonsson et al. 1999); and IR is the inhalation rate (16 m³/day; EPA 2011).

Convert rate of urinary excretion of mercury (Hg$_{ur}$, µg Hg/day) to air concentration (Hg$_{air}$, µg Hg/m³; Equation 7):

$$Hg_{air} = \frac{Hg_{ur}}{f_r \; \times \; f_u \; \times \; IR}$$

$$Hg_{air} = \frac{39.17}{0.80 \times 0.55 \times 16} = 5.57$$

Example of conversion of steady-state UHg levels (41.0 μg Hg/L; Boogaard et al. 1996) to equivalent steady-state air mercury levels (8.74 μg Hg/m³):

Convert urinary mercury (UHg$_L$, 41.0 μg Hg/L, Boogaard et al. 1996) to rate of urinary excretion of mercury (Hg$_{ur}$, μg/day; Equation 6):

$$Hg_{ur} = UHg_L \times UFR$$

$$Hg_{ur} = 41.0 \times 1.5 = 61.50$$

where UFR is the urine flow rate (1.5 L/day; approximately 1 L/day/kg body weight; CDC 2002).

Convert rate of urinary excretion of mercury (Hg$_{ur}$, μg Hg/day) to air concentration (Hg$_{air}$, μg Hg/m³; Equation 7):

$$Hg_{air} = \frac{Hg_{ur}}{f_r \times f_u \times IR}$$

$$Hg_{air} = \frac{61.50}{0.80 \times 0.55 \times 16} = 8.74$$

where f_r is the fraction of the inhaled dose initially retained in the body (0.80; Leggett et al. [2001]); f_u is the fraction of the retained mercury excreted in urine (0.55; Jonsson et al. 1999); and IR is the inhalation rate (16 m³/day; EPA 2011).

Uncertainty Factor: The 95% lower confidence limit (LCL) of the weighted median of the seven principal studies (Table A-6) is divided by a total uncertainty factor (UF) of 10.

- 10 for human variability

> Weighted Median$_{95\%LCL}$ ÷ UFs = MRL
> 2.84 μg Hg/m³ ÷ 10 = 0.28 μg Hg/m³ ≈ 0.3 μg Hg/m³

Other Additional Studies or Pertinent Information: A large number of studies in workers exposed to mercury vapor in various industries provide consistent evidence of the neurotoxicity of elemental mercury (Section 2.16.2, Elemental Mercury—Epidemiological Studies, for citations). A few shorter-term studies in animals also demonstrate neurotoxicity in animals exposed as adults; observed effects include impaired motor function and damage to the central nervous system (Ashe et al. 1953; Fukuda 1971; Sørensen et al. 2000; Stankovic 2006). Additionally, several animal studies have reported neurodevelopmental effects including altered motor activity and altered learning (Danielsson et al. 1993; Fredriksson et al. 1992, 1996; Yoshida et al. 2018).

Agency Contacts (Chemical Managers): Rae Benedict

APPENDIX A

MINIMAL RISK LEVEL (MRL) WORKSHEET

Chemical Name: Elemental mercury
CAS Number: 7439-97-6
Date: October 2024
Profile Status: Final
Route: Oral
Duration: Acute

MRL Summary: There are insufficient data for derivation of an acute-duration oral MRL for elemental mercury.

Rationale for Not Deriving an MRL: No acute-duration oral studies in humans or animals were identified.

Agency Contacts (Chemical Managers): Rae Benedict

APPENDIX A

MINIMAL RISK LEVEL (MRL) WORKSHEET

Chemical Name: Elemental mercury
CAS Number: 7439-97-6
Date: October 2024
Profile Status: Final
Route: Oral
Duration: Intermediate

MRL Summary: There are insufficient data for derivation of an intermediate-duration oral MRL for elemental mercury.

Rationale for Not Deriving an MRL: No intermediate-duration oral studies in humans or animals were identified.

Agency Contacts (Chemical Managers): Rae Benedict

APPENDIX A

MINIMAL RISK LEVEL (MRL) WORKSHEET

Chemical Name: Elemental mercury
CAS Number: 7439-97-6
Date: October 2024
Profile Status: Final
Route: Oral
Duration: Chronic

MRL Summary: There are insufficient data for derivation of a chronic-duration oral MRL for elemental mercury.

Rationale for Not Deriving an MRL: No chronic-duration oral studies in humans or animals were identified.

Agency Contacts (Chemical Managers): Rae Benedict

MINIMAL RISK LEVEL (MRL) WORKSHEET

Chemical Name: Mercury, inorganic salts (mercuric acetate, mercuric chloride, mercuric sulfide)
CAS Numbers: 1600-27-7, 7487-94-7, 1344-48-5
Date: October 2024
Profile Status: Final
Route: Inhalation
Duration: Acute

MRL Summary: There are insufficient data for derivation of an acute-duration inhalation MRL for inorganic mercury salts.

Rationale for Not Deriving an MRL: No human or animal studies evaluating acute-duration inhalation exposure to inorganic mercury salts or other inorganic mercury compounds were identified. Therefore, an acute-duration inhalation MRL was not derived.

Agency Contacts (Chemical Managers): Rae Benedict

APPENDIX A

MINIMAL RISK LEVEL (MRL) WORKSHEET

Chemical Name: Mercury, inorganic salts (mercuric acetate, mercuric chloride, mercuric sulfide)
CAS Numbers: 1600-27-7, 7487-94-7, 1344-48-5
Date: October 2024
Profile Status: Final
Route: Inhalation
Duration: Intermediate

MRL Summary: There are insufficient data for derivation of an intermediate-duration inhalation MRL for inorganic mercury salts.

Rationale for Not Deriving an MRL: No human studies or animal studies evaluating intermediate-duration inhalation exposure to inorganic mercury salts were identified. Two studies in rats evaluated effects of inhalation exposure to mercuric oxide on neurological (Altunkaynak et al. 2019) and female reproductive systems (Altunkaynak et al. 2016). In rats exposed to 1 mg Hg/m^3 for 45 days (9 hours/day), cerebellar gliosis and perineuronal and perivascular vacuolization, reduced cerebellar volume, and decreased number and density of Purkinje cells were observed (Altunkaynak et al. 2019). Purkinje cells from treated animals showed irregular cellular boundaries, eosinophilic cytoplasm, and heterochromatic nuclei. In female rats exposed to 0.9 mg Hg/m^3 for 45 days (24 hours/day), significant ovarian damage was observed, including thickened tunica albuginea, increased fibrils within connective tissue, congested capillaries and blood vessels, thinned walls of large and dilated veins, fibrin deposits in veins, edema and maldeveloped follicles in the stroma, and irregular oocyte borders within follicles (Altunkaynak et al. 2016). Treated females also showed reduced ovary volume and decreased number of follicles. Both studies evaluated a single exposure level and other systems were not evaluated. Therefore, effects of inhalation exposure to inorganic mercury have not been sufficiently characterized to derive an intermediate-duration inhalation MRL for inorganic mercury salts or other inorganic compounds.

Agency Contacts (Chemical Managers): Rae Benedict

APPENDIX A

MINIMAL RISK LEVEL (MRL) WORKSHEET

Chemical Name: Mercury, inorganic salts (mercuric acetate, mercuric chloride, mercuric sulfide)
CAS Numbers: 1600-27-7, 7487-94-7, 1344-48-5
Date: October 2024
Profile Status: Final
Route: Inhalation
Duration: Chronic

MRL Summary: There are insufficient data for derivation of a chronic-duration inhalation MRL for inorganic mercury salts.

Rationale for Not Deriving an MRL: No human or animal studies evaluating chronic-duration inhalation exposure to inorganic mercury salts or other inorganic mercury compounds were identified. Therefore, a chronic-duration inhalation MRL was not derived.

Agency Contacts (Chemical Manager): Rae Benedict

APPENDIX A

MINIMAL RISK LEVEL (MRL) WORKSHEET

Chemical Name: Mercury, inorganic salts (mercuric acetate, mercuric chloride, mercuric sulfide)
CAS Numbers: 1600-27-7, 7487-94-7, 1344-48-5
Date: October 2024
Profile Status: Final
Route: Oral
Duration: Acute
MRL: 0.002 mg Hg/kg/day (2×10^{-3} mg Hg/kg/day; 2 µg Hg/kg/day)
Critical Effect: Renal effects
Reference: Dieter et al. 1992; NTP 1993
Point of Departure: $BMDL_{1SD}$ of 0.29 mg Hg/kg/day ($BMDL_{ADJ}$ of 0.21 mg Hg/kg/day)
Uncertainty Factor: 100
LSE Graph Key: 6
Species: Rat

MRL Summary: An acute-duration oral MRL of 0.002 mg Hg/kg/day (2×10^{-3} mg Hg/kg/day; 2 µg Hg/kg/day) was derived based on renal effects (increased relative kidney weight) in male rats exposed to mercuric chloride by gavage for 5 days/week for 16 days (Dieter et al. 1992; NTP 1993). The MRL is based on a $BMDL_{1SD}$ of 0.29 mg Hg/kg/day adjusted to a $BMDL_{ADJ}$ of 0.21 mg Hg/kg/day and a total uncertainty factor of 100 (10 for extrapolation from rats to humans, and 10 for human variability).

The acute-duration oral MRL based on mercuric chloride is expected to be protective for all inorganic mercury salts. Mercuric chloride is water soluble (Section 3.1, Toxicokinetics) and the bioavailability of mercury salts is directly related to their solubility. Other mercuric salts are less soluble than mercury chloride and are expected to have lower oral bioavailability and, therefore, lower toxicity. For example, acute-duration oral LOAELs for mercuric sulfide and mercuric acetate range from 5 to 86 mg/kg/day (Section 2.1, Table 2-3), compared to the LOAEL of 1.8 mg/kg/day observed in the critical study.

Selection of the Critical Effect: Effects associated with acute-duration exposure of humans to inorganic mercury is limited to accidental or intentional exposure to near-fatal or fatal doses. Therefore, human data are not suitable for derivation of an acute-duration oral MRL. Several acute-duration oral studies have been conducted in laboratory animals. To identify the critical effect, ATSDR focused on: (1) reported effects associated with clear biological significance, and (2) high-quality acute-duration studies including, at minimum, five animals. The most sensitive LOAELs meeting these criteria are summarized in Table A-7.

Table A-7. Select LOAELs for Acute-Duration Oral Exposure to Mercuric Chloride

Species (n)	Duration	NOAEL/LOAEL (mg Hg/kg/day)		System: Effect	Reference
		NOAEL	LOAEL		
Rat (n=5)	16 days (5 days/week)	0.923	1.8	***Renal:*** 17% increase in relative kidney weight	Dieter et al. 1992; NTP 1993[a]
Rat (n=6)	3 or 7 days	ND	3	***Reproductive:*** Decreased sperm number and motility; non-monotonic changes in serum testosterone	Boujbiha et al. 2009

Table A-7. Select LOAELs for Acute-Duration Oral Exposure to Mercuric Chloride

	Duration	NOAEL/LOAEL (mg Hg/kg/day)		System: Effect	Reference
Mouse (n=16)	2 weeks	ND	3.7	**Endocrine:** ~17% increase in baseline plasma insulin and ~60% decrease in fasting plasma insulin; ~15% decrease in blood glucose and impaired glucose tolerance; apoptosis in pancreatic islet cells	Chen et al. 2012
Mouse (n=5)	16 days (5 days/week)	ND	4	**Renal:** 19% increase in relative kidney weight	NTP 1993[a]
Hamster (n=3–10)	Once (GD 7)	2.5	5	**Developmental:** Decreased crown-rump length	Gale 1974

[a]These 16-day studies were classified as acute-duration studies because exposure only occurred on 12 of 16 days.

GD = gestation day; LOAEL = lowest-observed-adverse-effect level; n = number; ND = not determined; NOAEL = no-observed-adverse-effect level

Renal toxicity was selected as the critical effect following acute-duration oral exposure to inorganic mercury because it represents the lowest reliable LOAEL (Dieter et al. 1992; NTP 1993). There is a preponderance of evidence that the kidney is a sensitive target for inorganic mercury salts, with substantial mechanistic support. Observed effects in acute-duration studies include elevated kidney weight at doses >1 mg Hg/kg/day (Dieter et al. 1992; Kim et al. 2003; NTP 1993) that progressed to histopathological changes (protein casts, cellular casts, interstitial sclerosis, necrosis) at ≥7.4 mg Hg/kg/day (Dieter et al. 1992; Lecavalier et al. 1994; Nielsen et al. 1991; NTP 1993). Nephrotoxicity of inorganic mercury is characterized primarily by damage to the *pars recta* segment of the proximal tubule, with involvement of the proximal convoluted tubule and distal tubule in severe toxicity (Berlin et al. 2015; Zalups and Diamond 2005). Damage to the *pars recta* segment of the proximal tubule is consistent with localized uptake of mercury in the renal cortex and outer stripe of the outer medulla (Section 3.1.2). In the proximal tubule, early changes include loss of the brush border membrane, resulting in urinary excretion of brush border enzymes, such as ALP and GGT. As damage to the proximal tubule becomes more severe and progresses to necrosis, intracellular enzymes, such as AAP and NAG, are excreted in the urine, and renal function declines. Substantial evidence from animal studies shows dose- and duration-dependent related damage to the kidneys.

Selection of the Principal Study: The acute-duration oral study in male rats reported by Dieter et al. (1992) and NTP (1993) was selected as the principal study because it identified the lowest LOAEL for the critical effect (renal toxicity).

Summary of the Principal Study:

Dieter MP, Boorman GA, Jameson CW, et al. 1992. Development of renal toxicity in F344 rats gavaged with mercuric chloride for 2 weeks, or 2, 4, 6, 15, and 24 months. J Toxicol Environ Health 36(4):319-340. http://doi.org/10.1080/15287399209531642.

NTP. 1993. Toxicology and carcinogenesis studies of mercuric chloride (CAS no. 7487-94-7) in F344/N rats and B6C3F1 mice (gavage studies). Research Triangle Park, NC: National Toxicology Program. NTP TR 408. NIH publication no. 91-3139.

APPENDIX A

Fischer 344 rats (5/sex/group) were administered mercuric chloride for 16 days (5 days/week) at doses of 0, 1.25, 2.5, 5, 10, or 20 mg $HgCl_2$/kg/day (equivalent to 0, 0.923, 1.8, 4, 7.4, or 15 mg Hg/kg/day) via gavage in deionized water. Body weights were measured and a complete necropsy was performed. Urinalysis was conducted in the control and 4 mg Hg/kg/day dose groups only. Organ weights were obtained for the brain, heart, kidney, liver, lung, and thymus. Histopathology was evaluated in all dose groups for kidney, stomach, preputial gland (males), and clitoral gland (females). Other organs were microscopically evaluated only in the high-dose group.

Two high-dose males died during the first week of exposure (exposure day 4 and 5). Body weight gains were significantly decreased by 17–18% at 7.4 mg Hg/kg/day and 30–41% at 15 mg Hg/kg/day. In females, final body weight was significantly decreased by 11% at 15 mg Hg/kg/day. Absolute and relative kidney weights were significantly increased by ≥17% in males at ≥1.8 mg Hg/kg/day and ≥28% in females at ≥4 mg Hg/kg/day. Decreases in other absolute organ weights in high-dose females is attributed to decreased body weight. Urinary ALP and AST were significantly elevated in males at 4 mg Hg/kg/day by approximately 80 and 83% (estimated from graphically presented data); these changes were not observed in females. No changes in urinary LDH or GGT were observed in males or females at 4 mg Hg/kg/day. Increased incidence and severity of acute renal necrosis was observed in males at ≥7.4 mg Hg/kg/day and in females at 15 mg Hg/kg/day. No histopathological findings in the stomach, preputial gland, or clitoral gland were reported.

Selection of the Point of Departure for the MRL: In order to identify the POD, BMD modeling was conducted for relative kidney weight data from the acute-duration oral study in the rat (Dieter et al. 1992; NTP 1993). Male rat relative kidney weight data (Table A-8) were fit to all available continuous models in EPA's BMDS (version 3.2) using a BMR of 1 SD. Adequate model fit was judged by four criteria: goodness-of-fit statistics (chi-square p-value >0.1); visual inspection of the dose-response curve; BMDL that is not 10 times lower than the lowest non-zero dose; and scaled residual within ±2 units at the data point (except the control) closest to the predefined BMR. Among all the models providing adequate fit to the data, the lowest BMDL values were selected as potential PODs when the difference between the BMDL estimated from these models was >3-fold; otherwise, the BMDL from the model with the lowest Akaike's Information Criterion (AIC) was chosen.

Table A-8. Relative Kidney Weights in Male Rats Exposed to Mercuric Chloride via Gavage 5 days/week for 16 Days

Dose level (mg Hg/kg/day)	Number of animals	Relative kidney weight (mg/g body weight)		
		Mean	Reported SE	Calculated SD
0	5	4.83	0.16	0.36
0.923	5	5.36	0.17	0.38
1.8	5	5.63[a]	0.10	0.22
4	5	5.74[a]	0.16	0.36
7.4	5	6.54[a]	0.46	1.03
15	5	6.89[a]	0.32	0.72

[a]Significantly different from control, p<0.05.

SD = standard deviation; SE = standard error

Source: Dieter et al. 1992; NTP 1993

For elevated relative kidney weight in male rats, the Exponential 4 and 5-degree and Hill models provided adequate fit to the data using non-constant variance. BMDLs were sufficiently close (differed by <3-fold), so the model with the lowest AIC was selected (Hill). The frequentist, restricted Hill model estimated a BMD_{1SD} and $BMDL_{1SD}$ of 0.64 and 0.29 mg Hg/kg/day, respectively. The results of the BMD modeling are summarized in Table A-9 and the model fit for the selected model is shown in Figure A-1.

The $BMDL_{1SD}$ of 0.29 mg Hg/kg/day for increased relative kidney weight in male rats was selected as the POD for deriving an MRL for acute-duration oral exposure to inorganic mercury salts.

Table A-9. Results from BMD Analysis (Nonconstant Variance) of Relative Kidney Weight in Male Rats Exposed to Mercuric Chloride via Gavage 5 Days/Week for 16 Days (Dieter et al. 1992; NTP 1993)

Model	BMD_{1SD} (mg Hg/kg/day)	$BMDL_{1SD}$ (mg Hg/kg/day)	Test 4 p-value[a]	AIC	Scaled residuals[b] Dose below BMD	Dose above BMD
Exponential 2[c]			0.02	56.24	1.23	0.18
Exponential 3[c]			0.02	56.24	1.23	0.18
Exponential 4[c,]	0.75	0.37	0.27	50.10	-0.57	0.75
Exponential 5[c]	0.75	0.37	0.27	50.10	-0.57	0.76
Hill[c,d]	**0.64**	**0.29**	**0.29**	**49.98**	**-0.40**	**0.62**
Polynomial Degree 5[c]			0.04	54.41	1.28	-0.01
Polynomial Degree 4[c]			0.04	54.41	1.28	-0.01
Polynomial Degree 3[c]			0.04	54.41	1.28	-0.01
Polynomial Degree 2[c]			0.04	54.41	1.28	-0.01
Power[c]			0.04	54.41	1.28	-0.01
Linear			0.04	54.41	1.28	-0.01

[a]Values <0.1 fail to meet adequate fit.
[b]Scaled residuals at doses immediately below and above the BMD.
[c]Restricted model.
[d]Recommended model. There was an adequate fit to the variance when assuming nonconstant variance. The Exponential 4- and 5-degree and Hill models provided adequate fit to the data. BMDLs were sufficiently close (differed by <3-fold), so the model with the lowest AIC was selected (Hill).

AIC = Akaike Information Criterion; BMD = maximum likelihood estimate of the exposure dose associated with the selected benchmark response; BMDL = 95% lower confidence limit on the BMD (subscripts denote benchmark response: i.e., $_{1SD}$ = exposure dose associated with a 1 standard deviation change from the control); NA = not applicable, goodness-of-fit test could not be performed

APPENDIX A

Figure A-1. Fit of Hill Model to Data for Relative Kidney Weight in Male Rats Exposed to Mercuric Chloride via Gavage 5 days/week for 16 Days (Dieter et al. 1992; NTP 1993)

Adjustment for Intermittent Exposure: The $BMDL_{ISD}$ was adjusted from intermittent exposure to account for a continuous exposure scenario:

$$BMDL_{ADJ} = 0.29 \text{ mg Hg/kg/day ppm x (5 days/7 days)} = 0.21 \text{ mg Hg/kg/day}$$

Uncertainty Factor: The $BMDL_{ADJ}$ of 0.21 mg Hg/kg/day was divided by a total uncertainty factor of 100:

- 10 for extrapolation from animals to humans
- 10 for human variability

$MRL = BMDL_{ADJ} \div UFs$
$MRL = 0.21 \text{ mg Hg/kg/day} \div (10x10)$
$MRL = 0.0021 \text{ mg Hg/kg/day} \approx 0.002 \text{ mg Hg/kg/day} = 2 \text{ μg Hg/kg/day}$

Other Additional Studies or Pertinent Information that Lend Support to this MRL: There is strong evidence for adverse renal effects in laboratory animals following oral exposure to mercuric chloride. Findings in acute-duration studies in rats and mice exposed to mercuric chloride include increased relative kidney weight, proximal tubular damage, and acute renal necrosis (Dieter et al. 1992; Kim et al. 2003; Lecavalier et al. 1994; Nielsen et al. 1991; NTP 1993). Numerous intermediate-duration studies in mice and rats also report elevated kidney weight, markers of altered renal function or renal damage, histopathological changes, and nephropathy and/or nephrosis (Table A-11, Renal Effects in Laboratory Animals Exposed to Oral Mercuric Chloride for Intermediate-Durations in the intermediate-duration inorganic mercury oral MRL worksheet for citations). Chronic-duration oral studies in rats and mice observed increased relative kidney weight and degeneration and atrophy of the proximal tubule, and increased incidence and/or severity of renal nephropathy (Dieter et al. 1992; NTP 1993). Kidney toxicity has been observed in human case studies of acute poisoning from ingestion of inorganic mercury compounds (Cappelletti et al. 2019).

Agency Contacts (Chemical Manager): Rae Benedict

APPENDIX A

MINIMAL RISK LEVEL (MRL) WORKSHEET

Chemical Name:	Mercury, inorganic salts (mercuric acetate, mercuric chloride, mercuric sulfide)
CAS Numbers:	1600-27-7, 7487-94-7, 1344-48-5
Date:	October 2024
Profile Status:	Final
Route:	Oral
Duration:	Intermediate
MRL:	0.00001 mg Hg/kg/day (1x10^{-5} mg Hg/kg/day; 0.01 µg Hg/kg/day)
Critical Effect:	Renal effects
Reference:	Apaydin et al. 2016
Point of Departure:	LOAEL of 0.015 mg Hg/kg/day
Uncertainty Factor:	1,000
LSE Graph Key:	37
Species:	Rat

MRL Summary: An intermediate-duration oral MRL of 0.00001 mg Hg/kg/day (1x10^{-5} mg Hg/kg/day; 0.01 µg Hg/kg/day) for inorganic mercury salts was derived based on renal effects (decreased renal function and histopathological changes) in rats exposed to mercuric chloride by gavage for 28 days (Apaydin et al. 2016). The MRL is based on a LOAEL of 0.015 mg Hg/kg/day and a total uncertainty factor of 1,000 (10 for use of a LOAEL, 10 for extrapolation from rats to humans, and 10 for human variability).

The intermediate-duration oral MRL based on mercuric chloride is expected to be protective for all inorganic mercury salts. Mercuric chloride is water soluble (Section 3.1, Toxicokinetics) and the bioavailability of mercury salts is directly related to their solubility. Other mercuric salts are less soluble than mercury chloride and are expected to have lower oral bioavailability and, therefore, lower toxicity. For example, LOAELs for intermediate-duration oral exposure to mercuric sulfide, a poorly soluble salt, are approximately 3–380-fold greater than the corresponding LOAELs identified for mercuric chloride (Table A-10).

Selection of the Critical Effect: No epidemiological studies evaluating intermediate-duration oral exposure to mercuric salts were identified. Toxicity data for intermediate-duration oral exposure to mercuric chloride and mercuric sulfide are available from studies in animals; no intermediate-duration oral studies on other inorganic mercury salts were identified. The lowest NOAEL and LOAEL values reported for mercuric chloride and mercuric sulfide for each organ system are summarized in Table A-10.

Table A-10. Summary of Lowest LOAELs for Intermediate-Duration Oral Exposure to Mercuric Chloride and Mercuric Sulfide

Species	Duration	NOAEL/LOAEL (mg Hg/kg/day)		System: Effect	Reference
		NOAEL	LOAEL		
Mercuric chloride					
Rat	28 days	ND	0.015	***Renal:*** Decreased renal function and histopathological changes	Apaydin et al. 2016

APPENDIX A

Table A-10. Summary of Lowest LOAELs for Intermediate-Duration Oral Exposure to Mercuric Chloride and Mercuric Sulfide

Species	Duration	NOAEL/LOAEL (mg Hg/kg/day)		System: Effect	Reference
		NOAEL	LOAEL		
Rat	21 days	ND	0.033	***Hematological:*** Decreased clotting time, 13% decrease in erythrocyte count, 5% decrease in hemoglobin, and 17% increase in leukocyte count	Mahour and Saxena 2009
Rat	12 weeks	ND	0.07	***Cardiovascular:*** Increase in systolic blood pressure at 5 weeks but not 12 weeks	Takahashi et al. 2000b
Rat	21 weeks	ND	0.07	***Hepatic:*** Decreased plasma HDL cholesterol and triglycerides	Takahashi et al. 2000b
Mouse	10 weeks	0.07	0.118	***Immunological:*** Polyclonal B-cell activation	Hultman and Nielsen 2001; Nielsen and Hultman 2002
Mouse	61–79 days	ND	0.18	***Reproductive:*** Decreased fertility index	Khan et al. 2004
Rat	45 days	ND	0.277	***Neurological:*** Impaired motor coordination and balance; apoptosis and loss of neurons and astrocytes in motor cortex; decreased motor activity; impaired learning and memory	Teixeira et al. 2014, 2018
Rat	7 weeks	ND	0.4	***Developmental (neurodevelopmental):*** Decreased peripheral sensory nerve conduction velocity	Huang et al. 2011
Rat	3 months	ND	2.2	***Endocrine:*** Impaired thyroid function	Goldman and Blackburn 1979
Mercuric sulfide					
Mouse	4 weeks	ND	6	***Endocrine:*** Decreased plasma T4 (28–41%)	Sin and Teh 1992
Mouse	4 weeks	ND	17	***Immunological:*** Altered T-cell populations in spleen	Son et al. 2010
Guinea pig	21 days	ND	86	***Neurological:*** Abnormal vestibular ocular reflex	Chuu et al. 2001b

HDL = high-density lipoprotein; LOAEL = lowest-observed-adverse-effect level; ND = not determined; NOAEL = no-observed-adverse-effect level; T4 = thyroxine

For mercuric chloride, the most sensitive effect for intermediate-duration oral exposure is renal toxicity in rats, with the lowest LOAEL value of 0.015 mg Hg/kg/day; a NOAEL was not identified as only one dose level was tested in this study (Apaydin et al. 2016). The next lowest LOAEL of 0.033 mg Hg/kg/day was for hematological effects in rats (Mahour and Saxena 2009), and is approximately 2-fold higher than the LOAEL for renal effects. For mercuric sulfide, the lowest LOAEL identified was 6 mg Hg/kg body

weight for endocrine effects in mice (Sin and Teh 1992). Available intermediate-duration oral studies on effects of mercuric sulfide did not evaluate renal effects. However, LOAEL values for mercuric sulfide for endocrine, immunological, and neurological effects are greater than corresponding LOAELs for mercuric chloride by approximately 3-, 144-, and 380-fold, respectively. Therefore, an MRL based on mercuric chloride is expected to be protective for exposure to mercuric sulfide.

Renal effects, long established as a sensitive target for inorganic mercury salts, were selected as basis for derivation of the intermediate-duration oral MRL. Nephrotoxicity of inorganic mercury is characterized primarily by damage to the *pars recta* segment of the proximal tubule, with involvement of proximal convoluted tubules and distal tubule in severe toxicity (Berlin et al. 2015; Zalups and Diamond 2005). Damage to the *pars recta* segment of the proximal tubule is consistent with localized uptake of mercury in the renal cortex and outer stripe of the outer medulla (Section 3.1.2). In the proximal tubule, early changes include loss of the brush border membrane, resulting in urinary excretion of brush border enzymes, such as ALP and GGT. As damage to the proximal tubule becomes more severe and progresses to necrosis, intracellular enzymes, such as AAP and NAG, are excreted in the urine, and renal function declines. Substantial evidence from animal studies shows dose- and duration-dependent related damage to the kidneys. Renal effects observed in intermediate-duration oral studies in laboratory animals are summarized in Table A-11.

Table A-11. Renal Effects in Laboratory Animals Exposed to Oral Mercuric Chloride for Intermediate-Durations

Effect	Species	References
Increased relative kidney weight	Rats and mice	Atkinson et al. 2001; Dieter et al. 1983, 1992; Jonker et al. 1993; Khan et al. 2004; NTP 1993; Takahashi et al. 2000a, 2000b; Wildemann et al. 2015a
Markers of altered renal function or renal damage (increased serum levels of urea, uric acid, and creatinine; elevated urine protein and/or ketones)	Rats	Apaydin et al. 2016; Carmignani et al. 1992; Jonker et al. 1993; Takahashi et al. 2000a
Histopathological changes (including tubular dilation and glomerular lobulation, tubular damage and degeneration, necrosis)	Rats and mice	Apaydin et al. 2016; Boscolo et al. 1989; Carmignani et al. 1989, 1992; Jonker et al. 1993; NTP 1993
Nephropathy and/or nephrosis	Rats and mice	Dieter et al. 1983, 1992; Jonker et al. 1993; NTP 1993

Selection of the Principal Study: The Apaydin et al. (2016) study provided the lowest LOAEL observed for renal effects in intermediate-duration animal studies and was selected as the principal study.

Summary of the Principal Study:

Apaydin FG, Bas H, Kalender S, et al. 2016. Subacute effects of low dose lead nitrate and mercury chloride on kidney of rats. Environ Toxicol Pharmacol 41:219-224.

Groups of six Wistar rats (90 days old; sex not specified) were administered distilled water or 0.02 mg/kg mercuric chloride in distilled water by gavage daily for 28 days (equivalent to 0.015 mg Hg/kg/day). At the end of the 28-day exposure period, blood samples were obtained and analyzed for serum urea, uric

acid, and creatinine levels. Kidneys were examined microscopically, and renal levels of the following were determined: malondialdehyde, glutathione peroxidase (GPX), glutathione S-transferase (GST), superoxide dismutase (SOD), and catalase.

In rats treated with mercuric chloride, serum levels of urea, uric acid, and creatinine were significantly increased by 28, 54, and 17%, respectively, compared to controls, indicating decreased renal function. Histopathological assessment of the kidneys showed tubular dilation and glomerular lobulation compared to normal appearance in controls. Kidney activity of antioxidant enzymes, GPX, GST, SOD, and catalase were significantly decreased by approximately 31, 25, 32, and 41%, respectively, compared to controls (data presented graphically). Kidney malondialdehyde levels were significantly increased by approximately 69%, compared to controls (data presented graphically). Findings are consistent with oxidative stress and peroxidation of lipid membranes.

Selection of the Point of Departure for the MRL: The LOAEL of 0.015 mg Hg/kg/day for decreased renal function and histopathological alterations in the kidneys was selected as the POD for deriving a MRL for intermediate-duration oral exposure to inorganic mercury salts. BMD modeling was not considered for this dataset, as only one dose level was tested in the study. Existing PBPK models were not suitable for extrapolation of inorganic mercuric mercury dosimetry between rats and humans.

Uncertainty Factor: The LOAEL of 0.015 mg Hg/kg/day was divided by a total uncertainty factor of 1,000:
- 10 for use of a LOAEL
- 10 for extrapolation from animals to humans
- 10 for human variability

MRL = LOAEL ÷ UFs
MRL = 0.015 mg Hg/kg/day ÷ (10x10x10)
MRL = 0.000015 mg Hg/kg/day ≈ 0.00001 mg Hg/kg/day = 0.01 µg Hg/kg/day

Other Additional Studies or Pertinent Information that Lend Support to this MRL: See *Selection of the Critical Effect* above for review of supporting evidence from intermediate-duration oral exposure studies in animals. In addition, acute- and chronic-duration oral studies in laboratory animals have observed renal toxicity. Findings in acute-duration studies in rats and mice exposed to mercuric chloride include increased relative kidney weight, proximal tubular damage, and acute renal necrosis (Kim et al. 2003; Lecavalier et al. 1994; Nielsen et al. 1991; NTP 1993). Chronic-duration oral studies in rats and mice observed increased relative kidney weight and degeneration and atrophy of the proximal tubule, and increased incidence and/or severity of renal nephropathy (Dieter et al. 1992; NTP 1993). Kidney toxicity has been observed in human case studies of acute poisoning from ingestion of inorganic mercury compounds (Cappelletti et al. 2019).

Agency Contacts (Chemical Managers): Rae Benedict

APPENDIX A

MINIMAL RISK LEVEL (MRL) WORKSHEET

Chemical Name: Mercury, inorganic salts (mercuric acetate, mercuric chloride, mercuric sulfide)
CAS Numbers: 1600-27-7, 7487-94-7, 1344-48-5
Date: October 2024
Profile Status: Final
Route: Oral
Duration: Chronic

MRL Summary: There are insufficient data for derivation of a chronic-duration oral MRL for inorganic mercury salts.

Rationale for Not Deriving an MRL: Epidemiological studies of chronic-duration oral exposure to inorganic mercury salts were not identified, and few studies have evaluated the effects of chronic-duration oral exposure to inorganic mercury salts in animals (Dieter et al. 1992; NTP 1993; Perry and Erlanger 1974). The lowest LOAELs identified for each study are summarized in Table A-12. The lowest LOAEL identified is 0.66 mg Hg/kg/day for increased systolic blood pressure in rats exposed to mercuric chloride in drinking water for 1 year, with a NOAEL of 0.33 mg Hg/kg/day (Perry and Erlanger 1974). The lowest chronic-duration LOAEL is 44-fold higher than the lowest intermediate-duration LOAEL of 0.015 mg Hg/kg/day that is the basis of the intermediate-duration oral MRL. Studies examining effects of chronic-duration oral exposure at lower levels were not identified. Therefore, a chronic-duration oral MRL was not derived for inorganic mercury.

Table A-12. Summary of LOAELs from Chronic-Duration Oral Studies in Laboratory Animals Exposed to Mercuric Chloride

Species	Duration	NOAEL/LOAEL[a] (mg Hg/kg/day)			Effect	Reference
		NOAEL	LOAEL	SLOAEL		
Rat	1 year	0.33 (F)	0.66 (F)	ND	Increased systolic blood pressure	Perry and Erlanger 1974
Rat	2 years	ND (M)	1.8 (M)	1.8 (M)	LOAEL: Decreased body weight, inflammatory lesions of the nasal mucosa, and epithelial hyperplasia of the forestomach SLOAEL: Decreased survival, degeneration and atrophy of the renal tubular epithelium	Dieter et al. 1992; NTP 1993
Mouse	2 years[b]	ND	4	ND	Nephropathy and increased kidney weight	NTP 1993

[a]Unless otherwise specified, NOAEL and LOAEL values are for both males and females.
[b]Continuous mating study.

F = female; LOAEL = lowest-observed-adverse-effect level; M = male; ND = not determined; NOAEL = no-observed-adverse-effect level; SLOAEL = serious lowest-observed-adverse-effect level

Agency Contacts (Chemical Managers): Rae Benedict

APPENDIX A

MINIMAL RISK LEVEL (MRL) WORKSHEET

Chemical Name: Methylmercury
CAS Number: 22967-92-6
Date: October 2024
Profile Status: Final
Route: Inhalation
Duration: Acute

MRL Summary: There are insufficient data for derivation of an acute-duration inhalation MRL for methylmercury.

Rationale for Not Deriving an MRL: No human or animal studies evaluating acute-duration inhalation exposure to methylmercury were identified. Therefore, an acute-duration inhalation MRL was not derived.

Agency Contacts (Chemical Managers): Rae Benedict

APPENDIX A

MINIMAL RISK LEVEL (MRL) WORKSHEET

Chemical Name: Methylmercury
CAS Number: 22967-92-6
Date: October 2024
Profile Status: Final
Route: Inhalation
Duration: Intermediate

MRL Summary: There are insufficient data for derivation of an intermediate-duration inhalation MRL for methylmercury.

Rationale for Not Deriving an MRL: No human or animal studies evaluating intermediate-duration inhalation exposure to methylmercury were identified. Therefore, an intermediate-duration inhalation MRL was not derived.

Agency Contacts (Chemical Managers): Rae Benedict

APPENDIX A

MINIMAL RISK LEVEL (MRL) WORKSHEET

Chemical Name: Methylmercury
CAS Number: 22967-92-6
Date: October 2024
Profile Status: Final
Route: Inhalation
Duration: Chronic

MRL Summary: There are insufficient data for derivation of a chronic-duration inhalation MRL for methylmercury.

Rationale for Not Deriving an MRL: No human or animal studies evaluating chronic-duration inhalation exposure to methylmercury were identified. Therefore, a chronic-duration inhalation MRL was not derived.

Agency Contacts (Chemical Managers): Rae Benedict

APPENDIX A

MINIMAL RISK LEVEL (MRL) WORKSHEET

Chemical Name: Methylmercury
CAS Number: 22967-92-6
Date: October 2024
Profile Status: Final
Route: Oral
Duration: Acute

MRL Summary: There are insufficient data for derivation of an acute-duration oral MRL for methylmercury.

Rationale for Not Deriving an MRL: No studies examining effects of acute-duration oral exposure to methylmercury in humans were identified. Numerous studies in laboratory animals have investigated effects of acute-duration oral exposure to methylmercury. Table A-13 lists the lowest reported NOAELs and LOAELs for acute toxicity endpoints. The lowest LOAEL of 0.008 mg Hg/kg/day identified the developing nervous system as the most sensitive target for acute-duration oral exposure (Bornhausen et al. 1980). The associated NOAEL is 0.004 mg Hg/kg/day.

Table A-13. Summary of Lowest NOAELs and LOAELs for Acute-Duration Oral Exposure to Methylmercury

Species	Duration	NOAEL/LOAEL (mg Hg/kg/day)		System: Effect	Reference
		NOAEL	LOAEL		
Rat	4 days (GDs 6–9)	0.004	0.008	**Developmental (neurodevelopmental):** Impaired operant conditioning at 4 months	Bornhausen et al. 1980
Rat	14 days	ND	0.5	**Reproductive:** Nonmonotonic sperm effects (decreased count and motility, increased abnormal); inflammatory foci and thickening of epithelium in prostate	Fossato da Silva et al. 2011, 2012
Rat	1–2 weeks	ND	0.7	**Neurological:** Ultrastructural changes in dorsal root ganglia and cerebellum	Chang and Hartmann 1972
Mouse	14 days	ND	1.6	**Endocrine:** Altered glucose homeostasis; apoptosis in pancreatic islet cells	Chen et al. 2012
Rat	14 days	ND	1.9	**Body weight:** Decreased body weight (~10%)	Chuu et al. 2007
Rat	14 days	0.93	2.8	**Renal:** Increased relative kidney weight (18%)	Fossato da Silva et al. 2011
Rat	12 days	ND	4	**Musculoskeletal:** Muscle weakness and wasting	Usuki et al. 1998
Mouse	14 days	ND	5.6	**Hepatic:** Elevated total cholesterol	Moreira et al. 2012

Table A-13. Summary of Lowest NOAELs and LOAELs for Acute-Duration Oral Exposure to Methylmercury

	Duration	NOAEL/LOAEL (mg Hg/kg/day)		System: Effect	Reference
Rat	2 days	ND	12	*Cardiovascular:* Decreased heart rate (10–18%)	Arito and Takahashi 1991

GD = gestation day; LOAEL = lowest-observed-adverse-effect level; ND = not determined; NOAEL = no-observed-adverse-effect level

Several animal studies provide support for neurodevelopmental effects as the most sensitive target of acute-duration oral exposure to methylmercury. Studies observing neurodevelopmental effects at doses ≤0.5 mg Hg/kg/day (the lowest LOAEL for reproductive effects, the second most sensitive target of acute-duration oral exposure to methylmercury) are summarized in Table A-14. Two neurodevelopmental studies reported similar LOAELs for neurodevelopmental effects: the Bornhausen et al. (1980) study in rats, with a LOAEL of 0.008 mg Hg/kg/day and the Montgomery et al. (2008) study in mice, with a LOAEL of 0.009 mg Hg/kg/day. The study in rats identified a NOAEL of 0.004 mg Hg/kg/day; however, the study in mice did not identify a NOAEL, as only one dose (0.009 mg Hg/kg/day) was tested.

Table A-14. Neurodevelopmental Effects in Laboratory Animals Exposed to Methylmercury Doses ≤0.5 mg Hg/kg/day for Acute Durations.

Species	Duration	NOAEL/LOAEL (mg Hg/kg/day)		Effect	Reference
		NOAEL	LOAEL		
Rat	4 days, GDs 6–9	0.004	0.008	Impaired operant conditioning at 4 months	Bornhausen et al. 1980
Mouse	11 days, GDs 8–18	ND	0.009	Impaired learning and memory, decreased motor activity and coordination in adult offspring	Montgomery et al. 2008
Mouse	5 days, PNDs 29–33	ND	0.2	Impaired balance and motor coordination on PND 38	Bellum et al. 2007
Mouse	Once, PND 10	ND	0.37	Decreased motor activity and impaired learning and memory at 2–6 months of age	Fischer et al. 2008
Rat	4 days, GDs 6–9	0.04	0.4	Increased startle response in adult offspring Effects at 4 mg Hg/kg/day: impaired swimming, impaired visual discrimination, decreased activity, and decreased habituation	Stoltenburg-Didinger and Markwort 1990

GD = gestation day; LOAEL = lowest-observed-adverse-effect level; ND = not determined; NOAEL = no-observed-adverse-effect level PND = postnatal day

The NOAEL of 0.004 mg Hg/kg/day in rats (Bornhausen et al. 1980) and the LOAEL of 0.009 mg Hg/kg/day in mice (Montgomery et al. 2008) were considered as possible PODs for an acute-duration oral MRL, as shown in Table A-15. Based on the NOAEL of 0.004 mg Hg/kg/day in rats and a total

uncertainty factor of 100, the MRL would be 0.00004 mg Hg/kg/day (0.04 µg Hg/kg/day). Based on the
LOAEL of 0.009 mg Hg/kg/day and a total uncertainty factor of 1,000, the MRL would be 0.000009 mg
Hg/kg/day (0.009 µg Hg/kg/day). These acute-duration MRLs are less than the chronic-duration oral
MRL for methylmercury of 0.1 µg Hg/kg/day based on data in humans. Therefore, an acute-duration oral
MRL for methylmercury was not derived.

Table A-15. Possible Acute-Duration Oral Minimal Risk Levels (MRLs) for Methylmercury Based on Neurodevelopmental Effects

Species	MRL (µg Hg/kg/day)	Critical effect	Point of departure (mg Hg/kg/day)	Uncertainty factors	Reference
Rat	0.04	Impaired operant conditioning at 4 months	NOAEL: 0.004	100[a]	Bornhausen et al. 1980
Mouse	0.009	Impaired learning and memory, and decreased motor activity and coordination in adult offspring	LOAEL: 0.009	1,000[b]	Montgomery et al. 2008

[a]Total uncertainty factor = 100 (10 for extrapolation from rats to humans; 10 for human variability).
[b]Total uncertainty factor = 1,000 (10 for use of LOAEL; 10 for extrapolation from mice to humans; 10 for human variability).

LOAEL = lowest-observed-adverse-effect level; NOAEL = No-observed-adverse-effect level

Agency Contacts (Chemical Managers): Rae Benedict

APPENDIX A

MINIMAL RISK LEVEL (MRL) WORKSHEET

Chemical Name: Methylmercury
CAS Number: 22967-92-6
Date: October 2024
Profile Status: Final
Route: Oral
Duration: Intermediate

MRL Summary: There are insufficient data for derivation of an intermediate-duration oral MRL for methylmercury.

Rationale for Not Deriving an MRL: In humans, intermediate-duration oral exposure to methylmercury occurred in Iraq in 1972–1973 as a result of widespread consumption of bread made from wheat that had been treated with a methylmercuric fungicide (Al-Mufti et al. 1976; Bakir et al. 1973; Clarkson et al. 1976). BHg levels in poisoning cases measured approximately 65 days after exposure ranged from 10 to 3,000 µg Hg/L (Clarkson et al. 1976). Severe neurological and neurodevelopmental effects were observed in this population; therefore, findings in this population cannot be used to derive an intermediate-duration oral MRL for methylmercury.

Numerous studies in laboratory animals have investigated effects of intermediate-duration oral exposure to methylmercury. The lowest LOAELs for each system are summarized in Table A-16. The lowest dose of methylmercury tested in intermediate-duration oral studies was 0.0003 mg Hg/kg/day in rats exposed during pre-mating through PND 21 (Wild et al. 1997). At this dose, immunodevelopmental effects (enhanced lymphoproliferation in response to mitogens) were observed in offspring assessed on PND 84. This is the lowest LOAEL observed in intermediate-duration oral studies. The next lowest dose tested was 0.0004 mg Hg/kg/day in rats exposed for 8 weeks (Ortega et al. 1997a, 1997b); this dose is a LOAEL for immunological effects in adult rats (immune stimulation). The lowest LOAEL values for renal, neurological, and neurodevelopmental effects were 0.006, 0.0073, and 0.02 mg Hg/kg/day, respectively. Results of these studies indicate that the immune system is a sensitive target for methylmercury. Several animal studies provide support that the developing immunological system is the most sensitive target of methylmercury; studies are summarized in Table A-17. Immunodevelopmental effects have been observed at doses ranging from 0.0003 to 0.37 mg Hg/kg/day.

Table A-16. Summary of Lowest LOAELs for Intermediate-Duration Oral Exposure to Methylmercury

Species	Duration	NOAEL/LOAEL (mg Hg/kg/day)		System: Effect	Reference
		NOAEL	LOAEL		
Rat	14–16 weeks premating to PND 21	ND	0.0003	*Immunodevelopmental:* Altered functional immune function (enhanced lymphoproliferation in response to mitogens) in PND 84 offspring	Wild et al. 1997
Rat	8 weeks	ND	0.0004	*Immunological:* Immune stimulation followed by immune suppression at higher doses	Ortega et al. 1997a, 1997b
Rat	8 weeks	ND	0.0004	*Endocrine:* Increase in adrenocorticotrophic hormone	Ortega et al. 1997b

Table A-16. Summary of Lowest LOAELs for Intermediate-Duration Oral Exposure to Methylmercury

	Duration	NOAEL/LOAEL (mg Hg/kg/day)		System: Effect	Reference
Rat	4 weeks	0.002	0.005	*Cardiovascular:* Elevated systolic blood pressure and pulse pressure	Wildemann et al. 2015a
Rat	4 weeks	0.006	0.285	*Renal:* Elevated urinary creatinine	Wildemann et al. 2016
Mouse	2 months	0.00046	0.0073	*Neurological:* Impaired memory	Bourdineaud et al. 2011
Rat	19 weeks[a]	0.0008	0.008	*Reproductive:* No viable litters produced	Friedmann et al. 1998
Mouse	10–17 weeks premating through PNDs 21–70	ND	0.02	*Neurodevelopmental:* Decreased motor activity and impaired hearing and motor coordination in offspring	Huang et al. 2011
Rabbit	14 weeks	0.05	0.49	*Body weight:* Decreased body weight gain	Koller et al. 1977
Mouse	21 days	ND	5.6	*Hepatic:* Elevated plasma total cholesterol	Moreira et al. 2012

[a]Rats were dosed 2 times/week.

LOAEL = lowest-observed-adverse-effect level; ND = not determined; NOAEL = no-observed-adverse-effect level; PND = postnatal day

Table A-17. Summary of LOAELs for Immunodevelopmental Effects in Animals Exposed to Oral Methylmercury for Intermediate Durations

Species	Duration	NOAEL/LOAEL (mg Hg/kg/day)		Effect	Reference
		NOAEL	LOAEL		
Rat	14–16 weeks (premating through PND 21)	ND	0.0003	Altered functional immune endpoints (enhanced lymphoproliferation in response to mitogens) in PND 12 offspring	Wild et al. 1997
Rat	14–16 weeks (premating through PND 21)	ND	0.0006	Altered functional immune endpoints in PND 6–12 offspring (enhanced lymphoproliferation in response to mitogens; decreased NK cell activity)	Wild et al. 1997
Mouse[a]	5 weeks (GD 8 to PND 21)	ND	0.06	Cerebellar inflammation, attributed to autoimmune effects, at PNDs 21 and 70	Zhang et al. 2011

Table A-17. Summary of LOAELs for Immunodevelopmental Effects in Animals Exposed to Oral Methylmercury for Intermediate Durations

Species	Duration	NOAEL/LOAEL (mg Hg/kg/day)		Effect	Reference
Rat	26 days (GD 6 to PND 10)	ND	0.08	Altered functional immune endpoints in PND 21–70 offspring (decrease in the primary KLH-specific IgG antibody response on PND 35)	Tonk et al. 2010
Mouse	15–16 weeks (10 weeks premating through PND 15)	ND	0.098	Alterations in functional immune endpoints (increased primary antibody response to a viral antigen) and thymocyte cell populations in PNDs 10–22 offspring	Thuvander et al. 1996
Rat	15 days (PNDs 1–15, via dam)	ND	0.37	13% decrease in relative spleen weight; altered immune function in offspring (decreased splenic lymphoproliferative response to mitogen)	Ilback et al. 1991
Rat	~15 weeks (11 weeks premating through GD 21)	ND	0.37	45% increase in WBCs in offspring on PND 15	Ilback et al. 1991
Rat	~17 weeks (11 weeks premating through PND 15)	ND	0.37	Altered immune function in offspring (increased thymic lymphoproliferative response to mitogen, decreased cell-mediated cytotoxicity)	Ilback et al. 1991

[a]Immune susceptible mouse strain.

GD = gestational day; LOAEL = lowest-observed-adverse-effect level; ND = not determined; NK = natural killer; NOAEL = no-observed-adverse-effect level; PND = postnatal day WBC = white blood cell

If an intermediate-duration oral MRL was derived based on the lowest LOAEL of 0.0003 mg Hg/kg/day (0.3 µg Hg/kg/day) for immunodevelopmental effects and a total uncertainty factor of 1,000 (10 for use of a LOAEL, 10 for extrapolation from animals to humans, and 10 for human variability), the intermediate-duration oral LOAEL for methylmercury would be 0.0003 µg Hg/kg/day. This value is lower that the chronic-duration oral MRL of 0.1 µg Hg/kg/day; therefore, an intermediate-duration oral MRL for methylmercury was not derived.

Agency Contacts (Chemical Managers): Rae Benedict

APPENDIX A

MINIMAL RISK LEVEL (MRL) WORKSHEET

Chemical Name: Methylmercury
CAS Number: 22967-92-6
Date: October 2024
Profile Status: Final
Route: Oral
Duration: Chronic
MRL: 0.1 µg Hg/kg/day
Critical Effect: Neurodevelopmental effects (decreased IQ)
Reference: Axelrad et al. 2007a, 2007b
Point of Departure: NAEL of 0.41 µg Hg/kg/day
Uncertainty Factor: 3
LSE Graph Key: 173
Species: Human

MRL Summary: A chronic-duration oral MRL of 0.0001 mg Hg/kg/day (0.1 µg Hg/kg/day) was derived based on neurodevelopmental effects (decreased full-scale IQ) in humans chronically exposed to methylmercury from consumption of dietary fish (Axelrad et al. 2007a, 2007b). The MRL is based on a NAEL of 0.00041 mg Hg/kg/day (0.41 µg Hg/kg/day) and a total uncertainty factor of 3 for human variability.

Selection of the Critical Effect: Studies conducted in animals (nonhuman primates and rodents) and human epidemiological studies provide strong support for the developing nervous system being the most sensitive target of methylmercury. In humans, severe neurodevelopmental effects (congenital Minamata disease) occurred in association with maternal ingestion of methylmercury in seafood (Harada 1995) and from ingestion of wheat contaminated with a methylmercury fungicide (Iraq outbreak) (Amin-Zaki et al. 1974). In both incidents, exposure levels were sufficient to produce severe neurological effects in adults. Studies of lower levels of prenatal exposures have largely focused on populations that consume large amounts of marine fish. In these populations, the dominant source of the mercury body burden derives from consumption of methylmercury in fish, providing a strong basis for use of BHG or HHg as a biomarker of methylmercury exposure. Studies of general populations have also relied on biomarkers for assessing exposure; however, in these populations, BHg and HHg will be more greatly affected by exposures to other forms of mercury, including mercury released from mercury amalgam dental restorations. Therefore, general population studies that estimated oral intake of methylmercury are stronger designs for the purpose of dose-response assessments of methylmercury.

Cognitive and neurosensory effects have been observed in association with prenatal exposures to methylmercury via maternal fish consumption. Consistent findings have been observed at relatively high exposure levels (e.g., Iraq outbreak, Minamata outbreak). However, results of studies that have explored lower exposure levels have been inconsistent. Some studies found improved function or no associations with mercury, and some studies found non-monotonic responses (e.g., declines at lower levels of exposure and improvements at higher levels). Differences in effect estimates may be due to differences in confounders and how they were controlled in models. These variables include fish intake and related nutritional factors (e.g., 3-omega polyunsaturated long-chain fatty acids), co-exposure to other contaminants (e.g., lead, PCBs), and social variables affecting child development. In addition, presence of genetic susceptibility factors (of lack thereof) may act as effect measure modifiers, impacting the associations observed between mercury and a health outcome.

Several high fish consuming populations have been studied to evaluate possible associations between prenatal mercury exposure and neurodevelopment. These include populations in the Amazon River basin,

Arctic Canada, Faroe Islands, North Island New Zealand, and Seychelle Islands. Studies conducted in the Faroe Islands, North Island New Zealand, and Seychelle Islands are particularly important because of several features: (1) prospective design; (2) relatively large sample populations in main cohort (approximately 700–1,000); (3) high quality assurance procedures for biomarker measurements; (4) multiple follow-ups at different ages; (5) multiple tests of cognitive and neurosensory performance that assessed a wide range of cognitive domains; (6) extensive exploration and control of confounding; (7) assessments of biomarker measurement error (Faroe Islands and Seychelle Islands studies); and (8) multiple analyses of the data, which included linear and non-linear regression, cross-sectional and longitudinal analyses, individual and aggregated outcome metrics, and BMD analyses. For each study, observed biomarkers of exposure (e.g., BHg) were converted to estimates of oral mercury doses and categorized as either an AEL if an adverse effect was observed or a NAEL if no adverse effect was observed (Appendix E for definitions of AEL and NAEL).

Selection of the Principal Study: Neurodevelopmental outcomes from studies conducted on populations from the Faroe Islands, North Island New Zealand, and Seychelle Islands are summarized below. A summary of a meta-analysis that includes data from the Faroe Islands, North Island New Zealand, and Seychelle Islands is also described (Axelrad et al. 2007a, 2007b). In addition, detailed summaries of two studies evaluating neurodevelopmental outcomes in a large general population from Norway are included (Vejrup et al. 2016, 2018).

Faroe Islands study. The Faroe Islands study followed a prospective cohort of high fish and marine mammal consumers (n=1,022 mother-infant pairs, recruited 1986–1987) from age 2 weeks to 22 years. The primary methylmercury prenatal exposure metric was total mercury in cord blood, which was predominantly (>80%) methylmercury (Grandjean et al. 1992). The median cord blood mercury concentration was 24 µg Hg/L and the IQR (25th to 75th percentile range) was 13–40 µg Hg/L; approximately 25% of the cord mercury levels were >40 µg Hg/L (Grandjean et al. 1992). Cord blood mercury levels (µg Hg/L) were approximately 5 times maternal HHg levels measured at parturition with a median of 4.5 µg Hg/g, and an IQR of 2.5–7.7 (Grandjean et al. 1992). In most studies, depending on the outcome measured, outcome associations were adjusted for covariates: child age, sex, birth weight; breastfeeding; maternal age, alcohol, tobacco use, medical history; and caregiver general intelligence (Raven's Progressive Matrices). Other potential confounders were also explored (e.g., fish consumption, blood selenium, blood PCBs).

The study found associations between prenatal (cord) BHg and decreasing performance on tests of cognitive function assessed at age 7 years (Grandjean et al. 1997, 1998, 2003, 2014; Oulhote et al. 2019), 14 years (Debes et al. 2006; Julvez et al. 2010), and 22 years (Debes et al. 2016). The associations were not consistently observed in all tests of cognitive function. The associations tended to cluster into domains of fluid reasoning (e.g., identifying rules for visual similarities and differences), comprehension and knowledge (e.g., naming, word synonyms and antonyms), decision and reaction speed, and motor coordination (Debes et al. 2016). Latencies of brainstem auditory evoked potentials measured at age 7 or 14 years increased in association with increasing prenatal or child HHg levels (Grandjean et al. 1997; Murata et al. 2004a).

Exposure measurement error based on estimation of biomarker imprecision was estimated to exceed laboratory measurement error (Grandjean and Budtz-Jorgensen 2007; Grandjean et al. 2004b). The observed associations with cognitive test outcomes persisted after excluding subjects who had large variability in HHg levels during pregnancy (Grandjean et al. 2003). Findings from the Faroe Islands included:

- Postnatal HHg levels correlated with duration of breastfeeding, although breastfeeding was not a significant explanatory variable for cognitive test outcomes in the cohort (Grandjean et al. 1995; Jensen et al. 2005).

- Blood selenium levels correlated with BHg levels and whale consumption (Grandjean et al. 1992); however, prenatal selenium level (cord blood) was not a significant explanatory variable for cognitive test outcomes in the cohort (Choi et al. 2008b).
- Although cord blood PCB concentration correlated with BHg levels, associations between cord blood mercury levels and cognitive tests scores persisted after adjustment for cord blood PCB concentrations (Grandjean et al. 1997). Analysis of data from the 7-year follow-up found no evidence of interactions between mercury and exposure to PCBs and long-chain perfluoroalkyls (Oulhote et al. 2019).
- Adjustment for cord serum omega-3 long-chain polyunsaturated fatty acids (LCPUFA) strengthened associations between prenatal mercury exposure and cognitive test scores or brainstem evoked potential latencies (Choi et al. 2008b; Yorifuji et al. 2013).

Additional details for the Grandjean et al. (1997, 1999) studies are summarized in Table A-18. These studies were included in the Axelrad et al. (2007a, 2007b) meta-analysis.

Table A-18. Summary of the Grandjean et al. (1997) and Grandjean et al. (1999) Studies of the Faroe Islands Population

Study type and population: Prospective study of birth cohort, follow-up at age 7 years (n=917)

Biomarkers:
BHg (geometric mean µg Hg/L, IQR)
 Cord: 22.9 (13.4–41.3)
 Child (7 years): 8.82 (4.8–18.2)

HHg (geometric mean µg Hg/g, IQR)
 Maternal: 4.27 (2.6–7.7)
 Child (12 months): 1.12 (0.69–1.88)
 Child (7 years): 2.99 (1.7–6.1)

Estimated oral dose[a]: 0.34 µg Hg/kg/day (based on cord BHg)

Analysis: Data were analyzed using multiple regression analysis. Outcome associations were adjusted for age and sex for all analyses. Additional covariates included strabismus (abnormal eye alignment) and eye glasses (VEP); current middle ear infection (BAEP); height (postural sway), maternal cognitive function, maternal smoking and alcohol use, social background, and major medical risk factors such as low birth weight, small-for-gestational date, history of head trauma and meningitis (neuropsychological tests); and child's acquaintance with computers and computer games (computer-assisted tests). Data from neuropsychological tests were also analyzed using the Peters-Belson approach. In this approach, any regression coefficients with p<0.1 in the lowest quartile of cord blood (<15 µg Hg/L) group were included in multiple regressing models for all children. By identifying potential confounders in the lowest quartile BHg group, rather than in the full cohort, this approach may provide a less biased estimate of the association between mercury exposure and outcomes in the presence of confounding.

Results[b]:

Adjusted regression coefficients between cord BHg and neurophysiological tests
- BAEPL at 40 Hz
  - I = 0.043, p=0.10
  - III = 0.053, p=0.06
  - V = 0.059, p=0.01
- VEPL at 15 minutes
  - N75 = 0.21, p=0.70

Peters-Belson regression coefficients between cord BHg and neuropsychological tests
- NES FTT
  - D hand =-1.18, p=0.03
  - ND hand = -0.37, p=0.47
  - Both hands = -1.86, p=0.08
- NES HECT = 0.033, p=0.20
- NES CPT

Table A-18. Summary of the Grandjean et al. (1997) and Grandjean et al. (1999) Studies of the Faroe Islands Population

- o P100 = -0.75, p=0.33
- o N145 = -0.99, p=0.37
- Postural sway
  - o Eyes open = -0.04, p=0.90
  - o Eyes closed = -1.54, p=0.09
  - o Eyes open, on foam = -0.43, p=0.40
  - o Eyes closed, on foam = -0.19, p=0.86
- HRV R-R interval: -0.39, p=0.29

Adjusted regression coefficients between cord BHg and neuropsychological tests
- WISC-R
  - o Digit span^c = -0.27, p=0.05
  - o Similarities^c = -0.05, p=0.90
  - o Block design^c = -0.17, p=0.11
- CVLT
  - o Learning = -1.25, p=0.12
  - o Short-term^c = -0.57, p=0.02
  - o Long-term = -0.55, p=0.05
  - o Recognition = -0.29, p=0.15
- BNT
  - o No cues^c = -1.77, p=0.0003
  - o Cues = -1.91, p=0.0001
- BVMGT
  - o Copy error^c = 0.67, p=0.15
  - o Reproduction = -0.25, p=0.10
- NES FTT
  - o D hand = -1.10, p=0.05
  - o ND hand = -0.39, p=0.46
  - o Both hands = -1.67, p=0.14
- NES HECT = 0.034, p=0.19
- NES CPT
  - o Missed response = 0.12, p=0.02
  - o Reaction time = 40.3, p=0.001
- TPT (D hand) = -14.3, p=0.63
- NVAPMS
  - o Positive moods = 2.61, p=0.31
  - o Negative moods = -0.04, p=0.99

- o Missed response = 0.14, p=0.007
- o Reaction time = 38.2, p=0.0002
- WISC-R
  - o Digit span^c = -0.27, p=0.05
  - o Similarities^c = 0.14, p=0.70
  - o Block design^c = -0.25, p=0.02
- CVLT
  - o Learning = -1.30, p=0.11
  - o Short-term^c = -0.63, p=0.009
  - o Long-term = -0.64, p=0.02
  - o Recognition = -0.28, p=0.15
- BNT
  - o No cues^c = -1.66, p=0.0007
  - o Cues = -1.82, p=0.0002
- BVMGT
  - o Copy error^c = 1.04, p=0.03
  - o Reproduction = -0.16, p=0.31
- TPT (D hand) = -18.8, p=0.60
- NVAPMS
  - o Positive moods = 2.39, p=0.34
  - o Negative moods = 0.17, p=0.94

Adjusted regression coefficients between cord BHg and neuropsychological tests in low exposure children only (maternal HHg <10 µg Hg/g)
- WISC-R
  - o Digit span^c = -0.31, p=0.05
  - o Similarities^c = 0.65, p=0.15
  - o Block design^c = -0.13, p=0.27
- CVLT
  - o Learning = -1.55, p=0.10
  - o Short-term^c = -0.74, p=0.009
  - o Long-term = -0.56, p=0.08
  - o Recognition = -0.22, p=0.34
- BNT
  - o No cues^c = -1.42, p=0.01
  - o Cues = -1.57, p=0.005
- BVMGT
  - o Copy error^c = 0.71, p=0.19
  - o Reproduction = -0.43, p=0.02
- CBCL
- NES FTT
  - o D hand = -0.68, p=0.29
  - o ND hand = -0.13, p=0.83
  - o Both hands = -0.62, p=0.63
- NES HECT = 0.033, p=0.28
- NES CPT
  - o Missed response = 0.21, p=0.0005
  - o Reaction time = 46.9, p=0.0003

Table A-18. Summary of the Grandjean et al. (1997) and Grandjean et al. (1999) Studies of the Faroe Islands Population

- TPT (D hand) = -11.3, p=0.76
- NVAPMS
  - Positive moods = 3.66, p=0.20
  - Negative moods = 1.83, p=0.51

[a]See *Calculations* for how oral mercury doses were calculated.
[b]Interpretation of neurobehavioral test scores:
   Age of crawling, sitting, or walking: increase = delay in development
   BVMGT: higher score = lower performance
   BNT: higher score = higher performance
   CTRS: higher score = higher behavioral problems
   CVLT: higher score = higher performance
   Digit span: higher score = higher performance
   NES CPT: longer response time = lower performance
   NES FTT: higher score = higher performance
   NES HECT: higher score = higher performance
   Neurologic optimality score: higher score = higher performance
   NVAPMS: higher score = more negative mood
   Postural sway: higher score = lower performance
   RSPM: higher score = lower performance
   Spatial span: higher score = higher performance
   ST-BI copying: higher score = higher performance
   WFRT: higher score = higher performance
   WISC-R: higher score = higher performance
   WJTA: higher score = higher performance
   WMS: higher score = higher performance
[c]Metric included in the meta-analysis by Axelrad et al. (2007a, 2007b).

BAEPL = brain steam auditory evoked potential latencies; BHg = blood mercury; BNT = Boston Naming Test; BVMGT = Bender Visual Motor Gestalt Test; CBCL = Child Behavior Checklist; CPT = Continuous Performance Task; CVLT = California Verbal Learning Test; FTT = Finger Tapping Test; HECT = Hand-Eye Coordination Test; HHg = hair mercury; HRV R-R = Heart Rate Variability of electrocardiogram RR interval; IQR = interquartile range; NES = Neurobehavioral Evaluation System; NVAPMS = Nonverbal Analogue Profile of Mood States; TPT = Tactual Performance Test; VEPL = visual evoked potential; VEPL = visual evoked potential latencies; WISC-R = Weschler Intelligence Scale for Children, Revised

New Zealand study. The New Zealand study followed a prospective cohort to age 6 years (Kjellstrom et al. 1989). The original cohort consisted of 10,930 children and mother pairs recruited in 1978. Consumption of marine fish was the major contributor to methylmercury exposure in this population. The prenatal exposure metric was the average total mercury in maternal hair during pregnancy. A subset of 935 high consumer subjects was selected based on consumption ≥4 fish meals per week. HHg levels in this group ranged from 6 to 86 µg Hg/g. From the ≥4 fish meals per week group, a subset of 73 high consumers was selected based on HHg level >6 µg Hg/g, from which 38 were tested at age 4 years, along with a set of 31 matched referents from mothers who consumed no more than one fish meal per week and matched for maternal ethnic group, age, residence time in New Zealand, tobacco smoking, and child birth date and sex. Assessment of neurodevelopmental outcomes occurred at age 4 and 6 years. At age 4 years, children were assessed for performance on the DDST (function, language, and personal-social behavior), Sheridan-Gardiner Letter Matching Test or Miniature Toy Test (vision), and tactile sensory function (touch, temperature), and parents were surveyed with a questionnaire on child health and neurological signs (Kjellstrom et al. 1986). The OR for abnormal or questionable scores on the DDST at age 4 years (n=31, relative matched referents) was 6.5 (p<0.005). Performance of high exposure children on vision and sensory function tests were not different from matched referents.

At age 6 years, 61 children in the high exposure group were re-evaluated, along with a set of three referent groups (n=58–60), each matched with the high exposure group for maternal ethnic group, age, residence time in New Zealand, tobacco smoking, and child birth date and sex (Kjellstrom et al. 1989). The geometric mean maternal HHg level was 8.3 µg Hg/g (range 6–86 µg Hg/g) in the high exposure group. Geometric mean HHg levels in the three referent groups ranged from 2.0 to 4.5 µg Hg/g. Children were assessed for cognitive performance, academic attainment, language development, motor coordination, intelligence, and behavior. Language development was assessed from performance on the TOLD (phonology, syntax, semantics) and Peabody picture vocabulary test (word knowledge). Intelligence was assessed using the McCarthy Scales for Children's Abilities (MSCA) and WISC. Increased maternal HHg was associated with lower scores on the TOLD spoken language quotient and WISC full-scale IQ and McCarthy perceptual scale. When the high exposure group (Group 1) was split into two maternal HHg categories, 6–<10 or ≥10 µg Hg/g, a larger fraction of variance in the TOLD and WISC tests was explained by that higher HHg category. Performance on the TOLD spoken language quotient was inversely associated with the HHg in lower category only (6–<10 µg Hg/g), whereas performance on both the TOLD spoken language quotient and WISC full scale were inversely associated with HHg in the higher category (≥10 µg Hg/g). Children scored as having an abnormal DDST at age 4 years had lower WISC full-scale IQ scores at age 6 years. Additional details of the Kjellstrom et al. (1989) study, which is included in the Axelrad et al. (2007a, 2007b) meta-analysis, are provided in Table A-19.

Table A-19. Summary of the Kjellstrom et al. (1989) Study of the North Island, New Zealand Population

Study type and population: Prospective study of birth cohort, follow-up at age 6 (n=238; 61 with high mercury exposure [maternal fish consumption ≥4 meals per week and HHg >6 µg Hg/L]) and matched referents from three referent populations (n=57 per group)

Biomarkers:
Maternal HHg (geometric mean µg Hg/g, range)
  High mercury: 8.3 (6–86)
  Referent 2 (≥4 fish meals/week): 4.5 (3–5.99)
  Referent 3 (≥4 fish meals/week): 2.0 (0.1–2.99)
  Referent 4 (≤3 fish meals/week): 2.0 (0.1–2.99)

Estimated oral dose[a]: 0.62 µg Hg/kg/day (based on high mercury group)

Analysis: Data were analyzed using robust weighted multiple regression analysis. This approach can decrease potential bias from outlier observations. Outcome associations were adjusted for significant covariates; variables explored included: maternal ethnic group, age, smoking and alcohol consumption, residence time in New Zealand, social class, language spoken at home, siblings, duration of breastfeeding, and child sex and birth weight, maturity at birth, and Apgar score.

Results[b]:
Adjusted regression coefficients between HHg (>6 µg Hg/g) and measures of intelligence
  • WISC-R (FSIQ)[c] = -4.41, p=0.019
  • WISC-R (PIQ)[c] = -3.79, p=0.072
  • MSCA (perceptual scale)[c] = -4.23, p=0.0034

Adjusted regression coefficients between HHg (>6 µg Hg/g) and measures of language development
  • TOLD[c] = -5.48, p=0.0064

Adjusted regression coefficients between HHg (>6 µg Hg/g) and measures of motor coordination

Table A-19. Summary of the Kjellstrom et al. (1989) Study of the North Island, New Zealand Population

- MSCA (motor scale) = -2.36, p=0.074

[a]See *Calculations* for how oral mercury doses were calculated.
[b]Inverse associations indicate declining performance.
[c]Metric included in the meta-analysis by Axelrad et al. 2007a, 2007b.

HHg = hair mercury; FSIQ = Full-Scale Intelligence Quotient; MCSA = McCarthy Scale of Children's Abilities; PIQ = Performance Intelligence Quotient; TOLD = Test of Language Development; WISC-R = Wechsler Intelligence Scales for Children, Revised

Seychelle Islands study. The Seychelle Islands study followed a prospective cohort of high fish consumers (n=779 mother-infant pairs, recruited 1989–1990) from age 6 months to 24 years. The primary methylmercury exposure metric was the average maternal gestational HHg level. Methylmercury accounted for >80% of total mercury in hair (Cernichiari et al. 1995). Annual median maternal HHg levels measured over the period 1986–1989 ranged from 5.9 to 8.2 µg Hg/g; the highest observed value was 36 µg Hg/g (Cernichiari et al. 1995). The main cohort, followed from age 6 months and later, had a median prenatal maternal level of 5.9 µg Hg/g (range 0.5–26.7 µg Hg/g) (Myers et al. 1995). Approximately half of the maternal HHg levels were ≤6 µg Hg/g, while the highest 15% (approximately 95 women) were >12 µg Hg/g; therefore, the power to discern significant associations was higher at HHg levels <12 µg Hg/g. Outcome associations were adjusted for covariates that included (in most studies): child sex, birth weight, birth order, gestational age, medical history and breastfeeding; maternal age, alcohol and tobacco use, and medical history; parental education, caregiver general intelligence (Raven's Progressive Matrices), family income, family language, home learning, and social stimulation (HOME score).

The Seychelle Islands has not found consistent evidence for associations between prenatal exposure (maternal HHg) and neurodevelopmental outcomes at any age studied thus far. This conclusion is supported by cross-sectional follow-ups of the cohort from ages 6.5 months to 24 years (Davidson et al. 1995, 1998, 1999, 2008a, 2010, 2011; Huang et al. 2005; Myers et al. 1995, 1997, 2000, 2003, 2009, 2020; Orlando et al. 2014; Thurston et al. 2022; van Wijngaarden et al. 2009, 2013, 2017; Young et al. 2020), longitudinal analyses of individual outcome metrics (Axtell et al. 1998; Davidson et al. 1998; Myers et al. 1997), and longitudinal analysis of metrics of global cognition based on aggregation of outcome metrics (Davidson et al. 2006a). Accounting for error in measuring HHg levels (and other covariates) had no appreciable effect on dose-response models assessed at 66 months (Huang et al. 2003). Although linear regression models consistently found no association between exposure (maternal or child HHg) and cognitive development, nonlinear models of cognitive test scores suggested that performance improved or declined in association with prenatal maternal HHg or child HHg, depending on the hair level (Axtell et al. 1998, 2000; Davidson et al. 1998, 2006a; Huang et al. 2005, 2007, 2018; Myers et al. 1997, 2003, 2020). For some outcomes, performance declined at lower HHg levels (e.g., ≤7 µg Hg/g), but improved at higher levels, and, for some outcomes, the opposite pattern was observed. At age 66 months, lower performance was not evident in a subgroup of the cohort that had a mean HHg level of 15.3 µg Hg/g (>85th percentile) (Davidson et al. 1998). It is uncertain if these nonlinear patterns reflect actual dose-level effects, differential statistical power across the HHg range, or, possibly, random outcomes from the numerous (>20) tests evaluated (Axtell et al. 2000; Davidson et al. 2006b; Huang et al. 2005, 2007). Age of walking increased with increasing prenatal maternal HHg over the range 1–7 µg Hg/g, however; the effect size was <1 day and the association was not evident at higher levels of HHg (Axtell et al. 1998). Aggregating scores of cognitive performance into metrics of global cognitive function (Davidson et al. 2006a) or dichotomizing test scores into a binomial metric (benchmark

response) also revealed no associations in cognitive development and prenatal maternal HHg <20 µg Hg/g (Crump et al. 2000; van Wijngaarden et al. 2006, 2009). After correction of statistical significance criteria for multiple comparisons, no association was found between mercury exposure and general cognition or fine motor speed assessed at ages 9, 10.5, 17, 19, 22, or 24 years (Thurston et al. 2022). Associations between exposure and cognitive function were modified by an interaction with maternal omega-3 fatty acid status, a source of negative confounding through fish consumption (Strain et al. 2008, 2012, 2021). Study details for the Myers et al. (2003) studies are summarized in Table A-20. These studies were included in the Axelrad et al. (2007a, 2007b) meta-analysis.

Table A-20. Summary of the Myers et al. (2003) Study of the Seychelle Islands Population

Study type and population: Prospective study of birth cohort, follow-up at age 9 years (n=643 of 779 in cohort)

Biomarkers:
Maternal HHg (mean µg Hg/g, SD)
   6.9 (4.5)

Estimated oral dose[a]: 0.51 µg Hg/kg/day (based on mean maternal HHg)

Analysis: Data were analyzed using multiple regression analysis. Outcome associations were adjusted for sex, examiner, family resource scale, family status (number of biological parents in the home), Henderson early learning process scale, child's age at testing, child's medical history of IUGR or head circumference >2 SD from normal, maternal age, home observation for measurement of the environment (HOME) score, caregiver intelligence, socioeconomic status, and hearing.

Results[b]:

Adjusted regression coefficients (95% CI for a 10 µg Hg/g change in HHg) for measures of general intelligence, cognition and achievement
- WISC-III FSIQ[c] = -0.13 (-3.3, 0.7), p=0.20
- CVLT
    - Short[c] = 0.013 (-0.1, 0.3), p=0.19
    - Long = 0.011 (-0.1, 0.3), p=0.28
- BNT[c] = -0.012 (-1.0, 0.8), p=0.79
- WJTA
    - LWR = 0.19 (-5.8, 9.6), p=0.62
    - AP = -0.057 (-3.5, 2.4), p=0.71

Adjusted regression coefficients (95% CI for a 10 µg Hg/g change in HHg) for measures of motor, perceptual motor, and memory
- VMI[c] = -0.010 (-2.4, 2.2), p=0.93
- BOT = 0.093 (-0.2, 2.0), p=0.10
- HAPDT = -0.010 (-0.5, 0.3), p=0.60
- Grooved peg board
    - D hand = 3.3×10^{-5} (91.4, 98.1), p=0.08
    - ND hand, male = 6.5×10^{-5} (101.7, 112.9), p=0.01
    - ND hand, female = -2.5×10^{-5} (100.0, 111.3), p=0.34

Adjusted regression coefficients (95% CI for a 10 µg Hg/g change in HHg) for measures of attention and behavior
- CPT
    - Reaction time = -0.13 (-4.4, 1.8), p=0.41
    - Attention = -0.0063 (-2.1, 2.0), p=0.95
    - Risk taking = 0.11 (-3.1, 5.4), p=0.60
- CBCL = -0.031 (-2.3, 1.7), p=0.76
- CTRS = -0.0067 (49.4, 54.1), p=0.004

Adjusted regression coefficients (95% CI for a 10 µg Hg/g change in HHg) for measures of motor, perceptual motor, and memory
- Trail making
    - A = 0.0037 (32.5, 37.6), p = 0.33
    - B = 0.0067 (79.1, 96.0), p=0.17
- FTT
    - D hand = -0.050 (-1.5, 0.5), p=0.34
    - ND hand = 0.016 (-0.6, 1.0), p=0.69
- WRAML[c] = -0.021 (-0.8, 0.4), p=0.48

APPENDIX A

Table A-20. Summary of the Myers et al. (2003) Study of the Seychelle Islands Population

- FTT
  - D hand = -0.050 (-1.5, 0.5), p=0.34
  - ND hand = 0.016 (-0.6, 1.0), p=0.69
- WRAML[c] = -0.021 (-0.8, 0.4), p=0.48

[a]See *Calculations* for how oral mercury doses were calculated.
[b]Interpretation of neurobehavioral test scores:
Age of talking or walking: increase = delay in development
Barkley ADHD: higher score = lower performance
BNT: higher score = higher performance
BOT: higher score = higher performance
BVMGT: higher score = lower performance
CANTAB: higher score = higher performance
CVLT: higher score = higher performance
FTII: higher score = higher performance
BSID IBR: higher score = higher performance
BSID MDI: higher score = higher performance
BSID PDI: higher score = higher performance
BVMGT: higher score = lower performance
CBCL: higher score = lower performance
CDI: higher score = higher performance
CELF-5: higher score = higher performance
CTRS: higher score = lower performance
CVLT: higher score = higher performance
DDST: milestones evaluated against a standard; below standard = delayed development
DSA: higher score = higher performance
Finger tapping: higher score = higher performance
GPB: higher score = lower performance
HAPDT: higher score = higher performance
KBIT-2: higher score = higher performance
MSCA: higher score = higher performance
PLS: higher score = higher performance
SCQ: higher score = higher performance
SRS-2: higher score = higher performance
Stroop interference: higher score = higher performance
TSRSS: higher score = higher performance
VEXP: higher score = higher performance
WJTA: higher score = higher performance
WRAML: higher score = higher performance
[c]Metric included in the meta-analysis by Axelrad et al. (2007a, 2007b).

AP = applied problems; BNT = Boston Naming Test; BOT = Bruininks-Oseretsky Test of Motor Proficiency; CBCL = Child Behavior Checklist; CI = confidence interval; CPT = Continuous performance task; CTRS = Connors' Teacher Rating Scale (hyperactivity index); CVLT = California Verbal Learning Test; D = dominant; FSIQ = full-scale intelligence quotient; FTT = Finger Tapping Test; HAPDT = Haptic Discrimination Test; HHg = hair mercury; HOME = Home Observation Measurement of the Environment; IUGR = intrauterine growth retardation; LWR = letter word recognition; ND = non-dominant; SD = standard deviation; VMI = Visual Motor Integration; WJTA = Woodcock-Johnson Test of Achievement; WISC-III = Wechsler Intelligence Scales for Children, 3rd ed.; WRAML = Wide Range Assessment of Memory and Learning

Meta-analysis of Faroe Islands, North Island, New Zealand, and Seychelles Islands studies. Two meta-analyses of the populations from the Faroe Islands, North Island, New Zealand, and Seychelles Islands have been conducted; these are reported in publications by Axelrad et al. (2007a, 2007b) Cohen et al. (2005), and Ryan (2008). In the more recent analysis, Axelrad et al. (2007a, 2007b; Ryan 2008)

converted regression slopes for several cognitive test scores measured in each study into an IQ point scale (Axelrad et al. 2007a, 2007b). The meta estimate for the effect size was -0.18 IQ points per increase of 1 µg Hg/g hair (95% CI -0.378, -0.009). The meta-analysis is described in detail in the *Summary of the Principal Study* section. Ryan (2008) reported a sensitivity analysis of the meta-slope from Axelrad et al. (2007a, 2007b).

Cohen et al. (2005) used a similar analytical approach as Axelrad et al. (2007a, 2007b) in a meta-analysis of the Faroe Islands, North Island, New Zealand, and Seychelles Islands studies. However, Cohen et al. (2005) included results from a wider selection of cognitive tests. The meta estimate from Cohen et al. (2005) was an average decrease of 0.043 SDs in cognitive performance per increase of 1 µg Hg/g maternal hair. For a SD of 15 IQ points, the meta estimate corresponds to an equivalent change in IQ of 0.7 points per 1 µg Hg/g hair, with a plausible range of 0 to 1.5 points per 1 µg Hg/g hair (Cohen et al. 2005).

The Axelrad et al. (2007a, 2007b) meta-analysis was selected as the principal study over the Cohen et al. (2005) because bounds on the meta-estimate from the Cohen et al. (2005) meta-analysis were wider and included zero. A likely contributor to this difference was the inclusion of a wider selection of outcomes in the Cohen et al. (2005) metal-analysis.

Norwegian Mother and Child Cohort Study. In addition to the above studies of high fish consumers, a large prospective study of a general population found associations between dietary fish mercury intake and language proficiency (Vejrup et al. 2016, 2018, Table A-21). This study examined a birth cohort consisting of 46,750 mother-infant pairs recruited during the period 1999–2008 with outcomes measured at age 3 years (Vejrup et al. 2016) and 5 years (Vejrup et al. 2018). Dietary intake of mercury from fish consumption was estimated in each mother based on outcomes of a food frequency questionnaire completed during pregnancy and a survey of mercury levels in fish consumed by Norwegians (Jenssen et al. 2012). Median fish consumption was estimated to be 32 g/day. Median mercury intake from consumption of fish was estimated to be 0.14 µg Hg/kg/week. The 90th percentile was 0.29 µg Hg/kg/week (Vejrup et al. 2016). Estimation of dietary intakes of mercury in fish (which is dominated by methylmercury) precluded reliance on biomarkers as dose metrics for methylmercury exposure. The study evaluated language proficiency and communication skills using parent-reported questionnaires. This study found associations between increasing dietary intake of mercury in fish with decreasing performance on language proficiency tests administered at age 3 and 5 years. These associations persisted after adjustment for known important confounders related to fish consumption, including fish consumption rate (adjustment strengthened the association with mercury), 3-omega LCPUFA consumption, and exposure to PCBs (Vejrup et al. 2016). The language outcomes associated with mercury intake (>0.29 µg Hg/kg/week) were described as "unintelligible speech" on the Dale and Bishop Grammar Rating and "weak communication development" on the Ages and Stages Communication Scale.

In a follow-up at age 5 years, children were assessed with three outcome tests: Ages and Stages Communication Scale, Speech and Language Assessment Scale, and Twenty Statements about Language-Related Difficulties. At age 5 years, in the full cohort (n=38,297) among women who consumed <400 g fish/week, both fish consumption and mercury intake were associated with improvement of scores (negative error scores) in the Ages and Stages Communication Scale and Speech and Language Assessment Scale. When the analysis was confined to matched siblings (n=7,404), dietary fish mercury intake at the 90th percentile level (>3.18 µg Hg/day) was associated with decreasing performance on the Speech and Language Assessment Scale but not on the Ages and Stages Communication Scale or Language-Related Difficulties scale. No associations were observed with mid-pregnancy maternal BHg concentrations in a subcohort of the main cohort (2,239 subjects) in which BHg levels were measured (median 1.0 µg Hg/L; range 0, 14 µg Hg/L) (Vejrup et al. 2018). These results suggest that fish intake was a confounding variable in this study (correlation between dietary fish mercury intake and dietary

seafood intake was 0.88) and may have attenuated associations between dietary methylmercury intake and delays in attainment of language skills. The absence of an association with maternal BHg may represent variance in BHg levels that is unrelated to dietary methylmercury intake (e.g., mercury from amalgam restorations).

Table A-21. Summary of the Vejrup et al. (2016, 2018) Studies of the Norwegian Population

Study: Vejrup et al. 2016

Study type and population: Prospective cohort of mother-infant pairs, follow-up at age 3 years (n=46,750)

Estimated oral dose: 0.041 µg Hg/kg/day (based on 90th percentile weekly intake)
- Maternal dietary mercury intake from fish (median):
  - 1.3 µg Hg/day
  - 0.14 µg Hg/kg/week
- 90th percentile:
  - 2.6 µg Hg/day
  - 0.29 µg Hg/kg/week

Analysis: Maternal methylmercury was estimated based on fish intake reported in an FFQ administered mid-pregnancy. Outcomes evaluated were performance on the Dale Bishop Grammar Rating and Ages and Stages communication scale (ASQ). ORs were calculated to assess risk in children with high mercury exposure, defined as >90th percentile (>2.64 µg Hg/day, >0.29 µg Hg/kg/week), compared to children with mercury exposure <90th percentile. ORs were adjusted for parity, maternal education, paternal education, pre-pregnancy BMI, bilingual parents, and age of child when reporting language development. Additional models were further adjusted for intake of lean and oily fish, n-3 LCPUFA from diet, n-3 LCPUFA from supplements, and dioxin and PCB exposures.

Results:
Adjusted OR (95% CI) between high prenatal methylmercury exposure (>90th percentile) and language development for Dale and Bishop Grammar rating (n=46,750)
- Complete grammar (reference): 1
- Low grammar: 1.01 (0.93, 1.10)
- Moderate delay: 1.06 (0.88, 1.26)
- Unintelligible speech: 2.22 (1.31, 3.72)
- Severe delay: 1.04 (0.69, 1.57)
Further adjusted for intake of lean and oily fish
- Unintelligible speech: 3.02 (1.47, 6.21)
Adjusted OR (95% CI) between high prenatal methylmercury exposure (>90th percentile) and communication development (ASQ, n=45,332)
- Normal skills (reference): 1
- Weak skills: 1.33 (1.03, 1.70)
Further adjusted for intake of lean and oily fish
- Weak skills: 1.46 (1.07, 2.00)

Table A-21. Summary of the Vejrup et al. (2016, 2018) Studies of the Norwegian Population

Study: Vejrup et al. 2018

Study type and population: Prospective cohort of mother-infant pairs, follow-up at age 5 years (n=38,581)

Biomarker: Maternal BHg 1.03 µg Hg/L (median; n=2,239)

Estimated oral dose[a]: 0.049 µg Hg/kg/day (based on 90th percentile adjusted for 65 kg body weight)
- Maternal dietary mercury intake from fish
  - Median: 0.15 µg Hg/kg/week
  - 90th percentile: 3.18 µg Hg/week

Analysis: Outcomes evaluated were performance on the Speech and Language Assessment Scale, Ages and Stages communication scale, and Twenty Statements about Language-Related Difficulties. Data were analyzed using multiple regression analysis. Outcome associations were adjusted for maternal age, education, parity, pre-pregnancy BMI, Hopkins Symptom Checklist-5 (SCL-5), total energy intake, eicosapentaenoic acid and docosahexaenoic acid (DHA) from total diet and/or supplement. A sibling fixed-effect analysis was also conducted.

Results:
Adjusted regression coefficients (95% CI) between maternal BHg and measures of language and communication (n=2,239), NS
- ASQ: -0.02 (-0.1, 0.03)
- Language 20: 0.01 (-0.03, 0.05)
- SLAS: -0.01 (-0.1, 0.03)

Adjusted regression coefficients (95% CI) between dietary seafood mercury intake >400 g/week and measures of language and communication (n=4,375), NS
- ASQ: 0.1 (-0.1, 0.4)
- Language 20: 0.31 (-0.01, 0.6)
- SLAS: -0.17 (-0.4, 0.1)

Adjusted regression coefficients (95% CI) between maternal seafood intake >400 g/week and measures of language and communication (n=38,297), $p<0.05$
- ASQ: -0.06 (-0.1, -0.01)
- Language 20: -0.05 (-0.1, -0.01)
- SLAS: -0.07 (-0.1, -0.03)

Adjusted regression coefficients (95% CI) between >90th percentile maternal dietary mercury intake and measures of language and communication in sibling fixed effect analysis (n=647)
- ASQ: 0.03 (-0.1, 0.1), NS
- Language 20: 0.02 (-0.1, 0.1), NS
- SLAS: 0.1 (0.01, 0.2), $p<0.05$

[a]See *Calculations* for how oral mercury doses were calculated.

ASQ = Ages and Stages Communication Scale; BHg = blood mercury; BMI = body mass index; CI = confidence interval; DHA = docosahexaenoic acid; FFQ = food frequency questionnaire; Language 20 = Twenty Statements about Language-Related Difficulties; NS = not specified; OR = odds ratio; SLAS = Speech and Language Assessment Scale

Given the variable outcomes within and across the Faroe, New Zealand, and Seychelles studies of high fish consumers, selection of a single population as the basis for the MRL was not considered an ideal approach. Instead, the Axelrad et al. (2007a, 2007b) meta-analysis was considered a better representation of the weight of evidence from the three high fish consumer studies. The meta-analysis was selected over the Norwegian Mother and Child Cohort Study (Vejrup et al. 2016, 2018) as the principal study after weighing strengths and weaknesses of both studies (Table A-22). The key strength of the Axelrad et al. (2007a, 2007b) meta-analysis is that it included outcomes from multiple tests of cognitive performance from three independent prospective studies (approximately 1,800 subjects) after transforming the data into a global metric of full-scale IQ, which can be more readily generalized than individual test scores. The analysis included a test of language proficiency (New Zealand study, Test of Language Development). Language development was also evaluated in the Norwegian Mother and Child Cohort Study, using a different set of tests (Ages and Stages Communication, Dale Bishop Grammar Rating, Speech and Language Assessment Scale) (Vejrup et al. 2016, 2018). The studies included in the meta-analysis also provided biomarkers of exposure in each individual subject, which is likely to have decreased exposure misclassification inherent to using data from dietary recall and national data on mercury concentrations in recalled fish meals, as was used in the Norwegian Mother and Child Cohort Study.

Table A-22. Strengths and Weaknesses of Axelrad et al. (2007a, 2007b) and Vejrup et al. (2016, 2018) for Establishing a Point of Departure for the Chronic-Duration Oral MRL for Methylmercury

Study	Strengths	Weaknesses
Axelrad et al. 2007a, 2007b meta-analysis of Faroes, New Zealand, and Seychelles studies of high fish consumers	• Utilized and weighted data from three independent prospective studies (total number ~1,800) • Direct measure of individual subject exposure from biomarker (hair mercury) • Subjects were high fish consumers, which strengthens association between biomarkers and exposure to methylmercury • Included multiple tests of cognitive performance scaled to equivalent IQ points • Language proficiency included as an outcome metric • Sensitivity analysis indicated a narrow range for the effect size estimate • Effect size reported as linear regression β that can be transformed into a *di minimis* change in the biomarker (or equivalent dose); e.g., change in dose above background dietary level associated with a 1-point change in IQ	• Pharmacokinetic model needed to transform biomarkers to equivalent mercury intakes • To derive MRL, must select magnitude of change in IQ that corresponds to an IQ POD • Effect size may have been depressed by negative confounding with nutritional benefits from high fish consumption

APPENDIX A

Table A-22. Strengths and Weaknesses of Axelrad et al. (2007a, 2007b) and Vejrup et al. (2016, 2018) for Establishing a Point of Departure for the Chronic-Duration Oral MRL for Methylmercury

Study	Strengths	Weaknesses
Vejrup et al. 2016, 2018 Norwegian Mother and Child Cohort Study of general population	• Large prospective study • Larger size of cohort (~47,000 subjects) of general population, with lower fish consumption than high consumption studies	• Associations with dietary methylmercury intake were based on a semi-quantitative food survey and national data on fish mercury concentrations, rather than biomarkers of mercury exposure in individual subjects • The association with dietary methylmercury intake predicted lower language proficiency at age 3 years, whereas the association predicted higher proficiency at age 5 years • In a subset of the cohort with measurements of individual subject BHg levels, there was no association between language proficiency and BHg • Outcome evaluation was limited language proficiency, which was assessed using a parental self-report survey of their children and not by unbiased experts

BHg = blood mercury; CI = confidence interval; FFQ = food frequency questionnaire; IQ = intelligence quotient; MRL = Minimal Risk Level; POD = point of departure

Summary of the Principal Study:

Axelrad DA, Bellinger DC, Ryan LM, et al. 2007a. Dose-response relationship of prenatal mercury exposure and IQ: An integrative analysis of epidemiologic data. Environ Health Perspect 115(4):609-615. http://doi.org/10.1289/ehp.9303.

Axelrad DA, Bellinger DC, Ryan LM, et al. 2007b. Supplemental material: Dose-response relationship of prenatal mercury exposure and IQ: An integrative analysis of epidemiologic data. Environmental health perspectives. https://ehp.niehs.nih.gov/action/downloadSupplement?doi=10.1289%2Fehp.9303&file=9303_suppl.pdf. March 18, 2021.

Ryan L. 2008. Combining data from multiple sources, with applications to environmental risk assessment. Statist Med 27:698-710. http://doi.org/10.1002/sim.3053.

The meta-analysis included outcomes from the Faroe Islands study at age 7 years, New Zealand study at age 6 years, and Seychelles Islands study at age 9 years (Axelrad et al. 2007a, 2007b). Outcomes included in the analysis are summarized in Table A-23. Additional study details are provided in Table A-24.

Table A-23. Cognitive Performance Tests[a] Included in Meta-analysis of Faroe Islands, New Zealand, and Seychelle Islands Studies

Cognitive domain	Faroe Islands	New Zealand	Seychelles Islands
General intelligence	WISC-R (full-scale IQ)	WISC-R (full-scale IQ) WISC-R (performance IQ)	WISC-III (full-scale IQ)
Verbal learning and memory	CVLT (short term)	NE	CVLT (short term)
Visual-motor integration	BGT	NE	VMI
Visual memory	NE	NE	WRAML (design memory)
Confrontational naming	BNT (no cues)	NE	BNT (total score)
General development	NE	MSCA (perceptual)	NE
General verbal skills	NE	TOLD (spoken language coefficient)	NE
Visual memory	NE	NE	WRAML (design memory)

[a]Regression slopes derived in these tests were rescaled to full-scale IQ.

BGT= Bender Gestalt Test; BNT = Boston Naming Test; CVLT = California Verbal Learning Test; IQ = intelligence quotient; MSCA = McCarthy Scales of Children's Abilities; NE = not evaluated; TOLD = Test of Language Development; VMI = Visual–Motor Integration; WISC-R = Wechsler Intelligence Scales for Children, Revised; WISC-III = Wechsler Intelligence Scales for Children, 3rd ed.; WRAML = Wide Range Assessment of Memory and Learning

Table A-24. Summary of the Axelrad et al. (2007a, 2007b) Meta-Analysis Study

Study type and population: Meta-analysis of prospective birth cohorts in Faroe Islands (n=917), Seychelles Islands (n=643), and New Zealand (n=237; Grandjean et al. 1997, 1999; Kjellstrom et al. 1989; Myers et al. 2003) with follow-up at age 7, 9, and 6 years, respectively

Estimated oral dose: 0.41 µg Hg/kg/day (based on 1 IQ point per 5.56 µg Hg/kg/day; -0.18 IQ points per µg Hg/g hair)

Analysis: Bayesian hierarchical modeling integrated data from the three study populations. A primary mercury-IQ dose-response analysis model was built using metrics with coefficients that were rescaled to be interpretable in the same scale as FSIQ estimates. FSIQ for the Faroe Islands data was estimated by combining three WISC subsets (Digit Span, Similarities, Block Design), which Axelrad et al. (2007a, 2007b) concluded would provide valid estimates of full-scale IQ.

APPENDIX A

Table A-24. Summary of the Axelrad et al. (2007a, 2007b) Meta-Analysis Study

Results:

Rescaled regression coefficients (SE) for cognitive endpoints from the Faroe Islands
- WISC-R (FSIQ) = -0.124 (0.057)
- BGT = -0.104 (0.083)
- BNT = -0.260 (0.086)
- CVLT = -0.169 (0.093)

Rescaled regression coefficients (SE) for cognitive endpoints from the Seychelle Islands
- WISC-III (FSIQ) = -0.17 (0.130)
- CVLT = 0.19 (0.144)
- BNT = -0.038 (0.144)
- WRAML = -0.109 (0.15)
- VMI = -0.013 (0.15)

Rescaled regression coefficients (SE) for cognitive endpoints from New Zealand
- WISC-R (FSIQ) = -0.50 (0.268)
- WISC-R (PIQ) = -0.51 (0.310)
- TOLD = -0.56 (0.282)
- MSCA = -0.80 (0.315)

Estimated IQ decrement per µg Hg/g maternal HHg (95% CI), at different R levels (ratio of study-to-study variability relative to endpoint-to-endpoint variability)
- 4.0 = -0.188 (-0.398, -0.010)
- 3.5 = -0.182 (-0.390, -0.007)
- 3.0 = -0.180 (-0.378, -0.009)
- 2.5 = -0.183 (-0.384, -0.017)
- 2.0 = -0.178 (-0.371, -0.012)
- 1.5 = -0.168 (-0.360, -0.003)
- 1.0 = -0.165 (-0.338, -0.015)
- 0.5 = -0.160 (-0.321, -0.026)
- 0.25 = -0.151 (-0.283, -0.033)

BGT = Bender Gestalt Test; BNT = Boston naming test; CVLT = California Verbal Learning Test; FSIQ = Full-Scale Intelligence Quotient; HHg = hair mercury; IQ = intelligence quotient; MSCA = McCarthy Scales of Children's Abilities; PIQ = performance intelligence quotient; SE = standard error; TOLD = Test of Language Development; VMI = Visual Motor Integration; WISC-R = Wechsler Intelligence Scales for Children, Revised; WISC-III = Wechsler Intelligence Scales for Children, 3rd ed.

Linear regression parameters, slope (β) and intercept (Int) for associations between mercury and scores on tests of cognitive performance were rescaled to IQ by adjusting the parameters by a scaling factor. The scaling factor was the ratio of the SDs for the full-scale IQ (SD_{IQ}) and the test (SD_{test}), SD_{IQ}/SD_{test}, where SD_{IQ} was assigned a value of 15. The adjusted parameters were calculated as follows:

$$\beta^* = \beta \times SD_{IQ}/SD_{test}$$
$$Int^* = Int \times SD_{IQ}/SD_{test}$$
$$SE^* = SE \times SD_{IQ}/SD_{test}$$

where β^* and Int^* are the rescaled values for the slope and intercept, respectively.

The Faroe Islands parameters required additional factors. A factor of 10 adjusted the Faroe Islands log-normal model to a normal model (Budtz-Jorgensen et al. 2004). A factor of 200 µg Hg/kg per µg Hg/L was used to convert Faroe Islands cord BHg levels to HHg (Budtz-Jorgensen et al. 2004).

Meta-β estimates were weighted by study-to-study variance (σ^2) in β and endpoint-to-endpoint variance endpoint outcomes, using a Bayesian approach with exploratory values for the variance ratio R ($\sigma^2_{study}/\sigma^2_{endpoint}$). The meta estimate for the effect size was -0.18 IQ points per µg Hg/g hair (95% CI -0.378, -0.009). Ryan (2008) conducted a sensitivity analysis of the Axelrad et al. (2007a, 2007b) meta-β to varying correlations between error (standard errors) of different outcomes measured in the same study. The analysis supports the estimate of the meta-β estimated by Axelrad et al. (2007a, 2007b). Increasing

error correlation was predicted to decrease the estimated β. The range in the estimated β was -0.18 to -0.20 IQ points per μg Hg/g hair. The low end of the range, -0.18, was predicted when correlation of within study outcome error was ignored.

To determine the change in HHg levels, one IQ point is divided by the meta estimate of 0.18 μg Hg/g hair (as seen in Equation 6, below). Because the meta-β is a parameter of a linear regression equation, the change in IQ points is predicted to be proportional to the change in HHg levels near the center of the distribution of the HHg scale. The central estimates of HHg levels for the three contributing studies ranged from approximately 4 to 9 μg Hg/g hair. Therefore, the proportional relationship can be expected for HHg levels within this range. The corresponding estimates of the change in HHg level corresponding to a specific change in IQ are shown in Table A-25 (see the Calculations section for equation used to convert change in IQ or change in HHg). As can be ascertained from Table A-25, a change in HHg of 5.56 μg Hg/g hair is predicted to result in a 1-point decrease in IQ.

Table A-25. Estimates of the Change in Hair Mercury Level Corresponding to a Specific Change in IQ

Change in IQ (points)	Change in hair mercury (μg Hg/g)
-1	5.56
-2	11.1
-3	16.7
-4	22.2
-5	27.8

Selection of the Point of Departure for the MRL: The POD selected for derivation of the chronic-duration oral MRL for methylmercury is 5.56 μg Hg/g hair. This value is the change in HHg level that corresponds to a decrease of 1 point in full-scale IQ, based on the meta-β of -0.18 IQ points per 1 μg Hg/g hair (see *Calculations*). A decrease in full-scale IQ of ≤1 point is considered a NAEL.

Loss of IQ has been used as a metric for assessing the health burden of neurotoxicants, including methylmercury (Bellanger et al. 2013; Bellinger 2012; Bellinger et al. 2019; Chen et al. 2023c). While IQ losses ranging from 1 to 5 points are not significant for most children (the SD associated with IQ tests is approximately 5 points), these small decrements may represent meaningful intellectual and economic achievement at a population level (Bellanger et al. 2013, Bellinger et al. 2019; EPA 1998; Griffiths et al. 2007; Trasande et al. 2005). Based on the meta-β of -0.18 IQ points per μg Hg/g hair (Axelrad et al. 2007a, 2007b) and regional data on maternal HHg levels, the global disability life years attributed to methylmercury exposure was estimated to range from 7 per 100,000 to 44 per 100,000 (Bellinger et al. 2019). Using the same meta (-0.18 IQ points per μg Hg/g hair), Chen et al. (2023c) estimated the disability life years in China attributed to methylmercury exposure to be 3.67 per 1,000 births. The neurological impact of IQ score decrements (≥1, ≥2, and ≥3 IQ points) was used for the risk assessment of lead in paint, dust, and soil (EPA 1998) and estimates of the economic impact per 1-point decrease in IQ was used to estimate benefits of revisions of the National Ambient Air Quality Standards for Lead (EPA 2008). Risk assessments of fluoride exposure have been conducted based on IQ point losses of both 1 and 5 points (Hirzy et al. 2016).

Calculations:

Conversion of meta-β to HHg POD. The linear regression model predicts a proportional relationship between the change in IQ points and change in HHg. Therefore, the conversion of the meta-β to a mercury POD in units of HHg (*POD$_{hair}$*) is as follows (Equation 8):

$$POD_{hair} = \frac{1\ IQ\ point}{0.18\ IQ\ points\ per\ \mu g\ Hg/g\ hair} \qquad \text{Eq. (8)}$$

The *POD* in units of HHg from Equation 1 is 5.56 μg Hg/g hair.

Conversion of HHg level to oral mercury dose. HHg levels were converted to equivalent oral doses by applying a steady-state mass balance model, which did the following: (1) converted the hair level (μg Hg/g, assumed to represent steady state) to an equivalent steady-state BHg level (μg Hg/L) and (2) converted the steady-state BHg level to an equivalent steady-state oral dose (μg Hg/kg/day). Steady-state mass balance models have been used to reconstruct methylmercury intakes in human populations (Sirot et al. 2008). The assumption of steady state requires that the exposures were relatively constant (or intermittent with a constant frequency) for periods >300 days. This is the exposure duration that would achieve 95% of steady-state body burden, assuming a terminal elimination half-time of 65 days (Albert et al. 2010; Equation 9):

$$Time\ to\ steady\ state = \frac{\ln\ (1-0.95)}{k_e} \qquad \text{Eq. (9)}$$

where 0.95 is the fraction of steady state and k_e is ln(2)/half-time.

The steady-state model is based on Albert et al. (2010) and is given in Equation 10:

$$Hg_{bl} = \frac{Hg_{dose} \cdot AF \cdot f_{bl} \cdot BW}{k_e \cdot V_{bl}} \qquad \text{Eq. (10)}$$

where Hg_{bl} is the steady-state BHg level (μg Hg/L), Hg_{dose} is the steady-state dose (μg Hg/kg/day) *AF* is the gastrointestinal absorption fraction, f_{bl} is the blood fraction of the mercury body burden, *BW* is body weight (kg), k_e is the terminal elimination rate constant for mercury and V_{bl} is the blood volume (L).

The corresponding steady-state HHg level was calculated assuming a hair/blood ratio (Equation 11):

$$Hg_{hair} = Hg_{bl} \cdot HBR \qquad \text{Eq (11)}$$

where *Hg$_{hair}$* is the HHg level (μg Hg/g hair) *HBR* is the hair/blood ratio (μg Hg/g per μg/L blood).

Parameter values for Equations 8 and 9 are presented in Table A-26. With these parameter values, the conversion factors for HHg and BHg are as follows (Equations 12 and 13):

$$Dose = \frac{Hg_{bl}}{66.51} \qquad \text{Eq. (12)}$$

$$Dose = \frac{Hg_{hair}}{13.50} \qquad \text{Eq. (13)}$$

where the dose is in units of μg Hg/kg/day, BHg in units of μg Hg/L and HHg in units of μg Hg/g.

Table A-26. Parameter Values for the Methylmercury Dose Equivalence Model[a]

Parameter	Unit	Value
Blood elimination half-time	Day	65.4
Blood elimination rate constant	Day^{-1}	0.0106
Steady-state external dose	µg Hg/kg/day	1.00
Gastrointestinal absorption fraction	Fraction	0.94
Blood fraction of body burden	Fraction	0.060
Body weight	kg	60
Blood fraction of body weight	L/kg	0.080
Hair/blood ratio	µg Hg/kg per µg Hg/L	203

[a]Parameter values from Albert et al. (2010).

Basis for parameter values. Albert et al. (2010) was used as the basis for parameter values in the dose equivalence model because it provided estimates for the full set model parameters in a sample of the critical population represented in the MRL, pregnant females. Albert et al. (2010) estimated values for parameters in Equations 8 and 9 based on HHg levels and dietary seafood mercury intakes in 125 pregnant women. Scalp and hair mercury levels were measured at weeks 12 and 32 of pregnancy. Dietary mercury intakes were estimated in each subject from a food frequency questionnaire with seafood items paired to a national (France) database on methylmercury content of foods (Verger et al. 2007). Values for parameters were assigned prior distributions based on various sources (Albert et al. 2010) and posterior distributions were estimated in Markov Chain Monte Carlo simulations. Studies similar to Albert et al. (2010) have also estimated the full set of parameters for the model in other adult populations (Jenssen et al. 2012; Jo et al. 2015).

Additional support for the individual parameter values in the dose equivalence model derive from a variety of sources summarized below.

Gastrointestinal absorption fraction. The value for the gastrointestinal absorption fraction used in the dose equivalence model is 0.94 (Albert et al. 2010). Studies conducted in humans, monkeys, and rodents have shown that gastrointestinal absorption of mercury is close to 100% following ingestion of methylmercury as the chloride salt or when incorporated into fish or other ingested protein (Aberg et al. 1969; Berlin et al. 1975; Clarkson 1971; Clarkson and Shapiro 1971; Miettinen et al. 1971; Mori et al. 2012; Nielsen 1992; Nielsen and Andersen 1991, Nielsen et al. 1992; Sundberg et al. 1999; Yannai and Sachs 1993).

Blood fraction of mercury body burden. The value for the blood fraction of the body burden used in the dose equivalence model is 0.06 (Albert et al. 2010). In clinical studies of known doses of methylmercury, BHg accounted for approximately 5–7% of the absorbed dose (Kershaw et al. 1980; Miettinen et al. 1971; Sherlock et al. 1984; Smith et al. 1994).

BHg elimination half-time. The value for the terminal blood elimination half-time used in the dose equivalence model is 65.4 days (Albert et al. 2010). The corresponding elimination rate constant used in Equation 8 is 0.0106 day^{-1}. Population-based estimates of the blood half-time for methylmercury have relied on fitting biokinetics models to data on BHg or HHg levels to dietary methylmercury intakes (Albert et al. 2010; Jo et al. 2015). Albert et al. (2010) estimated half-times in 125 pregnant women from measurements of HHg and dietary methylmercury intake estimated from a dietary survey. When estimated assuming a point estimate for the population dietary intake, the mean half-time was 65.4 days

(SD 6.0; 95% CI 54, 78). When interindividual variability in dietary mercury intake was included in the estimation of the half-time, the population mean half-time was 103 days (SD 9.5; 95% CI 83, 121). Jo et al. (2015) estimated half-times in 304 adults who were randomly selected from BHg quartiles of the KRIEFS cohort. The estimated population mean half-time (with interindividual variability in dietary intake included in the estimation) was 80.2 days (2.5–97.5 percentile range 64.0–97.4 days). The estimated mean half-time for males (n=167) was 81.6 days (range 66.0–98.8 days) and, for females (n=137), the estimated mean half-time was 78.9 days (range 62.8–96.4 days).

Hair/blood ratio. The value for the hair/blood ratio used in the dose equivalence model is 203 µg Hg/kg hair per µg Hg/L blood (Albert et al. 2010). The Faroe Islands study collected individual subject data on cord blood and parental hair at parturition (Budtz-Jorgensen et al. 2004). The median ratio (µg Hg/kg hair per µg Hg/L blood) was 190 (5th–95th percentile: 74–442) for full-length hair and 201 (5th–95th percentile: 89–439) for proximal hair (2-cm scalp segment). The hair/blood concentration ratio has been measured in numerous other studies and shows high inter-individual variability, with population means ranging from 100 to 400 (Akagi et al. 1995; Albert et al. 2010; Birke et al. 1972; Clarkson et al. 1988; Kershaw et al. 1980; Liberda et al. 2014; Muckle et al. 2001; Phelps et al. 1980; Sherlock et al. 1982; Yaginuma-Sakurai et al. 2012).

Blood volume. The value for the blood volume used in the dose equivalence model is 0.08 L/kg body weight (Albert et al. 2010). Data on blood volume in humans have been extensively reviewed (e.g., Brown et al. 1962; ICRP 1981; Stern 1997). These sources provide estimates that range from 0.06 to 0.08 L/kg. The upper end of the range is appropriate for the expanded blood volume that occurs during pregnancy (Hytten 1985).

Body weight. The value for body weight used in the dose equivalence model is 60 kg, based on ICRP (1981) and EPA (2011).

Evaluation of the dose equivalence model. The dose equivalence model was evaluated by comparing predicted doses with observed BHg or HHg levels in populations of pregnant women in which individual dietary methylmercury intakes were known or estimated (Pouzaud et al. 2010; Vejrup et al. 2018). The results of these comparisons are summarized below. The close agreement between the observed methylmercury intakes and dose equivalents predicted from BHG or HHG levels supports use of the model in derivation of the chronic-duration oral MRL.

Pouzaud et al. (2010) measured dietary scalp hair mercury levels in 137 pregnant women during weeks 12 and 32 of pregnancy and paired these data with estimates of dietary methylmercury intake from a dietary survey. The group mean hair level was 0.82 µg Hg/g at week 12 and 0.79 µg Hg/g at week 32. The corresponding mean dietary intakes were 0.56 µg Hg/kg/week (0.080 µg Hg/kg/day) and 0.67 µg Hg/kg/week (0.096 µg Hg/kg/day). The observed and predicted mercury doses for this study are as follows:

    Observed mean HHg: 0.82, 0.79 µg Hg/kg
    Observed mean mercury intake: 0.080, 0.096 µg Hg/kg/day
    Predicted mean dose equivalent: 0.061, 0.059 µg Hg/kg/day
    Predicted minus observed: -0.019, -0.037 µg Hg/kg/day

The differences between the predicted and observed mercury intakes ranged from 0.02 to 0.04 µg Hg/kg/day. Good agreement between the predicted and observed dietary methylmercury intakes are expected for this dataset, since it included data from 123 subjects used to estimate parameters for the dose equivalence model.

APPENDIX A

Vejrup et al. (2018) estimated median dietary fish mercury intakes and measured BHg levels for a subset of the full cohort of the Norwegian Mother and Child Cohort Study (n=2,239). The median maternal BHg level was 1.0 µg Hg/L (SD 0.9) and the median estimated dietary fish mercury intake was 0.15 µg Hg/kg/week (0.021 µg Hg/g/day). The observed and predicted mercury doses for this study are as follows:

> Observed median BHg: 1.0 µg Hg/L (SD 0.9)
> Observed median mercury intake: 0.021 µg Hg/kg/day
> Predicted median dose equivalent: 0.015 µg Hg/kg/day
> Predicted minus observed: -0.006 µg Hg/kg/day

The difference between the predicted and observed mercury intake was 0.006 µg Hg/kg/day.

Conversion of meta-β (IQ points per µg Hg/g hair) to POD$_{dose}$ (µg/kg/day per 1 IQ point).

Calculate POD$_{hair}$ (µg Hg/g hair per 1 IQ point) from meta-β (IQ points per µg Hg/g hair; Equation 8):

$$POD_{hair} = (IQ\ points)/(meta\beta)$$

$$POD_{hair} = \frac{1}{0.18} = 5.56$$

Calculate ratio of BHg to dose (µg/L blood per µg Hg/kg/day; Equation 10):

$$Ratio\ blood\!:\!dose = (AF \times f_{blood} \times BW)/(k_e \times V_{blood})$$

$$Ratio\ blood\!:\!dose = \frac{0.94 \times 0.060 \times 60\ kg}{0.0106\ day^{-1} \times 4.80\ L} = 66.51$$

where AF is the absorption fraction, f_{blood} is the fraction of the dose transferred to blood, BW is body weight, k_e is the elimination rate constant ($\ln(2)/t_{1/2}$) and V_{blood} is the blood volume ($0.080 \times$ body weight).

Calculate ratio of HHg to dose (µg Hg/g hair per µg Hg/kg/day; Equations 11 and 13):

$$Ratio\ hair\!:\!dose = (Ratio\ blood\!:\!dose \times Ratio\ hair\!:\!blood)/1,000$$

$$Ratio\ hair\!:\!dose = 66.51 \times \frac{203}{1,000} = 13.50$$

Calculate POD$_{dose}$ (µg Hg/kg/day) from POD$_{hair}$ (µg Hg/g hair):

$$POD_{dose} = POD_{hair}\ /\ Ratio\ hair\!:\!dose$$

$$POD_{dose} = \frac{5.56}{13.50} = 0.41$$

Uncertainty Factor: An uncertainty factor of 3 was applied to the POD of 0.41 µg Hg/kg/day to account for expected human variability in pharmacokinetics and dynamics. The uncertainty factor was reduced from the standard factor for 10 for the following reasons: (1) the principal study examined a highly sensitive target population, the fetus and (2) a well-supported biokinetic model was used to calculate the equivalent maternal dose from a well-supported biomarker of exposure to methylmercury in high fish consuming populations.

- 3 for human variability

MRL = POD ÷ UF
MRL = 0.41 µg Hg/kg/day ÷ 3
MRL = 0.1 µg Hg/kg/day

Other Additional Studies or Pertinent Information that Lend Support to this MRL: The chronic-duration oral MRL based on the meta-analysis of the Faroe Islands, North Island New Zealand, and Seychelle Islands is 0.1 µg Hg/kg/day. The MRL is lower than the equivalent doses predicted in the individual contributing studies, which were 0.34 µg Hg/kg/day for the Faroe Islands cohort, 0.61 µg Hg/kg/day for the North Island New Zealand cohort, and 0.41 µg Hg/kg/day for the Seychelle Islands cohort. The equivalent doses from the Faroe Islands and North Island New Zealand cohorts are AELs, while the equivalent dose from the Seychelle Island cohort is a NAEL.

In addition to the epidemiological studies conducted in the Faroe Islands, North Island New Zealand, and Seychelle Islands, studies of other populations have found associations between exposures to methylmercury and neurodevelopmental outcomes (Section 2.16). These include studies of high fish consumers in the Amazon River basin (Chevrier et al. 2009; Cordier et al. 2002), Arctic Canada (Boucher et al. 2012a, 2012b, 2014, 2016; Despres et al. 2005; Ethier et al. 2012; Jacobson et al. 2015), fishing villages on the Mediterranean coast (Murata et al. 1999a, 2004b), and populations residing in the vicinity of artisanal gold mining operations (Counter 2003; Counter et al. 1998, 2002, 2006, 2012; Nyanza et al. 2021; Ramirez et al. 2000, 2003; Reuben et al. 2020).

The MRL is approximately 2 times higher than the dietary fish methylmercury intakes in the Norwegian Mother and Child Cohort Study that were associated with effects on language proficiency. However, a POD based on the dietary intakes estimated in this study would have lower confidence than the POD used in the derivation of the MRL for several reasons: (1) the associations with dietary methylmercury intake were based on a semi-quantitative food survey and national data on fish mercury concentrations, rather than biomarkers of mercury exposure in individual subjects; (2) the association with dietary methylmercury intake predicted lower language proficiency at age 3 years, whereas the association predicted higher proficiency at age 5 years (Vejrup et al. 2016, 2018); (3) in a subset of the cohort for which measurements of individual subject BHg levels were available, there was no association between language proficiency and BHg (Vejrup et al. 2018); and (4) language proficiency assessment was assessed from results of a parental self-report survey of their children rather than an assessment made by professional, non-biased observers. The outcomes of the Kobayashi et al. (2022) study also contribute to uncertainty in the interpretation of the language outcomes from the Norwegian Mother and Child Cohort Study. This large-scale prospective study conducted in Japan (n=48,731), found no evidence for an association between maternal BHg levels (median 3.64 µg/kg) and communication skills assessed from scores on of the Ages and Stages Questionnaire, a survey instrument that was used in the Norwegian Mother and Child Cohort Study (Kobayashi et al. 2022). The median maternal BHg level in the Kobayashi et al. (2022) study (3.64 µg/L) was higher than the median in the Norwegian Mother and Child Cohort Study (1.03 µg/L; Vejrup et al. 2018). The Kobayashi et al. (2022) study adjusted their regression models for maternal n-3 PUFA consumption and other potential confounders, as was done in the Norwegian Mother and Child Cohort Study.

APPENDIX A

Studies conducted in animals (nonhuman primates and rodents) provide strong support for the developing nervous system being most sensitive target of methylmercury (Section 2.16.1, Neurodevelopmental Effects for references and additional details). Studies conducted in monkeys have shown that gestational exposure to methylmercury resulted in sensorimotor dysfunction, and vision and hearing deficits. Gestational exposures in rodents produced sensorimotor dysfunction, vision and hearing deficits, impaired learning and memory, and neuropathological changes in the central and peripheral nervous systems.

Agency Contacts (Chemical Managers): Rae Benedict

APPENDIX B. LITERATURE SEARCH FRAMEWORK FOR MERCURY

The objective of the toxicological profile is to evaluate the potential for human exposure and the potential health hazards associated with inhalation, oral, or dermal/ocular exposure to mercury.

B.1 LITERATURE SEARCH AND SCREEN

A literature search and screen were conducted to identify studies examining health effects, toxicokinetics, mechanisms of action, susceptible populations, biomarkers, chemical interactions, physical and chemical properties, production, use, environmental fate, environmental releases, and environmental and biological monitoring data for mercury. ATSDR primarily focused on peer-reviewed articles without publication date or language restrictions. Foreign language studies are reviewed based on available English-language abstracts and/or tables (or summaries in regulatory assessments, such as International Agency for Research on Cancer [IARC] documents). If the study appears critical for hazard identification or MRL derivation, translation into English is requested. Non-peer-reviewed studies that were considered relevant to the assessment of the health effects of mercury have undergone peer review by at least three ATSDR-selected experts who have been screened for conflict of interest. The inclusion criteria used to identify relevant studies examining the health effects of mercury are presented in Table B-1.

Table B-1. Inclusion Criteria for the Literature Search and Screen

Health Effects
  Species
    Human
    Laboratory mammals
  Route of exposure
    Inhalation
    Oral
    Dermal (or ocular)
    Parenteral (these studies will be considered supporting data)
  Health outcome
    Death
    Systemic effects
    Body weight effects
    Respiratory effects
    Cardiovascular effects
    Gastrointestinal effects
    Hematological effects
    Musculoskeletal effects
    Hepatic effects
    Renal effects
    Dermal effects
    Ocular effects
    Endocrine effects
    Immunological effects
    Neurological effects
    Reproductive effects

Table B-1. Inclusion Criteria for the Literature Search and Screen

    Developmental effects
    Other noncancer effects
    Cancer
Toxicokinetics
  Absorption
  Distribution
  Metabolism
  Excretion
  PBPK models
Biomarkers
  Biomarkers of exposure
  Biomarkers of effect
Interactions with other chemicals
Potential for human exposure
  Releases to the environment
    Air
    Water
    Soil
  Environmental fate
    Transport and partitioning
    Transformation and degradation
  Environmental monitoring
    Air
    Water
    Sediment and soil
    Other media
  Biomonitoring
    General populations
    Occupation populations

B.1.1 Literature Search

The current literature search was intended to update the Draft Toxicological Profile for Mercury released for public comment in 2022; thus, the literature search was restricted to studies published between December 2018 and October 2023. The following main databases were searched in October 2023:

- PubMed
- National Technical Reports Library
- Scientific and Technical Information Network's TOXCENTER

The search strategy used the chemical names, Chemical Abstracts Service (CAS) numbers, synonyms, Medical Subject Headings (MeSH) headings, and keywords for mercury. The query strings used for the literature search are presented in Table B-2.

The search was augmented by searching the Toxic Substances Control Act Test Submissions (TSCATS), NTP website, and National Institute of Health Research Portfolio Online Reporting Tools Expenditures and Results (NIH RePORTER) databases using the queries presented in Table B-3. Additional databases were searched in the creation of various tables and figures, such as the TRI Explorer, the Substance Priority List (SPL) resource page, and other items as needed. Regulations applicable to mercury were identified by searching international and U.S. agency websites and documents.

Review articles were identified and used for the purpose of providing background information and identifying additional references. ATSDR also identified reports from the grey literature, which included unpublished research reports, technical reports from government agencies, conference proceedings and abstracts, and theses and dissertations.

Table B-2. Database Query Strings

Database search date	Query string
PubMed	
10/2023	((("mercury/toxicity"[mh] OR "mercury/adverse effects"[mh] OR "mercury/poisoning"[mh] OR "mercury/pharmacokinetics"[mh] OR ("mercury"[mh] AND ("environmental exposure"[mh] OR ci[sh] OR "endocrine system"[mh] OR "hormones, hormone substitutes, and hormone antagonists"[mh] OR "endocrine disruptors"[mh] OR ("computational biology"[mh] OR "medical informatics"[mh] OR genomics[mh] OR genome[mh] OR proteomics[mh] OR proteome[mh] OR metabolomics[mh] OR metabolome[mh] OR genes[mh] OR "gene expression"[mh] OR phenotype[mh] OR genetics[mh] OR genotype[mh] OR transcriptome[mh] OR ("systems biology"[mh] AND ("environmental exposure"[mh] OR "epidemiological monitoring"[mh] OR analysis[sh])) OR "transcription, genetic "[mh] OR "reverse transcription"[mh] OR "transcriptional activation"[mh] OR "transcription factors"[mh] OR ("biosynthesis"[sh] AND (RNA[mh] OR DNA[mh])) OR "RNA, messenger"[mh] OR "RNA, transfer"[mh] OR "peptide biosynthesis"[mh] OR "protein biosynthesis"[mh] OR "reverse transcriptase polymerase chain reaction"[mh] OR "base sequence"[mh] OR "trans-activators"[mh] OR "gene expression profiling"[mh])) OR ("mercury"[mh] AND toxicokinetics[mh:noexp]) OR ("mercury/blood"[mh] OR "mercury/cerebrospinal fluid"[mh] OR "mercury/urine"[mh] OR "mercury/antagonists and inhibitors"[mh]) OR ("mercury/metabolism"[mh] AND ("humans"[mh] OR "animals"[mh])) OR ("mercury"[majr] AND (("Neoplasms"[mh] OR "Carcinogens"[mh] OR "Lymphoproliferative disorders"[mh] OR "Myeloproliferative disorders"[mh] OR "Toxicity Tests"[mh] OR ((cancer*[tiab] OR carcinogen*[tiab]) AND (risk*[tiab] OR health[tiab]) AND assessment*[tiab]) OR "Mutagens"[mh] OR "Mutagenicity Tests"[mh] OR "Chromosome Aberrations"[mh] OR "DNA Damage"[mh] OR "DNA Repair"[mh] OR "DNA Replication/drug effects"[mh] OR "DNA/drug effects"[mh] OR "DNA/metabolism"[mh] OR "Genomic Instability"[mh] OR "Salmonella typhimurium/drug effects"[mh] OR "Salmonella typhimurium/genetics"[mh] OR "Sister Chromatid Exchange"[mh] OR strand-break*[tiab]))) OR "mercury/pharmacology"[majr]) OR ("phenylmercuric acetate/toxicity"[mh] OR "phenylmercuric acetate/adverse effects"[mh] OR "phenylmercuric acetate/poisoning"[mh] OR "phenylmercuric acetate/pharmacokinetics"[mh] OR ("phenylmercuric acetate"[mh] AND ("environmental exposure"[mh] OR ci[sh] OR "endocrine system"[mh] OR "hormones, hormone substitutes, and hormone antagonists"[mh] OR "endocrine disruptors"[mh] OR ("computational biology"[mh] OR "medical informatics"[mh] OR genomics[mh] OR genome[mh] OR proteomics[mh] OR proteome[mh] OR metabolomics[mh] OR metabolome[mh] OR genes[mh] OR "gene expression"[mh] OR phenotype[mh] OR genetics[mh] OR genotype[mh] OR transcriptome[mh] OR ("systems biology"[mh] AND ("environmental exposure"[mh] OR "epidemiological monitoring"[mh] OR analysis[sh])) OR "transcription, genetic "[mh] OR "reverse transcription"[mh] OR "transcriptional

Table B-2. Database Query Strings	
Database search date	**Query string**
	activation"[mh] OR "transcription factors"[mh] OR ("biosynthesis"[sh] AND (RNA[mh] OR DNA[mh])) OR "RNA, messenger"[mh] OR "RNA, transfer"[mh] OR "peptide biosynthesis"[mh] OR "protein biosynthesis"[mh] OR "reverse transcriptase polymerase chain reaction"[mh] OR "base sequence"[mh] OR "trans-activators"[mh] OR "gene expression profiling"[mh])) OR ("phenylmercuric acetate"[mh] AND toxicokinetics[mh:noexp]) OR ("phenylmercuric acetate/blood"[mh] OR "phenylmercuric acetate/cerebrospinal fluid"[mh] OR "phenylmercuric acetate/urine"[mh] OR "phenylmercuric acetate/antagonists and inhibitors"[mh]) OR ("phenylmercuric acetate/metabolism"[mh] AND ("humans"[mh] OR "animals"[mh])) OR ("phenylmercuric acetate"[majr] AND (("Neoplasms"[mh] OR "Carcinogens"[mh] OR "Lymphoproliferative disorders"[mh] OR "Myeloproliferative disorders"[mh] OR "Toxicity Tests"[mh] OR ((cancer*[tiab] OR carcinogen*[tiab]) AND (risk*[tiab] OR health[tiab]) AND assessment*[tiab]) OR "Mutagens"[mh] OR "Mutagenicity Tests"[mh] OR "Chromosome Aberrations"[mh] OR "DNA Damage"[mh] OR "DNA Repair"[mh] OR "DNA Replication/drug effects"[mh] OR "DNA/drug effects"[mh] OR "DNA/metabolism"[mh] OR "Genomic Instability"[mh] OR "Salmonella typhimurium/drug effects"[mh] OR "Salmonella typhimurium/genetics"[mh] OR "Sister Chromatid Exchange"[mh] OR strand-break*[tiab]))) OR "phenylmercuric acetate/pharmacology"[majr]) OR ("mercuric chloride/toxicity"[mh] OR "mercuric chloride/adverse effects"[mh] OR "mercuric chloride/poisoning"[mh] OR "mercuric chloride/pharmacokinetics"[mh] OR ("mercuric chloride"[mh] AND ("environmental exposure"[mh] OR ci[sh] OR "endocrine system"[mh] OR "hormones, hormone substitutes, and hormone antagonists"[mh] OR "endocrine disruptors"[mh] OR ("computational biology"[mh] OR "medical informatics"[mh] OR genomics[mh] OR genome[mh] OR proteomics[mh] OR proteome[mh] OR metabolomics[mh] OR metabolome[mh] OR genes[mh] OR "gene expression"[mh] OR phenotype[mh] OR genetics[mh] OR genotype[mh] OR transcriptome[mh] OR ("systems biology"[mh] AND ("environmental exposure"[mh] OR "epidemiological monitoring"[mh] OR analysis[sh])) OR "transcription, genetic "[mh] OR "reverse transcription"[mh] OR "transcriptional activation"[mh] OR "transcription factors"[mh] OR ("biosynthesis"[sh] AND (RNA[mh] OR DNA[mh])) OR "RNA, messenger"[mh] OR "RNA, transfer"[mh] OR "peptide biosynthesis"[mh] OR "protein biosynthesis"[mh] OR "reverse transcriptase polymerase chain reaction"[mh] OR "base sequence"[mh] OR "trans-activators"[mh] OR "gene expression profiling"[mh])) OR ("mercuric chloride"[mh] AND toxicokinetics[mh:noexp]) OR ("mercuric chloride/blood"[mh] OR "mercuric chloride/cerebrospinal fluid"[mh] OR "mercuric chloride/urine"[mh] OR "mercuric chloride/antagonists and inhibitors"[mh]) OR ("mercuric chloride/metabolism"[mh] AND ("humans"[mh] OR "animals"[mh])) OR ("mercuric chloride"[majr] AND (("Neoplasms"[mh] OR "Carcinogens"[mh] OR "Lymphoproliferative disorders"[mh] OR "Myeloproliferative disorders"[mh] OR "Toxicity Tests"[mh] OR ((cancer*[tiab] OR carcinogen*[tiab]) AND (risk*[tiab] OR health[tiab]) AND assessment*[tiab]) OR "Mutagens"[mh] OR "Mutagenicity Tests"[mh] OR "Chromosome Aberrations"[mh] OR "DNA Damage"[mh] OR "DNA Repair"[mh] OR "DNA Replication/drug effects"[mh] OR "DNA/drug effects"[mh] OR "DNA/metabolism"[mh] OR "Genomic Instability"[mh] OR "Salmonella typhimurium/drug effects"[mh] OR "Salmonella typhimurium/genetics"[mh] OR "Sister Chromatid Exchange"[mh] OR strand-break*[tiab]))) OR "mercuric chloride/pharmacology"[majr]) OR "Mercury poisoning"[mh] OR 13966-62-6[rn] OR 72172-67-9[rn] OR (("mercury"[mh] OR "phenylmercuric acetate"[mh] OR "mercuric chloride"[mh]) AND ((indexingmethod_automated OR indexingmethod_curated) AND ("RNA"[mh] OR "DNA"[mh] OR "DNA Replication"[mh] OR "Salmonella typhimurium"[mh] OR antagonist*[tw] OR inhibitor*[tw] OR "blood"[tw] OR "serum"[tw] OR "plasma"[tw] OR pharmacokinetic*[tw] OR toxicokinetic*[tw] OR "pbpk"[tw] OR

APPENDIX B

Table B-2. Database Query Strings

Database search date	Query string
	"poisoned"[tw] OR "poisoning"[tw] OR "urine"[tw] OR "urinary"[tw] OR "toxicity"[sh] OR "occupational diseases"[mh] OR "hazardous substances"[mh] OR "epidemiology"[sh] OR "epidemiologic studies"[mh])))) AND (2022/09/26:3000[mhda])) OR (("cinnabar"[tw] OR "mercuric sulfide"[tw] OR "mercuric sulphide"[tw] OR "mercury (ii) sulfide"[tw] OR "mercury monosulfide"[tw] OR "mercury sulfide"[tw] OR "mercury sulphide"[tw] OR "mercury(2+) sulfide"[tw] OR "mercury(ii) sulfide"[tw] OR "monomercury sulfide"[tw]) AND (2022/09/26:3000[edat] OR 2022/09/26:3000[crdat]))
	(("mercury compounds/toxicity"[mh] OR "mercury compounds/adverse effects"[mh] OR "mercury compounds/poisoning"[mh] OR "mercury compounds/pharmacokinetics"[mh] OR ("mercury compounds"[mh] AND ("environmental exposure"[mh] OR ci[sh] OR "endocrine system"[mh] OR "hormones, hormone substitutes, and hormone antagonists"[mh] OR "endocrine disruptors"[mh] OR ("computational biology"[mh] OR "medical informatics"[mh] OR genomics[mh] OR genome[mh] OR proteomics[mh] OR proteome[mh] OR metabolomics[mh] OR metabolome[mh] OR genes[mh] OR "gene expression"[mh] OR phenotype[mh] OR genetics[mh] OR genotype[mh] OR transcriptome[mh] OR ("systems biology"[mh] AND ("environmental exposure"[mh] OR "epidemiological monitoring"[mh] OR analysis[sh])) OR "transcription, genetic "[mh] OR "reverse transcription"[mh] OR "transcriptional activation"[mh] OR "transcription factors"[mh] OR ("biosynthesis"[sh] AND (RNA[mh] OR DNA[mh])) OR "RNA, messenger"[mh] OR "RNA, transfer"[mh] OR "peptide biosynthesis"[mh] OR "protein biosynthesis"[mh] OR "reverse transcriptase polymerase chain reaction"[mh] OR "base sequence"[mh] OR "trans-activators"[mh] OR "gene expression profiling"[mh])) OR ("mercury compounds"[mh] AND toxicokinetics[mh:noexp]) OR ("mercury compounds/blood"[mh] OR "mercury compounds/cerebrospinal fluid"[mh] OR "mercury compounds/urine"[mh] OR "mercury compounds/antagonists and inhibitors"[mh]) OR ("mercury compounds/metabolism"[mh] AND ("humans"[mh] OR "animals"[mh])) OR ("mercury compounds"[majr] AND (("Neoplasms"[mh] OR "Carcinogens"[mh] OR "Lymphoproliferative disorders"[mh] OR "Myeloproliferative disorders"[mh] OR "Toxicity Tests"[mh] OR ((cancer*[tiab] OR carcinogen*[tiab]) AND (risk*[tiab] OR health[tiab]) AND assessment*[tiab]) OR "Mutagens"[mh] OR "Mutagenicity Tests"[mh] OR "Chromosome Aberrations"[mh] OR "DNA Damage"[mh] OR "DNA Repair"[mh] OR "DNA Replication/drug effects"[mh] OR "DNA/drug effects"[mh] OR "DNA/metabolism"[mh] OR "Genomic Instability"[mh] OR "Salmonella typhimurium/drug effects"[mh] OR "Salmonella typhimurium/genetics"[mh] OR "Sister Chromatid Exchange"[mh] OR strand-break*[tiab]))) OR "mercury compounds/pharmacology"[majr])) OR ("methylmercury compounds/toxicity"[mh] OR "methylmercury compounds/adverse effects"[mh] OR "methylmercury compounds/poisoning"[mh] OR "methylmercury compounds/pharmacokinetics"[mh] OR ("methylmercury compounds"[mh] AND ("environmental exposure"[mh] OR ci[sh] OR "endocrine system"[mh] OR "hormones, hormone substitutes, and hormone antagonists"[mh] OR "endocrine disruptors"[mh] OR ("computational biology"[mh] OR "medical informatics"[mh] OR genomics[mh] OR genome[mh] OR proteomics[mh] OR proteome[mh] OR metabolomics[mh] OR metabolome[mh] OR genes[mh] OR "gene expression"[mh] OR phenotype[mh] OR genetics[mh] OR genotype[mh] OR transcriptome[mh] OR ("systems biology"[mh] AND ("environmental exposure"[mh] OR "epidemiological monitoring"[mh] OR analysis[sh])) OR "transcription, genetic "[mh] OR "reverse transcription"[mh] OR "transcriptional activation"[mh] OR "transcription factors"[mh] OR ("biosynthesis"[sh] AND (RNA[mh] OR DNA[mh])) OR "RNA, messenger"[mh] OR "RNA, transfer"[mh] OR "peptide biosynthesis"[mh] OR "protein biosynthesis"[mh] OR "reverse transcriptase polymerase chain reaction"[mh] OR "base sequence"[mh] OR "trans-activators"[mh] OR "gene

APPENDIX B

Table B-2. Database Query Strings

Database search date	Query string
	expression profiling"[mh])) OR ("methylmercury compounds"[mh] AND toxicokinetics[mh:noexp]) OR ("methylmercury compounds/blood"[mh] OR "methylmercury compounds/cerebrospinal fluid"[mh] OR "methylmercury compounds/urine"[mh] OR "methylmercury compounds/antagonists and inhibitors"[mh]) OR ("methylmercury compounds/metabolism"[mh] AND ("humans"[mh] OR "animals"[mh])) OR ("methylmercury compounds"[majr] AND (("Neoplasms"[mh] OR "Carcinogens"[mh] OR "Lymphoproliferative disorders"[mh] OR "Myeloproliferative disorders"[mh] OR "Toxicity Tests"[mh] OR ((cancer*[tiab] OR carcinogen*[tiab]) AND (risk*[tiab] OR health[tiab]) AND assessment*[tiab]) OR "Mutagens"[mh] OR "Mutagenicity Tests"[mh] OR "Chromosome Aberrations"[mh] OR "DNA Damage"[mh] OR "DNA Repair"[mh] OR "DNA Replication/drug effects"[mh] OR "DNA/drug effects"[mh] OR "DNA/metabolism"[mh] OR "Genomic Instability"[mh] OR "Salmonella typhimurium/drug effects"[mh] OR "Salmonella typhimurium/genetics"[mh] OR "Sister Chromatid Exchange"[mh] OR strand-break*[tiab])) OR "methylmercury compounds/pharmacology"[majr]) OR ("mercury isotopes/toxicity"[mh] OR "mercury isotopes/adverse effects"[mh] OR "mercury isotopes/poisoning"[mh] OR "mercury isotopes/pharmacokinetics"[mh] OR ("mercury isotopes"[mh] AND ("environmental exposure"[mh] OR ci[sh] OR "endocrine system"[mh] OR "hormones, hormone substitutes, and hormone antagonists"[mh] OR "endocrine disruptors"[mh] OR ("computational biology"[mh] OR "medical informatics"[mh] OR genomics[mh] OR genome[mh] OR proteomics[mh] OR proteome[mh] OR metabolomics[mh] OR metabolome[mh] OR genes[mh] OR "gene expression"[mh] OR phenotype[mh] OR genetics[mh] OR genotype[mh] OR transcriptome[mh] OR ("systems biology"[mh] AND ("environmental exposure"[mh] OR "epidemiological monitoring"[mh] OR analysis[sh])) OR "transcription, genetic "[mh] OR "reverse transcription"[mh] OR "transcriptional activation"[mh] OR "transcription factors"[mh] OR ("biosynthesis"[sh] AND (RNA[mh] OR DNA[mh])) OR "RNA, messenger"[mh] OR "RNA, transfer"[mh] OR "peptide biosynthesis"[mh] OR "protein biosynthesis"[mh] OR "reverse transcriptase polymerase chain reaction"[mh] OR "base sequence"[mh] OR "trans-activators"[mh] OR "gene expression profiling"[mh])) OR ("mercury isotopes"[mh] AND toxicokinetics[mh:noexp]) OR ("mercury isotopes/blood"[mh] OR "mercury isotopes/cerebrospinal fluid"[mh] OR "mercury isotopes/urine"[mh] OR "mercury isotopes/antagonists and inhibitors"[mh]) OR ("mercury isotopes/metabolism"[mh] AND ("humans"[mh] OR "animals"[mh])) OR ("mercury isotopes"[majr] AND (("Neoplasms"[mh] OR "Carcinogens"[mh] OR "Lymphoproliferative disorders"[mh] OR "Myeloproliferative disorders"[mh] OR "Toxicity Tests"[mh] OR ((cancer*[tiab] OR carcinogen*[tiab]) AND (risk*[tiab] OR health[tiab]) AND assessment*[tiab]) OR "Mutagens"[mh] OR "Mutagenicity Tests"[mh] OR "Chromosome Aberrations"[mh] OR "DNA Damage"[mh] OR "DNA Repair"[mh] OR "DNA Replication/drug effects"[mh] OR "DNA/drug effects"[mh] OR "DNA/metabolism"[mh] OR "Genomic Instability"[mh] OR "Salmonella typhimurium/drug effects"[mh] OR "Salmonella typhimurium/genetics"[mh] OR "Sister Chromatid Exchange"[mh] OR strand-break*[tiab])) OR "mercury isotopes/pharmacology"[majr]) OR ("organomercury compounds/toxicity"[mh] OR "organomercury compounds/adverse effects"[mh] OR "organomercury compounds/poisoning"[mh] OR "organomercury compounds/pharmacokinetics"[mh] OR ("organomercury compounds"[mh] AND ("environmental exposure"[mh] OR ci[sh] OR "endocrine system"[mh] OR "hormones, hormone substitutes, and hormone antagonists"[mh] OR "endocrine disruptors"[mh] OR ("computational biology"[mh] OR "medical informatics"[mh] OR genomics[mh] OR genome[mh] OR proteomics[mh] OR proteome[mh] OR metabolomics[mh] OR metabolome[mh] OR genes[mh] OR "gene expression"[mh] OR phenotype[mh] OR genetics[mh] OR genotype[mh] OR transcriptome[mh] OR ("systems biology"[mh] AND

APPENDIX B

Table B-2. Database Query Strings

Database search date	Query string
	("environmental exposure"[mh] OR "epidemiological monitoring"[mh] OR analysis[sh])) OR "transcription, genetic "[mh] OR "reverse transcription"[mh] OR "transcriptional activation"[mh] OR "transcription factors"[mh] OR ("biosynthesis"[sh] AND (RNA[mh] OR DNA[mh])) OR "RNA, messenger"[mh] OR "RNA, transfer"[mh] OR "peptide biosynthesis"[mh] OR "protein biosynthesis"[mh] OR "reverse transcriptase polymerase chain reaction"[mh] OR "base sequence"[mh] OR "trans-activators"[mh] OR "gene expression profiling"[mh]]) OR ("organomercury compounds"[mh] AND toxicokinetics[mh:noexp]) OR ("organomercury compounds/blood"[mh] OR "organomercury compounds/cerebrospinal fluid"[mh] OR "organomercury compounds/urine"[mh] OR "organomercury compounds/antagonists and inhibitors"[mh]) OR ("organomercury compounds/metabolism"[mh] AND ("humans"[mh] OR "animals"[mh])) OR ("organomercury compounds"[majr] AND (("Neoplasms"[mh] OR "Carcinogens"[mh] OR "Lymphoproliferative disorders"[mh] OR "Myeloproliferative disorders"[mh] OR "Toxicity Tests"[mh] OR ((cancer*[tiab] OR carcinogen*[tiab]) AND (risk*[tiab] OR health[tiab]) AND assessment*[tiab]) OR "Mutagens"[mh] OR "Mutagenicity Tests"[mh] OR "Chromosome Aberrations"[mh] OR "DNA Damage"[mh] OR "DNA Repair"[mh] OR "DNA Replication/drug effects"[mh] OR "DNA/drug effects"[mh] OR "DNA/metabolism"[mh] OR "Genomic Instability"[mh] OR "Salmonella typhimurium/drug effects"[mh] OR "Salmonella typhimurium/genetics"[mh] OR "Sister Chromatid Exchange"[mh] OR strand-break*[tiab])) OR "organomercury compounds/pharmacology"[majr])) OR (("mercury compounds"[mh] OR "methylmercury compounds"[mh] OR "mercury isotopes"[mh] OR "organomercury compounds"[mh]) AND ((indexingmethod_automated OR indexingmethod_curated) AND ("RNA"[mh] OR "DNA"[mh] OR "DNA Replication"[mh] OR "Salmonella typhimurium"[mh] OR antagonist*[tw] OR inhibitor*[tw] OR "blood"[tw] OR "serum"[tw] OR "plasma"[tw] OR pharmacokinetic*[tw] OR toxicokinetic*[tw] OR "pbpk"[tw] OR "poisoned"[tw] OR "poisoning"[tw] OR "urine"[tw] OR "urinary"[tw] OR "toxicity"[sh] OR "occupational diseases"[mh] OR "hazardous substances"[mh] OR "epidemiology"[sh] OR "epidemiologic studies"[mh])))) AND (2022/09/26:3000[mhda]) ((((("(acetato)phenylmercury"[tw] OR "(acetato-kappao)phenylmercury"[tw] OR "(acetato-o)phenylmercury"[tw] OR "(acetoxymercuri)benzene"[tw] OR "(acetoxymercurio)benzene"[tw] OR "acetic acid, mercuridi-"[tw] OR "acetic acid, mercury(2+) salt"[tw] OR "acetic acid, phenylmercury deriv."[tw] OR "acetic acid, phenylmercury(ii) salt"[tw] OR "acetoxyphenylmercury"[tw] OR "benzene, (acetoxymercuri)-"[tw] OR "benzene, (acetoxymercurio)-"[tw] OR "bis(acetyloxy)mercury"[tw] OR "calochlor"[tw] OR "calomel"[tw] OR "chloromethylmercury"[tw] OR "cinnabar"[tw] OR "cinnabarite"[tw] OR "diacetoxymercury"[tw] OR "dichloromercury"[tw] OR "dimercury dichloride"[tw] OR "dimethylmercury"[tw] OR "fungche"[tw] OR "hydrargyrum"[tw] OR "mercuriacetate"[tw] OR "mercuric acetate"[tw] OR "mercuric bichloride"[tw] OR "mercuric chloride"[tw] OR "mercuric diacetate"[tw] OR "mercuric nitrate"[tw] OR "mercuric sulfide"[tw] OR "mercuric sulphide"[tw] OR "mercuridiacetic acid, "[tw] OR "mercuriphenyl acetate"[tw] OR "mercurius 6a"[tw] OR "mercurous chloride"[tw] OR "mercury"[tw] OR "mercury(1+), methyl-"[tw] OR "mercury(2+) acetate"[tw] OR "mercury(2+) chloride"[tw] OR "mercury(2+) nitrate"[tw] OR "mercury(2+) sulfide"[tw] OR "mercury(i) chloride"[tw] OR "mercury(ii) acetate"[tw] OR "mercury(ii) acetate, phenyl-"[tw] OR "mercury(ii) chloride"[tw] OR "mercury(ii) nitrate"[tw] OR "mercury(ii) sulfide"[tw] OR "mercury, (acetato)phenyl-"[tw] OR "mercury, (acetato-kappao)phenyl-"[tw] OR "mercury, (acetato-o)phenyl-"[tw] OR "mercury, acetoxyphenyl-"[tw] OR "mercury, chloromethyl-"[tw] OR "mercury, dimethyl-"[tw] OR

APPENDIX B

Table B-2. Database Query Strings

Database search date	Query string
	"mercuryl acetate"[tw] OR "mercurymethylchloride"[tw] OR "methyl mercuric chloride"[tw] OR "methyl mercuric(ii) chloride"[tw] OR "methyl meruric chloride"[tw] OR "methylmercuric chloride"[tw] OR "methylmercury"[tw] OR "methylmercury chloride"[tw] OR "methylmercury monochloride"[tw] OR "methylmercury(1+)"[tw] OR "methylmercury(ii) cation"[tw] OR "millon's reagent"[tw] OR "monomercury sulfide"[tw] OR "monomethylmercury cation"[tw] OR "nitric acid, mercury(2+) salt"[tw] OR "nitric acid, mercury(ii) salt"[tw] OR "phenomercuric acetate"[tw] OR "phenyl mercuric acetate"[tw] OR "phenylmercuriacetate"[tw] OR "phenylmercuric acetate"[tw] OR "phenylmercury acetate"[tw] OR "phenylmercury(ii) acetate"[tw] OR "Anticon"[tw] OR "Celmer"[tw] OR "Femma"[tw] OR "Hexasan"[tw] OR "Hostaquick"[tw] OR "Kwiksan"[tw] OR "Lorophyn"[tw] OR "Parasan"[tw] OR "Phix"[tw] OR "Samtol"[tw] OR "Sanitol"[tw] OR "Sc-110"[tw] OR "Verdasan"[tw] OR "Volpar"[tw] OR "Caspan"[tw] OR "Liquid silver"[tw] OR "Quick silver"[tw] OR "Quicksilver"[tw] OR "Sulem"[tw] OR "Agrosan D"[tw] OR "Agrosan GN 5"[tw] OR "Algimycin 200"[tw] OR "Antimucin WBR"[tw] OR "Antimucin WDR"[tw] OR "Bufen"[tw] OR "Bufen 30"[tw] OR "Cekusil"[tw] OR "Ceresol"[tw] OR "Contra Creme"[tw] OR "Dyanacide"[tw] OR "Fungicide R"[tw] OR "Fungitox OR"[tw] OR "Gallotox"[tw] OR "HI-331"[tw] OR "Hong nien"[tw] OR "Hostaquik"[tw] OR "Intercide 60"[tw] OR "Intercide PMA 18"[tw] OR "Liquiphene"[tw] OR "Meracen"[tw] OR "Mercron"[tw] OR "Mercuron"[tw] OR "Mergal A 25"[tw] OR "Mersolite"[tw] OR "Metasol 30"[tw] OR "Neantina"[tw] OR "Norforms"[tw] OR "Nuodex PMA 18"[tw] OR "Nylmerate"[tw] OR "PMA (fungicide)"[tw] OR "Pamisan"[tw] OR "Panomatic"[tw] OR "Parasan (bactericide)"[tw] OR "Phenmad"[tw] OR "Programin"[tw] OR "Purasan-SC-10"[tw] OR "Puraturf 10"[tw] OR "Quicksan"[tw] OR "Quicksan 20"[tw] OR "Riogen"[tw] OR "Ruberon"[tw] OR "Sanitized SPG"[tw] OR "Sanmicron"[tw] OR "Scutl"[tw] OR "Seed Dressing R"[tw] OR "Seedtox"[tw] OR "Setrete"[tw] OR "Shimmerex"[tw] OR "Spor-Kil"[tw] OR "Spruce Seal"[tw] OR "Tag (VAN)"[tw] OR "Tag 331"[tw] OR "Tag HL 331"[tw] OR "Tag fungicide"[tw] OR "Trigosan"[tw] OR "Troysan 30"[tw] OR "Troysan PMA 30"[tw] OR "Zaprawa Nasienna R"[tw] OR "Ziarnik"[tw] OR "Hydraargyrum bichloratum"[tw] OR "Calo-Clor"[tw] OR "Calocure"[tw] OR "Calogreen"[tw] OR "Calotab"[tw] OR "Abavit B"[tw] OR "Citrine ointment"[tw] OR "Ethiops mineral"[tw] OR "Mercurius vivus"[tw] OR "beta-Mercuric sulfide"[tw] OR "Phenylquecksilberacetate"[tw] OR "Quecksilber(II)-sulfid, rotes"[tw] OR "Rotes Quecksilbersulfid"[tw] OR "Paragite"[tw] OR "TL 898"[tw]) NOT medline[sb])) AND (2022/09/26:3000[edat] OR 2022/09/26:3000[crdat])) AND (toxicity[ti] OR death OR lethal OR fatal OR fatality OR necrosis OR LC50* OR LD50* OR "body weight" OR "weight loss" OR "weight gain" OR weight-change* OR overweight OR obesity OR inhal* OR respiratory OR pulmonary OR airway OR trachea OR tracheobronchial OR lung OR lungs OR nose OR nasal OR nasopharyngeal OR larynx OR laryngeal OR pharynx OR bronchial OR bronchi OR bronchioles OR bronchitis OR hemothorax OR alveolar OR alveoli OR irritation OR irritant OR sensitization OR sensitizer OR cilia OR mucocilliary OR cvd OR cardio OR vascular OR cardiovascular OR circulatory OR cardiac OR heart OR myocardial OR "chest pain" OR artery OR arteries OR veins OR venules OR cardiotox* OR intestinal OR gastrointestinal OR gastric OR digestive OR intestinal OR "gi tract" OR "gi disorder" OR abdominal OR esophagus OR stomach OR intestine OR pancreas OR pancreatic OR diarrhea OR nausea OR vomit OR ulcer OR constipation OR emesis OR "gut microbes" OR "gut flora" OR "gut microflora" OR anorexia OR hematological OR hematology OR hemato OR haemato OR blood OR anemia OR cyanosis OR erythrocytopenia OR leukopenia OR thrombocytopenia OR hemoglobin OR erythrocyte OR hematocrit OR "bone marrow" OR reticulocyte OR methemoglobin OR red-blood-cell OR musculoskeletal OR skeletal OR muscle OR muscular OR arthritis OR "altered bone" OR "joint pain" OR "joint-ache" OR "limb pain" OR "limb ache" OR hepatic OR liver OR hepatocytes OR

Table B-2. Database Query Strings

Database search date	Query string
	gallbladder OR cirrhosis OR jaundice OR hepatocellular OR hepatomegaly OR hepatotox* OR renal OR kidney OR urinary OR bladder OR urine OR "blood urea nitrogen" OR bun OR nephropathy OR nephrotox* OR dermal OR skin OR acanthosis OR dermatitis OR psoriasis OR edema OR ulceration OR acne OR ocular OR "eye function" OR "eye effect" OR "eye irritation" OR "eye drainage" OR "eye tearing" OR blindness OR myopia OR cataracts OR endocrine OR hormone OR "sella turcica" OR thyroid OR adrenal OR pituitary OR immunological OR immunologic OR immune OR lymphoreticular OR lymph-node OR spleen OR thymus OR macrophage OR leukocyte* OR white-blood-cell OR immunotox* OR neurological OR neurologic OR neurotoxic OR neurotoxicity OR neurodegenerat* OR "nervous system" OR brain OR neurotoxicant OR neurochemistry OR neurophysiology OR neuropathology OR "motor activity" OR motor change* OR behavior-change* OR behavioral-change* OR sensory-change* OR cognitive OR vertigo OR drowsiness OR headache OR ataxia OR reproductive OR "reproduction system" OR "reproduction function" OR "reproduction effect" OR "reproduction toxicity" OR fertility OR "maternal toxicity" OR developmental OR "in utero" OR terata* OR terato* OR embryo* OR fetus* OR foetus* OR fetal* OR foetal* OR prenatal* OR "pre-natal" OR perinatal* OR "post-natal" OR postnatal* OR neonat* OR newborn* OR zygote* OR child OR children OR infant* OR offspring OR elderly OR "altered food consumption" OR "altered water consumption" OR "metabolic effect" OR "metabolic toxicity" OR fever OR cancer OR cancerous OR neoplas* OR tumor OR tumors OR tumour* OR malignan* OR carcinoma OR carcinogen OR carcinogen* OR angiosarcoma OR blastoma OR fibrosarcoma OR glioma OR leukemia OR leukaemia OR lymphoma OR melanoma OR meningioma OR mesothelioma OR myeloma OR neuroblastoma OR osteosarcoma OR sarcoma OR mutation OR mutations OR genotoxicity OR genotoxic OR mutagenicity OR mutagenic OR "mechanism of action"[tiab:~0] OR "mechanism of absorption"[tiab:~0] OR "mechanism of distribution"[tiab:~0] OR "mechanism of excretion"[tiab:~0] OR "mechanism of metabolism"[tiab:~0] OR "mechanism of toxic effect"[tiab:~0] OR "mechanism of toxicity" OR "adverse effect" OR "adverse effects" OR "health effects" OR noncancer OR poisoning OR morbidity OR inflammation OR antagonist OR inhibitor OR metabolism OR "environmental exposure" OR toxicokinetics OR pharmacokinetics OR "gene expression" OR "population health" OR epidemiology OR epidemiological OR case-control* OR case-referent OR case-report OR case-series OR cohort* OR correlation-stud* OR cross-sectional-stud* OR ecological-studies OR ecological-study OR follow-up-stud* OR longitudinal-stud* OR metaanalyses OR metaanalysis OR meta-analysis OR prospective-stud* OR record-link* OR retrospective-stud* OR seroepidemiologic-stud* OR occupation* OR worker* OR workmen* OR workplace* OR "human health" OR "oral intake" OR "oral feed" OR "oral ingestion" OR "oral exposure" OR "oral administration" OR ingest* OR gavage* OR "drinking-water" OR NHANES OR "National Health and Nutrition Examination Survey" OR (human AND (risk OR toxic* OR safety)) OR mammal* OR ape OR apes OR baboon* OR balb OR beagle* OR boar OR boars OR bonobo* OR bovine OR C57 OR C57bl OR callithrix OR canine OR canis OR capra OR capuchin* OR cats OR cattle OR cavia OR chicken OR chickens OR chimpanzee* OR chinchilla* OR cow OR cows OR cricetinae OR dog OR dogs OR equus OR feline OR felis OR ferret OR ferrets OR flying-fox OR Fruit-bat OR gerbil* OR gibbon* OR goat OR goats OR guinea-pig* OR guppy OR hamster OR hamsters OR horse OR horses OR jird OR jirds OR lagomorph* OR leontopithecus OR longevans OR macaque* OR marmoset* OR medaka OR merione OR meriones OR mice OR monkey OR monkeys OR mouse OR muridae OR murinae OR murine OR mustela-putorius OR nomascus OR non-human-primate* OR orangutan* OR pan-paniscus OR pan-troglodytes OR pig OR piglet* OR pigs OR polecat* OR pongopygmaeus OR quail OR rabbit OR rabbits OR rat OR rats OR rhesus OR rodent OR

Table B-2. Database Query Strings

Database search date	Query string
	rodentia OR rodents OR saguinus OR sheep OR sheeps OR siamang* OR sow OR sows OR Sprague-Dawley OR swine OR swines OR symphalangus OR tamarin* OR vervet* OR wistar OR wood-mouse OR zebra-fish OR zebrafish) ("Cyclosan"[tw] OR "Mercurous iodide"[tw] OR "Mercury telluride"[tw] OR "Mercury hydride"[tw] OR "Mercurane"[tw] OR "Mercury bromide"[tw] OR "Mercury iodide"[tw] OR "Mercury oxide"[tw] OR "Mercuric selenide"[tw] OR "Mercury cyanide"[tw] OR ("Mercury chloride"[tw] NOT "mercuric chloride"[mh])) OR (("Cyclosan"[tw] OR "Mercury chloride"[tw] OR "Mercury bromide"[tw] OR "Mercuric bromide"[tw] OR "Mercuric dibromide"[tw] OR "Mercury dibromide"[tw] OR "Mercury(II) bromide"[tw] OR "Mercury fulminate"[tw] OR "Mercurous iodide"[tw] OR "Mercuric iodide"[tw] OR "Mercury iodide"[tw] OR "Mercury(II) iodide"[tw] OR "Mercuric oxide"[tw] OR "Mercury oxide"[tw] OR "Red Precipitate"[tw] OR "Yellow precipitate"[tw] OR "Mercuric selenide"[tw] OR "Mercury selenide"[tw] OR "Mercury-selenium complex"[tw] OR "Mercurous sulfate"[tw] OR "Mercury(I) sulfate"[tw] OR "Mercuric sulfate"[tw] OR "Mercuric sulphate"[tw] OR "Mercury sulfate"[tw] OR "Mercury sulphate"[tw] OR "Mercury telluride"[tw] OR "Mercuric cyanide"[tw] OR "Mercurius cyanatus"[tw] OR "Mercury cyanide"[tw] OR "Mercury hydride"[tw] OR "Mercurane"[tw] OR "Mercuric cation"[tw] OR "Mercuric cations"[tw] OR "Mercuric ion"[tw] OR "Mercuric ions"[tw]) NOT medline[sb]) AND (2022/09/26:3000[edat] OR 2022/09/26:3000[crdat])
9/2022	(("mercury/toxicity"[mh] OR "mercury/adverse effects"[mh] OR "mercury/poisoning"[mh] OR "mercury/pharmacokinetics"[mh] OR ("mercury"[mh] AND ("environmental exposure"[mh] OR ci[sh] OR "endocrine system"[mh] OR "hormones, hormone substitutes, and hormone antagonists"[mh] OR "endocrine disruptors"[mh] OR ("computational biology"[mh] OR "medical informatics"[mh] OR genomics[mh] OR genome[mh] OR proteomics[mh] OR proteome[mh] OR metabolomics[mh] OR metabolome[mh] OR genes[mh] OR "gene expression"[mh] OR phenotype[mh] OR genetics[mh] OR genotype[mh] OR transcriptome[mh] OR ("systems biology"[mh] AND ("environmental exposure"[mh] OR "epidemiological monitoring"[mh] OR analysis[sh])) OR "transcription, genetic "[mh] OR "reverse transcription"[mh] OR "transcriptional activation"[mh] OR "transcription factors"[mh] OR ("biosynthesis"[sh] AND (RNA[mh] OR DNA[mh])) OR "RNA, messenger"[mh] OR "RNA, transfer"[mh] OR "peptide biosynthesis"[mh] OR "protein biosynthesis"[mh] OR "reverse transcriptase polymerase chain reaction"[mh] OR "base sequence"[mh] OR "trans-activators"[mh] OR "gene expression profiling"[mh])) OR ("mercury"[mh] AND toxicokinetics[mh:noexp]) OR ("mercury/blood"[mh] OR "mercury/cerebrospinal fluid"[mh] OR "mercury/urine"[mh] OR "mercury/antagonists and inhibitors"[mh]) OR ("mercury/metabolism"[mh] AND ("humans"[mh] OR "animals"[mh])) OR ("mercury"[majr] AND (("Neoplasms"[mh] OR "Carcinogens"[mh] OR "Lymphoproliferative disorders"[mh] OR "Myeloproliferative disorders"[mh] OR "Toxicity Tests"[mh] OR ((cancer*[tiab] OR carcinogen*[tiab]) AND (risk*[tiab] OR health[tiab]) AND assessment*[tiab]) OR "Mutagens"[mh] OR "Mutagenicity Tests"[mh] OR "Chromosome Aberrations"[mh] OR "DNA Damage"[mh] OR "DNA Repair"[mh] OR "DNA Replication/drug effects"[mh] OR "DNA/drug effects"[mh] OR "DNA/metabolism"[mh] OR "Genomic Instability"[mh] OR "Salmonella typhimurium/drug effects"[mh] OR "Salmonella typhimurium/genetics"[mh] OR "Sister Chromatid Exchange"[mh] OR strand-break*[tiab]))) OR "mercury/pharmacology"[majr])) OR ("phenylmercuric acetate/toxicity"[mh] OR "phenylmercuric acetate/adverse effects"[mh] OR "phenylmercuric acetate/poisoning"[mh] OR "phenylmercuric acetate/pharmacokinetics"[mh] OR ("phenylmercuric acetate"[mh] AND ("environmental exposure"[mh] OR ci[sh] OR "endocrine system"[mh] OR "hormones, hormone substitutes, and hormone antagonists"[mh] OR "endocrine disruptors"[mh] OR

APPENDIX B

Table B-2. Database Query Strings

Database search date	Query string
	("computational biology"[mh] OR "medical informatics"[mh] OR genomics[mh] OR genome[mh] OR proteomics[mh] OR proteome[mh] OR metabolomics[mh] OR metabolome[mh] OR genes[mh] OR "gene expression"[mh] OR phenotype[mh] OR genetics[mh] OR genotype[mh] OR transcriptome[mh] OR ("systems biology"[mh] AND ("environmental exposure"[mh] OR "epidemiological monitoring"[mh] OR analysis[sh])) OR "transcription, genetic "[mh] OR "reverse transcription"[mh] OR "transcriptional activation"[mh] OR "transcription factors"[mh] OR ("biosynthesis"[sh] AND (RNA[mh] OR DNA[mh])) OR "RNA, messenger"[mh] OR "RNA, transfer"[mh] OR "peptide biosynthesis"[mh] OR "protein biosynthesis"[mh] OR "reverse transcriptase polymerase chain reaction"[mh] OR "base sequence"[mh] OR "trans-activators"[mh] OR "gene expression profiling"[mh]) OR ("phenylmercuric acetate"[mh] AND toxicokinetics[mh:noexp]) OR ("phenylmercuric acetate/blood"[mh] OR "phenylmercuric acetate/cerebrospinal fluid"[mh] OR "phenylmercuric acetate/urine"[mh] OR "phenylmercuric acetate/antagonists and inhibitors"[mh]) OR ("phenylmercuric acetate/metabolism"[mh] AND ("humans"[mh] OR "animals"[mh])) OR ("phenylmercuric acetate"[majr] AND (("Neoplasms"[mh] OR "Carcinogens"[mh] OR "Lymphoproliferative disorders"[mh] OR "Myeloproliferative disorders"[mh] OR "Toxicity Tests"[mh] OR ((cancer*[tiab] OR carcinogen*[tiab]) AND (risk*[tiab] OR health[tiab]) AND assessment*[tiab]) OR "Mutagens"[mh] OR "Mutagenicity Tests"[mh] OR "Chromosome Aberrations"[mh] OR "DNA Damage"[mh] OR "DNA Repair"[mh] OR "DNA Replication/drug effects"[mh] OR "DNA/drug effects"[mh] OR "DNA/metabolism"[mh] OR "Genomic Instability"[mh] OR "Salmonella typhimurium/drug effects"[mh] OR "Salmonella typhimurium/genetics"[mh] OR "Sister Chromatid Exchange"[mh] OR strand-break*[tiab]))) OR "phenylmercuric acetate/pharmacology"[majr]) OR ("mercuric chloride/toxicity"[mh] OR "mercuric chloride/adverse effects"[mh] OR "mercuric chloride/poisoning"[mh] OR "mercuric chloride/pharmacokinetics"[mh] OR ("mercuric chloride"[mh] AND ("environmental exposure"[mh] OR ci[sh] OR "endocrine system"[mh] OR "hormones, hormone substitutes, and hormone antagonists"[mh] OR "endocrine disruptors"[mh] OR ("computational biology"[mh] OR "medical informatics"[mh] OR genomics[mh] OR genome[mh] OR proteomics[mh] OR proteome[mh] OR metabolomics[mh] OR metabolome[mh] OR genes[mh] OR "gene expression"[mh] OR phenotype[mh] OR genetics[mh] OR genotype[mh] OR transcriptome[mh] OR ("systems biology"[mh] AND ("environmental exposure"[mh] OR "epidemiological monitoring"[mh] OR analysis[sh])) OR "transcription, genetic "[mh] OR "reverse transcription"[mh] OR "transcriptional activation"[mh] OR "transcription factors"[mh] OR ("biosynthesis"[sh] AND (RNA[mh] OR DNA[mh])) OR "RNA, messenger"[mh] OR "RNA, transfer"[mh] OR "peptide biosynthesis"[mh] OR "protein biosynthesis"[mh] OR "reverse transcriptase polymerase chain reaction"[mh] OR "base sequence"[mh] OR "trans-activators"[mh] OR "gene expression profiling"[mh]) OR ("mercuric chloride"[mh] AND toxicokinetics[mh:noexp]) OR ("mercuric chloride/blood"[mh] OR "mercuric chloride/cerebrospinal fluid"[mh] OR "mercuric chloride/urine"[mh] OR "mercuric chloride/antagonists and inhibitors"[mh]) OR ("mercuric chloride/metabolism"[mh] AND ("humans"[mh] OR "animals"[mh])) OR ("mercuric chloride"[majr] AND (("Neoplasms"[mh] OR "Carcinogens"[mh] OR "Lymphoproliferative disorders"[mh] OR "Myeloproliferative disorders"[mh] OR "Toxicity Tests"[mh] OR ((cancer*[tiab] OR carcinogen*[tiab]) AND (risk*[tiab] OR health[tiab]) AND assessment*[tiab]) OR "Mutagens"[mh] OR "Mutagenicity Tests"[mh] OR "Chromosome Aberrations"[mh] OR "DNA Damage"[mh] OR "DNA Repair"[mh] OR "DNA Replication/drug effects"[mh] OR "DNA/drug effects"[mh] OR "DNA/metabolism"[mh] OR "Genomic Instability"[mh] OR "Salmonella typhimurium/drug effects"[mh] OR "Salmonella typhimurium/genetics"[mh] OR "Sister Chromatid Exchange"[mh] OR strand-break*[tiab])))

Table B-2. Database Query Strings

Database search date	Query string
	OR "mercuric chloride/pharmacology"[majr])) OR ("cinnabar"[tw] OR "mercuric sulfide"[tw] OR "mercuric sulphide"[tw] OR "mercury (ii) sulfide"[tw] OR "mercury monosulfide"[tw] OR "mercury sulfide"[tw] OR "mercury sulphide"[tw] OR "mercury(2+) sulfide"[tw] OR "mercury(ii) sulfide"[tw] OR "monomercury sulfide"[tw] OR "Mercury poisoning"[mh])) AND (2018/12/01:3000[edat] OR 2018/12/01:3000[crdat] OR 2018/12/01:3000[mhda] OR 2018/12/01:3000[dp]) (("mercury compounds/toxicity"[mh] OR "mercury compounds/adverse effects"[mh] OR "mercury compounds/poisoning"[mh] OR "mercury compounds/pharmacokinetics"[mh] OR ("mercury compounds"[mh] AND ("environmental exposure"[mh] OR ci[sh] OR "endocrine system"[mh] OR "hormones, hormone substitutes, and hormone antagonists"[mh] OR "endocrine disruptors"[mh] OR ("computational biology"[mh] OR "medical informatics"[mh] OR genomics[mh] OR genome[mh] OR proteomics[mh] OR proteome[mh] OR metabolomics[mh] OR metabolome[mh] OR genes[mh] OR "gene expression"[mh] OR phenotype[mh] OR genetics[mh] OR genotype[mh] OR transcriptome[mh] OR ("systems biology"[mh] AND ("environmental exposure"[mh] OR "epidemiological monitoring"[mh] OR analysis[sh])) OR "transcription, genetic "[mh] OR "reverse transcription"[mh] OR "transcriptional activation"[mh] OR "transcription factors"[mh] OR ("biosynthesis"[sh] AND (RNA[mh] OR DNA[mh])) OR "RNA, messenger"[mh] OR "RNA, transfer"[mh] OR "peptide biosynthesis"[mh] OR "protein biosynthesis"[mh] OR "reverse transcriptase polymerase chain reaction"[mh] OR "base sequence"[mh] OR "trans-activators"[mh] OR "gene expression profiling"[mh])) OR ("mercury compounds"[mh] AND toxicokinetics[mh:noexp]) OR ("mercury compounds/blood"[mh] OR "mercury compounds/cerebrospinal fluid"[mh] OR "mercury compounds/urine"[mh] OR "mercury compounds/antagonists and inhibitors"[mh]) OR ("mercury compounds/metabolism"[mh] AND ("humans"[mh] OR "animals"[mh])) OR ("mercury compounds"[majr] AND (("Neoplasms"[mh] OR "Carcinogens"[mh] OR "Lymphoproliferative disorders"[mh] OR "Myeloproliferative disorders"[mh] OR "Toxicity Tests"[mh] OR ((cancer*[tiab] OR carcinogen*[tiab]) AND (risk*[tiab] OR health[tiab]) AND assessment*[tiab]) OR "Mutagens"[mh] OR "Mutagenicity Tests"[mh] OR "Chromosome Aberrations"[mh] OR "DNA Damage"[mh] OR "DNA Repair"[mh] OR "DNA Replication/drug effects"[mh] OR "DNA/drug effects"[mh] OR "DNA/metabolism"[mh] OR "Genomic Instability"[mh] OR "Salmonella typhimurium/drug effects"[mh] OR "Salmonella typhimurium/genetics"[mh] OR "Sister Chromatid Exchange"[mh] OR strand-break*[tiab]))) OR "mercury compounds/pharmacology"[majr])) OR ("methylmercury compounds/toxicity"[mh] OR "methylmercury compounds/adverse effects"[mh] OR "methylmercury compounds/poisoning"[mh] OR "methylmercury compounds/pharmacokinetics"[mh] OR ("methylmercury compounds"[mh] AND ("environmental exposure"[mh] OR ci[sh] OR "endocrine system"[mh] OR "hormones, hormone substitutes, and hormone antagonists"[mh] OR "endocrine disruptors"[mh] OR ("computational biology"[mh] OR "medical informatics"[mh] OR genomics[mh] OR genome[mh] OR proteomics[mh] OR proteome[mh] OR metabolomics[mh] OR metabolome[mh] OR genes[mh] OR "gene expression"[mh] OR phenotype[mh] OR genetics[mh] OR genotype[mh] OR transcriptome[mh] OR ("systems biology"[mh] AND ("environmental exposure"[mh] OR "epidemiological monitoring"[mh] OR analysis[sh])) OR "transcription, genetic "[mh] OR "reverse transcription"[mh] OR "transcriptional activation"[mh] OR "transcription factors"[mh] OR ("biosynthesis"[sh] AND (RNA[mh] OR DNA[mh])) OR "RNA, messenger"[mh] OR "RNA, transfer"[mh] OR "peptide biosynthesis"[mh] OR "protein biosynthesis"[mh] OR "reverse transcriptase polymerase chain reaction"[mh] OR "base sequence"[mh] OR "trans-activators"[mh] OR "gene expression profiling"[mh])) OR ("methylmercury compounds"[mh] AND

Table B-2. Database Query Strings

Database search date	Query string
	toxicokinetics[mh:noexp]) OR ("methylmercury compounds/blood"[mh] OR "methylmercury compounds/cerebrospinal fluid"[mh] OR "methylmercury compounds/urine"[mh] OR "methylmercury compounds/antagonists and inhibitors"[mh]) OR ("methylmercury compounds/metabolism"[mh] AND ("humans"[mh] OR "animals"[mh])) OR ("methylmercury compounds"[majr] AND (("Neoplasms"[mh] OR "Carcinogens"[mh] OR "Lymphoproliferative disorders"[mh] OR "Myeloproliferative disorders"[mh] OR "Toxicity Tests"[mh] OR ((cancer*[tiab] OR carcinogen*[tiab]) AND (risk*[tiab] OR health[tiab]) AND assessment*[tiab]) OR "Mutagens"[mh] OR "Mutagenicity Tests"[mh] OR "Chromosome Aberrations"[mh] OR "DNA Damage"[mh] OR "DNA Repair"[mh] OR "DNA Replication/drug effects"[mh] OR "DNA/drug effects"[mh] OR "DNA/metabolism"[mh] OR "Genomic Instability"[mh] OR "Salmonella typhimurium/drug effects"[mh] OR "Salmonella typhimurium/genetics"[mh] OR "Sister Chromatid Exchange"[mh] OR strand-break*[tiab]))) OR "methylmercury compounds/pharmacology"[majr]) OR ("mercury isotopes/toxicity"[mh] OR "mercury isotopes/adverse effects"[mh] OR "mercury isotopes/poisoning"[mh] OR "mercury isotopes/pharmacokinetics"[mh] OR ("mercury isotopes"[mh] AND ("environmental exposure"[mh] OR ci[sh] OR "endocrine system"[mh] OR "hormones, hormone substitutes, and hormone antagonists"[mh] OR "endocrine disruptors"[mh] OR ("computational biology"[mh] OR "medical informatics"[mh] OR genomics[mh] OR genome[mh] OR proteomics[mh] OR proteome[mh] OR metabolomics[mh] OR metabolome[mh] OR genes[mh] OR "gene expression"[mh] OR phenotype[mh] OR genetics[mh] OR genotype[mh] OR transcriptome[mh] OR ("systems biology"[mh] AND ("environmental exposure"[mh] OR "epidemiological monitoring"[mh] OR analysis[sh])) OR "transcription, genetic "[mh] OR "reverse transcription"[mh] OR "transcriptional activation"[mh] OR "transcription factors"[mh] OR ("biosynthesis"[sh] AND (RNA[mh] OR DNA[mh])) OR "RNA, messenger"[mh] OR "RNA, transfer"[mh] OR "peptide biosynthesis"[mh] OR "protein biosynthesis"[mh] OR "reverse transcriptase polymerase chain reaction"[mh] OR "base sequence"[mh] OR "trans-activators"[mh] OR "gene expression profiling"[mh])) OR ("mercury isotopes"[mh] AND toxicokinetics[mh:noexp]) OR ("mercury isotopes/blood"[mh] OR "mercury isotopes/cerebrospinal fluid"[mh] OR "mercury isotopes/urine"[mh] OR "mercury isotopes/antagonists and inhibitors"[mh]) OR ("mercury isotopes/metabolism"[mh] AND ("humans"[mh] OR "animals"[mh])) OR ("mercury isotopes"[majr] AND (("Neoplasms"[mh] OR "Carcinogens"[mh] OR "Lymphoproliferative disorders"[mh] OR "Myeloproliferative disorders"[mh] OR "Toxicity Tests"[mh] OR ((cancer*[tiab] OR carcinogen*[tiab]) AND (risk*[tiab] OR health[tiab]) AND assessment*[tiab]) OR "Mutagens"[mh] OR "Mutagenicity Tests"[mh] OR "Chromosome Aberrations"[mh] OR "DNA Damage"[mh] OR "DNA Repair"[mh] OR "DNA Replication/drug effects"[mh] OR "DNA/drug effects"[mh] OR "DNA/metabolism"[mh] OR "Genomic Instability"[mh] OR "Salmonella typhimurium/drug effects"[mh] OR "Salmonella typhimurium/genetics"[mh] OR "Sister Chromatid Exchange"[mh] OR strand-break*[tiab]))) OR "mercury isotopes/pharmacology"[majr]) OR ("organomercury compounds/toxicity"[mh] OR "organomercury compounds/adverse effects"[mh] OR "organomercury compounds/poisoning"[mh] OR "organomercury compounds/pharmacokinetics"[mh] OR ("organomercury compounds"[mh] AND ("environmental exposure"[mh] OR ci[sh] OR "endocrine system"[mh] OR "hormones, hormone substitutes, and hormone antagonists"[mh] OR "endocrine disruptors"[mh] OR ("computational biology"[mh] OR "medical informatics"[mh] OR genomics[mh] OR genome[mh] OR proteomics[mh] OR proteome[mh] OR metabolomics[mh] OR metabolome[mh] OR genes[mh] OR "gene expression"[mh] OR phenotype[mh] OR genetics[mh] OR genotype[mh] OR transcriptome[mh] OR ("systems biology"[mh] AND ("environmental exposure"[mh] OR "epidemiological monitoring"[mh] OR analysis[sh])) OR

Table B-2. Database Query Strings

Database search date	Query string
	"transcription, genetic "[mh] OR "reverse transcription"[mh] OR "transcriptional activation"[mh] OR "transcription factors"[mh] OR ("biosynthesis"[sh] AND (RNA[mh] OR DNA[mh])) OR "RNA, messenger"[mh] OR "RNA, transfer"[mh] OR "peptide biosynthesis"[mh] OR "protein biosynthesis"[mh] OR "reverse transcriptase polymerase chain reaction"[mh] OR "base sequence"[mh] OR "trans-activators"[mh] OR "gene expression profiling"[mh])) OR ("organomercury compounds"[mh] AND toxicokinetics[mh:noexp]) OR ("organomercury compounds/blood"[mh] OR "organomercury compounds/cerebrospinal fluid"[mh] OR "organomercury compounds/urine"[mh] OR "organomercury compounds/antagonists and inhibitors"[mh]) OR ("organomercury compounds/metabolism"[mh] AND ("humans"[mh] OR "animals"[mh])) OR ("organomercury compounds"[majr] AND (("Neoplasms"[mh] OR "Carcinogens"[mh] OR "Lymphoproliferative disorders"[mh] OR "Myeloproliferative disorders"[mh] OR "Toxicity Tests"[mh] OR ((cancer*[tiab] OR carcinogen*[tiab]) AND (risk*[tiab] OR health[tiab]) AND assessment*[tiab]) OR "Mutagens"[mh] OR "Mutagenicity Tests"[mh] OR "Chromosome Aberrations"[mh] OR "DNA Damage"[mh] OR "DNA Repair"[mh] OR "DNA Replication/drug effects"[mh] OR "DNA/drug effects"[mh] OR "DNA/metabolism"[mh] OR "Genomic Instability"[mh] OR "Salmonella typhimurium/drug effects"[mh] OR "Salmonella typhimurium/genetics"[mh] OR "Sister Chromatid Exchange"[mh] OR strand-break*[tiab]))) OR "organomercury compounds/pharmacology"[majr]))) AND (2018/12/01:3000[edat] OR 2018/12/01:3000[crdat] OR 2018/12/01:3000[mhda] OR 2018/12/01:3000[dp]) ((("(acetato)phenylmercury"[tw] OR "(acetato-kappao)phenylmercury"[tw] OR "(acetato-o)phenylmercury"[tw] OR "(acetoxymercuri)benzene"[tw] OR "(acetoxymercurio)benzene"[tw] OR "acetic acid, mercuridi-"[tw] OR "acetic acid, mercury(2+) salt"[tw] OR "acetic acid, phenylmercury deriv."[tw] OR "acetic acid, phenylmercury(ii) salt"[tw] OR "acetoxyphenylmercury"[tw] OR "benzene, (acetoxymercuri)-"[tw] OR "benzene, (acetoxymercurio)-"[tw] OR "bis(acetyloxy)mercury"[tw] OR "calochlor"[tw] OR "calomel"[tw] OR "chloromethylmercury"[tw] OR "cinnabar"[tw] OR "cinnabarite"[tw] OR "diacetoxymercury"[tw] OR "dichloromercury"[tw] OR "dimercury dichloride"[tw] OR "dimethylmercury"[tw] OR "fungche"[tw] OR "hydrargyrum"[tw] OR "mercuriacetate"[tw] OR "mercuric acetate"[tw] OR "mercuric bichloride"[tw] OR "mercuric chloride"[tw] OR "mercuric diacetate"[tw] OR "mercuric nitrate"[tw] OR "mercuric sulfide"[tw] OR "mercuric sulphide"[tw] OR "mercuridiacetic acid, "[tw] OR "mercuriphenyl acetate"[tw] OR "mercurius 6a"[tw] OR "mercurous chloride"[tw] OR "mercury"[tw] OR "mercury(1+), methyl-"[tw] OR "mercury(2+) acetate"[tw] OR "mercury(2+) chloride"[tw] OR "mercury(2+) nitrate"[tw] OR "mercury(2+) sulfide"[tw] OR "mercury(i) chloride"[tw] OR "mercury(ii) acetate"[tw] OR "mercury(ii) acetate, phenyl-"[tw] OR "mercury(ii) chloride"[tw] OR "mercury(ii) nitrate"[tw] OR "mercury(ii) sulfide"[tw] OR "mercury, (acetato)phenyl-"[tw] OR "mercury, (acetato-kappao)phenyl-"[tw] OR "mercury, (acetato-o)phenyl-"[tw] OR "mercury, acetoxyphenyl-"[tw] OR "mercury, chloromethyl-"[tw] OR "mercury, dimethyl-"[tw] OR "mercuryl acetate"[tw] OR "mercurymethylchloride"[tw] OR "methyl mercuric chloride"[tw] OR "methyl mercuric(ii) chloride"[tw] OR "methyl meruric chloride"[tw] OR "methylmercuric chloride"[tw] OR "methylmercury"[tw] OR "methylmercury chloride"[tw] OR "methylmercury monochloride"[tw] OR "methylmercury(1+)"[tw] OR "methylmercury(ii) cation"[tw] OR "millon's reagent"[tw] OR "monomercury sulfide"[tw] OR "monomethylmercury cation"[tw] OR "nitric acid, mercury(2+) salt"[tw] OR "nitric acid, mercury(ii) salt"[tw] OR "phenomercuric acetate"[tw] OR "phenyl mercuric acetate"[tw] OR "phenylmercuriacetate"[tw] OR "phenylmercuric acetate"[tw] OR "phenylmercury

APPENDIX B

Table B-2. Database Query Strings

Database search date	Query string
	acetate"[tw] OR "phenylmercury(ii) acetate"[tw] OR "Anticon"[tw] OR "Celmer"[tw] OR "Femma"[tw] OR "Hexasan"[tw] OR "Hostaquick"[tw] OR "Kwiksan"[tw] OR "Lorophyn"[tw] OR "Parasan"[tw] OR "Phix"[tw] OR "Samtol"[tw] OR "Sanitol"[tw] OR "Sc-110"[tw] OR "Verdasan"[tw] OR "Volpar"[tw] OR "Caspan"[tw] OR "Liquid silver"[tw] OR "Quick silver"[tw] OR "Quicksilver"[tw] OR "Sulem"[tw] OR "Agrosan D"[tw] OR "Agrosan GN 5"[tw] OR "Algimycin 200"[tw] OR "Antimucin WBR"[tw] OR "Antimucin WDR"[tw] OR "Bufen"[tw] OR "Bufen 30"[tw] OR "Cekusil"[tw] OR "Ceresol"[tw] OR "Contra Creme"[tw] OR "Dyanacide"[tw] OR "Fungicide R"[tw] OR "Fungitox OR"[tw] OR "Gallotox"[tw] OR "Hl-331"[tw] OR "Hong nien"[tw] OR "Hostaquik"[tw] OR "Intercide 60"[tw] OR "Intercide PMA 18"[tw] OR "Liquiphene"[tw] OR "Meracen"[tw] OR "Mercron"[tw] OR "Mercuron"[tw] OR "Mergal A 25"[tw] OR "Mersolite"[tw] OR "Metasol 30"[tw] OR "Neantina"[tw] OR "Norforms"[tw] OR "Nuodex PMA 18"[tw] OR "Nylmerate"[tw] OR "PMA (fungicide)"[tw] OR "Pamisan"[tw] OR "Panomatic"[tw] OR "Parasan (bactericide)"[tw] OR "Phenmad"[tw] OR "Programin"[tw] OR "Purasan-SC-10"[tw] OR "Puraturf 10"[tw] OR "Quicksan"[tw] OR "Quicksan 20"[tw] OR "Riogen"[tw] OR "Ruberon"[tw] OR "Sanitized SPG"[tw] OR "Sanmicron"[tw] OR "Scutl"[tw] OR "Seed Dressing R"[tw] OR "Seedtox"[tw] OR "Setrete"[tw] OR "Shimmerex"[tw] OR "Spor-Kil"[tw] OR "Spruce Seal"[tw] OR "Tag (VAN)"[tw] OR "Tag 331"[tw] OR "Tag HL 331"[tw] OR "Tag fungicide"[tw] OR "Trigosan"[tw] OR "Troysan 30"[tw] OR "Troysan PMA 30"[tw] OR "Zaprawa Nasienna R"[tw] OR "Ziarnik"[tw] OR "Hydraargyrum bichloratum"[tw] OR "Calo-Clor"[tw] OR "Calocure"[tw] OR "Calogreen"[tw] OR "Calotab"[tw] OR "Abavit B"[tw] OR "Citrine ointment"[tw] OR "Ethiops mineral"[tw] OR "Mercurius vivus"[tw] OR "beta-Mercuric sulfide"[tw] OR "Phenylquecksilberacetate"[tw] OR "Quecksilber(II)-sulfid, rotes"[tw] OR "Rotes Quecksilbersulfid"[tw] OR "Paragite"[tw] OR "TL 898"[tw]) NOT medline[sb])) AND (2018/12/01:3000[edat] OR 2018/12/01:3000[crdat] OR 2018/12/01:3000[dp]) (((7546-30-7[rn] OR 10031-18-2[rn] OR 7789-47-1[rn] OR 15385-58-7[rn] OR 628-86-4[rn] OR 7783-30-4[rn] OR 15385-57-6[rn] OR 7774-29-0[rn] OR 10415-75-5[rn] OR 14836-60-3[rn] OR 15829-53-5[rn] OR 21908-53-2[rn] OR 20601-83-6[rn] OR 11138-42-4[rn] OR 7783-36-0[rn] OR 7783-35-9[rn] OR 12068-90-5[rn] OR 592-04-1[rn] OR 631-60-7[rn] OR 14302-87-5[rn] OR 22542-11-6[rn]) AND (("mercury/toxicity"[mh] OR "mercury/adverse effects"[mh] OR "mercury/poisoning"[mh] OR "mercury/pharmacokinetics"[mh] OR ("mercury"[mh] AND ("environmental exposure"[mh] OR ci[sh] OR "endocrine system"[mh] OR "hormones, hormone substitutes, and hormone antagonists"[mh] OR "endocrine disruptors"[mh] OR ("computational biology"[mh] OR "medical informatics"[mh] OR genomics[mh] OR genome[mh] OR proteomics[mh] OR proteome[mh] OR metabolomics[mh] OR metabolome[mh] OR genes[mh] OR "gene expression"[mh] OR phenotype[mh] OR genetics[mh] OR genotype[mh] OR transcriptome[mh] OR ("systems biology"[mh] AND ("environmental exposure"[mh] OR "epidemiological monitoring"[mh] OR analysis[sh])) OR "transcription, genetic "[mh] OR "reverse transcription"[mh] OR "transcriptional activation"[mh] OR "transcription factors"[mh] OR ("biosynthesis"[sh] AND (RNA[mh] OR DNA[mh])) OR "RNA, messenger"[mh] OR "RNA, transfer"[mh] OR "peptide biosynthesis"[mh] OR "protein biosynthesis"[mh] OR "reverse transcriptase polymerase chain reaction"[mh] OR "base sequence"[mh] OR "trans-activators"[mh] OR "gene expression profiling"[mh])) OR ("mercury"[mh] AND toxicokinetics[mh:noexp]) OR ("mercury/blood"[mh] OR "mercury/cerebrospinal fluid"[mh] OR "mercury/urine"[mh] OR "mercury/antagonists and inhibitors"[mh]) OR ("mercury/metabolism"[mh] AND ("humans"[mh] OR "animals"[mh])) OR ("mercury"[majr] AND (("Neoplasms"[mh] OR "Carcinogens"[mh] OR "Lymphoproliferative disorders"[mh] OR "Myeloproliferative disorders"[mh] OR "Toxicity Tests"[mh] OR ((cancer*[tiab] OR carcinogen*[tiab]) AND

APPENDIX B

Table B-2. Database Query Strings

Database search date	Query string
	(risk*[tiab] OR health[tiab]) AND assessment*[tiab]) OR "Mutagens"[mh] OR "Mutagenicity Tests"[mh] OR "Chromosome Aberrations"[mh] OR "DNA Damage"[mh] OR "DNA Repair"[mh] OR "DNA Replication/drug effects"[mh] OR "DNA/drug effects"[mh] OR "DNA/metabolism"[mh] OR "Genomic Instability"[mh] OR "Salmonella typhimurium/drug effects"[mh] OR "Salmonella typhimurium/genetics"[mh] OR "Sister Chromatid Exchange"[mh] OR strand-break*[tiab]))) OR "mercury/pharmacology"[majr]) OR ("phenylmercuric acetate/toxicity"[mh] OR "phenylmercuric acetate/adverse effects"[mh] OR "phenylmercuric acetate/poisoning"[mh] OR "phenylmercuric acetate/pharmacokinetics"[mh] OR ("phenylmercuric acetate"[mh] AND ("environmental exposure"[mh] OR ci[sh] OR "endocrine system"[mh] OR "hormones, hormone substitutes, and hormone antagonists"[mh] OR "endocrine disruptors"[mh] OR ("computational biology"[mh] OR "medical informatics"[mh] OR genomics[mh] OR genome[mh] OR proteomics[mh] OR proteome[mh] OR metabolomics[mh] OR metabolome[mh] OR genes[mh] OR "gene expression"[mh] OR phenotype[mh] OR genetics[mh] OR genotype[mh] OR transcriptome[mh] OR ("systems biology"[mh] AND ("environmental exposure"[mh] OR "epidemiological monitoring"[mh] OR analysis[sh])) OR "transcription, genetic "[mh] OR "reverse transcription"[mh] OR "transcriptional activation"[mh] OR "transcription factors"[mh] OR ("biosynthesis"[sh] AND (RNA[mh] OR DNA[mh])) OR "RNA, messenger"[mh] OR "RNA, transfer"[mh] OR "peptide biosynthesis"[mh] OR "protein biosynthesis"[mh] OR "reverse transcriptase polymerase chain reaction"[mh] OR "base sequence"[mh] OR "trans-activators"[mh] OR "gene expression profiling"[mh])) OR ("phenylmercuric acetate"[mh] AND toxicokinetics[mh:noexp]) OR ("phenylmercuric acetate/blood"[mh] OR "phenylmercuric acetate/cerebrospinal fluid"[mh] OR "phenylmercuric acetate/urine"[mh] OR "phenylmercuric acetate/antagonists and inhibitors"[mh]) OR ("phenylmercuric acetate/metabolism"[mh] AND ("humans"[mh] OR "animals"[mh])) OR ("phenylmercuric acetate"[majr] AND (("Neoplasms"[mh] OR "Carcinogens"[mh] OR "Lymphoproliferative disorders"[mh] OR "Myeloproliferative disorders"[mh] OR "Toxicity Tests"[mh] OR ((cancer*[tiab] OR carcinogen*[tiab]) AND (risk*[tiab] OR health[tiab]) AND assessment*[tiab]) OR "Mutagens"[mh] OR "Mutagenicity Tests"[mh] OR "Chromosome Aberrations"[mh] OR "DNA Damage"[mh] OR "DNA Repair"[mh] OR "DNA Replication/drug effects"[mh] OR "DNA/drug effects"[mh] OR "DNA/metabolism"[mh] OR "Genomic Instability"[mh] OR "Salmonella typhimurium/drug effects"[mh] OR "Salmonella typhimurium/genetics"[mh] OR "Sister Chromatid Exchange"[mh] OR strand-break*[tiab]))) OR "phenylmercuric acetate/pharmacology"[majr]) OR ("mercuric chloride/toxicity"[mh] OR "mercuric chloride/adverse effects"[mh] OR "mercuric chloride/poisoning"[mh] OR "mercuric chloride/pharmacokinetics"[mh] OR ("mercuric chloride"[mh] AND ("environmental exposure"[mh] OR ci[sh] OR "endocrine system"[mh] OR "hormones, hormone substitutes, and hormone antagonists"[mh] OR "endocrine disruptors"[mh] OR ("computational biology"[mh] OR "medical informatics"[mh] OR genomics[mh] OR genome[mh] OR proteomics[mh] OR proteome[mh] OR metabolomics[mh] OR metabolome[mh] OR genes[mh] OR "gene expression"[mh] OR phenotype[mh] OR genetics[mh] OR genotype[mh] OR transcriptome[mh] OR ("systems biology"[mh] AND ("environmental exposure"[mh] OR "epidemiological monitoring"[mh] OR analysis[sh])) OR "transcription, genetic "[mh] OR "reverse transcription"[mh] OR "transcriptional activation"[mh] OR "transcription factors"[mh] OR ("biosynthesis"[sh] AND (RNA[mh] OR DNA[mh])) OR "RNA, messenger"[mh] OR "RNA, transfer"[mh] OR "peptide biosynthesis"[mh] OR "protein biosynthesis"[mh] OR "reverse transcriptase polymerase chain reaction"[mh] OR "base sequence"[mh] OR "trans-activators"[mh] OR "gene expression profiling"[mh])) OR ("mercuric chloride"[mh] AND toxicokinetics[mh:noexp]) OR ("mercuric chloride/blood"[mh]

Table B-2. Database Query Strings

Database search date	Query string
	OR "mercuric chloride/cerebrospinal fluid"[mh] OR "mercuric chloride/urine"[mh] OR "mercuric chloride/antagonists and inhibitors"[mh]) OR ("mercuric chloride/metabolism"[mh] AND ("humans"[mh] OR "animals"[mh])) OR ("mercuric chloride"[majr] AND (("Neoplasms"[mh] OR "Carcinogens"[mh] OR "Lymphoproliferative disorders"[mh] OR "Myeloproliferative disorders"[mh] OR "Toxicity Tests"[mh] OR ((cancer*[tiab] OR carcinogen*[tiab]) AND (risk*[tiab] OR health[tiab]) AND assessment*[tiab]) OR "Mutagens"[mh] OR "Mutagenicity Tests"[mh] OR "Chromosome Aberrations"[mh] OR "DNA Damage"[mh] OR "DNA Repair"[mh] OR "DNA Replication/drug effects"[mh] OR "DNA/drug effects"[mh] OR "DNA/metabolism"[mh] OR "Genomic Instability"[mh] OR "Salmonella typhimurium/drug effects"[mh] OR "Salmonella typhimurium/genetics"[mh] OR "Sister Chromatid Exchange"[mh] OR strand-break*[tiab]))) OR "mercuric chloride/pharmacology"[majr])) OR ("cinnabar"[tw] OR "mercuric sulfide"[tw] OR "mercuric sulphide"[tw] OR "mercury (ii) sulfide"[tw] OR "mercury monosulfide"[tw] OR "mercury sulfide"[tw] OR "mercury sulphide"[tw] OR "mercury(2+) sulfide"[tw] OR "mercury(ii) sulfide"[tw] OR "monomercury sulfide"[tw] OR "Mercury poisoning"[mh]))) OR ((7546-30-7[rn] OR 10031-18-2[rn] OR 7789-47-1[rn] OR 15385-58-7[rn] OR 628-86-4[rn] OR 7783-30-4[rn] OR 15385-57-6[rn] OR 7774-29-0[rn] OR 10415-75-5[rn] OR 14836-60-3[rn] OR 15829-53-5[rn] OR 21908-53-2[rn] OR 20601-83-6[rn] OR 11138-42-4[rn] OR 7783-36-0[rn] OR 7783-35-9[rn] OR 12068-90-5[rn] OR 592-04-1[rn] OR 631-60-7[rn] OR 14302-87-5[rn] OR 22542-11-6[rn]) AND (("mercury compounds/toxicity"[mh] OR "mercury compounds/adverse effects"[mh] OR "mercury compounds/poisoning"[mh] OR "mercury compounds/pharmacokinetics"[mh] OR ("mercury compounds"[mh] AND ("environmental exposure"[mh] OR ci[sh] OR "endocrine system"[mh] OR "hormones, hormone substitutes, and hormone antagonists"[mh] OR "endocrine disruptors"[mh] OR ("computational biology"[mh] OR "medical informatics"[mh] OR genomics[mh] OR genome[mh] OR proteomics[mh] OR proteome[mh] OR metabolomics[mh] OR metabolome[mh] OR genes[mh] OR "gene expression"[mh] OR phenotype[mh] OR genetics[mh] OR genotype[mh] OR transcriptome[mh] OR ("systems biology"[mh] AND ("environmental exposure"[mh] OR "epidemiological monitoring"[mh] OR analysis[sh])) OR "transcription, genetic "[mh] OR "reverse transcription"[mh] OR "transcriptional activation"[mh] OR "transcription factors"[mh] OR ("biosynthesis"[sh] AND (RNA[mh] OR DNA[mh])) OR "RNA, messenger"[mh] OR "RNA, transfer"[mh] OR "peptide biosynthesis"[mh] OR "protein biosynthesis"[mh] OR "reverse transcriptase polymerase chain reaction"[mh] OR "base sequence"[mh] OR "trans-activators"[mh] OR "gene expression profiling"[mh])) OR ("mercury compounds"[mh] AND toxicokinetics[mh:noexp]) OR ("mercury compounds/blood"[mh] OR "mercury compounds/cerebrospinal fluid"[mh] OR "mercury compounds/urine"[mh] OR "mercury compounds/antagonists and inhibitors"[mh]) OR ("mercury compounds/metabolism"[mh] AND ("humans"[mh] OR "animals"[mh])) OR ("mercury compounds"[majr] AND (("Neoplasms"[mh] OR "Carcinogens"[mh] OR "Lymphoproliferative disorders"[mh] OR "Myeloproliferative disorders"[mh] OR "Toxicity Tests"[mh] OR ((cancer*[tiab] OR carcinogen*[tiab]) AND (risk*[tiab] OR health[tiab]) AND assessment*[tiab]) OR "Mutagens"[mh] OR "Mutagenicity Tests"[mh] OR "Chromosome Aberrations"[mh] OR "DNA Damage"[mh] OR "DNA Repair"[mh] OR "DNA Replication/drug effects"[mh] OR "DNA/drug effects"[mh] OR "DNA/metabolism"[mh] OR "Genomic Instability"[mh] OR "Salmonella typhimurium/drug effects"[mh] OR "Salmonella typhimurium/genetics"[mh] OR "Sister Chromatid Exchange"[mh] OR strand-break*[tiab]))) OR "mercury compounds/pharmacology"[majr])) OR ("methylmercury compounds/toxicity"[mh] OR "methylmercury compounds/adverse effects"[mh] OR "methylmercury compounds/poisoning"[mh] OR "methylmercury compounds/pharmacokinetics"[mh] OR ("methylmercury compounds"[mh] AND

Table B-2. Database Query Strings

Database search date	Query string
	("environmental exposure"[mh] OR ci[sh] OR "endocrine system"[mh] OR "hormones, hormone substitutes, and hormone antagonists"[mh] OR "endocrine disruptors"[mh] OR ("computational biology"[mh] OR "medical informatics"[mh] OR genomics[mh] OR genome[mh] OR proteomics[mh] OR proteome[mh] OR metabolomics[mh] OR metabolome[mh] OR genes[mh] OR "gene expression"[mh] OR phenotype[mh] OR genetics[mh] OR genotype[mh] OR transcriptome[mh] OR ("systems biology"[mh] AND ("environmental exposure"[mh] OR "epidemiological monitoring"[mh] OR analysis[sh])) OR "transcription, genetic "[mh] OR "reverse transcription"[mh] OR "transcriptional activation"[mh] OR "transcription factors"[mh] OR ("biosynthesis"[sh] AND (RNA[mh] OR DNA[mh])) OR "RNA, messenger"[mh] OR "RNA, transfer"[mh] OR "peptide biosynthesis"[mh] OR "protein biosynthesis"[mh] OR "reverse transcriptase polymerase chain reaction"[mh] OR "base sequence"[mh] OR "trans-activators"[mh] OR "gene expression profiling"[mh])) OR ("methylmercury compounds"[mh] AND toxicokinetics[mh:noexp]) OR ("methylmercury compounds/blood"[mh] OR "methylmercury compounds/cerebrospinal fluid"[mh] OR "methylmercury compounds/urine"[mh] OR "methylmercury compounds/antagonists and inhibitors"[mh]) OR ("methylmercury compounds/metabolism"[mh] AND ("humans"[mh] OR "animals"[mh])) OR ("methylmercury compounds"[majr] AND (("Neoplasms"[mh] OR "Carcinogens"[mh] OR "Lymphoproliferative disorders"[mh] OR "Myeloproliferative disorders"[mh] OR "Toxicity Tests"[mh] OR ((cancer*[tiab] OR carcinogen*[tiab]) AND (risk*[tiab] OR health[tiab]) AND assessment*[tiab]) OR "Mutagens"[mh] OR "Mutagenicity Tests"[mh] OR "Chromosome Aberrations"[mh] OR "DNA Damage"[mh] OR "DNA Repair"[mh] OR "DNA Replication/drug effects"[mh] OR "DNA/drug effects"[mh] OR "DNA/metabolism"[mh] OR "Genomic Instability"[mh] OR "Salmonella typhimurium/drug effects"[mh] OR "Salmonella typhimurium/genetics"[mh] OR "Sister Chromatid Exchange"[mh] OR strand-break*[tiab]))) OR "methylmercury compounds/pharmacology"[majr]) OR ("mercury isotopes/toxicity"[mh] OR "mercury isotopes/adverse effects"[mh] OR "mercury isotopes/poisoning"[mh] OR "mercury isotopes/pharmacokinetics"[mh] OR ("mercury isotopes"[mh] AND ("environmental exposure"[mh] OR ci[sh] OR "endocrine system"[mh] OR "hormones, hormone substitutes, and hormone antagonists"[mh] OR "endocrine disruptors"[mh] OR ("computational biology"[mh] OR "medical informatics"[mh] OR genomics[mh] OR genome[mh] OR proteomics[mh] OR proteome[mh] OR metabolomics[mh] OR metabolome[mh] OR genes[mh] OR "gene expression"[mh] OR phenotype[mh] OR genetics[mh] OR genotype[mh] OR transcriptome[mh] OR ("systems biology"[mh] AND ("environmental exposure"[mh] OR "epidemiological monitoring"[mh] OR analysis[sh])) OR "transcription, genetic "[mh] OR "reverse transcription"[mh] OR "transcriptional activation"[mh] OR "transcription factors"[mh] OR ("biosynthesis"[sh] AND (RNA[mh] OR DNA[mh])) OR "RNA, messenger"[mh] OR "RNA, transfer"[mh] OR "peptide biosynthesis"[mh] OR "protein biosynthesis"[mh] OR "reverse transcriptase polymerase chain reaction"[mh] OR "base sequence"[mh] OR "trans-activators"[mh] OR "gene expression profiling"[mh])) OR ("mercury isotopes"[mh] AND toxicokinetics[mh:noexp]) OR ("mercury isotopes/blood"[mh] OR "mercury isotopes/cerebrospinal fluid"[mh] OR "mercury isotopes/urine"[mh] OR "mercury isotopes/antagonists and inhibitors"[mh]) OR ("mercury isotopes/metabolism"[mh] AND ("humans"[mh] OR "animals"[mh])) OR ("mercury isotopes"[majr] AND (("Neoplasms"[mh] OR "Carcinogens"[mh] OR "Lymphoproliferative disorders"[mh] OR "Myeloproliferative disorders"[mh] OR "Toxicity Tests"[mh] OR ((cancer*[tiab] OR carcinogen*[tiab]) AND (risk*[tiab] OR health[tiab]) AND assessment*[tiab]) OR "Mutagens"[mh] OR "Mutagenicity Tests"[mh] OR "Chromosome Aberrations"[mh] OR "DNA Damage"[mh] OR "DNA Repair"[mh] OR "DNA Replication/drug effects"[mh] OR "DNA/drug effects"[mh] OR "DNA/metabolism"[mh] OR

APPENDIX B

Table B-2. Database Query Strings

Database search date	Query string
	"Genomic Instability"[mh] OR "Salmonella typhimurium/drug effects"[mh] OR "Salmonella typhimurium/genetics"[mh] OR "Sister Chromatid Exchange"[mh] OR strand-break*[tiab]))) OR "mercury isotopes/pharmacology"[majr])) OR ("organomercury compounds/toxicity"[mh] OR "organomercury compounds/adverse effects"[mh] OR "organomercury compounds/poisoning"[mh] OR "organomercury compounds/pharmacokinetics"[mh] OR ("organomercury compounds"[mh] AND ("environmental exposure"[mh] OR ci[sh] OR "endocrine system"[mh] OR "hormones, hormone substitutes, and hormone antagonists"[mh] OR "endocrine disruptors"[mh] OR ("computational biology"[mh] OR "medical informatics"[mh] OR genomics[mh] OR genome[mh] OR proteomics[mh] OR proteome[mh] OR metabolomics[mh] OR metabolome[mh] OR genes[mh] OR "gene expression"[mh] OR phenotype[mh] OR genetics[mh] OR genotype[mh] OR transcriptome[mh] OR ("systems biology"[mh] AND ("environmental exposure"[mh] OR "epidemiological monitoring"[mh] OR analysis[sh])) OR "transcription, genetic "[mh] OR "reverse transcription"[mh] OR "transcriptional activation"[mh] OR "transcription factors"[mh] OR ("biosynthesis"[sh] AND (RNA[mh] OR DNA[mh])) OR "RNA, messenger"[mh] OR "RNA, transfer"[mh] OR "peptide biosynthesis"[mh] OR "protein biosynthesis"[mh] OR "reverse transcriptase polymerase chain reaction"[mh] OR "base sequence"[mh] OR "trans-activators"[mh] OR "gene expression profiling"[mh])) OR ("organomercury compounds"[mh] AND toxicokinetics[mh:noexp]) OR ("organomercury compounds/blood"[mh] OR "organomercury compounds/cerebrospinal fluid"[mh] OR "organomercury compounds/urine"[mh] OR "organomercury compounds/antagonists and inhibitors"[mh]) OR ("organomercury compounds/metabolism"[mh] AND ("humans"[mh] OR "animals"[mh])) OR ("organomercury compounds"[majr] AND (("Neoplasms"[mh] OR "Carcinogens"[mh] OR "Lymphoproliferative disorders"[mh] OR "Myeloproliferative disorders"[mh] OR "Toxicity Tests"[mh] OR ((cancer*[tiab] OR carcinogen*[tiab]) AND (risk*[tiab] OR health[tiab]) AND assessment*[tiab]) OR "Mutagens"[mh] OR "Mutagenicity Tests"[mh] OR "Chromosome Aberrations"[mh] OR "DNA Damage"[mh] OR "DNA Repair"[mh] OR "DNA Replication/drug effects"[mh] OR "DNA/drug effects"[mh] OR "DNA/metabolism"[mh] OR "Genomic Instability"[mh] OR "Salmonella typhimurium/drug effects"[mh] OR "Salmonella typhimurium/genetics"[mh] OR "Sister Chromatid Exchange"[mh] OR strand-break*[tiab])) OR "organomercury compounds/pharmacology"[majr]))))) AND (2018/12/01:3000[edat] OR 2018/12/01:3000[crdat] OR 2018/12/01:3000[mhda] OR 2018/12/01:3000[dp]) ("Cyclosan"[tw] OR "Mercurous iodide"[tw] OR "Mercury telluride"[tw] OR "Mercury hydride"[tw] OR "Mercurane"[tw] OR "Mercury bromide"[tw] OR "Mercury iodide"[tw] OR "Mercury oxide"[tw] OR "Mercuric selenide"[tw] OR "Mercury cyanide"[tw] OR ("Mercury chloride"[tw] NOT "mercuric chloride"[mh])) OR (("Cyclosan"[tw] OR "Mercury chloride"[tw] OR "Mercury bromide"[tw] OR "Mercuric bromide"[tw] OR "Mercuric dibromide"[tw] OR "Mercury dibromide"[tw] OR "Mercury(II) bromide"[tw] OR "Mercury fulminate"[tw] OR "Mercurous iodide"[tw] OR "Mercuric iodide"[tw] OR "Mercury iodide"[tw] OR "Mercury(II) iodide"[tw] OR "Mercuric oxide"[tw] OR "Mercury oxide"[tw] OR "Red Precipitate"[tw] OR "Yellow precipitate"[tw] OR "Mercuric selenide"[tw] OR "Mercury selenide"[tw] OR "Mercury-selenium complex"[tw] OR "Mercurous sulfate"[tw] OR "Mercury(I) sulfate"[tw] OR "Mercuric sulfate"[tw] OR "Mercuric sulphate"[tw] OR "Mercury sulfate"[tw] OR "Mercury sulphate"[tw] OR "Mercury telluride"[tw] OR "Mercuric cyanide"[tw] OR "Mercurius cyanatus"[tw] OR "Mercury cyanide"[tw] OR "Mercury hydride"[tw] OR "Mercurane"[tw] OR "Mercuric cation"[tw] OR "Mercuric cations"[tw] OR "Mercuric ion"[tw] OR "Mercuric ions"[tw]) NOT medline[sb]) AND (2018/12/01:3000[edat] OR

Table B-2. Database Query Strings

Database search date	Query string
	2018/12/01:3000[crdat] OR 2018/12/01:3000[mhda] OR 2018/12/01:3000[dp])
	13966-62-6[rn] OR 72172-67-9[rn]
NTRL 10/2023	2018-present, Titles or Keywords "mercuric" OR "mercurous" OR "mercury" OR "methylmercury" OR "methylmercuric" OR "phenylmercury" OR "phenylmercuric" OR "ethylmercury" OR "ethylmercuric" OR "calomel" OR "cinnabar" OR "Hg"

"(acetato)phenylmercury" OR "(acetato-kappao)phenylmercury" OR "(acetato-o)phenylmercury" OR "(acetoxymercuri)benzene" OR "(acetoxymercurio)benzene" OR "acetic acid, mercuridi-" OR "acetic acid, mercury(2+) salt" OR "acetic acid, phenylmercury deriv." OR "acetic acid, phenylmercury(ii) salt" OR "acetoxyphenylmercury" OR "benzene, (acetoxymercuri)-" OR "benzene, (acetoxymercurio)-" OR "bis(acetyloxy)mercury" OR "calochlor" OR "calomel" OR "chloromethylmercury" OR "cinnabar" OR "cinnabarite" OR "diacetoxymercury" OR "dichloromercury" OR "dimercury dichloride" OR "dimethylmercury" OR "fungche" OR "hydrargyrum" OR "mercuriacetate" OR "mercuric acetate" OR "mercuric bichloride" OR "mercuric chloride" OR "mercuric diacetate" OR "mercuric nitrate" OR "mercuric sulfide" OR "mercuric sulphide" OR "mercuridiacetic acid, " OR "mercuriphenyl acetate" OR "mercurius 6a" OR "mercurous chloride" OR "mercury(1+), methyl-" OR "mercury(2+) acetate" OR "mercury(2+) chloride" OR "mercury(2+) nitrate" OR "mercury(2+) sulfide" OR "mercury(i) chloride" OR "mercury(ii) acetate" OR "mercury(ii) acetate, phenyl-" OR "mercury(ii) chloride" OR "mercury(ii) nitrate" OR "mercury(ii) sulfide" OR "mercury, (acetato)phenyl-"

"mercury, (acetato-kappao)phenyl-" OR "mercury, (acetato-o)phenyl-" OR "mercury, acetoxyphenyl-" OR "mercury, chloromethyl-" OR "mercury, dimethyl-" OR "mercuryl acetate" OR "mercurymethylchloride" OR "methyl mercuric chloride" OR "methyl mercuric(ii) chloride" OR "methyl meruric chloride" OR "methylmercuric chloride" OR "methylmercury" OR "methylmercury chloride" OR "methylmercury monochloride" OR "methylmercury(1+)" OR "methylmercury(ii) cation" OR "millon's reagent" OR "monomercury sulfide" OR "monomethylmercury cation" OR "nitric acid, mercury(2+) salt" OR "nitric acid, mercury(ii) salt" OR "phenomercuric acetate" OR "phenyl mercuric acetate" OR "phenylmercuriacetate" OR "phenylmercuric acetate" OR "phenylmercury acetate" OR "phenylmercury(ii) acetate" OR "Anticon" OR "Celmer" OR "Femma" OR "Hexasan" OR "Hostaquick" OR "Kwiksan" OR "Lorophyn" OR "Parasan" OR "Phix" OR "Samtol" OR "Sanitol" OR "Sc-110" OR "Verdasan" OR "Volpar" OR "Caspan" OR "Liquid silver" OR "Quick silver" OR "Quicksilver" OR "Sulem" OR "Agrosan D" OR "Agrosan GN 5" OR "Algimycin 200" OR "Antimucin WBR" OR "Antimucin WDR" OR "Bufen"

"Bufen 30" OR "Cekusil" OR "Ceresol" OR "Contra Creme" OR "Dyanacide" OR "Fungicide R" OR "Fungitox OR" OR "Gallotox" OR "Hl-331" OR "Hong nien" OR "Hostaquik" OR "Intercide 60" OR "Intercide PMA 18" OR "Liquiphene" OR "Meracen" OR "Mercron" OR "Mercuron" OR "Mergal A 25" OR "Mersolite" OR "Metasol 30" OR "Neantina" OR "Norforms" OR "Nuodex PMA 18" OR "Nylmerate" OR "PMA (fungicide)" OR "Pamisan" OR "Panomatic" OR "Parasan (bactericide)" OR "Phenmad" OR "Programin" OR "Purasan-SC-10" OR "Puraturf 10" OR "Quicksan" OR "Quicksan 20" OR "Riogen" OR "Ruberon" OR "Sanitized SPG" OR "Sanmicron" OR "Scutl" OR "Seed Dressing R" OR "Seedtox" OR "Setrete" OR "Shimmerex" OR "Spor-Kil" OR "Spruce Seal" OR "Tag (VAN)" OR "Tag 331" OR "Tag HL 331" OR "Tag fungicide" OR "Trigosan" OR "Troysan 30" OR

Table B-2. Database Query Strings

Database search date	Query string
	"Troysan PMA 30" OR "Zaprawa Nasienna R" OR "Ziarnik" OR "Hydraargyrum bichloratum" OR "Calo-Clor" OR "Calocure" OR "Calogreen" OR "Calotab" OR "Abavit B" OR "Citrine ointment" OR "Ethiops mineral" OR "Mercurius vivus" OR "beta-Mercuric sulfide" OR "Phenylquecksilberacetate" OR "Quecksilber(II)-sulfid, rotes" OR "Rotes Quecksilbersulfid" OR "Paragite" OR "TL 898"
Toxcenter	

10/2023	FILE 'TOXCENTER' ENTERED AT 15:45:28 ON 09 OCT 2023
	CHARGED TO COST=EH038.10.02.LB.05
	L1 149470 SEA 7439-97-6
	L2 31298 SEA 7487-94-7 OR 1344-48-5 OR 10112-91-1 OR 1600-27-7 OR
	            115-09-3 OR 593-74-8 OR 62-38-4 OR 22967-92-6 OR 10045-94-0 OR
	            19122-79-3 OR 7546-30-7 OR 10031-18-2 OR 7789-47-1 OR 15385-58-
	            7 OR 628-86-4
	L3 9164 SEA 7783-30-4 OR 15385-57-6 OR 7774-29-0 OR 10415-75-5 OR
	            14836-60-3 OR 15829-53-5 OR 21908-53-2 OR 20601-83-6 OR
	            11138-42-4 OR 7783-36-0 OR 7783-35-9 OR 12068-90-5 OR 592-04-1
	            OR 631-60-7 OR 14302-87-5 OR 22542-11-6
	L4 175436 SEA L1 OR L2 OR L3
	L5 6694 SEA L4 AND ED>=20220926
	L6 6201 SEA L5 NOT PATENT/DT
	L7 6201 SEA L6 AND PY>1997
	L8 6 SEA 13966-62-6 OR 72172-67-9
	L9 0 SEA L8 AND ED>=20220926
	            ACT TOXQUERY/Q
	
	         --------- 	
	L10 QUE (CHRONIC OR IMMUNOTOX? OR NEUROTOX? OR TOXICOKIN? OR
	            BIOMARKER? OR NEUROLOG?)
	L11 QUE (PHARMACOKIN? OR SUBCHRONIC OR PBPK OR
	EPIDEMIOLOGY/ST,CT,
	            IT)
	L12 QUE (ACUTE OR SUBACUTE OR LD50# OR LD(W)50 OR LC50# OR
	            LC(W)50)
	L13 QUE (TOXICITY OR ADVERSE OR POISONING)/ST,CT,IT
	L14 QUE (INHAL? OR PULMON? OR NASAL? OR LUNG? OR RESPIR?)
	L15 QUE ((OCCUPATION? OR WORKPLACE? OR WORKER?) AND EXPOS?)
	L16 QUE (ORAL OR ORALLY OR INGEST? OR GAVAGE? OR DIET OR DIETS
	OR
	            DIETARY OR DRINKING(W)WATER?)
	L17 QUE (MAXIMUM AND CONCENTRATION? AND (ALLOWABLE OR
	PERMISSIBLE))
	
	L18 QUE (ABORT? OR ABNORMALIT? OR EMBRYO? OR CLEFT? OR FETUS?)
	L19 QUE (FOETUS? OR FETAL? OR FOETAL? OR FERTIL? OR MALFORM?
	OR
	            OVUM?)
	L20 QUE (OVA OR OVARY OR PLACENTA? OR PREGNAN? OR PRENATAL?)
	L21 QUE (PERINATAL? OR POSTNATAL? OR REPRODUC? OR STERIL? OR
	            TERATOGEN?)
	L22 QUE (SPERM OR SPERMAC? OR SPERMAG? OR SPERMATI? OR
	SPERMAS? OR

Table B-2. Database Query Strings

Database search date	Query string
	SPERMATOB? OR SPERMATOC? OR SPERMATOG?)
	L23 QUE (SPERMATOI? OR SPERMATOL? OR SPERMATOR? OR SPERMATOX? OR
	SPERMATOZ? OR SPERMATU? OR SPERMI? OR SPERMO?)
	L24 QUE (NEONAT? OR NEWBORN? OR DEVELOPMENT OR DEVELOPMENTAL?)
	L25 QUE (ENDOCRIN? AND DISRUPT?)
	L26 QUE (ZYGOTE? OR CHILD OR CHILDREN OR ADOLESCEN? OR INFANT?)
	L27 QUE (WEAN? OR OFFSPRING OR AGE(W)FACTOR?)
	L28 QUE (DERMAL? OR DERMIS OR SKIN OR EPIDERM? OR CUTANEOUS?)
	L29 QUE (CARCINOG? OR COCARCINOG? OR CANCER? OR PRECANCER? OR
	NEOPLAS?)
	L30 QUE (TUMOR? OR TUMOUR? OR ONCOGEN? OR LYMPHOMA? OR CARCINOM?)
	L31 QUE (GENETOX? OR GENOTOX? OR MUTAGEN? OR GENETIC(W)TOXIC?)
	L32 QUE (NEPHROTOX? OR HEPATOTOX?)
	L33 QUE (ENDOCRIN? OR ESTROGEN? OR ANDROGEN? OR HORMON?)
	L34 QUE (OCCUPATION? OR WORKER? OR WORKPLACE? OR EPIDEM?)
	L35 QUE L10 OR L11 OR L12 OR L13 OR L14 OR L15 OR L16 OR L17 OR L18 OR L19 OR L20 OR L21 OR L22 OR L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31 OR L32 OR L33 OR L34
	L36 QUE (RAT OR RATS OR MOUSE OR MICE OR GUINEA(W)PIG? OR MURIDAE
	OR DOG OR DOGS OR RABBIT? OR HAMSTER? OR PIG OR PIGS OR SWINE
	OR PORCINE OR MONKEY? OR MACAQUE?)
	L37 QUE (MARMOSET? OR FERRET? OR GERBIL? OR RODENT? OR LAGOMORPHA
	OR BABOON? OR CANINE OR CAT OR CATS OR FELINE OR MURINE)
	L38 QUE L35 OR L36 OR L37
	L39 QUE (NONHUMAN MAMMALS)/ORGN
	L40 QUE L38 OR L39
	L41 QUE (HUMAN OR HUMANS OR HOMINIDAE OR MAMMALS OR MAMMAL? OR
	PRIMATES OR PRIMATE?)
	L42 QUE L40 OR L41

	L43 3744 SEA L7 AND L42
	L44 760 SEA L43 AND MEDLINE/FS
	L45 1704 SEA L43 NOT CAPLUS/FS
	L46 944 SEA L45 NOT L44
	L47 1456 DUP REM L44 L46 (248 DUPLICATES REMOVED)
	D SCAN L47
9/2022	FILE 'TOXCENTER' ENTERED AT 15:30:27 ON 26 SEP 2022
	CHARGED TO COST=EH038.10.02.LB.05
	L1 143154 SEA FILE=TOXCENTER 7439-97-6
	L2 30530 SEA FILE=TOXCENTER 7487-94-7 OR 1344-48-5 OR 10112-91-1 OR

APPENDIX B

Table B-2. Database Query Strings

Database search date	Query string
	1600-27-7 OR 115-09-3 OR 593-74-8 OR 62-38-4 OR 22967-92-6 OR 10045-94-0 OR 19122-79-3 OR 7546-30-7 OR 10031-18-2 OR 7789-47-1 OR 15385-58-7 OR 628-86-4
L3	8428 SEA FILE=TOXCENTER 7783-30-4 OR 15385-57-6 OR 7774-29-0 OR 10415-75-5 OR 14836-60-3 OR 15829-53-5 OR 21908-53-2 OR 20601-83-6 OR 11138-42-4 OR 7783-36-0 OR 7783-35-9 OR 12068-90-5 OR 592-04-1 OR 631-60-7 OR 14302-87-5 OR 22542-11-6
L4	168057 SEA FILE=TOXCENTER L1 OR L2 OR L3
L5	151731 SEA FILE=TOXCENTER L4 NOT PATENT/DT
L6	151635 SEA FILE=TOXCENTER L5 NOT TSCATS/FS
L7	22428 SEA FILE=TOXCENTER L6 AND ED>=20181201
L8	22411 SEA FILE=TOXCENTER L7 AND PY>1997
L9	6 SEA FILE=TOXCENTER 13966-62-6 OR 72172-67-9
L10	4 SEA FILE=TOXCENTER L9 AND PY>1997
	D SCAN L10
L11	3 SEA FILE=TOXCENTER L10 NOT 7439-97-6
	ACT TOXQUERY/Q

L12	QUE (CHRONIC OR IMMUNOTOX? OR NEUROTOX? OR TOXICOKIN? OR BIOMARKER? OR NEUROLOG?)
L13	QUE (PHARMACOKIN? OR SUBCHRONIC OR PBPK OR EPIDEMIOLOGY/ST,CT, IT)
L14	QUE (ACUTE OR SUBACUTE OR LD50# OR LD(W)50 OR LC50# OR LC(W)50)
L15	QUE (TOXICITY OR ADVERSE OR POISONING)/ST,CT,IT
L16	QUE (INHAL? OR PULMON? OR NASAL? OR LUNG? OR RESPIR?)
L17	QUE ((OCCUPATION? OR WORKPLACE? OR WORKER?) AND EXPOS?)
L18	QUE (ORAL OR ORALLY OR INGEST? OR GAVAGE? OR DIET OR DIETS OR DIETARY OR DRINKING(W)WATER?)
L19	QUE (MAXIMUM AND CONCENTRATION? AND (ALLOWABLE OR PERMISSIBLE))
L20	QUE (ABORT? OR ABNORMALIT? OR EMBRYO? OR CLEFT? OR FETUS?)
L21	QUE (FOETUS? OR FETAL? OR FOETAL? OR FERTIL? OR MALFORM? OR OVUM?)
L22	QUE (OVA OR OVARY OR PLACENTA? OR PREGNAN? OR PRENATAL?)
L23	QUE (PERINATAL? OR POSTNATAL? OR REPRODUC? OR STERIL? OR TERATOGEN?)
L24	QUE (SPERM OR SPERMAC? OR SPERMAG? OR SPERMATI? OR SPERMAS? OR SPERMATOB? OR SPERMATOC? OR SPERMATOG?)
L25	QUE (SPERMATOI? OR SPERMATOL? OR SPERMATOR? OR SPERMATOX? OR SPERMATOZ? OR SPERMATU? OR SPERMI? OR SPERMO?)
L26	QUE (NEONAT? OR NEWBORN? OR DEVELOPMENT OR DEVELOPMENTAL?)
L27	QUE (ENDOCRIN? AND DISRUPT?)

APPENDIX B

Table B-2. Database Query Strings

Database search date	Query string
	L28 QUE (ZYGOTE? OR CHILD OR CHILDREN OR ADOLESCEN? OR INFANT?)
	L29 QUE (WEAN? OR OFFSPRING OR AGE(W)FACTOR?)
	L30 QUE (DERMAL? OR DERMIS OR SKIN OR EPIDERM? OR CUTANEOUS?)
	L31 QUE (CARCINOG? OR COCARCINOG? OR CANCER? OR PRECANCER? OR NEOPLAS?)
	L32 QUE (TUMOR? OR TUMOUR? OR ONCOGEN? OR LYMPHOMA? OR CARCINOM?)
	L33 QUE (GENETOX? OR GENOTOX? OR MUTAGEN? OR GENETIC(W)TOXIC?)
	L34 QUE (NEPHROTOX? OR HEPATOTOX?)
	L35 QUE (ENDOCRIN? OR ESTROGEN? OR ANDROGEN? OR HORMON?)
	L36 QUE (OCCUPATION? OR WORKER? OR WORKPLACE? OR EPIDEM?)

	L37 QUE L12 OR L13 OR L14 OR L15 OR L16 OR L17 OR L18 OR L19 OR
	        L20 OR L21 OR L22 OR L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR
	        L29 OR L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR L36

	L38 QUE (RAT OR RATS OR MOUSE OR MICE OR GUINEA(W)PIG? OR MURIDAE
	        OR DOG OR DOGS OR RABBIT? OR HAMSTER? OR PIG OR PIGS OR SWINE
	        OR PORCINE OR MONKEY? OR MACAQUE?)

	L39 QUE (MARMOSET? OR FERRET? OR GERBIL? OR RODENT? OR LAGOMORPHA OR BABOON? OR CANINE OR CAT OR CATS OR FELINE OR MURINE)
	L40 QUE L37 OR L38 OR L39
	L41 QUE (NONHUMAN MAMMALS)/ORGN
	L42 QUE L40 OR L41
	L43 QUE (HUMAN OR HUMANS OR HOMINIDAE OR MAMMALS OR MAMMAL? OR PRIMATES OR PRIMATE?)
	L44 QUE L42 OR L43

	L53 13117 SEA FILE=TOXCENTER L8 AND L44
	L54 6220 SEA FILE=TOXCENTER L53 NOT CAPLUS/FS
	L55 2389 SEA FILE=TOXCENTER L54 AND MEDLINE/FS
	L56 3831 SEA FILE=TOXCENTER L54 NOT L55
	L57 5347 DUP REM L55 L56 (873 DUPLICATES REMOVED)
	L*** DEL 2389 S L54 AND MEDLINE/FS
	L*** DEL 2389 S L54 AND MEDLINE/FS
	L58 2389 SEA FILE=TOXCENTER L57
	L*** DEL 3831 S L54 NOT L55
	L*** DEL 3831 S L54 NOT L55
	L59 2958 SEA FILE=TOXCENTER L57
	L60 2958 SEA FILE=TOXCENTER (L58 OR L59) NOT MEDLINE/FS
	L61 21 SEA FILE=TOXCENTER L52 NOT L60
	L62 577 SEA FILE=TOXCENTER L60 NOT L52
	D SCAN L60

Table B-3. Strategies to Augment the Literature Search	
Source	**Query and number screened when available**
TSCATS via ChemView	
10/2023	No date limit Compounds searched: 7439-97-6; 7487-94-7; 1344-48-5; 10112-91-1; 1600-27-7; 115-09-3; 593-74-8; 62-38-4; 22967-92-6; 10045-94-0; 19122-79-3; 7546-30-7; 10031-18-2; 7789-47-1; 15385-58-7; 628-86-4; 7783-30-4; 15385-57-6; 7774-29-0; 10415-75-5; 14836-60-3; 15829-53-5; 21908-53-2; 20601-83-6; 11138-42-4; 7783-36-0; 7783-35-9; 12068-90-5; 592-04-1; 631-60-7; 14302-87-5; 22542-11-6; 13966-62-6; 72172-67-9
NTP	
10/2023	Terms searched; exact word or phrase 2018-present: mercuric; mercurous; mercury; methylmercury; methylmercuric; phenylmercury; phenylmercuric; ethylmercury; ethylmercuric; calomel; cinnabar; 7439-97-6; 7487-94-7; 1344-48-5; 10112-91-1; 1600-27-7; 115-09-3; 593-74-8; 62-38-4; 22967-92-6; 10045-94-0; 19122-79-3; 7546-30-7; 10031-18-2; 7789-47-1; 15385-58-7; 628-86-4; 7783-30-4; 15385-57-6; 7774-29-0; 10415-75-5; 14836-60-3; 15829-53-5; 21908-53-2; 20601-83-6; 11138-42-4; 7783-36-0; 7783-35-9; 12068-90-5; 592-04-1; 631-60-7; 14302-87-5; 22542-11-6; 13966-62-6; 72172-67-9
Regulations.gov	
10/2023	Terms searched: "mercuric"; "mercurous"; "mercury"; "methylmercury"; "methylmercuric"; "phenylmercury"; "phenylmercuric"; "ethylmercury"; "ethylmercuric"; "calomel"; "cinnabar"; "7439-97-6"; "7487-94-7"; "1344-48-5"; "10112-91-1"; "1600-27-7"; "115-09-3"; "593-74-8"; "62-38-4"; "22967-92-6"; "10045-94-0"; "19122-79-3"; "7546-30-7"; "10031-18-2"; "7789-47-1"; "15385-58-7"; "628-86-4"; "7783-30-4"; "15385-57-6"; "7774-29-0"; "10415-75-5"; "14836-60-3"; "15829-53-5"; "21908-53-2"; "20601-83-6"; "11138-42-4"; "7783-36-0"; "7783-35-9"; "12068-90-5"; "592-04-1"; "631-60-7"; "14302-87-5"; "22542-11-6"; "13966-62-6"; "72172-67-9"
NIH RePORTER	
3/2024	Search Criteria Fiscal Year: Active Projects Text Search: "mercuric" OR "mercurous" OR "mercury" OR "methylmercury" OR "methylmercuric" OR "phenylmercury" OR "phenylmercuric" OR "ethylmercury" OR "ethylmercuric" OR "calomel" OR "cinnabar" (advanced) Limit to: Project Title, Project Terms, Project Abstracts
Other	Identified throughout the assessment process

The 2023 results were:
- Number of records identified from PubMed, NTRL, and TOXCENTER (after duplicate removal): 9,880
- Number of records identified from other strategies: 113
- Total number of records to undergo literature screening: 9,993

B.1.2 Literature Screening

A two-step process was used to screen the literature search to identify relevant studies on mercury:
- Title and abstract screen
- Full text screen

Title and Abstract Screen. Within the reference library, titles and abstracts were screened manually for relevance. Studies that were considered relevant (see Table B-1 for inclusion criteria) were moved to the second step of the literature screening process. Studies were excluded when the title and abstract clearly indicated that the study was not relevant to the toxicological profile.

- Number of titles and abstracts screened: 9,993
- Number of studies considered relevant and moved to the next step: 929

Full Text Screen. The second step in the literature screening process was a full text review of individual studies considered relevant in the title and abstract screen step. Each study was reviewed to determine whether it was relevant for inclusion in the toxicological profile.

- Number of studies undergoing full text review: 929
- Number of studies cited in the pre-public draft of the toxicological profile: 1,614
- Total number of studies cited in the profile: 1,895

Prioritization of Human Data. Due to the extent of the literature database, it is not practical or realistic to cite all, or even most, of the studies on health effects of mercury. This profile is not to provide a comprehensive review of all literature; instead, the purpose and scope of this profile is to summarize the major lines of evidence regarding health effects associated with environmental and occupational exposure to mercury compounds. Therefore, human data were prioritized for inclusion as follows:
- Epidemiological studies of environmental and occupational exposures were only considered for inclusion if they were well-conducted and reported and included the following: measurements of mercury intakes or biomarker data, measures of variance for outcome metrics, and reported methods for addressing confounding.
    o Exception: Studies of mercury poisoning outbreaks that lacked biomonitoring data but provided critical hazard identification information (e.g., Minamata disease)
- Human studies reporting health effects associated with consumer or medicinal products containing mercury (e.g., vaccines) were excluded, as these studies are not focused on sources of environmental or occupational exposure.
- Case reports were not included in the profile due to the extensive number of available epidemiological studies.
    o Exception 1: Case reports that included discussion of acute-duration accidental or intentional exposure to near-fatal or fatal levels of mercury
    o Exception 2: Case reports that described portal-of-entry effects following acute-duration exposures

Quality criteria were considered in selecting studies to include in the mercury profile and, in particular, for consideration as support for MRLs. In general, epidemiological studies that attempted dose-response assessments (e.g., regression models) were included in the profile if the following criteria were met: (1) reported estimates of variance in the dose-response metrics (e.g., SE, CL); (2) included adjustments for confounding; and (3) reported biomarker data. For studies used to derive MRLs, reporting of quality assurance of analytical methods was also required.

Prioritization of Animal Data
- All well-conducted and reported studies were considered for inclusion with a focus on routes of exposure most relevant to environmental exposure of humans (inhalation, oral, dermal).
- Parenteral studies were included only when needed to support understanding of mechanisms, but not for exposure-response relationships (since dose-response relationships observed following parenteral dosing may not accurately reflect exposure-response relationships).

- Animal studies focused on toxicity of traditional medicine or cultural uses of mercury-containing compounds (e.g., cinnabar) were excluded as not relevant to environmental exposures.

A summary of the results of the literature search and screening is presented in Figure B-1.

Figure B-1. October 2023 Literature Search Results and Screen for Mercury

APPENDIX C. USER'S GUIDE

Chapter 1. Relevance to Public Health

This chapter provides an overview of U.S. exposures, a summary of health effects based on evaluations of existing toxicologic, epidemiologic, and toxicokinetic information, and an overview of the minimal risk levels. This is designed to present interpretive, weight-of-evidence discussions for human health endpoints by addressing the following questions:

1. What effects are known to occur in humans?

2. What effects observed in animals are likely to be of concern to humans?

3. What exposure conditions are likely to be of concern to humans, especially around hazardous waste sites?

Minimal Risk Levels (MRLs)

Where sufficient toxicologic information is available, ATSDR derives MRLs for inhalation and oral routes of entry at each duration of exposure (acute, intermediate, and chronic). These MRLs are not meant to support regulatory action, but to acquaint health professionals with exposure levels at which adverse health effects are not expected to occur in humans.

MRLs should help physicians and public health officials determine the safety of a community living near a hazardous substance emission, given the concentration of a contaminant in air or the estimated daily dose in water. MRLs are based largely on toxicological studies in animals and on reports of human occupational exposure.

MRL users should be familiar with the toxicologic information on which the number is based. Section 1.2, Summary of Health Effects, contains basic information known about the substance. Other sections, such as Section 3.2 Children and Other Populations that are Unusually Susceptible and Section 3.4 Interactions with Other Substances, provide important supplemental information.

MRL users should also understand the MRL derivation methodology. MRLs are derived using a modified version of the risk assessment methodology that the Environmental Protection Agency (EPA) provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.

To derive an MRL, ATSDR generally selects the most sensitive endpoint which, in its best judgement, represents the most sensitive human health effect for a given exposure route and duration. ATSDR cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available for all potential systemic, neurological, and developmental effects. If this information and reliable quantitative data on the chosen endpoint are available, ATSDR derives an MRL using the most sensitive species (when information from multiple species is available) with the highest no-observed-adverse-effect level (NOAEL) that does not exceed any adverse effect levels. When a NOAEL is not available, a lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor of 10 must be employed. Additional uncertainty factors of 10 must be used both for human variability to protect sensitive subpopulations (people who are most susceptible to the health effects caused by the substance) and for interspecies variability (extrapolation from animals to humans). In deriving an MRL, these individual uncertainty factors are multiplied together. The product is then divided into the inhalation concentration or oral dosage selected from the study. Uncertainty factors used in developing a

substance-specific MRL are provided in the footnotes of the levels of significant exposure (LSE) tables that are provided in Chapter 2. Detailed discussions of the MRLs are presented in Appendix A.

Chapter 2. Health Effects

Tables and Figures for Levels of Significant Exposure (LSE)

Tables and figures are used to summarize health effects and illustrate graphically levels of exposure associated with those effects. These levels cover health effects observed at increasing dose concentrations and durations, differences in response by species and MRLs to humans for noncancer endpoints. The LSE tables and figures can be used for a quick review of the health effects and to locate data for a specific exposure scenario. The LSE tables and figures should always be used in conjunction with the text. All entries in these tables and figures represent studies that provide reliable, quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs).

The legends presented below demonstrate the application of these tables and figures. Representative examples of LSE tables and figures follow. The numbers in the left column of the legends correspond to the numbers in the example table and figure.

TABLE LEGEND
See Sample LSE Table (page C-5)

(1)   Route of exposure. One of the first considerations when reviewing the toxicity of a substance using these tables and figures should be the relevant and appropriate route of exposure. Typically, when sufficient data exist, three LSE tables and two LSE figures are presented in the document. The three LSE tables present data on the three principal routes of exposure (i.e., inhalation, oral, and dermal). LSE figures are limited to the inhalation and oral routes. Not all substances will have data on each route of exposure and will not, therefore, have all five of the tables and figures. Profiles with more than one chemical may have more LSE tables and figures.

(2)   Exposure period. Three exposure periods—acute (<15 days), intermediate (15–364 days), and chronic (≥365 days)—are presented within each relevant route of exposure. In this example, two oral studies of chronic-duration exposure are reported. For quick reference to health effects occurring from a known length of exposure, locate the applicable exposure period within the LSE table and figure.

(3)   Figure key. Each key number in the LSE table links study information to one or more data points using the same key number in the corresponding LSE figure. In this example, the study represented by key number 51 identified NOAELs and less serious LOAELs (also see the three "51R" data points in sample LSE Figure 2-X).

(4)   Species (strain) No./group. The test species (and strain), whether animal or human, are identified in this column. The column also contains information on the number of subjects and sex per group. Chapter 1, Relevance to Public Health, covers the relevance of animal data to human toxicity and Section 3.1, Toxicokinetics, contains any available information on comparative toxicokinetics. Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent human doses to derive an MRL.

(5)   Exposure parameters/doses. The duration of the study and exposure regimens are provided in these columns. This permits comparison of NOAELs and LOAELs from different studies. In this case (key number 51), rats were orally exposed to "Chemical X" via feed for 2 years. For a

more complete review of the dosing regimen, refer to the appropriate sections of the text or the original reference paper (i.e., Aida et al. 1992).

(6)   Parameters monitored. This column lists the parameters used to assess health effects. Parameters monitored could include serum (blood) chemistry (BC), biochemical changes (BI), body weight (BW), clinical signs (CS), developmental toxicity (DX), food intake (FI), gross necropsy (GN), hematology (HE), histopathology (HP), immune function (IX), lethality (LE), neurological function (NX), organ function (OF), ophthalmology (OP), organ weight (OW), reproductive function (RX), urinalysis (UR), and water intake (WI).

(7)   Endpoint. This column lists the endpoint examined. The major categories of health endpoints included in LSE tables and figures are death, body weight, respiratory, cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, dermal, ocular, endocrine, immunological, neurological, reproductive, developmental, other noncancer, and cancer. "Other noncancer" refers to any effect (e.g., alterations in blood glucose levels) not covered in these systems. In the example of key number 51, three endpoints (body weight, hematological, and hepatic) were investigated.

(8)   NOAEL. A NOAEL is the highest exposure level at which no adverse effects were seen in the organ system studied. The body weight effect reported in key number 51 is a NOAEL at 25.5 mg/kg/day. NOAELs are not reported for cancer and death; with the exception of these two endpoints, this field is left blank if no NOAEL was identified in the study.

(9)   LOAEL. A LOAEL is the lowest dose used in the study that caused an adverse health effect. LOAELs have been classified into "Less Serious" and "Serious" effects. These distinctions help readers identify the levels of exposure at which adverse health effects first appear and the gradation of effects with increasing dose. A brief description of the specific endpoint used to quantify the adverse effect accompanies the LOAEL. Key number 51 reports a less serious LOAEL of 6.1 mg/kg/day for the hepatic system, which was used to derive a chronic exposure, oral MRL of 0.008 mg/kg/day (see footnote "c"). MRLs are not derived from serious LOAELs. A cancer effect level (CEL) is the lowest exposure level associated with the onset of carcinogenesis in experimental or epidemiologic studies. CELs are always considered serious effects. The LSE tables and figures do not contain NOAELs for cancer, but the text may report doses not causing measurable cancer increases. If no LOAEL/CEL values were identified in the study, this field is left blank.

(10)   Reference. The complete reference citation is provided in Chapter 8 of the profile.

(11)   Footnotes. Explanations of abbreviations or reference notes for data in the LSE tables are found in the footnotes. For example, footnote "c" indicates that the LOAEL of 6.1 mg/kg/day in key number 51 was used to derive an oral MRL of 0.008 mg/kg/day.

FIGURE LEGEND
See Sample LSE Figure (page C-6)

LSE figures graphically illustrate the data presented in the corresponding LSE tables. Figures help the reader quickly compare health effects according to exposure concentrations for particular exposure periods.

(12)   Exposure period. The same exposure periods appear as in the LSE table. In this example, health effects observed within the chronic exposure period are illustrated.

(13) Endpoint. These are the categories of health effects for which reliable quantitative data exist. The same health effect endpoints appear in the LSE table.

(14) Levels of exposure. Concentrations or doses for each health effect in the LSE tables are graphically displayed in the LSE figures. Exposure concentration or dose is measured on the log scale "y" axis. Inhalation exposure is reported in mg/m^3 or ppm and oral exposure is reported in mg/kg/day.

(15) LOAEL. In this example, the half-shaded circle that is designated 51R identifies a LOAEL critical endpoint in the rat upon which a chronic oral exposure MRL is based. The key number 51 corresponds to the entry in the LSE table. The dashed descending arrow indicates the extrapolation from the exposure level of 6.1 mg/kg/day (see entry 51 in the sample LSE table) to the MRL of 0.008 mg/kg/day (see footnote "c" in the sample LSE table).

(16) CEL. Key number 59R is one of studies for which CELs were derived. The diamond symbol refers to a CEL for the test species (rat). The number 59 corresponds to the entry in the LSE table.

(17) Key to LSE figure. The key provides the abbreviations and symbols used in the figure.

APPENDIX C

| | | | | | | | Less serious | Serious | |
Figure key[a]	Species (strain) No./group	Exposure parameters	Doses (mg/kg/day)	Parameters monitored	Endpoint	NOAEL (mg/kg/day)	LOAEL (mg/kg/day)	LOAEL (mg/kg/day)	Effect

Table 2-X. Levels of Significant Exposure to [Chemical X] – Oral ← 1

(with callout boxes: 4 = Species (strain) No./group; 5 = Exposure parameters / Doses; 6 = Parameters monitored; 7 = Endpoint; 8 = NOAEL; 9 = Less serious LOAEL / Serious LOAEL)

2 → **CHRONIC EXPOSURE**

Figure key[a]	Species (strain) No./group	Exposure parameters	Doses (mg/kg/day)	Parameters monitored	Endpoint	NOAEL (mg/kg/day)	Less serious LOAEL (mg/kg/day)	Serious LOAEL (mg/kg/day)	Effect
51	Rat (Wistar) 40 M, 40 F	2 years (F)	M: 0, 6.1, 25.5, 138.0 F: 0, 8.0, 31.7, 168.4	CS, WI, BW, OW, HE, BC, HP	Bd wt	25.5	138.0		Decreased body weight gain in males (23–25%) and females (31–39%)
					Hemato	138.0			
					Hepatic		6.1[c]		Increases in absolute and relative weights at ≥6.1/8.0 mg/kg/day after 12 months of exposure; fatty generation at ≥6.1 mg/kg/day in males and at ≥31.7 mg/kg/day in females, and granulomas in females at 31.7 and 168.4 mg/kg/day after 12, 18, or 24 months of exposure and in males at ≥6.1 mg/kg/day only after 24 months of exposure

Aida et al. 1992

52	Rat (F344) 78 M	104 weeks (W)	0, 3.9, 20.6, 36.3	CS, BW, FI, BC, OW, HP	Hepatic	36.3			
					Renal	20.6	36.3		Increased incidence of renal tubular cell hyperplasia
					Endocr	36.3			

George et al. 2002

59	Rat (Wistar) 58M, 58F	Lifetime (W)	M: 0, 90 F: 0, 190	BW, HP	Cancer		190 F		Increased incidence of hepatic neoplastic nodules in females only; no additional description of the tumors was provided

Tumasonis et al. 1985

[a]The number corresponds to entries in Figure 2-x.

11 → [b]Used to derive an acute-duration oral minimal risk level (MRL) of 0.1 mg/kg/day based on the $BMDL_{05}$ of 10 mg/kg/day and an uncertainty factor of 100 (10 for extrapolation from animals to humans and 10 for human variability).

[c]Used to derive a chronic-duration oral MRL of 0.008 mg/kg/day based on the $BMDL_{10}$ of 0.78 mg/kg/day and an uncertainty factor of 100 (10 for extrapolation from animals to humans and 10 for human variability).

Figure 2-X. Levels of Significant Exposure to [Chemical X] - Oral

APPENDIX D. QUICK REFERENCE FOR HEALTH CARE PROVIDERS

Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances may find the following information helpful for fast answers to often-asked questions.

Primary Chapters/Sections of Interest

Chapter 1: Relevance to Public Health: The Relevance to Public Health Section provides an overview of exposure and health effects and evaluates, interprets, and assesses the significance of toxicity data to human health. A table listing minimal risk levels (MRLs) is also included in this chapter.

Chapter 2: Health Effects: Specific health effects identified in both human and animal studies are reported by type of health effect (e.g., death, hepatic, renal, immune, reproductive), route of exposure (e.g., inhalation, oral, dermal), and length of exposure (e.g., acute, intermediate, and chronic).
NOTE: Not all health effects reported in this section are necessarily observed in the clinical setting.

Pediatrics:
    Section 3.2   **Children and Other Populations that are Unusually Susceptible**
    Section 3.3   **Biomarkers of Exposure and Effect**

ATSDR Information Center

    Phone: 1-800-CDC-INFO (800-232-4636) or 1-888-232-6348 (TTY)
    Internet: http://www.atsdr.cdc.gov

ATSDR develops educational and informational materials for health care providers categorized by hazardous substance, clinical condition, and/or by susceptible population. The following additional materials are available online:

Clinician Briefs and Overviews discuss health effects and approaches to patient management in a brief/factsheet style. They are narrated PowerPoint presentations with Continuing Education credit available (see https://www.atsdr.cdc.gov/emes/health_professionals/clinician-briefs-overviews.html).

Managing Hazardous Materials Incidents is a set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials incident (see https://www.atsdr.cdc.gov/MHMI/index.html).

Fact Sheets (ToxFAQs™) provide answers to frequently asked questions about toxic substances (see https://www.atsdr.cdc.gov/toxfaqs/Index.asp).

APPENDIX D

Other Agencies and Organizations

The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015 • Web Page: https://www.cdc.gov/nceh/.

The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. Contact: NIOSH, 395 E Street, S.W., Suite 9200, Patriots Plaza Building, Washington, DC 20201 • Phone: 202-245-0625 or 1-800-CDC-INFO (800-232-4636) • Web Page: https://www.cdc.gov/niosh/.

The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. Contact: NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • Phone: 919-541-3212 • Web Page: https://www.niehs.nih.gov/.

Clinical Resources (Publicly Available Information)

The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. Contact: AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 • FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page: http://www.aoec.org/.

The American College of Occupational and Environmental Medicine (ACOEM) is an association of physicians and other health care providers specializing in the field of occupational and environmental medicine. Contact: ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk Grove Village, IL 60007-1030 • Phone: 847-818-1800 • FAX: 847-818-9266 • Web Page: http://www.acoem.org/.

The American College of Medical Toxicology (ACMT) is a nonprofit association of physicians with recognized expertise in medical toxicology. Contact: ACMT, 10645 North Tatum Boulevard, Suite 200-111, Phoenix AZ 85028 • Phone: 844-226-8333 • FAX: 844-226-8333 • Web Page: http://www.acmt.net.

The Pediatric Environmental Health Specialty Units (PEHSUs) is an interconnected system of specialists who respond to questions from public health professionals, clinicians, policy makers, and the public about the impact of environmental factors on the health of children and reproductive-aged adults. Contact information for regional centers can be found at http://pehsu.net/findhelp.html.

The American Association of Poison Control Centers (AAPCC) provide support on the prevention and treatment of poison exposures. Contact: AAPCC, 515 King Street, Suite 510, Alexandria VA 22314 • Phone: 701-894-1858 • Poison Help Line: 1-800-222-1222 • Web Page: http://www.aapcc.org/.

APPENDIX E. GLOSSARY

Absorption—The process by which a substance crosses biological membranes and enters systemic circulation. Absorption can also refer to the taking up of liquids by solids, or of gases by solids or liquids.

Acute Exposure—Exposure to a chemical for a duration of ≤14 days, as specified in the Toxicological Profiles.

Adsorption—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the surfaces of solid bodies or liquids with which they are in contact.

Adsorption Coefficient (K_{oc})—The ratio of the amount of a chemical adsorbed per unit weight of organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium.

Adsorption Ratio (Kd)—The amount of a chemical adsorbed by sediment or soil (i.e., the solid phase) divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a fixed solid/solution ratio. It is generally expressed in micrograms of chemical sorbed per gram of soil or sediment.

Adverse-Effect Level (AEL)—An estimate of an exposure concentration or dose at which an adverse outcome was observed. For example, in the derivation of the chronic-duration inhalation MRL for elemental mercury, urine mercury levels were converted to equivalent exposure concentrations at which tremor was observed. Unlike a LOAEL, an AEL is not a point of departure from a dose-response relationship and may not represent the LOAEL.

Benchmark Dose (BMD) or Benchmark Concentration (BMC)—is the dose/concentration corresponding to a specific response level estimate using a statistical dose-response model applied to either experimental toxicology or epidemiology data. For example, a BMD_{10} would be the dose corresponding to a 10% benchmark response (BMR). The BMD is determined by modeling the dose-response curve in the region of the dose-response relationship where biologically observable data are feasible. The BMDL or BMCL is the 95% lower confidence limit on the BMD or BMC.

Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms at a specific time or during a discrete time period of exposure divided by the concentration in the surrounding water at the same time or during the same period.

Biomarkers—Indicators signaling events in biologic systems or samples, typically classified as markers of exposure, effect, and susceptibility.

Cancer Effect Level (CEL)—The lowest dose of a chemical in a study, or group of studies, that produces significant increases in the incidence of cancer (or malignant tumors) between the exposed population and its appropriate control.

Carcinogen—A chemical capable of inducing cancer.

Case-Control Study—A type of epidemiological study that examines the relationship between a particular outcome (disease or condition) and a variety of potential causative agents (such as toxic chemicals). In a case-control study, a group of people with a specified and well-defined outcome is identified and compared to a similar group of people without the outcome.

Case Report—A report that describes a single individual with a particular disease or exposure. These reports may suggest some potential topics for scientific research, but are not actual research studies.

Case Series—Reports that describe the experience of a small number of individuals with the same disease or exposure. These reports may suggest potential topics for scientific research, but are not actual research studies.

Ceiling Value—A concentration that must not be exceeded.

Chronic Exposure—Exposure to a chemical for ≥365 days, as specified in the Toxicological Profiles.

Clastogen—A substance that causes breaks in chromosomes resulting in addition, deletion, or rearrangement of parts of the chromosome.

Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are followed forward from exposure to outcome, and who are disease-free at start of follow-up. Often, at least one exposed group is compared to one unexposed group, while in other cohorts, exposure is a continuous variable and analyses are directed towards analyzing an exposure-response coefficient.

Confounding—The confusion, or mixing, of effects; this definition implies that the effect of exposure, if mixed together with the effect of another variable, leads to bias. A confounder:
1. must be associated with the disease (as a cause or as a proxy for a cause but not as an effect of the disease);
2. must be associated with exposure, and
3. must not be an effect of the exposure.

Cross-sectional Study—A type of epidemiological study of a group or groups of people that examines the relationship between exposure and outcome to a chemical or to chemicals at a specific point in time.

Data Needs—Substance-specific informational needs that, if met, would reduce the uncertainties of human health risk assessment.

Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result from exposure to a chemical prior to conception (either parent), during prenatal development, or postnatally to the time of sexual maturation. Adverse developmental effects may be detected at any point in the life span of the organism.

Dose-Response Relationship—The quantitative relationship between the amount of exposure to a toxicant and the incidence of the response or amount of the response.

Effect Measure Modification—In epidemiology, effect measure modification occurs when the measure of an effect or association (e.g., risk ratio) for an exposure of interest changes over the values of some other variable. This other variable results in a departure from the underlying statistical model.

Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to a chemical; the distinguishing feature between the two terms is the stage of development during which the effect occurs. Effects include malformations and variations, altered growth, and *in utero* death.

Epidemiology—The investigation of factors that determine the frequency and distribution of disease or other health-related conditions within a defined human population during a specified period.

APPENDIX E

Excretion—The process by which metabolic waste products are removed from the body.

Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of affected cells, can be expressed as a mutagenic, clastogenic, or carcinogenic event because of specific alteration of the molecular structure of the genome.

Half-life—A measure of rate for the time required to eliminate one-half of a quantity of a chemical from the body or environmental media.

Health Advisory—An estimate of acceptable drinking water levels for a chemical substance derived by EPA and based on health effects information. A health advisory is not a legally enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials.

Immediately Dangerous to Life or Health (IDLH)—A condition that poses a threat of life or health, or conditions that pose an immediate threat of severe exposure to contaminants that are likely to have adverse cumulative or delayed effects on health.

Immunotoxicity—Adverse effect on the functioning of the immune system that may result from exposure to chemical substances.

Incidence—The ratio of new cases of individuals in a population who develop a specified condition to the total number of individuals in that population who could have developed that condition in a specified time period.

Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the Toxicological Profiles.

In Vitro—Isolated from the living organism and artificially maintained, as in a test tube.

In Vivo—Occurring within the living organism.

Lethal Concentration$_{(LO)}$ (LC$_{LO}$)—The lowest concentration of a chemical in air that has been reported to have caused death in humans or animals.

Lethal Concentration$_{(50)}$ (LC$_{50}$)—A calculated concentration of a chemical in air to which exposure for a specific length of time is expected to cause death in 50% of a defined experimental animal population.

Lethal Dose$_{(LO)}$ (LD$_{Lo}$)—The lowest dose of a chemical introduced by a route other than inhalation that has been reported to have caused death in humans or animals.

Lethal Dose$_{(50)}$ (LD$_{50}$)—The dose of a chemical that has been calculated to cause death in 50% of a defined experimental animal population.

Lethal Time$_{(50)}$ (LT$_{50}$)—A calculated period of time within which a specific concentration of a chemical is expected to cause death in 50% of a defined experimental animal population.

Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study, or group of studies, that produces statistically or biologically significant increases in frequency or severity of adverse effects between the exposed population and its appropriate control.

Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the lymph nodes, spleen, and thymus.

Malformations—Permanent structural changes that may adversely affect survival, development, or function.

Metabolism—Process in which chemical substances are biotransformed in the body that could result in less toxic and/or readily excreted compounds or produce a biologically active intermediate.

Minimal LOAEL—Indicates a minimal adverse effect or a reduced capacity of an organ or system to absorb additional toxic stress that does not necessarily lead to the inability of the organ or system to function normally.

Minimal Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is likely to be without an appreciable risk of adverse noncancer health effects over a specified route and duration of exposure.

Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation of a Minimal Risk Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty factors. The default value for a MF is 1.

Morbidity—The state of being diseased; the morbidity rate is the incidence or prevalence of a disease in a specific population.

Mortality—Death; the mortality rate is a measure of the number of deaths in a population during a specified interval of time.

Mutagen—A substance that causes mutations, which are changes in the DNA sequence of a cell's DNA. Mutations can lead to birth defects, miscarriages, or cancer.

Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of death or pathological conditions.

Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a hazardous substance.

No-Adverse-Effect Level (NAEL)—An estimate of an exposure concentration or dose at which an adverse outcome was not observed. For example, in the derivation of the chronic-duration inhalation MRL for elemental mercury, urine mercury levels were converted to equivalent exposure concentrations at which tremors were not observed. Unlike a NOAEL, a NAEL is not a point of departure from a dose-response relationship and may not represent the highest NOAEL.

No-Observed-Adverse-Effect Level (NOAEL)—The exposure level of a chemical at which there were no statistically or biologically significant increases in frequency or severity of adverse effects seen between the exposed population and its appropriate control. Although effects may be produced at this exposure level, they are not considered to be adverse.

Octanol-Water Partition Coefficient (K_{ow})—The equilibrium ratio of the concentrations of a chemical in *n*-octanol and water, in dilute solution.

APPENDIX E

Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances and a disease or condition) that represents the best estimate of relative risk (risk as a ratio of the incidence among subjects exposed to a particular risk factor divided by the incidence among subjects who were not exposed to the risk factor). An odds ratio that is greater than 1 is considered to indicate greater risk of disease in the exposed group compared to the unexposed group.

Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA) regulatory limit on the amount or concentration of a substance not to be exceeded in workplace air averaged over any 8-hour work shift of a 40-hour workweek.

Pesticide—General classification of chemicals specifically developed and produced for use in the control of agricultural and public health pests (insects or other organisms harmful to cultivated plants or animals).

Pharmacokinetics—The dynamic behavior of a material in the body, used to predict the fate (disposition) of an exogenous substance in an organism. Utilizing computational techniques, it provides the means of studying the absorption, distribution, metabolism, and excretion of chemicals by the body.

Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent chemical or metabolite in an animal system. There are two types of pharmacokinetic models: data-based and physiologically-based. A data-based model divides the animal system into a series of compartments, which, in general, do not represent real, identifiable anatomic regions of the body, whereas the physiologically-based model compartments represent real anatomic regions of the body.

Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically based dose-response model that quantitatively describes the relationship between target tissue dose and toxic endpoints. These models advance the importance of physiologically based models in that they clearly describe the biological effect (response) produced by the system following exposure to an exogenous substance.

Physiologically Based Pharmacokinetic (PBPK) Model—A type of physiologically based dose-response model that is comprised of a series of compartments representing organs or tissue groups with realistic weights and blood flows. These models require a variety of physiological information, including tissue volumes, blood flow rates to tissues, cardiac output, alveolar ventilation rates, and possibly membrane permeabilities. The models also utilize biochemical information, such as blood:air partition coefficients, and metabolic parameters. PBPK models are also called biologically based tissue dosimetry models.

Prevalence—The number of cases of a disease or condition in a population at one point in time.

Prospective Study—A type of cohort study in which a group is followed over time and the pertinent observations are made on events occurring after the start of the study.

Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health (NIOSH) time-weighted average (TWA) concentration for up to a 10-hour workday during a 40-hour workweek.

Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups) that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime. The inhalation RfC is expressed in units of mg/m^3 or ppm.

Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the daily oral exposure of the human population to a potential hazard that is likely to be without risk of deleterious noncancer health effects during a lifetime. The oral RfD is expressed in units of mg/kg/day.

Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA). RQs are (1) ≥1 pound or (2) for selected substances, an amount established by regulation either under CERCLA or under Section 311 of the Clean Water Act. Quantities are measured over a 24-hour period.

Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result from exposure to a hazardous substance. The toxicity may be directed to the reproductive organs and/or the related endocrine system. The manifestation of such toxicity may be noted as alterations in sexual behavior, fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of this system.

Retrospective Study—A type of cohort study based on a group of persons known to have been exposed at some time in the past. Data are collected from routinely recorded events, up to the time the study is undertaken. Retrospective studies are limited to causal factors that can be ascertained from existing records and/or examining survivors of the cohort.

Risk—The possibility or chance that some adverse effect will result from a given exposure to a hazardous substance.

Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, existing health condition, or an inborn or inherited characteristic that is associated with an increased occurrence of disease or other health-related event or condition.

Risk Ratio/Relative Risk—The ratio of the risk among persons with specific risk factors compared to the risk among persons without risk factors. A risk ratio that is greater than 1 indicates greater risk of disease in the exposed group compared to the unexposed group.

Serious LOAEL—A dose that evokes failure in a biological system and can lead to morbidity or mortality.

Short-Term Exposure Limit (STEL)—A STEL is a 15-minute TWA exposure that should not be exceeded at any time during a workday.

Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected number of deaths in a specific standard population.

Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited exposure to those assumed over a lifetime of exposure to a chemical.

Teratogen—A chemical that causes structural defects that affect the development of an organism.

Threshold Limit Value (TLV)—An American Conference of Governmental Industrial Hygienists (ACGIH) concentration of a substance to which it is believed that nearly all workers may be repeatedly exposed, day after day, for a working lifetime without adverse effect. The TLV may be expressed as a Time-Weighted Average (TLV-TWA), as a Short-Term Exposure Limit (TLV-STEL), or as a ceiling limit (TLV-C).

APPENDIX E

Time-Weighted Average (TWA)—An average exposure within a given time period.

Toxicokinetic—The absorption, distribution, metabolism, and elimination of toxic compounds in the living organism.

Toxics Release Inventory (TRI)—The TRI is an EPA program that tracks toxic chemical releases and pollution prevention activities reported by industrial and federal facilities.

Uncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL), Reference Dose (RfD), or Reference Concentration (RfC) from experimental data. UFs are intended to account for (1) the variation in sensitivity among the members of the human population, (2) the uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using lowest-observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data. A default for each individual UF is 10; if complete certainty in data exists, a value of 1 can be used; however, a reduced UF of 3 may be used on a case-by-case basis (3 being the approximate logarithmic average of 10 and 1).

Xenobiotic—Any substance that is foreign to the biological system.

APPENDIX F. ACRONYMS, ABBREVIATIONS, AND SYMBOLS

AAPCC	American Association of Poison Control Centers
ACGIH	American Conference of Governmental Industrial Hygienists
ACOEM	American College of Occupational and Environmental Medicine
ACMT	American College of Medical Toxicology
ADI	acceptable daily intake
ADME	absorption, distribution, metabolism, and excretion
AEGL	Acute Exposure Guideline Level
AEL	adverse-effect level
AIC	Akaike's information criterion
AIHA	American Industrial Hygiene Association
ALT	alanine aminotransferase
ANA	antinuclear antibody
ANoA	antinucleolar antibody
AOEC	Association of Occupational and Environmental Clinics
AP	alkaline phosphatase
AST	aspartate aminotransferase
atm	atmosphere
ATSDR	Agency for Toxic Substances and Disease Registry
AWQC	Ambient Water Quality Criteria
BCF	bioconcentration factor
BMD/C	benchmark dose or benchmark concentration
BMD_X	dose that produces a X% change in response rate of an adverse effect
$BMDL_X$	95% lower confidence limit on the BMD_X
BMDS	Benchmark Dose Software
BMR	benchmark response
BUN	blood urea nitrogen
C	centigrade
CAA	Clean Air Act
CAS	Chemical Abstract Services
CDC	Centers for Disease Control and Prevention
CEL	cancer effect level
CERCLA	Comprehensive Environmental Response, Compensation, and Liability Act
CFR	Code of Federal Regulations
Ci	curie
CI	confidence interval
cm	centimeter
CPSC	Consumer Products Safety Commission
CWA	Clean Water Act
DNA	deoxyribonucleic acid
DOD	Department of Defense
DOE	Department of Energy
DWEL	drinking water exposure level
EAFUS	Everything Added to Food in the United States
ECG/EKG	electrocardiogram
EEG	electroencephalogram
EPA	Environmental Protection Agency
ERPG	emergency response planning guidelines
F	Fahrenheit
F1	first-filial generation

APPENDIX F

FDA	Food and Drug Administration
FIFRA	Federal Insecticide, Fungicide, and Rodenticide Act
FR	Federal Register
FSH	follicle stimulating hormone
g	gram
GC	gas chromatography
gd	gestational day
GGT	γ-glutamyl transferase
GRAS	generally recognized as safe
HEC	human equivalent concentration
HED	human equivalent dose
HHS	Department of Health and Human Services
HPLC	high-performance liquid chromatography
HSDB	Hazardous Substance Data Bank
IARC	International Agency for Research on Cancer
IDLH	immediately dangerous to life and health
IRIS	Integrated Risk Information System
Kd	adsorption ratio
kg	kilogram
kkg	kilokilogram; 1 kilokilogram is equivalent to 1,000 kilograms and 1 metric ton
K_{oc}	organic carbon partition coefficient
K_{ow}	octanol-water partition coefficient
L	liter
LC	liquid chromatography
LC_{50}	lethal concentration, 50% kill
LC_{Lo}	lethal concentration, low
LD_{50}	lethal dose, 50% kill
LD_{Lo}	lethal dose, low
LDH	lactic dehydrogenase
LH	luteinizing hormone
LOAEL	lowest-observed-adverse-effect level
LSE	Level of Significant Exposure
LT_{50}	lethal time, 50% kill
m	meter
mCi	millicurie
MCL	maximum contaminant level
MCLG	maximum contaminant level goal
MF	modifying factor
mg	milligram
mL	milliliter
mm	millimeter
mmHg	millimeters of mercury
mmol	millimole
MRL	Minimal Risk Level
MS	mass spectrometry
MSHA	Mine Safety and Health Administration
Mt	metric ton
NAAQS	National Ambient Air Quality Standard
NAEL	no-adverse-effect level
NAS	National Academy of Science
NCEH	National Center for Environmental Health

APPENDIX F

ND	not detected
ng	nanogram
NHANES	National Health and Nutrition Examination Survey
NIEHS	National Institute of Environmental Health Sciences
NIOSH	National Institute for Occupational Safety and Health
NLM	National Library of Medicine
nm	nanometer
nmol	nanomole
NOAEL	no-observed-adverse-effect level
NPL	National Priorities List
NR	not reported
NRC	National Research Council
NS	not specified
NTP	National Toxicology Program
OR	odds ratio
OSHA	Occupational Safety and Health Administration
PAC	Protective Action Criteria
PAH	polycyclic aromatic hydrocarbon
PBPD	physiologically based pharmacodynamic
PBPK	physiologically based pharmacokinetic
PEHSU	Pediatric Environmental Health Specialty Unit
PEL	permissible exposure limit
PEL-C	permissible exposure limit-ceiling value
pg	picogram
PND	postnatal day
POD	point of departure
ppb	parts per billion
ppbv	parts per billion by volume
ppm	parts per million
ppt	parts per trillion
REL	recommended exposure level/limit
REL-C	recommended exposure level-ceiling value
RfC	reference concentration
RfD	reference dose
RNA	ribonucleic acid
SARA	Superfund Amendments and Reauthorization Act
SCE	sister chromatid exchange
SD	standard deviation
SE	standard error
SGOT	serum glutamic oxaloacetic transaminase (same as aspartate aminotransferase or AST)
SGPT	serum glutamic pyruvic transaminase (same as alanine aminotransferase or ALT)
SIC	standard industrial classification
SLOAEL	serious lowest-observed-adverse-effect level
SMR	standardized mortality ratio
sRBC	sheep red blood cell
STEL	short term exposure limit
TLV	threshold limit value
TLV-C	threshold limit value-ceiling value
TRI	Toxics Release Inventory
TSCA	Toxic Substances Control Act
TWA	time-weighted average

APPENDIX F

UF	uncertainty factor
U.S.	United States
USDA	United States Department of Agriculture
USGS	United States Geological Survey
USNRC	U.S. Nuclear Regulatory Commission
VOC	volatile organic compound
WBC	white blood cell
WHO	World Health Organization

$>$	greater than
$\geq$	greater than or equal to
$=$	equal to
$<$	less than
$\leq$	less than or equal to
$\%$	percent
α	alpha
β	beta
γ	gamma
δ	delta
μm	micrometer
μg	microgram
q_1^*	cancer slope factor
$-$	negative
$+$	positive
$(+)$	weakly positive result
$(-)$	weakly negative result